19761039
D010936_D004409 NONE sinensis_7\NN|rosa (r_pobj) of_4\IN|sinensis (r_prep) extract_3\NN|methanolic|of (r_pobj) of_1\IN|extract (r_prep) Effect_0\NN|of|(|mg/kg|) (r_nsubjpass) studied_15\VBN|effect|was|on|. (l_prep) on_16\IN|dyskinesia (l_pobj) dyskinesia_21\JJ|induced|orofacial|and|alterations
D010936_D004409 NONE sinensis_10\NN|rosa (r_nsubj) had_11\VBD|that|sinensis|role (l_dobj) role_14\NN|a|protective|against (l_prep) against_15\IN|dyskinesia (l_pobj) dyskinesia_20\JJ|induced|orofacial|and|stress
D012110_D004409 CID reserpine_17\NN| (r_npadvmod) induced_19\VBN|reserpine|- (r_amod) dyskinesia_21\JJ|induced|orofacial|and|alterations
D012110_D004409 CID reserpine_16\NN| (r_npadvmod) induced_18\VBN|reserpine|- (r_amod) dyskinesia_20\JJ|induced|orofacial|and|stress
17042884
C069541_D001480 NONE quetiapine_11\NN|in (r_pobj) with_10\IN|quetiapine (r_prep) incidence_3\NN|level|of|with|. (l_prep) of_4\IN|symptoms (l_pobj) symptoms_6\NNS|extrapyramidal|eps
C069541_D001480 NONE quetiapine_11\NN|in (r_pobj) with_10\IN|quetiapine (r_prep) incidence_3\NN|level|of|with|. (l_prep) of_4\IN|symptoms (l_pobj) symptoms_6\NNS|extrapyramidal|eps (l_appos) EPS_8\NNP|(|)
C069541_D001480 NONE quetiapine_14\NN|in (r_pobj) with_13\IN|quetiapine (r_prep) including_10\VBG|akathisia|,|with (r_prep) evaluate_3\VB|to|symptoms|,|including (l_dobj) symptoms_5\NNS|extrapyramidal|eps
C069541_D001480 NONE quetiapine_14\NN|in (r_pobj) with_13\IN|quetiapine (r_prep) including_10\VBG|akathisia|,|with (r_prep) evaluate_3\VB|to|symptoms|,|including (l_dobj) symptoms_5\NNS|extrapyramidal|eps (l_appos) EPS_7\NNP|(|)
C069541_D001480 NONE quetiapine_16\NN| (r_amod) monotherapy_17\NN|quetiapine|(|%|) (r_pobj) with_15\IN|monotherapy (r_prep) different_14\JJ|no|with|than (r_acomp) was_12\VBD|incidence|different|. (l_nsubj) incidence_1\NN|the|of|,|including|, (l_prep) of_2\IN|events (l_pobj) events_7\NNS|related|adverse (l_amod) related_5\VBN|eps|- (l_npadvmod) EPS_3\NNP|
C069541_D001480 NONE QTP_8\NNP|+|dvp (r_pobj) with_7\IN|qtp (r_prep) events_6\NNS|related|adverse|with (l_amod) related_4\VBN|eps|- (l_npadvmod) EPS_2\NNP|
C069541_D001480 NONE quetiapine_41\NN| (r_pcomp) than_40\IN|quetiapine (r_prep) tremor_21\NN|,|(|%|)|,|and|syndrome|than (l_conj) syndrome_32\NN|extrapyramidal|(|%|)
C069541_D001480 NONE quetiapine_13\NN| (r_amod) therapy_14\NN|quetiapine (r_nsubj) is_15\VBZ|in|,|incidence|with|therapy|similar|. (l_nsubj) incidence_5\NN|the|of|,|including|, (l_prep) of_6\IN|eps (l_pobj) EPS_7\NNP|
C069541_D001714 NONE quetiapine_11\NN|in (l_prep) in_12\IN|studies (l_pobj) studies_14\NNS|controlled|of (l_prep) of_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|mania (l_pobj) mania_19\NN|bipolar
C069541_D001714 NONE quetiapine_14\NN|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|mania (l_pobj) mania_19\NN|bipolar
C069541_D001714 NONE quetiapine_13\NN| (r_amod) therapy_14\NN|quetiapine (r_nsubj) is_15\VBZ|in|,|incidence|with|therapy|similar|. (l_prep) In_0\IN|mania (l_pobj) mania_2\NN|bipolar
C069541_D017109 NONE quetiapine_14\NN|in (r_pobj) with_13\IN|quetiapine (r_prep) including_10\VBG|akathisia|,|with (l_pobj) akathisia_11\NN|
C069541_D017109 NONE quetiapine_16\NN| (r_amod) monotherapy_17\NN|quetiapine|(|%|) (r_pobj) with_15\IN|monotherapy (r_prep) different_14\JJ|no|with|than (r_acomp) was_12\VBD|incidence|different|. (l_nsubj) incidence_1\NN|the|of|,|including|, (l_prep) including_9\VBG|akathisia (l_pobj) akathisia_10\NN|
C069541_D017109 NONE quetiapine_9\NN| (r_amod) monotherapy_10\NN|quetiapine|(|%|)|and|placebo (r_pobj) with_8\IN|monotherapy (r_prep) similar_7\JJ|with (r_conj) low_5\JJ|and|similar (r_acomp) was_4\VBD|incidence|low|,|and|with|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|akathisia (l_pobj) akathisia_3\NN|
C069541_D017109 NONE QTP_24\NNP|+|dvp (r_pobj) with_23\IN|qtp (r_conj) was_4\VBD|incidence|low|,|and|with|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|akathisia (l_pobj) akathisia_3\NN|
C069541_D017109 NONE quetiapine_41\NN| (r_pcomp) than_40\IN|quetiapine (r_prep) tremor_21\NN|,|(|%|)|,|and|syndrome|than (r_npadvmod) induced_1\VBD|haloperidol|incidence|tremor|. (l_dobj) incidence_5\NN|a|higher|0.001 (l_appos) 0.001_9\CD|(|p|<|)|of (l_prep) of_11\IN|akathisia (l_pobj) akathisia_12\NN|(|%|)
C069541_D017109 NONE quetiapine_13\NN| (r_amod) therapy_14\NN|quetiapine (r_nsubj) is_15\VBZ|in|,|incidence|with|therapy|similar|. (l_nsubj) incidence_5\NN|the|of|,|including|, (l_prep) including_9\VBG|akathisia (l_pobj) akathisia_10\NN|
D008094_D001480 CID Li_10\NNP| (r_nmod) DVP_12\NNP|li|/|(|%|) (r_conj) QTP_8\NNP|+|dvp (r_pobj) with_7\IN|qtp (r_prep) events_6\NNS|related|adverse|with (l_amod) related_4\VBN|eps|- (l_npadvmod) EPS_2\NNP|
D008094_D001480 CID Li_24\NNP| (r_nmod) DVP_26\NNP|li|/|(|%|) (r_conj) PBO_22\NNP|+|dvp (r_pobj) with_21\IN|pbo (r_prep) than_20\IN|with (r_prep) different_19\JJ|no|than (r_acomp) were_17\VBD|similarly|,|events|different|. (l_nsubj) events_6\NNS|related|adverse|with (l_amod) related_4\VBN|eps|- (l_npadvmod) EPS_2\NNP|
D008094_D001480 CID lithium_28\NN|(|n|98 (r_pobj) with_27\IN|lithium (r_prep) treated_26\VBN|with (r_acl) patients_25\NNS|treated (r_pobj) of_24\IN|patients (r_prep) %_23\NN|26.5|of (r_pobj) whereas_21\IN|% (r_prep) treated_11\VBN|with|whereas (r_acl) patients_10\NNS|treated (r_pobj) of_9\IN|patients (r_prep) %_8\NN|59.6|of (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|events|in|) (l_nsubj) events_1\NNS|adverse|related (l_acl) related_2\VBN|to (l_prep) to_3\IN|eps (l_pobj) EPS_4\NNP|
D014635_D001480 NONE DVP_12\NNP|li|/|(|%|) (r_conj) QTP_8\NNP|+|dvp (r_pobj) with_7\IN|qtp (r_prep) events_6\NNS|related|adverse|with (l_amod) related_4\VBN|eps|- (l_npadvmod) EPS_2\NNP|
D014635_D001480 NONE DVP_26\NNP|li|/|(|%|) (r_conj) PBO_22\NNP|+|dvp (r_pobj) with_21\IN|pbo (r_prep) than_20\IN|with (r_prep) different_19\JJ|no|than (r_acomp) were_17\VBD|similarly|,|events|different|. (l_nsubj) events_6\NNS|related|adverse|with (l_amod) related_4\VBN|eps|- (l_npadvmod) EPS_2\NNP|
D006220_D001480 CID haloperidol_13\NN|(|n|)|monotherapy|, (r_pobj) with_12\IN|haloperidol (r_prep) treated_11\VBN|with|whereas (r_acl) patients_10\NNS|treated (r_pobj) of_9\IN|patients (r_prep) %_8\NN|59.6|of (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|events|in|) (l_nsubj) events_1\NNS|adverse|related (l_acl) related_2\VBN|to (l_prep) to_3\IN|eps (l_pobj) EPS_4\NNP|
D006220_D001480 CID Haloperidol_0\NNP| (r_nsubj) induced_1\VBD|haloperidol|incidence|tremor|. (l_npadvmod) tremor_21\NN|,|(|%|)|,|and|syndrome|than (l_conj) syndrome_32\NN|extrapyramidal|(|%|)
D008094_D017109 NONE Li_26\NNP| (r_nmod) DVP_28\NNP|li|/|(|%|)|and|pbo (r_conj) QTP_24\NNP|+|dvp (r_pobj) with_23\IN|qtp (r_conj) was_4\VBD|incidence|low|,|and|with|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|akathisia (l_pobj) akathisia_3\NN|
D008094_D017109 NONE Li_36\NNP| (r_compound) DVP_38\NNP|li|/ (r_conj) PBO_34\NNP|+|dvp|(|%|) (r_conj) DVP_28\NNP|li|/|(|%|)|and|pbo (r_conj) QTP_24\NNP|+|dvp (r_pobj) with_23\IN|qtp (r_conj) was_4\VBD|incidence|low|,|and|with|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|akathisia (l_pobj) akathisia_3\NN|
D014635_D017109 NONE DVP_28\NNP|li|/|(|%|)|and|pbo (r_conj) QTP_24\NNP|+|dvp (r_pobj) with_23\IN|qtp (r_conj) was_4\VBD|incidence|low|,|and|with|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|akathisia (l_pobj) akathisia_3\NN|
D014635_D017109 NONE DVP_38\NNP|li|/ (r_conj) PBO_34\NNP|+|dvp|(|%|) (r_conj) DVP_28\NNP|li|/|(|%|)|and|pbo (r_conj) QTP_24\NNP|+|dvp (r_pobj) with_23\IN|qtp (r_conj) was_4\VBD|incidence|low|,|and|with|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|akathisia (l_pobj) akathisia_3\NN|
D008094_D014202 CID Lithium_0\NN| (r_nsubjpass) associated_2\VBN|lithium|was|with (l_prep) with_3\IN|incidence (l_pobj) incidence_7\NN|a|higher|0.05|(|%|)|than|(|%|) (l_appos) 0.05_11\CD|(|p|<|)|of (l_prep) of_13\IN|tremor (l_pobj) tremor_14\NN|
D008094_D014202 CID Lithium_0\NN| (r_nsubjpass) associated_2\VBN|lithium|was|with (r_ccomp) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_nsubj) tremor_27\NN|cerebellar|,|is|,
D008094_D014202 CID Lithium_0\NN| (r_nsubjpass) associated_2\VBN|lithium|was|with (r_ccomp) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_prep) to_41\IN|rate (l_pobj) rate_44\NN|the|elevated|of|in (l_prep) of_45\IN|tremor (l_pobj) tremor_46\NN|
D008094_D014202 CID lithium_36\NN| (r_pobj) of_35\IN|lithium (r_prep) effect_34\NN|a|known|adverse|of (r_attr) is_30\VBZ|which|effect (r_relcl) tremor_27\NN|cerebellar|,|is|, (r_nsubj) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_ccomp) associated_2\VBN|lithium|was|with (l_prep) with_3\IN|incidence (l_pobj) incidence_7\NN|a|higher|0.05|(|%|)|than|(|%|) (l_appos) 0.05_11\CD|(|p|<|)|of (l_prep) of_13\IN|tremor (l_pobj) tremor_14\NN|
D008094_D014202 CID lithium_36\NN| (r_pobj) of_35\IN|lithium (r_prep) effect_34\NN|a|known|adverse|of (r_attr) is_30\VBZ|which|effect (r_relcl) tremor_27\NN|cerebellar|,|is|,
D008094_D014202 CID lithium_36\NN| (r_pobj) of_35\IN|lithium (r_prep) effect_34\NN|a|known|adverse|of (r_attr) is_30\VBZ|which|effect (r_relcl) tremor_27\NN|cerebellar|,|is|, (r_nsubj) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_prep) to_41\IN|rate (l_pobj) rate_44\NN|the|elevated|of|in (l_prep) of_45\IN|tremor (l_pobj) tremor_46\NN|
D008094_D014202 CID lithium_50\NN| (r_compound) therapy_51\NN|lithium (r_dobj) receiving_49\VBG|therapy (r_acl) patients_48\NNS|receiving (r_pobj) in_47\IN|patients (r_prep) rate_44\NN|the|elevated|of|in (r_pobj) to_41\IN|rate (r_prep) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_ccomp) associated_2\VBN|lithium|was|with (l_prep) with_3\IN|incidence (l_pobj) incidence_7\NN|a|higher|0.05|(|%|)|than|(|%|) (l_appos) 0.05_11\CD|(|p|<|)|of (l_prep) of_13\IN|tremor (l_pobj) tremor_14\NN|
D008094_D014202 CID lithium_50\NN| (r_compound) therapy_51\NN|lithium (r_dobj) receiving_49\VBG|therapy (r_acl) patients_48\NNS|receiving (r_pobj) in_47\IN|patients (r_prep) rate_44\NN|the|elevated|of|in (r_pobj) to_41\IN|rate (r_prep) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_nsubj) tremor_27\NN|cerebellar|,|is|,
D008094_D014202 CID lithium_50\NN| (r_compound) therapy_51\NN|lithium (r_dobj) receiving_49\VBG|therapy (r_acl) patients_48\NNS|receiving (r_pobj) in_47\IN|patients (r_prep) rate_44\NN|the|elevated|of|in (l_prep) of_45\IN|tremor (l_pobj) tremor_46\NN|
C069541_D014202 NONE quetiapine_20\NN| (r_pobj) than_19\IN|quetiapine (r_prep) incidence_7\NN|a|higher|0.05|(|%|)|than|(|%|) (l_appos) 0.05_11\CD|(|p|<|)|of (l_prep) of_13\IN|tremor (l_pobj) tremor_14\NN|
C069541_D014202 NONE quetiapine_20\NN| (r_pobj) than_19\IN|quetiapine (r_prep) incidence_7\NN|a|higher|0.05|(|%|)|than|(|%|) (r_pobj) with_3\IN|incidence (r_prep) associated_2\VBN|lithium|was|with (r_ccomp) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_nsubj) tremor_27\NN|cerebellar|,|is|,
C069541_D014202 NONE quetiapine_20\NN| (r_pobj) than_19\IN|quetiapine (r_prep) incidence_7\NN|a|higher|0.05|(|%|)|than|(|%|) (r_pobj) with_3\IN|incidence (r_prep) associated_2\VBN|lithium|was|with (r_ccomp) contributed_40\VBN|associated|;|tremor|may|have|to|. (l_prep) to_41\IN|rate (l_pobj) rate_44\NN|the|elevated|of|in (l_prep) of_45\IN|tremor (l_pobj) tremor_46\NN|
C069541_D014202 NONE quetiapine_41\NN| (r_pcomp) than_40\IN|quetiapine (r_prep) tremor_21\NN|,|(|%|)|,|and|syndrome|than
D006220_D017109 CID Haloperidol_0\NNP| (r_nsubj) induced_1\VBD|haloperidol|incidence|tremor|. (l_dobj) incidence_5\NN|a|higher|0.001 (l_appos) 0.001_9\CD|(|p|<|)|of (l_prep) of_11\IN|akathisia (l_pobj) akathisia_12\NN|(|%|)
D006220_D014202 CID Haloperidol_0\NNP| (r_nsubj) induced_1\VBD|haloperidol|incidence|tremor|. (l_npadvmod) tremor_21\NN|,|(|%|)|,|and|syndrome|than
19692487
D008094_D011141 NONE lithium_6\NN| (r_npadvmod) induced_8\VBN|lithium|- (r_amod) polyuria_9\NN|induced
D008094_D011141 NONE lithium_8\NN| (r_npadvmod) induced_10\VBN|lithium|- (r_amod) polyuria_11\NN|induced
D008094_D011141 NONE lithium_7\NN| (r_npadvmod) induced_9\VBN|lithium|- (r_amod) polyuria_10\NN|induced|in
D008094_D011141 NONE lithium_10\NN| (r_npadvmod) induced_12\VBN|lithium|- (r_amod) polyuria_13\NN|induced|and|urine
D008094_D011141 NONE lithium_7\NN| (r_npadvmod) induced_9\VBN|lithium|- (r_amod) polyuria_10\NN|induced|likely
D011458_D011141 NONE E_17\NN|prostaglandin (r_appos) microsomal_15\JJ|e (r_pobj) in_14\IN|microsomal (r_prep) deficient_13\JJ|mice|in (r_pobj) in_11\IN|deficient (r_prep) polyuria_10\NN|induced|in
D015232_D011141 NONE )_29\-RRB-| (r_punct) PGE(2_28\NNP|) (r_appos) urine_27\NN|high|pge(2|and|output (r_pobj) of_25\IN|urine (r_prep) blockade_24\NN|complete|of (r_pobj) by_21\IN|blockade (r_agent) accompanied_20\VBN|by (r_advcl) were_6\VBD|in|,|mpges-1|mice|resistant|,|accompanied|. (l_acomp) resistant_8\JJ|largely|to (l_prep) to_9\IN|polyuria (l_pobj) polyuria_13\NN|induced|and|urine
D015232_D011141 NONE )_5\-RRB-| (r_punct) PGE(2_4\NNP|mpges-1-derived|) (r_nsubj) mediates_6\VBZ|that|pge(2|polyuria|via (l_dobj) polyuria_10\NN|induced|likely
11282081
D014700_D001281 CID verapamil_2\NN| (r_pobj) of_1\IN|verapamil (r_prep) Effects_0\NNS|of|on|and|determinants|. (l_prep) on_3\IN|fibrillation (l_pobj) fibrillation_5\NN|atrial
D014700_D001281 CID verapamil_17\NN| (r_dobj) administered_16\VBD|evaluate|,|we|verapamil|to|. (l_advcl) evaluate_1\VB|to|mechanisms (l_dobj) mechanisms_4\NNS|the|potential|of (l_prep) of_5\IN|promotion (l_pobj) promotion_7\NN|af|by (l_compound) AF_6\NNP|
D014700_D001281 CID Verapamil_1\NNP| (r_nsubj) caused_2\VBD|:|verapamil|promotion|in|,|increasing (l_dobj) promotion_4\NN|af (l_compound) AF_3\NNP|
D014700_D001281 CID Verapamil_1\NNP| (r_nsubj) caused_2\VBD|:|verapamil|promotion|in|,|increasing (l_advcl) increasing_9\VBG|duration (l_dobj) duration_11\NN|mean|of|induced (l_prep) of_12\IN|af (l_pobj) AF_13\NNP|
D014700_D001281 CID verapamil_4\NN| (r_nsubj) shortened_5\VBN|in|,|verapamil|mean|period|from|,|decreased|,|accelerated|. (l_conj) accelerated_43\VBN|heterogeneously|conduction|and|decreased (l_conj) decreased_47\VBD|length|to (l_dobj) length_50\NN|the|cycle|of (l_prep) of_51\IN|94+/-4 (l_pobj) 94+/-4_54\CD|af|( (l_nmod) AF_52\NNP|
D014700_D001281 CID verapamil_22\NNP| (r_nmod) n=5_24\NNS|verapamil|( (r_pobj) by_21\IN|n=5 (r_agent) caused_20\VBN|by (r_acl) that_19\DT|caused (r_pobj) to_18\IN|that (r_prep) similar_17\JJ|to (r_amod) acceleration_16\NN|conduction|similar (r_dobj) produced_14\VBD|acceleration|) (r_conj) affect_3\VB|diltiazem|did|not|erp|,|but|produced|. (l_dobj) ERP_4\NNP|,|length (l_conj) length_8\NN|af|cycle|or|duration (l_compound) AF_6\NNP|
D014700_D001281 CID verapamil_22\NNP| (r_nmod) n=5_24\NNS|verapamil|( (r_pobj) by_21\IN|n=5 (r_agent) caused_20\VBN|by (r_acl) that_19\DT|caused (r_pobj) to_18\IN|that (r_prep) similar_17\JJ|to (r_amod) acceleration_16\NN|conduction|similar (r_dobj) produced_14\VBD|acceleration|) (r_conj) affect_3\VB|diltiazem|did|not|erp|,|but|produced|. (l_dobj) ERP_4\NNP|,|length (l_conj) length_8\NN|af|cycle|or|duration (l_conj) duration_11\NN|af (l_compound) AF_10\NNP|
D014700_D001281 CID verapamil_7\NN| (r_nsubj) failed_8\VBD|in|,|verapamil|promote|refractoriness|. (l_xcomp) promote_10\VB|to|af|and|increased (l_dobj) AF_11\NNP|
D014700_D001281 CID verapamil_4\NN| (r_nsubj) promoted_5\VBD|that|verapamil|af|by (l_dobj) AF_6\NNP|
D014700_D001281 CID Verapamil_0\NNP| (r_nsubj) promotes_1\VBZ|verapamil|af|in|by|,|effect|. (l_dobj) AF_2\NNP|
D002118_D013617 NONE Ca(2_23\NNP|type|+|current (r_dobj) decreases_19\VBZ|ca(2 (r_conj) promotes_7\VBZ|tachycardia|occurrence|and|decreases (l_nsubj) tachycardia_3\NN|atrial|-|remodeling
D002118_D001281 NONE Ca(2_23\NNP|type|+|current (r_dobj) decreases_19\VBZ|ca(2 (r_conj) promotes_7\VBZ|tachycardia|occurrence|and|decreases (l_dobj) occurrence_9\NN|the|and|maintenance|of (l_prep) of_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|)
D002118_D001281 NONE Ca(2_23\NNP|type|+|current (r_dobj) decreases_19\VBZ|ca(2 (r_conj) promotes_7\VBZ|tachycardia|occurrence|and|decreases (l_dobj) occurrence_9\NN|the|and|maintenance|of (l_prep) of_12\IN|fibrillation (l_pobj) fibrillation_14\NN|atrial|(|af|) (l_appos) AF_16\NNP|
D002118_D001281 NONE Ca(2_11\NN| (r_nmod) channel_13\NN|ca(2|) (r_compound) blockade_14\NN|acute|type|channel (r_nsubj) promote_16\VB|that|blockade|can|af|,|consistent (l_dobj) AF_17\NNP|
D002118_D001281 NONE Ca(2_11\NN| (r_nmod) channel_13\NN|ca(2|) (r_compound) blockade_14\NN|acute|type|channel (r_nsubj) promote_16\VB|that|blockade|can|af|,|consistent (l_advcl) consistent_19\JJ|with (l_prep) with_20\IN|effect (l_pobj) effect_24\NN|an|af|promoting|of (l_compound) AF_22\NNP|
D002118_D001281 NONE Ca(2_26\NNP|+ (r_nmod) inhibition_30\NN|ca(2|channel (r_pobj) of_25\IN|inhibition (r_prep) effect_24\NN|an|af|promoting|of (r_pobj) with_20\IN|effect (r_prep) consistent_19\JJ|with (r_advcl) promote_16\VB|that|blockade|can|af|,|consistent (l_dobj) AF_17\NNP|
D002118_D001281 NONE Ca(2_26\NNP|+ (r_nmod) inhibition_30\NN|ca(2|channel (r_pobj) of_25\IN|inhibition (r_prep) effect_24\NN|an|af|promoting|of (l_compound) AF_22\NNP|
D002118_D001281 NONE Ca(2_9\NNP|+ (r_nmod) blockers_13\NNS|ca(2|channel (r_pobj) by_8\IN|blockers (r_prep) promotion_7\NN|af|by (l_compound) AF_6\NNP|
D009020_D001281 NONE morphine_19\NN| (r_npadvmod) chloralose_21\NN|morphine|- (r_amod) dogs_23\NNS|chloralose|anesthetized (r_pobj) to_18\IN|dogs (r_prep) administered_16\VBD|evaluate|,|we|verapamil|to|. (l_advcl) evaluate_1\VB|to|mechanisms (l_dobj) mechanisms_4\NNS|the|potential|of (l_prep) of_5\IN|promotion (l_pobj) promotion_7\NN|af|by (l_compound) AF_6\NNP|
D002698_D001281 NONE chloralose_21\NN|morphine|- (r_amod) dogs_23\NNS|chloralose|anesthetized (r_pobj) to_18\IN|dogs (r_prep) administered_16\VBD|evaluate|,|we|verapamil|to|. (l_advcl) evaluate_1\VB|to|mechanisms (l_dobj) mechanisms_4\NNS|the|potential|of (l_prep) of_5\IN|promotion (l_pobj) promotion_7\NN|af|by (l_compound) AF_6\NNP|
D004110_D001281 NONE Diltiazem_0\NNP| (r_nsubj) affect_3\VB|diltiazem|did|not|erp|,|but|produced|. (l_dobj) ERP_4\NNP|,|length (l_conj) length_8\NN|af|cycle|or|duration (l_compound) AF_6\NNP|
D004110_D001281 NONE Diltiazem_0\NNP| (r_nsubj) affect_3\VB|diltiazem|did|not|erp|,|but|produced|. (l_dobj) ERP_4\NNP|,|length (l_conj) length_8\NN|af|cycle|or|duration (l_conj) duration_11\NN|af (l_compound) AF_10\NNP|
D004110_D001281 NONE diltiazem_23\NN| (r_pobj) by_22\IN|diltiazem (r_agent) shared_21\VBN|not|by (r_conj) effect_13\NN|an|dependent|and|shared (r_dobj) promotes_1\VBZ|verapamil|af|in|by|,|effect|. (l_dobj) AF_2\NNP|
11900788
D009538_D002375 CID Nicotine_0\NN| (r_compound) potentiation_1\NN|nicotine|of|in|. (l_prep) of_2\IN|catalepsy (l_pobj) catalepsy_6\NN|induced
D009538_D002375 CID nicotine_7\NN| (r_pobj) of_6\IN|nicotine (r_prep) effects_5\NNS|of|on|induced (l_prep) on_8\IN|catalepsy (l_pobj) catalepsy_9\NN|
D009538_D002375 CID nicotine_3\NN|not (r_conj) Morphine_0\NNP|but|nicotine (r_nsubj) induced_4\VBD|morphine|catalepsy|. (l_dobj) catalepsy_9\NN|a|dependent
D009538_D002375 CID nicotine_22\NN| (r_pobj) with_21\IN|nicotine (r_prep) combination_18\NN|a|of|with (r_pobj) by_16\IN|combination (r_agent) induced_15\VBN|by (r_acl) catalepsy_14\NN|reduced|induced
D009538_D002375 CID nicotine_16\NN| (r_conj) morphine_14\NN|plus|nicotine (r_pobj) by_13\IN|morphine (r_agent) induced_12\VBN|by (r_acl) catalepsy_11\NN|induced
D009538_D002375 CID nicotine_22\NN| (r_pobj) by_21\IN|nicotine (r_agent) induced_20\VBN|by (r_acl) potentiation_17\NN|the|of|induced (r_nsubjpass) mediated_26\VBN|potentiation|may|also|be|through (r_conj) elicited_8\VBN|that|catalepsy|can|be|by|,|and|mediated (l_nsubjpass) catalepsy_5\NN|morphine
D009020_D002375 CID morphine_3\NN| (r_npadvmod) induced_5\VBN|morphine|- (r_amod) catalepsy_6\NN|induced
D009020_D002375 CID morphine_12\NN| (r_pobj) by_11\IN|morphine (r_agent) induced_10\VBN|by|in (r_acl) effects_5\NNS|of|on|induced (l_prep) on_8\IN|catalepsy (l_pobj) catalepsy_9\NN|
D009020_D002375 CID Morphine_0\NNP|but|nicotine (r_nsubj) induced_4\VBD|morphine|catalepsy|. (l_dobj) catalepsy_9\NN|a|dependent
D009020_D002375 CID morphine_20\NN| (r_pobj) of_19\IN|morphine (r_prep) combination_18\NN|a|of|with (r_pobj) by_16\IN|combination (r_agent) induced_15\VBN|by (r_acl) catalepsy_14\NN|reduced|induced
D009020_D002375 CID morphine_14\NN|plus|nicotine (r_pobj) by_13\IN|morphine (r_agent) induced_12\VBN|by (r_acl) catalepsy_11\NN|induced
D009020_D002375 CID morphine_4\NN| (r_compound) catalepsy_5\NN|morphine
D009020_D002375 CID morphine_19\NN| (r_pobj) of_18\IN|morphine (r_prep) potentiation_17\NN|the|of|induced (r_nsubjpass) mediated_26\VBN|potentiation|may|also|be|through (r_conj) elicited_8\VBN|that|catalepsy|can|be|by|,|and|mediated (l_nsubjpass) catalepsy_5\NN|morphine
D001285_D002375 NONE atropine_3\NN| (r_pobj) of_2\IN|atropine (r_prep) administration_1\NN|intraperitoneal|of|,|naloxone|catalepsy|. (l_appos) catalepsy_14\NN|reduced|induced
D001285_D002375 NONE atropine_3\NN|,|hexamethonium (r_pobj) of_2\IN|atropine (r_prep) injection_1\NN|intracerebroventricular|of (r_nsubj) decreased_10\VBD|injection|also|catalepsy|. (l_dobj) catalepsy_11\NN|induced
D009270_D002375 NONE naloxone_5\NN|,|mecamylamine (r_appos) administration_1\NN|intraperitoneal|of|,|naloxone|catalepsy|. (l_appos) catalepsy_14\NN|reduced|induced
D009270_D002375 NONE naloxone_8\NN| (r_conj) hexamethonium_5\NN|,|and|naloxone (r_conj) atropine_3\NN|,|hexamethonium (r_pobj) of_2\IN|atropine (r_prep) injection_1\NN|intracerebroventricular|of (r_nsubj) decreased_10\VBD|injection|also|catalepsy|. (l_dobj) catalepsy_11\NN|induced
D008464_D002375 NONE mecamylamine_7\NN|,|and|hexamethonium (r_conj) naloxone_5\NN|,|mecamylamine (r_appos) administration_1\NN|intraperitoneal|of|,|naloxone|catalepsy|. (l_appos) catalepsy_14\NN|reduced|induced
D018738_D002375 NONE hexamethonium_10\NN|to (r_conj) mecamylamine_7\NN|,|and|hexamethonium (r_conj) naloxone_5\NN|,|mecamylamine (r_appos) administration_1\NN|intraperitoneal|of|,|naloxone|catalepsy|. (l_appos) catalepsy_14\NN|reduced|induced
D018738_D002375 NONE hexamethonium_5\NN|,|and|naloxone (r_conj) atropine_3\NN|,|hexamethonium (r_pobj) of_2\IN|atropine (r_prep) injection_1\NN|intracerebroventricular|of (r_nsubj) decreased_10\VBD|injection|also|catalepsy|. (l_dobj) catalepsy_11\NN|induced
16960342
D019259_D006509 NONE lamivudine_17\NN| (r_amod) monotherapy_18\NN|lamivudine (r_pobj) with_16\IN|monotherapy (r_prep) treatment_15\NN|with (r_pobj) after_14\IN|treatment (r_prep) improvement_2\NN|sustained|clinical|of|after|. (l_prep) of_3\IN|patient (l_pobj) patient_5\NN|a|with (l_prep) with_6\IN|cirrhosis (l_pobj) cirrhosis_13\NN|decompensated|related (l_amod) related_12\VBN|virus|- (l_npadvmod) virus_10\NN|b (l_compound) B_9\NNP|hepatitis
D019259_D005355 NONE lamivudine_17\NN| (r_amod) monotherapy_18\NN|lamivudine (r_pobj) with_16\IN|monotherapy (r_prep) treatment_15\NN|with (r_pobj) after_14\IN|treatment (r_prep) improvement_2\NN|sustained|clinical|of|after|. (l_prep) of_3\IN|patient (l_pobj) patient_5\NN|a|with (l_prep) with_6\IN|cirrhosis (l_pobj) cirrhosis_13\NN|decompensated|related
D019259_D005355 NONE lamivudine_3\NN| (r_pobj) of_2\IN|lamivudine (r_prep) administration_1\NN|the|of|to (l_prep) to_4\IN|patients (l_pobj) patients_5\NNS|with (l_prep) with_6\IN|cirrhosis (l_pobj) cirrhosis_10\NN|related
16174948
D003042_D013345 CID cocaine_6\NN| (r_npadvmod) associated_8\VBN|cocaine|- (r_amod) hemorrhage_10\NN|associated|subarachnoid
D003042_D013345 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|cocaine|- (r_amod) hemorrhage_16\NN|associated|subarachnoid|sah|underwent
D003042_D013345 CID cocaine_12\NN| (r_npadvmod) associated_14\VBN|cocaine|- (r_amod) hemorrhage_16\NN|associated|subarachnoid|sah|underwent (l_appos) SAH_18\NNP|(|)
D003042_D013345 CID cocaine_25\NN| (r_compound) use_26\NN|cocaine (r_pobj) after_24\IN|shortly|use (r_prep) underwent_21\VBD|who|angiography|after (r_relcl) hemorrhage_16\NN|associated|subarachnoid|sah|underwent
D003042_D013345 CID cocaine_25\NN| (r_compound) use_26\NN|cocaine (r_pobj) after_24\IN|shortly|use (r_prep) underwent_21\VBD|who|angiography|after (r_relcl) hemorrhage_16\NN|associated|subarachnoid|sah|underwent (l_appos) SAH_18\NNP|(|)
D003042_D013345 CID cocaine_14\NN|or|metabolites (r_pobj) for_13\IN|cocaine (r_prep) toxicology_12\NN|positive|urine|for (r_pobj) with_9\IN|toxicology (r_prep) those_8\DT|with (r_dobj) identified_7\VBD|those (r_conj) screened_1\VBD|we|patients|retrospectively|and|identified|. (l_dobj) patients_2\NNS|with (l_prep) with_3\IN|sah (l_pobj) SAH_4\NNP|
D003042_D013345 CID cocaine_31\NN| (r_compound) use_32\NN|cocaine (r_pobj) with_30\IN|use (r_prep) associated_29\VBN|with (r_acl) SAH_28\NNP|aneurysmal|associated
D003042_D013901 NONE Cocaine_0\NN| (r_compound) use_1\NN|cocaine (r_nsubjpass) associated_4\VBN|use|has|been|with|. (l_prep) with_5\IN|complications (l_pobj) complications_7\NNS|neurovascular|,|including
D003042_D014657 NONE Cocaine_0\NN| (r_compound) use_1\NN|cocaine (r_nsubjpass) associated_4\VBN|use|has|been|with|. (l_prep) with_5\IN|complications (l_pobj) complications_7\NNS|neurovascular|,|including (l_prep) including_9\VBG|vasoconstriction (l_pobj) vasoconstriction_11\NN|arterial|and|vasculitis (l_conj) vasculitis_13\NN|
D003042_D014657 NONE cocaine_31\NN| (r_compound) use_32\NN|cocaine (r_pobj) with_30\IN|use (r_prep) associated_29\VBN|with (r_acl) SAH_28\NNP|aneurysmal|associated (r_pobj) after_26\IN|sah (r_prep) underwent_24\VBD|who|angiography|after (r_relcl) patients_22\NNS|underwent (r_pobj) in_21\IN|patients (r_prep) found_20\VBN|evidence|could|be|in|. (l_nsubjpass) evidence_2\NN|no|quantitative|for (l_prep) for_3\IN|narrowing (l_pobj) narrowing_4\VBG|of (l_prep) of_5\IN|arteries (l_pobj) arteries_8\NNS|large|cerebral|or|evidence (l_conj) evidence_12\NN|qualitative|angiographic|for (l_prep) for_13\IN|narrowing (l_pobj) narrowing_15\NN|distal|or|vasculitis (l_conj) vasculitis_17\NN|
D003042_D017542 CID cocaine_31\NN| (r_compound) use_32\NN|cocaine (r_pobj) with_30\IN|use (r_prep) associated_29\VBN|with (r_acl) SAH_28\NNP|aneurysmal|associated (l_amod) aneurysmal_27\NN|
8278214
D009020_D006930 CID morphine_11\NN|continuous|intravenous (r_pobj) with_8\IN|morphine (r_prep) treated_7\VBN|with (r_acl) patients_6\NNS|terminal|cancer|treated (r_pobj) in_3\IN|patients (r_prep) myoclonus_2\NN|in (r_conj) Hyperalgesia_0\NNP|and|myoclonus|.
D009020_D006930 CID morphine_16\NN|intravenous (r_pobj) of_14\IN|morphine (r_prep) doses_13\NNS|high|of (r_pobj) with_11\IN|doses (r_prep) treated_10\VBN|patients|with|developed|. (l_advcl) developed_17\VBN|hyperalgesia (l_dobj) hyperalgesia_18\NN|
D009020_D006930 CID morphine_16\NN| (r_pobj) of_15\IN|morphine (r_prep) doses_14\NNS|high|of (r_conj) myoclonus_11\NN|hyperalgesia|/|and|doses (l_nmod) hyperalgesia_9\NN|
D009020_D006930 CID morphine_27\NN|,|or|metabolites (r_nsubj) plays_33\VBZ|that|morphine|,|role|for (r_ccomp) indicates_25\VBZ|are|,|support|plays|. (l_advcl) are_17\VBP|although|descriptions|available (l_nsubj) descriptions_4\NNS|few|clinical|of (l_prep) of_5\IN|relationship (l_pobj) relationship_7\NN|the|between (l_prep) between_8\IN|myoclonus (l_pobj) myoclonus_11\NN|hyperalgesia|/|and|doses (l_nmod) hyperalgesia_9\NN|
D009020_D009207 CID morphine_11\NN|continuous|intravenous (r_pobj) with_8\IN|morphine (r_prep) treated_7\VBN|with (r_acl) patients_6\NNS|terminal|cancer|treated (r_pobj) in_3\IN|patients (r_prep) myoclonus_2\NN|in
D009020_D009207 CID morphine_16\NN| (r_pobj) of_15\IN|morphine (r_prep) doses_14\NNS|high|of (r_conj) myoclonus_11\NN|hyperalgesia|/|and|doses
D009020_D009207 CID morphine_27\NN|,|or|metabolites (r_nsubj) plays_33\VBZ|that|morphine|,|role|for (r_ccomp) indicates_25\VBZ|are|,|support|plays|. (l_advcl) are_17\VBP|although|descriptions|available (l_nsubj) descriptions_4\NNS|few|clinical|of (l_prep) of_5\IN|relationship (l_pobj) relationship_7\NN|the|between (l_prep) between_8\IN|myoclonus (l_pobj) myoclonus_11\NN|hyperalgesia|/|and|doses
D009020_D009369 NONE morphine_11\NN|continuous|intravenous (r_pobj) with_8\IN|morphine (r_prep) treated_7\VBN|with (r_acl) patients_6\NNS|terminal|cancer|treated (l_compound) cancer_5\NN|
D009020_D009369 NONE morphine_16\NN|intravenous (r_pobj) of_14\IN|morphine (r_prep) doses_13\NNS|high|of (r_pobj) with_11\IN|doses (r_prep) treated_10\VBN|patients|with|developed|. (l_nsubj) patients_2\NNS|eight|cancer|in (l_compound) cancer_1\NN|
10692744
D000086_D005862 CID Acetazolamide_0\RB| (r_npadvmod) induced_2\VBN|acetazolamide|- (r_amod) syndrome_4\NN|induced|gerstmann|.
D000086_D005862 CID acetazolamide_5\NN| (r_npadvmod) induced_7\VBN|acetazolamide|- (r_amod) syndrome_9\NN|induced|gerstmann
D000086_D003221 NONE acetazolamide_4\NN| (r_pobj) by_3\IN|acetazolamide (r_agent) induced_2\VBN|by (r_acl) confusion_1\NN|acute|induced
D000086_D007674 NONE acetazolamide_4\NN| (r_pobj) by_3\IN|acetazolamide (r_agent) induced_2\VBN|by (r_acl) confusion_1\NN|acute|induced (r_nsubj) is_5\VBZ|confusion|reaction|. (l_attr) reaction_11\NN|a|known|adverse|drug|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|impairment (l_pobj) impairment_16\NN|renal
9321531
D007980_D010300 NONE levodopa_11\RB| (r_npadvmod) induced_13\VBN|levodopa|- (r_amod) dyskinesias_14\NNS|induced|and|disability (r_dobj) reduces_10\VBZ|in|,|pallidotomy|significantly|dyskinesias|. (l_prep) In_0\IN|disease (l_pobj) disease_6\NN|parkinson
D007980_D004409 CID levodopa_11\RB| (r_npadvmod) induced_13\VBN|levodopa|- (r_amod) dyskinesias_14\NNS|induced|and|disability
19674115
D011718_D000857 CID pyrazinamide_4\NN| (r_pobj) by_3\IN|pyrazinamide (r_agent) induced_2\VBN|dysosmia|by|. (l_nsubj) dysosmia_1\NN|recurrent
D011718_D000857 CID pyrazinamide_10\VB|to|in (r_xcomp) related_8\VBN|pyrazinamide (r_acl) disorder_7\NN|reversible|olfactory|related
D011718_D000857 CID pyrazinamide_4\JJ| (r_compound) withdrawal_5\NN|pyrazinamide (r_pobj) after_3\IN|completely|withdrawal (r_prep) disappeared_1\VBD|dysosmia|after|and|recurred|. (l_nsubj) Dysosmia_0\NNP|
D011718_D056486 NONE Pyrazinamide_0\NNP| (r_nsubj) have_2\VB|pyrazinamide|can|effects|. (l_dobj) effects_4\NNS|adverse|as (l_prep) as_6\IN|such|toxicity (l_pobj) toxicity_8\NN|hepatic|,|disorders
D011718_D033461 NONE Pyrazinamide_0\NNP| (r_nsubj) have_2\VB|pyrazinamide|can|effects|. (l_dobj) effects_4\NNS|adverse|as (l_prep) as_6\IN|such|toxicity (l_pobj) toxicity_8\NN|hepatic|,|disorders (l_conj) disorders_13\NNS|hyperuricemia (l_nmod) hyperuricemia_10\NN|or|digestive
6454943
D002216_D011507 NONE captopril_2\NN| (r_pobj) of_1\IN|captopril (r_prep) Effect_0\NN|of|on (r_nsubj) induced_10\VBN|effect|-|proteinuria|in|. (l_dobj) proteinuria_11\NN|
D002216_D011507 NONE captopril_6\NN| (r_compound) treatment_7\NN|captopril|in (r_pobj) of_5\IN|treatment (r_prep) effect_4\NN|a|side|of (r_attr) is_1\VBZ|proteinuria|effect|. (l_nsubj) Proteinuria_0\NNP|
D002216_D011507 NONE captopril_3\NN| (r_pobj) of_2\IN|captopril (r_prep) administration_1\NN|oral|of|at|for (r_nsubj) failed_10\VBD|administration|aggravate|. (l_xcomp) aggravate_12\VB|to|proteinuria (l_dobj) proteinuria_13\JJ|
D002216_D011507 NONE captopril_2\NN| (r_compound) treatment_3\NN|captopril (r_nsubj) failed_4\VBD|also|,|treatment|potentiate|. (l_xcomp) potentiate_6\VB|to|or|facilitate (l_conj) facilitate_8\VB|development (l_dobj) development_9\NN|of (l_prep) of_10\IN|proteinuria (l_pobj) proteinuria_12\NN|massive|invoked
D002216_D006973 NONE captopril_2\NN| (r_pobj) of_1\IN|captopril (r_prep) Effect_0\NN|of|on (r_nsubj) induced_10\VBN|effect|-|proteinuria|in|. (l_prep) in_12\IN|rats (l_pobj) rats_15\NNS|hypertensive (l_amod) hypertensive_14\JJ|spontaneously
D002216_D006973 NONE captopril_6\NN| (r_compound) treatment_7\NN|captopril|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|hypertensive (l_amod) hypertensive_9\JJ|
D011692_D011507 CID aminonucleoside_8\RB| (r_punct) -_9\HYPH|existing|aminonucleoside (r_punct) induced_10\VBN|effect|-|proteinuria|in|. (l_dobj) proteinuria_11\NN|
D011692_D011507 CID aminonucleoside_16\NN|in (r_amod) puromycin_15\NNS|aminonucleoside (r_pobj) by_14\IN|puromycin (r_agent) invoked_13\VBN|by (r_acl) proteinuria_12\NN|massive|invoked
D011692_D006973 NONE aminonucleoside_8\RB| (r_punct) -_9\HYPH|existing|aminonucleoside (r_punct) induced_10\VBN|effect|-|proteinuria|in|. (l_prep) in_12\IN|rats (l_pobj) rats_15\NNS|hypertensive (l_amod) hypertensive_14\JJ|spontaneously
D002216_D007674 NONE captopril_9\NN| (r_pobj) with_8\IN|captopril (r_prep) abnormality_7\NN|the|same|renal|with
8617710
D020280_D003072 NONE sertraline_4\NN| (r_pobj) of_3\IN|sertraline (r_prep) effect_2\NN|of|on (l_prep) on_5\IN|sensitization (l_pobj) sensitization_9\NN|based|of (l_prep) of_10\IN|impairment (l_pobj) impairment_12\NN|cognitive|with
D020280_D003072 NONE sertraline_14\NN| (r_compound) administration_15\NN|concomitant|sertraline (r_pobj) by_12\IN|administration (r_agent) worsened_11\VBN|that|was|not|by (r_relcl) profile_4\NN|a|clear|of|worsened (l_prep) of_5\IN|impairment (l_pobj) impairment_7\NN|cognitive
D006220_D003072 CID haloperidol_14\NN| (r_pobj) with_13\IN|haloperidol (r_prep) impairment_12\NN|cognitive|with
D006220_D003072 CID haloperidol_13\NN| (r_pobj) of_12\IN|haloperidol (r_prep) administration_11\NN|of (r_pobj) after_10\IN|hours|administration (r_prep) observed_5\VBN|impairment|was|after|on|but|was|. (l_nsubjpass) Impairment_0\NN|of (l_prep) of_1\IN|function (l_pobj) function_3\NN|cognitive
D006220_D003072 CID Haloperidol_0\NNP| (r_nsubj) produced_1\VBD|haloperidol|profile|. (l_dobj) profile_4\NN|a|clear|of|worsened (l_prep) of_5\IN|impairment (l_pobj) impairment_7\NN|cognitive
8111719
D007069_D006212 CID ifosfamide_2\RB| (r_advmod) induced_4\VBN|ifosfamide|- (r_amod) neurotoxicity_5\NN|induced (r_conj) Hallucinations_0\NNS|and|neurotoxicity|.
D007069_D006212 CID ifosfamide_16\NN| (r_pobj) of_15\IN|ifosfamide (r_prep) effect_14\NN|a|known|side|of (r_attr) are_7\VBP|hallucinations|effect|. (l_nsubj) Hallucinations_0\NNS|as
D007069_D006212 CID ifosfamide_3\RB| (r_npadvmod) induced_5\VBN|ifosfamide|- (r_amod) hallucinations_6\NNS|induced
D007069_D006212 CID ifosfamide_6\RB| (r_npadvmod) induced_8\VBN|ifosfamide|- (r_amod) hallucinations_9\NNS|induced
D007069_D006212 CID ifosfamide_7\RB| (r_npadvmod) induced_9\VBN|ifosfamide|- (r_amod) hallucinations_10\NNS|possible|induced|,|occur
D007069_D020258 NONE ifosfamide_2\RB| (r_advmod) induced_4\VBN|ifosfamide|- (r_amod) neurotoxicity_5\NN|induced
D007069_D020258 NONE ifosfamide_16\NN| (r_pobj) of_15\IN|ifosfamide (r_prep) effect_14\NN|a|known|side|of (r_attr) are_7\VBP|hallucinations|effect|. (l_nsubj) Hallucinations_0\NNS|as (l_prep) as_1\IN|symptom (l_pobj) symptom_3\NN|a|of (l_prep) of_4\IN|neurotoxicity (l_pobj) neurotoxicity_6\NN|central
D007069_D020258 NONE ifosfamide_7\RB| (r_npadvmod) induced_9\VBN|ifosfamide|- (r_amod) hallucinations_10\NNS|possible|induced|,|occur (l_relcl) occur_14\VB|which|may|without (l_prep) without_15\IN|signs (l_pobj) signs_17\NNS|other|of (l_prep) of_18\IN|neurotoxicity (l_pobj) neurotoxicity_19\NN|
D006220_D011595 NONE haloperidol_12\NN|i.e.|, (r_appos) neuroleptics_8\NNS|marked|,|potency|(|haloperidol|) (l_amod) marked_3\JJ|becomes (l_auxpass) becomes_2\VBZ|if|agitation (l_nsubj) agitation_1\NN|
14736955
D004317_D009401 CID doxorubicin_10\NN| (r_compound) nephrosis_11\NN|doxorubicin
D004317_D007674 NONE Doxorubicin_0\NNP| (r_nsubj) induces_1\VBZ|doxorubicin|nephropathy|. (l_dobj) nephropathy_6\NN|a|perpetuating|characterized
D004317_D007674 NONE Doxorubicin_0\NNP| (r_nsubj) induces_1\VBZ|doxorubicin|nephropathy|. (l_dobj) nephropathy_6\NN|a|perpetuating|characterized (l_acl) characterized_7\VBN|by (l_agent) by_8\IN|lesions (l_pobj) lesions_16\NNS|glomerular|onset|tubular|in
D004317_D007674 NONE doxorubicin_27\RB| (r_npadvmod) induced_29\VBN|doxorubicin|- (r_amod) lesions_31\NNS|induced|renal
C102006_D007674 NONE citrate_32\NN| (r_compound) synthase_33\NN|citrate (r_compound) activity_34\NN|increased|synthase (r_conj) activities_15\NNS|depressed|of|and|activity (r_appos) lesions_12\NNS|significant|glomerular|,|activities
D013481_D007674 NONE superoxide_41\JJ| (r_amod) production_42\NN|superoxide|and|activities (r_pobj) with_40\IN|production (r_prep) correlated_39\VBN|injury|was|positively|with|. (r_conj) correlated_10\VBN|among|were|inversely|with|activities|correlated (l_prep) Among_0\IN|animals|injury (l_pobj) injury_7\NN|glomerular
D013481_D007674 NONE superoxide_25\NN|in (l_prep) in_26\IN|lesions (l_pobj) lesions_31\NNS|induced|renal
343678
D006514_D006509 NONE antigen_43\NN|b|surface (r_nmod) donors_46\NNS|antigen|(|hbsag)-positive (r_pobj) to_39\IN|donors (r_prep) exposure_38\NN|stick|to (r_pobj) after_34\IN|exposure (r_prep) preventing_30\VBG|hepatitis|after (r_pcomp) in_29\IN|preventing (r_prep) efficacies_28\NNS|their|relative|in (r_dobj) assess_25\VB|to|efficacies (r_advcl) examined_15\VBN|globulin|were|in|assess|. (l_nsubjpass) globulin_3\NN|b|immune|hbig|and|globulin (l_compound) B_1\NN|hepatitis
D006514_D006509 NONE antigen_43\NN|b|surface (r_nmod) donors_46\NNS|antigen|(|hbsag)-positive (r_pobj) to_39\IN|donors (r_prep) exposure_38\NN|stick|to (r_pobj) after_34\IN|exposure (r_prep) preventing_30\VBG|hepatitis|after (l_dobj) hepatitis_33\NN|type|b
D006514_D006509 NONE HBsAG)-positive_45\JJ| (r_compound) donors_46\NNS|antigen|(|hbsag)-positive (r_pobj) to_39\IN|donors (r_prep) exposure_38\NN|stick|to (r_pobj) after_34\IN|exposure (r_prep) preventing_30\VBG|hepatitis|after (r_pcomp) in_29\IN|preventing (r_prep) efficacies_28\NNS|their|relative|in (r_dobj) assess_25\VB|to|efficacies (r_advcl) examined_15\VBN|globulin|were|in|assess|. (l_nsubjpass) globulin_3\NN|b|immune|hbig|and|globulin (l_compound) B_1\NN|hepatitis
D006514_D006509 NONE HBsAG)-positive_45\JJ| (r_compound) donors_46\NNS|antigen|(|hbsag)-positive (r_pobj) to_39\IN|donors (r_prep) exposure_38\NN|stick|to (r_pobj) after_34\IN|exposure (r_prep) preventing_30\VBG|hepatitis|after (l_dobj) hepatitis_33\NN|type|b
12760988
D013390_D010149 CID succinylcholine_3\NN| (r_pobj) after_2\IN|succinylcholine (r_prep) myalgia_1\NN|postoperative|after|:|evidence|.
D013390_D010149 CID succinylcholine_6\NN| (r_pobj) with_5\IN|succinylcholine (r_prep) associated_4\VBN|with (r_acl) effect_3\NN|a|common|side|associated (r_nsubj) is_7\VBZ|effect|myalgia|. (l_attr) myalgia_9\NN|postoperative
D013390_D010149 CID succinylcholine_6\NN| (r_pobj) before_5\IN|succinylcholine (r_punct) IMPLICATIONS_0\NNS|:|administration|before (r_nsubj) was_7\VBD|implications|not|effective|. (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|decreasing (l_pcomp) decreasing_11\VBG|incidence (l_dobj) incidence_13\NN|the|or|severity (l_conj) severity_16\NN|the|of (l_prep) of_17\IN|myalgia (l_pobj) myalgia_22\NN|induced|postoperative
D013390_D010149 CID succinylcholine_18\NN| (r_npadvmod) induced_20\VBN|succinylcholine|- (r_amod) myalgia_22\NN|induced|postoperative
D013390_D010149 CID succinylcholine_11\NN| (r_pobj) after_10\IN|succinylcholine (r_prep) prevent_7\VB|to|myalgia|after (l_dobj) myalgia_9\NN|postoperative
D013390_D063806 CID succinylcholine_5\NN| (r_npadvmod) associated_7\VBN|succinylcholine|- (r_amod) myalgia_8\NN|associated
D013390_D063806 CID succinylcholine_20\NN|32 (r_pobj) before_19\IN|succinylcholine (r_prep) pretreated_14\VBN|with|before (r_acl) patients_13\NNS|64|pretreated (r_pobj) in_11\IN|patients (r_prep) determined_10\VBN|incidence|was|in|. (l_nsubjpass) incidence_1\NN|the|and|severity|of (l_prep) of_4\IN|myalgia (l_pobj) myalgia_8\NN|associated
D013390_D063806 CID succinylcholine_12\NN| (r_npadvmod) associated_14\VBN|succinylcholine|- (r_amod) myalgia_15\NN|associated
D003907_D063806 NONE dexamethasone_18\NN| (r_conj) saline_16\NN|or|dexamethasone (r_pobj) with_15\IN|saline (r_prep) pretreated_14\VBN|with|before (r_acl) patients_13\NNS|64|pretreated (r_pobj) in_11\IN|patients (r_prep) determined_10\VBN|incidence|was|in|. (l_nsubjpass) incidence_1\NN|the|and|severity|of (l_prep) of_4\IN|myalgia (l_pobj) myalgia_8\NN|associated
D003907_D063806 NONE dexamethasone_18\NN| (r_compound) group_19\NN|the|dexamethasone (r_pobj) in_16\IN|group (r_prep) patients_15\NNS|15|in (r_nsubj) complained_20\VBD|patients|of|compared|,|and|reported (r_acl) groups_12\NNS|the|two|:|complained (r_pobj) between_9\IN|groups (r_prep) differ_7\VB|incidence|did|not|significantly|between (l_nsubj) Incidence_0\NN|and|severity (l_conj) severity_2\NN|of (l_prep) of_3\IN|myalgia (l_pobj) myalgia_4\NN|
D003907_D063806 NONE dexamethasone_18\NN| (r_compound) group_19\NN|the|dexamethasone (r_pobj) in_16\IN|group (r_prep) patients_15\NNS|15|in (r_nsubj) complained_20\VBD|patients|of|compared|,|and|reported (l_prep) of_21\IN|myalgia (l_pobj) myalgia_22\NN|
D003907_D063806 NONE dexamethasone_18\NN| (r_compound) group_19\NN|the|dexamethasone (r_pobj) in_16\IN|group (r_prep) patients_15\NNS|15|in (r_nsubj) complained_20\VBD|patients|of|compared|,|and|reported (l_conj) reported_36\VBN|myalgia|was|by|. (l_nsubjpass) myalgia_34\NN|severe
D003907_D010149 NONE dexamethasone_4\NN| (r_pobj) of_3\IN|dexamethasone (r_prep) Administration_2\NN|of (r_appos) IMPLICATIONS_0\NNS|:|administration|before (r_nsubj) was_7\VBD|implications|not|effective|. (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|decreasing (l_pcomp) decreasing_11\VBG|incidence (l_dobj) incidence_13\NN|the|or|severity (l_conj) severity_16\NN|the|of (l_prep) of_17\IN|myalgia (l_pobj) myalgia_22\NN|induced|postoperative
D003907_D010149 NONE dexamethasone_2\NN| (r_pobj) with_1\IN|dexamethasone (r_prep) Pretreatment_0\NN|with (r_nsubj) is_3\VBZ|pretreatment|not|justified|. (l_acomp) justified_5\VBN|prevent (l_xcomp) prevent_7\VB|to|myalgia|after (l_dobj) myalgia_9\NN|postoperative
19721134
D010862_D001145 NONE pilocarpine_9\NN| (r_pobj) of_8\IN|pilocarpine (r_prep) effects_7\NNS|the|of (r_dobj) evaluate_5\VB|to|effects|and|explore (l_conj) explore_11\VB|mechanism|,|using (l_conj) using_17\VBG|rat (l_dobj) rat_22\NN|both|induced|and|models (l_conj) models_30\NNS|induced|arrhythmia (l_compound) arrhythmia_29\NN|pig
D010862_D001145 NONE pilocarpine_5\NN| (r_amod) onset_8\NN|that|pilocarpine|delayed|of (l_prep) of_9\IN|arrhythmias (l_pobj) arrhythmias_10\NNS|
D010862_D001145 NONE pilocarpine_5\NN| (r_amod) onset_8\NN|that|pilocarpine|delayed|of (r_dobj) showed_3\VBD|data|onset (r_ccomp) decreased_12\VBD|showed|,|course|,|score|. (l_npadvmod) score_24\NN|reduced|arrhythmia|,|and|increased (l_compound) arrhythmia_23\NN|
D010862_D001145 NONE pilocarpine_5\NN| (r_amod) onset_8\NN|that|pilocarpine|delayed|of (r_dobj) showed_3\VBD|data|onset (r_ccomp) decreased_12\VBD|showed|,|course|,|score|. (l_npadvmod) score_24\NN|reduced|arrhythmia|,|and|increased (l_conj) increased_27\VBD|time (l_dobj) time_30\NN|the|survival|of (l_prep) of_31\IN|rats (l_pobj) rats_33\NNS|arrhythmic|and|pigs (l_amod) arrhythmic_32\JJ|
D010862_D001145 NONE pilocarpine_4\NN| (r_nsubj) produced_5\VBD|that|pilocarpine|actions (l_dobj) actions_7\NNS|antiarrhythmic|on (l_prep) on_8\IN|models (l_pobj) models_14\NNS|rat|pig|induced (l_nmod) rat_10\NN|arrhythmic|and (l_amod) arrhythmic_9\JJ|
D000157_D001145 CID aconitine_19\NN| (r_npadvmod) induced_21\VBN|aconitine|- (r_amod) rat_22\NN|both|induced|and|models (l_conj) models_30\NNS|induced|arrhythmia (l_compound) arrhythmia_29\NN|pig
D000157_D001145 CID aconitine_17\NN|or|ouabain (r_pobj) by_16\IN|aconitine (r_agent) induced_15\VBN|by (r_acl) models_14\NNS|rat|pig|induced (l_nmod) rat_10\NN|arrhythmic|and (l_amod) arrhythmic_9\JJ|
D010042_D001145 CID ouabain_24\NN| (r_npadvmod) induced_26\VBN|ouabain|- (r_amod) models_30\NNS|induced|arrhythmia (l_compound) arrhythmia_29\NN|pig
D010042_D001145 CID ouabain_19\RB|via (r_conj) aconitine_17\NN|or|ouabain (r_pobj) by_16\IN|aconitine (r_agent) induced_15\VBN|by (r_acl) models_14\NNS|rat|pig|induced (l_nmod) rat_10\NN|arrhythmic|and (l_amod) arrhythmic_9\JJ|
D010862_D017180 NONE pilocarpine_5\NN| (r_amod) onset_8\NN|that|pilocarpine|delayed|of (r_dobj) showed_3\VBD|data|onset (r_ccomp) decreased_12\VBD|showed|,|course|,|score|. (l_dobj) course_15\NN|the|time|of (l_prep) of_16\IN|tachycardia (l_pobj) tachycardia_18\NN|ventricular|and|fibrillation (l_conj) fibrillation_20\NN|
D010862_D014693 NONE pilocarpine_5\NN| (r_amod) onset_8\NN|that|pilocarpine|delayed|of (r_dobj) showed_3\VBD|data|onset (r_ccomp) decreased_12\VBD|showed|,|course|,|score|. (l_dobj) course_15\NN|the|time|of (l_prep) of_16\IN|tachycardia (l_pobj) tachycardia_18\NN|ventricular|and|fibrillation (l_conj) fibrillation_20\NN|
D002118_D001145 NONE Ca(2_34\NNP|+|handling (r_pobj) of_33\IN|ca(2 (r_prep) improvement_32\NN|the|of (r_pobj) to_30\IN|improvement (r_prep) related_29\VBN|mechanism|may|be|to (r_relcl) cardiac_23\JJ|the|related (r_dobj) stimulating_21\VBG|cardiac (r_pcomp) via_20\IN|stimulating (r_prep) ouabain_19\RB|via (r_conj) aconitine_17\NN|or|ouabain (r_pobj) by_16\IN|aconitine (r_agent) induced_15\VBN|by (r_acl) models_14\NNS|rat|pig|induced (l_nmod) rat_10\NN|arrhythmic|and (l_amod) arrhythmic_9\JJ|
2466960
D005472_D066126 NONE fluorouracil_11\NN| (r_nmod) therapy_15\NN|fluorouracil|(|5-fu|) (r_pobj) with_10\IN|therapy (r_prep) associated_9\VBN|with (r_acl) toxicity_8\NN|cardiac|associated
D005472_D066126 NONE 5-FU_13\CD| (r_nmod) therapy_15\NN|fluorouracil|(|5-fu|) (r_pobj) with_10\IN|therapy (r_prep) associated_9\VBN|with (r_acl) toxicity_8\NN|cardiac|associated
D005472_D009369 NONE 5-FU_11\CD| (r_compound) infusion_12\NN|5-fu|for (l_prep) for_13\IN|treatment (l_pobj) treatment_14\NN|of (l_prep) of_15\IN|tumors (l_pobj) tumors_17\NNS|solid
D005472_D007511 CID 5-FU_11\CD| (r_compound) infusion_12\NN|5-fu|for (r_dobj) undergoing_10\VBG|infusion (r_acl) patients_9\NNS|25|undergoing (r_pobj) on_7\IN|patients (r_prep) monitoring_6\NN|continuous|ecg|on (r_dobj) performed_2\VBD|we|prospectively|monitoring|in|. (l_prep) in_18\IN|order (l_pobj) order_19\NN|assess (l_acl) assess_21\VB|to|incidence (l_dobj) incidence_23\NN|the|of (l_prep) of_24\IN|changes (l_pobj) changes_27\NNS|st (l_compound) ST_26\NNP|ischemic (l_amod) ischemic_25\JJ|
D005472_D007511 CID 5-FU_15\CD| (r_nummod) infusion_16\NN|5-fu|v|during (r_pobj) to_14\IN|infusion (r_prep) prior_13\RB|0.02|to (r_advmod) was_9\VBD|incidence|prior (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|episodes (l_pobj) episodes_4\NNS|ischemic|per|per (l_amod) ischemic_3\JJ|
D005472_D007511 CID 5-FU_22\CD| (r_nummod) infusion_23\NN|5-fu|(|p|) (r_pobj) during_21\IN|infusion (r_prep) infusion_16\NN|5-fu|v|during (r_pobj) to_14\IN|infusion (r_prep) prior_13\RB|0.02|to (r_advmod) was_9\VBD|incidence|prior (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|episodes (l_pobj) episodes_4\NNS|ischemic|per|per (l_amod) ischemic_3\JJ|
D005472_D007511 CID 5-FU_46\CD| (r_pobj) before_45\IN|5-fu (r_prep) was_36\VBD|was|;|duration|+/-|before|v|during|. (l_ccomp) was_9\VBD|incidence|prior (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|episodes (l_pobj) episodes_4\NNS|ischemic|per|per (l_amod) ischemic_3\JJ|
D005472_D007511 CID 5-FU_57\CD|(|p (r_pobj) during_56\IN|5-fu (r_prep) was_36\VBD|was|;|duration|+/-|before|v|during|. (l_ccomp) was_9\VBD|incidence|prior (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|episodes (l_pobj) episodes_4\NNS|ischemic|per|per (l_amod) ischemic_3\JJ|
D005472_D007511 CID 5-FU_3\CD| (r_compound) infusion_4\NN|5-fu (r_nsubjpass) associated_6\VBN|that|infusion|is|with (l_prep) with_7\IN|increase (l_pobj) increase_10\NN|a|significant|in|,|among (l_prep) in_11\IN|deviation (l_pobj) deviation_15\NN|silent|segment|suggestive (l_amod) suggestive_16\JJ|of (l_prep) of_17\IN|ischemia (l_pobj) ischemia_18\NN|
D005472_D000787 CID 5-FU_12\CD| (r_nummod) infusion_13\NN|5-fu (r_pobj) during_11\IN|infusion (r_prep) had_8\VBD|were|:|patient|angina|(|during|)|. (l_ccomp) were_2\VBD|episodes|rare (l_nsubj) episodes_1\NNS|anginal (l_compound) Anginal_0\JJ|
D005472_D000787 CID 5-FU_12\CD| (r_nummod) infusion_13\NN|5-fu (r_pobj) during_11\IN|infusion (r_prep) had_8\VBD|were|:|patient|angina|(|during|)|. (l_dobj) angina_9\NN|
D005472_D003324 NONE 5-FU_3\CD| (r_compound) infusion_4\NN|5-fu (r_nsubjpass) associated_6\VBN|that|infusion|is|with (l_prep) with_7\IN|increase (l_pobj) increase_10\NN|a|significant|in|,|among (l_prep) among_21\IN|particularly|patients (l_pobj) patients_22\NNS|with (l_prep) with_23\IN|disease (l_pobj) disease_26\NN|coronary|artery
8800187
D002122_D064420 NONE chloride_3\NN|calcium|and|therapy (l_conj) therapy_6\NN|4-aminopyridine|on (l_prep) on_7\IN|toxicity (l_pobj) toxicity_9\NN|desipramine|in
D015761_D064420 NONE 4-aminopyridine_5\CD| (r_compound) therapy_6\NN|4-aminopyridine|on (l_prep) on_7\IN|toxicity (l_pobj) toxicity_9\NN|desipramine|in
D003891_D064420 NONE desipramine_8\JJ| (r_amod) toxicity_9\NN|desipramine|in
D002118_D007022 NONE calcium_7\NN| (r_compound) channel_8\NN|calcium (r_compound) blockade_9\NN|channel|in (l_prep) in_10\IN|hypotension (l_pobj) hypotension_15\NN|tricyclic|induced
D002118_D007022 NONE calcium_8\NN| (r_compound) channel_9\NN|calcium (r_compound) inhibition_10\NN|channel|in (l_prep) in_11\IN|pathogenesis (l_pobj) pathogenesis_13\NN|the|of (l_prep) of_14\IN|hypotension (l_pobj) hypotension_19\NN|tricyclic|induced
D002118_D062787 NONE calcium_14\NN| (r_compound) channel_15\NN|calcium (r_compound) overdose_17\NN|channel|blocker
D003891_D007022 CID desipramine_6\NN| (r_compound) IP_7\NNP|the|antidepressant|desipramine (r_dobj) received_2\VBD|rats|ip|produce|. (l_advcl) produce_9\VB|to|hypotension|,|prolongation (l_dobj) hypotension_10\NN|
D003891_D001919 CID desipramine_6\NN| (r_compound) IP_7\NNP|the|antidepressant|desipramine (r_dobj) received_2\VBD|rats|ip|produce|. (l_advcl) produce_9\VB|to|hypotension|,|prolongation (l_dobj) prolongation_13\NN|qrs|,|and|bradycardia (l_conj) bradycardia_16\NN|
D017693_D007022 NONE NaHCO3_0\NNP|min (r_nsubj) reversed_6\VBD|nahco3|hypotension|. (l_dobj) hypotension_7\NN|and|prolongation
D002122_D001145 CID CaCl2_19\NNP| (r_compound) group_20\NN|the|cacl2 (r_pobj) in_17\IN|group (r_prep) seizures_11\NNS|(|0.03|)|in (r_conj) arrhythmias_4\NNS|ventricular|0.004|and|seizures
D002122_D012640 NONE CaCl2_19\NNP| (r_compound) group_20\NN|the|cacl2 (r_pobj) in_17\IN|group (r_prep) seizures_11\NNS|(|0.03|)|in
D002122_D007022 NONE CaCl2_3\NNP| (r_pobj) of_2\IN|cacl2|or (r_prep) administration_1\NN|the|of (r_nsubj) reverse_8\VB|administration|did|not|hypotension|. (l_dobj) hypotension_13\NN|tricyclic|induced|in
D015761_D007022 NONE 4-aminopyridine_5\NN| (r_punct) did_6\VBD|4-aminopyridine (r_aux) reverse_8\VB|administration|did|not|hypotension|. (l_dobj) hypotension_13\NN|tricyclic|induced|in
D002122_D002318 NONE CaCl2_0\NNP| (r_compound) therapy_1\NN|cacl2 (r_nsubj) worsen_4\VB|therapy|may|possibly|toxicity|. (l_dobj) toxicity_11\NN|both|system
D002122_D002493 NONE CaCl2_0\NNP| (r_compound) therapy_1\NN|cacl2 (r_nsubj) worsen_4\VB|therapy|may|possibly|toxicity|. (l_dobj) toxicity_11\NN|both|system
7604176
D017035_D009135 NONE Pravastatin_0\NNP| (r_npadvmod) associated_2\VBN|pravastatin|- (r_amod) myopathy_3\NN|associated|.
D017035_D009135 NONE pravastatin_17\JJ| (r_amod) discontinuation_18\NN|pravastatin (r_pobj) after_16\IN|discontinuation (r_prep) resolved_11\VBD|which|in|after (r_relcl) limbs_9\NNS|the|lower|resolved (r_pobj) of_6\IN|limbs (r_prep) myopathy_5\NN|acute|of
D017035_D009135 NONE pravastatin_11\RB| (r_npadvmod) associated_13\VBN|pravastatin|- (r_amod) myopathy_14\NNS|associated (r_nsubj) represent_16\VB|associated|,|myopathy|could|entity|. (l_advcl) associated_6\VBN|while|lovastatin|have|been|with (l_prep) with_7\IN|myopathy (l_pobj) myopathy_9\NNS|toxic
D017035_D009135 NONE pravastatin_11\RB| (r_npadvmod) associated_13\VBN|pravastatin|- (r_amod) myopathy_14\NNS|associated
D017035_D009220 CID pravastatin_11\NN| (r_pobj) of_10\IN|pravastatin (r_prep) use_9\NN|the|of (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) case_1\NN|a|of|associated|,|inhibitor (l_prep) of_2\IN|myopathy (l_pobj) myopathy_5\NNS|acute|inflammatory
D017035_D006937 NONE pravastatin_2\RB| (r_dobj) assumed_1\VBD|he|pravastatin|day|because|. (l_prep) because_9\IN|of|hypercholesterolemia (l_pobj) hypercholesterolemia_11\NN|
D008148_D009135 NONE lovastatin_1\NN|and|simvastatin (r_nsubjpass) associated_6\VBN|while|lovastatin|have|been|with (l_prep) with_7\IN|myopathy (l_pobj) myopathy_9\NNS|toxic
D008148_D009135 NONE lovastatin_1\NN|and|simvastatin (r_nsubjpass) associated_6\VBN|while|lovastatin|have|been|with (r_advcl) represent_16\VB|associated|,|myopathy|could|entity|. (l_nsubj) myopathy_14\NNS|associated
D019821_D009135 NONE simvastatin_3\NN| (r_conj) lovastatin_1\NN|and|simvastatin (r_nsubjpass) associated_6\VBN|while|lovastatin|have|been|with (l_prep) with_7\IN|myopathy (l_pobj) myopathy_9\NNS|toxic
D019821_D009135 NONE simvastatin_3\NN| (r_conj) lovastatin_1\NN|and|simvastatin (r_nsubjpass) associated_6\VBN|while|lovastatin|have|been|with (r_advcl) represent_16\VB|associated|,|myopathy|could|entity|. (l_nsubj) myopathy_14\NNS|associated
9431903
D005996_D046628 NONE trinitrate_3\NN|glyceryl|on (l_prep) on_4\IN|sphincter (l_pobj) sphincter_6\NN|the|of (l_prep) of_7\IN|spasm (l_pobj) spasm_9\NN|oddi|evoked
D005996_D046628 NONE trinitrate_9\NN|glyceryl|on (l_prep) on_10\IN|sphincter (l_pobj) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi
D005996_D046628 NONE trinitrate_9\NN|glyceryl|on (r_pobj) of_7\IN|trinitrate (r_prep) effect_6\NN|the|of (r_nsubjpass) evaluated_22\VBN|objective|:|in|effect|was|in|with|. (l_prep) with_27\IN|sphincter (l_pobj) sphincter_28\NN|of (l_prep) of_29\IN|dyskinesia (l_pobj) dyskinesia_31\NN|oddi
D005996_D046628 NONE trinitrate_11\NN|glyceryl|on (l_prep) on_12\IN|sphincter (l_pobj) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi|in
D005996_D046628 NONE trinitrate_2\NN|glyceryl (r_nsubj) is_3\VBZ|since|trinitrate|able (r_advcl) be_16\VB|is|,|it|might|of|in|. (l_prep) in_19\IN|treatment (l_pobj) treatment_21\NN|the|of (l_prep) of_22\IN|sphincter (l_pobj) sphincter_23\NN|of (l_prep) of_24\IN|dyskinesia (l_pobj) dyskinesia_26\NN|oddi
D005996_D013035 NONE trinitrate_3\NN|glyceryl|on (l_prep) on_4\IN|sphincter (l_pobj) sphincter_6\NN|the|of (l_prep) of_7\IN|spasm (l_pobj) spasm_9\NN|oddi|evoked
D005996_D013035 NONE trinitrate_9\NN|glyceryl|on (l_prep) on_10\IN|sphincter (l_pobj) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi
D005996_D013035 NONE trinitrate_11\NN|glyceryl|on (l_prep) on_12\IN|sphincter (l_pobj) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi|in
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|prostigmine|- (r_compound) administration_15\NN|morphine (r_pobj) by_11\IN|administration (r_agent) evoked_10\VBN|by (r_acl) spasm_9\NN|oddi|evoked
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|prostigmine|- (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi
D009388_D046628 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|prostigmine|- (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (r_pobj) on_10\IN|sphincter (r_prep) trinitrate_9\NN|glyceryl|on (r_pobj) of_7\IN|trinitrate (r_prep) effect_6\NN|the|of (r_nsubjpass) evaluated_22\VBN|objective|:|in|effect|was|in|with|. (l_prep) with_27\IN|sphincter (l_pobj) sphincter_28\NN|of (l_prep) of_29\IN|dyskinesia (l_pobj) dyskinesia_31\NN|oddi
D009388_D046628 CID prostigmine_7\JJ| (r_compound) morphine_9\NN|prostigmine|- (r_compound) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009388_D046628 CID prostigmine_14\NN|(|mg|intramuscularly|and|morphine|subcutaneously|) (r_parataxis) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009388_D013035 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|prostigmine|- (r_compound) administration_15\NN|morphine (r_pobj) by_11\IN|administration (r_agent) evoked_10\VBN|by (r_acl) spasm_9\NN|oddi|evoked
D009388_D013035 CID prostigmine_12\JJ| (r_compound) morphine_14\NN|prostigmine|- (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi
D009388_D013035 CID prostigmine_7\JJ| (r_compound) morphine_9\NN|prostigmine|- (r_compound) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009388_D013035 CID prostigmine_14\NN|(|mg|intramuscularly|and|morphine|subcutaneously|) (r_parataxis) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009388_D013035 CID Prostigmine_1\JJ| (r_compound) morphine_3\NN|prostigmine|- (r_compound) provocation_4\NN|morphine (r_nsubj) caused_5\VBD|:|provocation|increases|5.05|)|and|+/-|indicating|. (l_advcl) indicating_97\VBG|spasm (l_dobj) spasm_100\NN|a|complete|at
D009020_D046628 CID morphine_14\NN|prostigmine|- (r_compound) administration_15\NN|morphine (r_pobj) by_11\IN|administration (r_agent) evoked_10\VBN|by (r_acl) spasm_9\NN|oddi|evoked
D009020_D046628 CID morphine_14\NN|prostigmine|- (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi
D009020_D046628 CID morphine_14\NN|prostigmine|- (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (r_pobj) on_10\IN|sphincter (r_prep) trinitrate_9\NN|glyceryl|on (r_pobj) of_7\IN|trinitrate (r_prep) effect_6\NN|the|of (r_nsubjpass) evaluated_22\VBN|objective|:|in|effect|was|in|with|. (l_prep) with_27\IN|sphincter (l_pobj) sphincter_28\NN|of (l_prep) of_29\IN|dyskinesia (l_pobj) dyskinesia_31\NN|oddi
D009020_D046628 CID morphine_9\NN|prostigmine|- (r_compound) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009020_D046628 CID morphine_19\NN|mg (r_conj) prostigmine_14\NN|(|mg|intramuscularly|and|morphine|subcutaneously|) (r_parataxis) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009020_D046628 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi|in
D009020_D046628 CID morphine_12\NN| (r_pobj) of_11\IN|morphine (r_prep) effect_10\NN|even|the|drastic|of (r_dobj) overcome_6\VB|to|effect (r_xcomp) able_4\JJ|overcome (r_acomp) is_3\VBZ|since|trinitrate|able (r_advcl) be_16\VB|is|,|it|might|of|in|. (l_prep) in_19\IN|treatment (l_pobj) treatment_21\NN|the|of (l_prep) of_22\IN|sphincter (l_pobj) sphincter_23\NN|of (l_prep) of_24\IN|dyskinesia (l_pobj) dyskinesia_26\NN|oddi
D009020_D013035 CID morphine_14\NN|prostigmine|- (r_compound) administration_15\NN|morphine (r_pobj) by_11\IN|administration (r_agent) evoked_10\VBN|by (r_acl) spasm_9\NN|oddi|evoked
D009020_D013035 CID morphine_14\NN|prostigmine|- (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi
D009020_D013035 CID morphine_9\NN|prostigmine|- (r_compound) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009020_D013035 CID morphine_19\NN|mg (r_conj) prostigmine_14\NN|(|mg|intramuscularly|and|morphine|subcutaneously|) (r_parataxis) administration_10\NN|morphine|prostigmine (r_pobj) by_6\IN|administration (r_agent) induced_5\VBN|spasm|was|by|and|visualized|. (l_nsubjpass) spasm_3\NN|sphincter
D009020_D013035 CID morphine_3\NN|prostigmine|- (r_compound) provocation_4\NN|morphine (r_nsubj) caused_5\VBD|:|provocation|increases|5.05|)|and|+/-|indicating|. (l_advcl) indicating_97\VBG|spasm (l_dobj) spasm_100\NN|a|complete|at
D009020_D013035 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|morphine|- (r_amod) sphincter_17\NN|the|induced|of (l_prep) of_18\IN|spasm (l_pobj) spasm_20\NN|oddi|in
2339463
D015119_D020225 NONE acid_22\NN| (r_compound) therapy_23\NN|prolonged|aminocaproic|acid|for (r_pobj) with_17\IN|therapy (r_prep) associated_16\VBN|with (r_acl) thrombosis_15\NN|transverse|sinus|associated
D015119_D020227 NONE acid_22\NN| (r_compound) therapy_23\NN|prolonged|aminocaproic|acid|for (r_pobj) with_17\IN|therapy (r_prep) associated_16\VBN|with (r_acl) thrombosis_15\NN|transverse|sinus|associated
D015119_D008595 NONE acid_22\NN| (r_compound) therapy_23\NN|prolonged|aminocaproic|acid|for (l_prep) for_24\IN|menorrhagia (l_pobj) menorrhagia_25\NN|
D015119_D013923 NONE acid_15\NN|aminocaproic|,|thrombosis (r_pobj) with_11\IN|acid (r_prep) treatment_10\NN|with (r_pobj) during_9\IN|treatment (r_prep) reported_8\VBN|increased|risk|has|been|during (l_nsubjpass) risk_2\NN|of (l_prep) of_3\IN|disease (l_pobj) disease_5\NN|thromboembolic
D015119_D012851 NONE acid_15\NN|aminocaproic|,|thrombosis (l_appos) thrombosis_19\NN|cerebral|sinus
1255900
D006493_D013924 NONE heparin_8\JJ| (r_compound) therapy_9\NN|heparin (r_pobj) of_7\IN|therapy (r_prep) initiation_6\NN|the|of|for (l_prep) for_10\IN|thrombophlebitis (l_pobj) thrombophlebitis_13\NN|suspected|pelvic
7843916
D003907_D009798 CID Dexamethasone_0\NN| (r_npadvmod) induced_2\VBN|dexamethasone|-|hypertension|. (l_dobj) hypertension_4\NN|ocular|in
D003907_D009798 CID dexamethasone_4\NN| (r_npadvmod) treated_6\VBN|dexamethasone|- (r_amod) eyes_8\NNS|the|treated|hypertensive
D003907_D009798 CID Dexamethasone_0\NN| (r_compound) treatment_1\NN|dexamethasone|of (r_nsubj) led_10\VBD|treatment|to|. (l_prep) to_11\IN|generation (l_pobj) generation_13\NN|the|of|in (l_prep) of_14\IN|hypertension (l_pobj) hypertension_16\NN|ocular
D003907_D009798 CID dexamethasone_23\NN| (r_npadvmod) treated_25\VBN|dexamethasone|- (r_amod) eyes_26\NNS|the|treated (r_pobj) of_21\IN|eyes (r_prep) %_20\NN|30|of (r_pobj) in_17\IN|% (r_prep) generation_13\NN|the|of|in (l_prep) of_14\IN|hypertension (l_pobj) hypertension_16\NN|ocular
D013256_D005901 NONE Steroid_0\NN| (r_compound) treatment_1\NN|steroid (r_nsubj) resulted_2\VBD|treatment|in|. (l_prep) in_3\IN|changes (l_pobj) changes_5\NNS|morphologic|in (l_prep) in_6\IN|meshwork (l_pobj) meshwork_9\NN|the|trabecular|similar (l_amod) similar_10\JJ|to (l_prep) to_11\IN|those (l_pobj) those_12\DT|reported (l_acl) reported_13\VBN|for (l_prep) for_14\IN|glaucoma (l_pobj) glaucoma_16\NN|corticosteroid|and|glaucoma
D013256_D005902 NONE Steroid_0\NN| (r_compound) treatment_1\NN|steroid (r_nsubj) resulted_2\VBD|treatment|in|. (l_prep) in_3\IN|changes (l_pobj) changes_5\NNS|morphologic|in (l_prep) in_6\IN|meshwork (l_pobj) meshwork_9\NN|the|trabecular|similar (l_amod) similar_10\JJ|to (l_prep) to_11\IN|those (l_pobj) those_12\DT|reported (l_acl) reported_13\VBN|for (l_prep) for_14\IN|glaucoma (l_pobj) glaucoma_16\NN|corticosteroid|and|glaucoma (l_conj) glaucoma_20\NN|open|angle
11573852
D000666_D012640 CID B_1\NN|amphotericin (r_npadvmod) induced_3\VBN|b|- (r_amod) seizures_4\NNS|induced|in|.
D000666_D012640 CID B_16\NNP|amphotericin (r_compound) infusion_17\NN|b (r_pobj) following_14\VBG|infusion (r_prep) case_3\NN|a|of|following (l_prep) of_4\IN|episodes (l_pobj) episodes_6\NNS|multiple|of|in (l_prep) of_7\IN|activity (l_pobj) activity_9\NN|seizure (l_compound) seizure_8\NN|
D000666_D012640 CID B_18\NNP|amphotericin (r_pobj) of_16\IN|b (r_prep) infusion_15\NN|intravenous|of (r_pobj) during_13\IN|infusion (r_prep) experienced_8\VBD|man|seizures|during|,|then|stopped|. (l_conj) stopped_28\VBN|seizures|was|and|decreased (l_nsubjpass) seizures_23\NNS|mal|as
D000666_D012640 CID B_15\NNP| (r_compound) administration_16\NN|amphotercin|b (r_pobj) during_13\IN|only|administration (r_prep) occurred_11\VBD|during (r_conj) persisted_9\VBD|despite|,|seizures|and|occurred|. (l_nsubj) seizures_8\NNS|the
D000666_D012640 CID B_8\NNP|amphotericin (r_nsubj) was_9\VBD|that|b|cause (l_attr) cause_11\NN|the|of (l_prep) of_12\IN|seizures (l_pobj) seizures_14\NNS|the|in
D000666_D012640 CID B_1\NNP|amphotericin (r_nsubj) seems_2\VBZ|b|be|. (l_xcomp) be_4\VB|to|cause (l_attr) cause_7\NN|the|probable|of (l_prep) of_8\IN|seizures (l_pobj) seizures_10\NNS|the
D000666_D012640 CID B_11\NNP|amphotericin (r_pobj) with_9\IN|b (r_prep) associated_8\VBN|with (r_acl) seizures_7\NNS|associated
D000666_D000163 NONE B_1\NN|amphotericin (r_npadvmod) induced_3\VBN|b|- (r_amod) seizures_4\NNS|induced|in|. (l_prep) in_5\IN|patient (l_pobj) patient_7\NN|a|with (l_prep) with_8\IN|aids (l_pobj) AIDS_9\NNP|
D000666_D000163 NONE B_16\NNP|amphotericin (r_compound) infusion_17\NN|b (r_pobj) following_14\VBG|infusion (r_prep) case_3\NN|a|of|following (l_prep) of_4\IN|episodes (l_pobj) episodes_6\NNS|multiple|of|in (l_prep) in_10\IN|patent (l_pobj) patent_13\NN|an|aids (l_compound) AIDS_12\NNP|
D000666_D000163 NONE B_8\NNP|amphotericin (r_nsubj) was_9\VBD|that|b|cause (l_attr) cause_11\NN|the|of (l_prep) of_12\IN|seizures (l_pobj) seizures_14\NNS|the|in (l_prep) in_15\IN|patient (l_pobj) patient_18\NN|this|aids (l_compound) AIDS_17\NNP|
D000666_D004830 NONE B_18\NNP|amphotericin (r_pobj) of_16\IN|b (r_prep) infusion_15\NN|intravenous|of (r_pobj) during_13\IN|infusion (r_prep) experienced_8\VBD|man|seizures|during|,|then|stopped|. (l_dobj) seizures_12\NNS|recurrent|mal
D010672_D012640 NONE phenytoin_3\NN|and|lorazepam (r_pobj) of_2\IN|phenytoin (r_prep) administration_1\NN|of (r_pobj) Despite_0\IN|administration (r_prep) persisted_9\VBD|despite|,|seizures|and|occurred|. (l_nsubj) seizures_8\NNS|the
D008140_D012640 NONE lorazepam_5\NN| (r_conj) phenytoin_3\NN|and|lorazepam (r_pobj) of_2\IN|phenytoin (r_prep) administration_1\NN|of (r_pobj) Despite_0\IN|administration (r_prep) persisted_9\VBD|despite|,|seizures|and|occurred|. (l_nsubj) seizures_8\NNS|the
D000431_D000437 NONE alcohol_9\NN| (r_compound) intake_10\NN|alcohol|as|withdrawal (r_conj) history_4\NN|a|of|;|intake (l_prep) of_5\IN|abuse (l_pobj) abuse_7\NN|alcohol
D000431_D012640 NONE alcohol_9\NN| (r_compound) intake_10\NN|alcohol|as|withdrawal (r_conj) history_4\NN|a|of|;|intake (r_dobj) had_2\VBD|patient|history|cause|. (l_conj) cause_17\VB|can|also|seizures (l_dobj) seizures_18\NNS|
D016049_D012640 NONE Didanosine_0\NNP| (r_nsubj) has_2\VBZ|didanosine|also|potential|. (l_dobj) potential_4\NN|a|for (l_prep) for_5\IN|inducing (l_pcomp) inducing_6\VBG|seizures (l_dobj) seizures_7\NNS|
1595783
D000638_D008171 NONE Amiodarone_0\NN| (r_amod) toxicity_2\NN|amiodarone|pulmonary|.
D000638_D008171 NONE amiodarone_4\NN| (r_pobj) of_3\IN|amiodarone (r_prep) toxicity_2\NN|the|pulmonary|of
D000638_D008171 NONE amiodarone_6\NN| (r_npadvmod) induced_8\VBN|amiodarone|- (r_amod) toxicity_10\NN|induced|pulmonary
D000638_D011014 CID Amiodarone_0\NN| (r_nsubj) is_1\VBZ|amiodarone|agent|. (l_attr) agent_5\NN|an|effective|antiarrhythmic|limited|,|being (l_appos) being_19\VBG|the|problematic|pneumonitis (l_attr) pneumonitis_20\NN|
D000638_D004342 NONE amiodarone_4\NN| (r_pobj) of_3\IN|amiodarone (r_prep) toxicity_2\NN|the|pulmonary|of (r_nsubjpass) thought_6\VBN|toxicity|is|result|. (l_xcomp) result_8\VB|to|from (l_prep) from_9\IN|injury (l_pobj) injury_11\NN|direct|related (l_acl) related_12\VBN|to (l_prep) to_13\IN|accumulation (l_pobj) accumulation_16\NN|the|intracellular|of (l_prep) of_17\IN|pneumonitis (l_pobj) pneumonitis_25\NN|phospholipid|hypersensitivity
D000638_D000542 NONE amiodarone_4\NN| (r_pobj) of_3\IN|amiodarone (r_prep) toxicity_2\NN|the|pulmonary|of (r_nsubjpass) thought_6\VBN|toxicity|is|result|. (l_xcomp) result_8\VB|to|from (l_prep) from_9\IN|injury (l_pobj) injury_11\NN|direct|related (l_acl) related_12\VBN|to (l_prep) to_13\IN|accumulation (l_pobj) accumulation_16\NN|the|intracellular|of (l_prep) of_17\IN|pneumonitis (l_pobj) pneumonitis_25\NN|phospholipid|hypersensitivity
10533019
D004110_D013746 CID diltiazem_6\NN| (r_npadvmod) induced_8\VBN|diltiazem|- (r_amod) tetany_9\NN|threatening|induced|with
D004110_D013746 CID diltiazem_16\NN|intravenous (r_pobj) of_14\IN|diltiazem (r_prep) infusion_13\NN|the|of (r_pobj) after_11\IN|infusion (r_prep) developed_5\VBD|who|tetany|with|after (l_dobj) tetany_6\NN|
D004110_D013746 CID diltiazem_17\NN|intravenous (r_pobj) of_15\IN|diltiazem (r_prep) administration_14\NN|the|of (r_dobj) accompany_12\VB|that|tetany|may|administration|and|be (l_nsubj) tetany_10\NN|threatening
D002122_D013746 NONE chloride_12\NN|calcium (r_pobj) with_10\IN|chloride (r_prep) tetany_9\NN|threatening|induced|with
D002122_D013746 NONE chloride_4\NN|calcium (r_pobj) of_2\IN|chloride (r_prep) administration_1\NN|the|of (r_nsubj) resolved_6\VBD|administration|rapidly|tetany|,|averting|. (l_dobj) tetany_10\NN|patient|with
D002122_D013746 NONE chloride_21\NN|calcium (r_nsubj) be_23\VB|that|chloride|may|remedy (r_conj) accompany_12\VB|that|tetany|may|administration|and|be (l_nsubj) tetany_10\NN|threatening
D004110_D012131 NONE diltiazem_16\NN|intravenous (r_pobj) of_14\IN|diltiazem (r_prep) infusion_13\NN|the|of (r_pobj) after_11\IN|infusion (r_prep) developed_5\VBD|who|tetany|with|after (l_prep) with_7\IN|arrest (l_pobj) arrest_10\NN|sudden|respiratory
19707748
D064704_D012640 CID levofloxacin_3\NNS| (r_pobj) with_2\IN|levofloxacin (r_prep) associated_1\VBN|with (r_acl) Seizures_0\NNS|associated|:|presentation|.
D064704_D012640 CID levofloxacin_15\NNS| (r_pobj) with_14\IN|levofloxacin (r_prep) treatment_13\NN|with (r_dobj) initiating_12\VBG|treatment|and|discuss (r_pcomp) after_11\IN|shortly|initiating|as (r_prep) developed_8\VBD|who|seizures|after (l_dobj) seizures_9\NNS|
D064704_D012640 CID levofloxacin_15\NNS| (r_pobj) with_14\IN|levofloxacin (r_prep) treatment_13\NN|with (r_dobj) initiating_12\VBG|treatment|and|discuss (r_pcomp) after_11\IN|shortly|initiating|as (r_prep) developed_8\VBD|who|seizures|after (r_relcl) patient_6\NN|a|developed|,|of (l_prep) of_47\IN|seizures (l_pobj) seizures_51\NNS|induced
D064704_D012640 CID levofloxacin_48\NN| (r_npadvmod) induced_50\VBN|levofloxacin|- (r_amod) seizures_51\NNS|induced (r_pobj) of_47\IN|seizures (r_prep) patient_6\NN|a|developed|,|of (l_relcl) developed_8\VBD|who|seizures|after (l_dobj) seizures_9\NNS|
D064704_D012640 CID levofloxacin_48\NN| (r_npadvmod) induced_50\VBN|levofloxacin|- (r_amod) seizures_51\NNS|induced
D064704_D012640 CID levofloxacin_3\NN| (r_npadvmod) induced_5\VBN|levofloxacin|- (r_amod) seizures_6\NNS|induced
8958188
C045894_D009369 NONE lometrexol_9\NN| (r_nsubj) has_10\VBZ|that|lometrexol|activity (l_dobj) activity_11\NN|against (l_prep) against_12\IN|tumours (l_pobj) tumours_13\NNS|are
D008727_D009369 NONE methotrexate_22\NNP|notably (r_appos) drugs_19\NNS|other|,|methotrexate (r_pobj) to_17\IN|drugs (r_prep) refractory_16\JJ|to (r_acomp) are_15\VBP|which|refractory (r_relcl) tumours_13\NNS|are
C045894_D064420 NONE lometrexol_7\NN| (r_pobj) of_6\IN|lometrexol (r_prep) development_5\NN|the|initial|clinical|of (r_nsubjpass) curtailed_9\VBN|however|,|development|was|because|. (l_prep) because_10\IN|of|toxicities (l_pobj) toxicities_16\NNS|severe|antiproliferative
C045894_D064420 NONE lometrexol_8\NN| (r_pobj) of_7\IN|lometrexol (r_prep) toxicity_6\NN|the|of
C045894_D064420 NONE lometrexol_9\NN| (r_pobj) of_8\IN|lometrexol (r_prep) study_7\NN|i|clinical|of|given (l_acl) given_10\VBN|with (l_prep) with_11\IN|supplementation (l_pobj) supplementation_14\NN|folic|acid|confirmed (l_relcl) confirmed_17\VBN|which|has|reduced (l_ccomp) reduced_26\VBN|that|toxicity|can|be|markedly|by (l_nsubjpass) toxicity_20\NN|the|of
C045894_D064420 NONE lometrexol_22\NN| (r_pobj) of_21\IN|lometrexol (r_prep) toxicity_20\NN|the|of
C045894_D064420 NONE lometrexol_4\NN| (r_compound) plasma_5\NN|lometrexol (r_compound) pharmacokinetics_6\NNS|plasma (r_nsubjpass) altered_9\VBN|that|pharmacokinetics|were|not|by|indicating (l_advcl) indicating_14\VBG|is (l_ccomp) is_17\VBZ|that|supplementation|unlikely (l_acomp) unlikely_18\JJ|reduce (l_xcomp) reduce_20\VB|to|toxicity|by (l_dobj) toxicity_21\NN|
C045894_D064420 NONE lometrexol_24\NN| (r_compound) plasma_25\NN|lometrexol (r_compound) clearance_26\NN|plasma (r_dobj) enhancing_23\VBG|clearance (r_pcomp) by_22\IN|enhancing (r_prep) reduce_20\VB|to|toxicity|by (l_dobj) toxicity_21\NN|
D005492_D064420 NONE acid_16\NN| (r_compound) administration_17\NN|low|dose|folic|acid|, (r_pobj) by_12\IN|administration (r_agent) prevented_11\VBN|that|toxicity|can|be|by|for|following (l_nsubjpass) toxicity_6\NN|the|of
D005492_D064420 NONE acid_13\NN| (r_compound) supplementation_14\NN|folic|acid|confirmed (l_relcl) confirmed_17\VBN|which|has|reduced (l_ccomp) reduced_26\VBN|that|toxicity|can|be|markedly|by (l_nsubjpass) toxicity_20\NN|the|of
D005492_D064420 NONE acid_29\NN| (r_compound) supplementation_30\NN|folic|acid (r_pobj) by_27\IN|supplementation (r_agent) reduced_26\VBN|that|toxicity|can|be|markedly|by (l_nsubjpass) toxicity_20\NN|the|of
D005492_D064420 NONE folate_13\JJ| (r_compound) elevation_14\NN|plasma|folate (r_pobj) of_11\IN|elevation (r_prep) extent_10\NN|the|of (r_conj) toxicity_7\NN|clinical|and|extent
D005492_D064420 NONE acid_12\NN| (r_compound) administration_13\NN|folic|acid (r_pobj) by_10\IN|administration (r_agent) altered_9\VBN|that|pharmacokinetics|were|not|by|indicating (l_advcl) indicating_14\VBG|is (l_ccomp) is_17\VBZ|that|supplementation|unlikely (l_acomp) unlikely_18\JJ|reduce (l_xcomp) reduce_20\VB|to|toxicity|by (l_dobj) toxicity_21\NN|
9758264
D005492_D008180 CID acid_4\NN|folic (r_pobj) of_2\IN|acid (r_prep) activity_1\NN|epileptogenic|of (r_nsubj) induces_7\VBZ|activity|after|sle|) (l_dobj) SLE_8\NNP|(|acid
D005492_D008180 CID acid_11\NN|folic|and|epilepsy (r_appos) SLE_8\NNP|(|acid
D005492_D008180 CID acid_35\NN|folic (r_pobj) of_33\IN|acid (r_prep) dose_25\NN|the|therapeutic|(|>|)|of (r_nsubj) triggered_36\VBD|damage|,|therefore|dose|cluster|. (l_ccomp) damage_15\VB|disease|could|barrier (l_nsubj) disease_6\NN|patient|autoimmune|(|lupus|) (l_appos) lupus_12\NN|probably|induced
D005492_D004827 NONE acid_4\NN|folic (r_pobj) of_2\IN|acid (r_prep) activity_1\NN|epileptogenic|of (r_nsubj) induces_7\VBZ|activity|after|sle|) (l_dobj) SLE_8\NNP|(|acid (l_appos) acid_11\NN|folic|and|epilepsy (l_conj) epilepsy_13\NN|
D005492_D004827 NONE acid_11\NN|folic|and|epilepsy (l_conj) epilepsy_13\NN|
D005492_D004827 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|acid|- (r_amod) supplementation_10\NN|folic|containing|multivitamin|in (l_prep) in_11\IN|women (l_pobj) women_13\NNS|epileptic (l_amod) epileptic_12\JJ|
D005492_D004827 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|acid|- (r_amod) supplementation_10\NN|folic|containing|multivitamin|in (r_pobj) of_4\IN|supplementation (r_prep) effect_3\NN|the|of (r_dobj) study_1\VB|to|effect|before|in|. (l_prep) in_18\IN|order (l_pobj) order_19\NN|determine (l_acl) determine_21\VB|to|rate (l_dobj) rate_23\NN|the|of (l_prep) of_24\IN|defects (l_pobj) defects_27\NNS|structural|birth|and|effects (l_conj) effects_33\NNS|related|side (l_amod) related_31\VBN|epilepsy|- (l_npadvmod) epilepsy_29\NN|
D005492_D004827 NONE acid_7\NN|periconceptional|folic|(|supplementation|,|effects (r_pobj) with_4\IN|acid (r_prep) women_3\NNS|60|epileptic|with|. (l_amod) epileptic_2\JJ|
D005492_D004827 NONE acid_7\NN|periconceptional|folic|(|supplementation|,|effects (l_appos) effects_21\NNS|developed|related|side|during (l_amod) related_19\VBN|epilepsy|- (l_npadvmod) epilepsy_17\NN|
D005492_D004827 NONE acid_14\NN|a|folic|multivitamin (r_conj) carbamazepine_10\NN|and|acid (r_pobj) by_9\IN|carbamazepine (r_agent) treated_7\VBN|woman|was|continuously|by|. (l_nsubjpass) woman_5\NN|this|old|epileptic (l_amod) epileptic_4\JJ|
D005492_D004827 NONE acid_35\NN|folic (r_pobj) of_33\IN|acid (r_prep) dose_25\NN|the|therapeutic|(|>|)|of (r_nsubj) triggered_36\VBD|damage|,|therefore|dose|cluster|. (l_ccomp) damage_15\VB|disease|could|barrier (l_nsubj) disease_6\NN|patient|autoimmune|(|lupus|) (l_poss) patient_3\NN|the|epileptic|pregnant|'s (l_amod) epileptic_1\JJ|
D005492_D004827 NONE acid_9\NN|folic (r_pobj) of_7\IN|acid (r_prep) mg_5\NN|(|<|1|)|of (r_appos) dose_1\NN|physiological|mg|in|,|without|, (l_prep) in_11\IN|both|women (l_pobj) women_16\NNS|healthy|60|epileptic (l_amod) epileptic_15\JJ|
D005492_D004827 NONE acid_9\NN|folic (r_pobj) of_7\IN|acid (r_prep) mg_5\NN|(|<|1|)|of (r_appos) dose_1\NN|physiological|mg|in|,|without|, (r_nsubj) increase_26\VB|dose|did|not|risk|. (l_dobj) risk_28\NN|the|for (l_prep) for_29\IN|seizures (l_pobj) seizures_31\NNS|epileptic
D005492_D000014 NONE acid_6\NN| (r_npadvmod) containing_8\VBG|acid|- (r_amod) supplementation_10\NN|folic|containing|multivitamin|in (r_pobj) of_4\IN|supplementation (r_prep) effect_3\NN|the|of (r_dobj) study_1\VB|to|effect|before|in|. (l_prep) in_18\IN|order (l_pobj) order_19\NN|determine (l_acl) determine_21\VB|to|rate (l_dobj) rate_23\NN|the|of (l_prep) of_24\IN|defects (l_pobj) defects_27\NNS|structural|birth|and|effects
D002220_D004827 NONE carbamazepine_10\NN|and|acid (r_pobj) by_9\IN|carbamazepine (r_agent) treated_7\VBN|woman|was|continuously|by|. (l_nsubjpass) woman_5\NN|this|old|epileptic (l_amod) epileptic_4\JJ|
D005492_D001327 NONE acid_35\NN|folic (r_pobj) of_33\IN|acid (r_prep) dose_25\NN|the|therapeutic|(|>|)|of (r_nsubj) triggered_36\VBD|damage|,|therefore|dose|cluster|. (l_ccomp) damage_15\VB|disease|could|barrier (l_nsubj) disease_6\NN|patient|autoimmune|(|lupus|)
D005492_D001327 NONE acid_9\NN|folic (r_pobj) of_7\IN|acid (r_prep) mg_5\NN|(|<|1|)|of (r_appos) dose_1\NN|physiological|mg|in|,|without|, (l_prep) without_19\IN|all|disease (l_pobj) disease_22\NN|any|autoimmune
D005492_D012640 CID acid_35\NN|folic (r_pobj) of_33\IN|acid (r_prep) dose_25\NN|the|therapeutic|(|>|)|of (r_nsubj) triggered_36\VBD|damage|,|therefore|dose|cluster|. (l_dobj) cluster_38\NN|a|of (l_prep) of_39\IN|seizures (l_pobj) seizures_40\NNS|
12600698
C005435_D015837 NONE edaravone_3\NN| (r_pobj) of_2\IN|edaravone (r_prep) effect_1\NN|protective|of|against|. (l_prep) against_4\IN|vestibulotoxicity (l_pobj) vestibulotoxicity_8\NN|induced|in
C005435_D015837 NONE edaravone_10\NN| (r_pobj) by_9\IN|edaravone (r_prep) alleviation_3\NN|of|by|in (l_prep) of_4\IN|vestibulotoxicity (l_pobj) vestibulotoxicity_8\NN|induced
C005435_D015837 NONE edaravone_4\NN| (r_nsubj) suppresses_5\VBZ|that|edaravone|vestibulotoxicity (l_dobj) vestibulotoxicity_9\NN|induced
D013307_D015837 CID streptomycin_5\NN| (r_npadvmod) induced_7\VBN|streptomycin|- (r_amod) vestibulotoxicity_8\NN|induced|in
D013307_D015837 CID streptomycin_5\NNS| (r_npadvmod) induced_7\VBN|streptomycin|- (r_amod) vestibulotoxicity_8\NN|induced
D013307_D015837 CID streptomycin_6\NN| (r_npadvmod) induced_8\VBN|streptomycin|- (r_amod) vestibulotoxicity_9\NN|induced
C005435_D002544 NONE Edaravone_0\NNP|,|scavenger|, (r_nsubj) has_7\VBZ|edaravone|action|and|used|. (l_conj) used_15\VBN|is|in|treat (l_xcomp) treat_20\VB|to|infarction (l_dobj) infarction_22\NN|cerebral
8607407
D002110_D006973 CID caffeine_5\NN| (r_pobj) with_4\IN|caffeine (r_prep) elevations_3\NNS|acute|pressure|with|in|. (l_prep) in_6\IN|men (l_pobj) men_7\NNS|with (l_prep) with_8\IN|hypertension (l_pobj) hypertension_11\NN|borderline|systemic
D002110_D006973 CID caffeine_5\NN| (r_pobj) of_4\IN|caffeine (r_prep) actions_3\NNS|the|vasoconstrictive|of (r_nsubjpass) enhanced_7\VBN|whether|actions|are|in (l_prep) in_8\IN|persons (l_pobj) persons_10\NNS|hypertensive (l_amod) hypertensive_9\JJ|
D002110_D006973 CID caffeine_24\NN| (r_compound) ingestion_25\NN|caffeine (r_pobj) after_23\IN|ingestion (r_prep) achieved_19\VBD|consequently|,|exhibited|,|%|levels|after|. (l_dobj) levels_22\NNS|hypertensive|bp (l_amod) hypertensive_20\JJ|
D002110_D006973 CID caffeine_10\NN| (r_pobj) to_9\IN|caffeine (r_prep) responses_8\NNS|exaggerated|to (r_nsubj) were_11\VBD|thus|,|in|,|responses|:|selective|consistent|,|replicated|. (l_prep) in_2\IN|men (l_pobj) men_5\NNS|borderline|hypertensive (l_amod) hypertensive_4\JJ|
D002110_D006973 CID caffeine_10\NN| (r_pobj) to_9\IN|caffeine (r_prep) responses_8\NNS|exaggerated|to (r_nsubj) were_11\VBD|thus|,|in|,|responses|:|selective|consistent|,|replicated|. (l_advcl) replicated_23\VBN|in|,|and|representative (l_conj) representative_29\NN|of (l_prep) of_30\IN|hypertensives (l_pobj) hypertensives_34\NNS|all|borderline
17682013
D008727_D056784 CID methotrexate_21\NN|intrathecal|for (r_pobj) of_19\IN|methotrexate (r_prep) recipients_18\NNS|of (r_pobj) in_17\IN|commonly|recipients (r_prep) described_8\VBN|leukoencephalopathy|has|been|as|,|in|. (l_nsubjpass) leukoencephalopathy_2\JJ|a|transient|mimicking
D008727_D056784 CID methotrexate_12\NNP|(|systemic|, (r_pobj) with_11\IN|methotrexate (r_prep) treated_10\VBN|with (r_acl) patients_9\NNS|treated (r_pobj) in_8\IN|patients (r_prep) leukoencephalopathy_7\JJ|toxic|in
D008727_D002544 NONE methotrexate_21\NN|intrathecal|for (r_pobj) of_19\IN|methotrexate (r_prep) recipients_18\NNS|of (r_pobj) in_17\IN|commonly|recipients (r_prep) described_8\VBN|leukoencephalopathy|has|been|as|,|in|. (l_nsubjpass) leukoencephalopathy_2\JJ|a|transient|mimicking (l_acl) mimicking_3\VBG|accident (l_dobj) accident_5\NN|cerebrovascular
D008727_D007938 NONE methotrexate_21\NN|intrathecal|for (l_prep) for_22\IN|leukaemia (l_pobj) leukaemia_24\NN|childhood
D005472_D056784 CID 5-fluorouracil_19\CD| (r_punct) identified_2\VBD|:|we|reports|5-fluorouracil|and|carmofur|. (l_dobj) reports_4\NNS|27|of (l_prep) of_5\IN|leukoencephalopathy (l_pobj) leukoencephalopathy_7\JJ|toxic|in
C017367_D056784 CID carmofur_23\NN|its|derivative|,|and|capecitabine (r_conj) identified_2\VBD|:|we|reports|5-fluorouracil|and|carmofur|. (l_dobj) reports_4\NNS|27|of (l_prep) of_5\IN|leukoencephalopathy (l_pobj) leukoencephalopathy_7\JJ|toxic|in
C110904_D056784 CID capecitabine_26\NN| (r_conj) carmofur_23\NN|its|derivative|,|and|capecitabine (r_conj) identified_2\VBD|:|we|reports|5-fluorouracil|and|carmofur|. (l_dobj) reports_4\NNS|27|of (l_prep) of_5\IN|leukoencephalopathy (l_pobj) leukoencephalopathy_7\JJ|toxic|in
458486
D063325_D004409 NONE Tiapride_0\NNP|in|. (l_prep) in_1\IN|movements (l_pobj) movements_6\NNS|induced|involuntary
D063325_D004409 NONE Tiapride_0\NNP|,|movements|. (l_appos) movements_18\NNS|derivative|peak|dose|involuntary|in
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) movements_6\NNS|induced|involuntary
D007980_D004409 CID levodopa_12\NN| (r_npadvmod) induced_14\VBN|levodopa|- (r_amod) peak_15\NN|reduced|induced (r_nmod) movements_18\NNS|derivative|peak|dose|involuntary|in
D007980_D004409 CID levodopa_8\RB| (r_npadvmod) induced_10\VBN|levodopa|- (r_amod) dyskinesias_11\NNS|induced
D063325_D010300 NONE Tiapride_0\NNP|,|movements|. (l_appos) movements_18\NNS|derivative|peak|dose|involuntary|in (l_prep) in_19\IN|patients (l_pobj) patients_21\NNS|16|with (l_prep) with_22\IN|disease (l_pobj) disease_26\NN|parkinson
C037689_D004409 NONE benzamide_4\RB| (r_amod) derivative_5\JJ|a|substituted|benzamide|related|, (r_amod) movements_18\NNS|derivative|peak|dose|involuntary|in
C037689_D010300 NONE benzamide_4\RB| (r_amod) derivative_5\JJ|a|substituted|benzamide|related|, (r_amod) movements_18\NNS|derivative|peak|dose|involuntary|in (l_prep) in_19\IN|patients (l_pobj) patients_21\NNS|16|with (l_prep) with_22\IN|disease (l_pobj) disease_26\NN|parkinson
D008787_D004409 NONE metoclopramide_9\NN| (r_pobj) to_8\IN|metoclopramide (r_prep) related_7\JJ|closely|to (r_acl) derivative_5\JJ|a|substituted|benzamide|related|, (r_amod) movements_18\NNS|derivative|peak|dose|involuntary|in
D008787_D010300 NONE metoclopramide_9\NN| (r_pobj) to_8\IN|metoclopramide (r_prep) related_7\JJ|closely|to (r_acl) derivative_5\JJ|a|substituted|benzamide|related|, (r_amod) movements_18\NNS|derivative|peak|dose|involuntary|in (l_prep) in_19\IN|patients (l_pobj) patients_21\NNS|16|with (l_prep) with_22\IN|disease (l_pobj) disease_26\NN|parkinson
D007980_D010300 NONE levodopa_12\NN| (r_npadvmod) induced_14\VBN|levodopa|- (r_amod) peak_15\NN|reduced|induced (r_nmod) movements_18\NNS|derivative|peak|dose|involuntary|in (l_prep) in_19\IN|patients (l_pobj) patients_21\NNS|16|with (l_prep) with_22\IN|disease (l_pobj) disease_26\NN|parkinson
D063325_D004421 NONE Tiapride_0\NNP| (r_nsubj) had_1\VBD|tiapride|effect|induced|. (l_advcl) induced_7\VBN|levodopa|-|morning|of (l_prep) of_10\IN|dystonia (l_pobj) dystonia_17\NN|"|period|"|segmental
D007980_D004421 NONE levodopa_5\NN| (r_npadvmod) induced_7\VBN|levodopa|-|morning|of (l_prep) of_10\IN|dystonia (l_pobj) dystonia_17\NN|"|period|"|segmental
D004298_D004409 NONE dopamine_21\NN| (r_compound) receptors_22\NNS|dopamine (r_pobj) of_20\IN|receptors (r_prep) group_19\NN|a|separate|of (r_pobj) of_16\IN|group (r_prep) overstimulation_15\NN|of (r_pobj) by_14\IN|overstimulation (r_agent) caused_13\VBN|that|dyskinesias|are|by (l_nsubjpass) dyskinesias_11\NNS|induced
12452237
D008012_D010149 NONE lidocaine_1\RB| (r_nsubj) reduce_2\VB|can|lidocaine|succinylcholine|induced|? (l_conj) induced_4\VBD|myalgia (l_dobj) myalgia_6\NN|postoperative
D008012_D010149 NONE lidocaine_8\NN| (r_nsubjpass) proven_10\VBN|in|,|used|,|lidocaine|is|be|. (l_xcomp) be_12\VB|to|agent (l_attr) agent_16\NN|the|useful|pretreatment|for (l_prep) for_17\IN|reduction (l_pobj) reduction_19\NN|the|of (l_prep) of_20\IN|myalgia (l_pobj) myalgia_22\NN|postoperative
D013390_D010149 CID succinylcholine_3\NN| (r_dobj) reduce_2\VB|can|lidocaine|succinylcholine|induced|? (l_conj) induced_4\VBD|myalgia (l_dobj) myalgia_6\NN|postoperative
D013390_D010149 CID succinylcholine_4\NN| (r_nsubjpass) used_6\VBN|where|succinylcholine|is (r_advcl) proven_10\VBN|in|,|used|,|lidocaine|is|be|. (l_xcomp) be_12\VB|to|agent (l_attr) agent_16\NN|the|useful|pretreatment|for (l_prep) for_17\IN|reduction (l_pobj) reduction_19\NN|the|of (l_prep) of_20\IN|myalgia (l_pobj) myalgia_22\NN|postoperative
D008012_D063806 NONE lidocaine_9\JJ| (r_compound) pretreatment_10\NN|lidocaine|on (l_prep) on_11\IN|reduction (l_pobj) reduction_12\NN|of (l_prep) of_13\IN|myalgia (l_pobj) myalgia_17\NN|induced|in
D013390_D063806 NONE succinylcholine_14\NN| (r_npadvmod) induced_16\VBN|succinylcholine|- (r_amod) myalgia_17\NN|induced|in
19642243
C096918_D058186 NONE tenofovir_8\NNS| (r_pobj) on_7\IN|tenofovir (r_prep) patients_4\NNS|with|on (r_pobj) in_3\IN|patients (r_prep) failure_2\NN|acute|renal|in|receiving|.
C096918_D000163 NONE tenofovir_8\NNS| (r_pobj) on_7\IN|tenofovir (r_prep) patients_4\NNS|with|on (l_prep) with_5\IN|aids (l_pobj) AIDS_6\NNP|
C096918_D010019 NONE tenofovir_8\NNS| (r_pobj) on_7\IN|tenofovir (r_prep) patients_4\NNS|with|on (r_pobj) in_3\IN|patients (r_prep) failure_2\NN|acute|renal|in|receiving|. (l_advcl) receiving_10\VBG|while|course|for (l_prep) for_14\IN|osteomyelitis (l_pobj) osteomyelitis_15\NN|
D014640_D058186 CID vancomycin_12\NNP| (r_amod) course_13\NN|prolonged|vancomycin (r_dobj) receiving_10\VBG|while|course|for (r_advcl) failure_2\NN|acute|renal|in|receiving|.
D014640_D000163 NONE vancomycin_12\NNP| (r_amod) course_13\NN|prolonged|vancomycin (r_dobj) receiving_10\VBG|while|course|for (r_advcl) failure_2\NN|acute|renal|in|receiving|. (l_prep) in_3\IN|patients (l_pobj) patients_4\NNS|with|on (l_prep) with_5\IN|aids (l_pobj) AIDS_6\NNP|
D014640_D010019 NONE vancomycin_12\NNP| (r_amod) course_13\NN|prolonged|vancomycin (r_dobj) receiving_10\VBG|while|course|for (l_prep) for_14\IN|osteomyelitis (l_pobj) osteomyelitis_15\NN|
D014640_D051437 NONE vancomycin_8\NNP| (r_amod) therapy_9\NN|vancomycin (r_pobj) of_7\IN|therapy (r_prep) course_6\NN|a|prolonged|of|in (r_pobj) after_3\IN|course (r_prep) developed_2\VBD|failure|after|. (l_nsubj) failure_1\NN|renal
D014640_D051437 NONE vancomycin_17\NNP| (r_pobj) of_16\IN|vancomycin (r_prep) administration_15\NN|prolonged|of (r_pobj) during_13\IN|administration (r_prep) raise_7\VB|that|tenofovir|may|risk|during (l_dobj) risk_9\NN|the|of (l_prep) of_10\IN|failure (l_pobj) failure_12\NN|renal
C418563_D051437 NONE fumarate_18\NN|tenofovir|disoproxil (r_dobj) receiving_15\VBG|who|were|fumarate|as (r_relcl) patients_12\NNS|2|receiving (r_pobj) in_10\IN|patients (r_prep) course_6\NN|a|prolonged|of|in (r_pobj) after_3\IN|course (r_prep) developed_2\VBD|failure|after|. (l_nsubj) failure_1\NN|renal
C096918_D005198 NONE Tenofovir_0\NNP| (r_nsubjpass) implicated_3\VBN|tenofovir|has|been|in|because|. (l_prep) in_4\IN|development (l_pobj) development_6\NN|the|of (l_prep) of_7\IN|syndrome (l_pobj) syndrome_9\NN|fanconi|and|insufficiency
C096918_D051437 NONE Tenofovir_0\NNP| (r_nsubjpass) implicated_3\VBN|tenofovir|has|been|in|because|. (l_prep) in_4\IN|development (l_pobj) development_6\NN|the|of (l_prep) of_7\IN|syndrome (l_pobj) syndrome_9\NN|fanconi|and|insufficiency (l_conj) insufficiency_12\NN|renal
C096918_D051437 NONE tenofovir_5\NNS| (r_nsubj) raise_7\VB|that|tenofovir|may|risk|during (l_dobj) risk_9\NN|the|of (l_prep) of_10\IN|failure (l_pobj) failure_12\NN|renal
D014640_D007674 NONE Vancomycin_0\NNP| (r_compound) nephrotoxicity_1\NN|vancomycin
D014640_D007674 NONE Vancomycin_0\NNP| (r_compound) nephrotoxicity_1\NN|vancomycin (r_nsubj) is_2\VBZ|nephrotoxicity|infrequent|but|result|. (l_conj) result_6\VB|may|from (l_prep) from_7\IN|coadministration (l_pobj) coadministration_8\NN|with (l_prep) with_9\IN|agent (l_pobj) agent_12\NN|a|nephrotoxic (l_amod) nephrotoxic_11\JJ|
4069770
D005839_D007674 NONE Gentamicin_0\NNP| (r_amod) nephropathy_1\NN|gentamicin|in|.
D005839_D058186 CID gentamicin_18\NN| (r_pobj) with_17\IN|gentamicin (r_prep) therapy_16\NN|with|day|and|penicillin (r_pobj) after_15\IN|therapy (r_prep) died_10\VBD|who|of|after (l_prep) of_11\IN|failure (l_pobj) failure_14\NN|acute|renal
D010406_D058186 NONE penicillin_28\NN| (r_conj) therapy_16\NN|with|day|and|penicillin (r_pobj) after_15\IN|therapy (r_prep) died_10\VBD|who|of|after (l_prep) of_11\IN|failure (l_pobj) failure_14\NN|acute|renal
D005839_D001002 NONE gentamicin_2\NN| (r_compound) concentration_3\NN|the|serum|gentamicin (r_nsubj) reached_5\VBN|concentration|had|levels|developed|. (l_advcl) developed_10\VBD|when|anuria (l_nsubj) anuria_9\NN|
9098464
D005473_D062788 CID hydrochloride_13\NN|fluoxetine|,|inhibitor|, (r_pobj) by_11\IN|hydrochloride (r_agent) induced_10\VBN|by|on (r_acl) effects_7\NNS|the|of|induced (r_appos) model_2\NN|a|murine|of|:|effects|. (l_prep) of_3\IN|adenomyosis (l_pobj) adenomyosis_4\NN|
D005473_D062788 CID hydrochloride_13\NN|fluoxetine|,|inhibitor|, (r_pobj) by_11\IN|hydrochloride (r_agent) induced_10\VBN|by|on (l_prep) on_21\IN|induction (l_pobj) induction_23\NN|adenomyosis|in (l_compound) adenomyosis_22\NN|
D005473_D062788 CID fluoxetine_9\NN|given (r_nsubj) caused_16\VBD|whether|fluoxetine|hyperprolactinemia (l_dobj) hyperprolactinemia_17\NN|and|effects (l_conj) effects_20\NNS|its|with (l_prep) with_21\IN|respect (l_pobj) respect_22\NN|to (l_prep) to_23\IN|adenomyosis (l_pobj) adenomyosis_24\NN|
D005473_D062788 CID fluoxetine_14\NN| (r_dobj) receiving_13\VBG|fluoxetine (r_acl) group_12\NN|the|noncastrated|receiving (r_pobj) within_9\IN|all|group (r_prep) revealed_2\VBD|studies|cases|within|. (l_dobj) cases_4\NNS|11|of|, (l_prep) of_5\IN|adenomyosis (l_pobj) adenomyosis_6\NN|
D005473_D006966 CID hydrochloride_13\NN|fluoxetine|,|inhibitor|, (r_pobj) by_11\IN|hydrochloride (r_agent) induced_10\VBN|by|on (r_acl) effects_7\NNS|the|of|induced (l_prep) of_8\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_9\NN|
D005473_D006966 CID fluoxetine_9\NN|given (r_nsubj) caused_16\VBD|whether|fluoxetine|hyperprolactinemia (l_dobj) hyperprolactinemia_17\NN|and|effects
D005473_D006966 CID Fluoxetine_0\NNP|,|inhibitor|, (r_nsubjpass) given_8\VBN|fluoxetine|was|to|for|produce|. (l_advcl) produce_17\VB|to|hyperprolactinemia (l_dobj) hyperprolactinemia_18\NN|
D012701_D062788 NONE serotonin_17\NN| (r_compound) inhibitor_19\NN|a|selective|serotonin|reuptake (r_appos) hydrochloride_13\NN|fluoxetine|,|inhibitor|, (r_pobj) by_11\IN|hydrochloride (r_agent) induced_10\VBN|by|on (r_acl) effects_7\NNS|the|of|induced (r_appos) model_2\NN|a|murine|of|:|effects|. (l_prep) of_3\IN|adenomyosis (l_pobj) adenomyosis_4\NN|
D012701_D062788 NONE serotonin_17\NN| (r_compound) inhibitor_19\NN|a|selective|serotonin|reuptake (r_appos) hydrochloride_13\NN|fluoxetine|,|inhibitor|, (r_pobj) by_11\IN|hydrochloride (r_agent) induced_10\VBN|by|on (l_prep) on_21\IN|induction (l_pobj) induction_23\NN|adenomyosis|in (l_compound) adenomyosis_22\NN|
D012701_D006966 NONE serotonin_17\NN| (r_compound) inhibitor_19\NN|a|selective|serotonin|reuptake (r_appos) hydrochloride_13\NN|fluoxetine|,|inhibitor|, (r_pobj) by_11\IN|hydrochloride (r_agent) induced_10\VBN|by|on (r_acl) effects_7\NNS|the|of|induced (l_prep) of_8\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_9\NN|
D012701_D006966 NONE serotonin_3\NN| (r_compound) inhibitor_5\NN|a|serotonin|reuptake (r_appos) Fluoxetine_0\NNP|,|inhibitor|, (r_nsubjpass) given_8\VBN|fluoxetine|was|to|for|produce|. (l_advcl) produce_17\VB|to|hyperprolactinemia (l_dobj) hyperprolactinemia_18\NN|
19370593
D004967_D054556 CID oestrogen_3\NN|-|only (r_nmod) HT_6\NNP|term|oestrogen (r_nsubj) increased_8\VBD|ht|significantly|risk|after|,|but|increase|. (l_dobj) risk_10\NN|the|of (l_prep) of_11\IN|embolism (l_pobj) embolism_15\NN|venous|thrombo|-|,|disease|(
D004967_D020521 CID oestrogen_3\NN|-|only (r_nmod) HT_6\NNP|term|oestrogen (r_nsubj) increased_8\VBD|ht|significantly|risk|after|,|but|increase|. (l_dobj) risk_10\NN|the|of (l_prep) of_11\IN|embolism (l_pobj) embolism_15\NN|venous|thrombo|-|,|disease|( (l_appos) disease_20\NN|stroke|gallbladder (l_nmod) stroke_17\NN|and
D004967_D005705 CID oestrogen_3\NN|-|only (r_nmod) HT_6\NNP|term|oestrogen (r_nsubj) increased_8\VBD|ht|significantly|risk|after|,|but|increase|. (l_dobj) risk_10\NN|the|of (l_prep) of_11\IN|embolism (l_pobj) embolism_15\NN|venous|thrombo|-|,|disease|( (l_appos) disease_20\NN|stroke|gallbladder
D004967_D001943 NONE oestrogen_3\NN|-|only (r_nmod) HT_6\NNP|term|oestrogen (r_nsubj) increased_8\VBD|ht|significantly|risk|after|,|but|increase|. (l_conj) increase_42\VB|did|not|significantly|risk (l_dobj) risk_44\NN|the|of (l_prep) of_45\IN|cancer (l_pobj) cancer_47\NN|breast
6127992
D014700_D017202 NONE verapamil_18\NN|and (r_nmod) drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during (r_conj) hypotension_11\NN|and|bradycardia (r_conj) failure_9\NN|profound|cardiac|,|hypotension (r_dobj) developed_6\VBD|patients|failure|. (l_nsubj) patients_1\NNS|three|with (l_prep) with_2\IN|disease (l_pobj) disease_5\NN|ischaemic|heart
D014700_D006333 CID verapamil_18\NN|and (r_nmod) drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during (r_conj) hypotension_11\NN|and|bradycardia (r_conj) failure_9\NN|profound|cardiac|,|hypotension
D014700_D007022 CID verapamil_18\NN|and (r_nmod) drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during (r_conj) hypotension_11\NN|and|bradycardia
D014700_D001919 CID verapamil_18\NN|and (r_nmod) drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during
D000319_D017202 NONE drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during (r_conj) hypotension_11\NN|and|bradycardia (r_conj) failure_9\NN|profound|cardiac|,|hypotension (r_dobj) developed_6\VBD|patients|failure|. (l_nsubj) patients_1\NNS|three|with (l_prep) with_2\IN|disease (l_pobj) disease_5\NN|ischaemic|heart
D000319_D006333 CID drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during (r_conj) hypotension_11\NN|and|bradycardia (r_conj) failure_9\NN|profound|cardiac|,|hypotension
D000319_D007022 CID drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during (r_conj) hypotension_11\NN|and|bradycardia
D000319_D001919 CID drugs_24\NNS|verapamil|blocking (r_pobj) with_17\IN|drugs (r_prep) therapy_16\NN|combined|with (r_pobj) during_14\IN|therapy (r_prep) bradycardia_13\NN|during
20510337
C024989_D007674 NONE Q10_1\NNP| (r_compound) treatment_2\NN|coenzyme|q10 (r_nsubj) ameliorates_3\VBZ|treatment|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN|acute|cisplatin|in
C024989_D007674 NONE Q10_13\NNP| (r_compound) treatment_14\NN|coenzyme|q10 (r_pobj) by_11\IN|treatment (r_agent) ameliorated_10\VBN|also|,|damage|was|by|. (l_nsubjpass) damage_5\NN|histopathological|renal|tissue|mediated
C024989_D007674 NONE Q10_5\NNP|coenzyme (r_nsubj) represents_6\VBZ|that|q10|option (l_dobj) option_10\NN|a|potential|therapeutic|protect (l_acl) protect_12\VB|to|against (l_prep) against_13\IN|nephrotoxicity (l_pobj) nephrotoxicity_16\NN|acute|cisplatin|encountered
D002945_D007674 NONE cisplatin_5\NN| (r_amod) nephrotoxicity_6\NN|acute|cisplatin|in
D002945_D007674 NONE cisplatin_8\NN| (r_pobj) by_7\IN|cisplatin (r_agent) mediated_6\VBN|by (r_acl) damage_5\NN|histopathological|renal|tissue|mediated
D002945_D007674 NONE cisplatin_15\NN| (r_amod) nephrotoxicity_16\NN|acute|cisplatin|encountered
C024989_D058186 NONE Q10_5\NNP|coenzyme (r_pobj) of_3\IN|q10 (r_prep) effect_2\NN|the|nephroprotective|of (r_nsubjpass) investigated_7\VBN|effect|was|in|induced|. (l_prep) in_8\IN|mice (l_pobj) mice_9\NNS|with (l_prep) with_10\IN|injury (l_pobj) injury_13\NN|acute|renal
D002945_D058186 CID cisplatin_21\NN| (r_pobj) of_20\IN|cisplatin (r_prep) injection_19\NN|a|single|i.p.|of|(|mg/kg|) (r_pobj) by_15\IN|injection (r_agent) induced_14\VBN|by (r_advcl) investigated_7\VBN|effect|was|in|induced|. (l_prep) in_8\IN|mice (l_pobj) mice_9\NNS|with (l_prep) with_10\IN|injury (l_pobj) injury_13\NN|acute|renal
C024989_D009369 NONE Q10_1\NNP|coenzyme (r_nsubj) compensated_3\VBD|q10|significantly|deficits|(|level|)|,|suppressed|,|decreased|. (l_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
C024989_D009336 NONE Q10_1\NNP|coenzyme (r_nsubj) compensated_3\VBD|q10|significantly|deficits|(|level|)|,|suppressed|,|decreased|. (l_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D005978_D009369 NONE glutathione_12\NN| (r_compound) level_13\NN|reduced|glutathione|and|activity (r_dobj) compensated_3\VBD|q10|significantly|deficits|(|level|)|,|suppressed|,|decreased|. (l_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D005978_D009336 NONE glutathione_12\NN| (r_compound) level_13\NN|reduced|glutathione|and|activity (r_dobj) compensated_3\VBD|q10|significantly|deficits|(|level|)|,|suppressed|,|decreased|. (l_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D013481_D009369 NONE superoxide_15\NN| (r_amod) activity_17\NN|superoxide|dismutase (r_conj) level_13\NN|reduced|glutathione|and|activity (r_dobj) compensated_3\VBD|q10|significantly|deficits|(|level|)|,|suppressed|,|decreased|. (l_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D013481_D009336 NONE superoxide_15\NN| (r_amod) activity_17\NN|superoxide|dismutase (r_conj) level_13\NN|reduced|glutathione|and|activity (r_dobj) compensated_3\VBD|q10|significantly|deficits|(|level|)|,|suppressed|,|decreased|. (l_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D009569_D009369 NONE oxide_35\NN|nitric|and|concentration (r_conj) alpha_32\NN|-|,|oxide (r_appos) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D009569_D009336 NONE oxide_35\NN|nitric|and|concentration (r_conj) alpha_32\NN|-|,|oxide (r_appos) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D010984_D009369 NONE platinum_37\NN| (r_compound) ion_38\NN|platinum (r_compound) concentration_39\NN|ion (r_conj) oxide_35\NN|nitric|and|concentration (r_conj) alpha_32\NN|-|,|oxide (r_appos) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D010984_D009336 NONE platinum_37\NN| (r_compound) ion_38\NN|platinum (r_compound) concentration_39\NN|ion (r_conj) oxide_35\NN|nitric|and|concentration (r_conj) alpha_32\NN|-|,|oxide (r_appos) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D012643_D009369 NONE selenium_46\NN|and|zinc (r_nmod) ions_49\NNS|selenium|in (r_pobj) of_45\IN|ions (r_prep) reductions_44\NNS|the|of (r_dobj) attenuated_42\VBD|reductions|resulted (r_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D012643_D009336 NONE selenium_46\NN|and|zinc (r_nmod) ions_49\NNS|selenium|in (r_pobj) of_45\IN|ions (r_prep) reductions_44\NNS|the|of (r_dobj) attenuated_42\VBD|reductions|resulted (r_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D015032_D009369 NONE zinc_48\NN| (r_conj) selenium_46\NN|and|zinc (r_nmod) ions_49\NNS|selenium|in (r_pobj) of_45\IN|ions (r_prep) reductions_44\NNS|the|of (r_dobj) attenuated_42\VBD|reductions|resulted (r_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D015032_D009336 NONE zinc_48\NN| (r_conj) selenium_46\NN|and|zinc (r_nmod) ions_49\NNS|selenium|in (r_pobj) of_45\IN|ions (r_prep) reductions_44\NNS|the|of (r_dobj) attenuated_42\VBD|reductions|resulted (r_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
D002945_D009369 NONE cisplatin_55\JJ| (r_amod) administration_56\NN|cisplatin (r_pobj) from_54\IN|administration (r_prep) resulted_53\VBD|from (r_advcl) attenuated_42\VBD|reductions|resulted (r_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) tumor_28\NN|
D002945_D009336 NONE cisplatin_55\JJ| (r_amod) administration_56\NN|cisplatin (r_pobj) from_54\IN|administration (r_prep) resulted_53\VBD|from (r_advcl) attenuated_42\VBD|reductions|resulted (r_conj) decreased_24\VBD|elevations|,|and|attenuated (l_dobj) elevations_26\NNS|the|of (l_prep) of_27\IN|factor (l_pobj) factor_30\NN|tumor|necrosis|alpha (l_compound) necrosis_29\NN|
8742498
D009243_D056486 NONE NAD_5\NNP| (r_compound) precursors_7\NNS|nad|- (r_pobj) of_4\IN|precursors (r_prep) free_3\JJ|of|on (l_prep) on_8\IN|acetaminophen|hepatotoxicity (l_pobj) hepatotoxicity_10\NN|in
D009243_D056486 NONE NAD_13\NNP|,|substrate (l_appos) substrate_16\NN|the|acts (l_relcl) acts_20\VBZ|on|parp|,|in|and|evaluates (l_prep) in_22\IN|mice (l_pobj) mice_25\NNS|female|nmri|with (l_prep) with_26\IN|hepatitis (l_pobj) hepatitis_28\NN|aap
D009243_D056486 NONE NAD_37\NNP| (r_appos) substrate_36\NN|enzyme|nad (r_pobj) of_32\IN|substrate (r_prep) depletion_31\NN|dietary|of (r_pobj) by_29\IN|depletion (r_conj) by_26\IN|naa|or|by (r_prep) inhibition_23\NN|product|of|by (r_pobj) by_19\IN|inhibition (r_agent) reduced_18\VBN|that|hepatitis|can|either|be|by (l_nsubjpass) hepatitis_9\NN|the|induced|and|exacerbation
D000082_D056486 CID acetaminophen_9\NN| (r_pobj) on_8\IN|acetaminophen|hepatotoxicity (l_pobj) hepatotoxicity_10\NN|in
D000082_D056486 CID acetaminophen_31\NN| (r_pobj) from_30\IN|acetaminophen (r_prep) suffering_29\VBG|mice|from (r_pcomp) on_27\IN|suffering (r_prep) inhibitor_14\NN|a|selective|of|on (r_appos) amide_10\NN|nicotinic|acid|,|inhibitor (r_pobj) of_7\IN|amide (r_prep) effects_6\NNS|the|hepatoprotective|of (r_dobj) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_npadvmod) AAP)-hepatitis_33\NNP|(
D000082_D056486 CID acetaminophen_31\NN| (r_pobj) from_30\IN|acetaminophen (r_prep) suffering_29\VBG|mice|from (r_pcomp) on_27\IN|suffering (r_prep) inhibitor_14\NN|a|selective|of|on (r_appos) amide_10\NN|nicotinic|acid|,|inhibitor (r_pobj) of_7\IN|amide (r_prep) effects_6\NNS|the|hepatoprotective|of (r_dobj) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_advcl) suggesting_35\VBG|involves (l_ccomp) involves_43\VBZ|that|injury|step (l_nsubj) injury_42\NN|the|induced|liver
D000082_D056486 CID AAP)-hepatitis_33\NNP|(
D000082_D056486 CID AAP)-hepatitis_33\NNP|( (r_npadvmod) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_advcl) suggesting_35\VBG|involves (l_ccomp) involves_43\VBZ|that|injury|step (l_nsubj) injury_42\NN|the|induced|liver
D000082_D056486 CID AAP_38\NNP| (r_npadvmod) induced_40\VBN|aap|- (r_amod) injury_42\NN|the|induced|liver (r_nsubj) involves_43\VBZ|that|injury|step (r_ccomp) suggesting_35\VBG|involves (r_advcl) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_npadvmod) AAP)-hepatitis_33\NNP|(
D000082_D056486 CID AAP_38\NNP| (r_npadvmod) induced_40\VBN|aap|- (r_amod) injury_42\NN|the|induced|liver
D000082_D056486 CID AAP_27\NNP| (r_compound) hepatitis_28\NN|aap
D000082_D056486 CID AAP_17\NNP| (r_pobj) of_16\IN|aap (r_prep) presence_15\NN|the|of (r_pobj) in_13\IN|presence (r_prep) measured_12\VBN|in|,|increases|were|in|,|and|inhibited (l_conj) inhibited_37\VBN|unlike|,|damage|was|by|. (l_nsubjpass) damage_35\NN|the|liver
D000082_D056486 CID AAP_17\NNP| (r_compound) mice_19\NNS|ethanol|/|aap|- (r_pobj) to_14\IN|mice (r_dative) given_13\VBN|when|naa|was|to (r_advcl) observed_8\VBN|reduction|was|,|given|. (l_nsubjpass) reduction_4\NN|a|further|%|of (l_prep) of_5\IN|hepatitis (l_pobj) hepatitis_6\NN|
D000082_D056486 CID AAP_6\NNP| (r_npadvmod) induced_8\VBN|aap|- (r_amod) hepatitis_9\NN|the|induced|and|exacerbation
D000082_D056486 CID acetaminophen_16\NN| (r_pobj) of_15\IN|acetaminophen (r_prep) preparations_14\NNS|pharmaceutical|of (r_pobj) in_12\IN|preparations (r_prep) use_11\NN|the|combinational|in (r_pobj) for_8\IN|use (r_prep) as_7\IN|for (r_prep) see_1\VBP|we|application|as|in|. (l_prep) in_17\IN|order (l_pobj) order_18\NN|avoid (l_acl) avoid_20\VB|to|damage (l_dobj) damage_22\NN|hepatic|in
D009536_D056486 NONE amide_10\NN|nicotinic|acid|,|inhibitor (r_pobj) of_7\IN|amide (r_prep) effects_6\NNS|the|hepatoprotective|of (r_dobj) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_npadvmod) AAP)-hepatitis_33\NNP|(
D009536_D056486 NONE amide_10\NN|nicotinic|acid|,|inhibitor (r_pobj) of_7\IN|amide (r_prep) effects_6\NNS|the|hepatoprotective|of (r_dobj) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_advcl) suggesting_35\VBG|involves (l_ccomp) involves_43\VBZ|that|injury|step (l_nsubj) injury_42\NN|the|induced|liver
D009536_D056486 NONE NAA_11\NNP| (r_nsubjpass) given_13\VBN|when|naa|was|to (r_advcl) observed_8\VBN|reduction|was|,|given|. (l_nsubjpass) reduction_4\NN|a|further|%|of (l_prep) of_5\IN|hepatitis (l_pobj) hepatitis_6\NN|
D009536_D056486 NONE NAA_27\NNP| (r_pobj) by_26\IN|naa|or|by (r_prep) inhibition_23\NN|product|of|by (r_pobj) by_19\IN|inhibition (r_agent) reduced_18\VBN|that|hepatitis|can|either|be|by (l_nsubjpass) hepatitis_9\NN|the|induced|and|exacerbation
D009536_D056486 NONE NAA_6\NNP| (r_pobj) of_5\IN|naa (r_prep) application_4\NN|the|main|of (r_dobj) see_1\VBP|we|application|as|in|. (l_prep) in_17\IN|order (l_pobj) order_18\NN|avoid (l_acl) avoid_20\VB|to|damage (l_dobj) damage_22\NN|hepatic|in
D011064_D056486 NONE )_19\-RRB-| (r_punct) polymerase_20\NN|ribose|)|(|parp|;|ec|) (r_pobj) of_15\IN|polymerase (r_prep) inhibitor_14\NN|a|selective|of|on (r_appos) amide_10\NN|nicotinic|acid|,|inhibitor (r_pobj) of_7\IN|amide (r_prep) effects_6\NNS|the|hepatoprotective|of (r_dobj) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_npadvmod) AAP)-hepatitis_33\NNP|(
D011064_D056486 NONE )_19\-RRB-| (r_punct) polymerase_20\NN|ribose|)|(|parp|;|ec|) (r_pobj) of_15\IN|polymerase (r_prep) inhibitor_14\NN|a|selective|of|on (r_appos) amide_10\NN|nicotinic|acid|,|inhibitor (r_pobj) of_7\IN|amide (r_prep) effects_6\NNS|the|hepatoprotective|of (r_dobj) demonstrated_3\VBD|recently|,|we|effects|aap)-hepatitis|,|suggesting|. (l_advcl) suggesting_35\VBG|involves (l_ccomp) involves_43\VBZ|that|injury|step (l_nsubj) injury_42\NN|the|induced|liver
D000431_D056486 CID ethanol_35\NN| (r_compound) consumption_36\NN|simultaneous|ethanol|in (r_pobj) of_33\IN|consumption (r_prep) influence_32\NN|the|of (r_dobj) evaluates_30\VBZ|influence (r_conj) acts_20\VBZ|on|parp|,|in|and|evaluates (l_prep) in_22\IN|mice (l_pobj) mice_25\NNS|female|nmri|with (l_prep) with_26\IN|hepatitis (l_pobj) hepatitis_28\NN|aap
D000431_D056486 CID ethanol_25\NN| (r_pobj) by_24\IN|ethanol (r_agent) caused_23\VBN|by|in|on (r_acl) exacerbation_22\NN|the|caused (r_pobj) unlike_20\IN|exacerbation (r_prep) inhibited_37\VBN|unlike|,|damage|was|by|. (l_nsubjpass) damage_35\NN|the|liver
D000431_D056486 CID ethanol_42\NN| (r_pobj) by_41\IN|ethanol (r_prep) %_40\NN|50|by (r_pobj) by_38\IN|% (r_agent) inhibited_37\VBN|unlike|,|damage|was|by|. (l_nsubjpass) damage_35\NN|the|liver
D000431_D056486 CID ethanol_15\NN| (r_nmod) mice_19\NNS|ethanol|/|aap|- (r_pobj) to_14\IN|mice (r_dative) given_13\VBN|when|naa|was|to (r_advcl) observed_8\VBN|reduction|was|,|given|. (l_nsubjpass) reduction_4\NN|a|further|%|of (l_prep) of_5\IN|hepatitis (l_pobj) hepatitis_6\NN|
D000431_D056486 CID ethanol_14\NN| (r_pobj) by_13\IN|ethanol (r_prep) exacerbation_12\NN|its|by (r_conj) hepatitis_9\NN|the|induced|and|exacerbation
D018698_D056486 NONE glutamate_8\NN| (r_compound) oxaloacetate_10\NN|glutamate|- (r_compound) transaminase_11\NN|oxaloacetate|(|got|)|and|transaminase (r_pobj) of_7\IN|transaminase (r_prep) activities_6\NNS|serum|of (r_pobj) as_4\IN|activities (r_prep) quantified_3\VBN|injuries|were|as|. (l_nsubjpass) injuries_1\NNS|liver
D018698_D056486 NONE glutamate_16\NN| (r_npadvmod) pyruvate_18\NN|glutamate|- (r_compound) transaminase_19\NN|pyruvate|(|gpt|) (r_conj) transaminase_11\NN|oxaloacetate|(|got|)|and|transaminase (r_pobj) of_7\IN|transaminase (r_prep) activities_6\NNS|serum|of (r_pobj) as_4\IN|activities (r_prep) quantified_3\VBN|injuries|were|as|. (l_nsubjpass) injuries_1\NNS|liver
D062907_D056486 NONE oxaloacetate_10\NN|glutamate|- (r_compound) transaminase_11\NN|oxaloacetate|(|got|)|and|transaminase (r_pobj) of_7\IN|transaminase (r_prep) activities_6\NNS|serum|of (r_pobj) as_4\IN|activities (r_prep) quantified_3\VBN|injuries|were|as|. (l_nsubjpass) injuries_1\NNS|liver
D019289_D056486 NONE pyruvate_18\NN|glutamate|- (r_compound) transaminase_19\NN|pyruvate|(|gpt|) (r_conj) transaminase_11\NN|oxaloacetate|(|got|)|and|transaminase (r_pobj) of_7\IN|transaminase (r_prep) activities_6\NNS|serum|of (r_pobj) as_4\IN|activities (r_prep) quantified_3\VBN|injuries|were|as|. (l_nsubjpass) injuries_1\NNS|liver
3001299
D008094_D018500 NONE lithium_22\NN| (r_compound) treatment_23\NN|lithium (r_pobj) during_21\IN|treatment (r_prep) development_13\NN|the|of|during (l_prep) of_14\IN|insipidus (l_pobj) insipidus_18\NN|both|nephrogenic|diabetes|and|hypothyroidism
D008094_D007037 CID lithium_22\NN| (r_compound) treatment_23\NN|lithium (r_pobj) during_21\IN|treatment (r_prep) development_13\NN|the|of|during (l_prep) of_14\IN|insipidus (l_pobj) insipidus_18\NN|both|nephrogenic|diabetes|and|hypothyroidism (l_conj) hypothyroidism_20\NN|
D008094_D007037 CID lithium_9\NN| (r_dobj) taking_8\VBG|while|they|were|lithium (r_advcl) developed_1\VBD|hypothyroidism|in|taking|. (l_nsubj) Hypothyroidism_0\NN|
2840807
D009074_D004421 CID MSH_8\NNP| (r_nmod) ACTH_10\NNP|(|msh|/ (r_nmod) stimulation_12\NN|neuropeptide|acth|)|of (r_pobj) after_5\IN|stimulation (r_prep) syndrome_4\NN|a|like|after|. (l_amod) like_3\JJ|dystonia|- (l_npadvmod) dystonia_1\NN|
D000324_D004421 CID ACTH_10\NNP|(|msh|/ (r_nmod) stimulation_12\NN|neuropeptide|acth|)|of (r_pobj) after_5\IN|stimulation (r_prep) syndrome_4\NN|a|like|after|. (l_amod) like_3\JJ|dystonia|- (l_npadvmod) dystonia_1\NN|
D000324_D003866 NONE ACTH_20\NNP| (r_compound) terminal_23\NN|acth|n|- (r_compound) fragments_24\NNS|the|terminal|at|resulted (r_pobj) by_18\IN|fragments (r_agent) stimulated_17\VBN|(|a|)|receptors|were|by|; (r_ccomp) is_3\VBZ|however|,|it|not|certain|stimulated|released|,|cause|. (l_conj) cause_57\VB|did|indeed|resulted (l_ccomp) resulted_94\VBD|depression|c|whether|inhibition|in|, (l_nsubj) depression_62\NN|the|term|at|(|described|)|resulted|;|targets
D000324_D009069 NONE ACTH_20\NNP| (r_compound) terminal_23\NN|acth|n|- (r_compound) fragments_24\NNS|the|terminal|at|resulted (r_pobj) by_18\IN|fragments (r_agent) stimulated_17\VBN|(|a|)|receptors|were|by|; (r_ccomp) is_3\VBZ|however|,|it|not|certain|stimulated|released|,|cause|. (l_conj) cause_57\VB|did|indeed|resulted (l_ccomp) resulted_94\VBD|depression|c|whether|inhibition|in|, (l_nsubj) depression_62\NN|the|term|at|(|described|)|resulted|;|targets (l_relcl) resulted_74\VBD|that|in (l_prep) in_75\IN|duration (l_pobj) duration_78\NN|the|long|of (l_prep) of_79\IN|disorder (l_pobj) disorder_82\NN|the|movement
10074612
D008775_D007022 CID methylprednisolone_11\NN|dose|intravenous|in (r_pobj) after_6\IN|methylprednisolone (r_prep) asystole_5\NN|after (r_conj) bradycardia_2\NNP|,|and|asystole (r_conj) Hypotension_0\NN|,|bradycardia|.
D008775_D007022 CID methylprednisolone_18\NN|dose (r_pobj) of_14\IN|methylprednisolone (r_prep) administration_13\NN|intravenous|of|in (r_pobj) after_11\IN|administration (r_prep) asystole_10\NN|after (r_conj) bradycardia_7\NNP|,|and|asystole (r_conj) hypotension_5\NN|,|bradycardia
D008775_D001919 CID methylprednisolone_11\NN|dose|intravenous|in (r_pobj) after_6\IN|methylprednisolone (r_prep) asystole_5\NN|after (r_conj) bradycardia_2\NNP|,|and|asystole
D008775_D001919 CID methylprednisolone_18\NN|dose (r_pobj) of_14\IN|methylprednisolone (r_prep) administration_13\NN|intravenous|of|in (r_pobj) after_11\IN|administration (r_prep) asystole_10\NN|after (r_conj) bradycardia_7\NNP|,|and|asystole
D008775_D006323 CID methylprednisolone_11\NN|dose|intravenous|in (r_pobj) after_6\IN|methylprednisolone (r_prep) asystole_5\NN|after
D008775_D006323 CID methylprednisolone_18\NN|dose (r_pobj) of_14\IN|methylprednisolone (r_prep) administration_13\NN|intravenous|of|in (r_pobj) after_11\IN|administration (r_prep) asystole_10\NN|after
D008775_D003645 NONE methylprednisolone_16\NN|intravenous|ivmp (r_pobj) of_14\IN|methylprednisolone (r_prep) dose_13\NN|a|high|of (r_pobj) after_10\IN|dose (r_prep) reviews_2\VBZ|study|mechanisms|after|. (l_dobj) mechanisms_6\NNS|the|current|proposed|of (l_prep) of_7\IN|death (l_pobj) death_9\NN|sudden
D008775_D003645 NONE IVMP_18\NN|(|) (r_appos) methylprednisolone_16\NN|intravenous|ivmp (r_pobj) of_14\IN|methylprednisolone (r_prep) dose_13\NN|a|high|of (r_pobj) after_10\IN|dose (r_prep) reviews_2\VBZ|study|mechanisms|after|. (l_dobj) mechanisms_6\NNS|the|current|proposed|of (l_prep) of_7\IN|death (l_pobj) death_9\NN|sudden
18808529
D007545_D009202 CID Isoproterenol_0\NN| (r_nsubj) induces_1\VBZ|isoproterenol|loss|:|correlation|. (l_dobj) correlation_10\NN|with (l_prep) with_11\IN|injury (l_pobj) injury_13\NN|myocardial
D007545_D009202 CID isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|isoproterenol|- (r_amod) damage_7\NN|induced|myocardial
D007545_D009202 CID isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|isoproterenol|- (r_amod) damage_7\NN|induced|myocardial (r_pobj) of_2\IN|damage (r_prep) mechanism_1\NN|the|of (r_nsubj) is_8\VBZ|mechanism|unknown|,|but|is (l_conj) is_25\VBZ|mismatch|explanation|. (l_nsubj) mismatch_13\NN|a|of|vs. (l_prep) vs._17\IN|demand (l_pobj) demand_18\NN|following (l_prep) following_19\VBG|hyperactivity (l_pobj) hyperactivity_24\NN|hypotension|myocardial
D007545_D007022 NONE isoproterenol_3\NN| (r_npadvmod) induced_5\VBN|isoproterenol|- (r_amod) damage_7\NN|induced|myocardial (r_pobj) of_2\IN|damage (r_prep) mechanism_1\NN|the|of (r_nsubj) is_8\VBZ|mechanism|unknown|,|but|is (l_conj) is_25\VBZ|mismatch|explanation|. (l_nsubj) mismatch_13\NN|a|of|vs. (l_prep) vs._17\IN|demand (l_pobj) demand_18\NN|following (l_prep) following_19\VBG|hyperactivity (l_pobj) hyperactivity_24\NN|hypotension|myocardial (l_nmod) hypotension_21\NN|coronary|and
D010100_D009202 NONE oxygen_15\NN| (r_compound) supply_16\NN|oxygen (r_pobj) of_14\IN|supply (r_prep) mismatch_13\NN|a|of|vs. (r_nsubj) is_25\VBZ|mismatch|explanation|. (r_conj) is_8\VBZ|mechanism|unknown|,|but|is (l_nsubj) mechanism_1\NN|the|of (l_prep) of_2\IN|damage (l_pobj) damage_7\NN|induced|myocardial
D010100_D009202 NONE oxygen_15\NN| (r_compound) supply_16\NN|oxygen (r_pobj) of_14\IN|supply (r_prep) mismatch_13\NN|a|of|vs. (l_prep) vs._17\IN|demand (l_pobj) demand_18\NN|following (l_prep) following_19\VBG|hyperactivity (l_pobj) hyperactivity_24\NN|hypotension|myocardial
D010100_D007022 NONE oxygen_15\NN| (r_compound) supply_16\NN|oxygen (r_pobj) of_14\IN|supply (r_prep) mismatch_13\NN|a|of|vs. (l_prep) vs._17\IN|demand (l_pobj) demand_18\NN|following (l_prep) following_19\VBG|hyperactivity (l_pobj) hyperactivity_24\NN|hypotension|myocardial (l_nmod) hypotension_21\NN|coronary|and
D007545_D007511 CID isoproterenol_29\NN| (r_pobj) by_28\IN|isoproterenol (r_agent) induced_27\VBN|by (r_acl) alterations_11\NNS|the|severe|in|induced (r_dobj) explain_8\VBP|changes|alterations|. (l_nsubj) changes_1\NNS|these|,|related|, (l_acl) related_3\VBN|to (l_prep) to_4\IN|injury (l_pobj) injury_6\NN|ischaemic
3108839
D016685_D006463 CID C_1\NNP|mitomycin (r_nsubj) associated_2\VBD|c|syndrome|. (l_dobj) syndrome_5\NN|hemolytic|uremic
D016685_D006463 CID C_1\NNP|mitomycin (r_nsubj) associated_2\VBD|c|syndrome (l_dobj) Syndrome_5\NNP|hemolytic|uremic|hus|)
D016685_D006463 CID C_1\NNP|mitomycin (r_nsubj) associated_2\VBD|c|syndrome (l_dobj) Syndrome_5\NNP|hemolytic|uremic|hus|) (l_appos) HUS_7\NNP|(
D016685_D000743 NONE C_15\NN| (r_compound) treatment_16\NN|mitomycin|c (r_pobj) with_13\IN|treatment (r_prep) associated_12\VBN|with|and (r_acl) failure_11\NN|progressive|renal|associated (r_conj) thrombocytopenia_7\JJ|and|failure (r_conj) anemia_5\NN|microangiopathic|hemolytic|,|thrombocytopenia
D016685_D013921 NONE C_15\NN| (r_compound) treatment_16\NN|mitomycin|c (r_pobj) with_13\IN|treatment (r_prep) associated_12\VBN|with|and (r_acl) failure_11\NN|progressive|renal|associated (r_conj) thrombocytopenia_7\JJ|and|failure
D016685_D013921 NONE C_29\NN|mitomycin (r_pobj) with_27\IN|c (r_prep) treatment_26\NN|with (r_pobj) on_25\IN|while|treatment (r_advcl) describe_1\VBP|we|course|in|on|and|died|. (l_prep) in_8\IN|man (l_pobj) man_14\NN|a|65|old|with|developed (l_relcl) developed_19\VBD|who|failure|and|thrombocytopenia (l_conj) thrombocytopenia_23\NN|
D016685_D051437 CID C_15\NN| (r_compound) treatment_16\NN|mitomycin|c (r_pobj) with_13\IN|treatment (r_prep) associated_12\VBN|with|and (r_acl) failure_11\NN|progressive|renal|associated
D016685_D051437 CID C_14\NN| (r_compound) treatment_15\NN|mitomycin|c (r_pobj) of_12\IN|treatment (r_prep) start_11\NN|of (r_pobj) after_10\IN|start (r_prep) develops_4\VBZ|failure|usually|mth|after|and|is (l_nsubj) failure_2\NN|the|renal
D016685_D051437 CID C_14\NN| (r_compound) treatment_15\NN|mitomycin|c (r_pobj) of_12\IN|treatment (r_prep) start_11\NN|of (r_pobj) after_10\IN|start (r_prep) develops_4\VBZ|failure|usually|mth|after|and|is (l_conj) is_19\VBZ|mortality|%|. (l_attr) %_22\NN|60|from (l_prep) from_23\IN|failure (l_pobj) failure_25\NN|renal|or|edema
D016685_D051437 CID C_29\NN|mitomycin (r_pobj) with_27\IN|c (r_prep) treatment_26\NN|with (r_pobj) on_25\IN|while|treatment (r_advcl) describe_1\VBP|we|course|in|on|and|died|. (l_prep) in_8\IN|man (l_pobj) man_14\NN|a|65|old|with|developed (l_relcl) developed_19\VBD|who|failure|and|thrombocytopenia (l_dobj) failure_21\NN|renal
D016685_D011654 NONE C_14\NN| (r_compound) treatment_15\NN|mitomycin|c (r_pobj) of_12\IN|treatment (r_prep) start_11\NN|of (r_pobj) after_10\IN|start (r_prep) develops_4\VBZ|failure|usually|mth|after|and|is (l_conj) is_19\VBZ|mortality|%|. (l_attr) %_22\NN|60|from (l_prep) from_23\IN|failure (l_pobj) failure_25\NN|renal|or|edema (l_conj) edema_28\NN|pulmonary
D016685_D011654 NONE C_29\NN|mitomycin (r_pobj) with_27\IN|c (r_prep) treatment_26\NN|with (r_pobj) on_25\IN|while|treatment (r_advcl) describe_1\VBP|we|course|in|on|and|died|. (l_conj) died_31\VBD|in (l_prep) in_32\IN|edema (l_pobj) edema_34\NN|pulmonary
D016685_D013274 NONE C_29\NN|mitomycin (r_pobj) with_27\IN|c (r_prep) treatment_26\NN|with (r_pobj) on_25\IN|while|treatment (r_advcl) describe_1\VBP|we|course|in|on|and|died|. (l_prep) in_8\IN|man (l_pobj) man_14\NN|a|65|old|with|developed (l_prep) with_15\IN|adenocarcinoma (l_pobj) adenocarcinoma_17\NN|gastric
7724492
D004317_D007674 NONE doxorubicin_4\NN| (r_nmod) nanoparticles_8\NNS|doxorubicin|(|adriamycin)-loaded|cyanoacrylate (r_pobj) of_3\IN|nanoparticles (r_prep) toxicity_2\NN|acute|renal|of|.
D004317_D007674 NONE adriamycin)-loaded_6\VBN| (r_amod) nanoparticles_8\NNS|doxorubicin|(|adriamycin)-loaded|cyanoacrylate (r_pobj) of_3\IN|nanoparticles (r_prep) toxicity_2\NN|acute|renal|of|.
D004317_D007674 NONE doxorubicin_1\NN| (r_npadvmod) loaded_3\VBN|doxorubicin|- (r_amod) nanoparticle_4\NN|loaded (r_nmod) toxicity_9\NN|acute|nanoparticle|dxnp|renal
D004317_D007674 NONE DX_16\NNP|free (r_pobj) than_14\IN|dx (r_prep) animals_13\NNS|less|than (r_dobj) killed_11\VBD|that|,|in|,|dxnp|animals|,|despite (l_prep) despite_18\IN|of (l_prep) of_19\IN|toxicity (l_pobj) toxicity_23\NN|an|enhanced|renal|of
D003487_D007674 NONE cyanoacrylate_7\JJ| (r_compound) nanoparticles_8\NNS|doxorubicin|(|adriamycin)-loaded|cyanoacrylate (r_pobj) of_3\IN|nanoparticles (r_prep) toxicity_2\NN|acute|renal|of|.
D004317_D005921 NONE doxorubicin_1\NN| (r_npadvmod) loaded_3\VBN|doxorubicin|- (r_amod) nanoparticle_4\NN|loaded (r_nmod) toxicity_9\NN|acute|nanoparticle|dxnp|renal (r_nsubjpass) explored_11\VBN|toxicity|was|in|. (l_prep) in_12\IN|rats (l_pobj) rats_15\NNS|both|normal|and|rats (l_conj) rats_17\NNS|with (l_prep) with_18\IN|glomerulonephritis (l_pobj) glomerulonephritis_20\NN|experimental
D004317_D005921 NONE DX_10\NNP| (r_pobj) given_9\VBN|dx (r_prep) rats_8\NNS|5/6|given (r_nsubj) died_11\VBD|in|,|rats|within|,|in|. (l_prep) In_0\IN|rats (l_pobj) rats_1\NNS|with (l_prep) with_2\IN|glomerulonephritis (l_pobj) glomerulonephritis_5\NN|immune|experimental
D004317_D011507 CID DX_16\NNP| (r_pobj) with_15\IN|dx (r_prep) treated_14\VBN|with (r_acl) those_13\DT|treated (r_pobj) in_12\IN|those (r_prep) than_11\IN|in (r_prep) treated_8\VBN|with|than (r_acl) animals_7\NNS|treated (r_pobj) in_6\IN|animals (r_prep) appeared_5\VBD|proteinuria|in|. (l_nsubj) proteinuria_4\NN|a|higher
D004317_D011507 CID doxorubicin_22\NN| (r_compound) treatment_23\NN|doxorubicin|day (r_pobj) after_21\IN|treatment (r_prep) prolonged_20\VBN|after (r_conj) intense_13\JJ|2|more|0.001|and|prolonged (r_acomp) was_7\VBD|intense|,|without (r_conj) appeared_1\VBD|proteinuria|in|,|but|was|. (l_nsubj) Proteinuria_0\NNP|
D004317_D011507 CID DX_39\NNP| (r_conj) DXNP_37\NNP|and|dx (r_pobj) between_36\IN|dxnp (r_prep) difference_35\NN|significant|between (r_pobj) without_33\IN|difference (r_prep) was_7\VBD|intense|,|without (r_conj) appeared_1\VBD|proteinuria|in|,|but|was|. (l_nsubj) Proteinuria_0\NNP|
1610717
D003042_D012640 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) seizures_4\NNS|induced|brainstem|and|behavior|.
10354657
D008094_D013959 NONE lithium_9\NN| (r_compound) therapy_10\NN|lithium|,|age (r_pobj) of_8\IN|therapy (r_prep) duration_7\NN|the|of (r_pobj) to_5\IN|duration (r_prep) respect_4\NN|to (r_pobj) with_3\IN|respect (r_prep) evaluated_2\VBN|these|were|with|had|. (l_parataxis) had_25\VBD|(|whether|or|not|patient|relative|) (l_dobj) relative_30\NN|a|degree|with (l_prep) with_31\IN|disease (l_pobj) disease_33\NN|thyroid
D008094_D013959 NONE lithium_22\NN| (r_compound) therapy_23\NN|lithium (r_pobj) of_21\IN|therapy (r_prep) onset_20\NN|of (r_pobj) after_19\IN|years|onset (r_prep) accelerated_12\VBN|patients|had|onset|after|)|compared|(|after|)|. (l_nsubj) patients_1\NNS|all|having (l_acl) having_2\VBG|relatives (l_dobj) relatives_6\NNS|degree|affected (l_acl) affected_7\VBN|by (l_agent) by_8\IN|illness (l_pobj) illness_10\NN|thyroid
D008094_D013959 NONE lithium_38\NN| (r_compound) therapy_39\NN|lithium (r_pobj) of_37\IN|therapy (r_prep) onset_36\NN|of (r_pobj) after_35\IN|years|onset (r_prep) accelerated_12\VBN|patients|had|onset|after|)|compared|(|after|)|. (l_nsubj) patients_1\NNS|all|having (l_acl) having_2\VBG|relatives (l_dobj) relatives_6\NNS|degree|affected (l_acl) affected_7\VBN|by (l_agent) by_8\IN|illness (l_pobj) illness_10\NN|thyroid
D008094_D013959 NONE lithium_12\NN| (r_compound) therapy_13\NN|lithium (r_pobj) during_11\IN|therapy (r_prep) factor_6\NN|a|risk|for|during (r_attr) is_3\VBZ|illness|factor|. (l_nsubj) illness_2\NN|familial|thyroid
D008094_D001714 NONE lithium_16\NN| (r_compound) therapy_18\NN|lithium|maintenance|ranging (r_dobj) receiving_15\VBG|disorder|therapy (l_nsubj) disorder_14\NN|bipolar
D008094_D007037 CID lithium_22\NN| (r_compound) therapy_23\NN|lithium (r_pobj) of_21\IN|therapy (r_prep) onset_20\NN|of (r_pobj) after_19\IN|years|onset (r_prep) accelerated_12\VBN|patients|had|onset|after|)|compared|(|after|)|. (l_dobj) onset_13\NN|of|( (l_prep) of_14\IN|hypothyroidism (l_pobj) hypothyroidism_15\NN|
D008094_D007037 CID lithium_38\NN| (r_compound) therapy_39\NN|lithium (r_pobj) of_37\IN|therapy (r_prep) onset_36\NN|of (r_pobj) after_35\IN|years|onset (r_prep) accelerated_12\VBN|patients|had|onset|after|)|compared|(|after|)|. (l_dobj) onset_13\NN|of|( (l_prep) of_14\IN|hypothyroidism (l_pobj) hypothyroidism_15\NN|
D008094_D007037 CID lithium_12\NN| (r_compound) therapy_13\NN|lithium (r_pobj) during_11\IN|therapy (r_prep) factor_6\NN|a|risk|for|during (l_prep) for_7\IN|hypothyroidism (l_pobj) hypothyroidism_8\NN|and|hypercalcemia
D008094_D006934 NONE lithium_12\NN| (r_compound) therapy_13\NN|lithium (r_pobj) during_11\IN|therapy (r_prep) factor_6\NN|a|risk|for|during (l_prep) for_7\IN|hypothyroidism (l_pobj) hypothyroidism_8\NN|and|hypercalcemia (l_conj) hypercalcemia_10\NN|
7910951
D003473_D010243 NONE agents_7\NNS|blocking|and|corticosteroids (r_appos) neuromuscular_5\JJ|nondepolarizing|agents (r_pobj) due_2\IN|to|neuromuscular (r_prep) paralysis_1\NN|prolonged|due|.
D000305_D010243 NONE corticosteroids_9\NNS| (r_conj) agents_7\NNS|blocking|and|corticosteroids (r_appos) neuromuscular_5\JJ|nondepolarizing|agents (r_pobj) due_2\IN|to|neuromuscular (r_prep) paralysis_1\NN|prolonged|due|.
D003473_D018908 CID agents_9\NNS|neuromuscular|blocking|(|nmba|) (r_pobj) of_5\IN|agents (r_prep) use_4\NN|the|term|of (r_nsubjpass) implicated_18\VBN|use|has|recently|been|as|,|been|. (l_prep) as_19\IN|cause (l_pobj) cause_21\NN|a|of (l_prep) of_22\IN|weakness (l_pobj) weakness_25\NN|prolonged|muscle
D003473_D018908 CID NMBA_13\NNP|nd|- (r_appos) agents_9\NNS|neuromuscular|blocking|(|nmba|) (r_pobj) of_5\IN|agents (r_prep) use_4\NN|the|term|of (r_nsubjpass) implicated_18\VBN|use|has|recently|been|as|,|been|. (l_prep) as_19\IN|cause (l_pobj) cause_21\NN|a|of (l_prep) of_22\IN|weakness (l_pobj) weakness_25\NN|prolonged|muscle
D003473_D018908 CID NMBAs_25\NNP|nd|- (r_pobj) of_22\IN|nmbas (r_prep) discontinuation_21\NN|the|of (r_pobj) following_19\VBG|discontinuation (r_prep) weakness_18\NN|prolonged|following
D003473_D018908 CID NMBA_21\NNP|nd|-|)|and|muscle (r_pobj) due_17\IN|to|nmba (r_prep) likely_16\JJ|(|most|due|likely (r_parataxis) pathology_8\NN|at|likely (r_pobj) due_6\JJ|to|pathology (r_acomp) is_5\VBZ|weakness|due|. (l_nsubj) weakness_1\NN|the|in
D003473_D012131 NONE NMBAs_25\NNP|nd|- (r_pobj) of_22\IN|nmbas (r_prep) discontinuation_21\NN|the|of (r_pobj) following_19\VBG|discontinuation (r_prep) weakness_18\NN|prolonged|following (r_dobj) developed_16\VBD|who|weakness (r_relcl) insufficiency_14\NN|acute|respiratory|developed
D003473_D009468 CID NMBA_21\NNP|nd|-|)|and|muscle (r_pobj) due_17\IN|to|nmba (r_prep) likely_16\JJ|(|most|due|likely (r_parataxis) pathology_8\NN|at|likely (l_prep) at_9\IN|junction (l_pobj) junction_13\NN|both|the|neuromuscular
D000305_D018908 NONE corticosteroids_30\NNS| (r_pobj) due_28\IN|to|corticosteroids (r_prep) likely_27\JJ|(|most|due|) (r_parataxis) likely_16\JJ|(|most|due|likely (r_parataxis) pathology_8\NN|at|likely (r_pobj) due_6\JJ|to|pathology (r_acomp) is_5\VBZ|weakness|due|. (l_nsubj) weakness_1\NN|the|in
D000305_D009468 NONE corticosteroids_30\NNS| (r_pobj) due_28\IN|to|corticosteroids (r_prep) likely_27\JJ|(|most|due|) (r_parataxis) likely_16\JJ|(|most|due|likely (r_parataxis) pathology_8\NN|at|likely (l_prep) at_9\IN|junction (l_pobj) junction_13\NN|both|the|neuromuscular
3708922
D016572_D007674 CID cyclosporine_1\NN| (r_compound) nephrotoxicity_2\NN|experimental|cyclosporine|:|risk|.
D016572_D007674 CID cyclosporine_3\NN|csa (r_pobj) of_2\IN|cyclosporine|or|in (l_conj) in_9\IN|combination (l_pobj) combination_10\NN|with (l_prep) with_11\IN|chemotherapeutics (l_pobj) chemotherapeutics_13\NNS|various|in (l_prep) in_14\IN|development (l_pobj) development_16\NN|the|of (l_prep) of_17\IN|toxicity (l_pobj) toxicity_19\NN|renal
D016572_D007674 CID CSA_5\NNP|(|)|alone (r_appos) cyclosporine_3\NN|csa (r_pobj) of_2\IN|cyclosporine|or|in (l_conj) in_9\IN|combination (l_pobj) combination_10\NN|with (l_prep) with_11\IN|chemotherapeutics (l_pobj) chemotherapeutics_13\NNS|various|in (l_prep) in_14\IN|development (l_pobj) development_16\NN|the|of (l_prep) of_17\IN|toxicity (l_pobj) toxicity_19\NN|renal
D016572_D007674 CID CSA_4\NNP|and (r_pobj) of_3\IN|csa (r_prep) administration_2\NN|the|combined|of|drugs|with (l_prep) with_9\IN|potential (l_pobj) potential_12\NN|a|nephrotoxic|,|as (l_amod) nephrotoxic_11\JJ|
D016572_D007674 CID CSA_40\NNP|the (r_dobj) aggravate_38\VB|administration|did|not|csa|induced|. (l_nsubj) administration_2\NN|the|combined|of|drugs|with (l_prep) with_9\IN|potential (l_pobj) potential_12\NN|a|nephrotoxic|,|as (l_amod) nephrotoxic_11\JJ|
D016572_D007674 CID CSA_8\NNP| (r_compound) nephrotoxicity_9\NN|csa
D016572_D007674 CID CSA_6\NNP| (r_pobj) by_5\IN|csa (r_agent) induced_4\VBN|by (r_acl) nephrotoxicity_3\NN|the|induced
D016572_D064420 NONE CSA_4\NNP|and (r_pobj) of_3\IN|csa (r_prep) administration_2\NN|the|combined|of|drugs|with (r_nsubj) aggravate_38\VB|administration|did|not|csa|induced|. (l_ccomp) induced_41\VBN|toxicity (l_dobj) toxicity_42\NN|in
D016572_D064420 NONE CSA_40\NNP|the (r_dobj) aggravate_38\VB|administration|did|not|csa|induced|. (l_ccomp) induced_41\VBN|toxicity (l_dobj) toxicity_42\NN|in
D005839_D007674 NONE gentamicin_16\NN|(|at|)|,|b|,|used|, (r_pobj) as_15\IN|such|gentamicin (r_prep) potential_12\NN|a|nephrotoxic|,|as (l_amod) nephrotoxic_11\JJ|
D005839_D007674 NONE Gentamicin_0\NNP|at (r_nsubj) increased_7\VBD|gentamicin|,|however|,|nephrotoxicity|. (l_dobj) nephrotoxicity_9\NN|csa
D005839_D064420 NONE gentamicin_16\NN|(|at|)|,|b|,|used|, (r_pobj) as_15\IN|such|gentamicin (r_prep) potential_12\NN|a|nephrotoxic|,|as (r_pobj) with_9\IN|potential (r_prep) administration_2\NN|the|combined|of|drugs|with (r_nsubj) aggravate_38\VB|administration|did|not|csa|induced|. (l_ccomp) induced_41\VBN|toxicity (l_dobj) toxicity_42\NN|in
D000666_D007674 NONE B_24\NN|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN|(|at|)|,|b|,|used|, (r_pobj) as_15\IN|such|gentamicin (r_prep) potential_12\NN|a|nephrotoxic|,|as (l_amod) nephrotoxic_11\JJ|
D000666_D064420 NONE B_24\NN|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN|(|at|)|,|b|,|used|, (r_pobj) as_15\IN|such|gentamicin (r_prep) potential_12\NN|a|nephrotoxic|,|as (r_pobj) with_9\IN|potential (r_prep) administration_2\NN|the|combined|of|drugs|with (r_nsubj) aggravate_38\VB|administration|did|not|csa|induced|. (l_ccomp) induced_41\VBN|toxicity (l_dobj) toxicity_42\NN|in
D007654_D007674 NONE ketoconazole_26\NN| (r_conj) B_24\NN|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN|(|at|)|,|b|,|used|, (r_pobj) as_15\IN|such|gentamicin (r_prep) potential_12\NN|a|nephrotoxic|,|as (l_amod) nephrotoxic_11\JJ|
D007654_D064420 NONE ketoconazole_26\NN| (r_conj) B_24\NN|amphothericin|and|ketoconazole (r_conj) gentamicin_16\NN|(|at|)|,|b|,|used|, (r_pobj) as_15\IN|such|gentamicin (r_prep) potential_12\NN|a|nephrotoxic|,|as (r_pobj) with_9\IN|potential (r_prep) administration_2\NN|the|combined|of|drugs|with (r_nsubj) aggravate_38\VB|administration|did|not|csa|induced|. (l_ccomp) induced_41\VBN|toxicity (l_dobj) toxicity_42\NN|in
15764424
D002395_D011605 NONE catecholamines_12\NNS|and|hyperkinesia (r_conj) severity_10\NN|symptom|,|catecholamines (r_pobj) to_8\IN|severity (r_prep) relationship_7\NN|to (r_appos) levels_2\NNS|quantitative|drug|in|:|relationship|. (l_prep) in_3\IN|psychosis (l_pobj) psychosis_5\NN|stimulant
D002395_D011605 NONE catecholamines_10\NNS|,|and|symptoms (l_conj) symptoms_14\NNS|psychotic
D002395_D011605 NONE catecholamines_10\NNS|,|and|symptoms (r_conj) levels_8\NNS|quantitative|stimulant|drug|,|catecholamines (r_pobj) between_4\IN|levels (r_prep) relationship_3\NN|the|between (r_dobj) examine_1\VB|to|relationship (r_advcl) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS|nineteen|in (l_prep) in_18\IN|service (l_pobj) service_22\NN|a|psychiatric|emergency|with (l_prep) with_23\IN|diagnosis (l_pobj) diagnosis_25\NN|a|of (l_prep) of_26\IN|psychosis (l_pobj) psychosis_32\NN|induced
D002395_D011605 NONE catecholamine_49\NN| (r_conj) drug_47\NN|stimulant|and|catecholamine (r_nmod) levels_51\NNS|drug|metabolite (r_pobj) of_45\IN|levels (r_prep) assays_44\NNS|quantitative|of (r_pobj) for_42\IN|assays (r_prep) collected_41\VBN|plasma|were|for|. (r_conj) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_advcl) examine_1\VB|to|relationship (l_dobj) relationship_3\NN|the|between (l_prep) between_4\IN|levels (l_pobj) levels_8\NNS|quantitative|stimulant|drug|,|catecholamines (l_conj) catecholamines_10\NNS|,|and|symptoms (l_conj) symptoms_14\NNS|psychotic
D002395_D011605 NONE catecholamine_49\NN| (r_conj) drug_47\NN|stimulant|and|catecholamine (r_nmod) levels_51\NNS|drug|metabolite (r_pobj) of_45\IN|levels (r_prep) assays_44\NNS|quantitative|of (r_pobj) for_42\IN|assays (r_prep) collected_41\VBN|plasma|were|for|. (r_conj) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS|nineteen|in (l_prep) in_18\IN|service (l_pobj) service_22\NN|a|psychiatric|emergency|with (l_prep) with_23\IN|diagnosis (l_pobj) diagnosis_25\NN|a|of (l_prep) of_26\IN|psychosis (l_pobj) psychosis_32\NN|induced
D002395_D006948 NONE catecholamines_12\NNS|and|hyperkinesia (l_conj) hyperkinesia_14\NN|
D002395_D001523 NONE catecholamines_10\NNS|,|and|symptoms (r_conj) levels_8\NNS|quantitative|stimulant|drug|,|catecholamines (r_pobj) between_4\IN|levels (r_prep) relationship_3\NN|the|between (r_dobj) examine_1\VB|to|relationship (r_advcl) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS|nineteen|in (l_prep) in_18\IN|service (l_pobj) service_22\NN|a|psychiatric|emergency|with (l_amod) psychiatric_20\JJ|
D002395_D001523 NONE catecholamine_49\NN| (r_conj) drug_47\NN|stimulant|and|catecholamine (r_nmod) levels_51\NNS|drug|metabolite (r_pobj) of_45\IN|levels (r_prep) assays_44\NNS|quantitative|of (r_pobj) for_42\IN|assays (r_prep) collected_41\VBN|plasma|were|for|. (r_conj) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_nsubjpass) patients_17\NNS|nineteen|in (l_prep) in_18\IN|service (l_pobj) service_22\NN|a|psychiatric|emergency|with (l_amod) psychiatric_20\JJ|
D000661_D011605 CID amphetamine-_27\JJ|or|cocaine (r_npadvmod) induced_31\VBN|amphetamine-|- (r_amod) psychosis_32\NN|induced (r_pobj) of_26\IN|psychosis (r_prep) diagnosis_25\NN|a|of (r_pobj) with_23\IN|diagnosis (r_prep) service_22\NN|a|psychiatric|emergency|with (r_pobj) in_18\IN|service (r_prep) patients_17\NNS|nineteen|in (r_nsubjpass) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_advcl) examine_1\VB|to|relationship (l_dobj) relationship_3\NN|the|between (l_prep) between_4\IN|levels (l_pobj) levels_8\NNS|quantitative|stimulant|drug|,|catecholamines (l_conj) catecholamines_10\NNS|,|and|symptoms (l_conj) symptoms_14\NNS|psychotic
D000661_D011605 CID amphetamine-_27\JJ|or|cocaine (r_npadvmod) induced_31\VBN|amphetamine-|- (r_amod) psychosis_32\NN|induced
D000661_D001523 NONE amphetamine-_27\JJ|or|cocaine (r_npadvmod) induced_31\VBN|amphetamine-|- (r_amod) psychosis_32\NN|induced (r_pobj) of_26\IN|psychosis (r_prep) diagnosis_25\NN|a|of (r_pobj) with_23\IN|diagnosis (r_prep) service_22\NN|a|psychiatric|emergency|with (l_amod) psychiatric_20\JJ|
D003042_D011605 CID cocaine_29\NN| (r_conj) amphetamine-_27\JJ|or|cocaine (r_npadvmod) induced_31\VBN|amphetamine-|- (r_amod) psychosis_32\NN|induced (r_pobj) of_26\IN|psychosis (r_prep) diagnosis_25\NN|a|of (r_pobj) with_23\IN|diagnosis (r_prep) service_22\NN|a|psychiatric|emergency|with (r_pobj) in_18\IN|service (r_prep) patients_17\NNS|nineteen|in (r_nsubjpass) interviewed_34\VBN|examine|,|patients|were|,|and|collected (l_advcl) examine_1\VB|to|relationship (l_dobj) relationship_3\NN|the|between (l_prep) between_4\IN|levels (l_pobj) levels_8\NNS|quantitative|stimulant|drug|,|catecholamines (l_conj) catecholamines_10\NNS|,|and|symptoms (l_conj) symptoms_14\NNS|psychotic
D003042_D011605 CID cocaine_29\NN| (r_conj) amphetamine-_27\JJ|or|cocaine (r_npadvmod) induced_31\VBN|amphetamine-|- (r_amod) psychosis_32\NN|induced
D003042_D001523 NONE cocaine_29\NN| (r_conj) amphetamine-_27\JJ|or|cocaine (r_npadvmod) induced_31\VBN|amphetamine-|- (r_amod) psychosis_32\NN|induced (r_pobj) of_26\IN|psychosis (r_prep) diagnosis_25\NN|a|of (r_pobj) with_23\IN|diagnosis (r_prep) service_22\NN|a|psychiatric|emergency|with (l_amod) psychiatric_20\JJ|
D008694_D006948 CID Methamphetamine_0\NN|or|levels (r_nsubjpass) related_5\VBN|methamphetamine|were|to|. (l_prep) to_6\IN|scores (l_pobj) scores_9\NNS|several|psychopathology|and|rating (l_conj) rating_14\NN|the|global|hyperkinesia (l_compound) hyperkinesia_13\NN|
D000661_D006948 CID amphetamine_2\NN| (r_compound) levels_3\NNS|amphetamine (r_conj) Methamphetamine_0\NN|or|levels (r_nsubjpass) related_5\VBN|methamphetamine|were|to|. (l_prep) to_6\IN|scores (l_pobj) scores_9\NNS|several|psychopathology|and|rating (l_conj) rating_14\NN|the|global|hyperkinesia (l_compound) hyperkinesia_13\NN|
15580403
D012254_D006461 NONE ribavirin_3\JJ| (r_compound) reduction_4\NN|ribavirin|in (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|hemolysis (l_pobj) hemolysis_8\NN|during
D012254_D006461 NONE ribavirin_15\RB| (r_conj) interferon_13\NN|and|ribavirin (r_pobj) of_12\IN|interferon (r_prep) therapy_11\NN|combination|of|for (r_pobj) during_9\IN|therapy (r_prep) hemolysis_8\NN|during
D012254_D006461 NONE ribavirin_13\JJ| (r_compound) reduction_14\NN|ribavirin|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|with (l_prep) with_17\IN|hemolysis (l_pobj) hemolysis_18\NN|during
D012254_D019698 NONE ribavirin_3\JJ| (r_compound) reduction_4\NN|ribavirin|in (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|hemolysis (l_pobj) hemolysis_8\NN|during (l_prep) during_9\IN|therapy (l_pobj) therapy_11\NN|combination|of|for (l_prep) for_16\IN|c. (l_pobj) C._19\NNP|chronic|hepatitis
D012254_D019698 NONE ribavirin_15\RB| (r_conj) interferon_13\NN|and|ribavirin (r_pobj) of_12\IN|interferon (r_prep) therapy_11\NN|combination|of|for (l_prep) for_16\IN|c. (l_pobj) C._19\NNP|chronic|hepatitis
D007372_D006461 NONE interferon_13\NN|and|ribavirin (r_pobj) of_12\IN|interferon (r_prep) therapy_11\NN|combination|of|for (r_pobj) during_9\IN|therapy (r_prep) hemolysis_8\NN|during
D007372_D019698 NONE interferon_13\NN|and|ribavirin (r_pobj) of_12\IN|interferon (r_prep) therapy_11\NN|combination|of|for (l_prep) for_16\IN|c. (l_pobj) C._19\NNP|chronic|hepatitis
D007372_D000743 CID interferon_14\NN|and|ribavirin (r_pobj) of_13\IN|interferon (r_prep) therapy_12\NN|the|combination|of (r_pobj) of_9\IN|therapy (r_prep) events_8\NNS|the|major|adverse|of (r_pobj) of_4\IN|events (r_prep) one_3\CD|of (r_attr) is_2\VBZ|anemia|one|. (l_nsubj) anemia_1\NN|hemolytic
D012254_D000743 CID ribavirin_16\NN| (r_conj) interferon_14\NN|and|ribavirin (r_pobj) of_13\IN|interferon (r_prep) therapy_12\NN|the|combination|of (r_pobj) of_9\IN|therapy (r_prep) events_8\NNS|the|major|adverse|of (r_pobj) of_4\IN|events (r_prep) one_3\CD|of (r_attr) is_2\VBZ|anemia|one|. (l_nsubj) anemia_1\NN|hemolytic
D012254_D000743 CID ribavirin_2\RB| (r_npadvmod) related_4\VBN|ribavirin|- (r_amod) anemia_6\NN|related|hemolytic
D012254_D000740 NONE ribavirin_9\NN| (r_pobj) of_8\IN|ribavirin (r_prep) reduction_7\NN|of (r_pobj) with_6\IN|reduction (r_prep) patients_5\NNS|37|with (r_nsubj) continue_12\VB|however|,|patients|could|not|therapy|decreased|. (l_advcl) decreased_24\VBD|because|values|to|or|occurred (l_conj) occurred_33\VBD|effects|b|) (l_nsubj) effects_32\NNS|related|severe|side (l_amod) related_29\VBN|anemia|- (l_npadvmod) anemia_27\NN|
7421734
D004967_D010049 NONE estrogens_16\NNS|exogenous (r_dobj) received_14\VBD|estrogens|treatment (r_conj) had_1\VBD|she|failure|,|and|received|. (l_dobj) failure_3\NN|ovarian|after
D004967_D010049 NONE estrogens_4\NNS|replacement|for (l_prep) for_5\IN|failure (l_pobj) failure_7\NN|ovarian
D004967_D006689 NONE estrogens_16\NNS|exogenous (r_dobj) received_14\VBD|estrogens|treatment (r_conj) had_1\VBD|she|failure|,|and|received|. (l_dobj) failure_3\NN|ovarian|after (l_prep) after_4\IN|irradiation (l_pobj) irradiation_6\NN|abdominal|and|chemotherapy|for (l_prep) for_9\IN|disease (l_pobj) disease_11\NN|hodgkin
D004967_D016889 CID estrogens_16\NNS|exogenous (r_dobj) received_14\VBD|estrogens|treatment (l_npadvmod) treatment_19\NN|,|a|implicated (l_acl) implicated_20\VBN|in (l_prep) in_21\IN|development (l_pobj) development_23\NN|the|of (l_prep) of_24\IN|cancer (l_pobj) cancer_26\NN|endometrial|in
D004967_D016889 CID estrogens_4\NNS|replacement|for (r_pobj) on_2\IN|estrogens (r_prep) women_1\NNS|young|on (r_nsubj) increased_14\VBN|women|after|therapy|may|also|have|risk|and|examined|. (l_dobj) risk_15\NN|of (l_prep) of_16\IN|carcinoma (l_pobj) carcinoma_18\NN|endometrial
D004967_D009369 NONE estrogens_4\NNS|replacement|for (r_pobj) on_2\IN|estrogens (r_prep) women_1\NNS|young|on (r_nsubj) increased_14\VBN|women|after|therapy|may|also|have|risk|and|examined|. (l_nsubj) therapy_10\NN|cancer (l_compound) cancer_9\NN|
12739036
D003401_D008180 NONE creatine_5\NN|high|serum (r_compound) levels_7\NNS|creatine|kinase|in (l_prep) in_8\IN|erythematosus (l_pobj) erythematosus_11\NN|systemic|lupus
D002738_D009135 NONE chloroquine_15\NN| (r_advmod) induced_17\VBN|chloroquine|- (r_amod) myopathy_18\NN|severe|induced
D002738_D009135 NONE chloroquine_3\NN| (r_npadvmod) induced_5\VBN|chloroquine|- (r_compound) myopathy_6\NN|induced
D001379_D008180 NONE azathioprine_23\NN|and|cyclophosphamide (r_pobj) with_22\IN|azathioprine (r_prep) treatment_21\NN|with (r_pobj) of_20\IN|treatment (r_prep) periods_19\NNS|of (r_dobj) undergone_18\JJ|periods (r_conj) suffering_6\VBG|since|,|she|had|been|from|with|and|undergone|. (l_prep) from_7\IN|erythematosus (l_pobj) erythematosus_10\NN|systemic|lupus|(|sle|)
D001379_D008180 NONE azathioprine_23\NN|and|cyclophosphamide (r_pobj) with_22\IN|azathioprine (r_prep) treatment_21\NN|with (r_pobj) of_20\IN|treatment (r_prep) periods_19\NNS|of (r_dobj) undergone_18\JJ|periods (r_conj) suffering_6\VBG|since|,|she|had|been|from|with|and|undergone|. (l_prep) from_7\IN|erythematosus (l_pobj) erythematosus_10\NN|systemic|lupus|(|sle|) (l_appos) SLE_12\NNP|
D001379_D007674 NONE azathioprine_23\NN|and|cyclophosphamide (r_pobj) with_22\IN|azathioprine (r_prep) treatment_21\NN|with (r_pobj) of_20\IN|treatment (r_prep) periods_19\NNS|of (r_dobj) undergone_18\JJ|periods (r_conj) suffering_6\VBG|since|,|she|had|been|from|with|and|undergone|. (l_prep) with_14\IN|involvement (l_pobj) involvement_16\NN|renal
D003520_D008180 NONE cyclophosphamide_25\NN| (r_conj) azathioprine_23\NN|and|cyclophosphamide (r_pobj) with_22\IN|azathioprine (r_prep) treatment_21\NN|with (r_pobj) of_20\IN|treatment (r_prep) periods_19\NNS|of (r_dobj) undergone_18\JJ|periods (r_conj) suffering_6\VBG|since|,|she|had|been|from|with|and|undergone|. (l_prep) from_7\IN|erythematosus (l_pobj) erythematosus_10\NN|systemic|lupus|(|sle|)
D003520_D008180 NONE cyclophosphamide_25\NN| (r_conj) azathioprine_23\NN|and|cyclophosphamide (r_pobj) with_22\IN|azathioprine (r_prep) treatment_21\NN|with (r_pobj) of_20\IN|treatment (r_prep) periods_19\NNS|of (r_dobj) undergone_18\JJ|periods (r_conj) suffering_6\VBG|since|,|she|had|been|from|with|and|undergone|. (l_prep) from_7\IN|erythematosus (l_pobj) erythematosus_10\NN|systemic|lupus|(|sle|) (l_appos) SLE_12\NNP|
D003520_D007674 NONE cyclophosphamide_25\NN| (r_conj) azathioprine_23\NN|and|cyclophosphamide (r_pobj) with_22\IN|azathioprine (r_prep) treatment_21\NN|with (r_pobj) of_20\IN|treatment (r_prep) periods_19\NNS|of (r_dobj) undergone_18\JJ|periods (r_conj) suffering_6\VBG|since|,|she|had|been|from|with|and|undergone|. (l_prep) with_14\IN|involvement (l_pobj) involvement_16\NN|renal
D002738_D018771 NONE chloroquine_3\NN| (r_amod) CQ_5\NNP|chloroquine|( (r_pobj) with_2\IN|cq (r_prep) therapy_1\NN|additional|with|) (r_nsubjpass) started_8\VBN|therapy|was|because|. (l_prep) because_9\IN|of|arthralgia (l_pobj) arthralgia_11\NN|
D002738_D018771 NONE CQ_5\NNP|chloroquine|( (r_pobj) with_2\IN|cq (r_prep) therapy_1\NN|additional|with|) (r_nsubjpass) started_8\VBN|therapy|was|because|. (l_prep) because_9\IN|of|arthralgia (l_pobj) arthralgia_11\NN|
D013256_D009220 NONE steroids_10\NNS| (r_pobj) with_9\IN|steroids (r_prep) treated_8\VBN|patient|was|with|. (r_conj) suspected_2\VBN|myositis|was|,|and|treated (l_nsubjpass) Myositis_0\NNP|
804391
D012293_D011507 CID rifampin_8\NN| (r_advmod) treated_9\VBN|rifampin (r_amod) patients_10\NNS|treated|with (r_pobj) in_7\IN|patients (r_prep) proteinuria_2\NN|light|chain|and|immunity|in|.
D012293_D011507 CID rifampin_13\NN| (r_pobj) with_12\IN|rifampin (r_prep) treated_11\VBN|patients|with (r_advcl) found_4\VBN|proteinuria|was|in|treated|. (l_nsubjpass) proteinuria_2\NN|light|chain
D012293_D014376 NONE rifampin_8\NN| (r_advmod) treated_9\VBN|rifampin (r_amod) patients_10\NNS|treated|with (l_prep) with_11\IN|tuberculosis (l_pobj) tuberculosis_12\NN|
D012293_D014376 NONE rifampin_13\NN| (r_pobj) with_12\IN|rifampin (r_prep) treated_11\VBN|patients|with (l_nsubj) patients_10\NNS|17|tuberculosis (l_compound) tuberculosis_9\NN|
1564236
D013793_D023921 NONE thallium-201_18\JJ| (r_amod) tomography_23\NN|thallium-201|emission (r_pobj) with_17\IN|tomography (r_prep) correlation_16\NN|with (r_appos) observed_4\VBN|relation|with|:|correlation|. (l_prep) with_5\IN|contrast (l_pobj) contrast_7\NN|myocardial|echocardiography|to (l_prep) to_9\IN|severity (l_pobj) severity_11\NN|the|of (l_prep) of_12\IN|stenosis (l_pobj) stenosis_14\NN|coronary
D004176_D006940 CID dipyridamole_1\NN| (r_npadvmod) induced_3\VBN|dipyridamole|- (r_amod) hyperemia_4\NN|induced
D004176_D006940 CID dipyridamole_24\NN| (r_npadvmod) induced_26\VBN|dipyridamole|- (r_amod) hyperemia_27\NN|induced
D004176_D006940 CID dipyridamole_11\NN| (r_npadvmod) induced_13\VBN|dipyridamole|- (r_amod) hyperemia_14\NN|induced
D004176_D023921 NONE dipyridamole_1\NN| (r_npadvmod) induced_3\VBN|dipyridamole|- (r_amod) hyperemia_4\NN|induced (r_pobj) During_0\IN|hyperemia (r_prep) had_16\VBD|during|,|12|area|by|. (l_nsubj) 12_6\CD|of (l_prep) of_7\IN|dogs (l_pobj) dogs_10\NNS|the|16|with (l_prep) with_11\IN|stenosis (l_pobj) stenosis_15\NN|a|partial|coronary
8473723
D008728_D012640 CID levomepromazine_4\JJ| (r_amod) fluvoxamine_6\NN|levomepromazine|- (r_compound) treatment_7\NN|combined|fluvoxamine (r_pobj) by_2\IN|treatment (r_agent) induced_1\VBN|seizures|by|. (l_nsubj) Seizures_0\NNS|
D008728_D012640 CID levomepromazine_6\JJ| (r_amod) fluvoxamine_8\NN|levomepromazine|- (r_nmod) seizures_12\NNS|combined|fluvoxamine|induced
D016666_D012640 CID fluvoxamine_6\NN|levomepromazine|- (r_compound) treatment_7\NN|combined|fluvoxamine (r_pobj) by_2\IN|treatment (r_agent) induced_1\VBN|seizures|by|. (l_nsubj) Seizures_0\NNS|
D016666_D012640 CID fluvoxamine_8\NN|levomepromazine|- (r_nmod) seizures_12\NNS|combined|fluvoxamine|induced
9672273
D013629_D001943 NONE tamoxifen_5\NN| (r_pobj) with_4\IN|tamoxifen (r_prep) Prevention_0\NN|of|with|:|findings|. (l_prep) of_1\IN|cancer (l_pobj) cancer_3\NN|breast
D013629_D001943 NONE Tamoxifen_0\NNP| (r_nsubj) is_1\VBZ|tamoxifen|agent|,|associated|. (l_attr) agent_5\NN|a|candidate|chemopreventive|in (l_prep) in_6\IN|cancer (l_pobj) cancer_8\NN|breast
D013629_D001943 NONE tamoxifen_18\NN| (r_pobj) of_17\IN|tamoxifen (r_prep) trial_16\NN|a|blind|controlled|,|randomised|of|in|(|in|)|have (l_relcl) have_29\VB|who|did|not|cancer|and|had (l_dobj) cancer_31\NN|breast
D013629_D001943 NONE tamoxifen_17\NN| (r_nmod) arms_21\NNS|tamoxifen|(|19|) (r_conj) placebo_11\NN|the|(|cases|)|and|arms (r_pobj) between_9\IN|placebo (r_prep) frequency_8\NN|cancer|between (l_compound) cancer_7\NN|breast|-
D013629_D001943 NONE tamoxifen_12\NN| (r_dobj) receiving_11\VBG|tamoxifen (r_acl) women_10\NNS|receiving|used (r_pobj) among_9\IN|women (r_prep) reduction_5\NN|a|significant|of|among|:|among (l_prep) of_6\IN|cancer (l_pobj) cancer_8\NN|breast
D013629_D001943 NONE tamoxifen_12\NN| (r_dobj) receiving_11\VBG|tamoxifen (r_acl) women_10\NNS|receiving|used (r_pobj) among_9\IN|women (r_prep) reduction_5\NN|a|significant|of|among|:|among (r_attr) is_1\VBZ|there|reduction (r_ccomp) found_36\VBD|is|,|we|cases|compared|. (l_dobj) cases_38\NNS|eight|of (l_prep) of_39\IN|cancer (l_pobj) cancer_41\NN|breast
D013629_D001943 NONE tamoxifen_51\NN| (r_pobj) to_50\IN|tamoxifen (r_prep) allocated_49\VBN|to (r_acl) women_48\NNS|362|allocated (r_pobj) among_46\IN|women (r_prep) case_45\NN|one|among (r_pobj) with_43\IN|case (r_prep) compared_42\VBN|with (r_prep) found_36\VBD|is|,|we|cases|compared|. (l_ccomp) is_1\VBZ|there|reduction (l_attr) reduction_5\NN|a|significant|of|among|:|among (l_prep) of_6\IN|cancer (l_pobj) cancer_8\NN|breast
D013629_D001943 NONE tamoxifen_51\NN| (r_pobj) to_50\IN|tamoxifen (r_prep) allocated_49\VBN|to (r_acl) women_48\NNS|362|allocated (r_pobj) among_46\IN|women (r_prep) case_45\NN|one|among (r_pobj) with_43\IN|case (r_prep) compared_42\VBN|with (r_prep) found_36\VBD|is|,|we|cases|compared|. (l_dobj) cases_38\NNS|eight|of (l_prep) of_39\IN|cancer (l_pobj) cancer_41\NN|breast
D013629_D001943 NONE tamoxifen_29\NN| (r_pobj) of_28\IN|tamoxifen (r_prep) effects_27\NNS|the|postulated|protective|of (r_nsubj) are_30\VBP|has|,|in|,|effects|not|apparent|. (l_prep) in_8\IN|cohort|at (l_prep) at_13\IN|risk (l_pobj) risk_19\NN|low|of (l_prep) of_20\IN|cancer (l_pobj) cancer_22\NN|breast
D013629_D016889 NONE Tamoxifen_0\NNP| (r_nsubj) is_1\VBZ|tamoxifen|agent|,|associated|. (l_advcl) associated_15\VBN|although|drug|may|be|with (l_prep) with_16\IN|development (l_pobj) development_18\NN|the|of (l_prep) of_19\IN|cancer (l_pobj) cancer_21\NN|endometrial
D013629_D014652 CID tamoxifen_20\NN| (r_pobj) on_19\IN|tamoxifen (r_prep) women_18\NNS|on (r_pobj) among_17\IN|women (r_prep) events_14\NNS|vascular|and|hypertriglyceridaemia|among
D013629_D015228 CID tamoxifen_20\NN| (r_pobj) on_19\IN|tamoxifen (r_prep) women_18\NNS|on (r_pobj) among_17\IN|women (r_prep) events_14\NNS|vascular|and|hypertriglyceridaemia|among (l_conj) hypertriglyceridaemia_16\NN|
14982270
D008713_D041781 CID Methimazole_0\NN| (r_npadvmod) induced_2\VBN|methimazole|- (r_amod) jaundice_4\NN|induced|cholestatic|.
D008713_D007565 NONE methimazole_14\NN| (r_dobj) receiving_13\VBG|methimazole|(|tid|)|and|propranolol (r_pcomp) after_12\IN|receiving (r_prep) itching_9\NN|month|after (r_conj) had_5\VBD|woman|jaundice|and|itching|. (l_dobj) jaundice_7\NN|severe
D008713_D011537 CID methimazole_14\NN| (r_dobj) receiving_13\VBG|methimazole|(|tid|)|and|propranolol (r_pcomp) after_12\IN|receiving (r_prep) itching_9\NN|month|after
D008713_D006980 NONE methimazole_14\NN| (r_dobj) receiving_13\VBG|methimazole|(|tid|)|and|propranolol (l_conj) propranolol_21\NN|tid|for (l_prep) for_27\IN|treatment (l_pobj) treatment_28\NN|of (l_prep) of_29\IN|hyperthyroidism (l_pobj) hyperthyroidism_30\NN|
D011433_D007565 NONE propranolol_21\NN|tid|for (r_conj) receiving_13\VBG|methimazole|(|tid|)|and|propranolol (r_pcomp) after_12\IN|receiving (r_prep) itching_9\NN|month|after (r_conj) had_5\VBD|woman|jaundice|and|itching|. (l_dobj) jaundice_7\NN|severe
D011433_D011537 NONE propranolol_21\NN|tid|for (r_conj) receiving_13\VBG|methimazole|(|tid|)|and|propranolol (r_pcomp) after_12\IN|receiving (r_prep) itching_9\NN|month|after
D011433_D006980 NONE propranolol_21\NN|tid|for (l_prep) for_27\IN|treatment (l_pobj) treatment_28\NN|of (l_prep) of_29\IN|hyperthyroidism (l_pobj) hyperthyroidism_30\NN|
D008713_D002779 NONE Methimazole_0\NN| (r_npadvmod) induced_2\VBN|methimazole|- (r_amod) cholestasis_3\NN|induced
D011433_D002779 NONE propranolol_8\NN|therapy (r_conj) diagnosed_5\VBN|cholestasis|was|,|and|propranolol (l_nsubjpass) cholestasis_3\NN|induced
9514561
D002211_D010146 CID capsaicin_5\NN| (r_pobj) by_4\IN|capsaicin (r_agent) elicited_3\VBN|by (r_acl) pain_2\NN|experimental|cranial|elicited|:|study|.
D002211_D010146 CID capsaicin_4\NN| (r_pobj) of_3\IN|capsaicin (r_prep) amount_2\NN|a|small|of (r_nsubjpass) administered_6\VBN|amount|was|subcutaneously|in|evoke|. (l_advcl) evoke_13\VB|to|sensation (l_dobj) sensation_17\NN|a|burning|painful|in (l_amod) painful_16\JJ|
14704468
C066440_D012640 NONE Loreclezole_0\NNP|mg/kg (r_nsubj) exerted_5\VBD|loreclezole|action|,|reducing|. (l_advcl) reducing_16\VBG|seizure (l_dobj) seizure_18\NN|both|and|durations
18363626
D020927_D001919 CID dexmedetomidine_1\NN| (r_amod) sedation_2\NN|dexmedetomidine (r_nsubjpass) associated_4\VBN|although|sedation|was|with (l_prep) with_5\IN|incidence (l_pobj) incidence_9\NN|a|%|of (l_prep) of_10\IN|bradycardia (l_pobj) bradycardia_11\NN|
D010100_D001919 NONE oxygen_30\NN| (r_compound) saturations_31\NNS|oxygen (r_conj) range_28\NN|adjusted|normal|and|saturations (r_pobj) of_23\IN|range (r_prep) %_22\NN|20|of (r_pobj) within_20\IN|% (r_prep) were_19\VBD|associated|,|pressures|within|were|. (l_advcl) associated_4\VBN|although|sedation|was|with (l_prep) with_5\IN|incidence (l_pobj) incidence_9\NN|a|%|of (l_prep) of_10\IN|bradycardia (l_pobj) bradycardia_11\NN|
10411803
D015313_D000743 CID cefotetan_9\NN| (r_pobj) of_8\IN|cefotetan (r_prep) use_7\NN|prophylactic|of|in (r_pobj) with_5\IN|use (r_prep) associated_4\VBN|with (r_acl) anemia_3\NN|severe|immune|hemolytic|associated|.
D015313_D000743 CID cefotetan_8\JJ|especially (r_appos) cephalosporins_5\NNS|generation|,|cefotetan|, (r_conj) Second-_0\NNP|and|cephalosporins (r_nsubjpass) associated_12\VBN|second-|are|increasingly|with|. (l_prep) with_13\IN|anemia (l_pobj) anemia_20\NN|severe|,|fatal|immune|hemolytic
D015313_D000743 CID cefotetan_9\NN| (r_npadvmod) induced_11\VBN|cefotetan|- (r_amod) anemias_13\NNS|induced|hemolytic
D015313_D000743 CID cefotetan_20\JJ| (r_dobj) received_19\VBN|who|had|cefotetan|prophylactically|for (r_relcl) patients_16\NNS|received (r_pobj) in_15\IN|patients (r_prep) were_14\VBD|that|10|in (l_nsubj) 10_3\CD|of (l_prep) of_4\IN|cases (l_pobj) cases_7\NNS|our|35|of (l_prep) of_8\IN|anemias (l_pobj) anemias_13\NNS|induced|hemolytic
D002511_D000743 NONE cephalosporins_5\NNS|generation|,|cefotetan|, (r_conj) Second-_0\NNP|and|cephalosporins (r_nsubjpass) associated_12\VBN|second-|are|increasingly|with|. (l_prep) with_13\IN|anemia (l_pobj) anemia_20\NN|severe|,|fatal|immune|hemolytic
19058474
D014859_D010490 NONE warfarin_13\NN| (r_pobj) with_12\IN|warfarin (r_prep) interaction_8\NN|possible|of|with (r_pobj) due_5\IN|to|interaction (r_prep) haemorrhage_4\NN|haemopericardium|due|. (l_nmod) haemopericardium_1\NN|fatal|and|gastrointestinal
D014859_D006471 CID warfarin_13\NN| (r_pobj) with_12\IN|warfarin (r_prep) interaction_8\NN|possible|of|with (r_pobj) due_5\IN|to|interaction (r_prep) haemorrhage_4\NN|haemopericardium|due|.
D014859_D006470 NONE warfarin_26\NN| (r_pobj) of_25\IN|warfarin (r_prep) dosage_24\NN|his|usual|of (r_dobj) maintaining_21\VBG|while|dosage (r_advcl) consumed_13\VBD|who|juice|for|maintaining (r_relcl) man_11\NN|an|elderly|consumed (r_pobj) in_8\IN|man (r_prep) case_3\NN|a|of|in (l_prep) of_4\IN|haemorrhage (l_pobj) haemorrhage_7\NN|fatal|internal
16157917
C047781_D009207 CID Lamotrigine_0\NNP|associated|. (l_acl) associated_1\VBD|with (l_prep) with_2\IN|exacerbation (l_pobj) exacerbation_3\NN|or|myoclonus|in (l_conj) myoclonus_7\NN|de|novo
C047781_D009207 CID lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_advcl) experienced_15\VBD|exacerbation (l_dobj) exacerbation_16\NN|or|appearance (l_conj) appearance_20\NN|de|novo|of (l_prep) of_21\IN|jerks (l_pobj) jerks_23\NNS|myoclonic|(|mj|)
C047781_D009207 CID lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_advcl) experienced_15\VBD|exacerbation (l_dobj) exacerbation_16\NN|or|appearance (l_conj) appearance_20\NN|de|novo|of (l_prep) of_21\IN|jerks (l_pobj) jerks_23\NNS|myoclonic|(|mj|) (l_appos) MJ_25\NNP|
C047781_D009207 CID LTG_13\NNP| (r_appos) lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_advcl) experienced_15\VBD|exacerbation (l_dobj) exacerbation_16\NN|or|appearance (l_conj) appearance_20\NN|de|novo|of (l_prep) of_21\IN|jerks (l_pobj) jerks_23\NNS|myoclonic|(|mj|)
C047781_D009207 CID LTG_13\NNP| (r_appos) lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_advcl) experienced_15\VBD|exacerbation (l_dobj) exacerbation_16\NN|or|appearance (l_conj) appearance_20\NN|de|novo|of (l_prep) of_21\IN|jerks (l_pobj) jerks_23\NNS|myoclonic|(|mj|) (l_appos) MJ_25\NNP|
C047781_D009207 CID LTG_4\NNP| (r_nsubj) exacerbated_5\VBD|in|,|ltg|mj|in|. (l_dobj) MJ_6\NNP|
C047781_D009207 CID LTG_3\NNP| (r_compound) dose_4\NN|ltg (r_nsubjpass) decreased_6\VBN|when|dose|was|by (r_advcl) disappeared_1\VBD|mj|decreased|. (l_nsubj) MJ_0\NNP|
C047781_D009207 CID LTG_4\NNP| (r_nsubj) exacerbated_5\VBD|in|,|ltg|mj|in|,|with|. (l_dobj) MJ_6\NNP|
C047781_D009207 CID LTG_4\NNP| (r_nsubj) exacerbated_5\VBD|in|,|ltg|mj|in|,|with|. (l_prep) with_15\IN|status (l_pobj) status_17\NN|myoclonic|ceased
C047781_D009207 CID LTG_22\NNP| (r_compound) withdrawal_23\NN|ltg (r_pobj) after_21\IN|withdrawal (r_prep) ceased_20\VBD|that|only|after (r_relcl) status_17\NN|myoclonic|ceased (r_pobj) with_15\IN|status (r_prep) exacerbated_5\VBD|in|,|ltg|mj|in|,|with|. (l_dobj) MJ_6\NNP|
C047781_D009207 CID LTG_22\NNP| (r_compound) withdrawal_23\NN|ltg (r_pobj) after_21\IN|withdrawal (r_prep) ceased_20\VBD|that|only|after (r_relcl) status_17\NN|myoclonic|ceased
C047781_C562694 NONE Lamotrigine_0\NNP|associated|. (l_acl) associated_1\VBD|with (l_prep) with_2\IN|exacerbation (l_pobj) exacerbation_3\NN|or|myoclonus|in (l_prep) in_8\IN|epilepsies (l_pobj) epilepsies_11\NNS|idiopathic|generalized
C047781_C562694 NONE lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|epilepsies (l_pobj) epilepsies_5\NNS|idiopathic|generalized|(|ige|)
C047781_C562694 NONE lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|epilepsies (l_pobj) epilepsies_5\NNS|idiopathic|generalized|(|ige|) (l_appos) IGE_7\NNP|
C047781_C562694 NONE LTG_13\NNP| (r_appos) lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|epilepsies (l_pobj) epilepsies_5\NNS|idiopathic|generalized|(|ige|)
C047781_C562694 NONE LTG_13\NNP| (r_appos) lamotrigine_11\NNP|(|ltg|) (r_pobj) with_10\IN|lamotrigine (r_prep) treated_9\VBN|patients|with|experienced|. (l_nsubj) patients_1\NNS|five|with (l_prep) with_2\IN|epilepsies (l_pobj) epilepsies_5\NNS|idiopathic|generalized|(|ige|) (l_appos) IGE_7\NNP|
10840460
D003520_D003556 CID Cyclophosphamide_0\NNP| (r_npadvmod) induced_2\VBN|cyclophosphamide|- (r_amod) cystitis_3\NN|induced|in|:|approach|.
D003520_D003556 CID Cyclophosphamide_0\NNP|cp|,|agent|, (r_nsubjpass) used_25\VBN|cyclophosphamide|was|induce|. (l_xcomp) induce_27\VB|to|cystitis (l_dobj) cystitis_28\NN|
D003520_D003556 CID CP_2\NNP|(|) (r_appos) Cyclophosphamide_0\NNP|cp|,|agent|, (r_nsubjpass) used_25\VBN|cyclophosphamide|was|induce|. (l_xcomp) induce_27\VB|to|cystitis (l_dobj) cystitis_28\NN|
D003520_D003556 CID CP_10\NNP| (r_npadvmod) induced_12\VBN|cp|- (r_amod) cystitis_13\NN|induced
D003520_D059265 NONE Cyclophosphamide_0\NNP| (r_npadvmod) induced_2\VBN|cyclophosphamide|- (r_amod) cystitis_3\NN|induced|in|:|approach|. (l_appos) approach_12\NN|behavioral|to (l_prep) to_13\IN|model (l_pobj) model_16\NN|a|new|of (l_prep) of_17\IN|pain (l_pobj) pain_19\NN|visceral
D003520_D059265 NONE CP_10\NNP| (r_npadvmod) induced_12\VBN|cp|- (r_amod) cystitis_13\NN|induced (r_pobj) of_9\IN|cystitis (r_prep) model_8\NN|this|experimental|of (r_nsubj) be_15\VB|that|model|may|model|,|allowing (l_attr) model_20\NN|an|interesting|new|behavioral|of (l_prep) of_21\IN|pain (l_pobj) pain_24\NN|inflammatory|visceral
D000171_D003556 NONE acrolein_22\NN|its|main|metabolite (r_pobj) through_17\IN|acrolein (r_prep) produce_10\VB|to|effects|through (r_xcomp) known_8\VBN|produce (r_acl) agent_7\NN|an|antitumoral|known (r_appos) Cyclophosphamide_0\NNP|cp|,|agent|, (r_nsubjpass) used_25\VBN|cyclophosphamide|was|induce|. (l_xcomp) induce_27\VB|to|cystitis (l_dobj) cystitis_28\NN|
D009020_D001523 NONE Morphine_0\NNP| (r_nsubj) reversed_4\VBD|morphine|dependently|disorders|. (l_dobj) disorders_7\NNS|these|behavioral
D009020_D004487 NONE morphine_6\NN| (r_pobj) of_5\IN|morphine (r_prep) administration_4\NN|of|,|modifications (l_appos) modifications_9\NNS|histological|of|,|as (l_prep) as_16\IN|such|edema (l_pobj) edema_21\NN|chorionic
D003520_D010146 CID CP_10\NNP| (r_npadvmod) induced_12\VBN|cp|- (r_amod) cystitis_13\NN|induced (r_pobj) of_9\IN|cystitis (r_prep) model_8\NN|this|experimental|of (r_nsubj) be_15\VB|that|model|may|model|,|allowing (l_advcl) allowing_26\VBG|understanding (l_dobj) understanding_29\NN|a|better|of|and|approach (l_prep) of_30\IN|syndromes (l_pobj) syndromes_33\NNS|these|painful
48362
D011802_D056486 CID Quinidine_0\NN| (r_compound) hepatitis_1\NN|quinidine|.
D011802_D056486 CID quinidine_6\VBN| (r_poss) hepatotoxicity_7\NN|quinidine
12013711
D018967_D010468 CID Risperidone_0\NNP| (r_npadvmod) associated_2\VBN|risperidone|- (r_amod) disturbances_7\NNS|associated|,|benign|transient|visual|in|with|.
D018967_D010468 CID risperidone_17\NN| (r_pobj) with_16\IN|risperidone (r_prep) treatment_15\NN|with (r_dobj) starting_14\VBG|treatment (r_pcomp) after_13\IN|starting (r_prep) appeared_11\VBD|which|immediately|after (r_relcl) disturbances_8\NNS|transient|visual|,|appeared
D018967_D010468 CID Risperidone_0\NNP| (r_compound) administration_1\NN|risperidone (r_nsubjpass) continued_3\VBN|administration|was|and|wore (l_conj) wore_9\VBD|disturbances|gradually|off|. (l_nsubj) disturbances_7\NNS|the|visual
D018967_D012559 NONE Risperidone_0\NNP| (r_npadvmod) associated_2\VBN|risperidone|- (r_amod) disturbances_7\NNS|associated|,|benign|transient|visual|in|with|. (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|schizophrenic (l_amod) schizophrenic_9\JJ|
D018967_D012559 NONE risperidone_26\NN| (r_pobj) with_25\IN|risperidone (r_prep) treated_24\VBN|patients|were|successfully|with|. (l_nsubjpass) patients_2\NNS|two|schizophrenic|,|had|, (l_amod) schizophrenic_1\JJ|
D008238_D010468 NONE LSD_16\NNP| (r_compound) abuse_17\NN|lsd (r_pobj) of_15\IN|abuse (r_prep) history_14\NN|a|past|of (r_pobj) with_11\IN|history (r_prep) disturbances_7\NNS|associated|,|benign|transient|visual|in|with|.
D008238_D010468 NONE LSD_14\NNP| (r_compound) consumption_15\NN|prior|lsd (r_pobj) to_12\IN|consumption (r_prep) related_11\VBN|to (r_acl) flashbacks_9\NNS|"|"|related (r_pobj) as_7\IN|flashbacks (r_prep) experienced_6\VBN|previously|as (r_acl) disturbances_4\NNS|visual|experienced
D008238_D012559 NONE LSD_16\NNP| (r_compound) abuse_17\NN|lsd (r_pobj) of_15\IN|abuse (r_prep) history_14\NN|a|past|of (r_pobj) with_11\IN|history (r_prep) disturbances_7\NNS|associated|,|benign|transient|visual|in|with|. (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|schizophrenic (l_amod) schizophrenic_9\JJ|
D008238_D012559 NONE LSD_10\NNP| (r_compound) abuse_11\NN|lsd (r_pobj) of_9\IN|abuse (r_prep) history_8\NN|a|prior|of (r_dobj) had_5\VBD|who|history|and|developed (r_relcl) patients_2\NNS|two|schizophrenic|,|had|, (l_amod) schizophrenic_1\JJ|
D008238_D001480 NONE LSD_10\NNP| (r_compound) abuse_11\NN|lsd (r_pobj) of_9\IN|abuse (r_prep) history_8\NN|a|prior|of (r_dobj) had_5\VBD|who|history|and|developed (l_conj) developed_16\VBN|who|had|previously|eps|with (l_dobj) EPS_17\NNP|
D018967_D001480 NONE risperidone_26\NN| (r_pobj) with_25\IN|risperidone (r_prep) treated_24\VBN|patients|were|successfully|with|. (l_nsubjpass) patients_2\NNS|two|schizophrenic|,|had|, (l_relcl) had_5\VBD|who|history|and|developed (l_conj) developed_16\VBN|who|had|previously|eps|with (l_dobj) EPS_17\NNP|
20683499
C029036_D000544 NONE crocin_9\NNS|on (l_prep) on_10\IN|model (l_pobj) model_14\NN|induced|of (l_prep) of_15\IN|disease (l_pobj) disease_19\NN|sporadic|alzheimer|in
C029036_D000544 NONE crocins_8\NNS|on (l_prep) on_9\IN|disease (l_pobj) disease_13\NN|sporadic|alzheimer|induced
C029036_D000544 NONE crocin_8\NNS| (r_pobj) of_7\IN|crocin (r_prep) effectiveness_6\NN|the|of|(|mg/kg|)|in (l_prep) in_13\IN|antagonizing (l_pcomp) antagonizing_14\VBG|deficits (l_dobj) deficits_17\NNS|the|cognitive|caused (l_acl) caused_18\VBN|by|in (l_prep) in_23\IN|rats (l_pobj) rats_24\NNS|and|potential (l_conj) potential_27\NN|its|in (l_prep) in_28\IN|treatment (l_pobj) treatment_30\NN|the|of (l_prep) of_31\IN|diseases (l_pobj) diseases_33\NNS|neurodegenerative|as (l_prep) as_35\IN|such|disease (l_pobj) disease_38\NN|alzheimer
D013311_D000544 CID streptozocin_11\NNS| (r_npadvmod) induced_13\VBN|streptozocin|- (r_amod) model_14\NN|induced|of (l_prep) of_15\IN|disease (l_pobj) disease_19\NN|sporadic|alzheimer|in
D013311_D000544 CID streptozocin_20\NNP|(|icv|)|stz (r_appos) effect_6\NN|the|of|streptozocin (l_prep) of_7\IN|crocins (l_pobj) crocins_8\NNS|on (l_prep) on_9\IN|disease (l_pobj) disease_13\NN|sporadic|alzheimer|induced
D013311_D000544 CID STZ_22\NNP|(|)|in (r_appos) streptozocin_20\NNP|(|icv|)|stz (r_appos) effect_6\NN|the|of|streptozocin (l_prep) of_7\IN|crocins (l_pobj) crocins_8\NNS|on (l_prep) on_9\IN|disease (l_pobj) disease_13\NN|sporadic|alzheimer|induced
D013311_D000544 CID STZ_10\NNP| (r_compound) icv_12\NN|stz|- (r_pobj) with_9\IN|icv (r_prep) injected_8\VBN|in|,|rats|were|with|bilaterally|)|in (l_prep) In_0\IN|groups (l_pobj) groups_4\NNS|alzheimer|disease (l_compound) disease_3\NN|
D013311_D000544 CID STZ_28\NNP| (r_compound) icv_30\NN|stz|- (r_compound) application_31\NN|a|similar|icv (r_nsubjpass) repeated_33\VBN|injected|,|application|was|. (l_ccomp) injected_8\VBN|in|,|rats|were|with|bilaterally|)|in (l_prep) In_0\IN|groups (l_pobj) groups_4\NNS|alzheimer|disease (l_compound) disease_3\NN|
D013311_D000544 CID STZ_20\NNP| (r_compound) icv_22\NN|stz|- (r_pobj) by_19\IN|icv (r_agent) caused_18\VBN|by|in (l_prep) in_23\IN|rats (l_pobj) rats_24\NNS|and|potential (l_conj) potential_27\NN|its|in (l_prep) in_28\IN|treatment (l_pobj) treatment_30\NN|the|of (l_prep) of_31\IN|diseases (l_pobj) diseases_33\NNS|neurodegenerative|as (l_prep) as_35\IN|such|disease (l_pobj) disease_38\NN|alzheimer
C029036_D007859 NONE crocin_3\NNS|in|,|in|. (l_prep) in_4\IN|impairment (l_pobj) impairment_14\NN|dose|attenuated|learning|in
C029036_D008569 NONE crocin_3\NNS|in|,|in|. (l_prep) in_4\IN|impairment (l_pobj) impairment_14\NN|dose|attenuated|learning|in
D013311_D007859 NONE STZ_17\NNP| (r_npadvmod) injected_19\VBN|stz|- (r_amod) group_20\NN|treated|injected|in (r_pobj) in_15\IN|group (r_prep) impairment_14\NN|dose|attenuated|learning|in
D013311_D008569 NONE STZ_17\NNP| (r_npadvmod) injected_19\VBN|stz|- (r_amod) group_20\NN|treated|injected|in (r_pobj) in_15\IN|group (r_prep) impairment_14\NN|dose|attenuated|learning|in
C029036_D003072 NONE crocin_8\NNS| (r_pobj) of_7\IN|crocin (r_prep) effectiveness_6\NN|the|of|(|mg/kg|)|in (l_prep) in_13\IN|antagonizing (l_pcomp) antagonizing_14\VBG|deficits (l_dobj) deficits_17\NNS|the|cognitive|caused
C029036_D019636 NONE crocin_8\NNS| (r_pobj) of_7\IN|crocin (r_prep) effectiveness_6\NN|the|of|(|mg/kg|)|in (l_prep) in_13\IN|antagonizing (l_pcomp) antagonizing_14\VBG|deficits (l_dobj) deficits_17\NNS|the|cognitive|caused (l_acl) caused_18\VBN|by|in (l_prep) in_23\IN|rats (l_pobj) rats_24\NNS|and|potential (l_conj) potential_27\NN|its|in (l_prep) in_28\IN|treatment (l_pobj) treatment_30\NN|the|of (l_prep) of_31\IN|diseases (l_pobj) diseases_33\NNS|neurodegenerative|as
D013311_D003072 CID STZ_20\NNP| (r_compound) icv_22\NN|stz|- (r_pobj) by_19\IN|icv (r_agent) caused_18\VBN|by|in (r_acl) deficits_17\NNS|the|cognitive|caused
D013311_D019636 NONE STZ_20\NNP| (r_compound) icv_22\NN|stz|- (r_pobj) by_19\IN|icv (r_agent) caused_18\VBN|by|in (l_prep) in_23\IN|rats (l_pobj) rats_24\NNS|and|potential (l_conj) potential_27\NN|its|in (l_prep) in_28\IN|treatment (l_pobj) treatment_30\NN|the|of (l_prep) of_31\IN|diseases (l_pobj) diseases_33\NNS|neurodegenerative|as
8494478
D002939_D007674 NONE Ciprofloxacin_0\NNP| (r_npadvmod) induced_2\VBN|ciprofloxacin|-|nephrotoxicity|. (l_dobj) nephrotoxicity_3\NN|in
D002939_D007674 NONE ciprofloxacin_3\NNS| (r_pobj) with_2\IN|ciprofloxacin (r_prep) associated_1\VBN|with (r_acl) Nephrotoxicity_0\NN|associated
D002939_D009369 NONE Ciprofloxacin_0\NNP| (r_npadvmod) induced_2\VBN|ciprofloxacin|-|nephrotoxicity|. (l_dobj) nephrotoxicity_3\NN|in (l_prep) in_4\IN|patients (l_pobj) patients_5\NNS|with (l_prep) with_6\IN|cancer (l_pobj) cancer_7\NN|
D002939_D009369 NONE ciprofloxacin_13\NNS| (r_pobj) with_12\IN|ciprofloxacin (r_prep) treatment_11\NN|with (r_dobj) followed_10\VBD|that|treatment (r_relcl) failure_8\NN|acute|renal|followed (r_dobj) developed_5\VBD|who|failure (r_relcl) patients_1\NNS|five|with|developed (l_prep) with_2\IN|cancer (l_pobj) cancer_3\NN|
D002939_D058186 CID ciprofloxacin_13\NNS| (r_pobj) with_12\IN|ciprofloxacin (r_prep) treatment_11\NN|with (r_dobj) followed_10\VBD|that|treatment (r_relcl) failure_8\NN|acute|renal|followed
D002939_D058186 CID ciprofloxacin_18\NNS| (r_npadvmod) induced_20\VBN|ciprofloxacin|- (r_amod) failure_23\NN|induced|acute|renal
11705128
D012254_D000743 CID ribavirin_3\RB| (r_npadvmod) induced_5\VBN|ribavirin|- (r_amod) anemia_7\NN|induced|hemolytic|in
D012254_D000743 CID ribavirin_11\RB| (r_npadvmod) induced_13\VBN|associated|:|ribavirin|-|anemia|. (l_dobj) anemia_15\NN|hemolytic|(|riha|)
D012254_D000743 CID ribavirin_11\RB| (r_npadvmod) induced_13\VBN|associated|:|ribavirin|-|anemia|. (l_dobj) anemia_15\NN|hemolytic|(|riha|) (l_appos) RIHA_17\NNP|
D012254_D000743 CID ribavirin_14\JJ| (r_compound) dosage_15\NN|the|ribavirin (r_pobj) of_12\IN|dosage (r_prep) reduction_9\NN|or|discontinuation|of (r_attr) is_8\VBZ|standard|reduction|. (l_nsubj) standard_1\NN|the|of|for (l_prep) for_4\IN|management (l_pobj) management_5\NN|of (l_prep) of_6\IN|riha (l_pobj) RIHA_7\NNP|
D012254_D000743 CID ribavirin_7\NN| (r_pobj) of_6\IN|ribavirin (r_prep) dose_5\NN|the|optimal|of|and|incidence (l_conj) incidence_10\NN|the|of|in (l_prep) of_11\IN|riha (l_pobj) RIHA_12\NNP|
D012254_D006526 NONE ribavirin_3\RB| (r_npadvmod) induced_5\VBN|ribavirin|- (r_amod) anemia_7\NN|induced|hemolytic|in (l_prep) in_8\IN|treatment (l_pobj) treatment_10\NN|the|of (l_prep) of_11\IN|c (l_pobj) C_13\NNP|hepatitis|:|implications
D012254_D019698 NONE ribavirin_19\RB|alpha-2b|/ (r_conj) interferon_15\NN|and|ribavirin (r_pobj) with_14\IN|interferon (r_prep) therapy_13\NN|combination|with (r_pobj) of_11\IN|therapy (r_prep) efficacy_6\NN|increased|and|effectiveness|of (r_dobj) demonstrated_4\VBN|studies|have|efficacy|compared|. (l_prep) compared_20\VBN|with (l_prep) with_21\IN|monotherapy (l_pobj) monotherapy_25\NN|alpha|in (l_prep) in_26\IN|treatment (l_pobj) treatment_28\NN|the|of (l_prep) of_29\IN|c (l_pobj) C_32\NNP|chronic|hepatitis|(|chc|)
D012254_D019698 NONE ribavirin_19\RB|alpha-2b|/ (r_conj) interferon_15\NN|and|ribavirin (r_pobj) with_14\IN|interferon (r_prep) therapy_13\NN|combination|with (r_pobj) of_11\IN|therapy (r_prep) efficacy_6\NN|increased|and|effectiveness|of (r_dobj) demonstrated_4\VBN|studies|have|efficacy|compared|. (l_prep) compared_20\VBN|with (l_prep) with_21\IN|monotherapy (l_pobj) monotherapy_25\NN|alpha|in (l_prep) in_26\IN|treatment (l_pobj) treatment_28\NN|the|of (l_prep) of_29\IN|c (l_pobj) C_32\NNP|chronic|hepatitis|(|chc|) (l_appos) CHC_34\NNP|
D016898_D019698 NONE alpha_24\NN|interferon|- (r_compound) monotherapy_25\NN|alpha|in (l_prep) in_26\IN|treatment (l_pobj) treatment_28\NN|the|of (l_prep) of_29\IN|c (l_pobj) C_32\NNP|chronic|hepatitis|(|chc|)
D016898_D019698 NONE alpha_24\NN|interferon|- (r_compound) monotherapy_25\NN|alpha|in (l_prep) in_26\IN|treatment (l_pobj) treatment_28\NN|the|of (l_prep) of_29\IN|c (l_pobj) C_32\NNP|chronic|hepatitis|(|chc|) (l_appos) CHC_34\NNP|
14633084
D003907_D006470 NONE dexamethasone_2\NN| (r_pobj) of_1\IN|dexamethasone (r_prep) Use_0\NN|of|with|for|. (l_prep) for_5\IN|prevention (l_pobj) prevention_7\NN|the|of (l_prep) of_8\IN|cystitis (l_pobj) cystitis_13\NN|induced|hemorrhagic
D003907_D006470 NONE dexamethasone_11\NN| (r_pobj) of_10\IN|dexamethasone (r_prep) use_9\NN|the|of|in|for (l_prep) for_16\IN|prevention (l_pobj) prevention_18\NN|the|of (l_prep) of_19\IN|hc (l_pobj) HC_23\NN|induced
D003907_D006470 NONE Dexamethasone_0\NN|in (r_nsubj) was_5\VBD|dexamethasone|efficient|. (l_acomp) efficient_6\JJ|in (l_prep) in_7\IN|blocking (l_pcomp) blocking_8\VBG|hc (l_dobj) HC_12\NN|induced
D003907_D006470 NONE dexamethasone_19\NN| (r_pobj) with_18\IN|dexamethasone (r_prep) doses_17\NNS|the|mesna|with (r_pobj) of_14\IN|doses (r_prep) all_13\DT|of (r_conj) saline_11\NN|or|all (r_pobj) with_10\IN|saline (r_prep) doses_7\NNS|last|two|of|with (r_pobj) of_4\IN|doses (r_prep) replacement_3\NN|the|of (r_nsubj) prevent_22\VB|however|,|replacement|did|not|hc|. (l_dobj) HC_23\NN|
D003907_D003556 NONE dexamethasone_2\NN| (r_pobj) of_1\IN|dexamethasone (r_prep) Use_0\NN|of|with|for|. (l_prep) for_5\IN|prevention (l_pobj) prevention_7\NN|the|of (l_prep) of_8\IN|cystitis (l_pobj) cystitis_13\NN|induced|hemorrhagic
D003907_D003556 NONE dexamethasone_11\NN| (r_pobj) of_10\IN|dexamethasone (r_prep) use_9\NN|the|of|in|for (l_prep) for_16\IN|prevention (l_pobj) prevention_18\NN|the|of (l_prep) of_19\IN|hc (l_pobj) HC_23\NN|induced
D003907_D003556 NONE Dexamethasone_0\NN|in (r_nsubj) was_5\VBD|dexamethasone|efficient|. (l_acomp) efficient_6\JJ|in (l_prep) in_7\IN|blocking (l_pcomp) blocking_8\VBG|hc (l_dobj) HC_12\NN|induced
D003907_D003556 NONE dexamethasone_19\NN| (r_pobj) with_18\IN|dexamethasone (r_prep) doses_17\NNS|the|mesna|with (r_pobj) of_14\IN|doses (r_prep) all_13\DT|of (r_conj) saline_11\NN|or|all (r_pobj) with_10\IN|saline (r_prep) doses_7\NNS|last|two|of|with (r_pobj) of_4\IN|doses (r_prep) replacement_3\NN|the|of (r_nsubj) prevent_22\VB|however|,|replacement|did|not|hc|. (l_dobj) HC_23\NN|
D015080_D006470 NONE mesna_4\NN| (r_pobj) with_3\IN|mesna (r_prep) Use_0\NN|of|with|for|. (l_prep) for_5\IN|prevention (l_pobj) prevention_7\NN|the|of (l_prep) of_8\IN|cystitis (l_pobj) cystitis_13\NN|induced|hemorrhagic
D015080_D006470 NONE mesna_15\NN| (r_pobj) with_14\IN|mesna (r_prep) combination_13\NN|with (r_pobj) in_12\IN|combination (r_prep) use_9\NN|the|of|in|for (l_prep) for_16\IN|prevention (l_pobj) prevention_18\NN|the|of (l_prep) of_19\IN|hc (l_pobj) HC_23\NN|induced
D015080_D006470 NONE mesna_4\NN| (r_pobj) with_3\IN|mesna (r_prep) combination_2\NN|with (r_pobj) in_1\IN|combination (r_prep) Dexamethasone_0\NN|in (r_nsubj) was_5\VBD|dexamethasone|efficient|. (l_acomp) efficient_6\JJ|in (l_prep) in_7\IN|blocking (l_pcomp) blocking_8\VBG|hc (l_dobj) HC_12\NN|induced
D015080_D006470 NONE mesna_9\NN| (r_pobj) of_8\IN|mesna (r_prep) doses_7\NNS|last|two|of|with (r_pobj) of_4\IN|doses (r_prep) replacement_3\NN|the|of (r_nsubj) prevent_22\VB|however|,|replacement|did|not|hc|. (l_dobj) HC_23\NN|
D015080_D006470 NONE mesna_16\JJ| (r_amod) doses_17\NNS|the|mesna|with (r_pobj) of_14\IN|doses (r_prep) all_13\DT|of (r_conj) saline_11\NN|or|all (r_pobj) with_10\IN|saline (r_prep) doses_7\NNS|last|two|of|with (r_pobj) of_4\IN|doses (r_prep) replacement_3\NN|the|of (r_nsubj) prevent_22\VB|however|,|replacement|did|not|hc|. (l_dobj) HC_23\NN|
D015080_D003556 NONE mesna_4\NN| (r_pobj) with_3\IN|mesna (r_prep) Use_0\NN|of|with|for|. (l_prep) for_5\IN|prevention (l_pobj) prevention_7\NN|the|of (l_prep) of_8\IN|cystitis (l_pobj) cystitis_13\NN|induced|hemorrhagic
D015080_D003556 NONE mesna_15\NN| (r_pobj) with_14\IN|mesna (r_prep) combination_13\NN|with (r_pobj) in_12\IN|combination (r_prep) use_9\NN|the|of|in|for (l_prep) for_16\IN|prevention (l_pobj) prevention_18\NN|the|of (l_prep) of_19\IN|hc (l_pobj) HC_23\NN|induced
D015080_D003556 NONE mesna_4\NN| (r_pobj) with_3\IN|mesna (r_prep) combination_2\NN|with (r_pobj) in_1\IN|combination (r_prep) Dexamethasone_0\NN|in (r_nsubj) was_5\VBD|dexamethasone|efficient|. (l_acomp) efficient_6\JJ|in (l_prep) in_7\IN|blocking (l_pcomp) blocking_8\VBG|hc (l_dobj) HC_12\NN|induced
D015080_D003556 NONE mesna_9\NN| (r_pobj) of_8\IN|mesna (r_prep) doses_7\NNS|last|two|of|with (r_pobj) of_4\IN|doses (r_prep) replacement_3\NN|the|of (r_nsubj) prevent_22\VB|however|,|replacement|did|not|hc|. (l_dobj) HC_23\NN|
D015080_D003556 NONE mesna_16\JJ| (r_amod) doses_17\NNS|the|mesna|with (r_pobj) of_14\IN|doses (r_prep) all_13\DT|of (r_conj) saline_11\NN|or|all (r_pobj) with_10\IN|saline (r_prep) doses_7\NNS|last|two|of|with (r_pobj) of_4\IN|doses (r_prep) replacement_3\NN|the|of (r_nsubj) prevent_22\VB|however|,|replacement|did|not|hc|. (l_dobj) HC_23\NN|
D007069_D006470 CID ifosfamide_9\RB| (r_advmod) induced_11\VBN|ifosfamide|- (r_amod) cystitis_13\NN|induced|hemorrhagic
D007069_D006470 CID ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|)
D007069_D006470 CID ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|) (l_appos) HC_5\NNP|
D007069_D006470 CID IFS_18\NNP| (r_appos) ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|)
D007069_D006470 CID IFS_18\NNP| (r_appos) ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|) (l_appos) HC_5\NNP|
D007069_D006470 CID IFS_20\NNP| (r_npadvmod) induced_22\VBN|ifs|- (r_amod) HC_23\NN|induced
D007069_D006470 CID IFS_9\NNP| (r_npadvmod) induced_11\VBN|ifs|- (r_amod) HC_12\NN|induced
D007069_D003556 CID ifosfamide_9\RB| (r_advmod) induced_11\VBN|ifosfamide|- (r_amod) cystitis_13\NN|induced|hemorrhagic
D007069_D003556 CID ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|)
D007069_D003556 CID ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|) (l_appos) HC_5\NNP|
D007069_D003556 CID IFS_18\NNP| (r_appos) ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|)
D007069_D003556 CID IFS_18\NNP| (r_appos) ifosfamide_16\NN|(|ifs|) (r_pobj) with_15\IN|ifosfamide (r_prep) effect_12\NN|a|limiting|side|-|of|with (r_attr) is_7\VBZ|aim|effect|. (l_nsubj) AIM_0\VB|:|cystitis (l_appos) cystitis_3\NN|hemorrhagic|(|hc|) (l_appos) HC_5\NNP|
D007069_D003556 CID IFS_20\NNP| (r_npadvmod) induced_22\VBN|ifs|- (r_amod) HC_23\NN|induced
D007069_D003556 CID IFS_9\NNP| (r_npadvmod) induced_11\VBN|ifs|- (r_amod) HC_12\NN|induced
8012887
D006493_D013927 CID heparin_7\NN| (r_npadvmod) induced_9\VBN|heparin|- (r_amod) thrombosis_11\NN|induced|arterial
D006493_D013927 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|heparin|- (r_amod) thrombosis_9\NN|induced
D006493_D013927 CID heparin_14\JJ| (r_pobj) with_13\IN|heparin (r_prep) patients_12\NNS|with (r_pobj) in_11\IN|patients (r_prep) used_3\VBN|ancrod|has|been|successfully|for|in|induced|,|but|defined (l_prep) for_5\IN|prophylaxis (l_pobj) prophylaxis_6\NN|against (l_prep) against_7\IN|development (l_pobj) development_8\NN|of (l_prep) of_9\IN|thrombosis (l_pobj) thrombosis_10\NN|
D006493_D013927 CID heparin_14\JJ| (r_pobj) with_13\IN|heparin (r_prep) patients_12\NNS|with (r_pobj) in_11\IN|patients (r_prep) used_3\VBN|ancrod|has|been|successfully|for|in|induced|,|but|defined (l_conj) defined_39\VBN|is|not|well|. (l_auxpass) is_36\VBZ|success (l_nsubj) success_27\NN|its|in (l_prep) in_28\IN|patients (l_pobj) patients_29\NNS|developed (l_relcl) developed_32\VBN|who|have|syndrome (l_dobj) syndrome_35\NN|the|thrombosis (l_compound) thrombosis_34\NN|
D006493_D013927 CID heparin_23\NN| (r_pobj) to_22\IN|heparin (r_prep) reexposure_21\NN|brief|to (r_dobj) require_19\VBP|who|reexposure (r_relcl) aggregation_17\NN|platelet|require (r_dobj) induced_15\VBN|aggregation (r_advcl) used_3\VBN|ancrod|has|been|successfully|for|in|induced|,|but|defined (l_prep) for_5\IN|prophylaxis (l_pobj) prophylaxis_6\NN|against (l_prep) against_7\IN|development (l_pobj) development_8\NN|of (l_prep) of_9\IN|thrombosis (l_pobj) thrombosis_10\NN|
D006493_D013927 CID heparin_23\NN| (r_pobj) to_22\IN|heparin (r_prep) reexposure_21\NN|brief|to (r_dobj) require_19\VBP|who|reexposure (r_relcl) aggregation_17\NN|platelet|require (r_dobj) induced_15\VBN|aggregation (r_advcl) used_3\VBN|ancrod|has|been|successfully|for|in|induced|,|but|defined (l_conj) defined_39\VBN|is|not|well|. (l_auxpass) is_36\VBZ|success (l_nsubj) success_27\NN|its|in (l_prep) in_28\IN|patients (l_pobj) patients_29\NNS|developed (l_relcl) developed_32\VBN|who|have|syndrome (l_dobj) syndrome_35\NN|the|thrombosis (l_compound) thrombosis_34\NN|
D006493_D013927 CID heparin_14\NN| (r_npadvmod) induced_16\VBN|heparin|- (r_amod) thrombosis_17\NN|induced
D006493_D001791 NONE heparin_14\JJ| (r_pobj) with_13\IN|heparin (r_prep) patients_12\NNS|with (r_pobj) in_11\IN|patients (r_prep) used_3\VBN|ancrod|has|been|successfully|for|in|induced|,|but|defined (l_advcl) induced_15\VBN|aggregation (l_dobj) aggregation_17\NN|platelet|require
D006493_D001791 NONE heparin_23\NN| (r_pobj) to_22\IN|heparin (r_prep) reexposure_21\NN|brief|to (r_dobj) require_19\VBP|who|reexposure (r_relcl) aggregation_17\NN|platelet|require
19203554
D012460_D005921 NONE sulphasalazine_10\JJ| (r_compound) treatment_11\NN|sulphasalazine (r_dobj) restarting_9\VBG|treatment (r_pcomp) after_8\IN|restarting (r_prep) antibody-(PR3-ANCA_3\NNS|proteinase|3-antineutrophil|cytoplasmic|glomerulonephritis|after|. (l_appos) glomerulonephritis_7\NN|)|positive|necrotizing
D012460_D005921 NONE sulphasalazine_4\NN| (r_nsubj) induce_6\VB|that|sulphasalazine|can|glomerulonephritis (l_dobj) glomerulonephritis_11\NN|positive|necrotizing
D012460_D003093 NONE sulphasalazine_22\JJ| (r_compound) treatment_23\NN|sulphasalazine (r_pobj) of_21\IN|treatment (r_prep) restarting_20\VBG|of (r_pcomp) after_19\IN|restarting (r_prep) developed_8\VBD|woman|eyes|after|. (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|colitis (l_pobj) colitis_7\NN|ulcerative
D012460_D005128 NONE sulphasalazine_22\JJ| (r_compound) treatment_23\NN|sulphasalazine (r_pobj) of_21\IN|treatment (r_prep) restarting_20\VBG|of (r_pcomp) after_19\IN|restarting (r_prep) developed_8\VBD|woman|eyes|after|. (l_dobj) eyes_10\NNS|red|,|effusion
D012460_D005128 NONE sulphasalazine_3\NN| (r_compound) treatment_4\NN|sulphasalazine (r_pobj) of_2\IN|treatment (r_prep) cessation_1\NN|of (r_nsubj) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes (l_appos) eyes_12\NNS|red|,|pain
D012460_D010996 CID sulphasalazine_22\JJ| (r_compound) treatment_23\NN|sulphasalazine (r_pobj) of_21\IN|treatment (r_prep) restarting_20\VBG|of (r_pcomp) after_19\IN|restarting (r_prep) developed_8\VBD|woman|eyes|after|. (l_dobj) eyes_10\NNS|red|,|effusion (l_conj) effusion_13\NN|pleural|,|eosinophilia
D012460_D010996 CID sulphasalazine_3\NN| (r_compound) treatment_4\NN|sulphasalazine (r_pobj) of_2\IN|treatment (r_prep) cessation_1\NN|of (r_nsubj) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes (l_appos) eyes_12\NNS|red|,|pain (l_conj) pain_15\NN|chest|,|titer (l_conj) titer_17\NN|of (l_prep) of_18\IN|protein (l_pobj) protein_22\NN|reactive|and|volume|of (l_prep) of_25\IN|effusions (l_pobj) effusions_28\NNS|the|pleural
D012460_D010996 CID sulphasalazine_3\NN| (r_compound) treatment_4\NN|sulphasalazine (r_pobj) of_2\IN|treatment (r_prep) cessation_1\NN|of (r_nsubj) resulted_5\VBD|although|cessation|in (r_advcl) initiated_31\VBD|resulted|,|we|therapy|,|rose|increased (l_conj) increased_45\VBD|,|count|to|,|and|remained (l_conj) remained_56\VBD|effusion|. (l_nsubj) effusion_55\NN|the|pleural
D012460_D004802 NONE sulphasalazine_22\JJ| (r_compound) treatment_23\NN|sulphasalazine (r_pobj) of_21\IN|treatment (r_prep) restarting_20\VBG|of (r_pcomp) after_19\IN|restarting (r_prep) developed_8\VBD|woman|eyes|after|. (l_dobj) eyes_10\NNS|red|,|effusion (l_conj) effusion_13\NN|pleural|,|eosinophilia (l_conj) eosinophilia_15\NN|and|abnormalities
D012460_D001745 NONE sulphasalazine_22\JJ| (r_compound) treatment_23\NN|sulphasalazine (r_pobj) of_21\IN|treatment (r_prep) restarting_20\VBG|of (r_pcomp) after_19\IN|restarting (r_prep) developed_8\VBD|woman|eyes|after|. (l_dobj) eyes_10\NNS|red|,|effusion (l_conj) effusion_13\NN|pleural|,|eosinophilia (l_conj) eosinophilia_15\NN|and|abnormalities (l_conj) abnormalities_18\NNS|urinary
D012460_D005334 CID sulphasalazine_3\NN| (r_compound) treatment_4\NN|sulphasalazine (r_pobj) of_2\IN|treatment (r_prep) cessation_1\NN|of (r_nsubj) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes
D012460_D002637 NONE sulphasalazine_3\NN| (r_compound) treatment_4\NN|sulphasalazine (r_pobj) of_2\IN|treatment (r_prep) cessation_1\NN|of (r_nsubj) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes (l_appos) eyes_12\NNS|red|,|pain (l_conj) pain_15\NN|chest|,|titer
D013256_D005334 NONE steroid_32\NN| (r_compound) therapy_33\NN|steroid (r_dobj) initiated_31\VBD|resulted|,|we|therapy|,|rose|increased (l_advcl) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes
D013256_D005128 NONE steroid_32\NN| (r_compound) therapy_33\NN|steroid (r_dobj) initiated_31\VBD|resulted|,|we|therapy|,|rose|increased (l_advcl) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes (l_appos) eyes_12\NNS|red|,|pain
D013256_D002637 NONE steroid_32\NN| (r_compound) therapy_33\NN|steroid (r_dobj) initiated_31\VBD|resulted|,|we|therapy|,|rose|increased (l_advcl) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes (l_appos) eyes_12\NNS|red|,|pain (l_conj) pain_15\NN|chest|,|titer
D013256_D010996 NONE steroid_32\NN| (r_compound) therapy_33\NN|steroid (r_dobj) initiated_31\VBD|resulted|,|we|therapy|,|rose|increased (l_advcl) resulted_5\VBD|although|cessation|in (l_prep) in_6\IN|improvements (l_pobj) improvements_7\NNS|in (l_prep) in_8\IN|fever (l_pobj) fever_9\NN|,|eyes (l_appos) eyes_12\NNS|red|,|pain (l_conj) pain_15\NN|chest|,|titer (l_conj) titer_17\NN|of (l_prep) of_18\IN|protein (l_pobj) protein_22\NN|reactive|and|volume|of (l_prep) of_25\IN|effusions (l_pobj) effusions_28\NNS|the|pleural
D013256_D010996 NONE steroid_32\NN| (r_compound) therapy_33\NN|steroid (r_dobj) initiated_31\VBD|resulted|,|we|therapy|,|rose|increased (l_conj) increased_45\VBD|,|count|to|,|and|remained (l_conj) remained_56\VBD|effusion|. (l_nsubj) effusion_55\NN|the|pleural
D013256_D010996 NONE steroid_3\NN| (r_compound) therapy_4\NN|steroid (r_pobj) after_2\IN|month|therapy (r_prep) disappeared_9\VBD|after|,|effusion|,|and|normalized (l_nsubj) effusion_8\NN|the|pleural
1415380
D011803_D006463 CID quinine_8\NN| (r_pobj) of_7\IN|quinine (r_prep) ingestion_6\NN|of (r_pobj) with_5\IN|ingestion (r_prep) associated_4\VBN|with (r_acl) syndrome_3\NN|uremic|associated|.
D011803_D006463 CID quinine_5\NN| (r_compound) ingestion_6\NN|quinine (r_pobj) following_4\VBG|ingestion (r_prep) syndrome_3\NN|uremic|following
D011803_D006463 CID Quinine_0\NN| (r_npadvmod) associated_2\VBN|quinine|- (r_amod) syndrome_6\NN|associated|uremic
15811908
C012052_D010673 NONE amisulpride_3\NN|and|tiapride (r_pobj) by_2\IN|amisulpride (r_prep) unmasked_1\VBD|pheochromocytoma|by|. (l_nsubj) Pheochromocytoma_0\NNP|
C012052_D010673 NONE amisulpride_11\NN|and|tiapride (r_pobj) with_10\IN|amisulpride (r_prep) treated_9\VBN|with (r_acl) patient_8\NN|a|treated (r_pobj) in_6\IN|patient (r_prep) unmasking_3\NN|the|of|in (l_prep) of_4\IN|pheochromocytoma (l_pobj) pheochromocytoma_5\NN|
C012052_D010673 NONE amisulpride-_14\JJ|and|crisis (r_pobj) of_13\IN|amisulpride- (r_prep) case_12\NN|the|first|reported|of|in (l_prep) in_21\IN|patient (l_pobj) patient_23\NN|a|with (l_prep) with_24\IN|pheochromocytoma (l_pobj) pheochromocytoma_25\NN|
D063325_D010673 NONE tiapride_5\NN| (r_conj) amisulpride_3\NN|and|tiapride (r_pobj) by_2\IN|amisulpride (r_prep) unmasked_1\VBD|pheochromocytoma|by|. (l_nsubj) Pheochromocytoma_0\NNP|
D063325_D010673 NONE tiapride_13\NN| (r_conj) amisulpride_11\NN|and|tiapride (r_pobj) with_10\IN|amisulpride (r_prep) treated_9\VBN|with (r_acl) patient_8\NN|a|treated (r_pobj) in_6\IN|patient (r_prep) unmasking_3\NN|the|of|in (l_prep) of_4\IN|pheochromocytoma (l_pobj) pheochromocytoma_5\NN|
D063325_D010673 NONE tiapride_16\NN| (r_npadvmod) induced_18\VBN|tiapride|- (r_amod) crisis_20\NN|induced|hypertensive (r_conj) amisulpride-_14\JJ|and|crisis (r_pobj) of_13\IN|amisulpride- (r_prep) case_12\NN|the|first|reported|of|in (l_prep) in_21\IN|patient (l_pobj) patient_23\NN|a|with (l_prep) with_24\IN|pheochromocytoma (l_pobj) pheochromocytoma_25\NN|
C012052_D006973 CID amisulpride_21\NN| (r_pobj) of_20\IN|amisulpride (r_prep) doses_19\NNS|the|first|of (r_pobj) after_16\IN|hours|doses (r_prep) vomiting_13\NN|after (r_conj) developed_6\VBD|man|hypertension|and|vomiting (l_dobj) hypertension_8\NN|acute|with
C012052_D006973 CID amisulpride_19\NN|and|therapy (r_conj) crisis_17\NN|the|hypertensive|and|amisulpride (l_amod) hypertensive_16\JJ|
C012052_D006973 CID amisulpride-_14\JJ|and|crisis (l_conj) crisis_20\NN|induced|hypertensive (l_amod) hypertensive_19\JJ|
C012052_D006261 CID amisulpride_21\NN| (r_pobj) of_20\IN|amisulpride (r_prep) doses_19\NNS|the|first|of (r_pobj) after_16\IN|hours|doses (r_prep) vomiting_13\NN|after (r_conj) developed_6\VBD|man|hypertension|and|vomiting (l_dobj) hypertension_8\NN|acute|with (l_prep) with_9\IN|headache (l_pobj) headache_11\NN|severe
C012052_D014839 CID amisulpride_21\NN| (r_pobj) of_20\IN|amisulpride (r_prep) doses_19\NNS|the|first|of (r_pobj) after_16\IN|hours|doses (r_prep) vomiting_13\NN|after
C037689_D010673 NONE benzamide_14\JJ| (r_amod) drugs_15\NNS|substituted|benzamide (r_pobj) of_12\IN|drugs (r_prep) use_11\NN|the|of (r_pobj) with_9\IN|use (r_prep) associated_8\VBN|symptoms|are|often|with|,|but|is (l_nsubjpass) symptoms_3\NNS|induced|of (l_prep) of_4\IN|pheochromocytoma (l_pobj) pheochromocytoma_5\NN|
D063325_D006973 CID tiapride_21\NN| (r_compound) therapy_22\NN|tiapride (r_conj) amisulpride_19\NN|and|therapy (r_conj) crisis_17\NN|the|hypertensive|and|amisulpride (l_amod) hypertensive_16\JJ|
D063325_D006973 CID tiapride_16\NN| (r_npadvmod) induced_18\VBN|tiapride|- (r_amod) crisis_20\NN|induced|hypertensive (l_amod) hypertensive_19\JJ|
7803371
D003915_D003072 CID dextromethorphan_8\NN| (r_pobj) of_7\IN|dextromethorphan (r_prep) abuse_6\NN|term|of (r_pobj) from_2\IN|abuse (r_prep) deterioration_1\NN|cognitive|from|:|report|.
D003915_D003072 CID DM_13\NN| (r_pobj) of_12\IN|dm (r_prep) use_11\NN|prolonged|of (r_pobj) from_9\IN|use (r_prep) resulting_8\VBG|from (r_acl) deterioration_7\NN|cognitive|resulting
7791169
D016595_D007674 NONE misoprostol_3\NNP|on (r_pobj) of_2\IN|misoprostol (r_prep) effect_1\NN|protective|of (r_nsubj) induced_6\VBD|effect|dysfunction|. (l_dobj) dysfunction_8\NN|renal|in
D016595_D007674 NONE misoprostol_2\NNP| (r_pobj) of_1\IN|misoprostol (r_prep) Addition_0\NN|of (r_nsubj) minimize_4\VB|addition|can|impairment|without|. (l_dobj) impairment_7\NN|this|renal
D007213_D007674 CID indomethacin_5\NN| (r_pobj) on_4\IN|indomethacin (r_prep) misoprostol_3\NNP|on (r_pobj) of_2\IN|misoprostol (r_prep) effect_1\NN|protective|of (r_nsubj) induced_6\VBD|effect|dysfunction|. (l_dobj) dysfunction_8\NN|renal|in
D007213_D007674 CID indomethacin_8\NN|developing (r_nmod) dysfunction_11\NN|indomethacin|related|renal
D016595_D010146 NONE misoprostol_2\NNP| (r_pobj) of_1\IN|misoprostol (r_prep) Addition_0\NN|of (r_nsubj) minimize_4\VB|addition|can|impairment|without|. (l_prep) without_8\IN|affecting (l_pcomp) affecting_9\VBG|control (l_dobj) control_11\NN|pain (l_compound) pain_10\NN|
2722224
D006854_D006973 CID Hydrocortisone_0\NNP| (r_npadvmod) induced_2\VBN|hydrocortisone|-|hypertension|:|responsiveness|. (l_dobj) hypertension_3\NN|in
D006854_D006973 CID hydrocortisone_7\NN| (r_pobj) with_6\IN|hydrocortisone (r_prep) pressure_5\NN|blood|with
D006854_D016534 NONE hydrocortisone_7\NN| (r_pobj) with_6\IN|hydrocortisone (r_prep) pressure_5\NN|blood|with (r_dobj) resting_3\VBG|pressure (r_pcomp) in_2\IN|resting (r_prep) rise_1\NN|the|in (r_nsubjpass) associated_9\VBN|rise|is|with|. (l_prep) with_10\IN|output (l_pobj) output_14\NN|an|increased|cardiac|(|due|)
7161250
D006220_D010302 CID haloperidol_10\NN| (r_pobj) of_9\IN|haloperidol (r_prep) doses_8\NNS|higher|of (r_pobj) at_6\IN|doses|and|in (r_prep) was_4\VBD|incidence|higher|at|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|parkinsonism (l_pobj) parkinsonism_3\NN|
D001569_D017109 NONE benzodiazepine_5\JJ| (r_amod) lorazepam_6\NN|the|benzodiazepine|in|out (r_pobj) by_3\IN|lorazepam (r_agent) controlled_2\VBN|akathisia|was|by|,|were|. (l_nsubjpass) Akathisia_0\NNP|
D008140_D017109 NONE lorazepam_6\NN|the|benzodiazepine|in|out (r_pobj) by_3\IN|lorazepam (r_agent) controlled_2\VBN|akathisia|was|by|,|were|. (l_nsubjpass) Akathisia_0\NNP|
12091028
D003975_D006212 NONE Diazepam_0\NNP| (r_nsubj) remains_7\VBZ|diazepam|,|contraindicated|,|drug|. (l_attr) drug_12\NN|the|only|necessary|complementary|ketamine (l_relcl) ketamine_14\NN|to|buffers (l_advcl) buffers_17\VBZ|as|it|response|and|decreases (l_conj) decreases_22\VBZ|duration (l_dobj) duration_24\NN|the|and|intensity|of (l_prep) of_27\IN|hallucinations (l_pobj) hallucinations_31\NNS|operative
D007649_D006212 CID ketamine_14\NN|to|buffers (l_advcl) buffers_17\VBZ|as|it|response|and|decreases (l_conj) decreases_22\VBZ|duration (l_dobj) duration_24\NN|the|and|intensity|of (l_prep) of_27\IN|hallucinations (l_pobj) hallucinations_31\NNS|operative
2826064
D010096_D007008 NONE oxprenolol_8\NN| (r_pobj) by_7\IN|oxprenolol (r_prep) abolishment_6\NN|its|by (r_conj) hypokalemia_3\NN|mediated|and|abolishment|.
D010096_D007008 NONE oxprenolol_6\NN| (r_pobj) of_5\IN|oxprenolol (r_prep) efficacy_4\NN|the|of (r_dobj) investigated_2\VBD|subsequently|we|efficacy|in|,|with|. (l_prep) in_7\IN|antagonizing (l_pcomp) antagonizing_8\VBG|hypokalemia (l_dobj) hypokalemia_10\NN|such
D010096_D007008 NONE oxprenolol_7\NN| (r_amod) pretreatment_8\NN|oxprenolol (r_pobj) after_6\IN|pretreatment (r_prep) concentrations_5\NNS|higher|terbutaline|after (r_pobj) of_2\IN|concentrations (r_prep) spite_1\NN|of (r_pobj) In_0\IN|spite (r_prep) antagonized_15\VBN|in|,|hypokalemia|was|completely|by|. (l_nsubjpass) hypokalemia_11\NN|the
D013726_D007008 CID terbutaline_9\NN| (r_npadvmod) induced_11\VBN|terbutaline|- (r_amod) hypokalemia_12\NN|induced
D013726_D007008 CID terbutaline_4\JJ| (r_compound) concentrations_5\NNS|higher|terbutaline|after (r_pobj) of_2\IN|concentrations (r_prep) spite_1\NN|of (r_pobj) In_0\IN|spite (r_prep) antagonized_15\VBN|in|,|hypokalemia|was|completely|by|. (l_nsubjpass) hypokalemia_11\NN|the
11271907
D003520_D006470 CID cyclophosphamide_5\NN| (r_compound) therapy_6\NN|cyclophosphamide (r_pobj) to_4\IN|therapy (r_prep) secondary_3\JJ|haemorrhagic|myocarditis|to (l_amod) myocarditis_2\NN|
D003520_D006470 CID cyclophosphamide_9\NN| (r_compound) therapy_10\NN|cyclophosphamide (r_pobj) of_8\IN|therapy (r_prep) complication_7\NN|a|rare|of (r_attr) is_2\VBZ|myocarditis|complication|. (l_nsubj) myocarditis_1\NN|haemorrhagic
D003520_D009205 CID cyclophosphamide_5\NN| (r_compound) therapy_6\NN|cyclophosphamide (r_pobj) to_4\IN|therapy (r_prep) secondary_3\JJ|haemorrhagic|myocarditis|to (l_amod) myocarditis_2\NN|
D003520_D009205 CID cyclophosphamide_9\NN| (r_compound) therapy_10\NN|cyclophosphamide (r_pobj) of_8\IN|therapy (r_prep) complication_7\NN|a|rare|of (r_attr) is_2\VBZ|myocarditis|complication|. (l_nsubj) myocarditis_1\NN|haemorrhagic
11467664
D008687_D041781 CID metformin_7\NN| (r_pobj) of_6\IN|metformin (r_prep) use_5\NN|the|of (r_pobj) with_3\IN|use (r_prep) associated_2\VBN|with (r_acl) jaundice_1\NN|cholestatic|associated|.
D008687_D041781 CID hydrochloride_15\NN|metformin (r_pobj) with_13\IN|hydrochloride (r_prep) treatment_12\NN|with (r_pobj) of_11\IN|treatment (r_prep) initiation_10\NN|of (r_pobj) after_9\IN|shortly|initiation (r_prep) developed_5\VBD|who|jaundice|after (l_dobj) jaundice_7\NN|cholestatic
D008687_D007565 NONE hydrochloride_1\NN|metformin (r_nsubjpass) discontinued_3\VBN|hydrochloride|was|,|and|resolved (l_conj) resolved_10\VBN|jaundice|slowly|over|. (l_nsubj) jaundice_9\NN|patient
D008687_D007565 NONE metformin_12\NN| (r_pobj) of_11\IN|metformin (r_prep) initiation_10\NN|the|of (r_pobj) after_8\IN|wk|initiation (r_prep) onset_2\NN|the|of|after (l_prep) of_3\IN|jaundice (l_pobj) jaundice_5\NN|his
D008687_D007565 NONE metformin_23\NN| (r_npadvmod) associated_25\VBN|metformin|- (r_amod) hepatotoxicity_26\NN|associated (r_pobj) of_22\IN|hepatotoxicity (r_prep) example_21\NN|an|of (r_dobj) represents_19\VBZ|that|case|example (r_ccomp) believe_15\VBP|given|,|we|represents (l_prep) Given_0\VBN|onset (l_pobj) onset_2\NN|the|of|after (l_prep) of_3\IN|jaundice (l_pobj) jaundice_5\NN|his
D008687_D056486 NONE metformin_12\NN| (r_pobj) of_11\IN|metformin (r_prep) initiation_10\NN|the|of (r_pobj) after_8\IN|wk|initiation (r_prep) onset_2\NN|the|of|after (r_pobj) Given_0\VBN|onset (r_prep) believe_15\VBP|given|,|we|represents (l_ccomp) represents_19\VBZ|that|case|example (l_dobj) example_21\NN|an|of (l_prep) of_22\IN|hepatotoxicity (l_pobj) hepatotoxicity_26\NN|associated
D008687_D056486 NONE metformin_23\NN| (r_npadvmod) associated_25\VBN|metformin|- (r_amod) hepatotoxicity_26\NN|associated
6323692
C018824_D001259 CID acetate_3\NN|ammonium|nh4ac|(|s.c.|) (r_pobj) with_1\IN|acetate (r_prep) Pretreatment_0\NN|with (r_nsubj) doubled_15\VBD|pretreatment|approximately|time|. (l_npadvmod) time_17\NN|the|remained (l_relcl) remained_22\VBD|mice|on|and|incoordination|had (l_conj) incoordination_31\NN|increased|muscular|by|,|but
C018824_D001259 CID NH4Ac_5\NNP|(|) (r_appos) acetate_3\NN|ammonium|nh4ac|(|s.c.|) (r_pobj) with_1\IN|acetate (r_prep) Pretreatment_0\NN|with (r_nsubj) doubled_15\VBD|pretreatment|approximately|time|. (l_npadvmod) time_17\NN|the|remained (l_relcl) remained_22\VBD|mice|on|and|incoordination|had (l_conj) incoordination_31\NN|increased|muscular|by|,|but
C018824_D001259 CID NH4Ac_36\NNP| (r_compound) treatment_37\NN|nh4ac|alone (r_nsubj) had_39\VBD|treatment|effect (r_conj) remained_22\VBD|mice|on|and|incoordination|had (l_conj) incoordination_31\NN|increased|muscular|by|,|but
C018824_D001259 CID NH4Ac_8\NNP| (r_nmod) pretreatment_9\NN|nh4ac|morphine (r_conj) verapamil_1\NN|both|(|mg/kg|i.p.|)|and|pretreatment (r_nsubj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
C018824_D001259 CID NH4Ac_31\NNP| (r_conj) verapamil_29\NN|neither|nor|nh4ac (r_nsubj) affected_32\VBD|verapamil|action|. (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
D009020_D001259 NONE morphine_18\NN| (r_npadvmod) treated_20\VBN|morphine|- (r_amod) mice_21\NNS|treated (r_nsubj) remained_22\VBD|mice|on|and|incoordination|had (l_conj) incoordination_31\NN|increased|muscular|by|,|but
D009020_D001259 NONE morphine_11\NN|enhanced (r_appos) pretreatment_9\NN|nh4ac|morphine (r_conj) verapamil_1\NN|both|(|mg/kg|i.p.|)|and|pretreatment (r_nsubj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
D003975_D001259 CID diazepam_33\NN| (r_pobj) by_32\IN|diazepam (r_prep) incoordination_31\NN|increased|muscular|by|,|but
D003975_D001259 CID diazepam_14\NN| (r_npadvmod) induced_16\VBN|diazepam|- (r_amod) incoordination_18\NN|induced|muscular
D002118_D003866 NONE calcium_3\NN|excess (r_pobj) of_1\IN|calcium (r_prep) Addition_0\NN|of (r_nsubj) reversed_4\VBD|addition|depression|,|but|blocked (l_dobj) depression_6\NN|the|in
D002118_D003866 NONE calcium_12\NN| (r_npadvmod) independent_14\JJ|calcium|- (r_amod) release_16\NN|independent|catecholamine|by (r_nsubjpass) blocked_21\VBN|release|was|not|by|. (r_conj) reversed_4\VBD|addition|depression|,|but|blocked (l_dobj) depression_6\NN|the|in
D002395_D003866 NONE catecholamine_15\NN| (r_compound) release_16\NN|independent|catecholamine|by (r_nsubjpass) blocked_21\VBN|release|was|not|by|. (r_conj) reversed_4\VBD|addition|depression|,|but|blocked (l_dobj) depression_6\NN|the|in
D000079_D003866 NONE acetaldehyde_18\NN| (r_pobj) by_17\IN|acetaldehyde (r_prep) release_16\NN|independent|catecholamine|by (r_nsubjpass) blocked_21\VBN|release|was|not|by|. (r_conj) reversed_4\VBD|addition|depression|,|but|blocked (l_dobj) depression_6\NN|the|in
C018824_D003866 NONE NH4Ac_23\NNPS| (r_pobj) by_22\IN|nh4ac (r_agent) blocked_21\VBN|release|was|not|by|. (r_conj) reversed_4\VBD|addition|depression|,|but|blocked (l_dobj) depression_6\NN|the|in
D014700_D000699 NONE verapamil_1\NN|both|(|mg/kg|i.p.|)|and|pretreatment (r_nsubj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D014700_D000699 NONE verapamil_29\NN|neither|nor|nh4ac (r_nsubj) affected_32\VBD|verapamil|action|. (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D014700_D001259 NONE verapamil_1\NN|both|(|mg/kg|i.p.|)|and|pretreatment (r_nsubj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
D014700_D001259 NONE verapamil_29\NN|neither|nor|nh4ac (r_nsubj) affected_32\VBD|verapamil|action|. (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
C018824_D000699 NONE NH4Ac_8\NNP| (r_nmod) pretreatment_9\NN|nh4ac|morphine (r_conj) verapamil_1\NN|both|(|mg/kg|i.p.|)|and|pretreatment (r_nsubj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
C018824_D000699 NONE NH4Ac_31\NNP| (r_conj) verapamil_29\NN|neither|nor|nh4ac (r_nsubj) affected_32\VBD|verapamil|action|. (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D009020_D000699 NONE morphine_11\NN|enhanced (r_appos) pretreatment_9\NN|nh4ac|morphine (r_conj) verapamil_1\NN|both|(|mg/kg|i.p.|)|and|pretreatment (r_nsubj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D003975_D000699 NONE diazepam_14\NN| (r_npadvmod) induced_16\VBN|diazepam|- (r_amod) incoordination_18\NN|induced|muscular (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D000661_D000699 NONE amphetamine_21\NN| (r_npadvmod) induced_23\VBN|amphetamine|- (r_amod) activity_25\NN|induced|motor (r_dobj) antagonized_20\VBN|activity (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D000661_D001259 NONE amphetamine_21\NN| (r_npadvmod) induced_23\VBN|amphetamine|- (r_amod) activity_25\NN|induced|motor (r_dobj) antagonized_20\VBN|activity (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
D010433_D000699 NONE metrazol_37\NN| (r_pobj) of_36\IN|metrazol (r_prep) action_35\NN|the|convulsant|of (r_dobj) affected_32\VBD|verapamil|action|. (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected
D010433_D001259 NONE metrazol_37\NN| (r_pobj) of_36\IN|metrazol (r_prep) action_35\NN|the|convulsant|of (r_dobj) affected_32\VBD|verapamil|action|. (r_conj) analgesia-_12\JJ|verapamil|and|incoordination|and|antagonized|,|and|affected (l_conj) incoordination_18\NN|induced|muscular
D002118_D022124 NONE calcium_7\NN| (r_compound) channel_8\NN|a|calcium|blocking|enhances (r_dobj) exerts_5\VBZ|hyperammonemia|channel (l_nsubj) hyperammonemia_4\NN|that
2021202
D007530_D007022 CID isoflurane_6\RB| (r_npadvmod) induced_8\VBN|isoflurane|- (r_amod) hypotension_9\NN|prolonged|induced|in
D007530_D007022 CID isoflurane_3\RB| (r_npadvmod) induced_5\VBN|isoflurane|- (r_amod) hypotension_6\NN|induced|on
D007530_D007022 CID isoflurane_11\NN| (r_amod) concentration_13\NN|the|isoflurane|inspired (r_dobj) increasing_9\VBG|concentration|maintain (r_pcomp) by_8\IN|increasing (r_prep) induced_2\VBN|hypotension|was|for|by|mmhg|. (l_nsubjpass) Hypotension_0\NNP|
D007530_D007022 CID isoflurane_9\RB| (r_npadvmod) induced_11\VBN|isoflurane|- (r_amod) hypotension_12\NN|induced|and
11847945
D007530_D002779 CID isoflurane_6\RB| (r_pobj) to_5\IN|isoflurane (r_prep) exposure_4\NN|to (r_pobj) after_3\IN|exposure (r_prep) hepatitis_2\NN|acute|cholestatic|after|.
D007530_D002779 CID isoflurane_14\RB|the|inhalational|anesthetic (r_pobj) to_10\IN|isoflurane (r_prep) exposure_9\NN|to (r_pobj) following_8\VBG|exposure (r_prep) case_3\NN|a|of|following (l_prep) of_4\IN|hepatitis (l_pobj) hepatitis_7\NN|acute|cholestatic
D007530_D002779 CID Isoflurane_0\NNP|,|agent (r_nsubj) cause_8\VB|isoflurane|,|can|hepatitis|. (l_dobj) hepatitis_11\NN|severe|cholestatic
D007530_D056486 CID isoflurane_6\RB| (r_pobj) to_5\IN|isoflurane (r_prep) exposure_4\NN|to (r_pobj) after_3\IN|exposure (r_prep) hepatitis_2\NN|acute|cholestatic|after|.
D007530_D056486 CID isoflurane_14\RB|the|inhalational|anesthetic (r_pobj) to_10\IN|isoflurane (r_prep) exposure_9\NN|to (r_pobj) following_8\VBG|exposure (r_prep) case_3\NN|a|of|following (l_prep) of_4\IN|hepatitis (l_pobj) hepatitis_7\NN|acute|cholestatic
D007530_D056486 CID Isoflurane_0\NNP|,|agent (r_nsubj) cause_8\VB|isoflurane|,|can|hepatitis|. (l_dobj) hepatitis_11\NN|severe|cholestatic
D004177_D000699 NONE dipyrone_7\NN|for (l_prep) for_8\IN|analgesia (l_pobj) analgesia_9\NN|
20394767
D015016_D012021 CID yohimbine_2\NN| (r_nsubj) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_dobj) startle_5\NN|baseline|amplitude
D015016_D012021 CID yohimbine_2\NN| (r_nsubj) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_conj) suppressed_13\VBD|startle|and|suppressed (l_dobj) startle_15\NN|baseline|in
D015016_D012021 CID yohimbine_2\NN| (r_nsubj) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_conj) suppressed_13\VBD|startle|and|suppressed (l_conj) suppressed_24\VBD|ptz|startle|. (l_dobj) startle_26\NN|baseline|in
C015068_D012021 CID mCPP_12\NNS|while (r_advcl) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_dobj) startle_5\NN|baseline|amplitude
C015068_D012021 CID mCPP_12\NNS|while (r_advcl) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_conj) suppressed_13\VBD|startle|and|suppressed (l_dobj) startle_15\NN|baseline|in
C015068_D012021 CID mCPP_12\NNS|while (r_advcl) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_conj) suppressed_13\VBD|startle|and|suppressed (l_conj) suppressed_24\VBD|ptz|startle|. (l_dobj) startle_26\NN|baseline|in
D010433_D012021 CID PTZ_23\NNP| (r_nsubj) suppressed_24\VBD|ptz|startle|. (r_conj) suppressed_13\VBD|startle|and|suppressed (r_conj) increased_3\VBN|furthermore|,|yohimbine|startle|,|mcpp|suppressed (l_dobj) startle_5\NN|baseline|amplitude
D010433_D012021 CID PTZ_23\NNP| (r_nsubj) suppressed_24\VBD|ptz|startle|. (r_conj) suppressed_13\VBD|startle|and|suppressed (l_dobj) startle_15\NN|baseline|in
D010433_D012021 CID PTZ_23\NNP| (r_nsubj) suppressed_24\VBD|ptz|startle|. (l_dobj) startle_26\NN|baseline|in
11838826
D018967_D006966 CID risperidone_2\NN| (r_npadvmod) induced_4\VBN|risperidone|- (r_amod) hyperprolactinemia_5\NN|induced|with
D018967_D006966 CID Risperidone_0\NNP|,|antagonist (r_nsubjpass) associated_16\VBN|risperidone|is|with|. (l_prep) with_17\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_18\NN|in
D018967_D006966 CID risperidone_6\NN| (r_npadvmod) induced_8\VBN|risperidone|- (r_amod) hyperprolactinemia_9\NN|induced|with
D018967_D006966 CID risperidone_10\NN| (r_npadvmod) induced_12\VBN|risperidone|- (r_amod) hyperprolactinemia_13\NN|induced|treated
D018967_D006966 CID risperidone_8\NN| (r_npadvmod) induced_10\VBN|risperidone|- (r_amod) hyperprolactinemia_11\NN|induced
D004298_D006966 NONE dopamine_8\NN| (r_compound) agonist_9\NN|a|dopamine|in (r_pobj) with_6\IN|agonist (r_prep) hyperprolactinemia_5\NN|induced|with
C047047_D006966 NONE cabergoline_11\NN| (r_pobj) with_10\IN|cabergoline (r_prep) hyperprolactinemia_9\NN|induced|with
C047047_D006966 NONE cabergoline_16\NN| (r_pobj) with_15\IN|cabergoline (r_prep) treated_14\VBN|with (r_acl) hyperprolactinemia_13\NN|induced|treated
C047047_D006966 NONE Cabergoline_0\NNP| (r_nsubj) be_2\VB|cabergoline|may|useful|for (l_prep) for_4\IN|treatment (l_pobj) treatment_6\NN|the|of|in (l_prep) of_7\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_11\NN|induced
D018967_D001523 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|risperidone|- (r_amod) elevations_30\NNS|induced|in (r_pobj) with_26\IN|elevations (r_prep) males_1\NNS|four|(|age|)|with|,|with|(|ml|)|, (l_prep) with_9\IN|disorder (l_pobj) disorder_22\NN|diagnostic|edition|bipolar|or|psychoses (l_amod) Diagnostic_10\NNP|and|manual (l_conj) Manual_13\NNP|statistical|of (l_prep) of_14\IN|disorders (l_pobj) Disorders_16\NNPS|mental|(
D018967_D001714 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|risperidone|- (r_amod) elevations_30\NNS|induced|in (r_pobj) with_26\IN|elevations (r_prep) males_1\NNS|four|(|age|)|with|,|with|(|ml|)|, (l_prep) with_9\IN|disorder (l_pobj) disorder_22\NN|diagnostic|edition|bipolar|or|psychoses
D018967_D011605 NONE risperidone_27\NN| (r_npadvmod) induced_29\VBN|risperidone|- (r_amod) elevations_30\NNS|induced|in (r_pobj) with_26\IN|elevations (r_prep) males_1\NNS|four|(|age|)|with|,|with|(|ml|)|, (l_prep) with_9\IN|disorder (l_pobj) disorder_22\NN|diagnostic|edition|bipolar|or|psychoses (l_conj) psychoses_24\NNS|
C047047_D001523 NONE cabergoline_55\NN| (r_pobj) with_54\IN|cabergoline (r_prep) treated_53\VBN|males|were|with|dose|)|. (l_nsubjpass) males_1\NNS|four|(|age|)|with|,|with|(|ml|)|, (l_prep) with_9\IN|disorder (l_pobj) disorder_22\NN|diagnostic|edition|bipolar|or|psychoses (l_amod) Diagnostic_10\NNP|and|manual (l_conj) Manual_13\NNP|statistical|of (l_prep) of_14\IN|disorders (l_pobj) Disorders_16\NNPS|mental|(
C047047_D001714 NONE cabergoline_55\NN| (r_pobj) with_54\IN|cabergoline (r_prep) treated_53\VBN|males|were|with|dose|)|. (l_nsubjpass) males_1\NNS|four|(|age|)|with|,|with|(|ml|)|, (l_prep) with_9\IN|disorder (l_pobj) disorder_22\NN|diagnostic|edition|bipolar|or|psychoses
C047047_D011605 NONE cabergoline_55\NN| (r_pobj) with_54\IN|cabergoline (r_prep) treated_53\VBN|males|were|with|dose|)|. (l_nsubjpass) males_1\NNS|four|(|age|)|with|,|with|(|ml|)|, (l_prep) with_9\IN|disorder (l_pobj) disorder_22\NN|diagnostic|edition|bipolar|or|psychoses (l_conj) psychoses_24\NNS|
16596970
D010862_D012640 NONE Pilocarpine_0\NNP| (r_amod) seizures_1\NNS|pilocarpine
D010862_D012640 NONE Pilocarpine_0\NN|on (r_nsubj) induced_4\VBN|pilocarpine|status|epilepticus (r_ccomp) resulted_12\VBD|induced|;|epilepticus|in|,|had|. (l_prep) in_13\IN|loss (l_pobj) loss_16\NN|ca3|cell|and|seizures (l_conj) seizures_19\NNS|spontaneous
D010862_D012640 NONE Pilocarpine_0\NN|on (r_nsubj) induced_4\VBN|pilocarpine|status|epilepticus (r_ccomp) resulted_12\VBD|induced|;|epilepticus|in|,|had|. (l_advcl) had_24\VBD|whereas|rats|loss (l_dobj) loss_27\NN|no|cell|or|seizures (l_conj) seizures_30\NNS|spontaneous
D010862_D001308 CID Pilocarpine_0\NNP| (r_amod) seizures_1\NNS|pilocarpine (r_nsubj) cause_2\IN|seizures|impairment|. (l_dobj) impairment_6\NN|dependent|in (l_prep) in_7\IN|discrimination (l_pobj) discrimination_10\NN|location
D010862_D013226 CID Pilocarpine_0\NN|on (r_nsubj) induced_4\VBN|pilocarpine|status|epilepticus (l_advmod) epilepticus_6\NN|
D010862_D013226 CID Pilocarpine_0\NN|on (r_nsubj) induced_4\VBN|pilocarpine|status|epilepticus (r_ccomp) resulted_12\VBD|induced|;|epilepticus|in|,|had|. (l_nsubj) epilepticus_9\NN|status|at
18997632
D002110_D017180 CID caffeine_7\NN| (r_compound) pretreatment_8\NN|caffeine (r_pobj) to_6\IN|pretreatment (r_prep) related_5\VBN|to (r_acl) tachycardia_4\NN|ventricular|related
D002110_D017180 CID caffeine_25\NN| (r_compound) administration_26\NN|caffeine (r_pobj) after_24\IN|administration (r_prep) developed_14\VBD|who|bigeminy|after (l_dobj) bigeminy_16\JJ|sustained|and|runs (l_conj) runs_20\NNS|2|brief|of (l_prep) of_21\IN|tachycardia (l_pobj) tachycardia_23\NN|ventricular
D002110_D012640 CID caffeine_1\NN|intravenous (r_nsubjpass) used_4\VBN|caffeine|is|commonly|improve|and|tolerated|. (l_xcomp) improve_6\VB|to|duration (l_dobj) duration_8\NN|seizure|and|quality|in (l_compound) seizure_7\NN|
D002110_D018879 CID caffeine_1\NN|intravenous (r_nsubjpass) used_4\VBN|caffeine|is|commonly|improve|and|tolerated|. (l_conj) tolerated_18\VBN|is|generally|well|aside|from (l_prep) from_20\IN|reports (l_pobj) reports_22\NNS|occasional|of (l_prep) of_23\IN|ectopy (l_pobj) ectopy_27\NN|benign|ventricular
D002110_D006331 NONE caffeine_25\NN| (r_compound) administration_26\NN|caffeine (r_pobj) after_24\IN|administration (r_prep) developed_14\VBD|who|bigeminy|after (r_relcl) disease_10\NN|cardiac|or|arrhythmia|developed
D002110_D001145 NONE caffeine_25\NN| (r_compound) administration_26\NN|caffeine (r_pobj) after_24\IN|administration (r_prep) developed_14\VBD|who|bigeminy|after (r_relcl) disease_10\NN|cardiac|or|arrhythmia|developed (l_conj) arrhythmia_12\NN|
D002110_D001145 NONE caffeine_2\NN|intravenous (r_nsubjpass) tolerated_6\VBN|although|caffeine|is|generally|well (r_advcl) be_11\VB|tolerated|,|clinician|should|aware|. (l_acomp) aware_12\JJ|of (l_prep) of_13\IN|potential (l_pobj) potential_15\NN|the|for (l_prep) for_16\IN|arrhythmias (l_pobj) arrhythmias_21\NNS|unpredictable|ventricular
6115999
D001539_D006973 NONE bendrofluazide_3\VB|to|and|propranolol (l_conj) propranolol_5\NN|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|hypertension (l_pobj) hypertension_11\NN|mild
D001539_D006973 NONE bendrofluazide_21\NN|,|propranolol (r_amod) groups_19\NNS|four|treatment|:|bendrofluazide (r_pobj) of_16\IN|groups (r_prep) one_15\CD|of (r_pobj) to_14\IN|one (r_prep) allocated_13\VBN|participants|are|randomly|to|. (l_nsubjpass) Participants_0\NNS|in (l_prep) in_1\IN|trial (l_pobj) trial_7\NN|the|council|treatment|for (l_prep) for_8\IN|hypertension (l_pobj) hypertension_10\NN|mild
D011433_D006973 NONE propranolol_5\NN|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|hypertension (l_pobj) hypertension_11\NN|mild
D011433_D006973 NONE propranolol_23\NN|,|or|placebo (r_conj) bendrofluazide_21\NN|,|propranolol (r_amod) groups_19\NNS|four|treatment|:|bendrofluazide (r_pobj) of_16\IN|groups (r_prep) one_15\CD|of (r_pobj) to_14\IN|one (r_prep) allocated_13\VBN|participants|are|randomly|to|. (l_nsubjpass) Participants_0\NNS|in (l_prep) in_1\IN|trial (l_pobj) trial_7\NN|the|council|treatment|for (l_prep) for_8\IN|hypertension (l_pobj) hypertension_10\NN|mild
D001539_D007172 CID bendrofluazide_6\JJ| (r_amod) treatment_7\NN|bendrofluazide|and|impotence (l_conj) impotence_9\NN|
D001539_D007172 CID bendrofluazide_6\JJ| (r_amod) treatment_7\NN|bendrofluazide|and|impotence (r_pobj) between_5\IN|treatment (r_prep) association_4\NN|an|between (r_dobj) show_2\VBP|results|association|,|and|occurred (l_conj) occurred_14\VBD|impotence|also|frequently|in|. (l_nsubj) impotence_12\NN|
D011433_D007172 CID propranolol_20\RB| (r_dobj) taking_19\VBG|propranolol|than (r_acl) patients_18\NNS|taking (r_pobj) in_17\IN|patients (r_prep) occurred_14\VBD|impotence|also|frequently|in|. (r_conj) show_2\VBP|results|association|,|and|occurred (l_dobj) association_4\NN|an|between (l_prep) between_5\IN|treatment (l_pobj) treatment_7\NN|bendrofluazide|and|impotence (l_conj) impotence_9\NN|
D011433_D007172 CID propranolol_20\RB| (r_dobj) taking_19\VBG|propranolol|than (r_acl) patients_18\NNS|taking (r_pobj) in_17\IN|patients (r_prep) occurred_14\VBD|impotence|also|frequently|in|. (l_nsubj) impotence_12\NN|
D001539_D018149 CID bendrofluazide_23\NN| (r_amod) treatment_24\NN|bendrofluazide (r_pobj) with_22\IN|treatment (r_prep) associated_21\VBN|with (r_acl) tolerance_11\NN|impaired|glucose|in|,|associated|,|and|phenomenon
D001539_D006073 CID bendrofluazide_23\NN| (r_amod) treatment_24\NN|bendrofluazide (r_pobj) with_22\IN|treatment (r_prep) associated_21\VBN|with (r_acl) tolerance_11\NN|impaired|glucose|in|,|associated|,|and|phenomenon (l_prep) in_12\IN|men (l_pobj) men_13\NNS|and|women|in (l_conj) women_15\NNS|and|gout (l_conj) gout_17\NN|
D001539_D011928 NONE bendrofluazide_23\NN| (r_amod) treatment_24\NN|bendrofluazide (r_pobj) with_22\IN|treatment (r_prep) associated_21\VBN|with (r_acl) tolerance_11\NN|impaired|glucose|in|,|associated|,|and|phenomenon (l_conj) phenomenon_29\NN|raynaud|and|dyspnoea|in
D001539_D004417 NONE bendrofluazide_23\NN| (r_amod) treatment_24\NN|bendrofluazide (r_pobj) with_22\IN|treatment (r_prep) associated_21\VBN|with (r_acl) tolerance_11\NN|impaired|glucose|in|,|associated|,|and|phenomenon (l_conj) phenomenon_29\NN|raynaud|and|dyspnoea|in (l_conj) dyspnoea_31\NN|
D011433_D018149 NONE propranolol_37\NN| (r_dobj) taking_36\VBG|propranolol (r_acl) men_33\NNS|and|women|taking (r_pobj) in_32\IN|men (r_prep) phenomenon_29\NN|raynaud|and|dyspnoea|in (r_conj) tolerance_11\NN|impaired|glucose|in|,|associated|,|and|phenomenon
D011433_D006073 NONE propranolol_37\NN| (r_dobj) taking_36\VBG|propranolol (r_acl) men_33\NNS|and|women|taking (r_pobj) in_32\IN|men (r_prep) phenomenon_29\NN|raynaud|and|dyspnoea|in (r_conj) tolerance_11\NN|impaired|glucose|in|,|associated|,|and|phenomenon (l_prep) in_12\IN|men (l_pobj) men_13\NNS|and|women|in (l_conj) women_15\NNS|and|gout (l_conj) gout_17\NN|
D011433_D011928 CID propranolol_37\NN| (r_dobj) taking_36\VBG|propranolol (r_acl) men_33\NNS|and|women|taking (r_pobj) in_32\IN|men (r_prep) phenomenon_29\NN|raynaud|and|dyspnoea|in
D011433_D004417 CID propranolol_37\NN| (r_dobj) taking_36\VBG|propranolol (r_acl) men_33\NNS|and|women|taking (r_pobj) in_32\IN|men (r_prep) phenomenon_29\NN|raynaud|and|dyspnoea|in (l_conj) dyspnoea_31\NN|
D011433_D003316 NONE propranolol_10\NN| (r_amod) group_11\NN|the|propranolol (r_pobj) in_8\IN|group (r_prep) occurred_7\VBN|to|have|in (r_xcomp) known_4\VBN|disease|is|occurred|. (l_nsubjpass) disease_2\NN|no|corneal
16471092
C099041_D053201 NONE tolterodine_14\JJ| (r_amod) treatment_15\NN|tolterodine (r_pobj) after_13\IN|treatment (r_prep) symptoms_1\NNS|urinary|and|quality|after|. (l_conj) quality_3\NN|of (l_prep) of_4\IN|changes (l_pobj) changes_6\NNS|life|in|with (l_prep) with_10\IN|bladder (l_pobj) bladder_12\NN|overactive
C099041_D053201 NONE tolterodine_22\JJ| (r_amod) treatment_23\NN|tolterodine (r_pobj) after_21\IN|treatment (r_prep) study_3\VB|to|symptoms|after (l_dobj) symptoms_6\NNS|the|urinary|and|quality (l_conj) quality_8\NN|of (l_prep) of_9\IN|changes (l_pobj) changes_11\NNS|life|in|with (l_prep) with_15\IN|bladder (l_pobj) bladder_17\NN|overactive|(|oab|)
C099041_D053201 NONE tolterodine_22\JJ| (r_amod) treatment_23\NN|tolterodine (r_pobj) after_21\IN|treatment (r_prep) study_3\VB|to|symptoms|after (l_dobj) symptoms_6\NNS|the|urinary|and|quality (l_conj) quality_8\NN|of (l_prep) of_9\IN|changes (l_pobj) changes_11\NNS|life|in|with (l_prep) with_15\IN|bladder (l_pobj) bladder_17\NN|overactive|(|oab|) (l_appos) OAB_19\NNP|
C099041_D053201 NONE Tolterodine_0\NNP| (r_nsubjpass) tolerated_3\VBN|tolterodine|was|well|and|improved (l_conj) improved_7\VBD|effects|quality|. (l_dobj) quality_9\NN|the|of|in|with (l_prep) with_15\IN|oab (l_pobj) OAB_16\NNP|
11226639
D008550_D053608 CID melatonin_3\NN|on (l_prep) on_4\IN|narcosis (l_pobj) narcosis_8\NN|induced|in
D008550_D053608 CID Melatonin_0\NNP| (r_nsubj) affects_1\VBZ|melatonin|cycle|,|but|is (l_conj) is_11\VBZ|it|not|clear|influence|. (l_ccomp) influence_17\VB|whether|it|may|narcosis (l_dobj) narcosis_21\NN|induced
D008550_D053608 CID Melatonin_0\NNP| (r_nsubjpass) found_20\VBN|melatonin|,|however|,|correlation|was|. (l_punct) ,_11\,|affected (l_punct) affected_4\VBN|treatment|in (l_prep) in_5\IN|narcosis (l_pobj) narcosis_10\NN|a|manner|barbiturate
D008550_D053608 CID melatonin_7\NN|(|mg/kg|) (r_pobj) of_6\IN|melatonin (r_prep) dose_5\NN|the|highest|of (r_nsubj) caused_12\VBD|in|,|dose|increase|and|produced|and|reduction|. (l_conj) produced_20\VBD|reduction|, (l_dobj) reduction_23\NN|a|sustained|of (l_prep) of_24\IN|duration (l_pobj) duration_26\NN|the|of (l_prep) of_27\IN|narcosis (l_pobj) narcosis_28\NN|
D008550_D053608 CID Melatonin_0\NNP|0.5|and|mg/kg (r_nsubj) influenced_5\VBD|melatonin|duration|. (l_dobj) duration_7\NN|the|but|latency (l_conj) latency_11\NN|not|the|of (l_prep) of_12\IN|narcosis (l_pobj) narcosis_18\NN|ketamine-
D008550_D053608 CID melatonin_6\NN|on (l_prep) on_7\IN|narcosis (l_pobj) narcosis_9\NN|pharmacological
C032232_D053608 NONE barbiturate_5\NN| (r_npadvmod) induced_7\VBN|barbiturate|- (r_amod) narcosis_8\NN|induced|in
C032232_D053608 NONE barbiturate_9\NN| (r_compound) narcosis_10\NN|a|manner|barbiturate
C032232_D053608 NONE barbiturate_14\NN| (r_compound) narcosis_15\NN|barbiturate
C032232_D053608 NONE barbiturate_16\JJ| (r_compound) mechanism_17\NN|the|barbiturate|of (r_pobj) for_14\IN|mechanism (r_prep) specific_13\JJ|for (r_acomp) be_12\VB|to|specific (r_xcomp) seems_10\VBZ|thus|,|action|be|. (l_nsubj) action_4\NN|the|dual|of (l_prep) of_5\IN|melatonin (l_pobj) melatonin_6\NN|on (l_prep) on_7\IN|narcosis (l_pobj) narcosis_9\NN|pharmacological
D007649_D053608 CID ketamine-_13\NNS|or|induced (r_nmod) narcosis_18\NN|ketamine-
D003975_D053608 CID diazepam_15\NN| (r_npadvmod) induced_17\VBN|diazepam|- (r_conj) ketamine-_13\NNS|or|induced (r_nmod) narcosis_18\NN|ketamine-
16586083
D016861_D009203 CID inhibitors_25\NNS|cyclooxygenase (r_pobj) with_23\IN|inhibitors (r_prep) treatment_22\NN|with (r_pobj) during_21\IN|treatment (r_prep) stroke_15\NN|,|hypertension|during (r_conj) infarction_13\NN|myocardial|,|stroke
D016861_D020521 CID inhibitors_25\NNS|cyclooxygenase (r_pobj) with_23\IN|inhibitors (r_prep) treatment_22\NN|with (r_pobj) during_21\IN|treatment (r_prep) stroke_15\NN|,|hypertension|during
D016861_D006973 CID inhibitors_25\NNS|cyclooxygenase (r_pobj) with_23\IN|inhibitors (r_prep) treatment_22\NN|with (r_pobj) during_21\IN|treatment (r_prep) stroke_15\NN|,|hypertension|during (l_conj) hypertension_17\NN|and|failure
D016861_D006333 CID inhibitors_25\NNS|cyclooxygenase (r_pobj) with_23\IN|inhibitors (r_prep) treatment_22\NN|with (r_pobj) during_21\IN|treatment (r_prep) stroke_15\NN|,|hypertension|during (l_conj) hypertension_17\NN|and|failure (l_conj) failure_20\NN|heart
C109794_D002318 NONE peptide_10\NN|terminal|brain|natriuretic|(|probnp|)|or|protein (r_pobj) as_3\IN|such|peptide (r_prep) markers_1\NNS|diagnostic|as (r_nsubj) help_25\VB|markers|might|in|,|avoiding|. (l_advcl) avoiding_36\VBG|thus|occurrence (l_dobj) occurrence_38\NN|the|of (l_prep) of_39\IN|toxicity (l_pobj) toxicity_42\NN|serious|cardiovascular
C109794_D002318 NONE proBNP_14\NNP|nt|- (r_appos) peptide_10\NN|terminal|brain|natriuretic|(|probnp|)|or|protein (r_pobj) as_3\IN|such|peptide (r_prep) markers_1\NNS|diagnostic|as (r_nsubj) help_25\VB|markers|might|in|,|avoiding|. (l_advcl) avoiding_36\VBG|thus|occurrence (l_dobj) occurrence_38\NN|the|of (l_prep) of_39\IN|toxicity (l_pobj) toxicity_42\NN|serious|cardiovascular
17786501
D004221_D009901 NONE Disulfiram_0\NNP| (r_npadvmod) induced_2\VBN|disulfiram|- (r_amod) optic_4\JJ|induced|transient|and|neuropathy (l_conj) neuropathy_7\NN|peripheral
D004221_D009901 NONE disulfiram_15\NN| (r_pobj) of_14\IN|disulfiram (r_prep) use_13\NN|chronic|of|for (r_pobj) after_11\IN|use (r_prep) report_3\VB|to|case|after (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|optic (l_pobj) optic_7\JJ|and|neuropathy (l_conj) neuropathy_10\NN|peripheral
D004221_D010523 NONE Disulfiram_0\NNP| (r_npadvmod) induced_2\VBN|disulfiram|- (r_amod) optic_4\JJ|induced|transient|and|neuropathy (l_conj) neuropathy_7\NN|peripheral
D004221_D010523 NONE disulfiram_15\NN| (r_pobj) of_14\IN|disulfiram (r_prep) use_13\NN|chronic|of|for (r_pobj) after_11\IN|use (r_prep) report_3\VB|to|case|after (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|optic (l_pobj) optic_7\JJ|and|neuropathy (l_conj) neuropathy_10\NN|peripheral
D004221_D000437 NONE disulfiram_15\NN| (r_pobj) of_14\IN|disulfiram (r_prep) use_13\NN|chronic|of|for (l_prep) for_16\IN|management (l_pobj) management_19\NN|alcohol|dependence (l_compound) dependence_18\NN|
D004221_D000437 NONE disulfiram_4\NN| (r_dobj) taking_3\VBG|he|had|been|disulfiram|for|. (l_prep) for_5\IN|dependence (l_pobj) dependence_7\NN|alcohol|for
33969
C084820_D010302 NONE Ethopropazine_0\NN|and|benztropine|. (l_conj) benztropine_2\NN|in (l_prep) in_3\IN|parkinsonism (l_pobj) parkinsonism_7\NN|induced
C084820_D010302 NONE ethopropazine_5\NN|a|12-week|controlled|study (r_pobj) In_0\IN|ethopropazine (r_prep) compared_7\VBN|in|was|benztropine|. (l_xcomp) benztropine_9\VB|to|in|induced (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|parkinsonism (l_pobj) parkinsonism_14\NN|
C084820_D010302 NONE Ethopropazine_0\NN|and|benztropine (r_nsubjpass) found_4\VBN|ethopropazine|were|be|and|were|. (l_xcomp) be_6\VB|to|effective (l_acomp) effective_8\JJ|equally|in (l_prep) in_9\IN|controlling (l_pcomp) controlling_10\VBG|symptoms (l_dobj) symptoms_12\NNS|parkinsonian
D001590_D010302 NONE benztropine_2\NN|in (l_prep) in_3\IN|parkinsonism (l_pobj) parkinsonism_7\NN|induced
D001590_D010302 NONE benztropine_9\VB|to|in|induced (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|parkinsonism (l_pobj) parkinsonism_14\NN|
D001590_D010302 NONE benztropine_2\NN| (r_conj) Ethopropazine_0\NN|and|benztropine (r_nsubjpass) found_4\VBN|ethopropazine|were|be|and|were|. (l_xcomp) be_6\VB|to|effective (l_acomp) effective_8\JJ|equally|in (l_prep) in_9\IN|controlling (l_pcomp) controlling_10\VBG|symptoms (l_dobj) symptoms_12\NNS|parkinsonian
D001590_D010302 NONE benztropine_3\NN| (r_nsubj) is_4\VBZ|that|benztropine|not|drug|,|because (l_attr) drug_8\NN|the|anticholinergic|of|in (l_prep) in_11\IN|treatment (l_pobj) treatment_13\NN|the|of (l_prep) of_14\IN|symptoms (l_pobj) symptoms_19\NNS|induced|parkinsonian
C084820_D012559 NONE ethopropazine_5\NN|a|12-week|controlled|study (r_pobj) In_0\IN|ethopropazine (r_prep) compared_7\VBN|in|was|benztropine|. (l_xcomp) benztropine_9\VB|to|in|induced (l_advcl) induced_15\VBN|by (l_agent) by_16\IN|fluphenazine (l_pobj) fluphenazine_17\JJ|enanthate (l_amod) enanthate_18\NN|in (l_prep) in_19\IN|outpatients (l_pobj) outpatients_22\NNS|60|schizophrenic (l_amod) schizophrenic_21\JJ|
D001590_D012559 NONE benztropine_9\VB|to|in|induced (l_advcl) induced_15\VBN|by (l_agent) by_16\IN|fluphenazine (l_pobj) fluphenazine_17\JJ|enanthate (l_amod) enanthate_18\NN|in (l_prep) in_19\IN|outpatients (l_pobj) outpatients_22\NNS|60|schizophrenic (l_amod) schizophrenic_21\JJ|
C017610_D010302 CID enanthate_18\NN|in (r_amod) fluphenazine_17\JJ|enanthate (r_pobj) by_16\IN|fluphenazine (r_agent) induced_15\VBN|by (r_advcl) benztropine_9\VB|to|in|induced (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|parkinsonism (l_pobj) parkinsonism_14\NN|
C017610_D012559 NONE enanthate_18\NN|in (l_prep) in_19\IN|outpatients (l_pobj) outpatients_22\NNS|60|schizophrenic (l_amod) schizophrenic_21\JJ|
D011352_D010302 NONE procyclidine_18\NN| (r_pobj) as_17\IN|procyclidine (r_prep) efficacious_16\JJ|as|as (r_acomp) were_14\VBD|efficacious|,|drug (r_conj) found_4\VBN|ethopropazine|were|be|and|were|. (l_xcomp) be_6\VB|to|effective (l_acomp) effective_8\JJ|equally|in (l_prep) in_9\IN|controlling (l_pcomp) controlling_10\VBG|symptoms (l_dobj) symptoms_12\NNS|parkinsonian
D001590_D004409 CID benztropine_2\NN|patients (r_nsubj) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_dobj) increase_8\NN|a|significant|in (l_prep) in_9\IN|dyskinesia (l_pobj) dyskinesia_11\JJ|tardive
D001590_D001008 CID benztropine_2\NN|patients (r_nsubj) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_conj) treated_28\VBN|anxiety|than|patients|. (l_nsubj) anxiety_23\NN|more|and|depression
D001590_D003866 CID benztropine_2\NN|patients (r_nsubj) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_conj) treated_28\VBN|anxiety|than|patients|. (l_nsubj) anxiety_23\NN|more|and|depression (l_conj) depression_25\NN|
D011352_D004409 NONE procyclindine_17\JJ| (r_compound) treatment_18\NN|procyclindine (r_pobj) during_16\IN|treatment (r_prep) condition_15\NN|their|during (r_pobj) to_13\IN|condition (r_prep) compared_12\VBN|to (r_prep) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_dobj) increase_8\NN|a|significant|in (l_prep) in_9\IN|dyskinesia (l_pobj) dyskinesia_11\JJ|tardive
D011352_D001008 NONE procyclindine_17\JJ| (r_compound) treatment_18\NN|procyclindine (r_pobj) during_16\IN|treatment (r_prep) condition_15\NN|their|during (r_pobj) to_13\IN|condition (r_prep) compared_12\VBN|to (r_prep) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_conj) treated_28\VBN|anxiety|than|patients|. (l_nsubj) anxiety_23\NN|more|and|depression
D011352_D003866 NONE procyclindine_17\JJ| (r_compound) treatment_18\NN|procyclindine (r_pobj) during_16\IN|treatment (r_prep) condition_15\NN|their|during (r_pobj) to_13\IN|condition (r_prep) compared_12\VBN|to (r_prep) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_conj) treated_28\VBN|anxiety|than|patients|. (l_nsubj) anxiety_23\NN|more|and|depression (l_conj) depression_25\NN|
C084820_D004409 NONE ethopropazine_27\NN| (r_pobj) than_26\IN|ethopropazine (r_mark) treated_28\VBN|anxiety|than|patients|. (r_conj) had_5\VBD|however|,|benztropine|increase|compared|,|and|treated (l_dobj) increase_8\NN|a|significant|in (l_prep) in_9\IN|dyskinesia (l_pobj) dyskinesia_11\JJ|tardive
C084820_D001008 NONE ethopropazine_27\NN| (r_pobj) than_26\IN|ethopropazine (r_mark) treated_28\VBN|anxiety|than|patients|. (l_nsubj) anxiety_23\NN|more|and|depression
C084820_D003866 NONE ethopropazine_27\NN| (r_pobj) than_26\IN|ethopropazine (r_mark) treated_28\VBN|anxiety|than|patients|. (l_nsubj) anxiety_23\NN|more|and|depression (l_conj) depression_25\NN|
8475949
D010419_D017180 NONE pentamidine_3\NN|and|tachycardia (l_conj) tachycardia_7\NN|polymorphic|ventricular
D010419_D017180 NONE isethionate_1\NN|pentamidine (r_nsubjpass) associated_4\VBN|isethionate|has|been|with|. (l_prep) with_5\IN|tachyarrhythmias (l_pobj) tachyarrhythmias_7\NNS|ventricular|,|including
D010419_D016171 CID isethionate_1\NN|pentamidine (r_nsubjpass) associated_4\VBN|isethionate|has|been|with|. (l_prep) with_5\IN|tachyarrhythmias (l_pobj) tachyarrhythmias_7\NNS|ventricular|,|including (l_prep) including_9\VBG|pointes (l_pobj) pointes_12\FW|torsade|de
D010419_D016171 CID Pentamidine_0\NNP| (r_npadvmod) induced_2\VBN|pentamidine|- (r_amod) torsade_3\NN|induced (r_nmod) pointes_5\FW|torsade|de
D010419_D016171 CID pentamidine_13\NN| (r_pobj) with_12\IN|pentamidine (r_prep) treatment_11\NN|with (r_pobj) of_10\IN|treatment (r_prep) days_9\NNS|10|of (r_pobj) of_7\IN|days (r_prep) average_6\NN|an|of (r_pobj) after_4\IN|average (r_prep) occurred_3\VBD|pointes|after|. (l_nsubj) pointes_2\NNS|torsade|de
D010419_D016171 CID pentamidine_14\NN| (r_pobj) of_13\IN|pentamidine (r_prep) discontinuation_12\NN|of (r_pobj) without_11\IN|possibly|discontinuation (r_prep) recognized_7\VBN|when|early|,|without (r_advcl) treated_5\VBN|pointes|can|be|recognized|. (l_nsubjpass) pointes_2\FW|torsade|de
D010419_C537153 NONE Pentamidine_0\NNP| (r_npadvmod) induced_2\VBN|pentamidine|- (r_amod) torsade_3\NN|induced (r_nmod) pointes_5\FW|torsade|de (r_nsubjpass) related_8\VBN|pointes|may|be|to|induce|. (l_prep) to_9\IN|levels (l_pobj) levels_12\NNS|serum|magnesium|and|hypomagnesemia (l_conj) hypomagnesemia_14\NN|
D008274_D016171 NONE magnesium_11\NN| (r_compound) levels_12\NNS|serum|magnesium|and|hypomagnesemia (r_pobj) to_9\IN|levels (r_prep) related_8\VBN|pointes|may|be|to|induce|. (l_nsubjpass) pointes_5\FW|torsade|de
D008274_C537153 NONE magnesium_11\NN| (r_compound) levels_12\NNS|serum|magnesium|and|hypomagnesemia (l_conj) hypomagnesemia_14\NN|
D008274_D008133 NONE magnesium_8\NN| (r_compound) supplementation_9\NN|early|magnesium (r_nsubjpass) advocated_11\VBN|observed|,|supplementation|is|. (l_advcl) observed_5\VBN|when|prolongation|is (l_nsubjpass) prolongation_3\NN|qtc|interval
15686794
D000638_D017116 CID amiodarone_8\NN| (r_pobj) of_7\IN|amiodarone (r_prep) administration_6\NN|intravenous|of (r_pobj) during_4\IN|administration (r_prep) pain_3\NN|acute|back|during|:|report|.
D000638_D017116 CID amiodarone_28\NN| (r_compound) loading_29\NN|intravenous|amiodarone (r_pobj) of_26\IN|loading (r_prep) initiation_25\NN|of (r_pobj) after_24\IN|minutes|initiation (r_prep) experienced_14\VBD|who|pain|after (l_dobj) pain_20\NN|an|low|back
D000638_D001281 NONE Amiodarone_0\NNP| (r_nsubj) represents_1\VBZ|amiodarone|drug|. (l_dobj) drug_5\NN|an|effective|antiarrhythmic|for (l_prep) for_6\IN|cardioversion (l_pobj) cardioversion_7\NN|of (l_prep) of_8\IN|fibrillation (l_pobj) fibrillation_13\NN|onset|atrial|(|af
D000638_D001281 NONE Amiodarone_0\NNP| (r_nsubj) represents_1\VBZ|amiodarone|drug|. (l_dobj) drug_5\NN|an|effective|antiarrhythmic|for (l_prep) for_6\IN|cardioversion (l_pobj) cardioversion_7\NN|of (l_prep) of_8\IN|fibrillation (l_pobj) fibrillation_13\NN|onset|atrial|(|af (l_appos) AF_15\NNP|)|and|maintenance
D000638_D001281 NONE amiodarone_28\NN| (r_compound) loading_29\NN|intravenous|amiodarone (r_pobj) of_26\IN|loading (r_prep) initiation_25\NN|of (r_pobj) after_24\IN|minutes|initiation (r_prep) experienced_14\VBD|who|pain|after (r_relcl) fibrillation_11\NN|onset|atrial|,|experienced
3961813
D003345_D009422 NONE corticosterone_9\NN|dietary|on (l_prep) on_10\IN|neuropathy (l_pobj) neuropathy_15\NN|induced|delayed|in
D003345_D009422 NONE corticosterone_13\NN| (r_pobj) of_12\IN|corticosterone (r_prep) concentrations_2\NNS|low|(|less|)|of (r_nsubj) had_14\VBD|although|concentrations|effects|signs|. (l_dobj) effects_16\NNS|beneficial|on (l_prep) on_17\IN|neuropathy (l_pobj) neuropathy_21\NN|induced|,|greater
D010755_D009422 NONE organophosphorus_11\NN| (r_npadvmod) induced_13\VBN|organophosphorus|- (r_amod) neuropathy_15\NN|induced|delayed|in
C025541_D009422 CID TOTP_18\NNP| (r_npadvmod) induced_20\VBN|totp|- (r_amod) neuropathy_21\NN|induced|,|greater
C025541_D009422 CID TOTP_37\NNP|either|or|dfp (r_pobj) given_35\VBN|totp (r_acl) signs_32\NNS|exacerbated|clinical|in|given (r_dobj) had_14\VBD|although|concentrations|effects|signs|. (l_dobj) effects_16\NNS|beneficial|on (l_prep) on_17\IN|neuropathy (l_pobj) neuropathy_21\NN|induced|,|greater
D007531_D009422 CID DFP_39\NNP| (r_conj) TOTP_37\NNP|either|or|dfp (r_pobj) given_35\VBN|totp (r_acl) signs_32\NNS|exacerbated|clinical|in|given (r_dobj) had_14\VBD|although|concentrations|effects|signs|. (l_dobj) effects_16\NNS|beneficial|on (l_prep) on_17\IN|neuropathy (l_pobj) neuropathy_21\NN|induced|,|greater
C025541_D020258 NONE TOTP_6\NNP|or|dfp (r_pobj) after_5\IN|hr|totp (r_prep) activities_2\NNS|esterase|after (l_compound) esterase_1\NN|neurotoxic (l_amod) Neurotoxic_0\JJ|
D007531_D020258 NONE DFP_8\NNP| (r_conj) TOTP_6\NNP|or|dfp (r_pobj) after_5\IN|hr|totp (r_prep) activities_2\NNS|esterase|after (l_compound) esterase_1\NN|neurotoxic (l_amod) Neurotoxic_0\JJ|
D010755_D020258 NONE organophosphorous_21\JJ| (r_amod) compounds_22\NNS|organophosphorous (r_dobj) given_20\VBN|not|compounds (r_prep) were_9\VBD|activities|%|given|. (l_nsubj) activities_2\NNS|esterase|after (l_compound) esterase_1\NN|neurotoxic (l_amod) Neurotoxic_0\JJ|
C025541_D009410 CID TOTP_16\NNP|or|dfp (r_pobj) given_15\VBN|totp (r_prep) were_3\VBD|fibers|also|evident|given|. (l_nsubj) fibers_2\NNS|degenerating|myelinated
D007531_D009410 CID DFP_18\NNP| (r_conj) TOTP_16\NNP|or|dfp (r_pobj) given_15\VBN|totp (r_prep) were_3\VBD|fibers|also|evident|given|. (l_nsubj) fibers_2\NNS|degenerating|myelinated
20042557
D015742_D003693 CID propofol_39\NN| (r_amod) sedation_40\NN|propofol (r_pobj) with_38\IN|sedation (r_prep) anesthesia_37\NN|spinal|with (r_pobj) under_35\IN|anesthesia (r_prep) repair_34\NN|fracture|under (r_dobj) underwent_31\VBD|who|repair (r_relcl) delirium_26\NN|preoperative|or|dementia|underwent
D015742_D003693 CID propofol_4\NN| (r_amod) sedation_5\NN|light|propofol (r_pobj) of_2\IN|sedation (r_prep) use_1\NN|the|of (r_nsubj) decreased_6\VBD|use|prevalence|. (l_dobj) prevalence_8\NN|the|of|by|compared (l_prep) of_9\IN|delirium (l_pobj) delirium_11\NN|postoperative
D015742_D003704 NONE propofol_39\NN| (r_amod) sedation_40\NN|propofol (r_pobj) with_38\IN|sedation (r_prep) anesthesia_37\NN|spinal|with (r_pobj) under_35\IN|anesthesia (r_prep) repair_34\NN|fracture|under (r_dobj) underwent_31\VBD|who|repair (r_relcl) delirium_26\NN|preoperative|or|dementia|underwent (l_conj) dementia_29\NN|severe
D015742_D006620 NONE propofol_39\NN| (r_amod) sedation_40\NN|propofol (r_pobj) with_38\IN|sedation (r_prep) anesthesia_37\NN|spinal|with (r_pobj) under_35\IN|anesthesia (r_prep) repair_34\NN|fracture|under (l_compound) fracture_33\NN|hip
D015742_D011183 CID propofol_4\NN| (r_amod) sedation_5\NN|light|propofol (r_pobj) of_2\IN|sedation (r_prep) use_1\NN|the|of (r_nsubj) decreased_6\VBD|use|prevalence|. (l_dobj) prevalence_8\NN|the|of|by|compared (l_prep) of_9\IN|delirium (l_pobj) delirium_11\NN|postoperative
7197363
D001058_D012892 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|apomorphine|- (r_amod) aggressiveness_13\NN|induced|and|twitches (r_pobj) on_9\IN|aggressiveness (r_prep) effects_1\NNS|the|of|on (l_prep) of_2\IN|deprivation (l_pobj) deprivation_5\NN|rem|sleep|(|remd|)
D001058_D012892 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|apomorphine|- (r_amod) aggressiveness_13\NN|induced|and|twitches (r_pobj) on_9\IN|aggressiveness (r_prep) effects_1\NNS|the|of|on (l_prep) of_2\IN|deprivation (l_pobj) deprivation_5\NN|rem|sleep|(|remd|) (l_appos) REMD_7\NNP|
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|apomorphine|- (r_amod) aggressiveness_10\NN|induced (r_dobj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_nsubj) hr_3\NN|eight|of (l_prep) of_4\IN|remd (l_pobj) REMD_5\NNP|
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|apomorphine|- (r_amod) aggressiveness_10\NN|induced (r_dobj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_conj) reduced_13\VBN|(|after|)|or|increased (l_prep) after_16\IN|immediately|completing (l_pcomp) completing_17\VBG|of (l_prep) of_18\IN|remd (l_pobj) REMD_19\NNP|
D001058_D012892 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|apomorphine|- (r_amod) aggressiveness_10\NN|induced (r_dobj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_conj) reduced_13\VBN|(|after|)|or|increased (l_conj) increased_22\VBN|hr|after (l_prep) after_26\IN|completing (l_pcomp) completing_27\VBG|of (l_prep) of_28\IN|quipazine (l_pobj) quipazine_31\NN|remd|)|- (l_nmod) REMD_29\NNP|
D001058_D001523 CID apomorphine_10\NN| (r_npadvmod) induced_12\VBN|apomorphine|- (r_amod) aggressiveness_13\NN|induced|and|twitches
D001058_D001523 CID apomorphine_7\NN| (r_npadvmod) induced_9\VBN|apomorphine|- (r_amod) aggressiveness_10\NN|induced
D001058_D009069 NONE apomorphine_10\NN| (r_npadvmod) induced_12\VBN|apomorphine|- (r_amod) aggressiveness_13\NN|induced|and|twitches (l_conj) twitches_19\NNS|head|in
D001058_D009069 NONE apomorphine_7\NN| (r_npadvmod) induced_9\VBN|apomorphine|- (r_amod) aggressiveness_10\NN|induced (r_dobj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_conj) twitches_35\NNS|head
D011814_D012892 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|quipazine|- (r_amod) head_18\NN|induced (r_compound) twitches_19\NNS|head|in (r_conj) aggressiveness_13\NN|induced|and|twitches (r_pobj) on_9\IN|aggressiveness (r_prep) effects_1\NNS|the|of|on (l_prep) of_2\IN|deprivation (l_pobj) deprivation_5\NN|rem|sleep|(|remd|)
D011814_D012892 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|quipazine|- (r_amod) head_18\NN|induced (r_compound) twitches_19\NNS|head|in (r_conj) aggressiveness_13\NN|induced|and|twitches (r_pobj) on_9\IN|aggressiveness (r_prep) effects_1\NNS|the|of|on (l_prep) of_2\IN|deprivation (l_pobj) deprivation_5\NN|rem|sleep|(|remd|) (l_appos) REMD_7\NNP|
D011814_D012892 NONE quipazine_31\NN|remd|)|- (r_pobj) of_28\IN|quipazine (r_prep) completing_27\VBG|of (r_pcomp) after_26\IN|completing (r_prep) increased_22\VBN|hr|after (r_conj) reduced_13\VBN|(|after|)|or|increased (r_conj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_nsubj) hr_3\NN|eight|of (l_prep) of_4\IN|remd (l_pobj) REMD_5\NNP|
D011814_D012892 NONE quipazine_31\NN|remd|)|- (r_pobj) of_28\IN|quipazine (r_prep) completing_27\VBG|of (r_pcomp) after_26\IN|completing (r_prep) increased_22\VBN|hr|after (r_conj) reduced_13\VBN|(|after|)|or|increased (l_prep) after_16\IN|immediately|completing (l_pcomp) completing_17\VBG|of (l_prep) of_18\IN|remd (l_pobj) REMD_19\NNP|
D011814_D012892 NONE quipazine_31\NN|remd|)|- (l_nmod) REMD_29\NNP|
D011814_D001523 NONE quipazine_15\NN| (r_npadvmod) induced_17\VBN|quipazine|- (r_amod) head_18\NN|induced (r_compound) twitches_19\NNS|head|in (r_conj) aggressiveness_13\NN|induced|and|twitches
D011814_D001523 NONE quipazine_31\NN|remd|)|- (r_pobj) of_28\IN|quipazine (r_prep) completing_27\VBG|of (r_pcomp) after_26\IN|completing (r_prep) increased_22\VBN|hr|after (r_conj) reduced_13\VBN|(|after|)|or|increased (r_conj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_dobj) aggressiveness_10\NN|induced
D011814_D009069 CID quipazine_15\NN| (r_npadvmod) induced_17\VBN|quipazine|- (r_amod) head_18\NN|induced (r_compound) twitches_19\NNS|head|in
D011814_D009069 CID quipazine_31\NN|remd|)|- (r_pobj) of_28\IN|quipazine (r_prep) completing_27\VBG|of (r_pcomp) after_26\IN|completing (r_prep) increased_22\VBN|hr|after (r_conj) reduced_13\VBN|(|after|)|or|increased (r_conj) increased_6\VBD|hr|aggressiveness|,|and|reduced|twitches|. (l_conj) twitches_35\NNS|head
2528969
3183120
C033706_D001927 CID tiazofurin_5\NN| (r_compound) usage_6\NN|tiazofurin (r_pobj) with_4\IN|usage (r_prep) associated_3\VBN|with (r_acl) lesions_2\NNS|reversible|cerebral|associated|:|demonstration|.
11912119
D007980_D004409 CID levodopa_3\RB| (r_npadvmod) induced_5\VBN|levodopa|- (r_amod) dyskinesias_6\NNS|induced|in
D007980_D004409 CID levodopa_18\NN| (r_compound) therapy_19\NN|levodopa (r_pobj) of_17\IN|therapy (r_prep) complications_16\NNS|motor|of (r_pobj) to_14\IN|complications (r_prep) relationship_13\NN|its|to (r_conj) disease_10\NN|parkinson|and|relationship (r_pobj) in_7\IN|disease (r_prep) assessed_1\VBD|we|coordination|in|,|to|. (l_prep) to_22\IN|particularly|dyskinesias (l_pobj) dyskinesias_26\NNS|induced|(|lid|)
D007980_D004409 CID levodopa_18\NN| (r_compound) therapy_19\NN|levodopa (r_pobj) of_17\IN|therapy (r_prep) complications_16\NNS|motor|of (r_pobj) to_14\IN|complications (r_prep) relationship_13\NN|its|to (r_conj) disease_10\NN|parkinson|and|relationship (r_pobj) in_7\IN|disease (r_prep) assessed_1\VBD|we|coordination|in|,|to|. (l_prep) to_22\IN|particularly|dyskinesias (l_pobj) dyskinesias_26\NNS|induced|(|lid|) (l_appos) LID_28\NNP|
D007980_D004409 CID levodopa_23\VB| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid|)
D007980_D004409 CID levodopa_23\VB| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid|) (l_appos) LID_28\NNP|
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid (r_pobj) without_22\IN|dyskinesias (r_conj) with_9\IN|disease|)|and|without (l_pobj) disease_13\NN|(|parkinson|+|lid|,|n|23 (l_conj) LID_15\NNP|
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid
D007980_D004409 CID levodopa_23\NN| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid (l_appos) LID_32\NNP|parkinson|disease|-|,|n|10|)|,|and|controls
D007980_D004409 CID levodopa_28\RB|on (r_dobj) assessed_24\VBN|score|were|levodopa|. (l_nsubjpass) score_2\NN|the|motor|of (l_prep) of_3\IN|scale (l_pobj) Scale_10\NNP|parkinson|rating|,|score (l_appos) score_14\NN|a|dyskinesia|and|force|in (l_compound) dyskinesia_13\JJ|
D007980_D004409 CID levodopa_21\NN|(|by|,|p (r_pobj) by_20\IN|levodopa (r_agent) increased_19\VBN|in|,|force|was|significantly|by|)|. (l_prep) In_0\IN|disease (l_pobj) disease_3\NN|parkinson|+|lid (l_conj) LID_5\NNP|
D007980_D010300 NONE levodopa_3\RB| (r_npadvmod) induced_5\VBN|levodopa|- (r_amod) dyskinesias_6\NNS|induced|in (l_prep) in_7\IN|disease (l_pobj) disease_10\NN|parkinson
D007980_D010300 NONE levodopa_18\NN| (r_compound) therapy_19\NN|levodopa (r_pobj) of_17\IN|therapy (r_prep) complications_16\NNS|motor|of (r_pobj) to_14\IN|complications (r_prep) relationship_13\NN|its|to (r_conj) disease_10\NN|parkinson|and|relationship
D007980_D010300 NONE levodopa_23\VB| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid|) (r_pobj) to_22\IN|particularly|dyskinesias (r_prep) assessed_1\VBD|we|coordination|in|,|to|. (l_prep) in_7\IN|disease (l_pobj) disease_10\NN|parkinson|and|relationship
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid (r_pobj) without_22\IN|dyskinesias (r_conj) with_9\IN|disease|)|and|without (r_prep) studied_1\VBD|we|groups|with|. (l_dobj) groups_3\NNS|two|of (l_prep) of_4\IN|patients (l_pobj) patients_8\NNS|parkinson|disease (l_compound) disease_7\NN|
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid (r_pobj) without_22\IN|dyskinesias (r_conj) with_9\IN|disease|)|and|without (l_pobj) disease_13\NN|(|parkinson|+|lid|,|n|23
D007980_D010300 NONE levodopa_23\NN| (r_npadvmod) induced_25\VBN|levodopa|- (r_amod) dyskinesias_26\NNS|induced|(|lid (l_appos) LID_32\NNP|parkinson|disease|-|,|n|10|)|,|and|controls (l_compound) disease_30\NN|
D007980_D010300 NONE levodopa_28\RB|on (r_dobj) assessed_24\VBN|score|were|levodopa|. (l_nsubjpass) score_2\NN|the|motor|of (l_prep) of_3\IN|scale (l_pobj) Scale_10\NNP|parkinson|rating|,|score (l_compound) Rating_9\NNP|disease (l_compound) Disease_8\NNP|
D007980_D010300 NONE levodopa_21\NN|(|by|,|p (r_pobj) by_20\IN|levodopa (r_agent) increased_19\VBN|in|,|force|was|significantly|by|)|. (l_prep) In_0\IN|disease (l_pobj) disease_3\NN|parkinson|+|lid
2004
D013881_D017180 CID Mellaril_8\NNP|thioridazine|) (r_nsubj) appeared_12\VBD|receiving|,|mellaril|be|was|. (l_xcomp) be_14\VB|to|responsible (l_acomp) responsible_15\JJ|for (l_prep) for_16\IN|cases (l_pobj) cases_18\NNS|five|of|, (l_prep) of_19\IN|tachycardia (l_pobj) tachycardia_21\NN|ventricular
D013881_D017180 CID thioridazine_10\NNP|( (r_appos) Mellaril_8\NNP|thioridazine|) (r_nsubj) appeared_12\VBD|receiving|,|mellaril|be|was|. (l_xcomp) be_14\VB|to|responsible (l_acomp) responsible_15\JJ|for (l_prep) for_16\IN|cases (l_pobj) cases_18\NNS|five|of|, (l_prep) of_19\IN|tachycardia (l_pobj) tachycardia_21\NN|ventricular
D002746_D013617 NONE Thorazine_7\NN|chlorpromazine (r_dobj) receiving_6\VBG|thorazine (r_acl) patient_5\NN|one|receiving (r_pobj) in_3\IN|patient (r_prep) developed_2\VBN|tachycardia|in|. (l_nsubj) tachycardia_1\NN|supraventricular
D002746_D013617 NONE chlorpromazine_9\NN|(|) (r_appos) Thorazine_7\NN|chlorpromazine (r_dobj) receiving_6\VBG|thorazine (r_acl) patient_5\NN|one|receiving (r_pobj) in_3\IN|patient (r_prep) developed_2\VBN|tachycardia|in|. (l_nsubj) tachycardia_1\NN|supraventricular
D009661_D002037 CID Aventyl_0\NNP|nortriptyline|elavil (r_nsubj) block_14\NN|aventyl|each|produced|left|branch|in|.
D009661_D002037 CID nortriptyline_2\NN|(|)|and (r_appos) Aventyl_0\NNP|nortriptyline|elavil (r_nsubj) block_14\NN|aventyl|each|produced|left|branch|in|.
D000639_D002037 CID Elavil_5\NNP|amitriptyline (r_conj) Aventyl_0\NNP|nortriptyline|elavil (r_nsubj) block_14\NN|aventyl|each|produced|left|branch|in|.
D000639_D002037 CID amitriptyline_7\FW|(|) (r_appos) Elavil_5\NNP|amitriptyline (r_conj) Aventyl_0\NNP|nortriptyline|elavil (r_nsubj) block_14\NN|aventyl|each|produced|left|branch|in|.
D008012_D001145 NONE lidocaine_8\NN| (r_pobj) of_7\IN|lidocaine (r_prep) administration_6\NN|intravenous|of (r_pobj) to_4\IN|administration|and (r_prep) responded_3\VBD|arrhythmias|to|direct (l_nsubj) arrhythmias_2\NNS|the|ventricular
D011433_D001145 NONE propranolol_27\NN| (r_pobj) of_26\IN|propranolol (r_prep) instances_22\NNS|some|and|administration|of|combined (r_pobj) in_20\IN|instances (r_prep) required_19\VBN|responded|;|pacing|was|in|. (l_ccomp) responded_3\VBD|arrhythmias|to|direct (l_nsubj) arrhythmias_2\NNS|the|ventricular
D010640_D005117 NONE phenothiazines_16\NNS|or|drugs (r_dobj) receiving_15\VBG|phenothiazines (r_acl) patients_14\NNS|receiving (r_pobj) to_13\IN|patients (r_prep) complications_12\NNS|cardiac|to
1535072
D015016_D020018 NONE Yohimbine_0\NNP| (r_compound) treatment_1\NN|yohimbine|of|induced|. (l_prep) of_2\IN|effects (l_pobj) effects_5\NNS|sexual|side
D015016_D020018 NONE yohimbine_6\NN| (r_nsubjpass) used_9\VBN|that|yohimbine|may|be|treat (l_xcomp) treat_11\VB|to|effects (l_dobj) effects_15\NNS|the|side|of
D015016_D020018 NONE yohimbine_3\NN| (r_dobj) evaluated_2\VBD|study|yohimbine|as|. (l_prep) as_4\IN|treatment (l_pobj) treatment_6\NN|a|for (l_prep) for_7\IN|effects (l_pobj) effects_11\NNS|the|sexual|side|caused
D015016_D020018 NONE yohimbine_28\NN| (r_dobj) given_27\VBN|patients|were|yohimbine|on|basis|. (l_nsubjpass) patients_1\NNS|six|with (l_prep) with_2\IN|disorder (l_pobj) disorder_6\NN|either|obsessive|compulsive|,|trichotillomania (l_conj) trichotillomania_8\NN|,|anxiety (l_conj) anxiety_10\NN|,|or|disorders (l_conj) disorders_14\NNS|affective|suffered (l_relcl) suffered_16\VBD|who|effects|after (l_dobj) effects_19\NNS|sexual|side
D015016_D020018 NONE yohimbine_7\NN| (r_nsubj) be_9\VB|that|yohimbine|may|treatment (l_attr) treatment_12\NN|an|effective|for (l_prep) for_13\IN|effects (l_pobj) effects_17\NNS|the|sexual|side|caused
D012701_D020018 NONE serotonin_8\NN| (r_compound) blockers_10\NNS|serotonin|reuptake (r_pobj) by_7\IN|blockers (r_agent) induced_6\VBN|by (r_acl) treatment_1\NN|yohimbine|of|induced|. (l_prep) of_2\IN|effects (l_pobj) effects_5\NNS|sexual|side
D012701_D020018 NONE serotonin_14\NN| (r_compound) blockers_16\NNS|serotonin|reuptake (r_pobj) by_13\IN|blockers (r_agent) caused_12\VBN|by (r_acl) effects_11\NNS|the|sexual|side|caused
D012701_D020018 NONE serotonin_23\NN| (r_compound) blockers_25\NNS|serotonin|reuptake (r_pobj) with_22\IN|blockers (r_prep) treatment_21\NN|with (r_pobj) after_20\IN|treatment (r_prep) suffered_16\VBD|who|effects|after (l_dobj) effects_19\NNS|sexual|side
D012701_D020018 NONE serotonin_20\NN| (r_compound) blockers_22\NNS|serotonin|reuptake (r_pobj) by_19\IN|blockers (r_agent) caused_18\VBN|by (r_acl) effects_17\NNS|the|sexual|side|caused
D015016_D007172 NONE yohimbine_6\NN| (r_nsubj) facilitates_7\VBZ|that|yohimbine|behavior|and|be (l_conj) be_12\VB|may|helpful (l_acomp) helpful_13\JJ|in (l_prep) in_14\IN|treatment (l_pobj) treatment_16\NN|the|of (l_prep) of_17\IN|impotence (l_pobj) impotence_19\NN|male
D002997_D020018 CID clomipramine_17\NN| (r_pobj) of_16\IN|clomipramine (r_prep) effects_15\NNS|the|side|of
D012701_D009771 NONE serotonin_23\NN| (r_compound) blockers_25\NNS|serotonin|reuptake (r_pobj) with_22\IN|blockers (r_prep) treatment_21\NN|with (r_pobj) after_20\IN|treatment (r_prep) suffered_16\VBD|who|effects|after (r_relcl) disorders_14\NNS|affective|suffered (r_conj) anxiety_10\NN|,|or|disorders (r_conj) trichotillomania_8\NN|,|anxiety (r_conj) disorder_6\NN|either|obsessive|compulsive|,|trichotillomania
D012701_D014256 NONE serotonin_23\NN| (r_compound) blockers_25\NNS|serotonin|reuptake (r_pobj) with_22\IN|blockers (r_prep) treatment_21\NN|with (r_pobj) after_20\IN|treatment (r_prep) suffered_16\VBD|who|effects|after (r_relcl) disorders_14\NNS|affective|suffered (r_conj) anxiety_10\NN|,|or|disorders (r_conj) trichotillomania_8\NN|,|anxiety
D012701_D001008 NONE serotonin_23\NN| (r_compound) blockers_25\NNS|serotonin|reuptake (r_pobj) with_22\IN|blockers (r_prep) treatment_21\NN|with (r_pobj) after_20\IN|treatment (r_prep) suffered_16\VBD|who|effects|after (r_relcl) disorders_14\NNS|affective|suffered (r_conj) anxiety_10\NN|,|or|disorders
D012701_D019964 NONE serotonin_23\NN| (r_compound) blockers_25\NNS|serotonin|reuptake (r_pobj) with_22\IN|blockers (r_prep) treatment_21\NN|with (r_pobj) after_20\IN|treatment (r_prep) suffered_16\VBD|who|effects|after (r_relcl) disorders_14\NNS|affective|suffered
D015016_D009771 NONE yohimbine_28\NN| (r_dobj) given_27\VBN|patients|were|yohimbine|on|basis|. (l_nsubjpass) patients_1\NNS|six|with (l_prep) with_2\IN|disorder (l_pobj) disorder_6\NN|either|obsessive|compulsive|,|trichotillomania
D015016_D014256 NONE yohimbine_28\NN| (r_dobj) given_27\VBN|patients|were|yohimbine|on|basis|. (l_nsubjpass) patients_1\NNS|six|with (l_prep) with_2\IN|disorder (l_pobj) disorder_6\NN|either|obsessive|compulsive|,|trichotillomania (l_conj) trichotillomania_8\NN|,|anxiety
D015016_D001008 NONE yohimbine_28\NN| (r_dobj) given_27\VBN|patients|were|yohimbine|on|basis|. (l_nsubjpass) patients_1\NNS|six|with (l_prep) with_2\IN|disorder (l_pobj) disorder_6\NN|either|obsessive|compulsive|,|trichotillomania (l_conj) trichotillomania_8\NN|,|anxiety (l_conj) anxiety_10\NN|,|or|disorders
D015016_D001008 NONE yohimbine_3\NN| (r_pobj) of_2\IN|yohimbine (r_prep) effects_1\NNS|side|of (r_nsubj) included_4\VBD|effects|sweating|. (l_dobj) sweating_6\NN|excessive|,|anxiety (l_conj) anxiety_9\NN|increased|,|and|feeling
D015016_D019964 NONE yohimbine_28\NN| (r_dobj) given_27\VBN|patients|were|yohimbine|on|basis|. (l_nsubjpass) patients_1\NNS|six|with (l_prep) with_2\IN|disorder (l_pobj) disorder_6\NN|either|obsessive|compulsive|,|trichotillomania (l_conj) trichotillomania_8\NN|,|anxiety (l_conj) anxiety_10\NN|,|or|disorders (l_conj) disorders_14\NNS|affective|suffered
3653576
C001335_D058186 CID hexachloro-1:3-butadiene_24\,|(|hcbd|) (r_pobj) of_23\IN|hexachloro-1:3-butadiene (r_prep) administration_22\NN|of (r_pobj) by_21\IN|administration (r_agent) produced_20\VBN|models|were|by|, (l_nsubjpass) models_2\NNS|acute|experimental|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal|to
C001335_D058186 CID HCBD_26\NNP| (r_appos) hexachloro-1:3-butadiene_24\,|(|hcbd|) (r_pobj) of_23\IN|hexachloro-1:3-butadiene (r_prep) administration_22\NN|of (r_pobj) by_21\IN|administration (r_agent) produced_20\VBN|models|were|by|, (l_nsubjpass) models_2\NNS|acute|experimental|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal|to
D011692_D058186 CID aminonucleoside_30\NN| (r_nmod) PAN_32\NNP|aminonucleoside|(|) (r_npadvmod) puromycin_29\NNS|produced|pan|,|and|. (l_ccomp) produced_20\VBN|models|were|by|, (l_nsubjpass) models_2\NNS|acute|experimental|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal|to
D011692_D058186 CID PAN_32\NNP|aminonucleoside|(|) (r_npadvmod) puromycin_29\NNS|produced|pan|,|and|. (l_ccomp) produced_20\VBN|models|were|by|, (l_nsubjpass) models_2\NNS|acute|experimental|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal|to
C004504_D058186 CID 2-bromoethylamine_36\NN|bea|,|respectively (r_punct) ._42\.|2-bromoethylamine (r_punct) puromycin_29\NNS|produced|pan|,|and|. (l_ccomp) produced_20\VBN|models|were|by|, (l_nsubjpass) models_2\NNS|acute|experimental|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal|to
C004504_D058186 CID BEA_38\NNP|(|) (r_nmod) 2-bromoethylamine_36\NN|bea|,|respectively (r_punct) ._42\.|2-bromoethylamine (r_punct) puromycin_29\NNS|produced|pan|,|and|. (l_ccomp) produced_20\VBN|models|were|by|, (l_nsubjpass) models_2\NNS|acute|experimental|of (l_prep) of_3\IN|damage (l_pobj) damage_5\NN|renal|to
C001335_D007674 NONE HCBD_4\NNP|or|bea (r_pobj) by_3\IN|hcbd (r_agent) produced_2\VBN|by (r_acl) damage_1\NN|tubular|produced (r_nsubjpass) discriminated_8\VBN|damage|was|quantitatively|from|. (l_prep) from_13\IN|damage (l_pobj) damage_15\NN|glomerular|produced
C004504_D007674 NONE BEA_6\NNP| (r_conj) HCBD_4\NNP|or|bea (r_pobj) by_3\IN|hcbd (r_agent) produced_2\VBN|by (r_acl) damage_1\NN|tubular|produced (r_nsubjpass) discriminated_8\VBN|damage|was|quantitatively|from|. (l_prep) from_13\IN|damage (l_pobj) damage_15\NN|glomerular|produced
D011692_D007674 NONE PAN_18\NNP| (r_pobj) by_17\IN|pan (r_agent) produced_16\VBN|by (r_acl) damage_15\NN|glomerular|produced
8600333
C053519_D001859 NONE protocol_23\NN|rosen|t5|,|both (r_pobj) to_17\IN|protocol (r_prep) according_16\VBG|to (r_prep) treated_15\VBN|who|were|according (r_relcl) survivors_8\NNS|term|of|treated (l_prep) of_9\IN|tumors (l_pobj) tumors_12\NNS|malignant|bone
D004317_D001859 NONE doxorubicin_27\NN| (r_pobj) including_26\VBG|doxorubicin (r_prep) both_25\DT|including (r_appos) protocol_23\NN|rosen|t5|,|both (r_pobj) to_17\IN|protocol (r_prep) according_16\VBG|to (r_prep) treated_15\VBN|who|were|according (r_relcl) survivors_8\NNS|term|of|treated (l_prep) of_9\IN|tumors (l_pobj) tumors_12\NNS|malignant|bone
D004317_D066126 NONE doxorubicin_3\NN| (r_npadvmod) induced_5\VBN|doxorubicin|- (r_compound) cardiotoxicity_6\NN|induced
6942642
D049971_D007008 NONE Thiazide_0\NNP| (r_compound) diuretics_1\NNS|thiazide|,|hypokalemia|. (l_conj) hypokalemia_3\JJ|and|arrhythmias
D049971_D007008 NONE thiazide_9\NN| (r_compound) therapy_10\NN|chronic|thiazide (r_pobj) of_7\IN|therapy (r_prep) consequence_6\NN|a|encountered|metabolic|of (r_attr) is_1\VBZ|hypokalemia|consequence|. (l_nsubj) Hypokalemia_0\NNP|
D049971_D007008 NONE thiazide_5\JJ|diuretics (r_csubj) cause_7\VBP|that|thiazide|hypokalemia (l_dobj) hypokalemia_8\NN|and|depletion
D049971_D001145 NONE Thiazide_0\NNP| (r_compound) diuretics_1\NNS|thiazide|,|hypokalemia|. (l_conj) hypokalemia_3\JJ|and|arrhythmias (l_conj) arrhythmias_6\NNS|cardiac
D006852_C563897 NONE hydrochlorothiazide_18\NN|hctc|administered (r_pobj) with_17\IN|hydrochlorothiazide (r_prep) hypertension_16\NN|moderate|diastolic|with
D006852_C563897 NONE HCTC_20\NNP|(|) (r_appos) hydrochlorothiazide_18\NN|hctc|administered (r_pobj) with_17\IN|hydrochlorothiazide (r_prep) hypertension_16\NN|moderate|diastolic|with
D011188_D007008 NONE potassium_13\NN|body (r_pobj) of_11\IN|potassium (r_prep) depletion_10\NN|of (r_conj) hypokalemia_8\NN|and|depletion
3137399
D016685_D066126 NONE C._12\NNP|mitomycin (r_pobj) by_10\IN|c. (r_agent) induced_9\VBN|by (r_acl) study_2\NN|a|prospective|on|induced (l_prep) on_3\IN|dependency (l_pobj) dependency_6\NN|the|dose|of (l_prep) of_7\IN|cardiotoxicity (l_pobj) cardiotoxicity_8\NN|
D016685_D066126 NONE C_3\NNP|mitomycin|mmc (r_nsubjpass) suggested_9\VBN|since|c|has|been|be|,|combined|. (l_xcomp) be_11\VB|to|cardiotoxic (l_acomp) cardiotoxic_12\JJ|
D016685_D066126 NONE MMC_5\NN|(|) (r_appos) C_3\NNP|mitomycin|mmc (r_nsubjpass) suggested_9\VBN|since|c|has|been|be|,|combined|. (l_xcomp) be_11\VB|to|cardiotoxic (l_acomp) cardiotoxic_12\JJ|
D016685_D066126 NONE MMC_16\NN| (r_npadvmod) related_18\VBN|mmc|- (r_amod) cardiotoxicity_19\NN|related
D004317_D066126 NONE doxorubicin_21\NN| (r_dobj) following_20\VBG|doxorubicin (r_pcomp) given_19\VBN|following (r_conj) combined_16\VBN|especially|when|with|or|given (r_advcl) suggested_9\VBN|since|c|has|been|be|,|combined|. (l_xcomp) be_11\VB|to|cardiotoxic (l_acomp) cardiotoxic_12\JJ|
D004317_D066126 NONE doxorubicin_47\NN| (r_pobj) with_46\IN|doxorubicin (r_prep) treated_45\VBN|also|(|previously|)|with (r_acl) patients_38\NNS|treated (r_pobj) in_37\IN|mainly|patients (r_prep) is_20\VBZ|that|cardiotoxicity|dependent|,|occurring|,|in (l_nsubj) cardiotoxicity_19\NN|related
D016685_D006333 CID MMC_11\NNP|30|mg|m-2|and|doxorubicin (r_pobj) after_7\IN|mmc (r_prep) developed_4\VBD|one|failure|after|. (l_dobj) failure_6\NN|cardiac
D004317_D006333 CID doxorubicin_17\NN|m-2 (r_conj) MMC_11\NNP|30|mg|m-2|and|doxorubicin (r_pobj) after_7\IN|mmc (r_prep) developed_4\VBD|one|failure|after|. (l_dobj) failure_6\NN|cardiac
15893386
D013390_D014313 CID Succinylcholine_0\NN| (r_npadvmod) induced_2\VBN|succinylcholine|- (r_amod) rigidity_5\NN|induced|masseter|muscle|during|.
D013390_D014313 CID succinylcholine_17\NN| (r_nmod) administration_21\NN|succinylcholine|(|sch|)|during (r_pobj) after_16\IN|administration (r_prep) describe_3\VBP|here|,|we|case|after|. (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|rigidity (l_pobj) rigidity_10\NN|severe|masseter|muscle|(|jaw|)
D013390_D014313 CID succinylcholine_17\NN| (r_nmod) administration_21\NN|succinylcholine|(|sch|)|during (r_pobj) after_16\IN|administration (r_prep) describe_3\VBP|here|,|we|case|after|. (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|rigidity (l_pobj) rigidity_10\NN|severe|masseter|muscle|(|jaw|) (l_appos) jaw_12\NN|of (l_prep) of_13\IN|steel (l_pobj) steel_14\NN|
D013390_D014313 CID Sch_19\NNP| (r_nmod) administration_21\NN|succinylcholine|(|sch|)|during (r_pobj) after_16\IN|administration (r_prep) describe_3\VBP|here|,|we|case|after|. (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|rigidity (l_pobj) rigidity_10\NN|severe|masseter|muscle|(|jaw|)
D013390_D014313 CID Sch_19\NNP| (r_nmod) administration_21\NN|succinylcholine|(|sch|)|during (r_pobj) after_16\IN|administration (r_prep) describe_3\VBP|here|,|we|case|after|. (l_dobj) case_5\NN|a|of (l_prep) of_6\IN|rigidity (l_pobj) rigidity_10\NN|severe|masseter|muscle|(|jaw|) (l_appos) jaw_12\NN|of (l_prep) of_13\IN|steel (l_pobj) steel_14\NN|
D015742_D008305 NONE propofol_5\JJ| (r_amod) infusion_6\NN|propofol (r_pobj) with_4\IN|infusion (r_prep) continued_2\VBN|anesthesia|was|uneventfully|with|were|. (l_advcl) were_10\VBD|while|facilities|available (l_acomp) available_11\JJ|detect (l_xcomp) detect_13\VB|to|and|treat (l_conj) treat_15\VB|hyperthermia (l_dobj) hyperthermia_17\NN|malignant
14648024
D014212_D004893 CID acid_4\NN| (r_npadvmod) induced_6\VBN|acid|- (r_amod) erythema_7\NN|induced (r_compound) nodosum_8\NN|retinoic|erythema|in
D014212_D004893 CID acid_8\NN|all-|retinoic|(|atra|) (r_pobj) with_3\IN|acid (r_prep) associated_2\VBD|with|for (r_acl) nodosum_1\NN|erythema|associated
D014212_D004893 CID ATRA_10\NNP| (r_appos) acid_8\NN|all-|retinoic|(|atra|) (r_pobj) with_3\IN|acid (r_prep) associated_2\VBD|with|for (r_acl) nodosum_1\NN|erythema|associated
D014212_D004893 CID ATRA_12\NNP| (r_compound) therapy_13\NN|atra (r_pobj) during_11\IN|therapy (r_prep) developed_8\VBD|who|nodosum|during (l_dobj) nodosum_10\NN|erythema
D014212_D004893 CID ATRA_23\NNP| (r_compound) therapy_24\NN|atra (r_pobj) after_22\IN|therapy (r_prep) nodules_6\NNS|subsequent|multiple|painful|erythematous|over|,|after
D014212_D004893 CID ATRA_0\NNP| (r_nsubj) seemed_1\VBD|atra|be|. (l_xcomp) be_3\VB|to|etiology (l_attr) etiology_7\NN|the|possible|of (l_prep) of_8\IN|nodosum (l_pobj) nodosum_10\NN|erythema|in
D014212_D004893 CID ATRA_10\NNP| (r_npadvmod) induced_12\VBN|atra|- (r_amod) nodosum_14\NN|induced|erythema
D014212_D015473 NONE acid_4\NN| (r_npadvmod) induced_6\VBN|acid|- (r_amod) erythema_7\NN|induced (r_compound) nodosum_8\NN|retinoic|erythema|in (l_prep) in_9\IN|patients (l_pobj) patients_10\NNS|with (l_prep) with_11\IN|leukemia (l_pobj) leukemia_14\NN|acute|promyelocytic
D014212_D015473 NONE acid_8\NN|all-|retinoic|(|atra|) (r_pobj) with_3\IN|acid (r_prep) associated_2\VBD|with|for (l_prep) for_12\IN|leukemia (l_pobj) leukemia_15\NN|acute|promyelocytic|(|apl|)
D014212_D015473 NONE acid_8\NN|all-|retinoic|(|atra|) (r_pobj) with_3\IN|acid (r_prep) associated_2\VBD|with|for (l_prep) for_12\IN|leukemia (l_pobj) leukemia_15\NN|acute|promyelocytic|(|apl|) (l_appos) APL_17\NNP|
D014212_D015473 NONE ATRA_10\NNP| (r_appos) acid_8\NN|all-|retinoic|(|atra|) (r_pobj) with_3\IN|acid (r_prep) associated_2\VBD|with|for (l_prep) for_12\IN|leukemia (l_pobj) leukemia_15\NN|acute|promyelocytic|(|apl|)
D014212_D015473 NONE ATRA_10\NNP| (r_appos) acid_8\NN|all-|retinoic|(|atra|) (r_pobj) with_3\IN|acid (r_prep) associated_2\VBD|with|for (l_prep) for_12\IN|leukemia (l_pobj) leukemia_15\NN|acute|promyelocytic|(|apl|) (l_appos) APL_17\NNP|
D014212_D015473 NONE ATRA_12\NNP| (r_compound) therapy_13\NN|atra (r_pobj) during_11\IN|therapy (r_prep) developed_8\VBD|who|nodosum|during (r_relcl) APL_6\NNP|classic|developed
D014212_D005334 CID ATRA_23\NNP| (r_compound) therapy_24\NN|atra (r_pobj) after_22\IN|therapy (r_prep) nodules_6\NNS|subsequent|multiple|painful|erythematous|over|,|after (r_conj) Fever_0\NN|and|nodules|.
D014212_D010146 NONE ATRA_23\NNP| (r_compound) therapy_24\NN|atra (r_pobj) after_22\IN|therapy (r_prep) nodules_6\NNS|subsequent|multiple|painful|erythematous|over|,|after (l_amod) painful_4\JJ|
D013256_D004893 NONE steroid_5\NN| (r_pobj) of_4\IN|steroid (r_prep) use_3\NN|term|of (r_nsubj) is_6\VBZ|use|effective|in|. (l_prep) in_9\IN|nodosum (l_pobj) nodosum_14\NN|induced|erythema
19944333
C471405_D009203 NONE Sorafenib_0\NNP| (r_npadvmod) induced_2\VBN|sorafenib|-|infarction|due|. (l_dobj) infarction_5\NN|acute|myocardial
C471405_D003329 CID Sorafenib_0\NNP| (r_npadvmod) induced_2\VBN|sorafenib|-|infarction|due|. (l_prep) due_6\IN|to|spasm (l_pobj) spasm_10\NN|coronary|artery
C471405_D003329 CID sorafenib_6\NN| (r_npadvmod) induced_8\VBN|sorafenib|- (r_amod) spasm_11\NN|induced|coronary|artery
D020108_D060050 NONE nicorandil_3\NN|oral (r_pobj) of_1\IN|nicorandil (r_prep) Addition_0\NN|of (r_nsubj) reduced_4\VBD|addition|symptoms|and|maintained|. (l_conj) maintained_8\VBD|status (l_dobj) status_11\NN|angina (l_compound) angina_10\NN|stable
663266
D003973_D014693 NONE diatrizoate_3\JJ| (r_pobj) from_2\IN|diatrizoate|with (r_prep) fibrillation_1\NN|ventricular|from|.
C027278_D064420 NONE %_5\NN|76 (r_appos) toxicity_1\NN|the|of|%
C027278_D064420 NONE %_13\NN|76|by (r_npadvmod) compared_7\VBN|toxicity|was|with|%|into|. (l_nsubjpass) toxicity_1\NN|the|of|%
D003974_D014693 NONE Renografin_7\NNP| (r_pobj) with_6\IN|renografin (r_prep) occurred_2\VBD|fibrillation|often|with|,|suggesting|. (l_nsubj) fibrillation_1\NN|ventricular
D003974_D064420 NONE Renografin_7\NNP| (r_pobj) with_6\IN|renografin (r_prep) occurred_2\VBD|fibrillation|often|with|,|suggesting|. (l_advcl) suggesting_9\VBG|contribute (l_ccomp) contribute_13\VBP|that|agents|to|in (l_prep) to_14\IN|toxicity (l_pobj) toxicity_15\NN|
6732043
D000728_D020181 CID androgen_12\JJ| (r_compound) administration_13\NN|exogenous|androgen (r_pobj) by_10\IN|administration (r_prep) woman_9\NN|a|by (r_pobj) in_7\IN|woman (r_prep) syndrome_6\NN|the|apnea|in
D000728_D020181 CID androgens_36\NNS|exogenous (r_dobj) administered_34\VBN|while|being|androgens (r_advcl) developed_22\VBN|who|had|changes|administered (l_dobj) changes_24\NNS|physical|and|syndrome (l_conj) syndrome_27\NN|the|of (l_prep) of_28\IN|apnea (l_pobj) apnea_31\NN|obstructive|sleep
D000728_D020181 CID androgen_3\NN| (r_nmod) symptoms_5\NNS|androgen|produced|of|abated (l_prep) of_6\IN|apnea (l_pobj) apnea_9\NN|obstructive|sleep
D000728_D020181 CID androgen_15\NN| (r_compound) therapy_16\NN|androgen (r_pobj) of_14\IN|therapy (r_prep) effect_13\NN|a|possible|side|of (r_oprd) considered_9\VBN|development|must|be|effect|. (l_nsubjpass) Development_0\NN|of (l_prep) of_1\IN|syndrome (l_pobj) syndrome_6\NN|the|apnea
D000728_D012891 NONE androgens_7\NNS| (r_pobj) of_6\IN|androgens (r_prep) role_5\NN|a|of (r_dobj) favored_3\VBN|reports|have|role|in|. (l_prep) in_8\IN|pathogenesis (l_pobj) pathogenesis_10\NN|the|of (l_prep) of_11\IN|apnea (l_pobj) apnea_13\NN|sleep
1504402
D007741_D004342 CID dilevalol_7\NN| (r_npadvmod) associated_9\VBN|dilevalol|- (r_amod) hepatitis_10\NN|associated (r_pobj) for_6\IN|hepatitis (r_prep) mechanism_5\NN|a|for (r_pobj) as_3\IN|mechanism (r_prep) reaction_2\NN|hypersensitivity|immune|as|. (l_nmod) Hypersensitivity_0\NN|
D007741_D056486 CID dilevalol_7\NN| (r_npadvmod) associated_9\VBN|dilevalol|- (r_amod) hepatitis_10\NN|associated
D007741_D056486 CID dilevalol_7\VB|to|and|serum (l_conj) serum_10\VB|to|containing|in (l_prep) in_19\IN|case (l_pobj) case_21\NN|a|of (l_prep) of_22\IN|injury (l_pobj) injury_27\NN|induced|liver
D007741_D056486 CID dilevalol_15\JJ| (r_compound) antigens_16\NNS|putative|ex|vivo|dilevalol|or|metabolites (r_dobj) containing_11\VBG|antigens (r_xcomp) serum_10\VB|to|containing|in (l_prep) in_19\IN|case (l_pobj) case_21\NN|a|of (l_prep) of_22\IN|injury (l_pobj) injury_27\NN|induced|liver
D007741_D056486 CID dilevalol_23\NN| (r_npadvmod) induced_25\VBN|dilevalol|- (r_amod) injury_27\NN|induced|liver
D007741_D056486 CID dilevalol_10\NN| (r_npadvmod) induced_12\VBN|dilevalol|- (r_amod) injury_14\NN|induced|liver
D007741_D056486 CID dilevalol_16\JJ| (r_compound) antigens_17\NNS|ex|prepared|dilevalol (r_dobj) containing_11\VBG|antigens (r_acl) sera_10\NN|containing (r_pobj) to_9\IN|sera (r_prep) sensitization_8\NN|lymphocyte|to (r_pobj) of_6\IN|sensitization (r_prep) detection_5\NN|the|of (r_dobj) allowed_3\VBD|methodology|detection|,|suggesting|. (l_advcl) suggesting_19\VBG|involvement (l_dobj) involvement_21\NN|the|of (l_prep) of_22\IN|mechanism (l_pobj) mechanism_25\NN|an|immunologic|in (l_prep) in_26\IN|injury (l_pobj) injury_31\NN|induced|liver
D007741_D056486 CID dilevalol_27\NN| (r_npadvmod) induced_29\VBN|dilevalol|- (r_amod) injury_31\NN|induced|liver
11858397
D008787_D016171 CID metoclopramide_5\NN| (r_pobj) by_4\IN|metoclopramide (r_agent) induced_3\VBN|by|in|with (r_acl) pointes_2\NNS|torsade|de|induced|.
D008787_D016171 CID metoclopramide_26\NN| (r_pobj) of_25\IN|metoclopramide (r_prep) administration_24\NN|intravenous|of (r_pobj) after_20\IN|administration (r_prep) developed_16\VBD|who|pointes|after (l_dobj) pointes_19\NNS|torsade|de
D008787_D016171 CID metoclopramide_6\NN| (r_nsubj) provokes_7\VBZ|that|metoclopramide|pointes|clinically (l_dobj) pointes_10\FW|torsade|de
D008787_D016171 CID Metoclopramide_0\NNP| (r_nsubjpass) used_3\VBN|metoclopramide|should|be|cautiously|in|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|risk (l_pobj) risk_9\NN|a|of (l_prep) of_10\IN|pointes (l_pobj) pointes_13\FW|torsade|de
D008787_D002037 NONE metoclopramide_5\NN| (r_pobj) by_4\IN|metoclopramide (r_agent) induced_3\VBN|by|in|with (l_prep) with_10\IN|block (l_pobj) block_16\NN|preexisting|complete|left|branch
D008787_D002037 NONE metoclopramide_26\NN| (r_pobj) of_25\IN|metoclopramide (r_prep) administration_24\NN|intravenous|of (r_pobj) after_20\IN|administration (r_prep) developed_16\VBD|who|pointes|after (r_relcl) woman_7\NN|a|old|with|developed (l_prep) with_8\IN|block (l_pobj) block_14\NN|preexisting|complete|left|branch
D020117_D016171 CID cisapride_8\RB|and|erythromycin (r_nsubjpass) given_12\VBN|when|cisapride|were|simultaneously (r_advcl) developed_3\VBD|patient|also|pointes|given|. (l_dobj) pointes_6\FW|torsade|de
D004917_D016171 CID erythromycin_10\NNP| (r_conj) cisapride_8\RB|and|erythromycin (r_nsubjpass) given_12\VBN|when|cisapride|were|simultaneously (r_advcl) developed_3\VBD|patient|also|pointes|given|. (l_dobj) pointes_6\FW|torsade|de
2594614
C045856_D002318 NONE 52021_12\CD| (r_nummod) BN_11\NNP|52021 (r_appos) antagonist_9\NN|a|specific|activating|factor|,|bn|,|on (l_prep) on_14\IN|impairments (l_pobj) impairments_19\NNS|induced|cardiovascular|in
C045856_D002318 NONE 52021_5\CD| (r_nummod) BN_4\NNP|52021 (r_pobj) of_3\IN|bn (r_prep) administration_2\NN|the|of (r_nsubj) alter_14\VB|since|administration|,|at|,|did|not|mbp|at (r_advcl) demonstrate_29\VBP|alter|,|bulk|clearly|action|. (l_dobj) action_32\NN|a|protective|of|,|antagonist|,|against (l_prep) against_43\IN|toxicity (l_pobj) toxicity_48\NN|induced|cardiovascular
C045856_D002318 NONE 52021_35\CD| (r_nummod) BN_34\NNP|52021 (r_pobj) of_33\IN|bn (r_prep) action_32\NN|a|protective|of|,|antagonist|,|against (l_prep) against_43\IN|toxicity (l_pobj) toxicity_48\NN|induced|cardiovascular
D002045_D002318 NONE bupivacaine_15\NN| (r_npadvmod) induced_17\VBN|bupivacaine|- (r_amod) impairments_19\NNS|induced|cardiovascular|in
D002045_D002318 NONE bupivacaine_44\NN| (r_npadvmod) induced_46\VBN|bupivacaine|- (r_amod) toxicity_48\NN|induced|cardiovascular
D002045_D007022 CID bupivacaine_5\NN|the|local|anaesthetic (r_pobj) of_1\IN|bupivacaine (r_prep) Administration_0\NN|of|(|mg/kg|)|to (r_nsubj) elicited_16\VBD|administration|decrease|. (l_dobj) decrease_19\NN|a|marked|of|(|in|) (l_prep) of_20\IN|pressure (l_pobj) pressure_24\NN|mean|arterial|blood|(|mbp|leading (l_appos) MBP_26\NNP|)|and|rate (l_conj) rate_30\NN|heart|(|hr|) (l_punct) )_33\-RRB-|
D002045_D007022 CID bupivacaine_23\NN| (r_compound) administration_24\NN|bupivacaine (r_pobj) before_22\IN|administration (r_prep) min_21\NN|30|before|i.v.|) (r_appos) injection_1\NN|intravenous|of|antagonist|,|min (r_nsubj) suppressed_30\VBD|injection|decrease|. (l_dobj) decrease_33\NN|both|the|of (l_prep) of_34\IN|mbp (l_pobj) MBP_35\NNP|and|hr (l_conj) HR_37\NN|
D002045_D007022 CID bupivacaine_12\NN| (r_pobj) after_11\IN|bupivacaine (r_prep) injected_9\VBN|when|bn|was|immediately|after|mg/kg (r_advcl) observed_29\VBN|injected|,|reversion|was|,|was|. (l_nsubjpass) reversion_20\NN|a|partial|of (l_prep) of_21\IN|decrease (l_pobj) decrease_23\NN|the|of (l_prep) of_24\IN|mbp (l_pobj) MBP_25\NNP|and|hr (l_conj) HR_27\NN|
D002045_D001919 CID bupivacaine_5\NN|the|local|anaesthetic (r_pobj) of_1\IN|bupivacaine (r_prep) Administration_0\NN|of|(|mg/kg|)|to (r_nsubj) elicited_16\VBD|administration|decrease|. (l_dobj) decrease_19\NN|a|marked|of|(|in|) (l_prep) of_20\IN|pressure (l_pobj) pressure_24\NN|mean|arterial|blood|(|mbp|leading (l_appos) MBP_26\NNP|)|and|rate (l_conj) rate_30\NN|heart|(|hr|) (l_punct) )_33\-RRB-|
D002045_D001919 CID bupivacaine_23\NN| (r_compound) administration_24\NN|bupivacaine (r_pobj) before_22\IN|administration (r_prep) min_21\NN|30|before|i.v.|) (r_appos) injection_1\NN|intravenous|of|antagonist|,|min (r_nsubj) suppressed_30\VBD|injection|decrease|. (l_dobj) decrease_33\NN|both|the|of (l_prep) of_34\IN|mbp (l_pobj) MBP_35\NNP|and|hr (l_conj) HR_37\NN|
D002045_D001919 CID bupivacaine_12\NN| (r_pobj) after_11\IN|bupivacaine (r_prep) injected_9\VBN|when|bn|was|immediately|after|mg/kg (r_advcl) observed_29\VBN|injected|,|reversion|was|,|was|. (l_nsubjpass) reversion_20\NN|a|partial|of (l_prep) of_21\IN|decrease (l_pobj) decrease_23\NN|the|of (l_prep) of_24\IN|mbp (l_pobj) MBP_25\NNP|and|hr (l_conj) HR_27\NN|
C045856_D007022 NONE 52021_14\CD|bn (r_appos) antagonist_12\NN|(|paf|)|52021|mg/kg|) (r_appos) injection_1\NN|intravenous|of|antagonist|,|min (r_nsubj) suppressed_30\VBD|injection|decrease|. (l_dobj) decrease_33\NN|both|the|of (l_prep) of_34\IN|mbp (l_pobj) MBP_35\NNP|and|hr (l_conj) HR_37\NN|
C045856_D007022 NONE 52021_2\CD| (r_nummod) BN_1\NNP|52021|mg/kg|i.v.|) (r_nsubjpass) injected_9\VBN|when|bn|was|immediately|after|mg/kg (r_advcl) observed_29\VBN|injected|,|reversion|was|,|was|. (l_nsubjpass) reversion_20\NN|a|partial|of (l_prep) of_21\IN|decrease (l_pobj) decrease_23\NN|the|of (l_prep) of_24\IN|mbp (l_pobj) MBP_25\NNP|and|hr (l_conj) HR_27\NN|
C045856_D001919 NONE 52021_14\CD|bn (r_appos) antagonist_12\NN|(|paf|)|52021|mg/kg|) (r_appos) injection_1\NN|intravenous|of|antagonist|,|min (r_nsubj) suppressed_30\VBD|injection|decrease|. (l_dobj) decrease_33\NN|both|the|of (l_prep) of_34\IN|mbp (l_pobj) MBP_35\NNP|and|hr (l_conj) HR_37\NN|
C045856_D001919 NONE 52021_2\CD| (r_nummod) BN_1\NNP|52021|mg/kg|i.v.|) (r_nsubjpass) injected_9\VBN|when|bn|was|immediately|after|mg/kg (r_advcl) observed_29\VBN|injected|,|reversion|was|,|was|. (l_nsubjpass) reversion_20\NN|a|partial|of (l_prep) of_21\IN|decrease (l_pobj) decrease_23\NN|the|of (l_prep) of_24\IN|mbp (l_pobj) MBP_25\NNP|and|hr (l_conj) HR_27\NN|
D002045_D018376 NONE bupivacaine_16\NN| (r_npadvmod) induced_18\VBN|bupivacaine|- (r_amod) alterations_20\NNS|induced|cardiovascular
430165
D010672_D010291 CID diphenylhydantoin_7\JJ| (r_compound) toxicity_8\NN|diphenylhydantoin (r_pobj) of_6\IN|toxicity (r_prep) manifestation_5\NN|a|rare|of (r_appos) hemiparesis_1\NN|transient|:|manifestation|.
D010672_D010291 CID DPH_10\NNP| (r_compound) overdose_11\NN|dph (r_pobj) due_8\IN|to|overdose (r_prep) suffered_5\VBD|who|hemiparesis|due (l_dobj) hemiparesis_7\NN|progressive
D010672_D064420 NONE diphenylhydantoin_7\JJ| (r_compound) toxicity_8\NN|diphenylhydantoin
D010672_D064420 NONE DPH_13\NNP| (r_compound) toxicity_14\NN|dph
D010672_D062787 CID diphenylhydantoin_6\NN| (r_nmod) overdose_10\NN|diphenylhydantoin|(|dph|)
D010672_D062787 CID DPH_8\NNP| (r_nmod) overdose_10\NN|diphenylhydantoin|(|dph|)
D010672_D062787 CID DPH_10\NNP| (r_compound) overdose_11\NN|dph
D010672_D002526 CID diphenylhydantoin_6\NN| (r_nmod) overdose_10\NN|diphenylhydantoin|(|dph|) (r_pobj) of_5\IN|overdose (r_prep) effects_4\NNS|the|common|side|of (r_pobj) Among_0\IN|effects (r_prep) are_18\VBP|among|,|signs|those|. (l_nsubj) those_19\DT|of (l_prep) of_20\IN|dysfunction (l_pobj) dysfunction_22\NN|cerebellar
D010672_D002526 CID DPH_8\NNP| (r_nmod) overdose_10\NN|diphenylhydantoin|(|dph|) (r_pobj) of_5\IN|overdose (r_prep) effects_4\NNS|the|common|side|of (r_pobj) Among_0\IN|effects (r_prep) are_18\VBP|among|,|signs|those|. (l_nsubj) those_19\DT|of (l_prep) of_20\IN|dysfunction (l_pobj) dysfunction_22\NN|cerebellar
D010672_D001927 NONE DPH_13\NNP| (r_compound) toxicity_14\NN|dph (r_dobj) manifest_12\VB|to|toxicity|as (r_xcomp) liable_10\JJ|manifest (r_acomp) are_9\VBP|that|patients|liable (l_nsubj) patients_4\NNS|with (l_prep) with_5\IN|damage (l_pobj) damage_8\NN|some|cerebral
18086064
D020927_D009203 NONE Dexmedetomidine_0\NNP| (r_nsubjpass) associated_2\VBN|dexmedetomidine|was|with (r_ccomp) mortality_14\NN|associated|;|cause|(|ci|infarction|%|, (l_appos) infarction_35\NN|fatal|myocardial|(|or|,
18674790
D004041_D009765 CID fat_1\JJ| (r_amod) rats_6\NNS|high|fat|fed|obese (l_amod) obese_5\JJ|
D004041_D009765 CID fat_16\JJ| (r_amod) diet_17\NN|%|high|fat|(|hfd|)|,|induces (l_relcl) induces_23\VBZ|which|obesity|g (l_dobj) obesity_24\NN|in
D004041_D066126 NONE fat_1\JJ| (r_amod) rats_6\NNS|high|fat|fed|obese (r_nsubj) are_7\VBP|rats|sensitive|. (l_acomp) sensitive_9\JJ|highly|to (l_prep) to_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_14\NN|induced
D004041_D066126 NONE fat_16\JJ| (r_amod) diet_17\NN|%|high|fat|(|hfd|)|,|induces (r_dobj) feeding_12\VBG|diet (r_pcomp) by_11\IN|feeding (r_prep) intervention_10\NN|a|physiological|by (r_nsubj) sensitizes_38\VBZ|whether|intervention|,|to (l_prep) to_39\IN|cardiotoxicity (l_pobj) cardiotoxicity_43\NN|induced
D004317_D009765 NONE doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|doxorubicin|- (r_compound) cardiotoxicity_14\NN|induced (r_pobj) to_10\IN|cardiotoxicity (r_prep) sensitive_9\JJ|highly|to (r_acomp) are_7\VBP|rats|sensitive|. (l_nsubj) rats_6\NNS|high|fat|fed|obese (l_amod) obese_5\JJ|
D004317_D009765 NONE doxorubicin_40\RB| (r_npadvmod) induced_42\VBN|doxorubicin|- (r_compound) cardiotoxicity_43\NN|induced (r_pobj) to_39\IN|cardiotoxicity (r_prep) sensitizes_38\VBZ|whether|intervention|,|to (l_nsubj) intervention_10\NN|a|physiological|by (l_prep) by_11\IN|feeding (l_pcomp) feeding_12\VBG|diet (l_dobj) diet_17\NN|%|high|fat|(|hfd|)|,|induces (l_relcl) induces_23\VBZ|which|obesity|g (l_dobj) obesity_24\NN|in
D004317_D009765 NONE doxorubicin_7\NN| (r_nmod) kg_9\NNS|(|mg|doxorubicin|/|,|ip|) (r_appos) dose_3\NN|a|ld(10|kg|administered|. (l_acl) administered_13\VBN|on (l_prep) on_14\IN|day (l_pobj) day_15\NN|43 (l_nummod) 43_16\CD|of (l_prep) of_17\IN|regimen (l_pobj) regimen_21\NN|the|hfd|feeding|led (l_acl) led_22\VBD|to (l_prep) to_23\IN|cardiotoxicity (l_pobj) cardiotoxicity_25\NN|higher|,|dysfunction (l_conj) dysfunction_28\NN|cardiac|,|peroxidation (l_conj) peroxidation_31\NN|lipid|,|and|mortality (l_conj) mortality_36\NN|%|in|in (l_prep) in_37\IN|rats (l_pobj) rats_43\NNS|the|obese|(|ob|) (l_amod) obese_39\JJ|
D004317_D009765 NONE doxorubicin_7\NN| (r_nmod) kg_9\NNS|(|mg|doxorubicin|/|,|ip|) (r_appos) dose_3\NN|a|ld(10|kg|administered|. (l_acl) administered_13\VBN|on (l_prep) on_14\IN|day (l_pobj) day_15\NN|43 (l_nummod) 43_16\CD|of (l_prep) of_17\IN|regimen (l_pobj) regimen_21\NN|the|hfd|feeding|led (l_acl) led_22\VBD|to (l_prep) to_23\IN|cardiotoxicity (l_pobj) cardiotoxicity_25\NN|higher|,|dysfunction (l_conj) dysfunction_28\NN|cardiac|,|peroxidation (l_conj) peroxidation_31\NN|lipid|,|and|mortality (l_conj) mortality_36\NN|%|in|in (l_prep) in_37\IN|rats (l_pobj) rats_43\NNS|the|obese|(|ob|) (l_nmod) OB_41\NNP|
D004317_D009765 NONE Doxorubicin_0\NNP| (r_compound) toxicokinetics_1\NNS|doxorubicin (r_compound) studies_2\NNS|toxicokinetics (r_nsubj) revealed_3\VBD|studies|change|. (l_dobj) change_5\NN|no|in|in|)|and|hearts (l_conj) hearts_27\NNS|ob (l_compound) OB_26\NNP|
D004317_D009765 NONE doxorubicin_9\NN|and|doxorubicinol (r_pobj) of_8\IN|doxorubicin (r_prep) accumulation_7\NN|of (r_pobj) in_6\IN|accumulation (r_prep) change_5\NN|no|in|in|)|and|hearts (l_conj) hearts_27\NNS|ob (l_compound) OB_26\NNP|
D004317_D009765 NONE doxorubicin_109\NN| (r_compound) administration_110\NN|doxorubicin (r_pobj) after_108\IN|administration (r_prep) ratio_107\NN|decreased|adp|after (r_pobj) by_102\IN|ratio (r_agent) accompanied_101\VBN|by (r_acl) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (r_ccomp) revealed_2\VBD|studies|sensitized|decreased|. (l_ccomp) sensitized_7\VBN|that|rats|are|due (l_nsubjpass) rats_5\NNS|ob (l_compound) OB_4\NNP|
D004317_D009765 NONE doxorubicin_109\NN| (r_compound) administration_110\NN|doxorubicin (r_pobj) after_108\IN|administration (r_prep) ratio_107\NN|decreased|adp|after (r_pobj) by_102\IN|ratio (r_agent) accompanied_101\VBN|by (r_acl) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (l_nsubj) stress_16\NN|(|1|)|higher|oxyradical|leading|activated (l_acl) activated_35\VBN|downregulation|alpha|oxidation (l_dobj) oxidation_56\NN|decreased|cardiac|acid|(|heart|,|5|) (l_appos) heart_64\NN|min|g|in|versus|) (l_prep) versus_67\IN|heart (l_pobj) heart_74\NN|400.2+/-11.8|g|in (l_prep) in_75\IN|ob (l_pobj) OB_76\NNP|
D004317_D009765 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|doxorubicin|- (r_amod) cardiotoxicity_15\NN|induced (r_pobj) to_11\IN|cardiotoxicity (r_prep) sensitized_10\JJ|highly|to|by (r_acomp) are_8\VBP|in|,|rats|sensitized|. (l_nsubj) rats_7\NNS|induced|obese (l_amod) obese_6\JJ|
D004317_D066126 NONE doxorubicin_11\RB| (r_npadvmod) induced_13\VBN|doxorubicin|- (r_compound) cardiotoxicity_14\NN|induced
D004317_D066126 NONE doxorubicin_4\NN| (r_pobj) by_3\IN|doxorubicin (r_prep) chemotherapy_2\NN|by (r_nsubjpass) limited_9\VBN|often|,|chemotherapy|is|due|. (l_prep) due_10\IN|to|life (l_pobj) life_12\NN|threatening (l_acl) threatening_13\VBG|cardiotoxicity|during (l_dobj) cardiotoxicity_14\NN|in
D004317_D066126 NONE Adriamycin_6\NNP|( (r_punct) )_7\-RRB-|adriamycin (r_punct) is_8\VBZ|) (r_auxpass) limited_9\VBN|often|,|chemotherapy|is|due|. (l_prep) due_10\IN|to|life (l_pobj) life_12\NN|threatening (l_acl) threatening_13\VBG|cardiotoxicity|during (l_dobj) cardiotoxicity_14\NN|in
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|doxorubicin|- (r_amod) cardiotoxicity_15\NN|induced
D004317_D066126 NONE doxorubicin_40\RB| (r_npadvmod) induced_42\VBN|doxorubicin|- (r_compound) cardiotoxicity_43\NN|induced
D004317_D066126 NONE doxorubicin_7\NN| (r_nmod) kg_9\NNS|(|mg|doxorubicin|/|,|ip|) (r_appos) dose_3\NN|a|ld(10|kg|administered|. (l_acl) administered_13\VBN|on (l_prep) on_14\IN|day (l_pobj) day_15\NN|43 (l_nummod) 43_16\CD|of (l_prep) of_17\IN|regimen (l_pobj) regimen_21\NN|the|hfd|feeding|led (l_acl) led_22\VBD|to (l_prep) to_23\IN|cardiotoxicity (l_pobj) cardiotoxicity_25\NN|higher|,|dysfunction
D004317_D066126 NONE doxorubicin_12\RB| (r_npadvmod) induced_14\VBN|doxorubicin|- (r_amod) cardiotoxicity_15\NN|induced
D004317_D006331 CID doxorubicin_7\NN| (r_nmod) kg_9\NNS|(|mg|doxorubicin|/|,|ip|) (r_appos) dose_3\NN|a|ld(10|kg|administered|. (l_acl) administered_13\VBN|on (l_prep) on_14\IN|day (l_pobj) day_15\NN|43 (l_nummod) 43_16\CD|of (l_prep) of_17\IN|regimen (l_pobj) regimen_21\NN|the|hfd|feeding|led (l_acl) led_22\VBD|to (l_prep) to_23\IN|cardiotoxicity (l_pobj) cardiotoxicity_25\NN|higher|,|dysfunction (l_conj) dysfunction_28\NN|cardiac|,|peroxidation
D004317_D007674 NONE doxorubicin_7\NN| (r_nmod) kg_9\NNS|(|mg|doxorubicin|/|,|ip|) (r_appos) dose_3\NN|a|ld(10|kg|administered|. (l_acl) administered_13\VBN|on (l_prep) on_14\IN|day (l_pobj) day_15\NN|43 (l_nummod) 43_16\CD|of (l_prep) of_17\IN|regimen (l_pobj) regimen_21\NN|the|hfd|feeding|led (l_acl) led_22\VBD|to (l_prep) to_23\IN|cardiotoxicity (l_pobj) cardiotoxicity_25\NN|higher|,|dysfunction (l_conj) dysfunction_28\NN|cardiac|,|peroxidation (l_conj) peroxidation_31\NN|lipid|,|and|mortality (l_conj) mortality_36\NN|%|in|in (l_prep) in_44\IN|absence (l_pobj) absence_46\NN|the|of (l_prep) of_47\IN|toxicity (l_pobj) toxicity_53\NN|any|significant|renal
D004317_D056486 NONE doxorubicin_7\NN| (r_nmod) kg_9\NNS|(|mg|doxorubicin|/|,|ip|) (r_appos) dose_3\NN|a|ld(10|kg|administered|. (l_acl) administered_13\VBN|on (l_prep) on_14\IN|day (l_pobj) day_15\NN|43 (l_nummod) 43_16\CD|of (l_prep) of_17\IN|regimen (l_pobj) regimen_21\NN|the|hfd|feeding|led (l_acl) led_22\VBD|to (l_prep) to_23\IN|cardiotoxicity (l_pobj) cardiotoxicity_25\NN|higher|,|dysfunction (l_conj) dysfunction_28\NN|cardiac|,|peroxidation (l_conj) peroxidation_31\NN|lipid|,|and|mortality (l_conj) mortality_36\NN|%|in|in (l_prep) in_44\IN|absence (l_pobj) absence_46\NN|the|of (l_prep) of_47\IN|toxicity (l_pobj) toxicity_53\NN|any|significant|renal
C010013_D009765 NONE doxorubicinol_11\NN|(|metabolite|) (r_conj) doxorubicin_9\NN|and|doxorubicinol (r_pobj) of_8\IN|doxorubicin (r_prep) accumulation_7\NN|of (r_pobj) in_6\IN|accumulation (r_prep) change_5\NN|no|in|in|)|and|hearts (l_conj) hearts_27\NNS|ob (l_compound) OB_26\NNP|
D000249_D009765 NONE AMP_84\NN| (r_compound) alpha2_86\NN|amp|- (r_compound) kinase_88\NN|mitochondrial|alpha2|protein (r_dobj) decreased_82\VBD|stress|kinase|,|and|drop (r_ccomp) revealed_2\VBD|studies|sensitized|decreased|. (l_ccomp) sensitized_7\VBN|that|rats|are|due (l_nsubjpass) rats_5\NNS|ob (l_compound) OB_4\NNP|
D000249_D009765 NONE AMP_84\NN| (r_compound) alpha2_86\NN|amp|- (r_compound) kinase_88\NN|mitochondrial|alpha2|protein (r_dobj) decreased_82\VBD|stress|kinase|,|and|drop (l_nsubj) stress_16\NN|(|1|)|higher|oxyradical|leading|activated (l_acl) activated_35\VBN|downregulation|alpha|oxidation (l_dobj) oxidation_56\NN|decreased|cardiac|acid|(|heart|,|5|) (l_appos) heart_64\NN|min|g|in|versus|) (l_prep) versus_67\IN|heart (l_pobj) heart_74\NN|400.2+/-11.8|g|in (l_prep) in_75\IN|ob (l_pobj) OB_76\NNP|
D000255_D009765 NONE ATP_99\NNP| (r_compound) levels_100\NNS|cardiac|atp (r_pobj) in_97\IN|levels (r_prep) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (r_ccomp) revealed_2\VBD|studies|sensitized|decreased|. (l_ccomp) sensitized_7\VBN|that|rats|are|due (l_nsubjpass) rats_5\NNS|ob (l_compound) OB_4\NNP|
D000255_D009765 NONE ATP_99\NNP| (r_compound) levels_100\NNS|cardiac|atp (r_pobj) in_97\IN|levels (r_prep) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (l_nsubj) stress_16\NN|(|1|)|higher|oxyradical|leading|activated (l_acl) activated_35\VBN|downregulation|alpha|oxidation (l_dobj) oxidation_56\NN|decreased|cardiac|acid|(|heart|,|5|) (l_appos) heart_64\NN|min|g|in|versus|) (l_prep) versus_67\IN|heart (l_pobj) heart_74\NN|400.2+/-11.8|g|in (l_prep) in_75\IN|ob (l_pobj) OB_76\NNP|
D000255_D009765 NONE ATP_104\NNP| (r_nmod) ADP_106\NNP|atp|/ (r_compound) ratio_107\NN|decreased|adp|after (r_pobj) by_102\IN|ratio (r_agent) accompanied_101\VBN|by (r_acl) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (r_ccomp) revealed_2\VBD|studies|sensitized|decreased|. (l_ccomp) sensitized_7\VBN|that|rats|are|due (l_nsubjpass) rats_5\NNS|ob (l_compound) OB_4\NNP|
D000255_D009765 NONE ATP_104\NNP| (r_nmod) ADP_106\NNP|atp|/ (r_compound) ratio_107\NN|decreased|adp|after (r_pobj) by_102\IN|ratio (r_agent) accompanied_101\VBN|by (r_acl) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (l_nsubj) stress_16\NN|(|1|)|higher|oxyradical|leading|activated (l_acl) activated_35\VBN|downregulation|alpha|oxidation (l_dobj) oxidation_56\NN|decreased|cardiac|acid|(|heart|,|5|) (l_appos) heart_64\NN|min|g|in|versus|) (l_prep) versus_67\IN|heart (l_pobj) heart_74\NN|400.2+/-11.8|g|in (l_prep) in_75\IN|ob (l_pobj) OB_76\NNP|
D000255_D009765 NONE ATP_21\NNP| (r_compound) generation_22\NN|cardiac|mitochondrial|atp (r_dobj) downregulating_18\VBG|substantially|generation|,|increasing (r_pcomp) by_16\IN|downregulating (r_prep) sensitized_10\JJ|highly|to|by (r_acomp) are_8\VBP|in|,|rats|sensitized|. (l_nsubj) rats_7\NNS|induced|obese (l_amod) obese_6\JJ|
D000244_D009765 NONE ADP_106\NNP|atp|/ (r_compound) ratio_107\NN|decreased|adp|after (r_pobj) by_102\IN|ratio (r_agent) accompanied_101\VBN|by (r_acl) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (r_ccomp) revealed_2\VBD|studies|sensitized|decreased|. (l_ccomp) sensitized_7\VBN|that|rats|are|due (l_nsubjpass) rats_5\NNS|ob (l_compound) OB_4\NNP|
D000244_D009765 NONE ADP_106\NNP|atp|/ (r_compound) ratio_107\NN|decreased|adp|after (r_pobj) by_102\IN|ratio (r_agent) accompanied_101\VBN|by (r_acl) drop_96\NN|(|6|)|%|in|accompanied (r_conj) decreased_82\VBD|stress|kinase|,|and|drop (l_nsubj) stress_16\NN|(|1|)|higher|oxyradical|leading|activated (l_acl) activated_35\VBN|downregulation|alpha|oxidation (l_dobj) oxidation_56\NN|decreased|cardiac|acid|(|heart|,|5|) (l_appos) heart_64\NN|min|g|in|versus|) (l_prep) versus_67\IN|heart (l_pobj) heart_74\NN|400.2+/-11.8|g|in (l_prep) in_75\IN|ob (l_pobj) OB_76\NNP|
D000255_D066126 NONE ATP_21\NNP| (r_compound) generation_22\NN|cardiac|mitochondrial|atp (r_dobj) downregulating_18\VBG|substantially|generation|,|increasing (r_pcomp) by_16\IN|downregulating (r_prep) sensitized_10\JJ|highly|to|by (l_prep) to_11\IN|cardiotoxicity (l_pobj) cardiotoxicity_15\NN|induced
6203632
D007545_D006332 CID isoproterenol_2\NN| (r_npadvmod) induced_4\VBN|isoproterenol|- (r_amod) hypertrophy_6\NN|induced|cardiac
D007545_D006332 CID isoproterenol_17\NN| (r_pobj) of_16\IN|isoproterenol (r_prep) injections_15\NNS|daily|subcutaneous|of|iso|(|weight|) (r_pobj) following_12\VBG|injections (r_prep) studied_6\VBN|development|was|in|following|. (l_nsubjpass) development_1\NN|the|of (l_prep) of_2\IN|hypertrophy (l_pobj) hypertrophy_4\NN|cardiac
D007545_D006332 CID ISO_19\NN|(|) (r_appos) injections_15\NNS|daily|subcutaneous|of|iso|(|weight|) (r_pobj) following_12\VBG|injections (r_prep) studied_6\VBN|development|was|in|following|. (l_nsubjpass) development_1\NN|the|of (l_prep) of_2\IN|hypertrophy (l_pobj) hypertrophy_4\NN|cardiac
D007545_D006984 NONE ISO_8\NN| (r_pobj) to_7\IN|iso (r_prep) response_6\NN|the|adaptive|to (r_nsubj) shows_9\VBZ|that|response|phase (l_dobj) phase_13\NN|an|early|hypertrophic|(|days|)|characterized (l_amod) hypertrophic_12\JJ|
8686832
D008012_D001416 CID lignocaine_11\NN|hyperbaric|% (r_dobj) involving_7\VBG|lignocaine (r_acl) anaesthesia_6\NN|spinal|involving (r_pobj) after_4\IN|anaesthesia (r_prep) pain_3\NN|back|after
D008012_D001416 CID lignocaine_14\NN|hyperbaric|% (r_pobj) of_10\IN|lignocaine (r_prep) use_9\NN|the|intrathecal|of (r_pobj) with_6\IN|use (r_prep) associated_5\VBN|leg|is|with|. (l_nsubjpass) Leg_0\NNP|and/or|back|pain (l_conj) pain_3\NN|
D000431_D010146 NONE alcohol_27\NN| (r_compound) intake_28\NN|a|high|alcohol|,|be (r_pobj) to_24\IN|intake (r_prep) admitted_23\VBD|to (r_acl) pain_22\NN|admitted (r_pobj) without_21\IN|pain (r_prep) pain_10\NN|and|seven|without
D000431_D010146 NONE alcohol_27\NN| (r_compound) intake_28\NN|a|high|alcohol|,|be (r_pobj) to_24\IN|intake (r_prep) admitted_23\VBD|to (r_acl) pain_22\NN|admitted
8854309
D003042_D011681 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|cocaine|- (r_amod) paranoia_12\NN|induced (r_pobj) of_8\IN|paranoia (r_prep) marker_7\NN|a|of (r_pobj) as_5\IN|marker (r_prep) measure_1\NN|a|of|as|. (l_prep) of_2\IN|oscillation (l_pobj) oscillation_4\NN|pupillary
D003042_D010259 CID cocaine_9\NN| (r_npadvmod) induced_11\VBN|cocaine|- (r_amod) paranoia_12\NN|induced
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) paranoia_3\NN|induced|(|cip|)
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) paranoia_3\NN|induced|(|cip|) (l_appos) CIP_5\NNP|
D003042_D010259 CID Cocaine_0\NN| (r_npadvmod) induced_2\VBN|cocaine|- (r_amod) paranoia_3\NN|induced|(|cip|) (r_nsubj) remains_7\VBZ|paranoia|model|. (l_attr) model_13\NN|an|important|induced|of (l_prep) of_14\IN|paranoia (l_pobj) paranoia_16\NN|idiopathic|emerged
D016578_D011681 NONE cocaine_14\NN| (r_compound) abusers_15\NNS|crack|cocaine|endorsing (r_pobj) of_11\IN|abusers (r_prep) group_10\NN|a|of (r_dobj) distinguish_8\VB|to|significantly|group (r_xcomp) able_5\JJ|distinguish (r_acomp) were_4\VBD|measures|able|. (l_nsubj) Measures_0\NNS|of (l_prep) of_1\IN|oscillation (l_pobj) oscillation_3\NN|pupillary
D016578_D011681 NONE crack_28\NN| (r_compound) addicts_29\NNS|crack (r_pobj) of_27\IN|addicts (r_prep) group_26\NN|another|of|denied (r_pobj) from_24\IN|group (r_prep) endorsing_16\VBG|past|from (r_acl) abusers_15\NNS|crack|cocaine|endorsing (r_pobj) of_11\IN|abusers (r_prep) group_10\NN|a|of (r_dobj) distinguish_8\VB|to|significantly|group (r_xcomp) able_5\JJ|distinguish (r_acomp) were_4\VBD|measures|able|. (l_nsubj) Measures_0\NNS|of (l_prep) of_1\IN|oscillation (l_pobj) oscillation_3\NN|pupillary
D016578_D010259 NONE cocaine_14\NN| (r_compound) abusers_15\NNS|crack|cocaine|endorsing (l_acl) endorsing_16\VBG|past|from (l_prep) past_17\IN|cip (l_pobj) CIP_18\NNP|n
D016578_D010259 NONE cocaine_14\NN| (r_compound) abusers_15\NNS|crack|cocaine|endorsing (l_acl) endorsing_16\VBG|past|from (l_prep) from_24\IN|group (l_pobj) group_26\NN|another|of|denied (l_relcl) denied_31\VBD|who|past (l_prep) past_32\IN|cip (l_pobj) CIP_33\NNP|n
D016578_D010259 NONE crack_28\NN| (r_compound) addicts_29\NNS|crack (r_pobj) of_27\IN|addicts (r_prep) group_26\NN|another|of|denied (r_pobj) from_24\IN|group (r_prep) endorsing_16\VBG|past|from (l_prep) past_17\IN|cip (l_pobj) CIP_18\NNP|n
D016578_D010259 NONE crack_28\NN| (r_compound) addicts_29\NNS|crack (r_pobj) of_27\IN|addicts (r_prep) group_26\NN|another|of|denied (l_relcl) denied_31\VBD|who|past (l_prep) past_32\IN|cip (l_pobj) CIP_33\NNP|n
3535719
D009428_D064420 NONE netilmicin_5\NNS| (r_pobj) of_4\IN|netilmicin (r_prep) toxicity_3\NN|of|and
D014031_D064420 NONE tobramycin_7\JJ|efficacy|in|. (l_nsubj) efficacy_1\NN|relative|and|toxicity (l_conj) toxicity_3\NN|of|and
D009428_D007239 NONE sulfate_9\NN|netilmicin|or|sulfate (r_pobj) of_7\IN|sulfate (r_prep) efficacy_4\NN|the|and|safety|of (r_dobj) compared_2\VBD|we|prospectively|efficacy|in|. (l_prep) in_13\IN|conjunction (l_pobj) conjunction_14\NN|with|in (l_prep) in_18\IN|patients (l_pobj) patients_21\NNS|118|immunocompromised|with (l_prep) with_22\IN|infections (l_pobj) infections_25\NNS|presumed|severe
D014031_D007239 NONE sulfate_12\NN|tobramycin (r_conj) sulfate_9\NN|netilmicin|or|sulfate (r_pobj) of_7\IN|sulfate (r_prep) efficacy_4\NN|the|and|safety|of (r_dobj) compared_2\VBD|we|prospectively|efficacy|in|. (l_prep) in_13\IN|conjunction (l_pobj) conjunction_14\NN|with|in (l_prep) in_18\IN|patients (l_pobj) patients_21\NNS|118|immunocompromised|with (l_prep) with_22\IN|infections (l_pobj) infections_25\NNS|presumed|severe
D010878_D007239 NONE sodium_17\NN|piperacillin (r_pobj) with_15\IN|sodium (r_prep) conjunction_14\NN|with|in (l_prep) in_18\IN|patients (l_pobj) patients_21\NNS|118|immunocompromised|with (l_prep) with_22\IN|infections (l_pobj) infections_25\NNS|presumed|severe
D009428_D007674 CID netilmicin_10\NNS|and|tobramycin (r_pobj) with_9\IN|netilmicin (r_prep) treated_8\VBN|with (r_acl) patients_7\NNS|treated (r_pobj) in_6\IN|patients (r_prep) proportion_5\NN|a|similar|in|(|%|) (r_pobj) in_2\IN|proportion (r_prep) occurred_1\VBD|nephrotoxicity|in|. (l_nsubj) Nephrotoxicity_0\NN|
D014031_D007674 CID tobramycin_12\JJ| (r_conj) netilmicin_10\NNS|and|tobramycin (r_pobj) with_9\IN|netilmicin (r_prep) treated_8\VBN|with (r_acl) patients_7\NNS|treated (r_pobj) in_6\IN|patients (r_prep) proportion_5\NN|a|similar|in|(|%|) (r_pobj) in_2\IN|proportion (r_prep) occurred_1\VBD|nephrotoxicity|in|. (l_nsubj) Nephrotoxicity_0\NN|
D009428_D006311 CID netilmicin_10\NNS|42|and|piperacillin (r_pobj) of_8\IN|netilmicin (r_prep) %_6\NN|four|(|9.5|)|of (r_pobj) in_2\IN|%|and|in (r_prep) occurred_1\VBD|ototoxicity|in|. (l_nsubj) Ototoxicity_0\NN|
D009428_D006311 CID netilmicin_15\NNS| (r_pobj) with_14\IN|netilmicin (r_prep) reversible_13\JJ|often|with|than (r_conj) severe_9\JJ|less|and|reversible (r_acomp) was_7\VBD|that|ototoxicity|severe (l_nsubj) ototoxicity_6\NN|associated
D010878_D006311 CID piperacillin_12\VB| (r_conj) netilmicin_10\NNS|42|and|piperacillin (r_pobj) of_8\IN|netilmicin (r_prep) %_6\NN|four|(|9.5|)|of (r_pobj) in_2\IN|%|and|in (r_prep) occurred_1\VBD|ototoxicity|in|. (l_nsubj) Ototoxicity_0\NN|
D010878_D006311 CID piperacillin_24\NN| (r_npadvmod) treated_26\VBN|piperacillin|- (r_amod) patients_27\NNS|treated (r_conj) tobramycin_22\NNS|54|and|patients (r_pobj) of_20\IN|tobramycin (r_prep) %_18\NN|12|(|22|)|of (r_pobj) in_14\IN|% (r_conj) in_2\IN|%|and|in (r_prep) occurred_1\VBD|ototoxicity|in|. (l_nsubj) Ototoxicity_0\NN|
D014031_D006311 CID tobramycin_22\NNS|54|and|patients (r_pobj) of_20\IN|tobramycin (r_prep) %_18\NN|12|(|22|)|of (r_pobj) in_14\IN|% (r_conj) in_2\IN|%|and|in (r_prep) occurred_1\VBD|ototoxicity|in|. (l_nsubj) Ototoxicity_0\NN|
D014031_D006311 CID tobramycin_18\NNS| (r_pobj) with_17\IN|tobramycin (r_prep) than_16\IN|with (r_prep) reversible_13\JJ|often|with|than (r_conj) severe_9\JJ|less|and|reversible (r_acomp) was_7\VBD|that|ototoxicity|severe (l_nsubj) ototoxicity_6\NN|associated
D000617_D006311 NONE aminoglycoside_3\NN| (r_npadvmod) associated_5\VBN|aminoglycoside|- (r_amod) ototoxicity_6\NN|associated
10091616
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesias_5\NNS|induced|by
D001058_D010300 NONE apomorphine_69\NN| (r_pobj) of_68\IN|apomorphine (r_prep) dose_67\NN|an|effective|single|of (r_pobj) of_63\IN|dose (r_prep) administration_62\NN|of (r_pobj) following_61\VBG|administration (r_prep) worsening_55\VBG|the|of|following (r_pobj) on_53\IN|worsening (r_prep) tasks_52\NNS|)|on (r_dobj) speaking_49\VBG|aloud|tasks (r_dep) evaluate_16\VB|to|role|,|speaking (r_advcl) included_11\VBN|patients|were|in|evaluate|. (l_nsubjpass) patients_1\NNS|ten|had (l_relcl) had_3\VBD|who|disease|with (l_dobj) disease_6\NN|parkinson
D001058_D004409 CID apomorphine_69\NN| (r_pobj) of_68\IN|apomorphine (r_prep) dose_67\NN|an|effective|single|of (r_pobj) of_63\IN|dose (r_prep) administration_62\NN|of (r_pobj) following_61\VBG|administration (r_prep) worsening_55\VBG|the|of|following (r_pobj) on_53\IN|worsening (r_prep) tasks_52\NNS|)|on (r_dobj) speaking_49\VBG|aloud|tasks (r_dep) evaluate_16\VB|to|role|,|speaking (r_advcl) included_11\VBN|patients|were|in|evaluate|. (l_nsubjpass) patients_1\NNS|ten|had (l_relcl) had_3\VBD|who|disease|with (l_prep) with_7\IN|disabling (l_pcomp) disabling_8\VBG|dyskinesia (l_dobj) dyskinesia_9\NN|
D001058_D004409 CID apomorphine_69\NN| (r_pobj) of_68\IN|apomorphine (r_prep) dose_67\NN|an|effective|single|of (r_pobj) of_63\IN|dose (r_prep) administration_62\NN|of (r_pobj) following_61\VBG|administration (r_prep) worsening_55\VBG|the|of|following (l_prep) of_56\IN|dyskinesia (l_pobj) dyskinesia_60\JJ|dose
4090988
D000082_D001749 CID paracetamol_2\NN|of|in (l_prep) of_3\IN|tumours (l_pobj) tumours_7\NNS|bladder
D000082_D001749 CID paracetamol_11\RB| (r_npadvmod) treated_13\VBN|paracetamol|- (r_amod) groups_14\NNS|all|treated (r_pobj) in_9\IN|groups (r_prep) developed_8\VBN|papillomas|in|,|and|bore (l_conj) bore_19\VBD|rats|carcinomas|. (l_dobj) carcinomas_21\NNS|bladder
D000082_D008113 CID paracetamol_2\NN|of|in (l_prep) of_3\IN|tumours (l_pobj) tumours_7\NNS|bladder
D000082_D008113 CID paracetamol_8\NN| (r_npadvmod) treated_10\VBN|paracetamol|- (r_amod) rats_11\NNS|treated (r_pobj) of_7\IN|rats (r_prep) livers_6\NNS|the|of (r_pobj) of_4\IN|livers (r_prep) study_3\NN|an|microscope|of (r_nsubj) revealed_12\VBD|study|changes|. (l_dobj) changes_14\NNS|ultrastructural|in|resemble (l_relcl) resemble_19\VBP|that|those (l_dobj) those_20\DT|result (l_relcl) result_22\NN|that|from (l_prep) from_23\IN|exposure (l_pobj) exposure_24\NN|to (l_prep) to_25\IN|variety (l_pobj) variety_27\NN|a|of (l_prep) of_28\IN|hepatocarcinogens (l_pobj) hepatocarcinogens_30\NNS|known
D000082_D010212 NONE paracetamol_11\RB| (r_npadvmod) treated_13\VBN|paracetamol|- (r_amod) groups_14\NNS|all|treated (r_pobj) in_9\IN|groups (r_prep) developed_8\VBN|papillomas|in|,|and|bore (l_nsubj) Papillomas_0\NNP|of
D000082_D006965 CID paracetamol_7\NN| (r_npadvmod) treated_9\VBN|paracetamol|- (r_amod) rats_10\NNS|treated (r_pobj) of_6\IN|rats (r_prep) %_5\NN|25|of (r_nsubj) developed_11\VBD|additionally|,|%|hyperplasia|. (l_dobj) hyperplasia_12\NN|of
D000082_D001744 NONE paracetamol_7\NN| (r_npadvmod) treated_9\VBN|paracetamol|- (r_amod) rats_10\NNS|treated (r_pobj) of_6\IN|rats (r_prep) %_5\NN|25|of (r_nsubj) developed_11\VBD|additionally|,|%|hyperplasia|. (l_dobj) hyperplasia_12\NN|of (l_prep) of_13\IN|epithelium (l_pobj) epithelium_16\NN|the|bladder|,|was (l_relcl) was_19\VBD|which|not|coincident (l_acomp) coincident_21\JJ|with (l_prep) with_22\IN|presence (l_pobj) presence_24\NN|the|of (l_prep) of_25\IN|calculi (l_pobj) calculi_27\NNS|bladder
D000082_D009369 NONE paracetamol_12\JJ| (r_compound) feeding_13\NN|paracetamol (r_dobj) following_11\VBG|feeding (r_prep) arose_10\VBD|yield|also|following|. (l_nsubj) yield_2\NN|a|low|of|at (l_prep) of_3\IN|tumours (l_pobj) tumours_4\NNS|
8492347
D005665_D013746 CID furosemide_6\NN|surreptitious (r_pobj) due_3\JJ|to|furosemide (r_prep) Tetany_0\NNP|and|rhabdomyolysis|due|--|importance|.
D005665_D012206 CID furosemide_6\NN|surreptitious (r_pobj) due_3\JJ|to|furosemide (r_prep) Tetany_0\NNP|and|rhabdomyolysis|due|--|importance|. (l_conj) rhabdomyolysis_2\NN|
D008274_D013746 NONE magnesium_10\NN| (r_compound) supplementation_11\NN|magnesium (r_pobj) of_9\IN|supplementation (r_prep) importance_8\NN|of (r_appos) Tetany_0\NNP|and|rhabdomyolysis|due|--|importance|.
D008274_D012206 NONE magnesium_10\NN| (r_compound) supplementation_11\NN|magnesium (r_pobj) of_9\IN|supplementation (r_prep) importance_8\NN|of (r_appos) Tetany_0\NNP|and|rhabdomyolysis|due|--|importance|. (l_conj) rhabdomyolysis_2\NN|
D011188_D007008 NONE potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_advcl) cause_4\VB|while|hypokalemia|may|weakness (l_nsubj) hypokalemia_2\NN|severe
D011188_D018908 NONE potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_advcl) cause_4\VB|while|hypokalemia|may|weakness (l_dobj) weakness_6\NN|muscle
D011188_C537153 NONE potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_nsubjpass) hypomagnesemia_9\NN|severe
D011188_D013035 NONE potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_prep) with_12\IN|spasms (l_pobj) spasms_14\NNS|muscle|and|tetany
D011188_D013746 NONE potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_prep) with_12\IN|spasms (l_pobj) spasms_14\NNS|muscle|and|tetany (l_conj) tetany_16\NN|
D002118_D007008 NONE calcium_25\NN| (r_conj) potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_advcl) cause_4\VB|while|hypokalemia|may|weakness (l_nsubj) hypokalemia_2\NN|severe
D002118_D018908 NONE calcium_25\NN| (r_conj) potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_advcl) cause_4\VB|while|hypokalemia|may|weakness (l_dobj) weakness_6\NN|muscle
D002118_C537153 NONE calcium_25\NN| (r_conj) potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_nsubjpass) hypomagnesemia_9\NN|severe
D002118_D013035 NONE calcium_25\NN| (r_conj) potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_prep) with_12\IN|spasms (l_pobj) spasms_14\NNS|muscle|and|tetany
D002118_D013746 NONE calcium_25\NN| (r_conj) potassium_23\NN|and|calcium (r_nmod) supplementation_26\NN|potassium|alone (r_pobj) by_22\IN|supplementation (r_agent) corrected_21\VBN|which|can|not|be|by (r_ccomp) associated_11\VBN|cause|,|hypomagnesemia|is|with|corrected|. (l_prep) with_12\IN|spasms (l_pobj) spasms_14\NNS|muscle|and|tetany (l_conj) tetany_16\NN|
D008274_D007008 NONE magnesium_27\NN| (r_compound) depletion_28\NN|magnesium (r_pobj) of_26\IN|depletion (r_prep) effects_25\NNS|the|of (r_nsubjpass) noted_31\VBN|effects|were|not|in|. (r_conj) observed_19\VBN|in|was|(|8)|,|but|noted (r_conj) reported_4\VBN|hypokalemia|has|been|in|(|3|)|and|observed (l_nsubjpass) hypokalemia_1\NN|symptomatic
D008274_D006996 NONE magnesium_27\NN| (r_compound) depletion_28\NN|magnesium (r_pobj) of_26\IN|depletion (r_prep) effects_25\NNS|the|of (r_nsubjpass) noted_31\VBN|effects|were|not|in|. (r_conj) observed_19\VBN|in|was|(|8)|,|but|noted (l_prep) in_14\IN|hypocalcemia (l_pobj) hypocalcemia_17\NN|one|case
7337133
D000082_D001929 CID acetaminophen_9\NN| (r_compound) overdose_10\NN|acetaminophen (r_pobj) in_8\IN|overdose (r_prep) failure_7\NN|fulminant|hepatic|in (r_pobj) with_4\IN|failure (r_prep) associated_3\VBN|with (r_acl) edema_2\NN|massive|cerebral|associated|:|role|.
D000082_D001929 CID acetaminophen_6\RB| (r_advmod) induced_8\VBN|acetaminophen|- (r_amod) failure_11\NN|fatal|induced|fulminant|hepatic (r_pobj) with_4\IN|failure (r_prep) patient_3\NN|a|with (r_dobj) present_1\VBP|we|patient|,|with|. (l_prep) with_13\IN|signs (l_pobj) signs_14\NNS|and|symptoms|of (l_prep) of_17\IN|edema (l_pobj) edema_19\NN|cerebral|,|unresponsive
D000082_D017093 CID acetaminophen_9\NN| (r_compound) overdose_10\NN|acetaminophen (r_pobj) in_8\IN|overdose (r_prep) failure_7\NN|fulminant|hepatic|in
D000082_D017093 CID acetaminophen_6\RB| (r_advmod) induced_8\VBN|acetaminophen|- (r_amod) failure_11\NN|fatal|induced|fulminant|hepatic
D000082_D062787 NONE acetaminophen_9\NN| (r_compound) overdose_10\NN|acetaminophen
1355091
D011224_D007024 CID prazosin_9\NN|chronic (r_npadvmod) pretreated_11\VBN|prazosin|- (r_amod) conscious_12\JJ|pretreated (r_amod) rats_15\NNS|conscious|hypertensive (r_pobj) in_7\IN|rats (r_prep) blockade_6\NN|alpha|2-adrenoceptor|in (r_pobj) following_3\VBG|blockade (r_prep) occurs_2\VBZ|hypotension|following|. (l_nsubj) hypotension_1\NN|orthostatic
D011224_D007024 CID prazosin_15\NN|(|map|) (r_pobj) with_14\IN|prazosin (r_prep) treated_13\VBN|with (r_acl) hypotension_9\NN|orthostatic|in|treated
D011224_D007024 CID prazosin_22\NN|(|kg-1|) (r_pobj) of_21\IN|prazosin (r_prep) dosing_20\NN|acute|of (r_pobj) after_18\IN|dosing (r_conj) to_16\IN|or|after (r_prep) prior_15\RB|either|to (r_advmod) performed_13\VBN|when|prior (r_advcl) produce_9\VB|tilts|did|not|hypotension|performed|. (l_dobj) hypotension_11\NN|orthostatic
D011224_D006973 NONE prazosin_9\NN|chronic (r_npadvmod) pretreated_11\VBN|prazosin|- (r_amod) conscious_12\JJ|pretreated (r_amod) rats_15\NNS|conscious|hypertensive (l_amod) hypertensive_14\JJ|spontaneously
D011224_D006973 NONE prazosin_7\NN| (r_compound) treatment_8\NN|chronic|prazosin (r_nsubj) alters_9\VBZ|whether|treatment|function|for (l_prep) for_14\IN|control (l_pobj) control_16\NN|orthostatic|of|in (l_prep) in_21\IN|rats (l_pobj) rats_25\NNS|conscious|hypertensive|(|shr|) (l_amod) hypertensive_24\JJ|spontaneously
D015016_D007024 NONE rauwolscine_33\JJ|(|map|) (r_pobj) with_32\IN|rauwolscine (r_prep) treated_31\VBN|with (r_acl) SHR_30\NN|the|treated (r_pobj) in_28\IN|not|shr (r_conj) induced_7\VBN|however|,|tilt|hypotension|,|but|in|. (l_dobj) hypotension_9\NN|orthostatic|in|treated
C014282_D001919 CID cirazoline_9\NN|the|alpha|1-agonist (r_pobj) to_5\IN|cirazoline (r_prep) bradycardia_4\NNS|to
C014282_D001919 CID cirazoline_7\NN| (r_pobj) of_6\IN|cirazoline (r_prep) effects_5\NNS|bradycardia|of (l_amod) bradycardia_4\NN|
C056299_D001919 CID Abbott-53693_22\NNP|the|alpha|2-agonist (r_appos) responses_2\NNS|the|pressor|and|bradycardia|micrograms|kg-1|i.v.|)|,|abbott-53693|kg-1|,|and|noradrenaline (l_conj) bradycardia_4\NNS|to
C056299_D001919 CID Abbott-53693_9\NNP| (r_pobj) of_8\IN|abbott-53693 (r_prep) effects_7\NNS|the|pressor|of (r_nsubj) were_10\VBD|on|,|effects|similar|,|but|was (l_conj) was_22\VBD|bradycardia|greater|. (l_nsubj) bradycardia_21\NN|the|accompanying
D009638_D001919 CID noradrenaline_33\NN|(|0.1|kg-1|i.v.|) (r_conj) responses_2\NNS|the|pressor|and|bradycardia|micrograms|kg-1|i.v.|)|,|abbott-53693|kg-1|,|and|noradrenaline (l_conj) bradycardia_4\NNS|to
D009638_D001919 CID noradrenaline_7\NN| (r_npadvmod) induced_9\VBN|noradrenaline|- (r_amod) effect_11\NN|the|induced|pressor|in (r_dobj) accompanied_5\VBD|that|effect (r_relcl) bradycardia_3\NN|the|accompanied
D011224_D001919 NONE prazosin_51\NN| (r_compound) pretreatment_52\NN|chronic|prazosin (r_pobj) without_49\IN|pretreatment (r_conj) with_47\IN|and|without (r_prep) determined_43\VBN|responses|were|in|with|. (l_nsubjpass) responses_2\NNS|the|pressor|and|bradycardia|micrograms|kg-1|i.v.|)|,|abbott-53693|kg-1|,|and|noradrenaline (l_conj) bradycardia_4\NNS|to
D011224_D001919 NONE prazosin_12\NN|chronic (r_pobj) in_10\IN|prazosin (r_prep) abolished_9\VBN|pressor|were|in|treated|compared|. (l_nsubjpass) pressor_2\NN|both|the|and|effects (l_conj) effects_5\NNS|bradycardia|of (l_amod) bradycardia_4\NN|
D011224_D001919 NONE prazosin_28\NN| (r_compound) treatment_29\NN|chronic|prazosin (r_pobj) with_26\IN|treatment (r_prep) SHR_25\NNP|with (r_pobj) in_24\IN|shr (r_prep) greater_23\JJR|in|than (r_acomp) was_22\VBD|bradycardia|greater|. (l_nsubj) bradycardia_21\NN|the|accompanying
D011224_D001919 NONE prazosin_20\NN| (r_compound) treatment_21\NN|chronic|prazosin (r_pobj) without_18\IN|treatment (r_conj) with_16\IN|and|without (r_prep) similar_15\JJ|with (r_acomp) was_14\VBD|furthermore|,|bradycardia|similar|despite (l_nsubj) bradycardia_3\NN|the|accompanied
3670965
D012459_D012202 NONE salicylates_14\NNS|or|ingestion (r_pobj) with_13\IN|salicylates (r_prep) association_12\NN|with (r_pobj) of_11\IN|association (r_prep) lack_10\NN|a|total|of (r_pobj) despite_7\IN|lack (r_prep) disappearing_4\VBG|syndrome|may|be|from|despite|,|were|. (l_nsubj) syndrome_1\NN|reye
D001241_D012202 CID aspirin_16\JJ| (r_compound) ingestion_17\NN|aspirin (r_conj) salicylates_14\NNS|or|ingestion (r_pobj) with_13\IN|salicylates (r_prep) association_12\NN|with (r_pobj) of_11\IN|association (r_prep) lack_10\NN|a|total|of (r_pobj) despite_7\IN|lack (r_prep) disappearing_4\VBG|syndrome|may|be|from|despite|,|were|. (l_nsubj) syndrome_1\NN|reye
12691807
D007980_D004421 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dystonia|. (l_dobj) dystonia_4\NN|oromandibular|in
D007980_D013494 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dystonia|. (l_dobj) dystonia_4\NN|oromandibular|in (l_prep) in_5\IN|palsy (l_pobj) palsy_8\JJ|progressive|supranuclear
D007980_D013494 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|levodopa|- (r_amod) dystonia_14\NN|reversible|induced|oromandibular|(|omd|) (r_pobj) of_8\IN|dystonia (r_prep) case_7\NN|an|unusual|of|in (l_prep) in_18\IN|patient (l_pobj) patient_21\NN|a|psp (l_compound) PSP_20\NNP|
D007980_D013494 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|levodopa|- (r_amod) dystonia_14\NN|reversible|induced|oromandibular|(|omd|) (r_pobj) of_8\IN|dystonia (r_prep) case_7\NN|an|unusual|of|in (r_dobj) describe_4\VBP|in|we|case|highlight|. (l_advcl) highlight_23\VB|to|importance (l_dobj) importance_25\NN|the|of (l_prep) of_26\IN|recognizing (l_pcomp) recognizing_27\VBG|complication|,|and|discuss (l_dobj) complication_31\NN|this|related|in (l_prep) in_32\IN|management (l_pobj) management_34\NN|the|of (l_prep) of_35\IN|psp (l_pobj) PSP_36\NNP|
D007980_D004409 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced
D007980_D010300 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced (r_nsubjpass) reported_6\VBN|dyskinesias|have|been|in|. (l_prep) in_7\IN|disease (l_pobj) disease_10\NN|parkinson|and|atrophy
D007980_D019578 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesias_3\NNS|induced (r_nsubjpass) reported_6\VBN|dyskinesias|have|been|in|. (l_prep) in_7\IN|disease (l_pobj) disease_10\NN|parkinson|and|atrophy (l_conj) atrophy_14\NN|multiple|system
D007980_D008538 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|levodopa|- (r_amod) dystonia_14\NN|reversible|induced|oromandibular|(|omd|)
D007980_D008538 NONE levodopa_10\NN| (r_npadvmod) induced_12\VBN|levodopa|- (r_amod) dystonia_14\NN|reversible|induced|oromandibular|(|omd|) (l_appos) OMD_16\NNP|
17049862
D010672_D007035 NONE phenytoin_1\JJ| (r_compound) administration_2\NN|phenytoin (r_nsubj) Is_0\VBZ|administration|safe|? (l_acomp) safe_3\JJ|in (l_prep) in_4\IN|child (l_pobj) child_7\NN|a|hypothermic (l_amod) hypothermic_6\JJ|
D010672_D007035 NONE phenytoin_5\NN|and|hypothermia (l_conj) hypothermia_7\NN|
D010672_D007035 NONE phenytoin_2\NN| (r_pobj) of_1\IN|phenytoin (r_prep) Administration_0\NN|of|in (l_prep) in_3\IN|presence (l_pobj) presence_5\NN|the|of (l_prep) of_6\IN|hypothermia (l_pobj) hypothermia_7\NN|
D010672_D012640 NONE phenytoin_1\NN|intravenous (r_nsubjpass) administered_3\VBN|phenytoin|was|during|. (l_prep) during_4\IN|part (l_pobj) part_7\NN|the|later|of (l_prep) of_8\IN|surgery (l_pobj) surgery_10\NN|the|for (l_prep) for_11\IN|prophylaxis (l_pobj) prophylaxis_13\NN|seizure (l_compound) seizure_12\NN|
D010672_D001919 CID phenytoin_1\JJ| (r_compound) administration_2\NN|phenytoin (r_pobj) Following_0\VBG|administration (r_prep) developed_6\VBD|following|,|patient|bradycardia|,|refractory|. (l_dobj) bradycardia_9\NN|acute|severe
D001285_D001919 NONE atropine_13\NN|and|adrenaline (r_pobj) to_12\IN|atropine (r_prep) refractory_11\JJ|to (r_advcl) developed_6\VBD|following|,|patient|bradycardia|,|refractory|. (l_dobj) bradycardia_9\NN|acute|severe
D004837_D001919 NONE adrenaline_15\NN| (r_conj) atropine_13\NN|and|adrenaline (r_pobj) to_12\IN|atropine (r_prep) refractory_11\JJ|to (r_advcl) developed_6\VBD|following|,|patient|bradycardia|,|refractory|. (l_dobj) bradycardia_9\NN|acute|severe
16710500
D004977_D009901 CID Ethambutol_0\NN| (r_npadvmod) associated_2\VBN|ethambutol|- (r_amod) neuropathy_4\NN|associated|optic|.
D004977_D009901 CID ethambutol_3\NN| (r_npadvmod) associated_5\VBN|ethambutol|- (r_amod) neuropathy_8\NNS|associated|optic
D004977_D014376 NONE Ethambutol_2\NNP| (r_nsubjpass) used_4\VBN|introduction|:|ethambutol|is|in|,|and|associated|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of|,|is (l_prep) of_8\IN|tuberculosis (l_pobj) tuberculosis_9\NN|
D004977_D014786 CID Ethambutol_2\NNP| (r_nsubjpass) used_4\VBN|introduction|:|ethambutol|is|in|,|and|associated|. (l_conj) associated_22\VBN|can|be|with (l_prep) with_23\IN|loss (l_pobj) loss_26\NN|permanent|visual
D004977_D014786 CID Ethambutol_0\NNP| (r_compound) usage_1\NN|ethambutol (r_nsubjpass) associated_3\VBN|usage|is|with|and|avoided|. (l_prep) with_4\IN|loss (l_pobj) loss_7\NN|permanent|visual
6504332
D010634_D004409 CID Phenobarbital_0\NN| (r_npadvmod) induced_2\VBN|phenobarbital|- (r_amod) dyskinesia_3\NN|induced|in|.
D010634_D004409 CID phenobarbital_15\JJ| (r_amod) therapy_16\NN|phenobarbital|for (r_dobj) starting_14\VBG|therapy (r_pcomp) after_13\IN|soon|starting (r_prep) developed_9\VBD|child|dyskinesia|after|. (l_dobj) dyskinesia_11\JJ|a
D010634_D004409 CID phenobarbital_4\JJ| (r_pobj) with_3\IN|phenobarbital (r_prep) challenge_2\NN|repeat|with (r_pobj) On_0\IN|challenge (r_prep) recurred_8\VBD|on|,|dyskinesia|. (l_nsubj) dyskinesia_7\NN|the
D010634_D009422 NONE Phenobarbital_0\NN| (r_npadvmod) induced_2\VBN|phenobarbital|- (r_amod) dyskinesia_3\NN|induced|in|. (l_prep) in_4\IN|child (l_pobj) child_9\NN|a|impaired (l_amod) impaired_8\VBN|neurologically|-
D010634_D009422 NONE phenobarbital_15\JJ| (r_amod) therapy_16\NN|phenobarbital|for (r_dobj) starting_14\VBG|therapy (r_pcomp) after_13\IN|soon|starting (r_prep) developed_9\VBD|child|dyskinesia|after|. (l_nsubj) child_4\NN|a|old|with (l_prep) with_5\IN|impairment (l_pobj) impairment_8\NN|known|neurologic
D010634_D012640 NONE phenobarbital_15\JJ| (r_amod) therapy_16\NN|phenobarbital|for (l_prep) for_17\IN|seizures (l_pobj) seizures_18\NNS|
D010634_D009069 NONE Phenobarbital_0\NN| (r_nsubjpass) added_3\VBN|phenobarbital|should|be|to|. (l_prep) to_4\IN|list (l_pobj) list_6\NN|the|of (l_prep) of_7\IN|drugs (l_pobj) drugs_9\NNS|anticonvulsant|cause (l_relcl) cause_12\VB|that|can|disorders (l_dobj) disorders_14\NNS|movement
7647582
D004737_D056486 CID enflurane_4\NN|and|isoflurane (r_conj) anesthetics_2\NNS|two|halogenated|,|enflurane|, (r_nsubjpass) associated_10\VBN|anesthetics|have|been|with|alone|following|. (l_prep) with_11\IN|injury (l_pobj) injury_17\NN|an|type|hepatic
D004737_D056486 CID enflurane_11\NN|by|and/or|isoflurane (r_nsubj) produce_15\VB|supports|enflurane|could|condition|alone|halothane|. (l_dobj) condition_18\NN|a|hypersensitivity|similar (l_amod) similar_19\JJ|to (l_prep) to_20\IN|that (l_pobj) that_21\DT|of (l_prep) of_22\IN|hepatitis (l_pobj) hepatitis_24\NN|halothane
D007530_D056486 CID isoflurane_6\RB| (r_conj) enflurane_4\NN|and|isoflurane (r_conj) anesthetics_2\NNS|two|halogenated|,|enflurane|, (r_nsubjpass) associated_10\VBN|anesthetics|have|been|with|alone|following|. (l_prep) with_11\IN|injury (l_pobj) injury_17\NN|an|type|hepatic
D007530_D056486 CID isoflurane_13\NN| (r_conj) enflurane_11\NN|by|and/or|isoflurane (r_nsubj) produce_15\VB|supports|enflurane|could|condition|alone|halothane|. (l_dobj) condition_18\NN|a|hypersensitivity|similar (l_amod) similar_19\JJ|to (l_prep) to_20\IN|that (l_pobj) that_21\DT|of (l_prep) of_22\IN|hepatitis (l_pobj) hepatitis_24\NN|halothane
D006221_D056486 CID halothane_25\NN|to (r_relcl) exposure_23\NN|previous|halothane (r_pobj) following_21\VBG|exposure (r_agent) associated_10\VBN|anesthetics|have|been|with|alone|following|. (l_prep) with_11\IN|injury (l_pobj) injury_17\NN|an|type|hepatic
D006221_D056486 CID Halothane_0\NNP| (r_compound) hepatitis_1\NN|halothane
D006221_D056486 CID halothane_18\NN| (r_amod) patients_20\NNS|halothane|hepatitis (l_compound) hepatitis_19\NN|
D006221_D056486 CID halothane_23\NN| (r_compound) hepatitis_24\NN|halothane
D006221_D056486 CID halothane_30\NN|to|administration (r_advcl) produce_15\VB|supports|enflurane|could|condition|alone|halothane|. (l_dobj) condition_18\NN|a|hypersensitivity|similar (l_amod) similar_19\JJ|to (l_prep) to_20\IN|that (l_pobj) that_21\DT|of (l_prep) of_22\IN|hepatitis (l_pobj) hepatitis_24\NN|halothane
D014269_D056486 NONE trifluoroacetyl_11\JJ| (r_compound) adduct_12\NN|trifluoroacetyl (r_appos) product_9\NN|a|bound|biotransformation|(|adduct|) (r_pobj) to_3\IN|product (r_prep) response_2\NN|an|antibody|to (r_nsubjpass) detected_16\VBN|response|has|been|on|. (l_prep) on_17\IN|patients (l_pobj) patients_20\NNS|halothane|hepatitis (l_compound) hepatitis_19\NN|
D004737_D004342 NONE enflurane_10\NN|and|isoflurane (l_conj) isoflurane_12\RB|with (l_prep) with_13\IN|hypersensitivity (l_pobj) hypersensitivity_15\NN|the|induced
D004737_D004342 NONE enflurane_11\NN|by|and/or|isoflurane (r_nsubj) produce_15\VB|supports|enflurane|could|condition|alone|halothane|. (l_dobj) condition_18\NN|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN|
D007530_D004342 NONE isoflurane_12\RB|with (l_prep) with_13\IN|hypersensitivity (l_pobj) hypersensitivity_15\NN|the|induced
D007530_D004342 NONE isoflurane_13\NN| (r_conj) enflurane_11\NN|by|and/or|isoflurane (r_nsubj) produce_15\VB|supports|enflurane|could|condition|alone|halothane|. (l_dobj) condition_18\NN|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN|
D006221_D004342 NONE halothane_18\NN| (r_pobj) by_17\IN|halothane (r_agent) induced_16\VBN|by (r_acl) hypersensitivity_15\NN|the|induced
D006221_D004342 NONE halothane_23\NN| (r_compound) hepatitis_24\NN|halothane (r_pobj) of_22\IN|hepatitis (r_prep) that_21\DT|of (r_pobj) to_20\IN|that (r_prep) similar_19\JJ|to (r_amod) condition_18\NN|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN|
D006221_D004342 NONE halothane_30\NN|to|administration (r_advcl) produce_15\VB|supports|enflurane|could|condition|alone|halothane|. (l_dobj) condition_18\NN|a|hypersensitivity|similar (l_compound) hypersensitivity_17\NN|
8441146
D006046_D000741 CID gold_12\NN| (r_pobj) by_11\IN|gold (r_agent) caused_10\VBN|which|was|by|in (r_relcl) anemia_7\NN|severe|aplastic|caused
D010396_D000741 CID penicillamine_19\NN|d|- (r_conj) case_15\NN|one|and|penicillamine|in (r_pobj) in_13\IN|case (r_prep) caused_10\VBN|which|was|by|in (r_relcl) anemia_7\NN|severe|aplastic|caused
19719056
D019342_D010146 NONE acid_9\NN|acetic (r_dobj) using_7\VBG|acid (r_advcl) ascertained_6\VBN|activities|were|using|induced|. (l_conj) induced_10\VBD|writhing (l_xcomp) writhing_11\VBG|model|respectively
D019342_D004487 NONE acid_9\NN|acetic (r_dobj) using_7\VBG|acid (r_advcl) ascertained_6\VBN|activities|were|using|induced|. (l_conj) induced_10\VBD|writhing (l_xcomp) writhing_11\VBG|model|respectively (l_attr) model_12\NN|(|mice (l_appos) mice_14\NNS|)|and|model (l_conj) model_23\NN|induced|rat|paw|edema|, (l_compound) edema_22\NN|
D002351_D010146 CID carrageenan_17\NN| (r_npadvmod) induced_19\VBN|carrageenan|- (r_amod) model_23\NN|induced|rat|paw|edema|, (r_conj) mice_14\NNS|)|and|model (r_appos) model_12\NN|(|mice (r_attr) writhing_11\VBG|model|respectively
D002351_D004487 CID carrageenan_17\NN| (r_npadvmod) induced_19\VBN|carrageenan|- (r_amod) model_23\NN|induced|rat|paw|edema|, (l_compound) edema_22\NN|
1732442
D004317_D009202 CID adriamycin_8\NNS| (r_npadvmod) induced_10\VBN|adriamycin|- (r_amod) cardiomyopathy_11\NN|induced|with
D004317_D009202 CID adriamycin_5\NNS| (r_amod) induced_7\VBN|adriamycin|- (r_amod) cardiomyopathy_8\NN|induced
D004317_D009202 CID adriamycin_5\NNS| (r_amod) induced_7\VBN|adriamycin|- (r_amod) cardiomyopathy_8\NN|induced (r_pobj) of_4\IN|cardiomyopathy (r_prep) model_3\NN|a|rat|of (r_dobj) Using_0\VBG|model (r_advcl) tested_11\VBD|using|,|we|hypothesis|. (l_dobj) hypothesis_13\NN|the|appear (l_acl) appear_21\VB|that|activity|may|and|exacerbated (l_conj) exacerbated_24\VBN|be|dependently (l_advmod) dependently_27\RB|dose|-|in (l_prep) in_28\IN|cardiomyopathy (l_pobj) cardiomyopathy_30\NN|adriamycin
D004317_D009202 CID adriamycin_29\FW| (r_amod) cardiomyopathy_30\NN|adriamycin (r_pobj) in_28\IN|cardiomyopathy (r_prep) dependently_27\RB|dose|-|in (r_advmod) exacerbated_24\VBN|be|dependently (r_conj) appear_21\VB|that|activity|may|and|exacerbated (r_acl) hypothesis_13\NN|the|appear (r_dobj) tested_11\VBD|using|,|we|hypothesis|. (l_advcl) Using_0\VBG|model (l_dobj) model_3\NN|a|rat|of (l_prep) of_4\IN|cardiomyopathy (l_pobj) cardiomyopathy_8\NN|induced
D004317_D009202 CID adriamycin_29\FW| (r_amod) cardiomyopathy_30\NN|adriamycin
D004317_D009202 CID adriamycin_34\NNS| (r_amod) induced_36\VBN|adriamycin|- (r_amod) cardiomyopathy_37\NN|induced (r_pobj) of_33\IN|cardiomyopathy (r_prep) detection_32\NN|of (r_pobj) for_31\IN|detection (r_prep) method_30\NN|a|useful|for (r_attr) be_27\VB|that|scintigraphy|may|method (r_ccomp) indicates_22\VBZ|appearance|be|. (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|activity (l_pobj) activity_7\NN|impaired|cardiac|neuron|in (l_prep) in_8\IN|presence (l_pobj) presence_10\NN|the|of (l_prep) of_11\IN|impairment (l_pobj) impairment_14\NN|slight|myocardial|(|degeneration|)
D004317_D009202 CID adriamycin_34\NNS| (r_amod) induced_36\VBN|adriamycin|- (r_amod) cardiomyopathy_37\NN|induced
D019797_D009202 NONE iodine-125-metaiodobenzylguanidine_13\NNP| (r_pcomp) with_12\IN|iodine-125-metaiodobenzylguanidine (r_prep) cardiomyopathy_11\NN|induced|with
D019797_D009202 NONE MIBG_24\NNP| (r_compound) scintigraphy_25\NN|mibg (r_nsubj) be_27\VB|that|scintigraphy|may|method (r_ccomp) indicates_22\VBZ|appearance|be|. (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|activity (l_pobj) activity_7\NN|impaired|cardiac|neuron|in (l_prep) in_8\IN|presence (l_pobj) presence_10\NN|the|of (l_prep) of_11\IN|impairment (l_pobj) impairment_14\NN|slight|myocardial|(|degeneration|)
D019797_D009202 NONE MIBG_24\NNP| (r_compound) scintigraphy_25\NN|mibg (r_nsubj) be_27\VB|that|scintigraphy|may|method (l_attr) method_30\NN|a|useful|for (l_prep) for_31\IN|detection (l_pobj) detection_32\NN|of (l_prep) of_33\IN|cardiomyopathy (l_pobj) cardiomyopathy_37\NN|induced
D004317_C536522 NONE adriamycin_16\JJ| (r_amod) treatment_17\NN|adriamycin (r_pobj) of_15\IN|treatment (r_prep) duration_14\NN|the|of (r_pobj) to_12\IN|duration (r_prep) relation_11\NN|to (r_pobj) in_10\IN|relation (r_prep) analyzed_9\VBN|degree|was|in|mg/kg|. (l_nsubjpass) degree_1\NN|the|of (l_prep) of_2\IN|degeneration (l_pobj) degeneration_4\NN|vacuolar|of (l_prep) of_5\IN|cells (l_pobj) cells_7\NNS|myocardial
D004317_C536522 NONE adriamycin_34\NNS| (r_amod) induced_36\VBN|adriamycin|- (r_amod) cardiomyopathy_37\NN|induced (r_pobj) of_33\IN|cardiomyopathy (r_prep) detection_32\NN|of (r_pobj) for_31\IN|detection (r_prep) method_30\NN|a|useful|for (r_attr) be_27\VB|that|scintigraphy|may|method (r_ccomp) indicates_22\VBZ|appearance|be|. (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|activity (l_pobj) activity_7\NN|impaired|cardiac|neuron|in (l_prep) in_8\IN|presence (l_pobj) presence_10\NN|the|of (l_prep) of_11\IN|impairment (l_pobj) impairment_14\NN|slight|myocardial|(|degeneration|) (l_appos) degeneration_20\NN|scattered|vacuolar
D019797_C536522 NONE MIBG_24\NNP| (r_compound) scintigraphy_25\NN|mibg (r_nsubj) be_27\VB|that|scintigraphy|may|method (r_ccomp) indicates_22\VBZ|appearance|be|. (l_nsubj) appearance_1\NN|the|of (l_prep) of_2\IN|activity (l_pobj) activity_7\NN|impaired|cardiac|neuron|in (l_prep) in_8\IN|presence (l_pobj) presence_10\NN|the|of (l_prep) of_11\IN|impairment (l_pobj) impairment_14\NN|slight|myocardial|(|degeneration|) (l_appos) degeneration_20\NN|scattered|vacuolar
1728915
D002220_D006331 NONE Carbamazepine_0\NNP| (r_npadvmod) induced_2\VBN|carbamazepine|- (r_amod) dysfunction_4\NN|induced|cardiac|.
D002220_D006331 NONE carbamazepine_11\NN| (r_npadvmod) associated_13\VBN|carbamazepine|- (r_amod) dysfunction_15\NN|associated|cardiac
D002220_D001919 CID carbamazepine_11\NN| (r_pobj) by_10\IN|carbamazepine (r_agent) induced_9\VBN|by (r_acl) patient_1\NN|a|with|,|induced|, (l_prep) with_2\IN|bradycardia (l_pobj) bradycardia_4\NNP|sinus|and|block
D002220_D001919 CID carbamazepine_28\NN| (r_compound) levels_30\NNS|therapeutic|carbamazepine|serum (r_pobj) with_22\IN|levels (r_prep) associated_21\VBN|with (r_advcl) consisted_3\VBD|group|exclusively|associated|. (l_advmod) exclusively_5\RB|almost|of (l_prep) of_6\IN|women (l_pobj) women_8\NNS|elderly|developed|, (l_relcl) developed_10\VBD|who|bradyarrhythmias (l_dobj) bradyarrhythmias_15\NNS|threatening|or|delay
D002220_D054537 CID carbamazepine_11\NN| (r_pobj) by_10\IN|carbamazepine (r_agent) induced_9\VBN|by (r_acl) patient_1\NN|a|with|,|induced|, (l_prep) with_2\IN|bradycardia (l_pobj) bradycardia_4\NNP|sinus|and|block (l_conj) block_7\NN|atrioventricular
D002220_D054537 CID carbamazepine_28\NN| (r_compound) levels_30\NNS|therapeutic|carbamazepine|serum (r_pobj) with_22\IN|levels (r_prep) associated_21\VBN|with (r_advcl) consisted_3\VBD|group|exclusively|associated|. (l_advmod) exclusively_5\RB|almost|of (l_prep) of_6\IN|women (l_pobj) women_8\NNS|elderly|developed|, (l_relcl) developed_10\VBD|who|bradyarrhythmias (l_dobj) bradyarrhythmias_15\NNS|threatening|or|delay (l_conj) delay_19\NN|atrioventricular|conduction
D002220_D013616 CID carbamazepine_12\NN| (r_compound) overdose_13\NN|a|massive|carbamazepine (r_pobj) of_9\IN|overdose (r_prep) setting_8\NN|the|of (r_pobj) in_6\IN|setting (r_prep) developed_3\VBD|group|tachycardias|in|. (l_dobj) tachycardias_5\NNS|sinus
D002220_D062787 NONE carbamazepine_12\NN| (r_compound) overdose_13\NN|a|massive|carbamazepine
D002220_D001523 NONE carbamazepine_1\NN| (r_nsubjpass) used_4\VBN|because|carbamazepine|is|widely|in (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|conditions (l_pobj) conditions_13\NNS|many|neurologic (l_amod) neurologic_10\JJ|and|psychiatric (l_conj) psychiatric_12\JJ|
1445986
D015313_D000743 CID Cefotetan_0\NNP| (r_npadvmod) induced_2\VBN|cefotetan|- (r_amod) anemia_5\NN|induced|immune|hemolytic|.
D010406_D000743 NONE penicillins_17\NNS|and|cephalosporins (r_dobj) receiving_16\VBG|penicillins (r_acl) patients_15\NNS|receiving (r_pobj) in_14\IN|patients (r_prep) described_12\VBN|anemia|has|been|primarily|in|. (l_nsubjpass) anemia_2\NN|immune|hemolytic|due
D002511_D000743 NONE cephalosporins_22\NNS|generation (r_conj) penicillins_17\NNS|and|cephalosporins (r_dobj) receiving_16\VBG|penicillins (r_acl) patients_15\NNS|receiving (r_pobj) in_14\IN|patients (r_prep) described_12\VBN|anemia|has|been|primarily|in|. (l_nsubjpass) anemia_2\NN|immune|hemolytic|due
D015313_D000740 NONE cefotetan_10\NN|intravenous (r_dobj) receiving_8\VBG|while|cefotetan (r_advcl) developed_5\VBD|who|anemia|receiving (l_dobj) anemia_6\NN|
12109865
17490790
D007505_D009410 CID dextran_2\NN|peripheral|iron (r_nsubj) induced_3\VBD|dextran|degeneration|. (l_dobj) degeneration_4\NN|of (l_prep) of_5\IN|neurons (l_pobj) neurons_7\NNS|dopaminergic|in
D007505_D009410 CID dextran_66\NN| (r_amod) animals_68\NNS|iron|dextran|overloaded (r_pobj) of_64\IN|animals (r_prep) SN_63\NN|the|of (r_pobj) in_61\IN|sn (r_prep) content_60\NN|increased|iron|in (r_conj) staining_40\NN|perls|iron|,|and|detection|content (l_conj) detection_49\NN|performance|liquid|electrochemical|study|and (l_acl) study_51\VB|to|degeneration (l_dobj) degeneration_53\NN|the|of (l_prep) of_54\IN|neurons (l_pobj) neurons_56\NNS|dopaminergic
D007505_D009410 CID dextran_6\NN|peripheral|iron (r_nsubj) increase_8\VB|that|dextran|can|level (l_dobj) level_11\NN|the|iron|in|,|causes (l_relcl) causes_19\VBZ|where|iron|degeneration (l_dobj) degeneration_21\NN|the|of (l_prep) of_22\IN|neurons (l_pobj) neurons_24\NNS|dopaminergic
D007501_D010300 NONE Iron_0\NN| (r_compound) accumulation_1\NN|iron (r_nsubjpass) considered_3\VBN|accumulation|is|involved|. (l_xcomp) involved_6\VBN|to|be|in (l_prep) in_7\IN|pathogenesis (l_pobj) pathogenesis_9\NN|the|of (l_prep) of_10\IN|disease (l_pobj) disease_13\NN|parkinson
D007501_D009410 NONE iron_6\NN| (r_compound) overload_7\NN|peripheral|iron|and|loss (r_pobj) between_4\IN|overload (r_prep) relationship_3\NN|the|between (r_dobj) demonstrate_1\VB|to|relationship (r_advcl) used_25\VBD|demonstrate|,|in|we|voltammetry|. (l_dobj) voltammetry_28\NN|fast|cyclic|,|immunohistochemistry (l_conj) immunohistochemistry_35\NN|tyrosine|hydroxylase|(|th|)|,|staining (l_conj) staining_40\NN|perls|iron|,|and|detection|content (l_conj) detection_49\NN|performance|liquid|electrochemical|study|and (l_acl) study_51\VB|to|degeneration (l_dobj) degeneration_53\NN|the|of (l_prep) of_54\IN|neurons (l_pobj) neurons_56\NNS|dopaminergic
D007501_D009410 NONE iron_39\NN| (r_compound) staining_40\NN|perls|iron|,|and|detection|content (l_conj) detection_49\NN|performance|liquid|electrochemical|study|and (l_acl) study_51\VB|to|degeneration (l_dobj) degeneration_53\NN|the|of (l_prep) of_54\IN|neurons (l_pobj) neurons_56\NNS|dopaminergic
D007501_D009410 NONE iron_59\NN| (r_compound) content_60\NN|increased|iron|in (r_conj) staining_40\NN|perls|iron|,|and|detection|content (l_conj) detection_49\NN|performance|liquid|electrochemical|study|and (l_acl) study_51\VB|to|degeneration (l_dobj) degeneration_53\NN|the|of (l_prep) of_54\IN|neurons (l_pobj) neurons_56\NNS|dopaminergic
D007501_D009410 NONE iron_10\NN| (r_compound) level_11\NN|the|iron|in|,|causes (l_relcl) causes_19\VBZ|where|iron|degeneration (l_dobj) degeneration_21\NN|the|of (l_prep) of_22\IN|neurons (l_pobj) neurons_24\NNS|dopaminergic
D007501_D009410 NONE iron_18\NN|excessive (r_nsubj) causes_19\VBZ|where|iron|degeneration (l_dobj) degeneration_21\NN|the|of (l_prep) of_22\IN|neurons (l_pobj) neurons_24\NNS|dopaminergic
D014443_D009410 NONE tyrosine_30\NN| (r_det) immunohistochemistry_35\NN|tyrosine|hydroxylase|(|th|)|,|staining (l_conj) staining_40\NN|perls|iron|,|and|detection|content (l_conj) detection_49\NN|performance|liquid|electrochemical|study|and (l_acl) study_51\VB|to|degeneration (l_dobj) degeneration_53\NN|the|of (l_prep) of_54\IN|neurons (l_pobj) neurons_56\NNS|dopaminergic
19923525
D009553_D008569 NONE Nimodipine_0\NNP| (r_nsubj) prevents_1\VBZ|nimodipine|impairment|. (l_dobj) impairment_3\NN|memory|caused
D009553_D007022 NONE Nimodipine_0\NNP| (r_nsubj) prevents_1\VBZ|nimodipine|impairment|. (l_dobj) impairment_3\NN|memory|caused (l_acl) caused_4\VBN|by (l_agent) by_5\IN|hypotension (l_pobj) hypotension_9\NN|induced|in
D009553_D007022 NONE nimodipine_5\NN|that|(|nimo|) (r_nsubj) administered_9\VBN|nimodipine|at (r_acl) hypothesis_3\NN|the|administered (r_dobj) tested_1\VBD|we|hypothesis (r_ccomp) preserve_19\VB|tested|(|hypotension|would|memory|. (l_nsubj) hypotension_17\NN|ntg)-induced
D009553_D007022 NONE NIMO_7\NNP| (r_appos) nimodipine_5\NN|that|(|nimo|) (r_nsubj) administered_9\VBN|nimodipine|at (r_acl) hypothesis_3\NN|the|administered (r_dobj) tested_1\VBD|we|hypothesis (r_ccomp) preserve_19\VB|tested|(|hypotension|would|memory|. (l_nsubj) hypotension_17\NN|ntg)-induced
D009553_D007022 NONE NIMO_27\NN| (r_conj) NTG_25\NNP|+|nimo (r_appos) saline_23\NN|,|ntg (r_pobj) with_22\IN|saline (r_prep) injected_21\VBN|with (r_acl) those_20\DT|injected (r_pobj) with_19\IN|those (r_prep) compared_18\VBN|with (r_prep) showed_5\VBD|decrease|compared|,|or|delayed (r_conj) subjected_1\VBN|mice|to|showed|. (l_prep) to_2\IN|episodes (l_pobj) episodes_4\NNS|hypotensive (l_amod) hypotensive_3\JJ|
D009553_D007022 NONE NIMO_0\NN| (r_advmod) attenuated_1\VBD|nimo|disruption|but|improve|. (l_conj) improve_17\VB|did|not|latency|in (l_prep) in_19\IN|absence (l_pobj) absence_21\NN|the|of (l_prep) of_22\IN|hypotension (l_pobj) hypotension_23\NN|
D009553_D007022 NONE NIMO_4\NNP| (r_pobj) of_3\IN|nimo (r_prep) effect_2\NN|the|observed|of (r_nsubj) been_7\VBN|effect|may|have|attributable|,|were|. (l_acomp) attributable_8\JJ|to (l_prep) to_9\IN|preservation (l_pobj) preservation_11\NN|the|of|during (l_prep) during_15\IN|hypotension (l_pobj) hypotension_16\NN|
D005996_D008569 CID nitroglycerin_6\NN| (r_npadvmod) induced_8\VBN|nitroglycerin|- (r_amod) hypotension_9\NN|induced|in (r_pobj) by_5\IN|hypotension (r_agent) caused_4\VBN|by (r_acl) impairment_3\NN|memory|caused
D005996_D007022 CID nitroglycerin_6\NN| (r_npadvmod) induced_8\VBN|nitroglycerin|- (r_amod) hypotension_9\NN|induced|in
D005996_D007022 CID nitroglycerin_14\NN| (r_pobj) of_13\IN|nitroglycerin (r_prep) onset_12\NN|the|of (r_pobj) at_10\IN|onset (r_prep) administered_9\VBN|nimodipine|at (r_acl) hypothesis_3\NN|the|administered (r_dobj) tested_1\VBD|we|hypothesis (r_ccomp) preserve_19\VB|tested|(|hypotension|would|memory|. (l_nsubj) hypotension_17\NN|ntg)-induced
D005996_D007022 CID NTG)-induced_16\JJ| (r_amod) hypotension_17\NN|ntg)-induced
D005996_D007022 CID NTG_25\NNP|+|nimo (r_appos) saline_23\NN|,|ntg (r_pobj) with_22\IN|saline (r_prep) injected_21\VBN|with (r_acl) those_20\DT|injected (r_pobj) with_19\IN|those (r_prep) compared_18\VBN|with (r_prep) showed_5\VBD|decrease|compared|,|or|delayed (r_conj) subjected_1\VBN|mice|to|showed|. (l_prep) to_2\IN|episodes (l_pobj) episodes_4\NNS|hypotensive (l_amod) hypotensive_3\JJ|
D005996_D007022 CID NTG_31\NNP|(|s|s|, (r_dobj) delayed_30\VBN|ntg|respectively|) (r_conj) showed_5\VBD|decrease|compared|,|or|delayed (r_conj) subjected_1\VBN|mice|to|showed|. (l_prep) to_2\IN|episodes (l_pobj) episodes_4\NNS|hypotensive (l_amod) hypotensive_3\JJ|
D005996_D007022 CID NTG_9\NNP| (r_pobj) of_8\IN|ntg (r_prep) injection_7\NN|the|of (r_nsubj) produced_13\VBD|in|,|injection|after|impairment|,|had|. (l_conj) had_30\VBD|delayed|effect (l_advcl) delayed_27\VBN|whereas|hypotension (l_dobj) hypotension_29\NN|induced
D005996_D007022 CID NTG_13\NNP| (r_pobj) by_12\IN|ntg (r_agent) caused_11\VBN|by (r_acl) memory_10\NN|term|caused (r_pobj) of_6\IN|memory (r_prep) consolidation_5\NN|of (r_pobj) in_4\IN|consolidation (r_prep) disruption_3\NN|the|in (r_dobj) attenuated_1\VBD|nimo|disruption|but|improve|. (l_conj) improve_17\VB|did|not|latency|in (l_prep) in_19\IN|absence (l_pobj) absence_21\NN|the|of (l_prep) of_22\IN|hypotension (l_pobj) hypotension_23\NN|
D002118_D007022 NONE calcium_13\NN| (r_compound) homeostasis_14\NN|calcium (r_pobj) of_12\IN|homeostasis (r_prep) preservation_11\NN|the|of|during (l_prep) during_15\IN|hypotension (l_pobj) hypotension_16\NN|
2716967
D007649_D002375 CID ketamine_5\NN|and|morphine (r_pobj) of_4\IN|ketamine (r_prep) combinations_3\NNS|of|:|potentiation (r_pobj) by_2\IN|combinations (r_agent) induced_1\VBN|catalepsy|by|. (l_nsubj) Catalepsy_0\NNP|
D007649_D002375 CID ketamine_5\NN|both|and|morphine (r_nsubj) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D007649_D002375 CID ketamine_5\NN|both|and|morphine (r_nsubj) induced_8\VBN|that|ketamine|analgesia (r_ccomp) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_advcl) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D007649_D002375 CID ketamine_20\NN| (r_pobj) with_19\IN|ketamine (r_prep) treatment_18\NN|-|with (r_nsubj) produced_21\VBD|treatment (r_amod) tolerance_24\NN|produced|cross|-|to (r_dobj) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D007649_D002375 CID ketamine_20\NN| (r_pobj) with_19\IN|ketamine (r_prep) treatment_18\NN|-|with (r_nsubj) produced_21\VBD|treatment (r_amod) tolerance_24\NN|produced|cross|-|to (r_dobj) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_advcl) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D007649_D002375 CID ketamine_39\NN| (r_pobj) to_38\IN|ketamine (r_prep) tolerance_37\NN|cross|-|to (r_dobj) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (r_advcl) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D007649_D002375 CID ketamine_39\NN| (r_pobj) to_38\IN|ketamine (r_prep) tolerance_37\NN|cross|-|to (r_dobj) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D009020_D002375 CID morphine_7\NN| (r_conj) ketamine_5\NN|and|morphine (r_pobj) of_4\IN|ketamine (r_prep) combinations_3\NNS|of|:|potentiation (r_pobj) by_2\IN|combinations (r_agent) induced_1\VBN|catalepsy|by|. (l_nsubj) Catalepsy_0\NNP|
D009020_D002375 CID morphine_7\NN| (r_conj) ketamine_5\NN|both|and|morphine (r_nsubj) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D009020_D002375 CID morphine_7\NN| (r_conj) ketamine_5\NN|both|and|morphine (r_nsubj) induced_8\VBN|that|ketamine|analgesia (r_ccomp) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_advcl) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D009020_D002375 CID morphine_26\NN| (r_pobj) to_25\IN|morphine (r_prep) tolerance_24\NN|produced|cross|-|to (r_dobj) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D009020_D002375 CID morphine_26\NN| (r_pobj) to_25\IN|morphine (r_prep) tolerance_24\NN|produced|cross|-|to (r_dobj) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_advcl) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D009020_D002375 CID morphine_31\NN| (r_pobj) with_30\IN|morphine (r_prep) pretreatment_29\NN|with (r_nsubj) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (r_advcl) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D009020_D002375 CID morphine_31\NN| (r_pobj) with_30\IN|morphine (r_prep) pretreatment_29\NN|with (r_nsubj) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D009020_D002375 CID morphine_53\NN|residual|in (r_pobj) to_51\IN|morphine (r_prep) attributed_50\VBN|demonstrated|;|augmentation|was|to|. (l_ccomp) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in (l_conj) catalepsy_11\NN|
D009020_D002375 CID morphine_53\NN|residual|in (r_pobj) to_51\IN|morphine (r_prep) attributed_50\VBN|demonstrated|;|augmentation|was|to|. (l_ccomp) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_advcl) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (l_conj) augmented_42\VBD|rather|response (l_dobj) response_45\NN|the|cataleptic (l_amod) cataleptic_44\JJ|
D007649_D000699 NONE ketamine_5\NN|both|and|morphine (r_nsubj) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D007649_D000699 NONE ketamine_20\NN| (r_pobj) with_19\IN|ketamine (r_prep) treatment_18\NN|-|with (r_nsubj) produced_21\VBD|treatment (r_amod) tolerance_24\NN|produced|cross|-|to (r_dobj) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D007649_D000699 NONE ketamine_39\NN| (r_pobj) to_38\IN|ketamine (r_prep) tolerance_37\NN|cross|-|to (r_dobj) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (r_advcl) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D009020_D000699 NONE morphine_7\NN| (r_conj) ketamine_5\NN|both|and|morphine (r_nsubj) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D009020_D000699 NONE morphine_26\NN| (r_pobj) to_25\IN|morphine (r_prep) tolerance_24\NN|produced|cross|-|to (r_dobj) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D009020_D000699 NONE morphine_31\NN| (r_pobj) with_30\IN|morphine (r_prep) pretreatment_29\NN|with (r_nsubj) induce_34\VB|whereas|pretreatment|did|not|tolerance|but|augmented (r_advcl) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D009020_D000699 NONE morphine_53\NN|residual|in (r_pobj) to_51\IN|morphine (r_prep) attributed_50\VBN|demonstrated|;|augmentation|was|to|. (l_ccomp) demonstrated_2\VBD|studies|induced|tolerance|,|induce (l_ccomp) induced_8\VBN|that|ketamine|analgesia (l_dobj) analgesia_9\NN|and|catalepsy|in
D007649_D009127 NONE ketamine_19\NN|or|morphine (r_pobj) of_18\IN|ketamine (r_prep) predominance_17\NN|the|relative|of|in (r_dobj) reflected_14\VBD|latency|,|predominance|. (l_nsubj) Latency_0\NN|to (l_prep) to_1\IN|loss (l_pobj) loss_3\NN|the|of (l_prep) of_4\IN|reflex (l_pobj) reflex_6\NN|righting|,|rigidity (l_conj) rigidity_8\NN|and|behavior|on
D009020_D009127 NONE morphine_21\NN| (r_conj) ketamine_19\NN|or|morphine (r_pobj) of_18\IN|ketamine (r_prep) predominance_17\NN|the|relative|of|in (r_dobj) reflected_14\VBD|latency|,|predominance|. (l_nsubj) Latency_0\NN|to (l_prep) to_1\IN|loss (l_pobj) loss_3\NN|the|of (l_prep) of_4\IN|reflex (l_pobj) reflex_6\NN|righting|,|rigidity (l_conj) rigidity_8\NN|and|behavior|on
D009270_D002375 NONE Naloxone_0\NN| (r_nsubj) inhibited_1\VBD|naloxone|effects|. (l_dobj) effects_5\NNS|the|induced|cataleptic (l_amod) cataleptic_4\JJ|
D009270_D002375 NONE naloxone_36\NN| (r_pobj) for_35\IN|naloxone (r_prep) ID50_34\NNP|a|different|for (r_conj) asymmetry_24\NN|of|and|id50 (r_conj) differences_16\NNS|in|,|asymmetry (r_conj) catalepsy_14\NN|the|induced|,|differences
D009270_D009127 NONE naloxone_36\NN| (r_pobj) for_35\IN|naloxone (r_prep) ID50_34\NNP|a|different|for (r_conj) asymmetry_24\NN|of|and|id50 (r_conj) differences_16\NNS|in|,|asymmetry (l_prep) in_17\IN|latency (l_pobj) latency_18\NN|,|rigidity (l_conj) rigidity_20\NN|and|behavior
8988571
D003042_D003693 CID cocaine_4\NN| (r_compound) use_5\NN|cocaine (r_dobj) following_3\VBG|use (r_acl) delirium_2\NN|fatal|excited|following
D003042_D003693 CID cocaine_15\NN| (r_compound) toxicity_16\NN|cocaine (r_pobj) of_14\IN|toxicity (r_prep) mechanisms_13\NNS|of (r_pobj) for_12\IN|mechanisms (r_prep) evidence_11\NN|new|for (r_dobj) provide_9\VBP|delirium|:|findings|evidence|. (l_dep) delirium_2\NN|fatal|excited|following
D003042_D003693 CID cocaine_7\NN| (r_npadvmod) induced_9\VBN|cocaine|- (r_amod) delirium_11\NN|induced|excited|(|edds|between
D003042_D003693 CID cocaine_7\NN| (r_npadvmod) induced_9\VBN|cocaine|- (r_amod) delirium_11\NN|induced|excited|(|edds|between (l_appos) EDDs_13\NNP|)|in
D003042_D003693 CID cocaine_5\NN| (r_npadvmod) related_7\VBN|cocaine|- (r_amod) deaths_8\NNS|all|related|in (r_pobj) of_3\IN|deaths (r_prep) registry_2\NN|a|of (r_pobj) From_0\IN|registry (r_prep) compared_23\VBN|from|,|from|,|edds|were|with|. (l_nsubjpass) EDDs_21\NNS|58
D003042_D003693 CID cocaine_5\NN| (r_npadvmod) related_7\VBN|cocaine|- (r_amod) deaths_8\NNS|all|related|in (r_pobj) of_3\IN|deaths (r_prep) registry_2\NN|a|of (r_pobj) From_0\IN|registry (r_prep) compared_23\VBN|from|,|from|,|edds|were|with|. (l_prep) with_24\IN|victims (l_pobj) victims_26\NNS|125|of|without (l_prep) without_31\IN|delirium (l_pobj) delirium_33\NN|excited
D003042_D003693 CID cocaine_29\NN| (r_compound) overdose_30\NN|accidental|cocaine (r_pobj) of_27\IN|overdose (r_prep) victims_26\NNS|125|of|without (r_pobj) with_24\IN|victims (r_prep) compared_23\VBN|from|,|from|,|edds|were|with|. (l_nsubjpass) EDDs_21\NNS|58
D003042_D003693 CID cocaine_29\NN| (r_compound) overdose_30\NN|accidental|cocaine (r_pobj) of_27\IN|overdose (r_prep) victims_26\NNS|125|of|without (l_prep) without_31\IN|delirium (l_pobj) delirium_33\NN|excited
D003042_D003693 CID cocaine_4\NN|and|benzoylecgonine (r_pobj) of_3\IN|cocaine (r_prep) concentrations_2\NNS|of|in|were (r_dobj) had_1\VBD|edds|concentrations|. (l_nsubj) EDDs_0\NNS|
D003042_D003693 CID cocaine_11\NN| (r_compound) use_12\NN|chronic|cocaine (r_nsubj) disrupts_13\VBZ|that|use|function|and (r_acl) hypothesis_8\NN|the|disrupts (r_pobj) with_6\IN|hypothesis (r_prep) consistent_5\JJ|most|with (r_acomp) are_3\VBP|findings|consistent|,|precipitate|. (l_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium (l_conj) delirium_29\NN|,|thermoregulation
D003042_D003693 CID cocaine_22\NN| (r_compound) use_23\NN|recent|cocaine (r_pobj) with_20\IN|use (r_prep) coupled_19\VBN|when|with (r_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium (l_conj) delirium_29\NN|,|thermoregulation
D003042_D064420 NONE cocaine_4\NN| (r_compound) use_5\NN|cocaine (r_dobj) following_3\VBG|use (r_acl) delirium_2\NN|fatal|excited|following (r_dep) provide_9\VBP|delirium|:|findings|evidence|. (l_dobj) evidence_11\NN|new|for (l_prep) for_12\IN|mechanisms (l_pobj) mechanisms_13\NNS|of (l_prep) of_14\IN|toxicity (l_pobj) toxicity_16\NN|cocaine
D003042_D064420 NONE cocaine_15\NN| (r_compound) toxicity_16\NN|cocaine
D003042_D062787 NONE cocaine_5\NN| (r_npadvmod) related_7\VBN|cocaine|- (r_amod) deaths_8\NNS|all|related|in (r_pobj) of_3\IN|deaths (r_prep) registry_2\NN|a|of (r_pobj) From_0\IN|registry (r_prep) compared_23\VBN|from|,|from|,|edds|were|with|. (l_prep) with_24\IN|victims (l_pobj) victims_26\NNS|125|of|without (l_prep) of_27\IN|overdose (l_pobj) overdose_30\NN|accidental|cocaine
D003042_D062787 NONE cocaine_29\NN| (r_compound) overdose_30\NN|accidental|cocaine
C005618_D003693 NONE benzoylecgonine_6\NN| (r_conj) cocaine_4\NN|and|benzoylecgonine (r_pobj) of_3\IN|cocaine (r_prep) concentrations_2\NNS|of|in|were (r_dobj) had_1\VBD|edds|concentrations|. (l_nsubj) EDDs_0\NNS|
D003042_D011595 NONE cocaine_11\NN| (r_compound) use_12\NN|chronic|cocaine (r_nsubj) disrupts_13\VBZ|that|use|function|and (r_acl) hypothesis_8\NN|the|disrupts (r_pobj) with_6\IN|hypothesis (r_prep) consistent_5\JJ|most|with (r_acomp) are_3\VBP|findings|consistent|,|precipitate|. (l_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium
D003042_D011595 NONE cocaine_22\NN| (r_compound) use_23\NN|recent|cocaine (r_pobj) with_20\IN|use (r_prep) coupled_19\VBN|when|with (r_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium
D003042_D012206 CID cocaine_11\NN| (r_compound) use_12\NN|chronic|cocaine (r_nsubj) disrupts_13\VBZ|that|use|function|and (r_acl) hypothesis_8\NN|the|disrupts (r_pobj) with_6\IN|hypothesis (r_prep) consistent_5\JJ|most|with (r_acomp) are_3\VBP|findings|consistent|,|precipitate|. (l_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium (l_conj) delirium_29\NN|,|thermoregulation (l_conj) thermoregulation_32\NN|aberrant|,|rhabdomyolysis (l_conj) rhabdomyolysis_34\NN|,|and|death
D003042_D012206 CID cocaine_22\NN| (r_compound) use_23\NN|recent|cocaine (r_pobj) with_20\IN|use (r_prep) coupled_19\VBN|when|with (r_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium (l_conj) delirium_29\NN|,|thermoregulation (l_conj) thermoregulation_32\NN|aberrant|,|rhabdomyolysis (l_conj) rhabdomyolysis_34\NN|,|and|death
D003042_D003645 CID cocaine_11\NN| (r_compound) use_12\NN|chronic|cocaine (r_nsubj) disrupts_13\VBZ|that|use|function|and (r_acl) hypothesis_8\NN|the|disrupts (r_pobj) with_6\IN|hypothesis (r_prep) consistent_5\JJ|most|with (r_acomp) are_3\VBP|findings|consistent|,|precipitate|. (l_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium (l_conj) delirium_29\NN|,|thermoregulation (l_conj) thermoregulation_32\NN|aberrant|,|rhabdomyolysis (l_conj) rhabdomyolysis_34\NN|,|and|death (l_conj) death_38\NN|sudden
D003042_D003645 CID cocaine_22\NN| (r_compound) use_23\NN|recent|cocaine (r_pobj) with_20\IN|use (r_prep) coupled_19\VBN|when|with (r_advcl) precipitate_26\VB|coupled|,|may|agitation (l_dobj) agitation_27\NN|,|delirium (l_conj) delirium_29\NN|,|thermoregulation (l_conj) thermoregulation_32\NN|aberrant|,|rhabdomyolysis (l_conj) rhabdomyolysis_34\NN|,|and|death (l_conj) death_38\NN|sudden
19105845
D016642_D012640 CID hydrochloride_8\NN| (r_npadvmod) induced_10\VBN|hydrochloride|- (r_amod) seizures_11\NNS|induced|in
D016642_D012640 CID bupropion_15\NN| (r_npadvmod) induced_17\VBN|bupropion|- (r_amod) seizures_18\NNS|induced
D016642_D012640 CID HCl_12\NNP|bupropion (r_pobj) of_10\IN|hcl (r_prep) rates_9\NNS|the|intraperitoneal|infusion|of (r_dobj) varying_5\VBG|rates|mg/kg (r_pcomp) of_4\IN|varying (r_prep) effect_3\NN|the|of|,|cd50 (l_appos) CD50_22\NNP|a|convulsive|dose|(|) (l_amod) convulsive_18\JJ|known
D016642_D012640 CID HCl_12\NNP|bupropion (r_pobj) of_10\IN|hcl (r_prep) rates_9\NNS|the|intraperitoneal|infusion|of (r_dobj) varying_5\VBG|rates|mg/kg (r_pcomp) of_4\IN|varying (r_prep) effect_3\NN|the|of|,|cd50 (r_dobj) investigated_1\VBD|we|effect|,|on|. (l_prep) on_25\IN|incidence (l_pobj) incidence_27\NN|the|and|severity|of (l_prep) of_30\IN|convulsions (l_pobj) convulsions_34\NNS|induced|in
D016642_D012640 CID bupropion_31\NN| (r_npadvmod) induced_33\VBN|bupropion|- (r_amod) convulsions_34\NNS|induced|in (r_pobj) of_30\IN|convulsions (r_prep) incidence_27\NN|the|and|severity|of (r_pobj) on_25\IN|incidence (r_prep) investigated_1\VBD|we|effect|,|on|. (l_dobj) effect_3\NN|the|of|,|cd50 (l_appos) CD50_22\NNP|a|convulsive|dose|(|) (l_amod) convulsive_18\JJ|known
D016642_D012640 CID bupropion_31\NN| (r_npadvmod) induced_33\VBN|bupropion|- (r_amod) convulsions_34\NNS|induced|in
D016642_D012640 CID HCl_9\NNP|that|administration (r_ccomp) showed_3\VBD|:|results|hcl|mg/kg|by|induced|%|. (l_advcl) induced_15\VBD|convulsions (l_dobj) convulsions_16\NNS|in
D016642_D012640 CID HCl_27\NNP|bupropion (r_pobj) of_25\IN|hcl (r_prep) time_24\NN|the|infusion|of (r_dobj) increasing_20\VBG|time|mg/kg (r_conj) ratio_15\NN|;|odds|=|0.974|)|and|increasing (r_nsubjpass) associated_31\VBN|ratio|was|with|compared (l_prep) with_32\IN|odds (l_pobj) odds_37\NNS|a|%|reduced|of (l_prep) of_38\IN|convulsions (l_pobj) convulsions_39\NNS|at
D016642_D012640 CID bupropion_19\NN| (r_pobj) of_18\IN|bupropion (r_prep) dose_17\NN|a|fixed|of|and|risk (l_amod) fixed_14\JJ|and|convulsive (l_conj) convulsive_16\JJ|
D016642_D012640 CID bupropion_19\NN| (r_pobj) of_18\IN|bupropion (r_prep) dose_17\NN|a|fixed|of|and|risk (l_conj) risk_22\NN|the|of (l_prep) of_23\IN|convulsions (l_pobj) convulsions_24\NNS|in
11195262
D014635_D007177 CID valproate_3\NN|contribution|to|. (l_prep) to_4\IN|syndrome (l_pobj) syndrome_6\NN|the|of (l_prep) of_7\IN|secretion (l_pobj) secretion_9\NN|inappropriate|of (l_prep) of_10\IN|hormone (l_pobj) hormone_12\NN|antidiuretic
D014635_D007177 CID valproate_14\NN|(|vpa|)|and|developed (l_conj) developed_21\VBD|who|subsequently|syndrome (l_dobj) syndrome_23\NN|the|of (l_prep) of_24\IN|secretion (l_pobj) secretion_26\NN|inappropriate|of (l_prep) of_27\IN|hormone (l_pobj) hormone_29\NN|antidiuretic|(|siadh|)
D014635_D007177 CID valproate_14\NN|(|vpa|)|and|developed (l_conj) developed_21\VBD|who|subsequently|syndrome (l_dobj) syndrome_23\NN|the|of (l_prep) of_24\IN|secretion (l_pobj) secretion_26\NN|inappropriate|of (l_prep) of_27\IN|hormone (l_pobj) hormone_29\NN|antidiuretic|(|siadh|) (l_appos) SIADH_31\NNP|
D014635_D007177 CID VPA_16\NNP| (r_npadvmod) valproate_14\NN|(|vpa|)|and|developed (l_conj) developed_21\VBD|who|subsequently|syndrome (l_dobj) syndrome_23\NN|the|of (l_prep) of_24\IN|secretion (l_pobj) secretion_26\NN|inappropriate|of (l_prep) of_27\IN|hormone (l_pobj) hormone_29\NN|antidiuretic|(|siadh|)
D014635_D007177 CID VPA_16\NNP| (r_npadvmod) valproate_14\NN|(|vpa|)|and|developed (l_conj) developed_21\VBD|who|subsequently|syndrome (l_dobj) syndrome_23\NN|the|of (l_prep) of_24\IN|secretion (l_pobj) secretion_26\NN|inappropriate|of (l_prep) of_27\IN|hormone (l_pobj) hormone_29\NN|antidiuretic|(|siadh|) (l_appos) SIADH_31\NNP|
D014635_D007177 CID VPA_30\NNP| (r_pobj) of_29\IN|vpa (r_prep) administration_28\NN|the|term|of (r_conj) weakness_17\NN|a|of|and|administration (r_pobj) including_15\VBG|weakness (r_prep) factors_14\NNS|including (r_pobj) of_13\IN|factors (r_prep) combination_12\NN|a|of (r_pobj) of_10\IN|combination (r_prep) result_9\NN|the|of (r_attr) be_7\VB|episode|to|result (l_nsubj) episode_3\NN|this|of (l_prep) of_4\IN|siadh (l_pobj) SIADH_5\NNP|
D014635_D004830 NONE VPA_4\NNP| (r_dobj) taking_3\VBG|he|had|been|vpa|for|was|. (l_prep) for_5\IN|treatment (l_pobj) treatment_6\NN|of (l_prep) of_7\IN|convulsions (l_pobj) convulsions_13\NNS|idiopathic|generalized|clonic
D014635_D002493 NONE VPA_30\NNP| (r_pobj) of_29\IN|vpa (r_prep) administration_28\NN|the|term|of (r_conj) weakness_17\NN|a|of|and|administration (l_prep) of_18\IN|system (l_pobj) system_22\NN|the|central|nervous
3088349
D000661_D009069 CID amphetamine_17\NN| (r_pobj) by_16\IN|amphetamine (r_prep) exhaustion_15\NN|by (r_pobj) to_14\TO|exhaustion (r_prep) reflects_8\VBZ|rotation|susceptibility|to|. (l_nsubj) rotation_2\NN|transient|contralateral|following
D000661_D009069 CID amphetamine_26\NN| (r_npadvmod) induced_28\VBN|amphetamine|- (r_amod) behavior_30\NN|induced|rotational (r_pobj) on_25\IN|behavior (r_prep) examined_12\VBD|in|we|effect|,|on|. (l_prep) In_0\IN|order (l_pobj) order_1\NN|clarify (l_acl) clarify_3\VB|to|nature (l_dobj) nature_5\NN|the|of (l_prep) of_6\IN|rotation (l_pobj) rotation_10\NN|this|initial|contralateral
D000661_D009069 CID amphetamine_26\NN| (r_npadvmod) induced_28\VBN|amphetamine|- (r_amod) behavior_30\NN|induced|rotational
D000661_D009069 CID amphetamine_10\NN| (r_nsubjpass) administered_12\VBN|when|amphetamine|was|for (r_advcl) was_6\VBD|degree|still|evident|administered|,|indicating|. (l_advcl) indicating_22\VBG|involvement (l_dobj) involvement_23\NN|of (l_prep) of_24\IN|cells (l_pobj) cells_26\NNS|spared|in (l_prep) in_27\IN|rotation (l_pobj) rotation_30\NN|the|contralateral
D000661_D009069 CID amphetamine_16\NN| (r_compound) dose_17\NN|amphetamine|,|or|exercise (r_conj) volume_14\NN|either|lesion|,|dose (r_pobj) of_11\IN|volume (r_prep) irrespective_10\RB|of (r_conj) duration_5\NN|the|of|(|and|irrespective (r_pobj) of_3\IN|duration (r_prep) regardless_2\RB|of (r_advmod) tended_31\VBD|however|,|regardless|,|rotation|become|,|and|circled (l_nsubj) rotation_30\NN|induced
D000661_D009069 CID amphetamine_27\NN| (r_npadvmod) induced_29\VBN|amphetamine|- (r_amod) rotation_30\NN|induced
D000661_D009069 CID amphetamine_55\NN| (r_compound) injections_56\NNS|further|amphetamine (r_pobj) to_53\IN|injections (r_prep) response_52\NN|to (r_pobj) in_51\IN|response (r_prep) circled_46\VBD|rats|ipsilaterally|to|in|. (r_conj) tended_31\VBD|however|,|regardless|,|rotation|become|,|and|circled (l_nsubj) rotation_30\NN|induced
D000661_D009069 CID amphetamine_4\NN| (r_nsubj) has_5\VBZ|that|amphetamine|effect (l_dobj) effect_8\NN|an|irreversible|on (l_prep) on_9\IN|pool (l_pobj) pool_15\NN|the|lesion|da|contributing (l_acl) contributing_16\VBG|to (l_prep) to_17\IN|rotation (l_pobj) rotation_19\NN|contralateral
D000661_-1 NONE amphetamine_17\NN| (r_pobj) by_16\IN|amphetamine (r_prep) exhaustion_15\NN|by (r_pobj) to_14\TO|exhaustion (r_prep) reflects_8\VBZ|rotation|susceptibility|to|. (l_nsubj) rotation_2\NN|transient|contralateral|following (l_prep) following_3\VBG|lesion (l_pobj) lesion_7\NN|unilateral|nigra
D016627_-1 NONE 6-OHDA_2\CD|unilateral (r_pobj) Following_0\VBG|6-ohda (r_prep) induced_3\VBN|following|lesion (l_dobj) lesion_5\NN|sn|,
D016627_D009069 NONE 6-OHDA_2\CD|unilateral (r_pobj) Following_0\VBG|6-ohda (r_prep) induced_3\VBN|following|lesion (r_ccomp) reported_15\VBN|induced|period|has|been|precede|. (l_nsubjpass) period_9\NN|a|transient|of (l_prep) of_10\IN|rotation (l_pobj) rotation_12\NN|contralateral
D016627_D009069 NONE 6-OHDA_2\CD|unilateral (r_pobj) Following_0\VBG|6-ohda (r_prep) induced_3\VBN|following|lesion (r_ccomp) reported_15\VBN|induced|period|has|been|precede|. (l_xcomp) precede_17\VB|to|circling (l_dobj) circling_21\NN|the|predominant|ipsilateral
11243580
D008012_D012640 CID lidocaine_6\NN| (r_npadvmod) induced_8\VBN|lidocaine|- (r_amod) convulsion_9\NN|induced|in
D008012_D012640 CID lidocaine_38\NN| (r_npadvmod) induced_40\VBN|lidocaine|- (r_amod) convulsions_41\NNS|induced
D008012_D012640 CID lidocaine_20\NN| (r_pobj) of_19\IN|lidocaine (r_prep) incidence_18\NN|the|of|convulsions (l_appos) convulsions_26\NNS|kg)-induced
D008012_D012640 CID lidocaine_12\NN| (r_pobj) of_11\IN|lidocaine (r_prep) incidence_10\NN|the|of|(|mg/kg|,|convulsions (l_appos) convulsions_18\NNS|i.p.)-induced|significantly
D008012_D012640 CID lidocaine_11\NN| (r_npadvmod) induced_13\VBN|lidocaine|- (r_amod) convulsions_14\NNS|induced
D019331_D012640 NONE ester_12\NN|methyl|(|name|)|oxide (r_pobj) of_2\IN|ester (r_prep) effects_1\NNS|the|of (r_nsubjpass) investigated_36\VBN|effects|,|were|on|. (l_prep) on_37\IN|convulsions (l_pobj) convulsions_41\NNS|induced
D019331_D012640 NONE NAME_16\NN|l|- (r_appos) ester_12\NN|methyl|(|name|)|oxide (r_pobj) of_2\IN|ester (r_prep) effects_1\NNS|the|of (r_nsubjpass) investigated_36\VBN|effects|,|were|on|. (l_prep) on_37\IN|convulsions (l_pobj) convulsions_41\NNS|induced
D019331_D012640 NONE NAME_2\NNP|l|-|mg/kg|i.p.|)|and|diazepam (r_nsubj) decreased_16\VBD|name|significantly|incidence|. (l_dobj) incidence_18\NN|the|of|convulsions (l_appos) convulsions_26\NNS|kg)-induced
D009569_D012640 NONE oxide_20\NN|a|nitric|(|inhibitor|,|precursor (r_appos) ester_12\NN|methyl|(|name|)|oxide (r_pobj) of_2\IN|ester (r_prep) effects_1\NNS|the|of (r_nsubjpass) investigated_36\VBN|effects|,|were|on|. (l_prep) on_37\IN|convulsions (l_pobj) convulsions_41\NNS|induced
D009569_D012640 NONE NO_22\NNP| (r_intj) inhibitor_25\NN|no|)|synthase|and|arginine (r_appos) oxide_20\NN|a|nitric|(|inhibitor|,|precursor (r_appos) ester_12\NN|methyl|(|name|)|oxide (r_pobj) of_2\IN|ester (r_prep) effects_1\NNS|the|of (r_nsubjpass) investigated_36\VBN|effects|,|were|on|. (l_prep) on_37\IN|convulsions (l_pobj) convulsions_41\NNS|induced
D009569_D012640 NONE NO_32\JJ| (r_det) precursor_33\NN|a|no (r_appos) oxide_20\NN|a|nitric|(|inhibitor|,|precursor (r_appos) ester_12\NN|methyl|(|name|)|oxide (r_pobj) of_2\IN|ester (r_prep) effects_1\NNS|the|of (r_nsubjpass) investigated_36\VBN|effects|,|were|on|. (l_prep) on_37\IN|convulsions (l_pobj) convulsions_41\NNS|induced
D009569_D012640 NONE NO_5\DT| (r_nsubj) is_6\VBZ|that|no|mediator (l_attr) mediator_9\NN|a|proconvulsant|in (l_prep) in_10\IN|convulsions (l_pobj) convulsions_14\NNS|induced
D001120_D012640 NONE arginine_29\NN|l|- (r_conj) inhibitor_25\NN|no|)|synthase|and|arginine (r_appos) oxide_20\NN|a|nitric|(|inhibitor|,|precursor (r_appos) ester_12\NN|methyl|(|name|)|oxide (r_pobj) of_2\IN|ester (r_prep) effects_1\NNS|the|of (r_nsubjpass) investigated_36\VBN|effects|,|were|on|. (l_prep) on_37\IN|convulsions (l_pobj) convulsions_41\NNS|induced
D001120_D012640 NONE arginine_6\NN|l|- (r_compound) treatment_7\NN|the|arginine (r_nsubj) increased_8\VBD|in|,|treatment|incidence|. (l_dobj) incidence_10\NN|the|of|(|mg/kg|,|convulsions (l_appos) convulsions_18\NNS|i.p.)-induced|significantly
D003975_D012640 NONE diazepam_10\NN|(|mg/kg|) (r_conj) NAME_2\NNP|l|-|mg/kg|i.p.|)|and|diazepam (r_nsubj) decreased_16\VBD|name|significantly|incidence|. (l_dobj) incidence_18\NN|the|of|convulsions (l_appos) convulsions_26\NNS|kg)-induced
11230490
D004317_D066126 NONE doxorubicin_10\NN|encapsulated|and|cyclophosphamide (r_pobj) of_6\IN|doxorubicin (r_prep) efficacy_5\NN|preserved|antitumor|of (r_conj) cardiotoxicity_1\NN|reduced|and|efficacy|compared|.
D004317_D066126 NONE doxorubicin_16\NN|conventional|and|cyclophosphamide (r_pobj) with_14\IN|doxorubicin (r_prep) compared_13\VBN|with|in (r_prep) cardiotoxicity_1\NN|reduced|and|efficacy|compared|.
D004317_D066126 NONE Myocet_3\NNP|( (r_nmod) doxorubicin_8\NN|whether|myocet|encapsulated (r_dobj) determine_1\VB|to|doxorubicin (r_advcl) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_dobj) cardiotoxicity_28\NN|doxorubicin
D004317_D066126 NONE doxorubicin_8\NN|whether|myocet|encapsulated (r_dobj) determine_1\VB|to|doxorubicin (r_advcl) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_dobj) cardiotoxicity_28\NN|doxorubicin
D004317_D066126 NONE doxorubicin_27\NN| (r_compound) cardiotoxicity_28\NN|doxorubicin
D004317_D066126 NONE Myocet_0\NNP| (r_nsubj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_prep) by_7\IN|reducing (l_pcomp) reducing_9\VBG|significantly|cardiotoxicity (l_dobj) cardiotoxicity_10\NN|and|grade
D004317_D066126 NONE doxorubicin_6\NN| (r_pobj) of_5\IN|doxorubicin (r_prep) index_4\NN|the|therapeutic|of (r_dobj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_prep) by_7\IN|reducing (l_pcomp) reducing_9\VBG|significantly|cardiotoxicity (l_dobj) cardiotoxicity_10\NN|and|grade
D004317_D001943 NONE doxorubicin_10\NN|encapsulated|and|cyclophosphamide (r_pobj) of_6\IN|doxorubicin (r_prep) efficacy_5\NN|preserved|antitumor|of (r_conj) cardiotoxicity_1\NN|reduced|and|efficacy|compared|. (l_prep) compared_13\VBN|with|in (l_prep) in_19\IN|trial (l_pobj) trial_24\NN|a|randomized|,|multicenter|of (l_prep) of_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D004317_D001943 NONE doxorubicin_16\NN|conventional|and|cyclophosphamide (r_pobj) with_14\IN|doxorubicin (r_prep) compared_13\VBN|with|in (l_prep) in_19\IN|trial (l_pobj) trial_24\NN|a|randomized|,|multicenter|of (l_prep) of_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D004317_D001943 NONE Myocet_3\NNP|( (r_nmod) doxorubicin_8\NN|whether|myocet|encapsulated (r_dobj) determine_1\VB|to|doxorubicin (r_advcl) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc
D004317_D001943 NONE Myocet_3\NNP|( (r_nmod) doxorubicin_8\NN|whether|myocet|encapsulated (r_dobj) determine_1\VB|to|doxorubicin (r_advcl) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc (l_appos) MBC_44\NNP|(|)
D004317_D001943 NONE doxorubicin_8\NN|whether|myocet|encapsulated (r_dobj) determine_1\VB|to|doxorubicin (r_advcl) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc
D004317_D001943 NONE doxorubicin_8\NN|whether|myocet|encapsulated (r_dobj) determine_1\VB|to|doxorubicin (r_advcl) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc (l_appos) MBC_44\NNP|(|)
D004317_D001943 NONE doxorubicin_27\NN| (r_compound) cardiotoxicity_28\NN|doxorubicin (r_dobj) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc
D004317_D001943 NONE doxorubicin_27\NN| (r_compound) cardiotoxicity_28\NN|doxorubicin (r_dobj) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc (l_appos) MBC_44\NNP|(|)
D004317_D001943 NONE Myocet_26\NNP| (r_nmod) M_28\NNP|myocet|(|) (r_pobj) of_25\IN|m (r_prep) m(2_23\NN|either|60|mg|/|)|of|or (r_dobj) receive_18\VB|to|m(2|doxorubicin|,|in|,|weeks (r_xcomp) randomized_16\VBN|patients|were|receive|. (l_nsubjpass) patients_5\NNS|seven|with|and|chemotherapy (l_prep) with_6\IN|mbc (l_pobj) MBC_7\NNP|
D004317_D001943 NONE doxorubicin_32\NN|conventional|a (r_dobj) receive_18\VB|to|m(2|doxorubicin|,|in|,|weeks (r_xcomp) randomized_16\VBN|patients|were|receive|. (l_nsubjpass) patients_5\NNS|seven|with|and|chemotherapy (l_prep) with_6\IN|mbc (l_pobj) MBC_7\NNP|
D004317_D001943 NONE Myocet_0\NNP| (r_nsubj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_conj) provides_16\VBZ|efficacy|,|used (l_advcl) used_22\VBN|when|in|as (l_prep) as_27\IN|therapy (l_pobj) therapy_31\NN|line|for (l_prep) for_32\IN|mbc (l_pobj) MBC_33\NNP|
D004317_D001943 NONE doxorubicin_6\NN| (r_pobj) of_5\IN|doxorubicin (r_prep) index_4\NN|the|therapeutic|of (r_dobj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_conj) provides_16\VBZ|efficacy|,|used (l_advcl) used_22\VBN|when|in|as (l_prep) as_27\IN|therapy (l_pobj) therapy_31\NN|line|for (l_prep) for_32\IN|mbc (l_pobj) MBC_33\NNP|
D003520_D066126 NONE cyclophosphamide_12\NN| (r_conj) doxorubicin_10\NN|encapsulated|and|cyclophosphamide (r_pobj) of_6\IN|doxorubicin (r_prep) efficacy_5\NN|preserved|antitumor|of (r_conj) cardiotoxicity_1\NN|reduced|and|efficacy|compared|.
D003520_D066126 NONE cyclophosphamide_18\NN| (r_conj) doxorubicin_16\NN|conventional|and|cyclophosphamide (r_pobj) with_14\IN|doxorubicin (r_prep) compared_13\VBN|with|in (r_prep) cardiotoxicity_1\NN|reduced|and|efficacy|compared|.
D003520_D066126 NONE cyclophosphamide_24\NN| (r_pobj) with_23\IN|cyclophosphamide (r_prep) combination_22\NN|with (r_pobj) in_21\IN|combination (r_prep) Company_12\NNP|the|liposome|,|corporation|)|in (r_nsubj) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_dobj) cardiotoxicity_28\NN|doxorubicin
D003520_D066126 NONE cyclophosphamide_26\NN| (r_pobj) with_25\IN|cyclophosphamide (r_prep) combination_24\NN|with (r_pobj) in_23\IN|combination (r_prep) used_22\VBN|when|in|as (r_advcl) provides_16\VBZ|efficacy|,|used (r_conj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_prep) by_7\IN|reducing (l_pcomp) reducing_9\VBG|significantly|cardiotoxicity (l_dobj) cardiotoxicity_10\NN|and|grade
D003520_D001943 NONE cyclophosphamide_12\NN| (r_conj) doxorubicin_10\NN|encapsulated|and|cyclophosphamide (r_pobj) of_6\IN|doxorubicin (r_prep) efficacy_5\NN|preserved|antitumor|of (r_conj) cardiotoxicity_1\NN|reduced|and|efficacy|compared|. (l_prep) compared_13\VBN|with|in (l_prep) in_19\IN|trial (l_pobj) trial_24\NN|a|randomized|,|multicenter|of (l_prep) of_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D003520_D001943 NONE cyclophosphamide_18\NN| (r_conj) doxorubicin_16\NN|conventional|and|cyclophosphamide (r_pobj) with_14\IN|doxorubicin (r_prep) compared_13\VBN|with|in (l_prep) in_19\IN|trial (l_pobj) trial_24\NN|a|randomized|,|multicenter|of (l_prep) of_25\IN|cancer (l_pobj) cancer_28\NN|metastatic|breast
D003520_D001943 NONE cyclophosphamide_24\NN| (r_pobj) with_23\IN|cyclophosphamide (r_prep) combination_22\NN|with (r_pobj) in_21\IN|combination (r_prep) Company_12\NNP|the|liposome|,|corporation|)|in (r_nsubj) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc
D003520_D001943 NONE cyclophosphamide_24\NN| (r_pobj) with_23\IN|cyclophosphamide (r_prep) combination_22\NN|with (r_pobj) in_21\IN|combination (r_prep) Company_12\NNP|the|liposome|,|corporation|)|in (r_nsubj) reduces_26\VBZ|determine|;|company|significantly|cardiotoxicity|providing|. (l_advcl) providing_30\VBG|while|efficacy|in (l_prep) in_34\IN|treatment (l_pobj) treatment_38\NN|line|of (l_prep) of_39\IN|cancer (l_pobj) cancer_42\NN|metastatic|breast|mbc (l_appos) MBC_44\NNP|(|)
D003520_D001943 NONE cyclophosphamide_46\NN|c (r_pobj) of_45\IN|cyclophosphamide (r_prep) combination_38\NN|with|)|of (r_pobj) in_37\IN|combination (r_prep) receive_18\VB|to|m(2|doxorubicin|,|in|,|weeks (r_xcomp) randomized_16\VBN|patients|were|receive|. (l_nsubjpass) patients_5\NNS|seven|with|and|chemotherapy (l_prep) with_6\IN|mbc (l_pobj) MBC_7\NNP|
D003520_D001943 NONE cyclophosphamide_26\NN| (r_pobj) with_25\IN|cyclophosphamide (r_prep) combination_24\NN|with (r_pobj) in_23\IN|combination (r_prep) used_22\VBN|when|in|as (l_prep) as_27\IN|therapy (l_pobj) therapy_31\NN|line|for (l_prep) for_32\IN|mbc (l_pobj) MBC_33\NNP|
D004317_D064420 NONE Myocet_26\NNP| (r_nmod) M_28\NNP|myocet|(|) (r_pobj) of_25\IN|m (r_prep) m(2_23\NN|either|60|mg|/|)|of|or (r_dobj) receive_18\VB|to|m(2|doxorubicin|,|in|,|weeks (l_npadvmod) weeks_53\NNS|every|3|until (l_prep) until_54\IN|progression (l_pobj) progression_56\NN|disease|or|toxicity (l_conj) toxicity_59\NN|unacceptable
D004317_D064420 NONE doxorubicin_32\NN|conventional|a (r_dobj) receive_18\VB|to|m(2|doxorubicin|,|in|,|weeks (l_npadvmod) weeks_53\NNS|every|3|until (l_prep) until_54\IN|progression (l_pobj) progression_56\NN|disease|or|toxicity (l_conj) toxicity_59\NN|unacceptable
D003520_D064420 NONE cyclophosphamide_46\NN|c (r_pobj) of_45\IN|cyclophosphamide (r_prep) combination_38\NN|with|)|of (r_pobj) in_37\IN|combination (r_prep) receive_18\VB|to|m(2|doxorubicin|,|in|,|weeks (l_npadvmod) weeks_53\NNS|every|3|until (l_prep) until_54\IN|progression (l_pobj) progression_56\NN|disease|or|toxicity (l_conj) toxicity_59\NN|unacceptable
D004317_D009503 CID Myocet_0\NNP| (r_nsubj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_dobj) neutropenia_14\NN|4
D004317_D009503 CID doxorubicin_6\NN| (r_pobj) of_5\IN|doxorubicin (r_prep) index_4\NN|the|therapeutic|of (r_dobj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_dobj) neutropenia_14\NN|4
D003520_D009503 CID cyclophosphamide_26\NN| (r_pobj) with_25\IN|cyclophosphamide (r_prep) combination_24\NN|with (r_pobj) in_23\IN|combination (r_prep) used_22\VBN|when|in|as (r_advcl) provides_16\VBZ|efficacy|,|used (r_conj) improves_1\VBZ|myocet|index|by|neutropenia|and|provides|. (l_dobj) neutropenia_14\NN|4
16574713
D018817_D020258 NONE 3,4-methylenedioxymethamphetamine_1\CD| (r_nsubjpass) shown_9\VBN|although|3,4-methylenedioxymethamphetamine|mdma|has|been|damage (r_advcl) known_26\VBN|shown|,|little|is|about|. (l_prep) about_27\IN|consequences (l_pobj) consequences_32\NNS|the|term|of (l_prep) of_33\IN|lesions (l_pobj) lesions_39\NNS|induced|5-ht|neurotoxic|on
D018817_D020258 NONE MDMA_3\NNP|(|or|ecstasy|) (r_nsubjpass) shown_9\VBN|although|3,4-methylenedioxymethamphetamine|mdma|has|been|damage (r_advcl) known_26\VBN|shown|,|little|is|about|. (l_prep) about_27\IN|consequences (l_pobj) consequences_32\NNS|the|term|of (l_prep) of_33\IN|lesions (l_pobj) lesions_39\NNS|induced|5-ht|neurotoxic|on
D018817_D020258 NONE ecstasy_5\NN| (r_conj) MDMA_3\NNP|(|or|ecstasy|) (r_nsubjpass) shown_9\VBN|although|3,4-methylenedioxymethamphetamine|mdma|has|been|damage (r_advcl) known_26\VBN|shown|,|little|is|about|. (l_prep) about_27\IN|consequences (l_pobj) consequences_32\NNS|the|term|of (l_prep) of_33\IN|lesions (l_pobj) lesions_39\NNS|induced|5-ht|neurotoxic|on
D018817_D020258 NONE MDMA_34\NNP| (r_npadvmod) induced_36\VBN|mdma|- (r_amod) lesions_39\NNS|induced|5-ht|neurotoxic|on
D012701_D020258 NONE serotonin_13\NN|brain|neurons (r_dobj) damage_11\VB|to|serotonin (r_xcomp) shown_9\VBN|although|3,4-methylenedioxymethamphetamine|mdma|has|been|damage (r_advcl) known_26\VBN|shown|,|little|is|about|. (l_prep) about_27\IN|consequences (l_pobj) consequences_32\NNS|the|term|of (l_prep) of_33\IN|lesions (l_pobj) lesions_39\NNS|induced|5-ht|neurotoxic|on
D012701_D020258 NONE 5-HT_15\CD| (r_nmod) neurons_17\NNS|(|5-ht|)|in|and|humans (r_appos) serotonin_13\NN|brain|neurons (r_dobj) damage_11\VB|to|serotonin (r_xcomp) shown_9\VBN|although|3,4-methylenedioxymethamphetamine|mdma|has|been|damage (r_advcl) known_26\VBN|shown|,|little|is|about|. (l_prep) about_27\IN|consequences (l_pobj) consequences_32\NNS|the|term|of (l_prep) of_33\IN|lesions (l_pobj) lesions_39\NNS|induced|5-ht|neurotoxic|on
D012701_D020258 NONE 5-HT_37\CD| (r_nummod) lesions_39\NNS|induced|5-ht|neurotoxic|on
D012701_D020258 NONE 5-HT_44\CD| (r_nsubjpass) involved_46\VBN|in|5-ht|is (r_relcl) functions_41\NNS|involved|,|as (r_pobj) on_40\IN|functions (r_prep) lesions_39\NNS|induced|5-ht|neurotoxic|on
D018817_D008569 CID MDMA_12\NNP| (r_compound) users_13\NNS|moderate|mdma (r_pobj) in_10\IN|users (r_prep) observed_9\VBN|in|,|evidence|was|in|. (l_nsubjpass) evidence_4\NN|no|of (l_prep) of_5\IN|impairment (l_pobj) impairment_7\NN|memory
D018817_D008569 CID MDMA_4\NNP| (r_pobj) of_3\IN|mdma (r_prep) use_2\NN|the|of|in (l_prep) in_5\IN|quantities (l_pobj) quantities_6\NNS|considered (l_relcl) considered_10\VBN|that|may|be|associated (l_oprd) associated_16\VBN|"|"|is|not|with (l_prep) with_17\IN|functioning (l_pobj) functioning_20\VBG|memory|,
D018817_D008569 CID MDMA_4\NNP| (r_pobj) of_3\IN|mdma (r_prep) use_2\NN|the|of|in (r_nsubj) lead_28\VB|while|use|use|may|to|. (l_prep) to_29\IN|impairments (l_pobj) impairments_33\NNS|lasting|memory
D018817_D008569 CID MDMA_25\NNP| (r_compound) use_26\NN|mdma (r_pobj) of_24\IN|use (r_prep) use_23\NN|heavy|of (r_nsubj) lead_28\VB|while|use|use|may|to|. (l_nsubj) use_2\NN|the|of|in (l_prep) in_5\IN|quantities (l_pobj) quantities_6\NNS|considered (l_relcl) considered_10\VBN|that|may|be|associated (l_oprd) associated_16\VBN|"|"|is|not|with (l_prep) with_17\IN|functioning (l_pobj) functioning_20\VBG|memory|,
D018817_D008569 CID MDMA_25\NNP| (r_compound) use_26\NN|mdma (r_pobj) of_24\IN|use (r_prep) use_23\NN|heavy|of (r_nsubj) lead_28\VB|while|use|use|may|to|. (l_prep) to_29\IN|impairments (l_pobj) impairments_33\NNS|lasting|memory
1928887
D009270_D007022 NONE Naloxone_0\NN| (r_compound) reversal_1\NN|naloxone|of|due|. (l_prep) of_2\IN|hypotension (l_pobj) hypotension_3\NN|
D009270_D007022 NONE naloxone_3\NN| (r_appos) antagonist_2\NN|the|opioid|naloxone (r_nsubjpass) shown_6\VBN|antagonist|has|been|block|. (l_xcomp) block_8\VB|to|or|reverse (l_conj) reverse_10\VB|actions (l_dobj) actions_13\NNS|the|hypotensive|of (l_amod) hypotensive_12\JJ|
D009270_D007022 NONE naloxone_22\NN| (r_pobj) of_21\IN|naloxone (r_prep) administration_20\NN|the|of (r_pobj) with_18\IN|administration (r_prep) resolved_16\VBD|,|that|promptly|with (r_ccomp) report_1\VBP|we|case|,|manifested|resolved|. (l_advcl) manifested_10\VBN|by (l_agent) by_11\IN|hypotension (l_pobj) hypotension_13\NN|marked
D009270_D007022 NONE naloxone_17\NN| (r_pobj) with_16\IN|naloxone (r_prep) treated_15\VBN|with (r_acl) hypotension_14\NN|induced|treated
D009270_D007022 NONE naloxone_7\NN|in (l_prep) in_8\IN|reversal (l_pobj) reversal_10\NN|the|of (l_prep) of_11\IN|hypotension (l_pobj) hypotension_12\NN|resulting
D009270_D062787 NONE Naloxone_0\NN| (r_compound) reversal_1\NN|naloxone|of|due|. (l_prep) due_4\IN|to|overdose (l_pobj) overdose_7\NN|captopril
D009270_D062787 NONE naloxone_22\NN| (r_pobj) of_21\IN|naloxone (r_prep) administration_20\NN|the|of (r_pobj) with_18\IN|administration (r_prep) resolved_16\VBD|,|that|promptly|with (r_ccomp) report_1\VBP|we|case|,|manifested|resolved|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|overdose (l_pobj) overdose_8\NN|an|intentional|captopril
D002216_D007022 NONE captopril_6\NN| (r_compound) overdose_7\NN|captopril (r_pobj) due_4\IN|to|overdose (r_prep) reversal_1\NN|naloxone|of|due|. (l_prep) of_2\IN|hypotension (l_pobj) hypotension_3\NN|
D002216_D007022 NONE captopril_15\NN| (r_pobj) of_14\IN|captopril (r_prep) actions_13\NNS|the|hypotensive|of (l_amod) hypotensive_12\JJ|
D002216_D007022 NONE captopril_7\NN| (r_compound) overdose_8\NN|an|intentional|captopril (r_pobj) of_4\IN|overdose (r_prep) case_3\NN|a|of (r_dobj) report_1\VBP|we|case|,|manifested|resolved|. (l_advcl) manifested_10\VBN|by (l_agent) by_11\IN|hypotension (l_pobj) hypotension_13\NN|marked
D002216_D007022 NONE captopril_11\NN| (r_npadvmod) induced_13\VBN|captopril|- (r_amod) hypotension_14\NN|induced|treated
D002216_D007022 NONE captopril_15\NN| (r_pobj) from_14\IN|captopril (r_prep) resulting_13\VBG|from (r_acl) hypotension_12\NN|resulting
D002216_D062787 NONE captopril_6\NN| (r_compound) overdose_7\NN|captopril
D002216_D062787 NONE captopril_7\NN| (r_compound) overdose_8\NN|an|intentional|captopril
19944736
D013619_D012640 CID Tacrine_0\NNP|,|administered|rats|, (r_nsubj) induces_10\VBZ|tacrine|seizures|and|delayed|. (l_dobj) seizures_12\NNS|electrocorticographic
D013619_D001930 CID Tacrine_0\NNP|,|administered|rats|, (r_nsubj) induces_10\VBZ|tacrine|seizures|and|delayed|. (l_conj) delayed_14\VBD|damage (l_dobj) damage_16\NN|hippocampal
D013619_D001930 CID tacrine_3\NN| (r_npadvmod) loaded_5\VBN|tacrine|- (r_amod) administration_7\NN|loaded|nanoparticles (r_nsubj) induced_8\VBD|in|,|administration|damage|,|solution|. (l_dobj) damage_9\NN|of|in (l_prep) of_10\IN|cells (l_pobj) cells_12\NNS|neuronal|in
D013619_D001930 CID tacrine_29\NN| (r_pobj) of_28\IN|tacrine (r_prep) solution_27\NN|while|the|saline|of|% (r_advcl) induced_8\VBD|in|,|administration|damage|,|solution|. (l_dobj) damage_9\NN|of|in (l_prep) of_10\IN|cells (l_pobj) cells_12\NNS|neuronal|in
D018021_D012640 CID LiCl_4\NNP| (r_pobj) in_3\IN|licl (r_prep) administered_2\VBN|in (r_acl) Tacrine_0\NNP|,|administered|rats|, (r_nsubj) induces_10\VBZ|tacrine|seizures|and|delayed|. (l_dobj) seizures_12\NNS|electrocorticographic
D018021_D001930 CID LiCl_4\NNP| (r_pobj) in_3\IN|licl (r_prep) administered_2\VBN|in (r_acl) Tacrine_0\NNP|,|administered|rats|, (r_nsubj) induces_10\VBZ|tacrine|seizures|and|delayed|. (l_conj) delayed_14\VBD|damage (l_dobj) damage_16\NN|hippocampal
D013619_D004827 NONE tacrine_5\NN| (r_npadvmod) loaded_7\VBN|tacrine|- (r_amod) nanoparticles_8\NNS|loaded (r_pobj) with_4\IN|nanoparticles (r_prep) treated_3\VBN|animals|with (r_csubj) showed_9\VBD|treated|outcome|. (l_dobj) outcome_12\NN|an|earlier|of|with (l_prep) of_13\IN|symptoms (l_pobj) symptoms_16\NNS|cns|adverse|,|onset|, (l_appos) onset_20\NN|i.e.|epileptic (l_amod) epileptic_19\JJ|
D013619_D004827 NONE tacrine_22\NN| (r_compound) lithium_24\NN|tacrine|- (r_compound) model_25\NN|the|lithium|of|in (l_prep) of_26\IN|epilepsy (l_pobj) epilepsy_27\NN|
D008094_D004827 NONE lithium_24\NN|tacrine|- (r_compound) model_25\NN|the|lithium|of|in (l_prep) of_26\IN|epilepsy (l_pobj) epilepsy_27\NN|
6674249
D015119_D009135 CID acid_5\NN|aminocaproic|eaca (r_nsubj) induce_9\VBP|why|may|acid|myopathy|in|? (l_dobj) myopathy_10\NNS|
D015119_D009135 CID EACA_7\NNP|(|) (r_appos) acid_5\NN|aminocaproic|eaca (r_nsubj) induce_9\VBP|why|may|acid|myopathy|in|? (l_dobj) myopathy_10\NNS|
D015119_D009135 CID acid_12\NN| (r_nmod) EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (r_pobj) due_5\IN|to|treatment (r_prep) necrotizing_3\VBG|myopathy|due (l_advmod) myopathy_4\NNS|
D015119_D009135 CID EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (r_pobj) due_5\IN|to|treatment (r_prep) necrotizing_3\VBG|myopathy|due (l_advmod) myopathy_4\NNS|
D015119_D009336 CID acid_12\NN| (r_nmod) EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (r_pobj) due_5\IN|to|treatment (r_prep) necrotizing_3\VBG|myopathy|due (l_advmod) myopathy_4\NNS|
D015119_D009336 CID EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (r_pobj) due_5\IN|to|treatment (r_prep) necrotizing_3\VBG|myopathy|due (l_advmod) myopathy_4\NNS|
D015119_D013345 NONE acid_12\NN| (r_nmod) EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (l_prep) in_17\IN|patient (l_pobj) patient_23\NN|a|old|with (l_prep) with_24\IN|haemorrhage (l_pobj) haemorrhage_26\NN|subarachnoid
D015119_D013345 NONE acid_12\NN| (r_nmod) EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (r_pobj) due_5\IN|to|treatment (r_prep) necrotizing_3\VBG|myopathy|due (r_pcomp) of_2\IN|necrotizing (r_prep) case_1\NN|a|of (r_nsubjpass) described_31\VBN|case|(|)|is|. (l_punct) (_27\-LRB-|sah (l_preconj) SAH_28\NNP|
D015119_D013345 NONE EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (l_prep) in_17\IN|patient (l_pobj) patient_23\NN|a|old|with (l_prep) with_24\IN|haemorrhage (l_pobj) haemorrhage_26\NN|subarachnoid
D015119_D013345 NONE EACA_14\NNP|acid|(|) (r_nmod) treatment_16\NN|a|short|aminocaproic|eaca|in (r_pobj) due_5\IN|to|treatment (r_prep) necrotizing_3\VBG|myopathy|due (r_pcomp) of_2\IN|necrotizing (r_prep) case_1\NN|a|of (r_nsubjpass) described_31\VBN|case|(|)|is|. (l_punct) (_27\-LRB-|sah (l_preconj) SAH_28\NNP|
6540303
D000588_D002389 NONE amine_2\NN| (r_compound) pretreatment_3\NN|amine|on (l_prep) on_4\IN|catatonia (l_pobj) catatonia_6\NN|ketamine
D007649_D002389 CID ketamine_5\NN| (r_compound) catatonia_6\NN|ketamine
D007649_D002389 CID ketamine_15\NN| (r_npadvmod) induced_17\VBN|ketamine|- (r_amod) catatonia_18\NN|induced
D007649_D002389 CID ketamine_17\NN| (r_pobj) after_16\IN|ketamine (r_prep) increased_8\VBD|in|,|pretreatment|duration|after|,|but|did (l_dobj) duration_10\NN|the|of (l_prep) of_11\IN|catatonia (l_pobj) catatonia_12\NNP|doc
D007649_D002389 CID ketamine_15\NN| (r_compound) catatonia_16\NNP|ketamine|than
D002395_D002389 NONE catecholamines_10\NNS|and|idolamines (r_pobj) of_9\IN|catecholamines (r_prep) role_8\NN|the|of|on (l_prep) on_14\IN|catatonia (l_pobj) catatonia_18\NN|induced
D004298_D002389 CID dopamine_7\NN| (r_pobj) with_6\IN|dopamine (r_prep) pretreatment_5\NN|with (r_nsubj) increased_8\VBD|in|,|pretreatment|duration|after|,|but|did (l_dobj) duration_10\NN|the|of (l_prep) of_11\IN|catatonia (l_pobj) catatonia_12\NNP|doc
D004298_D002389 CID dopamine_2\NN| (r_nsubj) appeared_3\VBD|furthermore|,|dopamine|act|. (l_xcomp) act_5\VB|to|on (l_prep) on_6\IN|systems (l_pobj) systems_7\NNS|involved (l_acl) involved_10\JJ|closely|with (l_prep) with_11\IN|induction (l_pobj) induction_13\NN|the|of|on (l_prep) of_14\IN|catatonia (l_pobj) catatonia_16\NNP|ketamine|than
D009638_D002389 NONE norepinephrine_22\NN| (r_pobj) with_21\IN|norepinephrine (r_prep) pretreatment_20\NN|with (r_nsubj) did_23\VBD|pretreatment|not|. (r_conj) increased_8\VBD|in|,|pretreatment|duration|after|,|but|did (l_dobj) duration_10\NN|the|of (l_prep) of_11\IN|catatonia (l_pobj) catatonia_12\NNP|doc
3952818
D005472_D066126 NONE 5-fluorouracil_3\CD| (r_punct) ._4\.|5-fluorouracil (r_punct) toxicity_1\NN|cardiac|of|.
D005472_D066126 NONE 5-FU_14\CD| (r_pobj) to_13\IN|5-fu (r_pcomp) due_12\JJ|to (r_prep) be_7\VB|that|spasm|may|cause|due|,|and|used (l_attr) cause_9\NN|the|of (l_prep) of_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
D005472_D066126 NONE 5-FU_14\CD| (r_pobj) to_13\IN|5-fu (r_pcomp) due_12\JJ|to (r_prep) be_7\VB|that|spasm|may|cause|due|,|and|used (l_conj) used_23\VBN|that|antagonists|may|probably|be|in (l_prep) in_24\IN|prevention (l_pobj) prevention_26\NN|the|or|treatment|of (l_prep) of_29\IN|cardiotoxicity (l_pobj) cardiotoxicity_31\NN|5-fu
D005472_D066126 NONE 5-FU_30\CD| (r_compound) cardiotoxicity_31\NN|5-fu (r_pobj) of_29\IN|cardiotoxicity (r_prep) prevention_26\NN|the|or|treatment|of (r_pobj) in_24\IN|prevention (r_prep) used_23\VBN|that|antagonists|may|probably|be|in (r_conj) be_7\VB|that|spasm|may|cause|due|,|and|used (l_attr) cause_9\NN|the|of (l_prep) of_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
D005472_D066126 NONE 5-FU_30\CD| (r_compound) cardiotoxicity_31\NN|5-fu
D005472_D003110 NONE 5-fluorouracil_18\CD| (r_punct) administration_22\NN|5-fluorouracil|(|5-fu|) (r_pobj) after_17\IN|administration (r_prep) presented_14\VBD|who|pain|after (r_relcl) patient_6\NN|a|with|presented (l_prep) with_7\IN|carcinoma (l_pobj) carcinoma_9\NN|colon|and|metastasis
D005472_D003110 NONE 5-FU_20\CD| (r_nmod) administration_22\NN|5-fluorouracil|(|5-fu|) (r_pobj) after_17\IN|administration (r_prep) presented_14\VBD|who|pain|after (r_relcl) patient_6\NN|a|with|presented (l_prep) with_7\IN|carcinoma (l_pobj) carcinoma_9\NN|colon|and|metastasis
D005472_D009362 NONE 5-fluorouracil_18\CD| (r_punct) administration_22\NN|5-fluorouracil|(|5-fu|) (r_pobj) after_17\IN|administration (r_prep) presented_14\VBD|who|pain|after (r_relcl) patient_6\NN|a|with|presented (l_prep) with_7\IN|carcinoma (l_pobj) carcinoma_9\NN|colon|and|metastasis (l_conj) metastasis_12\NN|liver
D005472_D009362 NONE 5-FU_20\CD| (r_nmod) administration_22\NN|5-fluorouracil|(|5-fu|) (r_pobj) after_17\IN|administration (r_prep) presented_14\VBD|who|pain|after (r_relcl) patient_6\NN|a|with|presented (l_prep) with_7\IN|carcinoma (l_pobj) carcinoma_9\NN|colon|and|metastasis (l_conj) metastasis_12\NN|liver
D005472_D002637 CID 5-fluorouracil_18\CD| (r_punct) administration_22\NN|5-fluorouracil|(|5-fu|) (r_pobj) after_17\IN|administration (r_prep) presented_14\VBD|who|pain|after (l_dobj) pain_16\NN|chest
D005472_D002637 CID 5-FU_20\CD| (r_nmod) administration_22\NN|5-fluorouracil|(|5-fu|) (r_pobj) after_17\IN|administration (r_prep) presented_14\VBD|who|pain|after (l_dobj) pain_16\NN|chest
D009543_D000788 NONE nifedipine_19\NN| (r_pobj) with_18\IN|nifedipine (r_prep) resolved_17\VBD|pain|promptly|with|. (r_conj) was_3\VBD|evolution|similar|,|and|resolved (l_acomp) similar_4\JJ|to (l_prep) to_5\IN|that (l_pobj) that_6\DT|observed (l_acl) observed_7\VBN|in (l_prep) in_8\IN|angina (l_pobj) angina_11\NN|prinzmetal
D009543_D002637 NONE nifedipine_19\NN| (r_pobj) with_18\IN|nifedipine (r_prep) resolved_17\VBD|pain|promptly|with|. (l_nsubj) pain_15\NN|chest
D005472_D003329 NONE 5-FU_14\CD| (r_pobj) to_13\IN|5-fu (r_pcomp) due_12\JJ|to (r_prep) be_7\VB|that|spasm|may|cause|due|,|and|used (l_nsubj) spasm_5\NN|coronary
D005472_D003329 NONE 5-FU_30\CD| (r_compound) cardiotoxicity_31\NN|5-fu (r_pobj) of_29\IN|cardiotoxicity (r_prep) prevention_26\NN|the|or|treatment|of (r_pobj) in_24\IN|prevention (r_prep) used_23\VBN|that|antagonists|may|probably|be|in (r_conj) be_7\VB|that|spasm|may|cause|due|,|and|used (l_nsubj) spasm_5\NN|coronary
D002118_D003329 NONE calcium_18\NN| (r_compound) antagonists_19\NNS|calcium (r_nsubjpass) used_23\VBN|that|antagonists|may|probably|be|in (r_conj) be_7\VB|that|spasm|may|cause|due|,|and|used (l_nsubj) spasm_5\NN|coronary
D002118_D066126 NONE calcium_18\NN| (r_compound) antagonists_19\NNS|calcium (r_nsubjpass) used_23\VBN|that|antagonists|may|probably|be|in (r_conj) be_7\VB|that|spasm|may|cause|due|,|and|used (l_attr) cause_9\NN|the|of (l_prep) of_10\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|
D002118_D066126 NONE calcium_18\NN| (r_compound) antagonists_19\NNS|calcium (r_nsubjpass) used_23\VBN|that|antagonists|may|probably|be|in (l_prep) in_24\IN|prevention (l_pobj) prevention_26\NN|the|or|treatment|of (l_prep) of_29\IN|cardiotoxicity (l_pobj) cardiotoxicity_31\NN|5-fu
9630698
D006220_D009127 CID haloperidol_5\NN|(|mg/kg|i.p. (r_pobj) by_4\IN|haloperidol (r_agent) induced_3\VBN|rigidity|was|by|)|. (l_nsubjpass) rigidity_1\NN|muscle
D006220_D009127 CID haloperidol_34\NN| (r_advmod) induced_36\VBN|haloperidol|- (r_amod) rigidity_38\NN|both|the|induced|muscle|(|mmg|)|and|activity
C066192_D009127 NONE acid_1\NN|5,7-dichlorokynurenic|5,7-dcka|)|,|antagonist|, (r_nsubj) injected_12\VBN|acid|in|,|into|,|decreased|. (l_conj) decreased_31\VBD|rigidity (l_dobj) rigidity_38\NN|both|the|induced|muscle|(|mmg|)|and|activity
C066192_D009127 NONE 5,7-DCKA_3\CD|( (r_appos) acid_1\NN|5,7-dichlorokynurenic|5,7-dcka|)|,|antagonist|, (r_nsubj) injected_12\VBN|acid|in|,|into|,|decreased|. (l_conj) decreased_31\VBD|rigidity (l_dobj) rigidity_38\NN|both|the|induced|muscle|(|mmg|)|and|activity
D005998_D009127 NONE glycine_8\NN| (r_compound) site_9\NN|glycine (r_compound) antagonist_10\NN|a|selective|site (r_appos) acid_1\NN|5,7-dichlorokynurenic|5,7-dcka|)|,|antagonist|, (r_nsubj) injected_12\VBN|acid|in|,|into|,|decreased|. (l_conj) decreased_31\VBD|rigidity (l_dobj) rigidity_38\NN|both|the|induced|muscle|(|mmg|)|and|activity
11827497
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|heparin|- (r_amod) thrombocytopenia_6\NN|onset|induced|.
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced
D006493_D013921 CID heparin_10\JJ| (r_compound) exposure_11\NN|heparin|,|with (r_pobj) after_9\IN|days|exposure (r_prep) presents_4\VBZ|thrombocytopenia|after|. (l_nsubj) thrombocytopenia_3\NN|induced
D006493_D013921 CID heparin_5\NN| (r_npadvmod) induced_7\VBN|heparin|- (r_amod) thrombocytopenia_8\NN|induced
D006493_D013921 CID heparin_16\NN| (r_npadvmod) induced_18\VBN|heparin|- (r_amod) thrombocytopenia_19\NN|induced
D006493_D013921 CID heparin_9\NN| (r_npadvmod) induced_11\VBN|heparin|- (r_amod) thrombocytopenia_12\NN|induced
D006493_D013921 CID heparin_9\JJ| (r_compound) exposure_10\NN|heparin (r_dobj) included_8\VBN|that|had|exposure (r_relcl) hospitalizations_5\NNS|included (r_pobj) after_4\IN|hospitalizations (r_prep) went_2\VBD|:|patients|home|after|--|in|,|with|--|return|. (l_prep) with_16\IN|thrombocytopenia (l_pobj) thrombocytopenia_18\NN|no|recognized
D006493_D013921 CID heparin_3\NN| (r_npadvmod) induced_5\VBN|heparin|- (r_amod) thrombocytopenia_6\NN|onset|induced
D006493_D013921 CID heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced
D006493_D013921 CID heparin_27\VBN| (r_appos) anticoagulants_24\NNS|alternative|,|not|heparin (r_pobj) with_22\IN|anticoagulants (r_prep) therapy_21\NN|with (r_nsubjpass) initiated_31\VBN|consider|;|therapy|,|should|be|. (l_ccomp) consider_7\VB|avoid|,|physicians|must|thrombocytopenia|returns (l_dobj) thrombocytopenia_11\NN|induced
D006493_D001157 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced (r_nsubj) presents_4\VBZ|thrombocytopenia|after|. (l_prep) after_9\IN|days|exposure (l_pobj) exposure_11\NN|heparin|,|with (l_prep) with_13\IN|or|without (l_conj) without_15\IN|thromboemboli (l_pobj) thromboemboli_19\NN|arterial
D006493_D001157 CID heparin_10\JJ| (r_compound) exposure_11\NN|heparin|,|with (l_prep) with_13\IN|or|without (l_conj) without_15\IN|thromboemboli (l_pobj) thromboemboli_19\NN|arterial
D006493_D054556 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced (r_nsubj) presents_4\VBZ|thrombocytopenia|after|. (l_prep) after_9\IN|days|exposure (l_pobj) exposure_11\NN|heparin|,|with (l_prep) with_13\IN|or|without (l_conj) without_15\IN|thromboemboli (l_pobj) thromboemboli_19\NN|arterial
D006493_D054556 CID heparin_10\JJ| (r_compound) exposure_11\NN|heparin|,|with (l_prep) with_13\IN|or|without (l_conj) without_15\IN|thromboemboli (l_pobj) thromboemboli_19\NN|arterial
D006493_D013923 NONE heparin_9\NN| (r_npadvmod) induced_11\VBN|heparin|- (r_amod) thrombocytopenia_12\NN|induced (r_nsubj) became_13\VBD|in|thrombocytopenia|apparent|on (l_prep) on_15\IN|presentation (l_pobj) presentation_17\NN|delayed|with (l_prep) with_18\IN|complications (l_pobj) complications_20\NNS|thromboembolic (l_compound) thromboembolic_19\JJ|
D006493_D013923 NONE heparin_13\NN| (r_npadvmod) induced_15\VBN|heparin|- (r_nmod) factor_17\NN|induced|platelet|tests (r_pobj) of_12\IN|factor (r_prep) results_11\NNS|of (r_appos) counts_3\VBZ|platelet|,|onset|,|results (l_appos) onset_5\NN|of (l_prep) of_6\IN|thromboembolism (l_pobj) thromboembolism_9\NN|determined
D006493_D013923 NONE heparin_9\JJ| (r_compound) exposure_10\NN|heparin (r_dobj) included_8\VBN|that|had|exposure (r_relcl) hospitalizations_5\NNS|included (r_pobj) after_4\IN|hospitalizations (r_prep) went_2\VBD|:|patients|home|after|--|in|,|with|--|return|. (l_advcl) return_23\VB|only|to|to|with (l_prep) with_33\IN|complications (l_pobj) complications_35\NNS|thromboembolic (l_compound) thromboembolic_34\JJ|
D006493_D013923 NONE heparin_8\NN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) thrombocytopenia_11\NN|induced (r_dobj) consider_7\VB|avoid|,|physicians|must|thrombocytopenia|returns (l_advcl) returns_17\NNS|whenever|a|hospitalized|patient|with (l_prep) with_18\IN|thromboembolism (l_pobj) thromboembolism_19\NN|
D006493_D013923 NONE heparin_27\VBN| (r_appos) anticoagulants_24\NNS|alternative|,|not|heparin (r_pobj) with_22\IN|anticoagulants (r_prep) therapy_21\NN|with (r_nsubjpass) initiated_31\VBN|consider|;|therapy|,|should|be|. (l_ccomp) consider_7\VB|avoid|,|physicians|must|thrombocytopenia|returns (l_advcl) returns_17\NNS|whenever|a|hospitalized|patient|with (l_prep) with_18\IN|thromboembolism (l_pobj) thromboembolism_19\NN|
2220369
C015173_D020246 CID epinephrine_6\NN|dipivalyl (r_conj) thrombosis_2\NN|central|vein|and|epinephrine|.
C015173_D020246 CID epinephrine_28\NN|dipivalyl|for (r_pobj) with_26\IN|epinephrine (r_prep) started_23\VBN|having|medication|with (r_pcomp) after_21\IN|started (r_prep) acquired_11\VBD|who|thrombosis|in|day|after (l_dobj) thrombosis_14\NN|vein
C015173_D005901 NONE epinephrine_28\NN|dipivalyl|for (l_prep) for_29\IN|glaucoma (l_pobj) glaucoma_31\NN|advanced|discovered
3131282
C009166_D063646 NONE acetate_6\NN|retinyl (r_pobj) of_4\IN|acetate (r_prep) effect_3\NN|carcinogenic|of|on (l_amod) carcinogenic_2\JJ|co|-
C009166_D013274 NONE acetate_6\NN|retinyl (r_pobj) of_4\IN|acetate (r_prep) effect_3\NN|carcinogenic|of|on (l_prep) on_7\IN|carcinogenesis (l_pobj) carcinogenesis_9\NN|forestomach|of
C009166_D013274 NONE acetate_6\NN|retinyl|ra (r_pobj) of_4\IN|acetate (r_prep) effect_3\NN|the|potential|modifying|of|on (r_nsubjpass) examined_19\VBN|effect|(|tumorigenesis|was|. (l_nsubjpass) tumorigenesis_17\NN|rat|forestomach
C009166_D013274 NONE RA_8\NNP|(|) (r_appos) acetate_6\NN|retinyl|ra (r_pobj) of_4\IN|acetate (r_prep) effect_3\NN|the|potential|modifying|of|on (r_nsubjpass) examined_19\VBN|effect|(|tumorigenesis|was|. (l_nsubjpass) tumorigenesis_17\NN|rat|forestomach
C009166_D013274 NONE RA_27\NNP|of|%|significantly|p (r_nsubj) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_prep) of_38\IN|tumors (l_pobj) tumors_40\NNS|forestomach
C009166_D013274 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|ra|- (r_amod) water_77\NN|free (r_dobj) given_73\VBN|water (r_acl) group_72\NN|the|given (r_pobj) in_70\IN|group (r_prep) from_59\IN|%|in (r_prep) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_prep) of_38\IN|tumors (l_pobj) tumors_40\NNS|forestomach
C009166_D013274 NONE RA_4\NNP| (r_nsubj) acted_5\VBD|that|ra|as|carcinogenesis (l_dobj) carcinogenesis_15\NN|the|bha|forestomach|of
D002083_D063646 NONE hydroxyanisole_17\NN|butylated (r_pobj) with_15\IN|hydroxyanisole (r_prep) induced_14\VBN|effect|with|. (l_nsubj) effect_3\NN|carcinogenic|of|on (l_amod) carcinogenic_2\JJ|co|-
D002083_D013274 CID hydroxyanisole_17\NN|butylated (r_pobj) with_15\IN|hydroxyanisole (r_prep) induced_14\VBN|effect|with|. (l_nsubj) effect_3\NN|carcinogenic|of|on (l_prep) on_7\IN|carcinogenesis (l_pobj) carcinogenesis_9\NN|forestomach|of
D002083_D013274 CID hydroxyanisole_12\NN|butylated (r_pobj) on_10\IN|hydroxyanisole (r_prep) effect_3\NN|the|potential|modifying|of|on (r_nsubjpass) examined_19\VBN|effect|(|tumorigenesis|was|. (l_nsubjpass) tumorigenesis_17\NN|rat|forestomach
D002083_D013274 CID BHA)-induced_14\JJ| (r_amod) rat_15\NN|bha)-induced (r_compound) tumorigenesis_17\NN|rat|forestomach
D002083_D013274 CID BHA_5\NNP|% (r_dobj) given_2\VBN|bha (r_acl) groups_1\NNS|given (r_pobj) In_0\IN|groups (r_prep) observed_16\VBN|in|,|marked|changes|were|in|increased|. (l_conj) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_prep) of_38\IN|tumors (l_pobj) tumors_40\NNS|forestomach
D002083_D013274 CID BHA_13\NNP| (r_compound) carcinogenesis_15\NN|the|bha|forestomach|of
D002083_D010212 NONE BHA_5\NNP|% (r_dobj) given_2\VBN|bha (r_acl) groups_1\NNS|given (r_pobj) In_0\IN|groups (r_prep) observed_16\VBN|in|,|marked|changes|were|in|increased|. (l_conj) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_appos) papilloma_44\NN|squamous|cell|and|carcinoma
D002083_D002277 NONE BHA_5\NNP|% (r_dobj) given_2\VBN|bha (r_acl) groups_1\NNS|given (r_pobj) In_0\IN|groups (r_prep) observed_16\VBN|in|,|marked|changes|were|in|increased|. (l_conj) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_appos) papilloma_44\NN|squamous|cell|and|carcinoma (l_conj) carcinoma_46\NN|
D002083_D002277 NONE BHA_5\NNP|% (r_dobj) given_2\VBN|bha (r_acl) groups_1\NNS|given (r_pobj) In_0\IN|groups (r_prep) observed_16\VBN|in|,|marked|changes|were|in|increased|. (l_conj) increased_35\VBD|ra|incidence|to|from (l_prep) to_48\IN|% (l_pobj) %_50\NN|60|rats (l_appos) rats_55\NNS|(|9/15|,|2|with|) (l_prep) with_56\IN|carcinoma (l_pobj) carcinoma_57\NN|
D002083_D002277 NONE BHA_5\NNP|% (r_dobj) given_2\VBN|bha (r_acl) groups_1\NNS|given (r_pobj) In_0\IN|groups (r_prep) observed_16\VBN|in|,|marked|changes|were|in|increased|. (l_conj) increased_35\VBD|ra|incidence|to|from (l_prep) from_59\IN|%|in (l_pobj) %_61\NN|15|(|3/20|,|rat|) (l_appos) rat_66\NN|one|with (l_prep) with_67\IN|carcinoma (l_pobj) carcinoma_68\NN|
C009166_D010212 NONE RA_27\NNP|of|%|significantly|p (r_nsubj) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_appos) papilloma_44\NN|squamous|cell|and|carcinoma
C009166_D010212 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|ra|- (r_amod) water_77\NN|free (r_dobj) given_73\VBN|water (r_acl) group_72\NN|the|given (r_pobj) in_70\IN|group (r_prep) from_59\IN|%|in (r_prep) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_appos) papilloma_44\NN|squamous|cell|and|carcinoma
C009166_D010212 NONE RA_17\NN|% (r_pobj) with_14\IN|ra|and|in (r_prep) rats_9\NNS|3|(|%|)|with (r_pobj) in_7\IN|rats (r_prep) induced_6\VBN|tumors|were|in|. (l_nsubjpass) Tumors_0\NNS|,|papillomas|, (l_appos) papillomas_3\NNS|all
C009166_D010212 NONE RA_29\NNP| (r_compound) administration_32\NN|%|ra|- (r_punct) ._33\.|administration (r_punct) induced_6\VBN|tumors|were|in|. (l_nsubjpass) Tumors_0\NNS|,|papillomas|, (l_appos) papillomas_3\NNS|all
C009166_D002277 NONE RA_27\NNP|of|%|significantly|p (r_nsubj) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_appos) papilloma_44\NN|squamous|cell|and|carcinoma (l_conj) carcinoma_46\NN|
C009166_D002277 NONE RA_27\NNP|of|%|significantly|p (r_nsubj) increased_35\VBD|ra|incidence|to|from (l_prep) to_48\IN|% (l_pobj) %_50\NN|60|rats (l_appos) rats_55\NNS|(|9/15|,|2|with|) (l_prep) with_56\IN|carcinoma (l_pobj) carcinoma_57\NN|
C009166_D002277 NONE RA_27\NNP|of|%|significantly|p (r_nsubj) increased_35\VBD|ra|incidence|to|from (l_prep) from_59\IN|%|in (l_pobj) %_61\NN|15|(|3/20|,|rat|) (l_appos) rat_66\NN|one|with (l_prep) with_67\IN|carcinoma (l_pobj) carcinoma_68\NN|
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|ra|- (r_amod) water_77\NN|free (r_dobj) given_73\VBN|water (r_acl) group_72\NN|the|given (r_pobj) in_70\IN|group (r_prep) from_59\IN|%|in (r_prep) increased_35\VBD|ra|incidence|to|from (l_dobj) incidence_37\NN|the|of|(|papilloma|) (l_appos) papilloma_44\NN|squamous|cell|and|carcinoma (l_conj) carcinoma_46\NN|
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|ra|- (r_amod) water_77\NN|free (r_dobj) given_73\VBN|water (r_acl) group_72\NN|the|given (r_pobj) in_70\IN|group (r_prep) from_59\IN|%|in (r_prep) increased_35\VBD|ra|incidence|to|from (l_prep) to_48\IN|% (l_pobj) %_50\NN|60|rats (l_appos) rats_55\NNS|(|9/15|,|2|with|) (l_prep) with_56\IN|carcinoma (l_pobj) carcinoma_57\NN|
C009166_D002277 NONE RA_74\NNP| (r_npadvmod) free_76\JJ|ra|- (r_amod) water_77\NN|free (r_dobj) given_73\VBN|water (r_acl) group_72\NN|the|given (r_pobj) in_70\IN|group (r_prep) from_59\IN|%|in (l_pobj) %_61\NN|15|(|3/20|,|rat|) (l_appos) rat_66\NN|one|with (l_prep) with_67\IN|carcinoma (l_pobj) carcinoma_68\NN|
D002083_D017573 NONE BHA_5\NNP|%|, (r_dobj) given_2\VBN|bha|at (r_acl) rats_1\NNS|given (r_pobj) In_0\IN|rats (r_prep) showed_23\VBD|in|%|effect|. (l_dobj) effect_29\NN|a|dependent|enhancing|on (l_prep) on_30\IN|development (l_pobj) development_32\NN|the|of (l_prep) of_33\IN|hyperplasia (l_pobj) hyperplasia_39\NN|the|induced|epithelial
D002083_D017573 NONE BHA_35\NNP| (r_npadvmod) induced_37\VBN|bha|- (r_amod) hyperplasia_39\NN|the|induced|epithelial
C009166_D017573 NONE RA_7\NNP| (r_punct) co_8\NNP|ra (r_punct) -_9\HYPH|co (r_punct) administered_10\VBN|- (r_punct) at_11\IN|administered|dose (r_prep) given_2\VBN|bha|at (r_acl) rats_1\NNS|given (r_pobj) In_0\IN|rats (r_prep) showed_23\VBD|in|%|effect|. (l_dobj) effect_29\NN|a|dependent|enhancing|on (l_prep) on_30\IN|development (l_pobj) development_32\NN|the|of (l_prep) of_33\IN|hyperplasia (l_pobj) hyperplasia_39\NN|the|induced|epithelial
C009166_D009369 NONE RA_17\NN|% (r_pobj) with_14\IN|ra|and|in (r_prep) rats_9\NNS|3|(|%|)|with (r_pobj) in_7\IN|rats (r_prep) induced_6\VBN|tumors|were|in|. (l_nsubjpass) Tumors_0\NNS|,|papillomas|,
C009166_D009369 NONE RA_29\NNP| (r_compound) administration_32\NN|%|ra|- (r_punct) ._33\.|administration (r_punct) induced_6\VBN|tumors|were|in|. (l_nsubjpass) Tumors_0\NNS|,|papillomas|,
625456
D002119_D006934 CID ate_24\VBN| (r_amod) sodium_26\NN|carbon|-|ate|- (r_compound) powders_28\NNS|calcium|sodium|bicarbonate (r_pobj) of_20\IN|powders (r_prep) amounts_19\NNS|large|of (r_dobj) consumed_17\VBN|who|had|regularly|amounts|for (r_relcl) patients_13\NNS|consumed (r_pobj) in_12\IN|patients (r_prep) reported_11\VBN|case|two|are|in|. (l_nsubjpass) case_1\NN|one|of|and (l_prep) of_2\IN|hypercalcaemia (l_pobj) hypercalcaemia_4\NN|acute
D002119_D053040 CID ate_24\VBN| (r_amod) sodium_26\NN|carbon|-|ate|- (r_compound) powders_28\NNS|calcium|sodium|bicarbonate (r_pobj) of_20\IN|powders (r_prep) amounts_19\NNS|large|of (r_dobj) consumed_17\VBN|who|had|regularly|amounts|for (r_relcl) patients_13\NNS|consumed (r_pobj) in_12\IN|patients (r_prep) reported_11\VBN|case|two|are|in|. (l_nsubjpass) two_6\CD|of (l_prep) of_7\IN|nephrolithiasis (l_pobj) nephrolithiasis_9\NN|recurrent
D017693_D006934 CID bicarbonate_27\NN| (r_compound) powders_28\NNS|calcium|sodium|bicarbonate (r_pobj) of_20\IN|powders (r_prep) amounts_19\NNS|large|of (r_dobj) consumed_17\VBN|who|had|regularly|amounts|for (r_relcl) patients_13\NNS|consumed (r_pobj) in_12\IN|patients (r_prep) reported_11\VBN|case|two|are|in|. (l_nsubjpass) case_1\NN|one|of|and (l_prep) of_2\IN|hypercalcaemia (l_pobj) hypercalcaemia_4\NN|acute
D017693_D053040 CID bicarbonate_27\NN| (r_compound) powders_28\NNS|calcium|sodium|bicarbonate (r_pobj) of_20\IN|powders (r_prep) amounts_19\NNS|large|of (r_dobj) consumed_17\VBN|who|had|regularly|amounts|for (r_relcl) patients_13\NNS|consumed (r_pobj) in_12\IN|patients (r_prep) reported_11\VBN|case|two|are|in|. (l_nsubjpass) two_6\CD|of (l_prep) of_7\IN|nephrolithiasis (l_pobj) nephrolithiasis_9\NN|recurrent
19234905
D007980_D004409 CID levodopa_55\RB| (r_npadvmod) induced_57\VBN|levodopa|- (r_amod) dyskinesias_58\NNS|induced
D014635_D006423 NONE Valproate_33\NNP|day (r_pobj) with_32\IN|valproate (r_prep) improved_28\VBD|which|partly|within|with (r_advcl) developed_18\VBN|one|movements|after|improved (r_conj) had_8\VBD|observed|:|one|hemianopsia|after|and|developed|. (l_dobj) hemianopsia_12\NN|a|left|homonymous
16629641
D007372_D006526 NONE interferon_12\NN|pegylated|and|ribavirin (r_pobj) with_10\IN|interferon (r_prep) therapy_9\NN|combination|with (r_attr) is_7\VBZ|treatment|therapy|. (l_nsubj) treatment_3\NN|the|current|best|for (l_prep) for_4\IN|infection (l_pobj) infection_6\NN|hcv
D012254_D006526 NONE ribavirin_14\NN| (r_conj) interferon_12\NN|pegylated|and|ribavirin (r_pobj) with_10\IN|interferon (r_prep) therapy_9\NN|combination|with (r_attr) is_7\VBZ|treatment|therapy|. (l_nsubj) treatment_3\NN|the|current|best|for (l_prep) for_4\IN|infection (l_pobj) infection_6\NN|hcv
D012254_D006526 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|ribavirin|- (r_amod) hemolysis_11\NN|induced (r_pobj) of_7\IN|hemolysis (r_prep) result_6\NN|a|of (r_pobj) as_4\IN|mainly|result (r_prep) decrease_2\VBP|concentrations|as|,|and|be (l_conj) be_17\VB|anemia|can|problematic|in|comorbid|. (l_prep) in_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|infection (l_pobj) infection_23\NN|hcv|,
D012254_D006461 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|ribavirin|- (r_amod) hemolysis_11\NN|induced
D012254_D000740 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|ribavirin|- (r_amod) hemolysis_11\NN|induced (r_pobj) of_7\IN|hemolysis (r_prep) result_6\NN|a|of (r_pobj) as_4\IN|mainly|result (r_prep) decrease_2\VBP|concentrations|as|,|and|be (l_conj) be_17\VB|anemia|can|problematic|in|comorbid|. (l_nsubj) anemia_15\NN|this
D012254_D000740 NONE ribavirin_1\RB| (r_npadvmod) associated_3\VBN|ribavirin|- (r_amod) anemia_4\NN|associated
D012254_D000740 NONE ribavirin_8\RB| (r_npadvmod) associated_10\VBN|ribavirin|- (r_amod) anemia_11\NN|associated
D012254_D007674 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|ribavirin|- (r_amod) hemolysis_11\NN|induced (r_pobj) of_7\IN|hemolysis (r_prep) result_6\NN|a|of (r_pobj) as_4\IN|mainly|result (r_prep) decrease_2\VBP|concentrations|as|,|and|be (l_conj) be_17\VB|anemia|can|problematic|in|comorbid|. (l_conj) comorbid_29\VBN|those|have|disorders (l_dobj) disorders_33\NNS|renal
D012254_D002318 NONE ribavirin_8\RB| (r_npadvmod) induced_10\VBN|ribavirin|- (r_amod) hemolysis_11\NN|induced (r_pobj) of_7\IN|hemolysis (r_prep) result_6\NN|a|of (r_pobj) as_4\IN|mainly|result (r_prep) decrease_2\VBP|concentrations|as|,|and|be (l_conj) be_17\VB|anemia|can|problematic|in|comorbid|. (l_conj) comorbid_29\VBN|those|have|disorders (l_dobj) disorders_33\NNS|renal
C026956_D000743 NONE Viramidine_0\NNP|,|prodrug|, (r_nsubj) has_10\VBZ|viramidine|potential (l_dobj) potential_12\NN|the|maintain (l_acl) maintain_14\VB|to|efficacy|decreasing (l_advcl) decreasing_21\VBG|while|risk (l_dobj) risk_23\NN|the|of (l_prep) of_24\IN|anemia (l_pobj) anemia_26\NN|hemolytic|in
C026956_D019698 NONE Viramidine_0\NNP|,|prodrug|, (r_nsubj) has_10\VBZ|viramidine|potential (l_dobj) potential_12\NN|the|maintain (l_acl) maintain_14\VB|to|efficacy|decreasing (l_advcl) decreasing_21\VBG|while|risk (l_dobj) risk_23\NN|the|of (l_prep) of_24\IN|anemia (l_pobj) anemia_26\NN|hemolytic|in (l_prep) in_27\IN|patients (l_pobj) patients_28\NNS|with (l_prep) with_29\IN|c. (l_pobj) C._32\NNP|chronic|hepatitis
D012254_D000743 CID ribavirin_8\NN| (r_pobj) of_7\IN|ribavirin (r_prep) prodrug_6\NN|a|targeting|of (r_appos) Viramidine_0\NNP|,|prodrug|, (r_nsubj) has_10\VBZ|viramidine|potential (l_dobj) potential_12\NN|the|maintain (l_acl) maintain_14\VB|to|efficacy|decreasing (l_advcl) decreasing_21\VBG|while|risk (l_dobj) risk_23\NN|the|of (l_prep) of_24\IN|anemia (l_pobj) anemia_26\NN|hemolytic|in
D012254_D000743 CID ribavirin_19\RB| (r_pobj) of_18\IN|ribavirin (r_prep) efficacy_17\NN|the|virologic|of (r_dobj) maintain_14\VB|to|efficacy|decreasing (l_advcl) decreasing_21\VBG|while|risk (l_dobj) risk_23\NN|the|of (l_prep) of_24\IN|anemia (l_pobj) anemia_26\NN|hemolytic|in
D012254_D019698 NONE ribavirin_8\NN| (r_pobj) of_7\IN|ribavirin (r_prep) prodrug_6\NN|a|targeting|of (r_appos) Viramidine_0\NNP|,|prodrug|, (r_nsubj) has_10\VBZ|viramidine|potential (l_dobj) potential_12\NN|the|maintain (l_acl) maintain_14\VB|to|efficacy|decreasing (l_advcl) decreasing_21\VBG|while|risk (l_dobj) risk_23\NN|the|of (l_prep) of_24\IN|anemia (l_pobj) anemia_26\NN|hemolytic|in (l_prep) in_27\IN|patients (l_pobj) patients_28\NNS|with (l_prep) with_29\IN|c. (l_pobj) C._32\NNP|chronic|hepatitis
D012254_D019698 NONE ribavirin_19\RB| (r_pobj) of_18\IN|ribavirin (r_prep) efficacy_17\NN|the|virologic|of (r_dobj) maintain_14\VB|to|efficacy|decreasing (l_advcl) decreasing_21\VBG|while|risk (l_dobj) risk_23\NN|the|of (l_prep) of_24\IN|anemia (l_pobj) anemia_26\NN|hemolytic|in (l_prep) in_27\IN|patients (l_pobj) patients_28\NNS|with (l_prep) with_29\IN|c. (l_pobj) C._32\NNP|chronic|hepatitis
11009181
D001058_D010300 NONE Apomorphine_0\NNP|:|therapy|. (l_appos) therapy_4\NN|an|underutilized|for (l_prep) for_5\IN|disease (l_pobj) disease_8\NN|parkinson
D001058_D010300 NONE Apomorphine_0\NNP| (r_nsubj) was_1\VBD|apomorphine|drug|. (l_attr) drug_5\NN|the|first|dopaminergic|used (l_acl) used_7\VBN|ever|treat (l_xcomp) treat_9\VB|to|symptoms (l_dobj) symptoms_10\NNS|of (l_prep) of_11\IN|disease (l_pobj) disease_14\NN|parkinson
D001058_D010300 NONE apomorphine_24\NN| (r_pobj) of_23\IN|apomorphine (r_prep) administration_22\NN|subcutaneous|of (r_pobj) by_20\IN|administration (r_prep) treating_15\VBG|disease|by (l_dobj) disease_19\NN|fluctuating|parkinson
D001058_D010300 NONE apomorphine_8\NN| (r_compound) treatment_9\NN|subcutaneous|apomorphine|in (l_prep) in_10\IN|disease (l_pobj) disease_14\NN|fluctuating|parkinson
D001058_D004409 NONE apomorphine_13\NN|subcutaneous (r_compound) infusions_14\NNS|continuous|apomorphine (r_pobj) with_10\IN|infusions (r_prep) monotherapy_9\NN|with (r_nsubjpass) associated_16\VBN|that|monotherapy|is|with (l_prep) with_17\IN|reductions (l_pobj) reductions_19\NNS|marked|of (l_prep) of_20\IN|dyskinesias (l_pobj) dyskinesias_25\NNS|preexisting|induced
D007980_D004409 CID levodopa_22\NN| (r_npadvmod) induced_24\VBN|levodopa|- (r_amod) dyskinesias_25\NNS|preexisting|induced
D001058_D001523 NONE apomorphine_6\NN| (r_compound) treatment_7\NN|subcutaneous|apomorphine (r_pobj) of_4\IN|treatment (r_prep) effects_3\NNS|the|main|side|of (r_nsubjpass) related_9\VBN|effects|are|to|,|play|. (l_advcl) play_20\VBP|whereas|sedation|role (l_nsubj) sedation_16\NN|and|complications (l_conj) complications_19\NNS|psychiatric (l_amod) psychiatric_18\JJ|
11185967
D003042_D012640 NONE cocaine_16\NN|or|amphetamine|in (l_prep) in_19\IN|patients (l_pobj) patients_24\NNS|emergency|seizure (l_compound) seizure_23\NN|department
D003042_D012640 NONE cocaine_9\NN|and|amphetamines|in (l_prep) in_12\IN|patients (l_pobj) patients_15\NNS|seizure (l_compound) seizure_14\NN|adult
D000661_D012640 NONE amphetamine_18\NN| (r_conj) cocaine_16\NN|or|amphetamine|in (l_prep) in_19\IN|patients (l_pobj) patients_24\NNS|emergency|seizure (l_compound) seizure_23\NN|department
D000431_D012640 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|alcohol|- (r_amod) disorder_12\NN|related|seizure (l_compound) seizure_11\NN|
D000431_D012640 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|alcohol|- (r_amod) disorder_12\NN|related|seizure (r_conj) drug_6\NN|underlying|or|disorder (r_pobj) of_4\IN|drug (r_prep) history_3\NN|of (r_appos) demographics_1\NNS|patient|,|history|, (r_nsubj) estimated_14\VBN|demographics|time|from|,|results|recorded|. (l_prep) from_16\IN|seizure|to (l_pobj) seizure_17\NN|
D000431_D019970 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|alcohol|- (r_amod) disorder_12\NN|related|seizure (r_conj) drug_6\NN|underlying|or|disorder (r_pobj) of_4\IN|drug (r_prep) history_3\NN|of (r_appos) demographics_1\NNS|patient|,|history|, (r_nsubj) estimated_14\VBN|demographics|time|from|,|results|recorded|. (l_prep) from_16\IN|seizure|to (l_prep) to_18\IN|collection (l_pobj) collection_20\NN|sample|,|history (l_conj) history_22\NN|or|suspicion (l_conj) suspicion_24\NN|of (l_prep) of_25\IN|cocaine (l_pobj) cocaine_26\NN|or|abuse (l_conj) abuse_29\NN|amphetamine
D000431_D019969 NONE alcohol_8\NN| (r_npadvmod) related_10\VBN|alcohol|- (r_amod) disorder_12\NN|related|seizure (r_conj) drug_6\NN|underlying|or|disorder (r_pobj) of_4\IN|drug (r_prep) history_3\NN|of (r_appos) demographics_1\NNS|patient|,|history|, (r_nsubj) estimated_14\VBN|demographics|time|from|,|results|recorded|. (l_prep) from_16\IN|seizure|to (l_prep) to_18\IN|collection (l_pobj) collection_20\NN|sample|,|history (l_conj) history_22\NN|or|suspicion (l_conj) suspicion_24\NN|of (l_prep) of_25\IN|cocaine (l_pobj) cocaine_26\NN|or|abuse (l_conj) abuse_29\NN|amphetamine
D000662_D012640 NONE amphetamines_11\NNS| (r_conj) cocaine_9\NN|and|amphetamines|in (l_prep) in_12\IN|patients (l_pobj) patients_15\NNS|seizure (l_compound) seizure_14\NN|adult
20705401
D012701_D011605 NONE Serotonin_0\NN| (r_nmod) gene_3\NN|serotonin|6|receptor (r_nsubjpass) associated_5\VBN|gene|is|with|. (l_prep) with_6\IN|psychosis (l_pobj) psychosis_10\NN|induced|in
D012701_D011605 NONE 5-HT6_20\CD| (r_nummod) receptors_21\NNS|altered|5-ht6 (r_nsubjpass) involved_23\VBN|that|receptors|are|in (l_prep) in_24\IN|pathophysiology (l_pobj) pathophysiology_26\NN|the|of (l_prep) of_27\IN|disorders (l_pobj) disorders_29\NNS|psychotic
D012701_D011605 NONE 5-HT6_11\CD| (r_nummod) gene_12\NN|the|5-ht6|(|htr6|)|with (l_prep) with_16\IN|psychosis (l_pobj) psychosis_20\NN|induced
D008694_D011605 CID methamphetamine_7\NN| (r_npadvmod) induced_9\VBN|methamphetamine|- (r_amod) psychosis_10\NN|induced|in
D008694_D011605 CID methamphetamine_3\NN| (r_pobj) of_2\IN|methamphetamine (r_prep) symptoms_1\NNS|the|of|psychosis (l_appos) psychosis_6\NN|(|meth)-induced
D008694_D011605 CID METH)-induced_5\JJ| (r_amod) psychosis_6\NN|(|meth)-induced
D008694_D011605 CID METH_17\NNP| (r_npadvmod) induced_19\VBN|meth|- (r_amod) psychosis_20\NN|induced
D008694_D011605 CID METH_29\NN| (r_npadvmod) induced_31\VBN|meth|- (r_amod) patients_33\NNS|(|197|induced|psychosis|and|controls|)|in (l_compound) psychosis_32\NN|
D008694_D011605 CID METH_4\NNP| (r_npadvmod) induced_6\VBN|meth|- (r_amod) patients_8\NNS|induced|psychosis|in (l_compound) psychosis_7\NN|
D008694_D011605 CID METH_32\NNP| (r_npadvmod) induced_34\VBN|meth|- (r_amod) patients_36\NNS|induced|psychosis (l_compound) psychosis_35\NN|
D008694_D011605 CID METH_10\NNP| (r_npadvmod) induced_12\VBN|meth|- (r_amod) psychosis_13\NN|induced|in
D012701_D006948 NONE serotonin_1\NN|the|receptor (r_nsubjpass) targeted_9\VBN|serotonin|is|therapeutically|by|corrected|. (l_agent) by_10\IN|antipsychotics (l_pobj) antipsychotics_14\NNS|several|generation|,|as (l_prep) as_17\IN|such|clozapine (l_pobj) clozapine_18\NN|and|olanzapine|,|and|induced|hyperactivity (l_conj) hyperactivity_28\NN|in
D012701_D006948 NONE 5-HT6_4\CD| (r_nummod) receptor_6\NN|6|(|5-ht6|) (r_appos) serotonin_1\NN|the|receptor (r_nsubjpass) targeted_9\VBN|serotonin|is|therapeutically|by|corrected|. (l_agent) by_10\IN|antipsychotics (l_pobj) antipsychotics_14\NNS|several|generation|,|as (l_prep) as_17\IN|such|clozapine (l_pobj) clozapine_18\NN|and|olanzapine|,|and|induced|hyperactivity (l_conj) hyperactivity_28\NN|in
D012701_D006948 NONE 5-HT6_39\CD| (r_nummod) antagonist_41\NN|a|selective|5-ht6|receptor (r_pobj) of_36\IN|antagonist (r_prep) use_35\NN|the|of (r_pobj) with_33\IN|use (r_prep) corrected_32\VBN|is|with (r_conj) targeted_9\VBN|serotonin|is|therapeutically|by|corrected|. (l_agent) by_10\IN|antipsychotics (l_pobj) antipsychotics_14\NNS|several|generation|,|as (l_prep) as_17\IN|such|clozapine (l_pobj) clozapine_18\NN|and|olanzapine|,|and|induced|hyperactivity (l_conj) hyperactivity_28\NN|in
D003024_D006948 NONE clozapine_18\NN|and|olanzapine|,|and|induced|hyperactivity (l_conj) hyperactivity_28\NN|in
C076029_D006948 NONE olanzapine_20\NN| (r_conj) clozapine_18\NN|and|olanzapine|,|and|induced|hyperactivity (l_conj) hyperactivity_28\NN|in
D003913_D006948 NONE amphetamine_25\NN| (r_npadvmod) induced_27\VBN|d|-|amphetamine|- (r_conj) clozapine_18\NN|and|olanzapine|,|and|induced|hyperactivity (l_conj) hyperactivity_28\NN|in
D012701_D012559 NONE 5-HT6_20\CD| (r_nummod) receptors_21\NNS|altered|5-ht6 (r_nsubjpass) involved_23\VBN|that|receptors|are|in (r_ccomp) suggests_17\VBZ|evidence|involved|. (r_conj) considered_4\VBN|models|were|reflect|,|and|suggests (l_xcomp) reflect_6\VB|to|symptoms (l_dobj) symptoms_9\NNS|the|positive|of (l_prep) of_10\IN|schizophrenia (l_pobj) schizophrenia_11\NN|
D008694_D012563 NONE methamphetamine_3\NN| (r_pobj) of_2\IN|methamphetamine (r_prep) symptoms_1\NNS|the|of|psychosis (r_nsubj) are_7\VBP|symptoms|similar|. (l_acomp) similar_8\JJ|to (l_prep) to_9\IN|those (l_pobj) those_10\DT|of (l_prep) of_11\IN|schizophrenia (l_pobj) schizophrenia_14\NN|paranoid|type
D008694_D012563 NONE METH)-induced_5\JJ| (r_amod) psychosis_6\NN|(|meth)-induced (r_appos) symptoms_1\NNS|the|of|psychosis (r_nsubj) are_7\VBP|symptoms|similar|. (l_acomp) similar_8\JJ|to (l_prep) to_9\IN|those (l_pobj) those_10\DT|of (l_prep) of_11\IN|schizophrenia (l_pobj) schizophrenia_14\NN|paranoid|type
2980315
C053571_D014693 NONE iopentol_14\NN|%|and|iohexol (r_pobj) after_13\IN|iopentol (r_prep) 0.05_11\CD|(|p|less|than|)|after (r_parataxis) were_4\VBD|frequencies|lower|0.05|than|. (l_nsubj) Frequencies_0\NNS|of (l_prep) of_1\IN|fibrillation (l_pobj) fibrillation_3\NN|ventricular
D007472_D014693 NONE iohexol_20\NN|(|%|) (r_conj) iopentol_14\NN|%|and|iohexol (r_pobj) after_13\IN|iopentol (r_prep) 0.05_11\CD|(|p|less|than|)|after (r_parataxis) were_4\VBD|frequencies|lower|0.05|than|. (l_nsubj) Frequencies_0\NNS|of (l_prep) of_1\IN|fibrillation (l_pobj) fibrillation_3\NN|ventricular
D008794_D014693 CID metrizoate_27\NN|(|%|) (r_pobj) after_26\IN|metrizoate (r_prep) than_25\IN|after (r_prep) were_4\VBD|frequencies|lower|0.05|than|. (l_nsubj) Frequencies_0\NNS|of (l_prep) of_1\IN|fibrillation (l_pobj) fibrillation_3\NN|ventricular
18356633
D000583_D007674 CID amikacin_3\JJ| (r_amod) nephrotoxicity_4\NN|amikacin|in
D000583_D007674 CID amikacin_2\RB| (r_npadvmod) associated_4\VBN|amikacin|- (r_amod) nephrotoxicity_5\NN|associated
D000583_D007674 CID amikacin_17\JJ|concentrations (r_prep) via_16\IN|amikacin (r_prep) evaluation_13\NN|of|via (r_conj) creatinine_11\NN|serum|and|evaluation (r_pobj) in_9\IN|creatinine (r_prep) increase_8\NN|an|in (r_pobj) of_6\IN|increase (r_prep) means_5\NNS|of (r_pobj) by_4\IN|means (r_prep) occurrence_1\NN|the|of|by (l_prep) of_2\IN|nephrotoxicity (l_pobj) nephrotoxicity_3\NN|
D000583_D009503 NONE Amikacin_0\NNP| (r_nsubj) is_1\VBZ|amikacin|aminoglycoside|. (l_attr) aminoglycoside_3\NN|an|used (l_acl) used_5\VBN|commonly|provide (l_xcomp) provide_7\VB|to|treatment (l_dobj) treatment_13\NN|empirical|double|negative|for (l_prep) for_14\IN|neutropenia (l_pobj) neutropenia_16\NN|febrile|and|infections
D000583_D007239 NONE Amikacin_0\NNP| (r_nsubj) is_1\VBZ|amikacin|aminoglycoside|. (l_attr) aminoglycoside_3\NN|an|used (l_acl) used_5\VBN|commonly|provide (l_xcomp) provide_7\VB|to|treatment (l_dobj) treatment_13\NN|empirical|double|negative|for (l_prep) for_14\IN|neutropenia (l_pobj) neutropenia_16\NN|febrile|and|infections (l_conj) infections_20\NNS|other|suspected
D000617_D009503 NONE aminoglycoside_3\NN|an|used (l_acl) used_5\VBN|commonly|provide (l_xcomp) provide_7\VB|to|treatment (l_dobj) treatment_13\NN|empirical|double|negative|for (l_prep) for_14\IN|neutropenia (l_pobj) neutropenia_16\NN|febrile|and|infections
D000617_D007239 NONE aminoglycoside_3\NN|an|used (l_acl) used_5\VBN|commonly|provide (l_xcomp) provide_7\VB|to|treatment (l_dobj) treatment_13\NN|empirical|double|negative|for (l_prep) for_14\IN|neutropenia (l_pobj) neutropenia_16\NN|febrile|and|infections (l_conj) infections_20\NNS|other|suspected
D000617_D006402 NONE aminoglycoside_17\NN|an (r_pobj) with_15\IN|aminoglycoside (r_prep) treatment_14\NN|with (r_dobj) required_13\VBD|that|treatment (r_relcl) disorder_11\NN|a|oncologic|required
D000617_D009369 NONE aminoglycoside_17\NN|an (r_pobj) with_15\IN|aminoglycoside (r_prep) treatment_14\NN|with (r_dobj) required_13\VBD|that|treatment (r_relcl) disorder_11\NN|a|oncologic|required
D000583_D006402 NONE amikacin_27\JJ|conventional (r_pobj) to_20\IN|amikacin (r_prep) randomized_19\VBN|patients|were|to|. (l_nsubjpass) patients_1\NNS|forty|with (l_prep) with_2\IN|diagnosis (l_pobj) diagnosis_4\NN|a|consistent (l_amod) consistent_5\JJ|with (l_prep) with_6\IN|disorder (l_pobj) disorder_11\NN|a|oncologic|required
D000583_D009369 NONE amikacin_27\JJ|conventional (r_pobj) to_20\IN|amikacin (r_prep) randomized_19\VBN|patients|were|to|. (l_nsubjpass) patients_1\NNS|forty|with (l_prep) with_2\IN|diagnosis (l_pobj) diagnosis_4\NN|a|consistent (l_amod) consistent_5\JJ|with (l_prep) with_6\IN|disorder (l_pobj) disorder_11\NN|a|oncologic|required
D003404_D007674 NONE creatinine_11\NN|serum|and|evaluation (r_pobj) in_9\IN|creatinine (r_prep) increase_8\NN|an|in (r_pobj) of_6\IN|increase (r_prep) means_5\NNS|of (r_pobj) by_4\IN|means (r_prep) occurrence_1\NN|the|of|by (l_prep) of_2\IN|nephrotoxicity (l_pobj) nephrotoxicity_3\NN|
2320800
D007069_D001002 CID ifosfamide_5\JJ| (r_compound) chemotherapy_6\NN|dose|ifosfamide (r_dobj) complicating_2\VBG|anuria|chemotherapy|in|. (l_nsubj) anuria_1\NN|lethal
D007069_D001002 CID ifosfamide_34\NN|m2|bolus (r_pobj) after_28\IN|5|ifosfamide (r_prep) day_27\NN|the|after (r_npadvmod) developed_17\VBD|woman|failure|,|day|. (l_dobj) failure_22\NN|an|irreversible|lethal|renal|with (l_prep) with_23\IN|anuria (l_pobj) anuria_24\NN|
D007069_D001002 CID ifosfamide_11\NN|to (r_xcomp) due_9\JJ|ifosfamide (r_acomp) was_7\VBD|that|anuria|mainly|due|,|occurring (l_nsubj) anuria_6\NN|this|lethal
D007069_D001943 NONE ifosfamide_5\JJ| (r_compound) chemotherapy_6\NN|dose|ifosfamide (r_dobj) complicating_2\VBG|anuria|chemotherapy|in|. (l_prep) in_7\IN|patient (l_pobj) patient_11\NN|a|cancer|with (l_compound) cancer_10\NN|breast
D007069_D001943 NONE ifosfamide_34\NN|m2|bolus (r_pobj) after_28\IN|5|ifosfamide (r_prep) day_27\NN|the|after (r_npadvmod) developed_17\VBD|woman|failure|,|day|. (l_nsubj) woman_6\NN|a|old|with|,|treated|, (l_prep) with_7\IN|cancer (l_pobj) cancer_10\NN|advanced|breast
D007069_D007674 CID ifosfamide_5\JJ| (r_compound) chemotherapy_6\NN|dose|ifosfamide (r_dobj) complicating_2\VBG|anuria|chemotherapy|in|. (l_prep) in_7\IN|patient (l_pobj) patient_11\NN|a|cancer|with (l_prep) with_12\IN|function (l_pobj) function_16\NN|an|impaired|renal
D007069_D007674 CID Ifosfamide_0\NNP| (r_nsubj) is_1\VBZ|ifosfamide|drug|. (l_attr) drug_5\NN|a|known|nephrotoxic|with (l_amod) nephrotoxic_4\JJ|
D007069_D007674 CID Ifosfamide_0\NNP| (r_nsubj) is_1\VBZ|ifosfamide|drug|. (l_attr) drug_5\NN|a|known|nephrotoxic|with (l_prep) with_6\IN|tubulopathies (l_pobj) tubulopathies_8\NNS|demonstrated
D007069_D007674 CID ifosfamide_5\NN| (r_pobj) of_4\IN|ifosfamide (r_prep) use_3\NN|careful|of|in (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|pretreated (l_acl) pretreated_8\VBN|with (l_prep) with_9\IN|chemotherapy (l_pobj) chemotherapy_11\NN|nephrotoxic|and|perfusion (l_amod) nephrotoxic_10\JJ|
D002945_D001943 NONE cisplatin_15\NN| (r_pobj) with_14\IN|cisplatin (r_prep) treated_13\VBN|previously|with (r_acl) woman_6\NN|a|old|with|,|treated|, (l_prep) with_7\IN|cancer (l_pobj) cancer_10\NN|advanced|breast
D002945_D051437 NONE cisplatin_15\NN| (r_pobj) with_14\IN|cisplatin (r_prep) treated_13\VBN|previously|with (r_acl) woman_6\NN|a|old|with|,|treated|, (r_nsubj) developed_17\VBD|woman|failure|,|day|. (l_dobj) failure_22\NN|an|irreversible|lethal|renal|with
D002945_D001002 NONE cisplatin_15\NN| (r_pobj) with_14\IN|cisplatin (r_prep) treated_13\VBN|previously|with (r_acl) woman_6\NN|a|old|with|,|treated|, (r_nsubj) developed_17\VBD|woman|failure|,|day|. (l_dobj) failure_22\NN|an|irreversible|lethal|renal|with (l_prep) with_23\IN|anuria (l_pobj) anuria_24\NN|
D002945_D001002 NONE cisplatin_20\NN| (r_amod) chemotherapy_21\NN|previous|cisplatin (r_dobj) received_18\VBN|having|chemotherapy|and|with (r_advcl) occurring_13\VBG|in|received (r_advcl) was_7\VBD|that|anuria|mainly|due|,|occurring (l_nsubj) anuria_6\NN|this|lethal
D007069_D051437 NONE ifosfamide_34\NN|m2|bolus (r_pobj) after_28\IN|5|ifosfamide (r_prep) day_27\NN|the|after (r_npadvmod) developed_17\VBD|woman|failure|,|day|. (l_dobj) failure_22\NN|an|irreversible|lethal|renal|with
D007069_D007022 NONE ifosfamide_11\NN|to (r_xcomp) due_9\JJ|ifosfamide (r_acomp) was_7\VBD|that|anuria|mainly|due|,|occurring (l_advcl) occurring_13\VBG|in|received (l_advcl) received_18\VBN|having|chemotherapy|and|with (l_prep) with_23\IN|perfusion (l_pobj) perfusion_26\NN|poor|kidney|due (l_prep) due_27\IN|to (l_pcomp) to_28\IN|hypotension (l_pobj) hypotension_30\NN|transient
D002945_D007022 NONE cisplatin_20\NN| (r_amod) chemotherapy_21\NN|previous|cisplatin (r_dobj) received_18\VBN|having|chemotherapy|and|with (l_prep) with_23\IN|perfusion (l_pobj) perfusion_26\NN|poor|kidney|due (l_prep) due_27\IN|to (l_pcomp) to_28\IN|hypotension (l_pobj) hypotension_30\NN|transient
1628552
D002738_D006327 NONE Chloroquine_0\NNP| (r_nsubj) related_1\VBD|chloroquine|block|: (l_dobj) block_4\NN|complete|heart|with
D002738_D006327 NONE chloroquine_5\NN| (r_amod) retinopathy_6\NN|chloroquine (r_pobj) of_4\IN|retinopathy (r_prep) features_3\NNS|of (r_dobj) revealed_2\VBD|assessment|features (r_ccomp) revealed_10\VBD|revealed|,|assessment|features|. (l_dobj) features_11\NNS|of|and|block (l_conj) block_19\NN|a|complete|heart|with
D002738_D006327 NONE chloroquine_15\NN| (r_amod) discontinuation_16\NN|chloroquine (r_dobj) following_14\VBG|discontinuation (r_prep) resolved_12\VBD|failure|spontaneously|following|. (r_conj) treated_4\VBN|block|was|by|and|resolved (l_nsubjpass) block_2\NN|the|heart
D002738_D001766 CID Chloroquine_0\NNP| (r_nsubj) related_1\VBD|chloroquine|block|: (l_dobj) block_4\NN|complete|heart|with (l_prep) with_5\IN|blindness (l_pobj) blindness_6\NN|
D002738_D015354 NONE chloroquine_9\NN| (r_amod) ingestion_10\NN|regular|chloroquine (r_pobj) of_7\IN|ingestion (r_prep) history_6\NN|of (r_pobj) with_5\IN|history (r_prep) woman_4\NN|a|27-year|old|african|with (r_nsubj) presented_11\VBN|woman|with|. (l_prep) with_12\IN|deterioration (l_pobj) deterioration_14\NN|progressive|of|,|fatiguability (l_prep) of_15\IN|vision (l_pobj) vision_16\NN|
D002738_D005221 CID chloroquine_9\NN| (r_amod) ingestion_10\NN|regular|chloroquine (r_pobj) of_7\IN|ingestion (r_prep) history_6\NN|of (r_pobj) with_5\IN|history (r_prep) woman_4\NN|a|27-year|old|african|with (r_nsubj) presented_11\VBN|woman|with|. (l_prep) with_12\IN|deterioration (l_pobj) deterioration_14\NN|progressive|of|,|fatiguability (l_conj) fatiguability_19\NN|easy|,|dyspnoea
D002738_D004417 CID chloroquine_9\NN| (r_amod) ingestion_10\NN|regular|chloroquine (r_pobj) of_7\IN|ingestion (r_prep) history_6\NN|of (r_pobj) with_5\IN|history (r_prep) woman_4\NN|a|27-year|old|african|with (r_nsubj) presented_11\VBN|woman|with|. (l_prep) with_12\IN|deterioration (l_pobj) deterioration_14\NN|progressive|of|,|fatiguability (l_conj) fatiguability_19\NN|easy|,|dyspnoea (l_conj) dyspnoea_21\NN|,|dizziness
D002738_D004244 CID chloroquine_9\NN| (r_amod) ingestion_10\NN|regular|chloroquine (r_pobj) of_7\IN|ingestion (r_prep) history_6\NN|of (r_pobj) with_5\IN|history (r_prep) woman_4\NN|a|27-year|old|african|with (r_nsubj) presented_11\VBN|woman|with|. (l_prep) with_12\IN|deterioration (l_pobj) deterioration_14\NN|progressive|of|,|fatiguability (l_conj) fatiguability_19\NN|easy|,|dyspnoea (l_conj) dyspnoea_21\NN|,|dizziness (l_conj) dizziness_23\NN|progressing
D002738_D013575 CID chloroquine_9\NN| (r_amod) ingestion_10\NN|regular|chloroquine (r_pobj) of_7\IN|ingestion (r_prep) history_6\NN|of (r_pobj) with_5\IN|history (r_prep) woman_4\NN|a|27-year|old|african|with (r_nsubj) presented_11\VBN|woman|with|. (l_prep) with_12\IN|deterioration (l_pobj) deterioration_14\NN|progressive|of|,|fatiguability (l_conj) fatiguability_19\NN|easy|,|dyspnoea (l_conj) dyspnoea_21\NN|,|dizziness (l_conj) dizziness_23\NN|progressing (l_acl) progressing_24\VBG|to (l_prep) to_25\IN|attacks (l_pobj) attacks_27\NNS|syncopal
D002738_D012164 CID chloroquine_5\NN| (r_amod) retinopathy_6\NN|chloroquine
D002738_D006333 CID chloroquine_5\NN| (r_amod) retinopathy_6\NN|chloroquine (r_pobj) of_4\IN|retinopathy (r_prep) features_3\NNS|of (r_dobj) revealed_2\VBD|assessment|features (r_ccomp) revealed_10\VBD|revealed|,|assessment|features|. (l_dobj) features_11\NNS|of|and|block (l_prep) of_12\IN|failure (l_pobj) failure_14\NN|heart
D002738_D006333 CID chloroquine_15\NN| (r_amod) discontinuation_16\NN|chloroquine (r_dobj) following_14\VBG|discontinuation (r_prep) resolved_12\VBD|failure|spontaneously|following|. (l_nsubj) failure_11\NN|the|heart
D002738_D002037 CID chloroquine_5\NN| (r_amod) retinopathy_6\NN|chloroquine (r_pobj) of_4\IN|retinopathy (r_prep) features_3\NNS|of (r_dobj) revealed_2\VBD|assessment|features (r_ccomp) revealed_10\VBD|revealed|,|assessment|features|. (l_dobj) features_11\NNS|of|and|block (l_conj) block_19\NN|a|complete|heart|with (l_prep) with_20\IN|pattern (l_pobj) pattern_25\NN|right|bundle|block (l_compound) block_24\NN|branch
18441470
D008094_D054537 CID lithium_5\NN| (r_compound) therapy_6\NN|lithium (r_pobj) to_4\IN|therapy (r_prep) secondary_3\JJ|to (r_amod) block_2\NN|complete|atrioventricular|secondary|.
D008094_D054537 CID lithium_17\NN| (r_compound) therapy_18\NN|lithium (r_pobj) to_16\IN|therapy (r_prep) developed_14\VBD|in|,|block|secondary|to|,|necessitating|. (l_nsubj) block_10\NN|complete|atrioventricular|(|av|)|with
D008094_D012804 CID lithium_14\NN| (r_pobj) of_13\IN|lithium (r_prep) effects_12\NNS|the|adverse|cardiovascular|of (r_pobj) among_8\IN|effects (r_prep) reported_5\VBN|dysfunction|has|been|frequently|among|. (l_nsubjpass) dysfunction_2\NN|sinus|node
D008094_D013575 NONE lithium_17\NN| (r_compound) therapy_18\NN|lithium (r_pobj) to_16\IN|therapy (r_prep) developed_14\VBD|in|,|block|secondary|to|,|necessitating|. (l_nsubj) block_10\NN|complete|atrioventricular|(|av|)|with (l_prep) with_11\IN|attacks (l_pobj) attacks_13\NNS|syncopal
D008094_D013575 NONE lithium_1\NN|serum (r_compound) levels_2\NNS|lithium (r_nsubj) remained_3\VBD|levels|under|during|. (l_prep) during_10\IN|attacks (l_pobj) attacks_13\NNS|the|syncopal
2917114
D006024_D001919 NONE glycopyrronium_2\NN| (r_pobj) of_1\IN|glycopyrronium (r_prep) Use_0\NN|of|micrograms|given|. (l_acl) given_12\VBN|,|min|,|was (l_conj) was_19\VBD|sufficient (l_acomp) sufficient_20\JJ|minimize (l_xcomp) minimize_22\VB|to|bradycardias (l_dobj) bradycardias_28\NNS|early|,|induced
D004491_D001919 CID edrophonium_17\NN|the (r_pobj) before_15\IN|edrophonium (r_prep) min_14\NN|1|before (r_dobj) given_12\VBN|,|min|,|was (l_conj) was_19\VBD|sufficient (l_acomp) sufficient_20\JJ|minimize (l_xcomp) minimize_22\VB|to|bradycardias (l_dobj) bradycardias_28\NNS|early|,|induced
D004491_D001919 CID edrophonium_25\NN| (r_npadvmod) induced_27\VBN|edrophonium|- (r_amod) bradycardias_28\NNS|early|,|induced
2598570
D013496_D021501 CID suprofen_9\NN| (r_pobj) from_8\IN|suprofen (r_prep) epidemiology_1\NN|the|of|from|. (l_prep) of_2\IN|syndrome (l_pobj) syndrome_7\NN|flank|pain (l_compound) pain_6\NN|
D000431_D006255 NONE alcohol_83\NN|(|ratio (r_dobj) use_82\VB|to|alcohol (r_conj) participate_47\VB|were|;|to|in|;|and|use|. (l_ccomp) were_2\VBD|patients|likely|suffer (l_conj) suffer_24\VB|from (l_prep) from_25\IN|fever (l_pobj) fever_27\NN|hay|and|asthma|(|ratio
D000431_D001249 NONE alcohol_83\NN|(|ratio (r_dobj) use_82\VB|to|alcohol (r_conj) participate_47\VB|were|;|to|in|;|and|use|. (l_ccomp) were_2\VBD|patients|likely|suffer (l_conj) suffer_24\VB|from (l_prep) from_25\IN|fever (l_pobj) fever_27\NN|hay|and|asthma|(|ratio (l_conj) asthma_29\NN|
D007052_D007674 NONE ibuprofen_15\NNP|especially (r_appos) agents_12\NNS|other|analgesic|(|ibuprofen|) (r_pobj) of_9\IN|agents (r_prep) use_8\NN|concurrent|of (r_appos) age_5\NN|young|,|use|,|disease (l_conj) disease_20\NN|preexisting|renal|,|history|,|history|,|increase|,|increase
D007052_D007669 NONE ibuprofen_15\NNP|especially (r_appos) agents_12\NNS|other|analgesic|(|ibuprofen|) (r_pobj) of_9\IN|agents (r_prep) use_8\NN|concurrent|of (r_appos) age_5\NN|young|,|use|,|disease (l_conj) disease_20\NN|preexisting|renal|,|history|,|history|,|increase|,|increase (l_conj) history_23\NN|a|of (l_prep) of_24\IN|stones (l_pobj) stones_26\NNS|kidney
D007052_D006073 NONE ibuprofen_15\NNP|especially (r_appos) agents_12\NNS|other|analgesic|(|ibuprofen|) (r_pobj) of_9\IN|agents (r_prep) use_8\NN|concurrent|of (r_appos) age_5\NN|young|,|use|,|disease (l_conj) disease_20\NN|preexisting|renal|,|history|,|history|,|increase|,|increase (l_conj) history_29\NN|a|of (l_prep) of_30\IN|gout (l_pobj) gout_31\NN|
17263743
C009250_D006323 NONE sevoflurane_9\NN| (r_amod) induction_10\NN|sevoflurane|of (r_dobj) undergoing_8\VBG|induction (r_acl) arrest_1\NN|cardiac|in|undergoing|.
C009250_D002547 NONE sevoflurane_9\NN| (r_amod) induction_10\NN|sevoflurane|of (r_dobj) undergoing_8\VBG|induction (r_acl) arrest_1\NN|cardiac|in|undergoing|. (l_prep) in_2\IN|child (l_pobj) child_4\NN|a|with (l_prep) with_5\IN|palsy (l_pobj) palsy_7\JJ|cerebral
D003000_D006323 CID clonidine_15\NN|preoperative (r_pobj) after_13\IN|clonidine (r_prep) anesthesia_12\NN|after (r_pobj) of_11\IN|anesthesia (r_prep) induction_10\NN|sevoflurane|of (r_dobj) undergoing_8\VBG|induction (r_acl) arrest_1\NN|cardiac|in|undergoing|.
D003000_D006323 CID clonidine_6\NN| (r_npadvmod) associated_8\VBN|clonidine|- (r_amod) arrest_10\NN|associated|cardiac|in
D003000_D002547 NONE clonidine_15\NN|preoperative (r_pobj) after_13\IN|clonidine (r_prep) anesthesia_12\NN|after (r_pobj) of_11\IN|anesthesia (r_prep) induction_10\NN|sevoflurane|of (r_dobj) undergoing_8\VBG|induction (r_acl) arrest_1\NN|cardiac|in|undergoing|. (l_prep) in_2\IN|child (l_pobj) child_4\NN|a|with (l_prep) with_5\IN|palsy (l_pobj) palsy_7\JJ|cerebral
D003000_D002547 NONE clonidine_18\NN| (r_dobj) receiving_17\VBG|clonidine|for (r_advcl) present_1\VBP|we|case|,|receiving|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|child (l_pobj) child_9\NN|a|old|with (l_prep) with_10\IN|disorder (l_pobj) disorder_15\NN|palsy|seizure (l_nmod) palsy_12\JJ|cerebral|and
D003000_D004827 NONE clonidine_18\NN| (r_dobj) receiving_17\VBG|clonidine|for (r_advcl) present_1\VBP|we|case|,|receiving|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|child (l_pobj) child_9\NN|a|old|with (l_prep) with_10\IN|disorder (l_pobj) disorder_15\NN|palsy|seizure
D003000_D011595 NONE clonidine_18\NN| (r_dobj) receiving_17\VBG|clonidine|for (l_prep) for_19\IN|restlessness (l_pobj) restlessness_20\NN|,|presented
D001418_D002547 NONE baclofen_28\JJ| (r_compound) pump_29\NN|a|baclofen (r_pobj) of_26\IN|pump (r_prep) placement_25\NN|of (r_pobj) for_24\IN|placement (r_prep) presented_23\VBD|who|for (r_relcl) restlessness_20\NN|,|presented (r_pobj) for_19\IN|restlessness (r_prep) receiving_17\VBG|clonidine|for (r_advcl) present_1\VBP|we|case|,|receiving|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|child (l_pobj) child_9\NN|a|old|with (l_prep) with_10\IN|disorder (l_pobj) disorder_15\NN|palsy|seizure (l_nmod) palsy_12\JJ|cerebral|and
D001418_D004827 NONE baclofen_28\JJ| (r_compound) pump_29\NN|a|baclofen (r_pobj) of_26\IN|pump (r_prep) placement_25\NN|of (r_pobj) for_24\IN|placement (r_prep) presented_23\VBD|who|for (r_relcl) restlessness_20\NN|,|presented (r_pobj) for_19\IN|restlessness (r_prep) receiving_17\VBG|clonidine|for (r_advcl) present_1\VBP|we|case|,|receiving|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|child (l_pobj) child_9\NN|a|old|with (l_prep) with_10\IN|disorder (l_pobj) disorder_15\NN|palsy|seizure
D001418_D011595 NONE baclofen_28\JJ| (r_compound) pump_29\NN|a|baclofen (r_pobj) of_26\IN|pump (r_prep) placement_25\NN|of (r_pobj) for_24\IN|placement (r_prep) presented_23\VBD|who|for (r_relcl) restlessness_20\NN|,|presented
D003000_D001008 NONE clonidine_16\NN| (r_pobj) of_15\IN|clonidine (r_prep) doses_14\NNS|three|of (r_dobj) administered_12\VBD|without|,|mother|doses|during|before|reduce|. (l_advcl) reduce_26\VB|to|anxiety (l_dobj) anxiety_27\NN|
18657397
D010406_D004827 NONE penicillin_5\NN| (r_npadvmod) induced_7\VBN|penicillin|- (r_amod) activity_9\NN|induced|epileptiform|in
D010406_D004827 NONE Penicillin_0\NNP| (r_compound) model_1\NN|penicillin (r_nsubj) is_2\VBZ|model|model|. (l_attr) model_7\NN|a|used|experimental|for (l_prep) for_8\IN|research (l_pobj) research_10\NN|epilepsy (l_compound) epilepsy_9\NN|
D010406_D004827 NONE penicillin_13\NN| (r_npadvmod) induced_15\VBN|penicillin|- (r_amod) activity_17\NN|induced|epileptiform
D010406_D004827 NONE penicillin_7\NN| (r_npadvmod) induced_9\VBN|penicillin|- (r_amod) periods_12\NNS|the|induced|activity (l_compound) activity_11\NN|epileptiform
D010400_D004827 CID potassium_20\NN|microl|g (r_dobj) injecting_14\VBG|potassium|into|recorded (r_pcomp) by_13\IN|injecting (r_prep) induced_12\VBN|after|,|focus|was|by|. (l_nsubjpass) focus_10\NN|epileptic (l_amod) epileptic_9\JJ|
15579441
D011692_D000860 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|aminonucleoside|- (r_amod) syndrome_19\NN|induced|nephrotic|and|hypoxia (r_appos) puromycin_14\NNS|the|syndrome (r_pobj) in_12\IN|puromycin (r_prep) identify_8\VB|to|hypoxia|in (l_dobj) hypoxia_11\NN|diffuse|cortical
D011692_D000860 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|aminonucleoside|- (r_amod) syndrome_19\NN|induced|nephrotic|and|hypoxia (l_conj) hypoxia_24\NN|focal|in
D011692_D000860 CID aminonucleoside_21\NN| (r_compound) model_22\NN|puromycin|aminonucleoside (r_pobj) in_18\IN|model|and|2.6-fold (r_prep) reaching_13\VBG|2.2-fold|at|in|,|showed (r_advcl) increased_7\VBD|expression|throughout|,|reaching|. (l_nsubj) Expression_0\NN|of (l_prep) of_1\IN|transgene (l_pobj) transgene_6\NN|the|responsive (l_amod) responsive_5\JJ|hypoxia|- (l_npadvmod) hypoxia_3\NN|
D011692_D009404 CID aminonucleoside_15\NN| (r_advmod) induced_17\VBN|aminonucleoside|- (r_amod) syndrome_19\NN|induced|nephrotic|and|hypoxia
12549952
D016642_D017114 CID bupropion_5\NN|concurrent|and|therapy (r_pobj) with_3\IN|bupropion (r_prep) failure_2\NN|acute|liver|with|.
D016642_D017114 CID bupropion_9\NN| (r_pobj) by_8\IN|bupropion (r_agent) induced_7\VBN|by (r_acl) evidence_4\NN|of|induced (r_dobj) increasing_3\VBG|is|evidence (r_advcl) is_12\VBZ|increasing|,|this|case|. (l_attr) case_15\NN|the|first|of|resulted (l_relcl) resulted_21\VBN|that|could|have|from|on (l_prep) from_22\IN|failure (l_pobj) failure_25\NN|acute|liver|in
D016642_D017114 CID bupropion_30\NN| (r_dobj) receiving_29\VBG|bupropion (r_acl) patient_28\JJ|a|receiving (r_pobj) in_26\IN|patient (r_prep) failure_25\NN|acute|liver|in
D016642_D017114 CID bupropion_13\NN|given (r_pobj) by_12\IN|bupropion (r_agent) induced_11\VBN|by (r_acl) insult_10\NN|acute|liver|induced
D002231_D017114 CID carbimazole_7\NN| (r_compound) therapy_8\NN|carbimazole (r_conj) bupropion_5\NN|concurrent|and|therapy (r_pobj) with_3\IN|bupropion (r_prep) failure_2\NN|acute|liver|with|.
D002231_D017114 CID carbimazole_36\NN| (r_pobj) with_35\IN|carbimazole (r_prep) treatment_34\NN|concomitant|with (r_pobj) on_32\IN|while|treatment (r_prep) resulted_21\VBN|that|could|have|from|on (l_prep) from_22\IN|failure (l_pobj) failure_25\NN|acute|liver|in
D016642_D017093 NONE bupropion_14\NN|and|carbimazole (r_pobj) of_13\IN|bupropion (r_prep) use_12\NN|concurrent|of (r_pobj) with_10\IN|use (r_prep) associated_9\VBN|possibly|with (r_acl) failure_7\NN|fatal|liver|associated
D002231_D017093 NONE carbimazole_16\NN| (r_conj) bupropion_14\NN|and|carbimazole (r_pobj) of_13\IN|bupropion (r_prep) use_12\NN|concurrent|of (r_pobj) with_10\IN|use (r_prep) associated_9\VBN|possibly|with (r_acl) failure_7\NN|fatal|liver|associated
D002231_D006980 NONE carbimazole_15\NN| (r_pobj) with_14\IN|carbimazole (r_prep) treated_13\VBN|man|had|been|with|and|propranolol|. (l_nsubjpass) man_5\NN|a|old|chinese|with (l_prep) with_6\IN|history (l_pobj) history_8\NN|a|of (l_prep) of_9\IN|hyperthyroidism (l_pobj) hyperthyroidism_10\NN|
D011433_D006980 NONE propranolol_17\NN|for (r_conj) treated_13\VBN|man|had|been|with|and|propranolol|. (l_nsubjpass) man_5\NN|a|old|chinese|with (l_prep) with_6\IN|history (l_pobj) history_8\NN|a|of (l_prep) of_9\IN|hyperthyroidism (l_pobj) hyperthyroidism_10\NN|
D016642_D056486 CID bupropion_3\NN| (r_nsubj) induced_4\VBD|that|bupropion|hepatotoxicity|in (l_dobj) hepatotoxicity_5\NN|
D016642_D056486 CID bupropion_9\NN| (r_pobj) by_8\IN|bupropion (r_agent) induced_7\VBN|by (r_acl) evidence_4\NN|of|induced (l_prep) of_5\IN|hepatotoxicity (l_pobj) hepatotoxicity_6\NN|
D016642_D056486 CID bupropion_30\NN| (r_dobj) receiving_29\VBG|bupropion (r_acl) patient_28\JJ|a|receiving (r_pobj) in_26\IN|patient (r_prep) failure_25\NN|acute|liver|in (r_pobj) from_22\IN|failure (r_prep) resulted_21\VBN|that|could|have|from|on (r_relcl) case_15\NN|the|first|of|resulted (r_attr) is_12\VBZ|increasing|,|this|case|. (l_advcl) increasing_3\VBG|is|evidence (l_dobj) evidence_4\NN|of|induced (l_prep) of_5\IN|hepatotoxicity (l_pobj) hepatotoxicity_6\NN|
D016642_D056486 CID bupropion_13\NN|given (l_acl) given_14\VBN|concurrently|with (l_prep) with_16\IN|drugs (l_pobj) drugs_19\NNS|other|hepatotoxic (l_amod) hepatotoxic_18\JJ|
D002231_D056486 CID carbimazole_36\NN| (r_pobj) with_35\IN|carbimazole (r_prep) treatment_34\NN|concomitant|with (r_pobj) on_32\IN|while|treatment (r_prep) resulted_21\VBN|that|could|have|from|on (r_relcl) case_15\NN|the|first|of|resulted (r_attr) is_12\VBZ|increasing|,|this|case|. (l_advcl) increasing_3\VBG|is|evidence (l_dobj) evidence_4\NN|of|induced (l_prep) of_5\IN|hepatotoxicity (l_pobj) hepatotoxicity_6\NN|
9636837
D016190_D020258 NONE carboplatin_4\NN|'s (r_poss) advantages_6\NNS|carboplatin|(|cbdca|) (r_pobj) of_3\IN|advantages (r_prep) striking_2\JJ|the|most|of|over (r_nsubj) is_15\VBZ|striking|)|rate|. (l_attr) rate_19\NN|its|reduced|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|neurotoxic (l_amod) neurotoxic_21\JJ|
D016190_D020258 NONE CBDCA_8\NNP| (r_appos) advantages_6\NNS|carboplatin|(|cbdca|) (r_pobj) of_3\IN|advantages (r_prep) striking_2\JJ|the|most|of|over (r_nsubj) is_15\VBZ|striking|)|rate|. (l_attr) rate_19\NN|its|reduced|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|neurotoxic (l_amod) neurotoxic_21\JJ|
D016190_D020258 NONE CBDCA_5\NNP| (r_nmod) schedules_9\NNS|cbdca|intensity|and|association (l_conj) association_12\NN|the|with|in (l_prep) with_13\IN|drugs (l_pobj) drugs_16\NNS|other|neurotoxic (l_amod) neurotoxic_15\JJ|
D016190_D020258 NONE CBDCA_0\NNP| (r_nsubj) is_1\VBZ|cbdca|neurotoxic|in|,|and|are (l_acomp) neurotoxic_2\JJ|
D016190_D020258 NONE CBDCA_0\NNP| (r_nsubj) is_1\VBZ|cbdca|neurotoxic|in|,|and|are (l_conj) are_15\VBP|type|similar|is|. (l_ccomp) is_26\VBZ|that|it|probable|induced (l_ccomp) induced_31\VBN|that|neurotoxicity|is|in|by (l_nsubjpass) neurotoxicity_29\NN|
D002945_D020258 NONE cisplatin_11\NN| (r_nmod) CDDP_13\NNP|cisplatin|( (r_pobj) over_10\IN|cddp (r_prep) striking_2\JJ|the|most|of|over (r_nsubj) is_15\VBZ|striking|)|rate|. (l_attr) rate_19\NN|its|reduced|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|neurotoxic (l_amod) neurotoxic_21\JJ|
D002945_D020258 NONE CDDP_13\NNP|cisplatin|( (r_pobj) over_10\IN|cddp (r_prep) striking_2\JJ|the|most|of|over (r_nsubj) is_15\VBZ|striking|)|rate|. (l_attr) rate_19\NN|its|reduced|of (l_prep) of_20\IN|effects (l_pobj) effects_22\NNS|neurotoxic (l_amod) neurotoxic_21\JJ|
D002945_D020258 NONE CDDP_23\NNP| (r_pobj) by_22\IN|cddp (r_agent) caused_21\VBN|by (r_acl) those_20\DT|caused (r_pobj) to_19\IN|those (r_prep) similar_18\JJ|closely|to (r_acomp) are_15\VBP|type|similar|is|. (r_conj) is_1\VBZ|cbdca|neurotoxic|in|,|and|are (l_acomp) neurotoxic_2\JJ|
D002945_D020258 NONE CDDP_23\NNP| (r_pobj) by_22\IN|cddp (r_agent) caused_21\VBN|by (r_acl) those_20\DT|caused (r_pobj) to_19\IN|those (r_prep) similar_18\JJ|closely|to (r_acomp) are_15\VBP|type|similar|is|. (l_ccomp) is_26\VBZ|that|it|probable|induced (l_ccomp) induced_31\VBN|that|neurotoxicity|is|in|by (l_nsubjpass) neurotoxicity_29\NN|
D016190_D010523 CID CBDCA_5\NNP| (r_nmod) schedules_9\NNS|cbdca|intensity|and|association (r_pobj) of_4\IN|schedules (r_prep) use_3\NN|the|of (r_nsubj) cause_20\VB|however|,|use|may|concern|. (l_dobj) concern_22\NN|some|about (l_prep) about_23\IN|safety (l_pobj) safety_25\NN|its|with (l_prep) with_26\IN|respect (l_pobj) respect_27\NN|to (l_prep) to_28\IN|damage (l_pobj) damage_32\NN|peripheral|nervous|system
D016190_D010523 CID CBDCA_0\JJ| (r_compound) administration_1\NN|cbdca (r_nsubj) induced_2\VBD|administration|neurotoxicity|. (l_dobj) neurotoxicity_7\NN|dependent|peripheral
20558148
D016202_D002375 NONE NMDA_4\NNP| (r_compound) receptors_5\NNS|nmda (r_pobj) by_3\IN|receptors (r_agent) mediated_2\VBN|by|in (r_acl) neurotransmission_1\NN|glutamatergic|mediated (r_nsubj) modulate_11\VB|neurotransmission|can|catalepsy|. (l_dobj) catalepsy_15\NN|induced
D016202_D002375 NONE NMDA_12\NNP| (r_compound) receptor_13\NN|nmda (r_compound) antagonists_14\NNS|glutamate|receptor|, (r_pobj) of_10\IN|antagonists (r_prep) microinjections_9\NNS|prior|intracollicular|of (r_pobj) with_6\IN|microinjections (r_prep) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
D016202_D002375 NONE NMDA_37\NNP| (r_compound) receptor_38\NN|the|nmda|nmda (r_pobj) of_35\IN|receptor (r_prep) microl_22\NN|mk-801|(|15|mmol/0.5|)|and|ap7|or|of (r_dobj) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
D016202_D002375 NONE aspartate_46\NNP|methyl|-|d|- (r_nmod) NMDA_48\NNP|agonist|aspartate|(|, (r_appos) receptor_38\NN|the|nmda|nmda (r_pobj) of_35\IN|receptor (r_prep) microl_22\NN|mk-801|(|15|mmol/0.5|)|and|ap7|or|of (r_dobj) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
D016202_D002375 NONE NMDA_48\NNP|agonist|aspartate|(|, (r_appos) receptor_38\NN|the|nmda|nmda (r_pobj) of_35\IN|receptor (r_prep) microl_22\NN|mk-801|(|15|mmol/0.5|)|and|ap7|or|of (r_dobj) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
D006220_D002375 CID haloperidol_12\NN| (r_npadvmod) induced_14\VBN|haloperidol|- (r_amod) catalepsy_15\NN|induced
D006220_D002375 CID haloperidol_25\NN|administered (r_appos) blocker_24\NN|the|receptor|haloperidol (r_pobj) by_20\IN|blocker (r_agent) induced_19\VBN|by (r_acl) catalepsy_18\NN|the|induced
D006220_D002375 CID Haloperidol_0\NN| (r_npadvmod) induced_2\VBN|haloperidol|- (r_amod) catalepsy_3\NN|induced
D006220_D002375 CID haloperidol_15\NN| (r_pobj) of_14\IN|haloperidol (r_prep) injections_13\NNS|systemic|of (r_pobj) to_11\IN|injections (r_prep) previous_10\JJ|to (r_amod) AP7_9\RB|previous (r_conj) microinjection_5\NN|that|intracollicular|of|and|ap7 (r_dobj) showed_2\VBD|results|microinjection|attenuated|. (l_ccomp) attenuated_17\VBD|significantly|catalepsy|,|indicated (l_dobj) catalepsy_19\NN|the
D006220_D002375 CID haloperidol_17\NN| (r_npadvmod) induced_19\VBN|haloperidol|- (r_amod) catalepsy_20\NN|influence|induced
D000596_D002375 NONE acid_9\NN| (r_npadvmod) mediated_11\VBN|acid|- (r_amod) mechanisms_12\NNS|excitatory|amino|mediated (r_pobj) of_6\IN|mechanisms (r_prep) influence_5\NN|the|of|in|on (l_prep) on_16\IN|catalepsy (l_pobj) catalepsy_18\NN|the|induced
D004298_D002375 NONE dopamine_22\NN| (r_compound) receptor_23\NN|dopamine (r_compound) blocker_24\NN|the|receptor|haloperidol (r_pobj) by_20\IN|blocker (r_agent) induced_19\VBN|by (r_acl) catalepsy_18\NN|the|induced
D018698_D002375 NONE glutamate_11\NN| (r_compound) antagonists_14\NNS|glutamate|receptor|, (r_pobj) of_10\IN|antagonists (r_prep) microinjections_9\NNS|prior|intracollicular|of (r_pobj) with_6\IN|microinjections (r_prep) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
D018698_D002375 NONE glutamate_4\NN| (r_npadvmod) mediated_6\VBN|glutamate|- (r_amod) mechanisms_7\NNS|that|mediated|in|and|participate (l_prep) in_8\IN|circuits (l_pobj) circuits_11\NNS|the|neural|at (l_prep) at_12\IN|catalepsy (l_pobj) catalepsy_20\NN|influence|induced
D016291_D002375 NONE MK-801_16\NNP| (r_punct) microl_22\NN|mk-801|(|15|mmol/0.5|)|and|ap7|or|of (r_dobj) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
D016291_D002375 NONE MK-801_7\NNP| (r_punct) and_8\CC|mk-801 (r_cc) microinjection_5\NN|that|intracollicular|of|and|ap7 (r_dobj) showed_2\VBD|results|microinjection|attenuated|. (l_ccomp) attenuated_17\VBD|significantly|catalepsy|,|indicated (l_dobj) catalepsy_19\NN|the
C031231_D002375 NONE AP7_25\RB|(|microl|)|, (r_conj) microl_22\NN|mk-801|(|15|mmol/0.5|)|and|ap7|or|of (r_dobj) challenged_5\VBN|catalepsy|was|with|microl|microl|)|. (l_nsubjpass) catalepsy_3\NN|induced
C031231_D002375 NONE AP7_9\RB|previous (r_conj) microinjection_5\NN|that|intracollicular|of|and|ap7 (r_dobj) showed_2\VBD|results|microinjection|attenuated|. (l_ccomp) attenuated_17\VBD|significantly|catalepsy|,|indicated (l_dobj) catalepsy_19\NN|the
3411101
C033457_D056486 CID phenylethylbarbiturate_1\NN| (r_npadvmod) induced_3\VBN|quinidine|phenylethylbarbiturate|-|hepatitis|in|. (l_dobj) hepatitis_5\NN|fulminant
C033457_D056486 CID phenylethylbarbiturate_28\NN|quinidine (r_pobj) of_26\IN|phenylethylbarbiturate (r_prep) administration_25\NN|a|1-month|of (r_pobj) after_22\IN|administration (r_prep) affected_11\VBN|by|during|after (l_agent) by_12\IN|hepatitis (l_pobj) hepatitis_14\NN|fulminant
C033457_D056486 CID phenylethylbarbiturate_3\NN| (r_conj) Quinidine_0\NN|itself|or|phenylethylbarbiturate (r_nsubj) be_5\VB|quinidine|may|responsible|. (l_acomp) responsible_6\JJ|for (l_prep) for_7\IN|hepatitis (l_pobj) hepatitis_9\NN|fulminant|in
D011802_D056486 NONE Quinidine_0\NN|itself|or|phenylethylbarbiturate (r_nsubj) be_5\VB|quinidine|may|responsible|. (l_acomp) responsible_6\JJ|for (l_prep) for_7\IN|hepatitis (l_pobj) hepatitis_9\NN|fulminant|in
85485
D001556_D006528 CID hexachloride_15\NN|benzene (r_pobj) by_11\IN|hexachloride (r_agent) induced_10\VBN|by (r_acl) Changes_0\NNS|in|induced|. (l_prep) in_1\IN|peroxisomes (l_pobj) peroxisomes_2\NNS|in (l_prep) in_3\IN|liver (l_pobj) liver_5\NN|preneoplastic|and|hepatoma (l_conj) hepatoma_7\NN|of
D001556_D006528 CID hexachloride_17\NN|ppm|benzene (r_pobj) by_11\IN|hexachloride (r_prep) induced_8\VBN|peroxisomes|in|by|examined|. (l_nsubj) Peroxisomes_0\NNS|in (l_prep) in_1\IN|hepatomas|lesions (l_pobj) hepatomas_2\NNS|and|hyperplastic
D001556_D017093 NONE hexachloride_17\NN|ppm|benzene (r_pobj) by_11\IN|hexachloride (r_prep) induced_8\VBN|peroxisomes|in|by|examined|. (l_nsubj) Peroxisomes_0\NNS|in (l_prep) in_1\IN|hepatomas|lesions (l_pobj) lesions_7\NNS|preneoplastic|liver
C012282_D006528 NONE chlorophenoxyisobutyrate_31\NN|-|p|- (r_appos) alpha_27\NN|-|chlorophenoxyisobutyrate (r_appos) ethyl_25\NN|alpha (r_pobj) to_24\IN|ethyl (r_prep) respond_23\VB|were|,|cells|did|not|to|with|. (l_advcl) were_5\VBD|although|most|tumors|and|contained (l_nsubj) most_1\JJS|of (l_prep) of_2\IN|hepatomas (l_pobj) hepatomas_4\NNS|the
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN|-|p|- (r_appos) alpha_27\NN|-|chlorophenoxyisobutyrate (r_appos) ethyl_25\NN|alpha (r_pobj) to_24\IN|ethyl (r_prep) respond_23\VB|were|,|cells|did|not|to|with|. (l_advcl) were_5\VBD|although|most|tumors|and|contained (l_attr) tumors_9\NNS|differentiated
C012282_D009369 NONE chlorophenoxyisobutyrate_31\NN|-|p|- (r_appos) alpha_27\NN|-|chlorophenoxyisobutyrate (r_appos) ethyl_25\NN|alpha (r_pobj) to_24\IN|ethyl (r_prep) respond_23\VB|were|,|cells|did|not|to|with|. (l_nsubj) cells_20\NNS|the|tumor (l_compound) tumor_19\NN|
4038130
D008619_D009135 CID mepivacaine_19\NN|and|lidocaine|plus|epinephrine (r_pobj) to_18\IN|mepivacaine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|especially|exposure (r_prep) seen_10\VBN|in|,|damage|was|also|in|,|after|. (l_prep) In_0\IN|addition (l_pobj) addition_1\NN|to (l_prep) to_2\IN|damage (l_pobj) damage_4\NN|muscle
D008012_D009135 CID lidocaine_21\NN| (r_conj) mepivacaine_19\NN|and|lidocaine|plus|epinephrine (r_pobj) to_18\IN|mepivacaine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|especially|exposure (r_prep) seen_10\VBN|in|,|damage|was|also|in|,|after|. (l_prep) In_0\IN|addition (l_pobj) addition_1\NN|to (l_prep) to_2\IN|damage (l_pobj) damage_4\NN|muscle
D004837_D009135 NONE epinephrine_23\NN| (r_conj) mepivacaine_19\NN|and|lidocaine|plus|epinephrine (r_pobj) to_18\IN|mepivacaine (r_prep) exposure_17\NN|to (r_pobj) after_16\IN|especially|exposure (r_prep) seen_10\VBN|in|,|damage|was|also|in|,|after|. (l_prep) In_0\IN|addition (l_pobj) addition_1\NN|to (l_prep) to_2\IN|damage (l_pobj) damage_4\NN|muscle
6150641
D002927_D007172 CID cimetidine_12\NN| (r_dobj) taking_11\VBG|while|cimetidine|and|disappeared (r_advcl) developed_5\VBD|percent|changes|taking|. (l_dobj) changes_7\NNS|breast|or|impotence (l_conj) impotence_9\NN|
D002927_D007172 CID cimetidine_21\NN| (r_nsubjpass) replaced_23\VBN|when|cimetidine|was|by (r_advcl) disappeared_19\VBD|in|changes|replaced (r_conj) taking_11\VBG|while|cimetidine|and|disappeared (r_advcl) developed_5\VBD|percent|changes|taking|. (l_dobj) changes_7\NNS|breast|or|impotence (l_conj) impotence_9\NN|
D011899_D007172 NONE ranitidine_25\NN| (r_pobj) by_24\IN|ranitidine (r_agent) replaced_23\VBN|when|cimetidine|was|by (r_advcl) disappeared_19\VBD|in|changes|replaced (r_conj) taking_11\VBG|while|cimetidine|and|disappeared (r_advcl) developed_5\VBD|percent|changes|taking|. (l_dobj) changes_7\NNS|breast|or|impotence (l_conj) impotence_9\NN|
D002927_D056486 NONE cimetidine_5\NN|(|months|;|median (r_pobj) of_4\IN|cimetidine (r_prep) doses_3\NNS|high|of (r_pobj) with_1\IN|doses (r_prep) Treatment_0\NN|with (r_nsubjpass) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D002927_D056486 NONE cimetidine_60\NN| (r_compound) therapy_61\NN|cimetidine (r_pobj) with_59\IN|therapy (r_prep) seen_58\VBN|than|with (r_advcl) level_56\NN|a|lower|creatinine|seen (r_pobj) with_50\IN|level (r_prep) associated_49\VBN|therapy|was|with|. (r_conj) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D002927_D006402 NONE cimetidine_5\NN|(|months|;|median (r_pobj) of_4\IN|cimetidine (r_prep) doses_3\NNS|high|of (r_pobj) with_1\IN|doses (r_prep) Treatment_0\NN|with (r_nsubjpass) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D002927_D006402 NONE cimetidine_60\NN| (r_compound) therapy_61\NN|cimetidine (r_pobj) with_59\IN|therapy (r_prep) seen_58\VBN|than|with (r_advcl) level_56\NN|a|lower|creatinine|seen (r_pobj) with_50\IN|level (r_prep) associated_49\VBN|therapy|was|with|. (r_conj) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D011899_D056486 NONE ranitidine_18\NN|(|months|;|median|) (r_conj) median_12\NN|,|months|)|or|ranitidine (r_conj) cimetidine_5\NN|(|months|;|median (r_pobj) of_4\IN|cimetidine (r_prep) doses_3\NNS|high|of (r_pobj) with_1\IN|doses (r_prep) Treatment_0\NN|with (r_nsubjpass) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D011899_D056486 NONE ranitidine_46\NN| (r_compound) therapy_47\NN|ranitidine (r_nsubjpass) associated_49\VBN|therapy|was|with|. (r_conj) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D011899_D006402 NONE ranitidine_18\NN|(|months|;|median|) (r_conj) median_12\NN|,|months|)|or|ranitidine (r_conj) cimetidine_5\NN|(|months|;|median (r_pobj) of_4\IN|cimetidine (r_prep) doses_3\NNS|high|of (r_pobj) with_1\IN|doses (r_prep) Treatment_0\NN|with (r_nsubjpass) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D011899_D006402 NONE ranitidine_46\NN| (r_compound) therapy_47\NN|ranitidine (r_nsubjpass) associated_49\VBN|therapy|was|with|. (r_conj) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D003404_D056486 NONE creatinine_55\NN|serum (r_compound) level_56\NN|a|lower|creatinine|seen (r_pobj) with_50\IN|level (r_prep) associated_49\VBN|therapy|was|with|. (r_conj) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
D003404_D006402 NONE creatinine_55\NN|serum (r_compound) level_56\NN|a|lower|creatinine|seen (r_pobj) with_50\IN|level (r_prep) associated_49\VBN|therapy|was|with|. (r_conj) associated_32\VBN|treatment|was|not|with|,|but|associated (l_prep) with_33\IN|toxicity (l_pobj) toxicity_37\NN|hepatic|or|alterations
7189975
D002045_D012640 CID bupivacaine_21\NN| (r_npadvmod) induced_23\VBN|bupivacaine|- (r_amod) seizures_24\NNS|induced (r_pobj) of_20\IN|seizures (r_prep) %_19\NN|90|of (r_pobj) in_17\IN|% (r_prep) was_15\VBD|dose|fatal|in|,|in|. (l_nsubj) dose_2\NN|a|cd50|of|convulsions|) (l_appos) convulsions_8\NNS|(|causing|in
D002045_D012640 CID bupivacaine_21\NN| (r_npadvmod) induced_23\VBN|bupivacaine|- (r_amod) seizures_24\NNS|induced
C004616_D012640 CID chloroprocaine_31\NN| (r_compound) group_32\NN|the|chloroprocaine (r_pobj) of_29\IN|group (r_prep) %_28\NN|57|of (r_pobj) in_26\IN|%|,|and|in (r_prep) was_15\VBD|dose|fatal|in|,|in|. (l_nsubj) dose_2\NN|a|cd50|of|convulsions|) (l_appos) convulsions_8\NNS|(|causing|in
C004616_D012640 CID chloroprocaine_31\NN| (r_compound) group_32\NN|the|chloroprocaine (r_pobj) of_29\IN|group (r_prep) %_28\NN|57|of (r_pobj) in_26\IN|%|,|and|in (r_prep) was_15\VBD|dose|fatal|in|,|in|. (l_prep) in_17\IN|% (l_pobj) %_19\NN|90|of (l_prep) of_20\IN|seizures (l_pobj) seizures_24\NNS|induced
D008012_D012640 CID lidocaine_40\NN| (r_compound) group_41\NN|the|lidocaine (r_pobj) of_38\IN|group (r_prep) %_37\NN|6|of (r_pobj) in_35\IN|% (r_conj) in_26\IN|%|,|and|in (r_prep) was_15\VBD|dose|fatal|in|,|in|. (l_nsubj) dose_2\NN|a|cd50|of|convulsions|) (l_appos) convulsions_8\NNS|(|causing|in
D008012_D012640 CID lidocaine_40\NN| (r_compound) group_41\NN|the|lidocaine (r_pobj) of_38\IN|group (r_prep) %_37\NN|6|of (r_pobj) in_35\IN|% (r_conj) in_26\IN|%|,|and|in (r_prep) was_15\VBD|dose|fatal|in|,|in|. (l_prep) in_17\IN|% (l_pobj) %_19\NN|90|of (l_prep) of_20\IN|seizures (l_pobj) seizures_24\NNS|induced
15930398
D015742_D000647 CID propofol_12\NN| (r_pobj) with_11\IN|propofol (r_prep) sedation_10\NN|procedural|with (r_pobj) during_8\IN|sedation (r_prep) onset_3\NN|the|and|persistence|of|during (l_prep) of_6\IN|amnesia (l_pobj) amnesia_7\NN|
21418164
D008130_D064420 NONE CCNU_0\NNP| (r_npadvmod) lomustine_2\NN|ccnu|(|)|toxicity|. (l_dobj) toxicity_4\NN|in|:|study
D008130_D064420 NONE lomustine_2\NN|ccnu|(|)|toxicity|. (l_dobj) toxicity_4\NN|in|:|study
D008130_D064420 NONE CCNU_6\NNP| (r_pobj) with_5\IN|ccnu (r_prep) treated_4\VBN|with (r_acl) dogs_3\NNS|the|206|treated (r_pobj) Of_0\IN|dogs (r_prep) met_9\VBD|of|,|185|criteria|. (l_dobj) criteria_12\NNS|the|inclusion|for (l_prep) for_13\IN|class (l_pobj) class_17\NN|one|of (l_prep) of_18\IN|toxicity (l_pobj) toxicity_19\NN|
D008130_D064420 NONE CCNU_0\NN| (r_npadvmod) associated_2\VBN|ccnu|- (r_amod) toxicity_3\NN|associated|in
D008130_D006402 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ| (r_nmod) CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D006402 NONE CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D007674 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ| (r_nmod) CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D007674 NONE CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D056486 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ| (r_nmod) CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D056486 NONE CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D005767 NONE 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\JJ| (r_nmod) CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D005767 NONE CCNU_21\NNP|1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea|( (r_dobj) receiving_18\VBG|ccnu (r_acl) dogs_17\NNS|bearing|receiving (r_pobj) in_13\IN|dogs (r_prep) toxicities_12\NNS|haematological|in
D008130_D008223 NONE CCNU_0\NNP| (r_nsubjpass) used_2\VBN|ccnu|was|commonly|in|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|lymphoma (l_pobj) lymphoma_9\NN|,|tumour
D008130_D008223 NONE CCNU_0\NNP| (r_nsubjpass) used_2\VBN|ccnu|was|commonly|in|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|lymphoma (l_pobj) lymphoma_9\NN|,|tumour (l_conj) tumour_13\NN|mast|cell|,|tumour (l_conj) tumour_16\NN|brain|,|tumours (l_conj) tumours_19\NNS|histiocytic|and|lymphoma (l_conj) lymphoma_22\NN|epitheliotropic
D008130_D034801 NONE CCNU_0\NNP| (r_nsubjpass) used_2\VBN|ccnu|was|commonly|in|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|lymphoma (l_pobj) lymphoma_9\NN|,|tumour (l_conj) tumour_13\NN|mast|cell|,|tumour
D008130_D001932 NONE CCNU_0\NNP| (r_nsubjpass) used_2\VBN|ccnu|was|commonly|in|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|lymphoma (l_pobj) lymphoma_9\NN|,|tumour (l_conj) tumour_13\NN|mast|cell|,|tumour (l_conj) tumour_16\NN|brain|,|tumours
D008130_D015620 NONE CCNU_0\NNP| (r_nsubjpass) used_2\VBN|ccnu|was|commonly|in|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|lymphoma (l_pobj) lymphoma_9\NN|,|tumour (l_conj) tumour_13\NN|mast|cell|,|tumour (l_conj) tumour_16\NN|brain|,|tumours (l_conj) tumours_19\NNS|histiocytic|and|lymphoma
D000409_D064420 NONE alanine_5\NN| (r_compound) transaminase_6\NN|elevated|alanine (r_nmod) concentration_10\NN|transaminase|(|alt (r_conj) toxicity_2\NN|potential|renal|and|concentration
9105126
D013256_D018658 CID steroid_9\NN| (r_compound) therapy_10\NN|term|steroid (r_pobj) with_5\IN|therapy (r_prep) associated_4\VBN|with (r_acl) defect_3\NN|postinfarction|ventricular|septal|associated|.
D013256_D018658 CID steroid_13\NN| (r_compound) therapy_14\NN|term|steroid (r_pobj) on_9\IN|therapy (r_prep) patients_8\NNS|on (r_pobj) in_7\IN|patients (r_prep) rupture_6\NN|postinfarction|ventricular|septal|in
D013256_D018658 CID steroid_4\NN| (r_compound) therapy_5\NN|steroid|and|rupture (l_conj) rupture_10\NN|subsequent|postinfarction|septal
21294084
D010406_D004827 NONE penicillin_12\NN| (r_npadvmod) induced_14\VBN|penicillin|- (r_amod) model_16\NN|induced|epilepsy|in (r_pobj) in_11\IN|model (r_prep) discharges_10\NNS|cortical|epileptic|in (l_amod) epileptic_9\JJ|
D010406_D004827 NONE penicillin_12\NN| (r_npadvmod) induced_14\VBN|penicillin|- (r_amod) model_16\NN|induced|epilepsy|in (l_compound) epilepsy_15\NN|
D010406_D004827 NONE penicillin_17\NN| (r_npadvmod) induced_19\VBN|penicillin|- (r_amod) model_21\NN|induced|epilepsy (r_pobj) in_16\IN|model (r_prep) activity_15\NN|cortical|epileptic|in (l_amod) epileptic_14\JJ|
D010406_D004827 NONE penicillin_17\NN| (r_npadvmod) induced_19\VBN|penicillin|- (r_amod) model_21\NN|induced|epilepsy (l_compound) epilepsy_20\NN|
D010406_D004827 NONE penicillin_7\NN| (r_npadvmod) induced_9\VBN|penicillin|- (r_amod) activity_12\NN|the|acute|induced|cortical|epileptic|independent (l_amod) epileptic_11\JJ|
6381653
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|- (r_amod) dyskinesia_3\JJ|induced|and|thalamotomy|.
D007980_D004409 CID Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesia|alleviated|. (l_dobj) dyskinesia_3\NN|of|in
D007980_D004409 CID levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesias_5\NNS|induced|by
D007980_D010302 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesia|alleviated|. (l_dobj) dyskinesia_3\NN|of|in (l_prep) in_7\IN|cases (l_pobj) cases_9\NNS|thirteen|of (l_prep) of_10\IN|parkinsonism (l_pobj) Parkinsonism_11\NNP|,|was|,
D007980_D010302 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesias_5\NNS|induced|by (r_pobj) of_1\IN|dyskinesias (r_prep) Control_0\NN|of|in (l_prep) in_9\IN|course (l_pobj) course_11\NN|the|of (l_prep) of_12\IN|treatment (l_pobj) treatment_14\NN|routine|of (l_prep) of_15\IN|parkinsonism (l_pobj) Parkinsonism_16\NNP|
D007980_D020821 NONE Levodopa_0\NNP| (r_npadvmod) induced_2\VBN|levodopa|-|dyskinesia|alleviated|. (l_dobj) dyskinesia_3\NN|of|in (l_prep) in_7\IN|cases (l_pobj) cases_9\NNS|thirteen|of (l_prep) of_10\IN|parkinsonism (l_pobj) Parkinsonism_11\NNP|,|was|, (l_relcl) was_14\VBD|which|choreic (l_attr) choreic_15\JJ|,|ballistic|in (l_conj) ballistic_17\JJ|or|dystonic (l_conj) dystonic_19\JJ|
D007980_D013786 NONE levodopa_2\NN| (r_npadvmod) induced_4\VBN|levodopa|- (r_amod) dyskinesias_5\NNS|induced|by (l_prep) by_6\IN|lesions (l_pobj) lesions_8\NNS|thalamic
20103708
D013311_D003928 CID streptozotocin_6\JJ| (r_npadvmod) induced_8\VBN|streptozotocin|- (r_amod) nephropathy_10\NN|induced|diabetic
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|streptozotocin|- (r_amod) model_27\NN|:|explore|,|a|induced|nephropathy|in|. (l_ccomp) explore_2\VBP|we|role (l_dobj) role_5\NN|the|protective|of|against (l_prep) against_8\IN|nephropathy (l_pobj) nephropathy_10\NN|diabetic|using
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|streptozotocin|- (r_amod) model_27\NN|:|explore|,|a|induced|nephropathy|in|. (l_ccomp) explore_2\VBP|we|role (l_dobj) role_5\NN|the|protective|of|against (l_prep) against_8\IN|nephropathy (l_pobj) nephropathy_10\NN|diabetic|using (l_acl) using_11\VBG|tissues|from (l_prep) from_16\IN|patients (l_pobj) patients_19\NNS|diabetic|nephropathy (l_compound) nephropathy_18\NN|
D013311_D003928 CID streptozotocin_22\RB| (r_npadvmod) induced_24\VBN|streptozotocin|- (r_amod) model_27\NN|:|explore|,|a|induced|nephropathy|in|. (l_compound) nephropathy_26\NN|diabetic
D010100_D003928 NONE oxygen_20\NN| (r_compound) species_21\NNS|reactive|oxygen|(|ros|) (r_pobj) of_18\IN|species (r_prep) production_17\NN|the|of (r_pobj) by_15\IN|production (r_agent) accompanied_14\VBN|which|is|by (r_relcl) causes_7\NNS|the|major|of|,|accompanied (r_pobj) of_4\IN|causes (r_prep) one_3\CD|of (r_attr) is_2\VBZ|nephropathy|one|. (l_nsubj) nephropathy_1\NN|diabetic
D010100_D051437 NONE oxygen_20\NN| (r_compound) species_21\NNS|reactive|oxygen|(|ros|) (r_pobj) of_18\IN|species (r_prep) production_17\NN|the|of (r_pobj) by_15\IN|production (r_agent) accompanied_14\VBN|which|is|by (r_relcl) causes_7\NNS|the|major|of|,|accompanied (l_prep) of_8\IN|failure (l_pobj) failure_10\NN|renal
D013311_D058186 NONE streptozotocin_13\RB| (r_npadvmod) induced_15\VBN|streptozotocin|- (r_amod) damage_17\NN|induced|renal
9228650
C049860_D000647 CID NIK-247_2\NNP|on (l_prep) on_3\IN|cholinesterase (l_pobj) cholinesterase_4\NN|and|amnesia (l_conj) amnesia_9\NN|induced
C049860_D000647 CID NIK-247_3\NNP|on (r_pobj) of_2\IN|nik-247 (r_prep) effects_1\NNS|the|of (r_nsubjpass) examined_15\VBN|effects|,|amnesia|were|and|compared|. (l_nsubjpass) amnesia_10\NN|induced|and|movement
C049860_D000647 CID NIK-247_4\NNP|at|p.o.|) (r_nsubj) improves_16\VBZ|that|nik-247|amnesia|but|affect (l_dobj) amnesia_20\NN|induced
D012601_D000647 CID scopolamine_6\NN| (r_npadvmod) induced_8\VBN|scopolamine|- (r_amod) amnesia_9\NN|induced
D012601_D000647 CID scopolamine_7\NN| (r_npadvmod) induced_9\VBN|scopolamine|- (r_amod) amnesia_10\NN|induced|and|movement
D012601_D000647 CID scopolamine_14\NN|(|mg/kg|) (r_pobj) by_13\IN|scopolamine (r_agent) induced_12\VBN|by|in (r_acl) amnesia_11\NN|the|induced
D012601_D000647 CID scopolamine_17\NN| (r_npadvmod) induced_19\VBN|scopolamine|- (r_amod) amnesia_20\NN|induced
D013619_D000647 CID tacrine_27\NN|and|e-2020 (r_appos) inhibitors_26\NNS|the|known|cholinesterase|tacrine (r_pobj) of_20\IN|inhibitors (r_prep) those_19\DT|of (r_pobj) with_18\IN|those (r_prep) compared_17\VBN|with (r_conj) examined_15\VBN|effects|,|amnesia|were|and|compared|. (l_nsubjpass) amnesia_10\NN|induced|and|movement
C076946_D000647 CID E-2020_29\NNS| (r_conj) tacrine_27\NN|and|e-2020 (r_appos) inhibitors_26\NNS|the|known|cholinesterase|tacrine (r_pobj) of_20\IN|inhibitors (r_prep) those_19\DT|of (r_pobj) with_18\IN|those (r_prep) compared_17\VBN|with (r_conj) examined_15\VBN|effects|,|amnesia|were|and|compared|. (l_nsubjpass) amnesia_10\NN|induced|and|movement
C049860_D000544 NONE NIK-247_4\NNP| (r_nsubj) be_6\VB|that|nik-247|may|drug (l_attr) drug_9\NN|a|useful|for (l_prep) for_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|disease (l_pobj) disease_16\NN|alzheimer
6118280
D001569_D009207 NONE benzodiazepines_3\NNS|and|block (r_conj) drugs_1\NNS|serotonergic|,|benzodiazepines (r_nsubj) induced_9\VBN|drugs|muscimol|-|jerks|in|. (l_dobj) jerks_11\NNS|myoclonic
D001569_D009207 NONE benzodiazepines_2\NNS|the (r_pobj) Of_0\IN|benzodiazepines (r_prep) found_12\VBN|of|,|clonazepam|was|be|. (l_xcomp) be_14\VB|to|potent|mg/kg|in (l_prep) in_27\IN|blocking (l_pcomp) blocking_28\VBG|jerks (l_dobj) jerks_31\NNS|the|myoclonic
D001569_D009207 NONE benzodiazepines_7\NNS|the (r_conj) 5-HTP_4\NN|and|benzodiazepines (r_nsubjpass) found_10\VBN|that|5-htp|have|been|be (l_xcomp) be_12\VB|to|beneficial (l_acomp) beneficial_13\JJ|in (l_prep) in_14\IN|management (l_pobj) management_16\NN|the|of (l_prep) of_17\IN|myoclonus (l_pobj) myoclonus_19\NN|clinical|,|myoclonus
D001569_D009207 NONE benzodiazepines_7\NNS|the (r_conj) 5-HTP_4\NN|and|benzodiazepines (r_nsubjpass) found_10\VBN|that|5-htp|have|been|be (l_xcomp) be_12\VB|to|beneficial (l_acomp) beneficial_13\JJ|in (l_prep) in_14\IN|management (l_pobj) management_16\NN|the|of (l_prep) of_17\IN|myoclonus (l_pobj) myoclonus_19\NN|clinical|,|myoclonus (l_appos) myoclonus_25\NN|the|induced
D001418_D009207 NONE baclofen_5\JJ| (r_compound) block_6\NN|baclofen (r_conj) benzodiazepines_3\NNS|and|block (r_conj) drugs_1\NNS|serotonergic|,|benzodiazepines (r_nsubj) induced_9\VBN|drugs|muscimol|-|jerks|in|. (l_dobj) jerks_11\NNS|myoclonic
D001418_D009207 NONE -)-baclofen_11\:|and|( (r_punct) in_12\IN|-)-baclofen|management (l_pobj) management_14\NN|the|of (l_prep) of_15\IN|myoclonus (l_pobj) myoclonus_17\NN|clinical
D009118_D009207 CID muscimol_7\NNS| (r_npadvmod) induced_9\VBN|drugs|muscimol|-|jerks|in|. (l_dobj) jerks_11\NNS|myoclonic
D009118_D009207 CID muscimol_5\NNS| (r_nsubj) produced_6\VBD|in|,|muscimol|jerks|. (l_dobj) jerks_8\NNS|myoclonic
D009118_D009207 CID muscimol_22\NN| (r_npadvmod) induced_24\VBN|muscimol|- (r_amod) myoclonus_25\NN|the|induced (r_appos) myoclonus_19\NN|clinical|,|myoclonus
D009118_D009207 CID muscimol_22\NN| (r_npadvmod) induced_24\VBN|muscimol|- (r_amod) myoclonus_25\NN|the|induced
D002998_D009207 NONE clonazepam_4\NN|(|mg/kg|) (r_nsubjpass) found_12\VBN|of|,|clonazepam|was|be|. (l_xcomp) be_14\VB|to|potent|mg/kg|in (l_prep) in_27\IN|blocking (l_pcomp) blocking_28\VBG|jerks (l_dobj) jerks_31\NNS|the|myoclonic
D003975_D009207 NONE diazepam_20\NN| (r_pobj) than_19\IN|diazepam (r_prep) potent_18\JJ|fold|more|than (r_acomp) be_14\VB|to|potent|mg/kg|in (l_prep) in_27\IN|blocking (l_pcomp) blocking_28\VBG|jerks (l_dobj) jerks_31\NNS|the|myoclonic
D006916_D009207 NONE 5-HTP_4\NN|and|benzodiazepines (r_nsubjpass) found_10\VBN|that|5-htp|have|been|be (l_xcomp) be_12\VB|to|beneficial (l_acomp) beneficial_13\JJ|in (l_prep) in_14\IN|management (l_pobj) management_16\NN|the|of (l_prep) of_17\IN|myoclonus (l_pobj) myoclonus_19\NN|clinical|,|myoclonus
D006916_D009207 NONE 5-HTP_4\NN|and|benzodiazepines (r_nsubjpass) found_10\VBN|that|5-htp|have|been|be (l_xcomp) be_12\VB|to|beneficial (l_acomp) beneficial_13\JJ|in (l_prep) in_14\IN|management (l_pobj) management_16\NN|the|of (l_prep) of_17\IN|myoclonus (l_pobj) myoclonus_19\NN|clinical|,|myoclonus (l_appos) myoclonus_25\NN|the|induced
C014896_D009207 NONE MK-212_8\NNP| (r_punct) and_9\CC|mk-212 (r_punct) -)-baclofen_11\:|and|( (r_punct) in_12\IN|-)-baclofen|management (l_pobj) management_14\NN|the|of (l_prep) of_15\IN|myoclonus (l_pobj) myoclonus_17\NN|clinical
14975762
D004317_D009369 NONE Doxorubicin_0\NNP| (r_nsubj) is_1\VBZ|doxorubicin|agent (l_attr) agent_6\NN|an|tumor|represses (l_compound) tumor_5\NN|anti|-
D004317_D006333 CID doxorubicin_11\RB| (r_compound) induced_13\VBN|doxorubicin|- (r_pobj) from_10\IN|induced (r_prep) myocytes_9\NNS|p300|protects|cardiac|from (r_pobj) of_5\IN|myocytes (r_prep) overexpression_4\NN|that|of (r_nsubj) apoptosis_14\NN|overexpression|and|reduces (l_conj) reduces_16\VBZ|extent (l_dobj) extent_18\NN|the|of (l_prep) of_19\IN|failure (l_pobj) failure_22\NN|acute|heart|in
2819587
11022397
D014331_D008569 NONE tropicamide_8\NN|and|pilocarpine (r_pobj) of_7\IN|tropicamide (r_prep) administration_6\NN|of (r_pobj) after_5\IN|administration (r_prep) size_1\NN|pupil|at|after (r_ccomp) impairment_15\NN|size|;|induced|in|. (l_prep) in_16\IN|recall (l_pobj) recall_18\NN|word
D010862_D008569 NONE pilocarpine_10\NN| (r_conj) tropicamide_8\NN|and|pilocarpine (r_pobj) of_7\IN|tropicamide (r_prep) administration_6\NN|of (r_pobj) after_5\IN|administration (r_prep) size_1\NN|pupil|at|after (r_ccomp) impairment_15\NN|size|;|induced|in|. (l_prep) in_16\IN|recall (l_pobj) recall_18\NN|word
D012601_D008569 CID scopolamine_12\NN| (r_npadvmod) induced_14\VBN|scopolamine|- (r_amod) impairment_15\NN|size|;|induced|in|. (l_prep) in_16\IN|recall (l_pobj) recall_18\NN|word
D012601_D008569 CID scopolamine_11\NN| (r_npadvmod) induced_13\VBN|scopolamine|- (r_amod) impairment_14\NN|greater|induced|in (r_dobj) had_9\VBD|compared|,|group|impairment|recall|after|)|. (l_dobj) recall_17\NN|60|,
2557556
D015232_D006930 CID E2-induced_23\VBN| (r_amod) hyperalgesia_24\NN|prostaglandin|e2-induced
D009020_D006930 NONE Morphine_0\NNP| (r_nsubj) alter_6\VB|morphine|did|not|,|however|,|hyperalgesia|. (l_dobj) hyperalgesia_8\NN|the|induced
D015124_D006930 CID monophosphate_14\NN|8-bromo|cyclic|adenosine (r_pobj) by_10\IN|monophosphate (r_agent) induced_9\VBN|by (r_acl) hyperalgesia_8\NN|the|induced
7542793
D016572_D007674 CID A_3\NNP|cyclosporin (r_pobj) of_1\IN|a (r_prep) Nephrotoxicity_0\NN|of|and|fk506|:|inhibition|.
D016572_D007674 CID CsA_8\NNP| (r_pobj) of_7\IN|csa (r_prep) effects_6\NNS|the|nephrotoxic|of|and (l_amod) nephrotoxic_5\JJ|
D016559_D007674 CID FK506_5\NNP| (r_conj) Nephrotoxicity_0\NN|of|and|fk506|:|inhibition|.
D016559_D007674 CID FK506_10\NNP| (r_nsubjpass) mediated_13\VBN|that|effects|fk506|is|likely|through (l_nsubjpass) effects_6\NNS|the|nephrotoxic|of|and (l_amod) nephrotoxic_5\JJ|
D016572_D006984 NONE A_1\NNP|cyclosporin|csa|;|mg/kg|, (r_nsubj) caused_29\VBD|a|reduction|given|. (l_dobj) reduction_31\NN|a|of (l_prep) of_32\IN|rate (l_pobj) rate_35\NN|glomerular|filtration|,|changes (l_appos) changes_38\NNS|degenerative|of|,|and|hypertrophy (l_conj) hypertrophy_45\NN|of
D016572_D006984 NONE CsA_3\NNP|( (r_appos) A_1\NNP|cyclosporin|csa|;|mg/kg|, (r_nsubj) caused_29\VBD|a|reduction|given|. (l_dobj) reduction_31\NN|a|of (l_prep) of_32\IN|rate (l_pobj) rate_35\NN|glomerular|filtration|,|changes (l_appos) changes_38\NNS|degenerative|of|,|and|hypertrophy (l_conj) hypertrophy_45\NN|of
D016559_D006984 NONE Fujimycine_9\NNP|(|fk506|;|mg/kg|,|but|rapamycin (r_conj) mg/kg_6\NN|50|)|and|fujimycine (r_appos) A_1\NNP|cyclosporin|csa|;|mg/kg|, (r_nsubj) caused_29\VBD|a|reduction|given|. (l_dobj) reduction_31\NN|a|of (l_prep) of_32\IN|rate (l_pobj) rate_35\NN|glomerular|filtration|,|changes (l_appos) changes_38\NNS|degenerative|of|,|and|hypertrophy (l_conj) hypertrophy_45\NN|of
D016559_D006984 NONE FK506_11\NNP| (r_appos) Fujimycine_9\NNP|(|fk506|;|mg/kg|,|but|rapamycin (r_conj) mg/kg_6\NN|50|)|and|fujimycine (r_appos) A_1\NNP|cyclosporin|csa|;|mg/kg|, (r_nsubj) caused_29\VBD|a|reduction|given|. (l_dobj) reduction_31\NN|a|of (l_prep) of_32\IN|rate (l_pobj) rate_35\NN|glomerular|filtration|,|changes (l_appos) changes_38\NNS|degenerative|of|,|and|hypertrophy (l_conj) hypertrophy_45\NN|of
D018942_D006984 NONE macrolide_21\NN| (r_amod) rapamycin_23\NNS|not|the|related|macrolide|immunosuppressant|(|mg/kg|) (r_conj) Fujimycine_9\NNP|(|fk506|;|mg/kg|,|but|rapamycin (r_conj) mg/kg_6\NN|50|)|and|fujimycine (r_appos) A_1\NNP|cyclosporin|csa|;|mg/kg|, (r_nsubj) caused_29\VBD|a|reduction|given|. (l_dobj) reduction_31\NN|a|of (l_prep) of_32\IN|rate (l_pobj) rate_35\NN|glomerular|filtration|,|changes (l_appos) changes_38\NNS|degenerative|of|,|and|hypertrophy (l_conj) hypertrophy_45\NN|of
D020123_D006984 NONE rapamycin_23\NNS|not|the|related|macrolide|immunosuppressant|(|mg/kg|) (r_conj) Fujimycine_9\NNP|(|fk506|;|mg/kg|,|but|rapamycin (r_conj) mg/kg_6\NN|50|)|and|fujimycine (r_appos) A_1\NNP|cyclosporin|csa|;|mg/kg|, (r_nsubj) caused_29\VBD|a|reduction|given|. (l_dobj) reduction_31\NN|a|of (l_prep) of_32\IN|rate (l_pobj) rate_35\NN|glomerular|filtration|,|changes (l_appos) changes_38\NNS|degenerative|of|,|and|hypertrophy (l_conj) hypertrophy_45\NN|of
D016572_D064420 NONE CsA_4\NNP|and|toxicity (l_conj) toxicity_7\NN|fk506
D016559_D064420 NONE FK506_6\NNP| (r_compound) toxicity_7\NN|fk506
20552622
D000420_D013617 CID salbutamol_7\NN| (r_pobj) by_6\IN|salbutamol (r_agent) triggered_5\VBN|by (r_acl) tachyarrhythmia_4\NN|induced|atrial|triggered|report
D000420_D013617 CID Salbutamol_0\NNP| (r_nsubjpass) presented_2\VBN|salbutamol|is|here|as|. (l_prep) as_4\IN|trigger (l_pobj) trigger_7\NN|a|possible|for (l_prep) for_8\IN|siat (l_pobj) SIAT_9\NNP|
D001262_D001145 NONE atenolol_6\NN| (r_pobj) with_5\IN|atenolol (r_prep) resolved_2\VBD|arrhythmia|after|with|,|but|recurred|. (l_nsubj) arrhythmia_1\NN|the
D001262_D001145 NONE atenolol_13\NN|the (r_pobj) with_11\IN|atenolol (r_prep) week_10\NN|a|with (r_pobj) after_8\IN|week (r_prep) disappeared_17\VBD|after|after|,|arrhythmia|. (l_nsubj) arrhythmia_16\NN|the
D000420_D013610 NONE salbutamol_23\NN| (r_pobj) like_22\IN|salbutamol (r_prep) agonist_21\NN|a|beta|-|like|known (l_acl) known_25\VBN|(|induce|) (l_xcomp) induce_27\VB|to|tachycardia (l_dobj) tachycardia_28\NN|
D001262_D013610 NONE atenolol_51\NN|blocks (r_pobj) as_50\IN|such|atenolol (r_prep) blocker_48\NN|a|beta|-|as (r_nsubj) relieve_60\VB|that|blocker|may|it (r_conj) swallowing_42\VBG|while|and|relieve (r_advcl) be_31\VB|that|agonist|may|trigger|swallowing (l_nsubj) agonist_21\NN|a|beta|-|like|known (l_acl) known_25\VBN|(|induce|) (l_xcomp) induce_27\VB|to|tachycardia (l_dobj) tachycardia_28\NN|
9545159
D020117_D008133 CID cisapride_7\NN| (r_compound) diltiazem_9\NN|cisapride|- (r_compound) interaction_10\NN|diltiazem (r_pobj) to_6\IN|interaction (r_prep) related_5\VBN|to (r_acl) interval_4\NN|the|qt|related
D004110_D008133 CID diltiazem_9\NN|cisapride|- (r_compound) interaction_10\NN|diltiazem (r_pobj) to_6\IN|interaction (r_prep) related_5\VBN|to (r_acl) interval_4\NN|the|qt|related
D020117_D015835 NONE Cisapride_0\NNP|,|substrate|, (r_nsubjpass) prescribed_13\VBN|cisapride|is|widely|for|. (l_prep) for_14\IN|treatment (l_pobj) treatment_16\NN|the|of (l_prep) of_17\IN|disorders (l_pobj) disorders_20\NNS|gastrointestinal|motility
D004917_D008133 CID erythromycin_20\NNP|or|agents (r_pobj) with_19\IN|erythromycin (r_prep) administration_18\NN|concomitant|with (r_pobj) after_16\IN|administration (r_prep) reported_15\VBN|torsades|have|been|after|,|but|with|. (l_nsubjpass) torsades_5\NNS|prolongation|pointes (l_nsubj) Prolongation_0\NN|of|, (l_prep) of_1\IN|interval (l_pobj) interval_3\NN|qt
D004917_D016171 CID erythromycin_20\NNP|or|agents (r_pobj) with_19\IN|erythromycin (r_prep) administration_18\NN|concomitant|with (r_pobj) after_16\IN|administration (r_prep) reported_15\VBN|torsades|have|been|after|,|but|with|. (l_nsubjpass) torsades_5\NNS|prolongation|pointes (l_dobj) pointes_7\FW|de|,|and|death
D004917_D016757 CID erythromycin_20\NNP|or|agents (r_pobj) with_19\IN|erythromycin (r_prep) administration_18\NN|concomitant|with (r_pobj) after_16\IN|administration (r_prep) reported_15\VBN|torsades|have|been|after|,|but|with|. (l_nsubjpass) torsades_5\NNS|prolongation|pointes (l_dobj) pointes_7\FW|de|,|and|death (l_conj) death_12\NN|sudden|cardiac
D001393_D008133 CID azole_22\JJ| (r_amod) agents_24\NNS|azole|antifungal (r_conj) erythromycin_20\NNP|or|agents (r_pobj) with_19\IN|erythromycin (r_prep) administration_18\NN|concomitant|with (r_pobj) after_16\IN|administration (r_prep) reported_15\VBN|torsades|have|been|after|,|but|with|. (l_nsubjpass) torsades_5\NNS|prolongation|pointes (l_nsubj) Prolongation_0\NN|of|, (l_prep) of_1\IN|interval (l_pobj) interval_3\NN|qt
D001393_D016171 CID azole_22\JJ| (r_amod) agents_24\NNS|azole|antifungal (r_conj) erythromycin_20\NNP|or|agents (r_pobj) with_19\IN|erythromycin (r_prep) administration_18\NN|concomitant|with (r_pobj) after_16\IN|administration (r_prep) reported_15\VBN|torsades|have|been|after|,|but|with|. (l_nsubjpass) torsades_5\NNS|prolongation|pointes (l_dobj) pointes_7\FW|de|,|and|death
D001393_D016757 CID azole_22\JJ| (r_amod) agents_24\NNS|azole|antifungal (r_conj) erythromycin_20\NNP|or|agents (r_pobj) with_19\IN|erythromycin (r_prep) administration_18\NN|concomitant|with (r_pobj) after_16\IN|administration (r_prep) reported_15\VBN|torsades|have|been|after|,|but|with|. (l_nsubjpass) torsades_5\NNS|prolongation|pointes (l_dobj) pointes_7\FW|de|,|and|death (l_conj) death_12\NN|sudden|cardiac
D020117_D005764 NONE cisapride_14\NN| (r_dobj) taking_13\VBG|who|was|cisapride|for|,|for (l_prep) for_15\IN|disorder (l_pobj) disorder_18\NN|gastroesophageal|reflux|and|diltiazem|,|agent
D020117_D006973 NONE cisapride_14\NN| (r_dobj) taking_13\VBG|who|was|cisapride|for|,|for (l_prep) for_31\IN|hypertension (l_pobj) hypertension_32\NN|
D004110_D005764 NONE diltiazem_20\NN| (r_conj) disorder_18\NN|gastroesophageal|reflux|and|diltiazem|,|agent
D004110_D006973 NONE diltiazem_20\NN| (r_conj) disorder_18\NN|gastroesophageal|reflux|and|diltiazem|,|agent (r_pobj) for_15\IN|disorder (r_prep) taking_13\VBG|who|was|cisapride|for|,|for (l_prep) for_31\IN|hypertension (l_pobj) hypertension_32\NN|
9669632
D020117_D043183 NONE cisapride_2\NN| (r_pobj) of_1\IN|cisapride (r_prep) Effects_0\NNS|of|on|and|function|. (l_conj) function_11\NN|postcibal|bowel|motor|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|syndrome (l_pobj) syndrome_17\NN|irritable|bowel
D020117_D043183 NONE cisapride_17\NN|,|on (l_prep) on_19\IN|motility (l_pobj) motility_22\NN|postprandial|jejunal|and|symptoms|in (l_prep) in_25\IN|syndrome (l_pobj) syndrome_29\NN|the|irritable|bowel|(|ibs|)
D020117_D043183 NONE cisapride_17\NN|,|on (l_prep) on_19\IN|motility (l_pobj) motility_22\NN|postprandial|jejunal|and|symptoms|in (l_prep) in_25\IN|syndrome (l_pobj) syndrome_29\NN|the|irritable|bowel|(|ibs|) (l_appos) IBS_31\NNP|
D020117_D043183 NONE cisapride_36\NN|after|[ (r_conj) before_28\IN|and|cisapride (r_advmod) underwent_23\VBD|patients|;|,|)|manometry|before|,|daily|. (l_nsubj) patients_3\NNS|eight|with (l_prep) with_4\IN|ibs (l_pobj) IBS_5\NNP|(|predominant
D020117_D043183 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|cisapride|- (r_amod) patients_18\NNS|treated|predominant|ibs|score (l_compound) IBS_17\NNP|
D020117_D043183 NONE cisapride_11\NN| (r_compound) therapy_12\NN|cisapride (r_nmod) score_14\NN|after|therapy|[|,|+/-|,|cisapride|(|p|) (r_advcl) had_5\VBD|patients|score|score|;|pretreatment|. (l_nsubj) patients_4\NNS|predominant|ibs (l_compound) IBS_3\NNP|
D020117_D043183 NONE cisapride_25\NN|versus (r_conj) score_14\NN|after|therapy|[|,|+/-|,|cisapride|(|p|) (r_advcl) had_5\VBD|patients|score|score|;|pretreatment|. (l_nsubj) patients_4\NNS|predominant|ibs (l_compound) IBS_3\NNP|
D020117_D043183 NONE Cisapride_0\NNP| (r_nsubj) affects_1\VBZ|cisapride|characteristics|. (l_dobj) characteristics_4\NNS|jejunal|contraction|and|symptoms (l_conj) symptoms_7\NNS|some|in (l_prep) in_8\IN|ibs (l_pobj) IBS_9\NNP|
D020117_D003248 NONE cisapride_36\NN|after|[ (r_conj) before_28\IN|and|cisapride (r_advmod) underwent_23\VBD|patients|;|,|)|manometry|before|,|daily|. (l_nsubj) patients_3\NNS|eight|with (l_prep) with_4\IN|ibs (l_pobj) IBS_5\NNP|(|predominant (l_appos) predominant_9\JJ|constipation|-|, (l_compound) constipation_7\NN|
D020117_D003248 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|cisapride|- (r_amod) patients_18\NNS|treated|predominant|ibs|score (r_pobj) in_10\IN|patients (r_prep) were_8\VBD|scores|lower|in (l_nsubj) scores_1\NNS|symptom|relating (l_acl) relating_2\VBG|to (l_prep) to_3\IN|severity (l_pobj) severity_5\NN|the|of (l_prep) of_6\IN|constipation (l_pobj) constipation_7\NN|
D020117_D003248 NONE cisapride_11\NN| (r_npadvmod) treated_13\VBN|cisapride|- (r_amod) patients_18\NNS|treated|predominant|ibs|score (l_amod) predominant_16\JJ|constipation|- (l_compound) constipation_14\NN|
D020117_D003967 NONE cisapride_36\NN|after|[ (r_conj) before_28\IN|and|cisapride (r_advmod) underwent_23\VBD|patients|;|,|)|manometry|before|,|daily|. (l_punct) ;_14\:|predominant (l_preconj) predominant_17\JJ|diarrhoea|- (l_compound) diarrhoea_15\NN|
D020117_D003967 NONE cisapride_14\NN|and|placebo (r_nmod) groups_17\NNS|the|cisapride (r_pobj) between_12\IN|groups (r_prep) observed_11\VBN|in|differences|were|between|. (l_prep) In_0\IN|patients (l_pobj) patients_4\NNS|predominant (l_amod) predominant_3\JJ|diarrhoea|- (l_npadvmod) diarrhoea_1\NN|
D020117_D003967 NONE cisapride_1\NN| (r_npadvmod) treated_3\VBN|cisapride|- (r_amod) patients_7\NNS|treated|predominant (l_amod) predominant_6\JJ|diarrhoea|- (l_npadvmod) diarrhoea_4\NN|
D020117_D003967 NONE cisapride_11\NN| (r_compound) therapy_12\NN|cisapride (r_nmod) score_14\NN|after|therapy|[|,|+/-|,|cisapride|(|p|) (r_advcl) had_5\VBD|patients|score|score|;|pretreatment|. (l_nsubj) patients_4\NNS|predominant|ibs (l_amod) predominant_2\JJ|diarrhoea|- (l_npadvmod) Diarrhoea_0\NN|
D020117_D003967 NONE cisapride_25\NN|versus (r_conj) score_14\NN|after|therapy|[|,|+/-|,|cisapride|(|p|) (r_advcl) had_5\VBD|patients|score|score|;|pretreatment|. (l_nsubj) patients_4\NNS|predominant|ibs (l_amod) predominant_2\JJ|diarrhoea|- (l_npadvmod) Diarrhoea_0\NN|
D020117_D010146 NONE cisapride_11\NN| (r_compound) therapy_12\NN|cisapride (r_nmod) score_14\NN|after|therapy|[|,|+/-|,|cisapride|(|p|) (r_advcl) had_5\VBD|patients|score|score|;|pretreatment|. (l_dobj) score_9\NN|a|higher|pain (l_compound) pain_8\NN|
D020117_D010146 NONE cisapride_25\NN|versus (r_conj) score_14\NN|after|therapy|[|,|+/-|,|cisapride|(|p|) (r_advcl) had_5\VBD|patients|score|score|;|pretreatment|. (l_dobj) score_9\NN|a|higher|pain (l_compound) pain_8\NN|
8586822
D002216_D006973 NONE captopril_12\FW| (r_npadvmod) treated_14\VBN|contribution|captopril|-|rats|. (l_dobj) rats_17\NNS|hypertensive (l_amod) hypertensive_16\JJ|spontaneously
D002216_D006973 NONE captopril_8\FW| (r_npadvmod) treated_10\VBN|that|,|in|captopril|-|spontaneously|rats (l_dobj) rats_13\NNS|hypertensive|(|shr|) (l_amod) hypertensive_12\JJ|
D002216_D006973 NONE captopril_8\FW| (r_npadvmod) treated_10\VBN|that|,|in|captopril|-|spontaneously|rats (r_relcl) hypothesis_3\NN|the|treated (r_dobj) test_1\VB|to|hypothesis (r_advcl) contributes_22\VBZ|test|,|system|importantly|to|. (l_prep) to_24\IN|effect (l_pobj) effect_27\NN|the|hypertensive|of (l_amod) hypertensive_26\JJ|
D017673_D006973 CID chloride_31\NN|sodium (r_compound) supplementation_32\NN|dietary|chloride (r_pobj) of_28\IN|supplementation (r_prep) effect_27\NN|the|hypertensive|of (r_pobj) to_24\IN|effect (r_prep) contributes_22\VBZ|test|,|system|importantly|to|. (l_advcl) test_1\VB|to|hypothesis (l_dobj) hypothesis_3\NN|the|treated (l_relcl) treated_10\VBN|that|,|in|captopril|-|spontaneously|rats (l_dobj) rats_13\NNS|hypertensive|(|shr|) (l_amod) hypertensive_12\JJ|
D017673_D006973 CID chloride_31\NN|sodium (r_compound) supplementation_32\NN|dietary|chloride (r_pobj) of_28\IN|supplementation (r_prep) effect_27\NN|the|hypertensive|of (l_amod) hypertensive_26\JJ|
D017673_D006973 CID chloride_19\NN| (r_npadvmod) induced_21\VBN|chloride|- (r_amod) increase_22\NN|the|sodium|induced|in|in (l_prep) in_23\IN|map (l_pobj) MAP_24\NNP|
D018738_D006973 NONE hexamethonium_6\NN|the|ganglionic|blocker (r_pobj) of_2\IN|hexamethonium (r_prep) infusion_1\NN|intravenous|of (r_nsubj) resulted_7\VBD|infusion|in|. (l_prep) in_8\IN|decline (l_pobj) decline_11\NN|a|rapid|in|eliminated (l_relcl) eliminated_15\VBD|that|increase (l_dobj) increase_22\NN|the|sodium|induced|in|in (l_prep) in_23\IN|map (l_pobj) MAP_24\NNP|
7263204
D007213_D000741 CID indomethacin_5\NN| (r_pobj) due_3\IN|to|indomethacin (r_amod) anemia_2\NN|fatal|aplastic|due|--|lymphocyte|.
D007213_D000741 CID indomethacin_1\NN| (r_nsubjpass) implicated_4\VBN|although|indomethacin|has|been|as (l_prep) as_5\IN|cause (l_pobj) cause_8\NN|a|possible|of (l_prep) of_9\IN|anemia (l_pobj) anemia_11\NN|aplastic|on
D007213_D000741 CID indomethacin_16\NN| (r_conj) allopurinol_14\NN|and|indomethacin (r_pobj) than_13\IN|allopurinol (r_prep) other_12\JJ|than (r_amod) drugs_11\NNS|no|other (r_nsubjpass) given_18\VBN|in|drugs|were (r_relcl) described_7\VBN|case|is|given|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|anemia (l_pobj) anemia_5\NN|fatal|aplastic
D007213_D000741 CID indomethacin_6\NN|in (r_pobj) with_5\IN|indomethacin (r_prep) test_4\NN|a|positive|transformation|with (r_nsubj) substantiates_10\VBZ|test|further|role|. (l_dobj) role_13\NN|the|potential|of|in (l_prep) in_17\IN|causing (l_pcomp) causing_18\VBG|anemia|in (l_dobj) anemia_20\NN|aplastic
D000493_D000741 NONE allopurinol_14\NN|and|indomethacin (r_pobj) than_13\IN|allopurinol (r_prep) other_12\JJ|than (r_amod) drugs_11\NNS|no|other (r_nsubjpass) given_18\VBN|in|drugs|were (r_relcl) described_7\VBN|case|is|given|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|anemia (l_pobj) anemia_5\NN|fatal|aplastic
2051906
D001379_D002779 CID azathioprine_7\JJ| (r_amod) therapy_8\NN|azathioprine (r_pobj) following_6\VBG|therapy (r_prep) cholestasis_1\NN|reversible|with|following|.
D001379_D002779 CID azathioprine_7\JJ| (r_amod) therapy_8\NN|azathioprine (r_pobj) following_6\VBG|therapy (r_prep) cholestasis_1\NN|reversible|with|following|. (l_prep) with_2\IN|injury (l_pobj) injury_5\NN|duct
D001379_D002779 CID azathioprine_30\NN| (r_amod) therapy_31\NN|azathioprine (r_pobj) of_29\IN|therapy (r_prep) initiation_28\NN|of (r_pobj) after_27\IN|months|initiation (r_prep) developed_17\VBD|patient|features|after|. (l_dobj) features_21\NNS|clinical|of (l_prep) of_22\IN|cholestasis (l_pobj) cholestasis_24\NN|severe
D001379_D002779 CID azathioprine_12\RB| (r_advmod) induced_14\VBN|azathioprine|- (r_amod) cholestasis_15\NN|reversible|induced|associated
D001379_D002779 CID azathioprine_12\RB| (r_advmod) induced_14\VBN|azathioprine|- (r_amod) cholestasis_15\NN|reversible|induced|associated (l_acl) associated_16\VBN|with (l_prep) with_17\IN|evidence (l_pobj) evidence_19\NN|histological|of (l_prep) of_20\IN|injury (l_pobj) injury_23\NN|duct
D001379_D017285 NONE azathioprine_30\NN| (r_amod) therapy_31\NN|azathioprine (r_pobj) of_29\IN|therapy (r_prep) initiation_28\NN|of (r_pobj) after_27\IN|months|initiation (r_prep) developed_17\VBD|patient|features|after|. (l_nsubj) patient_4\NN|a|old|,|with (l_prep) with_6\IN|polymyositis|and|without (l_pobj) polymyositis_8\NN|primary
D001379_D008107 NONE azathioprine_30\NN| (r_amod) therapy_31\NN|azathioprine (r_pobj) of_29\IN|therapy (r_prep) initiation_28\NN|of (r_pobj) after_27\IN|months|initiation (r_prep) developed_17\VBD|patient|features|after|. (l_nsubj) patient_4\NN|a|old|,|with (l_prep) with_6\IN|polymyositis|and|without (l_conj) without_10\IN|evidence (l_pobj) evidence_12\NN|previous|of (l_prep) of_13\IN|disease (l_pobj) disease_15\NN|liver|,
16826348
D003561_D010523 CID arabinoside_8\NN| (r_amod) treatment_9\NN|dose|cytosine|arabinoside|in (r_pobj) by_3\IN|treatment (r_agent) caused_2\VBN|by (r_acl) neuropathy_1\NNS|peripheral|caused|.
D003561_D010523 CID arabinoside_14\NN|dose|cytosine (r_nsubj) is_15\VBZ|are|,|arabinoside|therapy|,|and|play (l_advcl) are_6\VBP|although|mechanisms|still|unclear (l_nsubj) mechanisms_2\NNS|the|of (l_prep) of_3\IN|neuropathy (l_pobj) neuropathy_5\NN|peripheral
D003561_D015470 NONE arabinoside_8\NN| (r_amod) treatment_9\NN|dose|cytosine|arabinoside|in (l_prep) in_10\IN|patient (l_pobj) patient_12\NN|a|with (l_prep) with_13\IN|leukemia (l_pobj) leukemia_16\NN|acute|myeloid
D003561_D064420 NONE arabinoside_10\NN|dose|cytosine (r_pobj) of_5\IN|arabinoside (r_prep) toxicity_4\NN|the|central|system|of
D003561_D064420 NONE arabinoside_10\NN|dose|cytosine (r_pobj) of_5\IN|arabinoside (r_prep) toxicity_4\NN|the|central|system|of (r_nsubjpass) recognized_13\VBN|toxicity|is|well|,|but|reported (l_conj) reported_29\VBN|toxicity|has|been|infrequently|. (l_nsubjpass) toxicity_17\NN|the|of
D003561_D064420 NONE arabinoside_20\NN|cytosine|in (r_pobj) of_18\IN|arabinoside (r_prep) toxicity_17\NN|the|of (r_nsubjpass) reported_29\VBN|toxicity|has|been|infrequently|. (r_conj) recognized_13\VBN|toxicity|is|well|,|but|reported (l_nsubjpass) toxicity_4\NN|the|central|system|of
D003561_D064420 NONE arabinoside_20\NN|cytosine|in (r_pobj) of_18\IN|arabinoside (r_prep) toxicity_17\NN|the|of
D003561_D006987 NONE arabinoside_8\NN|dose|cytosine (r_pobj) of_3\IN|arabinoside (r_prep) course_2\NN|the|first|of (r_nsubj) resulted_9\VBD|course|in|,|but|complained (l_conj) complained_28\VBD|on|,|patient|of|in|. (l_prep) of_29\IN|numbness (l_pobj) numbness_30\NN|
D008775_D009422 NONE methylprednisolone_38\NN| (r_pobj) to_37\IN|methylprednisolone (r_prep) responded_36\VBD|symptoms|subsequently|to|. (r_conj) worsened_19\VBD|received|,|symptoms|,|with|,|and|responded (l_ccomp) received_11\VBD|resolving|;|however|,|after|patient|transplantation (l_ccomp) resolving_4\VBG|neuropathy|was|gradually (l_nsubj) neuropathy_1\NN|this
D008775_D006086 NONE methylprednisolone_38\NN| (r_pobj) to_37\IN|methylprednisolone (r_prep) responded_36\VBD|symptoms|subsequently|to|. (r_conj) worsened_19\VBD|received|,|symptoms|,|with|,|and|responded (l_prep) with_21\IN|development (l_pobj) development_23\NN|the|of (l_prep) of_24\IN|disease (l_pobj) disease_30\NN|graft
11245434
D003520_D000740 NONE cyclophosphamide_8\NN| (r_compound) cytotoxicity_9\NN|cyclophosphamide|in (r_pobj) in_7\IN|cytotoxicity (r_prep) reduction_6\NN|the|induced|in (l_amod) induced_5\VBN|anemia|- (l_npadvmod) anemia_3\NN|
D003520_D000740 NONE cyclophosphamide_25\NN| (r_pobj) of_24\IN|cyclophosphamide (r_prep) cytotoxicity_23\NN|the|of|in (r_pobj) on_21\IN|cytotoxicity (r_prep) treatment_20\NN|erythropoietin|(|rhuepo|)|on (r_pobj) by_13\IN|treatment (r_prep) impact_9\NN|the|of|by (l_prep) of_10\IN|prevention (l_pobj) prevention_12\NN|anemia (l_compound) anemia_11\NN|
D003520_D000740 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) cytotoxicity_9\NN|of|in (r_dobj) reduces_8\VBZ|that|anemia|cytotoxicity|,|increases (l_nsubj) anemia_7\NN|induced
D003520_D000740 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) cytotoxicity_9\NN|of|in (r_dobj) reduces_8\VBZ|that|anemia|cytotoxicity|,|increases (l_advcl) increases_26\VBZ|whereas|correction|sensitivity|,|as (l_nsubj) correction_16\NN|of|by (l_prep) of_17\IN|anemia (l_pobj) anemia_18\NN|
D003520_D064420 NONE cyclophosphamide_8\NN| (r_compound) cytotoxicity_9\NN|cyclophosphamide|in
D003520_D064420 NONE cyclophosphamide_25\NN| (r_pobj) of_24\IN|cyclophosphamide (r_prep) cytotoxicity_23\NN|the|of|in
D003520_D064420 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) cytotoxicity_9\NN|of|in
D003520_D009369 NONE cyclophosphamide_8\NN| (r_compound) cytotoxicity_9\NN|cyclophosphamide|in (l_prep) in_10\IN|tumors (l_pobj) tumors_12\NNS|rat
D003520_D009369 NONE cyclophosphamide_25\NN| (r_pobj) of_24\IN|cyclophosphamide (r_prep) cytotoxicity_23\NN|the|of|in (l_prep) in_26\IN|tumors (l_pobj) tumors_29\NNS|solid|experimental
D003520_D009369 NONE cyclophosphamide_9\NN| (r_pobj) of_8\IN|cyclophosphamide (r_prep) dose_7\NN|a|single|of|(|mg/kg|) (r_pobj) with_4\IN|dose (r_prep) treated_3\VBN|when|tumors|were|with|after (l_nsubjpass) tumors_1\NNS|
D003520_D009369 NONE cyclophosphamide_9\NN| (r_pobj) of_8\IN|cyclophosphamide (r_prep) dose_7\NN|a|single|of|(|mg/kg|) (r_pobj) with_4\IN|dose (r_prep) treated_3\VBN|when|tumors|were|with|after (r_advcl) observed_31\VBN|treated|,|delay|was|. (l_nsubjpass) delay_22\NN|a|growth|with (l_prep) with_23\IN|regrowth (l_pobj) regrowth_26\NN|a|subsequent|of (l_prep) of_27\IN|tumors (l_pobj) tumors_29\NNS|the
D003520_D009369 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) cytotoxicity_9\NN|of|in (l_prep) in_12\IN|tumors (l_pobj) tumors_13\NNS|
D003520_D009369 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) cytotoxicity_9\NN|of|in (r_dobj) reduces_8\VBZ|that|anemia|cytotoxicity|,|increases (l_advcl) increases_26\VBZ|whereas|correction|sensitivity|,|as (l_prep) as_31\IN|probably|result (l_pobj) result_33\NN|a|of (l_prep) of_34\IN|supply (l_pobj) supply_38\NN|an|improved|oxygen|to (l_prep) to_39\IN|tissue (l_pobj) tissue_41\NN|tumor (l_compound) tumor_40\NN|
D016190_D000740 CID carboplatin_8\NN| (r_pobj) of_7\IN|carboplatin (r_prep) dose_6\NN|a|single|of|i.v.|)|resulting (r_dobj) using_3\VBG|dose (r_xcomp) induced_2\VBN|anemia|was|using|. (l_nsubjpass) Anemia_0\NN|
D016190_D000740 CID carboplatin_29\NN| (r_amod) application_30\NN|carboplatin (r_pobj) before_28\IN|application (r_prep) days_27\NNS|7|before (r_dobj) starting_25\VBG|days (r_advcl) administered_19\VBN|s.c.|week|starting (r_conj) prevented_10\VBN|in|,|development|was|by|administered|. (l_nsubjpass) development_6\NN|the|of (l_prep) of_7\IN|anemia (l_pobj) anemia_8\NN|
D016190_D009369 NONE carboplatin_3\NN| (r_amod) treatment_4\NN|carboplatin (r_pobj) after_2\IN|days|treatment (r_prep) implanted_16\VBN|after|,|tumors|were|s.c.|onto|. (l_nsubjpass) tumors_6\NNS|(|sarcoma|)
D016190_D009369 NONE carboplatin_1\NN|neither|nor|treatment|influenced|. (l_conj) influenced_5\VBN|rate|se (l_dobj) rate_8\NN|tumor|growth (l_compound) tumor_6\NN|
D016190_D012509 NONE carboplatin_3\NN| (r_amod) treatment_4\NN|carboplatin (r_pobj) after_2\IN|days|treatment (r_prep) implanted_16\VBN|after|,|tumors|were|s.c.|onto|. (l_nsubjpass) tumors_6\NNS|(|sarcoma|) (l_appos) sarcoma_10\NN|ds|-|of
D010100_D000740 NONE oxygen_37\NN| (r_compound) supply_38\NN|an|improved|oxygen|to (r_pobj) of_34\IN|supply (r_prep) result_33\NN|a|of (r_pobj) as_31\IN|probably|result (r_prep) increases_26\VBZ|whereas|correction|sensitivity|,|as (r_advcl) reduces_8\VBZ|that|anemia|cytotoxicity|,|increases (l_nsubj) anemia_7\NN|induced
D010100_D000740 NONE oxygen_37\NN| (r_compound) supply_38\NN|an|improved|oxygen|to (r_pobj) of_34\IN|supply (r_prep) result_33\NN|a|of (r_pobj) as_31\IN|probably|result (r_prep) increases_26\VBZ|whereas|correction|sensitivity|,|as (l_nsubj) correction_16\NN|of|by (l_prep) of_17\IN|anemia (l_pobj) anemia_18\NN|
D010100_D064420 NONE oxygen_37\NN| (r_compound) supply_38\NN|an|improved|oxygen|to (r_pobj) of_34\IN|supply (r_prep) result_33\NN|a|of (r_pobj) as_31\IN|probably|result (r_prep) increases_26\VBZ|whereas|correction|sensitivity|,|as (r_advcl) reduces_8\VBZ|that|anemia|cytotoxicity|,|increases (l_dobj) cytotoxicity_9\NN|of|in
D010100_D009369 NONE oxygen_37\NN| (r_compound) supply_38\NN|an|improved|oxygen|to (r_pobj) of_34\IN|supply (r_prep) result_33\NN|a|of (r_pobj) as_31\IN|probably|result (r_prep) increases_26\VBZ|whereas|correction|sensitivity|,|as (r_advcl) reduces_8\VBZ|that|anemia|cytotoxicity|,|increases (l_dobj) cytotoxicity_9\NN|of|in (l_prep) in_12\IN|tumors (l_pobj) tumors_13\NNS|
D010100_D009369 NONE oxygen_37\NN| (r_compound) supply_38\NN|an|improved|oxygen|to (l_prep) to_39\IN|tissue (l_pobj) tissue_41\NN|tumor (l_compound) tumor_40\NN|
3084782
D008625_D009393 CID Tiopronin_12\NNP|(|penicillamine|)|and|class|b35-cw4 (r_pobj) to_11\IN|tiopronin (r_pcomp) due_10\IN|to (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis
D008625_D009393 CID Tiopronin_17\NNP| (r_npadvmod) related_18\VBN|tiopronin (r_amod) group_20\NN|the|related|nephritis (l_compound) nephritis_19\NN|
D008625_D003872 CID Tiopronin_12\NNP|(|penicillamine|)|and|class|b35-cw4 (r_pobj) to_11\IN|tiopronin (r_pcomp) due_10\IN|to (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis (l_conj) dermatitis_9\NN|
D008625_D003872 CID Tiopronin_12\NNP|(|penicillamine|)|and|class|b35-cw4 (r_pobj) to_11\IN|tiopronin (r_pcomp) due_10\IN|to (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_28\IN|dermatitis|due (l_pobj) dermatitis_29\NN|
D010396_D009393 NONE Penicillamine_17\NN|a|d|-|like (r_appos) Tiopronin_12\NNP|(|penicillamine|)|and|class|b35-cw4 (r_pobj) to_11\IN|tiopronin (r_pcomp) due_10\IN|to (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis
D010396_D003872 NONE Penicillamine_17\NN|a|d|-|like (r_appos) Tiopronin_12\NNP|(|penicillamine|)|and|class|b35-cw4 (r_pobj) to_11\IN|tiopronin (r_pcomp) due_10\IN|to (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis (l_conj) dermatitis_9\NN|
D010396_D003872 NONE Penicillamine_17\NN|a|d|-|like (r_appos) Tiopronin_12\NNP|(|penicillamine|)|and|class|b35-cw4 (r_pobj) to_11\IN|tiopronin (r_pcomp) due_10\IN|to (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_28\IN|dermatitis|due (l_pobj) dermatitis_29\NN|
D006046_D009393 NONE gold_32\NN| (r_compound) thiosulphate_33\NN|gold|and|b35 (r_pobj) due_30\IN|to|thiosulphate (r_prep) between_28\IN|dermatitis|due (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis
D006046_D003872 CID gold_32\NN| (r_compound) thiosulphate_33\NN|gold|and|b35 (r_pobj) due_30\IN|to|thiosulphate (r_prep) between_28\IN|dermatitis|due (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis (l_conj) dermatitis_9\NN|
D006046_D003872 CID gold_32\NN| (r_compound) thiosulphate_33\NN|gold|and|b35 (r_pobj) due_30\IN|to|thiosulphate (r_prep) between_28\IN|dermatitis|due (l_pobj) dermatitis_29\NN|
-1_D009393 NONE thiosulphate_33\NN|gold|and|b35 (r_pobj) due_30\IN|to|thiosulphate (r_prep) between_28\IN|dermatitis|due (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis
-1_D003872 NONE thiosulphate_33\NN|gold|and|b35 (r_pobj) due_30\IN|to|thiosulphate (r_prep) between_28\IN|dermatitis|due (r_prep) found_5\VBN|association|has|been|between|due|,|and|between|. (l_prep) between_6\IN|nephritis (l_pobj) nephritis_7\NN|and|dermatitis (l_conj) dermatitis_9\NN|
-1_D003872 NONE thiosulphate_33\NN|gold|and|b35 (r_pobj) due_30\IN|to|thiosulphate (r_prep) between_28\IN|dermatitis|due (l_pobj) dermatitis_29\NN|
D008625_D001172 NONE Tiopronin_17\NNP| (r_npadvmod) related_18\VBN|tiopronin (r_amod) group_20\NN|the|related|nephritis (r_pobj) for_15\IN|group (r_prep) except_14\IN|for (r_prep) patients_11\NNS|with|except (l_prep) with_12\IN|ra (l_pobj) RA_13\NNP|
1848636
D008790_D007008 NONE metoprolol_8\NN|of (l_prep) of_9\IN|hypokalemia (l_pobj) hypokalemia_13\NN|induced
D013726_D007008 CID terbutaline_10\NN| (r_npadvmod) induced_12\VBN|terbutaline|- (r_amod) hypokalemia_13\NN|induced
16225977
C012052_D013981 CID Amisulpride_0\NNP| (r_amod) symptoms_5\NNS|amisulpride|related|like|in|.
C012052_D013981 CID amisulpride_13\NN| (r_pobj) of_12\IN|amisulpride (r_prep) dose_11\NN|the|of|mg (r_dobj) reduced_9\VBD|completely|after|we|dose (r_advcl) resolved_5\VBN|symptoms|reduced|. (l_nsubj) symptoms_4\NNS|the|like
C012052_D013981 CID amisulpride_32\NN| (r_conj) clozapine_29\NN|,|or|amisulpride (r_conj) quetiapine_27\NN|,|clozapine (r_pobj) as_26\IN|such|quetiapine (r_prep) antipsychotics_24\NNS|atypical|as (r_pobj) with_22\IN|antipsychotics (r_prep) treatment_21\NN|with (r_pobj) during_20\IN|treatment (r_prep) occur_15\VB|that|symptoms|might|in|during (l_nsubj) symptoms_13\NNS|like
C012052_D012559 NONE Amisulpride_0\NNP| (r_amod) symptoms_5\NNS|amisulpride|related|like|in|. (l_prep) in_6\IN|schizophrenic (l_pobj) schizophrenic_9\NN|an|adolescent
C012052_D012559 NONE amisulpride_20\JJ| (r_amod) treatment_21\NN|amisulpride (r_pobj) of_19\IN|treatment (r_prep) months_18\NNS|5|of (r_pobj) after_16\IN|months (r_prep) developed_9\VBD|who|movements|after (r_relcl) schizophrenic_7\NN|a|old|girl|developed|mg
D018967_D013981 NONE risperidone_11\NN|,|olanzapine (r_pobj) as_10\IN|such|risperidone (r_prep) antipsychotics_8\NNS|atypical|as (r_pobj) by_6\IN|antipsychotics (r_agent) treated_5\VBN|disorders|can|be|effectively|by|. (l_nsubjpass) disorders_1\NNS|tic
C076029_D013981 NONE olanzapine_13\NN|and|ziprasidone (r_conj) risperidone_11\NN|,|olanzapine (r_pobj) as_10\IN|such|risperidone (r_prep) antipsychotics_8\NNS|atypical|as (r_pobj) by_6\IN|antipsychotics (r_agent) treated_5\VBN|disorders|can|be|effectively|by|. (l_nsubjpass) disorders_1\NNS|tic
C092292_D013981 NONE ziprasidone_15\NN| (r_conj) olanzapine_13\NN|and|ziprasidone (r_conj) risperidone_11\NN|,|olanzapine (r_pobj) as_10\IN|such|risperidone (r_prep) antipsychotics_8\NNS|atypical|as (r_pobj) by_6\IN|antipsychotics (r_agent) treated_5\VBN|disorders|can|be|effectively|by|. (l_nsubjpass) disorders_1\NNS|tic
C069541_D013981 NONE quetiapine_24\NN|or|clozapine (r_pobj) with_23\IN|quetiapine (r_prep) treatment_22\NN|with (r_pobj) during_21\IN|treatment (r_prep) occurring_20\VBG|during (r_xcomp) show_8\VBP|that|symptoms|occurring (l_dobj) symptoms_12\NNS|like|,|including|,
C069541_D013981 NONE quetiapine_27\NN|,|clozapine (r_pobj) as_26\IN|such|quetiapine (r_prep) antipsychotics_24\NNS|atypical|as (r_pobj) with_22\IN|antipsychotics (r_prep) treatment_21\NN|with (r_pobj) during_20\IN|treatment (r_prep) occur_15\VB|that|symptoms|might|in|during (l_nsubj) symptoms_13\NNS|like
D003024_D013981 NONE clozapine_26\NN| (r_conj) quetiapine_24\NN|or|clozapine (r_pobj) with_23\IN|quetiapine (r_prep) treatment_22\NN|with (r_pobj) during_21\IN|treatment (r_prep) occurring_20\VBG|during (r_xcomp) show_8\VBP|that|symptoms|occurring (l_dobj) symptoms_12\NNS|like|,|including|,
D003024_D013981 NONE clozapine_29\NN|,|or|amisulpride (r_conj) quetiapine_27\NN|,|clozapine (r_pobj) as_26\IN|such|quetiapine (r_prep) antipsychotics_24\NNS|atypical|as (r_pobj) with_22\IN|antipsychotics (r_prep) treatment_21\NN|with (r_pobj) during_20\IN|treatment (r_prep) occur_15\VB|that|symptoms|might|in|during (l_nsubj) symptoms_13\NNS|like
C012052_D020820 NONE amisulpride_20\JJ| (r_amod) treatment_21\NN|amisulpride (r_pobj) of_19\IN|treatment (r_prep) months_18\NNS|5|of (r_pobj) after_16\IN|months (r_prep) developed_9\VBD|who|movements|after (l_dobj) movements_15\NNS|frequent|involuntary|blinking
3703509
D011241_D053609 NONE prednisone_5\NN|oral (r_pobj) to_3\IN|prednisone (r_prep) exposure_2\NN|short|to (r_pobj) Following_0\VBG|exposure (r_prep) developed_9\VBD|following|,|boys|lethargy|,|increasing|. (l_dobj) lethargy_10\NN|
D011241_D006970 NONE prednisone_5\NN|oral (r_pobj) to_3\IN|prednisone (r_prep) exposure_2\NN|short|to (r_pobj) Following_0\VBG|exposure (r_prep) developed_9\VBD|following|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG|somnolence (l_dobj) somnolence_13\NN|,|polydipsia
D011241_D059606 NONE prednisone_5\NN|oral (r_pobj) to_3\IN|prednisone (r_prep) exposure_2\NN|short|to (r_pobj) Following_0\VBG|exposure (r_prep) developed_9\VBD|following|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG|somnolence (l_dobj) somnolence_13\NN|,|polydipsia (l_conj) polydipsia_15\NN|,|polyphagia
D011241_D006963 NONE prednisone_5\NN|oral (r_pobj) to_3\IN|prednisone (r_prep) exposure_2\NN|short|to (r_pobj) Following_0\VBG|exposure (r_prep) developed_9\VBD|following|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG|somnolence (l_dobj) somnolence_13\NN|,|polydipsia (l_conj) polydipsia_15\NN|,|polyphagia (l_conj) polyphagia_17\NN|,|and|polyuria
D011241_D011141 NONE prednisone_5\NN|oral (r_pobj) to_3\IN|prednisone (r_prep) exposure_2\NN|short|to (r_pobj) Following_0\VBG|exposure (r_prep) developed_9\VBD|following|,|boys|lethargy|,|increasing|. (l_advcl) increasing_12\VBG|somnolence (l_dobj) somnolence_13\NN|,|polydipsia (l_conj) polydipsia_15\NN|,|polyphagia (l_conj) polyphagia_17\NN|,|and|polyuria (l_conj) polyuria_20\NN|
D019344_D000140 NONE lactate_13\NN|serum (r_compound) level_14\NN|a|known|lactate (r_pobj) without_9\IN|level (r_prep) present_4\JJ|in|without (r_acomp) was_3\VBD|acidosis|present|was|. (l_nsubj) acidosis_2\NN|nonketotic|lactic
D019344_D007662 NONE lactate_13\NN|serum (r_compound) level_14\NN|a|known|lactate (r_pobj) without_9\IN|level (r_prep) present_4\JJ|in|without (l_prep) in_5\IN|one (l_pobj) one_6\CD|and|ketosis (l_conj) ketosis_8\NN|
7072798
D002701_D000741 CID chloramphenicol_8\NN|ophthalmic (r_pobj) of_6\IN|chloramphenicol (r_prep) administration_5\NN|topical|of (r_pobj) following_3\VBG|administration (r_prep) anemia_2\NN|fatal|aplastic|following|.
D002701_D000741 CID chloramphenicol_22\NN| (r_pobj) with_21\IN|chloramphenicol (r_prep) therapy_20\NN|topical|with (r_dobj) beginning_18\VBG|therapy (r_conj) undergoing_14\VBG|extraction|and|beginning (r_pcomp) after_13\IN|months|undergoing (r_prep) died_5\VBD|woman|of|after|. (l_prep) of_6\IN|anemia (l_pobj) anemia_8\NN|aplastic
D002701_D000741 CID chloramphenicol_13\NN|to (r_acl) response_11\NN|an|idiosyncratic|chloramphenicol (r_pobj) with_8\IN|response (r_prep) associated_7\VBN|pattern|was|with|. (l_nsubjpass) pattern_1\NN|the|of (l_prep) of_2\IN|anemia (l_pobj) anemia_5\NN|the|aplastic
D002701_D000741 CID chloramphenicol_13\NN| (r_pobj) with_12\IN|chloramphenicol (r_prep) treatment_11\NN|topical|with|for (r_pobj) after_9\IN|treatment (r_prep) report_4\NN|the|second|of|after (l_prep) of_5\IN|anemia (l_pobj) anemia_8\NN|fatal|aplastic
D002701_D002386 NONE chloramphenicol_22\NN| (r_pobj) with_21\IN|chloramphenicol (r_prep) therapy_20\NN|topical|with (r_dobj) beginning_18\VBG|therapy (r_conj) undergoing_14\VBG|extraction|and|beginning (l_dobj) extraction_16\NN|cataract (l_compound) cataract_15\NN|
D002701_D001855 NONE chloramphenicol_13\NN| (r_pobj) with_12\IN|chloramphenicol (r_prep) treatment_11\NN|topical|with|for (r_pobj) after_9\IN|treatment (r_prep) report_4\NN|the|second|of|after (r_attr) was_1\VBD|this|report|,|reported|. (l_advcl) reported_29\VBN|although|cases|have|also|been (l_nsubjpass) cases_20\NNS|two|of (l_prep) of_21\IN|hypoplasia (l_pobj) hypoplasia_25\NN|reversible|marrow
D002701_D005128 NONE chloramphenicol_11\NN|applied (r_pobj) with_8\IN|chloramphenicol (r_prep) associated_7\VBN|with (r_acl) toxicity_6\NN|ocular|associated
14742097
D004809_D020018 NONE ephedrine_10\NN| (r_pobj) of_9\IN|ephedrine (r_prep) study_8\NN|a|randomized|,|controlled|,|crossover|of|for|. (l_prep) for_11\IN|dysfunction (l_pobj) dysfunction_17\NN|induced|female|sexual
D004809_D020018 NONE ephedrine_9\NN|,|agonist (r_nsubj) has_28\VBZ|whether|ephedrine|,|effects (l_dobj) effects_30\NNS|beneficial|in (l_prep) in_31\IN|reversing (l_pcomp) reversing_32\VBG|dysfunction (l_dobj) dysfunction_37\NN|induced|sexual
D004809_D020018 NONE ephedrine_35\NN| (r_pobj) of_34\IN|ephedrine (r_prep) effects_33\NNS|the|of|mg|on (r_pobj) of_31\IN|effects (r_prep) study_30\NN|an|week|,|blind|,|controlled|,|cross|of (r_pobj) in_13\IN|study (r_prep) participated_12\VBD|women|in|. (l_nsubj) women_3\NNS|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ|sexually
D005473_D020018 CID fluoxetine_6\NN|either|,|sertraline (r_dobj) receiving_4\VBG|fluoxetine (r_acl) women_3\NNS|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ|sexually
D020280_D020018 CID sertraline_8\NN|,|or|paroxetine (r_conj) fluoxetine_6\NN|either|,|sertraline (r_dobj) receiving_4\VBG|fluoxetine (r_acl) women_3\NNS|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ|sexually
D017374_D020018 CID paroxetine_11\NN| (r_conj) sertraline_8\NN|,|or|paroxetine (r_conj) fluoxetine_6\NN|either|,|sertraline (r_dobj) receiving_4\VBG|fluoxetine (r_acl) women_3\NNS|nineteen|dysfunctional|receiving (l_amod) dysfunctional_2\JJ|sexually
11890511
3431591
C031662_D064420 NONE 3717_1\CD| (r_nummod) CB_0\NN|3717|,|acid|, (r_nsubj) is_6\VBZ|cb|inhibitor|. (l_attr) inhibitor_11\NN|a|binding|of|mediated (l_relcl) mediated_21\VBN|cytotoxicity|is|through (l_nsubjpass) cytotoxicity_19\NN|whose
C031662_D064420 NONE acid_4\NN|n10-propargyl-5,8-dideazafolic (r_appos) CB_0\NN|3717|,|acid|, (r_nsubj) is_6\VBZ|cb|inhibitor|. (l_attr) inhibitor_11\NN|a|binding|of|mediated (l_relcl) mediated_21\VBN|cytotoxicity|is|through (l_nsubjpass) cytotoxicity_19\NN|whose
C031662_D064420 NONE 3717_28\CD| (r_nummod) CB_27\NNP|3717|, (r_pobj) than_26\IN|cb (r_prep) potent_25\JJ|more|than (r_amod) 26-_17\NNPS|,|87-|,|119-|potent (r_attr) are_16\VBP|as|26-|respectively|,|and|be (l_conj) be_39\VB|formation|may|,|therefore|,|determinant|. (l_attr) determinant_42\NN|an|important|of (l_prep) of_43\IN|cytotoxicity (l_pobj) cytotoxicity_46\NN|cb|3717
C031662_D064420 NONE 3717_45\CD| (r_nummod) cytotoxicity_46\NN|cb|3717
C031662_D001943 NONE 3717_6\CD| (r_nummod) CB_5\NNP|3717 (r_pobj) with_4\IN|cb (r_prep) studies_3\NNS|early|clinical|with (r_pobj) In_0\IN|studies (r_prep) seen_11\VBN|in|,|activity|has|been|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_14\NN|breast|,|cancer
C031662_D010051 NONE 3717_6\CD| (r_nummod) CB_5\NNP|3717 (r_pobj) with_4\IN|cb (r_prep) studies_3\NNS|early|clinical|with (r_pobj) In_0\IN|studies (r_prep) seen_11\VBN|in|,|activity|has|been|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_14\NN|breast|,|cancer (l_conj) cancer_17\NN|ovarian|,|hepatoma
C031662_D006528 NONE 3717_6\CD| (r_nummod) CB_5\NNP|3717 (r_pobj) with_4\IN|cb (r_prep) studies_3\NNS|early|clinical|with (r_pobj) In_0\IN|studies (r_prep) seen_11\VBN|in|,|activity|has|been|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_14\NN|breast|,|cancer (l_conj) cancer_17\NN|ovarian|,|hepatoma (l_conj) hepatoma_19\NN|,|and|mesothelioma
C031662_D008654 NONE 3717_6\CD| (r_nummod) CB_5\NNP|3717 (r_pobj) with_4\IN|cb (r_prep) studies_3\NNS|early|clinical|with (r_pobj) In_0\IN|studies (r_prep) seen_11\VBN|in|,|activity|has|been|in|. (l_prep) in_12\IN|cancer (l_pobj) cancer_14\NN|breast|,|cancer (l_conj) cancer_17\NN|ovarian|,|hepatoma (l_conj) hepatoma_19\NN|,|and|mesothelioma (l_conj) mesothelioma_22\NN|
15276120
D014859_D006470 CID warfarin_3\RB| (r_npadvmod) associated_5\VBN|warfarin|- (r_amod) hemorrhage_6\NN|associated
D014859_D006470 CID warfarin_4\RB| (r_npadvmod) related_6\VBN|warfarin|- (r_amod) bleeding_7\NN|related|at
19274460
D003520_D009101 NONE cyclophosphamide_8\NN|intravenous (r_pobj) for_6\IN|cyclophosphamide (r_prep) definition_5\NN|dose|for|in|for (l_prep) for_15\IN|induction (l_pobj) induction_17\NN|remission|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|myeloma (l_pobj) myeloma_23\NN|diagnosed
D003520_D009101 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) dose_9\NN|the|recommended|of (r_dobj) evaluate_6\VB|to|dose|in|as (l_prep) as_18\IN|treatment (l_pobj) treatment_20\NN|induction|before (l_prep) before_21\IN|transplantation (l_pobj) transplantation_24\NN|cell|for (l_prep) for_25\IN|patients (l_pobj) patients_27\NNS|younger|with (l_prep) with_28\IN|myeloma (l_pobj) myeloma_32\NN|diagnosed|multiple|mm
D003520_D009101 NONE cyclophosphamide_11\NN| (r_pobj) of_10\IN|cyclophosphamide (r_prep) dose_9\NN|the|recommended|of (r_dobj) evaluate_6\VB|to|dose|in|as (l_prep) as_18\IN|treatment (l_pobj) treatment_20\NN|induction|before (l_prep) before_21\IN|transplantation (l_pobj) transplantation_24\NN|cell|for (l_prep) for_25\IN|patients (l_pobj) patients_27\NNS|younger|with (l_prep) with_28\IN|myeloma (l_pobj) myeloma_32\NN|diagnosed|multiple|mm (l_appos) MM_34\NNP|(|)
D003520_D009101 NONE cyclophosphamide_8\NN| (r_pobj) with_7\IN|cyclophosphamide (r_prep) combination_6\NN|with (r_pobj) in_5\IN|combination (r_prep) bortezomib_4\NNS|in|at|and (r_nsubj) is_17\VBZ|that|bortezomib|dexamethasone|treatment (l_attr) treatment_21\NN|an|effective|induction|for|warrants (l_prep) for_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|mm (l_pobj) MM_27\NNP|diagnosed
C400082_D009101 NONE bortezomib_12\NNS| (r_amod) dexamethasone_14\NN|bortezomib|/ (r_pobj) with_11\IN|dexamethasone (r_prep) combination_10\NN|with (r_pobj) in_9\IN|combination (r_prep) definition_5\NN|dose|for|in|for (l_prep) for_15\IN|induction (l_pobj) induction_17\NN|remission|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|myeloma (l_pobj) myeloma_23\NN|diagnosed
C400082_D009101 NONE bortezomib_15\NNS|and|dexamethasone (r_pobj) with_14\IN|bortezomib (r_prep) combination_13\NN|with (r_pobj) in_12\IN|combination (r_prep) evaluate_6\VB|to|dose|in|as (l_prep) as_18\IN|treatment (l_pobj) treatment_20\NN|induction|before (l_prep) before_21\IN|transplantation (l_pobj) transplantation_24\NN|cell|for (l_prep) for_25\IN|patients (l_pobj) patients_27\NNS|younger|with (l_prep) with_28\IN|myeloma (l_pobj) myeloma_32\NN|diagnosed|multiple|mm
C400082_D009101 NONE bortezomib_15\NNS|and|dexamethasone (r_pobj) with_14\IN|bortezomib (r_prep) combination_13\NN|with (r_pobj) in_12\IN|combination (r_prep) evaluate_6\VB|to|dose|in|as (l_prep) as_18\IN|treatment (l_pobj) treatment_20\NN|induction|before (l_prep) before_21\IN|transplantation (l_pobj) transplantation_24\NN|cell|for (l_prep) for_25\IN|patients (l_pobj) patients_27\NNS|younger|with (l_prep) with_28\IN|myeloma (l_pobj) myeloma_32\NN|diagnosed|multiple|mm (l_appos) MM_34\NNP|(|)
C400082_D009101 NONE bortezomib_4\NNS|in|at|and (r_nsubj) is_17\VBZ|that|bortezomib|dexamethasone|treatment (l_attr) treatment_21\NN|an|effective|induction|for|warrants (l_prep) for_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|mm (l_pobj) MM_27\NNP|diagnosed
D003907_D009101 NONE dexamethasone_14\NN|bortezomib|/ (r_pobj) with_11\IN|dexamethasone (r_prep) combination_10\NN|with (r_pobj) in_9\IN|combination (r_prep) definition_5\NN|dose|for|in|for (l_prep) for_15\IN|induction (l_pobj) induction_17\NN|remission|in (l_prep) in_18\IN|patients (l_pobj) patients_19\NNS|with (l_prep) with_20\IN|myeloma (l_pobj) myeloma_23\NN|diagnosed
D003907_D009101 NONE dexamethasone_17\NN| (r_conj) bortezomib_15\NNS|and|dexamethasone (r_pobj) with_14\IN|bortezomib (r_prep) combination_13\NN|with (r_pobj) in_12\IN|combination (r_prep) evaluate_6\VB|to|dose|in|as (l_prep) as_18\IN|treatment (l_pobj) treatment_20\NN|induction|before (l_prep) before_21\IN|transplantation (l_pobj) transplantation_24\NN|cell|for (l_prep) for_25\IN|patients (l_pobj) patients_27\NNS|younger|with (l_prep) with_28\IN|myeloma (l_pobj) myeloma_32\NN|diagnosed|multiple|mm
D003907_D009101 NONE dexamethasone_17\NN| (r_conj) bortezomib_15\NNS|and|dexamethasone (r_pobj) with_14\IN|bortezomib (r_prep) combination_13\NN|with (r_pobj) in_12\IN|combination (r_prep) evaluate_6\VB|to|dose|in|as (l_prep) as_18\IN|treatment (l_pobj) treatment_20\NN|induction|before (l_prep) before_21\IN|transplantation (l_pobj) transplantation_24\NN|cell|for (l_prep) for_25\IN|patients (l_pobj) patients_27\NNS|younger|with (l_prep) with_28\IN|myeloma (l_pobj) myeloma_32\NN|diagnosed|multiple|mm (l_appos) MM_34\NNP|(|)
D003907_D009101 NONE dexamethasone_16\NN| (r_nsubj) is_17\VBZ|that|bortezomib|dexamethasone|treatment (l_attr) treatment_21\NN|an|effective|induction|for|warrants (l_prep) for_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|mm (l_pobj) MM_27\NNP|diagnosed
7437994
12852481
D001241_D000014 CID Aspirin_0\NNP| (r_nsubj) acetylsalicylic_2\JJ|aspirin|(|acid|)|,|cyclooxygenase|,|induces|9|. (l_conj) induces_17\VBZ|anomalies|administered (l_dobj) anomalies_19\NNS|developmental
D001241_D000014 CID acid_3\NN|asa (r_npadvmod) acetylsalicylic_2\JJ|aspirin|(|acid|)|,|cyclooxygenase|,|induces|9|. (l_conj) induces_17\VBZ|anomalies|administered (l_dobj) anomalies_19\NNS|developmental
D001241_D000014 CID ASA_5\NNP|[|] (r_appos) acid_3\NN|asa (r_npadvmod) acetylsalicylic_2\JJ|aspirin|(|acid|)|,|cyclooxygenase|,|induces|9|. (l_conj) induces_17\VBZ|anomalies|administered (l_dobj) anomalies_19\NNS|developmental
D001241_D000014 CID ASA_20\NNP| (r_nsubjpass) administered_22\VBN|when|asa|is|on (r_advcl) compare_7\VB|to|results|administered (r_xcomp) were_5\VBD|objectives|compare|;|. (l_nsubj) Objectives_0\NNS|of|compare (l_acl) compare_33\VB|to|patterns|;|and|test (l_conj) test_50\VB|to|hypothesis (l_dobj) hypothesis_52\NN|the|confounds (l_acl) confounds_57\VBZ|that|toxicity|detection|used (l_dobj) detection_59\NN|the|of (l_prep) of_60\IN|malformations (l_pobj) malformations_63\NNS|low|incidence|with
D001241_D000014 CID ASA_65\NNP| (r_pobj) with_64\IN|asa (r_prep) malformations_63\NNS|low|incidence|with
D001241_D000014 CID ASA_16\NNP| (r_nsubj) induces_17\VBZ|even|though|asa|malformations (r_advcl) focused_9\VBD|,|)|;|hence|,|study|on|,|induces|. (l_prep) on_10\IN|malformations (l_pobj) malformations_12\NNS|these
D001241_D000014 CID ASA_16\NNP| (r_nsubj) induces_17\VBZ|even|though|asa|malformations (l_dobj) malformations_23\NNS|several|other|incidence
D001241_D000014 CID ASA_6\NNP| (r_nsubjpass) administered_8\VBN|when|asa|was|as (r_advcl) were_3\VBD|variations|similar|administered|gds|. (l_nsubj) Variations_0\NNS|and|malformations (l_conj) malformations_2\NNS|
D001241_D000014 CID ASA_38\NNP|given (r_pobj) with_37\IN|asa (r_prep) induced_36\VBN|that|,|malformations|,|could|also|be|with (l_nsubjpass) malformations_17\NNS|by|,|occur|,|reported
D001241_D005767 NONE ASA_20\NNP| (r_nsubjpass) administered_22\VBN|when|asa|is|on (r_advcl) compare_7\VB|to|results|administered (r_xcomp) were_5\VBD|objectives|compare|;|. (l_nsubj) Objectives_0\NNS|of|compare (l_acl) compare_33\VB|to|patterns|;|and|test (l_conj) test_50\VB|to|hypothesis (l_dobj) hypothesis_52\NN|the|confounds (l_acl) confounds_57\VBZ|that|toxicity|detection|used (l_nsubj) toxicity_56\NN|maternal|gastrointestinal
D001241_D005767 NONE ASA_65\NNP| (r_pobj) with_64\IN|asa (r_prep) malformations_63\NNS|low|incidence|with (r_pobj) of_60\IN|malformations (r_prep) detection_59\NN|the|of (r_dobj) confounds_57\VBZ|that|toxicity|detection|used (l_nsubj) toxicity_56\NN|maternal|gastrointestinal
20304337
D003042_-1 NONE cocaine_8\NN| (r_pobj) to_7\IN|cocaine (r_prep) exposed_6\VBN|dysgenesis|prenatally|to|. (l_nsubj) dysgenesis_1\NN|brainstem|in
10524660
D005996_D020326 CID trinitrate_1\NN|glyceryl (r_nsubj) induces_2\VBZ|trinitrate|attacks|. (l_dobj) attacks_3\NNS|of|without (l_prep) without_6\IN|aura (l_pobj) aura_7\NN|in
D005996_D020325 NONE trinitrate_1\NN|glyceryl (r_nsubj) induces_2\VBZ|trinitrate|attacks|. (l_dobj) attacks_3\NNS|of|without (l_prep) without_6\IN|aura (l_pobj) aura_7\NN|in (l_prep) in_8\IN|sufferers (l_pobj) sufferers_9\NNS|of|with (l_prep) with_12\IN|aura (l_pobj) aura_13\NN|
D005996_D020325 NONE trinitrate_28\NN|glyceryl|(|gtn|) (r_pobj) of_26\IN|trinitrate (r_prep) infusion_25\NN|intravenous|of (r_pobj) to_23\IN|infusion (r_prep) response_22\NN|the|headache|to (r_dobj) examined_19\VBD|in|,|in|we|response|min|. (l_prep) In_0\IN|order (l_pobj) order_1\NN|clarify (l_acl) clarify_3\VB|to|is (l_ccomp) is_7\VBZ|whether|same|true (l_acomp) true_8\JJ|for (l_prep) for_9\IN|migraine (l_pobj) migraine_10\NN|with (l_prep) with_11\IN|aura (l_pobj) aura_12\NN|
D005996_D020325 NONE trinitrate_28\NN|glyceryl|(|gtn|) (r_pobj) of_26\IN|trinitrate (r_prep) infusion_25\NN|intravenous|of (r_pobj) to_23\IN|infusion (r_prep) response_22\NN|the|headache|to (r_dobj) examined_19\VBD|in|,|in|we|response|min|. (l_parataxis) min_38\NN|(|0.5|microg|/|for|)|in (l_prep) in_43\IN|sufferers (l_pobj) sufferers_45\NNS|12|of|with (l_prep) with_48\IN|aura (l_pobj) aura_49\NN|
D005996_D020325 NONE GTN_30\NNP| (r_appos) trinitrate_28\NN|glyceryl|(|gtn|) (r_pobj) of_26\IN|trinitrate (r_prep) infusion_25\NN|intravenous|of (r_pobj) to_23\IN|infusion (r_prep) response_22\NN|the|headache|to (r_dobj) examined_19\VBD|in|,|in|we|response|min|. (l_prep) In_0\IN|order (l_pobj) order_1\NN|clarify (l_acl) clarify_3\VB|to|is (l_ccomp) is_7\VBZ|whether|same|true (l_acomp) true_8\JJ|for (l_prep) for_9\IN|migraine (l_pobj) migraine_10\NN|with (l_prep) with_11\IN|aura (l_pobj) aura_12\NN|
D005996_D020325 NONE GTN_30\NNP| (r_appos) trinitrate_28\NN|glyceryl|(|gtn|) (r_pobj) of_26\IN|trinitrate (r_prep) infusion_25\NN|intravenous|of (r_pobj) to_23\IN|infusion (r_prep) response_22\NN|the|headache|to (r_dobj) examined_19\VBD|in|,|in|we|response|min|. (l_parataxis) min_38\NN|(|0.5|microg|/|for|)|in (l_prep) in_43\IN|sufferers (l_pobj) sufferers_45\NNS|12|of|with (l_prep) with_48\IN|aura (l_pobj) aura_49\NN|
D009569_D010146 NONE oxide_13\NN|the|molecule|nitric|(|no|) (r_nsubjpass) involved_18\VBN|that|oxide|is|in (l_prep) in_19\IN|mechanisms (l_pobj) mechanisms_21\NNS|pain|of|without (l_compound) pain_20\NN|
D009569_D010146 NONE NO_15\NNP| (r_appos) oxide_13\NN|the|molecule|nitric|(|no|) (r_nsubjpass) involved_18\VBN|that|oxide|is|in (l_prep) in_19\IN|mechanisms (l_pobj) mechanisms_21\NNS|pain|of|without (l_compound) pain_20\NN|
D009569_D010146 NONE NO_5\DT| (r_nsubjpass) involved_7\VBN|that|no|is|in (l_prep) in_8\IN|mechanisms (l_pobj) mechanisms_11\NNS|the|pain|of|with (l_compound) pain_10\NN|
D009569_D020326 CID oxide_13\NN|the|molecule|nitric|(|no|) (r_nsubjpass) involved_18\VBN|that|oxide|is|in (l_prep) in_19\IN|mechanisms (l_pobj) mechanisms_21\NNS|pain|of|without (l_prep) without_24\IN|aura (l_pobj) aura_25\NN|
D009569_D020326 CID NO_15\NNP| (r_appos) oxide_13\NN|the|molecule|nitric|(|no|) (r_nsubjpass) involved_18\VBN|that|oxide|is|in (l_prep) in_19\IN|mechanisms (l_pobj) mechanisms_21\NNS|pain|of|without (l_prep) without_24\IN|aura (l_pobj) aura_25\NN|
D005996_D006261 NONE trinitrate_28\NN|glyceryl|(|gtn|) (r_pobj) of_26\IN|trinitrate (r_prep) infusion_25\NN|intravenous|of (r_pobj) to_23\IN|infusion (r_prep) response_22\NN|the|headache|to (l_compound) headache_21\NN|
D005996_D006261 NONE GTN_30\NNP| (r_appos) trinitrate_28\NN|glyceryl|(|gtn|) (r_pobj) of_26\IN|trinitrate (r_prep) infusion_25\NN|intravenous|of (r_pobj) to_23\IN|infusion (r_prep) response_22\NN|the|headache|to (l_compound) headache_21\NN|
D005996_D006261 NONE GTN_14\NNP| (r_compound) infusion_15\NN|after|gtn|p=0.037|as|during (r_advcl) was_1\VBD|headache|severe|infusion|. (l_nsubj) Headache_0\NNP|
D005996_D006261 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|gtn|- (r_amod) headache_8\NN|the|induced
D005996_D006261 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|gtn|- (r_amod) headache_8\NN|the|induced (r_nsubj) disappeared_10\VBD|in|,|headache|gradually|,|peak|. (l_advcl) peak_15\JJ|whereas|in|occurred (l_ccomp) occurred_18\VBD|intensity|at (l_nsubj) intensity_17\NN|headache (l_compound) headache_16\NN|
D005996_D008881 NONE GTN_14\NNP| (r_compound) infusion_15\NN|after|gtn|p=0.037|as|during (r_advcl) was_1\VBD|headache|severe|infusion|. (l_acomp) severe_3\JJ|more|in|than (l_prep) in_4\IN|migraineurs (l_pobj) migraineurs_5\NNS|
D005996_D008881 NONE GTN_5\NNP| (r_npadvmod) induced_7\VBN|gtn|- (r_amod) headache_8\NN|the|induced (r_nsubj) disappeared_10\VBD|in|,|headache|gradually|,|peak|. (l_advcl) peak_15\JJ|whereas|in|occurred (l_prep) in_13\IN|migraineurs (l_pobj) migraineurs_14\NNS|
D009569_D020325 NONE NO_5\DT| (r_nsubjpass) involved_7\VBN|that|no|is|in (l_prep) in_8\IN|mechanisms (l_pobj) mechanisms_11\NNS|the|pain|of|with (l_prep) with_14\IN|aura (l_pobj) aura_15\NN|
D009569_D020325 NONE NO_9\DT| (r_intj) liberate_8\VB|to|no|in (r_xcomp) shown_6\VBN|since|depression|has|been|liberate (r_advcl) help_16\VB|shown|,|finding|may|understanding|. (l_dobj) understanding_18\NN|our|of (l_prep) of_19\IN|coupling (l_pobj) coupling_21\NN|the|between (l_prep) between_22\IN|depression (l_pobj) depression_25\NN|cortical|spreading|and|headache (l_conj) headache_27\NN|in|with (l_prep) with_30\IN|aura (l_pobj) aura_31\NN|
D009569_D003866 NONE NO_9\DT| (r_intj) liberate_8\VB|to|no|in (r_xcomp) shown_6\VBN|since|depression|has|been|liberate (l_nsubjpass) depression_3\NN|cortical|spreading
D009569_D003866 NONE NO_9\DT| (r_intj) liberate_8\VB|to|no|in (r_xcomp) shown_6\VBN|since|depression|has|been|liberate (r_advcl) help_16\VB|shown|,|finding|may|understanding|. (l_dobj) understanding_18\NN|our|of (l_prep) of_19\IN|coupling (l_pobj) coupling_21\NN|the|between (l_prep) between_22\IN|depression (l_pobj) depression_25\NN|cortical|spreading|and|headache
D009569_D006261 NONE NO_9\DT| (r_intj) liberate_8\VB|to|no|in (r_xcomp) shown_6\VBN|since|depression|has|been|liberate (r_advcl) help_16\VB|shown|,|finding|may|understanding|. (l_dobj) understanding_18\NN|our|of (l_prep) of_19\IN|coupling (l_pobj) coupling_21\NN|the|between (l_prep) between_22\IN|depression (l_pobj) depression_25\NN|cortical|spreading|and|headache (l_conj) headache_27\NN|in|with
2435991
C032151_D001145 NONE cibenzoline_4\NN| (r_pobj) of_3\IN|cibenzoline (r_prep) concentrations_2\NNS|antiarrhythmic|plasma|of|on|. (l_prep) on_5\IN|arrhythmias (l_pobj) arrhythmias_8\NNS|canine|ventricular
C032151_D001145 NONE cibenzoline_20\NN| (r_pobj) of_19\IN|cibenzoline (r_prep) effects_18\NNS|antiarrhythmic|of (r_nsubjpass) examined_22\VBN|using|,|effects|were|and|determined (l_advcl) Using_0\VBG|arrhythmias (l_dobj) arrhythmias_15\NNS|ligation-|canine|ventricular
C032151_D001145 NONE cibenzoline_20\NN| (r_pobj) of_19\IN|cibenzoline (r_prep) effects_18\NNS|antiarrhythmic|of (r_nsubjpass) examined_22\VBN|using|,|effects|were|and|determined (l_conj) determined_34\VBN|concentration|was|. (l_nsubjpass) concentration_28\NN|the|minimum|effective|plasma|for (l_prep) for_29\IN|model (l_pobj) model_32\NN|each|arrhythmia (l_compound) arrhythmia_31\NN|
C032151_D001145 NONE Cibenzoline_0\NNP| (r_nsubj) suppressed_1\VBD|cibenzoline|arrhythmias|,|and|induced|were|. (l_dobj) arrhythmias_4\NNS|all|the
C032151_D001145 NONE Cibenzoline_0\NNP| (r_nsubj) suppressed_1\VBD|cibenzoline|arrhythmias|,|and|induced|were|. (l_conj) induced_14\VBN|concentrations|by (l_nsubj) concentrations_11\NNS|the|minimum|effective|plasma|for (l_prep) for_12\IN|arrhythmias (l_pobj) arrhythmias_13\NNS|
C032151_D001145 NONE cibenzoline_1\NN| (r_nsubj) had_2\VBD|because|cibenzoline|effects|and|found|given (l_advcl) given_19\VBN|when|to (l_prep) to_20\IN|dogs (l_pobj) dogs_24\NNS|coronary|arrhythmia (l_compound) arrhythmia_23\NN|ligation
D004071_D001145 CID digitalis-_7\NN|,|and|induced (r_conj) ligation-_5\JJ|stage|coronary|,|digitalis- (r_nmod) arrhythmias_15\NNS|ligation-|canine|ventricular
D004071_D001145 CID digitalis-_7\NN|,|and|induced (r_conj) ligation-_5\JJ|stage|coronary|,|digitalis- (r_nmod) arrhythmias_15\NNS|ligation-|canine|ventricular (r_dobj) Using_0\VBG|arrhythmias (r_advcl) examined_22\VBN|using|,|effects|were|and|determined (l_conj) determined_34\VBN|concentration|was|. (l_nsubjpass) concentration_28\NN|the|minimum|effective|plasma|for (l_prep) for_29\IN|model (l_pobj) model_32\NN|each|arrhythmia (l_compound) arrhythmia_31\NN|
D004071_D001145 CID digitalis_24\NN|,|and|adrenaline (r_conj) ligation_22\NN|48-h|coronary|,|digitalis (r_appos) ligation_18\NN|24-h|coronary|,|ligation (r_pobj) by_15\IN|ligation (r_agent) induced_14\VBN|concentrations|by (r_conj) suppressed_1\VBD|cibenzoline|arrhythmias|,|and|induced|were|. (l_dobj) arrhythmias_4\NNS|all|the
D004071_D001145 CID digitalis_24\NN|,|and|adrenaline (r_conj) ligation_22\NN|48-h|coronary|,|digitalis (r_appos) ligation_18\NN|24-h|coronary|,|ligation (r_pobj) by_15\IN|ligation (r_agent) induced_14\VBN|concentrations|by (l_nsubj) concentrations_11\NNS|the|minimum|effective|plasma|for (l_prep) for_12\IN|arrhythmias (l_pobj) arrhythmias_13\NNS|
D004837_D001145 CID adrenaline_10\RB| (r_npadvmod) induced_12\VBN|adrenaline|- (r_conj) digitalis-_7\NN|,|and|induced (r_conj) ligation-_5\JJ|stage|coronary|,|digitalis- (r_nmod) arrhythmias_15\NNS|ligation-|canine|ventricular
D004837_D001145 CID adrenaline_10\RB| (r_npadvmod) induced_12\VBN|adrenaline|- (r_conj) digitalis-_7\NN|,|and|induced (r_conj) ligation-_5\JJ|stage|coronary|,|digitalis- (r_nmod) arrhythmias_15\NNS|ligation-|canine|ventricular (r_dobj) Using_0\VBG|arrhythmias (r_advcl) examined_22\VBN|using|,|effects|were|and|determined (l_conj) determined_34\VBN|concentration|was|. (l_nsubjpass) concentration_28\NN|the|minimum|effective|plasma|for (l_prep) for_29\IN|model (l_pobj) model_32\NN|each|arrhythmia (l_compound) arrhythmia_31\NN|
D004837_D001145 CID adrenaline_27\NN| (r_conj) digitalis_24\NN|,|and|adrenaline (r_conj) ligation_22\NN|48-h|coronary|,|digitalis (r_appos) ligation_18\NN|24-h|coronary|,|ligation (r_pobj) by_15\IN|ligation (r_agent) induced_14\VBN|concentrations|by (r_conj) suppressed_1\VBD|cibenzoline|arrhythmias|,|and|induced|were|. (l_dobj) arrhythmias_4\NNS|all|the
D004837_D001145 CID adrenaline_27\NN| (r_conj) digitalis_24\NN|,|and|adrenaline (r_conj) ligation_22\NN|48-h|coronary|,|digitalis (r_appos) ligation_18\NN|24-h|coronary|,|ligation (r_pobj) by_15\IN|ligation (r_agent) induced_14\VBN|concentrations|by (l_nsubj) concentrations_11\NNS|the|minimum|effective|plasma|for (l_prep) for_12\IN|arrhythmias (l_pobj) arrhythmias_13\NNS|
D004837_D001145 CID adrenaline_3\NN| (r_npadvmod) induced_5\VBN|adrenaline|- (r_amod) arrhythmia_6\NN|induced
D004837_D001145 CID adrenaline_3\NN| (r_npadvmod) induced_5\VBN|adrenaline|- (r_amod) arrhythmia_6\NN|induced (r_pobj) for_2\IN|arrhythmia (r_prep) concentration_1\NN|the|for (r_nsubj) was_7\VBD|concentration|higher|. (l_acomp) higher_9\JJR|significantly|than (l_prep) than_10\IN|those (l_pobj) those_11\DT|for (l_prep) for_12\IN|types (l_pobj) types_15\NNS|the|other|of (l_prep) of_16\IN|arrhythmias (l_pobj) arrhythmias_17\NNS|
C032151_D007022 NONE cibenzoline_1\NN| (r_nsubj) had_2\VBD|because|cibenzoline|effects|and|found|given (l_dobj) effects_10\NNS|node|depressive (l_nmod) node_8\NN|only|weak|hypotensive (l_amod) hypotensive_5\JJ|and|sinus
C032151_D003866 NONE cibenzoline_1\NN| (r_nsubj) had_2\VBD|because|cibenzoline|effects|and|found|given (l_dobj) effects_10\NNS|node|depressive (l_amod) depressive_9\JJ|
9867728
D005277_D006349 NONE fenfluramine_8\NN|and|dexfenfluramine (r_pobj) of_7\IN|fenfluramine (r_prep) users_6\NNS|of|underwent (r_pobj) among_5\IN|users (r_prep) disease_4\NN|valvular|heart|among
D005277_D006349 NONE fenfluramine_16\NN|and|dexfenfluramine (r_pobj) of_15\IN|fenfluramine (r_prep) users_14\NNS|of (r_pobj) of_13\IN|users (r_prep) %_12\NN|38|of (r_nsubj) had_19\VBD|%|disease (l_dobj) disease_21\NN|valvular
D005277_D006349 NONE fenfluramine_13\NN|or|dexfenfluramine (r_pobj) of_12\IN|fenfluramine (r_prep) users_11\NNS|of|underwent (r_pobj) among_10\IN|users (r_prep) abnormalities_9\NNS|new|valvular|among
D005277_D006349 NONE fenfluramine_18\JJ| (r_compound) phentermine_20\NN|fenfluramine|- (r_dobj) receiving_17\VBG|phentermine (r_acl) patients_1\NNS|two|(|%|]|)|receiving (r_nsubj) developed_21\VBD|patients|disease|. (l_dobj) disease_24\NN|valvular|heart
D020372_D006349 NONE dexfenfluramine_10\NN| (r_conj) fenfluramine_8\NN|and|dexfenfluramine (r_pobj) of_7\IN|fenfluramine (r_prep) users_6\NNS|of|underwent (r_pobj) among_5\IN|users (r_prep) disease_4\NN|valvular|heart|among
D020372_D006349 NONE dexfenfluramine_18\NN| (r_conj) fenfluramine_16\NN|and|dexfenfluramine (r_pobj) of_15\IN|fenfluramine (r_prep) users_14\NNS|of (r_pobj) of_13\IN|users (r_prep) %_12\NN|38|of (r_nsubj) had_19\VBD|%|disease (l_dobj) disease_21\NN|valvular
D020372_D006349 NONE dexfenfluramine_15\NN| (r_conj) fenfluramine_13\NN|or|dexfenfluramine (r_pobj) of_12\IN|fenfluramine (r_prep) users_11\NNS|of|underwent (r_pobj) among_10\IN|users (r_prep) abnormalities_9\NNS|new|valvular|among
D010645_D006349 NONE phentermine_20\NN|fenfluramine|- (r_dobj) receiving_17\VBG|phentermine (r_acl) patients_1\NNS|two|(|%|]|)|receiving (r_nsubj) developed_21\VBD|patients|disease|. (l_dobj) disease_24\NN|valvular|heart
3732088
D011188_D001145 NONE potassium_2\NN|and|arrhythmias (l_conj) arrhythmias_4\NNS|
D011188_D001145 NONE potassium_9\NN|plasma (r_pobj) in_7\IN|potassium (r_prep) changes_6\NNS|modest|in (r_nsubj) alter_11\VB|that|changes|can|tendency (l_dobj) tendency_13\NN|the|towards (l_prep) towards_14\IN|arrhythmias (l_pobj) arrhythmias_16\NNS|cardiac
D011188_D006973 NONE potassium_2\NN|and|arrhythmias (r_conj) Diuretics_0\NNS|,|potassium|in|. (l_prep) in_5\IN|disease (l_pobj) disease_8\NN|hypertensive|coronary (l_amod) hypertensive_6\JJ|
D011188_D006973 NONE potassium_25\NN| (r_npadvmod) conserving_27\VBG|potassium|- (r_amod) diuretic_28\JJ|conserving (r_amod) amiloride_30\NN|a|diuretic|( (r_pobj) with_23\IN|amiloride (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) weeks_20\NNS|8|of (r_pobj) after_18\IN|weeks (r_prep) known_14\VBN|disease|after|) (r_conj) measured_6\VBN|thus|,|excitability|was|in|and|known|and|period|. (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|hypertension (l_pobj) hypertension_12\NN|mild|essential
D011188_D006973 NONE potassium_38\NN| (r_npadvmod) losing_40\VBG|potassium|- (r_amod) chlorthalidone_43\NN|a|losing|diuretic|(|) (r_pobj) on_36\IN|chlorthalidone (r_prep) period_35\NN|a|similar|on|in (r_conj) measured_6\VBN|thus|,|excitability|was|in|and|known|and|period|. (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|hypertension (l_pobj) hypertension_12\NN|mild|essential
D011188_D003327 NONE potassium_2\NN|and|arrhythmias (r_conj) Diuretics_0\NNS|,|potassium|in|. (l_prep) in_5\IN|disease (l_pobj) disease_8\NN|hypertensive|coronary
D011188_D003324 NONE potassium_25\NN| (r_npadvmod) conserving_27\VBG|potassium|- (r_amod) diuretic_28\JJ|conserving (r_amod) amiloride_30\NN|a|diuretic|( (r_pobj) with_23\IN|amiloride (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) weeks_20\NNS|8|of (r_pobj) after_18\IN|weeks (r_prep) known_14\VBN|disease|after|) (l_dobj) disease_17\NN|coronary|artery
D011188_D003324 NONE potassium_38\NN| (r_npadvmod) losing_40\VBG|potassium|- (r_amod) chlorthalidone_43\NN|a|losing|diuretic|(|) (r_pobj) on_36\IN|chlorthalidone (r_prep) period_35\NN|a|similar|on|in (r_conj) measured_6\VBN|thus|,|excitability|was|in|and|known|and|period|. (l_conj) known_14\VBN|disease|after|) (l_dobj) disease_17\NN|coronary|artery
D000584_D006973 NONE amiloride_30\NN|a|diuretic|( (r_pobj) with_23\IN|amiloride (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) weeks_20\NNS|8|of (r_pobj) after_18\IN|weeks (r_prep) known_14\VBN|disease|after|) (r_conj) measured_6\VBN|thus|,|excitability|was|in|and|known|and|period|. (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|hypertension (l_pobj) hypertension_12\NN|mild|essential
D000584_D003324 NONE amiloride_30\NN|a|diuretic|( (r_pobj) with_23\IN|amiloride (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) weeks_20\NNS|8|of (r_pobj) after_18\IN|weeks (r_prep) known_14\VBN|disease|after|) (l_dobj) disease_17\NN|coronary|artery
D002752_D006973 NONE chlorthalidone_43\NN|a|losing|diuretic|(|) (r_pobj) on_36\IN|chlorthalidone (r_prep) period_35\NN|a|similar|on|in (r_conj) measured_6\VBN|thus|,|excitability|was|in|and|known|and|period|. (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|hypertension (l_pobj) hypertension_12\NN|mild|essential
D002752_D003324 NONE chlorthalidone_43\NN|a|losing|diuretic|(|) (r_pobj) on_36\IN|chlorthalidone (r_prep) period_35\NN|a|similar|on|in (r_conj) measured_6\VBN|thus|,|excitability|was|in|and|known|and|period|. (l_conj) known_14\VBN|disease|after|) (l_dobj) disease_17\NN|coronary|artery
D000584_D018879 NONE amiloride_2\NN| (r_compound) treatment_3\NN|amiloride (r_pobj) to_1\IN|treatment (r_prep) Compared_0\VBN|to (r_prep) associated_9\VBN|compared|,|phase|was|with|period|,|and|increased|. (l_prep) with_10\IN|frequency (l_pobj) frequency_13\NN|an|increased|of|and|grading (l_prep) of_14\IN|beats (l_pobj) beats_17\NNS|ventricular|ectopic|monitoring
D002752_D018879 CID chlorthalidone_6\NN| (r_compound) phase_7\NN|the|chlorthalidone (r_nsubjpass) associated_9\VBN|compared|,|phase|was|with|period|,|and|increased|. (l_prep) with_10\IN|frequency (l_pobj) frequency_13\NN|an|increased|of|and|grading (l_prep) of_14\IN|beats (l_pobj) beats_17\NNS|ventricular|ectopic|monitoring
D011188_D017202 NONE potassium_6\NN| (r_npadvmod) losing_8\VBG|potassium|- (r_amod) therapy_10\NN|losing|diuretic (r_nsubj) increase_12\VB|because|therapy|can|excitability (l_dobj) excitability_15\NN|myocardial|electrical|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|ischaemic|heart
D011188_D017202 NONE potassium_28\NN| (r_compound) concentrations_29\NNS|plasma|potassium (r_pobj) in_26\IN|concentrations (r_prep) falls_25\VBZ|that|increase|,|minor|in (l_advcl) increase_12\VB|because|therapy|can|excitability (l_dobj) excitability_15\NN|myocardial|electrical|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|disease (l_pobj) disease_21\NN|ischaemic|heart
3311455
D016572_D007674 CID cyclosporine_17\NN| (r_pobj) with_16\IN|cyclosporine (r_prep) therapy_15\NN|term|with (r_pobj) to_11\IN|therapy (r_prep) secondary_10\JJ|to (r_amod) nephrotoxicity_9\NN|chronic|secondary
D016572_D007674 CID cyclosporine_8\NN| (r_pobj) of_7\IN|cyclosporine (r_prep) dosages_6\NNS|even|these|lower|of (r_nsubj) cause_10\VB|that|dosages|can|nephrotoxicity|required (l_dobj) nephrotoxicity_12\NN|chronic|and
10539815
D000809_D051437 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|angiotensin|- (r_amod) enzyme_14\NN|converting (r_compound) therapy_16\NN|enzyme|inhibitor (r_pobj) during_10\IN|therapy (r_prep) patients_6\NNS|with|during (r_pobj) in_5\IN|patients (r_prep) function_4\NN|decreased|renal|in
D000809_D051437 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|angiotensin|- (r_amod) enzyme_4\NN|converting (r_compound) therapy_6\NN|enzyme|inhibitor (r_nsubj) reduces_7\VBZ|although|therapy|rates|in (r_advcl) cause_23\VB|reduces|,|it|may|also|function|. (l_dobj) function_26\NN|decreased|renal
D000809_D051437 NONE angiotensin_17\NN| (r_npadvmod) converting_19\VBG|angiotensin|- (r_amod) enzyme_20\NN|converting (r_compound) therapy_22\NN|enzyme|inhibitor (r_dobj) prescribed_16\VBN|who|are|therapy (r_relcl) CHF_13\NNP|prescribed (r_pobj) with_12\IN|chf (r_prep) patients_11\NNS|with (r_pobj) in_10\IN|patients (r_prep) reduction_6\NN|in|in (l_prep) in_7\IN|function (l_pobj) function_9\NN|renal
D000809_D006333 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|angiotensin|- (r_amod) enzyme_14\NN|converting (r_compound) therapy_16\NN|enzyme|inhibitor (r_pobj) during_10\IN|therapy (r_prep) patients_6\NNS|with|during (l_prep) with_7\IN|failure (l_pobj) failure_9\NN|heart
D000809_D006333 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|angiotensin|- (r_amod) enzyme_4\NN|converting (r_compound) therapy_6\NN|enzyme|inhibitor (r_nsubj) reduces_7\VBZ|although|therapy|rates|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|failure (l_pobj) failure_15\NN|congestive|heart|chf
D000809_D006333 NONE angiotensin_1\NN| (r_npadvmod) converting_3\VBG|angiotensin|- (r_amod) enzyme_4\NN|converting (r_compound) therapy_6\NN|enzyme|inhibitor (r_nsubj) reduces_7\VBZ|although|therapy|rates|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|failure (l_pobj) failure_15\NN|congestive|heart|chf (l_appos) CHF_17\NNP|(|)
D000809_D006333 NONE angiotensin_17\NN| (r_npadvmod) converting_19\VBG|angiotensin|- (r_amod) enzyme_20\NN|converting (r_compound) therapy_22\NN|enzyme|inhibitor (r_dobj) prescribed_16\VBN|who|are|therapy (r_relcl) CHF_13\NNP|prescribed
D000809_D018487 NONE angiotensin_11\NN| (r_npadvmod) converting_13\VBG|angiotensin|- (r_amod) enzyme_14\NN|converting (r_compound) therapy_16\NN|enzyme|inhibitor (r_pobj) during_10\IN|therapy (r_prep) patients_6\NNS|with|during (r_pobj) in_5\IN|patients (r_prep) function_4\NN|decreased|renal|in (r_pobj) of_1\IN|function (r_prep) Predictors_0\NNS|of (r_dep) results_18\NNS|predictors|:|from (l_prep) from_19\IN|studies (l_pobj) studies_21\NNS|the|of (l_prep) of_22\IN|dysfunction (l_pobj) dysfunction_25\NN|left|ventricular|(|solvd|)
D004656_D018487 NONE enalapril_26\NN| (r_pobj) of_25\IN|enalapril (r_prep) trial_24\NN|a|randomized|,|blind|,|controlled|of|for (r_appos) Dysfunction_9\NNP|left|ventricular|(|solvd|)|,|trial
D004656_D006333 NONE enalapril_26\NN| (r_pobj) of_25\IN|enalapril (r_prep) trial_24\NN|a|randomized|,|blind|,|controlled|of|for (l_prep) for_27\IN|treatment (l_pobj) treatment_29\NN|the|of (l_prep) of_30\IN|chf (l_pobj) CHF_31\NNP|
D004656_D006333 NONE Enalapril_0\NNP| (r_compound) use_1\NN|enalapril (r_nsubj) caused_2\VBD|use|increase|. (l_dobj) increase_6\NN|a|%|in (l_prep) in_7\IN|risk (l_pobj) risk_9\NN|the|of (l_prep) of_10\IN|function (l_pobj) function_13\NN|decreased|renal|in (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|chf (l_pobj) CHF_17\NNP|
D004656_D006333 NONE enalapril_23\JJ| (r_compound) group_24\NN|the|enalapril (r_pobj) in_21\IN|group (r_prep) reduced_20\VBN|risk|was|in|compared|. (r_conj) associated_2\VBN|diabetes|was|with|,|but|reduced (l_prep) with_3\IN|risk (l_pobj) risk_6\NN|an|increased|of (l_prep) of_7\IN|impairment (l_pobj) impairment_9\NN|renal|in (l_prep) in_10\IN|patients (l_pobj) patients_12\NNS|all|with (l_prep) with_13\IN|chf (l_pobj) CHF_14\NNP|
D003404_D051437 NONE creatinine_10\NN|serum (r_pobj) in_8\IN|creatinine (r_prep) rise_7\NN|a|in (r_pobj) as_5\IN|rise (r_prep) defined_4\VBN|function|was|as|>|/=0.5 (l_nsubjpass) function_2\NN|decreased|renal
D003404_D006973 NONE creatinine_25\NN|baseline|,|pressure (r_conj) fraction_22\NN|ejection|,|creatinine (r_conj) age_18\NN|,|fraction|,|history (l_appos) history_38\NN|of (l_prep) of_39\IN|hypertension (l_pobj) hypertension_40\NN|,|diabetes
D003404_D003920 NONE creatinine_25\NN|baseline|,|pressure (r_conj) fraction_22\NN|ejection|,|creatinine (r_conj) age_18\NN|,|fraction|,|history (l_appos) history_38\NN|of (l_prep) of_39\IN|hypertension (l_pobj) hypertension_40\NN|,|diabetes (l_conj) diabetes_42\NNS|,|and|use
D004232_D006973 NONE diuretic_49\JJ|,|and|therapy (r_conj) antiplatelet_47\JJ|,|diuretic (r_pobj) of_46\IN|antiplatelet (r_prep) use_45\NN|of (r_conj) diabetes_42\NNS|,|and|use (r_conj) hypertension_40\NN|,|diabetes
D004232_D003920 NONE diuretic_49\JJ|,|and|therapy (r_conj) antiplatelet_47\JJ|,|diuretic (r_pobj) of_46\IN|antiplatelet (r_prep) use_45\NN|of (r_conj) diabetes_42\NNS|,|and|use
D004232_D003920 NONE diuretic_14\JJ| (r_amod) therapy_15\NN|diuretic|,|and|diabetes (l_conj) diabetes_18\NNS|
D004656_D051437 CID enalapril_4\NN| (r_pobj) to_3\IN|enalapril (r_prep) assigned_2\VBN|randomly|to (r_acl) Patients_0\NNS|assigned (r_nsubj) had_5\VBD|patients|likelihood|. (l_dobj) likelihood_10\NN|a|greater|of (l_prep) of_11\IN|function (l_pobj) function_14\NN|decreased|renal|than
D004656_D051437 CID enalapril_9\NN| (r_compound) groups_10\NNS|enalapril (r_conj) placebo_7\NN|both|the|and|groups|age (r_pobj) in_4\IN|placebo (r_prep) associated_20\VBN|by|,|in|were|with|,|were|. (l_prep) with_21\IN|function (l_pobj) function_24\NN|decreased|renal
D004656_D051437 CID enalapril_23\JJ| (r_compound) group_24\NN|the|enalapril|ratio (r_pobj) in_21\IN|group (r_prep) more_19\RBR|significantly|so|in|,|interval (r_conj) associated_3\VBN|age|was|with|,|but|more (l_prep) with_4\IN|risk (l_pobj) risk_7\NN|a|greater|of (l_prep) of_8\IN|developing (l_pcomp) developing_9\VBG|function (l_dobj) function_12\NN|decreased|renal|in
D004656_D051437 CID enalapril_26\NN| (r_dep) ratio_29\NN|(|enalapril|:|risk|[|rr|]|years (r_appos) group_24\NN|the|enalapril|ratio (r_pobj) in_21\IN|group (r_prep) more_19\RBR|significantly|so|in|,|interval (r_conj) associated_3\VBN|age|was|with|,|but|more (l_prep) with_4\IN|risk (l_pobj) risk_7\NN|a|greater|of (l_prep) of_8\IN|developing (l_pcomp) developing_9\VBG|function (l_dobj) function_12\NN|decreased|renal|in
D004656_D051437 CID enalapril_15\JJ| (r_compound) group_16\NN|the|enalapril|(|%|) (r_pobj) in_13\IN|group (r_prep) function_12\NN|decreased|renal|in
D004656_D051437 CID Enalapril_0\NNP| (r_compound) use_1\NN|enalapril (r_nsubj) caused_2\VBD|use|increase|. (l_dobj) increase_6\NN|a|%|in (l_prep) in_7\IN|risk (l_pobj) risk_9\NN|the|of (l_prep) of_10\IN|function (l_pobj) function_13\NN|decreased|renal|in
D004656_D051437 CID enalapril_23\JJ| (r_compound) group_24\NN|the|enalapril (r_pobj) in_21\IN|group (r_prep) reduced_20\VBN|risk|was|in|compared|. (r_conj) associated_2\VBN|diabetes|was|with|,|but|reduced (l_prep) with_3\IN|risk (l_pobj) risk_6\NN|an|increased|of (l_prep) of_7\IN|impairment (l_pobj) impairment_9\NN|renal|in
D004656_D003920 NONE enalapril_9\NN| (r_compound) groups_10\NNS|enalapril (r_conj) placebo_7\NN|both|the|and|groups|age (l_conj) age_12\NN|older|,|therapy (l_conj) therapy_15\NN|diuretic|,|and|diabetes (l_conj) diabetes_18\NNS|
D004656_D003920 NONE enalapril_2\NN| (r_nsubj) had_3\VBD|conversely|,|enalapril|effect|rr|. (l_npadvmod) RR_9\NN|(|1.33 (l_nummod) 1.33_10\CD|compared (l_prep) compared_19\VBN|,|with (l_prep) with_20\IN|placebo (l_pobj) placebo_21\NN|(|ci (l_appos) CI_28\NNP|rr|,|%|2.44|)|in (l_prep) in_33\IN|patients (l_pobj) patients_34\NNS|with (l_prep) with_35\IN|diabetes (l_pobj) diabetes_36\NNS|
D004656_D003920 NONE enalapril_23\JJ| (r_compound) group_24\NN|the|enalapril (r_pobj) in_21\IN|group (r_prep) reduced_20\VBN|risk|was|in|compared|. (r_conj) associated_2\VBN|diabetes|was|with|,|but|reduced (l_nsubjpass) Diabetes_0\NN|
D004232_D051437 CID diuretic_14\JJ| (r_amod) therapy_15\NN|diuretic|,|and|diabetes (r_conj) age_12\NN|older|,|therapy (r_conj) placebo_7\NN|both|the|and|groups|age (r_pobj) in_4\IN|placebo (r_prep) associated_20\VBN|by|,|in|were|with|,|were|. (l_prep) with_21\IN|function (l_pobj) function_24\NN|decreased|renal
D004232_D051437 CID Diuretic_0\JJ| (r_compound) therapy_1\NN|diuretic (r_nsubjpass) associated_4\VBN|therapy|was|likewise|with|. (l_prep) with_5\IN|risk (l_pobj) risk_8\NN|a|greater|of|than (l_prep) of_9\IN|function (l_pobj) function_12\NN|decreased|renal|in
9067481
C013440_D056486 NONE hemisuccinate_14\NN|cholesteryl|,|administration (r_conj) rigidifier_9\NN|stabilizer|of|,|hemisuccinate (r_pobj) as_5\IN|rigidifier (r_prep) use_4\NN|its|as (r_pobj) to_2\IN|use (r_prep) addition_1\NN|to (r_pobj) In_0\IN|addition (r_prep) shown_25\VBN|in|has|also|been|protect|. (l_xcomp) protect_27\VB|to|rats|from (l_prep) from_29\IN|effects (l_pobj) effects_32\NNS|the|hepatotoxic|of|tetrachloride|ccl4 (l_amod) hepatotoxic_31\JJ|
-1_D056486 NONE salt_17\NN| (r_nmod) administration_21\NN|tris|salt|(|cs|) (r_conj) hemisuccinate_14\NN|cholesteryl|,|administration (r_conj) rigidifier_9\NN|stabilizer|of|,|hemisuccinate (r_pobj) as_5\IN|rigidifier (r_prep) use_4\NN|its|as (r_pobj) to_2\IN|use (r_prep) addition_1\NN|to (r_pobj) In_0\IN|addition (r_prep) shown_25\VBN|in|has|also|been|protect|. (l_xcomp) protect_27\VB|to|rats|from (l_prep) from_29\IN|effects (l_pobj) effects_32\NNS|the|hepatotoxic|of|tetrachloride|ccl4 (l_amod) hepatotoxic_31\JJ|
-1_D056486 NONE CS_19\NNP| (r_nmod) administration_21\NN|tris|salt|(|cs|) (r_conj) hemisuccinate_14\NN|cholesteryl|,|administration (r_conj) rigidifier_9\NN|stabilizer|of|,|hemisuccinate (r_pobj) as_5\IN|rigidifier (r_prep) use_4\NN|its|as (r_pobj) to_2\IN|use (r_prep) addition_1\NN|to (r_pobj) In_0\IN|addition (r_prep) shown_25\VBN|in|has|also|been|protect|. (l_xcomp) protect_27\VB|to|rats|from (l_prep) from_29\IN|effects (l_pobj) effects_32\NNS|the|hepatotoxic|of|tetrachloride|ccl4 (l_amod) hepatotoxic_31\JJ|
-1_D056486 NONE CS_13\NNP| (r_nmod) kg_17\NNS|cs|(|100mg|/|,|i.p.|) (r_pobj) of_12\IN|kg (r_prep) dose_11\NN|a|single|of (r_pobj) with_8\IN|dose (r_prep) pretreatment_2\NN|a|24-h|of|with (r_nsubj) resulted_22\VBD|pretreatment|,|in|. (l_prep) in_23\IN|protection (l_pobj) protection_25\NN|significant|against (l_prep) against_26\IN|effects (l_pobj) effects_29\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_28\JJ|
-1_D056486 NONE CS_3\NNP| (r_compound) protection_4\NN|cs (r_pobj) of_2\IN|protection (r_prep) mechanism_1\NN|the|of (r_nsubj) appear_7\VB|mechanism|does|not|be|)|. (l_xcomp) be_9\VB|to|dependent (l_acomp) dependent_10\JJ|on (l_prep) on_11\IN|inhibition (l_pobj) inhibition_13\NN|the|of|to (l_prep) to_17\IN|in (l_pobj) in_23\IN|intermediate|(|light (l_pobj) light_24\NN|of (l_prep) of_25\IN|protection (l_pobj) protection_27\NN|the|observed (l_acl) observed_28\VBN|against (l_prep) against_29\IN|hepatotoxicity (l_pobj) hepatotoxicity_31\NN|galactosamine
D002251_D056486 CID tetrachloride_35\NN| (r_advmod) effects_32\NNS|the|hepatotoxic|of|tetrachloride|ccl4 (l_amod) hepatotoxic_31\JJ|
D002251_D056486 CID CCl4_37\NNP|(|) (r_appos) effects_32\NNS|the|hepatotoxic|of|tetrachloride|ccl4 (l_amod) hepatotoxic_31\JJ|
D002251_D056486 CID CCl4_31\NNP| (r_nmod) CHCl3_33\NNP|ccl4|,|,|acetaminophen (r_pobj) of_30\IN|chcl3 (r_prep) effects_29\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_28\JJ|
-1_D064420 NONE CS_8\NNP| (r_compound) cytoprotection_9\NN|cs (r_pobj) of_7\IN|cytoprotection (r_prep) mechanism_6\NN|the|of (r_pobj) of_4\IN|mechanism (r_prep) understanding_3\NN|our|of (r_dobj) further_1\VB|to|understanding (r_advmod) examined_12\VBD|further|,|we|in|and|mice|. (l_conj) mice_16\NNS|abilities (l_dobj) abilities_19\NNS|the|protective|of (l_prep) of_20\IN|cs (l_pobj) CS_21\NNP|and|form (l_conj) form_28\NN|the|hydrolyzable|ether|of (l_prep) of_29\IN|cs (l_pobj) CS_30\NNP|,|acid (l_conj) acid_35\NN|cholesteryloxybutyric|,|salt (l_conj) salt_38\NN|tris|cse|against (l_prep) against_42\IN|tetrachloride- (l_pobj) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
-1_D064420 NONE CS_21\NNP|and|form (l_conj) form_28\NN|the|hydrolyzable|ether|of (l_prep) of_29\IN|cs (l_pobj) CS_30\NNP|,|acid (l_conj) acid_35\NN|cholesteryloxybutyric|,|salt (l_conj) salt_38\NN|tris|cse|against (l_prep) against_42\IN|tetrachloride- (l_pobj) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
-1_D064420 NONE CS_30\NNP|,|acid (l_conj) acid_35\NN|cholesteryloxybutyric|,|salt (l_conj) salt_38\NN|tris|cse|against (l_prep) against_42\IN|tetrachloride- (l_pobj) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
-1_D064420 NONE salt_38\NN|tris|cse|against (l_prep) against_42\IN|tetrachloride- (l_pobj) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
-1_D064420 NONE CSE_40\NNP|(|) (r_appos) salt_38\NN|tris|cse|against (l_prep) against_42\IN|tetrachloride- (l_pobj) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
C103872_D064420 NONE acid_35\NN|cholesteryloxybutyric|,|salt (l_conj) salt_38\NN|tris|cse|against (l_prep) against_42\IN|tetrachloride- (l_pobj) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
D000082_D064420 NONE acetaminophen-_43\NN|,|adriamycin-|, (r_nmod) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
D004317_D064420 NONE adriamycin-_45\JJ| (r_conj) acetaminophen-_43\NN|,|adriamycin-|, (r_nmod) tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
D002251_D064420 NONE tetrachloride-_48\NN|acetaminophen-|carbon|,|toxicity (l_appos) toxicity_55\NN|chloroform-
D002725_D064420 NONE chloroform-_50\JJ|and|induced (r_nmod) toxicity_55\NN|chloroform-
D005688_D064420 NONE galactosamine_52\NN| (r_npadvmod) induced_54\VBN|galactosamine|- (r_conj) chloroform-_50\JJ|and|induced (r_nmod) toxicity_55\NN|chloroform-
-1_D066126 NONE CS_13\NNP| (r_nmod) kg_17\NNS|cs|(|100mg|/|,|i.p.|) (r_pobj) of_12\IN|kg (r_prep) dose_11\NN|a|single|of (r_pobj) with_8\IN|dose (r_prep) pretreatment_2\NN|a|24-h|of|with (r_nsubj) resulted_22\VBD|pretreatment|,|in|. (l_prep) in_23\IN|protection (l_pobj) protection_25\NN|significant|against (l_prep) against_26\IN|effects (l_pobj) effects_29\NNS|the|hepatotoxic|of (l_prep) of_30\IN|chcl3 (l_pobj) CHCl3_33\NNP|ccl4|,|,|acetaminophen (l_conj) acetaminophen_35\RB|and|galactosamine|and|against (l_conj) against_39\IN|lethal (l_pobj) lethal_41\JJ|the|(|and|effect (l_conj) effect_47\NN|cardiotoxic|)|of (l_amod) cardiotoxic_45\JJ|presumably
D002251_D066126 NONE CCl4_31\NNP| (r_nmod) CHCl3_33\NNP|ccl4|,|,|acetaminophen (l_conj) acetaminophen_35\RB|and|galactosamine|and|against (l_conj) against_39\IN|lethal (l_pobj) lethal_41\JJ|the|(|and|effect (l_conj) effect_47\NN|cardiotoxic|)|of (l_amod) cardiotoxic_45\JJ|presumably
D002725_D056486 CID CHCl3_33\NNP|ccl4|,|,|acetaminophen (r_pobj) of_30\IN|chcl3 (r_prep) effects_29\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_28\JJ|
D002725_D066126 NONE CHCl3_33\NNP|ccl4|,|,|acetaminophen (l_conj) acetaminophen_35\RB|and|galactosamine|and|against (l_conj) against_39\IN|lethal (l_pobj) lethal_41\JJ|the|(|and|effect (l_conj) effect_47\NN|cardiotoxic|)|of (l_amod) cardiotoxic_45\JJ|presumably
D000082_D056486 CID acetaminophen_35\RB|and|galactosamine|and|against (r_conj) CHCl3_33\NNP|ccl4|,|,|acetaminophen (r_pobj) of_30\IN|chcl3 (r_prep) effects_29\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_28\JJ|
D000082_D066126 NONE acetaminophen_35\RB|and|galactosamine|and|against (l_conj) against_39\IN|lethal (l_pobj) lethal_41\JJ|the|(|and|effect (l_conj) effect_47\NN|cardiotoxic|)|of (l_amod) cardiotoxic_45\JJ|presumably
D005688_D056486 CID galactosamine_37\NN| (r_conj) acetaminophen_35\RB|and|galactosamine|and|against (r_conj) CHCl3_33\NNP|ccl4|,|,|acetaminophen (r_pobj) of_30\IN|chcl3 (r_prep) effects_29\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_28\JJ|
D005688_D056486 CID galactosamine_30\NN| (r_amod) hepatotoxicity_31\NN|galactosamine
D005688_D066126 NONE galactosamine_37\NN| (r_conj) acetaminophen_35\RB|and|galactosamine|and|against (l_conj) against_39\IN|lethal (l_pobj) lethal_41\JJ|the|(|and|effect (l_conj) effect_47\NN|cardiotoxic|)|of (l_amod) cardiotoxic_45\JJ|presumably
D004317_D056486 NONE adriamycin_49\NNS| (r_amod) administration_50\NN|adriamycin (r_pobj) of_48\IN|administration (r_prep) effect_47\NN|cardiotoxic|)|of (r_conj) lethal_41\JJ|the|(|and|effect (r_pobj) against_39\IN|lethal (r_conj) acetaminophen_35\RB|and|galactosamine|and|against (r_conj) CHCl3_33\NNP|ccl4|,|,|acetaminophen (r_pobj) of_30\IN|chcl3 (r_prep) effects_29\NNS|the|hepatotoxic|of (l_amod) hepatotoxic_28\JJ|
D004317_D066126 CID adriamycin_49\NNS| (r_amod) administration_50\NN|adriamycin (r_pobj) of_48\IN|administration (r_prep) effect_47\NN|cardiotoxic|)|of (l_amod) cardiotoxic_45\JJ|presumably
20466178
D016559_D003872 NONE tacrolimus_5\NN| (r_compound) treatment_6\NN|topical|tacrolimus (r_pobj) with_3\IN|treatment (r_prep) associated_2\VBN|with (r_acl) dermatitis_1\NN|rosaceiform|associated|.
D016559_D003872 NONE tacrolimus_19\NN| (r_compound) ointment_20\NN|%|tacrolimus (r_dobj) using_13\VBG|while|ointment|for (r_advcl) developed_6\VBD|who|eruptions|using (l_dobj) eruptions_11\NNS|like|dermatitis (l_compound) dermatitis_10\NN|
D016559_D003872 NONE tacrolimus_7\NN|or|pimecrolimus (r_pobj) as_6\IN|such|tacrolimus (r_prep) immunomodulators_4\NNS|as (r_pobj) of_3\IN|immunomodulators (r_prep) use_2\NN|continuous|topical|of (r_nsubjpass) regarded_12\VBN|use|should|be|as|,|reported|. (l_prep) as_13\IN|cause (l_pobj) cause_16\NN|a|potential|of (l_prep) of_17\IN|dermatitis (l_pobj) dermatitis_19\NN|rosaceiform
D016559_D012393 NONE tacrolimus_19\NN| (r_compound) ointment_20\NN|%|tacrolimus (r_dobj) using_13\VBG|while|ointment|for (r_advcl) developed_6\VBD|who|eruptions|using (l_dobj) eruptions_11\NNS|like|dermatitis (l_amod) like_9\JJ|rosacea|- (l_npadvmod) rosacea_7\NN|
D016559_D003875 NONE tacrolimus_19\NN| (r_compound) ointment_20\NN|%|tacrolimus (r_dobj) using_13\VBG|while|ointment|for (r_advcl) developed_6\VBD|who|eruptions|using (l_dobj) eruptions_11\NNS|like|dermatitis
D016559_D005148 NONE tacrolimus_19\NN| (r_compound) ointment_20\NN|%|tacrolimus (r_dobj) using_13\VBG|while|ointment|for (l_prep) for_21\IN|dermatitis (l_pobj) dermatitis_23\NN|facial
C117268_D003872 CID pimecrolimus_9\NN| (r_conj) tacrolimus_7\NN|or|pimecrolimus (r_pobj) as_6\IN|such|tacrolimus (r_prep) immunomodulators_4\NNS|as (r_pobj) of_3\IN|immunomodulators (r_prep) use_2\NN|continuous|topical|of (r_nsubjpass) regarded_12\VBN|use|should|be|as|,|reported|. (l_prep) as_13\IN|cause (l_pobj) cause_16\NN|a|potential|of (l_prep) of_17\IN|dermatitis (l_pobj) dermatitis_19\NN|rosaceiform
15531665
D001205_D002318 CID C_3\NN|supplemental|vitamin (r_nsubj) increase_4\VB|does|c|risk|? (l_dobj) risk_7\NN|disease|in (l_compound) disease_6\NN|cardiovascular
D001205_D002318 CID C_10\NN|vitamin (r_compound) intake_11\NN|c|and|mortality|from (l_prep) from_14\IN|disease (l_pobj) disease_16\NN|cardiovascular
D001205_D002318 CID C_6\NN|vitamin (r_compound) intake_7\NN|c|and|mortality|from (l_prep) from_10\IN|disease (l_pobj) disease_13\NN|total|cardiovascular|(|n|281
D001205_D002318 CID C_63\NN|vitamin (r_compound) intake_64\NN|total|c|from (r_pobj) of_60\IN|intake (r_prep) quintiles_59\NNS|of (r_pobj) across_58\IN|quintiles (r_prep) 1.0_41\CD|,|0.97|,|1.11|(|p|across (r_attr) were_40\VBD|after|adjustment|1.0|. (l_nsubj) adjustment_1\NN|for (l_prep) for_2\IN|factors (l_pobj) factors_6\NNS|risk|,|type (l_compound) risk_5\NN|disease (l_compound) disease_4\NN|cardiovascular
D001205_D002318 CID C_63\NN|vitamin (r_compound) intake_64\NN|total|c|from (r_pobj) of_60\IN|intake (r_prep) quintiles_59\NNS|of (r_pobj) across_58\IN|quintiles (r_prep) 1.0_41\CD|,|0.97|,|1.11|(|p|across (r_attr) were_40\VBD|after|adjustment|1.0|. (l_nsubj) adjustment_1\NN|for (l_prep) for_2\IN|factors (l_pobj) factors_6\NNS|risk|,|type (l_appos) type_8\NN|of|used|duration (l_conj) duration_14\NN|of|,|and|intakes (l_conj) intakes_19\NNS|of (l_prep) of_20\IN|e (l_pobj) E_24\NN|folate|,|vitamin|,|and|carotene (l_conj) carotene_29\NN|beta|-|,|risks (l_appos) risks_34\NNS|the|adjusted|relative|of (l_prep) of_35\IN|mortality (l_pobj) mortality_39\NN|total|cardiovascular|disease (l_compound) disease_38\NN|
D001205_D002318 CID C_1\NN|vitamin (r_compound) intake_2\NN|c (r_nsubj) was_3\VBD|intake|unrelated|. (l_acomp) unrelated_4\JJ|to (l_prep) to_5\IN|mortality (l_pobj) mortality_6\NN|from|in (l_prep) from_7\IN|disease (l_pobj) disease_9\NN|cardiovascular
D001205_D002318 CID C_3\NN|vitamin (r_compound) intake_4\NN|a|high|c|from (r_nsubjpass) associated_8\VBN|intake|is|with|. (l_prep) with_9\IN|risk (l_pobj) risk_12\NN|an|increased|of (l_prep) of_13\IN|mortality (l_pobj) mortality_16\NN|cardiovascular|disease|in (l_compound) disease_15\NN|
D001205_D003920 NONE C_3\NN|supplemental|vitamin (r_nsubj) increase_4\VB|does|c|risk|? (l_dobj) risk_7\NN|disease|in (l_prep) in_8\IN|women (l_pobj) women_9\NNS|with (l_prep) with_10\IN|diabetes (l_pobj) diabetes_11\NNS|
D001205_D003920 NONE C_12\NN|vitamin (r_pobj) of_10\IN|c (r_prep) intake_9\NN|a|high|of|in (l_prep) in_13\IN|persons (l_pobj) persons_15\NNS|diabetic (l_amod) diabetic_14\JJ|
D001205_D003920 NONE C_6\NN|vitamin (r_compound) intake_7\NN|c|and|mortality|from (r_pobj) between_4\IN|intake (r_prep) relation_3\NN|the|between (r_dobj) studied_1\VBD|we|relation|)|,|disease|. (l_dep) disease_22\NN|coronary|artery|n|175|,|and|stroke (l_conj) stroke_30\NN|(|n|57|)|in (l_prep) in_36\IN|women (l_pobj) women_39\NNS|1923|postmenopausal|reported (l_relcl) reported_41\VBD|who|being (l_xcomp) being_42\VBG|diabetic (l_acomp) diabetic_43\JJ|at
D001205_D003920 NONE C_63\NN|vitamin (r_compound) intake_64\NN|total|c|from (r_pobj) of_60\IN|intake (r_prep) quintiles_59\NNS|of (r_pobj) across_58\IN|quintiles (r_prep) 1.0_41\CD|,|0.97|,|1.11|(|p|across (r_attr) were_40\VBD|after|adjustment|1.0|. (l_nsubj) adjustment_1\NN|for (l_prep) for_2\IN|factors (l_pobj) factors_6\NNS|risk|,|type (l_appos) type_8\NN|of|used|duration (l_prep) of_9\IN|medication (l_pobj) medication_11\NN|diabetes (l_compound) diabetes_10\NN|
D001205_D003920 NONE C_63\NN|vitamin (r_compound) intake_64\NN|total|c|from (r_pobj) of_60\IN|intake (r_prep) quintiles_59\NNS|of (r_pobj) across_58\IN|quintiles (r_prep) 1.0_41\CD|,|0.97|,|1.11|(|p|across (r_attr) were_40\VBD|after|adjustment|1.0|. (l_nsubj) adjustment_1\NN|for (l_prep) for_2\IN|factors (l_pobj) factors_6\NNS|risk|,|type (l_appos) type_8\NN|of|used|duration (l_conj) duration_14\NN|of|,|and|intakes (l_prep) of_15\IN|diabetes (l_pobj) diabetes_16\NNS|
D001205_D003920 NONE C_3\NN|vitamin (r_compound) intake_4\NN|a|high|c|from (r_nsubjpass) associated_8\VBN|intake|is|with|. (l_prep) with_9\IN|risk (l_pobj) risk_12\NN|an|increased|of (l_prep) of_13\IN|mortality (l_pobj) mortality_16\NN|cardiovascular|disease|in (l_prep) in_17\IN|women (l_pobj) women_19\NNS|postmenopausal|with (l_prep) with_20\IN|diabetes (l_pobj) diabetes_21\NNS|
D001205_D050197 NONE C_12\NN|vitamin (r_pobj) of_10\IN|c (r_prep) intake_9\NN|a|high|of|in (r_nsubj) promote_17\VB|that|intake|might|atherosclerosis (l_dobj) atherosclerosis_18\NN|
D001205_D003324 NONE C_6\NN|vitamin (r_compound) intake_7\NN|c|and|mortality|from (r_pobj) between_4\IN|intake (r_prep) relation_3\NN|the|between (r_dobj) studied_1\VBD|we|relation|)|,|disease|. (l_dep) disease_22\NN|coronary|artery|n|175|,|and|stroke
D001205_D020521 NONE C_6\NN|vitamin (r_compound) intake_7\NN|c|and|mortality|from (r_pobj) between_4\IN|intake (r_prep) relation_3\NN|the|between (r_dobj) studied_1\VBD|we|relation|)|,|disease|. (l_dep) disease_22\NN|coronary|artery|n|175|,|and|stroke (l_conj) stroke_30\NN|(|n|57|)|in
D005492_D002318 NONE folate_21\NN| (r_nmod) E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (r_conj) type_8\NN|of|used|duration (r_appos) factors_6\NNS|risk|,|type (l_compound) risk_5\NN|disease (l_compound) disease_4\NN|cardiovascular
D005492_D002318 NONE folate_21\NN| (r_nmod) E_24\NN|folate|,|vitamin|,|and|carotene (l_conj) carotene_29\NN|beta|-|,|risks (l_appos) risks_34\NNS|the|adjusted|relative|of (l_prep) of_35\IN|mortality (l_pobj) mortality_39\NN|total|cardiovascular|disease (l_compound) disease_38\NN|
D005492_D003920 NONE folate_21\NN| (r_nmod) E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (r_conj) type_8\NN|of|used|duration (l_prep) of_9\IN|medication (l_pobj) medication_11\NN|diabetes (l_compound) diabetes_10\NN|
D005492_D003920 NONE folate_21\NN| (r_nmod) E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (l_prep) of_15\IN|diabetes (l_pobj) diabetes_16\NNS|
D014810_D002318 NONE E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (r_conj) type_8\NN|of|used|duration (r_appos) factors_6\NNS|risk|,|type (l_compound) risk_5\NN|disease (l_compound) disease_4\NN|cardiovascular
D014810_D002318 NONE E_24\NN|folate|,|vitamin|,|and|carotene (l_conj) carotene_29\NN|beta|-|,|risks (l_appos) risks_34\NNS|the|adjusted|relative|of (l_prep) of_35\IN|mortality (l_pobj) mortality_39\NN|total|cardiovascular|disease (l_compound) disease_38\NN|
D014810_D003920 NONE E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (r_conj) type_8\NN|of|used|duration (l_prep) of_9\IN|medication (l_pobj) medication_11\NN|diabetes (l_compound) diabetes_10\NN|
D014810_D003920 NONE E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (l_prep) of_15\IN|diabetes (l_pobj) diabetes_16\NNS|
D019207_D002318 NONE carotene_29\NN|beta|-|,|risks (r_conj) E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (r_conj) type_8\NN|of|used|duration (r_appos) factors_6\NNS|risk|,|type (l_compound) risk_5\NN|disease (l_compound) disease_4\NN|cardiovascular
D019207_D002318 NONE carotene_29\NN|beta|-|,|risks (l_appos) risks_34\NNS|the|adjusted|relative|of (l_prep) of_35\IN|mortality (l_pobj) mortality_39\NN|total|cardiovascular|disease (l_compound) disease_38\NN|
D019207_D003920 NONE carotene_29\NN|beta|-|,|risks (r_conj) E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (r_conj) type_8\NN|of|used|duration (l_prep) of_9\IN|medication (l_pobj) medication_11\NN|diabetes (l_compound) diabetes_10\NN|
D019207_D003920 NONE carotene_29\NN|beta|-|,|risks (r_conj) E_24\NN|folate|,|vitamin|,|and|carotene (r_pobj) of_20\IN|e (r_prep) intakes_19\NNS|of (r_conj) duration_14\NN|of|,|and|intakes (l_prep) of_15\IN|diabetes (l_pobj) diabetes_16\NNS|
7059267
D002747_D009901 CID Chlorpropamide_0\NN| (r_npadvmod) induced_2\VBN|chlorpropamide|- (r_amod) neuropathy_4\NN|induced|optic|.
D002747_D009901 CID chlorpropamide_12\NN|(|diabenese|) (r_pobj) with_11\IN|chlorpropamide (r_prep) treated_10\VBN|woman|with (r_csubj) had_16\VBD|treated|neuropathy|. (l_dobj) neuropathy_20\NN|a|toxic|optic|resolved
D002747_D009901 CID Diabenese_14\NNP| (r_appos) chlorpropamide_12\NN|(|diabenese|) (r_pobj) with_11\IN|chlorpropamide (r_prep) treated_10\VBN|woman|with (r_csubj) had_16\VBD|treated|neuropathy|. (l_dobj) neuropathy_20\NN|a|toxic|optic|resolved
D002747_D009901 CID chlorpropamide_26\NN| (r_amod) therapy_27\NN|chlorpropamide (r_pobj) of_25\IN|therapy (r_prep) discontinuation_24\NN|of (r_pobj) with_23\IN|discontinuation (r_prep) resolved_22\VBD|that|with (r_relcl) neuropathy_20\NN|a|toxic|optic|resolved
D002747_D003924 NONE chlorpropamide_12\NN|(|diabenese|) (r_pobj) with_11\IN|chlorpropamide (r_prep) treated_10\VBN|woman|with (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|diabetes (l_pobj) diabetes_9\NNS|onset
D002747_D003924 NONE Diabenese_14\NNP| (r_appos) chlorpropamide_12\NN|(|diabenese|) (r_pobj) with_11\IN|chlorpropamide (r_prep) treated_10\VBN|woman|with (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|diabetes (l_pobj) diabetes_9\NNS|onset
D002747_D003924 NONE chlorpropamide_26\NN| (r_amod) therapy_27\NN|chlorpropamide (r_pobj) of_25\IN|therapy (r_prep) discontinuation_24\NN|of (r_pobj) with_23\IN|discontinuation (r_prep) resolved_22\VBD|that|with (r_relcl) neuropathy_20\NN|a|toxic|optic|resolved (r_dobj) had_16\VBD|treated|neuropathy|. (l_csubj) treated_10\VBN|woman|with (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|diabetes (l_pobj) diabetes_9\NNS|onset
10193809
D011692_D011507 CID aminonucleoside_1\NN|pan (r_amod) Puromycin_0\NNP|aminonucleoside (r_nsubjpass) administered_6\VBN|puromycin|was|to|induce|. (l_advcl) induce_12\VB|to|proteinuria (l_dobj) proteinuria_13\NN|
D011692_D011507 CID PAN_3\NNP|(|) (r_appos) aminonucleoside_1\NN|pan (r_amod) Puromycin_0\NNP|aminonucleoside (r_nsubjpass) administered_6\VBN|puromycin|was|to|induce|. (l_advcl) induce_12\VB|to|proteinuria (l_dobj) proteinuria_13\NN|
2343592
D015378_D012640 NONE imipenem_3\NN| (r_compound) therapy_4\NN|imipenem|:|factors (r_pobj) with_2\IN|therapy (r_prep) activity_1\NN|seizure|with|. (l_compound) Seizure_0\NN|
C044650_D020521 NONE cilastatin_32\NN|imipenem|/ (r_pobj) of_29\IN|cilastatin (r_prep) doses_28\NNS|maximum|of (r_dobj) receiving_26\VBG|while|doses (r_advcl) developed_23\VBN|evidence|seizures|receiving|. (r_conj) head_15\NN|patients|trauma|and|developed (l_nsubj) patients_2\NNS|two|elderly|with (l_prep) with_3\IN|history (l_pobj) history_5\NN|a|of (l_prep) of_6\IN|accident (l_pobj) accident_10\NN|either|cerebral|vascular|(|cva|or
C044650_D020521 NONE cilastatin_32\NN|imipenem|/ (r_pobj) of_29\IN|cilastatin (r_prep) doses_28\NNS|maximum|of (r_dobj) receiving_26\VBG|while|doses (r_advcl) developed_23\VBN|evidence|seizures|receiving|. (r_conj) head_15\NN|patients|trauma|and|developed (l_nsubj) patients_2\NNS|two|elderly|with (l_prep) with_3\IN|history (l_pobj) history_5\NN|a|of (l_prep) of_6\IN|accident (l_pobj) accident_10\NN|either|cerebral|vascular|(|cva|or (l_appos) CVA_12\NNP|)
C044650_D006259 NONE cilastatin_32\NN|imipenem|/ (r_pobj) of_29\IN|cilastatin (r_prep) doses_28\NNS|maximum|of (r_dobj) receiving_26\VBG|while|doses (r_advcl) developed_23\VBN|evidence|seizures|receiving|. (r_conj) head_15\NN|patients|trauma|and|developed (l_dobj) trauma_16\NN|
C044650_D007674 NONE cilastatin_32\NN|imipenem|/ (r_pobj) of_29\IN|cilastatin (r_prep) doses_28\NNS|maximum|of (r_dobj) receiving_26\VBG|while|doses (r_advcl) developed_23\VBN|evidence|seizures|receiving|. (l_nsubj) evidence_19\NN|no|of (l_prep) of_20\IN|disease (l_pobj) disease_22\NN|renal
C044650_D012640 CID cilastatin_32\NN|imipenem|/ (r_pobj) of_29\IN|cilastatin (r_prep) doses_28\NNS|maximum|of (r_dobj) receiving_26\VBG|while|doses (r_advcl) developed_23\VBN|evidence|seizures|receiving|. (l_dobj) seizures_24\NNS|
D010672_D012640 NONE phenytoin_8\NN| (r_pobj) of_7\IN|phenytoin (r_prep) doses_6\NNS|therapeutic|of (r_pobj) with_4\IN|doses (r_prep) controlled_3\VBN|seizures|were|with|. (l_nsubjpass) seizures_1\NNS|all
D047090_D012640 NONE lactam_10\NN|beta|- (r_compound) antibiotics_11\NNS|other|lactam (r_pobj) of_6\IN|antibiotics (r_prep) doses_5\NNS|maximum|of (r_dobj) received_3\VBN|patients|had|doses|without|. (l_prep) without_12\IN|evidence (l_pobj) evidence_13\NN|of (l_prep) of_14\IN|activity (l_pobj) activity_16\NN|seizure (l_compound) seizure_15\NN|
6637851
D000638_D064420 NONE amiodarone_10\NN| (r_compound) therapy_11\NN|dose|amiodarone (r_pobj) of_6\IN|therapy (r_prep) toxicity_5\NN|of
D000638_D064420 NONE amiodarone_4\NN|dose (r_nsubj) is_5\VBZ|although|amiodarone|effective|in (r_advcl) causes_25\VBZ|is|,|it|toxicity|. (l_dobj) toxicity_27\NN|significant|in
D000638_D017180 NONE amiodarone_10\NN| (r_compound) therapy_11\NN|dose|amiodarone (r_pobj) of_6\IN|therapy (r_prep) toxicity_5\NN|of (r_conj) efficacy_3\NN|term|and|toxicity|for|. (l_prep) for_12\IN|tachycardia (l_pobj) tachycardia_14\NN|ventricular|or|fibrillation
D000638_D017180 NONE Amiodarone_0\NNP| (r_nsubjpass) administered_2\VBN|amiodarone|was|to|. (l_prep) to_3\IN|patients (l_pobj) patients_5\NNS|154|sustained|118|or|arrest (l_relcl) sustained_8\VBN|who|had|,|tachycardia (l_dobj) tachycardia_12\NN|symptomatic|ventricular|(|vt|)
D000638_D017180 NONE Amiodarone_0\NNP| (r_nsubjpass) administered_2\VBN|amiodarone|was|to|. (l_prep) to_3\IN|patients (l_pobj) patients_5\NNS|154|sustained|118|or|arrest (l_relcl) sustained_8\VBN|who|had|,|tachycardia (l_dobj) tachycardia_12\NN|symptomatic|ventricular|(|vt|) (l_appos) VT_14\NNP|
D000638_D017180 NONE amiodarone_9\NN| (r_pobj) with_8\IN|amiodarone (r_prep) treatment_7\NN|with (r_dobj) continued_6\VBD|percent|treatment|and|had|. (l_conj) had_11\VBD|recurrence (l_dobj) recurrence_13\NN|no|of|over (l_prep) of_14\IN|vt (l_pobj) VT_16\NNP|symptomatic|or|fibrillation|(|vf|)
D000638_D017180 NONE amiodarone_17\NN|continuing|at (r_pobj) by_15\IN|amiodarone (r_agent) managed_14\VBN|were|successfully|by (r_conj) had_5\VBD|percent|recurrence|and|managed|. (l_dobj) recurrence_8\NN|a|nonfatal|of (l_prep) of_9\IN|vt (l_pobj) VT_10\NNP|
D000638_D017180 NONE amiodarone_4\NN|dose (r_nsubj) is_5\VBZ|although|amiodarone|effective|in (l_prep) in_8\IN|treatment (l_pobj) treatment_13\NN|the|term|of (l_prep) of_14\IN|vt (l_pobj) VT_15\NNP|or|refractory
D000638_D017180 NONE amiodarone_31\NN| (r_pobj) with_30\IN|amiodarone (r_prep) managed_29\VBN|however|,|adjusted|,|%|can|be|successfully|with|. (l_nsubjpass) %_19\NN|75|of (l_prep) of_20\IN|patients (l_pobj) patients_21\NNS|with (l_prep) with_22\IN|vt (l_pobj) VT_23\NNP|or|vf
D000638_D014693 NONE amiodarone_10\NN| (r_compound) therapy_11\NN|dose|amiodarone (r_pobj) of_6\IN|therapy (r_prep) toxicity_5\NN|of (r_conj) efficacy_3\NN|term|and|toxicity|for|. (l_prep) for_12\IN|tachycardia (l_pobj) tachycardia_14\NN|ventricular|or|fibrillation (l_conj) fibrillation_17\NN|ventricular
D000638_D014693 NONE amiodarone_9\NN| (r_pobj) with_8\IN|amiodarone (r_prep) treatment_7\NN|with (r_dobj) continued_6\VBD|percent|treatment|and|had|. (l_conj) had_11\VBD|recurrence (l_dobj) recurrence_13\NN|no|of|over (l_prep) of_14\IN|vt (l_pobj) VT_16\NNP|symptomatic|or|fibrillation|(|vf|) (l_conj) fibrillation_19\NN|ventricular
D000638_D014693 NONE amiodarone_9\NN| (r_pobj) with_8\IN|amiodarone (r_prep) treatment_7\NN|with (r_dobj) continued_6\VBD|percent|treatment|and|had|. (l_conj) had_11\VBD|recurrence (l_dobj) recurrence_13\NN|no|of|over (l_prep) of_14\IN|vt (l_pobj) VT_16\NNP|symptomatic|or|fibrillation|(|vf|) (l_appos) VF_21\NNP|
D000638_D014693 NONE amiodarone_4\NN|dose (r_nsubj) is_5\VBZ|although|amiodarone|effective|in (l_prep) in_8\IN|treatment (l_pobj) treatment_13\NN|the|term|of (l_prep) of_14\IN|vt (l_pobj) VT_15\NNP|or|refractory (l_conj) refractory_18\NN|vf|to (l_compound) VF_17\NNP|
D000638_D014693 NONE amiodarone_31\NN| (r_pobj) with_30\IN|amiodarone (r_prep) managed_29\VBN|however|,|adjusted|,|%|can|be|successfully|with|. (l_nsubjpass) %_19\NN|75|of (l_prep) of_20\IN|patients (l_pobj) patients_21\NNS|with (l_prep) with_22\IN|vt (l_pobj) VT_23\NNP|or|vf (l_conj) VF_25\NNP|
D000638_D006323 NONE Amiodarone_0\NNP| (r_nsubjpass) administered_2\VBN|amiodarone|was|to|. (l_prep) to_3\IN|patients (l_pobj) patients_5\NNS|154|sustained|118|or|arrest (l_conj) arrest_24\NN|a|cardiac|(|n|36|)|and|were
7905523
C059896_D015658 NONE deoxynojirimycin_10\NNP|n|-|butyl|-|sc-48334|and|zidovudine (l_conj) zidovudine_15\NN|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with|and (l_prep) with_18\IN|infection (l_pobj) infection_20\NN|hiv-1
C059896_D015658 NONE SC-48334_12\NNP|(|) (r_appos) deoxynojirimycin_10\NNP|n|-|butyl|-|sc-48334|and|zidovudine (l_conj) zidovudine_15\NN|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with|and (l_prep) with_18\IN|infection (l_pobj) infection_20\NN|hiv-1
D015215_D015658 NONE zidovudine_15\NN|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with|and (l_prep) with_18\IN|infection (l_pobj) infection_20\NN|hiv-1
C059896_D007153 NONE SC-48334_2\VBP| (r_nmod) level_7\NN|the|mean|sc-48334|state|trough|ml (r_nsubj) was_16\VBD|level|below|. (l_prep) below_17\IN|concentration (l_pobj) concentration_22\NN|the|vitro|inhibitory|for (l_prep) for_23\IN|virus (l_pobj) virus_26\NN|human|immunodeficiency|(|hiv|) (l_compound) immunodeficiency_25\NN|
18483878
D003520_D003556 CID cyclophosphamide_15\NN| (r_pobj) with_14\IN|cyclophosphamide (r_prep) mice_13\NNS|with (r_appos) knockout_9\NN|polypeptide|(|vip-/-|)|mice|cystitis (l_appos) cystitis_18\NN|cyp)-induced
D003520_D003556 CID CYP)-induced_17\VBN|( (r_compound) cystitis_18\NN|cyp)-induced
D003520_D003556 CID cyclophosphamide_14\NN| (r_pobj) after_13\IN|cyclophosphamide (r_prep) altered_4\JJ|vip(-/-|function|after|cystitis|. (l_dobj) cystitis_17\NN|(|cyp)-induced
D003520_D003556 CID CYP)-induced_16\VBN| (r_amod) cystitis_17\NN|(|cyp)-induced
D003520_D003556 CID CYP_32\NNP| (r_npadvmod) induced_34\VBN|cyp|- (r_amod) cystitis_35\NN|induced|(|mg/kg|;|i.p.|;|h|)
D003520_D001745 NONE CYP_22\NNP| (r_pobj) with_21\IN|cyp (r_prep) WT_20\NNP|with (r_pobj) in_19\IN|wt (r_prep) observed_18\VBD|that|in (r_advcl) increased_15\VBN|mice|,|mediators|are|above|observed (l_advcl) mice_7\NNS|that|in|with (l_prep) with_8\IN|inflammation (l_pobj) inflammation_10\NN|bladder
1423339
D011433_D000647 CID propranolol_4\JJ| (r_amod) toxicity_5\NN|propranolol (r_pobj) with_3\IN|toxicity (r_prep) associated_2\VBN|with (r_acl) syndrome_1\NN|amnestic|associated|:|report|.
D011433_D064420 NONE propranolol_4\JJ| (r_amod) toxicity_5\NN|propranolol
D011433_D064420 NONE propranolol_14\JJ| (r_amod) toxicity_15\NN|propranolol
D011433_D000544 NONE propranolol_14\JJ| (r_amod) toxicity_15\NN|propranolol (r_pobj) of_13\IN|toxicity (r_prep) result_12\NN|a|of (r_pobj) as_10\IN|result (r_prep) developed_3\VBD|woman|dementia|as|. (l_dobj) dementia_9\NN|an|like|subacute (l_amod) like_7\JJ|alzheimer|- (l_npadvmod) Alzheimer_5\NNP|
D011433_D003704 NONE propranolol_14\JJ| (r_amod) toxicity_15\NN|propranolol (r_pobj) of_13\IN|toxicity (r_prep) result_12\NN|a|of (r_pobj) as_10\IN|result (r_prep) developed_3\VBD|woman|dementia|as|. (l_dobj) dementia_9\NN|an|like|subacute
11099450
D007980_D010300 NONE levodopa_33\RB| (r_npadvmod) induced_35\VBN|levodopa|- (r_amod) dyskinesias_36\NNS|induced|(|lid|) (r_conj) signs_31\NNS|parkinsonian|off|and|dyskinesias (l_poss) parkinsonian_27\NN|'
D007980_D010300 NONE levodopa_5\JJ| (r_compound) responsiveness_6\NN|levodopa|for (l_prep) for_7\IN|outcome (l_pobj) outcome_9\NN|the|of (l_prep) of_10\IN|signs (l_pobj) signs_15\NNS|parkinsonian|off|and|lid (l_poss) parkinsonian_11\NN|'
D007980_D010300 NONE levodopa_5\JJ| (r_compound) responsiveness_6\NN|levodopa|for (l_prep) for_7\IN|outcome (l_pobj) outcome_9\NN|the|of (l_prep) of_10\IN|signs (l_pobj) signs_15\NNS|parkinsonian|off|and|lid (l_conj) LID_17\NNP|and|correlations (l_conj) correlations_21\NNS|the|different|of (l_prep) of_22\IN|volume (l_pobj) volume_25\NN|ventral|lesion|with (l_prep) with_26\IN|dyskinesias (l_pobj) dyskinesias_27\NNS|and|parkinsonian|signs (l_conj) parkinsonian_29\NN|'
D007980_D010300 NONE levodopa_5\JJ| (r_compound) responsiveness_6\NN|levodopa|for (r_pobj) of_4\IN|responsiveness (r_prep) value_3\NN|the|differential|predictive|of (r_nsubj) indicate_34\VBP|value|be|. (l_ccomp) be_42\VB|that|substrates|may|responsible (l_acomp) responsible_43\JJ|for (l_prep) for_44\IN|generation|signs (l_pobj) generation_46\NN|the|of (l_prep) of_47\IN|parkinsonian (l_pobj) parkinsonian_48\NN|'
D007980_D004409 CID levodopa_33\RB| (r_npadvmod) induced_35\VBN|levodopa|- (r_amod) dyskinesias_36\NNS|induced|(|lid|)
D007980_D004409 CID levodopa_33\RB| (r_npadvmod) induced_35\VBN|levodopa|- (r_amod) dyskinesias_36\NNS|induced|(|lid|) (l_appos) LID_38\NNP|
D007980_D004409 CID levodopa_8\JJ| (r_compound) responsiveness_9\NN|the|preoperative|levodopa|of|and|responsiveness (r_pobj) between_5\IN|responsiveness (r_prep) correlations_4\NNS|significant|positive|between|program (r_dobj) found_1\VBD|we|correlations|in|,|was|. (l_advcl) was_45\VBD|whereas|there|correlation (l_attr) correlation_47\NN|no|with (l_prep) with_48\IN|improvement (l_pobj) improvement_50\NN|the|in (l_prep) in_51\IN|lid (l_pobj) LID_52\NNP|
D007980_D004409 CID levodopa_15\JJ| (r_compound) responsiveness_16\NN|the|levodopa|of (r_conj) responsiveness_9\NN|the|preoperative|levodopa|of|and|responsiveness (r_pobj) between_5\IN|responsiveness (r_prep) correlations_4\NNS|significant|positive|between|program (r_dobj) found_1\VBD|we|correlations|in|,|was|. (l_advcl) was_45\VBD|whereas|there|correlation (l_attr) correlation_47\NN|no|with (l_prep) with_48\IN|improvement (l_pobj) improvement_50\NN|the|in (l_prep) in_51\IN|lid (l_pobj) LID_52\NNP|
D007980_D004409 CID levodopa_5\JJ| (r_compound) responsiveness_6\NN|levodopa|for (l_prep) for_7\IN|outcome (l_pobj) outcome_9\NN|the|of (l_prep) of_10\IN|signs (l_pobj) signs_15\NNS|parkinsonian|off|and|lid (l_conj) LID_17\NNP|and|correlations
D007980_D004409 CID levodopa_5\JJ| (r_compound) responsiveness_6\NN|levodopa|for (l_prep) for_7\IN|outcome (l_pobj) outcome_9\NN|the|of (l_prep) of_10\IN|signs (l_pobj) signs_15\NNS|parkinsonian|off|and|lid (l_conj) LID_17\NNP|and|correlations (l_conj) correlations_21\NNS|the|different|of (l_prep) of_22\IN|volume (l_pobj) volume_25\NN|ventral|lesion|with (l_prep) with_26\IN|dyskinesias (l_pobj) dyskinesias_27\NNS|and|parkinsonian|signs
D007980_D004409 CID levodopa_5\JJ| (r_compound) responsiveness_6\NN|levodopa|for (r_pobj) of_4\IN|responsiveness (r_prep) value_3\NN|the|differential|predictive|of (r_nsubj) indicate_34\VBP|value|be|. (l_ccomp) be_42\VB|that|substrates|may|responsible (l_acomp) responsible_43\JJ|for (l_prep) for_44\IN|generation|signs (l_pobj) signs_52\NNS|off|and|dyskinesias (l_conj) dyskinesias_54\NNS|
11868798
D013148_D007008 NONE Spironolactone_0\NNP| (r_npadvmod) is_2\VBZ|spironolactone|:|it|drug|? (l_attr) drug_6\NN|a|novel|for (l_prep) for_7\IN|prevention (l_pobj) prevention_9\NN|the|of (l_prep) of_10\IN|hypokalemia (l_pobj) hypokalemia_15\NN|related|in
D013148_D007008 NONE spironolactone_9\NN| (r_pobj) of_8\IN|spironolactone (r_prep) ability_7\NN|the|of|reduce (l_acl) reduce_11\VB|to|requirements|and|prevent (l_conj) prevent_16\VB|to|hypokalemia (l_dobj) hypokalemia_17\NN|in
D013148_D007008 NONE spironolactone_4\NN| (r_nsubj) reduce_6\VB|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_10\VBP|hypokalemia|by (l_dobj) hypokalemia_11\NN|
D013148_D009369 NONE Spironolactone_0\NNP| (r_npadvmod) is_2\VBZ|spironolactone|:|it|drug|? (l_attr) drug_6\NN|a|novel|for (l_prep) for_7\IN|prevention (l_pobj) prevention_9\NN|the|of (l_prep) of_10\IN|hypokalemia (l_pobj) hypokalemia_15\NN|related|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|cancer (l_compound) cancer_17\NN|
D000666_D007008 CID B_12\NN|amphotericin (r_npadvmod) related_14\VBN|b|- (r_amod) hypokalemia_15\NN|related|in
D000666_D007008 CID AmB_22\JJ| (r_compound) treatment_23\NN|amb (r_pobj) on_21\IN|treatment (r_prep) patients_20\NNS|neutropenic|on (r_pobj) in_18\IN|patients (r_prep) hypokalemia_17\NN|in
D000666_D007008 CID AmB_21\JJ| (r_compound) treatment_22\NN|amb (r_pobj) on_20\IN|treatment (r_prep) patients_19\NNS|neutropenic|on (r_pobj) in_17\IN|patients (r_prep) loss_16\NN|urinary|potassium|in (r_dobj) reducing_13\VBG|loss (r_pcomp) by_12\IN|reducing (r_prep) prevent_10\VBP|hypokalemia|by (l_dobj) hypokalemia_11\NN|
D000666_D009369 NONE B_12\NN|amphotericin (r_npadvmod) related_14\VBN|b|- (r_amod) hypokalemia_15\NN|related|in (l_prep) in_16\IN|patients (l_pobj) patients_18\NNS|cancer (l_compound) cancer_17\NN|
D000666_D007674 NONE B_9\NNP|amphotericin|amb (r_pobj) of_7\IN|b (r_prep) effect_6\NN|the|major|adverse|of (r_attr) is_2\VBZ|:|nephrotoxicity|effect|,|limiting|. (l_nsubj) Nephrotoxicity_1\NN|
D000666_D007674 NONE AmB_11\NNP|(|) (r_appos) B_9\NNP|amphotericin|amb (r_pobj) of_7\IN|b (r_prep) effect_6\NN|the|major|adverse|of (r_attr) is_2\VBZ|:|nephrotoxicity|effect|,|limiting|. (l_nsubj) Nephrotoxicity_1\NN|
D011188_D064420 NONE potassium_12\NN| (r_compound) wasting_13\VBG|the|profound|potassium|is (r_pobj) for_9\IN|wasting (r_prep) responsible_8\JJ|for (r_acomp) be_7\VB|to|responsible (r_xcomp) seems_5\VBZ|toxicity|be|potentiates (l_nsubj) toxicity_4\NN|selective|distal|epithelial
D011188_D064420 NONE potassium_12\NN| (r_compound) wasting_13\VBG|the|profound|potassium|is (r_pobj) for_9\IN|wasting (r_prep) responsible_8\JJ|for (r_acomp) be_7\VB|to|responsible (r_xcomp) seems_5\VBZ|toxicity|be|potentiates (l_conj) potentiates_28\VBZ|also|toxicity (l_dobj) toxicity_31\NN|the|tubular|of
D011188_D064420 NONE Potassium_25\NN|amb. (r_compound) depletion_26\NN|potassium (r_pobj) with_23\IN|depletion (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) effect_20\NN|a|major|side|of (r_attr) is_15\VBZ|that|effect (r_relcl) wasting_13\VBG|the|profound|potassium|is (r_pobj) for_9\IN|wasting (r_prep) responsible_8\JJ|for (r_acomp) be_7\VB|to|responsible (r_xcomp) seems_5\VBZ|toxicity|be|potentiates (l_nsubj) toxicity_4\NN|selective|distal|epithelial
D011188_D064420 NONE Potassium_25\NN|amb. (r_compound) depletion_26\NN|potassium (r_pobj) with_23\IN|depletion (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) effect_20\NN|a|major|side|of (r_attr) is_15\VBZ|that|effect (r_relcl) wasting_13\VBG|the|profound|potassium|is (r_pobj) for_9\IN|wasting (r_prep) responsible_8\JJ|for (r_acomp) be_7\VB|to|responsible (r_xcomp) seems_5\VBZ|toxicity|be|potentiates (l_conj) potentiates_28\VBZ|also|toxicity (l_dobj) toxicity_31\NN|the|tubular|of
D000666_D064420 NONE AmB._24\NNP| (r_compound) Potassium_25\NN|amb. (r_compound) depletion_26\NN|potassium (r_pobj) with_23\IN|depletion (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) effect_20\NN|a|major|side|of (r_attr) is_15\VBZ|that|effect (r_relcl) wasting_13\VBG|the|profound|potassium|is (r_pobj) for_9\IN|wasting (r_prep) responsible_8\JJ|for (r_acomp) be_7\VB|to|responsible (r_xcomp) seems_5\VBZ|toxicity|be|potentiates (l_nsubj) toxicity_4\NN|selective|distal|epithelial
D000666_D064420 NONE AmB._24\NNP| (r_compound) Potassium_25\NN|amb. (r_compound) depletion_26\NN|potassium (r_pobj) with_23\IN|depletion (r_prep) treatment_22\NN|with (r_pobj) of_21\IN|treatment (r_prep) effect_20\NN|a|major|side|of (r_attr) is_15\VBZ|that|effect (r_relcl) wasting_13\VBG|the|profound|potassium|is (r_pobj) for_9\IN|wasting (r_prep) responsible_8\JJ|for (r_acomp) be_7\VB|to|responsible (r_xcomp) seems_5\VBZ|toxicity|be|potentiates (l_conj) potentiates_28\VBZ|also|toxicity (l_dobj) toxicity_31\NN|the|tubular|of
D000666_D064420 NONE AmB._33\NN| (r_pobj) of_32\IN|amb. (r_prep) toxicity_31\NN|the|tubular|of (r_dobj) potentiates_28\VBZ|also|toxicity (r_conj) seems_5\VBZ|toxicity|be|potentiates (l_nsubj) toxicity_4\NN|selective|distal|epithelial
D000666_D064420 NONE AmB._33\NN| (r_pobj) of_32\IN|amb. (r_prep) toxicity_31\NN|the|tubular|of
D013148_D009503 NONE spironolactone_9\NN| (r_pobj) of_8\IN|spironolactone (r_prep) ability_7\NN|the|of|reduce (l_acl) reduce_11\VB|to|requirements|and|prevent (l_conj) prevent_16\VB|to|hypokalemia (l_dobj) hypokalemia_17\NN|in (l_prep) in_18\IN|patients (l_pobj) patients_20\NNS|neutropenic|on (l_amod) neutropenic_19\JJ|
D013148_D009503 NONE spironolactone_4\NN| (r_nsubj) reduce_6\VB|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_10\VBP|hypokalemia|by (l_prep) by_12\IN|reducing (l_pcomp) reducing_13\VBG|loss (l_dobj) loss_16\NN|urinary|potassium|in (l_prep) in_17\IN|patients (l_pobj) patients_19\NNS|neutropenic|on (l_amod) neutropenic_18\JJ|
D011188_D007008 NONE potassium_12\NN| (r_compound) requirements_13\NNS|potassium (r_dobj) reduce_11\VB|to|requirements|and|prevent (l_conj) prevent_16\VB|to|hypokalemia (l_dobj) hypokalemia_17\NN|in
D011188_D007008 NONE potassium_7\NN| (r_compound) requirements_8\NNS|potassium (r_dobj) reduce_6\VB|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_10\VBP|hypokalemia|by (l_dobj) hypokalemia_11\NN|
D011188_D007008 NONE potassium_15\NN| (r_compound) loss_16\NN|urinary|potassium|in (r_dobj) reducing_13\VBG|loss (r_pcomp) by_12\IN|reducing (r_prep) prevent_10\VBP|hypokalemia|by (l_dobj) hypokalemia_11\NN|
D011188_D009503 NONE potassium_12\NN| (r_compound) requirements_13\NNS|potassium (r_dobj) reduce_11\VB|to|requirements|and|prevent (l_conj) prevent_16\VB|to|hypokalemia (l_dobj) hypokalemia_17\NN|in (l_prep) in_18\IN|patients (l_pobj) patients_20\NNS|neutropenic|on (l_amod) neutropenic_19\JJ|
D011188_D009503 NONE potassium_7\NN| (r_compound) requirements_8\NNS|potassium (r_dobj) reduce_6\VB|that|spironolactone|can|requirements|and|prevent (l_conj) prevent_10\VBP|hypokalemia|by (l_prep) by_12\IN|reducing (l_pcomp) reducing_13\VBG|loss (l_dobj) loss_16\NN|urinary|potassium|in (l_prep) in_17\IN|patients (l_pobj) patients_19\NNS|neutropenic|on (l_amod) neutropenic_18\JJ|
D011188_D009503 NONE potassium_15\NN| (r_compound) loss_16\NN|urinary|potassium|in (l_prep) in_17\IN|patients (l_pobj) patients_19\NNS|neutropenic|on (l_amod) neutropenic_18\JJ|
D000666_D009503 NONE AmB_22\JJ| (r_compound) treatment_23\NN|amb (r_pobj) on_21\IN|treatment (r_prep) patients_20\NNS|neutropenic|on (l_amod) neutropenic_19\JJ|
D000666_D009503 NONE AmB_21\JJ| (r_compound) treatment_22\NN|amb (r_pobj) on_20\IN|treatment (r_prep) patients_19\NNS|neutropenic|on (l_amod) neutropenic_18\JJ|
D000666_D006402 NONE AmB_15\VB|either|intravenous|alone|or|amb|spironolactone (r_dobj) receive_12\VB|to|amb|twice|daily|developing (r_xcomp) randomized_10\VBN|in|patients|were|receive|. (l_nsubjpass) patients_4\NNS|26|with (l_prep) with_5\IN|disorders (l_pobj) disorders_8\NNS|various|hematological
D000666_D006402 NONE AmB_18\JJ|and (r_conj) AmB_15\VB|either|intravenous|alone|or|amb|spironolactone (r_dobj) receive_12\VB|to|amb|twice|daily|developing (r_xcomp) randomized_10\VBN|in|patients|were|receive|. (l_nsubjpass) patients_4\NNS|26|with (l_prep) with_5\IN|disorders (l_pobj) disorders_8\NNS|various|hematological
D000666_D009181 NONE AmB_15\VB|either|intravenous|alone|or|amb|spironolactone (r_dobj) receive_12\VB|to|amb|twice|daily|developing (l_advcl) developing_27\VBG|when|infection (l_dobj) infection_33\NN|a|proven|fungal
D000666_D009181 NONE AmB_18\JJ|and (r_conj) AmB_15\VB|either|intravenous|alone|or|amb|spironolactone (r_dobj) receive_12\VB|to|amb|twice|daily|developing (l_advcl) developing_27\VBG|when|infection (l_dobj) infection_33\NN|a|proven|fungal
D013148_D006402 NONE spironolactone_21\NN|oral (r_conj) AmB_15\VB|either|intravenous|alone|or|amb|spironolactone (r_dobj) receive_12\VB|to|amb|twice|daily|developing (r_xcomp) randomized_10\VBN|in|patients|were|receive|. (l_nsubjpass) patients_4\NNS|26|with (l_prep) with_5\IN|disorders (l_pobj) disorders_8\NNS|various|hematological
D013148_D009181 NONE spironolactone_21\NN|oral (r_conj) AmB_15\VB|either|intravenous|alone|or|amb|spironolactone (r_dobj) receive_12\VB|to|amb|twice|daily|developing (l_advcl) developing_27\VBG|when|infection (l_dobj) infection_33\NN|a|proven|fungal
6615052
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|,|thrombosis|.
D006493_D013921 CID heparin_6\NN| (r_npadvmod) induced_8\VBN|heparin|- (r_amod) thrombocytopenia_9\NN|a|induced
D006493_D013927 NONE Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|,|thrombosis|. (l_conj) thrombosis_5\NN|,|and|hemorrhage
D006493_D006470 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|,|thrombosis|. (l_conj) thrombosis_5\NN|,|and|hemorrhage (l_conj) hemorrhage_8\NN|
D006493_D006470 CID heparin_17\VBN| (r_dobj) receiving_16\VBG|heparin (r_acl) patients_15\NNS|receiving (r_pobj) in_14\IN|patients (r_prep) events_13\NNS|thromboembolic|in (r_appos) hemorrhage_6\NN|or|,|frequently|,|events
D006493_D013923 CID heparin_17\VBN| (r_dobj) receiving_16\VBG|heparin (r_acl) patients_15\NNS|receiving (r_pobj) in_14\IN|patients (r_prep) events_13\NNS|thromboembolic|in (l_compound) thromboembolic_12\JJ|
D006493_D001791 NONE heparin_12\NN| (r_pobj) to_11\IN|heparin (r_prep) resistance_10\NN|to (r_dobj) increased_9\VBN|resistance|,|and|added (r_conj) revealed_3\VBN|testing|has|count|,|increased|. (l_dobj) count_7\NN|a|falling|platelet
D006493_D001791 NONE heparin_24\NN| (r_nsubjpass) added_26\VBN|aggregation|when|heparin|is (r_conj) increased_9\VBN|resistance|,|and|added (r_conj) revealed_3\VBN|testing|has|count|,|increased|. (l_dobj) count_7\NN|a|falling|platelet
D006493_D001791 NONE heparin_15\JJ|,|testing (l_appos) testing_19\NN|aggregation (l_compound) aggregation_18\NN|platelet
7053705
D013866_D006504 CID 6-thioguanine_7\CD| (r_pobj) by_6\IN|6-thioguanine (r_agent) caused_5\VBN|by (r_acl) disease_4\NN|hepatic|occlusive|caused|.
D013866_D006504 CID 6-thioguanine_27\CD| (r_punct) ._28\.|6-thioguanine (r_punct) disease_5\NN|reversible|occlusive|of|. (l_prep) of_6\IN|liver (l_pobj) liver_8\NN|the|developed
D013866_D006504 CID 6-thioguanine_35\CD| (r_pobj) to_34\IN|solely|6-thioguanine (r_prep) related_32\VBN|occlusive|to (r_pobj) of_28\IN|related (r_prep) case_27\NN|the|first|of (r_attr) be_24\VB|may|case (r_conj) presented_2\VBD|case|opportunity|,|and|be|. (l_dobj) opportunity_5\NN|a|unique|observe (l_acl) observe_7\VB|to|features|over (l_dobj) features_10\NNS|the|histologic|of (l_prep) of_11\IN|disease (l_pobj) disease_18\NN|reversible|hepatic|occlusive
D013866_D054198 NONE 6-thioguanine_27\CD| (r_punct) ._28\.|6-thioguanine (r_punct) disease_5\NN|reversible|occlusive|of|. (l_prep) of_6\IN|liver (l_pobj) liver_8\NN|the|developed (l_acl) developed_9\VBN|in|after|with (l_prep) in_10\IN|man (l_pobj) man_15\NN|a|old|with (l_prep) with_16\IN|leukemia (l_pobj) leukemia_19\NN|acute|lymphocytic
3015327
D007538_D009422 CID isoniazid_6\NN|experimental (r_compound) neuropathy_7\NN|isoniazid|in
D007538_D009422 CID isoniazid_8\NN| (r_pobj) of_7\IN|isoniazid (r_prep) dose_6\NN|a|single|of|in (r_pobj) by_3\IN|dose (r_agent) caused_2\VBN|by (r_acl) neuropathy_1\NN|the|caused
8766220
D014147_D006212 CID tramadol_9\NN| (r_pobj) of_8\IN|tramadol (r_prep) intake_7\NN|term|of (r_pobj) after_3\IN|intake (r_prep) Nightmares_0\NNS|and|hallucinations|after|combined|. (l_conj) hallucinations_2\NNS|
D014147_D006212 CID tramadol_25\NN| (r_conj) drugs_23\NNS|active|and|tramadol (r_pobj) of_19\IN|drugs (r_prep) withdrawal_18\NN|the|of (r_pobj) after_16\IN|withdrawal (r_prep) stopped_15\VBD|that|only|after (r_relcl) hallucinations_12\NNS|stopped
D014147_D009369 NONE Tramadol_0\NNP| (r_nsubj) is_1\VBZ|tramadol|opioid|. (l_attr) opioid_4\NN|a|weak|with (l_prep) with_5\IN|effects (l_pobj) effects_6\NNS|on|used (l_relcl) used_14\VBN|that|is|treat (l_xcomp) treat_16\VB|to|pain (l_dobj) pain_18\NN|cancer|and|pain (l_compound) cancer_17\NN|
D014147_D010146 NONE Tramadol_0\NNP| (r_nsubj) is_1\VBZ|tramadol|opioid|. (l_attr) opioid_4\NN|a|weak|with (l_prep) with_5\IN|effects (l_pobj) effects_6\NNS|on|used (l_relcl) used_14\VBN|that|is|treat (l_xcomp) treat_16\VB|to|pain (l_dobj) pain_18\NN|cancer|and|pain
D014147_D010146 NONE Tramadol_0\NNP| (r_nsubj) is_1\VBZ|tramadol|opioid|. (l_attr) opioid_4\NN|a|weak|with (l_prep) with_5\IN|effects (l_pobj) effects_6\NNS|on|used (l_relcl) used_14\VBN|that|is|treat (l_xcomp) treat_16\VB|to|pain (l_dobj) pain_18\NN|cancer|and|pain (l_conj) pain_23\NN|chronic|non|malignant
D017374_-1 NONE paroxetine_7\NN| (r_pobj) with_6\IN|paroxetine (r_prep) association_5\NN|with (r_pobj) in_4\IN|association (r_prep) initiated_3\VBN|drug|was|in|and|dosulepine|. (l_conj) dosulepine_9\JJ|hydrochloride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|tetraparetic|with (l_amod) tetraparetic_13\JJ|
D017374_D059350 NONE paroxetine_7\NN| (r_pobj) with_6\IN|paroxetine (r_prep) association_5\NN|with (r_pobj) in_4\IN|association (r_prep) initiated_3\VBN|drug|was|in|and|dosulepine|. (l_conj) dosulepine_9\JJ|hydrochloride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|tetraparetic|with (l_prep) with_15\IN|pain (l_pobj) pain_17\NN|chronic
D004308_-1 NONE hydrochloride_10\NN| (r_dobj) dosulepine_9\JJ|hydrochloride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|tetraparetic|with (l_amod) tetraparetic_13\JJ|
D004308_D059350 NONE hydrochloride_10\NN| (r_dobj) dosulepine_9\JJ|hydrochloride|in (l_prep) in_11\IN|patient (l_pobj) patient_14\NN|a|tetraparetic|with (l_prep) with_15\IN|pain (l_pobj) pain_17\NN|chronic
17702969
D005473_D005315 CID fluoxetine_3\NN| (r_advmod) induces_4\VBZ|to|fluoxetine|hypertension (l_dobj) hypertension_7\NN|fetal|pulmonary|in
D005473_D005315 CID fluoxetine_5\NN| (r_amod) exposure_6\NN|fluoxetine (r_nsubj) resulted_7\VBD|compared|,|exposure|in|evidenced|and|by|. (l_prep) in_8\IN|hypertension (l_pobj) hypertension_11\NN|fetal|pulmonary
D005473_D006976 CID fluoxetine_3\NN| (r_advmod) induces_4\VBZ|to|fluoxetine|hypertension (l_dobj) hypertension_7\NN|fetal|pulmonary|in
D005473_D006976 CID fluoxetine_4\NN| (r_amod) exposure_5\NN|fluoxetine (r_nsubj) increases_7\VBZ|that|exposure|prenatally|prevalence (l_dobj) prevalence_9\NN|the|of (l_prep) of_10\IN|syndrome (l_pobj) syndrome_14\NN|persistent|hypertension|of
D005473_D006976 CID fluoxetine_20\NN| (r_amod) effect_21\NN|protective|fluoxetine|in (r_appos) evidence_14\NN|the|current|of|effect (l_prep) of_15\IN|hypertension (l_pobj) hypertension_18\NN|a|pulmonary
D005473_D006976 CID fluoxetine_5\NN| (r_amod) exposure_6\NN|fluoxetine (r_nsubj) resulted_7\VBD|compared|,|exposure|in|evidenced|and|by|. (l_prep) in_8\IN|hypertension (l_pobj) hypertension_11\NN|fetal|pulmonary
D005473_D006976 CID fluoxetine_6\NN| (r_amod) exposure_7\NN|fluoxetine|in (r_nsubj) induces_10\VBZ|in|,|exposure|hypertension|as|. (l_dobj) hypertension_12\NN|pulmonary|in
8911359
D003520_D001749 CID Cyclophosphamide_0\NN| (r_nmod) cancer_3\NN|cyclophosphamide|associated|bladder|--|disease|.
D003520_D001749 CID cyclophosphamide_17\NN| (r_pobj) with_16\IN|cyclophosphamide|cancer (l_pobj) cancer_20\NN|associated|bladder
D003520_D001749 CID Cyclophosphamide_0\NN| (r_nmod) tumor_3\NN|cyclophosphamide|associated|bladder
D003520_D014523 NONE cyclophosphamide_13\NN| (r_pobj) of_12\IN|cyclophosphamide (r_prep) etiology_7\NN|the|,|treatment|of (r_pobj) of_5\IN|etiology (r_prep) knowledge_4\NN|of (r_dobj) gained_3\VBD|we|knowledge|cancer|. (l_dobj) cancer_16\NN|associated|urothelial
3123611
D003276_D002819 CID contraception_4\NN|oral (r_pobj) with_2\IN|contraception (r_prep) associated_1\VBN|with (r_acl) Chorea_0\NNP|associated|.
D003276_D002819 CID contraceptives_7\NNS|oral (r_dobj) receiving_5\VBG|while|contraceptives (r_advcl) developed_2\VBD|patients|chorea|receiving|. (l_dobj) chorea_3\NN|
D003276_D002819 CID contraception_12\NN|prolonged|oral (r_pobj) after_9\IN|contraception (r_prep) had_3\VBD|patient|chorea|after|. (l_dobj) chorea_8\NN|acute|induced
D000661_D002819 CID amphetamine_5\NN| (r_npadvmod) induced_7\VBN|amphetamine|- (r_amod) chorea_8\NN|acute|induced
803783
D010121_D014869 CID oxytocin_4\NN| (r_compound) administration_5\NN|oxytocin (r_pobj) with_3\IN|administration (r_prep) associated_2\VBN|with|during (r_acl) intoxication_1\NN|water|associated|.
D010121_D014869 CID oxytocin_8\NN| (r_compound) administration_9\NN|oxytocin (r_pobj) with_7\IN|administration (r_prep) connection_6\NN|with|during (r_pobj) in_5\IN|connection (r_prep) intoxication_4\NN|water|in
D010121_D014869 CID Oxytocin_0\NN| (r_compound) administration_1\NN|oxytocin|during (r_nsubjpass) advocated_8\VBN|administration|is|carried|. (l_advcl) carried_14\VBN|only|if|it|can|be|out|under|,|aware|and|instructed (l_advcl) aware_25\JJ|of (l_prep) of_26\IN|symptoms (l_pobj) symptoms_28\NNS|the|of (l_prep) of_29\IN|intoxication (l_pobj) intoxication_31\NN|water
D010121_D000031 NONE oxytocin_4\NN| (r_compound) administration_5\NN|oxytocin (r_pobj) with_3\IN|administration (r_prep) associated_2\VBN|with|during (l_prep) during_6\IN|abortion (l_pobj) abortion_10\NN|induced
D010121_D000031 NONE oxytocin_8\NN| (r_compound) administration_9\NN|oxytocin (r_pobj) with_7\IN|administration (r_prep) connection_6\NN|with|during (l_prep) during_10\IN|abortions (l_pobj) abortions_14\NNS|induced
D010121_D000031 NONE Oxytocin_0\NN| (r_compound) administration_1\NN|oxytocin|during (l_prep) during_2\IN|abortions (l_pobj) abortions_6\NNS|induced
D010121_D001247 NONE Oxytocin_0\NN| (r_compound) administration_1\NN|oxytocin|during (r_nsubjpass) advocated_8\VBN|administration|is|carried|. (l_advcl) carried_14\VBN|only|if|it|can|be|out|under|,|aware|and|instructed (l_conj) instructed_33\VBD|watch (l_xcomp) watch_35\VB|to|diuresis|and|report (l_conj) report_39\VB|signs (l_dobj) signs_42\NNS|such|early|of|as (l_prep) as_46\IN|asthenia (l_pobj) asthenia_47\NNP|,|irritability
D010121_D001523 NONE Oxytocin_0\NN| (r_compound) administration_1\NN|oxytocin|during (r_nsubjpass) advocated_8\VBN|administration|is|carried|. (l_advcl) carried_14\VBN|only|if|it|can|be|out|under|,|aware|and|instructed (l_conj) instructed_33\VBD|watch (l_xcomp) watch_35\VB|to|diuresis|and|report (l_conj) report_39\VB|signs (l_dobj) signs_42\NNS|such|early|of|as (l_prep) as_46\IN|asthenia (l_pobj) asthenia_47\NNP|,|irritability (l_conj) irritability_50\NN|muscular|,|or|headaches
D010121_D006261 NONE Oxytocin_0\NN| (r_compound) administration_1\NN|oxytocin|during (r_nsubjpass) advocated_8\VBN|administration|is|carried|. (l_advcl) carried_14\VBN|only|if|it|can|be|out|under|,|aware|and|instructed (l_conj) instructed_33\VBD|watch (l_xcomp) watch_35\VB|to|diuresis|and|report (l_conj) report_39\VB|signs (l_dobj) signs_42\NNS|such|early|of|as (l_prep) as_46\IN|asthenia (l_pobj) asthenia_47\NNP|,|irritability (l_conj) irritability_50\NN|muscular|,|or|headaches (l_conj) headaches_53\NNS|
8268147
D010396_D017285 CID penicillamine_15\NN|d|- (r_pobj) with_12\IN|penicillamine (r_prep) treated_11\VBN|with (r_acl) cirrhosis_10\NN|primary|biliary|treated (r_pobj) with_7\IN|cirrhosis (r_prep) patient_6\NN|a|with (r_pobj) in_4\IN|patient (r_prep) case_1\NN|a|of|in|. (l_prep) of_2\IN|polymyositis (l_pobj) polymyositis_3\NN|
D010396_D017285 CID penicillamine_14\NN|d|- (r_compound) treatment_15\NN|penicillamine (r_pobj) of_11\IN|treatment (r_prep) complications_10\NNS|the|autoimmune|of (r_pobj) of_7\IN|complications (r_prep) one_6\CD|of (r_pobj) as_5\IN|one (r_prep) develop_4\VB|dermatomyositis|can|as|,|but|remains (l_nsubj) dermatomyositis_2\NN|polymyositis|/ (l_nmod) Polymyositis_0\NNP|
D010396_D017285 CID penicillamine_16\NN|d|- (r_compound) therapy_17\NN|penicillamine (r_dobj) receiving_13\VBG|while|therapy (r_advcl) developed_10\VBD|who|polymyositis|receiving (l_dobj) polymyositis_11\NN|
D010396_D017285 CID penicillamine_4\NN|d|- (r_compound) therapy_5\NN|penicillamine (r_dobj) receiving_1\VBG|therapy (r_acl) Patients_0\NNS|receiving (r_nsubjpass) followed_8\VBN|patients|should|be|carefully|for|. (l_prep) for_10\IN|development (l_pobj) development_12\NN|the|of (l_prep) of_13\IN|complications (l_pobj) complications_15\NNS|autoimmune|like (l_prep) like_16\IN|dermatomyositis (l_pobj) dermatomyositis_19\NN|polymyositis|/ (l_nmod) polymyositis_17\NN|
D010396_D008105 NONE penicillamine_15\NN|d|- (r_pobj) with_12\IN|penicillamine (r_prep) treated_11\VBN|with (r_acl) cirrhosis_10\NN|primary|biliary|treated
D010396_D008105 NONE penicillamine_16\NN|d|- (r_compound) therapy_17\NN|penicillamine (r_dobj) receiving_13\VBG|while|therapy (r_advcl) developed_10\VBD|who|polymyositis|receiving (r_relcl) cirrhosis_7\NN|primary|biliary|,|developed
D010396_D012216 NONE penicillamine_3\NN|d|- (r_nsubjpass) used_6\VBN|although|penicillamine|has|been|for (l_prep) for_7\IN|diseases (l_pobj) diseases_10\NNS|many|rheumatologic
D010396_D064420 NONE penicillamine_3\NN|d|- (r_nsubjpass) used_6\VBN|although|penicillamine|has|been|for (r_advcl) limits_13\VBZ|used|,|toxicity|usefulness|. (l_nsubj) toxicity_12\NN|
D010396_D003882 NONE penicillamine_14\NN|d|- (r_compound) treatment_15\NN|penicillamine (r_pobj) of_11\IN|treatment (r_prep) complications_10\NNS|the|autoimmune|of (r_pobj) of_7\IN|complications (r_prep) one_6\CD|of (r_pobj) as_5\IN|one (r_prep) develop_4\VB|dermatomyositis|can|as|,|but|remains (l_nsubj) dermatomyositis_2\NN|polymyositis|/
D010396_D003882 NONE penicillamine_4\NN|d|- (r_compound) therapy_5\NN|penicillamine (r_dobj) receiving_1\VBG|therapy (r_acl) Patients_0\NNS|receiving (r_nsubjpass) followed_8\VBN|patients|should|be|carefully|for|. (l_prep) for_10\IN|development (l_pobj) development_12\NN|the|of (l_prep) of_13\IN|complications (l_pobj) complications_15\NNS|autoimmune|like (l_prep) like_16\IN|dermatomyositis (l_pobj) dermatomyositis_19\NN|polymyositis|/
7282516
D004317_D009202 CID doxorubicin_9\NN| (r_compound) cardiomyopathy_10\NN|doxorubicin
D004317_D009202 CID doxorubicin_10\NN|cm|dxr|) (l_nsubj) CM_3\NNP|the|cardiomyopathy|(|)|produced (l_amod) cardiomyopathy_1\NN|
D004317_D009202 CID doxorubicin_10\NN|cm|dxr|) (l_nsubj) CM_3\NNP|the|cardiomyopathy|(|)|produced
D004317_D009202 CID DXR_12\NN|( (r_appos) doxorubicin_10\NN|cm|dxr|) (l_nsubj) CM_3\NNP|the|cardiomyopathy|(|)|produced (l_amod) cardiomyopathy_1\NN|
D004317_D009202 CID DXR_12\NN|( (r_appos) doxorubicin_10\NN|cm|dxr|) (l_nsubj) CM_3\NNP|the|cardiomyopathy|(|)|produced
D004317_D009202 CID Adriamycin_1\NNP| (r_nsubj) provides_3\VBZ|(|adriamycin|)|opportunity|. (l_dobj) opportunity_6\NN|a|unique|analyze (l_acl) analyze_8\VB|to|relationships (l_dobj) relationships_16\NNS|effect|during (l_prep) during_17\IN|development (l_pobj) development_18\NN|of (l_prep) of_19\IN|disease (l_pobj) disease_21\NN|myocardial
D004317_D009202 CID DXR_1\NNP| (r_compound) CM_3\NNP|dxr|-
D004317_D009202 CID DXR_1\NNP| (r_compound) CM_3\NNP|dxr|- (r_nmod) damage_5\NN|cm|myocardial
D004317_D009202 CID DXR_15\NNP| (r_compound) dose_16\NN|dxr (r_appos) insult_13\NN|cytotoxic|(|dose|) (r_pobj) of_11\IN|insult (r_prep) degree_10\NN|the|of (r_pobj) to_8\IN|degree (r_prep) proportional_7\JJ|to (r_acomp) is_6\VBZ|in|proportional|preserved|. (l_prep) In_0\IN|damage (l_pobj) damage_5\NN|cm|myocardial (l_nmod) CM_3\NNP|dxr|-
D004317_D009202 CID DXR_15\NNP| (r_compound) dose_16\NN|dxr (r_appos) insult_13\NN|cytotoxic|(|dose|) (r_pobj) of_11\IN|insult (r_prep) degree_10\NN|the|of (r_pobj) to_8\IN|degree (r_prep) proportional_7\JJ|to (r_acomp) is_6\VBZ|in|proportional|preserved|. (l_prep) In_0\IN|damage (l_pobj) damage_5\NN|cm|myocardial
326460
D001539_D007008 CID bendrofluazide_2\NN| (r_advmod) induced_4\VBN|bendrofluazide|- (r_amod) hypokalemia_5\NN|induced
D001539_D007008 CID bendrofluazide_17\NN| (r_amod) treatment_18\NN|term|bendrofluazide|in (r_pobj) of_13\IN|treatment (r_prep) hypokalemia_12\NN|the|of
D013999_D007008 NONE timolol_7\NN| (r_pobj) by_6\IN|timolol (r_prep) Amelioration_0\NN|of|by|. (l_prep) of_1\IN|hypokalemia (l_pobj) hypokalemia_5\NN|induced
D013999_D007008 NONE timolol_6\NN| (r_appos) drug_4\NN|the|beta|blocking|,|timolol|, (r_nsubj) tended_8\VBD|drug|correct|and|was (l_xcomp) correct_10\VB|to|hypokalemia (l_dobj) hypokalemia_12\NN|the|of
15517007
D003520_D006331 CID cyclophosphamide_6\NN|or|anthracyclines (r_nsubjpass) used_13\VBN|when|cyclophosphamide|are|in|,|for|,|patients (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|damage (l_pobj) damage_21\NN|a|possible|underlying|heart
D003520_D012595 NONE cyclophosphamide_6\NN|or|anthracyclines (r_nsubjpass) used_13\VBN|when|cyclophosphamide|are|in|,|for|,|patients (l_dobj) patients_28\NNS|systemic|sclerosis (l_compound) sclerosis_27\NN|
D018943_D006331 NONE anthracyclines_8\NNS|as (r_conj) cyclophosphamide_6\NN|or|anthracyclines (r_nsubjpass) used_13\VBN|when|cyclophosphamide|are|in|,|for|,|patients (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|damage (l_pobj) damage_21\NN|a|possible|underlying|heart
D018943_D012595 NONE anthracyclines_8\NNS|as (r_conj) cyclophosphamide_6\NN|or|anthracyclines (r_nsubjpass) used_13\VBN|when|cyclophosphamide|are|in|,|for|,|patients (l_dobj) patients_28\NNS|systemic|sclerosis (l_compound) sclerosis_27\NN|
D008942_D006331 CID mitoxantrone_11\NN| (r_pobj) as_10\IN|such|mitoxantrone (r_prep) anthracyclines_8\NNS|as (r_conj) cyclophosphamide_6\NN|or|anthracyclines (r_nsubjpass) used_13\VBN|when|cyclophosphamide|are|in|,|for|,|patients (l_prep) in_14\IN|patients (l_pobj) patients_15\NNS|with (l_prep) with_16\IN|damage (l_pobj) damage_21\NN|a|possible|underlying|heart
D008942_D012595 NONE mitoxantrone_11\NN| (r_pobj) as_10\IN|such|mitoxantrone (r_prep) anthracyclines_8\NNS|as (r_conj) cyclophosphamide_6\NN|or|anthracyclines (r_nsubjpass) used_13\VBN|when|cyclophosphamide|are|in|,|for|,|patients (l_dobj) patients_28\NNS|systemic|sclerosis (l_compound) sclerosis_27\NN|
8267029
D010396_D005921 CID Penicillamine_0\NN| (r_nsubj) induced_2\VBN|penicillamine|-|glomerulonephritis|in|. (l_dobj) glomerulonephritis_5\NN|progressive
D010396_D005921 CID penicillamine_21\NN|d|- (r_nmod) treatment_28\NN|penicillamine|(|day|) (r_pobj) of_18\IN|treatment (r_prep) months_17\NNS|5|of (r_pobj) after_15\IN|months (r_prep) presented_8\VBD|woman|glomerulonephritis|after|. (l_dobj) glomerulonephritis_11\NN|progressive|rpgn
D010396_D005921 CID penicillamine_21\NN|d|- (r_nmod) treatment_28\NN|penicillamine|(|day|) (r_pobj) of_18\IN|treatment (r_prep) months_17\NNS|5|of (r_pobj) after_15\IN|months (r_prep) presented_8\VBD|woman|glomerulonephritis|after|. (l_dobj) glomerulonephritis_11\NN|progressive|rpgn (l_appos) RPGN_13\NNP|(|)
D010396_D005921 CID penicillamine_11\NN|d|- (r_compound) treatment_12\NN|penicillamine (r_pobj) of_8\IN|treatment (r_prep) course_7\NN|the|of (r_pobj) in_5\IN|course (r_prep) case_2\NN|this|new|of|in (l_prep) of_3\IN|rpgn (l_pobj) RPGN_4\NNP|
D010396_D001172 NONE Penicillamine_0\NN| (r_nsubj) induced_2\VBN|penicillamine|-|glomerulonephritis|in|. (l_prep) in_6\IN|patient (l_pobj) patient_8\NN|a|with (l_prep) with_9\IN|arthritis (l_pobj) arthritis_11\NN|rheumatoid
D010396_D001172 NONE penicillamine_21\NN|d|- (r_nmod) treatment_28\NN|penicillamine|(|day|) (r_pobj) of_18\IN|treatment (r_prep) months_17\NNS|5|of (r_pobj) after_15\IN|months (r_prep) presented_8\VBD|woman|glomerulonephritis|after|. (l_nsubj) woman_4\NN|a|old|with (l_prep) with_5\IN|arthritis (l_pobj) arthritis_7\NN|rheumatoid
D010396_D011507 NONE penicillamine_11\NN|d|- (r_compound) treatment_12\NN|penicillamine (r_pobj) of_8\IN|treatment (r_prep) course_7\NN|the|of (r_pobj) in_5\IN|course (r_prep) case_2\NN|this|new|of|in (r_nsubj) emphasizes_13\VBZ|case|need|. (l_dobj) need_15\NN|the|for (l_prep) for_16\IN|monitoring (l_pobj) monitoring_18\NN|frequent|of (l_prep) of_19\IN|function (l_pobj) function_21\NN|renal|and|evaluation (l_conj) evaluation_23\NN|of (l_prep) of_24\IN|sediment (l_pobj) sediment_26\NN|urinary|and|proteinuria|in (l_conj) proteinuria_28\NN|
3762968
D014042_D014899 CID tolazamide_3\NN| (r_npadvmod) induced_5\VBN|tolazamide|- (r_amod) encephalopathy_8\NN|induced|wernicke
D014042_D014899 CID tolazamide_24\NN| (r_pobj) with_23\IN|tolazamide (r_prep) treated_22\VBN|when|with (r_advcl) developed_17\VBD|who|encephalopathy|treated (l_dobj) encephalopathy_20\NN|wernicke
D014042_D014899 CID tolazamide_15\NN| (r_npadvmod) induced_17\VBN|tolazamide|- (r_amod) encephalopathy_20\NN|induced|wernicke|from
D013831_D003920 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|thiamine|- (r_amod) enzyme_6\NN|a|dependent|,|transketolase|, (r_dobj) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) from_10\IN|fibroblasts (l_pobj) fibroblasts_11\NNS|of (l_prep) of_12\IN|patient (l_pobj) patient_15\NN|a|diabetic|developed (l_amod) diabetic_14\JJ|
D013831_D014899 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|thiamine|- (r_amod) enzyme_6\NN|a|dependent|,|transketolase|, (r_dobj) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) from_10\IN|fibroblasts (l_pobj) fibroblasts_11\NNS|of (l_prep) of_12\IN|patient (l_pobj) patient_15\NN|a|diabetic|developed (l_relcl) developed_17\VBD|who|encephalopathy|treated (l_dobj) encephalopathy_20\NN|wernicke
D013831_D020915 NONE thiamine_3\NN| (r_npadvmod) dependent_5\JJ|thiamine|- (r_amod) enzyme_6\NN|a|dependent|,|transketolase|, (r_dobj) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) in_26\IN|order (l_pobj) order_27\NN|delineate (l_acl) delineate_29\VB|to|had (l_ccomp) had_34\VBD|if|patient|also|abnormality|,|reported (l_advcl) reported_50\VBN|as|previously|in (l_prep) in_51\IN|syndrome (l_pobj) syndrome_56\NN|postalcoholic|korsakoff
D014042_D003920 NONE tolazamide_24\NN| (r_pobj) with_23\IN|tolazamide (r_prep) treated_22\VBN|when|with (r_advcl) developed_17\VBD|who|encephalopathy|treated (r_relcl) patient_15\NN|a|diabetic|developed (l_amod) diabetic_14\JJ|
D014042_D020915 NONE tolazamide_24\NN| (r_pobj) with_23\IN|tolazamide (r_prep) treated_22\VBN|when|with (r_advcl) developed_17\VBD|who|encephalopathy|treated (r_relcl) patient_15\NN|a|diabetic|developed (r_pobj) of_12\IN|patient (r_prep) fibroblasts_11\NNS|of (r_pobj) from_10\IN|fibroblasts (r_prep) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) in_26\IN|order (l_pobj) order_27\NN|delineate (l_acl) delineate_29\VB|to|had (l_ccomp) had_34\VBD|if|patient|also|abnormality|,|reported (l_advcl) reported_50\VBN|as|previously|in (l_prep) in_51\IN|syndrome (l_pobj) syndrome_56\NN|postalcoholic|korsakoff
D014042_D020915 NONE tolazamide_15\NN| (r_npadvmod) induced_17\VBN|tolazamide|- (r_amod) encephalopathy_20\NN|induced|wernicke|from (r_pobj) with_14\IN|encephalopathy (r_prep) patient_13\NN|the|with (r_conj) syndrome_10\NN|postalcoholic|korsakoff|and|patient
D013835_D003920 NONE pyrophosphate_42\NN|thiamine|(|tpp|) (r_pobj) for_40\IN|pyrophosphate (r_prep) Km_39\NNP|[|high|for|] (r_appos) abnormality_36\NN|transketolase|km (r_dobj) had_34\VBD|if|patient|also|abnormality|,|reported (r_ccomp) delineate_29\VB|to|had (r_acl) order_27\NN|delineate (r_pobj) in_26\IN|order (r_prep) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) from_10\IN|fibroblasts (l_pobj) fibroblasts_11\NNS|of (l_prep) of_12\IN|patient (l_pobj) patient_15\NN|a|diabetic|developed (l_amod) diabetic_14\JJ|
D013835_D003920 NONE TPP_44\NNP| (r_appos) pyrophosphate_42\NN|thiamine|(|tpp|) (r_pobj) for_40\IN|pyrophosphate (r_prep) Km_39\NNP|[|high|for|] (r_appos) abnormality_36\NN|transketolase|km (r_dobj) had_34\VBD|if|patient|also|abnormality|,|reported (r_ccomp) delineate_29\VB|to|had (r_acl) order_27\NN|delineate (r_pobj) in_26\IN|order (r_prep) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) from_10\IN|fibroblasts (l_pobj) fibroblasts_11\NNS|of (l_prep) of_12\IN|patient (l_pobj) patient_15\NN|a|diabetic|developed (l_amod) diabetic_14\JJ|
D013835_D003920 NONE TPP_30\NNP| (r_pobj) for_29\IN|tpp (r_prep) Km_28\NNP|its|for (r_pobj) by_26\IN|km (r_agent) determined_25\VBN|as|by (r_advcl) had_21\VBD|that|patient|transketolase|determined (l_nsubj) patient_7\NN|the|mentioned|and|one|with (l_conj) one_9\CD|of (l_prep) of_10\IN|kindreds (l_pobj) kindreds_13\NNS|the|diabetic (l_amod) diabetic_12\JJ|
D013835_D014899 NONE pyrophosphate_42\NN|thiamine|(|tpp|) (r_pobj) for_40\IN|pyrophosphate (r_prep) Km_39\NNP|[|high|for|] (r_appos) abnormality_36\NN|transketolase|km (r_dobj) had_34\VBD|if|patient|also|abnormality|,|reported (r_ccomp) delineate_29\VB|to|had (r_acl) order_27\NN|delineate (r_pobj) in_26\IN|order (r_prep) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) from_10\IN|fibroblasts (l_pobj) fibroblasts_11\NNS|of (l_prep) of_12\IN|patient (l_pobj) patient_15\NN|a|diabetic|developed (l_relcl) developed_17\VBD|who|encephalopathy|treated (l_dobj) encephalopathy_20\NN|wernicke
D013835_D014899 NONE TPP_44\NNP| (r_appos) pyrophosphate_42\NN|thiamine|(|tpp|) (r_pobj) for_40\IN|pyrophosphate (r_prep) Km_39\NNP|[|high|for|] (r_appos) abnormality_36\NN|transketolase|km (r_dobj) had_34\VBD|if|patient|also|abnormality|,|reported (r_ccomp) delineate_29\VB|to|had (r_acl) order_27\NN|delineate (r_pobj) in_26\IN|order (r_prep) studied_1\VBD|we|enzyme|from|,|in|. (l_prep) from_10\IN|fibroblasts (l_pobj) fibroblasts_11\NNS|of (l_prep) of_12\IN|patient (l_pobj) patient_15\NN|a|diabetic|developed (l_relcl) developed_17\VBD|who|encephalopathy|treated (l_dobj) encephalopathy_20\NN|wernicke
D013835_D014899 NONE TPP_30\NNP| (r_pobj) for_29\IN|tpp (r_prep) Km_28\NNP|its|for (r_pobj) by_26\IN|km (r_agent) determined_25\VBN|as|by (r_advcl) had_21\VBD|that|patient|transketolase|determined (l_nsubj) patient_7\NN|the|mentioned|and|one|with (l_prep) with_14\IN|history (l_pobj) history_16\NN|no|of (l_prep) of_17\IN|encephalopathy (l_pobj) encephalopathy_20\NN|wernicke
D013835_D020915 NONE pyrophosphate_42\NN|thiamine|(|tpp|) (r_pobj) for_40\IN|pyrophosphate (r_prep) Km_39\NNP|[|high|for|] (r_appos) abnormality_36\NN|transketolase|km (r_dobj) had_34\VBD|if|patient|also|abnormality|,|reported (l_advcl) reported_50\VBN|as|previously|in (l_prep) in_51\IN|syndrome (l_pobj) syndrome_56\NN|postalcoholic|korsakoff
D013835_D020915 NONE TPP_44\NNP| (r_appos) pyrophosphate_42\NN|thiamine|(|tpp|) (r_pobj) for_40\IN|pyrophosphate (r_prep) Km_39\NNP|[|high|for|] (r_appos) abnormality_36\NN|transketolase|km (r_dobj) had_34\VBD|if|patient|also|abnormality|,|reported (l_advcl) reported_50\VBN|as|previously|in (l_prep) in_51\IN|syndrome (l_pobj) syndrome_56\NN|postalcoholic|korsakoff
11694026
C012655_D014581 NONE nimesulide_2\NN|and|paracetamol (r_pobj) of_1\IN|nimesulide (r_prep) Tolerability_0\DT|of|in|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|angioedema (l_pobj) angioedema_13\NN|urticaria (l_nmod) urticaria_11\NN|induced|/
C012655_D014581 NONE nimesulide_9\NN|and|paracetamol (r_pobj) of_8\IN|nimesulide (r_prep) tolerability_5\NN|and|reliability|of (r_dobj) investigated_4\VBD|in|we|tolerability|in|. (l_prep) in_12\IN|number (l_pobj) number_16\NN|a|large|of (l_prep) of_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|history (l_pobj) history_25\NN|an|exclusive|documented|of (l_prep) of_26\IN|angioedema (l_pobj) angioedema_32\NN|urticaria|/ (l_nmod) urticaria_30\NN|induced
C012655_D014581 NONE nimesulide_10\NN|or|paracetamol (r_pobj) with_9\IN|nimesulide (r_prep) procedure_8\NN|a|controlled|oral|challenge|with (r_nsubjpass) applied_14\VBN|procedure|was|to|with|. (l_prep) with_18\IN|history (l_pobj) history_20\NN|a|of (l_prep) of_21\IN|angioedema (l_pobj) angioedema_27\NN|urticaria|/ (l_nmod) urticaria_25\NN|induced
C012655_D014581 NONE nimesulide_10\NN|and|paracetamol (r_pobj) of_9\IN|nimesulide (r_prep) tolerability_8\NN|the|good|of|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|experienced (l_relcl) experienced_16\VBD|who|angioedema (l_dobj) angioedema_19\NNP|urticaria|caused (l_nmod) urticaria_17\NN|/
C012655_D000799 CID nimesulide_2\NN|and|paracetamol (r_pobj) of_1\IN|nimesulide (r_prep) Tolerability_0\DT|of|in|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|angioedema (l_pobj) angioedema_13\NN|urticaria
C012655_D000799 CID nimesulide_9\NN|and|paracetamol (r_pobj) of_8\IN|nimesulide (r_prep) tolerability_5\NN|and|reliability|of (r_dobj) investigated_4\VBD|in|we|tolerability|in|. (l_prep) in_12\IN|number (l_pobj) number_16\NN|a|large|of (l_prep) of_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|history (l_pobj) history_25\NN|an|exclusive|documented|of (l_prep) of_26\IN|angioedema (l_pobj) angioedema_32\NN|urticaria|/
C012655_D000799 CID nimesulide_10\NN|or|paracetamol (r_pobj) with_9\IN|nimesulide (r_prep) procedure_8\NN|a|controlled|oral|challenge|with (r_nsubjpass) applied_14\VBN|procedure|was|to|with|. (l_prep) with_18\IN|history (l_pobj) history_20\NN|a|of (l_prep) of_21\IN|angioedema (l_pobj) angioedema_27\NN|urticaria|/
C012655_D000799 CID nimesulide_10\NN|and|paracetamol (r_pobj) of_9\IN|nimesulide (r_prep) tolerability_8\NN|the|good|of|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|experienced (l_relcl) experienced_16\VBD|who|angioedema (l_dobj) angioedema_19\NNP|urticaria|caused
D000082_D014581 NONE paracetamol_4\NN| (r_conj) nimesulide_2\NN|and|paracetamol (r_pobj) of_1\IN|nimesulide (r_prep) Tolerability_0\DT|of|in|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|angioedema (l_pobj) angioedema_13\NN|urticaria (l_nmod) urticaria_11\NN|induced|/
D000082_D014581 NONE paracetamol_11\NN| (r_conj) nimesulide_9\NN|and|paracetamol (r_pobj) of_8\IN|nimesulide (r_prep) tolerability_5\NN|and|reliability|of (r_dobj) investigated_4\VBD|in|we|tolerability|in|. (l_prep) in_12\IN|number (l_pobj) number_16\NN|a|large|of (l_prep) of_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|history (l_pobj) history_25\NN|an|exclusive|documented|of (l_prep) of_26\IN|angioedema (l_pobj) angioedema_32\NN|urticaria|/ (l_nmod) urticaria_30\NN|induced
D000082_D014581 NONE paracetamol_12\NNP| (r_conj) nimesulide_10\NN|or|paracetamol (r_pobj) with_9\IN|nimesulide (r_prep) procedure_8\NN|a|controlled|oral|challenge|with (r_nsubjpass) applied_14\VBN|procedure|was|to|with|. (l_prep) with_18\IN|history (l_pobj) history_20\NN|a|of (l_prep) of_21\IN|angioedema (l_pobj) angioedema_27\NN|urticaria|/ (l_nmod) urticaria_25\NN|induced
D000082_D014581 NONE paracetamol_12\NN| (r_conj) nimesulide_10\NN|and|paracetamol (r_pobj) of_9\IN|nimesulide (r_prep) tolerability_8\NN|the|good|of|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|experienced (l_relcl) experienced_16\VBD|who|angioedema (l_dobj) angioedema_19\NNP|urticaria|caused (l_nmod) urticaria_17\NN|/
D000082_D000799 CID paracetamol_4\NN| (r_conj) nimesulide_2\NN|and|paracetamol (r_pobj) of_1\IN|nimesulide (r_prep) Tolerability_0\DT|of|in|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|angioedema (l_pobj) angioedema_13\NN|urticaria
D000082_D000799 CID paracetamol_11\NN| (r_conj) nimesulide_9\NN|and|paracetamol (r_pobj) of_8\IN|nimesulide (r_prep) tolerability_5\NN|and|reliability|of (r_dobj) investigated_4\VBD|in|we|tolerability|in|. (l_prep) in_12\IN|number (l_pobj) number_16\NN|a|large|of (l_prep) of_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|history (l_pobj) history_25\NN|an|exclusive|documented|of (l_prep) of_26\IN|angioedema (l_pobj) angioedema_32\NN|urticaria|/
D000082_D000799 CID paracetamol_12\NNP| (r_conj) nimesulide_10\NN|or|paracetamol (r_pobj) with_9\IN|nimesulide (r_prep) procedure_8\NN|a|controlled|oral|challenge|with (r_nsubjpass) applied_14\VBN|procedure|was|to|with|. (l_prep) with_18\IN|history (l_pobj) history_20\NN|a|of (l_prep) of_21\IN|angioedema (l_pobj) angioedema_27\NN|urticaria|/
D000082_D000799 CID paracetamol_12\NN| (r_conj) nimesulide_10\NN|and|paracetamol (r_pobj) of_9\IN|nimesulide (r_prep) tolerability_8\NN|the|good|of|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|experienced (l_relcl) experienced_16\VBD|who|angioedema (l_dobj) angioedema_19\NNP|urticaria|caused
D000894_D014581 NONE NSAID_8\NNP| (r_npadvmod) induced_10\VBN|nsaid|- (r_amod) urticaria_11\NN|induced|/
D000894_D014581 NONE NSAID_27\NNP| (r_npadvmod) induced_29\VBN|nsaid|- (r_amod) urticaria_30\NN|induced
D000894_D014581 NONE NSAID_22\NNP| (r_npadvmod) induced_24\VBN|nsaid|- (r_amod) urticaria_25\NN|induced
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|nsaid|- (r_amod) urticaria_24\NN|induced|/ (r_nmod) angioedema_26\NN|urticaria|or|angioedema|alone|( (r_pobj) of_20\IN|angioedema (r_prep) history_19\NN|an|of|with (r_pobj) with_17\IN|history (r_prep) subjects_16\NNS|with (r_pobj) of_15\IN|subjects (r_prep) %_14\NN|11.8|of (r_conj) history_8\NN|a|of|and|% (l_prep) of_9\IN|urticaria (l_pobj) urticaria_11\NN|chronic
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|nsaid|- (r_amod) urticaria_24\NN|induced|/
D000894_D014581 NONE NSAID_21\NNP| (r_npadvmod) induced_23\VBN|nsaid|- (r_amod) urticaria_24\NN|induced|/ (r_nmod) angioedema_26\NN|urticaria|or|angioedema|alone|( (r_pobj) of_20\IN|angioedema (r_prep) history_19\NN|an|of|with (l_prep) with_31\IN|or|without (l_conj) without_33\IN|urticaria (l_pobj) urticaria_35\NN|chronic
D000894_D014581 NONE NSAIDs_22\NNS| (r_pobj) by_21\IN|nsaids (r_agent) caused_20\VBN|by (r_acl) angioedema_19\NNP|urticaria|caused (l_nmod) urticaria_17\NN|/
D000894_D014581 NONE NSAID_29\NNP| (r_npadvmod) induced_31\VBN|nsaid|- (r_amod) angioedema_32\NN|induced (r_pobj) of_28\IN|angioedema (r_prep) history_27\NN|a|of (r_pobj) by_25\IN|history (r_prep) increased_13\VBN|however|,|risk|is|statistically|by|and|,|all|,|by|. (l_agent) by_14\IN|history (l_pobj) history_16\NN|a|of (l_prep) of_17\IN|urticaria (l_pobj) urticaria_19\NN|chronic
D000894_D000799 CID NSAID_8\NNP| (r_npadvmod) induced_10\VBN|nsaid|- (r_amod) urticaria_11\NN|induced|/ (r_nmod) angioedema_13\NN|urticaria
D000894_D000799 CID NSAID_27\NNP| (r_npadvmod) induced_29\VBN|nsaid|- (r_amod) urticaria_30\NN|induced (r_nmod) angioedema_32\NN|urticaria|/
D000894_D000799 CID NSAID_22\NNP| (r_npadvmod) induced_24\VBN|nsaid|- (r_amod) urticaria_25\NN|induced (r_nmod) angioedema_27\NN|urticaria|/
D000894_D000799 CID NSAID_21\NNP| (r_npadvmod) induced_23\VBN|nsaid|- (r_amod) urticaria_24\NN|induced|/ (r_nmod) angioedema_26\NN|urticaria|or|angioedema|alone|(
D000894_D000799 CID NSAID_21\NNP| (r_npadvmod) induced_23\VBN|nsaid|- (r_amod) urticaria_24\NN|induced|/ (r_nmod) angioedema_26\NN|urticaria|or|angioedema|alone|( (l_conj) angioedema_28\NN|
D000894_D000799 CID NSAIDs_22\NNS| (r_pobj) by_21\IN|nsaids (r_agent) caused_20\VBN|by (r_acl) angioedema_19\NNP|urticaria|caused
D000894_D000799 CID NSAID_29\NNP| (r_npadvmod) induced_31\VBN|nsaid|- (r_amod) angioedema_32\NN|induced
11063349
D020123_D064420 NONE RAPA_11\NNP| (r_compound) conversion_12\NN|rapa|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|undergoing (l_acl) undergoing_15\VBG|cyclosporine (l_dobj) cyclosporine_16\NN|csa (l_appos) CsA_18\NNP|(|)|or|toxicity (l_conj) toxicity_25\NN|tacrolimus|(|tac|)
D016572_D064420 NONE cyclosporine_16\NN|csa (l_appos) CsA_18\NNP|(|)|or|toxicity (l_conj) toxicity_25\NN|tacrolimus|(|tac|)
D016572_D064420 NONE CsA_18\NNP|(|)|or|toxicity (l_conj) toxicity_25\NN|tacrolimus|(|tac|)
D016572_D064420 NONE CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) toxicity_18\NN|tac
D016572_D064420 NONE CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) toxicity_18\NN|tac
D016559_D064420 NONE tacrolimus_21\NN| (r_nmod) toxicity_25\NN|tacrolimus|(|tac|)
D016559_D064420 NONE Tac_23\NN| (r_nmod) toxicity_25\NN|tacrolimus|(|tac|)
D016559_D064420 NONE Tac_8\NNP| (r_compound) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) toxicity_18\NN|tac
D016559_D064420 NONE Tac_17\NNP| (r_compound) toxicity_18\NN|tac
D016572_D007674 CID CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder
D016572_D007674 CID CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder
D016572_-1 NONE CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) dysmorphism_25\NN|severe|facial|(|2|)
D016572_-1 NONE CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) dysmorphism_25\NN|severe|facial|(|2|)
D016572_D008232 NONE CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|)
D016572_D008232 NONE CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|) (l_appos) PTLD_34\NN|
D016572_D008232 NONE CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|)
D016572_D008232 NONE CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|) (l_appos) PTLD_34\NN|
D016572_D056486 NONE CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN|in
D016572_D056486 NONE CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (r_conj) CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN|in
D016559_D007674 CID Tac_8\NNP| (r_compound) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder
D016559_D007674 CID Tac_17\NNP| (r_compound) toxicity_18\NN|tac (r_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder
D016559_-1 NONE Tac_8\NNP| (r_compound) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) dysmorphism_25\NN|severe|facial|(|2|)
D016559_-1 NONE Tac_17\NNP| (r_compound) toxicity_18\NN|tac (r_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (l_conj) dysmorphism_25\NN|severe|facial|(|2|)
D016559_D008232 NONE Tac_8\NNP| (r_compound) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|)
D016559_D008232 NONE Tac_8\NNP| (r_compound) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|) (l_appos) PTLD_34\NN|
D016559_D008232 NONE Tac_17\NNP| (r_compound) toxicity_18\NN|tac (r_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|)
D016559_D008232 NONE Tac_17\NNP| (r_compound) toxicity_18\NN|tac (r_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (l_conj) disorder_32\NN|posttransplant|lymphoproliferative|(|ptld|) (l_appos) PTLD_34\NN|
D016559_D056486 NONE Tac_8\NNP| (r_compound) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (r_conj) CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN|in
D016559_D056486 NONE Tac_17\NNP| (r_compound) toxicity_18\NN|tac (r_conj) CsA_15\NNP|acute|or|toxicity|3|,|dysmorphism (r_conj) nephrotoxicity_9\NN|tac|12|,|csa|,|disorder (r_conj) CsA_6\NNP|chronic|or|nephrotoxicity|in|,|and|hepatotoxicity (l_conj) hepatotoxicity_43\NN|in
D003404_D007674 NONE creatinine_17\NN|serum (r_pobj) in_15\IN|creatinine (r_prep) decrease_14\NN|a|significant|in|233+/-34|to|at (r_attr) was_11\VBD|:|in|there|decrease|]|. (l_prep) In_1\IN|patients (l_pobj) patients_4\NNS|the|12|switched (l_acl) switched_5\VBD|because (l_prep) because_6\IN|of|nephrotoxicity (l_pobj) nephrotoxicity_9\NN|chronic
D020123_D011014 NONE RAPA_0\NNP| (r_nsubjpass) discontinued_2\VBN|rapa|was|in|,|because|ptld|. (l_prep) because_7\IN|of|pneumonia (l_pobj) pneumonia_9\NN|in
D020123_D008232 NONE RAPA_0\NNP| (r_nsubjpass) discontinued_2\VBN|rapa|was|in|,|because|ptld|. (l_appos) PTLD_13\NN|,|in|,|and|ulcers
D020123_D013281 NONE RAPA_0\NNP| (r_nsubjpass) discontinued_2\VBN|rapa|was|in|,|because|ptld|. (l_appos) PTLD_13\NN|,|in|,|and|ulcers (l_conj) ulcers_20\NNS|oral|aphtous|in
D020123_D011020 NONE RAPA_6\NNP| (r_compound) levels_8\NNS|rapa|drug (r_pobj) to_5\IN|levels (r_prep) converting_3\VBG|when|patients|to (r_csubjpass) monitored_11\VBN|however|,|converting|should|be|avoid|over (r_advcl) given_27\VBN|monitored|prophylaxis|should|be|. (l_nsubjpass) prophylaxis_24\NN|pneumonia (l_compound) pneumonia_23\NN|carinii
17574447
D010634_-1 NONE phenobarbital_8\JJ| (r_amod) therapy_9\NN|term|phenobarbital|:|report (r_pobj) to_4\IN|therapy (r_prep) related_3\VBN|to (r_acl) Hepatonecrosis_0\NNP|and|cholangitis|related|.
D010634_D002761 CID phenobarbital_8\JJ| (r_amod) therapy_9\NN|term|phenobarbital|:|report (r_pobj) to_4\IN|therapy (r_prep) related_3\VBN|to (r_acl) Hepatonecrosis_0\NNP|and|cholangitis|related|. (l_conj) cholangitis_2\NN|
D010634_D008107 CID Phenobarbital_0\NNP|(|pb|) (r_nsubj) has_4\VBZ|phenobarbital|reputation|,|and|believed (l_conj) believed_14\VBN|it|is|commonly|indicate|. (l_ccomp) indicate_26\VB|that|increases|do|not|or|predict (l_conj) predict_28\VB|development (l_dobj) development_30\NN|the|of (l_prep) of_31\IN|disease (l_pobj) disease_35\NN|significant|chronic|liver
D010634_D008107 CID PB_2\NNP| (r_appos) Phenobarbital_0\NNP|(|pb|) (r_nsubj) has_4\VBZ|phenobarbital|reputation|,|and|believed (l_conj) believed_14\VBN|it|is|commonly|indicate|. (l_ccomp) indicate_26\VB|that|increases|do|not|or|predict (l_conj) predict_28\VB|development (l_dobj) development_30\NN|the|of (l_prep) of_31\IN|disease (l_pobj) disease_35\NN|significant|chronic|liver
D010634_D008107 CID PB_16\NNP| (r_npadvmod) related_18\VBN|pb|- (r_amod) increases_19\NNS|related|in (r_nsubj) indicate_26\VB|that|increases|do|not|or|predict (l_conj) predict_28\VB|development (l_dobj) development_30\NN|the|of (l_prep) of_31\IN|disease (l_pobj) disease_35\NN|significant|chronic|liver
D010634_D008107 CID PB_4\NNP| (r_nsubjpass) associated_7\VBN|that|pb|may|be|with (l_prep) with_8\IN|damage (l_pobj) damage_11\NN|chronic|liver|,|lead
D010634_D004827 NONE PB_15\NNP|died (r_pobj) with_14\IN|pb (r_prep) treated_13\VBN|with (r_acl) history_10\NN|a|long|of|treated (l_prep) of_11\IN|epilepsy (l_pobj) epilepsy_12\NN|
D010634_D006323 NONE PB_15\NNP|died (r_pobj) with_14\IN|pb (r_prep) treated_13\VBN|with (r_acl) history_10\NN|a|long|of|treated (r_pobj) with_7\IN|history (r_prep) report_2\VBP|here|we|of|with|:|one|. (l_appos) one_20\CD|as|,|other (l_prep) as_21\IN|consequence (l_pobj) consequence_22\NN|of (l_prep) of_23\IN|arrest (l_pobj) arrest_25\NN|cardiac
D010634_D001996 NONE PB_15\NNP|died (r_pobj) with_14\IN|pb (r_prep) treated_13\VBN|with (r_acl) history_10\NN|a|long|of|treated (r_pobj) with_7\IN|history (r_prep) report_2\VBP|here|we|of|with|:|one|. (l_appos) one_20\CD|as|,|other (l_appos) other_28\JJ|the|of (l_prep) of_29\IN|bronchopneumonia (l_pobj) bronchopneumonia_31\NN|acute
D010634_D056487 NONE PB_15\NNP| (r_npadvmod) related_17\VBN|pb|- (r_amod) dysfunction_22\NN|related|asymptomatic|chronic|enzyme
7651879
D005442_D012640 CID flumazenil_2\JJ| (r_compound) administration_3\NN|flumazenil|in (r_pobj) after_1\IN|administration (r_prep) Seizure_0\NN|after|.
D005442_D012640 CID flumazenil_19\JJ| (r_pobj) of_18\IN|flumazenil (r_prep) administration_17\NN|the|of (r_pobj) following_15\VBG|administration (r_acl) patient_14\NN|a|pediatric|following (r_pobj) in_11\IN|patient (r_prep) seizure_10\NN|a|generalized|clonic|in
D005442_D012131 NONE Flumazenil_0\NNP| (r_nsubj) is_1\VBZ|flumazenil|antagonist|. (l_attr) antagonist_5\NN|a|benzodiazepine|receptor|used (l_acl) used_6\VBD|reverse (l_xcomp) reverse_8\VB|to|sedation (l_dobj) sedation_9\NN|and|depression|induced (l_conj) depression_12\NN|respiratory
D001569_D012131 NONE benzodiazepine_3\JJ| (r_amod) antagonist_5\NN|a|benzodiazepine|receptor|used (l_acl) used_6\VBD|reverse (l_xcomp) reverse_8\VB|to|sedation (l_dobj) sedation_9\NN|and|depression|induced (l_conj) depression_12\NN|respiratory
D001569_D012131 NONE benzodiazepines_15\NNS| (r_pobj) by_14\IN|benzodiazepines (r_agent) induced_13\VBN|by (r_acl) sedation_9\NN|and|depression|induced (l_conj) depression_12\NN|respiratory
18627295
D004317_D009202 CID Doxorubicin_0\NNP|inflammation|and|apoptosis (l_dobj) inflammation_4\NN|induced (l_amod) induced_3\VBN|cardiomyopathy|- (l_npadvmod) cardiomyopathy_1\NN|
D004317_D009202 CID DOX_17\NNP| (r_compound) cardiomyopathy_18\NN|dox
D004317_D009202 CID DOX_17\NNP| (r_compound) cardiomyopathy_18\NN|dox (r_pobj) of_16\IN|cardiomyopathy (r_prep) development_15\NN|the|of (r_pobj) during_13\IN|development (r_prep) elucidate_1\VB|to|role|)|during (r_advcl) studied_21\VBD|elucidate|,|we|mice|by|. (l_prep) by_29\IN|investigating (l_pcomp) investigating_30\VBG|inflammation|and|apoptosis (l_conj) apoptosis_34\NN|after (l_prep) after_35\IN|induction (l_pobj) induction_36\NN|of (l_prep) of_37\IN|cardiomyopathy (l_pobj) cardiomyopathy_41\NN|induced
D004317_D009202 CID DOX_38\NNP| (r_npadvmod) induced_40\VBN|dox|- (r_amod) cardiomyopathy_41\NN|induced (r_pobj) of_37\IN|cardiomyopathy (r_prep) induction_36\NN|of (r_pobj) after_35\IN|induction (r_prep) apoptosis_34\NN|after (r_conj) investigating_30\VBG|inflammation|and|apoptosis (r_pcomp) by_29\IN|investigating (r_prep) studied_21\VBD|elucidate|,|we|mice|by|. (l_advcl) elucidate_1\VB|to|role|)|during (l_prep) during_13\IN|development (l_pobj) development_15\NN|the|of (l_prep) of_16\IN|cardiomyopathy (l_pobj) cardiomyopathy_18\NN|dox
D004317_D009202 CID DOX_38\NNP| (r_npadvmod) induced_40\VBN|dox|- (r_amod) cardiomyopathy_41\NN|induced
D004317_D009202 CID DOX_8\NNP| (r_pobj) in_7\IN|dox (r_prep) is_5\VBZ|that|b1r|detrimental|in|cardiomyopathy|mediates (l_acl) cardiomyopathy_9\NN|in
D004317_D009202 CID DOX_16\NNP|human (r_compound) cardiomyopathy_17\NN|dox
D004317_D007249 NONE Doxorubicin_0\NNP|inflammation|and|apoptosis (l_dobj) inflammation_4\NN|induced
D004317_D007249 NONE DOX_17\NNP| (r_compound) cardiomyopathy_18\NN|dox (r_pobj) of_16\IN|cardiomyopathy (r_prep) development_15\NN|the|of (r_pobj) during_13\IN|development (r_prep) elucidate_1\VB|to|role|)|during (r_advcl) studied_21\VBD|elucidate|,|we|mice|by|. (l_prep) by_29\IN|investigating (l_pcomp) investigating_30\VBG|inflammation|and|apoptosis (l_dobj) inflammation_32\NN|cardiac
D004317_D007249 NONE DOX_38\NNP| (r_npadvmod) induced_40\VBN|dox|- (r_amod) cardiomyopathy_41\NN|induced (r_pobj) of_37\IN|cardiomyopathy (r_prep) induction_36\NN|of (r_pobj) after_35\IN|induction (r_prep) apoptosis_34\NN|after (r_conj) investigating_30\VBG|inflammation|and|apoptosis (l_dobj) inflammation_32\NN|cardiac
D018943_D066126 NONE anthracycline_4\NN| (r_amod) doxorubicin_5\NN|the|anthracycline|dox|) (r_pobj) of_2\IN|doxorubicin (r_prep) use_1\NN|clinical|of (r_nsubjpass) limited_10\VBN|use|is|by|. (l_agent) by_11\IN|effects (l_pobj) effects_14\NNS|its|cardiotoxic|,|attributed (l_amod) cardiotoxic_13\JJ|
D004317_D066126 NONE doxorubicin_5\NN|the|anthracycline|dox|) (r_pobj) of_2\IN|doxorubicin (r_prep) use_1\NN|clinical|of (r_nsubjpass) limited_10\VBN|use|is|by|. (l_agent) by_11\IN|effects (l_pobj) effects_14\NNS|its|cardiotoxic|,|attributed (l_amod) cardiotoxic_13\JJ|
D004317_D066126 NONE DOX_7\NNP|( (r_appos) doxorubicin_5\NN|the|anthracycline|dox|) (r_pobj) of_2\IN|doxorubicin (r_prep) use_1\NN|clinical|of (r_nsubjpass) limited_10\VBN|use|is|by|. (l_agent) by_11\IN|effects (l_pobj) effects_14\NNS|its|cardiotoxic|,|attributed (l_amod) cardiotoxic_13\JJ|
D004317_D006331 NONE DOX_0\NN| (r_compound) control_1\NN|dox (r_compound) mice_2\NNS|control (r_nsubj) showed_3\VBD|mice|dysfunction|. (l_dobj) dysfunction_5\NN|cardiac|measured
D004317_D006331 NONE DOX_1\NNP| (r_nmod) mice_4\NNS|dox|b1r(-/-|) (r_pobj) In_0\IN|mice (r_prep) improved_9\VBN|in|,|dysfunction|was|compared|. (l_nsubjpass) dysfunction_7\NN|cardiac
D004317_D006331 NONE DOX_12\NNP| (r_compound) mice_14\NNS|dox|control|,|associated (r_pobj) to_11\IN|mice (r_prep) compared_10\VBN|to (r_prep) improved_9\VBN|in|,|dysfunction|was|compared|. (l_nsubjpass) dysfunction_7\NN|cardiac
1300436
D005665_D007674 NONE furosemide_4\NN| (r_pobj) of_3\IN|furosemide (r_prep) effect_2\NN|potential|deleterious|of|in|. (l_prep) in_5\IN|nephropathy (l_pobj) nephropathy_7\NN|radiocontrast
D005665_D007674 NONE furosemide_11\NN| (r_pobj) of_10\IN|furosemide (r_prep) efficacy_9\NN|the|of (r_dobj) determine_7\VB|to|efficacy|in (l_prep) in_12\IN|addition (l_pobj) addition_13\NN|to|in (l_prep) in_17\IN|prevention (l_pobj) prevention_19\NN|the|of (l_prep) of_20\IN|nephropathy (l_pobj) nephropathy_22\NN|radiocontrast
D005665_D007674 NONE Furosemide_0\NNP| (r_nsubj) be_2\VB|furosemide|may|deleterious|in|. (l_prep) in_4\IN|prevention (l_pobj) prevention_6\NN|the|of (l_prep) of_7\IN|nephropathy (l_pobj) nephropathy_9\NN|radiocontrast
D005665_D058186 CID furosemide_32\NN|0.005 (r_pobj) with_31\IN|furosemide (r_prep) pretreated_30\VBN|with (r_acl) group_29\NN|the|pretreated (r_pobj) in_27\IN|group (r_prep) deteriorated_26\VBD|were|significantly|in|,|with|,|occurred|)|.
D003404_D058186 NONE creatinine_46\NN|serum (r_pobj) in_44\IN|creatinine (r_prep) rise_43\NN|a|in|from (r_pobj) with_41\IN|rise (r_prep) deteriorated_26\VBD|were|significantly|in|,|with|,|occurred|)|.
D005665_D051437 NONE furosemide_9\NN| (r_npadvmod) treated_11\VBN|furosemide|- (r_amod) group_12\NN|the|treated (r_pobj) in_7\IN|group (r_prep) loss_6\NN|weight|in (r_pobj) with_4\IN|loss (r_prep) associated_3\VBN|failure|was|with|. (l_nsubjpass) failure_1\NN|renal
D005665_D015431 NONE furosemide_9\NN| (r_npadvmod) treated_11\VBN|furosemide|- (r_amod) group_12\NN|the|treated (r_pobj) in_7\IN|group (r_prep) loss_6\NN|weight|in
17490864
D000661_D006948 CID Amphetamine_0\NN| (r_npadvmod) induced_2\VBN|amphetamine|- (r_amod) hyperactivity_4\NN|induced|locomotor
20331935
D018967_D006966 CID risperidone_12\NN| (r_npadvmod) induced_14\VBN|risperidone|- (r_amod) hyperprolactinemia_15\NN|induced|on
D018967_D006966 CID risperidone_17\NN|for (r_pobj) with_16\IN|risperidone (r_prep) treated_15\VBN|with (r_acl) %_6\NN|49|of|treated (r_pobj) in_4\IN|% (r_prep) present_3\JJ|in (r_acomp) was_2\VBD|:|hyperprolactinemia|present|. (l_nsubj) Hyperprolactinemia_1\NNP|
D018967_D006966 CID risperidone_8\NN|and|ssris (r_nsubjpass) started_12\VBN|after|risperidone|were (r_advcl) occurred_6\VBD|fractures|3|started|,|and|occurred (l_conj) occurred_16\VBD|none|in|. (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_20\NN|
D018967_D006966 CID risperidone_7\NN| (r_npadvmod) induced_9\VBN|risperidone|- (r_amod) hyperprolactinemia_10\NN|induced|and|treatment
D013739_D006966 NONE testosterone_1\NN| (r_compound) concentration_2\NN|serum|testosterone (r_nsubj) increased_3\VBD|concentration|with|but|affected|. (l_conj) affected_10\VBN|was|not|by (l_agent) by_11\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_12\NN|
D018967_D050723 NONE risperidone_8\NN|and|ssris (r_nsubjpass) started_12\VBN|after|risperidone|were (r_advcl) occurred_6\VBD|fractures|3|started|,|and|occurred (l_nsubj) fractures_3\NNS|13|documented|,
12851669
D017373_D054556 NONE acetate_12\NN|combined|cyproterone|and|ethinylestradiol (r_pobj) on_9\IN|acetate (r_prep) women_8\NNS|on (r_pobj) in_7\IN|women (r_prep) thromboembolism_6\NN|venous|in
D017373_D054556 NONE acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among
D017373_D054556 NONE acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among (l_appos) VTE_9\NNP|
D017373_D054556 NONE CPA_19\NNP| (r_nmod) EE_21\NNP|(|cpa|/|) (r_appos) ethinylestradiol_17\NN|ee (r_conj) acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among
D017373_D054556 NONE CPA_19\NNP| (r_nmod) EE_21\NNP|(|cpa|/|) (r_appos) ethinylestradiol_17\NN|ee (r_conj) acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among (l_appos) VTE_9\NNP|
D017373_D054556 NONE CPA_65\NNP| (r_nmod) EE_67\NNP|cpa|/ (r_pobj) on_64\IN|ee (r_prep) women_63\NNS|the|on (r_pobj) among_61\IN|women (r_prep) years_60\NNS|women|among (r_pobj) per_56\IN|years (r_prep) range_50\NN|3.1|(|,|1.3|)|per (r_conj) range_9\NN|3.4|(|,|range|per|,|and|range (r_attr) was_6\VBD|risk|range|. (l_nsubj) risk_3\NN|the|corresponding|absolute|of (l_prep) of_4\IN|vte (l_pobj) VTE_5\NNP|
D017373_D054556 NONE CPA_20\NNP| (r_nmod) EE_22\NNP|cpa|/ (r_dobj) taking_19\VBG|ee (r_acl) women_18\NNS|taking (r_pobj) among_17\IN|women (r_prep) that_16\DT|among (r_pobj) to_15\IN|that (r_prep) similar_14\JJ|to (r_acomp) is_13\VBZ|similar (r_ccomp) suggest_2\VBP|results|risk|is|. (l_dobj) risk_5\NN|the|absolute|of|among (l_prep) of_6\IN|vte (l_pobj) VTE_7\NNP|
D004997_D054556 NONE ethinylestradiol_14\NN| (r_conj) acetate_12\NN|combined|cyproterone|and|ethinylestradiol (r_pobj) on_9\IN|acetate (r_prep) women_8\NNS|on (r_pobj) in_7\IN|women (r_prep) thromboembolism_6\NN|venous|in
D004997_D054556 NONE ethinylestradiol_17\NN|ee (r_conj) acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among
D004997_D054556 NONE ethinylestradiol_17\NN|ee (r_conj) acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among (l_appos) VTE_9\NNP|
D004997_D054556 NONE EE_21\NNP|(|cpa|/|) (r_appos) ethinylestradiol_17\NN|ee (r_conj) acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among
D004997_D054556 NONE EE_21\NNP|(|cpa|/|) (r_appos) ethinylestradiol_17\NN|ee (r_conj) acetate_15\NN|cyproterone|plus|ethinylestradiol (r_pobj) on_13\IN|acetate (r_prep) women_12\NNS|on (r_pobj) among_11\IN|women (r_prep) thromboembolism_7\NN|venous|(|vte|)|among (l_appos) VTE_9\NNP|
D004997_D054556 NONE EE_67\NNP|cpa|/ (r_pobj) on_64\IN|ee (r_prep) women_63\NNS|the|on (r_pobj) among_61\IN|women (r_prep) years_60\NNS|women|among (r_pobj) per_56\IN|years (r_prep) range_50\NN|3.1|(|,|1.3|)|per (r_conj) range_9\NN|3.4|(|,|range|per|,|and|range (r_attr) was_6\VBD|risk|range|. (l_nsubj) risk_3\NN|the|corresponding|absolute|of (l_prep) of_4\IN|vte (l_pobj) VTE_5\NNP|
D004997_D054556 NONE EE_22\NNP|cpa|/ (r_dobj) taking_19\VBG|ee (r_acl) women_18\NNS|taking (r_pobj) among_17\IN|women (r_prep) that_16\DT|among (r_pobj) to_15\IN|that (r_prep) similar_14\JJ|to (r_acomp) is_13\VBZ|similar (r_ccomp) suggest_2\VBP|results|risk|is|. (l_dobj) risk_5\NN|the|absolute|of|among (l_prep) of_6\IN|vte (l_pobj) VTE_7\NNP|
D003277_D054556 CID contraceptives_30\NNS|combined|oral|(|cocs|) (r_pobj) on_27\IN|contraceptives (r_prep) women_26\NNS|on (r_pobj) among_25\IN|women (r_conj) achieve_1\VB|to|estimates|,|and|among|. (l_dobj) estimates_4\NNS|absolute|risk|of (l_prep) of_5\IN|thromboembolism (l_pobj) thromboembolism_7\NN|venous|(|vte|)|among
D003277_D054556 CID contraceptives_30\NNS|combined|oral|(|cocs|) (r_pobj) on_27\IN|contraceptives (r_prep) women_26\NNS|on (r_pobj) among_25\IN|women (r_conj) achieve_1\VB|to|estimates|,|and|among|. (l_dobj) estimates_4\NNS|absolute|risk|of (l_prep) of_5\IN|thromboembolism (l_pobj) thromboembolism_7\NN|venous|(|vte|)|among (l_appos) VTE_9\NNP|
D003277_D054556 CID COCs_32\NNPS| (r_appos) contraceptives_30\NNS|combined|oral|(|cocs|) (r_pobj) on_27\IN|contraceptives (r_prep) women_26\NNS|on (r_pobj) among_25\IN|women (r_conj) achieve_1\VB|to|estimates|,|and|among|. (l_dobj) estimates_4\NNS|absolute|risk|of (l_prep) of_5\IN|thromboembolism (l_pobj) thromboembolism_7\NN|venous|(|vte|)|among
D003277_D054556 CID COCs_32\NNPS| (r_appos) contraceptives_30\NNS|combined|oral|(|cocs|) (r_pobj) on_27\IN|contraceptives (r_prep) women_26\NNS|on (r_pobj) among_25\IN|women (r_conj) achieve_1\VB|to|estimates|,|and|among|. (l_dobj) estimates_4\NNS|absolute|risk|of (l_prep) of_5\IN|thromboembolism (l_pobj) thromboembolism_7\NN|venous|(|vte|)|among (l_appos) VTE_9\NNP|
D003277_D054556 CID COCs_19\NNS| (r_pobj) on_18\IN|while|cocs (r_advcl) had_15\VBN|to|have|vte|on (l_dobj) VTE_16\NNP|
D003277_D054556 CID COCs_24\NNS| (r_pobj) on_23\IN|cocs (r_prep) women_22\NNS|the|on (r_pobj) among_20\IN|women (r_prep) years_19\NNS|women|among (r_pobj) per_15\IN|years (r_prep) 3.1_11\CD|3.8|)|per (r_npadvmod) range_28\NN|3.1|,|4.2|(|,|3.2|) (r_appos) range_9\NN|3.4|(|,|range|per|,|and|range (r_attr) was_6\VBD|risk|range|. (l_nsubj) risk_3\NN|the|corresponding|absolute|of (l_prep) of_4\IN|vte (l_pobj) VTE_5\NNP|
D003277_D054556 CID COCs_45\NNS|containing (r_pobj) on_41\IN|cocs (r_prep) women_40\NNS|on (r_pobj) among_39\IN|women (r_prep) years_38\NNS|women|among (r_pobj) per_34\IN|years (r_prep) range_9\NN|3.4|(|,|range|per|,|and|range (r_attr) was_6\VBD|risk|range|. (l_nsubj) risk_3\NN|the|corresponding|absolute|of (l_prep) of_4\IN|vte (l_pobj) VTE_5\NNP|
D003277_D054556 CID COCs_12\NNS| (r_pobj) on_11\IN|cocs (r_prep) women_10\NNS|danish|on (r_pobj) among_8\IN|women (r_prep) risk_5\NN|the|absolute|of|among (l_prep) of_6\IN|vte (l_pobj) VTE_7\NNP|
D016912_D054556 NONE levonorgestrel_42\NN| (r_npadvmod) containing_44\VBG|levonorgestrel|- (r_amod) COCs_45\NNS|containing (r_pobj) on_41\IN|cocs (r_prep) women_40\NNS|on (r_pobj) among_39\IN|women (r_prep) years_38\NNS|women|among (r_pobj) per_34\IN|years (r_prep) range_9\NN|3.4|(|,|range|per|,|and|range (r_attr) was_6\VBD|risk|range|. (l_nsubj) risk_3\NN|the|corresponding|absolute|of (l_prep) of_4\IN|vte (l_pobj) VTE_5\NNP|
6292680
D004317_D009202 CID Doxorubicin_0\JJ| (r_nsubj) cardiomyopathy_1\NN|doxorubicin|in|.
D004317_D009202 CID doxorubicin_23\NN| (r_pobj) of_22\IN|doxorubicin (r_prep) dosage_21\NN|conventional|of (r_conj) bed_18\NN|the|tumor|and|dosage (r_pobj) to_15\IN|bed (r_prep) irradiation_14\NN|to (r_pobj) after_13\IN|irradiation (r_prep) experienced_9\VBD|children|cardiomyopathy|after|. (l_dobj) cardiomyopathy_12\NN|severe|anthracycline
D004317_D009202 CID doxorubicin_30\NN|and|irradiation (r_pobj) of_29\IN|doxorubicin (r_prep) interaction_28\NN|the|of|on (r_pobj) to_26\IN|interaction (r_prep) include_16\VBP|that|fields|portion|to (r_acl) fact_8\NN|the|include (r_pobj) to_6\IN|fact (r_prep) attributed_3\VBN|cardiomyopathy|is|1|)|to|. (l_nsubjpass) cardiomyopathy_1\NN|the
D004317_D009396 NONE Doxorubicin_0\JJ| (r_nsubj) cardiomyopathy_1\NN|doxorubicin|in|. (l_prep) in_2\IN|children (l_pobj) children_3\NNS|with (l_prep) with_4\IN|tumor (l_pobj) tumor_9\NN|sided|wilms
D004317_D009396 NONE doxorubicin_23\NN| (r_pobj) of_22\IN|doxorubicin (r_prep) dosage_21\NN|conventional|of (r_conj) bed_18\NN|the|tumor|and|dosage (r_pobj) to_15\IN|bed (r_prep) irradiation_14\NN|to (r_pobj) after_13\IN|irradiation (r_prep) experienced_9\VBD|children|cardiomyopathy|after|. (l_nsubj) children_1\NNS|two|with (l_prep) with_2\IN|tumor (l_pobj) tumor_4\NN|wilms|of
D004317_D009396 NONE doxorubicin_30\NN|and|irradiation (r_pobj) of_29\IN|doxorubicin (r_prep) interaction_28\NN|the|of|on (r_pobj) to_26\IN|interaction (r_prep) include_16\VBP|that|fields|portion|to (l_nsubj) fields_11\VBZ|radiation|for (l_prep) for_12\IN|tumor (l_pobj) tumor_15\NN|left|wilms
D004317_D009396 NONE doxorubicin_4\NN| (r_compound) dosage_5\NN|doxorubicin (r_nsubjpass) restricted_8\VBN|that|dosage|be|sharply|in (l_prep) in_9\IN|children (l_pobj) children_10\NNS|with (l_prep) with_11\IN|tumor (l_pobj) tumor_13\NN|wilms|of
D018943_D009396 NONE anthracycline_11\NN| (r_amod) cardiomyopathy_12\NN|severe|anthracycline (r_dobj) experienced_9\VBD|children|cardiomyopathy|after|. (l_nsubj) children_1\NNS|two|with (l_prep) with_2\IN|tumor (l_pobj) tumor_4\NN|wilms|of
D018943_D009202 NONE anthracycline_11\NN| (r_amod) cardiomyopathy_12\NN|severe|anthracycline
D018943_D009369 NONE anthracycline_11\NN| (r_amod) cardiomyopathy_12\NN|severe|anthracycline (r_dobj) experienced_9\VBD|children|cardiomyopathy|after|. (l_prep) after_13\IN|irradiation (l_pobj) irradiation_14\NN|to (l_prep) to_15\IN|bed (l_pobj) bed_18\NN|the|tumor|and|dosage (l_compound) tumor_17\NN|
D004317_D009369 NONE doxorubicin_23\NN| (r_pobj) of_22\IN|doxorubicin (r_prep) dosage_21\NN|conventional|of (r_conj) bed_18\NN|the|tumor|and|dosage (l_compound) tumor_17\NN|
11524350
D002045_D064420 NONE bupivacaine-_5\DT|,|levobupivacaine- (r_nmod) rats_13\NNS|bupivacaine- (r_pobj) in_4\IN|rats (r_prep) toxicity_1\NN|systemic|and|resuscitation|in|.
D002045_D064420 NONE bupivacaine_6\NN| (r_pobj) of_5\IN|bupivacaine (r_prep) toxicity_4\NN|the|systemic|of|,|levobupivacaine
D002045_D064420 NONE bupivacaine_15\NN| (r_conj) ropivacaine_13\NN|and|bupivacaine (r_pobj) of_12\IN|ropivacaine (r_prep) that_11\DT|of (r_pobj) between_10\IN|that (r_prep) intermediate_9\JJ|between (r_acomp) is_8\VBZ|that|toxicity|intermediate|administered (l_nsubj) toxicity_5\NN|the|systemic|of
D002045_D064420 NONE bupivacaine_40\NN|or|levobupivacaine (r_pobj) by_39\IN|bupivacaine (r_agent) induced_38\VBN|by (r_acl) that_37\DT|induced (r_pobj) than_36\IN|that (r_prep) susceptible_33\JJ|more|to|than (r_acomp) be_31\VB|to|susceptible (r_xcomp) appears_29\VBZ|arrest|be|. (r_conj) administered_17\VBN|when|at|and|appears (r_advcl) is_8\VBZ|that|toxicity|intermediate|administered (l_nsubj) toxicity_5\NN|the|systemic|of
C476513_D064420 NONE levobupivacaine-_7\JJ|,|or|infused (r_conj) bupivacaine-_5\DT|,|levobupivacaine- (r_nmod) rats_13\NNS|bupivacaine- (r_pobj) in_4\IN|rats (r_prep) toxicity_1\NN|systemic|and|resuscitation|in|.
C476513_D064420 NONE levobupivacaine_8\NN|,|and|ropivacaine (r_conj) toxicity_4\NN|the|systemic|of|,|levobupivacaine
C476513_D064420 NONE levobupivacaine_7\NN| (r_pobj) of_6\IN|levobupivacaine (r_prep) toxicity_5\NN|the|systemic|of
C476513_D064420 NONE levobupivacaine_42\NN| (r_conj) bupivacaine_40\NN|or|levobupivacaine (r_pobj) by_39\IN|bupivacaine (r_agent) induced_38\VBN|by (r_acl) that_37\DT|induced (r_pobj) than_36\IN|that (r_prep) susceptible_33\JJ|more|to|than (r_acomp) be_31\VB|to|susceptible (r_xcomp) appears_29\VBZ|arrest|be|. (r_conj) administered_17\VBN|when|at|and|appears (r_advcl) is_8\VBZ|that|toxicity|intermediate|administered (l_nsubj) toxicity_5\NN|the|systemic|of
C037663_D064420 NONE ropivacaine_10\NN| (r_npadvmod) infused_12\VBN|ropivacaine|- (r_conj) levobupivacaine-_7\JJ|,|or|infused (r_conj) bupivacaine-_5\DT|,|levobupivacaine- (r_nmod) rats_13\NNS|bupivacaine- (r_pobj) in_4\IN|rats (r_prep) toxicity_1\NN|systemic|and|resuscitation|in|.
C037663_D064420 NONE ropivacaine_11\NN|in (r_conj) levobupivacaine_8\NN|,|and|ropivacaine (r_conj) toxicity_4\NN|the|systemic|of|,|levobupivacaine
C037663_D064420 NONE ropivacaine_13\NN|and|bupivacaine (r_pobj) of_12\IN|ropivacaine (r_prep) that_11\DT|of (r_pobj) between_10\IN|that (r_prep) intermediate_9\JJ|between (r_acomp) is_8\VBZ|that|toxicity|intermediate|administered (l_nsubj) toxicity_5\NN|the|systemic|of
C037663_D064420 NONE ropivacaine_24\NN| (r_npadvmod) induced_26\VBN|ropivacaine|- (r_amod) arrest_28\NN|that|induced|cardiac (r_nsubj) appears_29\VBZ|arrest|be|. (r_conj) administered_17\VBN|when|at|and|appears (r_advcl) is_8\VBZ|that|toxicity|intermediate|administered (l_nsubj) toxicity_5\NN|the|systemic|of
C476513_D012640 CID levobupivacaine_4\NN|and|ropivacaine (r_pobj) of_3\IN|levobupivacaine (r_prep) doses_2\NNS|the|cumulative|of (r_nsubj) were_10\VBD|doses|seizures|similar|and|were|. (l_nsubj) seizures_9\NNS|produced
C037663_D012640 CID ropivacaine_6\VBP| (r_conj) levobupivacaine_4\NN|and|ropivacaine (r_pobj) of_3\IN|levobupivacaine (r_prep) doses_2\NNS|the|cumulative|of (r_nsubj) were_10\VBD|doses|seizures|similar|and|were|. (l_nsubj) seizures_9\NNS|produced
D002045_D012640 NONE bupivacaine_18\NN| (r_pobj) of_17\IN|bupivacaine (r_prep) those_16\DT|of (r_pobj) than_15\IN|those (r_prep) larger_14\JJR|than (r_acomp) were_13\VBD|larger (r_conj) were_10\VBD|doses|seizures|similar|and|were|. (l_nsubj) seizures_9\NNS|produced
C476513_D001145 CID levobupivacaine_4\NN| (r_pobj) of_3\IN|levobupivacaine (r_prep) doses_2\NNS|the|cumulative|of|produced (l_relcl) produced_6\VBD|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS|and|asystole
C476513_D006323 CID levobupivacaine_4\NN| (r_pobj) of_3\IN|levobupivacaine (r_prep) doses_2\NNS|the|cumulative|of|produced (l_relcl) produced_6\VBD|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS|and|asystole (l_conj) asystole_9\NN|
C476513_D006323 CID levobupivacaine_7\NN| (r_pobj) of_6\IN|levobupivacaine (r_prep) toxicity_5\NN|the|systemic|of (r_nsubj) is_8\VBZ|that|toxicity|intermediate|administered (l_advcl) administered_17\VBN|when|at|and|appears (l_conj) appears_29\VBZ|arrest|be|. (l_nsubj) arrest_28\NN|that|induced|cardiac
C476513_D006323 CID levobupivacaine_42\NN| (r_conj) bupivacaine_40\NN|or|levobupivacaine (r_pobj) by_39\IN|bupivacaine (r_agent) induced_38\VBN|by (r_acl) that_37\DT|induced (r_pobj) than_36\IN|that (r_prep) susceptible_33\JJ|more|to|than (r_acomp) be_31\VB|to|susceptible (r_xcomp) appears_29\VBZ|arrest|be|. (l_nsubj) arrest_28\NN|that|induced|cardiac
C037663_D001145 CID ropivacaine_17\NN| (r_pobj) of_16\IN|ropivacaine (r_prep) doses_15\NNS|the|corresponding|of (r_pobj) than_12\IN|doses (r_prep) smaller_11\JJR|than (r_acomp) were_10\VBD|doses|smaller|,|but|were (l_nsubj) doses_2\NNS|the|cumulative|of|produced (l_relcl) produced_6\VBD|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS|and|asystole
C037663_D006323 CID ropivacaine_17\NN| (r_pobj) of_16\IN|ropivacaine (r_prep) doses_15\NNS|the|corresponding|of (r_pobj) than_12\IN|doses (r_prep) smaller_11\JJR|than (r_acomp) were_10\VBD|doses|smaller|,|but|were (l_nsubj) doses_2\NNS|the|cumulative|of|produced (l_relcl) produced_6\VBD|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS|and|asystole (l_conj) asystole_9\NN|
C037663_D006323 CID ropivacaine_13\NN|and|bupivacaine (r_pobj) of_12\IN|ropivacaine (r_prep) that_11\DT|of (r_pobj) between_10\IN|that (r_prep) intermediate_9\JJ|between (r_acomp) is_8\VBZ|that|toxicity|intermediate|administered (l_advcl) administered_17\VBN|when|at|and|appears (l_conj) appears_29\VBZ|arrest|be|. (l_nsubj) arrest_28\NN|that|induced|cardiac
C037663_D006323 CID ropivacaine_24\NN| (r_npadvmod) induced_26\VBN|ropivacaine|- (r_amod) arrest_28\NN|that|induced|cardiac
D002045_D001145 NONE bupivacaine_26\NN| (r_pobj) of_25\IN|bupivacaine (r_prep) those_24\DT|of (r_pobj) than_23\IN|those (r_prep) larger_22\JJR|than (r_acomp) were_21\VBD|they|larger|. (r_conj) were_10\VBD|doses|smaller|,|but|were (l_nsubj) doses_2\NNS|the|cumulative|of|produced (l_relcl) produced_6\VBD|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS|and|asystole
D002045_D006323 NONE bupivacaine_26\NN| (r_pobj) of_25\IN|bupivacaine (r_prep) those_24\DT|of (r_pobj) than_23\IN|those (r_prep) larger_22\JJR|than (r_acomp) were_21\VBD|they|larger|. (r_conj) were_10\VBD|doses|smaller|,|but|were (l_nsubj) doses_2\NNS|the|cumulative|of|produced (l_relcl) produced_6\VBD|that|dysrhythmias (l_dobj) dysrhythmias_7\NNS|and|asystole (l_conj) asystole_9\NN|
D002045_D006323 NONE bupivacaine_15\NN| (r_conj) ropivacaine_13\NN|and|bupivacaine (r_pobj) of_12\IN|ropivacaine (r_prep) that_11\DT|of (r_pobj) between_10\IN|that (r_prep) intermediate_9\JJ|between (r_acomp) is_8\VBZ|that|toxicity|intermediate|administered (l_advcl) administered_17\VBN|when|at|and|appears (l_conj) appears_29\VBZ|arrest|be|. (l_nsubj) arrest_28\NN|that|induced|cardiac
D002045_D006323 NONE bupivacaine_40\NN|or|levobupivacaine (r_pobj) by_39\IN|bupivacaine (r_agent) induced_38\VBN|by (r_acl) that_37\DT|induced (r_pobj) than_36\IN|that (r_prep) susceptible_33\JJ|more|to|than (r_acomp) be_31\VB|to|susceptible (r_xcomp) appears_29\VBZ|arrest|be|. (l_nsubj) arrest_28\NN|that|induced|cardiac
15075188
D011692_D009404 CID aminonucleoside_11\RB| (r_advmod) induced_13\VBN|aminonucleoside|- (r_amod) syndrome_15\NN|puromycin|induced|nephrotic|in
D011692_D009404 CID PAN_38\NNP| (r_npadvmod) induced_40\VBN|pan|- (r_amod) syndrome_42\NN|induced|nephrotic
D012964_D009404 NONE sodium_6\NN| (r_compound) retention_7\NN|sodium|and|edema (r_pobj) by_5\IN|retention (r_agent) accompanied_4\VBN|syndrome|is|often|by|. (l_nsubjpass) syndrome_1\NN|nephrotic
D012964_D009404 NONE sodium_34\NN| (r_compound) retention_35\NN|the|sodium|associated (l_acl) associated_36\VBN|with (l_prep) with_37\IN|syndrome (l_pobj) syndrome_42\NN|induced|nephrotic
D012964_D004487 NONE sodium_6\NN| (r_compound) retention_7\NN|sodium|and|edema (l_conj) edema_10\NN|generalized
D011692_D011507 CID PAN_4\NNP| (r_compound) treatment_5\NN|pan (r_nsubj) induced_6\VBD|after|,|treatment|proteinuria (l_dobj) proteinuria_8\NN|significant|,|hypoalbuminemia
D011692_D034141 CID PAN_4\NNP| (r_compound) treatment_5\NN|pan (r_nsubj) induced_6\VBD|after|,|treatment|proteinuria (l_dobj) proteinuria_8\NN|significant|,|hypoalbuminemia (l_appos) hypoalbuminemia_10\NN|
D011692_D001201 CID PAN_4\NNP| (r_compound) treatment_5\NN|pan (r_nsubj) induced_6\VBD|after|,|treatment|proteinuria (r_advcl) decreased_12\VBD|induced|,|excretion|. (l_dobj) excretion_15\NN|sodium|,|and|ascites (l_conj) ascites_19\NNS|extensive
D012964_D011507 NONE sodium_14\NN|urinary (r_compound) excretion_15\NN|sodium|,|and|ascites (r_dobj) decreased_12\VBD|induced|,|excretion|. (l_advcl) induced_6\VBD|after|,|treatment|proteinuria (l_dobj) proteinuria_8\NN|significant|,|hypoalbuminemia
D012964_D034141 NONE sodium_14\NN|urinary (r_compound) excretion_15\NN|sodium|,|and|ascites (r_dobj) decreased_12\VBD|induced|,|excretion|. (l_advcl) induced_6\VBD|after|,|treatment|proteinuria (l_dobj) proteinuria_8\NN|significant|,|hypoalbuminemia (l_appos) hypoalbuminemia_10\NN|
D012964_D001201 NONE sodium_14\NN|urinary (r_compound) excretion_15\NN|sodium|,|and|ascites (l_conj) ascites_19\NNS|extensive
9154656
D000809_D009404 NONE angiotensin_9\NN|renin|- (r_compound) proteins_11\NNS|the|angiotensin|system (r_pobj) of_5\IN|proteins (r_prep) concentration_1\NN|plasma|and|excretion|of (r_nsubjpass) altered_13\VBN|concentration|are|in|. (l_prep) in_14\IN|rats (l_pobj) rats_15\NNS|with (l_prep) with_16\IN|syndrome (l_pobj) syndrome_18\NN|nephrotic|ns
D000809_D009404 NONE angiotensin_9\NN|renin|- (r_compound) proteins_11\NNS|the|angiotensin|system (r_pobj) of_5\IN|proteins (r_prep) concentration_1\NN|plasma|and|excretion|of (r_nsubjpass) altered_13\VBN|concentration|are|in|. (l_prep) in_14\IN|rats (l_pobj) rats_15\NNS|with (l_prep) with_16\IN|syndrome (l_pobj) syndrome_18\NN|nephrotic|ns (l_appos) NS_20\NNP|(|)
D011692_D009404 CID nucleoside_11\NN|amino|- (r_nmod) PAN_13\NNP|puromycin|nucleoside|( (r_pobj) of_7\IN|pan (r_prep) injection_6\NN|a|single|of (r_pobj) by_3\IN|injection (r_agent) induced_2\VBN|ns|was|by|)|. (l_nsubjpass) NS_0\NNP|
D011692_D009404 CID PAN_13\NNP|puromycin|nucleoside|( (r_pobj) of_7\IN|pan (r_prep) injection_6\NN|a|single|of (r_pobj) by_3\IN|injection (r_agent) induced_2\VBN|ns|was|by|)|. (l_nsubjpass) NS_0\NNP|
D011692_D009404 CID PAN_19\NNP| (r_compound) injection_20\NN|pan (r_pobj) after_18\IN|injection (r_prep) observed_14\VBN|although|excretion|were|on|after (r_advcl) change_34\VB|observed|,|established|,|levels|did|not|. (l_advcl) established_26\VBN|when|ns|was|clearly (l_nsubjpass) NS_23\NNP|
D011692_D009404 CID PAN_22\NNP| (r_pobj) by_21\IN|pan (r_agent) induced_20\VBN|by (r_acl) development_15\NN|the|of|induced (l_prep) of_16\IN|ns (l_pobj) NS_19\NNP|the|acute
12907924
D008774_D009771 CID Methylphenidate_0\NNP| (r_npadvmod) induced_2\VBN|methylphenidate|- (r_amod) symptoms_6\NNS|induced|compulsive|in|.
D008774_D009771 CID methylphenidate_12\NN| (r_nsubjpass) replaced_14\VBN|when|methylphenidate|was|by (r_advcl) diminished_7\VBN|over|replaced (r_conj) ensued_5\VBD|behavior|but|diminished|. (l_nsubj) behavior_4\NN|significant|compulsive
D008774_D061218 NONE methylphenidate_18\NN| (r_pobj) on_17\IN|methylphenidate (r_prep) started_16\VBN|man|was|on|. (l_nsubjpass) man_4\NN|an|old|with (l_prep) with_5\IN|depression (l_pobj) depression_9\NN|resistant|and|disease
D008774_D000544 NONE methylphenidate_18\NN| (r_pobj) on_17\IN|methylphenidate (r_prep) started_16\VBN|man|was|on|. (l_nsubjpass) man_4\NN|an|old|with (l_prep) with_5\IN|depression (l_pobj) depression_9\NN|resistant|and|disease (l_conj) disease_14\NN|early|alzheimer
D016666_D009771 NONE fluvoxamine_16\NN| (r_pobj) by_15\IN|fluvoxamine (r_agent) replaced_14\VBN|when|methylphenidate|was|by (r_advcl) diminished_7\VBN|over|replaced (r_conj) ensued_5\VBD|behavior|but|diminished|. (l_nsubj) behavior_4\NN|significant|compulsive
2790457
D002220_D012640 NONE carbamazepine_1\NN|chronic (r_nsubj) inhibits_2\VBZ|carbamazepine|development|. (l_dobj) development_4\NN|the|of (l_prep) of_5\IN|seizures (l_pobj) seizures_8\NNS|local|anesthetic|kindled
D002220_D012640 NONE carbamazepine_3\NN|treatment (l_appos) treatment_7\NN|(|cbz|)|on (l_prep) on_8\IN|seizures (l_pobj) seizures_13\NNS|local|kindled|and|lethality
D002220_D012640 NONE CBZ_5\NNP| (r_nmod) treatment_7\NN|(|cbz|)|on (l_prep) on_8\IN|seizures (l_pobj) seizures_13\NNS|local|kindled|and|lethality
D002220_D012640 NONE CBZ_30\NNP| (r_compound) administration_31\NN|cbz (r_pobj) of_29\IN|administration (r_prep) methods_28\NNS|different|of (r_pobj) under_26\IN|methods (r_conj) in_18\IN|stages|and|under (r_prep) evaluated_17\VBN|effects|were|in|. (l_nsubjpass) effects_1\NNS|the|of (l_prep) of_2\IN|carbamazepine (l_pobj) carbamazepine_3\NN|treatment (l_appos) treatment_7\NN|(|cbz|)|on (l_prep) on_8\IN|seizures (l_pobj) seizures_13\NNS|local|kindled|and|lethality
D002220_D012640 NONE CBZ_2\NN|oral (r_nsubj) inhibited_3\VBD|cbz|development|,|but|had|. (l_dobj) development_5\NN|the|of (l_prep) of_6\IN|seizures (l_pobj) seizures_13\NNS|lidocaine-
D002220_D012640 NONE CBZ_2\NN|oral (r_nsubj) inhibited_3\VBD|cbz|development|,|but|had|. (l_conj) had_16\VBD|effect (l_dobj) effect_18\NN|little|on (l_prep) on_19\IN|seizures (l_pobj) seizures_25\NNS|the|developed|local|anesthetic
D002220_D012640 NONE CBZ_1\NN|chronic (r_nsubj) decreased_3\VBD|cbz|also|incidence|. (l_dobj) incidence_5\NN|the|of (l_prep) of_6\IN|mortality (l_pobj) mortality_10\NN|related|in (l_amod) related_9\VBN|seizure|- (l_npadvmod) seizure_7\NN|
D002220_D012640 NONE CBZ_1\NN|acute|over (r_nsubj) had_13\VBD|cbz|effect|. (l_dobj) effect_15\NN|no|on (l_prep) on_16\IN|seizures (l_pobj) seizures_26\NNS|completed|kindled|induced
D002220_D012640 NONE CBZ_4\NNP|mg/kg (r_pobj) of_3\IN|cbz (r_prep) injection_2\NN|repeated|i.p.|of|) (r_nsubj) was_10\VBD|injection|also|without|. (l_prep) without_11\IN|effect (l_pobj) effect_12\NN|on (l_prep) on_13\IN|development (l_pobj) development_15\NN|the|of (l_prep) of_16\IN|seizures (l_pobj) seizures_22\NNS|lidocaine-|kindled
D002220_D012640 NONE CBZ_4\NN| (r_pobj) of_3\IN|cbz (r_prep) effects_2\NNS|the|differential|of|depending (l_prep) depending_5\VBG|upon (l_prep) upon_6\IN|stage (l_pobj) stage_7\NN|of (l_prep) of_8\IN|development (l_pobj) development_10\NN|seizure (l_compound) seizure_9\NN|
D002220_D012640 NONE CBZ_4\NN| (r_pobj) of_3\IN|cbz (r_prep) effects_2\NNS|the|differential|of|depending (r_nsubj) suggest_11\VBP|effects|underlie|. (l_ccomp) underlie_15\VBP|that|mechanisms|development (l_dobj) development_17\NN|the|versus (l_prep) versus_18\IN|maintenance (l_pobj) maintenance_19\NN|of (l_prep) of_20\IN|seizures (l_pobj) seizures_25\NNS|local|kindled
D003042_D012640 CID cocaine_11\NN|and|lidocaine (r_pobj) by_10\IN|cocaine (r_agent) kindled_9\VBN|by (r_acl) seizures_8\NNS|local|anesthetic|kindled
D003042_D012640 CID cocaine_10\NN| (r_npadvmod) induced_12\VBN|cocaine|- (r_conj) lidocaine-_8\NN|both|and|induced (r_nmod) seizures_13\NNS|lidocaine-
D003042_D012640 CID cocaine_10\NN| (r_npadvmod) induced_12\VBN|cocaine|- (r_conj) lidocaine-_8\NN|both|and|induced (r_nmod) seizures_13\NNS|lidocaine- (r_pobj) of_6\IN|seizures (r_prep) development_5\NN|the|of (r_dobj) inhibited_3\VBD|cbz|development|,|but|had|. (l_conj) had_16\VBD|effect (l_dobj) effect_18\NN|little|on (l_prep) on_19\IN|seizures (l_pobj) seizures_25\NNS|the|developed|local|anesthetic
D003042_D012640 CID cocaine_13\NN| (r_npadvmod) injected_15\VBN|cocaine|- (r_amod) rats_16\NNS|the|injected (r_pobj) in_11\IN|rats (r_prep) mortality_10\NN|related|in (l_amod) related_9\VBN|seizure|- (l_npadvmod) seizure_7\NN|
D003042_D012640 CID cocaine_23\NN| (r_npadvmod) induced_25\VBN|cocaine|- (r_amod) seizures_26\NNS|completed|kindled|induced
D003042_D012640 CID cocaine_19\NN| (r_npadvmod) kindled_21\VBN|cocaine|- (r_amod) seizures_22\NNS|lidocaine-|kindled
D008012_D012640 CID lidocaine_13\NN| (r_conj) cocaine_11\NN|and|lidocaine (r_pobj) by_10\IN|cocaine (r_agent) kindled_9\VBN|by (r_acl) seizures_8\NNS|local|anesthetic|kindled
D008012_D012640 CID lidocaine-_8\NN|both|and|induced (r_nmod) seizures_13\NNS|lidocaine-
D008012_D012640 CID lidocaine-_8\NN|both|and|induced (r_nmod) seizures_13\NNS|lidocaine- (r_pobj) of_6\IN|seizures (r_prep) development_5\NN|the|of (r_dobj) inhibited_3\VBD|cbz|development|,|but|had|. (l_conj) had_16\VBD|effect (l_dobj) effect_18\NN|little|on (l_prep) on_19\IN|seizures (l_pobj) seizures_25\NNS|the|developed|local|anesthetic
D008012_D012640 CID lidocaine_18\NN| (r_npadvmod) kindled_20\VBN|lidocaine|-|or|acute (r_amod) seizures_26\NNS|completed|kindled|induced
D008012_D012640 CID lidocaine-_17\NN|or (r_nmod) seizures_22\NNS|lidocaine-|kindled
7007443
D000082_D017114 CID paracetamol_26\JJ| (r_compound) overdose_27\NN|paracetamol (r_pobj) after_25\IN|overdose (r_prep) survived_21\VBD|who|failure|after (l_dobj) failure_24\NN|fulminant|hepatic
D000082_D017114 CID paracetamol_26\JJ| (r_compound) overdose_27\NN|paracetamol (r_pobj) after_25\IN|overdose (r_prep) survived_21\VBD|who|failure|after (r_relcl) those_19\DT|survived (r_pobj) in_18\IN|those (r_prep) fourfold_17\RB|nearly|in (r_conj) died_14\VBD|who|and|fourfold (r_relcl) patients_12\NNS|died (r_pobj) in_11\IN|patients (r_prep) increased_8\VBN|activity|was|tenfold|in|,|increased|. (l_advcl) increased_32\VBN|whereas|activities|were|equally|in|survived (l_prep) in_34\IN|patients (l_pobj) patients_35\NNS|with (l_prep) with_36\IN|failure (l_pobj) failure_39\NN|fulminant|hepatic|due
D000082_D062787 NONE paracetamol_26\JJ| (r_compound) overdose_27\NN|paracetamol
D000082_D006525 NONE paracetamol_26\JJ| (r_compound) overdose_27\NN|paracetamol (r_pobj) after_25\IN|overdose (r_prep) survived_21\VBD|who|failure|after (r_relcl) those_19\DT|survived (r_pobj) in_18\IN|those (r_prep) fourfold_17\RB|nearly|in (r_conj) died_14\VBD|who|and|fourfold (r_relcl) patients_12\NNS|died (r_pobj) in_11\IN|patients (r_prep) increased_8\VBN|activity|was|tenfold|in|,|increased|. (l_advcl) increased_32\VBN|whereas|activities|were|equally|in|survived (l_prep) in_34\IN|patients (l_pobj) patients_35\NNS|with (l_prep) with_36\IN|failure (l_pobj) failure_39\NN|fulminant|hepatic|due (l_amod) due_40\IN|to (l_pcomp) to_41\IN|hepatitis (l_pobj) hepatitis_43\NN|viral
17074608
D014635_D002819 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) chorea_3\NN|induced|and|encephalopathy|.
D014635_D002819 CID valproate_32\NN| (r_amod) therapy_33\NN|valproate (r_pobj) of_31\IN|therapy (r_prep) initiation_30\NN|of (r_pobj) after_29\IN|shortly|initiation (r_prep) presentation_22\NN|her|with|after (l_prep) with_23\IN|encephalopathy (l_pobj) encephalopathy_25\NN|acute|and|chorea (l_conj) chorea_27\NN|
D014635_D001927 CID Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) chorea_3\NN|induced|and|encephalopathy|. (l_conj) encephalopathy_5\JJ|in
D014635_D001927 CID valproate_32\NN| (r_amod) therapy_33\NN|valproate (r_pobj) of_31\IN|therapy (r_prep) initiation_30\NN|of (r_pobj) after_29\IN|shortly|initiation (r_prep) presentation_22\NN|her|with|after (l_prep) with_23\IN|encephalopathy (l_pobj) encephalopathy_25\NN|acute|and|chorea
D014635_D020158 NONE Valproate_0\NNP| (r_npadvmod) induced_2\VBN|valproate|- (r_amod) chorea_3\NN|induced|and|encephalopathy|. (l_conj) encephalopathy_5\JJ|in (l_prep) in_6\IN|hyperglycinemia (l_pobj) hyperglycinemia_9\NN|atypical|nonketotic
D014635_D020158 NONE valproate_32\NN| (r_amod) therapy_33\NN|valproate (r_pobj) of_31\IN|therapy (r_prep) initiation_30\NN|of (r_pobj) after_29\IN|shortly|initiation (r_prep) presentation_22\NN|her|with|after (r_pobj) following_20\VBG|presentation (r_prep) found_15\VBN|who|was|have|following (l_xcomp) have_17\VB|to|hyperglycinemia (l_dobj) hyperglycinemia_19\NN|nonketotic
D005998_D020158 NONE glycine_15\NN| (r_compound) system_17\NN|the|glycine|cleavage (r_pobj) in_13\IN|system (r_prep) defect_12\NN|a|in (r_nsubj) leads_18\VBZ|in|defect|to (r_relcl) metabolism_8\NN|acid|leads (r_pobj) of_5\IN|metabolism (r_prep) disorder_4\NN|a|of (r_attr) is_2\VBZ|hyperglycinemia|disorder|. (l_nsubj) hyperglycinemia_1\NN|nonketotic
D005998_D020158 NONE glycine_23\NN| (r_pobj) of_22\IN|glycine (r_prep) accumulation_21\NN|an|of|in (r_pobj) to_19\IN|accumulation (r_prep) leads_18\VBZ|in|defect|to (r_relcl) metabolism_8\NN|acid|leads (r_pobj) of_5\IN|metabolism (r_prep) disorder_4\NN|a|of (r_attr) is_2\VBZ|hyperglycinemia|disorder|. (l_nsubj) hyperglycinemia_1\NN|nonketotic
D005998_D000592 NONE glycine_15\NN| (r_compound) system_17\NN|the|glycine|cleavage (r_pobj) in_13\IN|system (r_prep) defect_12\NN|a|in (r_nsubj) leads_18\VBZ|in|defect|to (r_relcl) metabolism_8\NN|acid|leads
D005998_D000592 NONE glycine_23\NN| (r_pobj) of_22\IN|glycine (r_prep) accumulation_21\NN|an|of|in (r_pobj) to_19\IN|accumulation (r_prep) leads_18\VBZ|in|defect|to (r_relcl) metabolism_8\NN|acid|leads
D014635_D007805 NONE valproate_32\NN| (r_amod) therapy_33\NN|valproate (r_pobj) of_31\IN|therapy (r_prep) initiation_30\NN|of (r_pobj) after_29\IN|shortly|initiation (r_prep) presentation_22\NN|her|with|after (r_pobj) following_20\VBG|presentation (r_prep) found_15\VBN|who|was|have|following (r_relcl) delay_8\NN|mild|language|and|retardation|,|found
D014635_D008607 NONE valproate_32\NN| (r_amod) therapy_33\NN|valproate (r_pobj) of_31\IN|therapy (r_prep) initiation_30\NN|of (r_pobj) after_29\IN|shortly|initiation (r_prep) presentation_22\NN|her|with|after (r_pobj) following_20\VBG|presentation (r_prep) found_15\VBN|who|was|have|following (r_relcl) delay_8\NN|mild|language|and|retardation|,|found (l_conj) retardation_11\NN|mental
3686155
D001971_D011605 CID bromocriptine_4\NN| (r_pobj) by_3\IN|bromocriptine (r_prep) induced_2\VBN|psychosis|by|. (l_nsubj) psychosis_1\NN|postpartum
D001971_D011605 CID bromocriptine_16\NN| (r_dobj) received_15\VBN|having|bromocriptine|for (r_advcl) seen_9\VBN|patients|were|with|,|received|. (l_prep) with_10\IN|psychosis (l_pobj) psychosis_12\NN|postpartum
D001971_D011605 CID Bromocriptine_0\NNP|given (r_nsubjpass) associated_7\VBN|bromocriptine|has|been|with|. (l_prep) with_8\IN|psychosis (l_pobj) psychosis_9\NN|in
D001971_D011605 CID bromocriptine_4\NN|that (r_nsubj) cause_6\VB|bromocriptine|may|psychosis|given (l_dobj) psychosis_7\NN|
D001971_D001523 NONE bromocriptine_16\NN| (r_dobj) received_15\VBN|having|bromocriptine|for (r_advcl) seen_9\VBN|patients|were|with|,|received|. (l_nsubjpass) patients_2\NNS|two|multigravida|with (l_prep) with_3\IN|history (l_pobj) history_7\NN|no|prior|psychiatric (l_amod) psychiatric_6\JJ|
D001971_D007775 NONE bromocriptine_16\NN| (r_dobj) received_15\VBN|having|bromocriptine|for (l_prep) for_17\IN|inhibition (l_pobj) inhibition_18\NN|of (l_prep) of_19\IN|lactation (l_pobj) lactation_20\NN|
D001971_D010300 NONE Bromocriptine_0\NNP|given (r_nsubjpass) associated_7\VBN|bromocriptine|has|been|with|. (l_prep) with_8\IN|psychosis (l_pobj) psychosis_9\NN|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|receiving (l_acl) receiving_12\VBG|drug (l_dobj) drug_14\NN|the|for (l_prep) for_15\IN|disease (l_pobj) disease_18\NN|parkinson
3934126
D014640_D007239 NONE Vancomycin_0\NNP| (r_nsubj) was_1\VBD|vancomycin|curative|. (l_acomp) curative_2\JJ|in (l_prep) in_3\IN|% (l_pobj) %_5\NN|95|of (l_prep) of_6\IN|patients (l_pobj) patients_8\NNS|43|with (l_prep) with_9\IN|infection (l_pobj) infection_11\NN|proven
D014640_D007239 NONE vancomycin_3\NNP| (r_nsubj) constitutes_8\VBZ|that|vancomycin|,|administered|,|therapy (l_dobj) therapy_12\NN|safe|,|effective|for (l_prep) for_13\IN|infections (l_pobj) infections_14\NNS|caused
D000617_D013924 NONE aminoglycoside_18\NN|an|plus|vancomycin (r_dobj) receiving_16\VBG|aminoglycoside (r_acl) patients_15\NNS|receiving (r_pobj) to_14\IN|patients (r_prep) confined_13\VBN|occurred|;|nephrotoxicity|were|to|. (l_ccomp) occurred_1\VBD|thrombophlebitis|with (l_nsubj) Thrombophlebitis_0\NNP|
D000617_D007674 NONE aminoglycoside_18\NN|an|plus|vancomycin (r_dobj) receiving_16\VBG|aminoglycoside (r_acl) patients_15\NNS|receiving (r_pobj) to_14\IN|patients (r_prep) confined_13\VBN|occurred|;|nephrotoxicity|were|to|. (l_nsubjpass) nephrotoxicity_9\NN|and|ototoxicity
D000617_D006311 NONE aminoglycoside_18\NN|an|plus|vancomycin (r_dobj) receiving_16\VBG|aminoglycoside (r_acl) patients_15\NNS|receiving (r_pobj) to_14\IN|patients (r_prep) confined_13\VBN|occurred|;|nephrotoxicity|were|to|. (l_nsubjpass) nephrotoxicity_9\NN|and|ototoxicity (l_conj) ototoxicity_11\NN|
D014640_D013924 CID vancomycin_20\NNP| (r_appos) aminoglycoside_18\NN|an|plus|vancomycin (r_dobj) receiving_16\VBG|aminoglycoside (r_acl) patients_15\NNS|receiving (r_pobj) to_14\IN|patients (r_prep) confined_13\VBN|occurred|;|nephrotoxicity|were|to|. (l_ccomp) occurred_1\VBD|thrombophlebitis|with (l_nsubj) Thrombophlebitis_0\NNP|
D014640_D007674 NONE vancomycin_20\NNP| (r_appos) aminoglycoside_18\NN|an|plus|vancomycin (r_dobj) receiving_16\VBG|aminoglycoside (r_acl) patients_15\NNS|receiving (r_pobj) to_14\IN|patients (r_prep) confined_13\VBN|occurred|;|nephrotoxicity|were|to|. (l_nsubjpass) nephrotoxicity_9\NN|and|ototoxicity
D014640_D006311 CID vancomycin_20\NNP| (r_appos) aminoglycoside_18\NN|an|plus|vancomycin (r_dobj) receiving_16\VBG|aminoglycoside (r_acl) patients_15\NNS|receiving (r_pobj) to_14\IN|patients (r_prep) confined_13\VBN|occurred|;|nephrotoxicity|were|to|. (l_nsubjpass) nephrotoxicity_9\NN|and|ototoxicity (l_conj) ototoxicity_11\NN|
1636026
D013496_D058186 CID suprofen_1\NN| (r_nsubjpass) associated_4\VBN|although|suprofen|has|been|with (l_prep) with_5\IN|development (l_pobj) development_7\NN|the|of|in (l_prep) of_8\IN|failure (l_pobj) failure_11\NN|acute|renal
D013496_D058186 CID suprofen_3\VB| (r_nsubj) causes_4\VBZ|in|,|suprofen|declines|,|likely|. (l_dobj) declines_6\NNS|acute|in (l_prep) in_7\IN|function (l_pobj) function_9\NN|renal
D013496_D007674 NONE suprofen_12\NN| (r_pobj) of_11\IN|suprofen (r_prep) mg_10\NN|of (r_nsubjpass) compared_14\VBN|effects|mg|were|in|. (l_nsubjpass) effects_3\NNS|the|direct|nephrotoxic|of (l_amod) nephrotoxic_2\JJ|
D014527_D007674 NONE acid_39\NN|uric (r_pobj) of_37\IN|acid (r_prep) dL_36\NN|5|mg|/|of (r_pobj) of_32\IN|dl (r_prep) addition_31\NN|the|of (r_pobj) without_29\IN|addition (r_conj) with_27\IN|or|without (r_prep) buffer_26\NN|free|with (r_pobj) with_22\IN|buffer (r_prep) perfused_21\VBN|with (r_acl) kidney_20\NN|the|recirculating|isolated|rat|perfused (r_pobj) in_15\IN|kidney (r_prep) compared_14\VBN|effects|mg|were|in|. (l_nsubjpass) effects_3\NNS|the|direct|nephrotoxic|of (l_amod) nephrotoxic_2\JJ|
D014527_D058186 NONE acid_21\NN|uric (r_pobj) of_19\IN|acid (r_prep) distribution_18\NN|the|intrarenal|of (r_dobj) altering_15\VBG|directly|distribution (r_pcomp) by_13\IN|altering (r_prep) likely_12\JJ|most|by (r_advcl) causes_4\VBZ|in|,|suprofen|declines|,|likely|. (l_dobj) declines_6\NNS|acute|in (l_prep) in_7\IN|function (l_pobj) function_9\NN|renal
8888541
C047426_D020230 CID venlafaxine_3\NNP| (r_compound) tranylcypromine_5\NN|venlafaxine|- (r_compound) interaction_6\NN|tranylcypromine (r_pobj) from_2\IN|interaction (r_prep) syndrome_1\NN|serotonin|from|.
C047426_D020230 CID venlafaxine_3\NNP| (r_compound) MAOI_5\NNP|venlafaxine|- (r_compound) interaction_6\NN|a|maoi|resulted (l_relcl) resulted_8\VBD|that|in|in (l_prep) in_9\IN|syndrome (l_pobj) syndrome_12\NN|the|serotonin
D014191_D020230 CID tranylcypromine_5\NN|venlafaxine|- (r_compound) interaction_6\NN|tranylcypromine (r_pobj) from_2\IN|interaction (r_prep) syndrome_1\NN|serotonin|from|.
D014191_D020230 CID tranylcypromine_22\NN|for (r_dobj) taking_21\VBG|who|was|tranylcypromine (r_relcl) male_18\NN|a|old|taking (r_pobj) in_13\IN|male (r_prep) resulted_8\VBD|that|in|in (l_prep) in_9\IN|syndrome (l_pobj) syndrome_12\NN|the|serotonin
D012701_D009127 NONE serotonin_3\NN| (r_nmod) receptors_5\NNS|serotonin|5ht1a (r_pobj) of_2\IN|receptors (r_prep) stimulation_1\NN|excessive|of (r_nsubj) causes_6\VBZ|stimulation|syndrome|. (l_dobj) syndrome_8\NN|a|of (l_prep) of_9\IN|excess (l_pobj) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation
D012701_D009127 NONE serotonin_10\NN| (r_compound) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation
D012701_D012798 NONE serotonin_3\NN| (r_nmod) receptors_5\NNS|serotonin|5ht1a (r_pobj) of_2\IN|receptors (r_prep) stimulation_1\NN|excessive|of (r_nsubj) causes_6\VBZ|stimulation|syndrome|. (l_dobj) syndrome_8\NN|a|of (l_prep) of_9\IN|excess (l_pobj) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion
D012701_D012798 NONE serotonin_10\NN| (r_compound) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion
D012701_D003221 NONE serotonin_3\NN| (r_nmod) receptors_5\NNS|serotonin|5ht1a (r_pobj) of_2\IN|receptors (r_prep) stimulation_1\NN|excessive|of (r_nsubj) causes_6\VBZ|stimulation|syndrome|. (l_dobj) syndrome_8\NN|a|of (l_prep) of_9\IN|excess (l_pobj) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion (l_conj) confusion_22\NN|,|agitation
D012701_D003221 NONE serotonin_10\NN| (r_compound) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion (l_conj) confusion_22\NN|,|agitation
D012701_D011595 NONE serotonin_3\NN| (r_nmod) receptors_5\NNS|serotonin|5ht1a (r_pobj) of_2\IN|receptors (r_prep) stimulation_1\NN|excessive|of (r_nsubj) causes_6\VBZ|stimulation|syndrome|. (l_dobj) syndrome_8\NN|a|of (l_prep) of_9\IN|excess (l_pobj) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion (l_conj) confusion_22\NN|,|agitation (l_conj) agitation_24\NN|and|hyperthermia
D012701_D011595 NONE serotonin_10\NN| (r_compound) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion (l_conj) confusion_22\NN|,|agitation (l_conj) agitation_24\NN|and|hyperthermia
D012701_D005334 NONE serotonin_3\NN| (r_nmod) receptors_5\NNS|serotonin|5ht1a (r_pobj) of_2\IN|receptors (r_prep) stimulation_1\NN|excessive|of (r_nsubj) causes_6\VBZ|stimulation|syndrome|. (l_dobj) syndrome_8\NN|a|of (l_prep) of_9\IN|excess (l_pobj) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion (l_conj) confusion_22\NN|,|agitation (l_conj) agitation_24\NN|and|hyperthermia (l_conj) hyperthermia_26\NN|
D012701_D005334 NONE serotonin_10\NN| (r_compound) excess_11\NN|serotonin|consists (l_relcl) consists_13\VBZ|that|of (l_prep) of_14\IN|shivering (l_pcomp) shivering_15\VBG|,|rigidity (l_conj) rigidity_18\NN|muscle|,|salivation (l_conj) salivation_20\NN|,|confusion (l_conj) confusion_22\NN|,|agitation (l_conj) agitation_24\NN|and|hyperthermia (l_conj) hyperthermia_26\NN|
C047426_D003866 NONE venlafaxine_3\NNP| (r_compound) MAOI_5\NNP|venlafaxine|- (r_compound) interaction_6\NN|a|maoi|resulted (l_relcl) resulted_8\VBD|that|in|in (l_prep) in_13\IN|male (l_pobj) male_18\NN|a|old|taking (l_relcl) taking_21\VBG|who|was|tranylcypromine (l_dobj) tranylcypromine_22\NN|for (l_prep) for_23\IN|depression (l_pobj) depression_24\NN|
D014191_D003866 NONE tranylcypromine_22\NN|for (l_prep) for_23\IN|depression (l_pobj) depression_24\NN|
D003975_D009127 NONE diazepam_4\NN| (r_pobj) of_3\IN|diazepam (r_prep) mg_2\NN|180|of|i.v. (r_pobj) After_0\IN|mg (r_prep) remained_7\VBD|after|he|tremulous|. (l_acomp) tremulous_8\JJ|with (l_prep) with_9\IN|rigidity (l_pobj) rigidity_11\NN|muscle|and|jaws
8514073
D008874_D014652 CID midazolam_3\FW|versus (r_pobj) of_2\IN|midazolam (r_prep) complications_1\NNS|venous|of|.
D008874_D014652 CID midazolam_11\DT|than (r_pobj) with_10\IN|midazolam (r_prep) associated_9\VBN|complications|are|with (l_nsubjpass) complications_7\NNS|fewer|venous
D008874_D014652 CID midazolam_14\NN| (r_conj) diazepam_12\NN|or|midazolam (r_pobj) of_11\IN|diazepam (r_prep) injection_10\NN|intravenous|of|in (r_pobj) after_8\IN|injection (r_prep) evaluated_2\VBD|we|prospectively|incidence|after|. (l_dobj) incidence_4\NN|the|of (l_prep) of_5\IN|complications (l_pobj) complications_7\NNS|venous
D008874_D014652 CID midazolam_17\NNP|patients (r_pobj) with_16\IN|midazolam (r_prep) than_15\IN|with|0.001 (r_prep) 22_10\CD|(|of|)|than (r_npadvmod) were_4\VBD|overall|,|complications|frequent|22|. (l_nsubj) complications_3\NNS|venous
D003975_D014652 CID diazepam_5\NN| (r_pobj) versus_4\FW|diazepam (r_prep) midazolam_3\FW|versus (r_pobj) of_2\IN|midazolam (r_prep) complications_1\NNS|venous|of|.
D003975_D014652 CID diazepam_14\NN|for (r_pobj) with_13\IN|diazepam (r_prep) than_12\IN|with (r_prep) midazolam_11\DT|than (r_pobj) with_10\IN|midazolam (r_prep) associated_9\VBN|complications|are|with (l_nsubjpass) complications_7\NNS|fewer|venous
D003975_D014652 CID diazepam_12\NN|or|midazolam (r_pobj) of_11\IN|diazepam (r_prep) injection_10\NN|intravenous|of|in (r_pobj) after_8\IN|injection (r_prep) evaluated_2\VBD|we|prospectively|incidence|after|. (l_dobj) incidence_4\NN|the|of (l_prep) of_5\IN|complications (l_pobj) complications_7\NNS|venous
D003975_D014652 CID diazepam_8\NN| (r_pobj) with_7\IN|diazepam (r_prep) frequent_6\JJ|more|with (r_acomp) were_4\VBD|overall|,|complications|frequent|22|. (l_nsubj) complications_3\NNS|venous
D003975_D010146 NONE diazepam_18\NN| (r_compound) group_19\NN|the|diazepam (r_pobj) in_16\IN|group (r_prep) patients_15\NNS|in (r_pobj) of_14\IN|patients (r_prep) %_8\NN|35|(|22|)|of (r_pobj) in_6\IN|% (r_prep) occurred_5\VBD|pain|in|compared|. (l_nsubj) Pain_0\NN|at
D008874_D010146 NONE midazolam_32\JJ| (r_amod) group_33\NN|the|midazolam (r_pobj) in_30\IN|group (r_prep) %_23\NN|7|(|patients|)|in|0.001 (r_pobj) with_21\IN|% (r_prep) compared_20\VBN|with (r_prep) occurred_5\VBD|pain|in|compared|. (l_nsubj) Pain_0\NN|at
D000431_D010146 NONE alcohol_19\NN| (r_compound) use_20\NN|alcohol|,|and|pain (l_conj) pain_23\NN|during
D000431_D014652 NONE alcohol_19\NN| (r_compound) use_20\NN|alcohol|,|and|pain (r_conj) time_14\NN|dwell|of|,|use (r_conj) site_11\NN|intravenous|catheter|,|time (r_conj) use_7\NN|nonsteroidal|inflammatory|drug|,|site (r_appos) Smoking_0\NN|,|use (r_nsubj) had_27\VBD|smoking|effect|. (l_dobj) effect_29\NN|no|on (l_prep) on_30\IN|incidence (l_pobj) incidence_32\NN|the|of (l_prep) of_33\IN|complications (l_pobj) complications_35\NNS|venous
2576810
D016666_D006948 CID fluvoxamine_4\NNP| (r_pobj) with_3\IN|fluvoxamine (r_prep) treatment_2\NN|a|repeated|with|(|daily|) (r_nsubj) potentiated_12\VBN|treatment|in|weaker|hyperactivity|. (l_dobj) hyperactivity_25\NN|the|induced
D016666_D006948 CID fluvoxamine_10\NN| (r_pobj) by_9\IN|fluvoxamine (r_prep) unaffected_8\JJ|by (r_acomp) remained_7\VBD|hyperactivity|unaffected|. (l_nsubj) hyperactivity_1\NN|the|induced
D000661_D006948 CID amphetamine_22\NN| (r_npadvmod) induced_24\VBN|amphetamine|- (r_amod) hyperactivity_25\NN|the|induced
D009627_D006948 CID nomifensine_4\NN|in (r_pobj) by_3\IN|nomifensine (r_agent) induced_2\VBN|by (r_acl) hyperactivity_1\NN|the|induced
8643973
D017239_D010051 NONE Paclitaxel_0\NNP|combined|. (l_acl) combined_1\VBD|with|in (l_prep) in_4\IN|treatment (l_pobj) treatment_9\NN|the|line|of (l_prep) of_10\IN|cancer (l_pobj) cancer_13\NN|advanced|ovarian
D017239_D010051 NONE paclitaxel_12\NN| (r_pobj) of_11\IN|paclitaxel (r_prep) dose_10\NN|the|maximum|tolerated|of|taxol (r_dobj) determine_6\VB|to|dose|given (l_prep) given_26\VBN|as (l_prep) as_27\IN|infusion (l_pobj) infusion_30\NN|a|3-hour|in|administered (l_acl) administered_35\VBN|days|to (l_prep) to_39\IN|women (l_pobj) women_40\NNS|with (l_prep) with_41\IN|cancer (l_pobj) cancer_44\NN|advanced|ovarian|,
D017239_D010051 NONE Taxol_14\NNP|(|;|company|) (r_appos) dose_10\NN|the|maximum|tolerated|of|taxol (r_dobj) determine_6\VB|to|dose|given (l_prep) given_26\VBN|as (l_prep) as_27\IN|infusion (l_pobj) infusion_30\NN|a|3-hour|in|administered (l_acl) administered_35\VBN|days|to (l_prep) to_39\IN|women (l_pobj) women_40\NNS|with (l_prep) with_41\IN|cancer (l_pobj) cancer_44\NN|advanced|ovarian|,
D017239_D010051 NONE paclitaxel_46\NN| (r_compound) doses_47\NNS|paclitaxel (r_nsubjpass) escalated_49\VBN|doses|were|follows|level|. (r_conj) study_4\VBP|in|i|determine|escalated (l_xcomp) determine_6\VB|to|dose|given (l_prep) given_26\VBN|as (l_prep) as_27\IN|infusion (l_pobj) infusion_30\NN|a|3-hour|in|administered (l_acl) administered_35\VBN|days|to (l_prep) to_39\IN|women (l_pobj) women_40\NNS|with (l_prep) with_41\IN|cancer (l_pobj) cancer_44\NN|advanced|ovarian|,
D016190_D010051 NONE carboplatin_3\NN| (r_pobj) with_2\IN|carboplatin (r_prep) combined_1\VBD|with|in (l_prep) in_4\IN|treatment (l_pobj) treatment_9\NN|the|line|of (l_prep) of_10\IN|cancer (l_pobj) cancer_13\NN|advanced|ovarian
D016190_D010051 NONE carboplatin_34\NN| (r_pobj) with_33\IN|carboplatin (r_prep) combination_32\NN|with (r_pobj) in_31\IN|combination (r_prep) infusion_30\NN|a|3-hour|in|administered (l_acl) administered_35\VBN|days|to (l_prep) to_39\IN|women (l_pobj) women_40\NNS|with (l_prep) with_41\IN|cancer (l_pobj) cancer_44\NN|advanced|ovarian|,
9270571
C095427_D020734 NONE A-86929_0\NNS|:|study|. (l_dep) study_4\NN|an|acute|in (l_prep) in_5\IN|monkeys (l_pobj) monkeys_10\NNS|parkinsonian|primed (l_amod) parkinsonian_6\JJ|
C095427_D020734 NONE A-86929_3\NNS| (r_punct) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_acomp) efficacious_6\JJ|as|in (l_prep) in_7\IN|alleviating (l_pcomp) alleviating_8\VBG|parkinsonism|as (l_dobj) parkinsonism_12\NN|induced
D007980_D020734 NONE levodopa_7\NN| (r_npadvmod) primed_9\VBN|levodopa|- (r_amod) monkeys_10\NNS|parkinsonian|primed (l_amod) parkinsonian_6\JJ|
D007980_D020734 NONE levodopa_14\NN|and|ly-171555 (r_pobj) as_13\IN|levodopa (r_prep) alleviating_8\VBG|parkinsonism|as (l_dobj) parkinsonism_12\NN|induced
D007980_D020734 NONE levodopa_25\RB| (r_npadvmod) induced_27\VBN|levodopa|- (r_amod) dyskinesias_28\NNS|the|induced|in (r_dobj) reproduce_23\VB|to|dyskinesias|than (r_xcomp) likely_21\JJ|less|reproduce (r_acomp) was_19\VBD|likely (r_conj) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_acomp) efficacious_6\JJ|as|in (l_prep) in_7\IN|alleviating (l_pcomp) alleviating_8\VBG|parkinsonism|as (l_dobj) parkinsonism_12\NN|induced
D007980_D020734 NONE levodopa_40\NN| (r_pobj) of_39\IN|levodopa (r_prep) challenge_38\NN|ly-171555|of (r_pobj) with_33\IN|challenge (r_prep) than_32\IN|with (r_prep) reproduce_23\VB|to|dyskinesias|than (r_xcomp) likely_21\JJ|less|reproduce (r_acomp) was_19\VBD|likely (r_conj) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_acomp) efficacious_6\JJ|as|in (l_prep) in_7\IN|alleviating (l_pcomp) alleviating_8\VBG|parkinsonism|as (l_dobj) parkinsonism_12\NN|induced
D004298_D010300 NONE dopamine_4\NN| (r_pobj) of_3\IN|dopamine (r_prep) utility_2\NN|the|clinical|of|agonists (l_appos) agonists_10\NNS|(|da|)|d1|receptor|in (l_prep) in_11\IN|treatment (l_pobj) treatment_13\NN|the|of (l_prep) of_14\IN|disease (l_pobj) disease_17\NN|parkinson|(|pd|)
D004298_D010300 NONE dopamine_4\NN| (r_pobj) of_3\IN|dopamine (r_prep) utility_2\NN|the|clinical|of|agonists (l_appos) agonists_10\NNS|(|da|)|d1|receptor|in (l_prep) in_11\IN|treatment (l_pobj) treatment_13\NN|the|of (l_prep) of_14\IN|disease (l_pobj) disease_17\NN|parkinson|(|pd|) (l_appos) PD_19\NNP|
D004298_D010300 NONE DA_6\NNP| (r_nmod) agonists_10\NNS|(|da|)|d1|receptor|in (l_prep) in_11\IN|treatment (l_pobj) treatment_13\NN|the|of (l_prep) of_14\IN|disease (l_pobj) disease_17\NN|parkinson|(|pd|)
D004298_D010300 NONE DA_6\NNP| (r_nmod) agonists_10\NNS|(|da|)|d1|receptor|in (l_prep) in_11\IN|treatment (l_pobj) treatment_13\NN|the|of (l_prep) of_14\IN|disease (l_pobj) disease_17\NN|parkinson|(|pd|) (l_appos) PD_19\NNP|
D004298_D010300 NONE DA_1\NNP| (r_compound) D1_2\NN|potent|da (r_compound) agents_4\NNS|d1|receptor|with|a-86929 (r_nsubj) are_23\VBP|agents|tools|. (l_attr) tools_26\NNS|potential|therapeutic|in|and|merit (l_prep) in_27\IN|pd (l_pobj) PD_28\NNP|
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|four|monkeys (r_pobj) in_10\IN|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (r_prep) study_9\NN|the|present|acute|response|in (r_dobj) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_dobj) dyskinesias_23\NNS|induced
D015632_D004409 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|four|monkeys (r_pobj) in_10\IN|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (r_prep) study_9\NN|the|present|acute|response|in (r_dobj) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_advcl) evaluate_25\VB|to|effects (l_dobj) effects_30\NNS|the|locomotor|on (l_amod) locomotor_27\NN|and|dyskinetic (l_conj) dyskinetic_29\JJ|
D015632_D004409 NONE MPTP)-exposed_14\VBN| (r_amod) monkeys_16\NNS|(|mptp)-exposed|cynomolgus|primed (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|four|monkeys (r_pobj) in_10\IN|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (r_prep) study_9\NN|the|present|acute|response|in (r_dobj) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_dobj) dyskinesias_23\NNS|induced
D015632_D004409 NONE MPTP)-exposed_14\VBN| (r_amod) monkeys_16\NNS|(|mptp)-exposed|cynomolgus|primed (r_appos) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_12\CD|four|monkeys (r_pobj) in_10\IN|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (r_prep) study_9\NN|the|present|acute|response|in (r_dobj) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_advcl) evaluate_25\VB|to|effects (l_dobj) effects_30\NNS|the|locomotor|on (l_amod) locomotor_27\NN|and|dyskinetic (l_conj) dyskinetic_29\JJ|
D015632_D004409 NONE MPTP_9\NNP| (r_npadvmod) induced_11\VBN|mptp|- (r_amod) parkinsonism_12\NN|induced (r_dobj) alleviating_8\VBG|parkinsonism|as (r_pcomp) in_7\IN|alleviating (r_prep) efficacious_6\JJ|as|in (r_acomp) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_conj) was_19\VBD|likely (l_acomp) likely_21\JJ|less|reproduce (l_xcomp) reproduce_23\VB|to|dyskinesias|than (l_dobj) dyskinesias_28\NNS|the|induced|in
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|levodopa|- (r_amod) dyskinesias_23\NNS|induced
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|levodopa|- (r_amod) dyskinesias_23\NNS|induced (r_dobj) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_advcl) evaluate_25\VB|to|effects (l_dobj) effects_30\NNS|the|locomotor|on (l_amod) locomotor_27\NN|and|dyskinetic (l_conj) dyskinetic_29\JJ|
D007980_D004409 CID levodopa_14\NN|and|ly-171555 (r_pobj) as_13\IN|levodopa (r_prep) alleviating_8\VBG|parkinsonism|as (r_pcomp) in_7\IN|alleviating (r_prep) efficacious_6\JJ|as|in (r_acomp) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_conj) was_19\VBD|likely (l_acomp) likely_21\JJ|less|reproduce (l_xcomp) reproduce_23\VB|to|dyskinesias|than (l_dobj) dyskinesias_28\NNS|the|induced|in
D007980_D004409 CID levodopa_25\RB| (r_npadvmod) induced_27\VBN|levodopa|- (r_amod) dyskinesias_28\NNS|the|induced|in
D007980_D004409 CID levodopa_40\NN| (r_pobj) of_39\IN|levodopa (r_prep) challenge_38\NN|ly-171555|of (r_pobj) with_33\IN|challenge (r_prep) than_32\IN|with (r_prep) reproduce_23\VB|to|dyskinesias|than (l_dobj) dyskinesias_28\NNS|the|induced|in
C095427_D004409 NONE A-86929_44\NNS|( (r_punct) ,_57\,|a-86929|) (r_punct) doses_35\NNS|four|(|from|)|of|,|agonist (r_pobj) with_33\IN|doses (r_prep) challenge_32\NN|with (r_pobj) on_31\IN|challenge (r_prep) effects_30\NNS|the|locomotor|on (r_dobj) evaluate_25\VB|to|effects (r_advcl) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_dobj) dyskinesias_23\NNS|induced
C095427_D004409 NONE A-86929_44\NNS|( (r_punct) ,_57\,|a-86929|) (r_punct) doses_35\NNS|four|(|from|)|of|,|agonist (r_pobj) with_33\IN|doses (r_prep) challenge_32\NN|with (r_pobj) on_31\IN|challenge (r_prep) effects_30\NNS|the|locomotor|on (l_amod) locomotor_27\NN|and|dyskinetic (l_conj) dyskinetic_29\JJ|
C095427_D004409 NONE 10-diol_55\JJ|hexahydro-2-propyl-3-thia-5-+|ena[c]phenathrene-9|- (r_punct) )_56\-RRB-|10-diol (r_punct) ,_57\,|a-86929|) (r_punct) doses_35\NNS|four|(|from|)|of|,|agonist (r_pobj) with_33\IN|doses (r_prep) challenge_32\NN|with (r_pobj) on_31\IN|challenge (r_prep) effects_30\NNS|the|locomotor|on (r_dobj) evaluate_25\VB|to|effects (r_advcl) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_dobj) dyskinesias_23\NNS|induced
C095427_D004409 NONE 10-diol_55\JJ|hexahydro-2-propyl-3-thia-5-+|ena[c]phenathrene-9|- (r_punct) )_56\-RRB-|10-diol (r_punct) ,_57\,|a-86929|) (r_punct) doses_35\NNS|four|(|from|)|of|,|agonist (r_pobj) with_33\IN|doses (r_prep) challenge_32\NN|with (r_pobj) on_31\IN|challenge (r_prep) effects_30\NNS|the|locomotor|on (l_amod) locomotor_27\NN|and|dyskinetic (l_conj) dyskinetic_29\JJ|
C095427_D004409 NONE A-86929_3\NNS| (r_punct) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_conj) was_19\VBD|likely (l_acomp) likely_21\JJ|less|reproduce (l_xcomp) reproduce_23\VB|to|dyskinesias|than (l_dobj) dyskinesias_28\NNS|the|induced|in
D004298_D004409 NONE DA_62\NNP| (r_compound) agonist_65\NN|a|selective|da|d1-like|receptor|with (r_appos) doses_35\NNS|four|(|from|)|of|,|agonist (r_pobj) with_33\IN|doses (r_prep) challenge_32\NN|with (r_pobj) on_31\IN|challenge (r_prep) effects_30\NNS|the|locomotor|on (r_dobj) evaluate_25\VB|to|effects (r_advcl) conducted_2\VBD|we|therefore|study|dyskinesias|evaluate|. (l_dobj) dyskinesias_23\NNS|induced
D004298_D004409 NONE DA_62\NNP| (r_compound) agonist_65\NN|a|selective|da|d1-like|receptor|with (r_appos) doses_35\NNS|four|(|from|)|of|,|agonist (r_pobj) with_33\IN|doses (r_prep) challenge_32\NN|with (r_pobj) on_31\IN|challenge (r_prep) effects_30\NNS|the|locomotor|on (l_amod) locomotor_27\NN|and|dyskinetic (l_conj) dyskinetic_29\JJ|
D015632_D020734 CID MPTP_9\NNP| (r_npadvmod) induced_11\VBN|mptp|- (r_amod) parkinsonism_12\NN|induced
C416545_D020734 NONE LY-171555_16\NNP| (r_conj) levodopa_14\NN|and|ly-171555 (r_pobj) as_13\IN|levodopa (r_prep) alleviating_8\VBG|parkinsonism|as (l_dobj) parkinsonism_12\NN|induced
C416545_D020734 NONE LY-171555_35\NNP|either|or|subsequent (r_amod) challenge_38\NN|ly-171555|of (r_pobj) with_33\IN|challenge (r_prep) than_32\IN|with (r_prep) reproduce_23\VB|to|dyskinesias|than (r_xcomp) likely_21\JJ|less|reproduce (r_acomp) was_19\VBD|likely (r_conj) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_acomp) efficacious_6\JJ|as|in (l_prep) in_7\IN|alleviating (l_pcomp) alleviating_8\VBG|parkinsonism|as (l_dobj) parkinsonism_12\NN|induced
C416545_D004409 NONE LY-171555_16\NNP| (r_conj) levodopa_14\NN|and|ly-171555 (r_pobj) as_13\IN|levodopa (r_prep) alleviating_8\VBG|parkinsonism|as (r_pcomp) in_7\IN|alleviating (r_prep) efficacious_6\JJ|as|in (r_acomp) was_4\VBD|administration|a-86929|efficacious|,|but|was|. (l_conj) was_19\VBD|likely (l_acomp) likely_21\JJ|less|reproduce (l_xcomp) reproduce_23\VB|to|dyskinesias|than (l_dobj) dyskinesias_28\NNS|the|induced|in
C416545_D004409 NONE LY-171555_35\NNP|either|or|subsequent (r_amod) challenge_38\NN|ly-171555|of (r_pobj) with_33\IN|challenge (r_prep) than_32\IN|with (r_prep) reproduce_23\VB|to|dyskinesias|than (l_dobj) dyskinesias_28\NNS|the|induced|in
C095427_D010300 NONE A-86929_13\NNS|(|hr|) (r_punct) agents_4\NNS|d1|receptor|with|a-86929 (r_nsubj) are_23\VBP|agents|tools|. (l_attr) tools_26\NNS|potential|therapeutic|in|and|merit (l_prep) in_27\IN|pd (l_pobj) PD_28\NNP|
9041081
D013256_D009798 NONE steroid_13\NN| (r_npadvmod) induced_15\VBN|steroid|- (r_amod) pressure_18\NN|induced|elevated|intraocular|(|iop
D013256_D009798 NONE steroid_2\NN|the|transient (r_npadvmod) induced_4\VBN|steroid|- (r_amod) rise_6\NN|induced|iop
D000305_D009798 CID corticosteroid_25\NN| (r_compound) therapy_26\NN|corticosteroid (r_nsubjpass) discontinued_28\VBN|after|therapy|was (r_advcl) resolved_23\VBD|that|discontinued (r_relcl) IOP_20\NNP|)|resolved (r_appos) pressure_18\NN|induced|elevated|intraocular|(|iop
17511042
C417083_D063726 CID alpha-2b_16\NN|pegylated|interferon|and|treatment (r_pobj) during_13\IN|alpha-2b (r_prep) parasitosis_6\NN|delusional|in|during
C417083_D063726 CID alpha-2b_17\CD|weekly (r_prep) present_1\VBP|we|woman|alpha-2b|. (l_dobj) woman_6\NN|a|old|developed (l_relcl) developed_8\VBD|who|parasitosis (l_dobj) parasitosis_11\NN|a|delusional|during
C417083_D019698 NONE alpha-2b_16\NN|pegylated|interferon|and|treatment (r_pobj) during_13\IN|alpha-2b (r_prep) parasitosis_6\NN|delusional|in|during (l_prep) in_7\IN|patient (l_pobj) patient_12\NN|a|chronic|c (l_compound) C_11\NN|hepatitis
D012254_D063726 CID ribavirin_18\JJ| (r_compound) treatment_19\NN|ribavirin (r_conj) alpha-2b_16\NN|pegylated|interferon|and|treatment (r_pobj) during_13\IN|alpha-2b (r_prep) parasitosis_6\NN|delusional|in|during
D012254_D063726 CID ribavirin_20\RB| (r_conj) weekly_18\RB|and|ribavirin (r_amod) alpha-2b_17\CD|weekly (r_prep) present_1\VBP|we|woman|alpha-2b|. (l_dobj) woman_6\NN|a|old|developed (l_relcl) developed_8\VBD|who|parasitosis (l_dobj) parasitosis_11\NN|a|delusional|during
D012254_D019698 NONE ribavirin_18\JJ| (r_compound) treatment_19\NN|ribavirin (r_conj) alpha-2b_16\NN|pegylated|interferon|and|treatment (r_pobj) during_13\IN|alpha-2b (r_prep) parasitosis_6\NN|delusional|in|during (l_prep) in_7\IN|patient (l_pobj) patient_12\NN|a|chronic|c (l_compound) C_11\NN|hepatitis
D012254_D019698 NONE ribavirin_10\RB| (r_conj) interferon_8\NN|and|ribavirin (r_pobj) with_7\IN|interferon (r_prep) patients_6\NNS|chronic|c|with (l_compound) C_5\NNP|hepatitis
3780814
D010634_D063646 NONE phenobarbital_5\JJ| (r_pobj) of_4\IN|phenobarbital (r_prep) action_3\NN|carcinogenic|of|given|. (l_amod) carcinogenic_2\JJ|anti|-
D010634_D063646 NONE phenobarbital_13\JJ|(|pb|) (r_pobj) of_12\IN|phenobarbital (r_prep) effect_11\NN|the|of|on (l_prep) on_25\IN|carcinogenesis (l_pobj) carcinogenesis_26\NN|
D010634_D063646 NONE PB_15\NNP|:|mg (r_appos) phenobarbital_13\JJ|(|pb|) (r_pobj) of_12\IN|phenobarbital (r_prep) effect_11\NN|the|of|on (l_prep) on_25\IN|carcinogenesis (l_pobj) carcinogenesis_26\NN|
D010634_D063646 NONE PB_15\NNP| (r_conj) DEN_13\NNP|+|pb (r_pobj) by_12\IN|den (r_conj) by_8\IN|den|or|by (r_agent) treated_7\VBN|rats|were|by|during|according|. (l_prep) according_23\VBG|to (l_prep) to_24\IN|schedule (l_pobj) schedule_26\NN|our|for (l_prep) for_27\IN|hepatocarcinogenesis (l_pobj) hepatocarcinogenesis_28\NN|
D010634_D063646 NONE PB_4\NNP|,|promotes|, (l_relcl) promotes_7\VBZ|which|carcinogenesis|administered (l_dobj) carcinogenesis_8\NN|
D004052_D063646 NONE diethylnitrosamine_9\NN|in (r_pobj) with_8\IN|diethylnitrosamine (r_prep) given_6\VBN|simultaneously|with (r_prep) action_3\NN|carcinogenic|of|given|. (l_amod) carcinogenic_2\JJ|anti|-
D004052_D063646 NONE diethylnitrosamine_33\JJ| (r_pobj) with_32\IN|diethylnitrosamine (r_prep) administered_30\VBN|when|it|is|simultaneously|with (r_advcl) elucidate_9\VB|to|effect|administered (l_dobj) effect_11\NN|the|of|on (l_prep) on_25\IN|carcinogenesis (l_pobj) carcinogenesis_26\NN|
D004052_D063646 NONE DEN_35\NNP|(|:|kg|) (r_parataxis) planned_5\VBN|work|has|been|in|den|. (l_prep) in_6\IN|order (l_pobj) order_7\NN|elucidate (l_acl) elucidate_9\VB|to|effect|administered (l_dobj) effect_11\NN|the|of|on (l_prep) on_25\IN|carcinogenesis (l_pobj) carcinogenesis_26\NN|
D004052_D063646 NONE DEN_9\NNP|alone (r_pobj) by_8\IN|den|or|by (r_agent) treated_7\VBN|rats|were|by|during|according|. (l_prep) according_23\VBG|to (l_prep) to_24\IN|schedule (l_pobj) schedule_26\NN|our|for (l_prep) for_27\IN|hepatocarcinogenesis (l_pobj) hepatocarcinogenesis_28\NN|
D004052_D063646 NONE DEN_13\NNP|+|pb (r_pobj) by_12\IN|den (r_conj) by_8\IN|den|or|by (r_agent) treated_7\VBN|rats|were|by|during|according|. (l_prep) according_23\VBG|to (l_prep) to_24\IN|schedule (l_pobj) schedule_26\NN|our|for (l_prep) for_27\IN|hepatocarcinogenesis (l_pobj) hepatocarcinogenesis_28\NN|
D004052_D063646 NONE DEN_13\NNP| (r_compound) treatment_14\NN|the|den (r_pobj) after_11\IN|treatment (r_prep) administered_10\VBN|when|after (r_advcl) promotes_7\VBZ|which|carcinogenesis|administered (l_dobj) carcinogenesis_8\NN|
D004052_D063646 NONE DEN_24\NNP| (r_pobj) with_23\IN|den (r_prep) given_21\VBN|when|simultaneously|with (r_advcl) reduces_16\VBZ|that|pb|effect|given (l_nsubj) PB_4\NNP|,|promotes|, (l_relcl) promotes_7\VBZ|which|carcinogenesis|administered (l_dobj) carcinogenesis_8\NN|
D010634_D011230 NONE PB_22\NNP| (r_nsubjpass) given_24\VBN|when|pb|was|simultaneously|with|for (r_advcl) reduced_20\VBN|after|,|number|was|significantly|given|. (l_nsubjpass) number_8\NN|the|and|size (l_conj) size_11\NN|the|of (l_prep) of_12\IN|induced (l_pcomp) induced_13\VBN|foci (l_dobj) foci_17\NN|pas|positive|preneoplastic
D004052_D011230 CID DEN_27\NNP| (r_pobj) with_26\IN|den (r_prep) given_24\VBN|when|pb|was|simultaneously|with|for (r_advcl) reduced_20\VBN|after|,|number|was|significantly|given|. (l_nsubjpass) number_8\NN|the|and|size (l_conj) size_11\NN|the|of (l_prep) of_12\IN|induced (l_pcomp) induced_13\VBN|foci (l_dobj) foci_17\NN|pas|positive|preneoplastic
D004052_D009369 NONE DEN_1\NNP|+|pb (r_nsubj) treated_4\VBN|den|rats (r_ccomp) was_9\VBD|in|treated|,|survival|prolonged|and|decreased (l_conj) decreased_15\VBD|incidence|as|. (l_nsubj) incidence_14\NN|the|tumor (l_compound) tumor_13\NN|
D004052_D009369 NONE DEN_23\NNP| (r_pobj) by_22\IN|den (r_agent) obtained_21\VBN|by|alone (r_acl) results_20\NNS|the|obtained (r_pobj) with_18\IN|results (r_prep) compared_17\VBN|with (r_prep) as_16\IN|compared (r_prep) decreased_15\VBD|incidence|as|. (l_nsubj) incidence_14\NN|the|tumor (l_compound) tumor_13\NN|
D010634_D009369 NONE PB_3\NNP| (r_conj) DEN_1\NNP|+|pb (r_nsubj) treated_4\VBN|den|rats (r_ccomp) was_9\VBD|in|treated|,|survival|prolonged|and|decreased (l_conj) decreased_15\VBD|incidence|as|. (l_nsubj) incidence_14\NN|the|tumor (l_compound) tumor_13\NN|
7650771
D004456_D064420 NONE iodide_8\NN| (r_compound) drops_10\VBZ|echothiophate|iodide|eye (r_pobj) of_6\IN|drops (r_prep) instillation_5\NN|ocular|of (r_pobj) from_3\IN|instillation (r_prep) resulting_2\VBG|from (r_acl) toxicity_1\NN|cholinergic|resulting|.
D004456_D018908 CID iodide_12\NN| (r_nmod) drops_14\NNS|echothiophate|iodide|ophthalmic (r_pobj) of_10\IN|drops (r_prep) use_9\NN|the|of (r_pobj) from_7\IN|use (r_prep) syndrome_6\NN|a|severe|cholinergic|from (r_dobj) developed_2\VBD|patient|syndrome|,|presented|. (l_conj) presented_16\VBN|with|and|given (l_prep) with_17\IN|weakness (l_pobj) weakness_20\NN|profound|muscle
D004456_D009157 NONE iodide_12\NN| (r_nmod) drops_14\NNS|echothiophate|iodide|ophthalmic (r_pobj) of_10\IN|drops (r_prep) use_9\NN|the|of (r_pobj) from_7\IN|use (r_prep) syndrome_6\NN|a|severe|cholinergic|from (r_dobj) developed_2\VBD|patient|syndrome|,|presented|. (l_conj) presented_16\VBN|with|and|given (l_conj) given_24\VBN|was|initially|diagnosis (l_dobj) diagnosis_26\NN|the|of (l_prep) of_27\IN|gravis (l_pobj) gravis_29\NN|myasthenia
6817363
C036466_D007859 NONE aniracetam_5\RB|the|novel|compound|(|ro (l_appos) Ro_7\NNP|13|)|upon (l_prep) upon_12\IN|learning (l_pobj) learning_14\NN|impaired|and|memory|in (l_conj) memory_16\NN|
C036466_D007859 NONE 5057_10\CD|- (r_prep) 13_8\CD|5057 (r_nummod) Ro_7\NNP|13|)|upon (l_prep) upon_12\IN|learning (l_pobj) learning_14\NN|impaired|and|memory|in (l_conj) memory_16\NN|
C036466_D008569 NONE aniracetam_5\RB|the|novel|compound|(|ro (l_appos) Ro_7\NNP|13|)|upon (l_prep) upon_12\IN|learning (l_pobj) learning_14\NN|impaired|and|memory|in (l_conj) memory_16\NN|
C036466_D008569 NONE 5057_10\CD|- (r_prep) 13_8\CD|5057 (r_nummod) Ro_7\NNP|13|)|upon (l_prep) upon_12\IN|learning (l_pobj) learning_14\NN|impaired|and|memory|in (l_conj) memory_16\NN|
C036466_D003072 NONE aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
C036466_D003072 NONE 5057_8\CD|- (r_prep) 13_6\CD|5057 (r_nummod) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
C036466_D003072 NONE 1-anisoyl-2-pyrrolidinone_10\CD| (r_appos) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
C036466_D003072 NONE aniracetam_12\JJ| (r_amod) doses_13\NNS|oral|aniracetam|of (r_pobj) at_10\IN|doses (r_prep) seen_9\VBN|improvements|were|at|. (l_nsubjpass) improvements_1\NNS|these|or|normalizations (l_conj) normalizations_3\NNS|of (l_prep) of_4\IN|functions (l_pobj) functions_7\NNS|impaired|cognitive
C036466_D006935 NONE aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
C036466_D006935 NONE aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_conj) prevention_116\NN|(|4|)|of|for|;|reversal (l_conj) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
C036466_D006935 NONE 5057_8\CD|- (r_prep) 13_6\CD|5057 (r_nummod) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
C036466_D006935 NONE 5057_8\CD|- (r_prep) 13_6\CD|5057 (r_nummod) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_conj) prevention_116\NN|(|4|)|of|for|;|reversal (l_conj) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD| (r_appos) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
C036466_D006935 NONE 1-anisoyl-2-pyrrolidinone_10\CD| (r_appos) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_conj) prevention_116\NN|(|4|)|of|for|;|reversal (l_conj) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
C036466_D000647 NONE aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_prep) of_75\IN|amnesia (l_pobj) amnesia_83\NN|the|induced|term
C036466_D000647 NONE aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
C036466_D000647 NONE 5057_8\CD|- (r_prep) 13_6\CD|5057 (r_nummod) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_prep) of_75\IN|amnesia (l_pobj) amnesia_83\NN|the|induced|term
C036466_D000647 NONE 5057_8\CD|- (r_prep) 13_6\CD|5057 (r_nummod) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD| (r_appos) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_prep) of_75\IN|amnesia (l_pobj) amnesia_83\NN|the|induced|term
C036466_D000647 NONE 1-anisoyl-2-pyrrolidinone_10\CD| (r_appos) Ro_5\NNP|13|,|1-anisoyl-2-pyrrolidinone (r_appos) aniracetam_3\NN|(|ro|) (r_pobj) of_2\IN|aniracetam (r_prep) effect_1\NN|the|of (r_nsubjpass) studied_13\VBN|effect|was|on|and|produced|. (l_conj) produced_30\VBD|effects (l_dobj) effects_33\NNS|the|following|:|prevention (l_appos) prevention_40\NN|1|complete|of|;|rats (l_conj) rats_67\NNS|(|2|(|)|or|prevention (l_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
D012601_D003072 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|scopolamine|- (r_amod) amnesia_83\NN|the|induced|term (r_pobj) of_75\IN|amnesia (r_prep) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (r_appos) effects_33\NNS|the|following|:|prevention (r_dobj) produced_30\VBD|effects (r_conj) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
D012601_D006935 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|scopolamine|- (r_amod) amnesia_83\NN|the|induced|term (r_pobj) of_75\IN|amnesia (r_prep) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
D012601_D006935 NONE scopolamine_77\NN| (r_npadvmod) induced_79\VBN|scopolamine|- (r_amod) amnesia_83\NN|the|induced|term (r_pobj) of_75\IN|amnesia (r_prep) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_conj) prevention_116\NN|(|4|)|of|for|;|reversal (l_conj) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
D012601_D000647 CID scopolamine_77\NN| (r_npadvmod) induced_79\VBN|scopolamine|- (r_amod) amnesia_83\NN|the|induced|term
D012601_D000647 CID scopolamine_77\NN| (r_npadvmod) induced_79\VBN|scopolamine|- (r_amod) amnesia_83\NN|the|induced|term (r_pobj) of_75\IN|amnesia (r_prep) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
D002701_D003072 NONE chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (r_appos) effects_33\NNS|the|following|:|prevention (r_dobj) produced_30\VBD|effects (r_conj) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
D002701_D006935 NONE chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
D002701_D006935 NONE chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (l_conj) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
D002701_D000647 NONE chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_prep) of_75\IN|amnesia (l_pobj) amnesia_83\NN|the|induced|term
D002701_D000647 NONE chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
D003513_D003072 NONE cycloheximide_140\NN| (r_conj) chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (r_appos) effects_33\NNS|the|following|:|prevention (r_dobj) produced_30\VBD|effects (r_conj) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
D003513_D003072 NONE cycloheximide_177\NN| (r_pobj) by_176\IN|cycloheximide (r_agent) induced_175\VBN|by (r_acl) task_174\NN|a|passive|avoidance|induced (r_pobj) of_170\IN|task (r_prep) retention_167\NN|or|retrieval|of (r_pobj) in_166\IN|retention (r_prep) deficit_165\NN|the|in (r_pobj) of_163\IN|deficit (r_prep) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (r_conj) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (r_appos) effects_33\NNS|the|following|:|prevention (r_dobj) produced_30\VBD|effects (r_conj) studied_13\VBN|effect|was|on|and|produced|. (l_prep) on_14\IN|forms (l_pobj) forms_16\NNS|various|of|in (l_prep) of_17\IN|functions (l_pobj) functions_21\NNS|impaired|cognitive|(|learning|)
D003513_D006935 NONE cycloheximide_140\NN| (r_conj) chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
D003513_D006935 NONE cycloheximide_140\NN| (r_conj) chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (l_conj) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
D003513_D006935 NONE cycloheximide_177\NN| (r_pobj) by_176\IN|cycloheximide (r_agent) induced_175\VBN|by (r_acl) task_174\NN|a|passive|avoidance|induced (r_pobj) of_170\IN|task (r_prep) retention_167\NN|or|retrieval|of (r_pobj) in_166\IN|retention (r_prep) deficit_165\NN|the|in (r_pobj) of_163\IN|deficit (r_prep) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (r_conj) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (r_conj) rats_67\NNS|(|2|(|)|or|prevention (r_conj) prevention_40\NN|1|complete|of|;|rats (l_prep) of_41\IN|incapacity (l_pobj) incapacity_43\NN|the|learn (l_acl) learn_45\VB|to|response (l_dobj) response_49\NN|a|discrete|escape|in (l_prep) in_50\IN|rats (l_pobj) rats_51\NNS|exposed (l_acl) exposed_52\VBN|to|before (l_prep) to_53\IN|hypercapnia (l_pobj) hypercapnia_55\NN|sublethal
D003513_D006935 NONE cycloheximide_177\NN| (r_pobj) by_176\IN|cycloheximide (r_agent) induced_175\VBN|by (r_acl) task_174\NN|a|passive|avoidance|induced (r_pobj) of_170\IN|task (r_prep) retention_167\NN|or|retrieval|of (r_pobj) in_166\IN|retention (r_prep) deficit_165\NN|the|in (r_pobj) of_163\IN|deficit (r_prep) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (l_conj) prevention_186\NN|(|6|)|of|in (l_prep) in_190\IN|retrieval (l_pobj) retrieval_192\NN|the|of (l_prep) of_193\IN|task (l_pobj) task_197\NN|an|active|avoidance|induced|applied (l_acl) induced_198\VBN|in|by (l_agent) by_201\IN|electroshock (l_pobj) electroshock_203\NN|subconvulsant|or|hypercapnia (l_conj) hypercapnia_205\NN|
D003513_D000647 NONE cycloheximide_140\NN| (r_conj) chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_prep) of_75\IN|amnesia (l_pobj) amnesia_83\NN|the|induced|term
D003513_D000647 NONE cycloheximide_140\NN| (r_conj) chloramphenicol_138\NN|or|cycloheximide (r_pobj) by_137\IN|chloramphenicol (r_agent) induced_132\VBN|in|by (r_acl) task_131\NN|a|passive|avoidance|induced|administered (r_pobj) for_127\IN|task (r_prep) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
D003513_D000647 NONE cycloheximide_177\NN| (r_pobj) by_176\IN|cycloheximide (r_agent) induced_175\VBN|by (r_acl) task_174\NN|a|passive|avoidance|induced (r_pobj) of_170\IN|task (r_prep) retention_167\NN|or|retrieval|of (r_pobj) in_166\IN|retention (r_prep) deficit_165\NN|the|in (r_pobj) of_163\IN|deficit (r_prep) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (r_conj) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (r_conj) prevention_74\NN|complete|(|mice|)|of|for|;|protection (l_prep) of_75\IN|amnesia (l_pobj) amnesia_83\NN|the|induced|term
D003513_D000647 NONE cycloheximide_177\NN| (r_pobj) by_176\IN|cycloheximide (r_agent) induced_175\VBN|by (r_acl) task_174\NN|a|passive|avoidance|induced (r_pobj) of_170\IN|task (r_prep) retention_167\NN|or|retrieval|of (r_pobj) in_166\IN|retention (r_prep) deficit_165\NN|the|in (r_pobj) of_163\IN|deficit (r_prep) reversal_149\NN|(|5|)|,|administered|h|,|of|injected|;|prevention (r_conj) prevention_116\NN|(|4|)|of|for|;|reversal (r_conj) protection_94\NN|3|complete|against|for|;|prevention (l_prep) against_95\IN|amnesia (l_pobj) amnesia_96\NN|
15266362
D004280_D002312 NONE dobutamine_22\NN| (r_compound) infusion_23\NN|dobutamine|and|drugs (r_pobj) with_21\IN|infusion (r_prep) managed_19\VBD|aggressively|with|assessed (r_conj) admitted_14\VBN|patient|was|with|and|managed|. (l_nsubjpass) patient_5\NN|the|old|female|,|known|, (l_acl) known_7\VBN|have (l_xcomp) have_9\VB|to|cardiomyopathy (l_dobj) cardiomyopathy_11\NN|hypertrophic
D004280_D018754 NONE dobutamine_22\NN| (r_compound) infusion_23\NN|dobutamine|and|drugs (r_pobj) with_21\IN|infusion (r_prep) managed_19\VBD|aggressively|with|assessed (r_conj) admitted_14\VBN|patient|was|with|and|managed|. (l_prep) with_15\IN|failure (l_pobj) failure_17\NN|biventricular
D004280_D004342 CID dobutamine_13\NN|to|therapy (r_xcomp) related_11\VBN|that|hypersensitivity|was|dobutamine (l_nsubjpass) hypersensitivity_5\NN|the|(|eosinophilic|)|myocarditis
D004280_D004802 CID dobutamine_13\NN|to|therapy (r_xcomp) related_11\VBN|that|hypersensitivity|was|dobutamine (l_nsubjpass) hypersensitivity_5\NN|the|(|eosinophilic|)|myocarditis (l_amod) eosinophilic_7\JJ|
D004280_D009205 CID dobutamine_13\NN|to|therapy (r_xcomp) related_11\VBN|that|hypersensitivity|was|dobutamine (l_nsubjpass) hypersensitivity_5\NN|the|(|eosinophilic|)|myocarditis (l_amod) myocarditis_9\NN|
2569282
D020927_D009127 NONE Dexmedetomidine_0\NNP| (r_nsubj) prevents_8\VBZ|dexmedetomidine|,|acting|,|rigidity|. (l_dobj) rigidity_13\NN|induced|muscle|in
D020927_D009127 NONE MED_13\NNP|d|- (r_pobj) with_10\IN|med (r_prep) treatment_9\NN|with (r_nsubj) prevents_14\VBZ|if|treatment|rigidity (l_dobj) rigidity_17\NN|the|muscle|caused
D020927_D009127 NONE MED_5\NNP|d|- (r_nsubj) prevented_6\VBD|in|,|med|rigidity|. (l_dobj) rigidity_11\NN|induced|muscle|in
D020927_D009123 NONE dexmedetomidine_7\NN|the|selective|alpha-2|agonist|med (r_nsubj) is_13\VBZ|dexmedetomidine|capable|. (l_acomp) capable_14\JJ|of (l_prep) of_15\IN|inducing (l_pcomp) inducing_16\VBG|flaccidity (l_dobj) flaccidity_18\NN|muscle|and|anesthesia|in
D020927_D009123 NONE MED_11\NNP|(|d|-|) (r_appos) dexmedetomidine_7\NN|the|selective|alpha-2|agonist|med (r_nsubj) is_13\VBZ|dexmedetomidine|capable|. (l_acomp) capable_14\JJ|of (l_prep) of_15\IN|inducing (l_pcomp) inducing_16\VBG|flaccidity (l_dobj) flaccidity_18\NN|muscle|and|anesthesia|in
D015760_D009127 CID alfentanil_23\NN| (r_compound) anesthesia_24\NN|dose|alfentanil|in (r_pobj) by_19\IN|anesthesia (r_agent) caused_18\VBN|by (r_acl) rigidity_17\NN|the|muscle|caused
D015760_D009127 CID alfentanil_7\NN| (r_npadvmod) induced_9\VBN|alfentanil|- (r_amod) rigidity_11\NN|induced|muscle|in
D020927_D018476 NONE MED_6\NNP|d|- (r_compound) animals_7\NNS|the|dose|med (r_nsubj) were_8\VBD|animals|flaccid|,|and|lacked|. (l_acomp) flaccid_9\JJ|,|akinetic (l_conj) akinetic_11\JJ|
D020927_D012021 NONE MED_6\NNP|d|- (r_compound) animals_7\NNS|the|dose|med (r_nsubj) were_8\VBD|animals|flaccid|,|and|lacked|. (l_conj) lacked_14\VBD|response (l_dobj) response_17\NN|a|startle|during (l_compound) startle_16\JJ|
8841157
C081489_D006973 NONE Valsartan_0\NNP|,|antagonist|:|study|. (l_appos) antagonist_6\NN|a|angiotensin|ii|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|hypertension (l_pobj) hypertension_12\NN|essential
C081489_D006973 NONE valsartan_27\NN|80|mg|or|amlodipine (r_dobj) receive_24\VB|to|valsartan (r_advcl) allocated_14\VBN|outpatients|were|randomly|in|receive|. (l_nsubjpass) outpatients_6\NNS|hundred|eight|adult|with (l_prep) with_7\IN|hypertension (l_pobj) hypertension_11\NN|mild|moderate
C081489_D006973 NONE valsartan_4\NN| (r_nsubj) is_5\VBZ|that|valsartan|effective (l_acomp) effective_9\JJ|least|as|as (l_prep) as_10\IN|amlodipine (l_pobj) amlodipine_11\NN|in (l_prep) in_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|hypertension (l_pobj) hypertension_19\NN|mild|moderate
D000804_D006973 NONE II_5\CD| (r_compound) antagonist_6\NN|a|angiotensin|ii|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|hypertension (l_pobj) hypertension_12\NN|essential
D017311_D006973 NONE amlodipine_23\NN| (r_pobj) against_22\IN|amlodipine (r_prep) safety_21\NN|against (r_conj) efficacy_19\NN|the|and|safety (r_pobj) of_17\IN|efficacy (r_prep) study_16\NN|a|comparative|of (r_appos) Valsartan_0\NNP|,|antagonist|:|study|. (l_appos) antagonist_6\NN|a|angiotensin|ii|for (l_prep) for_7\IN|treatment (l_pobj) treatment_9\NN|the|of (l_prep) of_10\IN|hypertension (l_pobj) hypertension_12\NN|essential
D017311_D006973 NONE amlodipine_31\NN|mg|for (r_conj) valsartan_27\NN|80|mg|or|amlodipine (r_dobj) receive_24\VB|to|valsartan (r_advcl) allocated_14\VBN|outpatients|were|randomly|in|receive|. (l_nsubjpass) outpatients_6\NNS|hundred|eight|adult|with (l_prep) with_7\IN|hypertension (l_pobj) hypertension_11\NN|mild|moderate
D017311_D006973 NONE amlodipine_11\NN|in (l_prep) in_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|hypertension (l_pobj) hypertension_19\NN|mild|moderate
D017311_D004487 CID amlodipine_13\NN| (r_compound) group_14\NN|the|amlodipine (r_pobj) in_11\IN|group (r_prep) was_8\VBD|incidence|higher|in|,|at|%|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|edema (l_pobj) edema_7\NN|related|dependent
D017311_D004487 CID amlodipine_38\NN|mg (r_pobj) for_35\IN|amlodipine (r_prep) %_34\NN|3.6|for|;|%|;|%|) (r_npadvmod) was_8\VBD|incidence|higher|in|,|at|%|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|edema (l_pobj) edema_7\NN|related|dependent
D017311_D004487 CID amlodipine_47\NN|mg (r_conj) %_41\NN|0|for|plus|amlodipine (r_conj) %_34\NN|3.6|for|;|%|;|%|) (r_npadvmod) was_8\VBD|incidence|higher|in|,|at|%|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|edema (l_pobj) edema_7\NN|related|dependent
D017311_D004487 CID amlodipine_54\NN|mg (r_pobj) for_51\IN|amlodipine (r_prep) %_50\NN|14.3|for (r_appos) %_34\NN|3.6|for|;|%|;|%|) (r_npadvmod) was_8\VBD|incidence|higher|in|,|at|%|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|edema (l_pobj) edema_7\NN|related|dependent
C081489_D004487 CID valsartan_31\NN|80|mg (r_pobj) for_28\IN|valsartan (r_prep) %_27\NN|2.4|for (r_appos) dose_19\NN|a|of|(|%|; (r_pobj) at_17\IN|particularly|dose (r_prep) was_8\VBD|incidence|higher|in|,|at|%|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|edema (l_pobj) edema_7\NN|related|dependent
C081489_D004487 CID valsartan_43\NN| (r_pobj) for_42\IN|valsartan (r_prep) %_41\NN|0|for|plus|amlodipine (r_conj) %_34\NN|3.6|for|;|%|;|%|) (r_npadvmod) was_8\VBD|incidence|higher|in|,|at|%|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|edema (l_pobj) edema_7\NN|related|dependent
10027919
C051883_D006962 NONE 22-oxacalcitriol_0\JJ| (r_nsubj) suppresses_1\VBZ|22-oxacalcitriol|hyperparathyroidism|without|. (l_dobj) hyperparathyroidism_3\NN|secondary
C051883_D006962 NONE OCT_7\NNP|kg (r_nsubj) stabilized_14\VBD|in|,|oct|levels|during|. (l_prep) In_0\IN|hyperparathyroidism (l_pobj) hyperparathyroidism_5\NN|standing|secondary
C051883_D006962 NONE OCT_6\NNP| (r_nsubj) prevent_10\VB|even|though|oct|does|not|completely|occurrence (r_advcl) be_24\VB|that|prevent|,|it|may|of|in|induce (l_prep) in_27\IN|management (l_pobj) management_29\NN|the|of (l_prep) of_30\IN|hyperparathyroidism (l_pobj) hyperparathyroidism_32\NN|secondary
C051883_D001851 NONE 22-oxacalcitriol_0\JJ| (r_nsubj) suppresses_1\VBZ|22-oxacalcitriol|hyperparathyroidism|without|. (l_prep) without_4\IN|inducing (l_pcomp) inducing_5\VBG|turnover (l_dobj) turnover_8\NN|low|bone|in
C051883_D001851 NONE OCT_6\NNP| (r_nsubj) prevent_10\VB|even|though|oct|does|not|completely|occurrence (r_advcl) be_24\VB|that|prevent|,|it|may|of|in|induce (l_advcl) induce_37\VB|because|it|does|not|turnover|and|,|increase (l_dobj) turnover_40\NN|low|bone
C051883_D001851 NONE OCT_6\NNP| (r_nsubj) prevent_10\VB|even|though|oct|does|not|completely|occurrence (r_advcl) be_24\VB|that|prevent|,|it|may|of|in|induce (l_advcl) induce_37\VB|because|it|does|not|turnover|and|,|increase (l_conj) increase_47\VB|therefore|,|does|not|risk (l_dobj) risk_49\NN|the|of (l_prep) of_50\IN|disease (l_pobj) disease_53\NN|adynamic|bone
C051883_D051437 NONE 22-oxacalcitriol_0\JJ| (r_nsubj) suppresses_1\VBZ|22-oxacalcitriol|hyperparathyroidism|without|. (l_prep) without_4\IN|inducing (l_pcomp) inducing_5\VBG|turnover (l_dobj) turnover_8\NN|low|bone|in (l_prep) in_9\IN|dogs (l_pobj) dogs_10\NNS|with (l_prep) with_11\IN|failure (l_pobj) failure_13\NN|renal
C051883_D051437 NONE OCT_4\NNP| (r_nsubj) decreased_6\VBD|in|,|oct|significantly|levels|after|. (l_prep) after_11\IN|soon|induction (l_pobj) induction_13\NN|the|of (l_prep) of_14\IN|insufficiency (l_pobj) insufficiency_16\NN|renal
C051883_D051437 NONE OCT_6\NNP| (r_nsubj) prevent_10\VB|even|though|oct|does|not|completely|occurrence (l_dobj) occurrence_12\NN|the|of|in (l_prep) in_15\IN|dogs (l_pobj) dogs_17\NNS|experimental|with (l_prep) with_18\IN|insufficiency (l_pobj) insufficiency_20\NN|renal
D002117_D051437 NONE Calcitriol_0\NNP| (r_compound) therapy_1\NN|calcitriol (r_nsubj) suppresses_2\VBZ|therapy|levels|in|but|has|. (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|failure (l_pobj) failure_15\NN|renal
D002117_D006934 CID Calcitriol_0\NNP| (r_compound) therapy_1\NN|calcitriol (r_nsubj) suppresses_2\VBZ|therapy|levels|in|but|has|. (l_conj) has_17\VBZ|drawbacks (l_dobj) drawbacks_19\NNS|several|,|including (l_prep) including_21\VBG|hypercalcemia (l_pobj) hypercalcemia_22\NN|and/or|suppression
D002117_D001851 CID Calcitriol_0\NNP| (r_compound) therapy_1\NN|calcitriol (r_nsubj) suppresses_2\VBZ|therapy|levels|in|but|has|. (l_conj) has_17\VBZ|drawbacks (l_dobj) drawbacks_19\NNS|several|,|including (l_prep) including_21\VBG|hypercalcemia (l_pobj) hypercalcemia_22\NN|and/or|suppression (l_conj) suppression_25\NN|marked|of (l_prep) of_26\IN|turnover (l_pobj) turnover_28\NN|bone|,|lead
D002117_D001851 CID Calcitriol_0\NNP| (r_compound) therapy_1\NN|calcitriol (r_nsubj) suppresses_2\VBZ|therapy|levels|in|but|has|. (l_conj) has_17\VBZ|drawbacks (l_dobj) drawbacks_19\NNS|several|,|including (l_prep) including_21\VBG|hypercalcemia (l_pobj) hypercalcemia_22\NN|and/or|suppression (l_conj) suppression_25\NN|marked|of (l_prep) of_26\IN|turnover (l_pobj) turnover_28\NN|bone|,|lead (l_relcl) lead_32\VB|which|may|to (l_prep) to_33\IN|disease (l_pobj) disease_36\NN|adynamic|bone
C051883_D007674 NONE OCT_9\NNP| (r_pobj) of_8\IN|oct (r_prep) effects_7\NNS|the|of|on (l_prep) on_10\IN|levels (l_pobj) levels_13\NNS|serum|pth|and|turnover (l_conj) turnover_16\NN|bone|in (l_prep) in_17\IN|states (l_pobj) states_18\NNS|of (l_prep) of_19\IN|function (l_pobj) function_24\NN|normal|renal
C051883_-1 NONE OCT_4\NNP| (r_nsubj) reversed_5\VBD|in|,|oct|formation|,|but|alter|. (l_dobj) formation_8\NN|abnormal|bone|,|as (l_prep) as_11\IN|such|osteoid (l_pobj) osteoid_13\NN|woven|and|fibrosis
C051883_D005355 NONE OCT_4\NNP| (r_nsubj) reversed_5\VBD|in|,|oct|formation|,|but|alter|. (l_dobj) formation_8\NN|abnormal|bone|,|as (l_prep) as_11\IN|such|osteoid (l_pobj) osteoid_13\NN|woven|and|fibrosis (l_conj) fibrosis_15\NN|
C051883_D006934 CID OCT_6\NNP| (r_nsubj) prevent_10\VB|even|though|oct|does|not|completely|occurrence (l_dobj) occurrence_12\NN|the|of|in (l_prep) of_13\IN|hypercalcemia (l_pobj) hypercalcemia_14\NN|
10728962
D014667_D007022 CID Vasopressin_0\NN|in|. (l_prep) in_1\IN|treatment (l_pobj) treatment_3\NN|the|of (l_prep) of_4\IN|hypotension (l_pobj) hypotension_8\NN|induced|in
D014667_D007022 CID vasopressin_16\NN| (r_pobj) of_15\IN|vasopressin (r_prep) doses_14\NNS|low|of (r_nsubj) restored_17\VBD|in|doses|pressure|without|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|decompensated|heart|with (l_prep) with_6\IN|hypotension (l_pobj) hypotension_7\NN|after
D014667_D006333 NONE Vasopressin_0\NN|in|. (l_prep) in_1\IN|treatment (l_pobj) treatment_3\NN|the|of (l_prep) of_4\IN|hypotension (l_pobj) hypotension_8\NN|induced|in (l_prep) in_9\IN|failure (l_pobj) failure_12\NN|severe|heart
D014667_D006333 NONE vasopressin_16\NN| (r_pobj) of_15\IN|vasopressin (r_prep) doses_14\NNS|low|of (r_nsubj) restored_17\VBD|in|doses|pressure|without|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|decompensated|heart|with
D020105_D007022 CID milrinone_5\NN| (r_npadvmod) induced_7\VBN|milrinone|- (r_amod) hypotension_8\NN|induced|in
D020105_D007022 CID milrinone_7\NN|in (r_pobj) as_6\IN|such|milrinone (r_prep) inhibitors_4\NNS|phosphodiesterase|as (r_pobj) of_2\IN|inhibitors (r_prep) use_1\NN|the|of (r_nsubjpass) restricted_17\VBN|use|is|frequently|cause|. (l_advcl) cause_20\VBP|because|they|vasodilation (l_dobj) vasodilation_21\NN|and|hypotension (l_conj) hypotension_23\NN|
D020105_D007022 CID milrinone_11\NN|, (r_pobj) with_10\IN|milrinone (r_prep) treatment_9\NN|with (r_pobj) after_8\IN|treatment (r_prep) hypotension_7\NN|after
D020105_D007022 CID milrinone_26\NN| (r_pobj) of_25\IN|milrinone (r_prep) effect_24\NN|the|inotropic|of (r_dobj) inhibiting_21\VBG|effect (r_pcomp) without_20\IN|inhibiting (r_prep) restored_17\VBD|in|doses|pressure|without|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|decompensated|heart|with (l_prep) with_6\IN|hypotension (l_pobj) hypotension_7\NN|after
D020105_D006333 NONE milrinone_5\NN| (r_npadvmod) induced_7\VBN|milrinone|- (r_amod) hypotension_8\NN|induced|in (l_prep) in_9\IN|failure (l_pobj) failure_12\NN|severe|heart
D020105_D006333 NONE milrinone_7\NN|in (l_prep) in_8\IN|treatment (l_pobj) treatment_10\NN|the|of (l_prep) of_11\IN|failure (l_pobj) failure_14\NN|severe|heart
D020105_D006333 NONE milrinone_11\NN|, (r_pobj) with_10\IN|milrinone (r_prep) treatment_9\NN|with (r_pobj) after_8\IN|treatment (r_prep) hypotension_7\NN|after (r_pobj) with_6\IN|hypotension (r_prep) failure_5\NN|decompensated|heart|with
D020105_D006333 NONE milrinone_26\NN| (r_pobj) of_25\IN|milrinone (r_prep) effect_24\NN|the|inotropic|of (r_dobj) inhibiting_21\VBG|effect (r_pcomp) without_20\IN|inhibiting (r_prep) restored_17\VBD|in|doses|pressure|without|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|failure (l_pobj) failure_5\NN|decompensated|heart|with
9121607
D013256_D012640 NONE steroids_1\NNS|neuroactive (r_nsubj) protect_2\VBP|steroids|against|epilepticus|. (l_prep) against_3\IN|seizures (l_pobj) seizures_11\NNS|pilocarpine-|induced|limbic|and|status
D013256_D012640 NONE Steroids_0\NNS|with (r_nsubj) were_19\VBD|steroids|effective|mg/kg|values|. (l_parataxis) mg/kg_28\NNS|(|416|,|s.c.)-induced (l_conj) s.c.)-induced_30\VBN|seizures (l_dobj) seizures_33\NNS|limbic|motor|and|status
D013256_D012640 NONE steroids_3\NNS|the|neuroactive (r_nsubj) were_4\VBD|although|steroids|potent (l_acomp) potent_7\JJ|less|clonazepam (l_advcl) clonazepam_11\NN|than|the|benzodiazepine|in (l_prep) in_12\IN|protecting (l_pcomp) protecting_13\VBG|against (l_prep) against_14\IN|seizures (l_pobj) seizures_16\NNS|pilocarpine
D013256_D012640 NONE steroids_3\NNS|the|neuroactive (r_nsubj) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D013256_D012640 NONE steroids_18\NNS|with (r_nsubj) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) were_4\VBD|although|steroids|potent (l_acomp) potent_7\JJ|less|clonazepam (l_advcl) clonazepam_11\NN|than|the|benzodiazepine|in (l_prep) in_12\IN|protecting (l_pcomp) protecting_13\VBG|against (l_prep) against_14\IN|seizures (l_pobj) seizures_16\NNS|pilocarpine
D013256_D012640 NONE steroids_18\NNS|with (r_nsubj) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D013256_D012640 NONE steroids_52\NNS|some|neuroactive (r_nsubj) have_54\VB|that|steroids|may|toxicity (r_ccomp) indicating_48\VBG|have (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) were_4\VBD|although|steroids|potent (l_acomp) potent_7\JJ|less|clonazepam (l_advcl) clonazepam_11\NN|than|the|benzodiazepine|in (l_prep) in_12\IN|protecting (l_pcomp) protecting_13\VBG|against (l_prep) against_14\IN|seizures (l_pobj) seizures_16\NNS|pilocarpine
D013256_D012640 NONE steroids_52\NNS|some|neuroactive (r_nsubj) have_54\VB|that|steroids|may|toxicity (r_ccomp) indicating_48\VBG|have (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D013256_D012640 NONE Steroids_0\NNS|with (r_nsubj) produced_13\VBD|steroids|configurations|also|delay|,|but|protect|. (l_dobj) delay_18\NN|a|dependent|in|induced (l_prep) in_19\IN|onset (l_pobj) onset_21\NN|the|of (l_prep) of_22\IN|seizures (l_pobj) seizures_24\NNS|limbic
D013256_D012640 NONE Steroids_0\NNS|with (r_nsubj) produced_13\VBD|steroids|configurations|also|delay|,|but|protect|. (l_conj) protect_40\VB|did|not|completely|against (l_prep) against_41\IN|seizures (l_pobj) seizures_43\NNS|the
D013256_D012640 NONE steroid_8\NN|the (r_pobj) of_6\IN|steroid (r_prep) dose_5\NN|a|second|of (r_nsubjpass) administered_10\VBN|when|dose|was (r_advcl) hr_12\NN|however|,|administered|1|after (r_nmod) protection_19\NN|hr|,|complete|from (l_prep) from_20\IN|seizures (l_pobj) seizures_27\NNS|kainic|induced|limbic|and|epilepticus
D013256_D012640 NONE steroids_1\NNS|the (r_nsubj) caused_3\VBD|steroids|also|delay|,|but|protect|. (l_conj) protect_22\VB|did|not|completely|against (l_prep) against_23\IN|seizures (l_pobj) seizures_25\NNS|nmda|or|lethality
D013256_D012640 NONE steroids_4\NNS|neuroactive (r_nsubj) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_acomp) effective_7\JJ|highly|in (l_prep) in_8\IN|protecting (l_pcomp) protecting_9\VBG|against (l_prep) against_10\IN|seizures (l_pobj) seizures_17\NNS|pilocarpine-|induced|and|status
D013256_D013226 NONE steroids_1\NNS|neuroactive (r_nsubj) protect_2\VBP|steroids|against|epilepticus|. (l_advcl) epilepticus_14\NN|in
D013256_D013226 NONE Steroids_0\NNS|with (r_nsubj) were_19\VBD|steroids|effective|mg/kg|values|. (l_npadvmod) values_39\NNS|epilepticus|(|ed50|,|mg/kg|) (l_amod) epilepticus_36\NN|
D013256_D013226 NONE steroid_8\NN|the (r_pobj) of_6\IN|steroid (r_prep) dose_5\NN|a|second|of (r_nsubjpass) administered_10\VBN|when|dose|was (r_advcl) hr_12\NN|however|,|administered|1|after (r_nmod) protection_19\NN|hr|,|complete|from (l_prep) from_20\IN|seizures (l_pobj) seizures_27\NNS|kainic|induced|limbic|and|epilepticus (l_conj) epilepticus_30\NN|status
D013256_D013226 NONE steroids_4\NNS|neuroactive (r_nsubj) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_advcl) epilepticus_20\NN|in
D013256_D013226 NONE steroids_4\NNS|neuroactive (r_nsubj) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_conj) be_26\VB|may|of|in|epilepticus (l_advmod) epilepticus_37\NN|in
D010862_D012640 CID pilocarpine-_4\NN|and|kainic (r_nmod) seizures_11\NNS|pilocarpine-|induced|limbic|and|status
D010862_D012640 CID pilocarpine_25\NN| (r_pobj) against_24\IN|pilocarpine (r_prep) protecting_23\VBG|against (r_pcomp) in_22\IN|protecting (r_prep) effective_21\JJ|highly|in (r_acomp) were_19\VBD|steroids|effective|mg/kg|values|. (l_parataxis) mg/kg_28\NNS|(|416|,|s.c.)-induced (l_conj) s.c.)-induced_30\VBN|seizures (l_dobj) seizures_33\NNS|limbic|motor|and|status
D010862_D012640 CID pilocarpine_15\NN| (r_amod) seizures_16\NNS|pilocarpine
D010862_D012640 CID pilocarpine_15\NN| (r_amod) seizures_16\NNS|pilocarpine (r_pobj) against_14\IN|seizures (r_prep) protecting_13\VBG|against (r_pcomp) in_12\IN|protecting (r_prep) clonazepam_11\NN|than|the|benzodiazepine|in (r_advcl) potent_7\JJ|less|clonazepam (r_acomp) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D010862_D012640 CID pilocarpine-_11\NN|and|kainic (r_nmod) seizures_17\NNS|pilocarpine-|induced|and|status
D010862_D013226 CID pilocarpine-_4\NN|and|kainic (r_nmod) seizures_11\NNS|pilocarpine-|induced|limbic|and|status (r_pobj) against_3\IN|seizures (r_prep) protect_2\VBP|steroids|against|epilepticus|. (l_advcl) epilepticus_14\NN|in
D010862_D013226 CID pilocarpine_25\NN| (r_pobj) against_24\IN|pilocarpine (r_prep) protecting_23\VBG|against (r_pcomp) in_22\IN|protecting (r_prep) effective_21\JJ|highly|in (r_acomp) were_19\VBD|steroids|effective|mg/kg|values|. (l_npadvmod) values_39\NNS|epilepticus|(|ed50|,|mg/kg|) (l_amod) epilepticus_36\NN|
D010862_D013226 CID pilocarpine-_11\NN|and|kainic (r_nmod) seizures_17\NNS|pilocarpine-|induced|and|status (r_pobj) against_10\IN|seizures (r_prep) protecting_9\VBG|against (r_pcomp) in_8\IN|protecting (r_prep) effective_7\JJ|highly|in (r_acomp) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_advcl) epilepticus_20\NN|in
D010862_D013226 CID pilocarpine-_11\NN|and|kainic (r_nmod) seizures_17\NNS|pilocarpine-|induced|and|status (r_pobj) against_10\IN|seizures (r_prep) protecting_9\VBG|against (r_pcomp) in_8\IN|protecting (r_prep) effective_7\JJ|highly|in (r_acomp) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_conj) be_26\VB|may|of|in|epilepticus (l_advmod) epilepticus_37\NN|in
D007608_D012640 CID acid_7\NN| (r_npadvmod) induced_9\VBN|acid|- (r_amod) seizures_11\NNS|pilocarpine-|induced|limbic|and|status
D007608_D012640 CID acid_28\NN|kainic|mg/kg (r_pobj) by_26\IN|acid (r_agent) induced_25\VBN|by (r_acl) delay_18\NN|a|dependent|in|induced (l_prep) in_19\IN|onset (l_pobj) onset_21\NN|the|of (l_prep) of_22\IN|seizures (l_pobj) seizures_24\NNS|limbic
D007608_D012640 CID acid_28\NN|kainic|mg/kg (r_pobj) by_26\IN|acid (r_agent) induced_25\VBN|by (r_acl) delay_18\NN|a|dependent|in|induced (r_dobj) produced_13\VBD|steroids|configurations|also|delay|,|but|protect|. (l_conj) protect_40\VB|did|not|completely|against (l_prep) against_41\IN|seizures (l_pobj) seizures_43\NNS|the
D007608_D012640 CID acid_23\NN| (r_npadvmod) induced_25\VBN|acid|- (r_amod) seizures_27\NNS|kainic|induced|limbic|and|epilepticus
D007608_D012640 CID acid_14\NN| (r_npadvmod) induced_16\VBN|acid|- (r_amod) seizures_17\NNS|pilocarpine-|induced|and|status
D007608_D013226 CID acid_7\NN| (r_npadvmod) induced_9\VBN|acid|- (r_amod) seizures_11\NNS|pilocarpine-|induced|limbic|and|status (r_pobj) against_3\IN|seizures (r_prep) protect_2\VBP|steroids|against|epilepticus|. (l_advcl) epilepticus_14\NN|in
D007608_D013226 CID acid_23\NN| (r_npadvmod) induced_25\VBN|acid|- (r_amod) seizures_27\NNS|kainic|induced|limbic|and|epilepticus (l_conj) epilepticus_30\NN|status
D007608_D013226 CID acid_14\NN| (r_npadvmod) induced_16\VBN|acid|- (r_amod) seizures_17\NNS|pilocarpine-|induced|and|status (r_pobj) against_10\IN|seizures (r_prep) protecting_9\VBG|against (r_pcomp) in_8\IN|protecting (r_prep) effective_7\JJ|highly|in (r_acomp) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_advcl) epilepticus_20\NN|in
D007608_D013226 CID acid_14\NN| (r_npadvmod) induced_16\VBN|acid|- (r_amod) seizures_17\NNS|pilocarpine-|induced|and|status (r_pobj) against_10\IN|seizures (r_prep) protecting_9\VBG|against (r_pcomp) in_8\IN|protecting (r_prep) effective_7\JJ|highly|in (r_acomp) are_5\VBP|that|steroids|effective|epilepticus|,|and|be (l_conj) be_26\VB|may|of|in|epilepticus (l_advmod) epilepticus_37\NN|in
D016202_D012640 NONE aspartate_6\NNP|methyl|d|-|seizures|. (l_appos) seizures_9\NNS|(|nmda)-induced|in
D016202_D012640 NONE NMDA)-induced_8\JJ| (r_amod) seizures_9\NNS|(|nmda)-induced|in
D016202_D012640 NONE NMDA_10\NNP| (r_pobj) in_9\IN|nmda (r_prep) delay_8\NN|a|dependent|in|(|mg/kg (r_dobj) caused_3\VBD|steroids|also|delay|,|but|protect|. (l_conj) protect_22\VB|did|not|completely|against (l_prep) against_23\IN|seizures (l_pobj) seizures_25\NNS|nmda|or|lethality
D016202_D012640 NONE NMDA_24\NNP| (r_compound) seizures_25\NNS|nmda|or|lethality
D013256_D064420 NONE steroids_3\NNS|the|neuroactive (r_nsubj) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_48\VBG|have (l_ccomp) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
D013256_D064420 NONE steroids_18\NNS|with (r_nsubj) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_48\VBG|have (l_ccomp) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
D013256_D064420 NONE steroids_52\NNS|some|neuroactive (r_nsubj) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
D001569_D012640 NONE benzodiazepine_10\JJ| (r_amod) clonazepam_11\NN|than|the|benzodiazepine|in (l_prep) in_12\IN|protecting (l_pcomp) protecting_13\VBG|against (l_prep) against_14\IN|seizures (l_pobj) seizures_16\NNS|pilocarpine
D001569_D012640 NONE benzodiazepine_10\JJ| (r_amod) clonazepam_11\NN|than|the|benzodiazepine|in (r_advcl) potent_7\JJ|less|clonazepam (r_acomp) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D001569_D064420 NONE benzodiazepine_10\JJ| (r_amod) clonazepam_11\NN|than|the|benzodiazepine|in (r_advcl) potent_7\JJ|less|clonazepam (r_acomp) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_48\VBG|have (l_ccomp) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
D002998_D012640 NONE clonazepam_11\NN|than|the|benzodiazepine|in (l_prep) in_12\IN|protecting (l_pcomp) protecting_13\VBG|against (l_prep) against_14\IN|seizures (l_pobj) seizures_16\NNS|pilocarpine
D002998_D012640 NONE clonazepam_11\NN|than|the|benzodiazepine|in (r_advcl) potent_7\JJ|less|clonazepam (r_acomp) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D002998_D012640 NONE clonazepam_46\NN|than (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) were_4\VBD|although|steroids|potent (l_acomp) potent_7\JJ|less|clonazepam (l_advcl) clonazepam_11\NN|than|the|benzodiazepine|in (l_prep) in_12\IN|protecting (l_pcomp) protecting_13\VBG|against (l_prep) against_14\IN|seizures (l_pobj) seizures_16\NNS|pilocarpine
D002998_D012640 NONE clonazepam_46\NN|than (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_dobj) values_32\NNS|comparable|protective|index|(|td50|) (l_appos) TD50_34\NNP|for|divided (l_acl) divided_38\VBN|by|for (l_prep) for_41\IN|protection (l_pobj) protection_43\NN|seizure (l_compound) seizure_42\NN|
D002998_D064420 NONE clonazepam_11\NN|than|the|benzodiazepine|in (r_advcl) potent_7\JJ|less|clonazepam (r_acomp) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_48\VBG|have (l_ccomp) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
D002998_D064420 NONE clonazepam_46\NN|than (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_48\VBG|have (l_ccomp) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
D010862_D064420 NONE pilocarpine_15\NN| (r_amod) seizures_16\NNS|pilocarpine (r_pobj) against_14\IN|seizures (r_prep) protecting_13\VBG|against (r_pcomp) in_12\IN|protecting (r_prep) clonazepam_11\NN|than|the|benzodiazepine|in (r_advcl) potent_7\JJ|less|clonazepam (r_acomp) were_4\VBD|although|steroids|potent (r_advcl) had_26\VBD|were|,|steroids|values|clonazepam|,|indicating|. (l_advcl) indicating_48\VBG|have (l_ccomp) have_54\VB|that|steroids|may|toxicity (l_dobj) toxicity_57\NN|lower|relative
11704023
D013999_D005901 NONE timolol_6\NN|aqueous|ophthalmic|with|on (l_prep) on_9\IN|response (l_pobj) response_14\NN|the|24-hour|rate|in (l_prep) in_15\IN|patients (l_pobj) patients_16\NNS|on (l_prep) on_17\IN|treatment (l_pobj) treatment_18\NN|for (l_prep) for_19\IN|glaucoma (l_pobj) glaucoma_20\NN|
D013999_D005901 NONE timolol_11\NN|%|aqueous|(|solution|)|and|suspension (l_conj) suspension_21\NN|a|%|timolol|forms (l_relcl) forms_23\VBZ|that|gel|on (l_prep) on_26\IN|application (l_pobj) application_27\NN|to|on (l_prep) on_35\IN|rate (l_pobj) rate_39\NN|the|24-hour|heart|in (l_prep) in_40\IN|patients (l_pobj) patients_41\NNS|treated (l_acl) treated_44\VBN|currently|being|for|quantify (l_prep) for_45\IN|glaucoma (l_pobj) glaucoma_46\NN|
D013999_D005901 NONE timolol_13\NN| (r_compound) solution_14\NN|timolol (r_appos) timolol_11\NN|%|aqueous|(|solution|)|and|suspension (l_conj) suspension_21\NN|a|%|timolol|forms (l_relcl) forms_23\VBZ|that|gel|on (l_prep) on_26\IN|application (l_pobj) application_27\NN|to|on (l_prep) on_35\IN|rate (l_pobj) rate_39\NN|the|24-hour|heart|in (l_prep) in_40\IN|patients (l_pobj) patients_41\NNS|treated (l_acl) treated_44\VBN|currently|being|for|quantify (l_prep) for_45\IN|glaucoma (l_pobj) glaucoma_46\NN|
D013999_D005901 NONE timolol_20\NN| (r_compound) suspension_21\NN|a|%|timolol|forms (l_relcl) forms_23\VBZ|that|gel|on (l_prep) on_26\IN|application (l_pobj) application_27\NN|to|on (l_prep) on_35\IN|rate (l_pobj) rate_39\NN|the|24-hour|heart|in (l_prep) in_40\IN|patients (l_pobj) patients_41\NNS|treated (l_acl) treated_44\VBN|currently|being|for|quantify (l_prep) for_45\IN|glaucoma (l_pobj) glaucoma_46\NN|
D013999_D005901 NONE timolol_32\NN| (r_compound) gellan_33\NN|(|timolol|) (r_appos) conjunctiva_30\NN|the|gellan (r_pobj) to_28\IN|conjunctiva (r_prep) application_27\NN|to|on (l_prep) on_35\IN|rate (l_pobj) rate_39\NN|the|24-hour|heart|in (l_prep) in_40\IN|patients (l_pobj) patients_41\NNS|treated (l_acl) treated_44\VBN|currently|being|for|quantify (l_prep) for_45\IN|glaucoma (l_pobj) glaucoma_46\NN|
D013999_D005902 NONE timolol_56\NN| (r_compound) solution_57\NN|timolol|(|morning|)|,|or|gellan (r_conj) crossed_32\VBN|over|in|to|)|,|solution (r_conj) randomized_30\VBN|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS|three|caucasian|with (l_prep) with_5\IN|glaucoma (l_pobj) glaucoma_10\NN|primary|angle|or|hypertension
D013999_D005902 NONE timolol_68\NN| (r_compound) gellan_69\NN|timolol|(|morning|) (r_conj) solution_57\NN|timolol|(|morning|)|,|or|gellan (r_conj) crossed_32\VBN|over|in|to|)|,|solution (r_conj) randomized_30\VBN|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS|three|caucasian|with (l_prep) with_5\IN|glaucoma (l_pobj) glaucoma_10\NN|primary|angle|or|hypertension
D013999_D009798 NONE timolol_56\NN| (r_compound) solution_57\NN|timolol|(|morning|)|,|or|gellan (r_conj) crossed_32\VBN|over|in|to|)|,|solution (r_conj) randomized_30\VBN|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS|three|caucasian|with (l_prep) with_5\IN|glaucoma (l_pobj) glaucoma_10\NN|primary|angle|or|hypertension (l_conj) hypertension_13\NN|ocular|with
D013999_D009798 NONE timolol_68\NN| (r_compound) gellan_69\NN|timolol|(|morning|) (r_conj) solution_57\NN|timolol|(|morning|)|,|or|gellan (r_conj) crossed_32\VBN|over|in|to|)|,|solution (r_conj) randomized_30\VBN|patients|were|and|crossed|. (l_nsubjpass) patients_4\NNS|three|caucasian|with (l_prep) with_5\IN|glaucoma (l_pobj) glaucoma_10\NN|primary|angle|or|hypertension (l_conj) hypertension_13\NN|ocular|with
15897593
D064730_D001855 NONE Dexrazoxane_0\NNP| (r_nsubj) protects_1\VBZ|dexrazoxane|against|etoposide|. (l_prep) against_2\IN|myelosuppression (l_pobj) myelosuppression_3\NN|from
D064730_D001855 NONE dexrazoxane_3\NN| (r_npadvmod) reduced_4\VBN|dexrazoxane (r_amod) myelosuppression_5\NN|reduced|and|loss
D064730_D001855 NONE dexrazoxane_3\NN| (r_npadvmod) reduced_4\VBN|dexrazoxane (r_amod) myelosuppression_5\NN|reduced|and|loss (r_pobj) of_2\IN|myelosuppression (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss
D064730_D001855 NONE dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_nsubj) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss
D064730_D001855 NONE dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss
D005047_D001855 NONE etoposide_11\NN|and|daunorubicin|but|doxorubicin (r_advmod) protects_1\VBZ|dexrazoxane|against|etoposide|. (l_prep) against_2\IN|myelosuppression (l_pobj) myelosuppression_3\NN|from
D005047_D001855 NONE etoposide_8\NN| (r_appos) epipodophyllotoxin_7\NN|the|etoposide (r_conj) doxorubicin_4\NN|and|epipodophyllotoxin (r_conj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity
D005047_D001855 NONE etoposide_12\RB| (r_conj) daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss
D005047_D001855 NONE etoposide_12\RB| (r_conj) daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss
D003630_D001855 NONE daunorubicin_13\NNS| (r_conj) etoposide_11\NN|and|daunorubicin|but|doxorubicin (r_advmod) protects_1\VBZ|dexrazoxane|against|etoposide|. (l_prep) against_2\IN|myelosuppression (l_pobj) myelosuppression_3\NN|from
D003630_D001855 NONE daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity
D003630_D001855 NONE daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss
D003630_D001855 NONE daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss
D004317_D001855 NONE doxorubicin_16\RB|not (r_conj) etoposide_11\NN|and|daunorubicin|but|doxorubicin (r_advmod) protects_1\VBZ|dexrazoxane|against|etoposide|. (l_prep) against_2\IN|myelosuppression (l_pobj) myelosuppression_3\NN|from
D004317_D001855 NONE doxorubicin_4\NN|and|epipodophyllotoxin (r_conj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity
D004317_D001855 NONE doxorubicin_41\NN| (r_pobj) from_40\IN|doxorubicin (r_prep) cytotoxicity_39\NN|the|vitro|from (r_conj) loss_33\NN|weight|,|nor|cytotoxicity (r_conj) myelosuppression_30\NN|neither|reduced|,|loss (r_dobj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_nsubj) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss
D004317_D001855 NONE doxorubicin_41\NN| (r_pobj) from_40\IN|doxorubicin (r_prep) cytotoxicity_39\NN|the|vitro|from (r_conj) loss_33\NN|weight|,|nor|cytotoxicity (r_conj) myelosuppression_30\NN|neither|reduced|,|loss
D018943_D001855 NONE anthracyclines_1\NNS|the (r_nsubj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity
D018943_D066126 NONE anthracyclines_1\NNS|the (r_nsubj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity (l_conj) toxicity_29\NN|cardiac
D018943_D066126 NONE anthracycline_9\NN| (r_advmod) induced_11\VBN|anthracycline|- (r_amod) cardiotoxicity_12\NN|induced
D003630_D066126 NONE daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity (l_conj) toxicity_29\NN|cardiac
D004317_D066126 NONE doxorubicin_4\NN|and|epipodophyllotoxin (r_conj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity (l_conj) toxicity_29\NN|cardiac
D011034_D001855 NONE epipodophyllotoxin_7\NN|the|etoposide (r_conj) doxorubicin_4\NN|and|epipodophyllotoxin (r_conj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity
D011034_D066126 NONE epipodophyllotoxin_7\NN|the|etoposide (r_conj) doxorubicin_4\NN|and|epipodophyllotoxin (r_conj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity (l_conj) toxicity_29\NN|cardiac
D005047_D066126 NONE etoposide_8\NN| (r_appos) epipodophyllotoxin_7\NN|the|etoposide (r_conj) doxorubicin_4\NN|and|epipodophyllotoxin (r_conj) daunorubicin_2\NN|anthracyclines|and|doxorubicin|are (r_ccomp) limit_30\VBP|daunorubicin|;|however|,|myelosuppression|use|. (l_nsubj) myelosuppression_26\NN|and|toxicity (l_conj) toxicity_29\NN|cardiac
D064730_D066126 NONE Dexrazoxane_0\NNP|icrf-187 (r_nsubjpass) recommended_5\VBN|dexrazoxane|is|for|. (l_prep) for_6\IN|protection (l_pobj) protection_7\NN|against (l_prep) against_8\IN|cardiotoxicity (l_pobj) cardiotoxicity_12\NN|induced
D064730_D066126 NONE ICRF-187_2\NN|(|) (r_appos) Dexrazoxane_0\NNP|icrf-187 (r_nsubjpass) recommended_5\VBN|dexrazoxane|is|for|. (l_prep) for_6\IN|protection (l_pobj) protection_7\NN|against (l_prep) against_8\IN|cardiotoxicity (l_pobj) cardiotoxicity_12\NN|induced
D064730_D006402 NONE dexrazoxane_12\NN| (r_pobj) of_11\IN|dexrazoxane (r_prep) coadministration_10\NN|of|and (r_pobj) following_9\VBG|coadministration (r_prep) toxicity_8\NN|the|hematologic|following
D064730_D006402 NONE dexrazoxane_40\NN|+/- (r_dobj) doxorubicin_38\NN|dexrazoxane (r_conj) daunorubicin_35\NNS|,|and|doxorubicin (r_conj) etoposide_33\VB|,|daunorubicin (r_pobj) to_32\TO|etoposide (r_prep) Sensitivity_24\NN|of|to (r_nsubjpass) determined_42\VBN|investigated|sensitivity|was|in|. (l_advcl) investigated_22\VBN|because|,|toxicity|enhancers|was|: (l_nsubjpass) toxicity_8\NN|the|hematologic|following
D064730_D006402 NONE dexrazoxane_8\NN|and|high (r_nmod) doses_11\NNS|dexrazoxane|of (r_dobj) combining_7\VBG|doses (r_acl) metastases_6\NNS|brain|combining (r_pobj) with_4\IN|metastases (r_prep) patients_3\NNS|with (r_pobj) in_2\IN|patients (r_prep) trials_1\NNS|clinical|in (r_nsubj) is_14\VBZ|trials|ongoing|. (l_acomp) ongoing_15\JJ|with (l_prep) with_16\IN|aim (l_pobj) aim_18\NN|the|of (l_prep) of_19\IN|improving (l_pcomp) improving_20\VBG|efficacy|without (l_prep) without_22\IN|aggravating (l_pcomp) aggravating_23\VBG|toxicity (l_dobj) toxicity_25\NN|hematologic
D005047_D006402 CID etoposide_33\VB|,|daunorubicin (r_pobj) to_32\TO|etoposide (r_prep) Sensitivity_24\NN|of|to (r_nsubjpass) determined_42\VBN|investigated|sensitivity|was|in|. (l_advcl) investigated_22\VBN|because|,|toxicity|enhancers|was|: (l_nsubjpass) toxicity_8\NN|the|hematologic|following
D005047_D006402 CID etoposide_13\NN| (r_pobj) of_12\IN|etoposide (r_prep) doses_11\NNS|dexrazoxane|of (r_dobj) combining_7\VBG|doses (r_acl) metastases_6\NNS|brain|combining (r_pobj) with_4\IN|metastases (r_prep) patients_3\NNS|with (r_pobj) in_2\IN|patients (r_prep) trials_1\NNS|clinical|in (r_nsubj) is_14\VBZ|trials|ongoing|. (l_acomp) ongoing_15\JJ|with (l_prep) with_16\IN|aim (l_pobj) aim_18\NN|the|of (l_prep) of_19\IN|improving (l_pcomp) improving_20\VBG|efficacy|without (l_prep) without_22\IN|aggravating (l_pcomp) aggravating_23\VBG|toxicity (l_dobj) toxicity_25\NN|hematologic
D003630_D006402 CID daunorubicin_35\NNS|,|and|doxorubicin (r_conj) etoposide_33\VB|,|daunorubicin (r_pobj) to_32\TO|etoposide (r_prep) Sensitivity_24\NN|of|to (r_nsubjpass) determined_42\VBN|investigated|sensitivity|was|in|. (l_advcl) investigated_22\VBN|because|,|toxicity|enhancers|was|: (l_nsubjpass) toxicity_8\NN|the|hematologic|following
D004317_D006402 CID doxorubicin_38\NN|dexrazoxane (r_conj) daunorubicin_35\NNS|,|and|doxorubicin (r_conj) etoposide_33\VB|,|daunorubicin (r_pobj) to_32\TO|etoposide (r_prep) Sensitivity_24\NN|of|to (r_nsubjpass) determined_42\VBN|investigated|sensitivity|was|in|. (l_advcl) investigated_22\VBN|because|,|toxicity|enhancers|was|: (l_nsubjpass) toxicity_8\NN|the|hematologic|following
D064730_D015431 NONE dexrazoxane_3\NN| (r_npadvmod) reduced_4\VBN|dexrazoxane (r_amod) myelosuppression_5\NN|reduced|and|loss (l_conj) loss_8\NN|weight
D064730_D015431 NONE dexrazoxane_3\NN| (r_npadvmod) reduced_4\VBN|dexrazoxane (r_amod) myelosuppression_5\NN|reduced|and|loss (r_pobj) of_2\IN|myelosuppression (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity
D064730_D015431 NONE dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_nsubj) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss (l_conj) loss_8\NN|weight
D064730_D015431 NONE dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity
D064730_D064420 NONE dexrazoxane_3\NN| (r_npadvmod) reduced_4\VBN|dexrazoxane (r_amod) myelosuppression_5\NN|reduced|and|loss (r_pobj) of_2\IN|myelosuppression (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity (l_conj) cytotoxicity_39\NN|the|vitro|from
D064730_D064420 NONE dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity (l_conj) cytotoxicity_39\NN|the|vitro|from
D003630_D015431 CID daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss (l_conj) loss_8\NN|weight
D003630_D015431 CID daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity
D003630_D064420 NONE daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity (l_conj) cytotoxicity_39\NN|the|vitro|from
D005047_D015431 CID etoposide_12\RB| (r_conj) daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss (l_conj) loss_8\NN|weight
D005047_D015431 CID etoposide_12\RB| (r_conj) daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity
D005047_D064420 NONE etoposide_12\RB| (r_conj) daunorubicin_10\NN|and|etoposide (r_pobj) from_9\IN|daunorubicin (r_prep) doses_1\NNS|nontoxic|of|from|in|and|antagonized (r_nsubj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_dobj) myelosuppression_30\NN|neither|reduced|,|loss (l_conj) loss_33\NN|weight|,|nor|cytotoxicity (l_conj) cytotoxicity_39\NN|the|vitro|from
D004317_D015431 CID doxorubicin_41\NN| (r_pobj) from_40\IN|doxorubicin (r_prep) cytotoxicity_39\NN|the|vitro|from (r_conj) loss_33\NN|weight|,|nor|cytotoxicity (r_conj) myelosuppression_30\NN|neither|reduced|,|loss (r_dobj) dexrazoxane_27\NN|doses|;|however|,|myelosuppression|. (l_nsubj) doses_1\NNS|nontoxic|of|from|in|and|antagonized (l_prep) of_2\IN|myelosuppression (l_pobj) myelosuppression_5\NN|reduced|and|loss (l_conj) loss_8\NN|weight
D004317_D015431 CID doxorubicin_41\NN| (r_pobj) from_40\IN|doxorubicin (r_prep) cytotoxicity_39\NN|the|vitro|from (r_conj) loss_33\NN|weight|,|nor|cytotoxicity
D004317_D064420 NONE doxorubicin_41\NN| (r_pobj) from_40\IN|doxorubicin (r_prep) cytotoxicity_39\NN|the|vitro|from
D064730_D009362 NONE dexrazoxane_8\NN|and|high (r_nmod) doses_11\NNS|dexrazoxane|of (r_dobj) combining_7\VBG|doses (r_acl) metastases_6\NNS|brain|combining
D005047_D009362 NONE etoposide_13\NN| (r_pobj) of_12\IN|etoposide (r_prep) doses_11\NNS|dexrazoxane|of (r_dobj) combining_7\VBG|doses (r_acl) metastases_6\NNS|brain|combining
982002
D012293_D058186 CID rifampicin_8\NNS| (r_pobj) of_7\IN|rifampicin (r_prep) administration_6\NN|the|of (r_pobj) to_4\IN|administration (r_prep) subsequent_3\JJ|to (r_amod) failure_2\NN|acute|renal|subsequent|.
D012293_D051437 NONE rifampicin_12\NNS| (r_pobj) of_11\IN|rifampicin (r_prep) administration_10\NN|the|intermittent|of (r_pobj) after_7\IN|administration (r_prep) developed_3\VBN|patients|had|failure|after|. (l_dobj) failure_6\NN|transient|renal
16132524
D017239_D005909 NONE paclitaxel_3\NN| (r_nmod) carboplatin_5\VB|paclitaxel|/ (r_amod) phases_9\NNS|carboplatin|liquid|crystalline|cubic|)|for (l_prep) for_11\IN|glioblastoma (l_pobj) glioblastoma_13\NN|recurrent|--|observations
D017239_D005909 NONE paclitaxel_21\NN| (r_pobj) of_20\IN|paclitaxel (r_prep) application_19\NN|a|surgical|intracavitary|of (r_pobj) of_15\IN|application (r_prep) effects_14\NNS|term|of|and|encapsulated (r_conj) safety_8\NN|,|and|effects (r_conj) feasibility_6\NN|the|,|safety (r_nsubjpass) examined_31\VBN|for|,|feasibility|are|in|. (l_prep) For_0\IN|recurrences (l_pobj) recurrences_3\NNS|human|glioblastoma (l_compound) glioblastoma_2\NN|
D017239_D005909 NONE paclitaxel_22\NN| (r_pobj) of_21\IN|paclitaxel (r_prep) application_20\NN|an|intracavitary|of (r_dobj) received_17\VBD|application|and|phases (r_conj) underwent_12\VBN|and|received (r_acl) multiforme_11\NN|a|glioblastoma|underwent (l_compound) glioblastoma_10\NN|
D016190_D005909 NONE carboplatin_5\VB|paclitaxel|/ (r_amod) phases_9\NNS|carboplatin|liquid|crystalline|cubic|)|for (l_prep) for_11\IN|glioblastoma (l_pobj) glioblastoma_13\NN|recurrent|--|observations
D016190_D005909 NONE carboplatin_23\NN| (r_advmod) encapsulated_24\VBN|carboplatin|by (r_conj) effects_14\NNS|term|of|and|encapsulated (r_conj) safety_8\NN|,|and|effects (r_conj) feasibility_6\NN|the|,|safety (r_nsubjpass) examined_31\VBN|for|,|feasibility|are|in|. (l_prep) For_0\IN|recurrences (l_pobj) recurrences_3\NNS|human|glioblastoma (l_compound) glioblastoma_2\NN|
D016190_D005909 NONE carboplatin_24\VB| (r_amod) phases_26\NNS|carboplatin|cubic|in (r_conj) received_17\VBD|application|and|phases (r_conj) underwent_12\VBN|and|received (r_acl) multiforme_11\NN|a|glioblastoma|underwent (l_compound) glioblastoma_10\NN|
D017239_D001929 CID paclitaxel_9\NN|mg (r_dobj) received_4\VBD|six|paclitaxel|and|suffered|. (l_conj) suffered_11\VBD|from|,|received (l_prep) from_12\IN|moderate|to (l_prep) to_14\TO|edema (l_pobj) edema_17\NN|severe|brain
D017239_D001929 CID paclitaxel_30\NN|mg (r_pobj) of_27\IN|paclitaxel (r_prep) total_26\NN|only|a|of (r_dobj) received_23\VBD|while|patients|total (r_advcl) suffered_11\VBD|from|,|received (l_prep) from_12\IN|moderate|to (l_prep) to_14\TO|edema (l_pobj) edema_17\NN|severe|brain
9564988
D064704_D012852 NONE levofloxacin_5\NN| (r_pobj) of_4\IN|levofloxacin (r_prep) assessment_3\NN|label|of|for|. (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of|in (l_prep) of_9\IN|sinusitis (l_pobj) sinusitis_12\NN|acute|bacterial
D064704_D012852 NONE levofloxacin_7\NN| (r_pobj) of_6\IN|levofloxacin (r_prep) efficacy_3\NN|the|and|safety|of (r_dobj) evaluate_1\VB|to|efficacy|daily|in|. (l_prep) in_20\IN|treating (l_pcomp) treating_21\VBG|outpatients|with (l_prep) with_24\IN|sinusitis (l_pobj) sinusitis_27\NN|acute|bacterial
D064704_D012852 NONE levofloxacin_7\VBZ|that|once|daily (r_ccomp) indicate_5\VBP|results|levofloxacin|is|. (l_ccomp) is_12\VBZ|treatment (l_attr) treatment_17\NN|an|effective|for (l_prep) for_18\IN|sinusitis (l_pobj) sinusitis_21\NN|acute|bacterial
9022662
D010389_D002819 CID Pemoline_0\NNP| (r_nsubj) induced_1\VBD|pemoline|choreoathetosis (l_dobj) choreoathetosis_3\NN|acute
D010389_D002819 CID pemoline_9\NN|experienced (l_relcl) experienced_11\VBD|who|choreoathetosis (l_dobj) choreoathetosis_13\NN|profound
D010389_D002819 CID pemoline_12\NN| (r_compound) overdose_13\NN|pemoline (r_pobj) after_11\IN|overdose (r_prep) presenting_10\VBG|after (r_acl) patients_9\NNS|presenting (r_pobj) in_8\IN|patients (r_prep) considered_7\VBN|possibility|should|be|in|. (l_nsubjpass) possibility_1\NN|the|of (l_prep) of_2\IN|movements (l_pobj) movements_4\NNS|choreoathetoid (l_compound) choreoathetoid_3\JJ|
D010389_D001264 CID Pemoline_0\NNP| (r_nsubj) induced_1\VBD|pemoline|choreoathetosis (l_dobj) choreoathetosis_3\NN|acute
D010389_D001264 CID pemoline_9\NN|experienced (l_relcl) experienced_11\VBD|who|choreoathetosis (l_dobj) choreoathetosis_13\NN|profound
D010389_D001264 CID pemoline_12\NN| (r_compound) overdose_13\NN|pemoline (r_pobj) after_11\IN|overdose (r_prep) presenting_10\VBG|after (r_acl) patients_9\NNS|presenting (r_pobj) in_8\IN|patients (r_prep) considered_7\VBN|possibility|should|be|in|. (l_nsubjpass) possibility_1\NN|the|of (l_prep) of_2\IN|movements (l_pobj) movements_4\NNS|choreoathetoid (l_compound) choreoathetoid_3\JJ|
D010389_D001289 NONE Pemoline_0\NNP| (r_nsubj) is_1\VBZ|pemoline|derivative|. (l_attr) derivative_4\NN|an|oxazolidine|is (l_relcl) is_6\VBZ|that|different|and|used (l_conj) used_12\VBN|in (l_prep) in_13\IN|treatment (l_pobj) treatment_15\NN|the|of (l_prep) of_16\IN|disorder (l_pobj) disorder_19\NN|deficit
C064210_D001289 NONE oxazolidine_3\JJ| (r_compound) derivative_4\NN|an|oxazolidine|is (l_relcl) is_6\VBZ|that|different|and|used (l_conj) used_12\VBN|in (l_prep) in_13\IN|treatment (l_pobj) treatment_15\NN|the|of (l_prep) of_16\IN|disorder (l_pobj) disorder_19\NN|deficit
D000662_D001289 NONE amphetamines_10\NNS| (r_pobj) from_9\IN|amphetamines (r_prep) different_8\JJ|structurally|from (r_acomp) is_6\VBZ|that|different|and|used (l_conj) used_12\VBN|in (l_prep) in_13\IN|treatment (l_pobj) treatment_15\NN|the|of (l_prep) of_16\IN|disorder (l_pobj) disorder_19\NN|deficit
D010389_D009069 NONE Pemoline_0\NNP| (r_nsubjpass) associated_5\VBN|pemoline|has|not|been|commonly|in|as|. (l_prep) as_9\IN|cause (l_pobj) cause_11\NN|a|of (l_prep) of_12\IN|disorders (l_pobj) disorders_15\NNS|acute|movement
D010389_D009069 NONE Pemoline_0\NN| (r_nmod) disorder_3\NN|pemoline|associated|movement
D008774_D001289 NONE methylphenidate_14\NN| (r_pobj) with_13\IN|methylphenidate (r_prep) treated_12\VBN|previously|with|without (r_acl) disorder_10\NN|deficit|treated
D001569_D002819 NONE benzodiazepines_10\NNS|intravenous (r_pobj) of_8\IN|benzodiazepines (r_prep) doses_7\NNS|high|of (r_conj) decontamination_4\NN|gastrointestinal|and|doses (r_dobj) received_2\VBD|children|decontamination|in|. (l_prep) in_11\IN|attempt (l_pobj) attempt_13\NN|an|control (l_acl) control_15\VB|to|movements (l_dobj) movements_18\NNS|the|choreoathetoid (l_compound) choreoathetoid_17\JJ|
D001569_D001264 NONE benzodiazepines_10\NNS|intravenous (r_pobj) of_8\IN|benzodiazepines (r_prep) doses_7\NNS|high|of (r_conj) decontamination_4\NN|gastrointestinal|and|doses (r_dobj) received_2\VBD|children|decontamination|in|. (l_prep) in_11\IN|attempt (l_pobj) attempt_13\NN|an|control (l_acl) control_15\VB|to|movements (l_dobj) movements_18\NNS|the|choreoathetoid (l_compound) choreoathetoid_17\JJ|
D010389_D062787 CID pemoline_12\NN| (r_compound) overdose_13\NN|pemoline
9209318
D015215_D009190 CID azidothymidine_5\NN| (r_pcomp) with_4\IN|azidothymidine (r_prep) treatment_1\NN|lifetime|of|with|azt (r_nsubj) produces_9\VBZ|treatment|myelodysplasia|. (l_dobj) myelodysplasia_10\NN|
D015215_D009190 CID AZT_7\NNP|(|) (r_appos) treatment_1\NN|lifetime|of|with|azt (r_nsubj) produces_9\VBZ|treatment|myelodysplasia|. (l_dobj) myelodysplasia_10\NN|
D015215_D009190 CID AZT_2\NNP| (r_compound) incorporation_3\NN|azt (r_nsubj) induced_6\VBN|incorporation|may|have|hemopoiesis (l_dobj) hemopoiesis_9\NN|an|ineffective|in (l_prep) in_10\IN|cells (l_pobj) cells_15\NNS|the|primitive|progenitor|,|known (l_relcl) known_19\VBN|which|is|seen (l_xcomp) seen_22\VBN|to|be|commonly|in (l_prep) in_24\IN|syndrome (l_pobj) syndrome_27\NN|the|myelodysplastic
D015215_D000748 CID AZT_0\NNP| (r_nsubj) induced_2\VBN|azt|has|anemia|. (l_dobj) anemia_5\NN|a|macrocytic|in|on
D015215_D000748 CID AZT_12\NNP| (r_compound) therapy_13\NN|azt (r_appos) term_11\NN|long|therapy (r_pobj) on_9\IN|term (r_prep) anemia_5\NN|a|macrocytic|in|on
D015215_D000163 NONE AZT_0\NNP| (r_nsubj) induced_2\VBN|azt|has|anemia|. (l_dobj) anemia_5\NN|a|macrocytic|in|on (l_prep) in_6\IN|patients (l_pobj) patients_8\NNS|aids (l_compound) AIDS_7\NNP|
D015215_D000163 NONE AZT_12\NNP| (r_compound) therapy_13\NN|azt (r_appos) term_11\NN|long|therapy (r_pobj) on_9\IN|term (r_prep) anemia_5\NN|a|macrocytic|in|on (l_prep) in_6\IN|patients (l_pobj) patients_8\NNS|aids (l_compound) AIDS_7\NNP|
19996135
D014148_D012640 CID Acid_4\NNP|dose|tranexamic (r_nsubjpass) associated_6\VBN|acid|is|with|. (l_prep) with_7\IN|seizures (l_pobj) seizures_10\NNS|nonischemic|clinical|in
D014148_D012640 CID TXA_19\NNP| (r_compound) usage_20\NN|txa|and|seizures (l_conj) seizures_22\NNS|
D014148_D012640 CID TXA_9\NNP| (r_compound) intraoperatively_10\NN|txa (r_pobj) of_8\IN|intraoperatively (r_prep) doses_7\NNS|high|of|ranging (r_dobj) received_5\VBD|patients|doses|,|had|. (l_nsubj) patients_2\NNS|all|24|with (l_prep) with_3\IN|seizures (l_pobj) seizures_4\NNS|
D014148_D012640 CID TXA_9\NN|dose (r_pobj) of_5\IN|txa (r_prep) use_4\NN|of|in|in (r_nsubjpass) associated_25\VBN|that|use|is|with (l_prep) with_26\IN|seizures (l_pobj) seizures_28\NNS|clinical|in
12093990
D012254_D000257 NONE ribavirin_1\JJ| (r_compound) treatment_2\NN|intravenous|ribavirin|for|in|. (l_prep) for_3\IN|disease (l_pobj) disease_6\NN|severe|adenovirus
D012254_D000257 NONE ribavirin_7\NN| (r_compound) therapy_8\NN|intravenous|ribavirin (r_pobj) with_5\IN|therapy (r_prep) experience_4\NN|our|with|for|in (l_prep) for_9\IN|disease (l_pobj) disease_12\NN|severe|adenovirus
D012254_D000257 NONE ribavirin_12\RB|intravenous (r_pobj) with_10\IN|ribavirin (r_prep) treated_9\VBN|with|for (l_prep) for_13\IN|disease (l_pobj) disease_17\NN|documented|severe|adenovirus
D012254_D000257 NONE ribavirin_2\NN|intravenous (r_nsubj) was_3\VBD|although|ribavirin|not|effective (l_acomp) effective_5\JJ|for (l_prep) for_6\IN|children (l_pobj) children_8\NNS|all|with (l_prep) with_9\IN|disease (l_pobj) disease_12\NN|severe|adenovirus|in
D012254_D000257 NONE ribavirin_11\RB|intravenous (r_pobj) with_9\IN|ribavirin (r_prep) treated_8\VBN|children|with|recovered|. (l_nsubj) children_3\NNS|5|with (l_prep) with_4\IN|disease (l_pobj) disease_7\NN|severe|adenovirus
D012254_D000257 NONE ribavirin_33\NN|intravenous (r_pobj) as_31\IN|such|ribavirin (r_prep) therapies_28\NNS|useful|adenoviral|,|as|, (r_pobj) of_22\IN|therapies (r_prep) trial_21\NN|a|large|,|multicenter|clinical|of (r_conj) children_14\NNS|especially|,|trial (r_appos) hosts_11\NNS|certain|,|children (r_pobj) in_9\IN|hosts (r_prep) prevalence_5\NN|of|in (l_prep) of_6\IN|disease (l_pobj) disease_8\NN|adenovirus
D012254_D018357 NONE Ribavirin_0\NNP| (r_nsubjpass) licensed_2\VBN|ribavirin|is|in|,|and|treat|is|. (l_prep) in_3\IN|form (l_pobj) form_5\NN|aerosol|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|infection (l_pobj) infection_13\NN|virus
D012254_D018357 NONE ribavirin_26\RB|intravenous (r_dobj) treat_22\VB|in|to|ribavirin (r_conj) licensed_2\VBN|ribavirin|is|in|,|and|treat|is|. (l_prep) in_3\IN|form (l_pobj) form_5\NN|aerosol|for (l_prep) for_6\IN|treatment (l_pobj) treatment_8\NN|the|of (l_prep) of_9\IN|infection (l_pobj) infection_13\NN|virus
D012254_D006526 NONE Ribavirin_0\NNP| (r_nsubjpass) licensed_2\VBN|ribavirin|is|in|,|and|treat|is|. (l_conj) treat_22\VB|in|to|ribavirin (l_dobj) ribavirin_26\RB|intravenous (l_compound) Intravenous_25\NNP|hepatitis|c. (l_compound) C._24\NNP|
D012254_D006526 NONE ribavirin_26\RB|intravenous (l_compound) Intravenous_25\NNP|hepatitis|c. (l_compound) C._24\NNP|
D012254_D006482 NONE Ribavirin_0\NNP| (r_nsubjpass) licensed_2\VBN|ribavirin|is|in|,|and|treat|is|. (l_conj) is_27\VBZ|treatment (l_attr) treatment_29\NN|the|of|for (l_prep) for_32\IN|infection (l_pobj) infection_33\NN|with (l_prep) with_34\IN|viruses (l_pobj) viruses_37\NNS|hemorrhagic|fever
D012254_D006482 NONE ribavirin_26\RB|intravenous (r_dobj) treat_22\VB|in|to|ribavirin (r_conj) licensed_2\VBN|ribavirin|is|in|,|and|treat|is|. (l_conj) is_27\VBZ|treatment (l_attr) treatment_29\NN|the|of|for (l_prep) for_32\IN|infection (l_pobj) infection_33\NN|with (l_prep) with_34\IN|viruses (l_pobj) viruses_37\NNS|hemorrhagic|fever
D012254_D000740 NONE ribavirin_7\RB|intravenous (r_pobj) of_5\IN|ribavirin (r_prep) effect_4\NN|the|common|adverse|of (r_nsubj) is_8\VBZ|effect|anemia|. (l_attr) anemia_11\NN|reversible|mild
C059262_D000257 NONE cidofovir_3\NN| (r_pobj) of_2\IN|cidofovir (r_prep) use_1\NN|the|of|in (l_prep) in_4\IN|infection (l_pobj) infection_7\NN|severe|adenovirus
C059262_D007674 NONE cidofovir_3\NN| (r_pobj) of_2\IN|cidofovir (r_prep) use_1\NN|the|of|in (r_nsubjpass) limited_10\VBN|use|has|been|by (r_ccomp) is_20\VBZ|limited|,|significant|nephrotoxicity|. (l_attr) nephrotoxicity_21\NN|
C059262_D058186 CID cidofovir_2\NN| (r_pobj) of_1\IN|cidofovir (r_prep) Use_0\NN|of|in (r_nsubjpass) associated_7\VBN|use|was|with|. (l_prep) with_8\IN|failure (l_pobj) failure_11\NN|progressive|renal|and|neutropenia
C059262_D009503 CID cidofovir_2\NN| (r_pobj) of_1\IN|cidofovir (r_prep) Use_0\NN|of|in (r_nsubjpass) associated_7\VBN|use|was|with|. (l_prep) with_8\IN|failure (l_pobj) failure_11\NN|progressive|renal|and|neutropenia (l_conj) neutropenia_13\NN|
D012254_D007239 NONE ribavirin_2\NN|intravenous (r_nsubj) was_3\VBD|although|ribavirin|not|effective (r_advcl) is_22\VBZ|was|,|therapy|unlikely|begun|. (l_advcl) begun_29\VBN|if|in (l_prep) in_31\IN|late|course (l_pobj) course_33\NN|the|of (l_prep) of_34\IN|infection (l_pobj) infection_36\NN|the
6216862
D010396_D001172 NONE penicillamine_4\NN| (r_compound) therapy_5\NN|penicillamine (r_pobj) of_3\IN|therapy (r_prep) effects_2\NNS|multiple|side|of|in|. (l_prep) in_6\IN|patient (l_pobj) patient_8\NN|one|with (l_prep) with_9\IN|arthritis (l_pobj) arthritis_11\NN|rheumatoid
D010396_D001172 NONE penicillamine_20\NN| (r_compound) therapy_21\NN|penicillamine (r_pobj) of_19\IN|therapy (r_prep) complications_18\NNS|of|in (l_prep) in_22\IN|patients (l_pobj) patients_23\NNS|with (l_prep) with_24\IN|arthritis (l_pobj) arthritis_26\NN|rheumatoid
D010396_D001172 NONE penicillamine_32\NN| (r_pobj) with_31\IN|penicillamine (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|with|treated (l_prep) with_27\IN|arthritis (l_pobj) arthritis_29\NN|rheumatoid
D010396_D005076 CID penicillamine_20\NN| (r_compound) therapy_21\NN|penicillamine (r_pobj) of_19\IN|therapy (r_prep) complications_18\NNS|of|in (r_pobj) as_17\IN|complications (r_prep) recorded_16\VBN|rashes|have|all|been|as|. (l_nsubjpass) rashes_1\NNS|skin|,|proteinuria
D010396_D011507 CID penicillamine_20\NN| (r_compound) therapy_21\NN|penicillamine (r_pobj) of_19\IN|therapy (r_prep) complications_18\NNS|of|in (r_pobj) as_17\IN|complications (r_prep) recorded_16\VBN|rashes|have|all|been|as|. (l_nsubjpass) rashes_1\NNS|skin|,|proteinuria (l_conj) proteinuria_3\NN|,|erythematosus
D010396_D008180 CID penicillamine_20\NN| (r_compound) therapy_21\NN|penicillamine (r_pobj) of_19\IN|therapy (r_prep) complications_18\NNS|of|in (r_pobj) as_17\IN|complications (r_prep) recorded_16\VBN|rashes|have|all|been|as|. (l_nsubjpass) rashes_1\NNS|skin|,|proteinuria (l_conj) proteinuria_3\NN|,|erythematosus (l_conj) erythematosus_7\NN|systemic|lupus|,|polymyositis
D010396_D017285 CID penicillamine_20\NN| (r_compound) therapy_21\NN|penicillamine (r_pobj) of_19\IN|therapy (r_prep) complications_18\NNS|of|in (r_pobj) as_17\IN|complications (r_prep) recorded_16\VBN|rashes|have|all|been|as|. (l_nsubjpass) rashes_1\NNS|skin|,|proteinuria (l_conj) proteinuria_3\NN|,|erythematosus (l_conj) erythematosus_7\NN|systemic|lupus|,|polymyositis (l_conj) polymyositis_9\NN|and|myasthenia|gravis
D010396_D009157 CID penicillamine_20\NN| (r_compound) therapy_21\NN|penicillamine (r_pobj) of_19\IN|therapy (r_prep) complications_18\NNS|of|in (r_pobj) as_17\IN|complications (r_prep) recorded_16\VBN|rashes|have|all|been|as|. (l_nsubjpass) rashes_1\NNS|skin|,|proteinuria (l_conj) proteinuria_3\NN|,|erythematosus (l_conj) erythematosus_7\NN|systemic|lupus|,|polymyositis (l_conj) polymyositis_9\NN|and|myasthenia|gravis (l_conj) gravis_12\NN|
D010396_D012871 NONE penicillamine_32\NN| (r_pobj) with_31\IN|penicillamine (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|with|treated (r_pobj) in_25\IN|not|patients (r_conj) reported_11\VBN|which|has|been|as|but|in (r_relcl) serpiginosa_6\NN|elastosis|perforans|,|reported (r_dobj) resembled_3\VBD|lesion|serpiginosa|. (l_nsubj) lesion_2\NN|the|skin
D010396_C536202 NONE penicillamine_32\NN| (r_pobj) with_31\IN|penicillamine (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|with|treated (r_pobj) in_25\IN|not|patients (r_conj) reported_11\VBN|which|has|been|as|but|in (r_relcl) serpiginosa_6\NN|elastosis|perforans|,|reported
D010396_D006527 NONE penicillamine_32\NN| (r_pobj) with_31\IN|penicillamine (r_prep) treated_30\VBN|with (r_acl) patients_26\NNS|with|treated (r_pobj) in_25\IN|not|patients (r_conj) reported_11\VBN|which|has|been|as|but|in (l_prep) as_12\IN|effect (l_pobj) effect_16\NN|a|rare|side|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|disease (l_pobj) disease_22\NN|wilson
6111982
D011433_D001145 NONE propranolol_6\NN|and|pindolol (l_conj) pindolol_8\NN|inhibiting (l_xcomp) inhibiting_9\VBG|arrhythmia|in (l_dobj) arrhythmia_12\NN|the|ouabain
D010869_D001145 NONE pindolol_8\NN|inhibiting (l_xcomp) inhibiting_9\VBG|arrhythmia|in (l_dobj) arrhythmia_12\NN|the|ouabain
D010042_D001145 CID ouabain_11\JJ| (r_compound) arrhythmia_12\NN|the|ouabain
20973483
D058915_D010300 NONE antagonist_11\NN|a|adenosine|a2a|a1|receptor|in (l_prep) in_12\IN|models (l_pobj) models_14\NNS|animal|of (l_prep) of_15\IN|disease (l_pobj) disease_18\NN|parkinson
D058915_D010300 NONE antagonist_11\NN|a|adenosine|a(2a)/a(1|)|receptor|in (l_prep) in_12\IN|models (l_pobj) models_15\NNS|several|animal|of (l_prep) of_16\IN|disease (l_pobj) disease_19\NN|parkinson
D006220_D010300 NONE haloperidol_53\NN| (r_npadvmod) induced_55\VBN|haloperidol|- (r_amod) catalepsy_56\NN|induced|,|model|,|model (r_pobj) of_52\IN|catalepsy (r_prep) models_51\NNS|mouse|of (r_pobj) including_47\VBG|models (r_prep) disease_46\NN|parkinson|including
D006220_D002375 CID haloperidol_53\NN| (r_npadvmod) induced_55\VBN|haloperidol|- (r_amod) catalepsy_56\NN|induced|,|model|,|model
D006220_D004409 NONE haloperidol_53\NN| (r_npadvmod) induced_55\VBN|haloperidol|- (r_amod) catalepsy_56\NN|induced|,|model|,|model (l_appos) model_59\NN|mouse|of (l_prep) of_60\IN|akinesia (l_pobj) akinesia_64\NN|induced
D012110_D010300 NONE reserpine_61\NN| (r_npadvmod) induced_63\VBN|reserpine|- (r_compound) akinesia_64\NN|induced (r_pobj) of_60\IN|akinesia (r_prep) model_59\NN|mouse|of (r_appos) catalepsy_56\NN|induced|,|model|,|model (r_pobj) of_52\IN|catalepsy (r_prep) models_51\NNS|mouse|of (r_pobj) including_47\VBG|models (r_prep) disease_46\NN|parkinson|including
D012110_D002375 NONE reserpine_61\NN| (r_npadvmod) induced_63\VBN|reserpine|- (r_compound) akinesia_64\NN|induced (r_pobj) of_60\IN|akinesia (r_prep) model_59\NN|mouse|of (r_appos) catalepsy_56\NN|induced|,|model|,|model
D012110_D004409 CID reserpine_61\NN| (r_npadvmod) induced_63\VBN|reserpine|- (r_compound) akinesia_64\NN|induced
D016627_D010300 NONE 6-hydroxydopamine_67\NN| (r_nmod) 6-OHDA_69\CD|6-hydroxydopamine|(|) (r_nummod) model_72\NN|rat|6-ohda|lesion|of|, (r_appos) catalepsy_56\NN|induced|,|model|,|model (r_pobj) of_52\IN|catalepsy (r_prep) models_51\NNS|mouse|of (r_pobj) including_47\VBG|models (r_prep) disease_46\NN|parkinson|including
D016627_D010300 NONE 6-OHDA_69\CD|6-hydroxydopamine|(|) (r_nummod) model_72\NN|rat|6-ohda|lesion|of|, (r_appos) catalepsy_56\NN|induced|,|model|,|model (r_pobj) of_52\IN|catalepsy (r_prep) models_51\NNS|mouse|of (r_pobj) including_47\VBG|models (r_prep) disease_46\NN|parkinson|including
D016627_D002375 NONE 6-hydroxydopamine_67\NN| (r_nmod) 6-OHDA_69\CD|6-hydroxydopamine|(|) (r_nummod) model_72\NN|rat|6-ohda|lesion|of|, (r_appos) catalepsy_56\NN|induced|,|model|,|model
D016627_D002375 NONE 6-OHDA_69\CD|6-hydroxydopamine|(|) (r_nummod) model_72\NN|rat|6-ohda|lesion|of|, (r_appos) catalepsy_56\NN|induced|,|model|,|model
D016627_D004409 NONE 6-hydroxydopamine_67\NN| (r_nmod) 6-OHDA_69\CD|6-hydroxydopamine|(|) (r_nummod) model_72\NN|rat|6-ohda|lesion|of|, (r_appos) catalepsy_56\NN|induced|,|model|,|model (l_appos) model_59\NN|mouse|of (l_prep) of_60\IN|akinesia (l_pobj) akinesia_64\NN|induced
D016627_D004409 NONE 6-OHDA_69\CD|6-hydroxydopamine|(|) (r_nummod) model_72\NN|rat|6-ohda|lesion|of|, (r_appos) catalepsy_56\NN|induced|,|model|,|model (l_appos) model_59\NN|mouse|of (l_prep) of_60\IN|akinesia (l_pobj) akinesia_64\NN|induced
D015632_D010300 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|mptp|- (r_amod) model_87\NN|treated|human|primate (r_conj) across_37\IN|number|and|model (l_pobj) number_39\NN|a|of (l_prep) of_40\IN|models (l_pobj) models_42\NNS|animal|of (l_prep) of_43\IN|disease (l_pobj) disease_46\NN|parkinson|including
D015632_D002375 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|mptp|- (r_amod) model_87\NN|treated|human|primate (r_conj) across_37\IN|number|and|model (l_pobj) number_39\NN|a|of (l_prep) of_40\IN|models (l_pobj) models_42\NNS|animal|of (l_prep) of_43\IN|disease (l_pobj) disease_46\NN|parkinson|including (l_prep) including_47\VBG|models (l_pobj) models_51\NNS|mouse|of (l_prep) of_52\IN|catalepsy (l_pobj) catalepsy_56\NN|induced|,|model|,|model
D015632_D004409 NONE MPTP_80\NNP| (r_npadvmod) treated_82\VBN|mptp|- (r_amod) model_87\NN|treated|human|primate (r_conj) across_37\IN|number|and|model (l_pobj) number_39\NN|a|of (l_prep) of_40\IN|models (l_pobj) models_42\NNS|animal|of (l_prep) of_43\IN|disease (l_pobj) disease_46\NN|parkinson|including (l_prep) including_47\VBG|models (l_pobj) models_51\NNS|mouse|of (l_prep) of_52\IN|catalepsy (l_pobj) catalepsy_56\NN|induced|,|model|,|model (l_appos) model_59\NN|mouse|of (l_prep) of_60\IN|akinesia (l_pobj) akinesia_64\NN|induced
8546130
D017291_D006212 CID Clarithromycin_0\NN| (r_npadvmod) associated_2\VBN|clarithromycin|- (r_amod) hallucinations_4\NNS|associated|visual|in|.
D017291_D006212 CID clarithromycin_16\NN| (r_appos) antibiotic_14\NN|the|new|macrolide|,|clarithromycin (r_pobj) with_10\IN|antibiotic (r_prep) association_9\NN|with (r_pobj) in_8\IN|association (r_prep) occurring_7\VBG|in (r_acl) hallucinations_6\NNS|visual|occurring
D017291_D007676 NONE Clarithromycin_0\NN| (r_npadvmod) associated_2\VBN|clarithromycin|- (r_amod) hallucinations_4\NNS|associated|visual|in|. (l_prep) in_5\IN|patient (l_pobj) patient_7\NN|a|with (l_prep) with_8\IN|failure (l_pobj) failure_11\NN|chronic|renal|on
D017291_D007676 NONE clarithromycin_8\NN| (r_pobj) of_7\IN|clarithromycin (r_prep) dose_6\NN|a|high|of|in|in (l_prep) in_9\IN|face (l_pobj) face_10\NN|of (l_prep) of_11\IN|failure (l_pobj) failure_14\NN|chronic|renal
D018942_D006212 NONE macrolide_13\NN| (r_amod) antibiotic_14\NN|the|new|macrolide|,|clarithromycin (r_pobj) with_10\IN|antibiotic (r_prep) association_9\NN|with (r_pobj) in_8\IN|association (r_prep) occurring_7\VBG|in (r_acl) hallucinations_6\NNS|visual|occurring
D017291_D020258 NONE clarithromycin_8\NN| (r_pobj) of_7\IN|clarithromycin (r_prep) dose_6\NN|a|high|of|in|in (r_pobj) of_2\IN|dose (r_prep) combination_1\NN|the|of|,|with|, (r_nsubj) facilitated_28\VBN|combination|may|have|appearance|. (l_dobj) appearance_30\NN|the|of (l_prep) of_31\IN|effect (l_pobj) effect_35\NN|this|neurotoxic|side (l_amod) neurotoxic_33\JJ|
D000535_D007676 NONE aluminum_23\NN| (r_compound) intoxication_24\NN|underlying|aluminum (r_pobj) with_21\IN|intoxication (r_prep) combination_1\NN|the|of|,|with|, (l_prep) of_2\IN|dose (l_pobj) dose_6\NN|a|high|of|in|in (l_prep) in_9\IN|face (l_pobj) face_10\NN|of (l_prep) of_11\IN|failure (l_pobj) failure_14\NN|chronic|renal
D000535_D020258 NONE aluminum_23\NN| (r_compound) intoxication_24\NN|underlying|aluminum (r_pobj) with_21\IN|intoxication (r_prep) combination_1\NN|the|of|,|with|, (r_nsubj) facilitated_28\VBN|combination|may|have|appearance|. (l_dobj) appearance_30\NN|the|of (l_prep) of_31\IN|effect (l_pobj) effect_35\NN|this|neurotoxic|side (l_amod) neurotoxic_33\JJ|
6415512
D002220_D004831 CID carbamazepine_10\NN| (r_compound) therapy_11\NN|carbamazepine (r_pobj) of_9\IN|therapy (r_prep) institution_8\NN|of|in (r_dobj) following_7\VBG|institution (r_prep) seizures_6\NNS|myoclonic|following|.
D002220_D004831 CID carbamazepine_11\NN|for (r_pobj) with_10\IN|carbamazepine (r_prep) treated_9\VBN|children|with|,|had|. (l_conj) had_15\VBD|reaction (l_dobj) reaction_19\NN|an|acute|aberrant|characterized (l_acl) characterized_20\VBN|by (l_agent) by_21\IN|onset (l_pobj) onset_23\NN|the|of (l_prep) of_24\IN|absence (l_pobj) absence_28\NN|myoclonic|,|atypical|and/or|seizures (l_conj) seizures_35\NNS|atonic|(|minor|motor|)|within
D002220_D004832 CID carbamazepine_10\NN| (r_compound) therapy_11\NN|carbamazepine (r_pobj) of_9\IN|therapy (r_prep) institution_8\NN|of|in (r_dobj) following_7\VBG|institution (r_prep) seizures_6\NNS|myoclonic|following|.
D002220_D004832 CID carbamazepine_11\NN|for (r_pobj) with_10\IN|carbamazepine (r_prep) treated_9\VBN|children|with|,|had|. (l_conj) had_15\VBD|reaction (l_dobj) reaction_19\NN|an|acute|aberrant|characterized (l_acl) characterized_20\VBN|by (l_agent) by_21\IN|onset (l_pobj) onset_23\NN|the|of (l_prep) of_24\IN|absence (l_pobj) absence_28\NN|myoclonic|,|atypical|and/or|seizures (l_conj) seizures_35\NNS|atonic|(|minor|motor|)|within
D002220_D004827 NONE carbamazepine_11\NN|for (l_prep) for_12\IN|epilepsy (l_pobj) epilepsy_13\NN|
D002220_D012640 NONE carbamazepine_2\NN|the (r_nsubjpass) discontinued_4\VBN|when|carbamazepine|was (r_advcl) returned_10\VBD|discontinued|,|two|to|quickly (r_ccomp) had_19\VBD|returned|,|two|resolve|,|and|had (l_ccomp) resolve_24\VBP|seizures|in (l_nsubj) seizures_23\NNS|the|minor|motor
D002220_D012640 NONE carbamazepine_2\NN|the (r_nsubjpass) discontinued_4\VBN|when|carbamazepine|was (r_advcl) returned_10\VBD|discontinued|,|two|to|quickly (r_ccomp) had_19\VBD|returned|,|two|resolve|,|and|had (l_conj) had_33\VBD|one|persist|. (l_ccomp) persist_36\VB|seizures (l_nsubj) seizures_35\NNS|the
7565311
D016190_D058186 CID carboplatin_6\NN| (r_compound) chemotherapy_7\NN|high|dose|carboplatin (r_pobj) in_3\IN|chemotherapy (r_prep) failure_2\NN|acute|renal|in|.
D016190_D058186 CID Carboplatin_0\NNP| (r_nsubjpass) reported_3\VBN|carboplatin|has|been|cause|. (l_xcomp) cause_5\VB|to|failure|administered (l_dobj) failure_8\NN|acute|renal
D016190_D018233 NONE carboplatin_15\NN|dose (r_pobj) with_11\IN|carboplatin (r_prep) treated_10\VBN|who|was|with|for (l_prep) for_16\IN|rhabdomyosarcoma (l_pobj) rhabdomyosarcoma_20\NN|metastatic|parameningeal|embryonal
3973521
839274
D003276_D000236 CID contraceptives_14\NNS|oral (r_pobj) on_12\IN|contraceptives (r_prep) hyperplasia_5\NN|focal|nodular|of|on (r_conj) adenomas_1\NNS|hepatic|and|hyperplasia
D003276_D000236 CID contraceptives_18\NNS|oral (r_pobj) of_16\IN|contraceptives (r_prep) use_15\NN|the|of (r_pobj) with_13\IN|use (r_prep) associated_12\VBD|presumably|with (r_acl) one_6\CD|of|associated (r_conj) cases_1\NNS|two|of|and|one (l_prep) of_2\IN|adenoma (l_pobj) adenoma_4\NN|hepatic
D003276_D020518 CID contraceptives_14\NNS|oral (r_pobj) on_12\IN|contraceptives (r_prep) hyperplasia_5\NN|focal|nodular|of|on
D003276_D020518 CID contraceptives_18\NNS|oral (r_pobj) of_16\IN|contraceptives (r_prep) use_15\NN|the|of (r_pobj) with_13\IN|use (r_prep) associated_12\VBD|presumably|with (r_acl) one_6\CD|of|associated (l_prep) of_7\IN|hyperplasia (l_pobj) hyperplasia_10\NN|focal|nodular
1286498
D005442_D009325 CID flumazenil_11\JJ| (r_compound) group_12\NN|the|flumazenil|and|pain (r_pobj) in_9\IN|group (r_prep) vomiting_8\VBG|in (r_conj) nausea_6\NN|and|vomiting
D005442_D009325 CID flumazenil_11\JJ| (r_compound) group_12\NN|the|flumazenil|and|pain (l_conj) pain_19\NN|nausea|in (l_nmod) nausea_14\NN|and|site
D005442_D014839 CID flumazenil_11\JJ| (r_compound) group_12\NN|the|flumazenil|and|pain (r_pobj) in_9\IN|group (r_prep) vomiting_8\VBG|in
D005442_D010146 NONE flumazenil_11\JJ| (r_compound) group_12\NN|the|flumazenil|and|pain (l_conj) pain_19\NN|nausea|in
2894433
D003975_D001919 CID Diazepam_0\NNP| (r_nsubj) facilitates_1\VBZ|diazepam|bradycardia|. (l_dobj) bradycardia_3\NN|reflex|in
D003975_D001919 CID diazepam_6\NN| (r_pobj) with_5\IN|diazepam (r_prep) pretreatment_1\NN|intravenous|of|with|,|causing (r_nsubj) enhance_21\VB|pretreatment|,|did|bradycardia|. (l_dobj) bradycardia_27\NN|the|induced|reflex
D003975_D001919 CID diazepam_3\NN| (r_compound) enhancement_4\NN|the|diazepam|of (l_prep) of_5\IN|bradycardia (l_pobj) bradycardia_10\NN|induced|reflex
D003975_D001919 CID diazepam_4\NN| (r_nsubj) acts_5\VBZ|that|diazepam|through|facilitate (l_advcl) facilitate_22\VB|to|bradycardia (l_dobj) bradycardia_24\NN|reflex|mediated
D004837_D001919 CID adrenaline_12\NN| (r_pobj) of_11\IN|adrenaline (r_prep) infusion_10\NN|intravenous|of|(|micrograms|) (r_pobj) by_8\IN|infusion (r_agent) produced_5\VBN|also|,|bradycardia|was|in|by|. (l_nsubjpass) bradycardia_3\NN|reflex
D004837_D001919 CID adrenaline_14\NN| (r_npadvmod) induced_16\VBN|adrenaline|- (r_amod) effect_18\NN|the|induced|pressor (r_pobj) in_12\IN|effect (r_prep) change_11\NN|no|in (r_dobj) causing_9\VBG|although|change (r_advcl) pretreatment_1\NN|intravenous|of|with|,|causing (r_nsubj) enhance_21\VB|pretreatment|,|did|bradycardia|. (l_dobj) bradycardia_27\NN|the|induced|reflex
D004837_D001919 CID adrenaline_23\NN| (r_npadvmod) induced_25\VBN|adrenaline|- (r_amod) bradycardia_27\NN|the|induced|reflex
D004837_D001919 CID adrenaline_6\NN| (r_npadvmod) induced_8\VBN|adrenaline|- (r_amod) bradycardia_10\NN|induced|reflex
D010852_D001919 NONE picrotoxin_22\NN|(|blocks|) (r_pobj) of_21\IN|picrotoxin (r_prep) dose_20\NN|an|intravenous|of (r_pobj) with_17\IN|dose (r_prep) pretreatment_14\NN|of|with (r_pobj) by_13\IN|pretreatment (r_agent) antagonized_12\VBN|however|,|enhancement|was|by|. (l_nsubjpass) enhancement_4\NN|the|diazepam|of (l_prep) of_5\IN|bradycardia (l_pobj) bradycardia_10\NN|induced|reflex
D002712_D001919 NONE chloride_27\NN| (r_compound) channels_28\NNS|chloride (r_dobj) blocks_26\NNS|agent|channels|by (r_appos) picrotoxin_22\NN|(|blocks|) (r_pobj) of_21\IN|picrotoxin (r_prep) dose_20\NN|an|intravenous|of (r_pobj) with_17\IN|dose (r_prep) pretreatment_14\NN|of|with (r_pobj) by_13\IN|pretreatment (r_agent) antagonized_12\VBN|however|,|enhancement|was|by|. (l_nsubjpass) enhancement_4\NN|the|diazepam|of (l_prep) of_5\IN|bradycardia (l_pobj) bradycardia_10\NN|induced|reflex
D002712_D001919 NONE chloride_40\NN|-|gaba|- (r_compound) complex_43\NN|the|benzodiazepine|chloride|channel|macromolecular (r_pobj) with_34\IN|complex (r_prep) associated_33\VBN|with (r_acl) sites_32\NNS|associated (r_pobj) to_31\IN|sites (r_prep) binding_30\VBG|to (r_pcomp) by_29\IN|binding (r_prep) blocks_26\NNS|agent|channels|by (r_appos) picrotoxin_22\NN|(|blocks|) (r_pobj) of_21\IN|picrotoxin (r_prep) dose_20\NN|an|intravenous|of (r_pobj) with_17\IN|dose (r_prep) pretreatment_14\NN|of|with (r_pobj) by_13\IN|pretreatment (r_agent) antagonized_12\VBN|however|,|enhancement|was|by|. (l_nsubjpass) enhancement_4\NN|the|diazepam|of (l_prep) of_5\IN|bradycardia (l_pobj) bradycardia_10\NN|induced|reflex
D002712_D001919 NONE chloride_12\NN|-|gaba|- (r_compound) complex_15\NN|the|benzodiazepine|chloride|channel|macromolecular|within (r_pobj) through_6\IN|complex (r_prep) acts_5\VBZ|that|diazepam|through|facilitate (l_advcl) facilitate_22\VB|to|bradycardia (l_dobj) bradycardia_24\NN|reflex|mediated
D001569_D001919 NONE benzodiazepine_36\JJ| (r_amod) complex_43\NN|the|benzodiazepine|chloride|channel|macromolecular (r_pobj) with_34\IN|complex (r_prep) associated_33\VBN|with (r_acl) sites_32\NNS|associated (r_pobj) to_31\IN|sites (r_prep) binding_30\VBG|to (r_pcomp) by_29\IN|binding (r_prep) blocks_26\NNS|agent|channels|by (r_appos) picrotoxin_22\NN|(|blocks|) (r_pobj) of_21\IN|picrotoxin (r_prep) dose_20\NN|an|intravenous|of (r_pobj) with_17\IN|dose (r_prep) pretreatment_14\NN|of|with (r_pobj) by_13\IN|pretreatment (r_agent) antagonized_12\VBN|however|,|enhancement|was|by|. (l_nsubjpass) enhancement_4\NN|the|diazepam|of (l_prep) of_5\IN|bradycardia (l_pobj) bradycardia_10\NN|induced|reflex
D001569_D001919 NONE benzodiazepine_8\JJ| (r_amod) complex_15\NN|the|benzodiazepine|chloride|channel|macromolecular|within (r_pobj) through_6\IN|complex (r_prep) acts_5\VBZ|that|diazepam|through|facilitate (l_advcl) facilitate_22\VB|to|bradycardia (l_dobj) bradycardia_24\NN|reflex|mediated
D005680_D001919 NONE GABA_38\NNP| (r_compound) chloride_40\NN|-|gaba|- (r_compound) complex_43\NN|the|benzodiazepine|chloride|channel|macromolecular (r_pobj) with_34\IN|complex (r_prep) associated_33\VBN|with (r_acl) sites_32\NNS|associated (r_pobj) to_31\IN|sites (r_prep) binding_30\VBG|to (r_pcomp) by_29\IN|binding (r_prep) blocks_26\NNS|agent|channels|by (r_appos) picrotoxin_22\NN|(|blocks|) (r_pobj) of_21\IN|picrotoxin (r_prep) dose_20\NN|an|intravenous|of (r_pobj) with_17\IN|dose (r_prep) pretreatment_14\NN|of|with (r_pobj) by_13\IN|pretreatment (r_agent) antagonized_12\VBN|however|,|enhancement|was|by|. (l_nsubjpass) enhancement_4\NN|the|diazepam|of (l_prep) of_5\IN|bradycardia (l_pobj) bradycardia_10\NN|induced|reflex
D005680_D001919 NONE GABA_10\NNP| (r_compound) chloride_12\NN|-|gaba|- (r_compound) complex_15\NN|the|benzodiazepine|chloride|channel|macromolecular|within (r_pobj) through_6\IN|complex (r_prep) acts_5\VBZ|that|diazepam|through|facilitate (l_advcl) facilitate_22\VB|to|bradycardia (l_dobj) bradycardia_24\NN|reflex|mediated
9549528
D007980_D020734 NONE dopa_9\NN|l|- (r_npadvmod) induced_11\VBN|dopa|- (r_amod) dyskinesia_15\NN|induced|dose (r_pobj) with_6\IN|dyskinesia (r_prep) patients_5\NNS|parkinsonian|with (l_amod) parkinsonian_4\JJ|
D007980_D020734 NONE dopa_42\NN|l|- (r_compound) medication_43\NN|dopa|, (r_pobj) on_39\IN|medication (r_prep) patients_38\NNS|parkinsonian|on (l_amod) parkinsonian_37\JJ|
D007980_D020734 NONE dopa_51\NN|l|- (r_pobj) without_48\IN|dopa (r_prep) one_47\NN|the|first|without (r_nsubj) induced_52\VBD|one|dyskinesia|,|and|of (r_conj) studied_2\VBN|we|have|flow|induced|. (l_dobj) flow_7\NN|the|regional|cerebral|blood|(|rcbf|changes (l_conj) changes_11\NNS|)|induced (l_acl) induced_12\VBN|by (l_agent) by_13\IN|execution (l_pobj) execution_15\NN|the|of|in (l_prep) in_26\IN|cortex (l_pobj) cortex_32\NN|the|supplementary|motor|of (l_prep) of_33\IN|groups (l_pobj) groups_35\NNS|two|of (l_prep) of_36\IN|patients (l_pobj) patients_38\NNS|parkinsonian|on (l_amod) parkinsonian_37\JJ|
D007980_D004409 CID dopa_9\NN|l|- (r_npadvmod) induced_11\VBN|dopa|- (r_amod) dyskinesia_15\NN|induced|dose
D007980_D004409 CID dopa_42\NN|l|- (r_compound) medication_43\NN|dopa|, (r_pobj) on_39\IN|medication (r_prep) patients_38\NNS|parkinsonian|on (r_pobj) of_36\IN|patients (r_prep) groups_35\NNS|two|of (r_pobj) of_33\IN|groups (r_prep) cortex_32\NN|the|supplementary|motor|of (r_pobj) in_26\IN|cortex (r_prep) execution_15\NN|the|of|in (r_pobj) by_13\IN|execution (r_agent) induced_12\VBN|by (r_acl) changes_11\NNS|)|induced (r_conj) flow_7\NN|the|regional|cerebral|blood|(|rcbf|changes (r_dobj) studied_2\VBN|we|have|flow|induced|. (l_conj) induced_52\VBD|one|dyskinesia|,|and|of (l_dobj) dyskinesia_53\NN|(|n|23|)|and|other
D007980_D004409 CID dopa_42\NN|l|- (r_compound) medication_43\NN|dopa|, (r_pobj) on_39\IN|medication (r_prep) patients_38\NNS|parkinsonian|on (r_pobj) of_36\IN|patients (r_prep) groups_35\NNS|two|of (r_pobj) of_33\IN|groups (r_prep) cortex_32\NN|the|supplementary|motor|of (r_pobj) in_26\IN|cortex (r_prep) execution_15\NN|the|of|in (r_pobj) by_13\IN|execution (r_agent) induced_12\VBN|by (r_acl) changes_11\NNS|)|induced (r_conj) flow_7\NN|the|regional|cerebral|blood|(|rcbf|changes (r_dobj) studied_2\VBN|we|have|flow|induced|. (l_conj) induced_52\VBD|one|dyskinesia|,|and|of (l_dobj) dyskinesia_53\NN|(|n|23|)|and|other (l_conj) other_61\JJ|the|with (l_prep) with_62\IN|dyskinesia (l_pobj) dyskinesia_67\NN|moderate|dose|(|n|15|)
D007980_D004409 CID dopa_51\NN|l|- (r_pobj) without_48\IN|dopa (r_prep) one_47\NN|the|first|without (r_nsubj) induced_52\VBD|one|dyskinesia|,|and|of (l_dobj) dyskinesia_53\NN|(|n|23|)|and|other
D007980_D004409 CID dopa_51\NN|l|- (r_pobj) without_48\IN|dopa (r_prep) one_47\NN|the|first|without (r_nsubj) induced_52\VBD|one|dyskinesia|,|and|of (l_dobj) dyskinesia_53\NN|(|n|23|)|and|other (l_conj) other_61\JJ|the|with (l_prep) with_62\IN|dyskinesia (l_pobj) dyskinesia_67\NN|moderate|dose|(|n|15|)
D007980_D004409 CID dopa_17\NN|l|- (r_npadvmod) induced_19\VBN|dopa|- (r_amod) dyskinesia_22\NN|induced|dose (r_pobj) like_14\IN|dyskinesia (r_prep) movement_12\NN|an|hyperkinetic|abnormal|involuntary|,|like
D007980_D004409 CID dopa_17\NN|l|- (r_npadvmod) induced_19\VBN|dopa|- (r_amod) dyskinesia_22\NN|induced|dose
D007980_D006948 NONE dopa_17\NN|l|- (r_npadvmod) induced_19\VBN|dopa|- (r_amod) dyskinesia_22\NN|induced|dose (r_pobj) like_14\IN|dyskinesia (r_prep) movement_12\NN|an|hyperkinetic|abnormal|involuntary|,|like (l_amod) hyperkinetic_9\JJ|
2055425
D013311_D003920 CID streptozotocin_17\NNS| (r_npadvmod) induced_19\VBN|streptozotocin|- (r_amod) diabetes_20\NN|induced (r_compound) mellitus_21\NN|diabetes
D013311_D003920 CID streptozotocin_15\JJ| (r_npadvmod) diabetic_17\JJ|streptozotocin|-
D013311_D003920 CID streptozotocin_7\NNS| (r_npadvmod) induced_9\VBN|streptozotocin|- (r_amod) diabetes_10\NNS|induced|on
D000255_D003920 NONE ATP_20\NNP|,|and|bethanechol (r_conj) stimulation_18\NN|nerve|,|atp (r_pobj) to_16\TO|stimulation (r_prep) responses_8\NNS|contractile|of|from|to (l_prep) from_13\IN|rats (l_pobj) rats_15\NNS|diabetic (l_amod) diabetic_14\JJ|
D000255_D003920 NONE ATP_19\NNP|,|and|bethanechol (r_conj) stimulation_17\NN|nerve|,|atp (r_pobj) to_15\TO|stimulation (r_prep) responses_7\NNS|contractile|of|from|to (l_prep) from_12\IN|rats (l_pobj) rats_14\NNS|diabetic (l_amod) diabetic_13\JJ|
D018723_D003920 NONE bethanechol_23\NN| (r_conj) ATP_20\NNP|,|and|bethanechol (r_conj) stimulation_18\NN|nerve|,|atp (r_pobj) to_16\TO|stimulation (r_prep) responses_8\NNS|contractile|of|from|to (l_prep) from_13\IN|rats (l_pobj) rats_15\NNS|diabetic (l_amod) diabetic_14\JJ|
D018723_D003920 NONE bethanechol_22\NN| (r_conj) ATP_19\NNP|,|and|bethanechol (r_conj) stimulation_17\NN|nerve|,|atp (r_pobj) to_15\TO|stimulation (r_prep) responses_7\NNS|contractile|of|from|to (l_prep) from_12\IN|rats (l_pobj) rats_14\NNS|diabetic (l_amod) diabetic_13\JJ|
8424298
D007741_D007022 CID labetalol_6\NN|with (r_pobj) by_5\IN|labetalol (r_agent) induced_4\VBN|by (r_acl) hypotension_3\NN|deliberate|induced
D007741_D007022 CID labetalol_16\NN|with (r_pobj) by_15\IN|labetalol (r_agent) induced_14\VBN|by (r_acl) hypotension_13\NN|deliberate|induced
D007741_D007022 CID labetalol_16\NN|with (l_prep) with_17\IN|group (l_pobj) group_21\NN|isoflurane|(|hypotensive (l_amod) hypotensive_20\JJ|
D007741_D007022 CID labetalol_7\NN|with (r_pobj) by_6\IN|labetalol (r_prep) induced_5\VBN|that|hypotension|by (l_nsubj) hypotension_4\NN|
D007530_D007022 CID isoflurane_8\NN|on (r_pobj) with_7\IN|isoflurane (r_prep) labetalol_6\NN|with (r_pobj) by_5\IN|labetalol (r_agent) induced_4\VBN|by (r_acl) hypotension_3\NN|deliberate|induced
D007530_D007022 CID isoflurane_18\JJ| (r_amod) group_21\NN|isoflurane|(|hypotensive (r_pobj) with_17\IN|group (r_prep) labetalol_16\NN|with (r_pobj) by_15\IN|labetalol (r_agent) induced_14\VBN|by (r_acl) hypotension_13\NN|deliberate|induced
D007530_D007022 CID isoflurane_18\JJ| (r_amod) group_21\NN|isoflurane|(|hypotensive (l_amod) hypotensive_20\JJ|
D007530_D007022 CID isoflurane_9\NN| (r_pobj) with_8\IN|isoflurane (r_prep) labetalol_7\NN|with (r_pobj) by_6\IN|labetalol (r_prep) induced_5\VBN|that|hypotension|by (l_nsubj) hypotension_4\NN|
6436733
D014635_D004827 NONE acid_1\NN|valproic|(|vpa|) (r_nsubjpass) given_6\VBN|acid|was|to|. (l_dative) to_7\IN|patients (l_pobj) patients_10\NNS|24|epileptic|treated (l_amod) epileptic_9\JJ|
D014635_D004827 NONE VPA_3\NNP| (r_appos) acid_1\NN|valproic|(|vpa|) (r_nsubjpass) given_6\VBN|acid|was|to|. (l_dative) to_7\IN|patients (l_pobj) patients_10\NNS|24|epileptic|treated (l_amod) epileptic_9\JJ|
D000641_D006970 CID Ammonia_0\NN|nh3 (r_nsubj) was_4\VBD|ammonia|higher|in|)|,|were|. (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|complained (l_relcl) complained_14\VBD|who|,|during|,|of|than (l_prep) of_15\IN|drowsiness (l_pobj) drowsiness_16\NN|(|patients|)
D000641_D006970 CID NH3_2\NNP|(|) (r_appos) Ammonia_0\NN|nh3 (r_nsubj) was_4\VBD|ammonia|higher|in|)|,|were|. (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|complained (l_relcl) complained_14\VBD|who|,|during|,|of|than (l_prep) of_15\IN|drowsiness (l_pobj) drowsiness_16\NN|(|patients|)
D014635_D006970 CID VPA_35\NNP| (r_compound) levels_37\NNS|vpa|plasma (r_nsubj) were_38\VBD|although|levels|similar (r_advcl) was_4\VBD|ammonia|higher|in|)|,|were|. (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|complained (l_relcl) complained_14\VBD|who|,|during|,|of|than (l_prep) of_15\IN|drowsiness (l_pobj) drowsiness_16\NN|(|patients|)
10743694
2257294
C034753_D001855 NONE Benzylacyclouridine_0\NN| (r_nsubj) reverses_1\VBZ|benzylacyclouridine|suppression|without|. (l_dobj) suppression_6\NN|induced|marrow
C034753_D001855 NONE BAU_11\NNP| (r_nsubj) reduced_12\VBD|coadministered|,|bau|toxicity|. (l_dobj) toxicity_17\NN|induced|marrow
C034753_D007153 NONE Benzylacyclouridine_0\NN| (r_nsubj) reverses_1\VBZ|benzylacyclouridine|suppression|without|. (l_prep) without_7\IN|impairment (l_pobj) impairment_8\NN|of (l_prep) of_9\IN|activity (l_pobj) activity_15\NN|human|virus (l_compound) virus_14\NN|immunodeficiency (l_compound) immunodeficiency_13\NN|
D015215_D001855 CID azidothymidine_2\RB| (r_advmod) induced_4\VBN|azidothymidine|- (r_amod) suppression_6\NN|induced|marrow
D015215_D001855 CID AZT_3\NNP| (r_pobj) with_2\IN|azt (r_prep) coadministered_1\VBN|when|with|from (r_advcl) reduced_12\VBD|coadministered|,|bau|toxicity|. (l_dobj) toxicity_17\NN|induced|marrow
D015215_D001855 CID AZT_13\NNP| (r_npadvmod) induced_15\VBN|azt|- (r_amod) toxicity_17\NN|induced|marrow
D015215_D007153 NONE azidothymidine_2\RB| (r_advmod) induced_4\VBN|azidothymidine|- (r_amod) suppression_6\NN|induced|marrow (r_dobj) reverses_1\VBZ|benzylacyclouridine|suppression|without|. (l_prep) without_7\IN|impairment (l_pobj) impairment_8\NN|of (l_prep) of_9\IN|activity (l_pobj) activity_15\NN|human|virus (l_compound) virus_14\NN|immunodeficiency (l_compound) immunodeficiency_13\NN|
D015215_D007153 NONE azidothymidine_17\NN| (r_advmod) vitro_15\FW|,|azidothymidine (r_amod) in_14\IN|vitro (r_prep) reduce_12\VB|to|,|in|inhibition (l_dobj) inhibition_20\NN|(|azt)-induced|of|without (l_prep) without_28\IN|impairment (l_pobj) impairment_29\NN|of (l_prep) of_30\IN|virus (l_pobj) virus_34\NN|its|antihuman|immunodeficiency|activity (l_compound) immunodeficiency_33\NN|
D015215_D007153 NONE AZT)-induced_19\JJ| (r_compound) inhibition_20\NN|(|azt)-induced|of|without (l_prep) without_28\IN|impairment (l_pobj) impairment_29\NN|of (l_prep) of_30\IN|virus (l_pobj) virus_34\NN|its|antihuman|immunodeficiency|activity (l_compound) immunodeficiency_33\NN|
D014529_D007153 NONE uridine_4\NN|urd (r_pobj) of_3\IN|uridine (r_prep) concentrations_2\NNS|increased|extracellular|of (r_nsubjpass) reported_10\VBN|concentrations|have|been|reduce|. (l_xcomp) reduce_12\VB|to|,|in|inhibition (l_dobj) inhibition_20\NN|(|azt)-induced|of|without (l_prep) without_28\IN|impairment (l_pobj) impairment_29\NN|of (l_prep) of_30\IN|virus (l_pobj) virus_34\NN|its|antihuman|immunodeficiency|activity (l_compound) immunodeficiency_33\NN|
D014529_D007153 NONE Urd_6\NNP|(|) (r_appos) uridine_4\NN|urd (r_pobj) of_3\IN|uridine (r_prep) concentrations_2\NNS|increased|extracellular|of (r_nsubjpass) reported_10\VBN|concentrations|have|been|reduce|. (l_xcomp) reduce_12\VB|to|,|in|inhibition (l_dobj) inhibition_20\NN|(|azt)-induced|of|without (l_prep) without_28\IN|impairment (l_pobj) impairment_29\NN|of (l_prep) of_30\IN|virus (l_pobj) virus_34\NN|its|antihuman|immunodeficiency|activity (l_compound) immunodeficiency_33\NN|
D014529_D064420 NONE Urd_8\NNP| (r_compound) administration_9\NN|chronic|urd (r_pobj) with_6\IN|administration (r_prep) associated_5\VBN|with (r_acl) toxicities_4\NNS|the|clinical|associated
D014529_D064420 NONE Urd_3\NNP| (r_compound) catabolism_4\NN|urd (r_dobj) inhibits_2\VBZ|agent|catabolism|and|,|increases|. (l_conj) increases_10\VBZ|in|,|concentration|in|,|without (l_prep) without_23\IN|toxicity (l_pobj) toxicity_27\NN|related
D014529_D064420 NONE Urd_15\NNP| (r_pobj) of_14\IN|urd (r_prep) concentration_13\NN|the|plasma|of (r_dobj) increases_10\VBZ|in|,|concentration|in|,|without (l_prep) without_23\IN|toxicity (l_pobj) toxicity_27\NN|related
D014529_D064420 NONE Urd_24\NNP| (r_npadvmod) related_26\VBN|urd|- (r_amod) toxicity_27\NN|related
D014529_D000740 NONE Urd_8\NNP| (r_compound) administration_9\NN|chronic|urd (r_pobj) with_6\IN|administration (r_prep) associated_5\VBN|with (r_acl) toxicities_4\NNS|the|clinical|associated (r_pobj) Because_0\IN|of|toxicities (r_prep) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_nsubjpass) anemia_27\NN|induced|and|leukopenia
D014529_D007970 NONE Urd_8\NNP| (r_compound) administration_9\NN|chronic|urd (r_pobj) with_6\IN|administration (r_prep) associated_5\VBN|with (r_acl) toxicities_4\NNS|the|clinical|associated (r_pobj) Because_0\IN|of|toxicities (r_prep) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_nsubjpass) anemia_27\NN|induced|and|leukopenia (l_conj) leukopenia_29\NN|
C034753_D064420 NONE benzylacyclouridine_14\NN|(|bau|) (r_pobj) of_13\IN|benzylacyclouridine (r_prep) ability_12\NN|the|of|effect (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_prep) Because_0\IN|of|toxicities (l_pobj) toxicities_4\NNS|the|clinical|associated
C034753_D064420 NONE BAU_16\NNP| (r_appos) benzylacyclouridine_14\NN|(|bau|) (r_pobj) of_13\IN|benzylacyclouridine (r_prep) ability_12\NN|the|of|effect (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_prep) Because_0\IN|of|toxicities (l_pobj) toxicities_4\NNS|the|clinical|associated
C034753_D000740 NONE benzylacyclouridine_14\NN|(|bau|) (r_pobj) of_13\IN|benzylacyclouridine (r_prep) ability_12\NN|the|of|effect (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_nsubjpass) anemia_27\NN|induced|and|leukopenia
C034753_D000740 NONE BAU_16\NNP| (r_appos) benzylacyclouridine_14\NN|(|bau|) (r_pobj) of_13\IN|benzylacyclouridine (r_prep) ability_12\NN|the|of|effect (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_nsubjpass) anemia_27\NN|induced|and|leukopenia
C034753_D000740 NONE BAU_31\NNP|daily (r_conj) AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_prep) In_0\IN|mice (l_pobj) mice_1\NNS|rendered (l_acl) rendered_2\VBD|anemic|and|leukopenic (l_oprd) anemic_3\JJ|
C034753_D000740 NONE BAU_31\NNP|daily (r_conj) AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_dobj) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes
C034753_D007970 NONE benzylacyclouridine_14\NN|(|bau|) (r_pobj) of_13\IN|benzylacyclouridine (r_prep) ability_12\NN|the|of|effect (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_nsubjpass) anemia_27\NN|induced|and|leukopenia (l_conj) leukopenia_29\NN|
C034753_D007970 NONE BAU_16\NNP| (r_appos) benzylacyclouridine_14\NN|(|bau|) (r_pobj) of_13\IN|benzylacyclouridine (r_prep) ability_12\NN|the|of|effect (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_nsubjpass) anemia_27\NN|induced|and|leukopenia (l_conj) leukopenia_29\NN|
C034753_D007970 NONE BAU_31\NNP|daily (r_conj) AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_prep) In_0\IN|mice (l_pobj) mice_1\NNS|rendered (l_acl) rendered_2\VBD|anemic|and|leukopenic (l_conj) leukopenic_5\JJ|by|for|(|ml|)
C034753_D007970 NONE BAU_31\NNP|daily (r_conj) AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_dobj) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (l_conj) leukopenia_45\NN|
D015215_D064420 NONE AZT_24\NNP| (r_npadvmod) induced_26\VBN|azt|- (r_amod) anemia_27\NN|induced|and|leukopenia (r_nsubjpass) assessed_31\VBN|because|,|ability|,|in|,|anemia|was|. (l_prep) Because_0\IN|of|toxicities (l_pobj) toxicities_4\NNS|the|clinical|associated
D015215_D000740 CID AZT_24\NNP| (r_npadvmod) induced_26\VBN|azt|- (r_amod) anemia_27\NN|induced|and|leukopenia
D015215_D000740 CID AZT_10\NNP| (r_pobj) of_9\IN|azt (r_prep) administration_8\NN|the|of (r_pobj) by_6\IN|administration (r_prep) leukopenic_5\JJ|by|for|(|ml|) (r_conj) rendered_2\VBD|anemic|and|leukopenic (l_oprd) anemic_3\JJ|
D015215_D000740 CID AZT_10\NNP| (r_pobj) of_9\IN|azt (r_prep) administration_8\NN|the|of (r_pobj) by_6\IN|administration (r_prep) leukopenic_5\JJ|by|for|(|ml|) (r_conj) rendered_2\VBD|anemic|and|leukopenic (r_acl) mice_1\NNS|rendered (r_pobj) In_0\IN|mice (r_prep) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_dobj) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes
D015215_D000740 CID AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_prep) In_0\IN|mice (l_pobj) mice_1\NNS|rendered (l_acl) rendered_2\VBD|anemic|and|leukopenic (l_oprd) anemic_3\JJ|
D015215_D000740 CID AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_dobj) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes
D015215_D000740 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|azt|- (r_amod) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (r_dobj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_prep) In_0\IN|mice (l_pobj) mice_1\NNS|rendered (l_acl) rendered_2\VBD|anemic|and|leukopenic (l_oprd) anemic_3\JJ|
D015215_D000740 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|azt|- (r_amod) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes
D015215_D007970 CID AZT_24\NNP| (r_npadvmod) induced_26\VBN|azt|- (r_amod) anemia_27\NN|induced|and|leukopenia (l_conj) leukopenia_29\NN|
D015215_D007970 CID AZT_10\NNP| (r_pobj) of_9\IN|azt (r_prep) administration_8\NN|the|of (r_pobj) by_6\IN|administration (r_prep) leukopenic_5\JJ|by|for|(|ml|)
D015215_D007970 CID AZT_10\NNP| (r_pobj) of_9\IN|azt (r_prep) administration_8\NN|the|of (r_pobj) by_6\IN|administration (r_prep) leukopenic_5\JJ|by|for|(|ml|) (r_conj) rendered_2\VBD|anemic|and|leukopenic (r_acl) mice_1\NNS|rendered (r_pobj) In_0\IN|mice (r_prep) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_dobj) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (l_conj) leukopenia_45\NN|
D015215_D007970 CID AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_prep) In_0\IN|mice (l_pobj) mice_1\NNS|rendered (l_acl) rendered_2\VBD|anemic|and|leukopenic (l_conj) leukopenic_5\JJ|by|for|(|ml|)
D015215_D007970 CID AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_dobj) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (l_conj) leukopenia_45\NN|
D015215_D007970 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|azt|- (r_amod) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (r_dobj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_prep) In_0\IN|mice (l_pobj) mice_1\NNS|rendered (l_acl) rendered_2\VBD|anemic|and|leukopenic (l_conj) leukopenic_5\JJ|by|for|(|ml|)
D015215_D007970 CID AZT_40\NNP| (r_npadvmod) induced_42\VBN|azt|- (r_amod) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (l_conj) leukopenia_45\NN|
D015215_-1 NONE AZT_10\NNP| (r_pobj) of_9\IN|azt (r_prep) administration_8\NN|the|of (r_pobj) by_6\IN|administration (r_prep) leukopenic_5\JJ|by|for|(|ml|) (r_conj) rendered_2\VBD|anemic|and|leukopenic (r_acl) mice_1\NNS|rendered (r_pobj) In_0\IN|mice (r_prep) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_conj) increased_67\VBN|cellularity|in|,|and|improved (l_conj) improved_74\VBN|megaloblastosis (l_dobj) megaloblastosis_75\NN|
D015215_-1 NONE AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_conj) increased_67\VBN|cellularity|in|,|and|improved (l_conj) improved_74\VBN|megaloblastosis (l_dobj) megaloblastosis_75\NN|
D015215_-1 NONE AZT_40\NNP| (r_npadvmod) induced_42\VBN|azt|- (r_amod) anemia_43\NN|induced|and|leukopenia|(|p|reticulocytes (r_dobj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_conj) increased_67\VBN|cellularity|in|,|and|improved (l_conj) improved_74\VBN|megaloblastosis (l_dobj) megaloblastosis_75\NN|
C034753_-1 NONE BAU_31\NNP|daily (r_conj) AZT_28\NNP|plus|bau|(|mg/kg|, (r_pobj) of_27\IN|azt (r_prep) administration_26\NN|the|continued|of|orally (r_nsubj) reversed_39\VBD|in|,|administration|)|partially|anemia|p|,|increased|. (l_conj) increased_67\VBN|cellularity|in|,|and|improved (l_conj) improved_74\VBN|megaloblastosis (l_dobj) megaloblastosis_75\NN|
15814210
D003907_D009422 CID dexamethasone_19\NN| (r_compound) treatment_20\NN|dexamethasone|in (r_pobj) after_18\IN|treatment (r_prep) dysfunction_2\NN|minor|neurological|,|development|at|after|.
D003907_D009422 CID dexamethasone_19\NN| (r_compound) therapy_20\NN|dexamethasone|in (r_pobj) after_18\IN|therapy (r_prep) assess_7\VB|to|dysfunction|after (l_dobj) dysfunction_10\NN|minor|neurological|,|development
D003907_D009422 CID dexamethasone_1\NN| (r_compound) treatment_2\NN|dexamethasone (r_pobj) After_0\IN|treatment (r_prep) showed_5\VBD|after|,|children|rate|. (l_dobj) rate_8\NN|a|higher|of (l_prep) of_9\IN|dysfunctions (l_pobj) dysfunctions_12\NNS|minor|neurological
6433367
D011453_D012640 NONE prostaglandin_2\JJ| (r_amod) inhibitors_4\NNS|prostaglandin|synthetase (r_pobj) of_1\IN|inhibitors (r_prep) Effect_0\NN|of|on|. (l_prep) on_5\IN|convulsions (l_pobj) convulsions_8\NNS|induced|in
D011453_D012640 NONE prostaglandins_5\NNS|(|pgs|) (r_pobj) of_4\IN|prostaglandins (r_prep) relationship_3\NN|the|of (r_dobj) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D011453_D012640 NONE prostaglandins_5\NNS|(|pgs|) (r_pobj) of_4\IN|prostaglandins (r_prep) relationship_3\NN|the|of (r_dobj) investigate_1\VB|to|relationship|to (r_advcl) evaluated_37\VBN|investigate|,|effects|were|. (l_nsubjpass) effects_14\NNS|the|of|on (l_prep) on_20\IN|convulsions (l_pobj) convulsions_21\NNS|induced
D011453_D012640 NONE PGs_7\NNS| (r_appos) prostaglandins_5\NNS|(|pgs|) (r_pobj) of_4\IN|prostaglandins (r_prep) relationship_3\NN|the|of (r_dobj) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D011453_D012640 NONE PGs_7\NNS| (r_appos) prostaglandins_5\NNS|(|pgs|) (r_pobj) of_4\IN|prostaglandins (r_prep) relationship_3\NN|the|of (r_dobj) investigate_1\VB|to|relationship|to (r_advcl) evaluated_37\VBN|investigate|,|effects|were|. (l_nsubjpass) effects_14\NNS|the|of|on (l_prep) on_20\IN|convulsions (l_pobj) convulsions_21\NNS|induced
D011453_D012640 NONE PGs_4\NNS| (r_nsubjpass) involved_6\VBN|that|pgs|are|in|,|but|picrotoxin- (l_prep) in_7\IN|fluorthyl- (l_pobj) fluorthyl-_12\NNS|the|)|underlying|and|convulsions (l_conj) convulsions_17\NNS|induced
D011453_D012640 NONE PGs_4\NNS| (r_nsubjpass) involved_6\VBN|that|pgs|are|in|,|but|picrotoxin- (l_conj) picrotoxin-_21\XX|not|,|electroshock-|convulsions (l_pobj) convulsions_29\NNS|
D005481_D012640 CID flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced (r_pobj) on_20\IN|convulsions (r_prep) effects_14\NNS|the|of|on (r_nsubjpass) evaluated_37\VBN|investigate|,|effects|were|. (l_advcl) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D005481_D012640 CID flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced
D005481_D012640 CID fluorthyl-_12\NNS|the|)|underlying|and|convulsions (l_conj) convulsions_17\NNS|induced
D005481_D012640 CID fluorthyl-_12\NNS|the|)|underlying|and|convulsions (r_pobj) in_7\IN|fluorthyl- (r_prep) involved_6\VBN|that|pgs|are|in|,|but|picrotoxin- (l_conj) picrotoxin-_21\XX|not|,|electroshock-|convulsions (l_pobj) convulsions_29\NNS|
D010852_D012640 CID picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced (r_pobj) on_20\IN|convulsions (r_prep) effects_14\NNS|the|of|on (r_nsubjpass) evaluated_37\VBN|investigate|,|effects|were|. (l_advcl) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D010852_D012640 CID picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced
D010852_D012640 CID picrotoxin-_21\XX|not|,|electroshock-|convulsions (r_conj) involved_6\VBN|that|pgs|are|in|,|but|picrotoxin- (l_prep) in_7\IN|fluorthyl- (l_pobj) fluorthyl-_12\NNS|the|)|underlying|and|convulsions (l_conj) convulsions_17\NNS|induced
D010852_D012640 CID picrotoxin-_21\XX|not|,|electroshock-|convulsions (l_pobj) convulsions_29\NNS|
D010433_D012640 CID pentetrazol_28\NNP| (r_nmod) PTZ_30\NNP|pentetrazol|(|)|,|electroshock (r_conj) picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced (r_pobj) on_20\IN|convulsions (r_prep) effects_14\NNS|the|of|on (r_nsubjpass) evaluated_37\VBN|investigate|,|effects|were|. (l_advcl) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D010433_D012640 CID pentetrazol_28\NNP| (r_nmod) PTZ_30\NNP|pentetrazol|(|)|,|electroshock (r_conj) picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced
D010433_D012640 CID PTZ_30\NNP|pentetrazol|(|)|,|electroshock (r_conj) picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced (r_pobj) on_20\IN|convulsions (r_prep) effects_14\NNS|the|of|on (r_nsubjpass) evaluated_37\VBN|investigate|,|effects|were|. (l_advcl) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D010433_D012640 CID PTZ_30\NNP|pentetrazol|(|)|,|electroshock (r_conj) picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced
D010433_D012640 CID PTZ_14\NNP| (r_npadvmod) induced_16\VBN|ptz|- (r_amod) convulsions_17\NNS|induced
D010433_D012640 CID PTZ_14\NNP| (r_npadvmod) induced_16\VBN|ptz|- (r_amod) convulsions_17\NNS|induced (r_conj) fluorthyl-_12\NNS|the|)|underlying|and|convulsions (r_pobj) in_7\IN|fluorthyl- (r_prep) involved_6\VBN|that|pgs|are|in|,|but|picrotoxin- (l_conj) picrotoxin-_21\XX|not|,|electroshock-|convulsions (l_pobj) convulsions_29\NNS|
D001640_D012640 CID bicuculline_35\NN| (r_conj) electroshock_33\NN|or|bicuculline (r_conj) PTZ_30\NNP|pentetrazol|(|)|,|electroshock (r_conj) picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced (r_pobj) on_20\IN|convulsions (r_prep) effects_14\NNS|the|of|on (r_nsubjpass) evaluated_37\VBN|investigate|,|effects|were|. (l_advcl) investigate_1\VB|to|relationship|to (l_prep) to_9\TO|induction (l_pobj) induction_11\NN|seizure (l_compound) seizure_10\NN|
D001640_D012640 CID bicuculline_35\NN| (r_conj) electroshock_33\NN|or|bicuculline (r_conj) PTZ_30\NNP|pentetrazol|(|)|,|electroshock (r_conj) picrotoxin_26\JJ|,|ptz (r_conj) flurothyl_24\JJ|,|picrotoxin (r_pobj) by_23\IN|flurothyl (r_agent) induced_22\VBN|by (r_acl) convulsions_21\NNS|induced
D001640_D012640 CID bicuculline_26\NN| (r_advmod) induced_28\VBN|bicuculline|- (r_conj) electroshock-_23\XX|,|or|induced (r_conj) picrotoxin-_21\XX|not|,|electroshock-|convulsions (r_conj) involved_6\VBN|that|pgs|are|in|,|but|picrotoxin- (l_prep) in_7\IN|fluorthyl- (l_pobj) fluorthyl-_12\NNS|the|)|underlying|and|convulsions (l_conj) convulsions_17\NNS|induced
D001640_D012640 CID bicuculline_26\NN| (r_advmod) induced_28\VBN|bicuculline|- (r_conj) electroshock-_23\XX|,|or|induced (r_conj) picrotoxin-_21\XX|not|,|electroshock-|convulsions (l_pobj) convulsions_29\NNS|
8251368
D009543_D013684 CID nifedipine_1\RB| (r_advmod) induced_3\VBN|nifedipine|- (r_amod) telangiectasia_5\NN|induced|facial
D009543_D013684 CID nifedipine_4\NN| (r_dobj) starting_3\VBG|nifedipine|adalat (r_pcomp) after_2\IN|months|starting (r_prep) developed_11\VBD|after|,|patients|telangiectasia|. (l_dobj) telangiectasia_14\NN|photodistributed|facial|,|became
D009543_D013684 CID Adalat_6\NNP|(|) (r_oprd) starting_3\VBG|nifedipine|adalat (r_pcomp) after_2\IN|months|starting (r_prep) developed_11\VBD|after|,|patients|telangiectasia|. (l_dobj) telangiectasia_14\NN|photodistributed|facial|,|became
D017311_D013684 CID amlodipine_6\NN|the|related|drug (r_dobj) commenced_1\VBD|one|amlodipine|later|,|with|. (l_prep) with_11\IN|recurrence (l_pobj) recurrence_12\NN|of (l_prep) of_13\IN|telangiectasia (l_pobj) telangiectasia_14\NN|
12101159
D004110_D006323 CID diltiazem_5\NN| (r_compound) overdose_6\NN|diltiazem (r_pobj) after_4\IN|overdose (r_prep) arrest_3\NN|asystolic|cardiac|after (l_amod) asystolic_1\JJ|
D004110_D006323 CID diltiazem_5\NN| (r_compound) overdose_6\NN|diltiazem (r_pobj) after_4\IN|overdose (r_prep) arrest_3\NN|asystolic|cardiac|after
D004110_D006323 CID diltiazem_16\NN| (r_compound) overdose_17\NN|severe|diltiazem (r_pobj) in_14\IN|overdose (r_prep) therapy_13\NN|aggressive|dose|intravenous|calcium|in (r_pobj) for_7\IN|therapy (r_prep) role_6\NN|a|for|,|with (l_prep) with_20\IN|particularly|onset (l_pobj) onset_22\NN|the|of (l_prep) of_23\IN|asystole (l_pobj) asystole_24\NN|
D004110_D006323 CID diltiazem_11\NN| (r_compound) overdose_12\NN|diltiazem (r_pobj) after_10\IN|overdose (r_prep) cases_6\NNS|of|after (l_prep) of_7\IN|arrest (l_pobj) arrest_9\NN|cardiac
D004110_D062787 CID diltiazem_5\NN| (r_compound) overdose_6\NN|diltiazem
D004110_D062787 CID diltiazem_15\NN|,|paracetamol (r_pobj) of_14\IN|diltiazem (r_prep) g_13\NN|1.8|of (r_pobj) including_9\VBG|g (r_prep) overdose_8\NN|a|mixed|including
D004110_D062787 CID diltiazem_16\NN| (r_compound) overdose_17\NN|severe|diltiazem
D004110_D062787 CID diltiazem_11\NN| (r_compound) overdose_12\NN|diltiazem
D002118_D006323 NONE calcium_13\NN|high|dose|intravenous (r_pobj) with_9\IN|calcium (r_prep) resuscitation_8\NN|with (r_dep) Delayed_0\VBN|arrest|;|resuscitation|. (l_dobj) arrest_3\NN|asystolic|cardiac|after (l_amod) asystolic_1\JJ|
D002118_D006323 NONE calcium_13\NN|high|dose|intravenous (r_pobj) with_9\IN|calcium (r_prep) resuscitation_8\NN|with (r_dep) Delayed_0\VBN|arrest|;|resuscitation|. (l_dobj) arrest_3\NN|asystolic|cardiac|after
D002118_D006323 NONE calcium_12\NN| (r_compound) therapy_13\NN|aggressive|dose|intravenous|calcium|in (r_pobj) for_7\IN|therapy (r_prep) role_6\NN|a|for|,|with (l_prep) with_20\IN|particularly|onset (l_pobj) onset_22\NN|the|of (l_prep) of_23\IN|asystole (l_pobj) asystole_24\NN|
D002118_D062787 NONE calcium_13\NN|high|dose|intravenous (r_pobj) with_9\IN|calcium (r_prep) resuscitation_8\NN|with (r_dep) Delayed_0\VBN|arrest|;|resuscitation|. (l_dobj) arrest_3\NN|asystolic|cardiac|after (l_prep) after_4\IN|overdose (l_pobj) overdose_6\NN|diltiazem
D002118_D062787 NONE calcium_12\NN| (r_compound) therapy_13\NN|aggressive|dose|intravenous|calcium|in (l_prep) in_14\IN|overdose (l_pobj) overdose_17\NN|severe|diltiazem
D000082_D062787 NONE paracetamol_17\JJ|,|aspirin (r_conj) diltiazem_15\NN|,|paracetamol (r_pobj) of_14\IN|diltiazem (r_prep) g_13\NN|1.8|of (r_pobj) including_9\VBG|g (r_prep) overdose_8\NN|a|mixed|including
D001241_D062787 NONE aspirin_19\NN|,|nitrate (r_conj) paracetamol_17\JJ|,|aspirin (r_conj) diltiazem_15\NN|,|paracetamol (r_pobj) of_14\IN|diltiazem (r_prep) g_13\NN|1.8|of (r_pobj) including_9\VBG|g (r_prep) overdose_8\NN|a|mixed|including
D007547_D062787 NONE isosorbide_21\JJ| (r_compound) nitrate_22\NN|isosorbide|,|and|alcohol (r_conj) aspirin_19\NN|,|nitrate (r_conj) paracetamol_17\JJ|,|aspirin (r_conj) diltiazem_15\NN|,|paracetamol (r_pobj) of_14\IN|diltiazem (r_prep) g_13\NN|1.8|of (r_pobj) including_9\VBG|g (r_prep) overdose_8\NN|a|mixed|including
D009566_D062787 NONE nitrate_22\NN|isosorbide|,|and|alcohol (r_conj) aspirin_19\NN|,|nitrate (r_conj) paracetamol_17\JJ|,|aspirin (r_conj) diltiazem_15\NN|,|paracetamol (r_pobj) of_14\IN|diltiazem (r_prep) g_13\NN|1.8|of (r_pobj) including_9\VBG|g (r_prep) overdose_8\NN|a|mixed|including
D000431_D062787 NONE alcohol_25\NN| (r_conj) nitrate_22\NN|isosorbide|,|and|alcohol (r_conj) aspirin_19\NN|,|nitrate (r_conj) paracetamol_17\JJ|,|aspirin (r_conj) diltiazem_15\NN|,|paracetamol (r_pobj) of_14\IN|diltiazem (r_prep) g_13\NN|1.8|of (r_pobj) including_9\VBG|g (r_prep) overdose_8\NN|a|mixed|including
11302406
D015725_D016171 CID Fluconazole_0\NNP| (r_npadvmod) induced_2\VBN|fluconazole|- (r_amod) torsade_3\NN|induced (r_nmod) pointes_5\FW|torsade|de|.
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|fluconazole|- (r_amod) pointes_10\FW|associated|torsade|de|(|tdp|)
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|fluconazole|- (r_amod) pointes_10\FW|associated|torsade|de|(|tdp|) (l_appos) TDP_12\NNP|
D015725_D016171 CID fluconazole_5\NN| (r_advmod) associated_7\VBN|fluconazole|- (r_amod) pointes_10\FW|associated|torsade|de|(|tdp|) (r_pobj) of_4\IN|pointes (r_prep) case_3\NN|a|of (r_dobj) present_1\VB|to|case|and|discuss|. (l_conj) discuss_15\VB|role (l_dobj) role_18\NN|fluconazole|in (l_prep) in_19\IN|causing (l_pcomp) causing_20\VBG|tdp (l_dobj) TDP_21\NNP|
D015725_D016171 CID fluconazole_16\NN|'s (r_poss) role_18\NN|fluconazole|in (r_dobj) discuss_15\VB|role (r_conj) present_1\VB|to|case|and|discuss|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|pointes (l_pobj) pointes_10\FW|associated|torsade|de|(|tdp|)
D015725_D016171 CID fluconazole_16\NN|'s (r_poss) role_18\NN|fluconazole|in (r_dobj) discuss_15\VB|role (r_conj) present_1\VB|to|case|and|discuss|. (l_dobj) case_3\NN|a|of (l_prep) of_4\IN|pointes (l_pobj) pointes_10\FW|associated|torsade|de|(|tdp|) (l_appos) TDP_12\NNP|
D015725_D016171 CID fluconazole_16\NN|'s (r_poss) role_18\NN|fluconazole|in (l_prep) in_19\IN|causing (l_pcomp) causing_20\VBG|tdp (l_dobj) TDP_21\NNP|
D015725_D016171 CID fluconazole_21\NN|oral (r_dobj) commencing_19\VBG|fluconazole (r_pcomp) after_18\IN|days|commencing (r_prep) glabrata_8\NNS|woman|isolated|after (l_xcomp) isolated_9\VBN|from (l_prep) from_10\IN|abscess (l_pobj) abscess_13\NN|a|presacral|developed (l_acl) developed_14\VBD|tdp (l_dobj) TDP_15\NNP|
D015725_D016171 CID fluconazole_33\NN|and|tdp (r_pobj) of_32\IN|fluconazole (r_prep) initiation_31\NN|the|of (r_pobj) between_29\IN|initiation (r_prep) association_28\NN|a|temporal|between (r_attr) was_25\VBD|there|association (r_relcl) factors_6\NNS|no|other|risk|for|,|including|was (l_prep) for_7\IN|tdp (l_pobj) TDP_8\NNP|
D015725_D016171 CID fluconazole_33\NN|and|tdp (l_conj) TDP_35\NNP|
D015725_D016171 CID fluconazole_4\NN| (r_nsubjpass) discontinued_6\VBN|when|fluconazole|was (r_advcl) resolved_2\VBD|tdp|discontinued (l_nsubj) TDP_1\NNP|the
D015725_D016171 CID fluconazole_14\NN| (r_pobj) of_13\IN|fluconazole (r_prep) use_12\NN|the|of|and|development (l_conj) development_17\NN|the|of (l_prep) of_18\IN|tdp (l_pobj) TDP_19\NNP|
D015725_D016171 CID fluconazole_5\NN|that (r_ccomp) aware_3\JJ|fluconazole|, (r_acomp) be_2\VB|clinicians|should|aware|at|,|cause|. (l_conj) cause_13\VB|may|prolongation|,|leading (l_advcl) leading_20\VBG|to (l_prep) to_21\IN|tdp (l_pobj) TDP_22\NNP|
D015725_D003324 NONE fluconazole_33\NN|and|tdp (r_pobj) of_32\IN|fluconazole (r_prep) initiation_31\NN|the|of (r_pobj) between_29\IN|initiation (r_prep) association_28\NN|a|temporal|between (r_attr) was_25\VBD|there|association (r_relcl) factors_6\NNS|no|other|risk|for|,|including|was (l_prep) including_10\VBG|disease (l_pobj) disease_13\NN|coronary|artery|,|cardiomyopathy
D015725_D009202 NONE fluconazole_33\NN|and|tdp (r_pobj) of_32\IN|fluconazole (r_prep) initiation_31\NN|the|of (r_pobj) between_29\IN|initiation (r_prep) association_28\NN|a|temporal|between (r_attr) was_25\VBD|there|association (r_relcl) factors_6\NNS|no|other|risk|for|,|including|was (l_prep) including_10\VBG|disease (l_pobj) disease_13\NN|coronary|artery|,|cardiomyopathy (l_amod) cardiomyopathy_15\NN|,|failure
D015725_D006333 NONE fluconazole_33\NN|and|tdp (r_pobj) of_32\IN|fluconazole (r_prep) initiation_31\NN|the|of (r_pobj) between_29\IN|initiation (r_prep) association_28\NN|a|temporal|between (r_attr) was_25\VBD|there|association (r_relcl) factors_6\NNS|no|other|risk|for|,|including|was (l_prep) including_10\VBG|disease (l_pobj) disease_13\NN|coronary|artery|,|cardiomyopathy (l_amod) cardiomyopathy_15\NN|,|failure (l_conj) failure_19\NN|heart|,|and|abnormalities
D015725_D018879 NONE fluconazole_4\NN| (r_nsubjpass) discontinued_6\VBN|when|fluconazole|was (r_advcl) resolved_2\VBD|tdp|discontinued (r_ccomp) continued_12\VBD|resolved|;|however|,|patient|have|and|tachycardia|until|: (l_xcomp) have_14\VB|to|contractions (l_dobj) contractions_17\NNS|premature|ventricular
D015725_D018879 NONE fluconazole_22\NN| (r_dobj) suggests_21\VBZ|followed|strongly|fluconazole|as|. (l_csubj) followed_9\VBN|disappearance|by|stopped (l_nsubj) disappearance_2\NN|the|complete|of|and|contractions (l_conj) contractions_8\NNS|premature|ventricular
D015725_D017180 NONE fluconazole_4\NN| (r_nsubjpass) discontinued_6\VBN|when|fluconazole|was (r_advcl) resolved_2\VBD|tdp|discontinued (r_ccomp) continued_12\VBD|resolved|;|however|,|patient|have|and|tachycardia|until|: (l_conj) tachycardia_21\NN|nonsustained|ventricular|(|nsvt|)
D015725_D017180 NONE fluconazole_4\NN| (r_nsubjpass) discontinued_6\VBN|when|fluconazole|was (r_advcl) resolved_2\VBD|tdp|discontinued (r_ccomp) continued_12\VBD|resolved|;|however|,|patient|have|and|tachycardia|until|: (l_conj) tachycardia_21\NN|nonsustained|ventricular|(|nsvt|) (l_appos) NSVT_23\NNP|
D015725_D017180 NONE fluconazole_22\NN| (r_dobj) suggests_21\VBZ|followed|strongly|fluconazole|as|. (l_csubj) followed_9\VBN|disappearance|by|stopped (l_nsubj) disappearance_2\NN|the|complete|of|and|contractions (l_prep) of_3\IN|nsvt (l_pobj) NSVT_4\NNP|
D011188_D003866 NONE potassium_10\NN| (r_compound) currents_11\NNS|rectifier|potassium (r_dobj) activating_7\VBG|rapidly|currents (r_pcomp) of_5\IN|activating (r_prep) depression_4\NN|of
D015725_D008133 NONE fluconazole_5\NN|that (r_ccomp) aware_3\JJ|fluconazole|, (r_acomp) be_2\VB|clinicians|should|aware|at|,|cause|. (l_conj) cause_13\VB|may|prolongation|,|leading (l_dobj) prolongation_14\NN|of (l_prep) of_15\IN|interval (l_pobj) interval_18\NN|the|qt
D015725_D001145 NONE fluconazole_7\NN| (r_nsubjpass) administered_9\VBN|when|fluconazole|is|in (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|are (l_relcl) are_13\VBP|who|at (l_prep) at_14\IN|risk (l_pobj) risk_15\NN|for (l_prep) for_16\IN|arrhythmias (l_pobj) arrhythmias_18\NNS|ventricular
8305357
D003630_D012514 NONE daunorubicin_1\NN|liposomal|in|sarcoma|. (l_dobj) sarcoma_6\NN|advanced|kaposi|:|study
D003630_D012514 NONE daunorubicin_18\NN|liposomal|(|daunoxome|) (r_pobj) of_16\IN|daunorubicin (r_prep) safety_15\NN|of (r_conj) efficacy_13\NN|the|and|safety|in (r_dobj) assess_11\VB|to|efficacy (r_relcl) trial_9\NN|a|randomized|ii|clinical|assess (r_dobj) report_1\VBP|we|trial|related|. (l_ccomp) related_27\VBD|sarcoma (l_dobj) sarcoma_30\NN|kaposi
D003630_D012514 NONE daunorubicin_7\NN|liposomal (r_nsubj) was_8\VBD|in|,|daunorubicin|agent|. (l_attr) agent_14\NN|an|effective|in (l_prep) in_15\IN|treatment (l_pobj) treatment_17\NN|the|of (l_prep) of_18\IN|sarcoma (l_pobj) sarcoma_21\NN|kaposi
D003630_D000163 NONE daunorubicin_18\NN|liposomal|(|daunoxome|) (r_pobj) of_16\IN|daunorubicin (r_prep) safety_15\NN|of (r_conj) efficacy_13\NN|the|and|safety|in (l_prep) in_22\IN|treatment (l_pobj) treatment_24\NN|the|of (l_prep) of_25\IN|aids (l_pobj) AIDS_26\NNP|
19940105
D018698_D010300 NONE glutamate_1\NN|metabotropic (r_nmod) subtype_4\NN|glutamate|7|receptor (r_nsubj) modulates_5\VBZ|subtype|symptoms|in|. (l_prep) in_8\IN|models (l_pobj) models_10\NNS|rodent|of (l_prep) of_11\IN|disease (l_pobj) disease_14\NN|parkinson
D018698_D010300 NONE glutamate_1\NN|metabotropic (r_nmod) receptors_5\NNS|glutamate|mglu (r_nsubj) modulate_6\VBP|receptors|transmission|and|represent|. (l_conj) represent_15\VBP|targets (l_dobj) targets_18\NNS|promising|therapeutic|for (l_prep) for_19\IN|treatment (l_pobj) treatment_21\NN|symptomatic|of (l_prep) of_22\IN|disease (l_pobj) disease_25\NN|parkinson|(|pd|)
D018698_D010300 NONE glutamate_1\NN|metabotropic (r_nmod) receptors_5\NNS|glutamate|mglu (r_nsubj) modulate_6\VBP|receptors|transmission|and|represent|. (l_conj) represent_15\VBP|targets (l_dobj) targets_18\NNS|promising|therapeutic|for (l_prep) for_19\IN|treatment (l_pobj) treatment_21\NN|symptomatic|of (l_prep) of_22\IN|disease (l_pobj) disease_25\NN|parkinson|(|pd|) (l_appos) PD_27\NNP|
C507346_D010300 NONE AMN082_1\NNP|(|)|,|activator|, (r_nsubjpass) tested_15\VBN|amn082|were|thus|in|. (l_prep) in_16\IN|models (l_pobj) models_19\NNS|different|rodent|of (l_prep) of_20\IN|pd (l_pobj) PD_21\NNP|
C507346_D010300 NONE AMN082_18\NNP|mg/kg (r_nsubj) reverses_19\VBZ|in|,|amn082|time|respond|. (l_prep) In_0\IN|task (l_pobj) task_4\NN|a|complex|used (l_acl) used_6\VBN|commonly|evaluate (l_xcomp) evaluate_8\VB|to|symptoms (l_dobj) symptoms_11\NNS|major|akinetic|of (l_prep) of_12\IN|patients (l_pobj) patients_14\NNS|pd (l_compound) PD_13\NNP|
C507346_D010300 NONE AMN082_3\NNP|(|mg/kg|p.o.|) (r_pobj) of_2\IN|amn082 (r_prep) doses_1\NNS|higher|of (r_nsubj) have_11\VBP|doses|effect|. (l_dobj) effect_13\NN|no|on (l_prep) on_14\IN|models (l_pobj) models_17\NNS|the|same|of (l_prep) of_18\IN|pd (l_pobj) PD_19\NNP|
C507346_D002375 NONE AMN082_20\NNP| (r_pobj) of_19\IN|amn082 (r_prep) administration_12\NN|(|0.1|nmol|)|of (r_dobj) intrastriatal_11\JJ|administration (r_csubj) reverses_21\VBZ|that|intrastriatal|catalepsy (l_dobj) catalepsy_25\NN|induced|in
C507346_D002375 NONE AMN082_3\NNP| (r_nsubj) reduces_4\VBZ|in|,|amn082|duration|. (l_dobj) duration_6\NN|the|of|in (l_prep) of_7\IN|catalepsy (l_pobj) catalepsy_11\NN|induced
D006220_D002375 CID haloperidol_22\NN| (r_npadvmod) induced_24\VBN|haloperidol|- (r_amod) catalepsy_25\NN|induced|in
D006220_D002375 CID haloperidol_8\NN| (r_npadvmod) induced_10\VBN|haloperidol|- (r_amod) catalepsy_11\NN|induced
C507346_D018476 NONE AMN082_18\NNP|mg/kg (r_nsubj) reverses_19\VBZ|in|,|amn082|time|respond|. (l_prep) In_0\IN|task (l_pobj) task_4\NN|a|complex|used (l_acl) used_6\VBN|commonly|evaluate (l_xcomp) evaluate_8\VB|to|symptoms (l_dobj) symptoms_11\NNS|major|akinetic|of (l_amod) akinetic_10\JJ|
D016627_D018476 NONE 6-OHDA_31\CD| (r_advmod) lesioned_33\VBN|6-ohda|- (r_amod) rats_34\NNS|bilateral|lesioned (r_pobj) of_29\IN|rats (r_prep) cue_28\NN|a|of (r_pobj) to_26\IN|cue (r_prep) respond_25\VB|to|to (r_xcomp) reverses_19\VBZ|in|,|amn082|time|respond|. (l_prep) In_0\IN|task (l_pobj) task_4\NN|a|complex|used (l_acl) used_6\VBN|commonly|evaluate (l_xcomp) evaluate_8\VB|to|symptoms (l_dobj) symptoms_11\NNS|major|akinetic|of (l_amod) akinetic_10\JJ|
D016627_D010300 NONE 6-OHDA_31\CD| (r_advmod) lesioned_33\VBN|6-ohda|- (r_amod) rats_34\NNS|bilateral|lesioned (r_pobj) of_29\IN|rats (r_prep) cue_28\NN|a|of (r_pobj) to_26\IN|cue (r_prep) respond_25\VB|to|to (r_xcomp) reverses_19\VBZ|in|,|amn082|time|respond|. (l_prep) In_0\IN|task (l_pobj) task_4\NN|a|complex|used (l_acl) used_6\VBN|commonly|evaluate (l_xcomp) evaluate_8\VB|to|symptoms (l_dobj) symptoms_11\NNS|major|akinetic|of (l_prep) of_12\IN|patients (l_pobj) patients_14\NNS|pd (l_compound) PD_13\NNP|
16192988
D008694_D001523 CID Methamphetamine_0\NN| (r_nsubj) causes_1\VBZ|methamphetamine|alterations|. (l_dobj) alterations_2\NNS|in|display (l_relcl) display_16\VBP|that|aggressiveness (l_dobj) aggressiveness_18\NN|increased
D008694_D001523 CID methamphetamine_18\NN|(|abusers (r_pobj) in_17\IN|methamphetamine (r_prep) common_16\JJ|in (r_acomp) are_15\VBP|common (r_conj) reported_4\VBN|behaviors|have|been|in|,|and|are|. (l_nsubjpass) behaviors_1\NNS|aggressive
D008694_D001523 CID methamphetamine_18\NN|(|abusers (r_pobj) in_17\IN|methamphetamine (r_prep) common_16\JJ|in (r_acomp) are_15\VBP|common (r_conj) reported_4\VBN|behaviors|have|been|in|,|and|are|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|suffer (l_relcl) suffer_8\VBP|who|from (l_prep) from_9\IN|disorders (l_pobj) disorders_12\NNS|some|psychiatric
D008694_D001523 CID METH_20\NN|) (r_nmod) abusers_22\NNS|meth (r_appos) methamphetamine_18\NN|(|abusers (r_pobj) in_17\IN|methamphetamine (r_prep) common_16\JJ|in (r_acomp) are_15\VBP|common (r_conj) reported_4\VBN|behaviors|have|been|in|,|and|are|. (l_nsubjpass) behaviors_1\NNS|aggressive
D008694_D001523 CID METH_20\NN|) (r_nmod) abusers_22\NNS|meth (r_appos) methamphetamine_18\NN|(|abusers (r_pobj) in_17\IN|methamphetamine (r_prep) common_16\JJ|in (r_acomp) are_15\VBP|common (r_conj) reported_4\VBN|behaviors|have|been|in|,|and|are|. (l_prep) in_5\IN|patients (l_pobj) patients_6\NNS|suffer (l_relcl) suffer_8\VBP|who|from (l_prep) from_9\IN|disorders (l_pobj) disorders_12\NNS|some|psychiatric
D008694_D001523 CID METH_13\NNP| (r_pobj) of_12\IN|meth (r_prep) injections_11\NNS|multiple|(|single|)|of (r_nsubj) increased_15\VBD|that|injections|significantly|aggressiveness (l_dobj) aggressiveness_16\NN|in
D008694_D001523 CID METH_8\NNP| (r_npadvmod) induced_10\VBN|meth|- (r_amod) hyperactivity_11\NN|induced (r_pobj) to_7\IN|hyperactivity (r_prep) secondary_6\JJ|to (r_acomp) was_4\VBD|increase|not|secondary|. (l_nsubj) increase_1\NN|this|in (l_prep) in_2\IN|aggressiveness (l_pobj) aggressiveness_3\NN|
D008694_D006948 NONE METH_8\NNP| (r_npadvmod) induced_10\VBN|meth|- (r_amod) hyperactivity_11\NN|induced
2533791
D017325_D006509 NONE vaccine_25\NN|b (r_dobj) derived_22\VBN|injections|vaccine|. (r_conj) treated_3\VBN|infants|are|with|and|derived (l_prep) with_4\IN|injections (l_pobj) injections_6\NNS|two|of (l_prep) of_7\IN|globulin (l_pobj) globulin_11\NN|b|immune|hbig (l_compound) B_9\NNP|hepatitis
11027904
D008691_D010146 NONE methadone_3\NN| (r_npadvmod) maintained_5\VBN|methadone|- (r_amod) abusers_7\NNS|maintained|opioid (r_pobj) in_2\IN|abusers (r_prep) responses_1\NNS|pain|in|. (l_compound) Pain_0\NN|
D008691_D010146 NONE methadone_19\NN| (r_compound) maintenance_21\NN|methadone|- (r_nmod) treatment_25\NN|maintenance|(|mm|)|(|n|60|) (r_pobj) in_18\IN|treatment (r_prep) stabilized_17\VBD|in|in (r_acl) sample_13\NN|a|of|stabilized (r_pobj) in_11\IN|sample (r_prep) tolerance_7\NN|pain|and|response|in (l_compound) pain_6\NN|
D008691_D009293 NONE methadone_19\NN| (r_compound) maintenance_21\NN|methadone|- (r_nmod) treatment_25\NN|maintenance|(|mm|)|(|n|60|) (r_pobj) in_18\IN|treatment (r_prep) stabilized_17\VBD|in|in (r_acl) sample_13\NN|a|of|stabilized (l_prep) of_14\IN|addicts (l_pobj) addicts_16\NNS|opioid
D004091_D010146 NONE hydromorphone_38\NN|(|mg|)|and|nonsteroidal (r_parataxis) opioid_36\NN|common|hydromorphone (r_pobj) of_34\IN|opioid (r_prep) doses_33\NNS|therapeutic|of (r_pobj) of_31\IN|doses (r_prep) administration_30\NN|oral|of (r_pobj) after_28\IN|administration (r_conj) before_26\IN|both|and|after (r_advmod) examined_23\VBN|by|was|,|before|agents|. (l_prep) By_0\IN|using (l_pcomp) using_1\VBG|design|,|tolerance (l_dobj) tolerance_13\NN|to (l_prep) to_14\IN|pain (l_pobj) pain_21\NN|pressor|(|cp|)
D020910_D010146 NONE ketorolac_48\RB|(|mg|) (r_nmod) agents_53\NNS|ketorolac|analgesic (r_conj) examined_23\VBN|by|was|,|before|agents|. (l_prep) By_0\IN|using (l_pcomp) using_1\VBG|design|,|tolerance (l_dobj) tolerance_13\NN|to (l_prep) to_14\IN|pain (l_pobj) pain_21\NN|pressor|(|cp|)
9205462
D013629_C537296 CID tamoxifen_9\NN| (r_compound) use_10\NN|antecedent|tamoxifen (r_pobj) with_7\IN|use (r_prep) associated_6\VBN|with (r_acl) ovary_5\NN|the|associated
D013629_D009369 NONE tamoxifen_8\NN| (r_compound) use_9\NN|tamoxifen|and|tumors (l_conj) tumors_12\NNS|gynecologic
D013629_D001943 NONE tamoxifen_9\NN| (r_pobj) with_8\IN|tamoxifen (r_prep) treated_7\VBN|woman|was|with|for|. (l_prep) for_10\IN|carcinoma (l_pobj) carcinoma_18\NN|stage|ii|estrogen|positive|breast
D004967_D001943 NONE estrogen_13\NN| (r_compound) carcinoma_18\NN|stage|ii|estrogen|positive|breast
D013629_D017093 CID tamoxifen_2\NN| (r_npadvmod) induced_4\VBN|tamoxifen|- (r_amod) dysfunction_6\NN|induced|liver
D013629_D017093 CID tamoxifen_20\NN| (r_compound) metabolism_21\NN|tamoxifen (r_pobj) in_19\IN|metabolism (r_prep) alterations_18\NNS|in (r_pobj) because_16\IN|of|alterations (r_prep) be_8\VB|patients|may|at|because|. (l_nsubj) Patients_0\NNS|with (l_prep) with_1\IN|dysfunction (l_pobj) dysfunction_6\NN|induced|liver
D013629_D006106 NONE tamoxifen_2\NN| (r_npadvmod) induced_4\VBN|tamoxifen|- (r_amod) dysfunction_6\NN|induced|liver (r_pobj) with_1\IN|dysfunction (r_prep) Patients_0\NNS|with (r_nsubj) be_8\VB|patients|may|at|because|. (l_prep) at_9\IN|risk (l_pobj) risk_11\NN|increased|for (l_prep) for_12\IN|tumors (l_pobj) tumors_15\NNS|cell
D013629_D006106 NONE tamoxifen_20\NN| (r_compound) metabolism_21\NN|tamoxifen (r_pobj) in_19\IN|metabolism (r_prep) alterations_18\NNS|in (r_pobj) because_16\IN|of|alterations (r_prep) be_8\VB|patients|may|at|because|. (l_prep) at_9\IN|risk (l_pobj) risk_11\NN|increased|for (l_prep) for_12\IN|tumors (l_pobj) tumors_15\NNS|cell
12571256
C044834_D007674 NONE iodixanol_29\NN| (r_appos) medium_27\NN|an|osmolar|,|dimeric|,|nonionic|contrast|,|iodixanol|, (r_pobj) of_17\IN|medium (r_prep) effects_16\NNS|the|nephrotoxic|of|with (l_amod) nephrotoxic_15\JJ|
C044834_D007674 NONE iodixanol_17\NN| (r_nsubjpass) used_19\VBN|when|iodixanol|is|than (r_advcl) develop_10\VB|to|in|used (r_xcomp) likely_8\JJ|less|develop (r_acomp) be_6\VB|induced|may|likely|. (l_csubj) induced_1\VBN|nephropathy|by (l_nsubj) Nephropathy_0\NNP|
D007472_D007674 CID iohexol_45\NN|medium (r_pobj) of_33\IN|nonionic|iohexol (r_prep) those_32\DT|of (r_pobj) with_31\IN|those (r_prep) effects_16\NNS|the|nephrotoxic|of|with (l_amod) nephrotoxic_15\JJ|
D003404_D003920 NONE creatinine_9\JJ| (r_compound) concentrations_10\NNS|serum|creatinine|of|underwent (r_pobj) with_7\IN|concentrations (r_prep) diabetes_6\NNS|with
3969369
D013739_D063646 NONE testosterone_3\NN|and|fat (r_pobj) of_2\IN|testosterone (r_prep) effects_1\NNS|promotional|of|on|. (l_prep) on_7\IN|carcinogenesis (l_pobj) carcinogenesis_9\NN|prostate|in
D013739_D011471 CID testosterone_6\NN| (r_pobj) with_5\IN|testosterone (r_prep) implanted_4\VBN|with|at|months (r_acl) rats_2\NNS|lw|,|implanted|, (r_nsubj) developed_12\VBD|rats|incidence|after (l_dobj) incidence_15\NN|a|higher|of (l_prep) of_16\IN|cancer (l_pobj) cancer_18\NN|prostate
D013739_D011471 CID testosterone_4\NN| (r_npadvmod) treated_6\VBN|testosterone|- (r_amod) rats_8\NNS|that|treated|lw|fed (l_relcl) fed_11\VBN|that|were|diet (l_dobj) diet_14\NN|the|same|,|supplemented (l_relcl) supplemented_18\VBN|which|was|with|fat (l_dobj) fat_26\NN|%|,|cancer (l_conj) cancer_30\NN|developed|prostate|after
D013739_D009369 NONE testosterone_6\NN| (r_pobj) with_5\IN|testosterone (r_prep) implanted_4\VBN|with|at|months (r_acl) rats_2\NNS|lw|,|implanted|, (r_nsubj) developed_12\VBD|rats|incidence|after (r_ccomp) developed_30\VBN|developed|:|%|had|tumors|,|and|%|. (l_dobj) tumors_32\NNS|gross
D013739_D009369 NONE testosterone_6\NN| (r_pobj) with_5\IN|testosterone (r_prep) implanted_4\VBN|with|at|months (r_acl) rats_2\NNS|lw|,|implanted|, (r_nsubj) developed_12\VBD|rats|incidence|after (r_ccomp) developed_30\VBN|developed|:|%|had|tumors|,|and|%|. (l_conj) %_36\NN|40|included (l_advcl) included_39\VBD|when|it|tumors (l_dobj) tumors_41\NNS|microscopic
D013739_D011472 CID testosterone_9\NN| (r_pobj) with_8\IN|testosterone (r_prep) treated_7\VBN|with|developed (l_advcl) developed_10\VBD|prostatitis (l_dobj) prostatitis_12\NN|only
1545575
D003520_D006470 CID cyclophosphamide_11\NN| (r_compound) therapy_12\NN|dose|cyclophosphamide|administered (r_pobj) of_7\IN|therapy (r_prep) complication_6\NN|a|serious|of (r_attr) is_2\VBZ|cystitis|complication|. (l_nsubj) cystitis_1\NN|hemorrhagic
D003520_D006470 CID cyclophosphamide_27\NN| (r_pobj) of_26\IN|cyclophosphamide (r_prep) metabolite_25\NN|the|hepatic|of|causes (l_relcl) causes_29\VBZ|that|cystitis (l_dobj) cystitis_31\NN|hemorrhagic
D003520_D003556 CID cyclophosphamide_11\NN| (r_compound) therapy_12\NN|dose|cyclophosphamide|administered (r_pobj) of_7\IN|therapy (r_prep) complication_6\NN|a|serious|of (r_attr) is_2\VBZ|cystitis|complication|. (l_nsubj) cystitis_1\NN|hemorrhagic
D003520_D003556 CID cyclophosphamide_27\NN| (r_pobj) of_26\IN|cyclophosphamide (r_prep) metabolite_25\NN|the|hepatic|of|causes (l_relcl) causes_29\VBZ|that|cystitis (l_dobj) cystitis_31\NN|hemorrhagic
D015080_D006470 NONE mesna_19\NN| (r_pobj) with_18\IN|mesna (r_prep) trial_15\NN|a|feasibility|of|with|,|neutralizes (l_relcl) neutralizes_22\VBZ|which|metabolite (l_dobj) metabolite_25\NN|the|hepatic|of|causes (l_relcl) causes_29\VBZ|that|cystitis (l_dobj) cystitis_31\NN|hemorrhagic
D015080_D006470 NONE mesna_10\JJ| (r_amod) uroprophylaxis_11\NNS|mesna (r_dobj) received_9\VBD|who|uroprophylaxis|before (r_relcl) patients_7\NNS|four|consecutive|received (r_nsubj) had_17\VBD|in|,|patients|cystitis|for|. (l_dobj) cystitis_20\NN|severe|hemorrhagic
D015080_D003556 NONE mesna_19\NN| (r_pobj) with_18\IN|mesna (r_prep) trial_15\NN|a|feasibility|of|with|,|neutralizes (l_relcl) neutralizes_22\VBZ|which|metabolite (l_dobj) metabolite_25\NN|the|hepatic|of|causes (l_relcl) causes_29\VBZ|that|cystitis (l_dobj) cystitis_31\NN|hemorrhagic
D015080_D003556 NONE mesna_10\JJ| (r_amod) uroprophylaxis_11\NNS|mesna (r_dobj) received_9\VBD|who|uroprophylaxis|before (r_relcl) patients_7\NNS|four|consecutive|received (r_nsubj) had_17\VBD|in|,|patients|cystitis|for|. (l_dobj) cystitis_20\NN|severe|hemorrhagic
3115150
D007650_D009127 NONE Ketanserin_0\JJ| (r_compound) pretreatment_1\NN|ketanserin (r_nsubj) reverses_2\VBZ|pretreatment|rigidity|. (l_dobj) rigidity_7\NN|induced|muscle
D007650_D009127 NONE ketanserin_3\NN| (r_pobj) with_2\IN|ketanserin (r_prep) pretreatment_1\NN|systemic|with|,|antagonist|, (r_nsubj) attenuated_14\VBD|pretreatment|significantly|rigidity|alfentanil|. (l_dobj) rigidity_17\NN|the|muscle|produced
D007650_D009127 NONE ketanserin_9\JJ| (r_dobj) received_8\VBD|that|ketanserin (r_relcl) animals_6\NNS|received|mg/kg (r_nsubj) followed_17\VBN|despite|,|animals|by (l_prep) Despite_0\IN|absence (l_pobj) absence_2\NN|the|of (l_prep) of_3\IN|rigidity (l_pobj) rigidity_4\NN|
D015760_D009127 CID alfentanil_3\NN| (r_npadvmod) induced_5\VBN|alfentanil|- (r_amod) rigidity_7\NN|induced|muscle
D015760_D009127 CID alfentanil_29\NN| (r_advcl) attenuated_14\VBD|pretreatment|significantly|rigidity|alfentanil|. (l_dobj) rigidity_17\NN|the|muscle|produced
D015760_D009127 CID alfentanil_15\NNS| (r_pobj) by_14\IN|alfentanil (r_agent) produced_13\VBN|by (r_acl) rigidity_12\NN|the|produced
D015760_D009127 CID alfentanil_19\NNS| (r_pobj) by_18\IN|alfentanil (r_agent) followed_17\VBN|despite|,|animals|by (l_prep) Despite_0\IN|absence (l_pobj) absence_2\NN|the|of (l_prep) of_3\IN|rigidity (l_pobj) rigidity_4\NN|
D015760_D009127 CID alfentanil_35\NN| (r_advmod) receiving_34\VBG|alfentanil|alone (r_acl) animals_33\NNS|receiving (r_nsubj) were_32\VBD|than|animals (r_advcl) responsive_27\JJ|less|to|were (r_conj) flaccid_23\JJ|,|,|and|responsive (r_conj) motionless_21\JJ|flaccid (r_acomp) were_20\VBD|followed|motionless|. (l_csubj) followed_17\VBN|despite|,|animals|by (l_prep) Despite_0\IN|absence (l_pobj) absence_2\NN|the|of (l_prep) of_3\IN|rigidity (l_pobj) rigidity_4\NN|
D012701_D009127 NONE serotonin_9\NN|type-2 (r_compound) antagonist_11\NN|a|specific|serotonin|receptor (r_appos) pretreatment_1\NN|systemic|with|,|antagonist|, (r_nsubj) attenuated_14\VBD|pretreatment|significantly|rigidity|alfentanil|. (l_dobj) rigidity_17\NN|the|muscle|produced
D012701_D009127 NONE serotonin_3\NN|type-2 (r_compound) antagonists_4\NNS|serotonin (r_pobj) with_1\IN|antagonists (r_prep) Pretreatment_0\NN|with (r_nsubj) be_6\VB|pretreatment|may|useful|,|be|. (l_acomp) useful_8\JJ|clinically|in (l_prep) in_9\IN|attenuating (l_pcomp) attenuating_10\VBG|rigidity (l_dobj) rigidity_14\NN|induced
D002707_D009127 NONE Chlordiazepoxide_0\VB|at|mg/kg (r_nsubj) failed_7\VBD|chlordiazepoxide|influence|. (l_xcomp) influence_10\VB|to|significantly|rigidity (l_dobj) rigidity_12\NN|the|produced
D012701_D002318 NONE serotonin_3\NN|type-2 (r_compound) antagonists_4\NNS|serotonin (r_pobj) with_1\IN|antagonists (r_prep) Pretreatment_0\NN|with (r_nsubj) be_6\VB|pretreatment|may|useful|,|be|. (l_advcl) be_20\VB|although|studies|will|necessary|assess (l_xcomp) assess_23\VB|to|interaction (l_dobj) interaction_25\NN|the|of (l_prep) of_26\IN|cns (l_pobj) CNS_29\NNP|enhanced|,|cardiovascular (l_conj) cardiovascular_31\JJ|,|and|depression (l_conj) depression_35\NN|respiratory
D012701_D012131 NONE serotonin_3\NN|type-2 (r_compound) antagonists_4\NNS|serotonin (r_pobj) with_1\IN|antagonists (r_prep) Pretreatment_0\NN|with (r_nsubj) be_6\VB|pretreatment|may|useful|,|be|. (l_advcl) be_20\VB|although|studies|will|necessary|assess (l_xcomp) assess_23\VB|to|interaction (l_dobj) interaction_25\NN|the|of (l_prep) of_26\IN|cns (l_pobj) CNS_29\NNP|enhanced|,|cardiovascular (l_conj) cardiovascular_31\JJ|,|and|depression (l_conj) depression_35\NN|respiratory
11860278
D004298_D004827 NONE Dopamine_0\NNP|da|,|through (r_nsubj) plays_12\VBZ|dopamine|,|role|in|. (l_prep) in_16\IN|control (l_pobj) control_18\NN|the|of (l_prep) of_19\IN|seizures (l_pobj) seizures_21\NNS|epileptic|arising
D004298_D004827 NONE DA_2\NNP|(|) (r_appos) Dopamine_0\NNP|da|,|through (r_nsubj) plays_12\VBZ|dopamine|,|role|in|. (l_prep) in_16\IN|control (l_pobj) control_18\NN|the|of (l_prep) of_19\IN|seizures (l_pobj) seizures_21\NNS|epileptic|arising
D004298_D004827 NONE DA_11\NNP| (r_compound) receptors_12\NNS|da (r_pobj) of_10\IN|receptors (r_prep) role_9\NN|the|of|in (l_prep) in_13\IN|occurrence (l_pobj) occurrence_15\NN|the|of (l_prep) of_16\IN|death (l_pobj) death_22\NN|induced|neuronal|cell (l_amod) induced_19\VBN|epilepsy|- (l_npadvmod) epilepsy_17\NN|
D010862_D012640 CID pilocarpine_18\NN|the|cholinergic|agonist (r_pobj) with_14\IN|pilocarpine (r_prep) treated_13\VBN|with (r_acl) mice_12\NNS|d2r|-/-|treated (r_pobj) in_9\IN|mice (r_prep) seizures_6\NNS|and|neurotoxicity|in
D010862_D012640 CID pilocarpine_2\NN| (r_npadvmod) induced_4\VBN|pilocarpine|- (r_amod) seizures_5\NNS|induced
D010862_D020258 NONE pilocarpine_18\NN|the|cholinergic|agonist (r_pobj) with_14\IN|pilocarpine (r_prep) treated_13\VBN|with (r_acl) mice_12\NNS|d2r|-/-|treated (r_pobj) in_9\IN|mice (r_prep) seizures_6\NNS|and|neurotoxicity|in (l_conj) neurotoxicity_8\NN|
D007608_D012640 CID KA_23\NNP| (r_pobj) to_22\IN|ka (r_prep) comparison_21\NN|to (r_pobj) in_20\IN|comparison (r_prep) death_12\NN|a|widespread|neuronal|in|in (r_pobj) in_7\IN|death (r_prep) result_6\VBP|however|,|seizures|in|. (l_nsubj) seizures_5\NNS|induced
D018698_D012640 NONE glutamate_14\NN|both|and|acetylcholine (r_pobj) by_12\IN|glutamate (r_agent) induced_11\VBN|by (r_acl) seizures_10\NNS|induced
D000109_D012640 NONE acetylcholine_16\NN| (r_conj) glutamate_14\NN|both|and|acetylcholine (r_pobj) by_12\IN|glutamate (r_agent) induced_11\VBN|by (r_acl) seizures_10\NNS|induced
9305828
D010862_D004833 CID pilocarpine_6\NN| (r_amod) model_7\NN|the|pilocarpine|of (l_prep) of_8\IN|epilepsy (l_pobj) epilepsy_11\NN|temporal|lobe
D010862_D004833 CID PILO_30\NNP| (r_amod) model_31\NN|the|pilo|of (l_prep) of_32\IN|tle (l_pobj) TLE_33\NNP|
D010862_D004827 NONE pilocarpine_1\NN|the (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_nsubjpass) model_5\NN|(|pilo|)|of (l_prep) of_6\IN|epilepsy (l_pobj) epilepsy_7\NN|
D010862_D004827 NONE PILO_3\NNP| (r_nmod) model_5\NN|(|pilo|)|of (l_prep) of_6\IN|epilepsy (l_pobj) epilepsy_7\NN|
D010862_D013226 NONE pilocarpine_1\NN|the (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_agent) by_10\IN|period (l_pobj) period_13\NN|an|acute|of|followed (l_prep) of_14\IN|epilepticus (l_pobj) epilepticus_16\NN|status
D010862_D013226 NONE PILO_3\NNP| (r_nmod) model_5\NN|(|pilo|)|of (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_agent) by_10\IN|period (l_pobj) period_13\NN|an|acute|of|followed (l_prep) of_14\IN|epilepticus (l_pobj) epilepticus_16\NN|status
D010862_D012640 NONE pilocarpine_1\NN|the (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_agent) by_10\IN|period (l_pobj) period_13\NN|an|acute|of|followed (l_acl) followed_17\VBN|by (l_agent) by_18\IN|seizures (l_pobj) seizures_21\NNS|spontaneous|recurrent|and|damage
D010862_D012640 NONE PILO_3\NNP| (r_nmod) model_5\NN|(|pilo|)|of (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_agent) by_10\IN|period (l_pobj) period_13\NN|an|acute|of|followed (l_acl) followed_17\VBN|by (l_agent) by_18\IN|seizures (l_pobj) seizures_21\NNS|spontaneous|recurrent|and|damage
D010862_D001930 NONE pilocarpine_1\NN|the (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_agent) by_10\IN|period (l_pobj) period_13\NN|an|acute|of|followed (l_acl) followed_17\VBN|by (l_agent) by_18\IN|seizures (l_pobj) seizures_21\NNS|spontaneous|recurrent|and|damage (l_conj) damage_25\NN|related|brain
D010862_D001930 NONE PILO_3\NNP| (r_nmod) model_5\NN|(|pilo|)|of (r_nsubjpass) characterized_9\VBN|pilocarpine|model|is|by|. (l_agent) by_10\IN|period (l_pobj) period_13\NN|an|acute|of|followed (l_acl) followed_17\VBN|by (l_agent) by_18\IN|seizures (l_pobj) seizures_21\NNS|spontaneous|recurrent|and|damage (l_conj) damage_25\NN|related|brain
2886572
D004837_D006973 CID epinephrine_7\NN| (r_npadvmod) induced_9\VBN|epinephrine|- (r_amod) rats_11\NNS|induced|hypertensive (l_amod) hypertensive_10\JJ|
20533999
D004298_D020258 NONE Dopamine_0\NN| (r_nsubj) is_1\VBZ|dopamine|not|essential|. (l_acomp) essential_3\JJ|for (l_prep) for_4\IN|development (l_pobj) development_6\NN|the|of (l_prep) of_7\IN|neurotoxicity (l_pobj) neurotoxicity_11\NN|induced
D004298_D020258 NONE DA_29\NNP| (r_compound) neurotoxicity_30\NN|induced|da
D004298_D020258 NONE DA_13\NN|brain (r_pobj) in_11\IN|da (r_prep) deficient_10\JJ|in (r_acomp) be_9\VB|to|deficient (r_xcomp) engineered_7\VBN|that|mice|genetically|be|develop (l_conj) develop_14\VBP|neurotoxicity|,|long (l_dobj) neurotoxicity_16\NN|meth
D004298_D020258 NONE DA_7\NNP| (r_nsubj) is_8\VBZ|that|da|not|essential|and|suggest (l_acomp) essential_10\JJ|for (l_prep) for_11\IN|development (l_pobj) development_13\NN|the|of (l_prep) of_14\IN|neurotoxicity (l_pobj) neurotoxicity_19\NN|induced|dopaminergic
D004298_D020258 NONE DA_26\JJ| (r_pobj) of_25\IN|da (r_prep) independent_24\JJ|of (r_amod) mechanisms_23\NNS|independent (r_nsubj) warrant_27\NN|that|mechanisms|investigation (r_ccomp) suggest_21\VBP|warrant (r_conj) is_8\VBZ|that|da|not|essential|and|suggest (l_acomp) essential_10\JJ|for (l_prep) for_11\IN|development (l_pobj) development_13\NN|the|of (l_prep) of_14\IN|neurotoxicity (l_pobj) neurotoxicity_19\NN|induced|dopaminergic
D008694_D020258 CID methamphetamine_8\NN| (r_npadvmod) induced_10\VBN|methamphetamine|- (r_amod) neurotoxicity_11\NN|induced
D008694_D020258 CID METH_26\NNP| (r_npadvmod) induced_28\VBN|meth|- (r_amod) neurotoxicity_30\NN|induced|da
D008694_D020258 CID METH_15\NNP| (r_compound) neurotoxicity_16\NN|meth
D008694_D020258 CID METH_25\NNP| (r_pobj) of_24\IN|meth (r_prep) effects_23\NNS|the|thermic|of (r_nsubjpass) preserved_27\VBN|as|effects|are (r_advcl) long_19\RB|as|preserved (r_advmod) develop_14\VBP|neurotoxicity|,|long (l_dobj) neurotoxicity_16\NN|meth
D008694_D020258 CID METH_15\NNP| (r_npadvmod) induced_17\VBN|meth|- (r_amod) neurotoxicity_19\NN|induced|dopaminergic
D004298_D064420 NONE dopamine_5\NN|da (r_nsubj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_dobj) methamphetamine_10\NN|(|meth)-induced|, (l_acl) METH)-induced_12\JJ|toxicity|brain (l_dobj) toxicity_13\NN|
D004298_D064420 NONE dopamine_5\NN|da (r_nsubj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_dobj) toxicity_27\NN|
D004298_D064420 NONE dopamine_5\NN|da (r_nsubj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_advcl) enhance_35\VB|whereas|drugs|toxicity (l_dobj) toxicity_36\NN|
D004298_D064420 NONE DA_7\NNP|(|) (r_appos) dopamine_5\NN|da (r_nsubj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_dobj) methamphetamine_10\NN|(|meth)-induced|, (l_acl) METH)-induced_12\JJ|toxicity|brain (l_dobj) toxicity_13\NN|
D004298_D064420 NONE DA_7\NNP|(|) (r_appos) dopamine_5\NN|da (r_nsubj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_dobj) toxicity_27\NN|
D004298_D064420 NONE DA_7\NNP|(|) (r_appos) dopamine_5\NN|da (r_nsubj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_advcl) enhance_35\VB|whereas|drugs|toxicity (l_dobj) toxicity_36\NN|
D004298_D064420 NONE DA_24\NNP| (r_compound) neurotransmission_25\NN|da (r_pobj) with_23\IN|neurotransmission (r_prep) interfere_22\VBP|that|with (r_relcl) drugs_20\NNS|interfere (r_nsubj) decrease_26\NN|because|drugs|toxicity|,|enhance (r_advcl) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_dobj) methamphetamine_10\NN|(|meth)-induced|, (l_acl) METH)-induced_12\JJ|toxicity|brain (l_dobj) toxicity_13\NN|
D004298_D064420 NONE DA_24\NNP| (r_compound) neurotransmission_25\NN|da (r_pobj) with_23\IN|neurotransmission (r_prep) interfere_22\VBP|that|with (r_relcl) drugs_20\NNS|interfere (r_nsubj) decrease_26\NN|because|drugs|toxicity|,|enhance (l_dobj) toxicity_27\NN|
D004298_D064420 NONE DA_24\NNP| (r_compound) neurotransmission_25\NN|da (r_pobj) with_23\IN|neurotransmission (r_prep) interfere_22\VBP|that|with (r_relcl) drugs_20\NNS|interfere (r_nsubj) decrease_26\NN|because|drugs|toxicity|,|enhance (l_advcl) enhance_35\VB|whereas|drugs|toxicity (l_dobj) toxicity_36\NN|
D004298_D064420 NONE DA_33\NNP| (r_compound) neurotransmission_34\NN|da (r_dobj) increase_32\VBP|that|neurotransmission (r_relcl) drugs_30\NNS|increase (r_nsubj) enhance_35\VB|whereas|drugs|toxicity (r_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (r_advcl) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_dobj) methamphetamine_10\NN|(|meth)-induced|, (l_acl) METH)-induced_12\JJ|toxicity|brain (l_dobj) toxicity_13\NN|
D004298_D064420 NONE DA_33\NNP| (r_compound) neurotransmission_34\NN|da (r_dobj) increase_32\VBP|that|neurotransmission (r_relcl) drugs_30\NNS|increase (r_nsubj) enhance_35\VB|whereas|drugs|toxicity (r_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_dobj) toxicity_27\NN|
D004298_D064420 NONE DA_33\NNP| (r_compound) neurotransmission_34\NN|da (r_dobj) increase_32\VBP|that|neurotransmission (r_relcl) drugs_30\NNS|increase (r_nsubj) enhance_35\VB|whereas|drugs|toxicity (l_dobj) toxicity_36\NN|
D008694_D064420 NONE methamphetamine_10\NN|(|meth)-induced|, (l_acl) METH)-induced_12\JJ|toxicity|brain (l_dobj) toxicity_13\NN|
D008694_D064420 NONE methamphetamine_10\NN|(|meth)-induced|, (r_dobj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_dobj) toxicity_27\NN|
D008694_D064420 NONE methamphetamine_10\NN|(|meth)-induced|, (r_dobj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_advcl) enhance_35\VB|whereas|drugs|toxicity (l_dobj) toxicity_36\NN|
D008694_D064420 NONE METH)-induced_12\JJ|toxicity|brain (l_dobj) toxicity_13\NN|
D008694_D064420 NONE METH)-induced_12\JJ|toxicity|brain (r_acl) methamphetamine_10\NN|(|meth)-induced|, (r_dobj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_dobj) toxicity_27\NN|
D008694_D064420 NONE METH)-induced_12\JJ|toxicity|brain (r_acl) methamphetamine_10\NN|(|meth)-induced|, (r_dobj) mediates_9\VBZ|that|dopamine|methamphetamine|decrease (l_advcl) decrease_26\NN|because|drugs|toxicity|,|enhance (l_advcl) enhance_35\VB|whereas|drugs|toxicity (l_dobj) toxicity_36\NN|
D007980_D020258 NONE dihydroxyphenylalanine_11\NN|l|- (r_pobj) of_8\IN|dihydroxyphenylalanine (r_prep) ability_7\NN|the|reported|of|reverse (l_acl) reverse_13\VB|to|effect (l_dobj) effect_16\NN|the|protective|of (l_prep) of_17\IN|tyrosine (l_pobj) tyrosine_24\NN|para|-|on (l_prep) on_25\IN|neurotoxicity (l_pobj) neurotoxicity_30\NN|induced|da
D019805_D020258 NONE tyrosine_24\NN|para|-|on (l_prep) on_25\IN|neurotoxicity (l_pobj) neurotoxicity_30\NN|induced|da
D004298_D009461 NONE DA_13\NNP|brain (r_compound) deficits_14\NNS|unilateral|da (r_dobj) have_10\VB|to|deficits (r_xcomp) engineered_8\VBN|that|mice|genetically|have|develop (l_conj) develop_15\VBP|deficits (l_dobj) deficits_20\NNS|induced|dopaminergic|are
D008694_D009461 NONE METH_16\NN| (r_npadvmod) induced_18\VBN|meth|- (r_amod) deficits_20\NNS|induced|dopaminergic|are
2564649
D005283_D009127 CID fentanyl_8\NN| (r_npadvmod) induced_10\VBN|fentanyl|- (r_amod) rigidity_12\NN|induced|muscular|in
D005283_D009127 CID fentanyl_17\NN| (r_compound) anesthesia_18\NN|dose|fentanyl (r_pobj) with_13\IN|anesthesia (r_prep) associated_12\VBN|that|is|with (r_relcl) effect_9\NN|a|known|side|associated (r_attr) is_3\VBZ|whereas|rigidity|effect (l_nsubj) rigidity_2\NN|muscular
D005283_D009127 CID fentanyl_10\NN| (r_pobj) by_9\IN|fentanyl (r_prep) rigidity_8\NN|muscular|by
D011224_D009127 NONE prazosin_32\NN|blocker|, (r_pobj) with_25\IN|prazosin (r_prep) lesions_18\NNS|prior|electrolytic|of|with (r_pobj) by_15\IN|lesions (r_agent) reduced_14\VBN|even|by (r_conj) antagonized_11\VBN|rigidity|was|significantly|or|reduced|. (l_nsubjpass) rigidity_4\NN|such|an|induced|muscular|by
6153967
D004737_D012640 CID enflurane_4\NN|administered (r_nsubj) resulted_10\VBD|in|,|enflurane|in|. (l_prep) in_11\IN|seizures (l_pobj) seizures_15\NNS|unexpected|partial|motor
D004737_D012640 CID enflurane_6\NN| (r_pobj) by_5\IN|enflurane (r_agent) activated_4\VBN|by (r_conj) delineated_2\VBN|foci|and|activated|ablated|and|are (l_conj) are_13\VBP|patients|now|free|. (l_acomp) free_17\JJ|seizure|- (l_npadvmod) seizure_15\NN|
D004737_D004827 NONE enflurane_6\NN| (r_pobj) by_5\IN|enflurane (r_agent) activated_4\VBN|by (r_conj) delineated_2\VBN|foci|and|activated|ablated|and|are (l_nsubj) foci_1\NN|epileptic (l_amod) Epileptic_0\JJ|
D004737_D004827 NONE enflurane_5\NN| (r_nsubj) prove_7\VB|on|,|enflurane|may|be|. (l_xcomp) be_9\VB|to|activator (l_attr) activator_14\NN|a|safe|fast|acting|of|during (l_prep) of_15\IN|foci (l_pobj) foci_17\VBD|epileptic (l_amod) epileptic_16\JJ|
19893084
D005839_D058186 CID gentamicin_12\NN|response (r_pcomp) by_11\IN|gentamicin (r_agent) induced_10\VBN|by (r_acl) failure_9\NN|acute|renal|induced
16844102
D024502_D020258 NONE tocopherol_4\NN|alpha|-|and|deferoxamine (l_conj) deferoxamine_6\NN|on (l_prep) on_7\IN|neurotoxicity (l_pobj) neurotoxicity_11\NN|induced
D024502_D020258 NONE tocopherol_8\NN|alpha|-|(|tc|)|,|scavenger|,|chelator|, (r_pobj) of_5\IN|tocopherol (r_prep) effect_4\NN|the|of|on (l_prep) on_32\IN|neurotoxicity (l_pobj) neurotoxicity_37\NN|the|induced
D024502_D020258 NONE TC_12\NNP|alpha|- (r_appos) tocopherol_8\NN|alpha|-|(|tc|)|,|scavenger|,|chelator|, (r_pobj) of_5\IN|tocopherol (r_prep) effect_4\NN|the|of|on (l_prep) on_32\IN|neurotoxicity (l_pobj) neurotoxicity_37\NN|the|induced
D003676_D020258 NONE deferoxamine_6\NN|on (l_prep) on_7\IN|neurotoxicity (l_pobj) neurotoxicity_11\NN|induced
D003676_D020258 NONE deferoxamine_23\NN| (r_nmod) DFO_25\NNP|deferoxamine|(|) (r_conj) scavenger_16\NN|a|of|,|and|dfo (r_appos) tocopherol_8\NN|alpha|-|(|tc|)|,|scavenger|,|chelator|, (r_pobj) of_5\IN|tocopherol (r_prep) effect_4\NN|the|of|on (l_prep) on_32\IN|neurotoxicity (l_pobj) neurotoxicity_37\NN|the|induced
D003676_D020258 NONE DFO_25\NNP|deferoxamine|(|) (r_conj) scavenger_16\NN|a|of|,|and|dfo (r_appos) tocopherol_8\NN|alpha|-|(|tc|)|,|scavenger|,|chelator|, (r_pobj) of_5\IN|tocopherol (r_prep) effect_4\NN|the|of|on (l_prep) on_32\IN|neurotoxicity (l_pobj) neurotoxicity_37\NN|the|induced
D008694_D020258 NONE methamphetamine_8\NN| (r_npadvmod) induced_10\VBN|methamphetamine|- (r_amod) neurotoxicity_11\NN|induced
D008694_D020258 NONE Methamphetamine_0\NN|neurotoxicity (l_appos) neurotoxicity_4\NN|ma)-induced|dopaminergic
D008694_D020258 NONE MA)-induced_2\VBN|( (r_amod) neurotoxicity_4\NN|ma)-induced|dopaminergic
D008694_D020258 NONE MA_34\NNP| (r_npadvmod) induced_36\VBN|ma|- (r_amod) neurotoxicity_37\NN|the|induced
D010100_D020258 NONE oxygen_19\NN| (r_compound) species_20\NNS|reactive|oxygen (r_pobj) of_17\IN|species (r_prep) scavenger_16\NN|a|of|,|and|dfo (r_appos) tocopherol_8\NN|alpha|-|(|tc|)|,|scavenger|,|chelator|, (r_pobj) of_5\IN|tocopherol (r_prep) effect_4\NN|the|of|on (l_prep) on_32\IN|neurotoxicity (l_pobj) neurotoxicity_37\NN|the|induced
D007501_D020258 NONE iron_29\NN| (r_compound) chelator_30\NN|an|iron (r_appos) tocopherol_8\NN|alpha|-|(|tc|)|,|scavenger|,|chelator|, (r_pobj) of_5\IN|tocopherol (r_prep) effect_4\NN|the|of|on (l_prep) on_32\IN|neurotoxicity (l_pobj) neurotoxicity_37\NN|the|induced
D024502_D005334 NONE TC_2\NNP|alpha|-|and|dfo (r_nsubj) attenuated_5\VBD|tc|hyperthermia|as|alterations|. (l_dobj) hyperthermia_10\NN|the|induced
D003676_D005334 NONE DFO_4\NNP| (r_conj) TC_2\NNP|alpha|-|and|dfo (r_nsubj) attenuated_5\VBD|tc|hyperthermia|as|alterations|. (l_dobj) hyperthermia_10\NN|the|induced
D008694_D005334 CID MA_7\NNP| (r_npadvmod) induced_9\VBN|ma|- (r_amod) hyperthermia_10\NN|the|induced
D024502_D009422 NONE TC_5\NNP|alpha|-|and|dfo (r_nsubj) ameliorate_8\VB|that|tc|damage|by (l_dobj) damage_14\NN|the|induced|neuronal
D003676_D009422 NONE DFO_7\NNP| (r_conj) TC_5\NNP|alpha|-|and|dfo (r_nsubj) ameliorate_8\VB|that|tc|damage|by (l_dobj) damage_14\NN|the|induced|neuronal
D008694_D009422 CID MA_10\NNP| (r_npadvmod) induced_12\VBN|ma|- (r_amod) damage_14\NN|the|induced|neuronal
17366349
C092292_D009459 CID ziprasidone_5\NN|on (r_pobj) by_4\IN|ziprasidone (r_prep) induced_3\VBN|syndrome|by|. (l_nsubj) syndrome_2\NN|neuroleptic|malignant
C092292_D009459 CID ziprasidone_16\NN| (r_pobj) of_15\IN|ziprasidone (r_prep) use_14\NN|the|of (r_pobj) with_12\IN|use (r_prep) associated_11\VBN|with (r_acl) syndrome_7\NN|neuroleptic|malignant|nms|associated
C092292_D009459 CID ziprasidone_16\NN| (r_pobj) of_15\IN|ziprasidone (r_prep) use_14\NN|the|of (r_pobj) with_12\IN|use (r_prep) associated_11\VBN|with (r_acl) syndrome_7\NN|neuroleptic|malignant|nms|associated (l_appos) NMS_9\NNP|(|)
C092292_D009459 CID ziprasidone_14\NN| (r_pobj) like_13\IN|ziprasidone (r_prep) drugs_12\NNS|nms|,|atypical|antipsychotic|like (l_nmod) NMS_8\NNP|
C092292_D009459 CID ziprasidone_34\NNP|administrated (r_pobj) of_31\IN|ziprasidone (r_prep) dose_30\NN|an|day|of (r_pobj) with_25\IN|dose (r_prep) treatment_24\NN|with (r_pobj) of_23\IN|treatment (r_prep) days_22\NNS|2|of (r_pobj) after_20\IN|days (r_prep) developed_14\VBD|who|signs|after (l_dobj) signs_15\NNS|and|symptoms|of (l_prep) of_18\IN|nms (l_pobj) NMS_19\NNP|
C092292_D009459 CID ziprasidone_3\NNP|to (r_xcomp) due_1\IN|ziprasidone (r_amod) NMS_0\NNP|due
C092292_D012559 NONE ziprasidone_34\NNP|administrated (r_pobj) of_31\IN|ziprasidone (r_prep) dose_30\NN|an|day|of (r_pobj) with_25\IN|dose (r_prep) treatment_24\NN|with (r_pobj) of_23\IN|treatment (r_prep) days_22\NNS|2|of (r_pobj) after_20\IN|days (r_prep) developed_14\VBD|who|signs|after (r_relcl) schizophrenia_12\NN|developed
3769769
D014282_D001919 CID hydrochloride_4\NN|trihexyphenidyl (r_pobj) due_1\JJ|to|hydrochloride (r_amod) Bradycardia_0\NNS|due|.
D014282_D012559 NONE hydrochloride_12\NN| (r_dobj) trihexyphenidyl_11\JJ|hydrochloride (r_conj) treated_5\VBN|patient|was|with|trihexyphenidyl|. (l_nsubjpass) patient_3\NN|a|chronic|schizophrenic (l_amod) schizophrenic_2\JJ|
133615
D003276_D013923 NONE contraceptive_6\NN| (r_amod) therapy_7\NN|oral|contraceptive (r_pobj) of_4\IN|therapy (r_prep) complications_3\NNS|thromboembolic|of|in|:|report|. (l_amod) Thromboembolic_0\JJ|and|other
D003276_D001778 CID contraceptive_6\NN| (r_amod) therapy_7\NN|oral|contraceptive (r_pobj) of_4\IN|therapy (r_prep) complications_3\NNS|thromboembolic|of|in|:|report|. (l_prep) in_8\IN|relationship (l_pobj) relationship_9\NN|to (l_prep) to_10\IN|levels (l_pobj) levels_12\NNS|pretreatment|of (l_prep) of_13\IN|factors (l_pobj) factors_16\NNS|coagulation (l_compound) coagulation_15\NN|blood
16725121
D009638_D012640 NONE norepinephrine_4\NN| (r_amod) function_6\NN|norepinephrine|transporter (r_pobj) of_3\IN|function (r_prep) regulation_2\NN|down|-|of|induced|. (l_acl) induced_7\VBN|by|linking (l_xcomp) linking_13\VBG|to (l_prep) to_14\IN|alteration (l_pobj) alteration_16\NN|the|of|and|counteraction (l_prep) of_17\IN|sensitivity (l_pobj) sensitivity_18\NN|of (l_prep) of_19\IN|convulsions (l_pobj) convulsions_25\NNS|induced
D009638_D012640 NONE norepinephrine_2\NN| (r_compound) transporter_3\NN|norepinephrine|net|) (r_nmod) function_7\NN|transporter|by (l_prep) by_8\IN|inhibition (l_pobj) inhibition_10\NN|chronic|of|in (l_prep) in_13\IN|relation (l_pobj) relation_14\NN|to (l_prep) to_15\IN|sensitization (l_pobj) sensitization_16\NN|to (l_prep) to_17\IN|seizures (l_pobj) seizures_18\NNS|induce
D003891_D012640 NONE desipramine_12\NN| (r_pobj) of_11\IN|desipramine (r_prep) administration_10\NN|chronic|of (r_pobj) by_8\IN|administration (r_agent) induced_7\VBN|by|linking (l_xcomp) linking_13\VBG|to (l_prep) to_14\IN|alteration (l_pobj) alteration_16\NN|the|of|and|counteraction (l_prep) of_17\IN|sensitivity (l_pobj) sensitivity_18\NN|of (l_prep) of_19\IN|convulsions (l_pobj) convulsions_25\NNS|induced
D003891_D012640 NONE desipramine_3\NN| (r_pobj) of_2\IN|desipramine (r_prep) administration_1\NN|daily|of (r_nsubj) increased_4\VBD|administration|incidence|and|decreased|. (l_dobj) incidence_6\NN|the|of (l_prep) of_7\IN|appearance (l_pobj) appearance_8\NN|of (l_prep) of_9\IN|convulsions (l_pobj) convulsions_13\NNS|induced
D003891_D012640 NONE desipramine_3\NN| (r_pobj) of_2\IN|desipramine (r_prep) administration_1\NN|daily|of (r_nsubj) increased_4\VBD|administration|incidence|and|decreased|. (l_conj) decreased_15\VBD|that (l_dobj) that_16\DT|of (l_prep) of_17\IN|convulsions (l_pobj) convulsions_21\NNS|induced
D003891_D012640 NONE desipramine_6\NN| (r_pobj) with_5\IN|desipramine (r_prep) lidocaine_4\NN|with (r_pobj) of_3\IN|lidocaine (r_prep) administration_2\NN|co|-|of (r_nsubj) reversed_7\VBD|administration|changes|. (l_dobj) changes_9\NNS|the|of|induced (l_prep) of_10\IN|activity (l_pobj) activity_12\NN|convulsive|of (l_amod) convulsive_11\JJ|
D003891_D012640 NONE desipramine_22\NN| (r_pobj) of_21\IN|desipramine (r_prep) administration_20\NN|repeated|of (r_pobj) by_18\IN|administration (r_agent) induced_17\VBN|by (r_acl) changes_9\NNS|the|of|induced (l_prep) of_10\IN|activity (l_pobj) activity_12\NN|convulsive|of (l_amod) convulsive_11\JJ|
D003891_D012640 NONE desipramine_15\NN| (r_pobj) of_14\IN|desipramine (r_prep) administration_13\NN|chronic|of (r_pobj) by_11\IN|administration (r_agent) induced_10\VBN|by (r_acl) regulation_6\NN|down|-|of|induced (r_nsubj) be_17\VB|that|regulation|may|relevant (l_acomp) relevant_18\JJ|to (l_prep) to_19\IN|sensitization (l_pobj) sensitization_23\NN|induced|of (l_prep) of_24\IN|convulsions (l_pobj) convulsions_26\NNS|lidocaine
D003891_D012640 NONE desipramine_20\NN| (r_advmod) induced_22\VBN|desipramine|- (r_amod) sensitization_23\NN|induced|of (l_prep) of_24\IN|convulsions (l_pobj) convulsions_26\NNS|lidocaine
D003891_D012640 NONE Desipramine_0\NN| (r_nsubj) induced_2\VBN|desipramine|- (r_amod) sensitization_3\NN|induced|of (l_prep) of_4\IN|seizures (l_pobj) seizures_6\NNS|lidocaine
D003042_D012640 CID cocaine_21\NN|and|anesthetics (r_pobj) by_20\IN|cocaine (r_agent) induce_19\VB|by (r_acl) seizures_18\NNS|induce
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|cocaine|- (r_amod) convulsions_21\NNS|induced (r_pobj) of_17\IN|convulsions (r_prep) that_16\DT|of (r_dobj) decreased_15\VBD|that (r_conj) increased_4\VBD|administration|incidence|and|decreased|. (l_dobj) incidence_6\NN|the|of (l_prep) of_7\IN|appearance (l_pobj) appearance_8\NN|of (l_prep) of_9\IN|convulsions (l_pobj) convulsions_13\NNS|induced
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|cocaine|- (r_amod) convulsions_21\NNS|induced
D003042_D012640 CID cocaine_16\NN| (r_conj) lidocaine_14\NN|and|cocaine (r_pobj) of_13\IN|lidocaine (r_prep) activity_12\NN|convulsive|of (l_amod) convulsive_11\JJ|
D003042_D012640 CID cocaine_19\NN| (r_pobj) of_18\IN|cocaine (r_prep) administration_17\NN|repeated|of (r_pobj) from_15\IN|administration (r_prep) resulting_14\VBG|from (r_acl) kindling_13\VBG|resulting (r_pobj) from_12\IN|kindling (r_prep) distinct_11\JJ|from (r_amod) mechanism_10\NN|a|distinct (r_dobj) have_8\VB|sensitization|may|mechanism|. (l_nsubj) sensitization_3\NN|induced|of (l_prep) of_4\IN|seizures (l_pobj) seizures_6\NNS|lidocaine
D008012_D012640 CID lidocaine_10\NN| (r_npadvmod) induced_12\VBN|lidocaine|- (r_amod) convulsions_13\NNS|induced
D008012_D012640 CID lidocaine_10\NN| (r_npadvmod) induced_12\VBN|lidocaine|- (r_amod) convulsions_13\NNS|induced (r_pobj) of_9\IN|convulsions (r_prep) appearance_8\NN|of (r_pobj) of_7\IN|appearance (r_prep) incidence_6\NN|the|of (r_dobj) increased_4\VBD|administration|incidence|and|decreased|. (l_conj) decreased_15\VBD|that (l_dobj) that_16\DT|of (l_prep) of_17\IN|convulsions (l_pobj) convulsions_21\NNS|induced
D008012_D012640 CID lidocaine_4\NN|with (r_pobj) of_3\IN|lidocaine (r_prep) administration_2\NN|co|-|of (r_nsubj) reversed_7\VBD|administration|changes|. (l_dobj) changes_9\NNS|the|of|induced (l_prep) of_10\IN|activity (l_pobj) activity_12\NN|convulsive|of (l_amod) convulsive_11\JJ|
D008012_D012640 CID lidocaine_14\NN|and|cocaine (r_pobj) of_13\IN|lidocaine (r_prep) activity_12\NN|convulsive|of (l_amod) convulsive_11\JJ|
D008012_D012640 CID lidocaine_25\NN| (r_compound) convulsions_26\NNS|lidocaine
D008012_D012640 CID lidocaine_5\NN| (r_compound) seizures_6\NNS|lidocaine
19300240
D005472_D054549 CID flourouracil_1\NN| (r_npadvmod) induced_3\VBN|flourouracil|- (r_amod) syndrome_6\NN|5|induced|ballooning|:|report|.
D005472_D015179 NONE fluorouracil_5\NN| (r_pobj) with_4\IN|fluorouracil (r_prep) underwent_1\VBD|she|chemotherapy|with|for|. (l_prep) for_6\IN|cancer (l_pobj) cancer_9\NN|metastatic|colorectal
D002395_D009369 NONE catecholamines_9\NNS|plasma|and|neuropeptides (r_pobj) of_7\IN|catecholamines (r_prep) levels_6\NNS|both|supraphysiologic|of|caused (l_acl) caused_14\VBN|by (l_agent) by_15\IN|diagnosis (l_pobj) diagnosis_17\NN|cancer|as|chemotherapy (l_compound) cancer_16\NN|
D002395_D054549 NONE catecholamines_9\NNS|plasma|and|neuropeptides (r_pobj) of_7\IN|catecholamines (r_prep) levels_6\NNS|both|supraphysiologic|of|caused (r_nsubj) contributed_24\VBN|in|,|levels|may|have|development|. (l_dobj) development_26\NN|the|of (l_prep) of_27\IN|abs (l_pobj) ABS_28\NN|
3461217
D008770_D011471 CID methylurea_19\NN|nitroso|-|n|-|and|testosterone (r_pobj) with_12\IN|methylurea (r_prep) treatments_11\NNS|with (r_pobj) by_10\IN|treatments (r_prep) Production_0\NN|of|by|. (l_prep) of_1\IN|cancer (l_pobj) cancer_4\NN|autochthonous|prostate|in
D008770_D011471 CID methylurea_33\NN|nitroso|-|n|-|cas (r_pobj) with_26\IN|methylurea (r_prep) treatments_25\NNS|with (r_pobj) following_24\VBG|treatments (r_prep) developed_15\VBD|rats|pas|following (l_dobj) PAs_22\FW|large|,|palpable|prostate|adenocarcinomas|(|) (l_nmod) adenocarcinomas_20\NNS|
D008770_D011471 CID methylurea_33\NN|nitroso|-|n|-|cas (r_pobj) with_26\IN|methylurea (r_prep) treatments_25\NNS|with (r_pobj) following_24\VBG|treatments (r_prep) developed_15\VBD|rats|pas|following (l_dobj) PAs_22\FW|large|,|palpable|prostate|adenocarcinomas|(|)
D013739_D011471 NONE testosterone_21\NN| (r_conj) methylurea_19\NN|nitroso|-|n|-|and|testosterone (r_pobj) with_12\IN|methylurea (r_prep) treatments_11\NNS|with (r_pobj) by_10\IN|treatments (r_prep) Production_0\NN|of|by|. (l_prep) of_1\IN|cancer (l_pobj) cancer_4\NN|autochthonous|prostate|in
D043343_D011471 CID propionate_45\NN|testosterone (r_conj) CAS_35\NN|(|:|5|)|and|propionate (r_appos) methylurea_33\NN|nitroso|-|n|-|cas (r_pobj) with_26\IN|methylurea (r_prep) treatments_25\NNS|with (r_pobj) following_24\VBG|treatments (r_prep) developed_15\VBD|rats|pas|following (l_dobj) PAs_22\FW|large|,|palpable|prostate|adenocarcinomas|(|) (l_nmod) adenocarcinomas_20\NNS|
D043343_D011471 CID propionate_45\NN|testosterone (r_conj) CAS_35\NN|(|:|5|)|and|propionate (r_appos) methylurea_33\NN|nitroso|-|n|-|cas (r_pobj) with_26\IN|methylurea (r_prep) treatments_25\NNS|with (r_pobj) following_24\VBG|treatments (r_prep) developed_15\VBD|rats|pas|following (l_dobj) PAs_22\FW|large|,|palpable|prostate|adenocarcinomas|(|)
D043343_D011471 CID TP_19\NNP| (r_pobj) with_18\IN|only|tp (r_prep) treated_16\VBN|when|with (r_advcl) developed_10\VBD|within|,|rat|pa|treated|. (l_dobj) PA_14\NNP|a|similar|palpable
D043343_D011471 CID TP_6\NNP| (r_nsubj) acted_7\VBD|in|,|tp|as|,|with|. (l_prep) with_14\IN|emphasis (l_pobj) emphasis_16\NN|primary|on (l_prep) on_17\IN|development (l_pobj) development_19\NN|the|of (l_prep) of_20\IN|cancer (l_pobj) cancer_22\NN|prostate
D043343_D009369 NONE TP_6\NNP| (r_nsubj) acted_7\VBD|in|,|tp|as|,|with|. (l_prep) as_8\IN|agent (l_pobj) agent_12\NN|a|enhancement (l_compound) enhancement_11\NN|tumor (l_compound) tumor_10\NN|
9214597
D004967_D010911 NONE estrogen_14\NN| (r_npadvmod) induced_16\VBN|estrogen|- (r_amod) rat_17\NN|induced (r_nmod) tumors_19\NNS|rat|pituitary
D004967_D010911 NONE estrogen_22\NN| (r_npadvmod) initiated_24\VBN|estrogen|- (r_amod) angiogenesis_26\NN|initiated|tumor (r_dobj) mediate_21\VB|over|may|angiogenesis|. (l_prep) Over_0\IN|expression (l_pobj) expression_1\NN|of (l_prep) of_2\IN|factor (l_pobj) factor_6\NN|vascular|endothelial|growth|and|receptor (l_conj) receptor_9\NN|its|during (l_prep) during_10\IN|development (l_pobj) development_12\NN|the|of (l_prep) of_13\IN|tumors (l_pobj) tumors_19\NNS|rat|pituitary
D004967_D009369 NONE estrogen_14\NN| (r_npadvmod) induced_16\VBN|estrogen|- (r_amod) rat_17\NN|induced (r_nmod) tumors_19\NNS|rat|pituitary (r_pobj) of_13\IN|tumors (r_prep) development_12\NN|the|of (r_pobj) during_10\IN|development (r_prep) receptor_9\NN|its|during (r_conj) factor_6\NN|vascular|endothelial|growth|and|receptor (r_pobj) of_2\IN|factor (r_prep) expression_1\NN|of (r_pobj) Over_0\IN|expression (r_prep) mediate_21\VB|over|may|angiogenesis|. (l_dobj) angiogenesis_26\NN|initiated|tumor (l_compound) tumor_25\NN|
D004967_D009369 NONE estrogen_22\NN| (r_npadvmod) initiated_24\VBN|estrogen|- (r_amod) angiogenesis_26\NN|initiated|tumor (l_compound) tumor_25\NN|
D004967_D009369 NONE Estrogens_0\NNP|,|associated|, (l_relcl) associated_5\VBN|which|have|been|with (l_prep) with_6\IN|types (l_pobj) types_8\NNS|several|of (l_prep) of_9\IN|cancers (l_pobj) cancers_13\NNS|human
D004967_D009369 NONE Estrogens_0\NNP|,|associated|, (r_nsubj) induce_16\VB|estrogens|can|angiogenesis|in|. (l_dobj) angiogenesis_18\NN|tumor (l_compound) tumor_17\NN|
D004967_D009369 NONE estrogen_9\NN| (r_compound) carcinogenesis_10\NN|estrogen (r_pobj) during_8\IN|carcinogenesis (r_prep) are_12\VBP|details|,|during|,|still|unknown|. (l_nsubj) details_2\NNS|the|mechanistic|of|induction (l_prep) of_3\IN|angiogenesis (l_pobj) angiogenesis_5\NN|tumor (l_compound) tumor_4\NN|
D004967_D009369 NONE estrogen_5\NN| (r_pobj) of_4\IN|estrogen (r_prep) role_3\NN|the|of (r_dobj) elucidate_1\VB|to|role|in (l_prep) in_6\IN|regulation (l_pobj) regulation_8\NN|the|of|in (l_prep) of_9\IN|angiogenesis (l_pobj) angiogenesis_11\NN|tumor (l_compound) tumor_10\NN|
D004967_D009369 NONE estrogen_27\NN| (r_pobj) of_26\IN|estrogen (r_prep) regulation_25\NN|the|of (r_pobj) of_23\IN|regulation (r_prep) step_22\NN|the|initial|of (r_pobj) in_19\IN|step (r_prep) play_15\VB|that|over|may|role|in (r_ccomp) suggest_2\VBP|findings|play|induced|. (l_ccomp) induced_28\VBN|angiogenesis|in (l_dobj) angiogenesis_30\NN|tumor (l_compound) tumor_29\NN|
D004967_D063646 NONE estrogen_9\NN| (r_compound) carcinogenesis_10\NN|estrogen
12448656
D013792_D002292 NONE thalidomide_5\NN| (r_pobj) of_4\IN|thalidomide (r_prep) study_3\NN|a|phase|ii|of|in|. (l_prep) in_6\IN|carcinoma (l_pobj) carcinoma_11\NN|advanced|metastatic|cell
D013792_D002292 NONE thalidomide_9\NN| (r_pobj) of_8\IN|thalidomide (r_prep) toxicity_5\NN|the|and|activity|of (r_dobj) evaluate_3\VB|to|toxicity|in (l_prep) in_10\IN|patients|and|measure (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|cancer (l_pobj) cancer_17\NN|advanced|metastatic|cell
D013792_D002292 NONE thalidomide_11\NN| (r_pobj) of_10\IN|thalidomide (r_prep) activity_9\NN|of (r_pobj) of_8\IN|activity (r_prep) level_7\NN|a|low|of|in (l_prep) in_12\IN|carcinoma (l_pobj) carcinoma_15\NN|cell
D013792_D002292 NONE thalidomide_10\NN|for (l_prep) for_11\IN|carcinoma (l_pobj) carcinoma_14\NN|renal|cell
D013792_D064420 NONE thalidomide_9\NN| (r_pobj) of_8\IN|thalidomide (r_prep) toxicity_5\NN|the|and|activity|of
11058428
D008775_D013119 NONE methylprednisolone_3\NN|dose (r_nsubj) do_5\VB|methylprednisolone|may|harm|. (l_dobj) harm_7\NN|more|for (l_prep) for_8\IN|injury (l_pobj) injury_11\NN|spinal|cord
D008775_D013119 NONE methylprednisolone_16\NN|dose (r_nsubj) became_17\VBD|because|methylprednisolone|standard|. (l_prep) Because_0\IN|of|studies (l_pobj) Studies_8\NNP|the|national|injury|(|nascis|, (l_compound) Injury_7\NNP|spinal|cord
D008775_D013119 NONE methylprednisolone_16\NN|dose (r_nsubj) became_17\VBD|because|methylprednisolone|standard|. (l_attr) standard_19\NN|the|of|for (l_prep) for_22\IN|injury (l_pobj) injury_27\NN|the|acute|cord
D008775_D013119 NONE methylprednisolone_34\NN|that|offers (l_dobj) offers_35\VBZ|to (l_prep) to_36\IN|injury (l_pobj) injury_40\NN|the|spinal|cord
D000305_D009135 NONE corticosteroid_13\NN|acute (r_pobj) of_11\IN|corticosteroid (r_prep) possibility_10\NN|the|of|myopathy|cause (l_prep) myopathy_14\NNS|
D000305_D009135 NONE corticosteroid_21\NN|acute (r_nsubj) myopathy_22\NNS|corticosteroid
D008775_D009135 CID methylprednisolone_19\NN|dose (r_nsubj) cause_21\VB|that|methylprednisolone|may (r_acl) possibility_10\NN|the|of|myopathy|cause (l_prep) myopathy_14\NNS|
D008775_D009135 CID methylprednisolone_34\NN|that|offers (r_relcl) protection_32\NN|any|methylprednisolone (r_pobj) of_30\IN|instead|protection (r_cc) recording_18\NN|just|a|of|,|of (r_attr) be_15\VB|improvement|may|recording|. (r_conj) recovers_4\VBZ|further|,|myopathy|naturally|and|be (l_nsubj) myopathy_3\NN|steroid
D008775_D009135 CID methylprednisolone_34\NN|that|offers (r_relcl) protection_32\NN|any|methylprednisolone (r_pobj) of_30\IN|instead|protection (r_cc) recording_18\NN|just|a|of|,|of (l_prep) of_19\IN|recovery (l_pobj) recovery_23\NN|this|natural|motor|from (l_prep) from_24\IN|myopathy (l_pobj) myopathy_27\NNS|steroid
D008775_D009135 CID methylprednisolone_14\NN|the|recommended (r_nsubj) cause_19\VB|that|methylprednisolone|may|myopathy (l_ccomp) myopathy_22\NNS|corticosteroid
D013256_D009135 NONE steroid_2\NN| (r_compound) myopathy_3\NN|steroid
D013256_D009135 NONE steroid_2\NN| (r_compound) myopathy_3\NN|steroid (r_nsubj) recovers_4\VBZ|further|,|myopathy|naturally|and|be (l_conj) be_15\VB|improvement|may|recording|. (l_attr) recording_18\NN|just|a|of|,|of (l_prep) of_19\IN|recovery (l_pobj) recovery_23\NN|this|natural|motor|from (l_prep) from_24\IN|myopathy (l_pobj) myopathy_27\NNS|steroid
D013256_D009135 NONE steroid_26\NN|the (r_compound) myopathy_27\NNS|steroid (r_pobj) from_24\IN|myopathy (r_prep) recovery_23\NN|this|natural|motor|from (r_pobj) of_19\IN|recovery (r_prep) recording_18\NN|just|a|of|,|of (r_attr) be_15\VB|improvement|may|recording|. (r_conj) recovers_4\VBZ|further|,|myopathy|naturally|and|be (l_nsubj) myopathy_3\NN|steroid
D013256_D009135 NONE steroid_26\NN|the (r_compound) myopathy_27\NNS|steroid
D013256_D013119 NONE steroid_2\NN| (r_compound) myopathy_3\NN|steroid (r_nsubj) recovers_4\VBZ|further|,|myopathy|naturally|and|be (l_conj) be_15\VB|improvement|may|recording|. (l_attr) recording_18\NN|just|a|of|,|of (l_cc) of_30\IN|instead|protection (l_pobj) protection_32\NN|any|methylprednisolone (l_relcl) methylprednisolone_34\NN|that|offers (l_dobj) offers_35\VBZ|to (l_prep) to_36\IN|injury (l_pobj) injury_40\NN|the|spinal|cord
D013256_D013119 NONE steroid_26\NN|the (r_compound) myopathy_27\NNS|steroid (r_pobj) from_24\IN|myopathy (r_prep) recovery_23\NN|this|natural|motor|from (r_pobj) of_19\IN|recovery (r_prep) recording_18\NN|just|a|of|,|of (l_cc) of_30\IN|instead|protection (l_pobj) protection_32\NN|any|methylprednisolone (l_relcl) methylprednisolone_34\NN|that|offers (l_dobj) offers_35\VBZ|to (l_prep) to_36\IN|injury (l_pobj) injury_40\NN|the|spinal|cord
3220106
D009538_D006948 CID nicotine_3\NN| (r_npadvmod) induced_5\VBN|nicotine|- (r_amod) hyperactivity_7\NN|induced|locomotor|in
D009538_D006948 CID nicotine_10\NN| (r_npadvmod) treated_12\VBN|nicotine|- (r_amod) rats_13\NNS|chronic|treated (r_pobj) in_8\IN|rats (r_prep) hyperactivity_7\NN|induced|locomotor|in
D009538_D006948 CID nicotine_5\NN| (r_npadvmod) treated_7\VBN|nicotine|- (r_amod) rats_8\NNS|chronic|treated (r_nsubj) develop_9\VBP|that|rats|hyperactivity|in|initially|due|, (l_dobj) hyperactivity_11\NN|locomotor
D009538_D006948 CID nicotine_15\NN| (r_pobj) to_14\IN|nicotine (r_prep) response_13\NN|to (r_pobj) in_12\IN|response (r_prep) develop_9\VBP|that|rats|hyperactivity|in|initially|due|, (l_dobj) hyperactivity_11\NN|locomotor
D004298_D006948 NONE DA_28\NNP| (r_compound) concentration_29\NN|da (r_conj) receptors_26\NNS|nicotinic|and|concentration (r_pobj) of_24\IN|receptors (r_prep) density_23\NN|both|the|of (r_pobj) of_20\IN|density (r_prep) increases_19\NNS|of (r_pobj) due_17\JJ|to|increases (r_prep) develop_9\VBP|that|rats|hyperactivity|in|initially|due|, (l_dobj) hyperactivity_11\NN|locomotor
D004298_D006948 NONE DA_34\NNP| (r_compound) supersensitivity_36\NN|da|receptor|in (r_dobj) inducing_33\VBG|supersensitivity (r_pcomp) by_32\IN|inducing (r_agent) followed_31\VBN|by (r_advcl) suggest_2\VBP|results|develop|followed|. (l_ccomp) develop_9\VBP|that|rats|hyperactivity|in|initially|due|, (l_dobj) hyperactivity_11\NN|locomotor
6293644
D006220_D002375 CID haloperidol_7\NN| (r_npadvmod) induced_9\VBN|haloperidol|- (r_amod) catalepsy_10\NN|induced
D006220_D006948 NONE haloperidol_7\NN| (r_npadvmod) induced_9\VBN|haloperidol|- (r_amod) catalepsy_10\NN|induced (r_pobj) of_6\IN|catalepsy (r_prep) potentiation_5\NN|a|of|and|prevention (l_conj) prevention_14\NN|a|partial|of (l_prep) of_15\IN|hyperactivity (l_pobj) hyperactivity_19\NN|induced
D001058_D002375 NONE apomorphine_16\NN| (r_npadvmod) induced_18\VBN|apomorphine|- (r_amod) hyperactivity_19\NN|induced (r_pobj) of_15\IN|hyperactivity (r_prep) prevention_14\NN|a|partial|of (r_conj) potentiation_5\NN|a|of|and|prevention (l_prep) of_6\IN|catalepsy (l_pobj) catalepsy_10\NN|induced
D001058_D006948 CID apomorphine_16\NN| (r_npadvmod) induced_18\VBN|apomorphine|- (r_amod) hyperactivity_19\NN|induced
11583940
C063008_D007674 NONE mofetil_7\NNS|and|sirolimus|rapamycin (r_dobj) mycophenolate_6\VB|agents|mofetil|,|have|. (l_dep) have_14\VBP|nephrotoxicity (l_dobj) nephrotoxicity_16\NN|no
D020123_D007674 NONE sirolimus_9\NN| (r_conj) mofetil_7\NNS|and|sirolimus|rapamycin (r_dobj) mycophenolate_6\VB|agents|mofetil|,|have|. (l_dep) have_14\VBP|nephrotoxicity (l_dobj) nephrotoxicity_16\NN|no
D020123_D007674 NONE rapamycin_11\NNS|(|) (r_appos) mofetil_7\NNS|and|sirolimus|rapamycin (r_dobj) mycophenolate_6\VB|agents|mofetil|,|have|. (l_dep) have_14\VBP|nephrotoxicity (l_dobj) nephrotoxicity_16\NN|no
2709684
D010695_D006029 NONE Phlorizin_0\NNP| (r_npadvmod) induced_2\VBN|phlorizin|- (r_amod) glycosuria_3\NN|induced
D010695_D006029 NONE P_13\NN| (r_nmod) animals_15\NNS|the|p|treated (r_pobj) of_11\IN|animals (r_prep) that_10\DT|of (r_pobj) to_9\IN|that (r_prep) degree_8\NN|to (r_pobj) in_7\IN|degree (r_prep) similar_6\JJ|in (r_amod) glycosuria_4\NN|mild|(|similar|)
D010695_D006029 NONE P_4\NN| (r_nsubj) induced_5\VBD|in|i|,|p|glycosuria|and|ccr (l_dobj) glycosuria_10\NN|a|moderate|(|+/-|,
D010695_D007674 NONE Phlorizin_0\NNP| (r_npadvmod) induced_2\VBN|phlorizin|- (r_amod) glycosuria_3\NN|induced (r_nsubj) prevent_6\VB|glycosuria|does|not|nephrotoxicity|. (l_dobj) nephrotoxicity_8\NN|gentamicin|in
D010695_D007674 NONE phlorizin_24\NN|(|p|) (r_pobj) with_23\IN|phlorizin (r_prep) reabsorption_22\NN|tubular|glucose|with (r_pobj) of_19\IN|reabsorption (r_prep) blockage_18\NN|of (r_pobj) by_17\IN|blockage (r_agent) induced_16\VBN|by (r_acl) rats_11\NNS|diabetic|with|induced (r_pobj) in_7\IN|rats (r_prep) studied_6\VBN|protection|was|in|. (l_nsubjpass) protection_1\NN|the|from (l_prep) from_2\IN|nephrotoxicity (l_pobj) nephrotoxicity_4\NN|gentamicin
D010695_D007674 NONE P_26\NN| (r_appos) phlorizin_24\NN|(|p|) (r_pobj) with_23\IN|phlorizin (r_prep) reabsorption_22\NN|tubular|glucose|with (r_pobj) of_19\IN|reabsorption (r_prep) blockage_18\NN|of (r_pobj) by_17\IN|blockage (r_agent) induced_16\VBN|by (r_acl) rats_11\NNS|diabetic|with|induced (r_pobj) in_7\IN|rats (r_prep) studied_6\VBN|protection|was|in|. (l_nsubjpass) protection_1\NN|the|from (l_prep) from_2\IN|nephrotoxicity (l_pobj) nephrotoxicity_4\NN|gentamicin
D010695_D007674 NONE P_4\NN| (r_nsubj) induced_5\VBD|in|i|,|p|glycosuria|and|ccr (l_conj) CCr_33\IN|evidence|baseline|min|score|. (l_nsubj) evidence_27\NN|no|functional|of (l_prep) of_28\IN|dysfunction (l_pobj) dysfunction_30\NN|renal|(
D005839_D006029 NONE gentamicin_7\NN| (r_compound) nephrotoxicity_8\NN|gentamicin|in (r_dobj) prevent_6\VB|glycosuria|does|not|nephrotoxicity|. (l_nsubj) glycosuria_3\NN|induced
D005839_D006029 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|gentamicin|- (r_amod) failure_46\NN|induced|acute|renal|arf (r_pobj) to_40\IN|failure (r_prep) resistance_39\NN|their|to (r_pobj) for_37\IN|resistance (r_prep) responsible_36\JJ|for (r_acomp) be_35\VB|that|this|may|in|responsible (r_ccomp) suggested_29\VBN|have|,|we|have|be|. (l_advcl) have_11\VBP|because|rats|diuresis (l_dobj) diuresis_15\NN|a|solute|(|glycosuria|) (l_appos) glycosuria_17\NN|of
D005839_D007674 NONE gentamicin_7\NN| (r_compound) nephrotoxicity_8\NN|gentamicin|in
D005839_D007674 NONE gentamicin_3\NN| (r_amod) nephrotoxicity_4\NN|gentamicin
D005839_D007674 NONE gentamicin_11\NN| (r_pobj) of_10\IN|gentamicin (r_prep) doses_1\NNS|nephrotoxic|(|body|)|of (l_amod) Nephrotoxic_0\JJ|
D013311_D003920 CID streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|streptozotocin|- (r_amod) diabetes_6\NN|induced (r_compound) mellitus_7\NN|diabetes|dm
D013311_D003920 CID streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|streptozotocin|- (r_amod) diabetes_6\NN|induced (r_compound) mellitus_7\NN|diabetes|dm (l_appos) DM_9\NNP|(|)
D013311_D006029 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|streptozotocin|- (r_amod) diabetes_6\NN|induced (r_compound) mellitus_7\NN|diabetes|dm (r_pobj) with_2\IN|mellitus (r_prep) rats_1\NNS|with (r_nsubj) have_11\VBP|because|rats|diuresis (l_dobj) diuresis_15\NN|a|solute|(|glycosuria|) (l_appos) glycosuria_17\NN|of
D013311_D058186 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|streptozotocin|- (r_amod) diabetes_6\NN|induced (r_compound) mellitus_7\NN|diabetes|dm (r_pobj) with_2\IN|mellitus (r_prep) rats_1\NNS|with (r_nsubj) have_11\VBP|because|rats|diuresis (r_advcl) suggested_29\VBN|have|,|we|have|be|. (l_ccomp) be_35\VB|that|this|may|in|responsible (l_acomp) responsible_36\JJ|for (l_prep) for_37\IN|resistance (l_pobj) resistance_39\NN|their|to (l_prep) to_40\IN|failure (l_pobj) failure_46\NN|induced|acute|renal|arf
D013311_D058186 NONE streptozotocin_3\NNS| (r_npadvmod) induced_5\VBN|streptozotocin|- (r_amod) diabetes_6\NN|induced (r_compound) mellitus_7\NN|diabetes|dm (r_pobj) with_2\IN|mellitus (r_prep) rats_1\NNS|with (r_nsubj) have_11\VBP|because|rats|diuresis (r_advcl) suggested_29\VBN|have|,|we|have|be|. (l_ccomp) be_35\VB|that|this|may|in|responsible (l_acomp) responsible_36\JJ|for (l_prep) for_37\IN|resistance (l_pobj) resistance_39\NN|their|to (l_prep) to_40\IN|failure (l_pobj) failure_46\NN|induced|acute|renal|arf (l_appos) ARF_48\NNP|(|)
D005839_D003920 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|gentamicin|- (r_amod) failure_46\NN|induced|acute|renal|arf (r_pobj) to_40\IN|failure (r_prep) resistance_39\NN|their|to (r_pobj) for_37\IN|resistance (r_prep) responsible_36\JJ|for (r_acomp) be_35\VB|that|this|may|in|responsible (r_ccomp) suggested_29\VBN|have|,|we|have|be|. (l_advcl) have_11\VBP|because|rats|diuresis (l_nsubj) rats_1\NNS|with (l_prep) with_2\IN|mellitus (l_pobj) mellitus_7\NN|diabetes|dm
D005839_D003920 NONE gentamicin_41\NN| (r_npadvmod) induced_43\VBN|gentamicin|- (r_amod) failure_46\NN|induced|acute|renal|arf (r_pobj) to_40\IN|failure (r_prep) resistance_39\NN|their|to (r_pobj) for_37\IN|resistance (r_prep) responsible_36\JJ|for (r_acomp) be_35\VB|that|this|may|in|responsible (r_ccomp) suggested_29\VBN|have|,|we|have|be|. (l_advcl) have_11\VBP|because|rats|diuresis (l_nsubj) rats_1\NNS|with (l_prep) with_2\IN|mellitus (l_pobj) mellitus_7\NN|diabetes|dm (l_appos) DM_9\NNP|(|)
D005839_D003920 NONE gentamicin_3\NN| (r_amod) nephrotoxicity_4\NN|gentamicin (r_pobj) from_2\IN|nephrotoxicity (r_prep) protection_1\NN|the|from (r_nsubjpass) studied_6\VBN|protection|was|in|. (l_prep) in_7\IN|rats (l_pobj) rats_11\NNS|diabetic|with|induced (l_amod) diabetic_10\JJ|non|-
D005839_D003920 NONE gentamicin_23\NN| (r_conj) P_21\NN|+|gentamicin|) (r_appos) II_19\NNP|group|(|p|;|iii (l_conj) III_27\NNP|group|(|gentamicin|. (l_acl) gentamicin_29\NN|alone|)|and|iv (l_conj) IV_34\NNP|group|dm (l_appos) DM_37\NNP|(|mild|+|gentamicin|)
D005839_D003920 NONE gentamicin_29\NN|alone|)|and|iv (l_conj) IV_34\NNP|group|dm (l_appos) DM_37\NNP|(|mild|+|gentamicin|)
D005839_D003920 NONE gentamicin_39\NN| (r_conj) DM_37\NNP|(|mild|+|gentamicin|)
D005839_D058186 CID gentamicin_41\NN| (r_npadvmod) induced_43\VBN|gentamicin|- (r_amod) failure_46\NN|induced|acute|renal|arf
D005839_D058186 CID gentamicin_41\NN| (r_npadvmod) induced_43\VBN|gentamicin|- (r_amod) failure_46\NN|induced|acute|renal|arf (l_appos) ARF_48\NNP|(|)
D005839_D058186 CID gentamicin_8\NN| (r_compound) ARF_10\NNP|gentamicin|-|(|decrease|,|p
D005947_D007674 NONE glucose_21\NN| (r_compound) reabsorption_22\NN|tubular|glucose|with (r_pobj) of_19\IN|reabsorption (r_prep) blockage_18\NN|of (r_pobj) by_17\IN|blockage (r_agent) induced_16\VBN|by (r_acl) rats_11\NNS|diabetic|with|induced (r_pobj) in_7\IN|rats (r_prep) studied_6\VBN|protection|was|in|. (l_nsubjpass) protection_1\NN|the|from (l_prep) from_2\IN|nephrotoxicity (l_pobj) nephrotoxicity_4\NN|gentamicin
D005947_D003920 NONE glucose_21\NN| (r_compound) reabsorption_22\NN|tubular|glucose|with (r_pobj) of_19\IN|reabsorption (r_prep) blockage_18\NN|of (r_pobj) by_17\IN|blockage (r_agent) induced_16\VBN|by (r_acl) rats_11\NNS|diabetic|with|induced (l_amod) diabetic_10\JJ|non|-
D010695_D003920 NONE phlorizin_24\NN|(|p|) (r_pobj) with_23\IN|phlorizin (r_prep) reabsorption_22\NN|tubular|glucose|with (r_pobj) of_19\IN|reabsorption (r_prep) blockage_18\NN|of (r_pobj) by_17\IN|blockage (r_agent) induced_16\VBN|by (r_acl) rats_11\NNS|diabetic|with|induced (l_amod) diabetic_10\JJ|non|-
D010695_D003920 NONE P_26\NN| (r_appos) phlorizin_24\NN|(|p|) (r_pobj) with_23\IN|phlorizin (r_prep) reabsorption_22\NN|tubular|glucose|with (r_pobj) of_19\IN|reabsorption (r_prep) blockage_18\NN|of (r_pobj) by_17\IN|blockage (r_agent) induced_16\VBN|by (r_acl) rats_11\NNS|diabetic|with|induced (l_amod) diabetic_10\JJ|non|-
D010695_D003920 NONE P_13\NN| (r_nmod) animals_15\NNS|the|p|treated (r_pobj) of_11\IN|animals (r_prep) that_10\DT|of (r_pobj) to_9\IN|that (r_prep) degree_8\NN|to (r_pobj) in_7\IN|degree (r_prep) similar_6\JJ|in (r_amod) glycosuria_4\NN|mild|(|similar|) (r_pobj) with_2\IN|glycosuria (r_prep) rats_1\NNS|dm|with (l_compound) DM_0\NNP|
D010695_D003920 NONE P_3\NN|alone|) (r_nsubj) received_6\VBD|group|p|p|for|;|ii (l_conj) II_19\NNP|group|(|p|;|iii (l_conj) III_27\NNP|group|(|gentamicin|. (l_acl) gentamicin_29\NN|alone|)|and|iv (l_conj) IV_34\NNP|group|dm (l_appos) DM_37\NNP|(|mild|+|gentamicin|)
D010695_D003920 NONE P_7\NN|,|day|, (r_dobj) received_6\VBD|group|p|p|for|;|ii (l_conj) II_19\NNP|group|(|p|;|iii (l_conj) III_27\NNP|group|(|gentamicin|. (l_acl) gentamicin_29\NN|alone|)|and|iv (l_conj) IV_34\NNP|group|dm (l_appos) DM_37\NNP|(|mild|+|gentamicin|)
D010695_D003920 NONE P_21\NN|+|gentamicin|) (r_appos) II_19\NNP|group|(|p|;|iii (l_conj) III_27\NNP|group|(|gentamicin|. (l_acl) gentamicin_29\NN|alone|)|and|iv (l_conj) IV_34\NNP|group|dm (l_appos) DM_37\NNP|(|mild|+|gentamicin|)
D010695_D009956 NONE P_4\NN| (r_nsubj) induced_5\VBD|in|i|,|p|glycosuria|and|ccr (l_conj) CCr_33\IN|evidence|baseline|min|score|. (l_dobj) score_49\NN|(|tubular|necrosis|[|maximum|4|]|,|zero|) (l_compound) necrosis_48\NN|
D010695_D009956 NONE P_4\NN| (r_nsubj) prevent_7\VB|in|,|p|did|not|arf|less|;|day|. (l_conj) day_34\NN|micrograms|/|;|and|score (l_conj) score_39\NN|tubular|necrosis|,|0.1|) (l_compound) necrosis_38\NN|
D010695_D009956 NONE P_21\NN| (r_appos) ARF_10\NNP|gentamicin|-|(|decrease|,|p (r_dobj) prevent_7\VB|in|,|p|did|not|arf|less|;|day|. (l_conj) day_34\NN|micrograms|/|;|and|score (l_conj) score_39\NN|tubular|necrosis|,|0.1|) (l_compound) necrosis_38\NN|
D010695_D058186 NONE P_4\NN| (r_nsubj) prevent_7\VB|in|,|p|did|not|arf|less|;|day|. (l_dobj) ARF_10\NNP|gentamicin|-|(|decrease|,|p
D010695_D058186 NONE P_21\NN| (r_appos) ARF_10\NNP|gentamicin|-|(|decrease|,|p
D005839_D009956 NONE gentamicin_8\NN| (r_compound) ARF_10\NNP|gentamicin|-|(|decrease|,|p (r_dobj) prevent_7\VB|in|,|p|did|not|arf|less|;|day|. (l_conj) day_34\NN|micrograms|/|;|and|score (l_conj) score_39\NN|tubular|necrosis|,|0.1|) (l_compound) necrosis_38\NN|
12911170
D002939_D009395 CID Ciprofloxacin_0\NNP| (r_npadvmod) induced_2\VBN|ciprofloxacin|-|nephritis|. (l_dobj) nephritis_5\NN|acute|interstitial|and|anemia
D002939_D009395 CID Ciprofloxacin_0\NNP| (r_nsubjpass) associated_3\VBN|ciprofloxacin|has|been|with|. (l_prep) with_4\IN|effects (l_pobj) effects_7\NNS|several|side|including (l_prep) including_8\VBG|nephritis (l_pobj) nephritis_10\NN|interstitial|and|anemia
D002939_D009395 CID ciprofloxacin_9\NNS| (r_npadvmod) induced_11\VBN|ciprofloxacin|- (r_amod) nephritis_13\NN|induced|interstitial|and|anemia
D002939_D000744 NONE Ciprofloxacin_0\NNP| (r_npadvmod) induced_2\VBN|ciprofloxacin|-|nephritis|. (l_dobj) nephritis_5\NN|acute|interstitial|and|anemia (l_conj) anemia_9\NN|autoimmune|hemolytic
D002939_D000744 NONE ciprofloxacin_9\NNS| (r_npadvmod) induced_11\VBN|ciprofloxacin|- (r_amod) nephritis_13\NN|induced|interstitial|and|anemia (l_conj) anemia_17\NN|autoimmune|hemolytic
D002939_D000743 CID Ciprofloxacin_0\NNP| (r_nsubjpass) associated_3\VBN|ciprofloxacin|has|been|with|. (l_prep) with_4\IN|effects (l_pobj) effects_7\NNS|several|side|including (l_prep) including_8\VBG|nephritis (l_pobj) nephritis_10\NN|interstitial|and|anemia (l_conj) anemia_13\NN|hemolytic
D013256_D000743 NONE steroid_10\NN| (r_compound) therapy_11\NN|steroid (r_pobj) of_9\IN|therapy (r_prep) initiation_8\NN|of (r_conj) drug_6\NN|the|and|initiation (r_dobj) stopping_4\VBG|drug (r_pcomp) after_3\IN|stopping (r_prep) improved_2\VBD|anemia|after|. (l_nsubj) anemia_1\NN|hemolytic
7066357
D011692_D009404 CID aminonucleoside_18\RB| (r_advmod) induced_12\VBN|plasma|in|by|aminonucleoside|. (l_nsubj) Plasma_0\NN|and|lipids|during (l_prep) during_6\IN|development (l_pobj) development_8\NN|the|of (l_prep) of_9\IN|syndrome (l_pobj) syndrome_11\NN|nephrotic
D011692_D009404 CID aminonucleoside_19\NN|puromycin (r_pobj) by_17\IN|aminonucleoside (r_agent) induced_16\VBN|by (r_acl) alterations_8\NNS|the|of|induced (l_prep) of_9\IN|lipoproteins (l_pobj) lipoproteins_11\NNS|plasma|found (l_acl) found_12\VBN|in (l_prep) in_13\IN|syndrome (l_pobj) syndrome_15\NN|nephrotic
D011692_D009404 CID aminonucleoside_19\NN|puromycin (r_pobj) by_17\IN|aminonucleoside (r_agent) induced_16\VBN|by (r_acl) alterations_8\NNS|the|of|induced (r_nsubj) were_20\VBD|whether|alterations|due|,|or|,|to (l_acomp) due_21\JJ|to (l_prep) to_22\IN|syndrome (l_pobj) syndrome_24\NN|nephrotic|per
D011692_D009404 CID aminonucleoside_37\NN|the (r_pobj) to_35\IN|aminonucleoside (r_prep) were_20\VBD|whether|alterations|due|,|or|,|to (l_nsubj) alterations_8\NNS|the|of|induced (l_prep) of_9\IN|lipoproteins (l_pobj) lipoproteins_11\NNS|plasma|found (l_acl) found_12\VBN|in (l_prep) in_13\IN|syndrome (l_pobj) syndrome_15\NN|nephrotic
D011692_D009404 CID aminonucleoside_37\NN|the (r_pobj) to_35\IN|aminonucleoside (r_prep) were_20\VBD|whether|alterations|due|,|or|,|to (l_acomp) due_21\JJ|to (l_prep) to_22\IN|syndrome (l_pobj) syndrome_24\NN|nephrotic|per
D011692_D009404 CID aminonucleoside_21\NN|mg/kg|and|development (l_conj) development_32\NN|the|subsequent|of (l_prep) of_33\IN|syndrome (l_pobj) syndrome_35\NN|nephrotic
D005227_D009404 NONE acids_10\NNS|fatty|,|triacylglycerol (r_pobj) of_8\IN|acids (r_prep) level_7\NN|the|plasma|of (r_nsubj) decreased_15\VBD|in|level|remained|. (l_prep) In_0\IN|stage (l_pobj) stage_4\NN|nephrotic (l_amod) nephrotic_3\JJ|-
D014280_D009404 NONE triacylglycerol_12\NN|and|vldl (r_conj) acids_10\NNS|fatty|,|triacylglycerol (r_pobj) of_8\IN|acids (r_prep) level_7\NN|the|plasma|of (r_nsubj) decreased_15\VBD|in|level|remained|. (l_prep) In_0\IN|stage (l_pobj) stage_4\NN|nephrotic (l_amod) nephrotic_3\JJ|-
D002788_D009404 NONE esters_22\NNS|cholesteryl|and|hdl (r_nsubj) remained_25\VBD|while|that|esters|constant (r_advcl) decreased_15\VBD|in|level|remained|. (l_prep) In_0\IN|stage (l_pobj) stage_4\NN|nephrotic (l_amod) nephrotic_3\JJ|-
8599504
D004329_D000799 CID droperidol_3\NN| (r_compound) administration_4\NN|droperidol (r_pobj) with_2\IN|administration (r_prep) associated_1\VBD|with (r_acl) Angioedema_0\NNP|associated|.
D004329_D000799 CID droperidol_39\NN| (r_pobj) of_38\IN|droperidol (r_prep) dose_37\NN|a|single|iv|of (r_pobj) of_33\IN|dose (r_prep) administration_32\NN|the|of (r_pobj) of_30\IN|administration (r_prep) minutes_29\NNS|10|of (r_pobj) within_27\IN|minutes (r_prep) developed_26\VBN|in|angioedema|within (l_nsubj) angioedema_19\NN|with
D004329_D004342 NONE droperidol_39\NN| (r_pobj) of_38\IN|droperidol (r_prep) dose_37\NN|a|single|iv|of (r_pobj) of_33\IN|dose (r_prep) administration_32\NN|the|of (r_pobj) of_30\IN|administration (r_prep) minutes_29\NNS|10|of (r_pobj) within_27\IN|minutes (r_prep) developed_26\VBN|in|angioedema|within (r_relcl) allergies_16\NNS|no|known|drug|developed
D004329_D014060 NONE droperidol_39\NN| (r_pobj) of_38\IN|droperidol (r_prep) dose_37\NN|a|single|iv|of (r_pobj) of_33\IN|dose (r_prep) administration_32\NN|the|of (r_pobj) of_30\IN|administration (r_prep) minutes_29\NNS|10|of (r_pobj) within_27\IN|minutes (r_prep) developed_26\VBN|in|angioedema|within (l_nsubj) angioedema_19\NN|with (l_prep) with_20\IN|swelling (l_pobj) swelling_23\NN|significant|tongue|and|protrusion
D004329_D004487 NONE droperidol_39\NN| (r_pobj) of_38\IN|droperidol (r_prep) dose_37\NN|a|single|iv|of (r_pobj) of_33\IN|dose (r_prep) administration_32\NN|the|of (r_pobj) of_30\IN|administration (r_prep) minutes_29\NNS|10|of (r_pobj) within_27\IN|minutes (r_prep) developed_26\VBN|in|angioedema|within (l_nsubj) angioedema_19\NN|with (l_prep) with_20\IN|swelling (l_pobj) swelling_23\NN|significant|tongue|and|protrusion
12231232
D006220_D010300 NONE Haloperidol_0\NN|ip (r_nsubj) induced_6\VBD|haloperidol|rigidity|. (l_dobj) rigidity_11\NN|parkinsonian|muscle|,|measured (l_amod) parkinsonian_7\JJ|-|like
D006220_D009127 CID Haloperidol_0\NN|ip (r_nsubj) induced_6\VBD|haloperidol|rigidity|. (l_dobj) rigidity_11\NN|parkinsonian|muscle|,|measured
D006220_D009127 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|haloperidol|- (r_amod) rigidity_15\NN|the|induced|muscle
C095756_D009127 NONE AIDA_0\NNP|in (r_nsubj) diminished_9\VBD|aida|rigidity|. (l_dobj) rigidity_15\NN|the|induced|muscle
9523850
D008775_D018771 NONE methylprednisolone_2\NN| (r_pobj) of_1\IN|methylprednisolone (r_prep) Value_0\NN|of|in|:|trial|. (l_prep) in_3\IN|prevention (l_pobj) prevention_4\NN|of (l_prep) of_5\IN|syndrome (l_pobj) syndrome_10\NN|the|myalgia|associated (l_compound) myalgia_9\NN|arthralgia|- (l_compound) arthralgia_7\JJ|
D008775_D018771 NONE MP_6\NNP| (r_pobj) of_5\IN|mp (r_prep) administration_4\NN|of|before (r_nsubj) reduces_11\VBZ|that|administration|after|tdi|frequency (l_dobj) frequency_13\NN|the|and|severity|of (l_prep) of_16\IN|syndrome (l_pobj) syndrome_21\NN|the|myalgia (l_compound) myalgia_20\NN|arthralgia|- (l_compound) arthralgia_18\JJ|
D008775_D063806 NONE methylprednisolone_2\NN| (r_pobj) of_1\IN|methylprednisolone (r_prep) Value_0\NN|of|in|:|trial|. (l_prep) in_3\IN|prevention (l_pobj) prevention_4\NN|of (l_prep) of_5\IN|syndrome (l_pobj) syndrome_10\NN|the|myalgia|associated (l_compound) myalgia_9\NN|arthralgia|-
D008775_D063806 NONE MP_6\NNP| (r_pobj) of_5\IN|mp (r_prep) administration_4\NN|of|before (r_nsubj) reduces_11\VBZ|that|administration|after|tdi|frequency (l_dobj) frequency_13\NN|the|and|severity|of (l_prep) of_16\IN|syndrome (l_pobj) syndrome_21\NN|the|myalgia (l_compound) myalgia_20\NN|arthralgia|-
D007505_D018771 CID dextran_19\NN|iron (r_pobj) of_17\IN|dextran (r_prep) infusion_16\NN|the|total|dose|of (r_pobj) with_12\IN|infusion (r_prep) associated_11\VBN|with (r_acl) syndrome_10\NN|the|myalgia|associated (l_compound) myalgia_9\NN|arthralgia|- (l_compound) arthralgia_7\JJ|
D007505_D063806 NONE dextran_19\NN|iron (r_pobj) of_17\IN|dextran (r_prep) infusion_16\NN|the|total|dose|of (r_pobj) with_12\IN|infusion (r_prep) associated_11\VBN|with (r_acl) syndrome_10\NN|the|myalgia|associated (l_compound) myalgia_9\NN|arthralgia|-
12745515
D016642_D012640 CID bupropion_9\NN|release (r_conj) deprivation_4\NN|sleep|and|bupropion (r_pobj) with_2\IN|deprivation (r_prep) associated_1\VBN|with (r_acl) Seizure_0\NN|associated|.
D016642_D012640 CID bupropion_12\NN| (r_compound) use_13\NN|release|bupropion|and|deprivation (r_pobj) with_8\IN|use (r_prep) associated_7\VBN|with (r_acl) seizure_6\NN|a|generalized|associated
D016642_D012640 CID bupropion_4\NN| (r_compound) use_5\NN|bupropion (r_pobj) of_3\IN|use (r_prep) weeks_2\NNS|5|of (r_pobj) After_0\IN|weeks (r_prep) experienced_9\VBD|after|,|subject|seizure|after|. (l_dobj) seizure_14\NN|a|generalized|tonic|clonic
D016642_D012640 CID bupropion_11\NN| (r_npadvmod) associated_13\VBN|bupropion|- (r_amod) seizures_14\NNS|associated
D016642_D012892 NONE bupropion_9\NN|release (r_conj) deprivation_4\NN|sleep|and|bupropion
D016642_D012892 NONE bupropion_12\NN| (r_compound) use_13\NN|release|bupropion|and|deprivation (l_conj) deprivation_16\NN|sleep
D016642_D012892 NONE bupropion_11\NN| (r_npadvmod) associated_13\VBN|bupropion|- (r_amod) seizures_14\NNS|associated (r_pobj) of_10\IN|seizures (r_prep) risk_9\NN|the|of (r_pobj) to_7\IN|risk (r_prep) add_6\VB|that|deprivation|may|to (l_nsubj) deprivation_4\NN|sleep
15042318
D004317_C535648 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|doxorubicin|- (r_amod) chemotherapy_37\NN|based (r_pobj) of_33\IN|chemotherapy (r_prep) cycle_32\NN|one|of (r_pobj) following_30\VBG|cycle|in (r_prep) fibrillation_29\NN|sudden|atrial|following (r_conj) form_20\NN|the|common|of|,|and|fibrillation (r_appos) dystrophy_15\NN|diffuse|lymphoma|,|form (l_nmod) lymphoma_12\NN|cell|gastric|and|myotonic
D004317_D009223 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|doxorubicin|- (r_amod) chemotherapy_37\NN|based (r_pobj) of_33\IN|chemotherapy (r_prep) cycle_32\NN|one|of (r_pobj) following_30\VBG|cycle|in (r_prep) fibrillation_29\NN|sudden|atrial|following (r_conj) form_20\NN|the|common|of|,|and|fibrillation (r_appos) dystrophy_15\NN|diffuse|lymphoma|,|form
D004317_D009136 NONE doxorubicin_34\NN| (r_npadvmod) based_36\VBN|doxorubicin|- (r_amod) chemotherapy_37\NN|based (r_pobj) of_33\IN|chemotherapy (r_prep) cycle_32\NN|one|of (r_pobj) following_30\VBG|cycle|in (r_prep) fibrillation_29\NN|sudden|atrial|following (r_conj) form_20\NN|the|common|of|,|and|fibrillation (l_prep) of_21\IN|dystrophy (l_pobj) dystrophy_24\NN|adult|muscular
D004317_D001281 CID doxorubicin_34\NN| (r_npadvmod) based_36\VBN|doxorubicin|- (r_amod) chemotherapy_37\NN|based (r_pobj) of_33\IN|chemotherapy (r_prep) cycle_32\NN|one|of (r_pobj) following_30\VBG|cycle|in (r_prep) fibrillation_29\NN|sudden|atrial|following
8643966
D017239_D002289 NONE paclitaxel_11\NN| (r_pobj) with_10\IN|paclitaxel (r_prep) cancer_9\NN|advanced|inoperable|small|lung|with
D017239_D002289 NONE paclitaxel_6\NN| (r_compound) infusions_7\NNS|24-hour|paclitaxel|in (l_prep) in_8\IN|patients (l_pobj) patients_12\NNS|naive|with (l_prep) with_13\IN|iiib (l_pobj) IIIB_15\NNS|stage|or|cancer (l_conj) cancer_23\NN|iv|small|lung|(|nsclc|)
D017239_D002289 NONE paclitaxel_6\NN| (r_compound) infusions_7\NNS|24-hour|paclitaxel|in (l_prep) in_8\IN|patients (l_pobj) patients_12\NNS|naive|with (l_prep) with_13\IN|iiib (l_pobj) IIIB_15\NNS|stage|or|cancer (l_conj) cancer_23\NN|iv|small|lung|(|nsclc|) (l_appos) NSCLC_25\NNP|
D017239_D002289 NONE paclitaxel_9\NN| (r_compound) infusion_10\NN|a|3-hour|paclitaxel|in (l_prep) in_11\IN|trial (l_pobj) trial_15\NN|phase|ii|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|with (l_prep) with_18\IN|iiib (l_pobj) IIIB_21\NNS|stage|or|nsclc (l_conj) NSCLC_24\NNP|iv
D017239_D002289 NONE paclitaxel_5\NN| (r_pobj) with_4\IN|paclitaxel (r_prep) studies_3\NNS|ii|with|combined (l_acl) combined_6\VBN|with (l_prep) with_7\IN|drugs (l_pobj) drugs_9\NNS|other|active (l_amod) active_10\JJ|against (l_prep) against_11\IN|nsclc (l_pobj) NSCLC_12\NNP|
D017239_D002289 NONE paclitaxel_21\NN| (r_dobj) comparing_20\VBG|paclitaxel|with (r_acl) studies_19\NNS|iii|comparing (r_dobj) phase_17\NN|studies|remain (r_conj) indicated_14\VBN|phase|are|,|and|phase|. (l_nsubjpass) phase_1\NN|further|studies (l_dobj) studies_3\NNS|ii|with|combined (l_acl) combined_6\VBN|with (l_prep) with_7\IN|drugs (l_pobj) drugs_9\NNS|other|active (l_amod) active_10\JJ|against (l_prep) against_11\IN|nsclc (l_pobj) NSCLC_12\NNP|
D017239_D009369 NONE Paclitaxel_0\NNP|taxol|company (r_nsubj) demonstrated_15\VBN|paclitaxel|has|activity|. (l_dobj) activity_18\NN|significant|antineoplastic|against (l_prep) against_19\IN|types (l_pobj) types_22\NNS|different|tumor|,|carcinoma (l_compound) tumor_21\NN|
D017239_D009369 NONE Taxol_2\NNP|( (r_appos) Paclitaxel_0\NNP|taxol|company (r_nsubj) demonstrated_15\VBN|paclitaxel|has|activity|. (l_dobj) activity_18\NN|significant|antineoplastic|against (l_prep) against_19\IN|types (l_pobj) types_22\NNS|different|tumor|,|carcinoma (l_compound) tumor_21\NN|
D017239_D010051 NONE Paclitaxel_0\NNP|taxol|company (r_nsubj) demonstrated_15\VBN|paclitaxel|has|activity|. (l_dobj) activity_18\NN|significant|antineoplastic|against (l_prep) against_19\IN|types (l_pobj) types_22\NNS|different|tumor|,|carcinoma (l_appos) carcinoma_28\NN|ovarian|breast
D017239_D010051 NONE Taxol_2\NNP|( (r_appos) Paclitaxel_0\NNP|taxol|company (r_nsubj) demonstrated_15\VBN|paclitaxel|has|activity|. (l_dobj) activity_18\NN|significant|antineoplastic|against (l_prep) against_19\IN|types (l_pobj) types_22\NNS|different|tumor|,|carcinoma (l_appos) carcinoma_28\NN|ovarian|breast
D017239_D001943 NONE Paclitaxel_0\NNP|taxol|company (r_nsubj) demonstrated_15\VBN|paclitaxel|has|activity|. (l_dobj) activity_18\NN|significant|antineoplastic|against (l_prep) against_19\IN|types (l_pobj) types_22\NNS|different|tumor|,|carcinoma (l_appos) carcinoma_28\NN|ovarian|breast
D017239_D001943 NONE Taxol_2\NNP|( (r_appos) Paclitaxel_0\NNP|taxol|company (r_nsubj) demonstrated_15\VBN|paclitaxel|has|activity|. (l_dobj) activity_18\NN|significant|antineoplastic|against (l_prep) against_19\IN|types (l_pobj) types_22\NNS|different|tumor|,|carcinoma (l_appos) carcinoma_28\NN|ovarian|breast
D017239_D064420 NONE paclitaxel_9\NN| (r_compound) infusion_10\NN|a|3-hour|paclitaxel|in (r_pobj) of_6\IN|infusion (r_prep) efficacy_3\NN|the|and|toxicity|of (l_conj) toxicity_5\NN|
D017239_D064420 NONE Paclitaxel_0\NNP| (r_nsubj) is_1\VBZ|paclitaxel|thus|agent|,|with|. (l_prep) with_12\IN|infusion (l_pobj) infusion_15\NN|a|3-hour|proving (l_acl) proving_16\VBG|effective (l_oprd) effective_18\JJ|comparably|to (l_prep) to_19\IN|infusion (l_pobj) infusion_22\NN|a|24-hour|and|superior (l_conj) superior_24\JJ|in (l_prep) in_25\IN|terms (l_pobj) terms_26\NNS|of (l_prep) of_27\IN|incidence (l_pobj) incidence_29\NN|the|of (l_prep) of_30\IN|toxicity (l_pobj) toxicity_34\NN|hematologic
18405372
D012460_D056486 CID sulfasalazine_3\NN|in (r_pobj) with_2\IN|sulfasalazine (r_prep) associated_1\VBN|with (r_acl) Hepatotoxicity_0\NN|associated|:
D012460_D056486 CID sulfasalazine_7\NN| (r_pobj) on_6\IN|sulfasalazine (r_prep) had_4\VBD|who|hepatotoxicity|on|and|met (l_dobj) hepatotoxicity_5\NN|
D012460_D056486 CID sulfasalazine_6\NN| (r_pobj) with_5\IN|sulfasalazine (r_prep) hepatotoxicity_4\NN|with
D012460_D056486 CID sulfasalazine_7\NN| (r_pobj) with_6\IN|sulfasalazine (r_prep) hepatotoxicity_5\NN|serious|with
D012460_D056486 CID sulfasalazine_4\NN| (r_pobj) with_3\IN|sulfasalazine (r_prep) associated_2\VBN|with (r_acl) hepatotoxicity_1\NN|serious|associated
D012460_D001168 NONE sulfasalazine_3\NN|in (l_prep) in_4\IN|arthritis (l_pobj) arthritis_6\NN|inflammatory
16820346
C065179_D006973 NONE Atorvastatin_0\NNS| (r_nsubj) prevented_1\VBD|atorvastatin|and|reversed|. (l_conj) reversed_3\VBD|hypertension (l_dobj) hypertension_7\NN|induced|in
C065179_D006973 NONE atorvastatin_6\NN| (r_nmod) atorva_8\NN|atorvastatin|(|) (r_pobj) of_5\IN|atorva (r_prep) effects_4\NNS|the|antioxidant|of|on (l_prep) on_10\IN|dexamethasone (l_pobj) dexamethasone_11\NN|(|hypertension (l_appos) hypertension_14\NN|dex)-induced|,
C065179_D006973 NONE atorva_8\NN|atorvastatin|(|) (r_pobj) of_5\IN|atorva (r_prep) effects_4\NNS|the|antioxidant|of|on (l_prep) on_10\IN|dexamethasone (l_pobj) dexamethasone_11\NN|(|hypertension (l_appos) hypertension_14\NN|dex)-induced|,
C065179_D006973 NONE atorva_25\NN| (r_nmod) water_34\NN|atorva|kg|tap (r_pobj) with_24\IN|water (r_prep) treated_23\VBN|assess|rats|were|with|for|. (l_advcl) assess_1\VB|to|effects (l_dobj) effects_4\NNS|the|antioxidant|of|on (l_prep) on_10\IN|dexamethasone (l_pobj) dexamethasone_11\NN|(|hypertension (l_appos) hypertension_14\NN|dex)-induced|,
C065179_D006973 NONE Atorva_0\NN| (r_nsubj) reversed_1\VBN|atorva|hypertension|mmhg|,|vs.|mmhg|)|and|decreased (l_dobj) hypertension_5\NN|induced|+/-
C065179_D006973 NONE atorvastatin_2\NN| (r_nsubj) prevented_3\VBN|thus|,|atorvastatin|and|reversed|. (l_conj) reversed_5\VBN|hypertension (l_dobj) hypertension_9\NN|induced|in
D003907_D006973 CID dexamethasone_4\NN| (r_npadvmod) induced_6\VBN|dexamethasone|- (r_amod) hypertension_7\NN|induced|in
D003907_D006973 CID dexamethasone_11\NN|(|hypertension (l_appos) hypertension_14\NN|dex)-induced|,
D003907_D006973 CID dex)-induced_13\VBN| (r_amod) hypertension_14\NN|dex)-induced|,
D003907_D006973 CID dex_2\NN| (r_npadvmod) induced_4\VBN|dex|- (r_amod) hypertension_5\NN|induced|+/-
D003907_D006973 CID dexamethasone_6\NN| (r_npadvmod) induced_8\VBN|dexamethasone|- (r_amod) hypertension_9\NN|induced|in
D013481_D006973 NONE superoxide_25\RB| (r_advmod) decreased_23\VBD|plasma|superoxide (r_conj) reversed_1\VBN|atorva|hypertension|mmhg|,|vs.|mmhg|)|and|decreased (l_dobj) hypertension_5\NN|induced|+/-
16584858
C013592_D009203 NONE mangiferin_2\NN|on (l_prep) on_3\IN|alterations (l_pobj) alterations_5\NNS|biochemical|and|status|in (l_prep) in_9\IN|infarction (l_pobj) infarction_14\NN|induced|myocardial|in
C013592_D009203 NONE mangiferin_3\NN| (r_pobj) with_2\IN|mangiferin (r_prep) pretreatment_1\NN|with (r_pobj) Upon_0\IN|pretreatment (r_prep) suspended_9\VBN|upon|(|weight|in|given|protected|. (l_prep) given_17\VBN|intraperitoneally|for|to (l_prep) to_22\IN|rats (l_pobj) rats_24\NNS|mi (l_compound) MI_23\NNP|
C013592_D009203 NONE mangiferin_16\JJ| (r_compound) administration_17\NN|mangiferin (r_pobj) upon_15\IN|administration (r_prep) rose_13\VBD|tissue|significantly|upon|compared|. (l_prep) compared_19\VBN|as|to (l_prep) to_20\IN|rats (l_pobj) rats_25\NNS|induced|mi (l_compound) MI_24\NNP|
C013592_D009203 NONE mangiferin_8\NN| (r_nsubj) exerts_9\VBZ|that|mangiferin|effect|due (l_dobj) effect_12\NN|a|beneficial|against (l_prep) against_13\IN|mi (l_pobj) MI_17\NNP|induced
D007545_D009203 CID isoproterenol_10\NN| (r_npadvmod) induced_12\VBN|isoproterenol|- (r_amod) infarction_14\NN|induced|myocardial|in
D007545_D009203 CID isoproterenol_5\NN| (r_pobj) on_4\IN|isoproterenol (r_prep) infarction_9\NN|on|(|isph)-induced|myocardial|(|mi|)|in|through
D007545_D009203 CID isoproterenol_5\NN| (r_pobj) on_4\IN|isoproterenol (r_prep) infarction_9\NN|on|(|isph)-induced|myocardial|(|mi|)|in|through (l_appos) MI_11\NNP|
D007545_D009203 CID ISPH)-induced_7\JJ| (r_amod) infarction_9\NN|on|(|isph)-induced|myocardial|(|mi|)|in|through
D007545_D009203 CID ISPH)-induced_7\JJ| (r_amod) infarction_9\NN|on|(|isph)-induced|myocardial|(|mi|)|in|through (l_appos) MI_11\NNP|
D007545_D009203 CID ISPH_21\NNP| (r_npadvmod) induced_23\VBN|isph|- (r_amod) rats_25\NNS|induced|mi (l_compound) MI_24\NNP|
D007545_D009203 CID ISPH_14\NNP| (r_npadvmod) induced_16\VBN|isph|- (r_amod) MI_17\NNP|induced
D007545_D009202 NONE ISPH_3\NNP|(|weight|) (r_pobj) of_2\IN|isph (r_prep) injection_1\NN|subcutaneous|of|to (r_nsubj) caused_20\VBD|injection|damage|creatine (l_dobj) damage_22\NN|myocardial|in
D019344_D009202 NONE lactate_36\NN|serum (r_compound) dehydrogenase_37\NN|lactate|(|ldh|) (r_pobj) of_34\IN|dehydrogenase (r_prep) activity_33\NN|the|increased|of (r_pobj) by_30\IN|activity (r_agent) determined_29\VBN|which|was|by|and (r_relcl) heart_25\NN|rat|,|determined (r_pobj) in_23\IN|heart (r_prep) damage_22\NN|myocardial|in
D003401_D009202 NONE creatine_42\NN|isoenzymes (r_conj) caused_20\VBD|injection|damage|creatine (l_dobj) damage_22\NN|myocardial|in
D014527_D009202 NONE acid_53\NN| (r_compound) level_54\NN|uric|acid|and|capacity (r_dobj) increased_51\VBN|caused|,|level|. (l_ccomp) caused_20\VBD|injection|damage|creatine (l_dobj) damage_22\NN|myocardial|in
D007501_D009202 NONE iron_58\NN|plasma (r_nmod) capacity_60\NN|reduced|iron|binding (r_conj) level_54\NN|uric|acid|and|capacity (r_dobj) increased_51\VBN|caused|,|level|. (l_ccomp) caused_20\VBD|injection|damage|creatine (l_dobj) damage_22\NN|myocardial|in
C013592_D017202 NONE mangiferin_4\NN| (r_pobj) of_3\IN|mangiferin (r_prep) role_2\NN|the|protective|of (r_nsubjpass) analyzed_6\VBN|role|was|by|. (l_agent) by_7\IN|test (l_pobj) test_14\NN|chloride|ttc|used (l_acl) used_15\VBN|for (l_prep) for_16\IN|assay (l_pobj) assay_20\NN|macroscopic|mapping|of (l_prep) of_21\IN|myocardium (l_pobj) myocardium_24\NN|the|ischemic
C009591_D017202 NONE chloride_10\NN|triphenyl|tetrazolium (r_nmod) test_14\NN|chloride|ttc|used (l_acl) used_15\VBN|for (l_prep) for_16\IN|assay (l_pobj) assay_20\NN|macroscopic|mapping|of (l_prep) of_21\IN|myocardium (l_pobj) myocardium_24\NN|the|ischemic
C009591_D017202 NONE TTC_12\NNP|(|) (r_nmod) test_14\NN|chloride|ttc|used (l_acl) used_15\VBN|for (l_prep) for_16\IN|assay (l_pobj) assay_20\NN|macroscopic|mapping|of (l_prep) of_21\IN|myocardium (l_pobj) myocardium_24\NN|the|ischemic
D013481_D009203 NONE superoxide_7\JJ| (r_amod) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D005978_D009203 NONE glutathione_12\NN| (r_compound) peroxidase_13\NN|glutathione|,|transferase (r_conj) catalase_10\NNP|,|peroxidase (r_conj) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D005978_D009203 NONE glutathione_15\NN| (r_compound) transferase_16\NN|glutathione|and|activities (r_conj) peroxidase_13\NN|glutathione|,|transferase (r_conj) catalase_10\NNP|,|peroxidase (r_conj) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D005978_D009203 NONE glutathione_18\NN| (r_compound) reductase_19\NN|glutathione (r_compound) activities_20\NNS|reductase (r_conj) transferase_16\NN|glutathione|and|activities (r_conj) peroxidase_13\NN|glutathione|,|transferase (r_conj) catalase_10\NNP|,|peroxidase (r_conj) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D005978_D009203 NONE glutathione_36\NN| (r_conj) E_34\NN|vitamin|and|glutathione (r_conj) C_31\NN|vitamin|,|e (r_conj) cerruloplasmin_28\NN|,|c (r_pobj) as_27\IN|such|cerruloplasmin (r_prep) antioxidants_25\NNS|enzymic|as|levels (r_appos) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D001205_D009203 NONE C_31\NN|vitamin|,|e (r_conj) cerruloplasmin_28\NN|,|c (r_pobj) as_27\IN|such|cerruloplasmin (r_prep) antioxidants_25\NNS|enzymic|as|levels (r_appos) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D014810_D009203 NONE E_34\NN|vitamin|and|glutathione (r_conj) C_31\NN|vitamin|,|e (r_conj) cerruloplasmin_28\NN|,|c (r_pobj) as_27\IN|such|cerruloplasmin (r_prep) antioxidants_25\NNS|enzymic|as|levels (r_appos) dismutase_8\NN|superoxide|,|catalase|,|antioxidants (r_pobj) as_6\IN|such|dismutase (r_prep) enzymes_4\NNS|antioxidant|as (r_dobj) tissue_2\NN|heart|enzymes (r_nsubjpass) altered_39\VBN|tissue|were|in|. (l_prep) in_40\IN|rats (l_pobj) rats_42\NNS|mi (l_compound) MI_41\NNP|
D004121_D009203 NONE sulphoxide_15\RB|dimethyl (r_pobj) of_13\IN|sulphoxide (r_prep) ml_12\NNS|2|of|) (r_pobj) in_10\IN|ml (r_prep) suspended_9\VBN|upon|(|weight|in|given|protected|. (l_prep) given_17\VBN|intraperitoneally|for|to (l_prep) to_22\IN|rats (l_pobj) rats_24\NNS|mi (l_compound) MI_23\NNP|
C013592_D006331 NONE mangiferin_8\NN| (r_nsubj) exerts_9\VBZ|that|mangiferin|effect|due (l_prep) due_18\IN|to (l_pcomp) to_19\IN|potential (l_pobj) potential_22\NN|its|antioxidant|,|regulated (l_relcl) regulated_25\VBD|which|system|against (l_prep) against_30\IN|damage (l_pobj) damage_32\NN|cardiac
D007545_D006331 NONE ISPH_14\NNP| (r_npadvmod) induced_16\VBN|isph|- (r_amod) MI_17\NNP|induced (r_pobj) against_13\IN|mi (r_prep) effect_12\NN|a|beneficial|against (r_dobj) exerts_9\VBZ|that|mangiferin|effect|due (l_prep) due_18\IN|to (l_pcomp) to_19\IN|potential (l_pobj) potential_22\NN|its|antioxidant|,|regulated (l_relcl) regulated_25\VBD|which|system|against (l_prep) against_30\IN|damage (l_pobj) damage_32\NN|cardiac
15858223
D014635_D056486 CID acid_14\NN| (r_compound) metabolite_15\NN|acid (r_amod) levels_16\NNS|valproic|metabolite|in (r_conj) toxicity_10\NN|liver|,|and|levels
D014635_D056486 CID VPA_9\NNP| (r_npadvmod) associated_11\VBN|vpa|- (r_amod) stress_13\NN|associated|oxidative|and|hepatotoxicity|, (l_conj) hepatotoxicity_15\NN|
D014635_D056486 CID VPA_27\NNP|(|mg/kg|)|or|% (r_pobj) with_26\IN|vpa (r_prep) treated_24\VBN|determine|rats|were|ip|with|daily|for|. (l_advcl) determine_1\VB|to|was (l_ccomp) was_4\VBD|whether|there|relationship (l_attr) relationship_7\NN|a|temporal|between (l_prep) between_8\IN|stress (l_pobj) stress_13\NN|associated|oxidative|and|hepatotoxicity|, (l_conj) hepatotoxicity_15\NN|
D005978_D056486 NONE glutathione_11\NN|alpha|- (r_compound) transferase_14\NNP|glutathione|s|-|(|gst|) (r_pobj) of_8\IN|transferase (r_prep) levels_7\NNS|serum|of (r_pobj) on_5\IN|levels|and|by (r_prep) based_4\VBN|on (r_prep) evaluated_3\VBN|toxicity|was|based|. (l_nsubjpass) toxicity_1\NN|liver
D014635_D009336 CID VPA_6\NNP| (r_compound) results_8\NNS|that|vpa|treatment|in|,|measured (l_advcl) measured_14\VBN|as|by (l_agent) by_15\IN|levels (l_pobj) levels_16\NNS|of|,|precedes (l_relcl) precedes_21\VBZ|which|onset (l_dobj) onset_23\NN|the|of (l_prep) of_24\IN|necrosis (l_pobj) necrosis_25\NN|,|steatosis
D014635_D005234 CID VPA_6\NNP| (r_compound) results_8\NNS|that|vpa|treatment|in|,|measured (l_advcl) measured_14\VBN|as|by (l_agent) by_15\IN|levels (l_pobj) levels_16\NNS|of|,|precedes (l_relcl) precedes_21\VBZ|which|onset (l_dobj) onset_23\NN|the|of (l_prep) of_24\IN|necrosis (l_pobj) necrosis_25\NN|,|steatosis (l_conj) steatosis_27\NN|,|and|levels
C075750_D009336 NONE 15-F(2t)-IsoP_18\CD| (r_pobj) of_17\IN|15-f(2t)-isop (r_prep) levels_16\NNS|of|,|precedes (l_relcl) precedes_21\VBZ|which|onset (l_dobj) onset_23\NN|the|of (l_prep) of_24\IN|necrosis (l_pobj) necrosis_25\NN|,|steatosis
C075750_D005234 NONE 15-F(2t)-IsoP_18\CD| (r_pobj) of_17\IN|15-f(2t)-isop (r_prep) levels_16\NNS|of|,|precedes (l_relcl) precedes_21\VBZ|which|onset (l_dobj) onset_23\NN|the|of (l_prep) of_24\IN|necrosis (l_pobj) necrosis_25\NN|,|steatosis (l_conj) steatosis_27\NN|,|and|levels
16006300
D002119_D064420 NONE carbonate_1\NN|calcium (r_compound) toxicity_2\NN|carbonate|:|syndrome|.
D002119_D006934 CID carbonate_1\NN|calcium (r_compound) toxicity_2\NN|carbonate|:|syndrome|. (l_appos) syndrome_9\NN|the|updated|alkali|;|report
D002119_D006934 CID carbonate_6\NN|calcium (r_npadvmod) induced_8\VBN|carbonate|- (r_amod) hypercalcemia_9\NN|induced
D002119_D006934 CID carbonate_6\NN|calcium (r_npadvmod) induced_8\VBN|carbonate|- (r_amod) hypercalcemia_9\NN|induced (r_pobj) with_4\IN|hypercalcemia (r_prep) patients_3\NNS|3|with (r_dobj) describe_1\VB|to|patients|and|gain|. (l_conj) gain_11\VB|insights (l_dobj) insights_12\NNS|into (l_prep) into_13\IN|cause (l_pobj) cause_15\NN|the|and|management|of (l_prep) of_18\IN|syndrome (l_pobj) syndrome_23\NN|the|alkali
D002119_D006934 CID carbonate_23\NN|ingested|calcium (r_pobj) of_19\IN|carbonate (r_prep) amounts_18\NNS|small|of|in (r_pobj) by_16\IN|amounts (r_agent) precipitated_15\VBN|can|be|by (r_conj) be_5\VB|syndrome|may|cause|and|precipitated|. (l_nsubj) syndrome_3\NN|alkali
D002119_D006934 CID carbonate_23\NN|ingested|calcium (r_pobj) of_19\IN|carbonate (r_prep) amounts_18\NNS|small|of|in (r_pobj) by_16\IN|amounts (r_agent) precipitated_15\VBN|can|be|by (r_conj) be_5\VB|syndrome|may|cause|and|precipitated|. (l_attr) cause_8\NN|a|common|of (l_prep) of_9\IN|hypercalcemia (l_pobj) hypercalcemia_11\NN|unexplained
D002118_D006934 NONE calcium_18\NN|serum (r_dobj) corrected_16\VBN|(|calcium|>|and|review (r_parataxis) report_1\VBP|we|data|corrected|. (l_dobj) data_6\NNS|the|clinical|in (l_prep) in_7\IN|patients (l_pobj) patients_9\NNS|3|presented (l_relcl) presented_11\VBD|who|with (l_prep) with_12\IN|hypercalcemia (l_pobj) hypercalcemia_14\NN|severe
D002118_D006934 NONE calcium_18\NN|serum (r_dobj) corrected_16\VBN|(|calcium|>|and|review (l_conj) review_28\VB|literature (l_dobj) literature_31\NN|the|pertinent|on (l_prep) on_32\IN|syndrome (l_pobj) syndrome_36\NN|alkali
C097949_D058186 NONE D_27\JJ|1,25-dihydroxyvitamin (r_compound) concentrations_28\NNS|d (r_conj) peptide_23\NN|related|,|and|concentrations (r_conj) hormone_15\NN|low|parathyroid|(|pth|)|,|peptide (r_conj) alkalosis_10\NN|relative|metabolic|,|and|hormone (r_conj) insufficiency_6\NN|acute|renal|,|alkalosis
C097949_D000471 NONE D_27\JJ|1,25-dihydroxyvitamin (r_compound) concentrations_28\NNS|d (r_conj) peptide_23\NN|related|,|and|concentrations (r_conj) hormone_15\NN|low|parathyroid|(|pth|)|,|peptide (r_conj) alkalosis_10\NN|relative|metabolic|,|and|hormone
D002118_D006996 NONE calcium_7\NN|serum (r_compound) concentrations_8\NNS|the|higher|calcium|received (r_pobj) with_3\IN|concentrations (r_prep) patients_2\NNS|the|2|with (r_nsubj) pamidronate_10\JJ|patients|intravenously|mg|,|caused|. (l_relcl) caused_22\VBD|which|hypocalcemia (l_dobj) hypocalcemia_24\NN|severe
C019248_D006996 CID pamidronate_10\JJ|patients|intravenously|mg|,|caused|. (l_relcl) caused_22\VBD|which|hypocalcemia (l_dobj) hypocalcemia_24\NN|severe
C019248_D006996 CID Pamidronate_0\JJ| (r_compound) treatment_1\NN|pamidronate (r_nsubjpass) associated_3\VBN|treatment|is|with|,|in|. (l_prep) with_4\IN|risk (l_pobj) risk_6\NN|considerable|for (l_prep) for_7\IN|hypocalcemia (l_pobj) hypocalcemia_8\NN|
C019248_D006934 NONE Pamidronate_0\JJ| (r_compound) treatment_1\NN|pamidronate (r_nsubjpass) associated_3\VBN|treatment|is|with|,|in|. (l_prep) in_11\IN|even|cases (l_pobj) cases_12\NNS|of (l_prep) of_13\IN|hypercalcemia (l_pobj) hypercalcemia_16\NN|severe
15974569
D007608_D010146 NONE kainate_7\NN| (r_compound) antagonists_9\NNS|potent|glur5|kainate|receptor (r_compound) actives_10\NNS|antagonists|in (l_prep) in_11\IN|models (l_pobj) models_14\NNS|three|animal|of (l_prep) of_15\IN|pain (l_pobj) pain_16\NN|
D005557_D010146 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|formalin|- (r_amod) licking_21\NN|induced|paw (r_pobj) of_16\IN|licking (r_prep) reversal_15\NN|of|,|hyperalgesia (r_appos) models_11\NNS|three|of|:|reversal (l_prep) of_12\IN|pain (l_pobj) pain_13\NN|
D005557_D006930 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|formalin|- (r_amod) licking_21\NN|induced|paw (r_pobj) of_16\IN|licking (r_prep) reversal_15\NN|of|,|hyperalgesia (l_conj) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia
D005557_D006930 NONE formalin_17\NN| (r_npadvmod) induced_19\VBN|formalin|- (r_amod) licking_21\NN|induced|paw (r_pobj) of_16\IN|licking (r_prep) reversal_15\NN|of|,|hyperalgesia (l_conj) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia (l_conj) hyperalgesia_34\NN|induced|mechanical
D002351_D010146 NONE carrageenan_23\NN| (r_npadvmod) induced_25\VBN|carrageenan|- (r_amod) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia (r_conj) reversal_15\NN|of|,|hyperalgesia (r_appos) models_11\NNS|three|of|:|reversal (l_prep) of_12\IN|pain (l_pobj) pain_13\NN|
D002351_D006930 CID carrageenan_23\NN| (r_npadvmod) induced_25\VBN|carrageenan|- (r_amod) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia
D002351_D006930 CID carrageenan_23\NN| (r_npadvmod) induced_25\VBN|carrageenan|- (r_amod) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia (l_conj) hyperalgesia_34\NN|induced|mechanical
D002211_D010146 NONE capsaicin_30\NN| (r_npadvmod) induced_32\VBN|capsaicin|- (r_amod) hyperalgesia_34\NN|induced|mechanical (r_conj) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia (r_conj) reversal_15\NN|of|,|hyperalgesia (r_appos) models_11\NNS|three|of|:|reversal (l_prep) of_12\IN|pain (l_pobj) pain_13\NN|
D002211_D006930 CID capsaicin_30\NN| (r_npadvmod) induced_32\VBN|capsaicin|- (r_amod) hyperalgesia_34\NN|induced|mechanical (r_conj) hyperalgesia_27\NN|induced|thermal|,|and|hyperalgesia
D002211_D006930 CID capsaicin_30\NN| (r_npadvmod) induced_32\VBN|capsaicin|- (r_amod) hyperalgesia_34\NN|induced|mechanical
10414674
D007660_D013345 NONE ketoprofen_13\JJ|either|,|mg (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hemorrhage (l_pobj) hemorrhage_4\NN|aneurysmal|subarachnoid
D007660_D013345 NONE ketoprofen_13\JJ|either|,|mg (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_punct) (_5\-LRB-|sah (l_preconj) SAH_6\NNP|
D007660_D013345 NONE ketoprofen_13\JJ|either|,|mg (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (l_parataxis) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal
D007660_D013345 NONE ketoprofen_23\JJ| (r_compound) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hemorrhage (l_pobj) hemorrhage_4\NN|aneurysmal|subarachnoid
D007660_D013345 NONE ketoprofen_23\JJ| (r_compound) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_punct) (_5\-LRB-|sah (l_preconj) SAH_6\NNP|
D007660_D013345 NONE ketoprofen_23\JJ| (r_compound) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (l_parataxis) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal
D007660_D013345 NONE Ketoprofen_0\NNP|but|acetaminophen (l_conj) acetaminophen_3\RB|not|function|. (l_dobj) function_6\NN|impaired|platelet|in (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|sah (l_pobj) SAH_10\NNP|
D007660_D017542 NONE ketoprofen_13\JJ|either|,|mg (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (l_parataxis) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal (l_amod) aneurysmal_58\JJ|
D007660_D017542 NONE ketoprofen_23\JJ| (r_compound) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (l_parataxis) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal (l_amod) aneurysmal_58\JJ|
D000082_D013345 NONE acetaminophen_35\RB| (r_advmod) NSAID_33\NNP|a|weak|,|acetaminophen|, (r_conj) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hemorrhage (l_pobj) hemorrhage_4\NN|aneurysmal|subarachnoid
D000082_D013345 NONE acetaminophen_35\RB| (r_advmod) NSAID_33\NNP|a|weak|,|acetaminophen|, (r_conj) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_punct) (_5\-LRB-|sah (l_preconj) SAH_6\NNP|
D000082_D013345 NONE acetaminophen_35\RB| (r_advmod) NSAID_33\NNP|a|weak|,|acetaminophen|, (r_conj) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (l_parataxis) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal
D000082_D013345 NONE acetaminophen_45\NN| (r_compound) group_46\NN|acetaminophen|,|n|9 (r_nsubj) starting_52\VBG|(|group|immediately|after (r_parataxis) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_nsubjpass) Patients_0\NNS|with (l_prep) with_1\IN|hemorrhage (l_pobj) hemorrhage_4\NN|aneurysmal|subarachnoid
D000082_D013345 NONE acetaminophen_45\NN| (r_compound) group_46\NN|acetaminophen|,|n|9 (r_nsubj) starting_52\VBG|(|group|immediately|after (r_parataxis) receive_11\VB|to|ketoprofen|times|group|starting (r_xcomp) randomized_9\VBN|patients|(|)|were|receive|. (l_punct) (_5\-LRB-|sah (l_preconj) SAH_6\NNP|
D000082_D013345 NONE acetaminophen_45\NN| (r_compound) group_46\NN|acetaminophen|,|n|9 (r_nsubj) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal
D000082_D013345 NONE acetaminophen_3\RB|not|function|. (l_dobj) function_6\NN|impaired|platelet|in (l_prep) in_7\IN|patients (l_pobj) patients_8\NNS|with (l_prep) with_9\IN|sah (l_pobj) SAH_10\NNP|
D000082_D017542 NONE acetaminophen_35\RB| (r_advmod) NSAID_33\NNP|a|weak|,|acetaminophen|, (r_conj) group_24\NN|(|ketoprofen|,|n|9|)|or|nsaid|g|,|times (r_dobj) receive_11\VB|to|ketoprofen|times|group|starting (l_parataxis) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal (l_amod) aneurysmal_58\JJ|
D000082_D017542 NONE acetaminophen_45\NN| (r_compound) group_46\NN|acetaminophen|,|n|9 (r_nsubj) starting_52\VBG|(|group|immediately|after (l_prep) after_54\IN|diagnosis (l_pobj) diagnosis_56\NN|the|of (l_prep) of_57\IN|sah (l_pobj) SAH_59\NNP|aneurysmal (l_amod) aneurysmal_58\JJ|
D000244_D001791 NONE diphosphate_9\NN|adenosine (r_pobj) of_7\IN|diphosphate (r_prep) microM_6\NNS|6|of (r_pobj) by_4\IN|microm (r_prep) induced_3\VBN|aggregation|by|decreased|. (l_nsubj) aggregation_2\NN|maximal|platelet
D007660_D001791 CID ketoprofen_14\NN| (r_pobj) of_13\IN|ketoprofen (r_prep) administration_12\NN|of (r_pobj) after_11\IN|administration (r_prep) decreased_10\VBD|after (r_conj) induced_3\VBN|aggregation|by|decreased|. (l_nsubj) aggregation_2\NN|maximal|platelet
D000082_D001791 NONE acetaminophen_9\NN| (r_compound) group_10\NN|the|acetaminophen (r_pobj) in_7\IN|group (r_prep) increased_6\VBD|in|,|aggregation|in|on|compared|. (l_nsubj) aggregation_5\NN|maximal|platelet
D000082_D001791 NONE acetaminophen_9\NN| (r_compound) group_10\NN|the|acetaminophen (r_pobj) in_7\IN|group (r_prep) increased_6\VBD|in|,|aggregation|in|on|compared|. (l_advcl) compared_17\VBN|as|with (l_prep) with_18\IN|results (l_pobj) results_23\NNS|the|aggregation|(|p|) (l_compound) aggregation_22\NN|platelet
D007660_D006406 CID ketoprofen_4\JJ| (r_compound) group_5\NN|the|ketoprofen (r_pobj) in_2\IN|group (r_prep) patient_1\NN|one|in (r_nsubj) developed_6\VBD|patient|hematoma|. (l_dobj) hematoma_10\NN|a|postoperative|intracranial
D007660_D002532 NONE ketoprofen_1\NN| (r_nsubjpass) used_3\VBN|if|ketoprofen|is|before|on (l_prep) on_6\IN|aneurysms (l_pobj) aneurysms_9\NNS|cerebral|artery
D007660_D006470 NONE ketoprofen_1\NN| (r_nsubjpass) used_3\VBN|if|ketoprofen|is|before|on (r_advcl) pose_13\VB|used|,|it|may|factor|. (l_dobj) factor_17\NN|an|additional|risk|for (l_prep) for_18\IN|hemorrhage (l_pobj) hemorrhage_19\NN|
8106150
D007980_D004409 NONE dopa_7\NN|l|- (r_npadvmod) induced_9\VBN|dopa|- (r_amod) dyskinesias_10\NNS|induced|in
D007980_D004409 NONE DOPA_19\NNP|l|- (r_pobj) with_16\IN|dopa (r_prep) combination_15\NN|with (r_pobj) in_14\IN|combination (r_prep) tested_13\VBN|series|were|then|in|see|. (l_advcl) see_21\VB|to|modified (l_ccomp) modified_28\VBN|if|movements|would|be (l_nsubjpass) movements_25\NNS|the|dyskinetic (l_amod) dyskinetic_24\JJ|
D015632_D004409 NONE MPTP_12\NNP| (r_npadvmod) treated_14\VBN|mptp|- (r_amod) monkeys_15\NNS|treated (r_pobj) in_11\IN|monkeys (r_prep) dyskinesias_10\NNS|induced|in
D015632_D020734 CID MPTP_11\NNP|the|toxin (r_pobj) with_8\IN|mptp (r_prep) parkinsonian_7\NN|with
D004298_D004409 NONE dopamine_10\NN| (r_pobj) than_9\IN|dopamine (r_prep) other_8\JJ|than (r_amod) neurotransmitters_7\NNS|other (r_pobj) on_6\IN|neurotransmitters (r_prep) acting_4\VBG|primarily|on (r_acl) agents_3\NNS|acting (r_pobj) of_2\IN|agents (r_prep) series_1\NN|a|of (r_nsubjpass) tested_13\VBN|series|were|then|in|see|. (l_advcl) see_21\VB|to|modified (l_ccomp) modified_28\VBN|if|movements|would|be (l_nsubjpass) movements_25\NNS|the|dyskinetic (l_amod) dyskinetic_24\JJ|
D003000_D004409 NONE clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_dobj) movements_21\NNS|the|dyskinetic (l_amod) dyskinetic_20\JJ|
D003000_D020734 NONE clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_conj) at_23\IN|cost (l_pobj) cost_25\NN|the|of (l_prep) of_26\IN|return (l_pobj) return_28\NN|a|of (l_prep) of_29\IN|symptomatology (l_pobj) symptomatology_31\NN|parkinsonian (l_amod) parkinsonian_30\JJ|
D010830_D004409 NONE physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_dobj) movements_21\NNS|the|dyskinetic (l_amod) dyskinetic_20\JJ|
D010830_D020734 NONE physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_conj) at_23\IN|cost (l_pobj) cost_25\NN|the|of (l_prep) of_26\IN|return (l_pobj) return_28\NN|a|of (l_prep) of_29\IN|symptomatology (l_pobj) symptomatology_31\NN|parkinsonian (l_amod) parkinsonian_30\JJ|
D008784_D004409 NONE methysergide_8\NN|,|5-mdot|propranolol (r_conj) physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_dobj) movements_21\NNS|the|dyskinetic (l_amod) dyskinetic_20\JJ|
D008784_D020734 NONE methysergide_8\NN|,|5-mdot|propranolol (r_conj) physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_conj) at_23\IN|cost (l_pobj) cost_25\NN|the|of (l_prep) of_26\IN|return (l_pobj) return_28\NN|a|of (l_prep) of_29\IN|symptomatology (l_pobj) symptomatology_31\NN|parkinsonian (l_amod) parkinsonian_30\JJ|
-1_D004409 NONE 5-MDOT_10\CD| (r_conj) methysergide_8\NN|,|5-mdot|propranolol (r_conj) physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_dobj) movements_21\NNS|the|dyskinetic (l_amod) dyskinetic_20\JJ|
-1_D020734 NONE 5-MDOT_10\CD| (r_conj) methysergide_8\NN|,|5-mdot|propranolol (r_conj) physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_conj) at_23\IN|cost (l_pobj) cost_25\NN|the|of (l_prep) of_26\IN|return (l_pobj) return_28\NN|a|of (l_prep) of_29\IN|symptomatology (l_pobj) symptomatology_31\NN|parkinsonian (l_amod) parkinsonian_30\JJ|
D011433_D004409 NONE propranolol_12\NN|,|,|and (r_conj) methysergide_8\NN|,|5-mdot|propranolol (r_conj) physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_dobj) movements_21\NNS|the|dyskinetic (l_amod) dyskinetic_20\JJ|
D011433_D020734 NONE propranolol_12\NN|,|,|and (r_conj) methysergide_8\NN|,|5-mdot|propranolol (r_conj) physostigmine_6\NN|,|methysergide (r_conj) clonidine_4\NN|,|physostigmine (r_pobj) including_3\VBG|clonidine (r_prep) drugs_1\NNS|several|,|including (r_nsubj) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_conj) at_23\IN|cost (l_pobj) cost_25\NN|the|of (l_prep) of_26\IN|return (l_pobj) return_28\NN|a|of (l_prep) of_29\IN|symptomatology (l_pobj) symptomatology_31\NN|parkinsonian (l_amod) parkinsonian_30\JJ|
D016291_D004409 NONE MK-801_15\NNP| (r_punct) ,_16\,|mk-801 (r_punct) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_dobj) movements_21\NNS|the|dyskinetic (l_amod) dyskinetic_20\JJ|
D016291_D020734 NONE MK-801_15\NNP| (r_punct) ,_16\,|mk-801 (r_punct) reduced_18\VBD|drugs|,|markedly|movements|but|at|. (l_conj) at_23\IN|cost (l_pobj) cost_25\NN|the|of (l_prep) of_26\IN|return (l_pobj) return_28\NN|a|of (l_prep) of_29\IN|symptomatology (l_pobj) symptomatology_31\NN|parkinsonian (l_amod) parkinsonian_30\JJ|
D015016_D004409 NONE yohimbine_2\NN|and|meperidine (r_nsubj) reduced_5\VBN|however|,|yohimbine|predominantly|movements|. (l_dobj) movements_9\NNS|the|dyskinetic (l_amod) dyskinetic_8\JJ|
D008614_D004409 NONE meperidine_4\RB| (r_conj) yohimbine_2\NN|and|meperidine (r_nsubj) reduced_5\VBN|however|,|yohimbine|predominantly|movements|. (l_dobj) movements_9\NNS|the|dyskinetic (l_amod) dyskinetic_8\JJ|
D001418_D020821 NONE Baclofen_0\NNP| (r_nsubj) was_1\VBD|baclofen|also|useful|. (l_acomp) useful_3\JJ|in|against (l_prep) against_7\IN|form (l_pobj) form_11\NN|a|dystonic|of (l_amod) dystonic_10\JJ|more
D001418_D004409 NONE Baclofen_0\NNP| (r_nsubj) was_1\VBD|baclofen|also|useful|. (l_acomp) useful_3\JJ|in|against (l_prep) against_7\IN|form (l_pobj) form_11\NN|a|dystonic|of (l_prep) of_12\IN|dyskinesia (l_pobj) dyskinesia_13\NN|
D001285_D020821 NONE Atropine_0\NNP| (r_nsubj) converted_1\VBD|atropine|movements|into|. (l_dobj) movements_4\NNS|the|dystonic (l_amod) dystonic_3\JJ|
D001285_D002819 NONE Atropine_0\NNP| (r_nsubj) converted_1\VBD|atropine|movements|into|. (l_prep) into_5\IN|chorea (l_pobj) chorea_6\NN|
9579567
D013629_D001943 NONE tamoxifen_1\NN| (r_nsubjpass) used_4\VBN|since|tamoxifen|is|widely|in|and|proposed (l_prep) in_5\IN|treatment (l_pobj) treatment_8\NN|cancer (l_compound) cancer_7\NN|breast
D013629_D001943 NONE tamoxifen_1\NN| (r_nsubjpass) used_4\VBN|since|tamoxifen|is|widely|in|and|proposed (l_conj) proposed_12\VBN|has|been|for (l_prep) for_13\IN|prevention (l_pobj) prevention_15\NN|the|of (l_prep) of_16\IN|cancer (l_pobj) cancer_18\NN|breast
D013629_D001943 NONE tamoxifen_9\NN| (r_compound) use_10\NN|tamoxifen|or|treatments (r_conj) cancer_7\NN|endometrial|and|use (r_pobj) between_5\IN|cancer (r_prep) association_4\NN|the|between|treated (l_acl) treated_16\VBN|for|in (l_prep) for_17\IN|cancer (l_pobj) cancer_19\NN|breast
D013629_D001943 NONE tamoxifen_7\NN| (r_pobj) of_6\IN|tamoxifen (r_prep) role_5\NN|a|causal|of|in (r_dobj) suggest_2\VBP|results|role|,|used|. (l_advcl) used_14\VBN|particularly|when|proposed (l_xcomp) proposed_17\VBN|as|currently|for (l_prep) for_18\IN|prevention (l_pobj) prevention_21\NN|cancer (l_compound) cancer_20\NN|breast
D013629_D001943 NONE tamoxifen_3\NN| (r_dobj) receive_2\VBP|who|tamoxifen|for (l_prep) for_4\IN|cancer (l_pobj) cancer_6\NN|breast
D013629_D001943 NONE tamoxifen_12\NN| (r_pobj) of_11\IN|tamoxifen (r_prep) ratio_10\NN|the|benefit|of (r_pobj) of_5\IN|ratio (r_prep) evaluation_4\NN|a|term|of|as (l_prep) as_13\IN|treatment (l_pobj) treatment_16\NN|a|preventive|for (l_prep) for_17\IN|cancer (l_pobj) cancer_19\NN|breast
D013629_D016889 CID tamoxifen_9\NN| (r_compound) use_10\NN|tamoxifen|or|treatments (r_conj) cancer_7\NN|endometrial|and|use
D013629_D016889 CID tamoxifen_4\NN| (r_dobj) received_3\VBN|who|had|tamoxifen (r_relcl) Women_0\NNS|received (r_nsubj) were_5\VBD|women|likely|. (l_acomp) likely_8\JJ|more|have (l_xcomp) have_10\VB|to|cancer (l_dobj) cancer_12\NN|endometrial|diagnosed
D013629_D016889 CID tamoxifen_8\NN| (r_advmod) received_7\VBN|had|tamoxifen (r_conj) had_2\VBD|who|cancer|and|received (l_dobj) cancer_4\NN|endometrial
D013629_D016889 CID tamoxifen_8\NN| (r_advmod) received_7\VBN|had|tamoxifen (r_conj) had_2\VBD|who|cancer|and|received (r_relcl) Women_0\NNS|had (r_nsubj) had_9\VBD|women|disease|. (l_dobj) disease_12\NN|advanced|and|prognosis (l_conj) prognosis_15\NN|poorer|than (l_prep) than_16\IN|those (l_pobj) those_17\DT|with|received (l_prep) with_18\IN|cancer (l_pobj) cancer_20\NN|endometrial
D013629_D016889 CID tamoxifen_7\NN| (r_pobj) of_6\IN|tamoxifen (r_prep) role_5\NN|a|causal|of|in (l_prep) in_8\IN|cancer (l_pobj) cancer_10\NN|endometrial
D013629_D016889 CID tamoxifen_7\NN| (r_pobj) with_6\IN|tamoxifen (r_prep) treated_5\VBN|with (r_acl) women_4\NNS|treated (r_pobj) in_3\IN|women (r_prep) diagnosed_2\VBD|in (r_acl) cancers_1\NNS|endometrial|diagnosed
D013629_D020178 NONE tamoxifen_8\NN| (r_advmod) received_7\VBN|had|tamoxifen (r_conj) had_2\VBD|who|cancer|and|received (r_relcl) Women_0\NNS|had (r_nsubj) had_9\VBD|women|disease|. (l_dobj) disease_12\NN|advanced|and|prognosis
18589141
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|after|.
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|hit
D006493_D013921 CID Heparin_0\NNP| (r_npadvmod) induced_2\VBN|heparin|- (r_amod) thrombocytopenia_3\NN|induced|hit (l_appos) HIT_5\NNP|(|)
D006493_D013921 CID heparin_15\NN| (r_pobj) to_14\IN|heparin (r_prep) reaction_13\NN|an|adverse|mediated|to (r_attr) is_7\VBZ|thrombocytopenia|reaction|,|resulting|decreases|. (l_nsubj) thrombocytopenia_3\NN|induced|hit
D006493_D013921 CID heparin_15\NN| (r_pobj) to_14\IN|heparin (r_prep) reaction_13\NN|an|adverse|mediated|to (r_attr) is_7\VBZ|thrombocytopenia|reaction|,|resulting|decreases|. (l_nsubj) thrombocytopenia_3\NN|induced|hit (l_appos) HIT_5\NNP|(|)
D006493_D013921 CID 4/heparin_10\NN| (r_nummod) reactive_12\JJ|4/heparin|- (r_amod) antibody_13\NN|reactive (r_nmod) positivity_18\NN|antibody|(|antibody|)|in (r_conj) frequencies_1\NNS|the|of|after|positivity (l_prep) of_2\IN|hit (l_pobj) HIT_3\NN|
D006493_D013921 CID 4/heparin_10\NN| (r_nummod) reactive_12\JJ|4/heparin|- (r_amod) antibody_13\NN|reactive (r_nmod) positivity_18\NN|antibody|(|antibody|)|in (l_nmod) antibody_16\NN|hit (l_nmod) HIT_15\NNP|
D006493_D013921 CID UFH_7\NN| (r_npadvmod) related_9\VBN|ufh|- (r_amod) HIT_10\NN|related
D006493_D013927 NONE sodium_2\NN|unfractionated|heparin|(|ufh|)|or|heparin (r_nsubjpass) used_16\VBN|sodium|is|in|at|prevent|. (l_xcomp) prevent_24\VB|to|thrombosis|after (l_dobj) thrombosis_25\NN|
D006493_D013927 NONE UFH_4\NNP| (r_appos) sodium_2\NN|unfractionated|heparin|(|ufh|)|or|heparin (r_nsubjpass) used_16\VBN|sodium|is|in|at|prevent|. (l_xcomp) prevent_24\VB|to|thrombosis|after (l_dobj) thrombosis_25\NN|
D006495_D013927 NONE heparin_11\NN|molecular|weight|(|lmwh|) (r_conj) sodium_2\NN|unfractionated|heparin|(|ufh|)|or|heparin (r_nsubjpass) used_16\VBN|sodium|is|in|at|prevent|. (l_xcomp) prevent_24\VB|to|thrombosis|after (l_dobj) thrombosis_25\NN|
D006493_D001791 NONE heparin_1\NN| (r_npadvmod) induced_3\VBN|heparin|- (r_amod) test_6\NN|the|induced|aggregation (l_compound) aggregation_5\NN|platelet
8384253
D014750_D008228 NONE vincristine_10\NN| (r_pobj) with_9\IN|vincristine (r_prep) treated_8\VBN|patients|with|between|investigated|. (l_nsubj) patients_1\NNS|forty|with (l_prep) with_2\IN|lymphoma (l_pobj) Lymphoma_7\NNP|hodgkin
D014750_D008228 NONE vincristine_37\NN| (r_pobj) of_36\IN|vincristine (r_prep) effects_35\NNS|the|term|of|on (r_dobj) evaluate_31\VB|to|effects (r_acl) order_29\NN|evaluate (r_pobj) in_28\IN|order (r_prep) investigated_27\VBN|(|dose|were|in (r_parataxis) treated_8\VBN|patients|with|between|investigated|. (l_nsubj) patients_1\NNS|forty|with (l_prep) with_2\IN|lymphoma (l_pobj) Lymphoma_7\NNP|hodgkin
D014750_D009422 NONE vincristine_8\NN|the|mentioned (r_pobj) with_4\IN|vincristine (r_prep) are_17\VBP|that|with|signs|reversible (l_nsubj) signs_11\NNS|dose|schedule|and|symptoms (l_conj) symptoms_13\NNS|of (l_prep) of_14\IN|neuropathy (l_pobj) neuropathy_16\NN|vincristine
D014750_D009422 NONE vincristine_15\NN| (r_compound) neuropathy_16\NN|vincristine
15673851
D016202_D020760 NONE aspartate_10\NN|methyl|-|d|- (r_compound) receptors_11\NNS|spinal|aspartate (r_pobj) of_2\IN|receptors (r_prep) activation_1\NN|the|of (r_nsubj) contribute_13\VB|activation|may|to|. (l_prep) to_14\IN|degeneration (l_pobj) degeneration_15\NN|of|induced (l_acl) induced_20\VBN|by|after (l_prep) after_24\IN|interval (l_pobj) interval_27\NN|a|noninjurious|of (l_prep) of_28\IN|ischemia (l_pobj) ischemia_31\NN|cord
D016202_D020760 NONE NMDA_15\NNP| (r_compound) activation_17\NN|nmda|receptor (r_pobj) via_14\IN|activation (r_prep) ischemia_13\NN|cord|via
D009020_D020760 NONE morphine_23\NN|neuraxial (r_pobj) by_21\IN|morphine (r_agent) induced_20\VBN|by|after (l_prep) after_24\IN|interval (l_pobj) interval_27\NN|a|noninjurious|of (l_prep) of_28\IN|ischemia (l_pobj) ischemia_31\NN|cord
D016202_D001157 NONE aspartate_20\NNP|methyl|-|d|- (r_nmod) receptors_24\NNS|aspartate|(|nmda|) (r_pobj) of_13\IN|receptors (r_prep) activation_12\NN|of (r_conj) neurons_10\NNS|spinal|motor|and|activation (r_pobj) of_7\IN|neurons (r_prep) degeneration_6\NN|the|of|after|following (l_prep) following_28\VBG|interval (l_pobj) interval_31\NN|a|noninjurious|of (l_prep) of_32\IN|occlusion (l_pobj) occlusion_34\NN|aortic|in
D016202_D001157 NONE NMDA_22\NNP| (r_nmod) receptors_24\NNS|aspartate|(|nmda|) (r_pobj) of_13\IN|receptors (r_prep) activation_12\NN|of (r_conj) neurons_10\NNS|spinal|motor|and|activation (r_pobj) of_7\IN|neurons (r_prep) degeneration_6\NN|the|of|after|following (l_prep) following_28\VBG|interval (l_pobj) interval_31\NN|a|noninjurious|of (l_prep) of_32\IN|occlusion (l_pobj) occlusion_34\NN|aortic|in
D009020_D001157 NONE morphine_27\NN|neuraxial (r_pobj) after_25\IN|morphine (r_prep) degeneration_6\NN|the|of|after|following (l_prep) following_28\VBG|interval (l_pobj) interval_31\NN|a|noninjurious|of (l_prep) of_32\IN|occlusion (l_pobj) occlusion_34\NN|aortic|in
D016291_D020336 NONE MK-801_8\NNP| (r_punct) (_9\-LRB-|mk-801 (r_punct) mug_11\NN|(|30|)|on (l_prep) on_13\IN|changes (l_pobj) changes_16\NNS|the|histopathologic|in|after (l_prep) after_21\IN|paraparesis (l_pobj) paraparesis_26\NN|induced|spastic
D016291_D020336 NONE MK-801_1\NNP| (r_punct) reduced_3\VBD|it|mk-801|significantly|number|after|compared|. (l_prep) after_13\IN|paraparesis (l_pobj) paraparesis_18\NN|induced|spastic
D009020_D020336 CID morphine_22\NN| (r_npadvmod) induced_24\VBN|morphine|- (r_amod) paraparesis_26\NN|induced|spastic
D009020_D020336 CID morphine_14\NN| (r_npadvmod) induced_16\VBN|morphine|- (r_amod) paraparesis_18\NN|induced|spastic
D009020_D020336 CID morphine_5\NN|it (r_nsubj) induces_6\VBZ|that|morphine|paraparesis|with (l_dobj) paraparesis_8\NN|spastic
D018698_D020336 NONE glutamate_15\NN|csf|,|involved (r_pobj) in_13\IN|glutamate (r_prep) increase_12\NN|a|concomitant|in (r_pobj) with_9\IN|increase (r_prep) induces_6\VBZ|that|morphine|paraparesis|with (l_dobj) paraparesis_8\NN|spastic
D016202_D020336 NONE NMDA_21\NNP| (r_compound) activation_23\NN|nmda|receptor (r_pobj) in_20\IN|activation (r_prep) involved_19\VBN|which|is|in (r_relcl) glutamate_15\NN|csf|,|involved (r_pobj) in_13\IN|glutamate (r_prep) increase_12\NN|a|concomitant|in (r_pobj) with_9\IN|increase (r_prep) induces_6\VBZ|that|morphine|paraparesis|with (l_dobj) paraparesis_8\NN|spastic
D016202_D020258 NONE NMDA_15\NNP| (r_compound) activation_17\NN|nmda|receptor (r_pobj) via_14\IN|activation (r_prep) ischemia_13\NN|cord|via (r_pobj) of_10\IN|ischemia (r_prep) setting_9\NN|the|of (r_pobj) in_7\IN|setting (r_prep) be_5\VB|that|opioids|may|neurotoxic|in (l_acomp) neurotoxic_6\JJ|
20635749
D000638_D006333 NONE amiodarone_6\NN| (r_pobj) on_5\IN|amiodarone|presenting (r_prep) patient_4\NN|severe|failure|on|:|report|. (l_compound) failure_3\NN|heart
D000638_D006333 NONE amiodarone_10\NN| (r_npadvmod) induced_12\VBN|amiodarone|- (r_amod) hypothyroidism_13\NN|induced (r_pobj) to_9\IN|hypothyroidism (r_prep) coma_7\NN|secondary|to|in (l_prep) in_14\IN|patient (l_pobj) patient_16\NN|a|with (l_prep) with_17\IN|failure (l_pobj) failure_21\NN|severe|heart|chf
D000638_D006333 NONE amiodarone_10\NN| (r_npadvmod) induced_12\VBN|amiodarone|- (r_amod) hypothyroidism_13\NN|induced (r_pobj) to_9\IN|hypothyroidism (r_prep) coma_7\NN|secondary|to|in (l_prep) in_14\IN|patient (l_pobj) patient_16\NN|a|with (l_prep) with_17\IN|failure (l_pobj) failure_21\NN|severe|heart|chf (l_appos) CHF_23\NNP|(|)
D000638_D006333 NONE amiodarone_4\NN| (r_pobj) on_3\IN|amiodarone (r_prep) Patients_0\NNS|with|on (l_prep) with_1\IN|chf (l_pobj) CHF_2\NNP|
D000638_D006333 NONE amiodarone_13\NN|among (l_prep) among_14\IN|patients (l_pobj) patients_16\NNS|chf (l_compound) CHF_15\NNP|
D000638_D009230 CID amiodarone_6\NN| (r_pobj) on_5\IN|amiodarone|presenting (l_pcomp) presenting_7\VBG|with (l_prep) with_8\IN|coma (l_pobj) coma_10\NN|myxedemic
D000638_D009230 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|amiodarone|- (r_amod) hypothyroidism_13\NN|induced (r_pobj) to_9\IN|hypothyroidism (r_prep) coma_7\NN|secondary|to|in
D000638_D009230 CID amiodarone_19\NN| (r_compound) therapy_20\NN|term|amiodarone (r_pobj) during_16\IN|therapy (r_prep) report_12\NN|one|case|of|during (l_prep) of_13\IN|coma (l_pobj) coma_15\NN|myxedema
D000638_D003128 CID amiodarone_6\NN| (r_pobj) on_5\IN|amiodarone|presenting (l_pcomp) presenting_7\VBG|with (l_prep) with_8\IN|coma (l_pobj) coma_10\NN|myxedemic
D000638_D003128 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|amiodarone|- (r_amod) hypothyroidism_13\NN|induced (r_pobj) to_9\IN|hypothyroidism (r_prep) coma_7\NN|secondary|to|in
D000638_D003128 CID amiodarone_19\NN| (r_compound) therapy_20\NN|term|amiodarone (r_pobj) during_16\IN|therapy (r_prep) report_12\NN|one|case|of|during (l_prep) of_13\IN|coma (l_pobj) coma_15\NN|myxedema
D000638_D007037 CID amiodarone_10\NN| (r_npadvmod) induced_12\VBN|amiodarone|- (r_amod) hypothyroidism_13\NN|induced
D000638_D007037 CID amiodarone_4\NN| (r_pobj) on_3\IN|amiodarone (r_prep) Patients_0\NNS|with|on (r_nsubj) suffer_6\VB|patients|may|morbidity|,|and|deserve|. (l_dobj) morbidity_8\NN|serious|and|mortality|from (l_prep) from_11\IN|hypothyroidism (l_pobj) hypothyroidism_12\NN|
15565293
D004977_D009901 CID ethambutol_10\NN| (r_advmod) induced_12\VBN|ethambutol|- (r_amod) neuropathy_14\NN|induced|optic
D004977_D009901 CID ethambutol_14\NN| (r_advmod) induced_16\VBN|ethambutol|- (r_amod) neuropathy_18\NN|induced|optic
D004977_D009901 CID ethambutol_4\NN| (r_pobj) of_3\IN|ethambutol (r_prep) complication_2\NN|a|serious|of (r_nsubj) is_5\VBZ|complication|neuropathy|. (l_attr) neuropathy_8\NN|an|optic|impairs|,|sensitivity
D004977_D009901 CID ethambutol_6\NN| (r_amod) neuropathy_10\NN|ethambutol|(|optic|of|,|and
D004977_D009901 CID EMB)-induced_8\VBN| (r_amod) optic_9\JJ|emb)-induced (r_compound) neuropathy_10\NN|ethambutol|(|optic|of|,|and
D004977_D009901 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|emb|- (r_amod) neuropathy_10\NN|induced|optic
D004977_D009901 CID EMB_7\NNP| (r_npadvmod) induced_9\VBN|emb|- (r_amod) neuropathy_11\NN|induced|optic
D004977_D009901 CID EMB_7\NNP| (r_npadvmod) induced_9\VBN|emb|- (r_amod) neuropathy_11\NN|induced|optic
D004977_D009901 CID ethambutol_19\NN| (r_amod) dosing_20\VBG|ethambutol|in (r_dobj) manage_18\VB|to|properly|dosing|and|achieve (r_xcomp) important_15\JJ|manage (r_acomp) is_14\VBZ|additionally|,|in|,|it|important|reached|. (l_prep) in_2\IN|terms (l_pobj) terms_3\NNS|of (l_prep) of_4\IN|management (l_pobj) management_5\NN|of (l_prep) of_6\IN|neuropathy (l_pobj) neuropathy_11\NN|induced|optic
D004977_D009410 NONE ethambutol_14\NN| (r_advmod) induced_16\VBN|ethambutol|- (r_amod) neuropathy_18\NN|induced|optic (r_pobj) in_13\IN|neuropathy (r_prep) degeneration_12\NN|axonal|in|using
D004977_D014376 NONE Ethambutol_0\NNP| (r_nsubj) is_1\VBZ|ethambutol|agent|. (l_attr) agent_4\NN|an|antimycobacterial|used (l_acl) used_6\VBD|often|treat (l_xcomp) treat_8\VB|to|tuberculosis (l_dobj) tuberculosis_9\NN|
D004977_D014786 CID ethambutol_6\NN| (r_amod) neuropathy_10\NN|ethambutol|(|optic|of|,|and (r_pobj) of_5\IN|neuropathy (r_prep) history_4\NN|a|of (r_pobj) with_2\IN|history (r_prep) subjects_1\NNS|three|with (r_nsubjpass) administered_23\VBN|subjects|deficits|were|examination|. (l_nsubjpass) deficits_21\NNS|term|visual
D004977_D014786 CID EMB)-induced_8\VBN| (r_amod) optic_9\JJ|emb)-induced (r_compound) neuropathy_10\NN|ethambutol|(|optic|of|,|and (r_pobj) of_5\IN|neuropathy (r_prep) history_4\NN|a|of (r_pobj) with_2\IN|history (r_prep) subjects_1\NNS|three|with (r_nsubjpass) administered_23\VBN|subjects|deficits|were|examination|. (l_nsubjpass) deficits_21\NNS|term|visual
D004977_D014786 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|emb|- (r_amod) neuropathy_10\NN|induced|optic (r_pobj) of_5\IN|neuropathy (r_prep) history_4\NN|of (r_pobj) with_3\IN|history (r_prep) subjects_2\NNS|all|with (r_pobj) In_0\IN|subjects (r_prep) was_13\VBD|in|,|there|loss|,|with|. (l_attr) loss_16\NN|a|mean|of|in|with|,|loss|) (l_prep) with_32\IN|recovery (l_pobj) recovery_34\NN|eventual|of|with (l_prep) with_48\IN|deficits (l_pobj) deficits_51\NNS|intermediate|visual
D004977_D014786 CID EMB_6\NNP| (r_npadvmod) induced_8\VBN|emb|- (r_amod) neuropathy_10\NN|induced|optic (r_pobj) of_5\IN|neuropathy (r_prep) history_4\NN|of (r_pobj) with_3\IN|history (r_prep) subjects_2\NNS|all|with (r_pobj) In_0\IN|subjects (r_prep) was_13\VBD|in|,|there|loss|,|with|. (l_attr) loss_16\NN|a|mean|of|in|with|,|loss|) (l_conj) loss_55\NN|%|;|c (l_conj) C_58\NN|patient|,|with|,|loss (l_prep) with_60\IN|deficits (l_pobj) deficits_63\NNS|chronic|visual
D004977_D051437 NONE EMB_7\NNP| (r_npadvmod) induced_9\VBN|emb|- (r_amod) neuropathy_11\NN|induced|optic (r_pobj) of_6\IN|neuropathy (r_prep) management_5\NN|of (r_pobj) of_4\IN|management (r_prep) terms_3\NNS|of (r_pobj) in_2\IN|terms (r_prep) is_14\VBZ|additionally|,|in|,|it|important|reached|. (l_acomp) important_15\JJ|manage (l_xcomp) manage_18\VB|to|properly|dosing|and|achieve (l_dobj) dosing_20\VBG|ethambutol|in (l_prep) in_21\IN|patients (l_pobj) patients_22\NNS|with (l_prep) with_23\IN|impairment (l_pobj) impairment_25\NN|renal
D004977_D051437 NONE ethambutol_19\NN| (r_amod) dosing_20\VBG|ethambutol|in (l_prep) in_21\IN|patients (l_pobj) patients_22\NNS|with (l_prep) with_23\IN|impairment (l_pobj) impairment_25\NN|renal
18541230
D011692_D009401 CID aminonucleoside_6\JJ| (r_amod) nephrosis_7\NN|aminonucleoside|in
D011692_D009401 CID aminonucleoside_18\RB| (r_advmod) induced_20\VBN|aminonucleoside|- (r_amod) nephrosis_21\NN|puromycin|induced|,|is
D011692_D009404 NONE aminonucleoside_18\RB| (r_advmod) induced_20\VBN|aminonucleoside|- (r_amod) nephrosis_21\NN|puromycin|induced|,|is (l_relcl) is_24\VBZ|which|model (l_attr) model_27\NN|an|experimental|of (l_prep) of_28\IN|syndrome (l_pobj) syndrome_31\NN|human|nephrotic
D011692_D009404 NONE aminonucleoside_14\RB| (r_advmod) induced_16\VBN|aminonucleoside|- (r_amod) syndrome_18\NN|puromycin|induced|nephrotic
D011692_D006402 NONE aminonucleoside_6\NN| (r_advmod) induced_8\VBN|aminonucleoside|- (r_amod) abnormalities_10\NNS|induced|hematological
D011692_D007674 NONE aminonucleoside_1\RB| (r_advmod) induced_3\VBN|aminonucleoside|- (r_amod) dysfunction_5\NN|puromycin|induced|renal|and|hyperlipidemia
D011692_D006949 NONE aminonucleoside_1\RB| (r_advmod) induced_3\VBN|aminonucleoside|- (r_amod) dysfunction_5\NN|puromycin|induced|renal|and|hyperlipidemia (l_conj) hyperlipidemia_7\NN|
2893236
D005680_D012133 NONE GABA_0\NNP| (r_compound) involvement_1\NN|gaba|in (r_nsubj) induced_4\VBN|involvement|reversal|. (l_dobj) reversal_5\NN|of (l_prep) of_6\IN|paralysis (l_pobj) paralysis_8\NN|respiratory|produced
D005680_D012133 NONE GABA_13\NNP| (r_conj) glutamate_11\NN|and|gaba|levels (r_conj) paralysis_9\NN|respiratory|,|glutamate
D005680_D012133 NONE GABA_12\NNP| (r_dobj) involves_11\VBZ|gaba|in (r_conj) reverses_4\VBZ|naloxone|paralysis|and|involves (l_dobj) paralysis_6\NN|respiratory|produced
D009270_D012133 NONE naloxone_3\NN| (r_pobj) in_2\IN|naloxone (r_prep) involvement_1\NN|gaba|in (r_nsubj) induced_4\VBN|involvement|reversal|. (l_dobj) reversal_5\NN|of (l_prep) of_6\IN|paralysis (l_pobj) paralysis_8\NN|respiratory|produced
D009270_D012133 NONE naloxone_3\NN| (r_nsubj) reversed_4\VBD|in|naloxone|paralysis|. (l_dobj) paralysis_6\NN|respiratory|induced
D009270_D012133 NONE Naloxone_0\NN|(|mg/kg|,|i.v.|) (r_nsubj) reversed_7\VBD|naloxone|paralysis|control|. (l_dobj) paralysis_9\NN|respiratory|,|glutamate
D009270_D012133 NONE naloxone_3\NN| (r_nsubj) reverses_4\VBZ|naloxone|paralysis|and|involves (l_dobj) paralysis_6\NN|respiratory|produced
D013874_D012133 CID thiopental_11\NN| (r_pobj) by_10\IN|thiopental (r_agent) produced_9\VBN|by (r_acl) paralysis_8\NN|respiratory|produced
D013874_D012133 CID thiopental_9\NN|in (r_pobj) by_8\IN|thiopental (r_agent) induced_7\VBN|by (r_acl) paralysis_6\NN|respiratory|induced
D013874_D012133 CID thiopental_9\NN| (r_pobj) by_8\IN|thiopental (r_agent) produced_7\VBN|by (r_acl) paralysis_6\NN|respiratory|produced
D013874_D012131 NONE thiopental_4\NN| (r_npadvmod) produced_5\VBD|thiopental (r_amod) arrest_7\NN|mg/kg|,|i.v.|produced|respiratory|with
D005680_D012131 NONE GABA_12\NNP| (r_pobj) in_11\IN|gaba (r_prep) increase_10\NN|further|in|and|decrease (r_pobj) with_8\IN|increase (r_prep) arrest_7\NN|mg/kg|,|i.v.|produced|respiratory|with
D018698_D012131 NONE glutamate_16\NN| (r_pobj) in_15\IN|glutamate (r_prep) decrease_14\NN|in|again|in (r_conj) increase_10\NN|further|in|and|decrease (r_pobj) with_8\IN|increase (r_prep) arrest_7\NN|mg/kg|,|i.v.|produced|respiratory|with
D000596_D012131 NONE acids_29\NNS|the|amino|studied (r_pobj) of_26\IN|acids (r_prep) any_25\DT|of (r_dobj) affecting_24\VBG|any (r_pcomp) without_23\IN|affecting (r_prep) stem_22\NN|arrest|without|. (l_nsubj) arrest_7\NN|mg/kg|,|i.v.|produced|respiratory|with
D018698_D012133 NONE glutamate_11\NN|and|gaba|levels (r_conj) paralysis_9\NN|respiratory|,|glutamate
11284996
D009569_D006261 CID oxide_8\NN| (r_npadvmod) induced_10\VBN|oxide|- (r_amod) headache_11\NN|nitric|induced|in
D009569_D006261 CID oxide_6\NN|nitric|(|no|) (r_nsubj) induced_10\VBN|that|oxide|associated (l_ccomp) associated_17\VBN|headache|may|be|with (l_nsubjpass) headache_11\NN|in
D009569_D006261 CID NO_8\NNP| (r_intj) oxide_6\NN|nitric|(|no|) (r_nsubj) induced_10\VBN|that|oxide|associated (l_ccomp) associated_17\VBN|headache|may|be|with (l_nsubjpass) headache_11\NN|in
D009569_D006261 CID NO_17\JJ| (r_det) trinitrate_20\NN|the|no|glyceryl|(|gtn|) (r_pobj) by_15\IN|trinitrate (r_agent) induced_14\VBN|by|in (r_acl) headache_13\NN|induced
D009569_D006261 CID NO_5\RB| (r_intj) induced_7\VBN|no|- (r_amod) headache_9\NN|induced|immediate
D009569_D018781 NONE oxide_8\NN| (r_npadvmod) induced_10\VBN|oxide|- (r_amod) headache_11\NN|nitric|induced|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|headache (l_pobj) headache_19\NN|chronic|type
D009569_D018781 NONE NO_17\JJ| (r_det) trinitrate_20\NN|the|no|glyceryl|(|gtn|) (r_pobj) by_15\IN|trinitrate (r_agent) induced_14\VBN|by|in (l_prep) in_24\IN|patients (l_pobj) patients_26\NNS|16|with (l_prep) with_27\IN|headache (l_pobj) headache_32\NN|chronic|type|and|controls
D009569_D051270 NONE oxide_6\NN|nitric|(|no|) (r_nsubj) induced_10\VBN|that|oxide|associated (l_ccomp) associated_17\VBN|headache|may|be|with (l_nsubjpass) headache_11\NN|in (l_prep) in_12\IN|headaches (l_pobj) headaches_14\NNS|primary
D009569_D051270 NONE NO_8\NNP| (r_intj) oxide_6\NN|nitric|(|no|) (r_nsubj) induced_10\VBN|that|oxide|associated (l_ccomp) associated_17\VBN|headache|may|be|with (l_nsubjpass) headache_11\NN|in (l_prep) in_12\IN|headaches (l_pobj) headaches_14\NNS|primary
D005996_D006261 CID trinitrate_20\NN|the|no|glyceryl|(|gtn|) (r_pobj) by_15\IN|trinitrate (r_agent) induced_14\VBN|by|in (r_acl) headache_13\NN|induced
D005996_D006261 CID GTN_22\NNP| (r_appos) trinitrate_20\NN|the|no|glyceryl|(|gtn|) (r_pobj) by_15\IN|trinitrate (r_agent) induced_14\VBN|by|in (r_acl) headache_13\NN|induced
D005996_D006261 CID GTN_13\NNP|min|or|placebo (l_conj) placebo_15\NN|over (l_prep) over_16\IN|min (l_pobj) min_18\NN|20|on (l_prep) on_19\IN|days (l_pobj) days_24\NNS|two|free (l_amod) free_23\JJ|headache|- (l_npadvmod) headache_21\NN|
D005996_D006261 CID GTN_11\NNP| (r_compound) day_12\NN|the|gtn (r_pobj) on_9\IN|day (r_prep) headache_8\NN|stronger|immediate|on|than
D005996_D006261 CID GTN_11\NNP| (r_compound) day_12\NN|the|gtn (r_pobj) on_9\IN|day (r_prep) headache_8\NN|stronger|immediate|on|than (r_dobj) developed_4\VBD|patients|headache|and|was (l_conj) was_21\VBD|headache|pronounced|. (l_nsubj) headache_20\NN|the
D005996_D018781 NONE trinitrate_20\NN|the|no|glyceryl|(|gtn|) (r_pobj) by_15\IN|trinitrate (r_agent) induced_14\VBN|by|in (l_prep) in_24\IN|patients (l_pobj) patients_26\NNS|16|with (l_prep) with_27\IN|headache (l_pobj) headache_32\NN|chronic|type|and|controls
D005996_D018781 NONE GTN_22\NNP| (r_appos) trinitrate_20\NN|the|no|glyceryl|(|gtn|) (r_pobj) by_15\IN|trinitrate (r_agent) induced_14\VBN|by|in (l_prep) in_24\IN|patients (l_pobj) patients_26\NNS|16|with (l_prep) with_27\IN|headache (l_pobj) headache_32\NN|chronic|type|and|controls
17975693
D002939_D001008 CID ciprofloxacin-_5\JJ|and|treated (r_nmod) rats_10\NNS|ciprofloxacin- (r_nsubj) showed_11\VBD|that|rats|behaviour|in (l_dobj) behaviour_13\NN|anxious
D009643_D001008 CID norfloxacin_7\NNS| (r_npadvmod) treated_9\VBN|norfloxacin|- (r_conj) ciprofloxacin-_5\JJ|and|treated (r_nmod) rats_10\NNS|ciprofloxacin- (r_nsubj) showed_11\VBD|that|rats|behaviour|in (l_dobj) behaviour_13\NN|anxious
18161408
D002996_D009203 CID citrate_7\NN|clomiphene (r_pobj) with_5\IN|citrate (r_prep) associated_4\VBN|with|for (r_acl) infarction_1\NN|myocardial|in|associated|:|report|.
D002996_D009203 CID CC_13\NN|and|infarction (l_conj) infarction_16\NN|myocardial
D002996_D013923 CID CC_17\NN| (r_pobj) with_16\IN|cc (r_prep) induction_15\NN|ovulation|with (r_pobj) after_13\IN|induction (r_prep) reported_12\VBN|that|has|been|after (r_relcl) complication_8\NN|a|rare|reported (r_attr) is_1\VBZ|thromboembolism|complication|. (l_nsubj) Thromboembolism_0\NN|
D002996_D002637 NONE CC_12\NN| (r_dobj) received_11\VBN|woman|had|recently|cc|for|and|presented|. (l_conj) presented_17\VBD|with (l_prep) with_18\IN|pain (l_pobj) pain_20\NN|chest
D002996_D013927 NONE CC_9\NN| (r_pobj) of_8\IN|cc (r_prep) complication_7\NN|a|rare|of (r_attr) be_2\VB|thrombosis|might|complication|. (l_nsubj) Thrombosis_0\NN|
11999899
D012110_D009069 NONE Reserpine_0\NN|mg/kg|,|administered|, (r_nsubj) produced_15\VBD|reserpine|increases|. (l_dobj) increases_16\NNS|in (l_prep) in_17\IN|dyskinesia (l_pobj) dyskinesia_19\NN|orofacial|,|protrusion|,|are
D012110_D009069 NONE Reserpine_0\NN|mg/kg|, (r_nsubj) administered_6\VBN|reserpine|before|and|followed (r_ccomp) produce_29\VB|administered|,|did|not|dyskinesia|in|. (l_dobj) dyskinesia_31\NN|oral
D012110_D004409 CID Reserpine_0\NN|mg/kg|,|administered|, (r_nsubj) produced_15\VBD|reserpine|increases|. (l_dobj) increases_16\NNS|in (l_prep) in_17\IN|dyskinesia (l_pobj) dyskinesia_19\NN|orofacial|,|protrusion|,|are (l_relcl) are_30\VBP|which|signs (l_attr) signs_31\NNS|indicative (l_amod) indicative_32\JJ|of (l_prep) of_33\IN|dyskinesia (l_pobj) dyskinesia_35\NN|tardive
D012110_D004409 CID reserpine_4\NN| (r_nsubj) produces_5\VBZ|that|reserpine|movements (l_dobj) movements_9\NNS|different|,|related
D012110_D004409 CID reserpine_4\NN| (r_nsubj) produces_5\VBZ|that|reserpine|movements (l_dobj) movements_9\NNS|different|,|related (l_relcl) related_13\VBN|which|are|to|and|considered (l_conj) considered_22\VBN|can|be|as (l_prep) as_23\IN|signs (l_pobj) signs_30\NNS|parkinsonian|dsykinesia (l_compound) dsykinesia_29\NN|
D012110_D014202 CID Reserpine_0\NN| (r_nsubj) produced_2\VBD|reserpine|also|tremor|.|mk-801 (l_dobj) tremor_3\NN|and|catalepsy|,|are
D012110_D014202 CID reserpine_11\NN| (r_npadvmod) treated_13\VBN|reserpine|- (r_amod) mice_14\NNS|treated (r_pobj) in_10\IN|mice (r_prep) increase_7\NN|a|significant|of|in (l_prep) of_8\IN|tremor (l_pobj) tremor_9\NN|
D012110_D014202 CID reserpine_5\NN| (r_nsubj) induced_6\VBN|on|,|reserpine|increases|compared|.|mk-801 (l_dobj) increases_7\NNS|in (l_prep) in_8\IN|tremor (l_pobj) tremor_9\NN|and|catalepsy
D012110_D014202 CID reserpine_12\NN| (r_pobj) by_11\IN|reserpine (r_agent) induced_10\VBN|by (r_acl) catalepsy_7\NN|the|and|tremor|induced (l_conj) tremor_9\NN|
D012110_D014202 CID reserpine_2\NN| (r_pobj) with_1\IN|reserpine (r_prep) Pretreatment_0\NN|with|produced (l_acl) produced_13\VBD|(|mg/kg|h|before|test|increases|,|as|increases|,|reversed|. (l_conj) increases_26\NNS|in (l_prep) in_27\IN|tremor (l_pobj) tremor_28\NN|and|catalepsy
D012110_D014202 CID reserpine_48\NN| (r_pobj) of_47\IN|reserpine (r_prep) effects_46\NNS|the|of (r_dobj) reversed_44\VBD|whereas|min|before|test|effects (r_advcl) produced_13\VBD|(|mg/kg|h|before|test|increases|,|as|increases|,|reversed|. (l_conj) increases_26\NNS|in (l_prep) in_27\IN|tremor (l_pobj) tremor_28\NN|and|catalepsy
D012110_D002375 CID Reserpine_0\NN| (r_nsubj) produced_2\VBD|reserpine|also|tremor|.|mk-801 (l_dobj) tremor_3\NN|and|catalepsy|,|are (l_conj) catalepsy_5\NN|
D012110_D002375 CID reserpine_25\NN| (r_pobj) by_24\IN|reserpine (r_agent) induced_23\VBN|by (r_acl) movements_17\NNS|the|vacuous|chewing|,|protrusions|induced (l_conj) protrusions_20\NNS|tongue|and|catalepsy (l_conj) catalepsy_22\NN|
D012110_D002375 CID reserpine_5\NN| (r_nsubj) induced_6\VBN|on|,|reserpine|increases|compared|.|mk-801 (l_dobj) increases_7\NNS|in (l_prep) in_8\IN|tremor (l_pobj) tremor_9\NN|and|catalepsy (l_conj) catalepsy_11\NN|
D012110_D002375 CID reserpine_12\NN| (r_pobj) by_11\IN|reserpine (r_agent) induced_10\VBN|by (r_acl) catalepsy_7\NN|the|and|tremor|induced
D012110_D002375 CID reserpine_2\NN| (r_pobj) with_1\IN|reserpine (r_prep) Pretreatment_0\NN|with|produced (l_acl) produced_13\VBD|(|mg/kg|h|before|test|increases|,|as|increases|,|reversed|. (l_conj) increases_26\NNS|in (l_prep) in_27\IN|tremor (l_pobj) tremor_28\NN|and|catalepsy (l_conj) catalepsy_30\NN|
D012110_D002375 CID reserpine_48\NN| (r_pobj) of_47\IN|reserpine (r_prep) effects_46\NNS|the|of (r_dobj) reversed_44\VBD|whereas|min|before|test|effects (r_advcl) produced_13\VBD|(|mg/kg|h|before|test|increases|,|as|increases|,|reversed|. (l_conj) increases_26\NNS|in (l_prep) in_27\IN|tremor (l_pobj) tremor_28\NN|and|catalepsy (l_conj) catalepsy_30\NN|
D012110_D010300 NONE Reserpine_0\NN| (r_nsubj) produced_2\VBD|reserpine|also|tremor|.|mk-801 (l_dobj) tremor_3\NN|and|catalepsy|,|are (l_relcl) are_8\VBP|which|signs (l_attr) signs_9\NNS|suggestive (l_amod) suggestive_10\JJ|of (l_prep) of_11\IN|disease (l_pobj) disease_14\NN|parkinson
D012110_D010300 NONE reserpine_4\NN| (r_nsubj) produces_5\VBZ|that|reserpine|movements (l_dobj) movements_9\NNS|different|,|related (l_relcl) related_13\VBN|which|are|to|and|considered (l_conj) considered_22\VBN|can|be|as (l_prep) as_23\IN|signs (l_pobj) signs_30\NNS|parkinsonian|dsykinesia (l_amod) parkinsonian_24\JJ|-|like
D016291_D014202 NONE MK-801_16\NNP| (r_punct) produced_2\VBD|reserpine|also|tremor|.|mk-801 (l_dobj) tremor_3\NN|and|catalepsy|,|are
D016291_D014202 NONE MK-801_2\NNP| (r_punct) produced_4\VBD|however|,|mk-801|injection|increase|. (l_dobj) increase_7\NN|a|significant|of|in (l_prep) of_8\IN|tremor (l_pobj) tremor_9\NN|
D016291_D014202 NONE MK-801_17\NNP| (r_punct) induced_6\VBN|on|,|reserpine|increases|compared|.|mk-801 (l_dobj) increases_7\NNS|in (l_prep) in_8\IN|tremor (l_pobj) tremor_9\NN|and|catalepsy
D016291_D014202 NONE MK-801_33\NNP| (r_punct) injection_38\NN|mk-801|mg/kg|) (r_nsubj) min_40\NN|injection|90 (r_nsubj) reversed_44\VBD|whereas|min|before|test|effects (r_advcl) produced_13\VBD|(|mg/kg|h|before|test|increases|,|as|increases|,|reversed|. (l_conj) increases_26\NNS|in (l_prep) in_27\IN|tremor (l_pobj) tremor_28\NN|and|catalepsy
D016291_D002375 NONE MK-801_16\NNP| (r_punct) produced_2\VBD|reserpine|also|tremor|.|mk-801 (l_dobj) tremor_3\NN|and|catalepsy|,|are (l_conj) catalepsy_5\NN|
D016291_D002375 NONE MK-801_17\NNP| (r_punct) induced_6\VBN|on|,|reserpine|increases|compared|.|mk-801 (l_dobj) increases_7\NNS|in (l_prep) in_8\IN|tremor (l_pobj) tremor_9\NN|and|catalepsy (l_conj) catalepsy_11\NN|
D016291_D002375 NONE MK-801_33\NNP| (r_punct) injection_38\NN|mk-801|mg/kg|) (r_nsubj) min_40\NN|injection|90 (r_nsubj) reversed_44\VBD|whereas|min|before|test|effects (r_advcl) produced_13\VBD|(|mg/kg|h|before|test|increases|,|as|increases|,|reversed|. (l_conj) increases_26\NNS|in (l_prep) in_27\IN|tremor (l_pobj) tremor_28\NN|and|catalepsy (l_conj) catalepsy_30\NN|
D016291_D010300 NONE MK-801_16\NNP| (r_punct) produced_2\VBD|reserpine|also|tremor|.|mk-801 (l_dobj) tremor_3\NN|and|catalepsy|,|are (l_relcl) are_8\VBP|which|signs (l_attr) signs_9\NNS|suggestive (l_amod) suggestive_10\JJ|of (l_prep) of_11\IN|disease (l_pobj) disease_14\NN|parkinson
D001058_D009069 NONE apomophine_15\JJ| (r_amod) injection_16\NN|apomophine|min (r_pobj) by_14\IN|injection (r_agent) followed_13\VBN|by (r_conj) administered_6\VBN|reserpine|before|and|followed (r_ccomp) produce_29\VB|administered|,|did|not|dyskinesia|in|. (l_dobj) dyskinesia_31\NN|oral
D016202_D002375 NONE NMDA_5\NNP| (r_pobj) by_4\IN|nmda (r_agent) produced_3\VBN|by (r_acl) blockage_2\NN|the|glutamatergic|produced (r_nsubj) restore_7\VB|blockage|can|signs|according|. (l_dobj) signs_9\NNS|these|,|as (l_prep) as_12\IN|such|movements (l_pobj) movements_15\NNS|vacuous|chewing|,|protrusions (l_conj) protrusions_18\NNS|tongue|,|catalepsy (l_conj) catalepsy_20\NN|and|tremor
D016202_D014202 NONE NMDA_5\NNP| (r_pobj) by_4\IN|nmda (r_agent) produced_3\VBN|by (r_acl) blockage_2\NN|the|glutamatergic|produced (r_nsubj) restore_7\VB|blockage|can|signs|according|. (l_dobj) signs_9\NNS|these|,|as (l_prep) as_12\IN|such|movements (l_pobj) movements_15\NNS|vacuous|chewing|,|protrusions (l_conj) protrusions_18\NNS|tongue|,|catalepsy (l_conj) catalepsy_20\NN|and|tremor (l_conj) tremor_22\NN|
16563323
C071741_D009207 NONE Remifentanil_0\NNP| (r_compound) pretreatment_1\NN|remifentanil (r_nsubj) reduces_2\VBZ|pretreatment|myoclonus|etomidate|. (l_dobj) myoclonus_3\NN|
C071741_D009207 NONE remifentanil_13\NN| (r_nmod) kg_17\NNS|remifentanil|1|microg|/ (r_pobj) with_12\IN|kg (r_prep) pretreatment_11\NN|with|and|effect (l_conj) effect_20\NN|the|of|on|after (l_prep) on_23\IN|incidence (l_pobj) incidence_25\NN|the|of (l_prep) of_26\IN|myoclonus (l_pobj) myoclonus_27\NN|
C071741_D009207 NONE remifentanil_9\NN| (r_compound) group_10\NN|the|remifentanil|(|%|) (r_pobj) in_7\IN|group (r_prep) lower_6\JJR|significantly|in|than (r_acomp) was_4\VBD|incidence|lower|(|p|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|myoclonus (l_pobj) myoclonus_3\NN|
C071741_D009207 NONE remifentanil_2\NN|kg (r_pobj) with_1\IN|remifentanil (r_prep) Pretreatment_0\NN|with|myoclonus (l_appos) myoclonus_8\NN|reduced
D005045_D009207 CID etomidate_5\NN|after (r_advcl) reduces_2\VBZ|pretreatment|myoclonus|etomidate|. (l_dobj) myoclonus_3\NN|
D005045_D009207 CID etomidate_32\NN| (r_pobj) with_31\IN|etomidate (r_prep) induction_30\NN|with (r_amod) anesthesia_29\NN|induction (r_pobj) after_28\IN|anesthesia (r_prep) effect_20\NN|the|of|on|after (l_prep) on_23\IN|incidence (l_pobj) incidence_25\NN|the|of (l_prep) of_26\IN|myoclonus (l_pobj) myoclonus_27\NN|
D005045_D009207 CID etomidate_16\NN|after|administration (r_advcl) associated_8\VBN|in|,|patients|were|with|etomidate|. (l_prep) with_9\IN|incidence (l_pobj) incidence_12\NN|increased|of (l_prep) of_13\IN|myoclonus (l_pobj) myoclonus_14\NN|
D005045_D009207 CID etomidate_10\NN|pretreatment|after|induction|without|. (l_nsubj) Pretreatment_0\NN|with|myoclonus (l_appos) myoclonus_8\NN|reduced
D005045_D009207 CID etomidate_9\NN|after|administration (r_advcl) increased_2\VBD|experience|incidence|etomidate|. (l_dobj) incidence_3\NN|of (l_prep) of_4\IN|myoclonus (l_pobj) myoclonus_5\NN|than
C071741_D001049 NONE remifentanil_2\NN|kg (r_pobj) with_1\IN|remifentanil (r_prep) Pretreatment_0\NN|with|myoclonus (r_nsubj) etomidate_10\NN|pretreatment|after|induction|without|. (l_prep) without_12\IN|effects (l_pobj) effects_14\NNS|side|as (l_prep) as_16\IN|such|sedation (l_pobj) sedation_17\NN|,|apnea (l_conj) apnea_19\NN|,|nausea
C071741_D009325 NONE remifentanil_2\NN|kg (r_pobj) with_1\IN|remifentanil (r_prep) Pretreatment_0\NN|with|myoclonus (r_nsubj) etomidate_10\NN|pretreatment|after|induction|without|. (l_prep) without_12\IN|effects (l_pobj) effects_14\NNS|side|as (l_prep) as_16\IN|such|sedation (l_pobj) sedation_17\NN|,|apnea (l_conj) apnea_19\NN|,|nausea (l_conj) nausea_21\NN|,|or|pruritus
C071741_D011537 NONE remifentanil_2\NN|kg (r_pobj) with_1\IN|remifentanil (r_prep) Pretreatment_0\NN|with|myoclonus (r_nsubj) etomidate_10\NN|pretreatment|after|induction|without|. (l_prep) without_12\IN|effects (l_pobj) effects_14\NNS|side|as (l_prep) as_16\IN|such|sedation (l_pobj) sedation_17\NN|,|apnea (l_conj) apnea_19\NN|,|nausea (l_conj) nausea_21\NN|,|or|pruritus (l_conj) pruritus_24\NN|
D005045_D001049 NONE etomidate_10\NN|pretreatment|after|induction|without|. (l_prep) without_12\IN|effects (l_pobj) effects_14\NNS|side|as (l_prep) as_16\IN|such|sedation (l_pobj) sedation_17\NN|,|apnea (l_conj) apnea_19\NN|,|nausea
D005045_D009325 NONE etomidate_10\NN|pretreatment|after|induction|without|. (l_prep) without_12\IN|effects (l_pobj) effects_14\NNS|side|as (l_prep) as_16\IN|such|sedation (l_pobj) sedation_17\NN|,|apnea (l_conj) apnea_19\NN|,|nausea (l_conj) nausea_21\NN|,|or|pruritus
D005045_D011537 NONE etomidate_10\NN|pretreatment|after|induction|without|. (l_prep) without_12\IN|effects (l_pobj) effects_14\NNS|side|as (l_prep) as_16\IN|such|sedation (l_pobj) sedation_17\NN|,|apnea (l_conj) apnea_19\NN|,|nausea (l_conj) nausea_21\NN|,|or|pruritus (l_conj) pruritus_24\NN|
1711760
D007530_D006973 NONE isoflurane_1\JJ| (r_amod) anesthesia_2\NN|isoflurane (r_pobj) Under_0\IN|anesthesia (r_prep) occluded_12\VBN|under|,|mca|was|. (l_nsubjpass) MCA_5\NNP|the|of (l_prep) of_6\IN|14|rats (l_pobj) rats_10\NNS|hypertensive (l_amod) hypertensive_9\JJ|spontaneously
C009591_D009410 NONE 2,3,5-triphenyltetrazolium_8\CD| (r_nummod) staining_9\VBG|2,3,5-triphenyltetrazolium (r_pobj) by_7\IN|staining (r_agent) determined_6\VBN|extent|was|by|. (l_nsubjpass) extent_1\NN|the|of (l_prep) of_2\IN|injury (l_pobj) injury_4\NN|neuronal
D010656_D006973 CID phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced
D010656_D020244 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced (r_nsubj) instituted_8\VBD|that|hypertension|h|aggravate|, (l_advcl) aggravate_15\VB|after|mcao|does|not|edema (l_nsubj) MCAO_12\NNP|
D010656_D004487 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced (r_nsubj) instituted_8\VBD|that|hypertension|h|aggravate|, (l_advcl) aggravate_15\VB|after|mcao|does|not|edema (l_dobj) edema_16\NN|in|improves
D010656_D004487 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced (r_nsubj) instituted_8\VBD|that|hypertension|h|aggravate|, (l_advcl) aggravate_15\VB|after|mcao|does|not|edema (l_dobj) edema_16\NN|in|improves (l_acl) improves_24\VBZ|that|it|edema|,|and|reduces (l_dobj) edema_25\NN|in
D010656_D007511 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced (r_nsubj) instituted_8\VBD|that|hypertension|h|aggravate|, (l_advcl) aggravate_15\VB|after|mcao|does|not|edema (l_dobj) edema_16\NN|in|improves (l_prep) in_17\IN|core (l_pobj) core_20\NN|the|ischemic (l_amod) ischemic_19\JJ|
D010656_D007511 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced (r_nsubj) instituted_8\VBD|that|hypertension|h|aggravate|, (l_advcl) aggravate_15\VB|after|mcao|does|not|edema (l_dobj) edema_16\NN|in|improves (l_acl) improves_24\VBZ|that|it|edema|,|and|reduces (l_dobj) edema_25\NN|in (l_prep) in_26\IN|periphery (l_pobj) periphery_28\NN|the|of (l_prep) of_29\IN|territory (l_pobj) territory_32\NN|the|ischemic (l_amod) ischemic_31\JJ|
D010656_D009410 NONE phenylephrine_4\NN| (r_npadvmod) induced_6\VBN|phenylephrine|- (r_amod) hypertension_7\NN|induced (r_nsubj) instituted_8\VBD|that|hypertension|h|aggravate|, (l_advcl) aggravate_15\VB|after|mcao|does|not|edema (l_dobj) edema_16\NN|in|improves (l_acl) improves_24\VBZ|that|it|edema|,|and|reduces (l_conj) reduces_37\VBZ|that|it|area (l_dobj) area_39\NN|the|of (l_prep) of_40\IN|dysfunction (l_pobj) dysfunction_43\NN|histochemical|neuronal
873132
D003840_D002779 NONE acid_9\NN|deoxycholic (r_pobj) of_7\IN|acid (r_prep) hydroxylation_6\NN|7alpha|-|of|in (r_dobj) decreased_3\VBD|sulfation|hydroxylation|cholestasis|. (l_dobj) cholestasis_15\NN|induced|in
D004997_D002779 CID estradiol_12\NN| (r_npadvmod) induced_14\VBN|estradiol|- (r_amod) cholestasis_15\NN|induced|in
18201582
C084178_D006973 NONE telmisartan_32\NN|and|amlodipine|versus (r_pobj) of_31\IN|telmisartan|monotherapy (r_prep) combination_30\NN|a|dose|of|with (l_prep) with_41\IN|hypertension (l_pobj) hypertension_44\NN|ii
C084178_D006973 NONE telmisartan_23\NNP| (r_pobj) of_22\IN|telmisartan (r_prep) combination_18\NN|a|new|dose|(|fdc|)|of (r_pobj) of_12\IN|combination (r_prep) efficacy_9\NN|the|and|tolerability|of (r_dobj) evaluate_7\VB|to|efficacy|mg|+|amlodipine (l_conj) amlodipine_27\NN|mg|)|compared (l_prep) compared_33\VBN|with (l_prep) with_34\IN|amlodipine (l_pobj) amlodipine_35\NN|monotherapy (l_appos) monotherapy_37\NN|5-mg|a|in (l_prep) in_41\IN|patients (l_pobj) patients_44\NNS|adult|indian|with (l_prep) with_45\IN|hypertension (l_pobj) hypertension_48\NN|ii
D017311_D006973 NONE amlodipine_34\NN| (r_conj) telmisartan_32\NN|and|amlodipine|versus (r_pobj) of_31\IN|telmisartan|monotherapy (r_prep) combination_30\NN|a|dose|of|with (l_prep) with_41\IN|hypertension (l_pobj) hypertension_44\NN|ii
D017311_D006973 NONE amlodipine_36\NN| (r_pobj) versus_35\IN|amlodipine (r_prep) telmisartan_32\NN|and|amlodipine|versus (r_pobj) of_31\IN|telmisartan|monotherapy (r_prep) combination_30\NN|a|dose|of|with (l_prep) with_41\IN|hypertension (l_pobj) hypertension_44\NN|ii
D017311_D006973 NONE amlodipine_27\NN|mg|)|compared (l_prep) compared_33\VBN|with (l_prep) with_34\IN|amlodipine (l_pobj) amlodipine_35\NN|monotherapy (l_appos) monotherapy_37\NN|5-mg|a|in (l_prep) in_41\IN|patients (l_pobj) patients_44\NNS|adult|indian|with (l_prep) with_45\IN|hypertension (l_pobj) hypertension_48\NN|ii
D017311_D006973 NONE amlodipine_35\NN|monotherapy (l_appos) monotherapy_37\NN|5-mg|a|in (l_prep) in_41\IN|patients (l_pobj) patients_44\NNS|adult|indian|with (l_prep) with_45\IN|hypertension (l_pobj) hypertension_48\NN|ii
11337188
D010068_D018366 CID oxacillin_5\NN| (r_pobj) with_4\IN|oxacillin (r_prep) associated_3\VBN|with (r_acl) vasculitis_2\NN|cutaneous|leucocytoclastic|associated|.
D010068_D018366 CID Oxacillin_0\NNP| (r_nsubjpass) included_3\VBN|oxacillin|should|be|among|. (l_prep) among_4\IN|drugs (l_pobj) drugs_6\NNS|the|cause (l_relcl) cause_9\VB|that|can|vasculitis (l_dobj) vasculitis_11\NN|leucocytoclastic
D010068_D013203 NONE oxacillin_9\NN| (r_pobj) with_8\IN|oxacillin (r_prep) treated_7\VBN|who|was|with|for|because (l_prep) because_13\IN|of|bacteremia (l_pobj) bacteremia_17\NN|aureus|,
D010068_D016470 NONE oxacillin_9\NN| (r_pobj) with_8\IN|oxacillin (r_prep) treated_7\VBN|who|was|with|for|because (l_prep) because_13\IN|of|bacteremia (l_pobj) bacteremia_17\NN|aureus|,
D010068_D051437 CID oxacillin_9\NN| (r_pobj) with_8\IN|oxacillin (r_prep) treated_7\VBN|who|was|with|for|because (r_relcl) man_4\NN|a|old|treated (r_nsubj) developed_19\VBD|man|failure|. (l_dobj) failure_21\NN|renal|and|diffuse|,|lesions
D010068_D011693 NONE oxacillin_9\NN| (r_pobj) with_8\IN|oxacillin (r_prep) treated_7\VBN|who|was|with|for|because (r_relcl) man_4\NN|a|old|treated (r_nsubj) developed_19\VBD|man|failure|. (l_dobj) failure_21\NN|renal|and|diffuse|,|lesions (l_appos) lesions_29\NNS|symmetric|,|palpable|purpuric|on
8677458
D015080_D006470 CID mesna_4\NN| (r_pobj) of_3\IN|mesna (r_prep) administration_2\NN|continuous|subcutaneous|of|prevent|. (l_relcl) prevent_6\VB|to|cystitis (l_dobj) cystitis_11\NN|induced|hemorrhagic
D015080_D006470 CID mesna_15\NN| (r_dobj) administering_14\VBG|mesna|along (r_pcomp) by_13\IN|administering (r_agent) prevented_12\VBN|that|can|be|by (r_relcl) toxicity_6\NN|a|major|potential|of|prevented (r_attr) is_2\VBZ|cystitis|toxicity|. (l_nsubj) cystitis_1\NN|hemorrhagic
D015080_D003556 CID mesna_4\NN| (r_pobj) of_3\IN|mesna (r_prep) administration_2\NN|continuous|subcutaneous|of|prevent|. (l_relcl) prevent_6\VB|to|cystitis (l_dobj) cystitis_11\NN|induced|hemorrhagic
D015080_D003556 CID mesna_15\NN| (r_dobj) administering_14\VBG|mesna|along (r_pcomp) by_13\IN|administering (r_agent) prevented_12\VBN|that|can|be|by (r_relcl) toxicity_6\NN|a|major|potential|of|prevented (r_attr) is_2\VBZ|cystitis|toxicity|. (l_nsubj) cystitis_1\NN|hemorrhagic
D007069_D006470 CID ifosfamide_7\RB| (r_advmod) induced_9\VBN|ifosfamide|- (r_amod) cystitis_11\NN|induced|hemorrhagic
D007069_D006470 CID ifosfamide_8\NN| (r_pobj) of_7\IN|ifosfamide (r_prep) toxicity_6\NN|a|major|potential|of|prevented (r_attr) is_2\VBZ|cystitis|toxicity|. (l_nsubj) cystitis_1\NN|hemorrhagic
D007069_D003556 CID ifosfamide_7\RB| (r_advmod) induced_9\VBN|ifosfamide|- (r_amod) cystitis_11\NN|induced|hemorrhagic
D007069_D003556 CID ifosfamide_8\NN| (r_pobj) of_7\IN|ifosfamide (r_prep) toxicity_6\NN|a|major|potential|of|prevented (r_attr) is_2\VBZ|cystitis|toxicity|. (l_nsubj) cystitis_1\NN|hemorrhagic
D007069_D064420 NONE ifosfamide_8\NN| (r_pobj) of_7\IN|ifosfamide (r_prep) toxicity_6\NN|a|major|potential|of|prevented
D015080_D064420 NONE mesna_15\NN| (r_dobj) administering_14\VBG|mesna|along (r_pcomp) by_13\IN|administering (r_agent) prevented_12\VBN|that|can|be|by (r_relcl) toxicity_6\NN|a|major|potential|of|prevented
D015080_D014839 NONE mesna_19\NN|urinary (r_compound) concentrations_20\NNS|inadequate|mesna|,|as (l_prep) as_23\IN|such|in (l_prep) in_24\IN|patient (l_pobj) patient_26\NN|a|taking|experiences (l_relcl) experiences_31\VBZ|who|emesis|and|is (l_dobj) emesis_36\NN|severe|induced
D015080_D014839 NONE mesna_29\NN|oral (r_dobj) taking_27\VBG|mesna (r_acl) patient_26\NN|a|taking|experiences (l_relcl) experiences_31\VBZ|who|emesis|and|is (l_dobj) emesis_36\NN|severe|induced
D007069_D014839 NONE ifosfamide_33\RB| (r_advmod) induced_35\VBN|ifosfamide|- (r_amod) emesis_36\NN|severe|induced
19135948
C107135_D006086 NONE everolimus_8\NN|and|tacrolimus (r_pobj) with_7\IN|everolimus (r_prep) prophylaxis_6\VBN|graft|disease|with (l_compound) disease_5\NN|
C107135_D006504 CID everolimus_8\NN|and|tacrolimus (r_pobj) with_7\IN|everolimus (r_prep) prophylaxis_6\VBN|graft|disease|with (r_nsubjpass) associated_12\VBN|prophylaxis|is|with|and|microangiopathy|. (l_prep) with_13\IN|incidence (l_pobj) incidence_16\NN|a|high|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_20\NN|sinusoidal|obstruction
C107135_D014652 CID everolimus_8\NN|and|tacrolimus (r_pobj) with_7\IN|everolimus (r_prep) prophylaxis_6\VBN|graft|disease|with (r_nsubjpass) associated_12\VBN|prophylaxis|is|with|and|microangiopathy|. (l_conj) microangiopathy_22\NN|:|results
D016559_D006086 NONE tacrolimus_10\NN| (r_conj) everolimus_8\NN|and|tacrolimus (r_pobj) with_7\IN|everolimus (r_prep) prophylaxis_6\VBN|graft|disease|with (l_compound) disease_5\NN|
D016559_D006504 CID tacrolimus_10\NN| (r_conj) everolimus_8\NN|and|tacrolimus (r_pobj) with_7\IN|everolimus (r_prep) prophylaxis_6\VBN|graft|disease|with (r_nsubjpass) associated_12\VBN|prophylaxis|is|with|and|microangiopathy|. (l_prep) with_13\IN|incidence (l_pobj) incidence_16\NN|a|high|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_20\NN|sinusoidal|obstruction
D016559_D014652 CID tacrolimus_10\NN| (r_conj) everolimus_8\NN|and|tacrolimus (r_pobj) with_7\IN|everolimus (r_prep) prophylaxis_6\VBN|graft|disease|with (r_nsubjpass) associated_12\VBN|prophylaxis|is|with|and|microangiopathy|. (l_conj) microangiopathy_22\NN|:|results
D008727_D006086 NONE methotrexate_5\NNP| (r_pobj) with_4\IN|methotrexate (r_prep) combined_3\VBN|with (r_acl) inhibitor_2\NN|a|calcineurin|combined (r_nsubj) is_6\VBZ|inhibitor|prophylaxis|. (l_attr) prophylaxis_9\NN|the|standard|for|after (l_prep) for_10\IN|disease (l_pobj) disease_16\NN|graft|(|gvhd|)
D008727_D006086 NONE methotrexate_5\NNP| (r_pobj) with_4\IN|methotrexate (r_prep) combined_3\VBN|with (r_acl) inhibitor_2\NN|a|calcineurin|combined (r_nsubj) is_6\VBZ|inhibitor|prophylaxis|. (l_attr) prophylaxis_9\NN|the|standard|for|after (l_prep) for_10\IN|disease (l_pobj) disease_16\NN|graft|(|gvhd|) (l_appos) GVHD_18\NNP|
C107135_D009190 NONE everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing
C107135_D009190 NONE everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing (l_appos) leukemia_33\NN|(|mds|myeloid|(|aml|) (l_nmod) MDS_24\NNP|;|n|17|or|acute
C107135_D015470 NONE everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing (l_appos) leukemia_33\NN|(|mds|myeloid|(|aml|)
C107135_D015470 NONE everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing (l_appos) leukemia_33\NN|(|mds|myeloid|(|aml|) (l_appos) AML_35\NNP|;|n|7
D016559_D009190 NONE tacrolimus_8\NN| (r_conj) everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing
D016559_D009190 NONE tacrolimus_8\NN| (r_conj) everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing (l_appos) leukemia_33\NN|(|mds|myeloid|(|aml|) (l_nmod) MDS_24\NNP|;|n|17|or|acute
D016559_D015470 NONE tacrolimus_8\NN| (r_conj) everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing (l_appos) leukemia_33\NN|(|mds|myeloid|(|aml|)
D016559_D015470 NONE tacrolimus_8\NN| (r_conj) everolimus_6\NN|and|tacrolimus (r_pobj) of_5\IN|everolimus (r_prep) combination_4\NN|a|of|in|with (l_prep) with_19\IN|syndrome (l_pobj) syndrome_22\NN|either|myelodysplastic|leukemia|undergoing (l_appos) leukemia_33\NN|(|mds|myeloid|(|aml|) (l_appos) AML_35\NNP|;|n|7
10225068
D008012_D011128 CID lignocaine_10\NN|hyperbaric|% (r_pobj) with_6\IN|lignocaine (r_prep) anaesthesia_5\NN|spinal|with (r_pobj) after_3\IN|anaesthesia (r_prep) syndrome_2\NN|equina|after|:|review|.
D008012_D011128 CID lignocaine_10\NN|hyperbaric|% (r_pobj) with_6\IN|lignocaine (r_prep) anaesthesia_5\NN|spinal|with (r_pobj) after_3\IN|anaesthesia (r_prep) syndrome_2\NN|equina|after|:|review|. (l_appos) review_13\NN|a|of|reported (l_prep) of_14\IN|cases (l_pobj) cases_16\NNS|six|of (l_prep) of_17\IN|syndrome (l_pobj) syndrome_20\NN|cauda|equina
D008012_D020258 NONE lignocaine_6\NN|hyperbaric|%|administered (r_pobj) of_2\IN|lignocaine (r_prep) dose_1\NN|the|of (r_nsubj) ranged_8\VBD|dose|from (r_ccomp) caused_21\VBN|ranged|were|likely|by|. (l_agent) by_22\IN|neurotoxicity (l_pobj) neurotoxicity_24\NN|direct|of
D008012_D020258 NONE lignocaine_29\NN|hyperbaric|% (r_pobj) of_25\IN|lignocaine (r_prep) neurotoxicity_24\NN|direct|of
16047871
D014859_C535509 NONE Warfarin_0\NNP| (r_npadvmod) induced_2\VBN|warfarin|- (r_amod) vasculitis_4\NN|induced|leukocytoclastic|.
D014859_C535509 NONE warfarin_12\NN| (r_pobj) due_10\JJ|probably|to|warfarin (r_amod) patients_3\NNS|4|with|due (l_prep) with_4\IN|lv (l_pobj) LV_8\NNP|onset
D014859_C535509 NONE warfarin_11\JJ| (r_compound) therapy_12\NN|warfarin (r_pobj) with_10\IN|therapy (r_prep) associated_9\VBN|with (r_acl) reaction_8\NN|a|onset|adverse|associated (r_attr) be_2\VB|lv|may|reaction|. (l_nsubj) LV_0\NNP|
D014859_D012871 NONE warfarin_11\NN| (r_dobj) receiving_10\VBG|warfarin|for (r_pcomp) after_9\IN|receiving (r_prep) developed_8\VBD|that|after (r_relcl) eruptions_6\NNS|skin|developed
D014859_D012871 NONE warfarin_21\NN| (r_nsubjpass) discontinued_23\VBN|after|warfarin|was (r_advcl) resolved_16\VBD|in|discontinued (r_acl) lesions_15\NNS|lv|cutaneous|resolved (r_dobj) confirming_12\VBG|lesions (r_advcl) were_6\VBD|results|available|,|confirming|. (l_nsubj) results_1\NNS|the|of (l_prep) of_2\IN|biopsies (l_pobj) biopsies_5\NNS|lesion (l_compound) lesion_4\NN|skin
D014859_D018366 CID warfarin_21\NN| (r_nsubjpass) discontinued_23\VBN|after|warfarin|was (r_advcl) resolved_16\VBD|in|discontinued (r_acl) lesions_15\NNS|lv|cutaneous|resolved
17344330
D008691_D013575 CID methadone_8\NN| (r_pobj) with_7\IN|methadone (r_prep) treated_6\VBN|with|for (r_acl) patients_5\NNS|treated (r_pobj) among_4\IN|patients (r_prep) Syncope_0\NNP|and|prolongation|among|.
D008691_D013575 CID methadone_53\NN| (r_pobj) of_52\IN|methadone (r_prep) effect_51\NN|the|proarrhythmic|of (r_pobj) by_48\IN|effect (r_agent) caused_47\VBN|mortality|may|,|in|,|be|by|. (r_conj) attribute_12\VB|faint|,|doctors|might|episodes|and|underestimate|,|and|caused (l_dobj) episodes_15\NNS|many|of (l_prep) of_16\IN|syncope (l_pobj) syncope_17\NN|to
D008691_D013575 CID methadone_9\NN| (r_compound) dose_10\NN|methadone|and|reporting (l_conj) reporting_12\NN|of (l_prep) of_13\IN|syncope (l_pobj) syncope_14\NN|
D008691_D013575 CID methadone_4\NN|a|higher (r_compound) dose_5\NN|methadone (r_nsubjpass) associated_7\VBN|dose|was|with|. (l_prep) with_8\IN|ci (l_pobj) CI_14\NNP|a|%|1.1|to|)|odds (l_appos) odds_21\NNS|higher|for (l_prep) for_22\IN|syncope (l_pobj) syncope_23\NN|
D008691_D013575 CID Methadone_0\NNP| (r_nsubjpass) associated_2\VBN|methadone|is|with|. (l_prep) with_3\IN|prolongation (l_pobj) prolongation_5\NN|qt|and|reporting (l_conj) reporting_8\NN|higher|of (l_prep) of_9\IN|syncope (l_pobj) syncope_10\NN|in
D008691_D008133 CID methadone_8\NN| (r_pobj) with_7\IN|methadone (r_prep) treated_6\VBN|with|for (r_acl) patients_5\NNS|treated (r_pobj) among_4\IN|patients (r_prep) Syncope_0\NNP|and|prolongation|among|. (l_conj) prolongation_3\NN|qt
D008691_D008133 CID methadone_5\NN|,|men (r_pobj) with_4\IN|methadone (r_prep) treated_3\VBN|with (r_acl) subjects_2\NNS|the|treated (r_pobj) Among_0\IN|subjects (r_prep) had_14\VBD|among|interval|. (l_dobj) interval_17\NN|prolonged|qtc
D008691_D008133 CID Methadone_0\NNP| (r_nsubjpass) associated_2\VBN|methadone|is|with|. (l_prep) with_3\IN|prolongation (l_pobj) prolongation_5\NN|qt|and|reporting
D003932_D013575 NONE heroin_10\NN| (r_compound) dependence_11\NN|heroin|in (r_pobj) for_9\IN|dependence (r_prep) treated_6\VBN|with|for (r_acl) patients_5\NNS|treated (r_pobj) among_4\IN|patients (r_prep) Syncope_0\NNP|and|prolongation|among|.
D003932_D013575 NONE heroin_1\NN| (r_compound) addicts_2\NNS|heroin (r_nsubj) faint_4\JJ|as|addicts|sometimes|using (r_advcl) attribute_12\VB|faint|,|doctors|might|episodes|and|underestimate|,|and|caused (l_dobj) episodes_15\NNS|many|of (l_prep) of_16\IN|syncope (l_pobj) syncope_17\NN|to
D003932_D013575 NONE heroin_15\NN| (r_compound) addicts_16\NNS|heroin (r_pobj) of_14\IN|addicts (r_prep) population_13\NN|a|of (r_pobj) in_11\IN|population (r_prep) syncope_10\NN|in
D003932_D008133 NONE heroin_10\NN| (r_compound) dependence_11\NN|heroin|in (r_pobj) for_9\IN|dependence (r_prep) treated_6\VBN|with|for (r_acl) patients_5\NNS|treated (r_pobj) among_4\IN|patients (r_prep) Syncope_0\NNP|and|prolongation|among|. (l_conj) prolongation_3\NN|qt
D003932_D008133 NONE heroin_15\NN| (r_compound) addicts_16\NNS|heroin (r_pobj) of_14\IN|addicts (r_prep) population_13\NN|a|of (r_pobj) in_11\IN|population (r_prep) syncope_10\NN|in (r_pobj) of_9\IN|syncope (r_prep) reporting_8\NN|higher|of (r_conj) prolongation_5\NN|qt|and|reporting
D008691_D016171 NONE methadone_21\NN| (r_compound) users_22\NNS|methadone (r_pobj) in_20\IN|users (r_prep) reported_19\VBN|prolongation|has|been|in|. (l_nsubjpass) Prolongation_0\NN|of (l_prep) of_1\IN|interval (l_pobj) interval_4\NN|the|qt|in (l_prep) in_5\IN|ecg (l_pobj) ECG_7\NNP|the|of (l_prep) of_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|pointes (l_pobj) pointes_13\FW|torsade|de|(|tdp|)
D008691_D016171 NONE methadone_21\NN| (r_compound) users_22\NNS|methadone (r_pobj) in_20\IN|users (r_prep) reported_19\VBN|prolongation|has|been|in|. (l_nsubjpass) Prolongation_0\NN|of (l_prep) of_1\IN|interval (l_pobj) interval_4\NN|the|qt|in (l_prep) in_5\IN|ecg (l_pobj) ECG_7\NNP|the|of (l_prep) of_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|pointes (l_pobj) pointes_13\FW|torsade|de|(|tdp|) (l_appos) TdP_15\NN|
D008691_D016171 NONE methadone_53\NN| (r_pobj) of_52\IN|methadone (r_prep) effect_51\NN|the|proarrhythmic|of (r_pobj) by_48\IN|effect (r_agent) caused_47\VBN|mortality|may|,|in|,|be|by|. (r_conj) attribute_12\VB|faint|,|doctors|might|episodes|and|underestimate|,|and|caused (l_conj) underestimate_24\VBP|thereby|incidence (l_dobj) incidence_26\NN|the|of|in (l_prep) of_27\IN|tdp (l_pobj) TdP_28\NNP|
D003932_D016171 NONE heroin_1\NN| (r_compound) addicts_2\NNS|heroin (r_nsubj) faint_4\JJ|as|addicts|sometimes|using (r_advcl) attribute_12\VB|faint|,|doctors|might|episodes|and|underestimate|,|and|caused (l_conj) underestimate_24\VBP|thereby|incidence (l_dobj) incidence_26\NN|the|of|in (l_prep) of_27\IN|tdp (l_pobj) TdP_28\NNP|
9875685
D014031_D064420 NONE tobramicyn_17\NN|on (l_prep) on_18\IN|concentrations (l_pobj) concentrations_23\NNS|state|serum|and|toxicity (l_conj) toxicity_25\NN|
D003404_D007674 NONE creatinine_2\NN|increased|serum (r_nsubjpass) observed_4\VBN|creatinine|was|in|versus|,|without|. (l_prep) without_20\IN|evidence (l_pobj) evidence_21\NN|of (l_prep) of_22\IN|nephrotoxicity (l_pobj) nephrotoxicity_23\NN|
188339
D003276_D008113 CID contraceptives_11\NNS|oral (r_pobj) with_9\IN|contraceptives (r_prep) associated_8\VBN|with (r_acl) tumors_7\NNS|liver|associated
D003276_D008113 CID contraceptive_18\JJ| (r_amod) steroids_19\NNS|oral|contraceptive (r_dobj) using_16\VBG|steroids (r_advcl) seen_12\VBN|within|,|previously|tumors|have|been|in|using|. (l_nsubjpass) tumors_9\NNS|rare|liver
D013256_D008113 NONE steroids_19\NNS|oral|contraceptive (r_dobj) using_16\VBG|steroids (r_advcl) seen_12\VBN|within|,|previously|tumors|have|been|in|using|. (l_nsubjpass) tumors_9\NNS|rare|liver
9952311
D004317_D028361 CID adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|adriamycin|- (r_amod) cardiomyopathy_10\NN|induced (r_pobj) in_6\IN|cardiomyopathy (r_prep) impairment_3\NN|structural|of|in|in|:|suppression|. (l_prep) of_4\IN|mitochondria (l_pobj) mitochondria_5\NN|
D004317_D028361 CID ADR_21\NNP| (r_pobj) of_20\IN|adr (r_prep) effects_19\NNS|the|deteriorating|of|on (r_nsubj) involve_25\VBP|that|effects|impairment (l_dobj) impairment_30\NN|mitochondrial|structural
D004317_D009202 NONE adriamycin_7\NNS| (r_npadvmod) induced_9\VBN|adriamycin|- (r_amod) cardiomyopathy_10\NN|induced
D004317_D009369 NONE adriamycin_3\NNS|(|adr|) (r_pobj) of_2\IN|adriamycin (r_prep) use_1\NN|the|of|in (l_prep) in_7\IN|chemotherapy (l_pobj) chemotherapy_9\NN|cancer (l_compound) cancer_8\NN|
D004317_D009369 NONE ADR_5\NNP| (r_appos) adriamycin_3\NNS|(|adr|) (r_pobj) of_2\IN|adriamycin (r_prep) use_1\NN|the|of|in (l_prep) in_7\IN|chemotherapy (l_pobj) chemotherapy_9\NN|cancer (l_compound) cancer_8\NN|
D004317_D002318 NONE adriamycin_3\NNS|(|adr|) (r_pobj) of_2\IN|adriamycin (r_prep) use_1\NN|the|of|in (r_nsubjpass) limited_12\VBN|use|has|been|due|. (l_prep) due_13\IN|to (l_pcomp) to_14\IN|toxicity (l_pobj) toxicity_18\NN|its|cumulative|cardiovascular
D004317_D002318 NONE ADR_5\NNP| (r_appos) adriamycin_3\NNS|(|adr|) (r_pobj) of_2\IN|adriamycin (r_prep) use_1\NN|the|of|in (r_nsubjpass) limited_12\VBN|use|has|been|due|. (l_prep) due_13\IN|to (l_pcomp) to_14\IN|toxicity (l_pobj) toxicity_18\NN|its|cumulative|cardiovascular
D004317_D001145 NONE ADR_10\NNP| (r_pobj) with_9\IN|adr (r_prep) mice_8\NNS|with (r_pobj) of_7\IN|mice (r_prep) treatment_6\NN|1|of (r_nsubj) caused_11\VBD|that|treatment|arrhythmias|swelling (l_dobj) arrhythmias_13\NNS|cardiovascular|characterized
D004317_D001919 CID ADR_10\NNP| (r_pobj) with_9\IN|adr (r_prep) mice_8\NNS|with (r_pobj) of_7\IN|mice (r_prep) treatment_6\NN|1|of (r_nsubj) caused_11\VBD|that|treatment|arrhythmias|swelling (l_dobj) arrhythmias_13\NNS|cardiovascular|characterized (l_acl) characterized_14\VBN|by (l_agent) by_15\IN|bradycardia (l_pobj) bradycardia_16\NNP|,|extension
D004317_D004487 NONE ADR_10\NNP| (r_pobj) with_9\IN|adr (r_prep) mice_8\NNS|with (r_pobj) of_7\IN|mice (r_prep) treatment_6\NN|1|of (r_nsubj) caused_11\VBD|that|treatment|arrhythmias|swelling (l_ccomp) swelling_51\NN|;|2|mitochondria|underwent|,|fusion|after
871943
D013390_D001049 CID succinylcholine_6\NN| (r_compound) apnoea_7\NN|succinylcholine
D013390_D001049 CID succinylcholine_10\NN| (r_nsubjpass) treated_13\VBN|hours|after|succinylcholine|have|been|by (r_advcl) demonstrating_2\VBG|patients|apnoea|treated|. (l_dobj) apnoea_5\NN|unexpected|prolonged|lasting
D013390_D001049 CID succinylcholine_6\NN| (r_compound) apnoea_7\NN|succinylcholine
384871
D004977_D009901 CID ethambutol_6\NN|combined|and|isoniazid (r_nmod) treatment_9\NN|ethambutol (r_pobj) due_3\IN|to|treatment (r_prep) neuropathy_2\NN|optic|due|.
D007538_D009901 CID isoniazid_8\NN| (r_conj) ethambutol_6\NN|combined|and|isoniazid (r_nmod) treatment_9\NN|ethambutol (r_pobj) due_3\IN|to|treatment (r_prep) neuropathy_2\NN|optic|due|.
D004977_D064420 NONE ethambutol_8\NN| (r_pobj) due_6\IN|to|ethambutol (r_amod) hazards_1\NNS|the|of|due (l_prep) of_2\IN|toxicity (l_pobj) toxicity_5\NN|optic|nerve
7102237
D012601_D001049 NONE scopolamine_4\NN|+|morphine|(|+|mg (r_pobj) with_3\IN|scopolamine (r_prep) premedicated_2\VBN|with (r_acl) patients_1\NNS|premedicated (r_pobj) In_0\IN|patients (r_prep) was_28\VBD|in|)|,|effect|mg/kg|slower|found|,|but|,|occurred|. (l_advcl) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
D009020_D001049 NONE morphine_6\NN| (r_conj) scopolamine_4\NN|+|morphine|(|+|mg (r_pobj) with_3\IN|scopolamine (r_prep) premedicated_2\VBN|with (r_acl) patients_1\NNS|premedicated (r_pobj) In_0\IN|patients (r_prep) was_28\VBD|in|)|,|effect|mg/kg|slower|found|,|but|,|occurred|. (l_advcl) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
D009567_D001049 NONE nitrazepam_11\NN| (r_amod) mg_10\IN|5|nitrazepam|evening (r_conj) scopolamine_4\NN|+|morphine|(|+|mg (r_pobj) with_3\IN|scopolamine (r_prep) premedicated_2\VBN|with (r_acl) patients_1\NNS|premedicated (r_pobj) In_0\IN|patients (r_prep) was_28\VBD|in|)|,|effect|mg/kg|slower|found|,|but|,|occurred|. (l_advcl) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
D008874_D001049 CID midazolam_24\JJ| (r_pobj) of_23\IN|midazolam (r_prep) effect_22\NN|the|inducing|of (r_nsubj) was_28\VBD|in|)|,|effect|mg/kg|slower|found|,|but|,|occurred|. (l_advcl) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
D008874_D001049 CID midazolam_50\JJ| (r_amod) group_51\NN|the|midazolam (r_pobj) in_48\IN|group (r_prep) found_47\VBN|sequelae|were|in (r_conj) was_28\VBD|in|)|,|effect|mg/kg|slower|found|,|but|,|occurred|. (l_advcl) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
D008874_D001049 CID midazolam_62\JJ| (r_amod) group_63\NN|the|midazolam|lasted (r_pobj) in_60\IN|group (r_prep) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
D013874_D001049 CID thiopentone_36\NN|mg/kg (r_pobj) of_35\IN|thiopentone (r_prep) that_34\DT|of (r_pobj) than_33\IN|that (r_prep) onset_32\NN|than (r_pobj) in_31\IN|onset (r_prep) slower_30\JJR|clearly|in (r_acomp) was_28\VBD|in|)|,|effect|mg/kg|slower|found|,|but|,|occurred|. (l_advcl) occurred_57\VBD|although|apnoea|often|in (l_nsubj) apnoea_56\NN|
16364460
D016713_D000647 NONE ritanserin_2\NN| (r_pobj) of_1\IN|ritanserin (r_prep) Microinjection_0\NN|of|into (r_nsubj) improves_9\VBZ|microinjection|amnesia|. (l_dobj) amnesia_13\NN|induced|in
D016713_D000647 NONE ritanserin_3\NN| (r_pobj) of_2\IN|ritanserin (r_prep) effect_1\NN|the|of|antagonist|on (l_prep) on_8\IN|amnesia (l_pobj) amnesia_14\NN|scopolamine|(|muscarinic|cholinergic|antagonist)-induced|in
D016713_D000647 NONE ritanserin_6\NN| (r_pobj) of_5\IN|ritanserin (r_prep) microinjection_4\NN|of|into (r_nsubj) improves_14\VBZ|that|microinjection|amnesia (l_dobj) amnesia_19\NN|the|induced
D012601_D000647 CID scopolamine_10\NN| (r_npadvmod) induced_12\VBN|scopolamine|- (r_amod) amnesia_13\NN|induced|in
D012601_D000647 CID scopolamine_9\NN| (r_nmod) amnesia_14\NN|scopolamine|(|muscarinic|cholinergic|antagonist)-induced|in
D012601_D000647 CID scopolamine_16\NN| (r_npadvmod) induced_18\VBN|scopolamine|- (r_amod) amnesia_19\NN|the|induced
9915601
D007538_D001919 CID isoniazid_12\NN| (r_pobj) with_11\IN|isoniazid (r_prep) pretreated_10\VBD|with (r_acl) rats_9\NNS|pretreated (r_pobj) in_8\IN|rats (r_prep) antagonists_7\NNS|adrenoceptor|in (r_pobj) by_3\IN|antagonists (r_agent) induced_2\VBN|by (r_acl) bradycardia_1\NNS|enhanced|induced|.
D007538_D001919 CID isoniazid_3\NN| (r_pobj) of_2\IN|isoniazid (r_prep) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change (l_conj) change_10\VB|tachycardia|to (l_prep) to_15\IN|bradycardia (l_pobj) bradycardia_16\NNP|
D007538_D001919 CID isoniazid_9\NN|of (l_prep) of_10\IN|bradycardia (l_pobj) bradycardia_11\NN|
D007538_D001919 CID Isoniazid_0\NNP| (r_nsubj) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D007538_D007022 CID isoniazid_3\NN| (r_pobj) of_2\IN|isoniazid (r_prep) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change
D007538_D013610 NONE isoniazid_3\NN| (r_pobj) of_2\IN|isoniazid (r_prep) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change (l_conj) change_10\VB|tachycardia|to (l_dobj) tachycardia_14\NN|the|accompanying|reflex
D005680_D007022 NONE acid_29\NN|brain|aminobutyric|gaba (r_pobj) of_24\IN|acid (r_prep) synthesis_23\NN|decreased|of (r_pobj) to_21\IN|synthesis (r_prep) attributed_20\VBN|to (r_acl) interaction_19\NN|an|attributed (r_appos) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change
D005680_D007022 NONE GABA_31\NNP|(|) (r_appos) acid_29\NN|brain|aminobutyric|gaba (r_pobj) of_24\IN|acid (r_prep) synthesis_23\NN|decreased|of (r_pobj) to_21\IN|synthesis (r_prep) attributed_20\VBN|to (r_acl) interaction_19\NN|an|attributed (r_appos) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change
D005680_D013610 NONE acid_29\NN|brain|aminobutyric|gaba (r_pobj) of_24\IN|acid (r_prep) synthesis_23\NN|decreased|of (r_pobj) to_21\IN|synthesis (r_prep) attributed_20\VBN|to (r_acl) interaction_19\NN|an|attributed (r_appos) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change (l_conj) change_10\VB|tachycardia|to (l_dobj) tachycardia_14\NN|the|accompanying|reflex
D005680_D013610 NONE GABA_31\NNP|(|) (r_appos) acid_29\NN|brain|aminobutyric|gaba (r_pobj) of_24\IN|acid (r_prep) synthesis_23\NN|decreased|of (r_pobj) to_21\IN|synthesis (r_prep) attributed_20\VBN|to (r_acl) interaction_19\NN|an|attributed (r_appos) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change (l_conj) change_10\VB|tachycardia|to (l_dobj) tachycardia_14\NN|the|accompanying|reflex
D005680_D001919 NONE acid_29\NN|brain|aminobutyric|gaba (r_pobj) of_24\IN|acid (r_prep) synthesis_23\NN|decreased|of (r_pobj) to_21\IN|synthesis (r_prep) attributed_20\VBN|to (r_acl) interaction_19\NN|an|attributed (r_appos) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change (l_conj) change_10\VB|tachycardia|to (l_prep) to_15\IN|bradycardia (l_pobj) bradycardia_16\NNP|
D005680_D001919 NONE GABA_31\NNP|(|) (r_appos) acid_29\NN|brain|aminobutyric|gaba (r_pobj) of_24\IN|acid (r_prep) synthesis_23\NN|decreased|of (r_pobj) to_21\IN|synthesis (r_prep) attributed_20\VBN|to (r_acl) interaction_19\NN|an|attributed (r_appos) doses_1\NNS|high|of|hypotension|,|interaction|. (l_appos) hypotension_5\NN|increase|induced|and|change (l_conj) change_10\VB|tachycardia|to (l_prep) to_15\IN|bradycardia (l_pobj) bradycardia_16\NNP|
D002698_D001919 NONE chloralose_24\NN| (r_compound) urethane_26\NN|chloralose|- (r_pobj) with_23\IN|urethane (r_prep) anaesthetised_22\VBN|with (r_acl) rats_21\NNS|anaesthetised (r_pobj) in_20\IN|rats (r_prep) determined_19\VBN|in|,|enhancement|was|in|. (l_nsubjpass) enhancement_7\NN|the|possible|by|induced (l_prep) by_8\IN|isoniazid (l_pobj) isoniazid_9\NN|of (l_prep) of_10\IN|bradycardia (l_pobj) bradycardia_11\NN|
D014520_D001919 NONE urethane_26\NN|chloralose|- (r_pobj) with_23\IN|urethane (r_prep) anaesthetised_22\VBN|with (r_acl) rats_21\NNS|anaesthetised (r_pobj) in_20\IN|rats (r_prep) determined_19\VBN|in|,|enhancement|was|in|. (l_nsubjpass) enhancement_7\NN|the|possible|by|induced (l_prep) by_8\IN|isoniazid (l_pobj) isoniazid_9\NN|of (l_prep) of_10\IN|bradycardia (l_pobj) bradycardia_11\NN|
D011433_D001919 NONE propranolol_5\NN|after|,|pindolol (r_advcl) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D010869_D001919 NONE pindolol_7\NN|,|labetalol (r_conj) propranolol_5\NN|after|,|pindolol (r_advcl) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D007741_D001919 NONE labetalol_9\JJ|and|atenolol (r_conj) pindolol_7\NN|,|labetalol (r_conj) propranolol_5\NN|after|,|pindolol (r_advcl) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D001262_D001919 NONE atenolol_11\NN| (r_conj) labetalol_9\JJ|and|atenolol (r_conj) pindolol_7\NN|,|labetalol (r_conj) propranolol_5\NN|after|,|pindolol (r_advcl) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D003000_D001919 NONE clonidine_17\NN| (r_pobj) after_16\IN|clonidine (r_prep) as_15\IN|as|well|after (r_cc) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D018738_D001919 NONE hexamethonium_22\NN|or|carbachol (r_pobj) after_21\IN|not|hexamethonium (r_conj) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
D002217_D001919 NONE carbachol_24\NN| (r_conj) hexamethonium_22\NN|or|carbachol (r_pobj) after_21\IN|not|hexamethonium (r_conj) increased_2\VBD|isoniazid|significantly|bradycardia|propranolol|,|as|,|but|after|. (l_acomp) bradycardia_3\NNP|
9848575
D018943_D009202 NONE anthracycline_6\NN| (r_amod) derivative_7\JJ|a|novel|synthetic|anthracycline|(|sm-5887|) (r_pobj) of_2\IN|derivative (r_prep) effects_1\NNS|chronic|of|on|. (l_prep) on_11\IN|heart (l_pobj) heart_13\NN|normal|and|cardiomyopathy (l_conj) cardiomyopathy_18\NN|induced|in
C055866_D009202 NONE SM-5887_9\NNP| (r_appos) derivative_7\JJ|a|novel|synthetic|anthracycline|(|sm-5887|) (r_pobj) of_2\IN|derivative (r_prep) effects_1\NNS|chronic|of|on|. (l_prep) on_11\IN|heart (l_pobj) heart_13\NN|normal|and|cardiomyopathy (l_conj) cardiomyopathy_18\NN|induced|in
C055866_D009202 NONE SM-5887_35\NNP| (r_compound) administration_36\NN|the|sm-5887 (r_nsubj) show_39\VB|while|animals|administration|did|not|changes (r_advcl) demonstrated_8\VBD|animals|electrocardiogram|decrease|,|show|. (l_dobj) decrease_16\NN|of (l_prep) of_17\IN|pressure (l_pobj) pressure_19\NN|blood|and|cardiomyopathy (l_conj) cardiomyopathy_25\NN|grade|histopathological
C055866_D009202 NONE SM-5887_8\NNP| (r_nmod) cardiomyopathy_13\NN|sm-5887|,|grade
C055866_D009202 NONE SM-5887_5\NNP| (r_compound) treatment_6\NN|the|sm-5887 (r_nsubj) progress_9\VB|on|,|treatment|did|not|grade|. (l_dobj) grade_11\NN|the|of (l_prep) of_12\IN|cardiomyopathy (l_pobj) cardiomyopathy_13\NN|
D004317_D009202 CID doxorubicin_15\RB| (r_npadvmod) induced_17\VBN|doxorubicin|- (r_amod) cardiomyopathy_18\NN|induced|in
D004317_D009202 CID doxorubicin_7\NN| (r_pobj) of_6\IN|doxorubicin (r_prep) courses_5\NNS|six|of (r_dobj) received_2\VBD|which|courses (r_relcl) Animals_0\NNS|received (r_nsubj) demonstrated_8\VBD|animals|electrocardiogram|decrease|,|show|. (l_dobj) decrease_16\NN|of (l_prep) of_17\IN|pressure (l_pobj) pressure_19\NN|blood|and|cardiomyopathy (l_conj) cardiomyopathy_25\NN|grade|histopathological
D004317_D009202 CID doxorubicin_22\NN| (r_pobj) of_21\IN|doxorubicin (r_prep) courses_20\NNS|four|of|(|mg/kg|) (r_pobj) by_18\IN|courses (r_agent) induced_15\VBN|examine|was|in|by|. (l_csubjpass) examine_1\VB|to|effect (l_dobj) effect_6\NN|a|deteriorating|cardiotoxic|of (l_prep) of_7\IN|cardiomyopathy (l_pobj) cardiomyopathy_13\NN|sm-5887|,|grade
C055866_D066126 NONE SM-5887_11\NNP| (r_pobj) of_10\IN|sm-5887 (r_prep) potential_9\NN|the|chronic|cardiotoxic|of|and|effect|doxorubicin (l_amod) cardiotoxic_8\JJ|
C055866_D066126 NONE SM-5887_11\NNP| (r_pobj) of_10\IN|sm-5887 (r_prep) potential_9\NN|the|chronic|cardiotoxic|of|and|effect|doxorubicin (l_conj) effect_16\NN|a|possible|deteriorating|of|on (l_prep) on_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_23\NN|grade
C055866_D066126 NONE SM-5887_18\NNP| (r_pobj) of_17\IN|sm-5887 (r_prep) effect_16\NN|a|possible|deteriorating|of|on (r_conj) potential_9\NN|the|chronic|cardiotoxic|of|and|effect|doxorubicin (l_amod) cardiotoxic_8\JJ|
C055866_D066126 NONE SM-5887_18\NNP| (r_pobj) of_17\IN|sm-5887 (r_prep) effect_16\NN|a|possible|deteriorating|of|on (l_prep) on_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_23\NN|grade
C055866_D066126 NONE SM-5887_8\NNP| (r_nmod) cardiomyopathy_13\NN|sm-5887|,|grade (r_pobj) of_7\IN|cardiomyopathy (r_prep) effect_6\NN|a|deteriorating|cardiotoxic|of (l_amod) cardiotoxic_5\JJ|
C055866_D066126 NONE SM-5887_3\NNP| (r_nsubj) have_6\VB|in|,|sm-5887|does|not|potential|. (l_dobj) potential_8\NN|any|of (l_prep) of_9\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|chronic|and|effect
C055866_D066126 NONE SM-5887_3\NNP| (r_nsubj) have_6\VB|in|,|sm-5887|does|not|potential|. (l_dobj) potential_8\NN|any|of (l_prep) of_9\IN|cardiotoxicity (l_pobj) cardiotoxicity_11\NN|chronic|and|effect (l_conj) effect_14\NN|deteriorating|on (l_prep) on_15\IN|cardiotoxicity (l_pobj) cardiotoxicity_19\NN|induced|in
D004317_D066126 NONE doxorubicin_28\NN|by|in (r_appos) potential_9\NN|the|chronic|cardiotoxic|of|and|effect|doxorubicin (l_amod) cardiotoxic_8\JJ|
D004317_D066126 NONE doxorubicin_28\NN|by|in (r_appos) potential_9\NN|the|chronic|cardiotoxic|of|and|effect|doxorubicin (l_conj) effect_16\NN|a|possible|deteriorating|of|on (l_prep) on_19\IN|cardiotoxicity (l_pobj) cardiotoxicity_23\NN|grade
D004317_D066126 NONE doxorubicin_22\NN| (r_pobj) of_21\IN|doxorubicin (r_prep) courses_20\NNS|four|of|(|mg/kg|) (r_pobj) by_18\IN|courses (r_agent) induced_15\VBN|examine|was|in|by|. (l_csubjpass) examine_1\VB|to|effect (l_dobj) effect_6\NN|a|deteriorating|cardiotoxic|of (l_amod) cardiotoxic_5\JJ|
D004317_D066126 NONE doxorubicin_11\NN| (r_compound) treatment_12\NN|the|additional|doxorubicin (r_pobj) by_8\IN|treatment (r_agent) enhanced_7\VBN|changes|were|by|. (l_nsubjpass) changes_5\NNS|the|grade|cardiotoxic (l_amod) cardiotoxic_4\JJ|
D004317_D066126 NONE doxorubicin_16\RB| (r_npadvmod) induced_18\VBN|doxorubicin|- (r_amod) cardiotoxicity_19\NN|induced|in (r_pobj) on_15\IN|cardiotoxicity (r_prep) effect_14\NN|deteriorating|on (r_conj) cardiotoxicity_11\NN|chronic|and|effect
D004317_D066126 NONE doxorubicin_16\RB| (r_npadvmod) induced_18\VBN|doxorubicin|- (r_amod) cardiotoxicity_19\NN|induced|in
1700207
C032151_D001145 NONE cibenzoline_6\NN|on (l_prep) on_7\IN|arrhythmias (l_pobj) arrhythmias_10\NNS|canine|ventricular
C032151_D001145 NONE -cibenzoline_6\:|) (r_conj) of_2\IN|(|+|-cibenzoline (r_prep) effects_1\NNS|antiarrhythmic|of|and|examined (l_conj) examined_11\VBN|(|-)-cibenzoline|were|using|. (l_advcl) using_12\VBG|models (l_dobj) models_17\NNS|two|canine|arrhythmia (l_compound) arrhythmia_16\NN|ventricular
C032151_D001145 NONE -)-cibenzoline_9\:| (r_nsubjpass) examined_11\VBN|(|-)-cibenzoline|were|using|. (l_advcl) using_12\VBG|models (l_dobj) models_17\NNS|two|canine|arrhythmia (l_compound) arrhythmia_16\NN|ventricular
C032151_D001145 NONE -cibenzoline_8\,| (r_punct) suppressed_9\VBN|)|-cibenzoline (r_amod) arrhythmias_15\NNS|i.v.|suppressed|digitalis-|,|respectively|.
C032151_D001145 NONE -cibenzoline_9\:|) (r_punct) for_10\IN|-cibenzoline|arrhythmias (l_pobj) arrhythmias_16\NNS|digitalis-
C032151_D001145 NONE -)-cibenzoline_9\NNP| (r_nsubj) suppressed_10\VBD|(|-)-cibenzoline|arrhythmia|, (l_dobj) arrhythmia_15\NN|the|induced
C032151_D001145 NONE -)-cibenzoline_9\NNP| (r_nsubj) suppressed_10\VBD|(|-)-cibenzoline|arrhythmia|, (r_pcomp) of_7\IN|suppressed (r_prep) i.v._6\NN|of (r_appos) dose_2\NN|a|lower|of|i.v. (r_nsubjpass) needed_22\VBN|dose|whereas|mg/kg|was|suppress|. (l_advcl) suppress_24\VB|to|arrhythmias (l_dobj) arrhythmias_28\NNS|induced
C032151_D001145 NONE -)-cibenzoline_7\:|(|for (l_prep) for_8\IN|arrhythmia (l_pobj) arrhythmia_14\NN|digitalis-
D004070_D001145 NONE Digitalis_0\NNP| (r_compound) arrhythmia_1\NN|digitalis|,|suppressed|,
D004070_D001145 NONE digitalis-_10\NN|and|induced (r_amod) arrhythmias_15\NNS|i.v.|suppressed|digitalis-|,|respectively|.
D004070_D001145 NONE digitalis-_11\NN|and|induced (r_amod) arrhythmias_16\NNS|digitalis-
D004070_D001145 NONE digitalis_12\NN| (r_npadvmod) induced_14\VBN|digitalis|- (r_amod) arrhythmia_15\NN|the|induced
D004070_D001145 NONE digitalis_12\NN| (r_npadvmod) induced_14\VBN|digitalis|- (r_amod) arrhythmia_15\NN|the|induced (r_dobj) suppressed_10\VBD|(|-)-cibenzoline|arrhythmia|, (r_pcomp) of_7\IN|suppressed (r_prep) i.v._6\NN|of (r_appos) dose_2\NN|a|lower|of|i.v. (r_nsubjpass) needed_22\VBN|dose|whereas|mg/kg|was|suppress|. (l_advcl) suppress_24\VB|to|arrhythmias (l_dobj) arrhythmias_28\NNS|induced
D004070_D001145 NONE digitalis-_9\NN|and|induced (r_amod) arrhythmia_14\NN|digitalis-
D012964_D001145 NONE Na_7\NNP| (r_compound) blockers_9\NNS|na|channel (r_pobj) by_6\IN|blockers (r_agent) suppressed_5\VBN|which|is|by (r_relcl) arrhythmia_1\NN|digitalis|,|suppressed|,
D010042_D001145 CID ouabain_21\NN| (r_pobj) of_20\IN|ouabain (r_prep) injection_19\NN|(|i.v.|)|of|in (r_appos) intravenous_15\JJ|intermittent|injection (r_pobj) by_13\IN|intravenous (r_agent) induced_12\VBN|arrhythmia|was|by|. (l_nsubjpass) arrhythmia_1\NN|digitalis|,|suppressed|,
D010424_D001145 NONE pentobarbital_23\NN| (r_npadvmod) anesthetized_25\VBN|pentobarbital|- (r_amod) dogs_26\NNS|anesthetized (r_pobj) in_22\IN|dogs (r_prep) injection_19\NN|(|i.v.|)|of|in (r_appos) intravenous_15\JJ|intermittent|injection (r_pobj) by_13\IN|intravenous (r_agent) induced_12\VBN|arrhythmia|was|by|. (l_nsubjpass) arrhythmia_1\NN|digitalis|,|suppressed|,
D002118_D001145 NONE Ca_7\NNP| (r_aux) channel_8\NN|ca (r_compound) blockers_9\NNS|channel (r_pobj) by_6\IN|blockers (r_agent) suppressed_5\VBN|which|is|by (r_relcl) arrhythmia_1\NN|adrenaline|,|suppressed|,
D004837_D001145 CID adrenaline_14\NN| (r_amod) infusion_15\NN|adrenaline|in (r_pobj) by_13\IN|infusion (r_agent) induced_12\VBN|arrhythmia|was|by|. (l_nsubjpass) arrhythmia_1\NN|adrenaline|,|suppressed|,
D004837_D001145 CID adrenaline_12\NN| (r_npadvmod) induced_14\VBN|adrenaline|- (r_conj) digitalis-_10\NN|and|induced (r_amod) arrhythmias_15\NNS|i.v.|suppressed|digitalis-|,|respectively|.
D004837_D001145 CID adrenaline_13\NN| (r_npadvmod) induced_15\VBN|adrenaline|- (r_conj) digitalis-_11\NN|and|induced (r_amod) arrhythmias_16\NNS|digitalis-
D004837_D001145 CID adrenaline_25\NN| (r_npadvmod) induced_27\VBN|adrenaline|- (r_amod) arrhythmias_28\NNS|induced (r_dobj) suppress_24\VB|to|arrhythmias (r_advcl) needed_22\VBN|dose|whereas|mg/kg|was|suppress|. (l_nsubjpass) dose_2\NN|a|lower|of|i.v. (l_appos) i.v._6\NN|of (l_prep) of_7\IN|suppressed (l_pcomp) suppressed_10\VBD|(|-)-cibenzoline|arrhythmia|, (l_dobj) arrhythmia_15\NN|the|induced
D004837_D001145 CID adrenaline_25\NN| (r_npadvmod) induced_27\VBN|adrenaline|- (r_amod) arrhythmias_28\NNS|induced
D004837_D001145 CID adrenaline_11\NN| (r_npadvmod) induced_13\VBN|adrenaline|- (r_conj) digitalis-_9\NN|and|induced (r_amod) arrhythmia_14\NN|digitalis-
D006221_D001145 NONE halothane_17\NN| (r_npadvmod) anesthetized_19\VBN|halothane|- (r_amod) dogs_20\NNS|anesthetized (r_pobj) in_16\IN|dogs (r_prep) infusion_15\NN|adrenaline|in (r_pobj) by_13\IN|infusion (r_agent) induced_12\VBN|arrhythmia|was|by|. (l_nsubjpass) arrhythmia_1\NN|adrenaline|,|suppressed|,
7416947
D004077_D020018 CID digoxin_13\NN| (r_pobj) of_12\IN|digoxin (r_prep) administration_11\NN|term|of (r_pobj) on_7\IN|administration (r_prep) patients_6\NNS|on (r_pobj) of_5\IN|patients (r_prep) dysfunction_4\NN|sexual|of
D004077_D012214 NONE digoxin_10\NN| (r_pobj) without_9\IN|digoxin (r_prep) group_7\NN|the|study|(|without|) (r_pobj) of_2\IN|group (r_prep) patients_1\NNS|the|of (r_nsubj) were_12\VBD|patients|of|and|selected|. (l_conj) selected_29\VBN|were|randomly|from (l_prep) from_30\IN|patients (l_pobj) patients_35\NNS|the|rheumatic|disease (l_compound) disease_34\NN|heart
19917396
D016559_D006332 CID tacrolimus_5\NNS|in (r_pobj) by_4\IN|tacrolimus (r_agent) induced_3\VBN|by (r_acl) hypertrophy_2\NN|reversible|myocardial|induced
D016559_D006332 CID tacrolimus_8\NNS|after (r_pobj) by_7\IN|tacrolimus (r_agent) induced_6\VBN|by (r_acl) hypertrophy_5\NN|transient|myocardial|induced
D016559_D006332 CID tacrolimus_10\NN| (r_pobj) of_9\IN|tacrolimus (r_prep) concentration_8\NN|the|target|of (r_dobj) reducing_5\VBG|concentration (r_pcomp) upon_4\IN|reducing (r_prep) resolved_3\VBN|hypertrophy|completely|upon|and|recur|. (l_nsubj) hypertrophy_1\NN|myocardial
D016559_D006332 CID tacrolimus_5\NN| (r_nsubj) induces_6\VBZ|that|tacrolimus|hypertrophy (l_dobj) hypertrophy_9\NN|reversible|myocardial
10910842
D011239_D018908 CID Prednisolone_0\NNP| (r_npadvmod) induced_2\VBN|prednisolone|- (r_amod) dysfunction_4\NN|induced|muscle
D011239_D001284 NONE Prednisolone_0\NNP| (r_npadvmod) induced_2\VBN|prednisolone|- (r_amod) dysfunction_4\NN|induced|muscle (r_nsubjpass) caused_6\VBN|dysfunction|is|more|by|. (l_agent) by_8\IN|atrophy (l_pobj) atrophy_9\NN|than
D000109_D018908 NONE acetylcholine_13\NN| (r_compound) expression_15\NN|altered|acetylcholine|receptor (r_pobj) by_11\IN|expression (r_prep) than_10\IN|by (r_prep) atrophy_9\NN|than (r_pobj) by_8\IN|atrophy (r_agent) caused_6\VBN|dysfunction|is|more|by|. (l_nsubjpass) dysfunction_4\NN|induced|muscle
D000109_D001284 NONE acetylcholine_13\NN| (r_compound) expression_15\NN|altered|acetylcholine|receptor (r_pobj) by_11\IN|expression (r_prep) than_10\IN|by (r_prep) atrophy_9\NN|than
D014403_D013746 NONE tubocurarine_27\NN|d|- (r_pobj) of_24\IN|tubocurarine (r_prep) curves_23\NNS|the|response|of|in (r_conj) fatigability_16\NN|,|and|curves (r_conj) tensions_13\NNS|tetanic|,|and|fatigability (l_compound) tetanic_12\JJ|
D011239_D009468 NONE prednisolone_8\NN| (r_pobj) after_7\IN|prednisolone (r_prep) dysfunction_6\NN|the|neuromuscular|after
D011239_D009133 CID prednisolone_8\NN| (r_pobj) after_7\IN|prednisolone (r_prep) dysfunction_6\NN|the|neuromuscular|after (r_nsubj) is_9\VBZ|that|dysfunction|dependent|,|and|derives (l_conj) derives_15\VBZ|primarily|from|and|derives (l_prep) from_17\IN|atrophy (l_pobj) atrophy_19\NN|muscle
D000109_D009133 NONE acetylcholine_22\NN| (r_compound) expression_24\NN|acetylcholine|receptor (r_pobj) in_21\IN|expression (r_prep) changes_20\NNS|in (r_pobj) from_19\IN|changes (r_prep) less_18\JJR|from (r_advmod) derive_17\VB|less (r_conj) derive_11\VBP|primarily|from|and|derive (l_prep) from_13\IN|atrophy (l_pobj) atrophy_15\NN|muscle
11079278
D008790_D017202 NONE metoprolol_3\NN|intravenous|or|metoprolol (l_conj) metoprolol_6\NN|intravenous|plus|glucagon (l_conj) glucagon_8\NN|on (l_prep) on_9\IN|ischemia (l_pobj) ischemia_14\NN|induced|myocardial
D008790_D017202 NONE metoprolol_6\NN|intravenous|plus|glucagon (l_conj) glucagon_8\NN|on (l_prep) on_9\IN|ischemia (l_pobj) ischemia_14\NN|induced|myocardial
D008790_D017202 NONE metoprolol_5\FW| (r_nsubj) attenuates_6\VBZ|during|,|metoprolol|or|eliminates|. (l_conj) eliminates_8\VBZ|evidence (l_dobj) evidence_9\NN|of (l_prep) of_10\IN|ischemia (l_pobj) ischemia_12\NN|myocardial
D004280_D017202 CID dobutamine_10\NN| (r_npadvmod) induced_12\VBN|dobutamine|- (r_amod) ischemia_14\NN|induced|myocardial
D004280_D017202 CID dobutamine_1\NN|testing (r_pcomp) During_0\IN|dobutamine (r_prep) attenuates_6\VBZ|during|,|metoprolol|or|eliminates|. (l_conj) eliminates_8\VBZ|evidence (l_dobj) evidence_9\NN|of (l_prep) of_10\IN|ischemia (l_pobj) ischemia_12\NN|myocardial
7785794
D014700_D012770 NONE verapamil_8\NN| (r_compound) SR_9\NNP|verapamil (r_pobj) after_7\IN|sr (r_prep) shock_2\NN|refractory|cardiogenic|and|block|after|and|metoprolol|.
D014700_D006327 CID verapamil_8\NN| (r_compound) SR_9\NNP|verapamil (r_pobj) after_7\IN|sr (r_prep) shock_2\NN|refractory|cardiogenic|and|block|after|and|metoprolol|. (l_conj) block_6\NN|complete|heart
D014700_D006327 CID verapamil_27\NN|release (r_pobj) of_23\IN|verapamil (r_prep) dose_22\NN|a|therapeutic|of|with (r_pobj) after_19\IN|days|dose (r_prep) presented_9\VBN|woman|with|after|. (l_prep) with_10\IN|block (l_pobj) block_13\NN|complete|heart|and|hypotension
D008790_D012770 NONE metoprolol_11\NN|treatment (r_conj) shock_2\NN|refractory|cardiogenic|and|block|after|and|metoprolol|.
D008790_D006327 CID metoprolol_11\NN|treatment (r_conj) shock_2\NN|refractory|cardiogenic|and|block|after|and|metoprolol|. (l_conj) block_6\NN|complete|heart
D008790_D006327 CID metoprolol_32\NN| (r_pobj) of_31\IN|metoprolol (r_prep) use_30\NN|concomitant|of (r_pobj) with_28\IN|use (r_prep) dose_22\NN|a|therapeutic|of|with (r_pobj) after_19\IN|days|dose (r_prep) presented_9\VBN|woman|with|after|. (l_prep) with_10\IN|block (l_pobj) block_13\NN|complete|heart|and|hypotension
D014700_D007022 CID verapamil_27\NN|release (r_pobj) of_23\IN|verapamil (r_prep) dose_22\NN|a|therapeutic|of|with (r_pobj) after_19\IN|days|dose (r_prep) presented_9\VBN|woman|with|after|. (l_prep) with_10\IN|block (l_pobj) block_13\NN|complete|heart|and|hypotension (l_conj) hypotension_16\NN|refractory
D008790_D007022 CID metoprolol_32\NN| (r_pobj) of_31\IN|metoprolol (r_prep) use_30\NN|concomitant|of (r_pobj) with_28\IN|use (r_prep) dose_22\NN|a|therapeutic|of|with (r_pobj) after_19\IN|days|dose (r_prep) presented_9\VBN|woman|with|after|. (l_prep) with_10\IN|block (l_pobj) block_13\NN|complete|heart|and|hypotension (l_conj) hypotension_16\NN|refractory
D001285_D007022 NONE atropine_17\NN|intravenous|as (r_pobj) of_15\IN|atropine (r_prep) uses_14\NNS|multiple|of|doses (r_pobj) with_12\IN|even|uses (r_prep) remain_4\VB|to|hypotensive|,|with (l_acomp) hypotensive_5\JJ|with
D001285_D006327 NONE atropine_17\NN|intravenous|as (r_pobj) of_15\IN|atropine (r_prep) uses_14\NNS|multiple|of|doses (r_pobj) with_12\IN|even|uses (r_prep) remain_4\VB|to|hypotensive|,|with (l_acomp) hypotensive_5\JJ|with (l_prep) with_6\IN|block (l_pobj) block_9\NN|complete|heart
D004298_D007022 NONE dopamine_28\NN|and|dobutamine (r_pobj) as_27\IN|such|dopamine (r_prep) agents_25\NNS|pressor|as (r_pobj) of_23\IN|agents (r_prep) doses_22\NNS|high|of (r_conj) uses_14\NNS|multiple|of|doses (r_pobj) with_12\IN|even|uses (r_prep) remain_4\VB|to|hypotensive|,|with (l_acomp) hypotensive_5\JJ|with
D004298_D006327 NONE dopamine_28\NN|and|dobutamine (r_pobj) as_27\IN|such|dopamine (r_prep) agents_25\NNS|pressor|as (r_pobj) of_23\IN|agents (r_prep) doses_22\NNS|high|of (r_conj) uses_14\NNS|multiple|of|doses (r_pobj) with_12\IN|even|uses (r_prep) remain_4\VB|to|hypotensive|,|with (l_acomp) hypotensive_5\JJ|with (l_prep) with_6\IN|block (l_pobj) block_9\NN|complete|heart
D004280_D007022 NONE dobutamine_30\NN| (r_conj) dopamine_28\NN|and|dobutamine (r_pobj) as_27\IN|such|dopamine (r_prep) agents_25\NNS|pressor|as (r_pobj) of_23\IN|agents (r_prep) doses_22\NNS|high|of (r_conj) uses_14\NNS|multiple|of|doses (r_pobj) with_12\IN|even|uses (r_prep) remain_4\VB|to|hypotensive|,|with (l_acomp) hypotensive_5\JJ|with
D004280_D006327 NONE dobutamine_30\NN| (r_conj) dopamine_28\NN|and|dobutamine (r_pobj) as_27\IN|such|dopamine (r_prep) agents_25\NNS|pressor|as (r_pobj) of_23\IN|agents (r_prep) doses_22\NNS|high|of (r_conj) uses_14\NNS|multiple|of|doses (r_pobj) with_12\IN|even|uses (r_prep) remain_4\VB|to|hypotensive|,|with (l_acomp) hypotensive_5\JJ|with (l_prep) with_6\IN|block (l_pobj) block_9\NN|complete|heart
D002122_D007022 NONE chloride_9\NN|intravenous|calcium|,|hypotension (l_conj) hypotension_13\NN|the|refractory|and|block
D002122_D006327 NONE chloride_9\NN|intravenous|calcium|,|hypotension (l_conj) hypotension_13\NN|the|refractory|and|block (l_conj) block_17\NN|complete|heart
6794356
D016651_D014262 NONE carbonate_5\NN|lithium (r_compound) toxicity_6\NN|carbonate (r_conj) regurgitation_2\NN|tricuspid|valve|and|toxicity|in|.
D016651_D064420 NONE carbonate_5\NN|lithium (r_compound) toxicity_6\NN|carbonate
D008094_D014262 NONE lithium_18\NN|serum (r_compound) level_19\NN|a|high|lithium (r_conj) failure_12\NN|heart|,|and|level (r_conj) flutter_8\JJ|atrial|,|failure (r_conj) regurgitation_5\NN|massive|tricuspid|,|flutter
D008094_D014262 NONE lithium_26\NN| (r_compound) compounds_27\NNS|lithium (r_pobj) to_25\IN|compounds (r_prep) exposed_24\VBN|to|in (r_acl) infants_23\NNS|exposed (r_pobj) among_22\IN|infants (r_prep) disease_21\NN|cardiac|among (r_pobj) with_19\IN|disease (r_prep) patient_18\NN|with (r_dobj) described_17\VBN|11th|patient|. (r_conj) is_1\VBZ|this|patient|,|and|described (l_attr) patient_4\NN|the|first|manifest (l_relcl) manifest_7\VB|to|initially|regurgitation (l_dobj) regurgitation_9\NN|tricuspid|and|flutter
D008094_D001282 NONE lithium_18\NN|serum (r_compound) level_19\NN|a|high|lithium (r_conj) failure_12\NN|heart|,|and|level (r_conj) flutter_8\JJ|atrial|,|failure
D008094_D001282 NONE lithium_26\NN| (r_compound) compounds_27\NNS|lithium (r_pobj) to_25\IN|compounds (r_prep) exposed_24\VBN|to|in (r_acl) infants_23\NNS|exposed (r_pobj) among_22\IN|infants (r_prep) disease_21\NN|cardiac|among (r_pobj) with_19\IN|disease (r_prep) patient_18\NN|with (r_dobj) described_17\VBN|11th|patient|. (r_conj) is_1\VBZ|this|patient|,|and|described (l_attr) patient_4\NN|the|first|manifest (l_relcl) manifest_7\VB|to|initially|regurgitation (l_dobj) regurgitation_9\NN|tricuspid|and|flutter (l_conj) flutter_12\NN|atrial
D008094_D006333 NONE lithium_18\NN|serum (r_compound) level_19\NN|a|high|lithium (r_conj) failure_12\NN|heart|,|and|level
D008094_D006331 NONE lithium_26\NN| (r_compound) compounds_27\NNS|lithium (r_pobj) to_25\IN|compounds (r_prep) exposed_24\VBN|to|in (r_acl) infants_23\NNS|exposed (r_pobj) among_22\IN|infants (r_prep) disease_21\NN|cardiac|among
D016651_D006331 NONE carbonate_1\NN|lithium (r_nsubj) be_3\VB|carbonate|may|factor|in|taken|. (l_prep) in_6\IN|incidence (l_pobj) incidence_9\NN|the|increasing|of (l_prep) of_10\IN|disease (l_pobj) disease_13\NN|congenital|heart
10328196
D020123_D064420 NONE sirolimus_5\NN| (r_pobj) of_4\IN|sirolimus (r_prep) administration_3\NN|of (r_dobj) following_2\VBG|administration (r_prep) toxicity_1\NN|systemic|following|(|rapamycin|)|for|:|association|.
D020123_D064420 NONE rapamycin_8\VBZ|formerly (r_appos) toxicity_1\NN|systemic|following|(|rapamycin|)|for|:|association|.
D020123_D011565 NONE sirolimus_5\NN| (r_pobj) of_4\IN|sirolimus (r_prep) administration_3\NN|of (r_dobj) following_2\VBG|administration (r_prep) toxicity_1\NN|systemic|following|(|rapamycin|)|for|:|association|. (l_prep) for_10\IN|psoriasis (l_pobj) psoriasis_11\NN|
D020123_D011565 NONE rapamycin_8\VBZ|formerly (r_appos) toxicity_1\NN|systemic|following|(|rapamycin|)|for|:|association|. (l_prep) for_10\IN|psoriasis (l_pobj) psoriasis_11\NN|
D020123_D011565 NONE sirolimus_14\NN|oral (r_nmod) cells_17\NNS|sirolimus|lesional|skin (r_pobj) with_12\IN|cells (r_prep) treatment_11\NN|with (r_pobj) following_10\VBG|treatment (r_acl) syndrome_9\NN|a|leak|following (r_dobj) developed_5\VBD|after|individuals|syndrome|and|analyzed|. (l_nsubj) individuals_2\NNS|2|with (l_prep) with_3\IN|psoriasis (l_pobj) psoriasis_4\NN|
D020123_D011565 NONE sirolimus_8\NN| (r_npadvmod) induced_10\VBN|sirolimus|- (r_amod) syndrome_13\NN|induced|leak (r_pobj) with_7\IN|syndrome (r_prep) patient_6\NN|1|with (r_pobj) from_4\IN|patient (r_prep) specimen_3\NN|a|keratome|skin|from (r_nsubj) had_14\VBD|specimen|increase|compared|. (l_prep) compared_28\VBN|with (l_prep) with_29\IN|patient (l_pobj) patient_35\NN|an|unaffected|treated|with|(|%|) (l_prep) with_36\IN|psoriasis (l_pobj) psoriasis_37\NN|
D020123_D011565 NONE sirolimus_32\NN| (r_npadvmod) treated_34\VBN|sirolimus|- (r_amod) patient_35\NN|an|unaffected|treated|with|(|%|) (l_prep) with_36\IN|psoriasis (l_pobj) psoriasis_37\NN|
D020123_D011565 NONE sirolimus_30\NN| (r_pobj) of_29\IN|sirolimus (r_prep) presence_28\NN|the|of (r_pobj) in_26\IN|particularly|presence (r_prep) did_20\VBD|than|cells|,|in (r_advcl) apoptosis_18\NN|spontaneous|did (r_oprd) exhibit_11\VB|to|apoptosis (r_xcomp) tended_9\VBD|exhibit (r_ccomp) Activated_0\VBN|cells|tended|. (l_dobj) cells_4\NNS|peripheral|t|from (l_prep) from_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|psoriasis (l_pobj) psoriasis_8\NN|
D020123_D019559 CID sirolimus_5\NN| (r_pobj) of_4\IN|sirolimus (r_prep) administration_3\NN|of (r_dobj) following_2\VBG|administration (r_prep) toxicity_1\NN|systemic|following|(|rapamycin|)|for|:|association|. (l_appos) association_13\NN|of|with (l_prep) of_14\IN|syndrome (l_pobj) syndrome_17\NN|leak
D020123_D019559 CID rapamycin_8\VBZ|formerly (r_appos) toxicity_1\NN|systemic|following|(|rapamycin|)|for|:|association|. (l_appos) association_13\NN|of|with (l_prep) of_14\IN|syndrome (l_pobj) syndrome_17\NN|leak
D020123_D019559 CID sirolimus_14\NN|oral (r_nmod) cells_17\NNS|sirolimus|lesional|skin (r_pobj) with_12\IN|cells (r_prep) treatment_11\NN|with (r_pobj) following_10\VBG|treatment (r_acl) syndrome_9\NN|a|leak|following
D020123_D019559 CID sirolimus_8\NN| (r_npadvmod) induced_10\VBN|sirolimus|- (r_amod) syndrome_13\NN|induced|leak
D020123_D019559 CID sirolimus_32\NN| (r_npadvmod) treated_34\VBN|sirolimus|- (r_amod) patient_35\NN|an|unaffected|treated|with|(|%|) (r_pobj) with_29\IN|patient (r_prep) compared_28\VBN|with (r_prep) had_14\VBD|specimen|increase|compared|. (l_nsubj) specimen_3\NN|a|keratome|skin|from (l_prep) from_4\IN|patient (l_pobj) patient_6\NN|1|with (l_prep) with_7\IN|syndrome (l_pobj) syndrome_13\NN|induced|leak
D020123_D019559 CID sirolimus_4\NN| (r_pobj) of_3\IN|sirolimus (r_prep) effects_2\NNS|severe|adverse|of (r_nsubj) include_5\VBP|effects|fever|. (l_dobj) fever_6\NN|,|anemia (l_conj) anemia_8\NN|,|and|syndrome (l_conj) syndrome_13\NN|leak
D003907_D011565 NONE dexamethasone_15\NN| (r_npadvmod) induced_17\VBN|dexamethasone|- (r_conj) spontaneous_13\JJ|greater|or|induced (r_amod) apoptosis_18\NN|spontaneous|did (r_oprd) exhibit_11\VB|to|apoptosis (r_xcomp) tended_9\VBD|exhibit (r_ccomp) Activated_0\VBN|cells|tended|. (l_dobj) cells_4\NNS|peripheral|t|from (l_prep) from_5\IN|patients (l_pobj) patients_6\NNS|with (l_prep) with_7\IN|psoriasis (l_pobj) psoriasis_8\NN|
D020123_D005334 NONE sirolimus_4\NN| (r_pobj) of_3\IN|sirolimus (r_prep) effects_2\NNS|severe|adverse|of (r_nsubj) include_5\VBP|effects|fever|. (l_dobj) fever_6\NN|,|anemia
D020123_D000740 NONE sirolimus_4\NN| (r_pobj) of_3\IN|sirolimus (r_prep) effects_2\NNS|severe|adverse|of (r_nsubj) include_5\VBP|effects|fever|. (l_dobj) fever_6\NN|,|anemia (l_conj) anemia_8\NN|,|and|syndrome
11752998
D000241_D059787 NONE adenosine_4\NN|intrathecal (r_pobj) of_2\IN|adenosine (r_prep) studies_1\NNS|preclinical|of (r_nsubj) suggest_5\VBP|studies|be|and|suggests (l_ccomp) be_8\VB|it|may|effective|, (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|pain (l_pobj) pain_17\NN|acute|in
D000241_D059787 NONE adenosine_33\NN| (r_pobj) of_32\IN|adenosine (r_prep) formulation_31\NN|a|swedish|of (r_pobj) with_28\IN|formulation (r_prep) volunteers_25\NNS|and|patients|with (r_pobj) in_24\IN|volunteers (r_prep) studies_23\NNS|preliminary|in (r_nsubj) suggests_34\VBZ|studies|be|. (r_conj) suggest_5\VBP|studies|be|and|suggests (l_ccomp) be_8\VB|it|may|effective|, (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|pain (l_pobj) pain_17\NN|acute|in
D000241_D059350 NONE adenosine_4\NN|intrathecal (r_pobj) of_2\IN|adenosine (r_prep) studies_1\NNS|preclinical|of (r_nsubj) suggest_5\VBP|studies|be|and|suggests (l_ccomp) be_8\VB|it|may|effective|, (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|pain (l_pobj) pain_17\NN|acute|in
D000241_D059350 NONE adenosine_33\NN| (r_pobj) of_32\IN|adenosine (r_prep) formulation_31\NN|a|swedish|of (r_pobj) with_28\IN|formulation (r_prep) volunteers_25\NNS|and|patients|with (r_pobj) in_24\IN|volunteers (r_prep) studies_23\NNS|preliminary|in (r_nsubj) suggests_34\VBZ|studies|be|. (r_conj) suggest_5\VBP|studies|be|and|suggests (l_ccomp) be_8\VB|it|may|effective|, (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|treatment (l_pobj) treatment_12\NN|the|of (l_prep) of_13\IN|pain (l_pobj) pain_17\NN|acute|in
D000241_D004342 NONE adenosine_4\NN|intrathecal (r_pobj) of_2\IN|adenosine (r_prep) studies_1\NNS|preclinical|of (r_nsubj) suggest_5\VBP|studies|be|and|suggests (l_conj) suggests_34\VBZ|studies|be|. (l_ccomp) be_37\VB|it|may|effective|but|with (l_acomp) effective_38\JJ|in (l_prep) in_39\IN|states (l_pobj) states_41\NNS|hypersensitivity (l_compound) hypersensitivity_40\NN|
D000241_D004342 NONE adenosine_33\NN| (r_pobj) of_32\IN|adenosine (r_prep) formulation_31\NN|a|swedish|of (r_pobj) with_28\IN|formulation (r_prep) volunteers_25\NNS|and|patients|with (r_pobj) in_24\IN|volunteers (r_prep) studies_23\NNS|preliminary|in (r_nsubj) suggests_34\VBZ|studies|be|. (l_ccomp) be_37\VB|it|may|effective|but|with (l_acomp) effective_38\JJ|in (l_prep) in_39\IN|states (l_pobj) states_41\NNS|hypersensitivity (l_compound) hypersensitivity_40\NN|
D000241_D004342 NONE adenosine_15\NN|marketed (r_pobj) of_14\IN|adenosine (r_prep) formulation_13\NN|a|different|of (r_pobj) of_10\IN|formulation (r_prep) efficacy_9\NN|of (r_pobj) for_8\IN|efficacy (r_prep) screen_7\VB|to|for|,|using (l_advcl) using_21\VBG|stimulation (l_dobj) stimulation_25\NN|both|acute|noxious|and|hypersensitivity (l_conj) hypersensitivity_31\NN|evoked|mechanical
D000241_D004342 NONE adenosine_7\NN|intrathecal|of (l_prep) of_8\IN|hypersensitivity (l_pobj) hypersensitivity_9\NN|
D002211_D004342 NONE capsaicin_27\NN| (r_npadvmod) evoked_29\VBN|capsaicin|- (r_amod) hypersensitivity_31\NN|evoked|mechanical
D002211_D004342 NONE capsaicin_20\NN| (r_compound) injection_21\NN|peripheral|capsaicin (r_pobj) after_18\IN|injection (r_prep) reflect_13\VB|to|sensitization|after (r_xcomp) presumed_11\VBN|reflect (r_advcl) show_2\VBP|results|inhibition|,|presumed|. (l_dobj) inhibition_4\NN|selective|by (l_prep) by_5\IN|adenosine (l_pobj) adenosine_7\NN|intrathecal|of (l_prep) of_8\IN|hypersensitivity (l_pobj) hypersensitivity_9\NN|
D000241_D010146 NONE adenosine_34\NN| (r_amod) doses_35\NNS|intrathecal|adenosine|of|and|trial (r_pobj) with_32\IN|doses (r_prep) trial_31\NN|an|label|,|escalating|with|, (r_appos) trials_21\NNS|two|:|trial (r_pobj) in_19\IN|trials (r_prep) studied_18\VBN|following|,|volunteers|were|in|obtained (l_conj) obtained_59\VBN|fluid|was|for|,|and|determined (l_conj) determined_85\VBN|ratings|were|. (l_nsubjpass) ratings_66\NNS|pain|in (l_compound) pain_65\NN|
D000241_D010146 NONE adenosine_52\NN| (r_pobj) of_51\IN|adenosine (r_prep) trial_50\NN|a|blind|,|controlled|of (r_conj) doses_35\NNS|intrathecal|adenosine|of|and|trial (r_pobj) with_32\IN|doses (r_prep) trial_31\NN|an|label|,|escalating|with|, (r_appos) trials_21\NNS|two|:|trial (r_pobj) in_19\IN|trials (r_prep) studied_18\VBN|following|,|volunteers|were|in|obtained (l_conj) obtained_59\VBN|fluid|was|for|,|and|determined (l_conj) determined_85\VBN|ratings|were|. (l_nsubjpass) ratings_66\NNS|pain|in (l_compound) pain_65\NN|
D000241_D010146 NONE Adenosine_0\NNP| (r_nsubj) produced_1\VBD|adenosine|effect|to (l_dobj) effect_3\NN|no|on (l_prep) on_4\IN|report (l_pobj) report_6\NN|pain (l_compound) pain_5\NN|
D000241_D006930 NONE adenosine_34\NN| (r_amod) doses_35\NNS|intrathecal|adenosine|of|and|trial (r_pobj) with_32\IN|doses (r_prep) trial_31\NN|an|label|,|escalating|with|, (r_appos) trials_21\NNS|two|:|trial (r_pobj) in_19\IN|trials (r_prep) studied_18\VBN|following|,|volunteers|were|in|obtained (l_conj) obtained_59\VBN|fluid|was|for|,|and|determined (l_conj) determined_85\VBN|ratings|were|. (l_nsubjpass) ratings_66\NNS|pain|in (l_prep) in_67\IN|response (l_pobj) response_68\NN|to (l_prep) to_69\IN|stimuli (l_pobj) stimuli_72\NNS|acute|heat|and|areas|after (l_conj) areas_74\NNS|of (l_prep) of_75\IN|hyperalgesia (l_pobj) hyperalgesia_77\NN|mechanical|and|allodynia
D000241_D006930 NONE adenosine_34\NN| (r_amod) doses_35\NNS|intrathecal|adenosine|of|and|trial (r_pobj) with_32\IN|doses (r_prep) trial_31\NN|an|label|,|escalating|with|, (r_appos) trials_21\NNS|two|:|trial (r_pobj) in_19\IN|trials (r_prep) studied_18\VBN|following|,|volunteers|were|in|obtained (l_conj) obtained_59\VBN|fluid|was|for|,|and|determined (l_conj) determined_85\VBN|ratings|were|. (l_nsubjpass) ratings_66\NNS|pain|in (l_prep) in_67\IN|response (l_pobj) response_68\NN|to (l_prep) to_69\IN|stimuli (l_pobj) stimuli_72\NNS|acute|heat|and|areas|after (l_conj) areas_74\NNS|of (l_prep) of_75\IN|hyperalgesia (l_pobj) hyperalgesia_77\NN|mechanical|and|allodynia (l_conj) allodynia_79\NN|
D000241_D006930 NONE adenosine_52\NN| (r_pobj) of_51\IN|adenosine (r_prep) trial_50\NN|a|blind|,|controlled|of (r_conj) doses_35\NNS|intrathecal|adenosine|of|and|trial (r_pobj) with_32\IN|doses (r_prep) trial_31\NN|an|label|,|escalating|with|, (r_appos) trials_21\NNS|two|:|trial (r_pobj) in_19\IN|trials (r_prep) studied_18\VBN|following|,|volunteers|were|in|obtained (l_conj) obtained_59\VBN|fluid|was|for|,|and|determined (l_conj) determined_85\VBN|ratings|were|. (l_nsubjpass) ratings_66\NNS|pain|in (l_prep) in_67\IN|response (l_pobj) response_68\NN|to (l_prep) to_69\IN|stimuli (l_pobj) stimuli_72\NNS|acute|heat|and|areas|after (l_conj) areas_74\NNS|of (l_prep) of_75\IN|hyperalgesia (l_pobj) hyperalgesia_77\NN|mechanical|and|allodynia
D000241_D006930 NONE adenosine_52\NN| (r_pobj) of_51\IN|adenosine (r_prep) trial_50\NN|a|blind|,|controlled|of (r_conj) doses_35\NNS|intrathecal|adenosine|of|and|trial (r_pobj) with_32\IN|doses (r_prep) trial_31\NN|an|label|,|escalating|with|, (r_appos) trials_21\NNS|two|:|trial (r_pobj) in_19\IN|trials (r_prep) studied_18\VBN|following|,|volunteers|were|in|obtained (l_conj) obtained_59\VBN|fluid|was|for|,|and|determined (l_conj) determined_85\VBN|ratings|were|. (l_nsubjpass) ratings_66\NNS|pain|in (l_prep) in_67\IN|response (l_pobj) response_68\NN|to (l_prep) to_69\IN|stimuli (l_pobj) stimuli_72\NNS|acute|heat|and|areas|after (l_conj) areas_74\NNS|of (l_prep) of_75\IN|hyperalgesia (l_pobj) hyperalgesia_77\NN|mechanical|and|allodynia (l_conj) allodynia_79\NN|
D000241_D006930 NONE Adenosine_0\NNP| (r_nsubj) produced_1\VBD|adenosine|effect|to (l_prep) to_7\IN|stimulation (l_pobj) stimulation_13\NN|acute|noxious|thermal|but|hyperalgesia (l_conj) hyperalgesia_17\NN|reduced|mechanical|and|allodynia|for
D000241_D006930 NONE Adenosine_0\NNP| (r_nsubj) produced_1\VBD|adenosine|effect|to (l_prep) to_7\IN|stimulation (l_pobj) stimulation_13\NN|acute|noxious|thermal|but|hyperalgesia (l_conj) hyperalgesia_17\NN|reduced|mechanical|and|allodynia|for (l_conj) allodynia_19\NN|from
D002211_D010146 NONE capsaicin_82\NN| (r_compound) injection_83\NN|intradermal|capsaicin (r_pobj) after_80\IN|injection (r_prep) stimuli_72\NNS|acute|heat|and|areas|after (r_pobj) to_69\IN|stimuli (r_prep) response_68\NN|to (r_pobj) in_67\IN|response (r_prep) ratings_66\NNS|pain|in (l_compound) pain_65\NN|
D002211_D010146 NONE capsaicin_22\NN| (r_compound) injection_23\NN|intradermal|capsaicin (r_pobj) from_20\IN|injection (r_prep) allodynia_19\NN|from (r_conj) hyperalgesia_17\NN|reduced|mechanical|and|allodynia|for (r_conj) stimulation_13\NN|acute|noxious|thermal|but|hyperalgesia (r_pobj) to_7\IN|stimulation (r_prep) produced_1\VBD|adenosine|effect|to (l_dobj) effect_3\NN|no|on (l_prep) on_4\IN|report (l_pobj) report_6\NN|pain (l_compound) pain_5\NN|
D002211_D006930 CID capsaicin_82\NN| (r_compound) injection_83\NN|intradermal|capsaicin (r_pobj) after_80\IN|injection (r_prep) stimuli_72\NNS|acute|heat|and|areas|after (l_conj) areas_74\NNS|of (l_prep) of_75\IN|hyperalgesia (l_pobj) hyperalgesia_77\NN|mechanical|and|allodynia
D002211_D006930 CID capsaicin_82\NN| (r_compound) injection_83\NN|intradermal|capsaicin (r_pobj) after_80\IN|injection (r_prep) stimuli_72\NNS|acute|heat|and|areas|after (l_conj) areas_74\NNS|of (l_prep) of_75\IN|hyperalgesia (l_pobj) hyperalgesia_77\NN|mechanical|and|allodynia (l_conj) allodynia_79\NN|
D002211_D006930 CID capsaicin_22\NN| (r_compound) injection_23\NN|intradermal|capsaicin (r_pobj) from_20\IN|injection (r_prep) allodynia_19\NN|from (r_conj) hyperalgesia_17\NN|reduced|mechanical|and|allodynia|for
D002211_D006930 CID capsaicin_22\NN| (r_compound) injection_23\NN|intradermal|capsaicin (r_pobj) from_20\IN|injection (r_prep) allodynia_19\NN|from
D000241_D009437 NONE adenosine_27\NN| (r_pobj) of_26\IN|adenosine (r_prep) residence_25\NN|prolonged|of|in (r_pobj) due_22\JJ|to|residence (r_acomp) is_20\VBZ|not|due (r_conj) is_5\VBZ|effect|consistent|and|is|. (l_acomp) consistent_6\JJ|with (l_prep) with_7\IN|observed (l_pcomp) observed_9\VBN|that|in (l_prep) in_10\IN|reports (l_pobj) reports_12\NNS|preliminary|of (l_prep) of_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|pain (l_pobj) pain_18\NN|chronic|neuropathic
16634859
D000431_D006130 CID alcohol_9\NN| (r_npadvmod) related_11\VBN|alcohol|- (r_amod) impairment_14\NN|related|growth
D000431_D006130 CID alcohol_1\NN| (r_compound) consumption_2\NN|alcohol (r_compound) recognition_4\NN|any|consumption|postpregnancy|among (r_nsubj) resulted_9\VBD|recognition|in|. (l_prep) in_10\IN|growth (l_pobj) growth_13\NN|reduced|cerebellar|as|cranial
D000431_D006130 CID alcohol_1\NN| (r_compound) consumption_2\NN|alcohol (r_compound) recognition_4\NN|any|consumption|postpregnancy|among (r_nsubj) resulted_9\VBD|recognition|in|. (l_prep) in_10\IN|growth (l_pobj) growth_13\NN|reduced|cerebellar|as|cranial (l_conj) cranial_18\JJ|decreased|body (l_acl) body_20\NN|to|growth|in (l_dobj) growth_21\NN|
17923537
D005446_D014605 NONE acetonide_9\NN| (r_compound) implants_10\NNS|fluocinolone|acetonide (r_pobj) with_7\IN|implants (r_prep) treated_6\VBN|with (r_acl) pressure_1\NN|intraocular|in|treated|. (l_prep) in_2\IN|patients (l_pobj) patients_3\NNS|with (l_prep) with_4\IN|uveitis (l_pobj) uveitis_5\NN|
D005446_D014605 NONE acetonide_21\NN|the|fluocinolone|implant (r_pobj) with_18\IN|acetonide (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|with|treated (l_prep) with_15\IN|uveitis (l_pobj) uveitis_16\NN|
D005446_D014605 NONE FA_23\NNP| (r_nmod) implant_26\NN|(|fa|)|intravitreal (r_appos) acetonide_21\NN|the|fluocinolone|implant (r_pobj) with_18\IN|acetonide (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|with|treated (l_prep) with_15\IN|uveitis (l_pobj) uveitis_16\NN|
D005446_D009798 CID acetonide_21\NN|the|fluocinolone|implant (r_pobj) with_18\IN|acetonide (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|with|treated (r_pobj) in_13\IN|patients (r_prep) incidence_3\NN|the|and|management|of|in (l_prep) of_6\IN|pressure (l_pobj) pressure_9\NN|elevated|intraocular|(|iop|)
D005446_D009798 CID FA_23\NNP| (r_nmod) implant_26\NN|(|fa|)|intravitreal (r_appos) acetonide_21\NN|the|fluocinolone|implant (r_pobj) with_18\IN|acetonide (r_prep) treated_17\VBN|with (r_acl) patients_14\NNS|with|treated (r_pobj) in_13\IN|patients (r_prep) incidence_3\NN|the|and|management|of|in (l_prep) of_6\IN|pressure (l_pobj) pressure_9\NN|elevated|intraocular|(|iop|)
20727411
-1_D011605 NONE ketamine_5\NN|s|- (r_pobj) of_2\IN|ketamine (r_prep) correlates_1\NNS|neural|of (r_nsubj) induced_6\VBD|correlates|psychosis|during|. (l_dobj) psychosis_7\NN|
D016202_D012559 NONE aspartate_8\NNP|methyl|d|- (r_nmod) receptor_12\NN|the|glutamatergic|aspartate|(|nmda|) (r_nsubjpass) implicated_15\VBN|receptor|has|been|in|. (l_prep) in_16\IN|pathophysiology (l_pobj) pathophysiology_18\NN|the|of (l_prep) of_19\IN|schizophrenia (l_pobj) schizophrenia_20\NN|
D016202_D012559 NONE NMDA_10\NNP| (r_nmod) receptor_12\NN|the|glutamatergic|aspartate|(|nmda|) (r_nsubjpass) implicated_15\VBN|receptor|has|been|in|. (l_prep) in_16\IN|pathophysiology (l_pobj) pathophysiology_18\NN|the|of (l_prep) of_19\IN|schizophrenia (l_pobj) schizophrenia_20\NN|
D016202_D012559 NONE NMDA_13\NNP| (r_compound) antagonist_15\NN|competitive|nmda|receptor (r_compound) ketamine_16\NN|the|antagonist (r_pobj) of_8\IN|ketamine (r_prep) dose_7\NN|a|subanesthetic|of (r_nsubj) leads_17\VBZ|administered|,|dose|to|. (l_prep) to_18\IN|symptoms (l_pobj) symptoms_20\NNS|psychopathological|similar (l_amod) similar_21\JJ|to (l_prep) to_22\IN|those (l_pobj) those_23\DT|observed (l_acl) observed_24\VBN|in (l_prep) in_25\IN|schizophrenia (l_pobj) schizophrenia_26\NN|
D016202_D012559 NONE NMDA_10\NNP| (r_compound) dysfunction_12\NN|an|nmda|receptor|in (l_prep) in_13\IN|pathophysiology (l_pobj) pathophysiology_15\NN|the|of (l_prep) of_16\IN|schizophrenia (l_pobj) schizophrenia_17\NN|
D007649_D012559 NONE ketamine_16\NN|the|antagonist (r_pobj) of_8\IN|ketamine (r_prep) dose_7\NN|a|subanesthetic|of (r_nsubj) leads_17\VBZ|administered|,|dose|to|. (l_prep) to_18\IN|symptoms (l_pobj) symptoms_20\NNS|psychopathological|similar (l_amod) similar_21\JJ|to (l_prep) to_22\IN|those (l_pobj) those_23\DT|observed (l_acl) observed_24\VBN|in (l_prep) in_25\IN|schizophrenia (l_pobj) schizophrenia_26\NN|
D007649_D012559 NONE ketamine_5\NN| (r_nsubj) exacerbates_6\VBZ|in|,|ketamine|symptoms|,|supporting|. (l_prep) In_0\IN|patients (l_pobj) patients_1\NNS|with (l_prep) with_2\IN|schizophrenia (l_pobj) schizophrenia_3\NN|
D007649_D012559 NONE Ketamine_0\NN| (r_nsubj) induces_1\VBZ|ketamine|changes|,|in|. (l_dobj) changes_3\NNS|activation|in (l_prep) in_4\IN|subjects (l_pobj) subjects_6\NNS|healthy|similar (l_amod) similar_7\JJ|to (l_prep) to_8\IN|those (l_pobj) those_9\DT|observed (l_acl) observed_10\VBN|in (l_prep) in_11\IN|patients (l_pobj) patients_12\NNS|with (l_prep) with_13\IN|schizophrenia (l_pobj) schizophrenia_14\NN|
D007649_D018754 NONE ketamine_5\NN| (r_nsubj) exacerbates_6\VBZ|in|,|ketamine|symptoms|,|supporting|. (l_advcl) supporting_13\VBG|hypothesis (l_dobj) hypothesis_15\NN|the|of (l_prep) of_16\IN|dysfunction (l_pobj) dysfunction_19\NN|a|glutamatergic
D007649_D011605 CID Ketamine_0\NN| (r_nsubj) elicited_1\VBD|ketamine|psychosis|. (l_dobj) psychosis_2\NN|like
17943461
D015215_D009202 CID AZT_7\NNP| (r_npadvmod) induced_9\VBN|azt|- (r_amod) cardiomyopathy_10\NN|induced
D015215_D002311 CID zidovudine_12\NNP|3'-azido-2',3'-deoxythymidine (r_appos) component_11\NN|the|haart|zidovudine|;|azt (r_nsubj) triggers_18\VBZ|whether|component|pathway|and|cause (l_conj) cause_28\VB|disruption (l_dobj) disruption_30\NN|cytoskeletal|in (l_prep) in_31\IN|model (l_pobj) model_34\NN|a|murine|of (l_prep) of_35\IN|dcm (l_pobj) DCM_36\NNP|,|transgenic
D015215_D002311 CID 3'-azido-2',3'-deoxythymidine_14\CD|( (r_appos) zidovudine_12\NNP|3'-azido-2',3'-deoxythymidine (r_appos) component_11\NN|the|haart|zidovudine|;|azt (r_nsubj) triggers_18\VBZ|whether|component|pathway|and|cause (l_conj) cause_28\VB|disruption (l_dobj) disruption_30\NN|cytoskeletal|in (l_prep) in_31\IN|model (l_pobj) model_34\NN|a|murine|of (l_prep) of_35\IN|dcm (l_pobj) DCM_36\NNP|,|transgenic
D015215_D002311 CID AZT_16\NNP|) (r_appos) component_11\NN|the|haart|zidovudine|;|azt (r_nsubj) triggers_18\VBZ|whether|component|pathway|and|cause (l_conj) cause_28\VB|disruption (l_dobj) disruption_30\NN|cytoskeletal|in (l_prep) in_31\IN|model (l_pobj) model_34\NN|a|murine|of (l_prep) of_35\IN|dcm (l_pobj) DCM_36\NNP|,|transgenic
D015215_D002311 CID AZT_69\NNP|(|0|,|0.07|,|0.2|,|and|ml (r_pobj) of_68\IN|azt (r_prep) concentrations_67\NNS|different|of (r_dobj) containing_65\VBG|concentrations (r_acl) libitum_64\NN|ad|containing (r_dobj) received_61\VBD|methods|:|in|mice|libitum|. (l_prep) In_4\IN|order (l_pobj) order_5\NN|investigate (l_acl) investigate_7\VB|to|triggers (l_ccomp) triggers_18\VBZ|whether|component|pathway|and|cause (l_conj) cause_28\VB|disruption (l_dobj) disruption_30\NN|cytoskeletal|in (l_prep) in_31\IN|model (l_pobj) model_34\NN|a|murine|of (l_prep) of_35\IN|dcm (l_pobj) DCM_36\NNP|,|transgenic
D015215_D002311 CID AZT_3\NNP| (r_npadvmod) treated_5\VBN|azt|- (r_amod) FasL_6\NNPS|treated (r_compound) mice_8\NNS|fasl|tg (r_nsubj) developed_9\VBD|in|,|mice|dilation|in|,|with|. (l_dobj) dilation_11\NN|cardiac|and|function
28952
D011188_D007008 NONE potassium_1\NN| (r_compound) loss_2\NN|initial|potassium|and|hypokalaemia|:|influence|. (l_conj) hypokalaemia_4\NN|during
D011188_D007008 NONE potassium_4\NN| (r_compound) loss_5\NN|the|initial|potassium|and|development|during (l_conj) development_7\NN|of (l_prep) of_8\IN|hypokalaemia (l_pobj) hypokalaemia_9\NN|
D011188_D007008 NONE potassium_4\NN| (r_compound) loss_5\NN|the|initial|potassium|and|development|during (r_dobj) investigate_1\VB|to|loss (r_csubjpass) performed_22\VBN|investigate|were|in|. (l_prep) in_23\IN|patients (l_pobj) patients_25\NNS|ten|with (l_prep) with_26\IN|hypertension (l_pobj) hypertension_28\NN|essential|shown (l_relcl) shown_31\VBN|who|had|hypokalaemia|under (l_dobj) hypokalaemia_32\NN|
D011188_D006973 NONE potassium_1\NN| (r_compound) loss_2\NN|initial|potassium|and|hypokalaemia|:|influence|. (l_conj) hypokalaemia_4\NN|during (l_prep) during_5\IN|administration (l_pobj) administration_7\NN|chlorthalidone|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|hypertension (l_pobj) hypertension_12\NN|essential
D011188_D006973 NONE potassium_4\NN| (r_compound) loss_5\NN|the|initial|potassium|and|development|during (r_dobj) investigate_1\VB|to|loss (r_csubjpass) performed_22\VBN|investigate|were|in|. (l_prep) in_23\IN|patients (l_pobj) patients_25\NNS|ten|with (l_prep) with_26\IN|hypertension (l_pobj) hypertension_28\NN|essential|shown
D002752_D007008 CID chlorthalidone_6\NN| (r_compound) administration_7\NN|chlorthalidone|in (r_pobj) during_5\IN|administration (r_prep) hypokalaemia_4\NN|during
D002752_D006973 NONE chlorthalidone_6\NN| (r_compound) administration_7\NN|chlorthalidone|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|hypertension (l_pobj) hypertension_12\NN|essential
D012964_D007008 NONE sodium_18\NN| (r_compound) restriction_19\NN|dietary|sodium (r_pobj) of_16\IN|restriction (r_prep) influence_15\NN|the|of (r_appos) loss_2\NN|initial|potassium|and|hypokalaemia|:|influence|. (l_conj) hypokalaemia_4\NN|during
D012964_D006973 NONE sodium_18\NN| (r_compound) restriction_19\NN|dietary|sodium (r_pobj) of_16\IN|restriction (r_prep) influence_15\NN|the|of (r_appos) loss_2\NN|initial|potassium|and|hypokalaemia|:|influence|. (l_conj) hypokalaemia_4\NN|during (l_prep) during_5\IN|administration (l_pobj) administration_7\NN|chlorthalidone|in (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|hypertension (l_pobj) hypertension_12\NN|essential
15638391
D006220_D006966 CID haloperidol_16\NN| (r_pobj) by_15\IN|haloperidol (r_agent) induced_14\VBN|process|by|. (l_nsubj) process_1\NN|aging|of (l_prep) of_2\IN|cells (l_pobj) cells_4\NNS|epithelial|of (l_prep) of_5\IN|lobe (l_pobj) lobe_10\NN|the|rat|prostate|lateral|in (l_prep) in_11\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_13\NN|experimental
D006220_D006966 CID haloperidol_15\NN|hal|on (r_pobj) by_14\IN|haloperidol (r_agent) induced_13\VBN|by (r_advcl) was_5\VBD|aim|examine|induced|. (l_xcomp) examine_7\VB|to|influence|, (l_dobj) influence_9\NN|the|of (l_prep) of_10\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_11\NN|
D006220_D006966 CID HAL_17\NNP|(|) (r_appos) haloperidol_15\NN|hal|on (r_pobj) by_14\IN|haloperidol (r_agent) induced_13\VBN|by (r_advcl) was_5\VBD|aim|examine|induced|. (l_xcomp) examine_7\VB|to|influence|, (l_dobj) influence_9\NN|the|of (l_prep) of_10\IN|hyperprolactinemia (l_pobj) hyperprolactinemia_11\NN|
8665051
D000305_D009135 NONE corticosteroids_17\NNS| (r_pobj) of_16\IN|corticosteroids (r_prep) doses_15\NNS|massive|of (r_pobj) with_13\IN|doses (r_prep) treated_12\VBN|with (r_acl) patients_11\NNS|treated (r_pobj) in_10\IN|patients (r_prep) occur_9\VB|that|myopathy|may|in (l_nsubj) myopathy_7\NN|acute
D008775_D000855 CID methylprednisolone_18\NN|m|,|or|triamcinolone (r_appos) C_15\NNP|saline|(|)|,|methylprednisolone (r_pobj) of_12\IN|c (r_prep) injection_11\NN|daily|of (r_dobj) receive_9\VB|to|injection (r_xcomp) assigned_7\VBN|therefore|,|rats|were|randomly|receive|d|,|measured|,|showed|. (l_conj) showed_46\VBD|reduction|respectively|) (l_dobj) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D008775_D000855 CID M_20\NNP|(|) (r_appos) methylprednisolone_18\NN|m|,|or|triamcinolone (r_appos) C_15\NNP|saline|(|)|,|methylprednisolone (r_pobj) of_12\IN|c (r_prep) injection_11\NN|daily|of (r_dobj) receive_9\VB|to|injection (r_xcomp) assigned_7\VBN|therefore|,|rats|were|randomly|receive|d|,|measured|,|showed|. (l_conj) showed_46\VBD|reduction|respectively|) (l_dobj) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D008775_D000855 CID M_65\NNP|and|t|, (r_pobj) in_64\IN|m (r_prep) %_63\NN|in (r_appos) groups_58\NNS|the|treated|(|-50|% (r_pobj) in_53\IN|groups (r_prep) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D014221_D000855 CID triamcinolone_24\NN|t (r_conj) methylprednisolone_18\NN|m|,|or|triamcinolone (r_appos) C_15\NNP|saline|(|)|,|methylprednisolone (r_pobj) of_12\IN|c (r_prep) injection_11\NN|daily|of (r_dobj) receive_9\VB|to|injection (r_xcomp) assigned_7\VBN|therefore|,|rats|were|randomly|receive|d|,|measured|,|showed|. (l_conj) showed_46\VBD|reduction|respectively|) (l_dobj) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D014221_D000855 CID T_26\NNP|(|)|kg (r_appos) triamcinolone_24\NN|t (r_conj) methylprednisolone_18\NN|m|,|or|triamcinolone (r_appos) C_15\NNP|saline|(|)|,|methylprednisolone (r_pobj) of_12\IN|c (r_prep) injection_11\NN|daily|of (r_dobj) receive_9\VB|to|injection (r_xcomp) assigned_7\VBN|therefore|,|rats|were|randomly|receive|d|,|measured|,|showed|. (l_conj) showed_46\VBD|reduction|respectively|) (l_dobj) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D014221_D000855 CID T_67\NNP| (r_conj) M_65\NNP|and|t|, (r_pobj) in_64\IN|m (r_prep) %_63\NN|in (r_appos) groups_58\NNS|the|treated|(|-50|% (r_pobj) in_53\IN|groups (r_prep) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D013256_D000855 NONE steroid_55\NN| (r_npadvmod) treated_57\VBN|steroid|- (r_amod) groups_58\NNS|the|treated|(|-50|% (r_pobj) in_53\IN|groups (r_prep) reduction_49\NN|a|significant|of|in (l_prep) of_50\IN|intake (l_pobj) intake_52\NN|food
D013256_D013746 NONE steroid_8\NN| (r_compound) groups_9\NNS|both|steroid (r_pobj) in_6\IN|groups (r_prep) prolonged_5\VBN|time|was|in|,|and|was (l_conj) was_16\VBD|tension|longer|with|,|were|. (l_advcl) were_24\VBD|whereas|tensions|similar (l_nsubj) tensions_23\NNS|tetanic (l_compound) tetanic_22\JJ|
D008775_D013746 NONE M_19\NNP| (r_pobj) with_18\IN|m (r_prep) was_16\VBD|tension|longer|with|,|were|. (l_advcl) were_24\VBD|whereas|tensions|similar (l_nsubj) tensions_23\NNS|tetanic (l_compound) tetanic_22\JJ|
D013256_D009133 NONE steroid_18\NN| (r_compound) groups_19\NNS|the|steroid (r_pobj) in_16\IN|groups (r_prep) atrophy_15\NN|iib|fiber|in|and|atrophy
D013256_D009133 NONE steroid_18\NN| (r_compound) groups_19\NNS|the|steroid (r_pobj) in_16\IN|groups (r_prep) atrophy_15\NN|iib|fiber|in|and|atrophy (l_conj) atrophy_25\NN|also|iia|with
D013256_D009133 NONE steroids_14\NNS| (r_pobj) of_13\IN|steroids (r_prep) doses_12\NNS|massive|of (r_pobj) with_10\IN|doses (r_prep) treatment_9\NN|(|1|)|term|with (r_nsubj) induced_15\VBD|that|treatment|wasting (r_ccomp) conclude_1\VBP|we|induced (r_ccomp) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (r_ccomp) caused_51\VBD|induced|;|3|steroid|necrosis (r_ccomp) caused_63\VBN|caused|;|(|atrophy|was|not|by|alone|. (l_nsubjpass) atrophy_60\NN|4|)|iib
D013256_D009133 NONE steroids_29\NNS| (r_pobj) of_28\IN|steroids (r_prep) types_27\NNS|both|of (r_nsubj) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (r_ccomp) caused_51\VBD|induced|;|3|steroid|necrosis (r_ccomp) caused_63\VBN|caused|;|(|atrophy|was|not|by|alone|. (l_nsubjpass) atrophy_60\NN|4|)|iib
D013256_D009133 NONE steroid_50\NN|neither (r_nsubj) caused_51\VBD|induced|;|3|steroid|necrosis (r_ccomp) caused_63\VBN|caused|;|(|atrophy|was|not|by|alone|. (l_nsubjpass) atrophy_60\NN|4|)|iib
D013256_D009336 NONE steroid_18\NN| (r_compound) groups_19\NNS|the|steroid (r_pobj) in_16\IN|groups (r_prep) atrophy_15\NN|iib|fiber|in|and|atrophy (r_dobj) showed_11\VBD|atpase|atrophy|,|revealed|. (l_advcl) revealed_32\VBD|whereas|examinations|pattern (l_dobj) pattern_36\NN|a|normal|muscular|with (l_prep) with_37\IN|absence (l_pobj) absence_38\NN|of (l_prep) of_39\IN|necrosis (l_pobj) necrosis_40\NN|
D013256_D009336 NONE steroids_14\NNS| (r_pobj) of_13\IN|steroids (r_prep) doses_12\NNS|massive|of (r_pobj) with_10\IN|doses (r_prep) treatment_9\NN|(|1|)|term|with (r_nsubj) induced_15\VBD|that|treatment|wasting (r_ccomp) conclude_1\VBP|we|induced (r_ccomp) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (r_ccomp) caused_51\VBD|induced|;|3|steroid|necrosis (l_dobj) necrosis_53\NN|muscle
D013256_D009336 NONE steroids_29\NNS| (r_pobj) of_28\IN|steroids (r_prep) types_27\NNS|both|of (r_nsubj) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (r_ccomp) caused_51\VBD|induced|;|3|steroid|necrosis (l_dobj) necrosis_53\NN|muscle
D013256_D009336 NONE steroid_50\NN|neither (r_nsubj) caused_51\VBD|induced|;|3|steroid|necrosis (l_dobj) necrosis_53\NN|muscle
D014221_D009133 CID T_27\NNP| (r_pobj) with_26\IN|t (r_prep) atrophy_25\NN|also|iia|with (r_conj) atrophy_15\NN|iib|fiber|in|and|atrophy
D014221_D009133 CID T_27\NNP| (r_pobj) with_26\IN|t (r_prep) atrophy_25\NN|also|iia|with
D014221_D009133 CID T_18\NNP|,|and|pf (r_conj) C_16\NNP|,|t (r_appos) rats_14\NNS|18|(|c|) (r_pobj) in_12\IN|rats (r_prep) performed_11\VBN|in (r_acl) study_9\NN|a|fed|(|pf|)|,|performed|, (r_nsubj) showed_24\VBD|finally|,|study|was|. (l_ccomp) was_28\VBD|that|atrophy|pronounced (l_nsubj) atrophy_27\NN|muscle
D014221_D009133 CID T_37\NNP| (r_npadvmod) treated_39\VBN|t|- (r_amod) animals_40\NNS|treated (r_pobj) in_36\IN|animals (r_prep) than_35\IN|in (r_prep) pronounced_31\VBN|less|in|than (r_acomp) was_28\VBD|that|atrophy|pronounced (l_nsubj) atrophy_27\NN|muscle
D014221_D009336 NONE T_27\NNP| (r_pobj) with_26\IN|t (r_prep) atrophy_25\NN|also|iia|with (r_conj) atrophy_15\NN|iib|fiber|in|and|atrophy (r_dobj) showed_11\VBD|atpase|atrophy|,|revealed|. (l_advcl) revealed_32\VBD|whereas|examinations|pattern (l_dobj) pattern_36\NN|a|normal|muscular|with (l_prep) with_37\IN|absence (l_pobj) absence_38\NN|of (l_prep) of_39\IN|necrosis (l_pobj) necrosis_40\NN|
D013256_D001284 NONE steroids_14\NNS| (r_pobj) of_13\IN|steroids (r_prep) doses_12\NNS|massive|of (r_pobj) with_10\IN|doses (r_prep) treatment_9\NN|(|1|)|term|with (r_nsubj) induced_15\VBD|that|treatment|wasting (r_ccomp) conclude_1\VBP|we|induced (r_ccomp) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (l_dobj) atrophy_34\NN|type|iib
D013256_D001284 NONE steroids_29\NNS| (r_pobj) of_28\IN|steroids (r_prep) types_27\NNS|both|of (r_nsubj) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (l_dobj) atrophy_34\NN|type|iib
D013256_D001284 NONE steroid_50\NN|neither (r_nsubj) caused_51\VBD|induced|;|3|steroid|necrosis (l_ccomp) induced_30\VBD|conclude|;|2|types|atrophy|,|resulting (l_dobj) atrophy_34\NN|type|iib
12139551
D008787_D006323 CID metoclopramide_4\NN|- (r_compound) case_7\NN|intravenous|metoclopramide|a|of|causing (r_pobj) after_2\IN|case (r_prep) arrest_1\NN|cardiac|after|.
D008787_D006323 CID metoclopramide_4\NN|- (r_compound) case_7\NN|intravenous|metoclopramide|a|of|causing (l_acl) causing_14\VBG|episodes (l_dobj) episodes_16\NNS|five|of (l_prep) of_17\IN|arrest (l_pobj) arrest_19\NN|cardiac
D008787_D006323 CID metoclopramide_13\NN| (r_pobj) of_12\IN|metoclopramide (r_prep) injections_11\NNS|five|repeated|of (r_pobj) of_8\IN|injections (r_prep) case_7\NN|intravenous|metoclopramide|a|of|causing (r_pobj) after_2\IN|case (r_prep) arrest_1\NN|cardiac|after|.
D008787_D006323 CID metoclopramide_13\NN| (r_pobj) of_12\IN|metoclopramide (r_prep) injections_11\NNS|five|repeated|of (r_pobj) of_8\IN|injections (r_prep) case_7\NN|intravenous|metoclopramide|a|of|causing (l_acl) causing_14\VBG|episodes (l_dobj) episodes_16\NNS|five|of (l_prep) of_17\IN|arrest (l_pobj) arrest_19\NN|cardiac
D008787_D006323 CID metoclopramide_8\NN| (r_pobj) of_7\IN|metoclopramide (r_prep) injection_6\NN|intravenous|of (r_nsubjpass) followed_11\VBN|where|injection|was|immediately|by|repeatedly (l_agent) by_12\IN|asystole (l_pobj) asystole_13\NN|
D008787_D006323 CID metoclopramide_3\JJ| (r_dobj) received_2\VBD|patient|metoclopramide|mg|during|after (r_ccomp) is_24\VBZ|received|,|it|clear|was|followed|. (l_advcl) followed_37\VBN|by (l_agent) by_38\IN|asystole (l_pobj) asystole_39\NN|
D008787_D006323 CID metoclopramide_30\NN| (r_pobj) of_29\IN|metoclopramide (r_prep) administration_28\NN|every|of (r_nsubj) was_31\VBD|that|administration|immediately|(|within|) (r_ccomp) is_24\VBZ|received|,|it|clear|was|followed|. (l_advcl) followed_37\VBN|by (l_agent) by_38\IN|asystole (l_pobj) asystole_39\NN|
D008787_D006323 CID metoclopramide_10\NN| (r_pobj) by_9\IN|metoclopramide (r_agent) caused_8\VBN|by (r_acl) episodes_4\NNS|of|caused (l_prep) of_5\IN|arrest (l_pobj) arrest_7\NN|cardiac
783197
D010042_D003324 NONE ouabain_2\NN|on (l_prep) on_3\IN|supply (l_pobj) supply_6\NN|myocardial|oxygen|and|demand (l_conj) demand_8\NN|in (l_prep) in_9\IN|patients (l_pobj) patients_10\NNS|with (l_prep) with_11\IN|disease (l_pobj) disease_15\NN|chronic|coronary|artery
D010042_D003324 NONE ouabain_5\NN| (r_pobj) of_4\IN|ouabain (r_prep) effects_3\NNS|the|of|weight|)|on (l_prep) on_12\IN|parameters (l_pobj) parameters_19\NNS|volumetric|metabolic|in|without (l_prep) in_20\IN|patients (l_pobj) patients_22\NNS|11|with (l_prep) with_23\IN|disease (l_pobj) disease_28\NN|severe|chronic|coronary|artery
D010042_D003324 NONE ouabain_26\JJ| (r_compound) administration_27\NN|ouabain (r_pobj) after_25\IN|administration (r_prep) falls_24\VBZ|after|is (r_conj) conclude_1\VBP|we|left|falls|. (l_ccomp) left_18\VBD|that|in|patients|volume (l_nsubj) patients_4\NNS|with (l_prep) with_5\IN|disease (l_pobj) disease_9\NN|chronic|coronary|artery|are
D010100_D003324 NONE oxygen_5\NN| (r_compound) supply_6\NN|myocardial|oxygen|and|demand (l_conj) demand_8\NN|in (l_prep) in_9\IN|patients (l_pobj) patients_10\NNS|with (l_prep) with_11\IN|disease (l_pobj) disease_15\NN|chronic|coronary|artery
D010100_D003324 NONE oxygen_7\NN| (r_compound) supply_8\NN|myocardial|oxygen|and|demand (r_pobj) on_5\IN|supply (r_prep) glycosides_4\NNS|digitalis|on (r_pobj) of_2\IN|glycosides (r_prep) effects_1\NNS|the|of (r_nsubj) are_11\VBP|effects|of|,|but|measured|. (l_prep) of_12\IN|interest (l_pobj) interest_14\NN|particular|in (l_prep) in_15\IN|presence (l_pobj) presence_17\NN|the|of (l_prep) of_18\IN|disease (l_pobj) disease_22\NN|obstructive|coronary|artery
D004071_D003324 NONE glycosides_4\NNS|digitalis|on (r_pobj) of_2\IN|glycosides (r_prep) effects_1\NNS|the|of (r_nsubj) are_11\VBP|effects|of|,|but|measured|. (l_prep) of_12\IN|interest (l_pobj) interest_14\NN|particular|in (l_prep) in_15\IN|presence (l_pobj) presence_17\NN|the|of (l_prep) of_18\IN|disease (l_pobj) disease_22\NN|obstructive|coronary|artery
D010042_D006333 NONE ouabain_5\NN| (r_pobj) of_4\IN|ouabain (r_prep) effects_3\NNS|the|of|weight|)|on (l_prep) on_12\IN|parameters (l_pobj) parameters_19\NNS|volumetric|metabolic|in|without (l_prep) without_29\IN|failure (l_pobj) failure_33\NN|clinical|heart
D010042_D006333 NONE ouabain_26\JJ| (r_compound) administration_27\NN|ouabain (r_pobj) after_25\IN|administration (r_prep) falls_24\VBZ|after|is (r_conj) conclude_1\VBP|we|left|falls|. (l_ccomp) left_18\VBD|that|in|patients|volume (l_nsubj) patients_4\NNS|with (l_prep) with_5\IN|disease (l_pobj) disease_9\NN|chronic|coronary|artery|are (l_relcl) are_11\VBP|who|not|in (l_prep) in_13\IN|failure (l_pobj) failure_17\NN|clinical|heart
D010042_D002303 CID ouabain_26\JJ| (r_compound) administration_27\NN|ouabain (r_pobj) after_25\IN|administration (r_prep) falls_24\VBZ|after|is
18239197
D014282_D003072 CID trihexyphenidyl_10\JJ|challenge (r_pcomp) after_9\IN|trihexyphenidyl (r_prep) associated_3\VBN|with|after (r_acl) slowing_2\NN|increased|mental|associated|.
D014282_D003072 CID trihexyphenidyl_5\JJ| (r_pobj) of_4\IN|trihexyphenidyl (r_prep) dose_3\NN|a|2.0-mg|oral|of (r_nsubj) resulted_6\VBD|dose|in|. (l_prep) in_7\IN|ratings (l_pobj) ratings_10\NNS|increased|subjective|of (l_prep) of_11\IN|slowness (l_pobj) slowness_13\NN|mental|in|only
D014282_D003072 CID trihexyphenidyl_10\JJ|mg|and|placebo (r_pobj) between_7\IN|trihexyphenidyl (r_prep) scores_6\NNS|difference|between|on (l_prep) on_13\IN|ratings (l_pobj) ratings_14\NNS|of (l_prep) of_15\IN|slowness (l_pobj) slowness_17\NN|mental
D014282_D003072 CID trihexyphenidyl_14\JJ| (r_amod) challenge_16\NN|trihexyphenidyl|anticholinergic (r_pobj) after_13\IN|challenge (r_prep) slowing_12\NN|increased|subjective|mental|after
D014282_D003221 NONE trihexyphenidyl_19\NN|on (l_prep) on_20\IN|measures (l_pobj) measures_21\NNS|reflecting (l_acl) reflecting_22\VBG|sedation (l_dobj) sedation_23\NN|and|confusion (l_conj) confusion_25\NN|
D014282_D003221 NONE trihexyphenidyl_32\NN| (r_npadvmod) induced_34\VBN|trihexyphenidyl|- (r_amod) effects_36\NNS|induced|subjective|and|performance (r_pobj) between_31\IN|effects (r_prep) relationship_30\NN|the|between (r_dobj) investigate_28\VB|to|relationship (r_conj) examine_9\VB|to|relationship|and|investigate (l_dobj) relationship_11\NN|the|between|effects (l_conj) effects_17\NNS|subjective|of (l_prep) of_18\IN|trihexyphenidyl (l_pobj) trihexyphenidyl_19\NN|on (l_prep) on_20\IN|measures (l_pobj) measures_21\NNS|reflecting (l_acl) reflecting_22\VBG|sedation (l_dobj) sedation_23\NN|and|confusion (l_conj) confusion_25\NN|
6728084
D000617_D007674 NONE aminoglycoside_3\NN| (r_compound) treatment_4\NN|aminoglycoside|on (r_pobj) of_2\IN|treatment (r_prep) effects_1\NNS|nephrotoxic|of|. (l_amod) Nephrotoxic_0\JJ|
D000617_D007674 NONE aminoglycosides_2\NNS| (r_nsubj) act_4\VB|thus|,|aminoglycosides|may|as|. (l_prep) as_5\IN|nephrotoxicants (l_pobj) nephrotoxicants_6\NNS|at (l_prep) at_7\IN|impairment (l_pobj) impairment_13\NN|glomerular|inducing|of (l_prep) of_14\IN|reabsorption (l_pobj) reabsorption_16\NN|renal|and|accumulation
6402369
D007069_D001745 CID ifosfamide_2\RB| (r_advmod) induced_4\VBN|ifosfamide|- (r_amod) toxicity_6\NN|induced|urothelial|by
D007069_D001745 CID ifosfamide_21\NN| (r_pobj) by_20\IN|ifosfamide (r_agent) induced_19\VBN|by (r_acl) toxicity_18\NN|urothelial|induced
D007069_D001745 CID IF_23\IN| (r_mark) tested_26\VBN|effect|(|if|)|was|in|as|. (l_nsubjpass) effect_2\NN|the|protective|of|against (l_prep) against_16\IN|toxicity (l_pobj) toxicity_18\NN|urothelial|induced
D007069_D001745 CID IF_40\IN| (r_mark) m2_45\NN|if|(|2250|mg|/|on|) (r_pobj) with_39\IN|m2 (r_prep) treatment_38\NN|with (r_pobj) under_37\IN|treatment (r_prep) cancer_36\NN|inoperable|lung|under (r_pobj) with_33\IN|cancer (r_prep) patients_32\NNS|45|with (r_pobj) of_30\IN|patients (r_prep) group_29\NN|a|of (r_pobj) in_27\IN|group (r_prep) tested_26\VBN|effect|(|if|)|was|in|as|. (l_nsubjpass) effect_2\NN|the|protective|of|against (l_prep) against_16\IN|toxicity (l_pobj) toxicity_18\NN|urothelial|induced
D007069_D008175 NONE ifosfamide_2\RB| (r_advmod) induced_4\VBN|ifosfamide|- (r_amod) toxicity_6\NN|induced|urothelial|by (r_pobj) of_1\IN|toxicity (r_prep) Treatment_0\NN|of|to|. (l_prep) to_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|cancer (l_pobj) cancer_22\NN|inoperable|lung
D007069_D008175 NONE ifosfamide_21\NN| (r_pobj) by_20\IN|ifosfamide (r_agent) induced_19\VBN|by (r_acl) toxicity_18\NN|urothelial|induced (r_pobj) against_16\IN|toxicity (r_prep) effect_2\NN|the|protective|of|against (r_nsubjpass) tested_26\VBN|effect|(|if|)|was|in|as|. (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|45|with (l_prep) with_33\IN|cancer (l_pobj) cancer_36\NN|inoperable|lung|under
D007069_D008175 NONE IF_23\IN| (r_mark) tested_26\VBN|effect|(|if|)|was|in|as|. (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|45|with (l_prep) with_33\IN|cancer (l_pobj) cancer_36\NN|inoperable|lung|under
D007069_D008175 NONE IF_40\IN| (r_mark) m2_45\NN|if|(|2250|mg|/|on|) (r_pobj) with_39\IN|m2 (r_prep) treatment_38\NN|with (r_pobj) under_37\IN|treatment (r_prep) cancer_36\NN|inoperable|lung|under
D015080_D001745 NONE sulphonate_13\JJ|sodium|2-mercaptoethane|mesna (r_pobj) of_10\IN|sulphonate (r_prep) administration_9\NN|oral|of (r_pobj) by_7\IN|administration (r_prep) toxicity_6\NN|induced|urothelial|by
D015080_D001745 NONE MESNA_15\NNP|(|) (r_appos) sulphonate_13\JJ|sodium|2-mercaptoethane|mesna (r_pobj) of_10\IN|sulphonate (r_prep) administration_9\NN|oral|of (r_pobj) by_7\IN|administration (r_prep) toxicity_6\NN|induced|urothelial|by
D015080_D001745 NONE sulphonate_12\JJ|the|thiol|compound|sodium|2-mercaptoethane|mesna (r_pobj) of_6\IN|sulphonate (r_prep) administration_5\NN|oral|of (r_pobj) of_3\IN|administration (r_prep) effect_2\NN|the|protective|of|against (l_prep) against_16\IN|toxicity (l_pobj) toxicity_18\NN|urothelial|induced
D015080_D001745 NONE MESNA_14\NNP|(|) (r_appos) sulphonate_12\JJ|the|thiol|compound|sodium|2-mercaptoethane|mesna (r_pobj) of_6\IN|sulphonate (r_prep) administration_5\NN|oral|of (r_pobj) of_3\IN|administration (r_prep) effect_2\NN|the|protective|of|against (l_prep) against_16\IN|toxicity (l_pobj) toxicity_18\NN|urothelial|induced
D015080_D008175 NONE sulphonate_13\JJ|sodium|2-mercaptoethane|mesna (r_pobj) of_10\IN|sulphonate (r_prep) administration_9\NN|oral|of (r_pobj) by_7\IN|administration (r_prep) toxicity_6\NN|induced|urothelial|by (r_pobj) of_1\IN|toxicity (r_prep) Treatment_0\NN|of|to|. (l_prep) to_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|cancer (l_pobj) cancer_22\NN|inoperable|lung
D015080_D008175 NONE MESNA_15\NNP|(|) (r_appos) sulphonate_13\JJ|sodium|2-mercaptoethane|mesna (r_pobj) of_10\IN|sulphonate (r_prep) administration_9\NN|oral|of (r_pobj) by_7\IN|administration (r_prep) toxicity_6\NN|induced|urothelial|by (r_pobj) of_1\IN|toxicity (r_prep) Treatment_0\NN|of|to|. (l_prep) to_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|cancer (l_pobj) cancer_22\NN|inoperable|lung
D015080_D008175 NONE sulphonate_12\JJ|the|thiol|compound|sodium|2-mercaptoethane|mesna (r_pobj) of_6\IN|sulphonate (r_prep) administration_5\NN|oral|of (r_pobj) of_3\IN|administration (r_prep) effect_2\NN|the|protective|of|against (r_nsubjpass) tested_26\VBN|effect|(|if|)|was|in|as|. (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|45|with (l_prep) with_33\IN|cancer (l_pobj) cancer_36\NN|inoperable|lung|under
D015080_D008175 NONE MESNA_14\NNP|(|) (r_appos) sulphonate_12\JJ|the|thiol|compound|sodium|2-mercaptoethane|mesna (r_pobj) of_6\IN|sulphonate (r_prep) administration_5\NN|oral|of (r_pobj) of_3\IN|administration (r_prep) effect_2\NN|the|protective|of|against (r_nsubjpass) tested_26\VBN|effect|(|if|)|was|in|as|. (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|45|with (l_prep) with_33\IN|cancer (l_pobj) cancer_36\NN|inoperable|lung|under
D013438_D001745 NONE thiol_8\JJ| (r_compound) sulphonate_12\JJ|the|thiol|compound|sodium|2-mercaptoethane|mesna (r_pobj) of_6\IN|sulphonate (r_prep) administration_5\NN|oral|of (r_pobj) of_3\IN|administration (r_prep) effect_2\NN|the|protective|of|against (l_prep) against_16\IN|toxicity (l_pobj) toxicity_18\NN|urothelial|induced
D013438_D008175 NONE thiol_8\JJ| (r_compound) sulphonate_12\JJ|the|thiol|compound|sodium|2-mercaptoethane|mesna (r_pobj) of_6\IN|sulphonate (r_prep) administration_5\NN|oral|of (r_pobj) of_3\IN|administration (r_prep) effect_2\NN|the|protective|of|against (r_nsubjpass) tested_26\VBN|effect|(|if|)|was|in|as|. (l_prep) in_27\IN|group (l_pobj) group_29\NN|a|of (l_prep) of_30\IN|patients (l_pobj) patients_32\NNS|45|with (l_prep) with_33\IN|cancer (l_pobj) cancer_36\NN|inoperable|lung|under
D015080_D064420 NONE MESNA_7\NNP| (r_compound) series_8\NN|the|mesna|and|series (l_conj) series_13\NN|the|conventional|prophylaxis|with (l_prep) with_14\IN|respect (l_pobj) respect_15\NN|to (l_prep) to_16\IN|toxicity (l_pobj) toxicity_21\NN|haematological|of
17019386
D008353_D005910 NONE mannitol_2\NN| (r_pobj) of_1\IN|mannitol (r_prep) Passage_0\NN|of|into (r_nsubj) gliomas_7\NNS|passage|:|cause|.
D008353_D005910 NONE Mannitol_2\NN|(|solution|;|kg|) (r_appos) METHODS_0\NNS|:|mannitol (r_nsubjpass) administered_14\VBN|methods|was|as|had|. (l_parataxis) had_22\VBD|(|ten|glioma|before (l_dobj) glioma_24\NN|malignant|,|metastases|)
D008353_D005910 NONE mannitol_5\NN| (r_amod) concentrations_6\NNS|mannitol|in (r_nsubj) were_10\VBD|in|,|concentrations|higher|mean|. (l_prep) In_0\IN|patients (l_pobj) patients_3\NNS|most|glioma (l_compound) glioma_2\NN|
D008353_D005910 NONE mannitol_13\NN| (r_nsubj) leak_15\VB|that|after|,|mannitol|may|through|near|,|reversing (l_prep) near_20\IN|gliomas (l_pobj) gliomas_21\NNS|
D008353_D001929 NONE mannitol_5\NN| (r_pobj) of_4\IN|mannitol (r_prep) use_3\NN|widespread|of|reduce (l_acl) reduce_7\VB|to|edema (l_dobj) edema_9\NN|brain|and|icp
D008353_D019586 CID mannitol_5\NN| (r_pobj) of_4\IN|mannitol (r_prep) use_3\NN|widespread|of|reduce (l_acl) reduce_7\VB|to|edema (l_dobj) edema_9\NN|brain|and|icp (l_conj) ICP_13\NNP|lower|elevated|in
D008353_D001932 NONE mannitol_5\NN| (r_pobj) of_4\IN|mannitol (r_prep) use_3\NN|widespread|of|reduce (l_acl) reduce_7\VB|to|edema (l_dobj) edema_9\NN|brain|and|icp (l_conj) ICP_13\NNP|lower|elevated|in (l_prep) in_14\IN|patients (l_pobj) patients_17\NNS|tumor (l_compound) tumor_16\NN|brain
D008353_D001932 NONE mannitol_14\NN| (r_pobj) of_13\IN|mannitol (r_prep) passage_12\NN|the|possible|of|into (r_dobj) research_9\VB|to|passage|after|to (l_prep) to_20\IN|patients (l_pobj) patients_24\NNS|21|tumor (l_compound) tumor_23\NN|brain
D008353_D009362 NONE Mannitol_2\NN|(|solution|;|kg|) (r_appos) METHODS_0\NNS|:|mannitol (r_nsubjpass) administered_14\VBN|methods|was|as|had|. (l_parataxis) had_22\VBD|(|ten|glioma|before (l_dobj) glioma_24\NN|malignant|,|metastases|) (l_conj) metastases_28\NNS|seven|brain|and|meningioma
D008353_D009362 NONE mannitol_8\NN| (r_pobj) of_7\IN|mannitol (r_prep) concentrations_6\NNS|patients|plasma|of (l_compound) patients_4\NNS|meningioma (l_nmod) meningioma_1\NN|and|metastases (l_conj) metastases_3\NNS|
D008353_D008579 NONE Mannitol_2\NN|(|solution|;|kg|) (r_appos) METHODS_0\NNS|:|mannitol (r_nsubjpass) administered_14\VBN|methods|was|as|had|. (l_parataxis) had_22\VBD|(|ten|glioma|before (l_dobj) glioma_24\NN|malignant|,|metastases|) (l_conj) metastases_28\NNS|seven|brain|and|meningioma (l_conj) meningioma_31\NN|four
D008353_D008579 NONE mannitol_8\NN| (r_pobj) of_7\IN|mannitol (r_prep) concentrations_6\NNS|patients|plasma|of (l_compound) patients_4\NNS|meningioma (l_nmod) meningioma_1\NN|and|metastases
D008353_D004487 NONE mannitol_13\NN| (r_nsubj) leak_15\VB|that|after|,|mannitol|may|through|near|,|reversing (l_advcl) reversing_23\VBG|gradient|,|aggravating (l_conj) aggravating_34\VBG|edema|and|promoting (l_dobj) edema_36\NN|peritumoral
3057041
C020976_D006255 NONE azelastine_18\NN|,|chlorpheniramine (r_pobj) of_17\IN|azelastine (r_prep) trial_16\NN|safety|of (r_conj) efficacy_13\NN|,|dose|,|groups|and|trial|in (l_prep) in_24\IN|treatment (l_pobj) treatment_26\NN|the|of (l_prep) of_27\IN|rhinitis (l_pobj) rhinitis_30\NN|allergic
C020976_D006255 NONE Azelastine_0\NNP|,|medication|, (r_nsubjpass) compared_8\VBN|azelastine|was|with|. (l_prep) with_9\IN|maleate (l_pobj) maleate_11\NN|chlorpheniramine|and|placebo|for (l_prep) for_14\IN|efficacy (l_pobj) efficacy_15\NN|and|safety|in (l_prep) in_18\IN|treatment (l_pobj) treatment_20\NN|the|of|in (l_prep) of_21\IN|rhinitis (l_pobj) rhinitis_24\NN|spring|allergic
C020976_D006255 NONE Azelastine_0\NNP| (r_nsubj) appears_1\VBZ|azelastine|be|. (l_xcomp) be_3\VB|to|medication (l_attr) medication_8\NN|a|safe|,|efficacious|for (l_prep) for_9\IN|rhinitis (l_pobj) rhinitis_12\NN|seasonal|allergic
D002744_D006255 NONE chlorpheniramine_20\NN|,|and|placebo (r_conj) azelastine_18\NN|,|chlorpheniramine (r_pobj) of_17\IN|azelastine (r_prep) trial_16\NN|safety|of (r_conj) efficacy_13\NN|,|dose|,|groups|and|trial|in (l_prep) in_24\IN|treatment (l_pobj) treatment_26\NN|the|of (l_prep) of_27\IN|rhinitis (l_pobj) rhinitis_30\NN|allergic
D002744_D006255 NONE maleate_11\NN|chlorpheniramine|and|placebo|for (l_prep) for_14\IN|efficacy (l_pobj) efficacy_15\NN|and|safety|in (l_prep) in_18\IN|treatment (l_pobj) treatment_20\NN|the|of|in (l_prep) of_21\IN|rhinitis (l_pobj) rhinitis_24\NN|spring|allergic
C020976_D006970 CID azelastine_16\NN| (r_compound) group_17\NN|the|dose|azelastine (r_pobj) in_11\IN|only|group (r_prep) increased_6\VBN|drowsiness|were|significantly|over|in|. (l_nsubjpass) Drowsiness_0\VB|and|perception
C020976_D013651 CID azelastine_16\NN| (r_compound) group_17\NN|the|dose|azelastine (r_pobj) in_11\IN|only|group (r_prep) increased_6\VBN|drowsiness|were|significantly|over|in|. (l_nsubjpass) Drowsiness_0\VB|and|perception (l_conj) perception_4\NN|altered|taste
7880714
1899352
D015080_D006417 NONE Mesna_22\NNP| (r_dobj) adding_21\VBG|mesna|to (r_advcl) is_18\VBZ|monitoring|essential|,|adding|. (r_conj) are_6\VBP|frequency|not|precise|,|and|is (l_nsubj) frequency_1\NN|the|and|predictability (l_conj) predictability_3\NN|of (l_prep) of_4\IN|hematuria (l_pobj) hematuria_5\NN|
D015080_D006417 NONE Mesna_22\NNP| (r_dobj) adding_21\VBG|mesna|to (l_prep) to_23\IN|infusate (l_pobj) infusate_25\NN|the|in (l_prep) in_26\IN|patients (l_pobj) patients_27\NNS|with (l_prep) with_28\IN|hematuria (l_pobj) hematuria_30\NN|persistent
3962737
D000638_D056486 CID amiodarone_2\NN| (r_pobj) of_1\IN|amiodarone (r_prep) Hepatotoxicity_0\NN|of|.
D000638_D056486 CID amiodarone_7\NN| (r_compound) treatment_8\NN|amiodarone (r_appos) patient_1\NN|a|with|due|treatment (l_prep) with_2\IN|hepatitis (l_pobj) hepatitis_4\NN|cholestatic
D000638_D056486 CID amiodarone_7\NN| (r_compound) treatment_8\NN|amiodarone (r_appos) patient_1\NN|a|with|due|treatment (r_nsubjpass) presented_10\VBN|patient|is|below|and|given (l_conj) given_21\VBN|review|is|. (l_nsubjpass) review_14\NN|a|of (l_prep) of_15\IN|hepatotoxicity (l_pobj) hepatotoxicity_17\NN|the|of
D000638_D056486 CID amiodarone_19\NN| (r_pobj) of_18\IN|amiodarone (r_prep) hepatotoxicity_17\NN|the|of (r_pobj) of_15\IN|hepatotoxicity (r_prep) review_14\NN|a|of (r_nsubjpass) given_21\VBN|review|is|. (r_conj) presented_10\VBN|patient|is|below|and|given (l_nsubjpass) patient_1\NN|a|with|due|treatment (l_prep) with_2\IN|hepatitis (l_pobj) hepatitis_4\NN|cholestatic
D000638_D056486 CID amiodarone_19\NN| (r_pobj) of_18\IN|amiodarone (r_prep) hepatotoxicity_17\NN|the|of
D000638_D056486 CID amiodarone_12\NN| (r_compound) treatment_13\NN|amiodarone|,|including|, (r_pobj) to_11\IN|treatment (r_pcomp) due_10\IN|to|alterations (r_prep) exists_6\VBZ|that|evidence|of|due (l_prep) of_7\IN|injury (l_pobj) injury_9\NN|hepatic
D000638_D056486 CID amiodarone_12\NN| (r_compound) treatment_13\NN|amiodarone|,|including|, (r_pobj) to_11\IN|treatment (r_pcomp) due_10\IN|to|alterations (l_pobj) alterations_18\NNS|resembling (l_acl) resembling_19\VBG|hepatitis (l_dobj) hepatitis_21\NN|alcoholic|,|cirrhosis (l_appos) cirrhosis_27\NN|cholestatic|hepatitis|of (l_nmod) hepatitis_24\NN|and|micronodular
D000638_D013610 NONE Amiodarone_0\NNP| (r_nsubj) proved_2\VBN|amiodarone|has|effective|in|. (l_prep) in_5\IN|treatment (l_pobj) treatment_7\NN|the|of (l_prep) of_8\IN|tachyarrhythmias (l_pobj) tachyarrhythmias_12\NNS|resistant|cardiac
D000638_D002779 CID amiodarone_7\NN| (r_compound) treatment_8\NN|amiodarone (r_appos) patient_1\NN|a|with|due|treatment (l_prep) with_2\IN|hepatitis (l_pobj) hepatitis_4\NN|cholestatic
D000638_D002779 CID amiodarone_19\NN| (r_pobj) of_18\IN|amiodarone (r_prep) hepatotoxicity_17\NN|the|of (r_pobj) of_15\IN|hepatotoxicity (r_prep) review_14\NN|a|of (r_nsubjpass) given_21\VBN|review|is|. (r_conj) presented_10\VBN|patient|is|below|and|given (l_nsubjpass) patient_1\NN|a|with|due|treatment (l_prep) with_2\IN|hepatitis (l_pobj) hepatitis_4\NN|cholestatic
D000638_D002779 CID amiodarone_12\NN| (r_compound) treatment_13\NN|amiodarone|,|including|, (r_pobj) to_11\IN|treatment (r_pcomp) due_10\IN|to|alterations (l_pobj) alterations_18\NNS|resembling (l_acl) resembling_19\VBG|hepatitis (l_dobj) hepatitis_21\NN|alcoholic|,|cirrhosis (l_appos) cirrhosis_27\NN|cholestatic|hepatitis|of (l_nmod) hepatitis_24\NN|and|micronodular
D000638_D005234 CID amiodarone_12\NN| (r_compound) treatment_13\NN|amiodarone|,|including|, (l_prep) including_15\VBG|steatosis (l_pobj) steatosis_16\NN|
D000638_D006519 NONE amiodarone_12\NN| (r_compound) treatment_13\NN|amiodarone|,|including|, (r_pobj) to_11\IN|treatment (r_pcomp) due_10\IN|to|alterations (l_pobj) alterations_18\NNS|resembling (l_acl) resembling_19\VBG|hepatitis (l_dobj) hepatitis_21\NN|alcoholic|,|cirrhosis
D000638_D008103 CID amiodarone_12\NN| (r_compound) treatment_13\NN|amiodarone|,|including|, (r_pobj) to_11\IN|treatment (r_pcomp) due_10\IN|to|alterations (l_pobj) alterations_18\NNS|resembling (l_acl) resembling_19\VBG|hepatitis (l_dobj) hepatitis_21\NN|alcoholic|,|cirrhosis (l_appos) cirrhosis_27\NN|cholestatic|hepatitis|of (l_prep) of_28\IN|liver (l_pobj) liver_30\NN|the
591536
D006493_D013923 NONE heparin_6\JJ| (r_compound) therapy_7\NN|systemic|heparin (r_dobj) receiving_4\VBG|therapy (r_acl) patients_3\NNS|receiving (r_pobj) in_2\IN|patients (r_prep) thromboembolism_1\NN|arterial|in|:|complication|.
D006493_D013923 NONE heparin_13\NN| (r_npadvmod) induced_15\VBN|heparin|- (r_amod) thrombocytopenia_16\NN|induced (r_pobj) with_12\IN|thrombocytopenia (r_prep) associated_11\VBN|with (r_acl) complication_10\NN|a|associated (r_appos) thromboembolism_1\NN|arterial|in|:|complication|.
D006493_D013923 NONE heparin_8\JJ| (r_compound) therapy_9\NN|systemic|heparin (r_pobj) of_6\IN|therapy (r_prep) complication_5\NN|a|recognized|of (r_attr) is_2\VBZ|thromboembolism|complication|. (l_nsubj) thromboembolism_1\NN|arterial
D006493_D013923 NONE heparin_8\VBN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) aggregation_12\NN|induced|platelet (r_attr) is_7\VBZ|factor|aggregation|. (l_nsubj) factor_2\NN|the|common|relating (l_acl) relating_3\VBG|thromboembolism (l_dobj) thromboembolism_4\NN|and|thrombocytopenia
D006493_D013921 CID heparin_6\JJ| (r_compound) therapy_7\NN|systemic|heparin (r_dobj) receiving_4\VBG|therapy (r_acl) patients_3\NNS|receiving (r_pobj) in_2\IN|patients (r_prep) thromboembolism_1\NN|arterial|in|:|complication|. (l_appos) complication_10\NN|a|associated (l_acl) associated_11\VBN|with (l_prep) with_12\IN|thrombocytopenia (l_pobj) thrombocytopenia_16\NN|induced
D006493_D013921 CID heparin_13\NN| (r_npadvmod) induced_15\VBN|heparin|- (r_amod) thrombocytopenia_16\NN|induced
D006493_D013921 CID heparin_24\JJ| (r_compound) therapy_25\NN|heparin (r_pobj) of_23\IN|therapy (r_prep) initiation_22\NN|the|of (r_pobj) after_20\IN|days|initiation (r_prep) occurring_15\VBG|after (r_pcomp) by_7\IN|thrombi|occurring (r_prep) occlusion_6\NN|arterial|by|,|preceded (l_acl) preceded_27\VBN|by (l_agent) by_28\IN|thrombocytopenia (l_pobj) thrombocytopenia_30\NN|profound|with|in
D006493_D013921 CID heparin_8\VBN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) aggregation_12\NN|induced|platelet (r_attr) is_7\VBZ|factor|aggregation|. (l_nsubj) factor_2\NN|the|common|relating (l_acl) relating_3\VBG|thromboembolism (l_dobj) thromboembolism_4\NN|and|thrombocytopenia (l_conj) thrombocytopenia_6\NN|
D006493_D001157 CID heparin_24\JJ| (r_compound) therapy_25\NN|heparin (r_pobj) of_23\IN|therapy (r_prep) initiation_22\NN|the|of (r_pobj) after_20\IN|days|initiation (r_prep) occurring_15\VBG|after (r_pcomp) by_7\IN|thrombi|occurring (r_prep) occlusion_6\NN|arterial|by|,|preceded
D006493_D013927 NONE heparin_24\JJ| (r_compound) therapy_25\NN|heparin (r_pobj) of_23\IN|therapy (r_prep) initiation_22\NN|the|of (r_pobj) after_20\IN|days|initiation (r_prep) occurring_15\VBG|after (r_pcomp) by_7\IN|thrombi|occurring (l_pobj) thrombi_11\NN|fibrin|with
D006493_D007511 NONE heparin_24\JJ| (r_compound) therapy_25\NN|heparin (r_pobj) of_23\IN|therapy (r_prep) initiation_22\NN|the|of (r_pobj) after_20\IN|days|initiation (r_prep) occurring_15\VBG|after (r_pcomp) by_7\IN|thrombi|occurring (l_pobj) thrombi_11\NN|fibrin|with (l_prep) with_12\IN|ischemia (l_pobj) ischemia_14\NN|distal
D006493_D001791 NONE heparin_8\VBN| (r_npadvmod) induced_10\VBN|heparin|- (r_amod) aggregation_12\NN|induced|platelet
18006530
D015742_D010146 CID propofol_9\NN|controlled|and|remifentanil (r_pobj) with_5\IN|propofol (r_prep) induction_4\NN|with (r_pobj) during_3\IN|induction (r_prep) Reduction_0\NN|of|during|. (l_prep) of_1\IN|pain (l_pobj) pain_2\NN|
D015742_D010146 CID propofol_4\NN| (r_pobj) of_3\IN|propofol (r_prep) injection_2\NN|of (r_pobj) on_1\IN|injection (r_prep) Pain_0\NN|on
D015742_D010146 CID propofol_3\JJ| (r_amod) pain_5\NN|propofol|infusion
D015742_D010146 CID propofol_15\JJ| (r_amod) infusion_16\NN|the|propofol|in (r_dobj) starting_13\VBG|infusion (r_pcomp) before_12\IN|starting (r_prep) infusing_10\VBG|remifentanil|before (r_pcomp) by_9\IN|infusing (r_prep) prevented_8\VBN|that|pain|might|be|by (l_nsubjpass) pain_5\NN|propofol|infusion
D015742_D010146 CID propofol_15\NN| (r_pobj) by_14\IN|propofol (r_agent) caused_13\VBN|by (r_acl) pain_12\NN|caused
D015742_D010146 CID propofol_26\JJ| (r_amod) infusion_27\NN|the|propofol (r_pobj) during_24\IN|infusion (r_prep) using_18\VBG|scale|during (r_advcl) evaluated_17\VBN|pain|was|using|. (l_nsubjpass) pain_12\NN|caused
D015742_D010146 CID propofol_7\NN|and|remifentanil (r_pobj) of_6\IN|propofol (r_prep) anaesthesia_3\NN|with|of (r_pobj) of_2\IN|anaesthesia (r_prep) induction_1\NN|of (r_pobj) During_0\IN|induction (r_prep) achieved_19\VBN|during|,|reduction|was|without|)|. (l_nsubjpass) reduction_13\NN|a|significant|in (l_prep) in_14\IN|pain (l_pobj) pain_17\NN|propofol|infusion
D015742_D010146 CID propofol_15\JJ| (r_amod) pain_17\NN|propofol|infusion
C071741_D010146 NONE remifentanil_11\NN| (r_conj) propofol_9\NN|controlled|and|remifentanil (r_pobj) with_5\IN|propofol (r_prep) induction_4\NN|with (r_pobj) during_3\IN|induction (r_prep) Reduction_0\NN|of|during|. (l_prep) of_1\IN|pain (l_pobj) pain_2\NN|
C071741_D010146 NONE remifentanil_11\NN| (r_dobj) infusing_10\VBG|remifentanil|before (r_pcomp) by_9\IN|infusing (r_prep) prevented_8\VBN|that|pain|might|be|by (l_nsubjpass) pain_5\NN|propofol|infusion
C071741_D010146 NONE remifentanil_26\NN| (r_pobj) of_25\IN|remifentanil (r_prep) Ce_23\NNP|(|)|of (r_appos) concentration_21\NN|the|site|ce|prevent (l_relcl) prevent_28\VB|to|pain|without (l_dobj) pain_30\NN|the
C071741_D010146 NONE Remifentanil_0\NN| (r_npadvmod) related_2\VBN|remifentanil|- (r_amod) complications_3\NNS|related (r_nsubjpass) assessed_5\VBN|complications|were|during|,|and|evaluated (l_conj) evaluated_17\VBN|pain|was|using|. (l_nsubjpass) pain_12\NN|caused
C071741_D010146 NONE remifentanil_8\NN| (r_compound) infusion_9\NN|the|remifentanil (r_pobj) during_6\IN|infusion (r_prep) assessed_5\VBN|complications|were|during|,|and|evaluated (l_conj) evaluated_17\VBN|pain|was|using|. (l_nsubjpass) pain_12\NN|caused
C071741_D010146 NONE remifentanil_9\NN| (r_conj) propofol_7\NN|and|remifentanil (r_pobj) of_6\IN|propofol (r_prep) anaesthesia_3\NN|with|of (r_pobj) of_2\IN|anaesthesia (r_prep) induction_1\NN|of (r_pobj) During_0\IN|induction (r_prep) achieved_19\VBN|during|,|reduction|was|without|)|. (l_nsubjpass) reduction_13\NN|a|significant|in (l_prep) in_14\IN|pain (l_pobj) pain_17\NN|propofol|infusion
C071741_D010146 NONE remifentanil_27\NN| (r_pobj) of_26\IN|remifentanil (r_prep) administration_25\NN|prior|of (r_pobj) by_23\IN|administration (r_prep) complications_22\NNS|significant|by|at (r_pobj) without_20\IN|complications (r_prep) achieved_19\VBN|during|,|reduction|was|without|)|. (l_nsubjpass) reduction_13\NN|a|significant|in (l_prep) in_14\IN|pain (l_pobj) pain_17\NN|propofol|infusion
17285209
D017311_D006973 NONE amlodipine_26\NN| (r_pobj) of_25\IN|amlodipine (r_prep) pill_24\NN|a|combination|of|/|mg. (r_pobj) on_21\IN|pill (r_prep) started_20\VBN|who|was|on (r_relcl) female_12\NN|a|45-year|old|american|with|,|started (l_prep) with_13\IN|hypertension (l_pobj) hypertension_16\NN|diagnosed
C044946_D006973 NONE benazapril_28\NN| (r_compound) mg._30\CD|benazapril|10/5 (r_appos) pill_24\NN|a|combination|of|/|mg. (r_pobj) on_21\IN|pill (r_prep) started_20\VBN|who|was|on (r_relcl) female_12\NN|a|45-year|old|american|with|,|started (l_prep) with_13\IN|hypertension (l_pobj) hypertension_16\NN|diagnosed
D000809_D007410 NONE angiotensin_3\NN| (r_npadvmod) converting_5\VBG|angiotensin|- (r_amod) enzyme_6\NN|converting|(|ace|)|and|blocker (r_pobj) of_2\IN|enzyme (r_prep) recognition_1\NN|the|of (r_nsubj) constitutes_19\VBZ|recognition|(|angioedema|challenge|. (l_nsubj) angioedema_18\NN|arb|intestinal
D000809_D007410 NONE angiotensin_11\NN| (r_compound) blocker_13\NN|angiotensin|receptor (r_conj) enzyme_6\NN|converting|(|ace|)|and|blocker (r_pobj) of_2\IN|enzyme (r_prep) recognition_1\NN|the|of (r_nsubj) constitutes_19\VBZ|recognition|(|angioedema|challenge|. (l_nsubj) angioedema_18\NN|arb|intestinal
D000809_D000799 NONE angiotensin_3\NN| (r_npadvmod) converting_5\VBG|angiotensin|- (r_amod) enzyme_6\NN|converting|(|ace|)|and|blocker (r_pobj) of_2\IN|enzyme (r_prep) recognition_1\NN|the|of (r_nsubj) constitutes_19\VBZ|recognition|(|angioedema|challenge|. (l_nsubj) angioedema_18\NN|arb|intestinal
D000809_D000799 NONE angiotensin_11\NN| (r_compound) blocker_13\NN|angiotensin|receptor (r_conj) enzyme_6\NN|converting|(|ace|)|and|blocker (r_pobj) of_2\IN|enzyme (r_prep) recognition_1\NN|the|of (r_nsubj) constitutes_19\VBZ|recognition|(|angioedema|challenge|. (l_nsubj) angioedema_18\NN|arb|intestinal
20735774
D000082_D017114 CID paracetamol_10\NN| (r_npadvmod) induced_12\VBN|paracetamol|- (r_amod) failure_15\NN|induced|acute|liver
D000082_D017114 CID paracetamol_8\NN| (r_npadvmod) induced_10\VBN|paracetamol|- (r_amod) failure_13\NN|induced|acute|liver
D000082_D017114 CID paracetamol_5\NN| (r_advmod) induced_7\VBN|whether|paracetamol|- (r_nmod) increases_11\VBZ|induced|failure|mortality (l_nsubj) failure_10\NN|acute|liver
D000082_D017114 CID paracetamol_16\RB| (r_npadvmod) induced_18\VBN|paracetamol|- (r_amod) injury_20\NN|whose|induced|liver (r_nsubj) caused_22\VBN|injury|had|failure (l_dobj) failure_26\NN|an|acute|liver|(|ratio|)
D000082_D017114 CID paracetamol_16\RB| (r_npadvmod) induced_18\VBN|paracetamol|- (r_amod) injury_20\NN|whose|induced|liver (r_nsubj) caused_22\VBN|injury|had|failure (r_relcl) patients_14\NNS|the|101|caused (r_pobj) for_11\IN|patients (r_prep) higher_10\JJR|slightly|for (r_acomp) were_8\VBD|on|,|rates|higher|,|but|was (l_conj) was_46\VBD|association|dependent|,|and|died (l_conj) died_58\VBD|survivors|of|,|were|. (l_nsubj) survivors_53\NNS|no|of (l_prep) of_54\IN|failure (l_pobj) failure_57\NN|acute|liver
D000082_D017114 CID Paracetamol_0\NNP| (r_npadvmod) induced_2\VBN|paracetamol|- (r_amod) failure_5\NN|induced|acute|liver
D000082_D056486 NONE paracetamol_9\NN| (r_npadvmod) induced_11\VBN|paracetamol|- (r_amod) injury_14\NN|induced|acute|liver
D000082_D056486 NONE paracetamol_16\RB| (r_npadvmod) induced_18\VBN|paracetamol|- (r_amod) injury_20\NN|whose|induced|liver
D000082_D008107 NONE paracetamol_16\RB| (r_npadvmod) induced_18\VBN|paracetamol|- (r_amod) injury_20\NN|whose|induced|liver (r_nsubj) caused_22\VBN|injury|had|failure (r_relcl) patients_14\NNS|the|101|caused (r_pobj) for_11\IN|patients (r_prep) higher_10\JJR|slightly|for (r_acomp) were_8\VBD|on|,|rates|higher|,|but|was (l_conj) was_46\VBD|association|dependent|,|and|died (l_conj) died_58\VBD|survivors|of|,|were|. (l_prep) of_59\IN|disease (l_pobj) disease_61\NN|liver
12481039
D012964_D012640 NONE sodium_1\NN| (r_compound) channel_2\NN|sodium (r_compound) density_3\NN|reduced|channel|,|dependence|. (l_appos) dependence_7\NN|altered|voltage|of|,|and|susceptibility (l_conj) susceptibility_13\NN|increased|to (l_prep) to_14\IN|seizures (l_pobj) seizures_15\NNS|in
D012964_D012640 NONE sodium_19\NN| (r_compound) channel_20\NN|sodium (r_compound) 2-subunits_22\NNS|channel|beta (r_dobj) lacking_18\VBG|mice|2-subunits (r_pcomp) in_16\IN|lacking (r_prep) seizures_15\NNS|in
D010862_D012640 CID pilocarpine_17\NN| (r_npadvmod) induced_19\VBN|pilocarpine|- (r_amod) seizures_20\NNS|induced (r_pobj) for_16\IN|seizures (r_prep) threshold_15\NN|for (r_conj) latency_13\NN|reduced|and|threshold (r_pobj) by_11\IN|latency (r_agent) indicated_10\VBN|as|by (r_advcl) displayed_3\VBD|mice|susceptibility|,|indicated|,|but|seemed|. (l_dobj) susceptibility_5\NN|increased|to (l_prep) to_6\IN|seizures (l_pobj) seizures_7\NNS|
D010862_D012640 CID pilocarpine_17\NN| (r_npadvmod) induced_19\VBN|pilocarpine|- (r_amod) seizures_20\NNS|induced
19139001
D000518_D015179 NONE difluoromethylornithine_13\NN|and|sulindac (l_conj) sulindac_15\NN|for (l_prep) for_16\IN|prevention (l_pobj) prevention_17\NN|of (l_prep) of_18\IN|adenomas (l_pobj) adenomas_21\NNS|sporadic|colorectal
D013467_D015179 NONE sulindac_15\NN|for (l_prep) for_16\IN|prevention (l_pobj) prevention_17\NN|of (l_prep) of_18\IN|adenomas (l_pobj) adenomas_21\NNS|sporadic|colorectal
D000518_D018256 NONE difluoromethylornithine_17\NN|(|dfmo|)|plus|sulindac (r_pobj) with_16\IN|difluoromethylornithine (r_prep) months_15\NNS|36|with (r_pobj) for_13\IN|months (r_prep) treatment_12\NN|for (r_pobj) after_11\IN|treatment (r_prep) polyps_10\NNS|adenomatous|after
D000518_D018256 NONE DFMO_19\NN| (r_appos) difluoromethylornithine_17\NN|(|dfmo|)|plus|sulindac (r_pobj) with_16\IN|difluoromethylornithine (r_prep) months_15\NNS|36|with (r_pobj) for_13\IN|months (r_prep) treatment_12\NN|for (r_pobj) after_11\IN|treatment (r_prep) polyps_10\NNS|adenomatous|after
D013467_D018256 NONE sulindac_22\NN|or|matched (r_conj) difluoromethylornithine_17\NN|(|dfmo|)|plus|sulindac (r_pobj) with_16\IN|difluoromethylornithine (r_prep) months_15\NNS|36|with (r_pobj) for_13\IN|months (r_prep) treatment_12\NN|for (r_pobj) after_11\IN|treatment (r_prep) polyps_10\NNS|adenomatous|after
D000518_D034381 NONE DFMO_10\NN| (r_pobj) with_9\IN|dfmo (r_prep) treatment_8\NN|with (r_pobj) of_7\IN|treatment (r_prep) toxicity_6\NN|a|known|of|, (r_attr) is_3\VBZ|loss|toxicity|developed|. (l_nsubj) loss_2\NN|temporary|hearing
D000518_D034381 NONE DFMO_12\NN|plus (r_nmod) group_15\NN|the|dfmo|sulindac|experienced (l_relcl) experienced_17\VBD|who|loss|compared (l_dobj) loss_21\NN|significant|hearing
D000518_D064420 NONE DFMO_10\NN| (r_pobj) with_9\IN|dfmo (r_prep) treatment_8\NN|with (r_pobj) of_7\IN|treatment (r_prep) toxicity_6\NN|a|known|of|,
D013467_D034381 CID sulindac_14\NN| (r_compound) group_15\NN|the|dfmo|sulindac|experienced (l_relcl) experienced_17\VBD|who|loss|compared (l_dobj) loss_21\NN|significant|hearing
8410199
D018698_D012640 NONE glutamate_2\NN| (r_compound) decarboxylase_3\NN|glutamate (r_nmod) neurons_7\NNS|decarboxylase|containing|in (r_pobj) of_1\IN|neurons (r_prep) Loss_0\NN|of|following|. (l_prep) following_13\VBG|seizures (l_pobj) seizures_17\NNS|induced
D018698_D012640 NONE acid_10\NN| (r_compound) decarboxylase_11\NN|glutamic|acid|(|neurons (r_nsubj) are_26\VBP|if|decarboxylase|vulnerable (l_acomp) vulnerable_27\JJ|to (l_prep) to_28\IN|damage (l_pobj) damage_32\NN|induced|in (l_amod) induced_31\VBN|seizure|- (l_npadvmod) seizure_29\NN|
D018698_D012640 NONE acid_10\NN| (r_compound) decarboxylase_11\NN|glutamic|acid|(|neurons (r_nsubj) are_26\VBP|if|decarboxylase|vulnerable (l_acomp) vulnerable_27\JJ|to (l_prep) to_28\IN|damage (l_pobj) damage_32\NN|induced|in (l_prep) in_33\IN|model (l_pobj) model_35\NN|a|of (l_prep) of_36\IN|seizures (l_pobj) seizures_38\NNS|chronic
D010862_D012640 CID pilocarpine_14\NN| (r_npadvmod) induced_16\VBN|pilocarpine|- (r_amod) seizures_17\NNS|induced
D010862_D012640 CID pilocarpine_8\NN| (r_pobj) with_7\IN|pilocarpine (r_prep) injected_5\VBN|rats|were|intraperitoneally|with|,|and|studied (l_conj) studied_15\VBN|formation|was|histologically|at|,|and|intervals|. (l_conj) intervals_27\NNS|week|after (l_prep) after_28\IN|seizures (l_pobj) seizures_32\NNS|induced
D010862_D012640 CID pilocarpine_29\NN| (r_npadvmod) induced_31\VBN|pilocarpine|- (r_amod) seizures_32\NNS|induced
C028911_D009410 NONE violet_6\NN| (r_compound) staining_7\NN|cresyl|violet|,|methods (l_conj) methods_11\NNS|neuronal|degeneration|,|and|localization (l_compound) degeneration_10\NN|
C028911_D009410 NONE violet_6\NN| (r_compound) staining_7\NN|cresyl|violet|,|methods (r_pobj) including_4\VBG|staining (r_prep) studies_2\NNS|additional|neuronanatomical|,|including|, (r_nsubj) suggested_22\VBD|studies|related|. (l_ccomp) related_36\VBN|that|decrease|was|to (l_prep) to_37\IN|loss|than|to (l_pobj) loss_39\NN|neuronal
3120485
12734532
D010665_D009203 CID Dexatrim_3\NNP|(|phenylpropanolamine|)|as (l_prep) as_7\IN|cause (l_pobj) cause_9\NN|a|of (l_prep) of_10\IN|infarction (l_pobj) infarction_12\NN|myocardial
D010665_D009203 CID Phenylpropanolamine_5\NNP| (r_appos) Dexatrim_3\NNP|(|phenylpropanolamine|)|as (l_prep) as_7\IN|cause (l_pobj) cause_9\NN|a|of (l_prep) of_10\IN|infarction (l_pobj) infarction_12\NN|myocardial
D010665_D009202 NONE PPA_7\NNP| (r_pobj) of_6\IN|ppa (r_prep) abuse_5\NN|the|of|with (l_prep) with_8\IN|injury (l_pobj) injury_10\NN|myocardial
D010665_D009202 NONE Dexatrim_7\NNP| (r_nmod) injury_11\NN|dexatrim|ppa)-induced|myocardial|in
D010665_D009202 NONE PPA)-induced_9\VBN|( (r_amod) injury_11\NN|dexatrim|ppa)-induced|myocardial|in
D010665_D009202 NONE PPA_10\NN| (r_pobj) of_9\IN|ppa (r_prep) cases_8\NNS|the|7|other|of|related (l_acl) related_11\VBN|injury (l_dobj) injury_13\NN|myocardial|reported
D010665_D062787 NONE PPA_7\NNP| (r_pobj) of_6\IN|ppa (r_prep) abuse_5\NN|the|of|with (r_dobj) linked_3\VBN|reports|have|abuse|,|involved|. (l_advcl) involved_16\VBN|especially|when|overdose|is (l_nsubjpass) overdose_14\NN|
17965424
C422649_D001172 NONE etoricoxib_3\NN|in (l_prep) in_4\IN|patients (l_pobj) patients_7\NNS|rheumatoid|arthritis (l_compound) arthritis_6\NN|
C422649_D001172 NONE etoricoxib_12\NN|the|vs (r_pobj) of_10\IN|etoricoxib (r_prep) results_9\NNS|of|) (r_appos) tolerability_1\NN|gastrointestinal|of|:|results|. (l_prep) of_2\IN|etoricoxib (l_pobj) etoricoxib_3\NN|in (l_prep) in_4\IN|patients (l_pobj) patients_7\NNS|rheumatoid|arthritis (l_compound) arthritis_6\NN|
C422649_D001172 NONE etoricoxib_20\NN|and|diclofenac (r_pobj) of_19\IN|etoricoxib (r_prep) tolerability_14\NN|the|gastrointestinal|(|gi|)|,|safety|of (r_dobj) compare_8\VB|to|tolerability|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|arthritis (l_pobj) arthritis_27\NN|rheumatoid|(|ra|)
C422649_D001172 NONE etoricoxib_20\NN|and|diclofenac (r_pobj) of_19\IN|etoricoxib (r_prep) tolerability_14\NN|the|gastrointestinal|(|gi|)|,|safety|of (r_dobj) compare_8\VB|to|tolerability|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|arthritis (l_pobj) arthritis_27\NN|rheumatoid|(|ra|) (l_appos) RA_29\NNP|
C422649_D001172 NONE etoricoxib_18\RB| (r_dobj) received_17\VBN|etoricoxib|daily (r_conj) enrolled_15\VBN|years|were|and|received|or|twice|. (l_nsubjpass) years_9\NNS|a|age|60.8|)|diagnosed (l_acl) diagnosed_11\VBD|with (l_prep) with_12\IN|ra (l_pobj) RA_13\NNP|
D004008_D001172 NONE sodium_15\NN| (r_compound) tolerability_17\NN|diclofenac|sodium|gastrointestinal|and|trial|ii (r_pobj) vs_13\IN|tolerability (r_prep) etoricoxib_12\NN|the|vs (r_pobj) of_10\IN|etoricoxib (r_prep) results_9\NNS|of|) (r_appos) tolerability_1\NN|gastrointestinal|of|:|results|. (l_prep) of_2\IN|etoricoxib (l_pobj) etoricoxib_3\NN|in (l_prep) in_4\IN|patients (l_pobj) patients_7\NNS|rheumatoid|arthritis (l_compound) arthritis_6\NN|
D004008_D001172 NONE diclofenac_22\NN| (r_conj) etoricoxib_20\NN|and|diclofenac (r_pobj) of_19\IN|etoricoxib (r_prep) tolerability_14\NN|the|gastrointestinal|(|gi|)|,|safety|of (r_dobj) compare_8\VB|to|tolerability|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|arthritis (l_pobj) arthritis_27\NN|rheumatoid|(|ra|)
D004008_D001172 NONE diclofenac_22\NN| (r_conj) etoricoxib_20\NN|and|diclofenac (r_pobj) of_19\IN|etoricoxib (r_prep) tolerability_14\NN|the|gastrointestinal|(|gi|)|,|safety|of (r_dobj) compare_8\VB|to|tolerability|in (l_prep) in_23\IN|patients (l_pobj) patients_24\NNS|with (l_prep) with_25\IN|arthritis (l_pobj) arthritis_27\NN|rheumatoid|(|ra|) (l_appos) RA_29\NNP|
D004008_D001172 NONE diclofenac_28\NN| (r_nmod) mg_30\NN|diclofenac|75 (r_compound) twice_31\RB|mg|daily|2054|) (r_conj) enrolled_15\VBN|years|were|and|received|or|twice|. (l_nsubjpass) years_9\NNS|a|age|60.8|)|diagnosed (l_acl) diagnosed_11\VBD|with (l_prep) with_12\IN|ra (l_pobj) RA_13\NNP|
C422649_D005767 NONE etoricoxib_12\NN|than (r_pobj) with_11\IN|etoricoxib (r_prep) lower_10\JJR|significantly|with (r_acomp) was_8\VBD|rate|lower|;|ratio|. (l_nsubj) rate_3\NN|the|cumulative|discontinuation|due (l_amod) due_4\IN|to (l_pcomp) to_5\IN|aes (l_pobj) AEs_7\NNS|gi
C422649_D005767 NONE Etoricoxib_0\NNP| (r_nsubj) demonstrated_3\VBD|etoricoxib|mg|risk|,|common (l_dobj) risk_7\NN|a|lower|for (l_prep) for_8\IN|discontinuing (l_pcomp) discontinuing_9\VBG|treatment|due|compared (l_prep) due_11\IN|to (l_pcomp) to_12\IN|aes (l_pobj) AEs_14\NNS|gi
C422649_D005767 NONE Etoricoxib_0\NNP| (r_nsubj) demonstrated_3\VBD|etoricoxib|mg|risk|,|common (l_advcl) common_27\JJ|although|less|than (l_prep) than_28\IN|discontinuations (l_pobj) discontinuations_29\NNS|from (l_prep) from_30\IN|aes (l_pobj) AEs_32\NNS|gi
C422649_D005767 NONE etoricoxib_38\NN| (r_pobj) with_37\IN|etoricoxib (r_prep) higher_36\JJR|significantly|with (r_acomp) were_34\VBD|demonstrated|,|higher|. (l_ccomp) demonstrated_3\VBD|etoricoxib|mg|risk|,|common (l_dobj) risk_7\NN|a|lower|for (l_prep) for_8\IN|discontinuing (l_pcomp) discontinuing_9\VBG|treatment|due|compared (l_prep) due_11\IN|to (l_pcomp) to_12\IN|aes (l_pobj) AEs_14\NNS|gi
C422649_D005767 NONE etoricoxib_38\NN| (r_pobj) with_37\IN|etoricoxib (r_prep) higher_36\JJR|significantly|with (r_acomp) were_34\VBD|demonstrated|,|higher|. (l_ccomp) demonstrated_3\VBD|etoricoxib|mg|risk|,|common (l_advcl) common_27\JJ|although|less|than (l_prep) than_28\IN|discontinuations (l_pobj) discontinuations_29\NNS|from (l_prep) from_30\IN|aes (l_pobj) AEs_32\NNS|gi
D004008_D005767 CID diclofenac_14\NNP|events (r_pobj) than_13\IN|diclofenac (r_prep) etoricoxib_12\NN|than (r_pobj) with_11\IN|etoricoxib (r_prep) lower_10\JJR|significantly|with (r_acomp) was_8\VBD|rate|lower|;|ratio|. (l_nsubj) rate_3\NN|the|cumulative|discontinuation|due (l_amod) due_4\IN|to (l_pcomp) to_5\IN|aes (l_pobj) AEs_7\NNS|gi
D004008_D005767 CID diclofenac_17\NNP| (r_nmod) Discontinuations_20\NNS|diclofenac|150|mg.|from (r_pobj) with_16\IN|discontinuations (r_prep) compared_15\VBN|with (r_prep) discontinuing_9\VBG|treatment|due|compared (l_prep) due_11\IN|to (l_pcomp) to_12\IN|aes (l_pobj) AEs_14\NNS|gi
D004008_D005767 CID diclofenac_17\NNP| (r_nmod) Discontinuations_20\NNS|diclofenac|150|mg.|from (r_pobj) with_16\IN|discontinuations (r_prep) compared_15\VBN|with (r_prep) discontinuing_9\VBG|treatment|due|compared (r_pcomp) for_8\IN|discontinuing (r_prep) risk_7\NN|a|lower|for (r_dobj) demonstrated_3\VBD|etoricoxib|mg|risk|,|common (l_advcl) common_27\JJ|although|less|than (l_prep) than_28\IN|discontinuations (l_pobj) discontinuations_29\NNS|from (l_prep) from_30\IN|aes (l_pobj) AEs_32\NNS|gi
C422649_D006973 CID etoricoxib_17\NN|(|%|) (r_pobj) with_16\IN|etoricoxib (r_prep) higher_15\JJR|significantly|with (r_acomp) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|discontinuations (l_pobj) discontinuations_3\NNS|for (l_prep) for_4\IN|aes (l_pobj) AEs_12\NNS|related (l_amod) related_7\VBN|hypertension|-|and|related (l_npadvmod) hypertension_5\NN|
C422649_D006973 CID etoricoxib_17\NN|(|%|) (r_pobj) with_16\IN|etoricoxib (r_prep) higher_15\JJR|significantly|with (r_acomp) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_dep) p<0.001_37\VB|for|) (l_prep) for_38\IN|hypertension (l_pobj) hypertension_39\NN|and|p<0.01
C422649_D004487 CID etoricoxib_17\NN|(|%|) (r_pobj) with_16\IN|etoricoxib (r_prep) higher_15\JJR|significantly|with (r_acomp) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|discontinuations (l_pobj) discontinuations_3\NNS|for (l_prep) for_4\IN|aes (l_pobj) AEs_12\NNS|related (l_amod) related_7\VBN|hypertension|-|and|related (l_conj) related_11\VBN|oedema|- (l_npadvmod) oedema_9\NN|
C422649_D004487 CID etoricoxib_17\NN|(|%|) (r_pobj) with_16\IN|etoricoxib (r_prep) higher_15\JJR|significantly|with (r_acomp) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_dep) p<0.001_37\VB|for|) (l_prep) for_38\IN|hypertension (l_pobj) hypertension_39\NN|and|p<0.01 (l_conj) p<0.01_41\NN|for (l_prep) for_42\IN|oedema (l_pobj) oedema_43\NN|
D004008_D006973 NONE diclofenac_28\NNP|% (r_pobj) with_27\IN|diclofenac (r_prep) compared_26\VBN|with|respectively (r_prep) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|discontinuations (l_pobj) discontinuations_3\NNS|for (l_prep) for_4\IN|aes (l_pobj) AEs_12\NNS|related (l_amod) related_7\VBN|hypertension|-|and|related (l_npadvmod) hypertension_5\NN|
D004008_D006973 NONE diclofenac_28\NNP|% (r_pobj) with_27\IN|diclofenac (r_prep) compared_26\VBN|with|respectively (r_prep) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_dep) p<0.001_37\VB|for|) (l_prep) for_38\IN|hypertension (l_pobj) hypertension_39\NN|and|p<0.01
D004008_D004487 NONE diclofenac_28\NNP|% (r_pobj) with_27\IN|diclofenac (r_prep) compared_26\VBN|with|respectively (r_prep) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_nsubj) incidence_1\NN|the|of (l_prep) of_2\IN|discontinuations (l_pobj) discontinuations_3\NNS|for (l_prep) for_4\IN|aes (l_pobj) AEs_12\NNS|related (l_amod) related_7\VBN|hypertension|-|and|related (l_conj) related_11\VBN|oedema|- (l_npadvmod) oedema_9\NN|
D004008_D004487 NONE diclofenac_28\NNP|% (r_pobj) with_27\IN|diclofenac (r_prep) compared_26\VBN|with|respectively (r_prep) were_13\VBD|incidence|higher|compared|;|p<0.001|. (l_dep) p<0.001_37\VB|for|) (l_prep) for_38\IN|hypertension (l_pobj) hypertension_39\NN|and|p<0.01 (l_conj) p<0.01_41\NN|for (l_prep) for_42\IN|oedema (l_pobj) oedema_43\NN|
16720068
D017374_D009459 CID paroxetine_9\NN|and|alprazolam (r_pobj) with_8\IN|paroxetine (r_prep) treatment_7\NN|concomitant|with (r_pobj) to_5\IN|treatment (r_prep) related_4\VBN|to (r_acl) syndrome_3\NN|possible|neuroleptic|malignant|related|.
D017374_D009459 CID paroxetine_24\NN|combined|and|treatment (r_pobj) after_22\IN|paroxetine (r_prep) occur_21\VB|that|symptoms|can|after (r_ccomp) demonstrating_14\VBG|thus|occur (r_advcl) presented_2\VBN|patient|with|,|demonstrating|. (l_prep) with_3\IN|symptoms (l_pobj) symptoms_4\NNS|of (l_prep) of_5\IN|syndrome (l_pobj) syndrome_8\NN|neuroleptic|malignant|nms
D017374_D009459 CID paroxetine_24\NN|combined|and|treatment (r_pobj) after_22\IN|paroxetine (r_prep) occur_21\VB|that|symptoms|can|after (r_ccomp) demonstrating_14\VBG|thus|occur (r_advcl) presented_2\VBN|patient|with|,|demonstrating|. (l_prep) with_3\IN|symptoms (l_pobj) symptoms_4\NNS|of (l_prep) of_5\IN|syndrome (l_pobj) syndrome_8\NN|neuroleptic|malignant|nms (l_appos) NMS_10\NNP|(|)
D017374_D009459 CID paroxetine_24\NN|combined|and|treatment (r_pobj) after_22\IN|paroxetine (r_prep) occur_21\VB|that|symptoms|can|after (l_nsubj) symptoms_19\NNS|like (l_amod) like_18\JJ|nms|- (l_npadvmod) NMS_16\NNP|
D000525_D009459 CID alprazolam_11\NN| (r_conj) paroxetine_9\NN|and|alprazolam (r_pobj) with_8\IN|paroxetine (r_prep) treatment_7\NN|concomitant|with (r_pobj) to_5\IN|treatment (r_prep) related_4\VBN|to (r_acl) syndrome_3\NN|possible|neuroleptic|malignant|related|.
D000525_D009459 CID alprazolam_26\NN| (r_compound) treatment_27\NN|alprazolam (r_conj) paroxetine_24\NN|combined|and|treatment (r_pobj) after_22\IN|paroxetine (r_prep) occur_21\VB|that|symptoms|can|after (r_ccomp) demonstrating_14\VBG|thus|occur (r_advcl) presented_2\VBN|patient|with|,|demonstrating|. (l_prep) with_3\IN|symptoms (l_pobj) symptoms_4\NNS|of (l_prep) of_5\IN|syndrome (l_pobj) syndrome_8\NN|neuroleptic|malignant|nms
D000525_D009459 CID alprazolam_26\NN| (r_compound) treatment_27\NN|alprazolam (r_conj) paroxetine_24\NN|combined|and|treatment (r_pobj) after_22\IN|paroxetine (r_prep) occur_21\VB|that|symptoms|can|after (r_ccomp) demonstrating_14\VBG|thus|occur (r_advcl) presented_2\VBN|patient|with|,|demonstrating|. (l_prep) with_3\IN|symptoms (l_pobj) symptoms_4\NNS|of (l_prep) of_5\IN|syndrome (l_pobj) syndrome_8\NN|neuroleptic|malignant|nms (l_appos) NMS_10\NNP|(|)
D000525_D009459 CID alprazolam_26\NN| (r_compound) treatment_27\NN|alprazolam (r_conj) paroxetine_24\NN|combined|and|treatment (r_pobj) after_22\IN|paroxetine (r_prep) occur_21\VB|that|symptoms|can|after (l_nsubj) symptoms_19\NNS|like (l_amod) like_18\JJ|nms|- (l_npadvmod) NMS_16\NNP|
D017374_D011596 NONE paroxetine_5\NN|and|treatment (r_pobj) of_4\IN|paroxetine (r_prep) day_3\NN|the|10th|of (r_pobj) On_0\IN|day (r_prep) exhibited_12\VBD|on|,|patient|retardation|. (l_dobj) retardation_15\NN|marked|psychomotor|,|disorientation
D017374_D009127 NONE paroxetine_5\NN|and|treatment (r_pobj) of_4\IN|paroxetine (r_prep) day_3\NN|the|10th|of (r_pobj) On_0\IN|day (r_prep) exhibited_12\VBD|on|,|patient|retardation|. (l_dobj) retardation_15\NN|marked|psychomotor|,|disorientation (l_conj) disorientation_17\NN|,|and|rigidity (l_conj) rigidity_22\NN|severe|muscle|with
D017374_D014202 NONE paroxetine_5\NN|and|treatment (r_pobj) of_4\IN|paroxetine (r_prep) day_3\NN|the|10th|of (r_pobj) On_0\IN|day (r_prep) exhibited_12\VBD|on|,|patient|retardation|. (l_dobj) retardation_15\NN|marked|psychomotor|,|disorientation (l_conj) disorientation_17\NN|,|and|rigidity (l_conj) rigidity_22\NN|severe|muscle|with (l_prep) with_23\IN|tremors (l_pobj) tremors_24\NNS|
D000525_D011596 NONE alprazolam_7\NN| (r_compound) treatment_8\NN|alprazolam (r_conj) paroxetine_5\NN|and|treatment (r_pobj) of_4\IN|paroxetine (r_prep) day_3\NN|the|10th|of (r_pobj) On_0\IN|day (r_prep) exhibited_12\VBD|on|,|patient|retardation|. (l_dobj) retardation_15\NN|marked|psychomotor|,|disorientation
D000525_D009127 NONE alprazolam_7\NN| (r_compound) treatment_8\NN|alprazolam (r_conj) paroxetine_5\NN|and|treatment (r_pobj) of_4\IN|paroxetine (r_prep) day_3\NN|the|10th|of (r_pobj) On_0\IN|day (r_prep) exhibited_12\VBD|on|,|patient|retardation|. (l_dobj) retardation_15\NN|marked|psychomotor|,|disorientation (l_conj) disorientation_17\NN|,|and|rigidity (l_conj) rigidity_22\NN|severe|muscle|with
D000525_D014202 NONE alprazolam_7\NN| (r_compound) treatment_8\NN|alprazolam (r_conj) paroxetine_5\NN|and|treatment (r_pobj) of_4\IN|paroxetine (r_prep) day_3\NN|the|10th|of (r_pobj) On_0\IN|day (r_prep) exhibited_12\VBD|on|,|patient|retardation|. (l_dobj) retardation_15\NN|marked|psychomotor|,|disorientation (l_conj) disorientation_17\NN|,|and|rigidity (l_conj) rigidity_22\NN|severe|muscle|with (l_prep) with_23\IN|tremors (l_pobj) tremors_24\NNS|
20195852
D003287_D007674 CID media_8\NNS| (r_dobj) contrast_7\NN|risk|media|by|. (l_nsubj) Risk_0\NN|of|after (l_prep) of_1\IN|nephropathy (l_pobj) nephropathy_2\NN|
D003287_D007674 CID media_6\NNS| (r_npadvmod) induced_8\VBN|media|- (r_amod) nephropathy_9\NN|induced|(|cin|in
D003287_D007674 CID media_6\NNS| (r_npadvmod) induced_8\VBN|media|- (r_amod) nephropathy_9\NN|induced|(|cin|in (l_appos) CIN_11\NNP|)
D003287_D007674 CID media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (l_prep) of_6\IN|cin (l_pobj) CIN_7\NNP|
D003287_D007674 CID CM_14\NNP|) (r_appos) media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (l_prep) of_6\IN|cin (l_pobj) CIN_7\NNP|
D003287_D007674 CID CM_43\NNP| (r_pobj) of_42\IN|cm (r_prep) type_39\NN|the|and|dosage|of|and|presence (r_pobj) to_37\IN|type (r_prep) relation_36\NN|to (r_pobj) in_35\IN|relation (r_prep) complication_34\NN|this|in (r_pobj) for_32\IN|complication (r_prep) rates_31\NNS|the|for (r_dobj) compared_29\VBD|rates (r_conj) among_21\IN|patients|and|compared (r_prep) determined_3\VBD|study|incidence|,|among|. (l_dobj) incidence_5\NN|the|of|for (l_prep) of_6\IN|cin (l_pobj) CIN_7\NNP|
D003287_D007674 CID CM_17\NNP| (r_pobj) of_16\IN|cm (r_prep) dosage_15\NN|the|proper|of (r_dobj) received_12\VBD|who|dosage (r_relcl) those_10\DT|received (r_pobj) among_9\IN|those (r_prep) were_8\VBD|whereas|%|among (l_nsubj) %_2\NN|33.3|of (l_prep) of_3\IN|patients (l_pobj) patients_5\NNS|the|with (l_prep) with_6\IN|cin (l_pobj) CIN_7\NNP|
D003287_D007674 CID CM_17\NNP| (r_pobj) of_16\IN|cm (r_prep) dosage_15\NN|the|proper|of (r_dobj) received_12\VBD|who|dosage (r_relcl) those_10\DT|received (r_pobj) among_9\IN|those (r_prep) were_8\VBD|whereas|%|among (r_advcl) increased_21\VBD|were|,|percentage|to|among|,|with|)|. (l_prep) with_32\IN|difference (l_pobj) difference_35\NN|a|significant|in (l_prep) in_36\IN|incidence (l_pobj) incidence_38\NN|the|of|related (l_prep) of_39\IN|cin (l_pobj) CIN_40\NNP|
D003287_D007674 CID CM_47\NNP|0.014 (r_pobj) of_46\IN|cm (r_prep) dosages_45\NNS|the|different|of (r_pobj) to_42\IN|dosages (r_prep) related_41\VBN|to (r_acl) incidence_38\NN|the|of|related (r_pobj) in_36\IN|incidence (r_prep) difference_35\NN|a|significant|in (r_pobj) with_32\IN|difference (r_prep) increased_21\VBD|were|,|percentage|to|among|,|with|)|. (l_advcl) were_8\VBD|whereas|%|among (l_nsubj) %_2\NN|33.3|of (l_prep) of_3\IN|patients (l_pobj) patients_5\NNS|the|with (l_prep) with_6\IN|cin (l_pobj) CIN_7\NNP|
D003287_D007674 CID CM_47\NNP|0.014 (r_pobj) of_46\IN|cm (r_prep) dosages_45\NNS|the|different|of (r_pobj) to_42\IN|dosages (r_prep) related_41\VBN|to (r_acl) incidence_38\NN|the|of|related (l_prep) of_39\IN|cin (l_pobj) CIN_40\NNP|
D003287_D007674 CID CM_13\NNP|consumed|nonionic (r_pobj) of_10\IN|cm (r_prep) type_9\NN|the|of (r_pobj) on_7\IN|not|type|,|nor|on (r_conj) on_3\IN|dosage|but|on (r_prep) depends_2\VBZ|incidence|on|,|and|needed (l_conj) needed_32\VBN|is|,|concern|is|for|. (l_advcl) is_26\VBZ|although|cin|usually|reversible (l_nsubj) CIN_24\NNP|
D003287_D003490 NONE media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (r_dobj) determined_3\VBD|study|incidence|,|among|. (l_prep) among_21\IN|patients|and|compared (l_conj) compared_29\VBD|rates (l_dobj) rates_31\NNS|the|for (l_prep) for_32\IN|complication (l_pobj) complication_34\NN|this|in (l_prep) in_35\IN|relation (l_pobj) relation_36\NN|to (l_prep) to_37\IN|type (l_pobj) type_39\NN|the|and|dosage|of|and|presence (l_conj) presence_46\NN|the|of (l_prep) of_47\IN|cyanosis (l_pobj) cyanosis_48\NN|
D003287_D003490 NONE CM_14\NNP|) (r_appos) media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (r_dobj) determined_3\VBD|study|incidence|,|among|. (l_prep) among_21\IN|patients|and|compared (l_conj) compared_29\VBD|rates (l_dobj) rates_31\NNS|the|for (l_prep) for_32\IN|complication (l_pobj) complication_34\NN|this|in (l_prep) in_35\IN|relation (l_pobj) relation_36\NN|to (l_prep) to_37\IN|type (l_pobj) type_39\NN|the|and|dosage|of|and|presence (l_conj) presence_46\NN|the|of (l_prep) of_47\IN|cyanosis (l_pobj) cyanosis_48\NN|
D003287_D003490 NONE CM_43\NNP| (r_pobj) of_42\IN|cm (r_prep) type_39\NN|the|and|dosage|of|and|presence (l_conj) presence_46\NN|the|of (l_prep) of_47\IN|cyanosis (l_pobj) cyanosis_48\NN|
D003287_D003490 NONE CM_13\NNP|consumed|nonionic (r_pobj) of_10\IN|cm (r_prep) type_9\NN|the|of (r_pobj) on_7\IN|not|type|,|nor|on (l_conj) on_16\IN|presence (l_pobj) presence_18\NN|the|of (l_prep) of_19\IN|cyanosis (l_pobj) cyanosis_20\NN|
C038192_D007674 CID iopromide_17\JJ|and|iohexol (r_appos) media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (l_prep) of_6\IN|cin (l_pobj) CIN_7\NNP|
C038192_D003490 NONE iopromide_17\JJ|and|iohexol (r_appos) media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (r_dobj) determined_3\VBD|study|incidence|,|among|. (l_prep) among_21\IN|patients|and|compared (l_conj) compared_29\VBD|rates (l_dobj) rates_31\NNS|the|for (l_prep) for_32\IN|complication (l_pobj) complication_34\NN|this|in (l_prep) in_35\IN|relation (l_pobj) relation_36\NN|to (l_prep) to_37\IN|type (l_pobj) type_39\NN|the|and|dosage|of|and|presence (l_conj) presence_46\NN|the|of (l_prep) of_47\IN|cyanosis (l_pobj) cyanosis_48\NN|
D007472_D007674 CID iohexol_19\NN| (r_conj) iopromide_17\JJ|and|iohexol (r_appos) media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (l_prep) of_6\IN|cin (l_pobj) CIN_7\NNP|
D007472_D003490 NONE iohexol_19\NN| (r_conj) iopromide_17\JJ|and|iohexol (r_appos) media_12\NNS|two|contrast|(|cm|,|iopromide (r_pobj) for_8\IN|media (r_prep) incidence_5\NN|the|of|for (r_dobj) determined_3\VBD|study|incidence|,|among|. (l_prep) among_21\IN|patients|and|compared (l_conj) compared_29\VBD|rates (l_dobj) rates_31\NNS|the|for (l_prep) for_32\IN|complication (l_pobj) complication_34\NN|this|in (l_prep) in_35\IN|relation (l_pobj) relation_36\NN|to (l_prep) to_37\IN|type (l_pobj) type_39\NN|the|and|dosage|of|and|presence (l_conj) presence_46\NN|the|of (l_prep) of_47\IN|cyanosis (l_pobj) cyanosis_48\NN|
20164825
D008687_D007674 NONE Metformin_0\NNP| (r_nsubj) prevents_1\VBZ|metformin|nephropathy|by|. (l_dobj) nephropathy_6\NN|experimental|induced
D008687_D007674 NONE metformin_11\NN| (r_pobj) by_10\IN|metformin (r_prep) correction_9\NN|their|by (r_conj) markers_3\NNS|vivo|of|and|correction (l_prep) of_4\IN|dysfunction (l_pobj) dysfunction_6\NN|kidney
D008687_D007674 NONE metformin_9\NN| (r_pobj) of_8\IN|metformin (r_prep) effects_7\NNS|pleiotropic|of (r_nsubj) lessen_11\VB|that|effects|can|nephrotoxicity|and|improve (l_dobj) nephrotoxicity_13\NN|gentamicin
D005839_D007674 NONE gentamicin_3\NN| (r_npadvmod) induced_5\VBN|gentamicin|- (r_amod) nephropathy_6\NN|experimental|induced
D005839_D007674 NONE gentamicin_12\NN| (r_amod) nephrotoxicity_13\NN|gentamicin
D008687_D014652 NONE metformin_3\NN|drug (r_nsubj) diminish_5\VB|metformin|can|apoptosis|induced|and|prevent|. (l_conj) prevent_15\VB|dysfunction|in (l_dobj) dysfunction_17\NN|vascular
D005839_D064420 NONE gentamicin_14\NN| (r_amod) toxicity_15\NN|gentamicin
D008687_D058186 NONE Metformin_0\NNP| (r_compound) treatment_1\NN|metformin (r_nsubj) blocked_3\VBD|treatment|fully|failure|. (l_dobj) failure_9\NN|mediated|acute|renal
D005839_D058186 CID gentamicin_4\NN| (r_npadvmod) mediated_6\VBN|gentamicin|- (r_amod) failure_9\NN|mediated|acute|renal
9201797
D002354_D002375 NONE hydrochloride_5\NN|carteolol|,|antagonist|, (r_pobj) of_3\IN|hydrochloride (r_prep) effect_2\NN|the|attenuating|of|on|. (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|in
D002354_D002375 NONE carteolol_5\NN| (r_pobj) of_4\IN|carteolol (r_prep) effects_3\NNS|the|of|,|antagonist (l_appos) antagonist_11\NN|a|adrenoceptor|,|on (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|in
D002354_D002375 NONE Carteolol_0\NNP|,|as|propranolol|. (l_conj) propranolol_5\NN|and|biperiden|,|inhibited (l_conj) inhibited_9\VBD|catalepsy (l_dobj) catalepsy_14\NN|the|induced
D002354_D002375 NONE carteolol_5\NN| (r_nsubj) improves_6\VBZ|that|carteolol|catalepsy|via|and|expected (l_dobj) catalepsy_10\NN|induced
D006220_D002375 CID haloperidol_14\NN| (r_npadvmod) induced_16\VBN|haloperidol|- (r_amod) catalepsy_17\NN|induced|in
D006220_D002375 CID haloperidol_11\NN| (r_npadvmod) induced_13\VBN|haloperidol|- (r_amod) catalepsy_14\NN|the|induced
D006220_D002375 CID haloperidol_7\NN| (r_npadvmod) induced_9\VBN|haloperidol|- (r_amod) catalepsy_10\NN|induced
D011433_D002375 NONE propranolol_28\NN|and|biperiden (r_pobj) of_27\IN|propranolol (r_prep) those_26\DT|of|,|antagonist (r_pobj) with_25\IN|those (r_prep) compared_24\VBN|with (r_conj) studied_22\VBN|therefore|,|effects|were|behaviorally|and|compared|. (l_nsubjpass) effects_3\NNS|the|of|,|antagonist (l_appos) antagonist_11\NN|a|adrenoceptor|,|on (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|in
D011433_D002375 NONE propranolol_5\NN|and|biperiden|,|inhibited (l_conj) inhibited_9\VBD|catalepsy (l_dobj) catalepsy_14\NN|the|induced
D001712_D002375 NONE biperiden_30\VBN| (r_conj) propranolol_28\NN|and|biperiden (r_pobj) of_27\IN|propranolol (r_prep) those_26\DT|of|,|antagonist (r_pobj) with_25\IN|those (r_prep) compared_24\VBN|with (r_conj) studied_22\VBN|therefore|,|effects|were|behaviorally|and|compared|. (l_nsubjpass) effects_3\NNS|the|of|,|antagonist (l_appos) antagonist_11\NN|a|adrenoceptor|,|on (l_prep) on_13\IN|catalepsy (l_pobj) catalepsy_17\NN|induced|in
D001712_D002375 NONE biperiden_7\RB| (r_conj) propranolol_5\NN|and|biperiden|,|inhibited (l_conj) inhibited_9\VBD|catalepsy (l_dobj) catalepsy_14\NN|the|induced
D002354_D009069 NONE Carteolol_0\NNP| (r_nsubj) evoke_3\VB|carteolol|did|not|signs|. (l_dobj) signs_10\NNS|postsynaptic|dopamine|stimulating|behavioral|as (l_prep) as_12\IN|such|stereotypy (l_pobj) stereotypy_13\NN|and|hyperlocomotion|in (l_conj) hyperlocomotion_15\NN|
D004298_D009069 NONE dopamine_5\NN| (r_nmod) signs_10\NNS|postsynaptic|dopamine|stimulating|behavioral|as (l_prep) as_12\IN|such|stereotypy (l_pobj) stereotypy_13\NN|and|hyperlocomotion|in (l_conj) hyperlocomotion_15\NN|
D002354_D017109 NONE carteolol_5\NN| (r_nsubj) improves_6\VBZ|that|carteolol|catalepsy|via|and|expected (l_conj) expected_20\VBN|is|be (l_xcomp) be_22\VB|to|effective (l_acomp) effective_23\JJ|in (l_prep) in_24\IN|treatment (l_pobj) treatment_26\NN|the|of|without (l_prep) of_27\IN|akathisia (l_pobj) akathisia_28\NN|
D006220_D017109 NONE haloperidol_7\NN| (r_npadvmod) induced_9\VBN|haloperidol|- (r_amod) catalepsy_10\NN|induced (r_dobj) improves_6\VBZ|that|carteolol|catalepsy|via|and|expected (l_conj) expected_20\VBN|is|be (l_xcomp) be_22\VB|to|effective (l_acomp) effective_23\JJ|in (l_prep) in_24\IN|treatment (l_pobj) treatment_26\NN|the|of|without (l_prep) of_27\IN|akathisia (l_pobj) akathisia_28\NN|
D004298_D002375 NONE dopamine_40\NN| (r_nmod) receptor_41\NN|dopamine (r_nmod) activity_43\NN|its|postsynaptic|receptor|antagonistic (r_pobj) to_37\IN|activity (r_pcomp) due_36\IN|to (r_prep) attenuating_30\VBG|effects|due (r_pcomp) without_29\IN|attenuating (r_prep) treatment_26\NN|the|of|without (r_pobj) in_24\IN|treatment (r_prep) effective_23\JJ|in (r_acomp) be_22\VB|to|effective (r_xcomp) expected_20\VBN|is|be (r_conj) improves_6\VBZ|that|carteolol|catalepsy|via|and|expected (l_dobj) catalepsy_10\NN|induced
D004298_D017109 NONE dopamine_40\NN| (r_nmod) receptor_41\NN|dopamine (r_nmod) activity_43\NN|its|postsynaptic|receptor|antagonistic (r_pobj) to_37\IN|activity (r_pcomp) due_36\IN|to (r_prep) attenuating_30\VBG|effects|due (r_pcomp) without_29\IN|attenuating (r_prep) treatment_26\NN|the|of|without (l_prep) of_27\IN|akathisia (l_pobj) akathisia_28\NN|
12842176
D001556_D020258 NONE lindane_2\NN|on (r_pobj) of_1\IN|lindane (r_prep) Effect_0\NN|of (r_nsubj) induced_16\VBN|effect|influence|neurotoxicity|. (l_dobj) neurotoxicity_17\NN|
D001556_D020258 NONE lindane_15\NN| (r_pobj) in_14\IN|lindane (r_prep) modulation_13\NN|p450|in (r_pobj) of_11\IN|modulation (r_prep) influence_10\NN|of (r_nsubj) induced_16\VBN|effect|influence|neurotoxicity|. (l_dobj) neurotoxicity_17\NN|
D008748_D012640 NONE 3-methylcholanthrene_9\NN| (r_pobj) of_8\IN|3-methylcholanthrene|mc (r_prep) pretreatment_7\NN|of|,|inducer (r_nsubj) produce_21\VB|while|pretreatment|,|did|not|effect (r_advcl) induced_30\VBN|that|produce|convulsions (l_dobj) convulsions_31\NNS|,|pretreatment
D008748_D012640 NONE 3-methylcholanthrene_9\NN| (r_pobj) of_8\IN|3-methylcholanthrene|mc (r_prep) pretreatment_7\NN|of|,|inducer (r_nsubj) produce_21\VB|while|pretreatment|,|did|not|effect (r_advcl) induced_30\VBN|that|produce|convulsions (r_ccomp) shown_4\VBN|studies|have|further|induced (r_ccomp) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_advcl) induced_62\VBN|convulsions (l_dobj) convulsions_63\NNS|
D008748_D012640 NONE MC_11\NNP|(|) (r_pobj) of_8\IN|3-methylcholanthrene|mc (r_prep) pretreatment_7\NN|of|,|inducer (r_nsubj) produce_21\VB|while|pretreatment|,|did|not|effect (r_advcl) induced_30\VBN|that|produce|convulsions (l_dobj) convulsions_31\NNS|,|pretreatment
D008748_D012640 NONE MC_11\NNP|(|) (r_pobj) of_8\IN|3-methylcholanthrene|mc (r_prep) pretreatment_7\NN|of|,|inducer (r_nsubj) produce_21\VB|while|pretreatment|,|did|not|effect (r_advcl) induced_30\VBN|that|produce|convulsions (r_ccomp) shown_4\VBN|studies|have|further|induced (r_ccomp) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_advcl) induced_62\VBN|convulsions (l_dobj) convulsions_63\NNS|
D001556_D012640 CID lindane_29\NN| (r_pobj) of_28\IN|lindane (r_prep) incidence_27\NN|the|of (r_pobj) in_25\IN|incidence (r_prep) effect_24\NN|any|significant|in (r_dobj) produce_21\VB|while|pretreatment|,|did|not|effect (r_advcl) induced_30\VBN|that|produce|convulsions (l_dobj) convulsions_31\NNS|,|pretreatment
D001556_D012640 CID lindane_29\NN| (r_pobj) of_28\IN|lindane (r_prep) incidence_27\NN|the|of (r_pobj) in_25\IN|incidence (r_prep) effect_24\NN|any|significant|in (r_dobj) produce_21\VB|while|pretreatment|,|did|not|effect (r_advcl) induced_30\VBN|that|produce|convulsions (r_ccomp) shown_4\VBN|studies|have|further|induced (r_ccomp) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_advcl) induced_62\VBN|convulsions (l_dobj) convulsions_63\NNS|
D001556_D012640 CID lindane_61\NN| (r_pobj) of_60\IN|lindane (r_prep) incidence_59\NN|the|of (r_dobj) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_ccomp) shown_4\VBN|studies|have|further|induced (l_ccomp) induced_30\VBN|that|produce|convulsions (l_dobj) convulsions_31\NNS|,|pretreatment
D001556_D012640 CID lindane_61\NN| (r_pobj) of_60\IN|lindane (r_prep) incidence_59\NN|the|of (r_dobj) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_advcl) induced_62\VBN|convulsions (l_dobj) convulsions_63\NNS|
D001556_D012640 CID lindane_7\NN| (r_pobj) of_6\IN|lindane (r_prep) metabolism_5\NN|the|p450-mediated|of (r_nsubjpass) blocked_9\VBN|when|metabolism|was|by (l_agent) by_10\IN|incidence (l_pobj) incidence_13\NN|chloride|of (l_prep) of_14\IN|convulsions (l_pobj) convulsions_15\NNS|
D001556_D012640 CID lindane_22\NN| (r_pobj) with_21\IN|lindane (r_prep) treated_20\VBN|with (r_acl) animals_19\NNS|treated (r_pobj) in_18\IN|animals (r_prep) increased_17\VBN|similarly|,|blocked|was|in|indicating|. (l_advcl) blocked_9\VBN|when|metabolism|was|by (l_agent) by_10\IN|incidence (l_pobj) incidence_13\NN|chloride|of (l_prep) of_14\IN|convulsions (l_pobj) convulsions_15\NNS|
D001556_D012640 CID lindane_25\NN|per|or|metabolites (r_nsubjpass) involved_40\VBN|that|lindane|are|in (r_ccomp) indicating_23\VBG|involved (r_advcl) increased_17\VBN|similarly|,|blocked|was|in|indicating|. (l_advcl) blocked_9\VBN|when|metabolism|was|by (l_agent) by_10\IN|incidence (l_pobj) incidence_13\NN|chloride|of (l_prep) of_14\IN|convulsions (l_pobj) convulsions_15\NNS|
D010634_D012640 NONE phenobarbital_35\JJ|(|pb|)|,|inducer (r_pobj) with_34\IN|phenobarbital (r_prep) pretreatment_33\NN|with (r_conj) convulsions_31\NNS|,|pretreatment
D010634_D012640 NONE phenobarbital_35\JJ|(|pb|)|,|inducer (r_pobj) with_34\IN|phenobarbital (r_prep) pretreatment_33\NN|with (r_conj) convulsions_31\NNS|,|pretreatment (r_dobj) induced_30\VBN|that|produce|convulsions (r_ccomp) shown_4\VBN|studies|have|further|induced (r_ccomp) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_advcl) induced_62\VBN|convulsions (l_dobj) convulsions_63\NNS|
D000431_D012640 NONE ethanol_46\NN| (r_conj) inducer_41\NN|an|of|2b1/2b2|or|ethanol|,|inducer (r_appos) phenobarbital_35\JJ|(|pb|)|,|inducer (r_pobj) with_34\IN|phenobarbital (r_prep) pretreatment_33\NN|with (r_conj) convulsions_31\NNS|,|pretreatment
D000431_D012640 NONE ethanol_46\NN| (r_conj) inducer_41\NN|an|of|2b1/2b2|or|ethanol|,|inducer (r_appos) phenobarbital_35\JJ|(|pb|)|,|inducer (r_pobj) with_34\IN|phenobarbital (r_prep) pretreatment_33\NN|with (r_conj) convulsions_31\NNS|,|pretreatment (r_dobj) induced_30\VBN|that|produce|convulsions (r_ccomp) shown_4\VBN|studies|have|further|induced (r_ccomp) increased_57\VBD|shown|,|significantly|incidence|induced|. (l_advcl) induced_62\VBN|convulsions (l_dobj) convulsions_63\NNS|
D000431_D012640 NONE ethanol_35\NN| (r_conj) PB_33\NNP|or|ethanol (r_nmod) isoenzymes_38\NNS|pb|inducible|p450 (r_pobj) by_32\IN|isoenzymes (r_agent) formed_31\VBN|by (r_acl) metabolites_30\NNS|its|formed (r_conj) lindane_25\NN|per|or|metabolites (r_nsubjpass) involved_40\VBN|that|lindane|are|in (r_ccomp) indicating_23\VBG|involved (r_advcl) increased_17\VBN|similarly|,|blocked|was|in|indicating|. (l_advcl) blocked_9\VBN|when|metabolism|was|by (l_agent) by_10\IN|incidence (l_pobj) incidence_13\NN|chloride|of (l_prep) of_14\IN|convulsions (l_pobj) convulsions_15\NNS|
D001556_D064420 NONE lindane_7\NN| (r_pobj) of_6\IN|lindane (r_prep) metabolism_5\NN|the|p450-mediated|of (r_nsubjpass) blocked_9\VBN|when|metabolism|was|by (r_advcl) increased_17\VBN|similarly|,|blocked|was|in|indicating|. (l_advcl) indicating_23\VBG|involved (l_ccomp) involved_40\VBN|that|lindane|are|in (l_prep) in_41\IN|toxicity (l_pobj) toxicity_44\NN|its|neurobehavioral
D001556_D064420 NONE lindane_22\NN| (r_pobj) with_21\IN|lindane (r_prep) treated_20\VBN|with (r_acl) animals_19\NNS|treated (r_pobj) in_18\IN|animals (r_prep) increased_17\VBN|similarly|,|blocked|was|in|indicating|. (l_advcl) indicating_23\VBG|involved (l_ccomp) involved_40\VBN|that|lindane|are|in (l_prep) in_41\IN|toxicity (l_pobj) toxicity_44\NN|its|neurobehavioral
D001556_D064420 NONE lindane_25\NN|per|or|metabolites (r_nsubjpass) involved_40\VBN|that|lindane|are|in (l_prep) in_41\IN|toxicity (l_pobj) toxicity_44\NN|its|neurobehavioral
C018021_D012640 NONE chloride_12\NN|cobalt (r_compound) incidence_13\NN|chloride|of (l_prep) of_14\IN|convulsions (l_pobj) convulsions_15\NNS|
C018021_D064420 NONE chloride_12\NN|cobalt (r_compound) incidence_13\NN|chloride|of (r_pobj) by_10\IN|incidence (r_agent) blocked_9\VBN|when|metabolism|was|by (r_advcl) increased_17\VBN|similarly|,|blocked|was|in|indicating|. (l_advcl) indicating_23\VBG|involved (l_ccomp) involved_40\VBN|that|lindane|are|in (l_prep) in_41\IN|toxicity (l_pobj) toxicity_44\NN|its|neurobehavioral
D000431_D064420 NONE ethanol_35\NN| (r_conj) PB_33\NNP|or|ethanol (r_nmod) isoenzymes_38\NNS|pb|inducible|p450 (r_pobj) by_32\IN|isoenzymes (r_agent) formed_31\VBN|by (r_acl) metabolites_30\NNS|its|formed (r_conj) lindane_25\NN|per|or|metabolites (r_nsubjpass) involved_40\VBN|that|lindane|are|in (l_prep) in_41\IN|toxicity (l_pobj) toxicity_44\NN|its|neurobehavioral
18177388
D000661_D054549 CID amphetamine_21\NN| (r_compound) use_22\NN|amphetamine (r_pobj) of_20\IN|use (r_prep) setting_19\NN|the|of (r_pobj) in_17\IN|setting (r_prep) woman_16\NN|a|young|in (r_pobj) in_13\IN|woman (r_prep) left_3\VBN|reverse|syndrome|cardiomyopathy|)|in|. (l_dobj) syndrome_7\NN|ventricular|ballooning
D000661_D054549 CID amphetamine_21\NN| (r_compound) use_22\NN|amphetamine (r_pobj) of_20\IN|use (r_prep) setting_19\NN|the|of (r_pobj) in_17\IN|setting (r_prep) woman_16\NN|a|young|in (r_pobj) in_13\IN|woman (r_prep) left_3\VBN|reverse|syndrome|cardiomyopathy|)|in|. (l_oprd) cardiomyopathy_11\NN|reverse|takotsubo
D000661_D054549 CID amphetamine_26\NN| (r_compound) use_27\NN|amphetamine (r_pobj) after_25\IN|use (r_prep) occurring_24\VBG|after (r_acl) type_18\NN|this|rare|of|occurring (l_prep) of_19\IN|syndrome (l_pobj) syndrome_23\NN|ballooning
3950060
D000583_D007674 CID amikacin_10\JJ| (r_dobj) receiving_9\VBG|amikacin (r_acl) patients_8\NNS|receiving (r_pobj) in_7\IN|patients (r_prep) nephrotoxicity_3\NN|and|outcome|in
D000583_D007674 CID amikacin_6\JJ| (r_pobj) with_5\IN|amikacin (r_prep) treated_4\VBN|with (r_acl) patients_3\NNS|60|treated (r_pobj) from_1\IN|patients (r_prep) Data_0\NNS|from (r_nsubjpass) analyzed_8\VBN|data|were|for|. (l_prep) for_9\IN|factors (l_pobj) factors_10\NNS|associated (l_acl) associated_11\VBN|with (l_prep) with_12\IN|nephrotoxicity (l_pobj) nephrotoxicity_13\NN|
3413271
D004837_D017202 CID epinephrine_6\NN|:|comparison (r_pobj) by_5\IN|epinephrine (r_prep) induced_4\VBN|mechanisms|by|. (l_nsubj) Mechanisms_0\NNS|of (l_prep) of_1\IN|ischemia (l_pobj) ischemia_3\NN|myocardial
D004837_D017202 CID epinephrine_3\NN| (r_pobj) of_2\IN|epinephrine (r_prep) role_1\NN|the|of|in (l_prep) in_4\IN|eliciting (l_pcomp) eliciting_5\VBG|ischemia (l_dobj) ischemia_7\NN|myocardial
D004837_D017202 CID epinephrine_1\NN|both|and|exercise (r_nsubj) produced_4\VBD|epinephrine|ischemia|evidenced|. (l_dobj) ischemia_6\NN|myocardial
D004837_D017202 CID epinephrine_9\NN| (r_pobj) by_8\IN|epinephrine (r_agent) induced_7\VBN|by (r_acl) mechanisms_3\NNS|the|of|induced (l_prep) of_4\IN|ischemia (l_pobj) ischemia_6\NN|myocardial
D004837_D017202 CID epinephrine_28\NN| (r_npadvmod) induced_30\VBN|epinephrine|- (r_amod) ischemia_31\NN|induced (r_nsubjpass) characterized_33\VBN|while|ischemia|was|by (r_advcl) marked_6\VBN|ischemia|was|predominantly|by|with|,|characterized|. (l_nsubjpass) ischemia_4\NN|induced|myocardial
D004837_D007511 NONE epinephrine_6\NN|:|comparison (l_appos) comparison_8\NN|with (l_prep) with_9\IN|ischemia (l_pobj) ischemia_13\NN|induced
D004837_D007511 NONE epinephrine_13\NN| (r_amod) infusion_14\NN|epinephrine|and|exercise (r_pobj) during_12\IN|infusion (r_prep) compared_11\VBN|signs|consumption|were|during|. (l_nsubjpass) signs_1\NNS|objective|of (l_prep) of_2\IN|ischemia (l_pobj) ischemia_3\NN|and|factors
D004837_D007511 NONE epinephrine_28\NN| (r_npadvmod) induced_30\VBN|epinephrine|- (r_amod) ischemia_31\NN|induced
D004837_D007511 NONE epinephrine_7\NN| (r_pobj) by_6\IN|epinephrine (r_agent) produced_5\VBN|by (r_acl) ischemia_4\NN|that|produced|,
D004837_D003324 NONE epinephrine_3\NN| (r_pobj) of_2\IN|epinephrine (r_prep) role_1\NN|the|of|in (r_nsubjpass) examined_9\VBN|role|was|in|. (l_prep) in_10\IN|patients (l_pobj) patients_11\NNS|with (l_prep) with_12\IN|disease (l_pobj) disease_15\NN|coronary|artery
D010100_D007511 NONE oxygen_8\NN| (r_compound) consumption_9\NN|increasing|myocardial|oxygen (r_nsubjpass) compared_11\VBN|signs|consumption|were|during|. (l_nsubjpass) signs_1\NNS|objective|of (l_prep) of_2\IN|ischemia (l_pobj) ischemia_3\NN|and|factors
D004837_D003866 NONE epinephrine_1\NN|both|and|exercise (r_nsubj) produced_4\VBD|epinephrine|ischemia|evidenced|. (l_advcl) evidenced_8\VBN|as|by (l_agent) by_9\IN|depression (l_pobj) depression_12\NN|st|segment|and|angina
D004837_D000787 NONE epinephrine_1\NN|both|and|exercise (r_nsubj) produced_4\VBD|epinephrine|ischemia|evidenced|. (l_advcl) evidenced_8\VBN|as|by (l_agent) by_9\IN|depression (l_pobj) depression_12\NN|st|segment|and|angina (l_conj) angina_14\NN|
761833
D000641_D003128 NONE ammonia_2\NN| (r_compound) coma_3\NN|ammonia|in
D000641_D003128 NONE Ammonia_0\NN| (r_compound) coma_1\NN|ammonia
D000641_D003128 NONE ammonia_18\NN| (r_compound) coma_19\NN|the|ammonia
D000641_D003128 NONE ammonia_26\NN| (r_compound) concentrations_27\NNS|the|blood|ammonia (r_dobj) affect_21\VB|concentrations (r_conj) prevent_16\VB|did|not|coma|nor|affect (l_dobj) coma_19\NN|the|ammonia
D000641_D003128 NONE ammonia_14\NN|blood (r_pobj) on_10\IN|ammonia (r_prep) dopa_9\NN|l|-|on|and|coma (l_conj) coma_18\NN|the|ammonia
D000641_D003128 NONE ammonia_17\NN| (r_compound) coma_18\NN|the|ammonia
D000641_D003128 NONE ammonia_8\NN|blood (r_pobj) in_4\IN|ammonia (r_prep) reduction_3\NN|the|in|and|prevention (l_conj) prevention_11\NN|the|of|after (l_prep) of_12\IN|coma (l_pobj) coma_14\NN|ammonia
D000641_D003128 NONE ammonia_13\NN| (r_compound) coma_14\NN|ammonia
D007980_D003128 NONE dopa_9\NNP|l|-|:|effect (r_pobj) by_6\IN|dopa (r_prep) rats_5\NNS|by (r_pobj) in_4\IN|rats (r_prep) coma_3\NN|ammonia|in
D007980_D003128 NONE dopa_9\NN|1.68|mmol|l|-|given (r_pobj) with_4\IN|dopa (r_prep) prevented_3\VBN|coma|was|with|before|. (l_nsubjpass) coma_1\NN|this
D007980_D003128 NONE dopa_9\NN|l|-|on|and|coma (l_conj) coma_18\NN|the|ammonia
D007980_D003128 NONE dopa_18\NNP|l|- (r_pobj) after_15\IN|dopa (r_prep) prevention_11\NN|the|of|after (l_prep) of_12\IN|coma (l_pobj) coma_14\NN|ammonia
D000643_D003128 CID NH4CL_17\NN|1.7|mmol (r_pobj) of_14\IN|nh4cl (r_prep) intraperitonealinjection_13\NN|an|of (r_pobj) of_11\IN|intraperitonealinjection (r_prep) minutes_10\NNS|15|of (r_pobj) within_6\IN|minutes (r_prep) rats_5\NNS|within (r_pobj) in_4\IN|rats (r_prep) produced_3\VBN|coma|was|in|. (l_nsubjpass) coma_1\NN|ammonia
D064751_D003128 NONE salt_19\NN|ammonium (r_compound) injection_20\NN|the|salt (r_pobj) before_16\IN|minutes|injection (r_prep) prevented_3\VBN|coma|was|with|before|. (l_nsubjpass) coma_1\NN|this
D004298_D003128 NONE dopamine_3\NN| (r_pobj) of_2\IN|dopamine (r_prep) infusion_1\NN|intraventricular|of (r_nsubj) sufficient_4\JJ|infusion|raise|prevent|. (l_conj) prevent_16\VB|did|not|coma|nor|affect (l_dobj) coma_19\NN|the|ammonia
D004298_D003128 NONE dopamine_9\NN|the|brain (r_dobj) raise_6\VB|to|dopamine|to (r_xcomp) sufficient_4\JJ|infusion|raise|prevent|. (l_conj) prevent_16\VB|did|not|coma|nor|affect (l_dobj) coma_19\NN|the|ammonia
D004298_D003128 NONE dopamine_29\NN| (r_pobj) of_28\IN|dopamine (r_prep) effect_27\NN|the|peripheral|of|on (r_pobj) by_24\IN|effect (r_agent) accounted_22\VBN|thus|,|reduction|,|can|be|for|by|. (l_nsubjpass) reduction_3\NN|the|in|and|prevention (l_conj) prevention_11\NN|the|of|after (l_prep) of_12\IN|coma (l_pobj) coma_14\NN|ammonia
D007980_D001927 NONE dopa_18\NNP|l|- (r_dobj) receiving_15\VBG|dopa (r_acl) patients_14\NNS|some|encephalopathic|receiving (l_amod) encephalopathic_13\JJ|
9226773
D008094_D018500 CID lithium_5\NN| (r_compound) therapy_6\NN|lithium (r_dobj) following_4\VBG|therapy (r_prep) insipidus_3\NN|diabetes|following|.
D008094_D018500 CID lithium_9\NN| (r_npadvmod) induced_11\VBN|lithium|- (r_amod) insipidus_14\NN|induced|diabetes
D008094_D018500 CID lithium_17\NN| (r_compound) therapy_18\NN|lithium (r_nsubjpass) discontinued_21\VBN|therapy|had|been|. (r_conj) diagnosed_6\VBN|years|previously|he|had|been|have|,|and|discontinued (l_xcomp) have_8\VB|to|insipidus (l_dobj) insipidus_14\NN|induced|diabetes
D008094_D018500 CID lithium_8\NN|and|investigations|on (r_pobj) of_7\IN|lithium (r_prep) cessation_6\NN|of (r_pobj) despite_5\IN|cessation (r_prep) polyuric_4\JJ|despite (r_conj) thirsty_2\JJ|and|polyuric (r_acomp) remained_1\VBD|he|thirsty|showed|. (l_conj) showed_13\VBD|have (l_ccomp) have_16\VB|him|to|thirst|,|with (l_prep) with_24\IN|evidence (l_pobj) evidence_26\NN|clear|of (l_prep) of_27\IN|insipidus (l_pobj) insipidus_30\NN|nephrogenic|diabetes
D008094_D018500 CID Lithium_0\NN| (r_nsubj) induced_1\VBD|lithium|insipidus (l_dobj) insipidus_4\NN|nephrogenic|diabetes
D008094_D018500 CID lithium_24\NN| (r_nsubjpass) stopped_26\VBN|after|lithium|was (r_advcl) be_8\VB|to|reversible|stopped (r_xcomp) considered_6\VBN|induced|is|be|. (l_csubjpass) induced_1\VBD|lithium|insipidus (l_dobj) insipidus_4\NN|nephrogenic|diabetes
D008094_D018500 CID lithium_14\NN| (r_npadvmod) induced_16\VBN|lithium|- (r_amod) insipidus_19\NN|induced|diabetes
D008094_D011141 CID lithium_8\NN|and|investigations|on (r_pobj) of_7\IN|lithium (r_prep) cessation_6\NN|of (r_pobj) despite_5\IN|cessation (r_prep) polyuric_4\JJ|despite
D008094_D011141 CID Lithium_0\NN| (r_nsubj) induced_1\VBD|lithium|insipidus (r_csubjpass) considered_6\VBN|induced|is|be|. (l_xcomp) be_8\VB|to|reversible|stopped (l_acomp) reversible_9\JJ|on (l_prep) on_10\IN|cessation (l_pobj) cessation_11\NN|of|persisted (l_prep) of_12\IN|therapy (l_pobj) therapy_13\NN|but|polyuria (l_conj) polyuria_15\NN|
D008094_D011141 CID lithium_24\NN| (r_nsubjpass) stopped_26\VBN|after|lithium|was (r_advcl) be_8\VB|to|reversible|stopped (l_acomp) reversible_9\JJ|on (l_prep) on_10\IN|cessation (l_pobj) cessation_11\NN|of|persisted (l_prep) of_12\IN|therapy (l_pobj) therapy_13\NN|but|polyuria (l_conj) polyuria_15\NN|
D014667_D011141 NONE vasopressin_21\NN| (r_compound) secretion_22\NN|vasopressin (r_conj) thirst_19\NN|normal|osmoregulated|and|secretion (r_dobj) have_16\VB|him|to|thirst|,|with (r_ccomp) showed_13\VBD|have (r_conj) remained_1\VBD|he|thirsty|showed|. (l_acomp) thirsty_2\JJ|and|polyuric (l_conj) polyuric_4\JJ|despite
D014667_D018500 NONE vasopressin_21\NN| (r_compound) secretion_22\NN|vasopressin (r_conj) thirst_19\NN|normal|osmoregulated|and|secretion (r_dobj) have_16\VB|him|to|thirst|,|with (l_prep) with_24\IN|evidence (l_pobj) evidence_26\NN|clear|of (l_prep) of_27\IN|insipidus (l_pobj) insipidus_30\NN|nephrogenic|diabetes
18513945
D010121_D007022 CID Oxytocin_0\NN| (r_nsubj) is_1\VBZ|oxytocin|uterotonic|. (l_attr) uterotonic_5\NN|a|used|cause (l_relcl) cause_8\VB|that|can|hypotension|,|given (l_dobj) hypotension_13\NN|significant
D010121_D007022 CID Oxytocin_0\NN| (r_npadvmod) induced_2\VBN|oxytocin|- (r_amod) hypotension_3\NN|induced|at
D010121_D007022 CID oxytocin_4\NN| (r_pobj) to_3\IN|oxytocin (r_prep) response_2\NN|to (r_pobj) in_1\IN|response (r_prep) Hypotension_0\NN|in
D010121_D006473 NONE Oxytocin_0\NN| (r_npadvmod) induced_2\VBN|oxytocin|- (r_amod) hypotension_3\NN|induced|at (r_nsubjpass) attributed_10\VBN|hypotension|may|be|incorrectly|to|. (l_prep) to_11\IN|loss (l_pobj) loss_13\NN|blood
D010121_D020521 NONE oxytocin_4\NN| (r_pobj) to_3\IN|oxytocin (r_prep) response_2\NN|to (r_pobj) in_1\IN|response (r_prep) Hypotension_0\NN|in (r_nsubjpass) associated_6\VBN|hypotension|was|with|. (l_prep) with_7\IN|decrease (l_pobj) decrease_9\NN|a|in|and|increase (l_conj) increase_17\NN|a|compensatory|in (l_prep) in_18\IN|volume (l_pobj) volume_20\NN|stroke|,|rate (l_compound) stroke_19\NN|
7596955
D000242_D001791 NONE cAMP_19\NNS|intraplatelet (r_pobj) of_17\IN|camp (r_prep) determination_16\NN|of (r_conj) aggregation_14\NN|ex|platelet|and|determination
C045645_D006261 CID CLZ_25\NNP| (r_pobj) of_24\IN|clz (r_prep) ingestion_23\NN|of (r_pobj) after_22\IN|especially|ingestion (r_prep) accompanying_11\VBG|flush|in|,|after (r_acl) duration_10\NN|a|short|accompanying (r_pobj) of_7\IN|duration (r_prep) headache_6\NN|of
C045645_D005483 CID CLZ_25\NNP| (r_pobj) of_24\IN|clz (r_prep) ingestion_23\NN|of (r_pobj) after_22\IN|especially|ingestion (r_prep) accompanying_11\VBG|flush|in|,|after (l_dobj) flush_13\NN|facial|in
C045645_D009325 CID CLZ_25\NNP| (r_pobj) of_24\IN|clz (r_prep) ingestion_23\NN|of (r_pobj) after_22\IN|especially|ingestion (r_prep) accompanying_11\VBG|flush|in|,|after (l_dobj) flush_13\NN|facial|in (l_prep) in_14\IN|one (l_pobj) one_15\CD|and|nausea (l_conj) nausea_17\NN|
2004015
D015215_C565469 NONE azidothymidine_8\NN| (r_advmod) treated_9\VBN|sensitivity|azidothymidine|mice|. (l_dobj) mice_11\NNS|immunodeficient (l_amod) immunodeficient_10\JJ|
D015215_D000740 CID 3'-azido-3'dideoxythymidine_4\NN|azt (r_pobj) by_3\IN|3'-azido-3'dideoxythymidine (r_agent) induced_2\VBN|by (r_acl) anaemia_1\NN|the|induced
D015215_D000740 CID AZT_6\NNP|(|) (r_appos) 3'-azido-3'dideoxythymidine_4\NN|azt (r_pobj) by_3\IN|3'-azido-3'dideoxythymidine (r_agent) induced_2\VBN|by (r_acl) anaemia_1\NN|the|induced
D015215_D000740 CID AZT_28\NNP| (r_npadvmod) induced_30\VBN|azt|- (r_amod) anaemia_31\NN|induced
D015215_D000740 CID AZT_0\NNP| (r_nsubj) produced_1\VBD|azt|anaemia|in|,|in|. (l_dobj) anaemia_2\NN|
D015215_D000740 CID AZT_15\NNP| (r_pobj) in_14\IN|azt (r_prep) e_13\NNP|marrow|bfu|-|in (r_pobj) of_6\IN|e (r_prep) number_5\NN|the|of (r_nsubj) treated_16\VBD|despite|,|number|mice (l_prep) Despite_0\IN|anaemia (l_pobj) anaemia_2\NN|the
D015215_D000740 CID AZT_8\NNP| (r_pobj) in_7\IN|azt (r_prep) observed_6\VBD|levels|in|treated|were|treated|. (l_conj) were_11\VBD|appropriate (l_acomp) appropriate_12\JJ|for (l_prep) for_13\IN|degree (l_pobj) degree_15\NN|the|of|observed (l_prep) of_16\IN|anaemia (l_pobj) anaemia_17\NN|
D015215_D000740 CID AZT_17\NNP|and|phz (r_nsubj) treated_20\VBD|azt|mice|with (l_prep) with_22\IN|degrees (l_pobj) degrees_24\NNS|similar|of (l_prep) of_25\IN|anaemia (l_pobj) anaemia_26\NN|
D015215_D000740 CID AZT_12\NNP| (r_pobj) in_11\IN|azt (r_prep) observed_10\VBN|in (r_acl) degree_7\NN|the|of|observed (l_prep) of_8\IN|anaemia (l_pobj) anaemia_9\NN|
D015215_D000740 CID AZT_0\NNP| (r_npadvmod) induced_2\VBN|azt|-|anaemia|in|and|levels (l_dobj) anaemia_4\NN|peripheral
D015215_D000163 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|azt|- (r_amod) anaemia_31\NN|induced (r_nsubj) is_32\VBZ|if|anaemia|due|,|in (r_ccomp) determine_26\VB|to|is (r_xcomp) used_2\VBN|we|have|model|,|determine|decreased|. (l_dobj) model_5\NN|a|murine|of (l_prep) of_6\IN|aids (l_pobj) AIDS_7\NNP|,|infection
D015215_D007239 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|azt|- (r_amod) anaemia_31\NN|induced (r_nsubj) is_32\VBZ|if|anaemia|due|,|in (r_ccomp) determine_26\VB|to|is (r_xcomp) used_2\VBN|we|have|model|,|determine|decreased|. (l_dobj) model_5\NN|a|murine|of (l_prep) of_6\IN|aids (l_pobj) AIDS_7\NNP|,|infection (l_appos) infection_9\NN|of
D015215_D007938 NONE AZT_28\NNP| (r_npadvmod) induced_30\VBN|azt|- (r_amod) anaemia_31\NN|induced (r_nsubj) is_32\VBZ|if|anaemia|due|,|in (r_ccomp) determine_26\VB|to|is (r_xcomp) used_2\VBN|we|have|model|,|determine|decreased|. (l_dobj) model_5\NN|a|murine|of (l_prep) of_6\IN|aids (l_pobj) AIDS_7\NNP|,|infection (l_appos) infection_9\NN|of (l_prep) of_10\IN|mice (l_pobj) mice_13\NNS|female|c57bl/6|with (l_prep) with_14\IN|leukaemia (l_pobj) leukaemia_19\NN|bm5|murine|virus
C030299_D000740 NONE phenylhydrazine_22\NN| (r_npadvmod) treated_26\VBD|phenylhydrazine|(|phz|)|mice (r_conj) observed_6\VBD|levels|in|treated|were|treated|. (l_conj) were_11\VBD|appropriate (l_acomp) appropriate_12\JJ|for (l_prep) for_13\IN|degree (l_pobj) degree_15\NN|the|of|observed (l_prep) of_16\IN|anaemia (l_pobj) anaemia_17\NN|
C030299_D000740 NONE PHZ_24\NNP| (r_nsubj) treated_26\VBD|phenylhydrazine|(|phz|)|mice (r_conj) observed_6\VBD|levels|in|treated|were|treated|. (l_conj) were_11\VBD|appropriate (l_acomp) appropriate_12\JJ|for (l_prep) for_13\IN|degree (l_pobj) degree_15\NN|the|of|observed (l_prep) of_16\IN|anaemia (l_pobj) anaemia_17\NN|
C030299_D000740 NONE PHZ_19\NNP| (r_conj) AZT_17\NNP|and|phz (r_nsubj) treated_20\VBD|azt|mice|with (l_prep) with_22\IN|degrees (l_pobj) degrees_24\NNS|similar|of (l_prep) of_25\IN|anaemia (l_pobj) anaemia_26\NN|
D015215_D045262 NONE AZT_12\NNP| (r_pobj) in_11\IN|azt (r_prep) observed_10\VBN|in (r_acl) degree_7\NN|the|of|observed (r_pobj) for_5\IN|degree (r_prep) inappropriate_4\JJ|for (r_acomp) was_3\VBD|however|,|reticulocytosis|inappropriate|treated|. (l_nsubj) reticulocytosis_2\NN|
11077455
D020888_D014786 CID vigabatrin_16\NN| (r_npadvmod) attributed_18\VBN|vigabatrin|- (r_amod) constriction_21\NN|attributed|field
D020888_D014786 CID vigabatrin_9\NN| (r_pobj) with_8\IN|vigabatrin (r_prep) associated_7\VBN|to|be|with (r_xcomp) thought_4\NN|constriction|associated (l_nsubj) constriction_3\NN|symptomatic|field
D020888_D014786 CID vigabatrin_15\NN| (r_npadvmod) attributed_17\VBN|vigabatrin|- (r_amod) loss_20\NN|known|attributed|field
D020888_D014786 CID vigabatrin_9\NN| (r_compound) therapy_10\NN|vigabatrin (r_pobj) with_8\IN|therapy (r_prep) associated_7\VBN|to|be|with (r_xcomp) appears_4\VBZ|constriction|associated|. (l_nsubj) constriction_3\NN|marked|field
950631
D010396_D007674 CID penicillamine_2\NN| (r_npadvmod) induced_4\VBN|penicillamine|- (r_amod) disease_6\NN|induced|glomerular
D010396_D001172 NONE penicillamine_18\NN|d|- (r_pobj) with_15\IN|penicillamine (r_prep) treatment_14\NN|with (r_pobj) of_13\IN|treatment (r_prep) months_12\NNS|12|of (r_pobj) after_8\IN|months (r_prep) developed_5\VBD|patients|proteinuria|after|. (l_nsubj) patients_1\NNS|four|with (l_prep) with_2\IN|arthritis (l_pobj) arthritis_4\NN|rheumatoid
D010396_D011507 CID penicillamine_18\NN|d|- (r_pobj) with_15\IN|penicillamine (r_prep) treatment_14\NN|with (r_pobj) of_13\IN|treatment (r_prep) months_12\NNS|12|of (r_pobj) after_8\IN|months (r_prep) developed_5\VBD|patients|proteinuria|after|. (l_dobj) proteinuria_7\NN|heavy
921394
D007649_D003866 NONE ketamine_2\NN| (r_pobj) of_1\IN|ketamine (r_prep) Injections_0\NNS|of|in|mg|. (l_dep) mg_10\NN|into (l_prep) into_11\IN|artery (l_pobj) artery_13\NN|the|produced (l_acl) produced_14\VBD|depression|by (l_dobj) depression_16\NN|a|of
D007649_D013610 CID ketamine_18\NN| (r_npadvmod) induced_20\VBN|ketamine|- (r_amod) tachycardia_21\NN|the|induced
1079693
D000305_D014605 NONE corticosteroids_27\NNS|and|mydriatics (r_pobj) with_26\IN|corticosteroids (r_prep) treatment_25\NN|intensive|topical|with (r_pobj) of_22\IN|treatment (r_prep) months_21\NNS|six|of (r_pobj) to_17\IN|months (r_prep) respond_16\VB|after|,|%|did|not|to|. (l_nsubj) %_9\NN|41|of (l_prep) of_10\IN|cases (l_pobj) cases_11\NNS|of (l_prep) of_12\IN|uveitis (l_pobj) uveitis_13\NN|
D002738_D012164 NONE chloroquine_2\NN|or|hydroxychloroquine (r_xcomp) used_1\VBD|we|chloroquine|and|found|. (l_conj) found_11\VBD|case (l_dobj) case_14\NN|one|of (l_prep) of_15\IN|chorioretinopathy (l_pobj) chorioretinopathy_16\JJ|attributable
D006886_D012164 CID hydroxychloroquine_4\NN|in (r_conj) chloroquine_2\NN|or|hydroxychloroquine (r_xcomp) used_1\VBD|we|chloroquine|and|found|. (l_conj) found_11\VBD|case (l_dobj) case_14\NN|one|of (l_prep) of_15\IN|chorioretinopathy (l_pobj) chorioretinopathy_16\JJ|attributable
D000305_D002386 NONE corticosteroids_2\NNS| (r_dobj) administered_1\VBN|systemically|corticosteroids (r_csubjpass) used_4\VBN|administered|were|in (r_ccomp) found_19\VBN|used|;|number|was|. (l_nsubjpass) number_13\NN|a|significant|of (l_prep) of_14\IN|cataracts (l_pobj) cataracts_17\NNS|subcapsular
6695415
D010665_D002543 CID phenylpropanolamine_4\NN| (r_pobj) with_3\IN|phenylpropanolamine (r_prep) associated_2\VBN|with|in (r_acl) hemorrhage_1\NN|cerebral|associated|.
D010665_D002543 CID PPA_4\NNP| (r_nmod) caffeine_6\NN|ppa|/ (r_nsubj) lead_8\VB|that|caffeine|can|to|administered (l_prep) to_9\IN|hemorrhage (l_pobj) hemorrhage_11\NN|cerebral|in
D002110_D002543 CID caffeine_8\NN| (r_pobj) with_7\IN|caffeine (r_prep) combination_6\NN|with (r_pobj) in_5\IN|combination (r_prep) associated_2\VBN|with|in (r_acl) hemorrhage_1\NN|cerebral|associated|.
D002110_D002543 CID caffeine_6\NN|ppa|/ (r_nsubj) lead_8\VB|that|caffeine|can|to|administered (l_prep) to_9\IN|hemorrhage (l_pobj) hemorrhage_11\NN|cerebral|in
D010665_D020521 CID Phenylpropanolamine_0\NNP|(|ppa|) (r_nsubj) is_4\VBZ|phenylpropanolamine|drug|. (l_attr) drug_6\NN|a|associated (l_relcl) associated_10\VBN|that|has|been|with (l_prep) with_11\IN|effects (l_pobj) effects_14\NNS|serious|side|including (l_prep) including_15\VBG|stroke (l_pobj) stroke_16\NN|
D010665_D020521 CID PPA_2\NNP| (r_appos) Phenylpropanolamine_0\NNP|(|ppa|) (r_nsubj) is_4\VBZ|phenylpropanolamine|drug|. (l_attr) drug_6\NN|a|associated (l_relcl) associated_10\VBN|that|has|been|with (l_prep) with_11\IN|effects (l_pobj) effects_14\NNS|serious|side|including (l_prep) including_15\VBG|stroke (l_pobj) stroke_16\NN|
D010665_D020521 CID PPA_5\NNP| (r_nmod) caffeine_7\NN|ppa|/ (r_nsubj) lead_9\VB|if|caffeine|can|to|in (l_prep) to_10\IN|stroke (l_pobj) stroke_11\NN|
D010665_D006973 CID PPA_5\NNP| (r_nmod) caffeine_7\NN|ppa|/ (r_nsubj) lead_9\VB|if|caffeine|can|to|in (l_prep) in_12\IN|rats (l_pobj) rats_16\NNS|normotensive (l_amod) normotensive_13\NN|and/or|hypertensive (l_conj) hypertensive_15\JJ|
D010665_D006973 CID PPA_2\NNP| (r_nmod) caffeine_4\NN|ppa|/ (r_compound) administration_5\NN|a|single|caffeine|(|dose|) (r_nsubj) lead_10\NN|administration|to|. (l_prep) to_11\IN|hypertension (l_pobj) hypertension_13\NN|acute|in
D010665_D006973 CID PPA_2\NNP| (r_nmod) caffeine_4\NN|ppa|/ (r_compound) administration_5\NN|a|single|caffeine|(|dose|) (r_nsubj) lead_10\NN|administration|to|. (l_prep) to_11\IN|hypertension (l_pobj) hypertension_13\NN|acute|in (l_prep) in_14\IN|animals (l_pobj) animals_20\NNS|both|the|normotensive (l_amod) normotensive_17\NN|and|hypertensive (l_conj) hypertensive_19\JJ|
D010665_D006973 CID PPA_4\NNP| (r_nmod) caffeine_6\NN|ppa|/ (r_nsubj) lead_8\VB|that|caffeine|can|to|administered (l_prep) to_9\IN|hemorrhage (l_pobj) hemorrhage_11\NN|cerebral|in (l_prep) in_12\IN|animals (l_pobj) animals_15\NNS|hypertensive (l_amod) hypertensive_14\JJ|previously
D002110_D020521 NONE caffeine_7\NN|ppa|/ (r_nsubj) lead_9\VB|if|caffeine|can|to|in (l_prep) to_10\IN|stroke (l_pobj) stroke_11\NN|
D002110_D006973 CID caffeine_7\NN|ppa|/ (r_nsubj) lead_9\VB|if|caffeine|can|to|in (l_prep) in_12\IN|rats (l_pobj) rats_16\NNS|normotensive (l_amod) normotensive_13\NN|and/or|hypertensive (l_conj) hypertensive_15\JJ|
D002110_D006973 CID caffeine_4\NN|ppa|/ (r_compound) administration_5\NN|a|single|caffeine|(|dose|) (r_nsubj) lead_10\NN|administration|to|. (l_prep) to_11\IN|hypertension (l_pobj) hypertension_13\NN|acute|in
D002110_D006973 CID caffeine_4\NN|ppa|/ (r_compound) administration_5\NN|a|single|caffeine|(|dose|) (r_nsubj) lead_10\NN|administration|to|. (l_prep) to_11\IN|hypertension (l_pobj) hypertension_13\NN|acute|in (l_prep) in_14\IN|animals (l_pobj) animals_20\NNS|both|the|normotensive (l_amod) normotensive_17\NN|and|hypertensive (l_conj) hypertensive_19\JJ|
D002110_D006973 CID caffeine_6\NN|ppa|/ (r_nsubj) lead_8\VB|that|caffeine|can|to|administered (l_prep) to_9\IN|hemorrhage (l_pobj) hemorrhage_11\NN|cerebral|in (l_prep) in_12\IN|animals (l_pobj) animals_15\NNS|hypertensive (l_amod) hypertensive_14\JJ|previously
10565806
C076029_D001714 CID olanzapine_6\NN| (r_pobj) by_5\IN|olanzapine (r_prep) induced_4\VBN|hypomania|by|. (l_nsubj) Hypomania_0\NNP|like
C076029_D001714 CID olanzapine_28\JJ| (r_compound) treatment_29\NN|olanzapine (r_pobj) of_27\IN|treatment (r_prep) introduction_26\NN|the|of (r_pobj) after_24\IN|shortly|introduction (r_prep) developed_21\VBD|who|hypomania|after (l_dobj) hypomania_22\NN|
C076029_D011618 NONE olanzapine_28\JJ| (r_compound) treatment_29\NN|olanzapine (r_pobj) of_27\IN|treatment (r_prep) introduction_26\NN|the|of (r_pobj) after_24\IN|shortly|introduction (r_prep) developed_21\VBD|who|hypomania|after (r_relcl) disorder_14\NN|a|specified|psychotic|iv|developed
17241657
D003042_D012640 CID cocaine_21\NN|in (r_pobj) of_20\IN|cocaine (r_prep) actions_19\NNS|the|convulsive|,|lethal|,|locomotor|stimulatory|of (l_amod) convulsive_11\JJ|
D003042_D012640 CID cocaine_18\NN| (r_npadvmod) induced_20\VBN|cocaine|- (r_amod) convulsions_21\NNS|induced|and|activity
C519696_D012640 NONE UMB24_10\NNP|or|(|+|/-)-sm (r_pobj) with_9\IN|umb24 (r_prep) pretreatment_4\NN|of|with (r_nsubj) attenuated_17\VBN|in|,|pretreatment|significantly|convulsions|,|but|lethality|. (l_dobj) convulsions_21\NNS|induced|and|activity
C107044_D012640 NONE 21_15\CD| (r_nummod) /-)-SM_14\SYM|21 (r_conj) UMB24_10\NNP|or|(|+|/-)-sm (r_pobj) with_9\IN|umb24 (r_prep) pretreatment_4\NN|of|with (r_nsubj) attenuated_17\VBN|in|,|pretreatment|significantly|convulsions|,|but|lethality|. (l_dobj) convulsions_21\NNS|induced|and|activity
2334179
D010396_D012594 NONE penicillamine_2\NN|d|-|in|. (l_prep) in_3\IN|treatment (l_pobj) treatment_5\NN|the|of (l_prep) of_6\IN|scleroderma (l_pobj) scleroderma_8\NN|localized
D010396_D012594 NONE penicillamine_17\NN|d|- (r_pobj) with_14\IN|penicillamine (r_prep) treated_13\VBN|who|were|with (r_relcl) patients_4\NNS|11|with|treated (l_prep) with_5\IN|scleroderma (l_pobj) scleroderma_10\NN|severe|,|extensive|localized
D010396_D012594 NONE penicillamine_6\NN|d|- (r_nsubj) be_8\VB|that|penicillamine|may|effective (l_acomp) effective_9\JJ|in (l_prep) in_10\IN|cases (l_pobj) cases_12\NNS|severe|of (l_prep) of_13\IN|scleroderma (l_pobj) scleroderma_15\NN|localized
D010396_D009404 CID Penicillamine_2\NN|d|- (r_nsubj) caused_3\VBD|penicillamine|syndrome|in (l_dobj) syndrome_5\NN|nephrotic
D010396_D011507 CID Penicillamine_2\NN|d|- (r_nsubj) caused_3\VBD|penicillamine|syndrome|in (l_prep) in_6\IN|patient (l_pobj) patient_8\NN|1|and|proteinuria (l_conj) proteinuria_12\NN|milder|reversible|in
D010396_D051437 NONE Penicillamine_2\NN|d|- (r_nsubj) caused_3\VBD|penicillamine|syndrome|in (r_ccomp) developed_19\VBD|caused|;|none|insufficiency|. (l_dobj) insufficiency_21\NN|renal
11861791
D011064_D006333 NONE )_5\-RRB-| (r_punct) polymerase_6\NN|ribose|) (r_pobj) of_1\IN|polymerase (r_prep) Activation_0\NN|of (r_nsubj) contributes_7\VBZ|activation|to|. (l_prep) to_8\IN|development (l_pobj) development_9\NN|of (l_prep) of_10\IN|failure (l_pobj) failure_15\NN|induced|heart
D004317_D006333 CID doxorubicin_11\NN| (r_npadvmod) induced_13\VBN|doxorubicin|- (r_amod) failure_15\NN|induced|heart
D004317_D066126 NONE doxorubicin_12\NN|dox|,|antibiotic (r_pobj) of_11\IN|doxorubicin (r_prep) cardiotoxicity_10\NN|the|of
D004317_D066126 NONE DOX_14\NNP|(|) (r_appos) doxorubicin_12\NN|dox|,|antibiotic (r_pobj) of_11\IN|doxorubicin (r_prep) cardiotoxicity_10\NN|the|of
D004317_D066126 NONE DOX_13\NNP| (r_npadvmod) induced_15\VBN|dox|- (r_amod) cardiotoxicity_16\NN|the|induced
D004317_D066126 NONE DOX_9\NNP| (r_pobj) of_8\IN|dox (r_prep) cardiotoxicity_7\NN|the|of
D018943_D066126 NONE anthracycline_21\NN| (r_amod) antibiotic_22\NN|a|used|antitumor|anthracycline (r_appos) doxorubicin_12\NN|dox|,|antibiotic (r_pobj) of_11\IN|doxorubicin (r_prep) cardiotoxicity_10\NN|the|of
C434926_D006331 NONE PJ34_19\NNP|the|phenanthridinone|parp|inhibitor (r_pobj) with_14\IN|pj34 (r_prep) inhibition_13\NN|pharmacological|with (r_conj) deletion_10\NN|genetic|or|inhibition (r_pobj) by_8\IN|deletion (r_prep) Using_0\VBG|approach|,|by (r_advcl) demonstrate_23\VBP|using|,|we|now|role|. (l_dobj) role_25\NN|the|of|in (l_prep) in_28\IN|development (l_pobj) development_30\NN|the|of (l_prep) of_31\IN|dysfunction (l_pobj) dysfunction_33\NN|cardiac|induced
C434926_D006331 NONE PJ34_3\NNP|a (r_pobj) with_1\IN|pj34 (r_prep) Treatment_0\NN|with (r_nsubj) improved_5\VBD|treatment|significantly|dysfunction|and|increased|. (l_dobj) dysfunction_7\NN|cardiac
D004317_D006331 NONE DOX_36\NNP| (r_pobj) by_35\IN|dox (r_agent) induced_34\VBN|by (r_acl) dysfunction_33\NN|cardiac|induced
D004317_D005117 NONE DOX_16\NNP| (r_compound) treatment_17\NN|the|dox (r_pobj) with_14\IN|treatment (r_prep) associated_13\VBN|with (r_acl) complications_12\NNS|severe|cardiac|associated
1141447
D008094_D003919 CID lithium_7\NN| (r_npadvmod) induced_9\VBN|lithium|- (r_amod) insipidus_11\NN|induced|diabetes
D008094_D003919 CID lithium_3\NN| (r_npadvmod) induced_5\VBN|lithium|- (r_amod) insipidus_7\NN|induced|diabetes
7619765
D005047_D009203 CID Etoposide_0\RB| (r_npadvmod) related_2\VBN|etoposide|- (r_amod) infarction_4\NN|related|myocardial|.
D005047_D009203 CID etoposide_11\RB| (r_dobj) containing_10\VBG|etoposide (r_acl) chemotherapy_9\NN|containing (r_pobj) after_8\IN|chemotherapy (r_prep) reported_7\VBN|occurrence|is|after|,|in|. (l_nsubjpass) occurrence_1\NN|the|of (l_prep) of_2\IN|infarction (l_pobj) infarction_5\NN|a|myocardial
D005047_D003327 NONE etoposide_11\RB| (r_dobj) containing_10\VBG|etoposide (r_acl) chemotherapy_9\NN|containing (r_pobj) after_8\IN|chemotherapy (r_prep) reported_7\VBN|occurrence|is|after|,|in|. (l_prep) in_13\IN|man (l_pobj) man_15\NN|a|with (l_prep) with_16\IN|factors (l_pobj) factors_19\NNS|no|risk|for (l_prep) for_20\IN|disease (l_pobj) disease_23\NN|coronary|heart
16600756
D011453_D053201 NONE prostaglandins_4\NNS| (r_conj) factor_2\NN|nerve|growth|and|prostaglandins|in|. (l_prep) in_5\IN|urine (l_pobj) urine_7\NN|the|of (l_prep) of_8\IN|patients (l_pobj) patients_10\NNS|female|with (l_prep) with_11\IN|bladder (l_pobj) bladder_13\NN|overactive
D011453_D053201 NONE PGs_7\NNS|in (l_prep) in_8\IN|women (l_pobj) women_9\NNS|with (l_prep) with_10\IN|oab (l_pobj) OAB_11\NNP|
D011453_D053201 NONE PG_8\NNP| (r_conj) NGF_6\NNP|urinary|and|pg (r_pobj) between_4\IN|ngf (r_prep) correlations_3\NNS|between|,|and|parameters (l_conj) parameters_12\NNS|urodynamic|in (l_prep) in_13\IN|patients (l_pobj) patients_14\NNS|with (l_prep) with_15\IN|oab (l_pobj) OAB_16\NNP|
D011453_D053201 NONE PGs_2\NNS| (r_conj) NGF_0\NNP|and|pgs (r_nsubj) have_3\VBP|ngf|roles|. (l_dobj) roles_5\NNS|important|in (l_prep) in_6\IN|development (l_pobj) development_8\NN|the|of (l_prep) of_9\IN|symptoms (l_pobj) symptoms_11\NNS|oab|in (l_compound) OAB_10\NNP|
D015232_D053201 CID PGE2_3\NNP|and|pgf2alpha (r_conj) NGF_1\NNP|urinary|,|pge2 (r_nsubjpass) increased_8\VBN|ngf|were|significantly|in|compared|)|. (l_prep) in_9\IN|patients (l_pobj) patients_10\NNS|with (l_prep) with_11\IN|oab (l_pobj) OAB_12\NNP|
D015232_D053201 CID PGE2_5\NNP|oab|urinary (l_compound) OAB_3\NNP|
D015237_D053201 CID PGF2alpha_5\NNP| (r_conj) PGE2_3\NNP|and|pgf2alpha (r_conj) NGF_1\NNP|urinary|,|pge2 (r_nsubjpass) increased_8\VBN|ngf|were|significantly|in|compared|)|. (l_prep) in_9\IN|patients (l_pobj) patients_10\NNS|with (l_prep) with_11\IN|oab (l_pobj) OAB_12\NNP|
D015237_D053201 CID PGF2alpha_3\NNP|and|pgi2 (r_appos) NGF_1\NNP|urinary|,|pgf2alpha (r_nsubj) correlate_8\VB|ngf|did|not|with|. (l_prep) with_9\IN|parameters (l_pobj) parameters_11\NNS|urodynamic|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|oab (l_pobj) OAB_15\NNP|
D011464_D053201 NONE PGI2_3\NNP|urinary (r_nsubj) was_4\VBD|however|,|pgi2|not|different|. (l_acomp) different_6\JJ|between (l_prep) between_7\IN|controls (l_pobj) controls_8\NNS|and|patients|with (l_prep) with_11\IN|oab (l_pobj) OAB_12\NNP|
D011464_D053201 NONE PGI2_5\NNP| (r_conj) PGF2alpha_3\NNP|and|pgi2 (r_appos) NGF_1\NNP|urinary|,|pgf2alpha (r_nsubj) correlate_8\VB|ngf|did|not|with|. (l_prep) with_9\IN|parameters (l_pobj) parameters_11\NNS|urodynamic|in (l_prep) in_12\IN|patients (l_pobj) patients_13\NNS|with (l_prep) with_14\IN|oab (l_pobj) OAB_15\NNP|
6496797
D014196_D006327 CID trazodone_8\NN| (r_pobj) of_7\IN|trazodone (r_prep) dose_6\NN|a|single|of (r_pobj) following_3\VBG|dose (r_prep) block_2\NN|complete|heart|following|.
D014196_D006327 CID trazodone_9\NN| (r_pobj) of_8\IN|trazodone (r_prep) dose_7\NN|a|single|starting|of (r_dobj) receiving_3\VBG|dose (r_pcomp) after_2\IN|minutes|receiving (r_prep) developed_13\VBD|after|,|patient|block|. (l_dobj) block_16\NN|complete|heart
8480959
D008148_D006937 NONE lovastatin_4\NN| (r_pobj) of_3\IN|lovastatin (r_prep) Efficacy_0\NN|and|tolerability|of|in|. (l_prep) in_5\IN|women (l_pobj) women_7\NNS|3390|with (l_prep) with_8\IN|hypercholesterolemia (l_pobj) hypercholesterolemia_10\NN|moderate
D008148_D006937 NONE lovastatin_7\NN| (r_pobj) of_6\IN|lovastatin (r_prep) efficacy_3\NN|the|and|safety|of|in (r_dobj) evaluate_1\VB|to|efficacy|with|. (l_prep) with_10\IN|hypercholesterolemia (l_pobj) hypercholesterolemia_12\NN|moderate
D008148_D006937 NONE Lovastatin_0\NNP| (r_nsubj) is_1\VBZ|lovastatin|effective|and|tolerated|. (l_conj) tolerated_7\VBN|generally|well|as (l_prep) as_8\IN|therapy (l_pobj) therapy_9\NN|for (l_prep) for_10\IN|hypercholesterolemia (l_pobj) hypercholesterolemia_12\NN|primary|in
D003401_D009135 NONE creatine_7\NN| (r_compound) kinase_8\NN|creatine (r_compound) elevations_9\NNS|kinase|greater (r_pobj) with_6\IN|elevations (r_prep) symptoms_5\NNS|muscle|with (r_pobj) as_3\IN|symptoms (r_prep) defined_2\VBN|,|as (r_acl) Myopathy_0\NNP|defined
D008148_D009135 CID lovastatin_31\NN| (r_pobj) of_30\IN|lovastatin (r_prep) dose_29\NN|the|recommended|daily|of|mg (r_pobj) with_24\IN|dose (r_prep) associated_23\VBN|with (r_conj) was_20\VBD|myopathy|,|rare|and|associated|. (l_nsubj) Myopathy_0\NNP|defined
7710775
D008315_D002545 CID malondialdehyde_4\NN|plasma|, (r_pobj) of_2\IN|malondialdehyde (r_prep) dependence_1\NN|time|of (r_nsubj) oxypurines_6\NNS|dependence|,|and|nucleosides|. (l_conj) nucleosides_9\NNS|during (l_prep) during_10\IN|ischemia (l_pobj) ischemia_13\NN|incomplete|cerebral|in
-1_D002545 NONE oxypurines_6\NNS|dependence|,|and|nucleosides|. (l_conj) nucleosides_9\NNS|during (l_prep) during_10\IN|ischemia (l_pobj) ischemia_13\NN|incomplete|cerebral|in
D009705_D002545 NONE nucleosides_9\NNS|during (l_prep) during_10\IN|ischemia (l_pobj) ischemia_13\NN|incomplete|cerebral|in
-1_D007511 NONE oxypurines_10\NNS|plasma|and|nucleosides (r_pobj) of_8\IN|oxypurines (r_prep) increase_7\NN|a|dependent|of (r_nsubjpass) observed_14\VBN|during|,|increase|was|. (l_prep) During_0\IN|ischemia (l_pobj) ischemia_1\NN|
-1_D007511 NONE oxypurines_10\NNS|,|and|nucleosides (r_conj) malondialdehyde_8\NN|,|oxypurines (r_pobj) of_7\IN|malondialdehyde (r_prep) determination_6\NN|the|of (r_nsubjpass) used_20\VBN|that|determination|,|may|be|monitor (l_xcomp) monitor_22\VB|to|alterations (l_dobj) alterations_25\NNS|the|metabolic|of|occurring (l_acl) occurring_28\VBG|during (l_prep) during_29\IN|phenomena (l_pobj) phenomena_31\NNS|ischemic (l_amod) ischemic_30\JJ|
D009705_D007511 NONE nucleosides_12\NNS| (r_conj) oxypurines_10\NNS|plasma|and|nucleosides (r_pobj) of_8\IN|oxypurines (r_prep) increase_7\NN|a|dependent|of (r_nsubjpass) observed_14\VBN|during|,|increase|was|. (l_prep) During_0\IN|ischemia (l_pobj) ischemia_1\NN|
D009705_D007511 NONE nucleosides_13\NNS|in (r_conj) oxypurines_10\NNS|,|and|nucleosides (r_conj) malondialdehyde_8\NN|,|oxypurines (r_pobj) of_7\IN|malondialdehyde (r_prep) determination_6\NN|the|of (r_nsubjpass) used_20\VBN|that|determination|,|may|be|monitor (l_xcomp) monitor_22\VB|to|alterations (l_dobj) alterations_25\NNS|the|metabolic|of|occurring (l_acl) occurring_28\VBG|during (l_prep) during_29\IN|phenomena (l_pobj) phenomena_31\NNS|ischemic (l_amod) ischemic_30\JJ|
D008315_D007511 NONE malondialdehyde_1\NN|plasma|,|was|plasma|;|sd|, (r_nsubj) increased_23\VBD|malondialdehyde|after|,|resulting|. (l_prep) after_24\IN|min (l_pobj) min_26\NN|5|of (l_prep) of_27\IN|ischemia (l_pobj) ischemia_28\NN|
D008315_D007511 NONE malondialdehyde_23\NN|this|latter|group (r_pobj) in_19\IN|malondialdehyde (r_prep) was_24\VBD|although|in|higher (r_advcl) min_13\NN|of|/|intravenously|during|,|was|. (l_prep) during_15\IN|ischemia (l_pobj) ischemia_16\NN|
D008315_D007511 NONE malondialdehyde_8\NN|,|oxypurines (r_pobj) of_7\IN|malondialdehyde (r_prep) determination_6\NN|the|of (r_nsubjpass) used_20\VBN|that|determination|,|may|be|monitor (l_xcomp) monitor_22\VB|to|alterations (l_dobj) alterations_25\NNS|the|metabolic|of|occurring (l_acl) occurring_28\VBG|during (l_prep) during_29\IN|phenomena (l_pobj) phenomena_31\NNS|ischemic (l_amod) ischemic_30\JJ|
D001241_D007511 NONE acetylsalicylate_4\VBP|of|before|,|other|. (l_prep) before_7\IN|intravenously|immediately|ischemia (l_pobj) ischemia_8\NN|
D009599_D007022 NONE nitroprusside_4\NN|at (r_acl) drug_3\NN|the|hypotensive|nitroprusside (l_amod) hypotensive_2\JJ|
D009599_D007511 NONE nitroprusside_4\NN|at (r_acl) drug_3\NN|the|hypotensive|nitroprusside (r_pobj) of_0\IN|drug (r_prep) min_13\NN|of|/|intravenously|during|,|was|. (l_prep) during_15\IN|ischemia (l_pobj) ischemia_16\NN|
D008315_D007022 NONE malondialdehyde_23\NN|this|latter|group (r_pobj) in_19\IN|malondialdehyde (r_prep) was_24\VBD|although|in|higher (r_advcl) min_13\NN|of|/|intravenously|during|,|was|. (l_prep) of_0\IN|drug (l_pobj) drug_3\NN|the|hypotensive|nitroprusside (l_amod) hypotensive_2\JJ|
19289093
D006493_D007022 NONE heparin_8\JJ| (r_compound) products_9\NNS|heparin (r_pobj) of_7\IN|products (r_prep) lots_6\NNS|commercial|of (r_pobj) of_4\IN|lots (r_prep) number_3\NN|a|of (r_nsubjpass) found_11\VBN|recently|,|number|were|contaminated|. (l_xcomp) contaminated_14\VBN|to|be|with (l_prep) with_15\IN|derivative (l_pobj) derivative_23\NN|an|oversulfated|sulfate|elicit (l_relcl) elicit_26\VB|that|could|response|following (l_dobj) response_29\NN|a|hypotensive|in (l_amod) hypotensive_28\JJ|
D006493_D007022 NONE heparin_3\JJ| (r_compound) products_4\NNS|both|contaminated|heparin|and|derivative (r_dobj) Using_0\VBG|products (r_advcl) showed_12\VBD|using|,|we|produces|. (l_ccomp) produces_16\VBZ|that|oscs|hypotension (l_dobj) hypotension_20\NN|dependent|in
D002809_D007022 CID sulfate_19\NN|chondroitin|oscs|) (r_nmod) derivative_23\NN|an|oversulfated|sulfate|elicit (l_relcl) elicit_26\VB|that|could|response|following (l_dobj) response_29\NN|a|hypotensive|in (l_amod) hypotensive_28\JJ|
6769133
D004317_D066126 NONE adriamycin_6\NNS| (r_pobj) of_5\IN|adriamycin (r_prep) effects_4\NNS|possible|leukemogenic|of|in (r_conj) Cardiotoxic_0\NNP|and|effects|.
D004317_D006333 CID adriamycin_13\NNS| (r_compound) dose_14\NN|an|average|cumulative|adriamycin|m2|below|considered (r_pobj) at_9\IN|dose (r_prep) developed_5\VBD|8|failure|at|. (l_dobj) failure_8\NN|congestive|heart
D018943_D001768 NONE anthracycline_10\NN| (r_amod) induced_12\VBN|anthracycline|- (r_amod) cardiomyopathy_13\NN|human|induced (r_pobj) in_8\IN|cardiomyopathy (r_prep) found_7\VBN|in (r_acl) those_6\DT|found (r_dobj) resembled_5\VBD|histologically|,|lesions|those|. (l_nsubj) lesions_4\NNS|the|myocardial
D018943_D009202 NONE anthracycline_10\NN| (r_amod) induced_12\VBN|anthracycline|- (r_amod) cardiomyopathy_13\NN|human|induced
D004317_D015470 CID adriamycin_16\NNS| (r_pobj) of_15\IN|adriamycin (r_prep) m2_14\CD|324|mg|/|of (r_dobj) receiving_10\VBG|m2 (r_pcomp) after_9\IN|receiving (r_prep) developed_5\VBD|1|leukemia|after (l_dobj) leukemia_8\NN|myeloblastic
D004317_D007938 NONE adriamycin_4\NN| (r_nsubj) is_5\VBZ|that|adriamycin|cardiotoxin|than|,|and|be (l_conj) be_20\VB|that|leukemia|may|consequence (l_nsubj) leukemia_18\NN|
9165568
D018967_D009459 CID risperidone_4\NN| (r_pobj) with_3\IN|risperidone (r_prep) syndrome_2\NN|neuroleptic|malignant|with|.
D018967_D009459 CID risperidone_12\NN| (r_pobj) with_11\IN|risperidone (r_prep) monotherapy_10\NN|with (r_pobj) after_9\IN|monotherapy (r_prep) developed_5\VBD|woman|syndrome|after|. (l_dobj) syndrome_8\NN|neuroleptic|malignant
D018967_D009459 CID risperidone_11\NN| (r_pobj) with_10\IN|risperidone (r_prep) observed_9\VBN|that|protection|with (r_ccomp) appears_1\VBZ|it|observed|ensure|. (l_conj) ensure_14\VB|does|not|protection (l_dobj) protection_15\NN|from (l_prep) from_16\IN|syndrome (l_pobj) syndrome_19\NN|neuroleptic|malignant
D004298_D009459 NONE dopamine_10\NN| (r_compound) blockade_13\NN|dopamine|d2|receptor|in (r_pobj) of_9\IN|blockade (r_prep) result_8\NN|a|of (r_attr) be_6\VB|to|result (r_xcomp) thought_4\VBN|syndrome|is|be|. (l_nsubjpass) syndrome_2\NN|neuroleptic|malignant
D018967_D001480 NONE risperidone_14\NN|at (r_pobj) with_13\IN|risperidone (r_prep) frequency_9\NN|the|low|of|with (l_prep) of_10\IN|symptoms (l_pobj) symptoms_12\NNS|extrapyramidal
2750819
D008278_D020879 CID sulfate_4\NN|magnesium|and|nifedipine (r_pobj) with_2\IN|sulfate (r_prep) blockade_1\NN|neuromuscular|with|.
D008278_D020879 CID sulfate_15\NN|magnesium (r_pobj) of_13\IN|sulfate (r_prep) mg_12\NN|500|of (r_nsubjpass) administered_17\VBN|patient|after|mg|was|. (l_nsubjpass) patient_1\NN|a|received (l_relcl) received_3\VBD|who|tocolysis (l_dobj) tocolysis_4\NN|with (l_prep) with_5\IN|blockade (l_pobj) blockade_9\NN|nifedipine|developed|neuromuscular
D009543_D020879 CID nifedipine_6\NN| (r_conj) sulfate_4\NN|magnesium|and|nifedipine (r_pobj) with_2\IN|sulfate (r_prep) blockade_1\NN|neuromuscular|with|.
D009543_D020879 CID nifedipine_6\NN| (r_nmod) blockade_9\NN|nifedipine|developed|neuromuscular
D009543_D064420 NONE nifedipine_4\NN| (r_nsubj) potentiate_7\VB|that|nifedipine|can|seriously|toxicity (l_dobj) toxicity_9\NN|the|of
D008274_D064420 NONE magnesium_11\NN| (r_pobj) of_10\IN|magnesium (r_prep) toxicity_9\NN|the|of
6308526
C024224_D000699 NONE naloxazone_2\NN| (r_pobj) with_1\IN|naloxazone (r_prep) Pretreatment_0\NN|with (r_nsubj) blocked_4\VBD|pretreatment|significantly|morphine|analgesia|at|. (l_npadvmod) analgesia_6\NN|,|catalepsy
C024224_D002375 NONE naloxazone_2\NN| (r_pobj) with_1\IN|naloxazone (r_prep) Pretreatment_0\NN|with (r_nsubj) blocked_4\VBD|pretreatment|significantly|morphine|analgesia|at|. (l_npadvmod) analgesia_6\NN|,|catalepsy (l_conj) catalepsy_8\NN|and|hypothermia
C024224_D007035 NONE naloxazone_2\NN| (r_pobj) with_1\IN|naloxazone (r_prep) Pretreatment_0\NN|with (r_nsubj) blocked_4\VBD|pretreatment|significantly|morphine|analgesia|at|. (l_npadvmod) analgesia_6\NN|,|catalepsy (l_conj) catalepsy_8\NN|and|hypothermia (l_conj) hypothermia_10\VBN|
D009020_D000699 NONE morphine_5\NN| (r_dobj) blocked_4\VBD|pretreatment|significantly|morphine|analgesia|at|. (l_npadvmod) analgesia_6\NN|,|catalepsy
D009020_D002375 CID morphine_5\NN| (r_dobj) blocked_4\VBD|pretreatment|significantly|morphine|analgesia|at|. (l_npadvmod) analgesia_6\NN|,|catalepsy (l_conj) catalepsy_8\NN|and|hypothermia
D009020_D007035 CID morphine_5\NN| (r_dobj) blocked_4\VBD|pretreatment|significantly|morphine|analgesia|at|. (l_npadvmod) analgesia_6\NN|,|catalepsy (l_conj) catalepsy_8\NN|and|hypothermia (l_conj) hypothermia_10\VBN|
C024224_D007022 NONE naloxazone_2\NN| (r_nsubj) attenuated_4\VBD|moreover|,|naloxazone|significantly|depression|,|was|. (l_dobj) depression_12\NN|the|induced|hypotension (l_nmod) hypotension_9\NN|and|respiratory
C024224_D012131 NONE naloxazone_2\NN| (r_nsubj) attenuated_4\VBD|moreover|,|naloxazone|significantly|depression|,|was|. (l_dobj) depression_12\NN|the|induced|hypotension
C024224_D001919 NONE naloxazone_2\NN| (r_nsubj) attenuated_4\VBD|moreover|,|naloxazone|significantly|depression|,|was|. (l_advcl) was_19\VBD|whereas|bradycardia|affected (l_nsubj) bradycardia_18\NN|induced
D009020_D007022 CID morphine_6\NN| (r_npadvmod) induced_8\VBN|morphine|- (r_amod) depression_12\NN|the|induced|hypotension (l_nmod) hypotension_9\NN|and|respiratory
D009020_D007022 CID morphine_15\NN| (r_npadvmod) induced_17\VBN|morphine|- (r_amod) bradycardia_18\NN|induced (r_nsubj) was_19\VBD|whereas|bradycardia|affected (r_advcl) attenuated_4\VBD|moreover|,|naloxazone|significantly|depression|,|was|. (l_dobj) depression_12\NN|the|induced|hypotension (l_nmod) hypotension_9\NN|and|respiratory
D009020_D012131 NONE morphine_6\NN| (r_npadvmod) induced_8\VBN|morphine|- (r_amod) depression_12\NN|the|induced|hypotension
D009020_D012131 NONE morphine_15\NN| (r_npadvmod) induced_17\VBN|morphine|- (r_amod) bradycardia_18\NN|induced (r_nsubj) was_19\VBD|whereas|bradycardia|affected (r_advcl) attenuated_4\VBD|moreover|,|naloxazone|significantly|depression|,|was|. (l_dobj) depression_12\NN|the|induced|hypotension
D009020_D001919 CID morphine_6\NN| (r_npadvmod) induced_8\VBN|morphine|- (r_amod) depression_12\NN|the|induced|hypotension (r_dobj) attenuated_4\VBD|moreover|,|naloxazone|significantly|depression|,|was|. (l_advcl) was_19\VBD|whereas|bradycardia|affected (l_nsubj) bradycardia_18\NN|induced
D009020_D001919 CID morphine_15\NN| (r_npadvmod) induced_17\VBN|morphine|- (r_amod) bradycardia_18\NN|induced
2422478
D012701_D007022 NONE serotonin_2\NN|b3 (r_compound) nerves_3\NNS|serotonin|in (r_nsubjpass) involved_8\VBN|nerves|are|in|. (l_prep) in_9\IN|effect (l_pobj) effect_11\NN|hypotensive|of (l_amod) hypotensive_10\JJ|
D012701_D007022 NONE serotonin_18\NN|b3 (r_compound) neurons_19\NNS|the|serotonin (r_pobj) of_15\IN|neurons (r_prep) cells_14\NNS|the|ventrolateral|of|in (r_pobj) onto_11\IN|cells (r_prep) microinjection_8\NN|of|onto (r_nsubj) elicits_23\VBZ|that|microinjection|response (l_dobj) response_26\NN|a|hypotensive|mediated (l_amod) hypotensive_25\JJ|
D012701_D007022 NONE serotonin_19\NN|b3 (r_compound) group_21\NN|the|midline|serotonin|cell|in (r_pobj) of_15\IN|group (r_prep) area_14\NN|the|of (r_pobj) into_12\IN|area (r_prep) microinjection_9\NN|of|into (r_conj) rats_7\NNS|hypertensive|,|prone|,|microinjection (r_pobj) In_0\IN|rats (r_prep) caused_26\VBD|in|hypotension|h|and|abolished|. (l_dobj) hypotension_29\NN|a|potent|of
D012701_D007022 NONE serotonin_51\NN| (r_compound) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_dobj) hypotension_29\NN|a|potent|of
D012701_D007022 NONE serotonin_15\NN| (r_compound) projections_16\NNS|serotonin|in (r_dobj) descending_14\VBG|only|projections (r_pcomp) of_12\IN|descending (r_prep) lesion_11\NN|a|selective|of (r_dobj) produce_7\VB|to|lesion (r_relcl) injection_3\NN|intraspinal|of|produce (r_nsubj) affect_23\VB|however|,|injection|did|not|hypotension|. (l_dobj) hypotension_25\NN|this
D012701_D007022 NONE serotonin_24\NN| (r_compound) cells_26\NNS|the|midline|serotonin|b3|in (r_nsubj) contribute_30\VB|that|,|unlike|,|cells|to|,|by (l_prep) unlike_6\IN|cells (l_pobj) cells_10\NNS|the|ventrolateral|b3|mediate (l_relcl) mediate_12\VBP|which|hypotension|via (l_dobj) hypotension_17\NN|a|induced
D012701_D007022 NONE serotonin_24\NN| (r_compound) cells_26\NNS|the|midline|serotonin|b3|in (r_nsubj) contribute_30\VB|that|,|unlike|,|cells|to|,|by (l_prep) to_31\IN|action (l_pobj) action_34\NN|the|hypotensive|of (l_amod) hypotensive_33\JJ|
D008750_D007022 CID methyldopa_13\NN| (r_pobj) of_12\IN|methyldopa (r_prep) effect_11\NN|hypotensive|of (l_amod) hypotensive_10\JJ|
D008750_D007022 CID methyldopa_10\NN| (r_pobj) of_9\IN|methyldopa (r_prep) microinjection_8\NN|of|onto (r_nsubj) elicits_23\VBZ|that|microinjection|response (l_dobj) response_26\NN|a|hypotensive|mediated (l_amod) hypotensive_25\JJ|
D008750_D007022 CID methyldopa_11\NN| (r_pobj) of_10\IN|methyldopa (r_prep) microinjection_9\NN|of|into (r_conj) rats_7\NNS|hypertensive|,|prone|,|microinjection (r_pobj) In_0\IN|rats (r_prep) caused_26\VBD|in|hypotension|h|and|abolished|. (l_dobj) hypotension_29\NN|a|potent|of
D008750_D007022 CID methyldopa_14\NN| (r_npadvmod) induced_16\VBN|methyldopa|- (r_amod) hypotension_17\NN|a|induced
D008750_D007022 CID methyldopa_14\NN| (r_npadvmod) induced_16\VBN|methyldopa|- (r_amod) hypotension_17\NN|a|induced (r_dobj) mediate_12\VBP|which|hypotension|via (r_relcl) cells_10\NNS|the|ventrolateral|b3|mediate (r_pobj) unlike_6\IN|cells (r_prep) contribute_30\VB|that|,|unlike|,|cells|to|,|by (l_prep) to_31\IN|action (l_pobj) action_34\NN|the|hypotensive|of (l_amod) hypotensive_33\JJ|
D008750_D007022 CID methyldopa_36\NN| (r_pobj) of_35\IN|methyldopa (r_prep) action_34\NN|the|hypotensive|of (r_pobj) to_31\IN|action (r_prep) contribute_30\VB|that|,|unlike|,|cells|to|,|by (l_prep) unlike_6\IN|cells (l_pobj) cells_10\NNS|the|ventrolateral|b3|mediate (l_relcl) mediate_12\VBP|which|hypotension|via (l_dobj) hypotension_17\NN|a|induced
D008750_D007022 CID methyldopa_36\NN| (r_pobj) of_35\IN|methyldopa (r_prep) action_34\NN|the|hypotensive|of (l_amod) hypotensive_33\JJ|
D008750_D006973 NONE methyldopa_11\NN| (r_pobj) of_10\IN|methyldopa (r_prep) microinjection_9\NN|of|into (r_conj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) hypertensive_2\JJ|spontaneously
D008750_D020521 NONE methyldopa_11\NN| (r_pobj) of_10\IN|methyldopa (r_prep) microinjection_9\NN|of|into (r_conj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) prone_6\JJ|stroke|- (l_npadvmod) stroke_4\NN|
D012701_D006973 NONE serotonin_19\NN|b3 (r_compound) group_21\NN|the|midline|serotonin|cell|in (r_pobj) of_15\IN|group (r_prep) area_14\NN|the|of (r_pobj) into_12\IN|area (r_prep) microinjection_9\NN|of|into (r_conj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) hypertensive_2\JJ|spontaneously
D012701_D006973 NONE serotonin_51\NN| (r_compound) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_prep) In_0\IN|rats (l_pobj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) hypertensive_2\JJ|spontaneously
D012701_D020521 NONE serotonin_19\NN|b3 (r_compound) group_21\NN|the|midline|serotonin|cell|in (r_pobj) of_15\IN|group (r_prep) area_14\NN|the|of (r_pobj) into_12\IN|area (r_prep) microinjection_9\NN|of|into (r_conj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) prone_6\JJ|stroke|- (l_npadvmod) stroke_4\NN|
D012701_D020521 NONE serotonin_51\NN| (r_compound) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_prep) In_0\IN|rats (l_pobj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) prone_6\JJ|stroke|- (l_npadvmod) stroke_4\NN|
D015116_D006973 NONE 5,7-dihydroxytryptamine_53\CD|5,7-dht (r_appos) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_prep) In_0\IN|rats (l_pobj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) hypertensive_2\JJ|spontaneously
D015116_D006973 NONE 5,7-DHT_55\NNP|(|) (r_appos) 5,7-dihydroxytryptamine_53\CD|5,7-dht (r_appos) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_prep) In_0\IN|rats (l_pobj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) hypertensive_2\JJ|spontaneously
D015116_D020521 NONE 5,7-dihydroxytryptamine_53\CD|5,7-dht (r_appos) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_prep) In_0\IN|rats (l_pobj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) prone_6\JJ|stroke|- (l_npadvmod) stroke_4\NN|
D015116_D020521 NONE 5,7-DHT_55\NNP|(|) (r_appos) 5,7-dihydroxytryptamine_53\CD|5,7-dht (r_appos) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_prep) In_0\IN|rats (l_pobj) rats_7\NNS|hypertensive|,|prone|,|microinjection (l_amod) prone_6\JJ|stroke|- (l_npadvmod) stroke_4\NN|
D015116_D007022 NONE 5,7-dihydroxytryptamine_53\CD|5,7-dht (r_appos) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_dobj) hypotension_29\NN|a|potent|of
D015116_D007022 NONE 5,7-DHT_55\NNP|(|) (r_appos) 5,7-dihydroxytryptamine_53\CD|5,7-dht (r_appos) neurotoxin_52\NN|the|serotonin|5,7-dihydroxytryptamine (r_pobj) by_49\IN|neurotoxin (r_agent) abolished_48\VBN|was|by|injected (r_conj) caused_26\VBD|in|hypotension|h|and|abolished|. (l_dobj) hypotension_29\NN|a|potent|of
D015116_D007022 NONE 5,7-DHT_5\CD| (r_pobj) of_4\IN|5,7-dht (r_prep) injection_3\NN|intraspinal|of|produce (r_nsubj) affect_23\VB|however|,|injection|did|not|hypotension|. (l_dobj) hypotension_25\NN|this
7707116
D015474_D009447 NONE acid_7\NN|retinoic (r_pobj) of_3\IN|acid (r_prep) trial_2\NN|of|in|following (l_prep) in_8\IN|children (l_pobj) children_9\NNS|with (l_prep) with_10\IN|neuroblastoma (l_pobj) neuroblastoma_11\NN|
D015474_D009447 NONE acid_11\NN|retinoic|ra (r_pobj) with_7\IN|acid (r_prep) lines_6\NNS|neuroblastoma|cell|with (l_compound) neuroblastoma_4\NN|
D015474_D009447 NONE RA_15\NNP|(|cis|- (r_appos) acid_11\NN|retinoic|ra (r_pobj) with_7\IN|acid (r_prep) lines_6\NNS|neuroblastoma|cell|with (l_compound) neuroblastoma_4\NN|
D015474_D009447 NONE RA_3\NNP|cis|- (r_nsubj) demonstrated_5\VBN|since|ra|has|responses (l_dobj) responses_7\NNS|clinical|in (l_prep) in_8\IN|patients (l_pobj) patients_10\NNS|neuroblastoma (l_compound) neuroblastoma_9\NN|
D015474_D009447 NONE RA_24\NNP|cis|- (r_pobj) of_21\IN|ra (r_prep) toxicities_17\NNS|,|and|pharmacokinetics|of|administered (l_acl) administered_25\VBD|on (l_prep) on_26\IN|schedule (l_pobj) schedule_29\NN|an|intermittent|in (l_prep) in_30\IN|children (l_pobj) children_31\NNS|with (l_prep) with_32\IN|neuroblastoma (l_pobj) neuroblastoma_33\NN|
D015474_D064420 NONE RA_24\NNP|cis|- (r_pobj) of_21\IN|ra (r_prep) toxicities_17\NNS|,|and|pharmacokinetics|of|administered
D015474_D064420 NONE RA_6\NNP|cis|- (r_nsubjpass) discontinued_8\VBN|after|ra|was (r_advcl) resolved_2\VBD|toxicities|discontinued|. (l_nsubj) toxicities_1\NNS|all
D015474_D006934 CID RA_13\NNP|cis|- (r_compound) levels_14\NNS|serum|ra (r_pobj) by_9\IN|levels (r_agent) predicted_8\VBN|may|be|by (r_conj) included_2\VBD|dlt|hypercalcemia|,|and|predicted|. (l_dobj) hypercalcemia_3\NN|
11078231
D004280_D017202 NONE dobutamine_8\NN| (r_compound) stress_9\NN|dobutamine (r_compound) echocardiography_10\RB|stress (r_pobj) during_7\IN|echocardiography (r_prep) spasm_6\NN|coronary|artery|during (r_pobj) due_2\IN|to|spasm (r_amod) ischemia_1\NN|myocardial|due|.
D004280_D017202 NONE Dobutamine_0\NNP| (r_nsubj) stress_1\NN|dobutamine|echocardiography (r_nsubj) is_6\VBZ|stress|test|. (l_attr) test_12\NN|a|useful|provocation|for (l_prep) for_13\IN|ischemia (l_pobj) ischemia_15\NN|myocardial
D004280_D017202 NONE dobutamine_19\NN| (r_pobj) by_18\IN|dobutamine (r_agent) induced_17\VBN|whether|ischemia|is|by (l_nsubjpass) ischemia_11\NN|myocardial|due
D004280_D003329 CID dobutamine_8\NN| (r_compound) stress_9\NN|dobutamine (r_compound) echocardiography_10\RB|stress (r_pobj) during_7\IN|echocardiography (r_prep) spasm_6\NN|coronary|artery|during
D004280_D003329 CID dobutamine_19\NN| (r_pobj) by_18\IN|dobutamine (r_agent) induced_17\VBN|whether|ischemia|is|by (l_nsubjpass) ischemia_11\NN|myocardial|due (l_amod) due_12\IN|to (l_pcomp) to_13\IN|spasm (l_pobj) spasm_15\NN|coronary
D004280_D003329 CID dobutamine_4\NN|that (r_nsubj) provoke_6\VB|dobutamine|can|spasm|in (l_dobj) spasm_8\NN|coronary
D000109_D023921 NONE acetylcholine_8\NN| (r_pobj) of_7\IN|acetylcholine (r_prep) injection_6\NN|intracoronary|of (r_pobj) by_4\IN|injection (r_agent) induced_3\VBN|spasm|was|by|,|and|documented (l_conj) documented_17\VBN|stenosis|was|on|. (l_nsubjpass) stenosis_15\NN|no|fixed|coronary|artery
D004280_D000788 CID dobutamine_4\NN|that (r_nsubj) provoke_6\VB|dobutamine|can|spasm|in (l_prep) in_9\IN|patients (l_pobj) patients_11\NNS|some|with (l_prep) with_12\IN|angina (l_pobj) angina_15\NN|coronary|spastic
19319147
D014859_D006470 NONE warfarin_12\RB| (r_npadvmod) associated_14\VBN|warfarin|- (r_amod) hemorrhage_16\NN|associated|intracerebral (r_pobj) of_11\IN|hemorrhage (r_prep) model_10\NN|a|mouse|of (r_pobj) in_7\IN|model (r_prep) reduces_4\VBZ|reversal|volume|in|. (l_dobj) volume_6\NN|hemorrhage (l_compound) hemorrhage_5\NN|
D014859_D002543 CID warfarin_12\RB| (r_npadvmod) associated_14\VBN|warfarin|- (r_amod) hemorrhage_16\NN|associated|intracerebral
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|warfarin|- (r_amod) hemorrhage_4\NN|associated|intracerebral|ich|)
D014859_D002543 CID Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|warfarin|- (r_amod) hemorrhage_4\NN|associated|intracerebral|ich|) (l_appos) ICH_8\NNP|(|w|-
D014859_D020521 NONE Warfarin_0\NNP| (r_npadvmod) associated_2\VBN|warfarin|- (r_amod) hemorrhage_4\NN|associated|intracerebral|ich|) (r_nsubj) is_10\VBZ|hemorrhage|type|. (l_attr) type_13\NN|a|severe|of (l_prep) of_14\IN|stroke (l_pobj) stroke_15\NN|
C025667_D002543 NONE PCC_5\NNP| (r_nsubj) be_7\VB|pcc|to|treatment|in (l_attr) treatment_11\NN|an|effective|acute|for (l_prep) for_12\IN|ich (l_pobj) ICH_15\NNP|w|-
16418614
D011441_D014657 CID PTU_0\NNP| (r_npadvmod) associated_2\VBN|ptu|- (r_amod) vasculitis_3\NN|associated|in|.
D011441_D014657 CID propylthiouracil_3\NN| (r_pobj) of_2\IN|propylthiouracil (r_prep) diagnosis_1\NN|the|of (r_nsubjpass) made_8\VBN|diagnosis|(|vasculitis|was|by|,|detection|. (l_nsubjpass) vasculitis_6\NN|ptu)-associated
D011441_D014657 CID PTU)-associated_5\VBN| (r_amod) vasculitis_6\NN|ptu)-associated
D011441_D014657 CID PTU_37\NNP| (r_pobj) of_36\IN|ptu (r_prep) withdrawal_35\NN|of (r_dobj) following_34\VBG|withdrawal (r_acl) resolution_31\NN|the|observed|clinical|of|following (r_conj) detection_17\NN|the|of|,|and|resolution (r_appos) made_8\VBN|diagnosis|(|vasculitis|was|by|,|detection|. (l_nsubjpass) vasculitis_6\NN|ptu)-associated
D011441_D014424 NONE PTU_0\NNP| (r_npadvmod) associated_2\VBN|ptu|- (r_amod) vasculitis_3\NN|associated|in|. (l_prep) in_4\IN|girl (l_pobj) girl_6\NN|a|with (l_prep) with_7\IN|syndrome (l_pobj) Syndrome_9\NNP|turner|and|disease
D011441_D006111 NONE PTU_0\NNP| (r_npadvmod) associated_2\VBN|ptu|- (r_amod) vasculitis_3\NN|associated|in|. (l_prep) in_4\IN|girl (l_pobj) girl_6\NN|a|with (l_prep) with_7\IN|syndrome (l_pobj) Syndrome_9\NNP|turner|and|disease (l_conj) disease_13\NN|graves
15096016
D007980_D018476 NONE levodopa_20\RB| (r_npadvmod) induced_22\VBN|levodopa|- (r_amod) dyskinesias_23\NNS|induced (r_dobj) improving_19\VBG|dyskinesias (r_pcomp) in_18\IN|improving (r_prep) be_17\VB|to|in (r_xcomp) seems_15\VBZ|improves|;|however|,|strength|be|. (l_ccomp) improves_2\VBZ|stimulation|bradykinesia|to (l_dobj) bradykinesia_3\JJ|and|rigidity
D007980_D009127 NONE levodopa_20\RB| (r_npadvmod) induced_22\VBN|levodopa|- (r_amod) dyskinesias_23\NNS|induced (r_dobj) improving_19\VBG|dyskinesias (r_pcomp) in_18\IN|improving (r_prep) be_17\VB|to|in (r_xcomp) seems_15\VBZ|improves|;|however|,|strength|be|. (l_ccomp) improves_2\VBZ|stimulation|bradykinesia|to (l_dobj) bradykinesia_3\JJ|and|rigidity (l_conj) rigidity_5\NN|
D007980_D004409 CID levodopa_20\RB| (r_npadvmod) induced_22\VBN|levodopa|- (r_amod) dyskinesias_23\NNS|induced
12180796
D009569_D009369 NONE oxide_7\NN|nitric|(|inos|)|,|factor (l_appos) factor_15\NN|basic|growth|(|bfgf|)|and|growth (l_conj) growth_21\NN|tumor (l_compound) tumor_20\NN|
D009569_D009369 NONE oxide_21\NN| (r_compound) synthase_22\NN|nitric|oxide|(|inos|)|,|factor (l_appos) factor_30\NN|basic|growth|(|bfgf|)|and|beta1 (l_conj) beta1_39\NNP|factor|(|beta1|) (l_compound) factor_37\NN|tumor|growth|- (l_compound) tumor_35\NN|
D018818_D001167 CID fenoldopam_12\NN|and|theophylline (r_pobj) by_11\IN|fenoldopam (r_prep) rats_10\NNS|by (r_pobj) in_9\IN|rats (r_prep) induced_8\VBN|beta1|in|,|vasodilators|. (l_nsubj) beta1_0\NNP|(|beta1|)|in (l_prep) in_6\IN|arteritis (l_pobj) arteritis_7\NN|
D018818_D001167 CID fenoldopam_7\NN|and|theophylline (r_npadvmod) induced_1\VBN|arteritis|in|,|fenoldopam|examined (l_nsubj) Arteritis_0\NNP|
D013806_D001167 CID theophylline_14\NN| (r_conj) fenoldopam_12\NN|and|theophylline (r_pobj) by_11\IN|fenoldopam (r_prep) rats_10\NNS|by (r_pobj) in_9\IN|rats (r_prep) induced_8\VBN|beta1|in|,|vasodilators|. (l_nsubj) beta1_0\NNP|(|beta1|)|in (l_prep) in_6\IN|arteritis (l_pobj) arteritis_7\NN|
D013806_D001167 CID theophylline_9\NN| (r_conj) fenoldopam_7\NN|and|theophylline (r_npadvmod) induced_1\VBN|arteritis|in|,|fenoldopam|examined (l_nsubj) Arteritis_0\NNP|
D018818_D009369 NONE fenoldopam_7\NN|and|theophylline (r_npadvmod) induced_1\VBN|arteritis|in|,|fenoldopam|examined (l_conj) examined_12\VBN|,|was|immunohistochemically|for|. (l_prep) for_14\IN|expressions (l_pobj) expressions_15\NNS|of (l_prep) of_16\IN|type (l_pobj) type_18\NN|inducible|of (l_prep) of_19\IN|synthase (l_pobj) synthase_22\NN|nitric|oxide|(|inos|)|,|factor (l_appos) factor_30\NN|basic|growth|(|bfgf|)|and|beta1 (l_conj) beta1_39\NNP|factor|(|beta1|) (l_compound) factor_37\NN|tumor|growth|- (l_compound) tumor_35\NN|
D013806_D009369 NONE theophylline_9\NN| (r_conj) fenoldopam_7\NN|and|theophylline (r_npadvmod) induced_1\VBN|arteritis|in|,|fenoldopam|examined (l_conj) examined_12\VBN|,|was|immunohistochemically|for|. (l_prep) for_14\IN|expressions (l_pobj) expressions_15\NNS|of (l_prep) of_16\IN|type (l_pobj) type_18\NN|inducible|of (l_prep) of_19\IN|synthase (l_pobj) synthase_22\NN|nitric|oxide|(|inos|)|,|factor (l_appos) factor_30\NN|basic|growth|(|bfgf|)|and|beta1 (l_conj) beta1_39\NNP|factor|(|beta1|) (l_compound) factor_37\NN|tumor|growth|- (l_compound) tumor_35\NN|
D009569_D001167 NONE oxide_21\NN| (r_compound) synthase_22\NN|nitric|oxide|(|inos|)|,|factor (r_pobj) of_19\IN|synthase (r_prep) type_18\NN|inducible|of (r_pobj) of_16\IN|type (r_prep) expressions_15\NNS|of (r_pobj) for_14\IN|expressions (r_prep) examined_12\VBN|,|was|immunohistochemically|for|. (r_conj) induced_1\VBN|arteritis|in|,|fenoldopam|examined (l_nsubj) Arteritis_0\NNP|
14745746
16116131
D007980_D004409 CID levodopa_7\RB| (r_npadvmod) induced_9\VBN|levodopa|- (r_amod) dyskinesia_10\NN|induced
D001058_D010300 NONE apomorphine_46\NN| (r_compound) infusion_47\NN|continuous|apomorphine (r_pobj) by_44\IN|infusion (r_agent) induced_43\VBN|by (r_acl) state_42\NN|a|dyskinetic|induced (r_pobj) of_39\IN|state (r_prep) modification_38\NN|a|of (r_pobj) in_36\IN|modification (r_prep) result_35\VB|whether|modulation|may|in (r_ccomp) investigated_28\VBN|using|,|authors|result|. (l_advcl) Using_0\VBG|stimulation|rtms (l_parataxis) rTMS_6\NN|(|)|over (l_prep) over_8\IN|area (l_pobj) area_12\NN|the|supplementary|motor|sma|in (l_prep) in_16\IN|group (l_pobj) group_18\NN|a|of (l_prep) of_19\IN|patients (l_pobj) patients_20\NNS|with (l_prep) with_21\IN|disease (l_pobj) disease_24\NN|advanced|parkinson
D001058_D004409 NONE apomorphine_46\NN| (r_compound) infusion_47\NN|continuous|apomorphine (r_pobj) by_44\IN|infusion (r_agent) induced_43\VBN|by (r_acl) state_42\NN|a|dyskinetic|induced (l_amod) dyskinetic_41\JJ|
2907585
-1_D002375 NONE piperazine_10\NN|aryl|- (r_nmod) drugs_12\NNS|novel|piperazine|anxiolytic (r_pobj) by_6\IN|drugs (r_prep) Reversal_0\NN|of|by|. (l_prep) of_1\IN|catalepsy (l_pobj) catalepsy_5\NN|induced
-1_D002375 NONE piperazine_5\NN|aryl|- (r_compound) analogues_6\NNS|piperazine|of (r_pobj) of_2\IN|analogues (r_prep) series_1\NN|a|of (r_nsubjpass) tested_14\VBN|series|were|for|induced|. (l_conj) induced_21\VBN|catalepsy (l_dobj) catalepsy_22\NN|
D002065_D002375 NONE buspirone_5\NN| (r_appos) drug_3\NN|the|novel|anxiolytic|,|buspirone|, (r_nsubj) reverses_7\VBZ|drug|catalepsy|. (l_dobj) catalepsy_8\NN|induced
D002065_D002375 NONE buspirone_8\NN|and|agonists (r_pobj) of_7\IN|buspirone (r_prep) analogues_6\NNS|piperazine|of (r_pobj) of_2\IN|analogues (r_prep) series_1\NN|a|of (r_nsubjpass) tested_14\VBN|series|were|for|induced|. (l_conj) induced_21\VBN|catalepsy (l_dobj) catalepsy_22\NN|
D006220_D002375 CID haloperidol_11\NN| (r_pobj) by_10\IN|haloperidol (r_agent) induced_9\VBN|by (r_acl) catalepsy_8\NN|induced
D006220_D002375 CID haloperidol_20\NN| (r_dobj) reverse_19\VB|to|haloperidol (r_acl) ability_17\NN|their|reverse (r_pobj) for_15\IN|ability (r_prep) tested_14\VBN|series|were|for|induced|. (l_conj) induced_21\VBN|catalepsy (l_dobj) catalepsy_22\NN|
D058825_D002375 NONE agonists_12\NNS|other|5-hydroxytryptaminergic (r_conj) buspirone_8\NN|and|agonists (r_pobj) of_7\IN|buspirone (r_prep) analogues_6\NNS|piperazine|of (r_pobj) of_2\IN|analogues (r_prep) series_1\NN|a|of (r_nsubjpass) tested_14\VBN|series|were|for|induced|. (l_conj) induced_21\VBN|catalepsy (l_dobj) catalepsy_22\NN|
D012701_D002375 NONE 5-hydroxytryptamine1a_6\CD| (r_compound) receptors_7\NNS|5-hydroxytryptamine1a (r_pobj) for_5\IN|receptors (r_prep) affinity_4\NN|strong|for (r_pobj) with_2\IN|affinity (r_prep) drugs_1\NNS|those|with (r_nsubj) were_8\VBD|drugs|able|. (l_acomp) able_9\JJ|reverse (l_xcomp) reverse_11\VB|to|catalepsy (l_dobj) catalepsy_12\NN|
D012701_D002375 NONE 5-HT_5\CD| (r_compound) receptors_6\NNS|postsynaptic|5-ht (r_pobj) of_3\IN|receptors (r_prep) inhibition_2\NN|of (r_nsubj) inhibited_8\VBN|however|,|inhibition|neither|nor|potentiated|. (l_conj) potentiated_10\VBN|reversal|and|leaves (l_dobj) reversal_11\NN|of (l_prep) of_12\IN|catalepsy (l_pobj) catalepsy_13\NN|
9326871
D017291_D017180 CID Clarithromycin_0\NN| (r_npadvmod) induced_2\VBN|clarithromycin|- (r_amod) tachycardia_4\NN|induced|ventricular|.
D004917_D005759 CID erythromycin_7\NNP| (r_pobj) of_6\IN|erythromycin (r_prep) profile_5\NN|the|effect|of (r_nsubjpass) established_9\VBN|although|profile|is (r_advcl) recorded_35\VBN|established|experience|is|still|being|. (l_nsubjpass) experience_27\NN|,|including|,|with (l_prep) including_11\VBG|gastroenteritis (l_pobj) gastroenteritis_12\JJ|and|interactions
D018942_D005759 NONE macrolides_31\NNS|the|newer (r_pobj) with_28\IN|macrolides (r_prep) experience_27\NN|,|including|,|with (l_prep) including_11\VBG|gastroenteritis (l_pobj) gastroenteritis_12\JJ|and|interactions
D004917_D066126 NONE erythromycin_11\NNP| (r_pobj) of_10\IN|erythromycin (r_prep) administration_9\NN|intravenous|of (r_pobj) after_4\IN|administration (r_prep) demonstrated_3\VBN|cardiotoxicity|has|been|after|but|reported|. (l_nsubjpass) Cardiotoxicity_0\NN|
D018942_D066126 NONE macrolides_20\NNS|the|newer (r_pobj) with_17\IN|macrolides (r_prep) reported_16\VBN|has|never|been|with (r_conj) demonstrated_3\VBN|cardiotoxicity|has|been|after|but|reported|. (l_nsubjpass) Cardiotoxicity_0\NN|
D017291_D001145 NONE clarithromycin_14\NN| (r_pobj) of_13\IN|clarithromycin (r_prep) doses_12\NNS|six|therapeutic|of (r_pobj) after_9\IN|doses (r_prep) occurred_8\VBD|that|after (r_relcl) dysrhythmias_6\NNS|ventricular|occurred
12042105
C052342_D053040 CID Topiramate_0\NNP| (r_npadvmod) induced_2\VBN|topiramate|- (r_amod) nephrolithiasis_3\NN|induced|.
C052342_D053040 CID topiramate_7\RB| (r_npadvmod) induced_9\VBN|topiramate|- (r_amod) nephrolithiasis_10\NN|induced|in
C052342_D004827 NONE Topiramate_0\NNP| (r_nsubj) is_1\VBZ|topiramate|medication|. (l_attr) medication_6\NN|a|developed|antiepileptic|becoming (l_relcl) becoming_9\VBG|that|is|prescribed|because (l_prep) because_13\IN|of|efficacy (l_pobj) efficacy_16\NN|its|in (l_prep) in_17\IN|treating (l_pcomp) treating_18\VBG|seizures (l_dobj) seizures_20\NNS|refractory
C020243_D053040 NONE phosphate_29\NN|calcium (r_compound) nephrolithiasis_30\NN|phosphate
1687392
D004298_D002375 NONE dopamine_6\NN|d-2 (r_compound) receptors_7\NNS|both|dopamine (r_pobj) of_1\IN|receptors (r_prep) Blockade_0\NN|of (r_nsubj) induce_9\VB|blockade|may|catalepsy|in|. (l_dobj) catalepsy_10\NN|
D004298_D002375 NONE dopamine_4\NN| (r_compound) antagonists_5\NNS|dopamine (r_pobj) by_3\IN|antagonists (r_agent) induced_2\VBN|by (r_acl) catalepsy_1\NN|the|induced
D004298_D002375 NONE dopamine_4\NN| (r_compound) antagonists_5\NNS|dopamine (r_pobj) by_3\IN|antagonists (r_agent) induced_2\VBN|by (r_acl) catalepsy_1\NN|the|induced (r_nsubjpass) tested_8\VBN|catalepsy|has|been|and|determined (l_conj) determined_18\VBN|subtypes|was|. (l_nsubjpass) subtypes_13\NNS|the|possible|dopamine|involved (l_acl) involved_14\VBN|in (l_prep) in_15\IN|catalepsy (l_pobj) catalepsy_16\NN|
D004298_D002375 NONE dopamine_12\NN| (r_compound) subtypes_13\NNS|the|possible|dopamine|involved (r_nsubjpass) determined_18\VBN|subtypes|was|. (r_conj) tested_8\VBN|catalepsy|has|been|and|determined (l_nsubjpass) catalepsy_1\NN|the|induced
D004298_D002375 NONE dopamine_12\NN| (r_compound) subtypes_13\NNS|the|possible|dopamine|involved (l_acl) involved_14\VBN|in (l_prep) in_15\IN|catalepsy (l_pobj) catalepsy_16\NN|
D004298_D002375 NONE Dopamine_0\NN| (r_compound) fluphenazine_2\NN|dopamine|antagonist|,|sch (r_nsubj) induced_12\VBD|fluphenazine|sulpiride|catalepsy|. (l_dobj) catalepsy_13\NN|
D004298_D002375 NONE dopamine_16\NN| (r_compound) antagonists_17\NNS|dopamine (r_pobj) by_15\IN|antagonists (r_agent) induced_14\VBN|by (r_acl) effect_11\NN|inhibitory|on|induced (l_prep) on_12\IN|catalepsy (l_pobj) catalepsy_13\NN|
D005476_D002375 CID fluphenazine_2\NN|dopamine|antagonist|,|sch (r_nsubj) induced_12\VBD|fluphenazine|sulpiride|catalepsy|. (l_dobj) catalepsy_13\NN|
D005476_D002375 CID fluphenazine_15\NN|,|sch (r_pobj) by_14\IN|fluphenazine (r_agent) induced_13\VBN|by (r_acl) catalepsy_12\NN|the|induced
C534628_D002375 CID 23390_7\CD| (r_nummod) SCH_6\NNP|d-1|antagonist|23390|or (r_appos) fluphenazine_2\NN|dopamine|antagonist|,|sch (r_nsubj) induced_12\VBD|fluphenazine|sulpiride|catalepsy|. (l_dobj) catalepsy_13\NN|
C534628_D002375 CID 23390_3\CD| (r_nummod) SCH_2\NNP|23390 (r_pobj) of_1\IN|sch (r_prep) Combination_0\NN|of|with (r_nsubj) induce_8\VB|combination|did|not|potentiation|. (l_dobj) potentiation_10\NN|catalepsy (l_compound) catalepsy_9\NN|
C534628_D002375 CID 23390_18\CD| (r_nummod) SCH_17\NNP|23390|or|sulpiride (r_appos) fluphenazine_15\NN|,|sch (r_pobj) by_14\IN|fluphenazine (r_agent) induced_13\VBN|by (r_acl) catalepsy_12\NN|the|induced
D013469_D002375 CID sulpiride_11\NN|antagonist (r_npadvmod) induced_12\VBD|fluphenazine|sulpiride|catalepsy|. (l_dobj) catalepsy_13\NN|
D013469_D002375 CID sulpiride_5\NN| (r_pobj) with_4\IN|sulpiride (r_prep) Combination_0\NN|of|with (r_nsubj) induce_8\VB|combination|did|not|potentiation|. (l_dobj) potentiation_10\NN|catalepsy (l_compound) catalepsy_9\NN|
D013469_D002375 CID sulpiride_20\NN| (r_conj) SCH_17\NNP|23390|or|sulpiride (r_appos) fluphenazine_15\NN|,|sch (r_pobj) by_14\IN|fluphenazine (r_agent) induced_13\VBN|by (r_acl) catalepsy_12\NN|the|induced
D015647_D002375 NONE 38393_5\CD| (r_nummod) SKF_4\NNP|3|d-1|agonist|38393|or|agonist (r_nmod) quinpirole_9\NN|skf (r_nsubj) decreased_10\VBD|quinpirole|catalepsy|. (l_dobj) catalepsy_12\NN|the|induced
D015647_D002375 NONE 38393_3\CD| (r_nummod) SKF_2\NNP|38393 (r_pobj) of_1\IN|skf (r_prep) Combination_0\NN|of|with (r_nsubj) cause_8\VB|combination|did|not|potentiated|. (l_ccomp) potentiated_9\VBN|effect (l_dobj) effect_11\NN|inhibitory|on|induced (l_prep) on_12\IN|catalepsy (l_pobj) catalepsy_13\NN|
D019257_D002375 NONE quinpirole_9\NN|skf (r_nsubj) decreased_10\VBD|quinpirole|catalepsy|. (l_dobj) catalepsy_12\NN|the|induced
D019257_D002375 NONE quinpirole_5\NN| (r_pobj) with_4\IN|quinpirole (r_prep) Combination_0\NN|of|with (r_nsubj) cause_8\VB|combination|did|not|potentiated|. (l_ccomp) potentiated_9\VBN|effect (l_dobj) effect_11\NN|inhibitory|on|induced (l_prep) on_12\IN|catalepsy (l_pobj) catalepsy_13\NN|
3780697
D005283_D009127 CID fentanyl_5\NN| (r_compound) administration_6\NN|fentanyl (r_pobj) after_4\IN|administration (r_prep) rigidity_3\NN|operative|after|.
D005283_D009127 CID fentanyl_29\NN| (r_pobj) of_28\IN|fentanyl (r_prep) dose_27\NN|a|moderate|of (r_dobj) received_24\VBD|who|dose (r_relcl) patient_22\NN|an|elderly|received (r_pobj) in_19\IN|patient (r_prep) period_18\NN|the|operative|in (r_pobj) in_13\IN|period (r_prep) described_12\VBN|case|is|in|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|rigidity (l_pobj) rigidity_6\NN|abdominal|leading
D005283_D012131 NONE fentanyl_29\NN| (r_pobj) of_28\IN|fentanyl (r_prep) dose_27\NN|a|moderate|of (r_dobj) received_24\VBD|who|dose (r_relcl) patient_22\NN|an|elderly|received (r_pobj) in_19\IN|patient (r_prep) period_18\NN|the|operative|in (r_pobj) in_13\IN|period (r_prep) described_12\VBN|case|is|in|. (l_nsubjpass) case_1\NN|a|of (l_prep) of_2\IN|rigidity (l_pobj) rigidity_6\NN|abdominal|leading (l_acl) leading_7\VBG|to (l_prep) to_8\IN|failure (l_pobj) failure_10\NN|respiratory
6892185
D002122_D015878 NONE chloride_4\NN|calcium (r_pobj) of_2\IN|chloride (r_prep) effect_1\NN|the|of (r_nsubj) injected_5\VBD|effect|into|upon|)|,|fighting|injected (l_advcl) fighting_26\VBG|attack|,|mydriasis (l_conj) mydriasis_43\NN|,|tremor
D002122_D015878 NONE chloride_24\NN|calcium (r_pobj) by_22\IN|chloride (r_agent) changed_21\VBN|on|,|mydriasis|were|not|significantly|by|. (l_nsubjpass) mydriasis_5\NN|,|tremor|evoked
D002122_D015878 NONE chloride_5\NN|calcium (r_nsubj) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor
D002122_D014202 NONE chloride_4\NN|calcium (r_pobj) of_2\IN|chloride (r_prep) effect_1\NN|the|of (r_nsubj) injected_5\VBD|effect|into|upon|)|,|fighting|injected (l_advcl) fighting_26\VBG|attack|,|mydriasis (l_conj) mydriasis_43\NN|,|tremor (l_conj) tremor_45\NN|and|convulsions
D002122_D014202 NONE chloride_24\NN|calcium (r_pobj) by_22\IN|chloride (r_agent) changed_21\VBN|on|,|mydriasis|were|not|significantly|by|. (l_nsubjpass) mydriasis_5\NN|,|tremor|evoked (l_conj) tremor_7\NN|and|convulsions
D002122_D014202 NONE chloride_5\NN|calcium (r_nsubj) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor (l_conj) tremor_22\NN|and|convulsions
D002122_D004830 NONE chloride_4\NN|calcium (r_pobj) of_2\IN|chloride (r_prep) effect_1\NN|the|of (r_nsubj) injected_5\VBD|effect|into|upon|)|,|fighting|injected (l_advcl) fighting_26\VBG|attack|,|mydriasis (l_conj) mydriasis_43\NN|,|tremor (l_conj) tremor_45\NN|and|convulsions (l_conj) convulsions_50\NNS|tonic|produced
D002122_D004830 NONE chloride_24\NN|calcium (r_pobj) by_22\IN|chloride (r_agent) changed_21\VBN|on|,|mydriasis|were|not|significantly|by|. (l_nsubjpass) mydriasis_5\NN|,|tremor|evoked (l_conj) tremor_7\NN|and|convulsions (l_conj) convulsions_12\NNS|tonic
D002122_D004830 NONE chloride_5\NN|calcium (r_nsubj) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor (l_conj) tremor_22\NN|and|convulsions (l_conj) convulsions_27\NNS|tonic
D002217_D015878 CID carbachol_53\NN|and|eserine (r_pobj) by_52\IN|carbachol (r_agent) produced_51\VBN|by (r_acl) convulsions_50\NNS|tonic|produced (r_conj) tremor_45\NN|and|convulsions (r_conj) mydriasis_43\NN|,|tremor
D002217_D015878 CID carbachol_15\NN|and|eserine (r_pobj) by_14\IN|carbachol (r_agent) evoked_13\VBN|by (r_acl) mydriasis_5\NN|,|tremor|evoked
D002217_D015878 CID carbachol_30\NN|and|eserine (r_pobj) by_29\IN|carbachol (r_agent) caused_28\VBN|by (r_acl) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor
D002217_D014202 CID carbachol_53\NN|and|eserine (r_pobj) by_52\IN|carbachol (r_agent) produced_51\VBN|by (r_acl) convulsions_50\NNS|tonic|produced (r_conj) tremor_45\NN|and|convulsions
D002217_D014202 CID carbachol_15\NN|and|eserine (r_pobj) by_14\IN|carbachol (r_agent) evoked_13\VBN|by (r_acl) mydriasis_5\NN|,|tremor|evoked (l_conj) tremor_7\NN|and|convulsions
D002217_D014202 CID carbachol_30\NN|and|eserine (r_pobj) by_29\IN|carbachol (r_agent) caused_28\VBN|by (r_acl) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor (l_conj) tremor_22\NN|and|convulsions
D002217_D004830 CID carbachol_53\NN|and|eserine (r_pobj) by_52\IN|carbachol (r_agent) produced_51\VBN|by (r_acl) convulsions_50\NNS|tonic|produced
D002217_D004830 CID carbachol_15\NN|and|eserine (r_pobj) by_14\IN|carbachol (r_agent) evoked_13\VBN|by (r_acl) mydriasis_5\NN|,|tremor|evoked (l_conj) tremor_7\NN|and|convulsions (l_conj) convulsions_12\NNS|tonic
D002217_D004830 CID carbachol_30\NN|and|eserine (r_pobj) by_29\IN|carbachol (r_agent) caused_28\VBN|by (r_acl) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor (l_conj) tremor_22\NN|and|convulsions (l_conj) convulsions_27\NNS|tonic
D010830_D015878 CID eserine_55\NN| (r_conj) carbachol_53\NN|and|eserine (r_pobj) by_52\IN|carbachol (r_agent) produced_51\VBN|by (r_acl) convulsions_50\NNS|tonic|produced (r_conj) tremor_45\NN|and|convulsions (r_conj) mydriasis_43\NN|,|tremor
D010830_D015878 CID eserine_17\NN| (r_conj) carbachol_15\NN|and|eserine (r_pobj) by_14\IN|carbachol (r_agent) evoked_13\VBN|by (r_acl) mydriasis_5\NN|,|tremor|evoked
D010830_D015878 CID eserine_32\NN| (r_conj) carbachol_30\NN|and|eserine (r_pobj) by_29\IN|carbachol (r_agent) caused_28\VBN|by (r_acl) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor
D010830_D014202 CID eserine_55\NN| (r_conj) carbachol_53\NN|and|eserine (r_pobj) by_52\IN|carbachol (r_agent) produced_51\VBN|by (r_acl) convulsions_50\NNS|tonic|produced (r_conj) tremor_45\NN|and|convulsions
D010830_D014202 CID eserine_17\NN| (r_conj) carbachol_15\NN|and|eserine (r_pobj) by_14\IN|carbachol (r_agent) evoked_13\VBN|by (r_acl) mydriasis_5\NN|,|tremor|evoked (l_conj) tremor_7\NN|and|convulsions
D010830_D014202 CID eserine_32\NN| (r_conj) carbachol_30\NN|and|eserine (r_pobj) by_29\IN|carbachol (r_agent) caused_28\VBN|by (r_acl) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor (l_conj) tremor_22\NN|and|convulsions
D010830_D004830 CID eserine_55\NN| (r_conj) carbachol_53\NN|and|eserine (r_pobj) by_52\IN|carbachol (r_agent) produced_51\VBN|by (r_acl) convulsions_50\NNS|tonic|produced
D010830_D004830 CID eserine_17\NN| (r_conj) carbachol_15\NN|and|eserine (r_pobj) by_14\IN|carbachol (r_agent) evoked_13\VBN|by (r_acl) mydriasis_5\NN|,|tremor|evoked (l_conj) tremor_7\NN|and|convulsions (l_conj) convulsions_12\NNS|tonic
D010830_D004830 CID eserine_32\NN| (r_conj) carbachol_30\NN|and|eserine (r_pobj) by_29\IN|carbachol (r_agent) caused_28\VBN|by (r_acl) dissociate_8\VB|that|chloride|can|"|"|vocalization|from|caused (l_prep) from_13\IN|phenomena (l_pobj) phenomena_17\NNS|autonomic|as (l_prep) as_19\IN|such|mydriasis (l_pobj) mydriasis_20\NN|,|tremor (l_conj) tremor_22\NN|and|convulsions (l_conj) convulsions_27\NNS|tonic
11860495
D013256_D000647 NONE Steroid_0\NN| (r_compound) structure_1\NN|steroid|and|properties (r_nsubj) determine_5\VBP|structure|effects|. (l_dobj) effects_10\NNS|the|amnesic|of|in (l_amod) amnesic_9\JJ|anti|-
C018370_D000647 NONE sulphate_13\NN|pregnenolone (r_pobj) of_11\IN|sulphate (r_prep) effects_10\NNS|the|amnesic|of|in (l_amod) amnesic_9\JJ|anti|-
C018370_D000647 NONE PREGS_2\NNP| (r_nsubj) is_3\VBZ|moreover|,|pregs|able|. (l_acomp) able_4\JJ|reverse (l_xcomp) reverse_6\VB|to|effects (l_dobj) effects_11\NNS|the|like|of (l_amod) like_10\JJ|amnesic|- (l_amod) amnesic_8\JJ|
C018370_D000647 NONE PREGS_6\NNP|and|analogs (r_pobj) of_5\IN|pregs (r_prep) effects_4\NNS|the|enhancing|of (r_nsubjpass) tested_11\VBN|effects|were|in|. (l_prep) in_12\IN|task (l_pobj) task_16\NN|the|passive|avoidance|using (l_acl) using_17\VBG|model (l_dobj) model_19\NN|the|of (l_prep) of_20\IN|amnesia (l_pobj) amnesia_24\NN|induced
C018370_D000647 NONE PREGS_10\NNP|natural (r_pobj) of_8\IN|pregs (r_prep) ability_7\NN|the|of|be (l_acl) be_12\VB|to|order (l_attr) order_14\NN|an|of|effective (l_amod) effective_18\JJ|more|than (l_prep) than_19\IN|enantiomer (l_pobj) enantiomer_22\NN|its|synthetic|in (l_prep) in_23\IN|reversing (l_pcomp) reversing_24\VBG|amnesia (l_dobj) amnesia_28\NN|induced
D005680_D000647 NONE GABA(A)R_15\NNP| (r_compound) ligands_16\NNS|gaba(a)r (r_conj) NMDAR_13\NNP|and|ligands (r_pobj) of_12\IN|nmdar (r_prep) effects_11\NNS|the|like|of (l_amod) like_10\JJ|amnesic|- (l_amod) amnesic_8\JJ|
D012601_D000647 CID scopolamine_21\NN| (r_npadvmod) induced_23\VBN|scopolamine|- (r_amod) amnesia_24\NN|induced
D012601_D000647 CID scopolamine_25\NN| (r_npadvmod) induced_27\VBN|scopolamine|- (r_amod) amnesia_28\NN|induced
17194457
-1_D001523 NONE PCPA_3\NNP| (r_pobj) to_2\IN|pcpa (r_prep) exposure_1\NN|chronic|to|alone (r_nsubj) decreased_6\VBD|exposure|significantly|activity|and|increased|but|had|. (l_conj) increased_10\VBN|irritability (l_dobj) irritability_11\NN|
-1_D001523 NONE PCPA_3\NNP| (r_pobj) to_2\IN|pcpa (r_prep) exposure_1\NN|chronic|to|alone (r_nsubj) decreased_6\VBD|exposure|significantly|activity|and|increased|but|had|. (l_conj) had_13\VBD|effect (l_dobj) effect_15\NN|no|on (l_prep) on_16\IN|behavior (l_pobj) behavior_18\NN|sexual|,|preference (l_conj) preference_21\NN|partner|,|or|aggression (l_conj) aggression_24\NN|
D013739_D001523 CID T_0\NNP|alone (r_nsubj) had_2\VBD|t|effect|but|preference|. (l_dobj) effect_4\NN|no|on (l_prep) on_5\IN|locomotion (l_pobj) locomotion_6\NN|,|irritability (l_conj) irritability_8\NN|,|or|behavior
D013739_D001523 CID T_0\NNP|alone (r_nsubj) had_2\VBD|t|effect|but|preference|. (l_conj) preference_16\NN|increased|partner|and|aggression (l_conj) aggression_18\NN|
D012701_D001523 NONE 5-HT_16\CD|central (r_pobj) with_13\IN|5-ht (r_prep) users_12\NNS|pubertal|aas|with (r_nsubj) be_18\VB|that|users|may|prone (l_acomp) prone_20\JJ|especially|exhibit (l_xcomp) exhibit_22\VB|to|behavior (l_dobj) behavior_24\NN|aggressive
11208990
D009569_D007674 NONE oxide_3\NN|nitric (r_compound) production_4\NN|oxide (r_pobj) of_1\IN|production (r_prep) Association_0\NN|of|and|apoptosis|. (l_conj) apoptosis_6\NN|in (l_prep) in_7\IN|model (l_pobj) model_9\NN|a|of (l_prep) of_10\IN|nephropathy (l_pobj) nephropathy_12\NN|experimental
D009569_D009404 NONE NO_6\DT|and (r_intj) of_5\IN|no|association (l_pobj) association_9\NN|its|with (l_prep) with_10\IN|apoptosis (l_pobj) apoptosis_11\NN|in (l_prep) in_12\IN|model (l_pobj) model_15\NN|an|experimental|of|induced (l_prep) of_16\IN|syndrome (l_pobj) syndrome_18\NN|nephrotic
D004317_D009404 CID adriamycin_25\NNS|(|adr|) (r_pobj) of_24\IN|adriamycin (r_prep) injection_23\NN|a|single|of (r_pobj) by_20\IN|injection (r_agent) induced_19\VBN|by (r_acl) model_15\NN|an|experimental|of|induced (l_prep) of_16\IN|syndrome (l_pobj) syndrome_18\NN|nephrotic
D004317_D009404 CID ADR_27\NNP| (r_appos) adriamycin_25\NNS|(|adr|) (r_pobj) of_24\IN|adriamycin (r_prep) injection_23\NN|a|single|of (r_pobj) by_20\IN|injection (r_agent) induced_19\VBN|by (r_acl) model_15\NN|an|experimental|of|induced (l_prep) of_16\IN|syndrome (l_pobj) syndrome_18\NN|nephrotic
D004317_D007674 NONE ADR_7\NNP| (r_npadvmod) induced_9\VBN|adr|- (r_amod) nephropathy_10\NN|induced
D004317_D007674 NONE ADR_8\NNP| (r_compound) nephropathy_10\NN|adr|-
D004317_D007674 NONE ADR_13\NNP| (r_compound) nephropathy_15\NN|adr|-
D004317_D007674 NONE ADR_4\NNP| (r_compound) nephropathy_6\NN|adr|-
D004317_C537346 NONE ADR_9\NNP| (r_pobj) with_8\IN|adr (r_prep) treated_7\VBN|with (r_acl) rats_6\NNS|treated (r_pobj) of_5\IN|rats (r_prep) kidneys_4\NNS|the|of (r_pobj) of_2\IN|kidneys (r_prep) examination_1\NN|histopathological|of (r_nsubj) revealed_10\VBD|examination|areas|. (l_dobj) areas_12\NNS|focal|of (l_prep) of_13\IN|proliferation (l_pobj) proliferation_15\NN|mesangial|and|inflammation
D004317_D009395 NONE ADR_9\NNP| (r_pobj) with_8\IN|adr (r_prep) treated_7\VBN|with (r_acl) rats_6\NNS|treated (r_pobj) of_5\IN|rats (r_prep) kidneys_4\NNS|the|of (r_pobj) of_2\IN|kidneys (r_prep) examination_1\NN|histopathological|of (r_nsubj) revealed_10\VBD|examination|areas|. (l_dobj) areas_12\NNS|focal|of (l_prep) of_13\IN|proliferation (l_pobj) proliferation_15\NN|mesangial|and|inflammation (l_conj) inflammation_19\NN|mild|tubulointerstitial
D009573_D007674 NONE nitrite_1\NN| (r_compound) levels_2\NNS|urine|nitrite (r_nsubjpass) increased_5\VBN|levels|were|significantly|in|. (l_prep) in_6\IN|group (l_pobj) group_11\NN|the|nephropathy|(|p|) (l_compound) nephropathy_10\NN|adr|-
D010656_D007674 NONE phenylephrine_3\NN|iprk|and|related (r_nmod) responses_7\NNS|the|phenylephrine (r_pobj) In_0\IN|responses (r_prep) were_8\VBD|in|impaired|. (l_acomp) impaired_10\VBN|significantly|in (l_prep) in_11\IN|group (l_pobj) group_16\NN|the|nephropathy (l_compound) nephropathy_15\NN|adr|-
D000109_D007674 NONE acetylcholine_5\NN| (r_npadvmod) related_6\VBN|acetylcholine (r_conj) phenylephrine_3\NN|iprk|and|related (r_nmod) responses_7\NNS|the|phenylephrine (r_pobj) In_0\IN|responses (r_prep) were_8\VBD|in|impaired|. (l_acomp) impaired_10\VBN|significantly|in (l_prep) in_11\IN|group (l_pobj) group_16\NN|the|nephropathy (l_compound) nephropathy_15\NN|adr|-
D009569_D009401 NONE NO_5\UH|and|apoptosis (r_intj) between_4\IN|no (r_prep) interactions_3\NNS|between (r_nsubj) are_8\VBP|that|interactions|important|in (l_prep) in_10\IN|pathogenesis (l_pobj) pathogenesis_12\NN|the|of (l_prep) of_13\IN|nephrosis (l_pobj) nephrosis_18\NN|the|induced
D004317_D009401 NONE ADR_15\NNP| (r_npadvmod) induced_17\VBN|adr|- (r_amod) nephrosis_18\NN|the|induced
1969772
D018818_D007022 CID fenoldopam_9\NN| (r_pobj) with_8\IN|fenoldopam (r_prep) induced_7\VBN|preservation|with|in|. (l_nsubj) Preservation_0\NN|of|during (l_prep) during_5\IN|hypotension (l_pobj) hypotension_6\NN|
D018818_D007022 CID fenoldopam_3\NN|that (r_relcl) hypothesis_1\NN|the|fenoldopam (r_nsubjpass) used_6\VBN|hypothesis|could|be|induce|tested|. (l_xcomp) induce_8\VB|to|hypotension|and|preserve (l_dobj) hypotension_9\NN|
D018818_D007022 CID fenoldopam_8\NN| (r_npadvmod) induced_10\VBN|fenoldopam|- (r_amod) hypotension_11\NN|induced|11|+/-|7
D018818_D007022 CID fenoldopam_8\NN| (r_npadvmod) induced_10\VBN|fenoldopam|- (r_amod) hypotension_11\NN|induced|11|+/-|7 (r_pobj) during_7\IN|hypotension (r_prep) increased_6\VBD|flow|during|and|decreased|. (l_conj) decreased_18\VBD|+/-|8|during (l_prep) during_24\IN|hypotension (l_pobj) hypotension_29\NN|sodium|induced|(|p|)
D012964_D007022 NONE sodium_25\NN| (r_amod) hypotension_29\NN|sodium|induced|(|p|) (r_pobj) during_24\IN|hypotension (r_prep) decreased_18\VBD|+/-|8|during (r_conj) increased_6\VBD|flow|during|and|decreased|. (l_prep) during_7\IN|hypotension (l_pobj) hypotension_11\NN|induced|11|+/-|7
D012964_D007022 NONE sodium_25\NN| (r_amod) hypotension_29\NN|sodium|induced|(|p|)
D009599_D007022 CID nitroprusside_26\RB| (r_advmod) induced_28\VBN|nitroprusside|- (r_amod) hypotension_29\NN|sodium|induced|(|p|) (r_pobj) during_24\IN|hypotension (r_prep) decreased_18\VBD|+/-|8|during (r_conj) increased_6\VBD|flow|during|and|decreased|. (l_prep) during_7\IN|hypotension (l_pobj) hypotension_11\NN|induced|11|+/-|7
D009599_D007022 CID nitroprusside_26\RB| (r_advmod) induced_28\VBN|nitroprusside|- (r_amod) hypotension_29\NN|sodium|induced|(|p|)
D009599_D007022 CID nitroprusside_1\NN|sodium (r_nsubj) is_2\VBZ|nitroprusside|vasodilator|. (l_attr) vasodilator_10\NN|arteriolar|venous|produce (l_relcl) produce_13\VB|that|can|redistribution|during (l_prep) during_22\IN|hypotension (l_pobj) hypotension_24\NN|induced
D004298_D007022 NONE dopamine-1_4\NNS| (r_punct) agonist_9\NN|a|selective|dopamine-1|receptor|causes (l_relcl) causes_11\VBZ|that|vasodilatation|to|and|preserves (l_conj) preserves_23\VBZ|flow|during (l_prep) during_29\IN|hypotension (l_pobj) hypotension_31\NN|induced
9061311
D013481_D017114 NONE superoxide_1\NN|and|peroxide (r_nmod) production_5\NN|neutrophil|superoxide|in|. (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|failure (l_pobj) failure_11\NN|acute|liver
D013481_D017114 NONE superoxide_2\NN|and (r_amod) production_6\NN|superoxide|peroxide (r_pobj) in_1\IN|production (r_prep) Defects_0\NNS|in (r_nsubjpass) implicated_9\VBN|defects|may|be|in|. (l_prep) in_10\IN|incidence (l_pobj) incidence_13\NN|the|high|of (l_prep) of_14\IN|infections (l_pobj) infections_16\NNS|bacterial|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|failure (l_pobj) failure_22\NN|acute|liver|(|alf|)
D013481_D017114 NONE superoxide_2\NN|and (r_amod) production_6\NN|superoxide|peroxide (r_pobj) in_1\IN|production (r_prep) Defects_0\NNS|in (r_nsubjpass) implicated_9\VBN|defects|may|be|in|. (l_prep) in_10\IN|incidence (l_pobj) incidence_13\NN|the|high|of (l_prep) of_14\IN|infections (l_pobj) infections_16\NNS|bacterial|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|failure (l_pobj) failure_22\NN|acute|liver|(|alf|) (l_appos) ALF_24\NNP|
D013481_D017114 NONE Superoxide_0\NN|and|production|by (l_prep) by_5\IN|neutrophils (l_pobj) neutrophils_7\NNS|alf (l_compound) ALF_6\NNP|
D013481_D017114 NONE Superoxide_0\NN|and|production|by (r_nsubj) stimulated_8\VBN|superoxide|with|opsonized|reduced|. (l_dobj) opsonized_11\VBN|with (l_prep) with_12\IN|serum (l_pobj) serum_14\NN|alf (l_compound) ALF_13\NNP|
D013481_D017114 NONE Superoxide_0\NN|and|production|in (l_prep) in_5\IN|neutrophils (l_pobj) neutrophils_6\NNS|stimulated (l_acl) stimulated_7\VBN|with|from (l_prep) from_19\IN|patients (l_pobj) patients_24\NNS|a|further|18|alf (l_compound) ALF_23\NNP|
D006861_D017114 NONE peroxide_4\NN|hydrogen (r_conj) superoxide_1\NN|and|peroxide (r_nmod) production_5\NN|neutrophil|superoxide|in|. (l_prep) in_6\IN|patients (l_pobj) patients_7\NNS|with (l_prep) with_8\IN|failure (l_pobj) failure_11\NN|acute|liver
D006861_D017114 NONE peroxide_5\NN|hydrogen (r_compound) production_6\NN|superoxide|peroxide (r_pobj) in_1\IN|production (r_prep) Defects_0\NNS|in (r_nsubjpass) implicated_9\VBN|defects|may|be|in|. (l_prep) in_10\IN|incidence (l_pobj) incidence_13\NN|the|high|of (l_prep) of_14\IN|infections (l_pobj) infections_16\NNS|bacterial|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|failure (l_pobj) failure_22\NN|acute|liver|(|alf|)
D006861_D017114 NONE peroxide_5\NN|hydrogen (r_compound) production_6\NN|superoxide|peroxide (r_pobj) in_1\IN|production (r_prep) Defects_0\NNS|in (r_nsubjpass) implicated_9\VBN|defects|may|be|in|. (l_prep) in_10\IN|incidence (l_pobj) incidence_13\NN|the|high|of (l_prep) of_14\IN|infections (l_pobj) infections_16\NNS|bacterial|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|failure (l_pobj) failure_22\NN|acute|liver|(|alf|) (l_appos) ALF_24\NNP|
D006861_D017114 NONE peroxide_3\NN|hydrogen (r_compound) production_4\NN|peroxide (r_conj) Superoxide_0\NN|and|production|by (l_prep) by_5\IN|neutrophils (l_pobj) neutrophils_7\NNS|alf (l_compound) ALF_6\NNP|
D006861_D017114 NONE peroxide_3\NN|hydrogen (r_compound) production_4\NN|peroxide (r_conj) Superoxide_0\NN|and|production|by (r_nsubj) stimulated_8\VBN|superoxide|with|opsonized|reduced|. (l_dobj) opsonized_11\VBN|with (l_prep) with_12\IN|serum (l_pobj) serum_14\NN|alf (l_compound) ALF_13\NNP|
D006861_D017114 NONE peroxide_3\NN|hydrogen (r_compound) production_4\NN|peroxide (r_conj) Superoxide_0\NN|and|production|in (l_prep) in_5\IN|neutrophils (l_pobj) neutrophils_6\NNS|stimulated (l_acl) stimulated_7\VBN|with|from (l_prep) from_19\IN|patients (l_pobj) patients_24\NNS|a|further|18|alf (l_compound) ALF_23\NNP|
D013481_D001424 NONE superoxide_2\NN|and (r_amod) production_6\NN|superoxide|peroxide (r_pobj) in_1\IN|production (r_prep) Defects_0\NNS|in (r_nsubjpass) implicated_9\VBN|defects|may|be|in|. (l_prep) in_10\IN|incidence (l_pobj) incidence_13\NN|the|high|of (l_prep) of_14\IN|infections (l_pobj) infections_16\NNS|bacterial|in
D006861_D001424 NONE peroxide_5\NN|hydrogen (r_compound) production_6\NN|superoxide|peroxide (r_pobj) in_1\IN|production (r_prep) Defects_0\NNS|in (r_nsubjpass) implicated_9\VBN|defects|may|be|in|. (l_prep) in_10\IN|incidence (l_pobj) incidence_13\NN|the|high|of (l_prep) of_14\IN|infections (l_pobj) infections_16\NNS|bacterial|in
D010100_D017114 NONE oxygen_5\NN| (r_nmod) production_7\NN|oxygen|radical|in|due (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|alf (l_pobj) ALF_11\NNP|
D010100_D062787 NONE oxygen_5\NN| (r_nmod) production_7\NN|oxygen|radical|in|due (l_amod) due_12\IN|to|overdose (l_pobj) overdose_15\NN|paracetamol
D000082_D017114 CID paracetamol_14\JJ| (r_compound) overdose_15\NN|paracetamol (r_pobj) due_12\IN|to|overdose (r_amod) production_7\NN|oxygen|radical|in|due (l_prep) in_8\IN|patients (l_pobj) patients_9\NNS|with (l_prep) with_10\IN|alf (l_pobj) ALF_11\NNP|
D000082_D017114 CID paracetamol_10\JJ| (r_compound) overdose_11\NN|paracetamol (r_pobj) due_8\IN|to|overdose (r_prep) demonstrate_2\VBP|results|defect|due|,|complement|. (l_dobj) defect_5\NN|a|neutrophil|in (l_prep) in_6\IN|alf (l_pobj) ALF_7\NNP|
D000082_D062787 NONE paracetamol_14\JJ| (r_compound) overdose_15\NN|paracetamol
D000082_D062787 NONE paracetamol_10\JJ| (r_compound) overdose_11\NN|paracetamol
D009240_D017114 NONE phenylalanine_15\NN|methionyl|leucyl|- (r_nmod) fMLP_17\NN|phenylalanine|(|) (r_pobj) with_8\IN|fmlp (r_prep) stimulated_7\VBN|with|from (l_prep) from_19\IN|patients (l_pobj) patients_24\NNS|a|further|18|alf (l_compound) ALF_23\NNP|
D009240_D017114 NONE fMLP_17\NN|phenylalanine|(|) (r_pobj) with_8\IN|fmlp (r_prep) stimulated_7\VBN|with|from (l_prep) from_19\IN|patients (l_pobj) patients_24\NNS|a|further|18|alf (l_compound) ALF_23\NNP|
7752389
D015232_D053201 CID E2-induced_1\JJ| (r_amod) hyperactivity_3\NN|prostaglandin|e2-induced|bladder|in|?
D015320_D053201 NONE tachykinins_12\NNS| (r_pobj) of_11\IN|tachykinins (r_prep) involvement_10\NN|of (r_appos) rats_8\NNS|normal|,|conscious|:|involvement (r_pobj) in_4\IN|rats (r_prep) hyperactivity_3\NN|prostaglandin|e2-induced|bladder|in|?
D015320_D053201 NONE tachykinins_6\NNS| (r_pobj) of_5\IN|tachykinins (r_prep) release_4\NN|of (r_pobj) via_3\IN|release (r_prep) contribute_8\VBP|prostanoids|may|,|via|,|to|. (l_prep) to_9\IN|urge (l_pobj) urge_11\VB|both|and|hyperactivity|seen (l_conj) hyperactivity_14\NN|bladder
D011453_D053201 NONE Prostanoids_0\NNS| (r_nsubj) contribute_8\VBP|prostanoids|may|,|via|,|to|. (l_prep) to_9\IN|urge (l_pobj) urge_11\VB|both|and|hyperactivity|seen (l_conj) hyperactivity_14\NN|bladder
8638876
D011374_D006261 NONE progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (r_conj) developed_9\VBD|woman|headache|,|left|. (l_dobj) headache_10\NN|,|nausea
D011374_D009325 NONE progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (r_conj) developed_9\VBD|woman|headache|,|left|. (l_dobj) headache_10\NN|,|nausea (l_conj) nausea_12\NN|and|vomiting
D011374_D014839 NONE progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (r_conj) developed_9\VBD|woman|headache|,|left|. (l_dobj) headache_10\NN|,|nausea (l_conj) nausea_12\NN|and|vomiting (l_conj) vomiting_14\NN|
D011374_D010291 NONE progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (l_dobj) hemiparesis_17\NN|and|seizure
D011374_D012640 NONE progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (l_dobj) hemiparesis_17\NN|and|seizure (l_conj) seizure_19\NN|
D004958_D006261 NONE estradiol_28\NN| (r_conj) progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (r_conj) developed_9\VBD|woman|headache|,|left|. (l_dobj) headache_10\NN|,|nausea
D004958_D009325 NONE estradiol_28\NN| (r_conj) progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (r_conj) developed_9\VBD|woman|headache|,|left|. (l_dobj) headache_10\NN|,|nausea (l_conj) nausea_12\NN|and|vomiting
D004958_D014839 NONE estradiol_28\NN| (r_conj) progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (r_conj) developed_9\VBD|woman|headache|,|left|. (l_dobj) headache_10\NN|,|nausea (l_conj) nausea_12\NN|and|vomiting (l_conj) vomiting_14\NN|
D004958_D010291 NONE estradiol_28\NN| (r_conj) progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (l_dobj) hemiparesis_17\NN|and|seizure
D004958_D012640 NONE estradiol_28\NN| (r_conj) progesterone_26\NN|and|estradiol (r_pobj) of_25\IN|progesterone (r_prep) use_24\NN|parenteral|of (r_pobj) after_22\IN|days|use (r_prep) left_16\VBD|hemiparesis|after (l_dobj) hemiparesis_17\NN|and|seizure (l_conj) seizure_19\NN|
D004958_D003920 NONE estradiol_11\NN|and|progesterone (r_pobj) of_10\IN|estradiol (r_prep) use_9\NN|the|of|and|dm (l_conj) DM_17\NNP|the|underlying
D004958_D002341 CID estradiol_11\NN|and|progesterone (r_pobj) of_10\IN|estradiol (r_prep) use_9\NN|the|of|and|dm (r_nsubj) increased_18\VBD|that|use|thrombogenicity (l_dobj) thrombogenicity_20\NN|vascular|,|provided (l_relcl) provided_23\VBD|which|denominator (l_dobj) denominator_26\NN|a|common|for (l_prep) for_27\IN|thrombosis (l_pobj) thrombosis_28\NN|of (l_prep) of_29\IN|ica (l_pobj) ICA_32\NNP|both|the|and|sinus (l_conj) sinus_36\NN|the|venous
D004958_D012851 CID estradiol_11\NN|and|progesterone (r_pobj) of_10\IN|estradiol (r_prep) use_9\NN|the|of|and|dm (r_nsubj) increased_18\VBD|that|use|thrombogenicity (l_dobj) thrombogenicity_20\NN|vascular|,|provided (l_relcl) provided_23\VBD|which|denominator (l_dobj) denominator_26\NN|a|common|for (l_prep) for_27\IN|thrombosis (l_pobj) thrombosis_28\NN|of (l_prep) of_29\IN|ica (l_pobj) ICA_32\NNP|both|the|and|sinus (l_conj) sinus_36\NN|the|venous
D011374_D003920 NONE progesterone_13\NN| (r_conj) estradiol_11\NN|and|progesterone (r_pobj) of_10\IN|estradiol (r_prep) use_9\NN|the|of|and|dm (l_conj) DM_17\NNP|the|underlying
D011374_D002341 CID progesterone_13\NN| (r_conj) estradiol_11\NN|and|progesterone (r_pobj) of_10\IN|estradiol (r_prep) use_9\NN|the|of|and|dm (r_nsubj) increased_18\VBD|that|use|thrombogenicity (l_dobj) thrombogenicity_20\NN|vascular|,|provided (l_relcl) provided_23\VBD|which|denominator (l_dobj) denominator_26\NN|a|common|for (l_prep) for_27\IN|thrombosis (l_pobj) thrombosis_28\NN|of (l_prep) of_29\IN|ica (l_pobj) ICA_32\NNP|both|the|and|sinus (l_conj) sinus_36\NN|the|venous
D011374_D012851 CID progesterone_13\NN| (r_conj) estradiol_11\NN|and|progesterone (r_pobj) of_10\IN|estradiol (r_prep) use_9\NN|the|of|and|dm (r_nsubj) increased_18\VBD|that|use|thrombogenicity (l_dobj) thrombogenicity_20\NN|vascular|,|provided (l_relcl) provided_23\VBD|which|denominator (l_dobj) denominator_26\NN|a|common|for (l_prep) for_27\IN|thrombosis (l_pobj) thrombosis_28\NN|of (l_prep) of_29\IN|ica (l_pobj) ICA_32\NNP|both|the|and|sinus (l_conj) sinus_36\NN|the|venous
15266215
C406224_D013927 NONE valdecoxib_6\NNS|the|cyclooxygenase-2|specific|inhibitor|versus (l_prep) versus_7\IN|agents (l_pobj) agents_10\NNS|nonsteroidal|antiinflammatory|and|placebo (l_conj) placebo_12\NN|on (l_prep) on_13\IN|events (l_pobj) events_16\NNS|cardiovascular|thrombotic|in (l_amod) thrombotic_15\JJ|
C406224_D013927 NONE valdecoxib_23\NNS|pooled|daily|) (r_dobj) analyzing_21\VBG|valdecoxib (r_pcomp) by_20\IN|analyzing (r_prep) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_amod) thrombotic_4\JJ|
C406224_D013927 NONE valdecoxib_23\NNS|pooled|daily|) (r_dobj) analyzing_21\VBG|valdecoxib (r_pcomp) by_20\IN|analyzing (r_prep) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_appos) thrombotic_16\JJ|cardiac
C406224_D013927 NONE valdecoxib_12\NNS|,|nsaids (r_pobj) for_11\IN|valdecoxib (r_prep) similar_10\JJ|for (r_acomp) were_9\VBD|incidences|similar|. (l_nsubj) incidences_5\NNS|crude|adjusted|of (l_prep) of_6\IN|events (l_pobj) events_8\NNS|thrombotic (l_amod) thrombotic_7\JJ|
C406224_D013927 NONE valdecoxib_11\NN| (r_compound) dose_12\NN|each|valdecoxib (r_pobj) for_9\IN|dose (r_prep) similar_8\JJ|for (r_acomp) was_6\VBD|risk|also|similar|. (l_nsubj) risk_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|serious|thrombotic (l_amod) thrombotic_4\JJ|
C406224_D013927 NONE valdecoxib_23\NN|,|%|;|nsaids (r_conj) placebo_15\NN|,|%|;|valdecoxib (r_appos) nonusers_11\NNS|of|(|placebo|) (r_pobj) than_10\IN|nonusers (r_prep) users_9\NNS|aspirin|than (r_pobj) of_7\IN|users (r_prep) users_6\NNS|of (r_pobj) for_5\IN|users (r_prep) was_2\VBD|risk|higher|for|. (l_nsubj) risk_1\NN|thrombotic (l_amod) Thrombotic_0\JJ|
C406224_D013927 NONE valdecoxib_24\NN| (r_compound) doses_25\NNS|valdecoxib (r_conj) treatment_5\NN|short-|term|with|doses (r_nsubjpass) associated_28\VBN|treatment|was|not|with|. (l_prep) with_29\IN|incidence (l_pobj) incidence_32\NN|an|increased|of (l_prep) of_33\IN|events (l_pobj) events_35\NNS|thrombotic|relative (l_amod) thrombotic_34\JJ|
C406224_D001168 NONE valdecoxib_6\NNS|the|cyclooxygenase-2|specific|inhibitor|versus (l_prep) versus_7\IN|agents (l_pobj) agents_10\NNS|nonsteroidal|antiinflammatory|and|placebo (l_conj) placebo_12\NN|on (l_prep) on_13\IN|events (l_pobj) events_16\NNS|cardiovascular|thrombotic|in (l_prep) in_17\IN|patients (l_pobj) patients_18\NNS|with (l_prep) with_19\IN|arthritis (l_pobj) arthritis_20\NN|
C406224_D010003 NONE valdecoxib_6\NNS| (r_pobj) for_5\IN|valdecoxib (r_prep) data_4\NNS|cardiovascular|event|for|,|inhibitor (l_appos) inhibitor_11\NN|a|new|cox-2-specific|in|treated (l_prep) in_12\IN|patients (l_pobj) patients_15\NNS|8000|with (l_prep) with_16\IN|osteoarthritis (l_pobj) osteoarthritis_17\NN|and|arthritis
C406224_D010003 NONE valdecoxib_23\NNS|pooled|daily|) (r_dobj) analyzing_21\VBG|valdecoxib (r_pcomp) by_20\IN|analyzing (r_prep) determined_19\VBN|incidence|was|by|,|nsaid|. (l_appos) NSAID_33\NNP|nonselective|(|bid|ibuprofen (l_npadvmod) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_nmod) osteoarthritis_57\NN|10|randomized|and
C406224_D010003 NONE valdecoxib_24\NN| (r_compound) doses_25\NNS|valdecoxib (r_conj) treatment_5\NN|short-|term|with|doses (r_nsubjpass) associated_28\VBN|treatment|was|not|with|. (l_prep) with_29\IN|incidence (l_pobj) incidence_32\NN|an|increased|of (l_prep) of_33\IN|events (l_pobj) events_35\NNS|thrombotic|relative (l_amod) relative_36\JJ|to (l_prep) to_37\IN|nsaids (l_pobj) NSAIDs_39\NNPS|nonselective|or|placebo|in|in (l_prep) in_42\IN|patients (l_pobj) patients_47\NNS|osteoarthritis|arthritis (l_nmod) osteoarthritis_43\NN|and
C406224_D001172 NONE valdecoxib_6\NNS| (r_pobj) for_5\IN|valdecoxib (r_prep) data_4\NNS|cardiovascular|event|for|,|inhibitor (l_appos) inhibitor_11\NN|a|new|cox-2-specific|in|treated (l_prep) in_12\IN|patients (l_pobj) patients_15\NNS|8000|with (l_prep) with_16\IN|osteoarthritis (l_pobj) osteoarthritis_17\NN|and|arthritis (l_conj) arthritis_20\NN|rheumatoid
C406224_D001172 NONE valdecoxib_23\NNS|pooled|daily|) (r_dobj) analyzing_21\VBG|valdecoxib (r_pcomp) by_20\IN|analyzing (r_prep) determined_19\VBN|incidence|was|by|,|nsaid|. (l_appos) NSAID_33\NNP|nonselective|(|bid|ibuprofen (l_npadvmod) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_compound) arthritis_60\NN|rheumatoid
C406224_D001172 NONE valdecoxib_24\NN| (r_compound) doses_25\NNS|valdecoxib (r_conj) treatment_5\NN|short-|term|with|doses (r_nsubjpass) associated_28\VBN|treatment|was|not|with|. (l_prep) with_29\IN|incidence (l_pobj) incidence_32\NN|an|increased|of (l_prep) of_33\IN|events (l_pobj) events_35\NNS|thrombotic|relative (l_amod) relative_36\JJ|to (l_prep) to_37\IN|nsaids (l_pobj) NSAIDs_39\NNPS|nonselective|or|placebo|in|in (l_prep) in_42\IN|patients (l_pobj) patients_47\NNS|osteoarthritis|arthritis (l_compound) arthritis_46\NN|rheumatoid
D004008_D013927 NONE diclofenac_35\NN| (r_nmod) bid_38\NN|diclofenac|mg|, (r_appos) NSAID_33\NNP|nonselective|(|bid|ibuprofen (r_appos) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_amod) thrombotic_4\JJ|
D004008_D013927 NONE diclofenac_35\NN| (r_nmod) bid_38\NN|diclofenac|mg|, (r_appos) NSAID_33\NNP|nonselective|(|bid|ibuprofen (r_appos) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_appos) thrombotic_16\JJ|cardiac
D004008_D010003 NONE diclofenac_35\NN| (r_nmod) bid_38\NN|diclofenac|mg|, (r_appos) NSAID_33\NNP|nonselective|(|bid|ibuprofen (l_npadvmod) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_nmod) osteoarthritis_57\NN|10|randomized|and
D004008_D001172 NONE diclofenac_35\NN| (r_nmod) bid_38\NN|diclofenac|mg|, (r_appos) NSAID_33\NNP|nonselective|(|bid|ibuprofen (l_npadvmod) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_compound) arthritis_60\NN|rheumatoid
D007052_D013927 NONE ibuprofen_40\VBD|tid|,|or|naproxen|and|data (r_npadvmod) NSAID_33\NNP|nonselective|(|bid|ibuprofen (r_appos) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_amod) thrombotic_4\JJ|
D007052_D013927 NONE ibuprofen_40\VBD|tid|,|or|naproxen|and|data (r_npadvmod) NSAID_33\NNP|nonselective|(|bid|ibuprofen (r_appos) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_appos) thrombotic_16\JJ|cardiac
D007052_D010003 NONE ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_nmod) osteoarthritis_57\NN|10|randomized|and
D007052_D001172 NONE ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_compound) arthritis_60\NN|rheumatoid
D009288_D013927 NONE naproxen_46\NN|bid|) (r_conj) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (r_npadvmod) NSAID_33\NNP|nonselective|(|bid|ibuprofen (r_appos) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_amod) thrombotic_4\JJ|
D009288_D013927 NONE naproxen_46\NN|bid|) (r_conj) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (r_npadvmod) NSAID_33\NNP|nonselective|(|bid|ibuprofen (r_appos) determined_19\VBN|incidence|was|by|,|nsaid|. (l_nsubjpass) incidence_1\NN|the|of (l_prep) of_2\IN|events (l_pobj) events_5\NNS|cardiovascular|thrombotic|(|thrombotic|) (l_appos) thrombotic_16\JJ|cardiac
D009288_D010003 NONE naproxen_46\NN|bid|) (r_conj) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_nmod) osteoarthritis_57\NN|10|randomized|and
D009288_D001172 NONE naproxen_46\NN|bid|) (r_conj) ibuprofen_40\VBD|tid|,|or|naproxen|and|data (l_conj) data_53\NNS|placebo|from (l_prep) from_54\IN|trials (l_pobj) trials_61\NNS|osteoarthritis|arthritis|were (l_compound) arthritis_60\NN|rheumatoid
D001241_D013927 CID aspirin_8\NN| (r_compound) users_9\NNS|aspirin|than (r_pobj) of_7\IN|users (r_prep) users_6\NNS|of (r_pobj) for_5\IN|users (r_prep) was_2\VBD|risk|higher|for|. (l_nsubj) risk_1\NN|thrombotic (l_amod) Thrombotic_0\JJ|
D001241_D013927 CID aspirin_13\NN| (r_pobj) of_12\IN|aspirin (r_prep) nonusers_11\NNS|of|(|placebo|) (r_pobj) than_10\IN|nonusers (r_prep) users_9\NNS|aspirin|than (r_pobj) of_7\IN|users (r_prep) users_6\NNS|of (r_pobj) for_5\IN|users (r_prep) was_2\VBD|risk|higher|for|. (l_nsubj) risk_1\NN|thrombotic (l_amod) Thrombotic_0\JJ|
9799166
D003042_D020521 CID cocaine_2\NN|or|amphetamine (r_conj) Stroke_0\NN|and|cocaine
D003042_D020521 CID cocaine_3\NN|and|use (r_pobj) of_2\IN|cocaine (r_prep) association_1\NN|the|of|with (l_prep) with_7\IN|stroke (l_pobj) stroke_11\NN|hemorrhagic
D003042_D020521 CID cocaine_11\NN|and/or|amphetamine (r_pobj) of_10\IN|cocaine (r_prep) use_9\NN|of (r_conj) stroke_7\NN|and|use
D003042_D020521 CID cocaine_13\NN|and/or|amphetamine (r_dobj) using_12\VBG|cocaine (r_pcomp) to_11\IN|using (r_prep) admitted_10\VBD|who|to (r_relcl) stroke_6\NN|in|admitted
D003042_D020521 CID cocaine_3\NN|and/or|amphetamine (r_pobj) of_2\IN|cocaine (r_prep) use_1\NN|the|of (r_nsubj) is_6\VBZ|use|factor|. (l_attr) factor_10\NN|a|strong|risk|for (l_prep) for_11\IN|stroke (l_pobj) stroke_12\NN|in
D000661_D020521 CID amphetamine_4\NN| (r_conj) cocaine_2\NN|or|amphetamine (r_conj) Stroke_0\NN|and|cocaine
D000661_D020521 CID amphetamine_5\NN| (r_compound) use_6\NN|amphetamine (r_conj) cocaine_3\NN|and|use (r_pobj) of_2\IN|cocaine (r_prep) association_1\NN|the|of|with (l_prep) with_7\IN|stroke (l_pobj) stroke_11\NN|hemorrhagic
D000661_D020521 CID amphetamine_13\NN| (r_conj) cocaine_11\NN|and/or|amphetamine (r_pobj) of_10\IN|cocaine (r_prep) use_9\NN|of (r_conj) stroke_7\NN|and|use
D000661_D020521 CID amphetamine_15\NN| (r_conj) cocaine_13\NN|and/or|amphetamine (r_dobj) using_12\VBG|cocaine (r_pcomp) to_11\IN|using (r_prep) admitted_10\VBD|who|to (r_relcl) stroke_6\NN|in|admitted
D000661_D020521 CID amphetamine_5\NN| (r_conj) cocaine_3\NN|and/or|amphetamine (r_pobj) of_2\IN|cocaine (r_prep) use_1\NN|the|of (r_nsubj) is_6\VBZ|use|factor|. (l_attr) factor_10\NN|a|strong|risk|for (l_prep) for_11\IN|stroke (l_pobj) stroke_12\NN|in
D003042_D007511 NONE cocaine_3\NN|and|use (r_pobj) of_2\IN|cocaine (r_prep) association_1\NN|the|of|with (l_prep) with_7\IN|stroke (l_pobj) stroke_11\NN|hemorrhagic (l_amod) hemorrhagic_8\JJ|and|ischemic (l_conj) ischemic_10\JJ|
D000661_D007511 NONE amphetamine_5\NN| (r_compound) use_6\NN|amphetamine (r_conj) cocaine_3\NN|and|use (r_pobj) of_2\IN|cocaine (r_prep) association_1\NN|the|of|with (l_prep) with_7\IN|stroke (l_pobj) stroke_11\NN|hemorrhagic (l_amod) hemorrhagic_8\JJ|and|ischemic (l_conj) ischemic_10\JJ|
16428827
C004742_D000647 NONE Daidzein_0\NNP| (r_nsubj) activates_1\VBZ|daidzein|acetyltransferase|from|and|improves|. (l_conj) improves_10\VBZ|amnesia (l_dobj) amnesia_14\NN|induced
C004742_D000647 NONE daidzein_2\NN| (r_pobj) of_1\IN|daidzein (r_prep) Administration_0\NN|of|weight|to (r_nsubjpass) shown_12\VBN|administration|was|significantly|reverse|,|according|. (l_xcomp) reverse_15\VB|to|amnesia (l_dobj) amnesia_19\NN|induced
C004742_D000647 NONE daidzein_4\NN| (r_nsubj) play_6\VB|that|daidzein|might|role|as|,|and|ameliorates (l_conj) ameliorates_21\VBZ|that|it|also|amnesia (l_dobj) amnesia_25\NN|induced
D002794_D000647 NONE choline_2\NN| (r_compound) acetyltransferase_3\NN|choline (r_dobj) activates_1\VBZ|daidzein|acetyltransferase|from|and|improves|. (l_conj) improves_10\VBZ|amnesia (l_dobj) amnesia_14\NN|induced
D002794_D000544 NONE choline_1\NN| (r_compound) acetyltransferase_2\NN|the|choline|activator|, (r_nsubj) is_25\VBZ|acetyltransferase|factor|. (l_attr) factor_28\NN|an|important|in (l_prep) in_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|disease (l_pobj) disease_35\NN|alzheimer|ad|)
D002794_D000544 NONE choline_1\NN| (r_compound) acetyltransferase_2\NN|the|choline|activator|, (r_nsubj) is_25\VBZ|acetyltransferase|factor|. (l_attr) factor_28\NN|an|important|in (l_prep) in_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|disease (l_pobj) disease_35\NN|alzheimer|ad|) (l_appos) AD_37\NN|(
D000109_D000544 NONE acetylcholine_20\NN| (r_nmod) ACh_22\NNS|acetylcholine|( (r_pobj) of_19\IN|ach (r_prep) production_18\NN|the|enzymatic|of (r_pobj) of_15\IN|production (r_prep) augmentation_14\NN|an|of (r_pobj) via_12\IN|augmentation (r_prep) enhances_9\VBZ|which|transmission|via (r_relcl) activator_6\NN|(|chat|)|,|enhances|) (r_appos) acetyltransferase_2\NN|the|choline|activator|, (r_nsubj) is_25\VBZ|acetyltransferase|factor|. (l_attr) factor_28\NN|an|important|in (l_prep) in_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|disease (l_pobj) disease_35\NN|alzheimer|ad|)
D000109_D000544 NONE acetylcholine_20\NN| (r_nmod) ACh_22\NNS|acetylcholine|( (r_pobj) of_19\IN|ach (r_prep) production_18\NN|the|enzymatic|of (r_pobj) of_15\IN|production (r_prep) augmentation_14\NN|an|of (r_pobj) via_12\IN|augmentation (r_prep) enhances_9\VBZ|which|transmission|via (r_relcl) activator_6\NN|(|chat|)|,|enhances|) (r_appos) acetyltransferase_2\NN|the|choline|activator|, (r_nsubj) is_25\VBZ|acetyltransferase|factor|. (l_attr) factor_28\NN|an|important|in (l_prep) in_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|disease (l_pobj) disease_35\NN|alzheimer|ad|) (l_appos) AD_37\NN|(
D000109_D000544 NONE ACh_22\NNS|acetylcholine|( (r_pobj) of_19\IN|ach (r_prep) production_18\NN|the|enzymatic|of (r_pobj) of_15\IN|production (r_prep) augmentation_14\NN|an|of (r_pobj) via_12\IN|augmentation (r_prep) enhances_9\VBZ|which|transmission|via (r_relcl) activator_6\NN|(|chat|)|,|enhances|) (r_appos) acetyltransferase_2\NN|the|choline|activator|, (r_nsubj) is_25\VBZ|acetyltransferase|factor|. (l_attr) factor_28\NN|an|important|in (l_prep) in_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|disease (l_pobj) disease_35\NN|alzheimer|ad|)
D000109_D000544 NONE ACh_22\NNS|acetylcholine|( (r_pobj) of_19\IN|ach (r_prep) production_18\NN|the|enzymatic|of (r_pobj) of_15\IN|production (r_prep) augmentation_14\NN|an|of (r_pobj) via_12\IN|augmentation (r_prep) enhances_9\VBZ|which|transmission|via (r_relcl) activator_6\NN|(|chat|)|,|enhances|) (r_appos) acetyltransferase_2\NN|the|choline|activator|, (r_nsubj) is_25\VBZ|acetyltransferase|factor|. (l_attr) factor_28\NN|an|important|in (l_prep) in_29\IN|treatment (l_pobj) treatment_31\NN|the|of (l_prep) of_32\IN|disease (l_pobj) disease_35\NN|alzheimer|ad|) (l_appos) AD_37\NN|(
C004742_D007859 NONE daidzein_7\NN| (r_pobj) of_6\IN|daidzein (r_prep) effects_5\NNS|the|of|from (l_prep) from_8\IN|thunbergiana (l_pobj) thunbergiana_10\NNS|pueraria|on (l_prep) on_11\IN|impairments (l_pobj) impairments_15\NNS|induced|of (l_prep) of_16\IN|learning (l_pobj) learning_17\NN|and|memory (l_conj) memory_19\NN|
C004742_D008569 NONE daidzein_7\NN| (r_pobj) of_6\IN|daidzein (r_prep) effects_5\NNS|the|of|from (l_prep) from_8\IN|thunbergiana (l_pobj) thunbergiana_10\NNS|pueraria|on (l_prep) on_11\IN|impairments (l_pobj) impairments_15\NNS|induced|of (l_prep) of_16\IN|learning (l_pobj) learning_17\NN|and|memory (l_conj) memory_19\NN|
D012601_D007859 NONE scopolamine_12\NN| (r_npadvmod) induced_14\VBN|scopolamine|- (r_amod) impairments_15\NNS|induced|of (l_prep) of_16\IN|learning (l_pobj) learning_17\NN|and|memory (l_conj) memory_19\NN|
D012601_D008569 NONE scopolamine_12\NN| (r_npadvmod) induced_14\VBN|scopolamine|- (r_amod) impairments_15\NNS|induced|of (l_prep) of_16\IN|learning (l_pobj) learning_17\NN|and|memory (l_conj) memory_19\NN|
D012601_D000647 CID scopolamine_16\NN| (r_npadvmod) induced_18\VBN|scopolamine|- (r_amod) amnesia_19\NN|induced
D012601_D000647 CID scopolamine_22\NN| (r_npadvmod) induced_24\VBN|scopolamine|- (r_amod) amnesia_25\NN|induced
D000109_D000647 NONE acetylcholine_10\NN| (r_compound) biosynthesis_11\NN|acetylcholine (r_pobj) in_9\IN|biosynthesis (r_prep) role_8\NN|a|in (r_dobj) play_6\VB|that|daidzein|might|role|as|,|and|ameliorates (l_conj) ameliorates_21\VBZ|that|it|also|amnesia (l_dobj) amnesia_25\NN|induced
6699841
D009288_D007681 CID naproxen_5\NN| (r_pobj) due_3\IN|to|naproxen (r_prep) necrosis_2\NN|renal|papillary|due|.
D009288_D007681 CID naproxen_39\NN| (r_compound) therapy_40\NN|naproxen (r_pobj) of_38\IN|therapy (r_prep) institution_37\NN|of (r_pobj) after_36\IN|months|institution (r_prep) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|)
D009288_D007681 CID naproxen_39\NN| (r_compound) therapy_40\NN|naproxen (r_pobj) of_38\IN|therapy (r_prep) institution_37\NN|of (r_pobj) after_36\IN|months|institution (r_prep) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|) (l_appos) RPN_32\NNP|
D013467_D001172 NONE sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (l_prep) with_5\IN|arthritis (l_pobj) arthritis_7\NN|rheumatoid
D013467_D007681 NONE sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|)
D013467_D007681 NONE sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|) (l_appos) RPN_32\NNP|
D013467_D007681 NONE sulindac_15\NN|in (r_pobj) of_14\IN|sulindac (r_prep) advantages_13\NNS|possible|of (r_dobj) discuss_11\VB|advantages (r_conj) linking_4\VBG|rpn|to|and|discuss (l_dobj) RPN_5\NNP|
D005279_D001172 NONE calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (l_prep) with_5\IN|arthritis (l_pobj) arthritis_7\NN|rheumatoid
D005279_D007681 NONE calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|)
D005279_D007681 NONE calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|) (l_appos) RPN_32\NNP|
D012459_D001172 NONE salicylates_22\NNS|high|dose|and|salts (r_conj) calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (l_prep) with_5\IN|arthritis (l_pobj) arthritis_7\NN|rheumatoid
D012459_D007681 NONE salicylates_22\NNS|high|dose|and|salts (r_conj) calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|)
D012459_D007681 NONE salicylates_22\NNS|high|dose|and|salts (r_conj) calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|) (l_appos) RPN_32\NNP|
D006046_D001172 NONE gold_24\NN| (r_compound) salts_25\NNS|gold (r_conj) salicylates_22\NNS|high|dose|and|salts (r_conj) calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (l_prep) with_5\IN|arthritis (l_pobj) arthritis_7\NN|rheumatoid
D006046_D007681 NONE gold_24\NN| (r_compound) salts_25\NNS|gold (r_conj) salicylates_22\NNS|high|dose|and|salts (r_conj) calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|)
D006046_D007681 NONE gold_24\NN| (r_compound) salts_25\NNS|gold (r_conj) salicylates_22\NNS|high|dose|and|salts (r_conj) calcium_18\NN|fenoprofen|,|salicylates (r_conj) sulindac_15\NN|,|calcium (r_pobj) with_14\IN|sulindac (r_prep) treated_13\VBN|who|had|previously|been|with (r_relcl) man_4\NN|a|old|with|,|treated|, (r_nsubj) developed_27\VBD|man|necrosis|after|. (l_dobj) necrosis_30\NN|renal|papillary|(|rpn|) (l_appos) RPN_32\NNP|
D009288_D001172 NONE naproxen_39\NN| (r_compound) therapy_40\NN|naproxen (r_pobj) of_38\IN|therapy (r_prep) institution_37\NN|of (r_pobj) after_36\IN|months|institution (r_prep) developed_27\VBD|man|necrosis|after|. (l_nsubj) man_4\NN|a|old|with|,|treated|, (l_prep) with_5\IN|arthritis (l_pobj) arthritis_7\NN|rheumatoid
D013467_D007674 NONE sulindac_15\NN|in (l_prep) in_16\IN|patients (l_pobj) patients_17\NNS|experienced (l_relcl) experienced_20\VBN|who|have|toxicity (l_dobj) toxicity_22\NN|renal|from
8045270
C081198_D002375 NONE KF17837_3\NNP| (r_pobj) of_2\IN|kf17837 (r_prep) administration_1\NN|oral|of|2.5 (r_nsubj) ameliorated_13\VBD|administration|significantly|responses|,|in|. (l_dobj) responses_16\NNS|the|cataleptic|induced (l_amod) cataleptic_15\JJ|
C081198_D002375 NONE KF17837_0\NN| (r_nsubj) reduced_2\VBD|kf17837|also|catalepsy|. (l_dobj) catalepsy_4\NN|the|induced
D000241_D002375 NONE adenosine_23\NN| (r_amod) agonist_26\NN|an|adenosine|a2a|receptor|,|cgs (r_pobj) of_21\IN|agonist (r_prep) administration_20\NN|intracerebroventricular|of (r_pobj) by_18\IN|administration (r_agent) induced_17\VBN|by (r_acl) responses_16\NNS|the|cataleptic|induced (l_amod) cataleptic_15\JJ|
C061282_D002375 CID 21680_29\CD| (r_nummod) CGS_28\NNP|21680|(|micrograms|) (r_appos) agonist_26\NN|an|adenosine|a2a|receptor|,|cgs (r_pobj) of_21\IN|agonist (r_prep) administration_20\NN|intracerebroventricular|of (r_pobj) by_18\IN|administration (r_agent) induced_17\VBN|by (r_acl) responses_16\NNS|the|cataleptic|induced (l_amod) cataleptic_15\JJ|
D006220_D002375 CID haloperidol_7\NN|mg/kg|i.p.|) (r_pobj) by_6\IN|haloperidol|and|by (r_agent) induced_5\VBN|by (r_acl) catalepsy_4\NN|the|induced
D012110_D002375 CID reserpine_15\NN|mg/kg (r_pobj) by_14\IN|reserpine (r_conj) by_6\IN|haloperidol|and|by (r_agent) induced_5\VBN|by (r_acl) catalepsy_4\NN|the|induced
C081198_D010302 NONE KF17837_2\NN| (r_nsubj) be_4\VB|furthermore|,|kf17837|may|drug|. (l_attr) drug_7\NN|a|useful|in (l_prep) in_8\IN|treatment (l_pobj) treatment_10\NN|the|of (l_prep) of_11\IN|parkinsonism (l_pobj) parkinsonism_12\NN|
3300918
D008784_D014652 CID methysergide_20\NN| (r_pobj) of_19\IN|methysergide (r_prep) ingestion_18\NN|the|of|by (r_pobj) to_16\IN|ingestion (r_prep) described_14\VBN|case|,|is|secondary|to|. (l_nsubjpass) case_2\NN|a|rare|of|,|with (l_prep) of_3\IN|vasospasm (l_pobj) vasospasm_5\NN|morbid
D004876_D005734 NONE ergot_6\NN| (r_pobj) of_5\IN|ergot (r_prep) history_4\NN|the|of (r_pobj) of_2\IN|history (r_prep) discussion_1\NN|a|of (r_nsubj) includes_7\VBZ|discussion|discovery|. (l_dobj) discovery_10\NN|its|original|,|epidemics (l_appos) epidemics_13\NNS|the|of|caused (l_prep) of_14\IN|gangrene (l_pobj) gangrene_15\NN|
D004876_D008881 CID ergot_6\NN| (r_pobj) of_5\IN|ergot (r_prep) history_4\NN|the|of (r_pobj) of_2\IN|history (r_prep) discussion_1\NN|a|of (r_nsubj) includes_7\VBZ|discussion|discovery|. (l_dobj) discovery_10\NN|its|original|,|epidemics (l_appos) epidemics_13\NNS|the|of|caused (l_relcl) caused_19\VBN|that|it|has|through (l_prep) through_20\IN|ages (l_pobj) ages_22\NNS|the|and|role (l_conj) role_28\NN|its|past|in (l_prep) in_29\IN|management (l_pobj) management_31\NN|the|of (l_prep) of_32\IN|headache (l_pobj) headache_34\NN|migraine
D004876_D008881 CID ergot_13\NN| (r_compound) preparations_14\NNS|ergot (r_nsubj) continue_15\VBP|despite|,|preparations|play|,|persists|. (l_xcomp) play_17\VB|to|role (l_dobj) role_20\NN|a|major|in (l_prep) in_21\IN|therapy (l_pobj) therapy_23\NN|migraine (l_compound) migraine_22\NN|
D002118_D008881 NONE calcium_4\NN| (r_compound) channel_5\NN|calcium (r_compound) blockers_6\NNS|channel|and|antagonists (r_pobj) of_3\IN|blockers (r_prep) advent_2\NN|the|of (r_pobj) Despite_0\IN|advent (r_prep) continue_15\VBP|despite|,|preparations|play|,|persists|. (l_xcomp) play_17\VB|to|role (l_dobj) role_20\NN|a|major|in (l_prep) in_21\IN|therapy (l_pobj) therapy_23\NN|migraine (l_compound) migraine_22\NN|
D002118_D004881 NONE calcium_4\NN| (r_compound) channel_5\NN|calcium (r_compound) blockers_6\NNS|channel|and|antagonists (r_pobj) of_3\IN|blockers (r_prep) advent_2\NN|the|of (r_pobj) Despite_0\IN|advent (r_prep) continue_15\VBP|despite|,|preparations|play|,|persists|. (l_advcl) persists_34\VBZ|so|that|danger (l_nsubj) danger_28\NN|the|of (l_prep) of_29\IN|fire (l_pobj) fire_33\NN|anthony
D004876_D004881 NONE ergot_13\NN| (r_compound) preparations_14\NNS|ergot (r_nsubj) continue_15\VBP|despite|,|preparations|play|,|persists|. (l_advcl) persists_34\VBZ|so|that|danger (l_nsubj) danger_28\NN|the|of (l_prep) of_29\IN|fire (l_pobj) fire_33\NN|anthony
15985056
D017963_D006606 CID azithromycin_1\RB| (r_advmod) associated_3\VBN|azithromycin|- (r_amod) hiccups_4\NNS|possible|associated|.
D017963_D006606 CID azithromycin_9\CD| (r_amod) therapy_10\NN|azithromycin (r_pobj) by_8\IN|therapy (r_agent) associated_7\VBN|by (r_acl) hiccups_6\NNS|persistent|associated
D017963_D006606 CID azithromycin_11\RB| (r_advmod) beginning_10\VBG|azithromycin|for (r_pcomp) after_9\IN|beginning (r_prep) presented_5\VBN|man|with|after|. (l_prep) with_6\IN|hiccups (l_pobj) hiccups_8\NNS|persistent
D017963_D006606 CID azithromycin_2\NNP| (r_pobj) of_1\IN|azithromycin (r_prep) Discontinuation_0\NN|of|and|therapy (r_nsubj) resolved_8\VBD|discontinuation|finally|hiccups|. (l_dobj) hiccups_9\NNS|
D017963_D006606 CID azithromycin_9\WP| (r_pobj) by_8\IN|azithromycin (r_agent) mediated_7\VBN|by (r_acl) mechanism_6\NN|a|vagal|mediated (r_nsubj) be_11\VB|that|mechanism|could|pathogenesis (l_attr) pathogenesis_13\NN|the|of (l_prep) of_14\IN|hiccups (l_pobj) hiccups_15\NNS|in
D017963_D010612 NONE azithromycin_11\RB| (r_advmod) beginning_10\VBG|azithromycin|for (l_prep) for_12\IN|treatment (l_pobj) treatment_14\NN|the|of (l_prep) of_15\IN|pharyngitis (l_pobj) pharyngitis_16\NN|
D001418_D006606 CID baclofen_6\NN| (r_pobj) with_5\IN|baclofen (r_prep) therapy_4\NN|with (r_conj) Discontinuation_0\NN|of|and|therapy (r_nsubj) resolved_8\VBD|discontinuation|finally|hiccups|. (l_dobj) hiccups_9\NNS|
D003907_D006606 NONE dexamethasone_2\NN|and|methylprednisolone (r_appos) Corticosteroids_0\NNS|(|dexamethasone|)|,|benzodiazepines (r_nsubj) been_15\VBN|corticosteroids|have|agents|. (l_attr) agents_18\NNS|the|specific|mentioned (l_acl) mentioned_19\VBD|frequently|in|as (l_prep) as_25\IN|associated (l_pcomp) associated_27\VBN|being|with (l_prep) with_28\IN|development (l_pobj) development_30\NN|the|of (l_prep) of_31\IN|hiccups (l_pobj) hiccups_32\NNS|
D008775_D006606 NONE methylprednisolone_4\NN| (r_conj) dexamethasone_2\NN|and|methylprednisolone (r_appos) Corticosteroids_0\NNS|(|dexamethasone|)|,|benzodiazepines (r_nsubj) been_15\VBN|corticosteroids|have|agents|. (l_attr) agents_18\NNS|the|specific|mentioned (l_acl) mentioned_19\VBD|frequently|in|as (l_prep) as_25\IN|associated (l_pcomp) associated_27\VBN|being|with (l_prep) with_28\IN|development (l_pobj) development_30\NN|the|of (l_prep) of_31\IN|hiccups (l_pobj) hiccups_32\NNS|
D001569_D006606 NONE benzodiazepines_7\NNS|(|midazolam|anaesthesia (r_appos) Corticosteroids_0\NNS|(|dexamethasone|)|,|benzodiazepines (r_nsubj) been_15\VBN|corticosteroids|have|agents|. (l_attr) agents_18\NNS|the|specific|mentioned (l_acl) mentioned_19\VBD|frequently|in|as (l_prep) as_25\IN|associated (l_pcomp) associated_27\VBN|being|with (l_prep) with_28\IN|development (l_pobj) development_30\NN|the|of (l_prep) of_31\IN|hiccups (l_pobj) hiccups_32\NNS|
D008874_D006606 NONE midazolam_9\NN|)|and (r_appos) benzodiazepines_7\NNS|(|midazolam|anaesthesia (r_appos) Corticosteroids_0\NNS|(|dexamethasone|)|,|benzodiazepines (r_nsubj) been_15\VBN|corticosteroids|have|agents|. (l_attr) agents_18\NNS|the|specific|mentioned (l_acl) mentioned_19\VBD|frequently|in|as (l_prep) as_25\IN|associated (l_pcomp) associated_27\VBN|being|with (l_prep) with_28\IN|development (l_pobj) development_30\NN|the|of (l_prep) of_31\IN|hiccups (l_pobj) hiccups_32\NNS|
D018942_D006606 NONE macrolide_12\NN| (r_amod) antimicrobials_13\NNS|macrolide (r_pobj) to_11\IN|antimicrobials (r_prep) related_10\VBN|to (r_oprd) reported_9\VBN|cases|have|been|related|. (l_nsubjpass) cases_1\NNS|few|of (l_prep) of_2\IN|hiccups (l_pobj) hiccups_6\NNS|induced
D018942_D006606 NONE macrolides_36\NNS|other (r_pobj) with_34\IN|macrolides (r_prep) reaction_33\NN|this|with|and|absence (l_conj) absence_39\NN|the|of (l_prep) of_40\IN|explanation (l_pobj) explanation_43\NN|any|alternative|for (l_prep) for_44\IN|hiccups (l_pobj) hiccups_45\NNS|
D018942_D006606 NONE macrolide_2\NN| (r_amod) antimicrobials_3\NNS|macrolide (r_nsubjpass) reported_6\VBN|however|,|antimicrobials|have|been|associated|explain|. (l_xcomp) associated_9\VBN|to|be|with (l_prep) with_10\IN|mechanism (l_pobj) mechanism_14\NN|hiccups|vagal (l_nmod) hiccups_11\NNS|and
10523326
D009569_D006973 NONE oxide_1\NN| (r_compound) synthase_2\NN|oxide (r_compound) expression_3\NN|nitric|synthase|in|. (l_prep) in_4\IN|course (l_pobj) course_6\NN|the|of (l_prep) of_7\IN|hypertension (l_pobj) hypertension_11\NN|induced
D009569_D006973 NONE NO_15\DT| (r_det) metabolites_16\NNS|no|(|nox|) (r_pobj) of_14\IN|metabolites (r_prep) excretion_13\NN|reduced|urinary|of (r_dobj) showed_2\VBD|we|recently|species|excretion|,|and|increased|. (l_conj) increased_22\VBD|sequestration (l_dobj) sequestration_24\NN|no|as (l_prep) as_25\IN|nitrotyrosine (l_pobj) nitrotyrosine_26\JJ|in (l_prep) in_27\IN|tissues (l_pobj) tissues_29\NNS|various|in (l_prep) in_30\IN|rats (l_pobj) rats_31\NNS|with (l_prep) with_32\IN|hypertension (l_pobj) hypertension_36\NN|induced
D009569_D006973 NONE NO_23\DT| (r_det) sequestration_24\NN|no|as (l_prep) as_25\IN|nitrotyrosine (l_pobj) nitrotyrosine_26\JJ|in (l_prep) in_27\IN|tissues (l_pobj) tissues_29\NNS|various|in (l_prep) in_30\IN|rats (l_pobj) rats_31\NNS|with (l_prep) with_32\IN|hypertension (l_pobj) hypertension_36\NN|induced
D009569_D006973 NONE NO_25\DT| (r_det) synthase_26\NN|depressed|no (r_nmod) expression_30\NN|synthase|(|nos|) (r_pobj) due_22\IN|to|expression (r_prep) is_17\VBZ|whether|reduction|,|in|,|due (l_nsubj) reduction_8\NN|the|in|in (l_prep) in_12\IN|hypertension (l_pobj) hypertension_16\NN|induced
D009569_D006973 NONE NO_11\DT| (r_compound) inactivation_12\NN|mediated|no|,|inhibition (l_appos) inhibition_17\NN|associated|of|,|and|actions (l_conj) actions_25\NNS|perhaps|stimulatory|of (l_prep) of_26\IN|stress (l_pobj) stress_29\NN|increased|shear|associated (l_acl) associated_30\VBN|with (l_prep) with_31\IN|hypertension (l_pobj) hypertension_32\NN|
D007854_D006973 CID lead_8\NN| (r_npadvmod) induced_10\VBN|lead|- (r_amod) hypertension_11\NN|induced
D007854_D006973 CID lead_33\NN| (r_npadvmod) induced_35\VBN|lead|- (r_amod) hypertension_36\NN|induced
D007854_D006973 CID lead_13\NN| (r_npadvmod) induced_15\VBN|lead|- (r_amod) hypertension_16\NN|induced
D007854_D006973 CID lead_3\NN| (r_npadvmod) induced_5\VBN|lead|- (r_amod) hypertension_6\NN|induced|in
D007854_D006973 CID lead_14\NN| (r_npadvmod) associated_16\VBN|lead|- (r_amod) inhibition_17\NN|associated|of|,|and|actions (l_conj) actions_25\NNS|perhaps|stimulatory|of (l_prep) of_26\IN|stress (l_pobj) stress_29\NN|increased|shear|associated (l_acl) associated_30\VBN|with (l_prep) with_31\IN|hypertension (l_pobj) hypertension_32\NN|
D010100_D006973 NONE oxygen_5\NN| (r_compound) species_6\NNS|elevated|reactive|oxygen|(|ros|)|, (r_dobj) showed_2\VBD|we|recently|species|excretion|,|and|increased|. (l_conj) increased_22\VBD|sequestration (l_dobj) sequestration_24\NN|no|as (l_prep) as_25\IN|nitrotyrosine (l_pobj) nitrotyrosine_26\JJ|in (l_prep) in_27\IN|tissues (l_pobj) tissues_29\NNS|various|in (l_prep) in_30\IN|rats (l_pobj) rats_31\NNS|with (l_prep) with_32\IN|hypertension (l_pobj) hypertension_36\NN|induced
C002744_D006973 NONE nitrotyrosine_26\JJ|in (l_prep) in_27\IN|tissues (l_pobj) tissues_29\NNS|various|in (l_prep) in_30\IN|rats (l_pobj) rats_31\NNS|with (l_prep) with_32\IN|hypertension (l_pobj) hypertension_36\NN|induced
D014810_D006973 NONE E_1\NN|vitamin (r_compound) supplementation_2\NN|e (r_nsubj) ameliorated_3\VBD|supplementation|hypertension|,|lowered|. (l_dobj) hypertension_4\NN|
D008315_D006973 NONE MDA_8\NNP| (r_compound) concentration_9\NN|plasma|mda (r_dobj) lowered_6\VBD|concentration|,|and|raised|enos (r_conj) ameliorated_3\VBD|supplementation|hypertension|,|lowered|. (l_dobj) hypertension_4\NN|
2322844
D011453_D010146 NONE prostaglandins_6\NNS| (r_pobj) of_5\IN|prostaglandins (r_prep) administration_4\NN|intrathecal|of (r_pobj) of_2\IN|administration (r_prep) effects_1\NNS|the|of|on (l_prep) on_7\IN|responses (l_pobj) responses_9\NNS|pain|in (l_compound) pain_8\NN|
D019342_D010146 NONE acid_21\NN|acetic (r_conj) plate_18\NN|hot|and|acid (r_dobj) using_16\VBG|plate|writhing (r_pcomp) by_15\IN|using (r_prep) evaluated_14\VBN|effects|were|by|. (l_nsubjpass) effects_1\NNS|the|of|on (l_prep) on_7\IN|responses (l_pobj) responses_9\NNS|pain|in (l_compound) pain_8\NN|
D015230_D006930 CID D2_1\NN|prostaglandin|(|mouse|) (r_nsubj) had_10\VBD|d2|action|during|. (l_dobj) action_13\NN|a|hyperalgesic|on (l_amod) hyperalgesic_12\JJ|
D015230_D006930 CID D2_32\NN|prostaglandin (r_pobj) of_30\IN|d2 (r_prep) that_29\DT|of (r_pobj) than_28\IN|that (r_prep) min_26\NN|shorter|(|30|)|than (r_dobj) lasted_20\VBD|effect|min|. (r_conj) showed_2\VBD|e2|effect|,|but|lasted (l_dobj) effect_5\NN|a|hyperalgesic|at (l_amod) hyperalgesic_4\JJ|
D015230_D006930 CID D2_5\NN|prostaglandin (r_pobj) of_3\IN|d2 (r_prep) effect_2\NN|the|hyperalgesic|of (l_amod) hyperalgesic_1\JJ|
D015230_D006930 CID D2_6\NN|both|prostaglandin|and|e2 (r_nsubj) exert_10\VBP|that|d2|hyperalgesia|,|but|in (l_dobj) hyperalgesia_11\NN|in
D015232_D006930 CID E2_1\NNP|prostaglandin (r_nsubj) showed_2\VBD|e2|effect|,|but|lasted (l_dobj) effect_5\NN|a|hyperalgesic|at (l_amod) hyperalgesic_4\JJ|
D015232_D006930 CID E2-induced_3\NNP| (r_amod) hyperalgesia_4\NN|prostaglandin|e2-induced
D015232_D006930 CID E2_9\NNP|prostaglandin (r_conj) D2_6\NN|both|prostaglandin|and|e2 (r_nsubj) exert_10\VBP|that|d2|hyperalgesia|,|but|in (l_dobj) hyperalgesia_11\NN|in
D011453_D006930 NONE pg_10\NN|1 (r_pobj) of_8\IN|pg (r_prep) doses_7\NNS|of|to (r_pobj) at_6\IN|doses (r_prep) effect_5\NN|a|hyperalgesic|at (l_amod) hyperalgesic_4\JJ|
C053876_D006930 NONE AH6809_28\NN|,|antagonist (r_pobj) by_27\IN|not|ah6809 (r_agent) blocked_7\VBN|effect|was|by|but|by|. (l_nsubjpass) effect_2\NN|the|hyperalgesic|of (l_amod) hyperalgesic_1\JJ|
C053876_D006930 NONE AH6809_8\NN|(|greater|) (r_pobj) by_7\IN|ah6809 (r_agent) blocked_6\VBN|conversely|,|hyperalgesia|was|by|but|by|. (l_nsubjpass) hyperalgesia_4\NN|prostaglandin|e2-induced
D015237_D010146 NONE alpha_2\NN|prostaglandin|f2 (r_nsubj) had_3\VBD|alpha|effect|. (l_dobj) effect_5\NN|little|on (l_prep) on_6\IN|responses (l_pobj) responses_8\NNS|pain (l_compound) pain_7\NN|
15867025
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (r_pobj) to_38\IN|mothers (r_prep) born_37\VBN|who|were|to|to (r_relcl) infants_34\NNS|born (r_pobj) to_33\IN|infants (r_prep) administration_27\NN|of|to (r_conj) dose_22\NN|administration|to|,|administration (r_conj) screening_8\NN|prenatal|for|,|dose (l_prep) for_9\IN|b (l_pobj) B_11\NNP|hepatitis|and|rubella
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (r_pobj) to_38\IN|mothers (r_prep) born_37\VBN|who|were|to|to (r_relcl) infants_34\NNS|born (r_pobj) to_33\IN|infants (r_prep) administration_27\NN|of|to (r_conj) dose_22\NN|administration|to|,|administration (l_nsubj) administration_15\NN|of (l_prep) of_16\IN|birth (l_pobj) birth_21\NN|the|vaccine (l_compound) vaccine_20\NN|b (l_compound) B_19\NNP|hepatitis
D006514_D006509 CID antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (r_pobj) to_38\IN|mothers (r_prep) born_37\VBN|who|were|to|to (r_relcl) infants_34\NNS|born (r_pobj) to_33\IN|infants (r_prep) administration_27\NN|of|to (l_prep) of_28\IN|globulin (l_pobj) globulin_32\NN|b|immune (l_compound) B_30\NNP|hepatitis
D006514_D006509 CID antigen_9\NN| (r_npadvmod) positive_11\JJ|antigen|- (r_amod) mothers_12\NNS|b|surface|positive (r_pobj) to_5\IN|mothers (r_prep) born_4\VBN|who|were|to (r_relcl) infants_1\NNS|all|born (r_nsubj) received_14\VBD|infants|also|globulin|. (l_dobj) globulin_18\NN|b|immune (l_compound) B_16\NN|hepatitis
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (r_pobj) to_38\IN|mothers (r_prep) born_37\VBN|who|were|to|to (r_relcl) infants_34\NNS|born (r_pobj) to_33\IN|infants (r_prep) administration_27\NN|of|to (r_conj) dose_22\NN|administration|to|,|administration (r_conj) screening_8\NN|prenatal|for|,|dose (l_prep) for_9\IN|b (l_pobj) B_11\NNP|hepatitis|and|rubella (l_conj) rubella_13\NN|
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (l_conj) immunity_48\NN|rubella|,|and|administration (l_compound) rubella_47\NN|
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (l_conj) immunity_48\NN|rubella|,|and|administration (l_conj) administration_51\NN|of (l_prep) of_52\IN|vaccine (l_pobj) vaccine_58\NN|in|rubella (l_compound) rubella_57\NN|postpartum
D006514_D012409 NONE antigen_42\NN| (r_npadvmod) positive_44\JJ|antigen|- (r_amod) mothers_45\NNS|b|surface|positive|,|immunity (r_pobj) to_38\IN|mothers (r_prep) born_37\VBN|who|were|to|to (l_prep) to_59\TO|women (l_pobj) women_62\NNS|rubella|nonimmune (l_compound) rubella_60\VB|
